[{"id": 97001, "ingredient1": "Ivacaftor", "ingredient2": "Losartan", "severity": "Moderate", "effect": "Coadministration with ivacaftor may increase the plasma concentrations of drugs that are substrates of the CYP450 2C9 isoenzyme. The proposed mechanism, based on in vitro data, involves decreased metabolic clearance due to inhibition of CYP450 2C9 by ivacaftor.", "source": "DDInter", "management_text": "Caution is advised when ivacaftor is used concurrently with drugs that are known CYP450 2C9 substrates, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever ivacaftor is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when ivacaftor is used concurrently with drugs that are known CYP450 2C9 substrates, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97105/", "reference_text": "[1] \"Product Information. Trikafta (elexacaftor/ivacaftor/tezacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[2] \"Product Information. Symdeko 4-Week (ivacaftor-tezacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[3] \"Product Information. Orkambi (ivacaftor-lumacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[4] \"Product Information. Kalydeco (ivacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[5] \"Product Information. Ambien (zolpidem).\" sanofi-aventis, Bridgewater, NJ.[6] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84[7] \"Product Information. Trikafta (elexacaftor/ivacaftor/tezacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[8] \"Product Information. Kalydeco (ivacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[9] \"Product Information. Orkambi (ivacaftor-lumacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[10] \"Product Information. Symdeko 4-Week (ivacaftor-tezacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.", "alternatives_a": "Valsartan, Olmesartan, Azilsartan medoxomil, Telmisartan, Candesartan, Eprosartan, Valsartan, Hydrochlorothiazide, Olmesartan, Azilsartan medoxomil, Nebivolol, More", "alternatives_b": "Nitric Oxide, Doxapram, Elexacaftor, Lumacaftor", "updated_at": 1767369485}, {"id": 97002, "ingredient1": "Elexacaftor", "ingredient2": "Lovastatin", "severity": "Moderate", "effect": "Coadministration with elexacaftor may increase the plasma concentrations of drugs that are substrates of the organic anion transporting polypeptides (OATP) 1B1 and 1B3. The proposed mechanism, based on in vitro data, involves decreased metabolic clearance due to inhibition of OATP 1B1- and 1B3-mediated hepatic uptake by elexacaftor and its metabolite. The clinical relevance is unknown.", "source": "DDInter", "management_text": "Caution is advised when elexacaftor is used concurrently with drugs that are known OATP 1B1 and 1B3 substrates, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever elexacaftor is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when elexacaftor is used concurrently with drugs that are known OATP 1B1 and 1B3 substrates, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97106/", "reference_text": "[1] \"Product Information. Trikafta (elexacaftor/ivacaftor/tezacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[2] \"Product Information. Diovan (valsartan).\" Novartis Pharmaceuticals, East Hanover, NJ.[3] \"Product Information. Cozaar (losartan).\" Merck & Co, Inc, West Point, PA.[4] \"Product Information. Trikafta (elexacaftor/ivacaftor/tezacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[5] \"Product Information. Kalydeco (ivacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[6] \"Product Information. Orkambi (ivacaftor-lumacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[7] \"Product Information. Symdeko 4-Week (ivacaftor-tezacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.", "alternatives_a": "Gemfibrozil, Fenofibric acid, Mipomersen, Evinacumab, Evolocumab, Dextrothyroxine, Probucol, Cholestyramine, Clofibrate, Colestipol, Niacin, More", "alternatives_b": "Nitric Oxide, Doxapram", "updated_at": 1767369485}, {"id": 97003, "ingredient1": "Ivacaftor", "ingredient2": "Lumateperone", "severity": "Moderate", "effect": "Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of lumateperone, which is metabolized by the isoenzyme in vitro.", "source": "DDInter", "management_text": "Caution is advised when lumateperone is used with CYP450 3A4 inhibitors. Patients should be monitored for increased adverse effects such as dizziness, drowsiness, abnormal muscle movements, seizures, high blood sugar, diabetes, high cholesterol, weight gain, low white blood cell count, difficulty swallowing, and heat-related disorders such as heat intolerance or heat stroke.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when lumateperone is used with CYP450 3A4 inhibitors.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97107/", "reference_text": "[1] \"Product Information. Caplyta (lumateperone).\" Intra-Cellular Therapies, Inc., New York, NY.[2] \"Product Information. Accolate (zafirlukast).\" Zeneca Pharmaceuticals, Wilmington, DE.[3] \"Product Information. Caplyta (lumateperone).\" Intra-Cellular Therapies, Inc., New York, NY.", "alternatives_a": "Fluphenazine, Thiothixene, Risperidone, Amisulpride, Quetiapine, Prochlorperazine, Promazine, Thioridazine, Trifluoperazine, Paliperidone, Chlorpromazine, More", "alternatives_b": "Nitric Oxide, Doxapram, Elexacaftor", "updated_at": 1767369485}, {"id": 97004, "ingredient1": "Ivacaftor", "ingredient2": "Lurasidone", "severity": "Moderate", "effect": "Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of lurasidone and its active metabolite, both of which are primarily metabolized by the isoenzyme.", "source": "DDInter", "management_text": "Pharmacologic response to lurasidone should be monitored more closely whenever a CYP450 3A4 inhibitor is added to or withdrawn from therapy, and the lurasidone dosage adjusted as necessary. Patients should be monitored for potentially increased adverse effects such as dizziness, drowsiness, dry mouth, increased appetite, weight gain, extrapyramidal symptoms, tardive dyskinesia, hyperglycemia, dyslipidemia, hyperprolactinemia (galactorrhea, amenorrhea, gynecomastia), orthostatic hypotension, cognitive and motor impairment, seizures, dysphagia, and heat-related illnesses due to disruption of body temperature regulation.", "mechanism_text": "Metabolism", "recommendation": "Pharmacologic response to lurasidone should be monitored more closely whenever a CYP450 3A4 inhibitor is added to or withdrawn from therapy, and the lurasidone dosage adjusted as necessary.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97108/", "reference_text": "[1] \"Product Information. Latuda (lurasidone).\" Sunovion Pharmaceuticals Inc, Marlborough, MA.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] Cerner Multum, Inc. \"Australian Product Information.\" O 0[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Latuda (lurasidone).\" Sunovion Pharmaceuticals Inc, Marlborough, MA.[7] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid.\"[8] \"Product Information. Accolate (zafirlukast).\" Zeneca Pharmaceuticals, Wilmington, DE.", "alternatives_a": "Fluphenazine, Thiothixene, Risperidone, Amisulpride, Quetiapine, Prochlorperazine, Promazine, Thioridazine, Trifluoperazine, Paliperidone, Chlorpromazine, More", "alternatives_b": "Nitric Oxide, Doxapram, Elexacaftor", "updated_at": 1767369485}, {"id": 97005, "ingredient1": "Ivacaftor", "ingredient2": "Lurbinectedin", "severity": "Moderate", "effect": "Coadministration with a CYP450 3A4 inhibitor may increase lurbinectedin systemic exposure, which may increase the incidence and severity of adverse reactions to lurbinectedin, such as myelosuppression and hepatotoxicity.", "source": "DDInter", "management_text": "Clinical and laboratory monitoring is advised whenever a CYP450 3A4 inhibitor is added to or withdrawn from therapy with lurbinectedin. Patients should be advised to contact their physician if they experience symptoms suggestive of myelosuppression or hepatotoxicity, such as fever or any other signs of infection, unusual bruising or bleeding; or nausea or vomiting, or pain on the right side of the abdomen.", "mechanism_text": "Metabolism", "recommendation": "Clinical and laboratory monitoring is advised whenever a CYP450 3A4 inhibitor is added to or withdrawn from therapy with lurbinectedin.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97109/", "reference_text": "[1] \"Product Information. Zepzelca (lurbinectedin).\" Jazz Pharmaceuticals, Palo Alto, CA.[2] \"Product Information. Accolate (zafirlukast).\" Zeneca Pharmaceuticals, Wilmington, DE.[3] \"Product Information. Zepzelca (lurbinectedin).\" Jazz Pharmaceuticals, Palo Alto, CA.", "alternatives_a": "Nitric Oxide, Doxapram, Elexacaftor", "alternatives_b": "Pertuzumab, Oxaliplatin, Bortezomib, Tisagenlecleucel, Aminolevulinic acid, Omacetaxine mepesuccinate, Altretamine, Tagraxofusp, Ixazomib, Enasidenib, Porfimer sodium, More", "updated_at": 1767369485}, {"id": 97006, "ingredient1": "Ivacaftor", "ingredient2": "Lusutrombopag", "severity": "Moderate", "effect": "Coadministration with ivacaftor may increase the plasma concentrations of drugs that are substrates of the CYP450 3A4 isoenzyme and/or P-glycoprotein (P-gp) efflux transporter. The mechanism is decreased clearance via these pathways due to inhibition by ivacaftor and its pharmacologically active M1 metabolite.", "source": "DDInter", "management_text": "Caution is advised when ivacaftor is used with drugs that are substrates of CYP450 3A4 and/or P-gp, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever ivacaftor is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when ivacaftor is used with drugs that are substrates of CYP450 3A4 and/or P-gp, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97110/", "reference_text": "[1] \"Product Information. Kalydeco (ivacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[2] Richter WO, Jacob BG, Schwandt P \"Interaction between fibre and lovastatin.\" Lancet 338 (1991): 706[3] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors.\" Clin Pharmacol Ther 64 (1998): 477-83[4] Kantola T, Kivisto KT, Neuvonen PJ \"Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid.\" Clin Pharmacol Ther 63 (1998): 397-402[5] \"Product Information. Mevacor (lovastatin).\" Merck & Co, Inc, West Point, PA.[6] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions.\" Br J Clin Pharmacol 46 (1998): 101-10[7] Neuvonen PJ, Backman JT, Niemi M \"Pharmacokinetic comparison of the potential over-the-counter statins simvastatin, lovastatin, fluvastatin and pravastatin.\" Clin Pharmacokinet 47 (2008): 463-74[8] Thompson PD, Clarkson P, Karas RH \"Statin-associated myopathy.\" JAMA 289 (2003): 1681-90[9] \"Product Information. Zocor (simvastatin).\" Merck & Co, Inc, West Point, PA.[10] \"Product Information. Trikafta (elexacaftor/ivacaftor/tezacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[11] \"Product Information. Kalydeco (ivacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[12] \"Product Information. Orkambi (ivacaftor-lumacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[13] \"Product Information. Symdeko 4-Week (ivacaftor-tezacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.", "alternatives_a": "Nitric Oxide, Doxapram, Elexacaftor", "alternatives_b": "Eltrombopag, Romiplostim, Avatrombopag, Emicizumab, Coagulation factor VIIa Recombinant Human, Coagulation factor X human, Phylloquinone, Anti-inhibitor coagulant complex, Antihemophilic factor, human recombinant, Fibrinogen human, Epinephrine, Coagulation Factor IX Human", "updated_at": 1767369485}, {"id": 97007, "ingredient1": "Ivacaftor", "ingredient2": "Macitentan", "severity": "Moderate", "effect": "Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of macitentan, which is primarily metabolized by the isoenzyme.", "source": "DDInter", "management_text": "Caution is advisable if macitentan is used with inhibitors of CYP450 3A4. The product labeling recommends avoiding concomitant use with potent inhibitors (e.g., protease inhibitors, clarithromycin, cobicistat, conivaptan, delavirdine, itraconazole, ketoconazole, nefazodone, posaconazole, voriconazole), but no suggestions are given regarding use with less potent inhibitors. It may be reasonable to monitor therapeutic response to macitentan more closely.", "mechanism_text": "Metabolism", "recommendation": "Caution is advisable if macitentan is used with inhibitors of CYP450 3A4.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97111/", "reference_text": "[1] \"Product Information. Opsumit (macitentan).\" Actelion Pharmaceuticals US Inc, South San Francisco, CA.", "alternatives_a": "Nitric Oxide, Doxapram, Elexacaftor", "alternatives_b": "Metyrosine", "updated_at": 1767369485}, {"id": 97008, "ingredient1": "Ivacaftor", "ingredient2": "Maraviroc", "severity": "Moderate", "effect": "Coadministration with inhibitors of the CYP450 3A4 isoenzyme and/or P-glycoprotein efflux transporter may increase the plasma concentrations of maraviroc, which is a substrate of both.", "source": "DDInter", "management_text": "Caution is advised when maraviroc is used with inhibitors of CYP450 3A4 and/or P-glycoprotein. Dosage adjustment for maraviroc may be necessary if an interaction is suspected.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when maraviroc is used with inhibitors of CYP450 3A4 and/or P-glycoprotein.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97112/", "reference_text": "[1] \"Product Information. Selzentry (maraviroc).\" Pfizer U.S. Pharmaceuticals Group, New York, NY.[2] \"Product Information. Selzentry (maraviroc).\" Pfizer U.S. Pharmaceuticals Group, New York, NY.", "alternatives_a": "Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Simeprevir, Cabotegravir, Valaciclovir, Zanamivir, Velpatasvir, Oseltamivir, Acyclovir, More", "alternatives_b": "Nitric Oxide, Doxapram, Elexacaftor", "updated_at": 1767369485}, {"id": 97009, "ingredient1": "Ivacaftor", "ingredient2": "Medroxyprogesterone acetate", "severity": "Moderate", "effect": "Coadministration with ivacaftor may increase the plasma concentrations of drugs that are substrates of the CYP450 3A4 isoenzyme and/or P-glycoprotein (P-gp) efflux transporter. The mechanism is decreased clearance via these pathways due to inhibition by ivacaftor and its pharmacologically active M1 metabolite.", "source": "DDInter", "management_text": "Caution is advised when ivacaftor is used with drugs that are substrates of CYP450 3A4 and/or P-gp, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever ivacaftor is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when ivacaftor is used with drugs that are substrates of CYP450 3A4 and/or P-gp, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97113/", "reference_text": "[1] \"Product Information. Kalydeco (ivacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[2] Richter WO, Jacob BG, Schwandt P \"Interaction between fibre and lovastatin.\" Lancet 338 (1991): 706[3] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors.\" Clin Pharmacol Ther 64 (1998): 477-83[4] Kantola T, Kivisto KT, Neuvonen PJ \"Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid.\" Clin Pharmacol Ther 63 (1998): 397-402[5] \"Product Information. Mevacor (lovastatin).\" Merck & Co, Inc, West Point, PA.[6] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions.\" Br J Clin Pharmacol 46 (1998): 101-10[7] Neuvonen PJ, Backman JT, Niemi M \"Pharmacokinetic comparison of the potential over-the-counter statins simvastatin, lovastatin, fluvastatin and pravastatin.\" Clin Pharmacokinet 47 (2008): 463-74[8] Thompson PD, Clarkson P, Karas RH \"Statin-associated myopathy.\" JAMA 289 (2003): 1681-90[9] \"Product Information. Zocor (simvastatin).\" Merck & Co, Inc, West Point, PA.[10] \"Product Information. Trikafta (elexacaftor/ivacaftor/tezacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[11] \"Product Information. Kalydeco (ivacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[12] \"Product Information. Orkambi (ivacaftor-lumacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[13] \"Product Information. Symdeko 4-Week (ivacaftor-tezacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.", "alternatives_a": "Ulipristal, Norethisterone, Norelgestromin, Norgestimate, Etynodiol, Dienogest, Estetrol, Norgestrel, Dienogest, Norethisterone, Progesterone, More", "alternatives_b": "Nitric Oxide, Doxapram", "updated_at": 1767369485}, {"id": 97010, "ingredient1": "Ivacaftor", "ingredient2": "Mefenamic acid", "severity": "Moderate", "effect": "Coadministration with ivacaftor may increase the plasma concentrations of drugs that are substrates of the CYP450 2C9 isoenzyme. The proposed mechanism, based on in vitro data, involves decreased metabolic clearance due to inhibition of CYP450 2C9 by ivacaftor.", "source": "DDInter", "management_text": "Caution is advised when ivacaftor is used concurrently with drugs that are known CYP450 2C9 substrates, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever ivacaftor is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when ivacaftor is used concurrently with drugs that are known CYP450 2C9 substrates, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97114/", "reference_text": "[1] \"Product Information. Trikafta (elexacaftor/ivacaftor/tezacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[2] \"Product Information. Symdeko 4-Week (ivacaftor-tezacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[3] \"Product Information. Orkambi (ivacaftor-lumacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[4] \"Product Information. Kalydeco (ivacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[5] \"Product Information. Ambien (zolpidem).\" sanofi-aventis, Bridgewater, NJ.[6] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84[7] \"Product Information. Trikafta (elexacaftor/ivacaftor/tezacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[8] \"Product Information. Kalydeco (ivacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[9] \"Product Information. Orkambi (ivacaftor-lumacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[10] \"Product Information. Symdeko 4-Week (ivacaftor-tezacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.", "alternatives_a": "Fenoprofen, Rabeprazole, Meclofenamic acid, Ketorolac, Misoprostol, Ketoprofen, Glucosamine, Oxaprozin, Chondroitin sulfate, Nabumetone, Rofecoxib, More", "alternatives_b": "Nitric Oxide, Doxapram, Elexacaftor", "updated_at": 1767369485}, {"id": 97011, "ingredient1": "Ivacaftor", "ingredient2": "Mefloquine", "severity": "Moderate", "effect": "Coadministration with ivacaftor may increase the plasma concentrations of drugs that are substrates of the CYP450 3A4 isoenzyme and/or P-glycoprotein (P-gp) efflux transporter. The mechanism is decreased clearance via these pathways due to inhibition by ivacaftor and its pharmacologically active M1 metabolite.", "source": "DDInter", "management_text": "Caution is advised when ivacaftor is used with drugs that are substrates of CYP450 3A4 and/or P-gp, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever ivacaftor is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when ivacaftor is used with drugs that are substrates of CYP450 3A4 and/or P-gp, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97115/", "reference_text": "[1] \"Product Information. Kalydeco (ivacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[2] Richter WO, Jacob BG, Schwandt P \"Interaction between fibre and lovastatin.\" Lancet 338 (1991): 706[3] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors.\" Clin Pharmacol Ther 64 (1998): 477-83[4] Kantola T, Kivisto KT, Neuvonen PJ \"Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid.\" Clin Pharmacol Ther 63 (1998): 397-402[5] \"Product Information. Mevacor (lovastatin).\" Merck & Co, Inc, West Point, PA.[6] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions.\" Br J Clin Pharmacol 46 (1998): 101-10[7] Neuvonen PJ, Backman JT, Niemi M \"Pharmacokinetic comparison of the potential over-the-counter statins simvastatin, lovastatin, fluvastatin and pravastatin.\" Clin Pharmacokinet 47 (2008): 463-74[8] Thompson PD, Clarkson P, Karas RH \"Statin-associated myopathy.\" JAMA 289 (2003): 1681-90[9] \"Product Information. Zocor (simvastatin).\" Merck & Co, Inc, West Point, PA.[10] \"Product Information. Trikafta (elexacaftor/ivacaftor/tezacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[11] \"Product Information. Kalydeco (ivacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[12] \"Product Information. Orkambi (ivacaftor-lumacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[13] \"Product Information. Symdeko 4-Week (ivacaftor-tezacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.", "alternatives_a": "Lumefantrine, Pyrimethamine, Tafenoquine, Atovaquone, Hydroxychloroquine, Quinine, Primaquine, Proguanil, Sulfadoxine, Chloroquine", "alternatives_b": "Nitric Oxide, Doxapram, Elexacaftor, Lumacaftor", "updated_at": 1767369485}, {"id": 97012, "ingredient1": "Ivacaftor", "ingredient2": "Megestrol acetate", "severity": "Moderate", "effect": "Coadministration with ivacaftor may increase the plasma concentrations of drugs that are substrates of the CYP450 3A4 isoenzyme and/or P-glycoprotein (P-gp) efflux transporter. The mechanism is decreased clearance via these pathways due to inhibition by ivacaftor and its pharmacologically active M1 metabolite.", "source": "DDInter", "management_text": "Caution is advised when ivacaftor is used with drugs that are substrates of CYP450 3A4 and/or P-gp, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever ivacaftor is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when ivacaftor is used with drugs that are substrates of CYP450 3A4 and/or P-gp, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97116/", "reference_text": "[1] \"Product Information. Kalydeco (ivacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[2] Richter WO, Jacob BG, Schwandt P \"Interaction between fibre and lovastatin.\" Lancet 338 (1991): 706[3] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors.\" Clin Pharmacol Ther 64 (1998): 477-83[4] Kantola T, Kivisto KT, Neuvonen PJ \"Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid.\" Clin Pharmacol Ther 63 (1998): 397-402[5] \"Product Information. Mevacor (lovastatin).\" Merck & Co, Inc, West Point, PA.[6] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions.\" Br J Clin Pharmacol 46 (1998): 101-10[7] Neuvonen PJ, Backman JT, Niemi M \"Pharmacokinetic comparison of the potential over-the-counter statins simvastatin, lovastatin, fluvastatin and pravastatin.\" Clin Pharmacokinet 47 (2008): 463-74[8] Thompson PD, Clarkson P, Karas RH \"Statin-associated myopathy.\" JAMA 289 (2003): 1681-90[9] \"Product Information. Zocor (simvastatin).\" Merck & Co, Inc, West Point, PA.[10] \"Product Information. Trikafta (elexacaftor/ivacaftor/tezacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[11] \"Product Information. Kalydeco (ivacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[12] \"Product Information. Orkambi (ivacaftor-lumacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[13] \"Product Information. Symdeko 4-Week (ivacaftor-tezacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.", "alternatives_a": "Norethisterone, Progesterone, Norgestimate, Etynodiol, Dienogest, Norgestrel, Dienogest, Norethisterone, Progesterone, Etynodiol, Ulipristal, More", "alternatives_b": "Nitric Oxide, Doxapram, Elexacaftor", "updated_at": 1767369485}, {"id": 97013, "ingredient1": "Ivacaftor", "ingredient2": "Meloxicam", "severity": "Moderate", "effect": "Coadministration with ivacaftor may increase the plasma concentrations of drugs that are substrates of the CYP450 2C9 isoenzyme. The proposed mechanism, based on in vitro data, involves decreased metabolic clearance due to inhibition of CYP450 2C9 by ivacaftor.", "source": "DDInter", "management_text": "Caution is advised when ivacaftor is used concurrently with drugs that are known CYP450 2C9 substrates, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever ivacaftor is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when ivacaftor is used concurrently with drugs that are known CYP450 2C9 substrates, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97117/", "reference_text": "[1] \"Product Information. Trikafta (elexacaftor/ivacaftor/tezacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[2] \"Product Information. Symdeko 4-Week (ivacaftor-tezacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[3] \"Product Information. Orkambi (ivacaftor-lumacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[4] \"Product Information. Kalydeco (ivacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[5] \"Product Information. Ambien (zolpidem).\" sanofi-aventis, Bridgewater, NJ.[6] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84[7] \"Product Information. Trikafta (elexacaftor/ivacaftor/tezacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[8] \"Product Information. Kalydeco (ivacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[9] \"Product Information. Orkambi (ivacaftor-lumacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[10] \"Product Information. Symdeko 4-Week (ivacaftor-tezacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.", "alternatives_a": "Ropivacaine, Chloroprocaine, Levobupivacaine, Tetracaine, Bupivacaine, Mepivacaine, Procaine, Prilocaine, Articaine, Etidocaine, Fenoprofen, More", "alternatives_b": "Nitric Oxide, Doxapram, Elexacaftor", "updated_at": 1767369485}, {"id": 97014, "ingredient1": "Ivacaftor", "ingredient2": "Methylphenobarbital", "severity": "Moderate", "effect": "Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of ivacaftor, which is primarily metabolized by the isoenzyme.", "source": "DDInter", "management_text": "The potential for diminished pharmacologic effects of ivacaftor-containing medications should be considered during coadministration with CYP450 3A4 inducers. Alternative treatments may be required if an interaction is suspected.", "mechanism_text": "Metabolism", "recommendation": "The potential for diminished pharmacologic effects of ivacaftor-containing medications should be considered during coadministration with CYP450 3A4 inducers.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97118/", "reference_text": "[1] \"Product Information. Symdeko 4-Week (ivacaftor-tezacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[2] \"Product Information. Orkambi (ivacaftor-lumacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[3] \"Product Information. Trikafta (elexacaftor/ivacaftor/tezacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[4] \"Product Information. Kalydeco (ivacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[5] \"Product Information. Trikafta (elexacaftor/ivacaftor/tezacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[6] \"Product Information. Kalydeco (ivacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[7] \"Product Information. Orkambi (ivacaftor-lumacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[8] \"Product Information. Symdeko 4-Week (ivacaftor-tezacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.", "alternatives_a": "Brivaracetam, Topiramate, Ezogabine, Lamotrigine, Lacosamide, Levetiracetam, Tiagabine, Ethotoin, Paramethadione, Perampanel, Vigabatrin, More", "alternatives_b": "Nitric Oxide, Doxapram, Elexacaftor, Lumacaftor", "updated_at": 1767369485}, {"id": 97015, "ingredient1": "Ivacaftor", "ingredient2": "Methotrexate", "severity": "Moderate", "effect": "Coadministration of methotrexate with other agents known to induce hepatotoxicity may potentiate the risk of liver injury. Methotrexate, especially at higher doses or with prolonged treatment, has been associated with hepatotoxicity including acute hepatitis, chronic fibrosis, necrosis, cirrhosis, and liver enzyme elevations.", "source": "DDInter", "management_text": "The risk of hepatic injury should be considered when methotrexate is used with other potentially hepatotoxic agents (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; nucleoside reverse transcriptase inhibitors; proteasome inhibitors; retinoids; sulfonamides; tamoxifen; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice). Baseline and periodic monitoring of hepatic function is recommended, while liver biopsy may be warranted during long-term use of methotrexate. Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, right upper quadrant pain, dark urine, pale stools, and jaundice.", "mechanism_text": "Synergism", "recommendation": "The risk of hepatic injury should be considered when methotrexate is used with other potentially hepatotoxic agents (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97119/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Methotrexate (methotrexate).\" Lederle Laboratories, Wayne, NJ.[3] Nesher G, Mates M, Zevin S \"Effect of caffeine consumption on efficacy of methotrexate in rheumatoid arthritis.\" Arthritis Rheum 48 (2003): 571-572", "alternatives_a": "Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Abatacept, More", "alternatives_b": "Nitric Oxide, Doxapram, Lumacaftor", "updated_at": 1767369485}, {"id": 97016, "ingredient1": "Ivacaftor", "ingredient2": "Methylergometrine", "severity": "Moderate", "effect": "Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of ergot derivatives, which are primarily metabolized by the isoenzyme. The interaction has occurred in patients receiving ergotamine or dihydroergotamine with potent CYP450 3A4 inhibitors such as macrolide antibiotics and protease inhibitors.", "source": "DDInter", "management_text": "Caution is advised during concomitant use of ergot derivatives with mild or moderate CYP450 3A4 inhibitors. Patients should be monitored for potential ergot toxicity including peripheral vasospasm, ischemia, thrombosis, tachycardia, and hypertension.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised during concomitant use of ergot derivatives with mild or moderate CYP450 3A4 inhibitors.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97120/", "reference_text": "[1] Francis H, Tyndall A, Webb J \"Severe vascular spasm due to erythromycin-ergotamine interaction.\" Clin Rheumatol 3 (1984): 243-6[2] Horowitz RS, Dart RC, Gomez HF \"Clinical ergotism with lingual ischemia induced by clarithromycin-ergotamine interaction.\" Arch Intern Med 156 (1996): 456-8[3] Spiegel M, Schmidauer C, Kampfl A, Sarcletti M, Poewe W \"Cerebral ergotism under treatment with ergotamine and ritonavir.\" Neurology 57 (2001): 743-4[4] Mortier E, Pouchet J, Vinceneux P, Lalande M \"Ergotism related to interaction between nelfinavir and ergotamine.\" Am J Med 110 (2001): 594[5] Vila A, Mykietiuk A, Bonvehi P, Temporiti E, Uruena A, Herrera F \"Clinical ergotism induced by ritonavir.\" Scand J Infect Dis 33 (2001): 788-9[6] Rosenthal E, Sala F, Chichmanian RM, Batt M, Cassuto JP \"Ergotism related to concurrent administration of ergotamine tartrate and indinavir.\" JAMA 281 (1999): 987[7] Hayton AC \"Precipitation of acute ergotism by triacetyloleandomycin.\" N Z Med J 69 (1969): 42[8] Liaudet L \"Severe ergotism associated with interaction between ritonavir and ergotamine.\" BMJ 318 (1999): 771[9] Matthews NT, Havill JH \"Ergotism with therapeutic doses of ergotamine tartrate.\" N Z Med J 89 (1979): 476-7[10] Ausband SC, Goodman PE \"An unusual case of clarithromycin associated ergotism.\" J Emerg Med 4 (2001): 411-3[11] Baldwin ZK, Ceraldi CC \"Ergotism associated with HIV antiviral protease inhibitor therapy.\" J Vasc Surg 37 (2003): 676-8[12] \"Product Information. D.H.E. 45 (dihydroergotamine).\" Sandoz Pharmaceuticals Corporation, East Hanover, NJ.[13] Eadie MJ \"Clinically significant drug interactions with agents specific for migraine attacks.\" Cns Drugs 15 (2001): 105-18[14] Dresser GK, Spence JD, Bailey DG \"Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition.\" Clin Pharmacokinet 38 (2000): 41-57[15] Tribble MA, Gregg CR, Margolis DM, Amirkhan R, Smith JW \"Fatal ergotism induced by an HIV protease inhibitor.\" Headache 42 (2002): 694-5[16] Bird PA, Sturgess AD \"Clinical ergotism with severe bilateral upper limb ischaemia precipitated by an erythromycin - ergotamine drug interaction.\" Aust N Z J Med 30 (2000): 635-6[17] Liaudet L, Buclin T, Jaccard C, Eckert P \"Severe ergotism associated with interaction between ritonavir and ergotamine.\" Br Med J 318 (1999): 771[18] Caballero-Granado FJ, Viciana P, Cordero E, Gomez-Vera MJ, del Nozal M, Lopez-Cortes LF \"Ergotism related to concurrent administration of ergotamine tartrate and ritonavir in an AIDS patient.\" Antimicrob Agents Chemother 41 (1997): 1207[19] Montero A, Giovannoni AG, Tvrde PL \"Leg ischemia in a patient receiving ritonavir and ergotamine.\" Ann Intern Med 130 (1999): 329[20] Srisuma S, Lavonas EJ, Wananukul W \"Ergotism and factitious hypotension associated with interaction of ergotamine with CYP3A4 inhibitors.\" Clin Toxicol (Phila) (2014): 1-4[21] Blanche P, Rigolet A, Gombert B, Ginsburg C, Salmon D, Sicard D \"Ergotism related to a single dose of ergotamine tartrate in an AIDS patient treated with ritonavir.\" Postgrad Med J 75 (1999): 546-7[22] Ghali R, De Lean J, Douville Y, Noel HP, Labbe R \"Erythromycin-associated ergotamine intoxication: arteriographic and electrophysiologic analysis of a rare cause of severe ischemia of the lower extremities and associated ischemic neuropathy.\" Ann Vasc Surg 7 (1993): 291-6[23] \"Product Information. Migranal (dihydroergotamine nasal).\" Novartis Pharmaceuticals, East Hanover, NJ.[24] Leroy F, Asseman P, Pruvost P, Adnet P, Lacroix D, Thery C \"Dihydroergotamine-erythromycin-induced ergotism.\" Ann Intern Med 109 (1988): 249[25] \"Product Information. Cafergot (caffeine-ergotamine).\" Novartis Pharmaceuticals, East Hanover, NJ.[26] Gunston GD, Mehta U \"Potentially serious drug interactions with grapefruit juice.\" S Afr Med J 90 (2000): 41[27] Bailey DG, Arnold JMO, Spence JD \"Grapefruit juice and drugs - how significant is the interaction.\" Clin Pharmacokinet 26 (1994): 91-8[28] Fuhr U, Maier-Bruggemann A, Blume H, et al. \"Grapefruit juice increases oral nimodipine bioavailability.\" Int J Clin Pharmacol Ther 36 (1998): 126-32[29] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[30] Libersa CC, Brique SA, Motte KB, et al. \"Dramatic inhibition of amiodarone metabolism induced by grapefruit juice.\" Br J Clin Pharmacol 49 (2000): 373-8[31] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions.\" Br J Clin Pharmacol 46 (1998): 101-10[32] Bailey DG, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit juice felodipine interaction: Effect of naringin and 6',7'-dihydroxybergamottin in humans.\" Clin Pharmacol Ther 64 (1998): 248-56[33] Takanaga H, Ohnishi A, Maatsuo H, et al. \"Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model.\" Br J Clin Pharmacol 49 (2000): 49-58[34] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[35] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS \"Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice.\" Br J Clin Pharmacol 42 (1996): p662[36] Eagling VA, Profit L, Back DJ \"Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-I protease inhibitor saquinavir by grapefruit juice components.\" Br J Clin Pharmacol 48 (1999): 543-52[37] Bailey DG, Arnold JM, Strong HA, Munoz C, Spence JD \"Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics.\" Clin Pharmacol Ther 54 (1993): 589-94[38] Damkier P, Hansen LL, Brosen K \"Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine.\" Br J Clin Pharmacol 48 (1999): 829-38[39] Min DI, Ku YM, Geraets DR, Lee HC \"Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers.\" J Clin Pharmacol 36 (1996): 469-76[40] Josefsson M, Zackrisson AL, Ahlner J \"Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers.\" Eur J Clin Pharmacol 51 (1996): 189-93[41] Majeed A, Kareem A \"Effect of grapefruit juice on cyclosporine pharmacokinetics.\" Pediatr Nephrol 10 (1996): 395[42] Flanagan D \"Understanding the grapefruit-drug interaction.\" Gen Dent 53 (2005): 282-5; quiz 286[43] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ \"Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice.\" Clin Pharmacol Ther 58 (1995): 127-31[44] Jonkman JH, Sollie FA, Sauter R, Steinijans VW \"The influence of caffeine on the steady-state pharmacokinetics of theophylline.\" Clin Pharmacol Ther 49 (1991): 248-55[45] Ozdemir M, Aktan Y, Boydag BS, Cingi MI, Musmul A \"Interaction between grapefruit juice and diazepam in humans.\" Eur J Drug Metab Pharmacokinet 23 (1998): 55-9[46] Edgar B, Bailey D, Bergstrand R, et al \"Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics on felodipine and its potential clinical relevance.\" Eur J Clin Pharmacol 42 (1992): 313-7[47] Kantola T, Kivisto KT, Neuvonen PJ \"Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid.\" Clin Pharmacol Ther 63 (1998): 397-402[48] Lee AJ, Chan WK, Harralson AF, Buffum J, Bui BCC \"The effects of grapefruit juice on sertraline metabolism: An in vitro and in vivo study.\" Clin Ther 21 (1999): 1890-9[49] Sato J, Nakata H, Owada E, Kikuta T, Umetsu M, Ito K \"Influence of usual intake of dietary caffeine on single-dose kinetics of theophylline in healthy human subjects.\" Eur J Clin Pharmacol 44 (1993): 295-8[50] Dresser GK, Spence JD, Bailey DG \"Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition.\" Clin Pharmacokinet 38 (2000): 41-57[51] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin.\" Clin Pharmacol Ther 66 (1999): 118-27[52] Sigusch H, Hippius M, Henschel L, Kaufmann K, Hoffmann A \"Influence of grapefruit juice on the pharmacokinetics of a slow release nifedipine formulation.\" Pharmazie 49 (1994): 522-4[53] Bailey DG, Arnold JM, Munoz C, Spence JD \"Grapefruit juice--felodipine interaction: mechanism, predictability, and effect of naringin.\" Clin Pharmacol Ther 53 (1993): 637-42[54] Zaidenstein R, Soback S, Gips M, Avni B, Dishi V, Weissgarten Y, Golik A, Scapa E \"Effect of grapefruit juice on the pharmacokinetics of losartan and its active metabolite E3174 in healthy volunteers.\" Ther Drug Monit 23 (2001): 369-73[55] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84[56] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors.\" Clin Pharmacol Ther 64 (1998): 477-83[57] Garg SK, Kumar N, Bhargava VK, Prabhakar SK \"Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy.\" Clin Pharmacol Ther 64 (1998): 286-8", "alternatives_a": "Misoprostol, Dinoprostone, Oxytocin", "alternatives_b": "Nitric Oxide, Doxapram, Elexacaftor", "updated_at": 1767369485}, {"id": 97017, "ingredient1": "Ivacaftor", "ingredient2": "Methylprednisolone", "severity": "Moderate", "effect": "Coadministration with ivacaftor may increase the plasma concentrations of drugs that are substrates of the CYP450 3A4 isoenzyme and/or P-glycoprotein (P-gp) efflux transporter. The mechanism is decreased clearance via these pathways due to inhibition by ivacaftor and its pharmacologically active M1 metabolite.", "source": "DDInter", "management_text": "Caution is advised when ivacaftor is used with drugs that are substrates of CYP450 3A4 and/or P-gp, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever ivacaftor is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when ivacaftor is used with drugs that are substrates of CYP450 3A4 and/or P-gp, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97121/", "reference_text": "[1] \"Product Information. Kalydeco (ivacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[2] Richter WO, Jacob BG, Schwandt P \"Interaction between fibre and lovastatin.\" Lancet 338 (1991): 706[3] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors.\" Clin Pharmacol Ther 64 (1998): 477-83[4] Kantola T, Kivisto KT, Neuvonen PJ \"Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid.\" Clin Pharmacol Ther 63 (1998): 397-402[5] \"Product Information. Mevacor (lovastatin).\" Merck & Co, Inc, West Point, PA.[6] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions.\" Br J Clin Pharmacol 46 (1998): 101-10[7] Neuvonen PJ, Backman JT, Niemi M \"Pharmacokinetic comparison of the potential over-the-counter statins simvastatin, lovastatin, fluvastatin and pravastatin.\" Clin Pharmacokinet 47 (2008): 463-74[8] Thompson PD, Clarkson P, Karas RH \"Statin-associated myopathy.\" JAMA 289 (2003): 1681-90[9] \"Product Information. Zocor (simvastatin).\" Merck & Co, Inc, West Point, PA.[10] \"Product Information. Trikafta (elexacaftor/ivacaftor/tezacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[11] \"Product Information. Kalydeco (ivacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[12] \"Product Information. Orkambi (ivacaftor-lumacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[13] \"Product Information. Symdeko 4-Week (ivacaftor-tezacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.", "alternatives_a": "Minocycline, Clindamycin, Vitamin A, Fluorometholone, Tretinoin, Azelaic acid, Adapalene, Deflazacort, Fluocinolone acetonide, Fluocinonide, Fluorometholone, More", "alternatives_b": "Nitric Oxide, Doxapram, Elexacaftor", "updated_at": 1767369485}, {"id": 97018, "ingredient1": "Ivacaftor", "ingredient2": "Methysergide", "severity": "Moderate", "effect": "Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of ergot derivatives, which are primarily metabolized by the isoenzyme. The interaction has occurred in patients receiving ergotamine or dihydroergotamine with potent CYP450 3A4 inhibitors such as macrolide antibiotics and protease inhibitors.", "source": "DDInter", "management_text": "Caution is advised during concomitant use of ergot derivatives with mild or moderate CYP450 3A4 inhibitors. Patients should be monitored for potential ergot toxicity including peripheral vasospasm, ischemia, thrombosis, tachycardia, and hypertension.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised during concomitant use of ergot derivatives with mild or moderate CYP450 3A4 inhibitors.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97122/", "reference_text": "[1] Francis H, Tyndall A, Webb J \"Severe vascular spasm due to erythromycin-ergotamine interaction.\" Clin Rheumatol 3 (1984): 243-6[2] Horowitz RS, Dart RC, Gomez HF \"Clinical ergotism with lingual ischemia induced by clarithromycin-ergotamine interaction.\" Arch Intern Med 156 (1996): 456-8[3] Spiegel M, Schmidauer C, Kampfl A, Sarcletti M, Poewe W \"Cerebral ergotism under treatment with ergotamine and ritonavir.\" Neurology 57 (2001): 743-4[4] Mortier E, Pouchet J, Vinceneux P, Lalande M \"Ergotism related to interaction between nelfinavir and ergotamine.\" Am J Med 110 (2001): 594[5] Vila A, Mykietiuk A, Bonvehi P, Temporiti E, Uruena A, Herrera F \"Clinical ergotism induced by ritonavir.\" Scand J Infect Dis 33 (2001): 788-9[6] Rosenthal E, Sala F, Chichmanian RM, Batt M, Cassuto JP \"Ergotism related to concurrent administration of ergotamine tartrate and indinavir.\" JAMA 281 (1999): 987[7] Hayton AC \"Precipitation of acute ergotism by triacetyloleandomycin.\" N Z Med J 69 (1969): 42[8] Liaudet L \"Severe ergotism associated with interaction between ritonavir and ergotamine.\" BMJ 318 (1999): 771[9] Matthews NT, Havill JH \"Ergotism with therapeutic doses of ergotamine tartrate.\" N Z Med J 89 (1979): 476-7[10] Ausband SC, Goodman PE \"An unusual case of clarithromycin associated ergotism.\" J Emerg Med 4 (2001): 411-3[11] Baldwin ZK, Ceraldi CC \"Ergotism associated with HIV antiviral protease inhibitor therapy.\" J Vasc Surg 37 (2003): 676-8[12] \"Product Information. D.H.E. 45 (dihydroergotamine).\" Sandoz Pharmaceuticals Corporation, East Hanover, NJ.[13] Eadie MJ \"Clinically significant drug interactions with agents specific for migraine attacks.\" Cns Drugs 15 (2001): 105-18[14] Dresser GK, Spence JD, Bailey DG \"Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition.\" Clin Pharmacokinet 38 (2000): 41-57[15] Tribble MA, Gregg CR, Margolis DM, Amirkhan R, Smith JW \"Fatal ergotism induced by an HIV protease inhibitor.\" Headache 42 (2002): 694-5[16] Bird PA, Sturgess AD \"Clinical ergotism with severe bilateral upper limb ischaemia precipitated by an erythromycin - ergotamine drug interaction.\" Aust N Z J Med 30 (2000): 635-6[17] Liaudet L, Buclin T, Jaccard C, Eckert P \"Severe ergotism associated with interaction between ritonavir and ergotamine.\" Br Med J 318 (1999): 771[18] Caballero-Granado FJ, Viciana P, Cordero E, Gomez-Vera MJ, del Nozal M, Lopez-Cortes LF \"Ergotism related to concurrent administration of ergotamine tartrate and ritonavir in an AIDS patient.\" Antimicrob Agents Chemother 41 (1997): 1207[19] Montero A, Giovannoni AG, Tvrde PL \"Leg ischemia in a patient receiving ritonavir and ergotamine.\" Ann Intern Med 130 (1999): 329[20] Srisuma S, Lavonas EJ, Wananukul W \"Ergotism and factitious hypotension associated with interaction of ergotamine with CYP3A4 inhibitors.\" Clin Toxicol (Phila) (2014): 1-4[21] Blanche P, Rigolet A, Gombert B, Ginsburg C, Salmon D, Sicard D \"Ergotism related to a single dose of ergotamine tartrate in an AIDS patient treated with ritonavir.\" Postgrad Med J 75 (1999): 546-7[22] Ghali R, De Lean J, Douville Y, Noel HP, Labbe R \"Erythromycin-associated ergotamine intoxication: arteriographic and electrophysiologic analysis of a rare cause of severe ischemia of the lower extremities and associated ischemic neuropathy.\" Ann Vasc Surg 7 (1993): 291-6[23] \"Product Information. Migranal (dihydroergotamine nasal).\" Novartis Pharmaceuticals, East Hanover, NJ.[24] Leroy F, Asseman P, Pruvost P, Adnet P, Lacroix D, Thery C \"Dihydroergotamine-erythromycin-induced ergotism.\" Ann Intern Med 109 (1988): 249[25] \"Product Information. Cafergot (caffeine-ergotamine).\" Novartis Pharmaceuticals, East Hanover, NJ.[26] Gunston GD, Mehta U \"Potentially serious drug interactions with grapefruit juice.\" S Afr Med J 90 (2000): 41[27] Bailey DG, Arnold JMO, Spence JD \"Grapefruit juice and drugs - how significant is the interaction.\" Clin Pharmacokinet 26 (1994): 91-8[28] Fuhr U, Maier-Bruggemann A, Blume H, et al. \"Grapefruit juice increases oral nimodipine bioavailability.\" Int J Clin Pharmacol Ther 36 (1998): 126-32[29] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[30] Libersa CC, Brique SA, Motte KB, et al. \"Dramatic inhibition of amiodarone metabolism induced by grapefruit juice.\" Br J Clin Pharmacol 49 (2000): 373-8[31] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions.\" Br J Clin Pharmacol 46 (1998): 101-10[32] Bailey DG, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit juice felodipine interaction: Effect of naringin and 6',7'-dihydroxybergamottin in humans.\" Clin Pharmacol Ther 64 (1998): 248-56[33] Takanaga H, Ohnishi A, Maatsuo H, et al. \"Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model.\" Br J Clin Pharmacol 49 (2000): 49-58[34] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[35] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS \"Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice.\" Br J Clin Pharmacol 42 (1996): p662[36] Eagling VA, Profit L, Back DJ \"Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-I protease inhibitor saquinavir by grapefruit juice components.\" Br J Clin Pharmacol 48 (1999): 543-52[37] Bailey DG, Arnold JM, Strong HA, Munoz C, Spence JD \"Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics.\" Clin Pharmacol Ther 54 (1993): 589-94[38] Damkier P, Hansen LL, Brosen K \"Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine.\" Br J Clin Pharmacol 48 (1999): 829-38[39] Min DI, Ku YM, Geraets DR, Lee HC \"Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers.\" J Clin Pharmacol 36 (1996): 469-76[40] Josefsson M, Zackrisson AL, Ahlner J \"Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers.\" Eur J Clin Pharmacol 51 (1996): 189-93[41] Majeed A, Kareem A \"Effect of grapefruit juice on cyclosporine pharmacokinetics.\" Pediatr Nephrol 10 (1996): 395[42] Flanagan D \"Understanding the grapefruit-drug interaction.\" Gen Dent 53 (2005): 282-5; quiz 286[43] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ \"Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice.\" Clin Pharmacol Ther 58 (1995): 127-31[44] Jonkman JH, Sollie FA, Sauter R, Steinijans VW \"The influence of caffeine on the steady-state pharmacokinetics of theophylline.\" Clin Pharmacol Ther 49 (1991): 248-55[45] Ozdemir M, Aktan Y, Boydag BS, Cingi MI, Musmul A \"Interaction between grapefruit juice and diazepam in humans.\" Eur J Drug Metab Pharmacokinet 23 (1998): 55-9[46] Edgar B, Bailey D, Bergstrand R, et al \"Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics on felodipine and its potential clinical relevance.\" Eur J Clin Pharmacol 42 (1992): 313-7[47] Kantola T, Kivisto KT, Neuvonen PJ \"Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid.\" Clin Pharmacol Ther 63 (1998): 397-402[48] Lee AJ, Chan WK, Harralson AF, Buffum J, Bui BCC \"The effects of grapefruit juice on sertraline metabolism: An in vitro and in vivo study.\" Clin Ther 21 (1999): 1890-9[49] Sato J, Nakata H, Owada E, Kikuta T, Umetsu M, Ito K \"Influence of usual intake of dietary caffeine on single-dose kinetics of theophylline in healthy human subjects.\" Eur J Clin Pharmacol 44 (1993): 295-8[50] Dresser GK, Spence JD, Bailey DG \"Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition.\" Clin Pharmacokinet 38 (2000): 41-57[51] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin.\" Clin Pharmacol Ther 66 (1999): 118-27[52] Sigusch H, Hippius M, Henschel L, Kaufmann K, Hoffmann A \"Influence of grapefruit juice on the pharmacokinetics of a slow release nifedipine formulation.\" Pharmazie 49 (1994): 522-4[53] Bailey DG, Arnold JM, Munoz C, Spence JD \"Grapefruit juice--felodipine interaction: mechanism, predictability, and effect of naringin.\" Clin Pharmacol Ther 53 (1993): 637-42[54] Zaidenstein R, Soback S, Gips M, Avni B, Dishi V, Weissgarten Y, Golik A, Scapa E \"Effect of grapefruit juice on the pharmacokinetics of losartan and its active metabolite E3174 in healthy volunteers.\" Ther Drug Monit 23 (2001): 369-73[55] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84[56] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors.\" Clin Pharmacol Ther 64 (1998): 477-83[57] Garg SK, Kumar N, Bhargava VK, Prabhakar SK \"Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy.\" Clin Pharmacol Ther 64 (1998): 286-8", "alternatives_a": "Frovatriptan, Eptinezumab, Lasmiditan, Rizatriptan, Naratriptan, Galcanezumab, Zolmitriptan, Sumatriptan, Erenumab, Clonidine, Almotriptan, Fremanezumab", "alternatives_b": "Nitric Oxide, Doxapram, Elexacaftor", "updated_at": 1767369485}, {"id": 97019, "ingredient1": "Ivacaftor", "ingredient2": "Metreleptin", "severity": "Moderate", "effect": "Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of ivacaftor, which is primarily metabolized by the isoenzyme.", "source": "DDInter", "management_text": "The potential for diminished pharmacologic effects of ivacaftor-containing medications should be considered during coadministration with CYP450 3A4 inducers. Alternative treatments may be required if an interaction is suspected.", "mechanism_text": "Metabolism", "recommendation": "The potential for diminished pharmacologic effects of ivacaftor-containing medications should be considered during coadministration with CYP450 3A4 inducers.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97123/", "reference_text": "[1] \"Product Information. Symdeko 4-Week (ivacaftor-tezacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[2] \"Product Information. Orkambi (ivacaftor-lumacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[3] \"Product Information. Trikafta (elexacaftor/ivacaftor/tezacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[4] \"Product Information. Kalydeco (ivacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[5] \"Product Information. Trikafta (elexacaftor/ivacaftor/tezacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[6] \"Product Information. Kalydeco (ivacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[7] \"Product Information. Orkambi (ivacaftor-lumacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[8] \"Product Information. Symdeko 4-Week (ivacaftor-tezacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.", "alternatives_a": "Nitric Oxide, Doxapram, Elexacaftor, Lumacaftor", "alternatives_b": "Teduglutide, Fosdenopterin, Miglustat, Imiglucerase, Asfotase alfa, Glycerol phenylbutyrate, Pegvaliase, Triethylenetetramine, Sapropterin, Zinc acetate, Phenylbutyric acid, More", "updated_at": 1767369485}, {"id": 97020, "ingredient1": "Ivacaftor", "ingredient2": "Miconazole", "severity": "Moderate", "effect": "Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of ivacaftor, which is primarily metabolized by the isoenzyme. The interaction occurs to a greater extent when ivacaftor is administered as monotherapy than when administered in combination with lumacaftor, a potent CYP450 3A4 inducer.", "source": "DDInter", "management_text": "Caution is advised if ivacaftor is used with CYP450 3A4 inhibitors. A dosage adjustment for ivacaftor may be required if undue adverse effects occur.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if ivacaftor is used with CYP450 3A4 inhibitors.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97124/", "reference_text": "[1] \"Product Information. Kalydeco (ivacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[2] \"Product Information. Orkambi (ivacaftor-lumacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[3] \"Product Information. Accolate (zafirlukast).\" Zeneca Pharmaceuticals, Wilmington, DE.[4] \"Product Information. Trikafta (elexacaftor/ivacaftor/tezacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[5] \"Product Information. Kalydeco (ivacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[6] \"Product Information. Orkambi (ivacaftor-lumacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[7] \"Product Information. Symdeko 4-Week (ivacaftor-tezacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.", "alternatives_a": "Rifamycin, Kanamycin, Amphotericin B, Polymyxin B, Nystatin, Vancomycin, Streptomycin, Rifaximin, Paromomycin, Neomycin, Caspofungin, More", "alternatives_b": "Doxapram, Elexacaftor, Lumacaftor", "updated_at": 1767369485}, {"id": 97021, "ingredient1": "Ivacaftor", "ingredient2": "Midazolam", "severity": "Moderate", "effect": "Coadministration with ivacaftor may increase the plasma concentrations of drugs that are substrates of the CYP450 3A4 isoenzyme and/or P-glycoprotein (P-gp) efflux transporter. The mechanism is decreased clearance via these pathways due to inhibition by ivacaftor and its pharmacologically active M1 metabolite.", "source": "DDInter", "management_text": "Caution is advised when ivacaftor is used with drugs that are substrates of CYP450 3A4 and/or P-gp, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever ivacaftor is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when ivacaftor is used with drugs that are substrates of CYP450 3A4 and/or P-gp, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97125/", "reference_text": "[1] \"Product Information. Kalydeco (ivacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[2] Richter WO, Jacob BG, Schwandt P \"Interaction between fibre and lovastatin.\" Lancet 338 (1991): 706[3] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors.\" Clin Pharmacol Ther 64 (1998): 477-83[4] Kantola T, Kivisto KT, Neuvonen PJ \"Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid.\" Clin Pharmacol Ther 63 (1998): 397-402[5] \"Product Information. Mevacor (lovastatin).\" Merck & Co, Inc, West Point, PA.[6] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions.\" Br J Clin Pharmacol 46 (1998): 101-10[7] Neuvonen PJ, Backman JT, Niemi M \"Pharmacokinetic comparison of the potential over-the-counter statins simvastatin, lovastatin, fluvastatin and pravastatin.\" Clin Pharmacokinet 47 (2008): 463-74[8] Thompson PD, Clarkson P, Karas RH \"Statin-associated myopathy.\" JAMA 289 (2003): 1681-90[9] \"Product Information. Zocor (simvastatin).\" Merck & Co, Inc, West Point, PA.[10] \"Product Information. Trikafta (elexacaftor/ivacaftor/tezacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[11] \"Product Information. Kalydeco (ivacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[12] \"Product Information. Orkambi (ivacaftor-lumacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[13] \"Product Information. Symdeko 4-Week (ivacaftor-tezacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.", "alternatives_a": "Flurazepam, Methohexital, Zaleplon, Dichloralphenazone, Valerian, Temazepam, Chloral hydrate, Quazepam, Paraldehyde, Ramelteon, Ethchlorvynol, More", "alternatives_b": "Nitric Oxide, Doxapram, Elexacaftor", "updated_at": 1767369485}, {"id": 97022, "ingredient1": "Ivacaftor", "ingredient2": "Midostaurin", "severity": "Moderate", "effect": "Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of midostaurin and its active metabolites, which are all substrates of the isoenzyme.", "source": "DDInter", "management_text": "Caution is advised when midostaurin is used with CYP450 3A4 inhibitors. Patients should be closely monitored for increased adverse reactions (e.g., nausea, vomiting, diarrhea, edema, hyperglycemia, hyperuricemia, QT prolongation, neutropenia, lymphopenia, thrombocytopenia, anemia), especially during the first week of consecutive midostaurin administration in patients with advanced systemic mastocytosis and during the first week of midostaurin administration in each cycle of chemotherapy in patients with acute myeloid leukemia.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when midostaurin is used with CYP450 3A4 inhibitors.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97126/", "reference_text": "[1] Dutreix C, Munarini F, Lorenzo S, Roesel J, Wang Y \"Investigation into CYP3A4-mediated drug-drug interactions on midostaurin in healthy volunteers.\" Cancer Chemother Pharmacol 72 (2013): 1223-34[2] \"Product Information. Rydapt (midostaurin).\" Novartis Pharmaceuticals, East Hanover, NJ.[3] \"Product Information. Rydapt (midostaurin).\" Novartis Pharmaceuticals, East Hanover, NJ.[4] \"Product Information. Accolate (zafirlukast).\" Zeneca Pharmaceuticals, Wilmington, DE.", "alternatives_a": "Cabozantinib, Sunitinib, Regorafenib, Copanlisib, Ruxolitinib, Lenvatinib, Abemaciclib, Ponatinib, Neratinib, Vandetanib, Trametinib, More", "alternatives_b": "Nitric Oxide, Doxapram, Elexacaftor", "updated_at": 1767369485}, {"id": 97023, "ingredient1": "Ivacaftor", "ingredient2": "Mifepristone", "severity": "Moderate", "effect": "Based on in vitro inhibition data, coadministration with mifepristone may increase the plasma concentrations of drugs that are substrates of the CYP450 3A4 isoenzyme. The mechanism is decreased clearance due to inhibition of CYP450 3A4 activity by mifepristone.", "source": "DDInter", "management_text": "Caution is advised if mifepristone must be used concomitantly with medications that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever mifepristone is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if mifepristone must be used concomitantly with medications that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97127/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] He K, Woolf TF, Hollenberg PF \"Mechanism-based inactivation of cytochrome P-450-3A4 by mifepristone (RU486).\" J Pharmacol Exp Ther 288 (1999): 791-7[3] \"Product Information. Mifeprex (mifepristone)\" Danco Laboratories, New York, NY.[4] Cerner Multum, Inc. \"Australian Product Information.\" O 0[5] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[6] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[7] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[8] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[9] \"Product Information. Korlym (mifepristone).\" Corcept Therapeutics Incorporated, Menlo Park, CA.[10] \"Product Information. Mifeprex (mifepristone)\" Danco Laboratories, New York, NY.", "alternatives_a": "Ulipristal, Ospemifene, Raloxifene, Bazedoxifene, Prasterone", "alternatives_b": "Nitric Oxide, Doxapram, Elexacaftor, Lumacaftor", "updated_at": 1767369485}, {"id": 97024, "ingredient1": "Ivacaftor", "ingredient2": "Mipomersen", "severity": "Major", "effect": "Coadministration of mipomersen with other agents known to induce hepatotoxicity may potentiate the risk of liver injury. Mipomersen can cause elevations in serum transaminases and hepatic steatosis.", "source": "DDInter", "management_text": "Caution is advised if mipomersen is used with other potentially hepatotoxic agents (e.g., acetaminophen; alcohol; amiodarone; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; kinase inhibitors; methotrexate; nonsteroidal anti-inflammatory agents; nucleoside reverse transcriptase inhibitors; proteasome inhibitors; retinoids; tamoxifen; tetracyclines; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; other lipid-lowering medications such as fenofibrate, lomitapide, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice). Mipomersen has not been studied with other LDL-lowering agents that can also increase hepatic fat, thus concomitant use is not recommended. Patients treated with mipomersen should have serum ALT, AST, alkaline phosphatase, and total bilirubin measured prior to initiation of treatment and regularly during treatment in accordance with the product labeling, and the dosing adjusted or interrupted as necessary. Since alcohol may increase levels of hepatic fat and induce or exacerbate liver injury, the manufacturer recommends that patients taking mipomersen not consume more than one alcoholic drink per day. Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if mipomersen is used with other potentially hepatotoxic agents (e.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97128/", "reference_text": "[1] \"Product Information. Kynamro (mipomersen).\" Genzyme Corporation, Cambridge, MA.[2] \"Product Information. Kynamro (mipomersen).\" Genzyme Corporation, Cambridge, MA.", "alternatives_a": "Gemfibrozil, Fenofibric acid, Pitavastatin, Evinacumab, Evolocumab, Dextrothyroxine, Probucol, Cholestyramine, Ezetimibe, Rosuvastatin, Clofibrate, More", "alternatives_b": "Nitric Oxide, Doxapram, Elexacaftor, Lumacaftor", "updated_at": 1767369485}, {"id": 97025, "ingredient1": "Ivacaftor", "ingredient2": "Mirabegron", "severity": "Minor", "effect": "Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of mirabegron, which has been shown in vitro to be a substrate of the isoenzyme. However, in vivo results indicate that CYP450 3A4 may play a limited role in the overall elimination. No dosage adjustment is recommended when mirabegron is administered in combination with ketoconazole and probably other CYP450 3A4 inhibitors.", "source": "DDInter", "management_text": "-", "mechanism_text": "Metabolism", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97129/", "reference_text": "[1] \"Product Information. Myrbetriq (mirabegron).\" Astellas Pharma US, Inc, Deerfield, IL.[2] \"Product Information. Myrbetriq (mirabegron).\" Astellas Pharma US, Inc, Deerfield, IL.", "alternatives_a": "Nitric Oxide, Doxapram, Elexacaftor", "alternatives_b": "Apomorphine, Pentosan polysulfate, Calcium chloride, Phenazopyridine, Alprostadil, Trospium, Acetohydroxamic acid, Yohimbine, Flavoxate, Avanafil, Papaverine, More", "updated_at": 1767369485}, {"id": 97026, "ingredient1": "Ivacaftor", "ingredient2": "Mitotane", "severity": "Major", "effect": "Coadministration with potent inducers of CYP450 3A4 may significantly decrease the plasma concentrations of ivacaftor, which is primarily metabolized by the isoenzyme.", "source": "DDInter", "management_text": "Concomitant use of ivacaftor-containing medications with potent CYP450 3A4 inducers is not recommended.", "mechanism_text": "Metabolism", "recommendation": "Concomitant use of ivacaftor-containing medications with potent CYP450 3A4 inducers is not recommended.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97130/", "reference_text": "[1] \"Product Information. Orkambi (ivacaftor-lumacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] \"Product Information. Symdeko 4-Week (ivacaftor-tezacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[4] \"Product Information. Trikafta (elexacaftor/ivacaftor/tezacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[5] \"Product Information. Kalydeco (ivacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[6] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[7] Patel S, Robinson R, Burk M \"Hypertensive crisis associated with St. John's Wort.\" Am J Med 112 (2002): 507-8[8] \"Product Information. Trikafta (elexacaftor/ivacaftor/tezacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[9] \"Product Information. Kalydeco (ivacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[10] \"Product Information. Orkambi (ivacaftor-lumacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[11] \"Product Information. Symdeko 4-Week (ivacaftor-tezacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.", "alternatives_a": "Pertuzumab, Oxaliplatin, Bortezomib, Tisagenlecleucel, Aminolevulinic acid, Omacetaxine mepesuccinate, Altretamine, Tagraxofusp, Ixazomib, Enasidenib, Porfimer sodium, More", "alternatives_b": "Nitric Oxide, Doxapram, Elexacaftor, Lumacaftor", "updated_at": 1767369485}, {"id": 97027, "ingredient1": "Ivacaftor", "ingredient2": "Mitoxantrone", "severity": "Moderate", "effect": "Coadministration with inhibitors of P-glycoprotein (P-gp) may increase the plasma concentrations of mitoxantrone, which is a substrate of the efflux transporter also known as ABCB1 or MDR1. The interaction has been studied with cyclosporine, a potent P-gp inhibitor.", "source": "DDInter", "management_text": "Caution is advised if mitoxantrone is prescribed in combination with a P-gp inhibitor. Patients should be closely monitored for increased adverse effects including cardiotoxicity and myelosuppression.", "mechanism_text": "Others", "recommendation": "Caution is advised if mitoxantrone is prescribed in combination with a P-gp inhibitor.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97131/", "reference_text": "[1] \"Product Information. Novantrone (mitoxantrone).\" Immunex Corporation, Seattle, WA.[2] \"Multum Information Services, Inc. Expert Review Panel\"[3] \"Product Information. Novantrone (mitoxantrone).\" Immunex Corporation, Seattle, WA.[4] \"Multum Information Services, Inc. Expert Review Panel\"[5] \"Product Information. Mavyret (glecaprevir-pibrentasvir).\" Abbott Pharmaceutical, Abbott Park, IL.", "alternatives_a": "Valrubicin, Plicamycin, Bleomycin, Mitomycin, Dactinomycin", "alternatives_b": "Nitric Oxide, Doxapram, Elexacaftor, Lumacaftor", "updated_at": 1767369485}, {"id": 97028, "ingredient1": "Ivacaftor", "ingredient2": "Modafinil", "severity": "Minor", "effect": "Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of modafinil (the racemate) and armodafinil (the R-enantiomer), which are both partially metabolized by the isoenzyme. Conversely, the plasma levels of some of these inhibitors may decrease, since many of them are also substrates of CYP450 3A4, and modafinil and armodafinil have been found to be modest inducers of CYP450 3A4. The clinical significance of this potential interaction is unknown. Clinical monitoring for altered effects of modafinil and armodafinil as well as the CYP450 3A4 inhibitor may be appropriate following addition or withdrawal of one or the other drug.", "source": "DDInter", "management_text": "-", "mechanism_text": "Metabolism", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97132/", "reference_text": "[1] Cerner Multum, Inc. \"Australian Product Information.\" O 0[2] \"Product Information. Nuvigil (armodafinil).\" Cephalon Inc, West Chester, PA.[3] \"Product Information. Provigil (modafinil).\" Cephalon, Inc, West Chester, PA.[4] \"Product Information. Provigil (modafinil).\" Cephalon, Inc, West Chester, PA.[5] \"Product Information. Nuvigil (armodafinil).\" Cephalon Inc, West Chester, PA.", "alternatives_a": "Amphetamine, Pemoline, Atomoxetine, Metamfetamine, Lisdexamfetamine, Solriamfetol, Caffeine, Methylphenidate, Dexmethylphenidate, Dextroamphetamine, Citicoline", "alternatives_b": "Nitric Oxide, Doxapram, Elexacaftor", "updated_at": 1767369485}, {"id": 97029, "ingredient1": "Ivacaftor", "ingredient2": "Montelukast", "severity": "Moderate", "effect": "Coadministration with inhibitors of CYP450 2C8 and/or 2C9 may increase the plasma concentrations of montelukast, which is metabolized by these isoenzymes in addition to CYP450 3A4. When montelukast was administered with the potent CYP450 2C8/2C9 inhibitor gemfibrozil, montelukast systemic exposure (AUC) increased by 4.4-fold.", "source": "DDInter", "management_text": "According to the product labeling, no dosage adjustment of montelukast is required when used in combination with gemfibrozil. However, it may be advisable to monitor patients for potentially increased adverse effects during coadministration with gemfibrozil or other CYP450 2C8/2C9 inhibitors.", "mechanism_text": "Metabolism", "recommendation": "According to the product labeling, no dosage adjustment of montelukast is required when used in combination with gemfibrozil.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97133/", "reference_text": "[1] Karonen T, Filppula A, Laitila J, Niemi M, Neuvonen PJ, Backman JT \"Gemfibrozil Markedly Increases the Plasma Concentrations of Montelukast: A Previously Unrecognized Role for CYP2C8 in the Metabolism of Montelukast.\" Clin Pharmacol Ther (2010):[2] \"Product Information. Singulair (montelukast).\" Merck & Co, Inc, West Point, PA.[3] \"Product Information. Accolate (zafirlukast).\" Zeneca Pharmaceuticals, Wilmington, DE.", "alternatives_a": "Theophylline, Omalizumab, Tezepelumab, Mercaptopurine, Aminophylline, Benralizumab, Caffeine, Reslizumab, Dyphylline, Oxtriphylline, Mepolizumab, More", "alternatives_b": "Nitric Oxide, Doxapram, Elexacaftor", "updated_at": 1767369485}, {"id": 97030, "ingredient1": "Ivacaftor", "ingredient2": "Nafcillin", "severity": "Moderate", "effect": "Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of ivacaftor, which is primarily metabolized by the isoenzyme.", "source": "DDInter", "management_text": "The potential for diminished pharmacologic effects of ivacaftor-containing medications should be considered during coadministration with CYP450 3A4 inducers. Alternative treatments may be required if an interaction is suspected.", "mechanism_text": "Metabolism", "recommendation": "The potential for diminished pharmacologic effects of ivacaftor-containing medications should be considered during coadministration with CYP450 3A4 inducers.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97134/", "reference_text": "[1] \"Product Information. Symdeko 4-Week (ivacaftor-tezacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[2] \"Product Information. Orkambi (ivacaftor-lumacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[3] \"Product Information. Trikafta (elexacaftor/ivacaftor/tezacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[4] \"Product Information. Kalydeco (ivacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[5] \"Product Information. Trikafta (elexacaftor/ivacaftor/tezacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[6] \"Product Information. Kalydeco (ivacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[7] \"Product Information. Orkambi (ivacaftor-lumacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[8] \"Product Information. Symdeko 4-Week (ivacaftor-tezacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.", "alternatives_a": "Sulbactam, Oxacillin, Dicloxacillin, Piperacillin, Meticillin, Carbenicillin, Bacampicillin, Ticarcillin, Mezlocillin, Tazobactam, Cloxacillin, More", "alternatives_b": "Nitric Oxide, Doxapram, Elexacaftor, Lumacaftor", "updated_at": 1767369485}, {"id": 97031, "ingredient1": "Ivacaftor", "ingredient2": "Naldemedine", "severity": "Moderate", "effect": "Coadministration with moderate inhibitors of CYP450 3A4 and/or moderate or potent inhibitors of P-glycoprotein (P-gp) may increase the plasma concentrations of naldemedine, which is primarily metabolized by CYP450 3A4 to nor-naldemedine and to a minor extent by UGT1A3 to naldemedine 3-G. Both metabolites have demonstrated antagonistic activity for opioid receptors, but with less potency than the parent drug.", "source": "DDInter", "management_text": "Caution is advised during concomitant use of naldemedine with moderate inhibitors of CYP450 3A4 and/or moderate or potent inhibitors of P-glycoprotein (P-gp). Patients should be closely monitored for potential opioid withdrawal symptoms as well as other adverse effects of naldemedine.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised during concomitant use of naldemedine with moderate inhibitors of CYP450 3A4 and/or moderate or potent inhibitors of P-glycoprotein (P-gp).", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97135/", "reference_text": "[1] \"Product Information. Symproic (naldemedine).\" Shionogi USA Inc, Florham Park, NJ.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Symproic (naldemedine).\" Shionogi USA Inc, Florham Park, NJ.", "alternatives_a": "Nitric Oxide, Doxapram, Elexacaftor", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Bisacodyl, Lactulose, Methylnaltrexone, Lactitol, Sodium phosphate, monobasic, Magnesium oxide, Sodium sulfate, Linaclotide, More", "updated_at": 1767369485}, {"id": 97032, "ingredient1": "Ivacaftor", "ingredient2": "Naloxegol", "severity": "Minor", "effect": "Coadministration with inhibitors of P-glycoprotein (P-gp) and/or weak inhibitors of CYP450 3A4 may increase the plasma concentrations of naloxegol, which is a substrate of both the efflux transporter and the isoenzyme.", "source": "DDInter", "management_text": "-", "mechanism_text": "Metabolism, Absorption", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97136/", "reference_text": "[1] \"Product Information. Movantik (naloxegol).\" Astra-Zeneca Pharmaceuticals, Wilmington, DE.[2] \"Product Information. Movantik (naloxegol).\" Astra-Zeneca Pharmaceuticals, Wilmington, DE.[3] \"Product Information. Movantik (naloxegol).\" Astra-Zeneca Pharmaceuticals, Wilmington, DE.[4] \"Product Information. Mavyret (glecaprevir-pibrentasvir).\" Abbott Pharmaceutical, Abbott Park, IL.", "alternatives_a": "Nitric Oxide, Doxapram, Elexacaftor", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Bisacodyl, Lactulose, Methylnaltrexone, Lactitol, Sodium phosphate, monobasic, Magnesium oxide, Sodium sulfate, Linaclotide, More", "updated_at": 1767369485}, {"id": 97033, "ingredient1": "Ivacaftor", "ingredient2": "Naltrexone", "severity": "Moderate", "effect": "Coadministration of naltrexone with other agents known to induce hepatotoxicity may potentiate the risk of liver injury. Naltrexone, especially in larger than recommended doses (more than 50 mg/day), has been associated with hepatocellular injury, hepatitis, and elevations in liver transaminases and bilirubin. Other potential causative or contributory etiologies identified include preexisting alcoholic liver disease, hepatitis B and/or C infection, and concomitant usage of other hepatotoxic drugs.", "source": "DDInter", "management_text": "The use of naltrexone with other potentially hepatotoxic agents should be avoided whenever possible (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; nucleoside reverse transcriptase inhibitors; proteasome inhibitors; retinoids; sulfonamides; tamoxifen; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice). Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice. Periodic monitoring of hepatic function is advisable.", "mechanism_text": "Synergism", "recommendation": "The use of naltrexone with other potentially hepatotoxic agents should be avoided whenever possible (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97137/", "reference_text": "[1] \"Product Information. ReVia (naltrexone).\" DuPont Pharmaceuticals, Wilmington, DE.", "alternatives_a": "Codeine, Oliceridine, Oxymorphone, Tapentadol, Meperidine, Butorphanol, Acetaminophen, Hydromorphone, Dezocine, Opium, Dextropropoxyphene, More", "alternatives_b": "Nitric Oxide, Doxapram, Elexacaftor, Lumacaftor", "updated_at": 1767369485}, {"id": 97034, "ingredient1": "Ivacaftor", "ingredient2": "Naproxen", "severity": "Moderate", "effect": "Coadministration with ivacaftor may increase the plasma concentrations of drugs that are substrates of the CYP450 2C9 isoenzyme. The proposed mechanism, based on in vitro data, involves decreased metabolic clearance due to inhibition of CYP450 2C9 by ivacaftor.", "source": "DDInter", "management_text": "Caution is advised when ivacaftor is used concurrently with drugs that are known CYP450 2C9 substrates, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever ivacaftor is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when ivacaftor is used concurrently with drugs that are known CYP450 2C9 substrates, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97138/", "reference_text": "[1] \"Product Information. Trikafta (elexacaftor/ivacaftor/tezacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[2] \"Product Information. Symdeko 4-Week (ivacaftor-tezacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[3] \"Product Information. Orkambi (ivacaftor-lumacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[4] \"Product Information. Kalydeco (ivacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[5] \"Product Information. Ambien (zolpidem).\" sanofi-aventis, Bridgewater, NJ.[6] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84[7] \"Product Information. Trikafta (elexacaftor/ivacaftor/tezacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[8] \"Product Information. Kalydeco (ivacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[9] \"Product Information. Orkambi (ivacaftor-lumacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[10] \"Product Information. Symdeko 4-Week (ivacaftor-tezacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.", "alternatives_a": "Ritodrine, Bremelanotide, Cabergoline, Rabeprazole, Tolazoline, Ketoprofen, Tolmetin, Meclofenamic acid, Dimethyl sulfoxide, Fenoprofen, Rabeprazole, More", "alternatives_b": "Nitric Oxide, Doxapram, Elexacaftor", "updated_at": 1767369485}, {"id": 97035, "ingredient1": "Ivacaftor", "ingredient2": "Nateglinide", "severity": "Moderate", "effect": "Coadministration with ivacaftor may increase the plasma concentrations of drugs that are substrates of the CYP450 2C9 isoenzyme. The proposed mechanism, based on in vitro data, involves decreased metabolic clearance due to inhibition of CYP450 2C9 by ivacaftor.", "source": "DDInter", "management_text": "Caution is advised when ivacaftor is used concurrently with drugs that are known CYP450 2C9 substrates, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever ivacaftor is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when ivacaftor is used concurrently with drugs that are known CYP450 2C9 substrates, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97139/", "reference_text": "[1] \"Product Information. Trikafta (elexacaftor/ivacaftor/tezacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[2] \"Product Information. Symdeko 4-Week (ivacaftor-tezacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[3] \"Product Information. Orkambi (ivacaftor-lumacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[4] \"Product Information. Kalydeco (ivacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[5] \"Product Information. Ambien (zolpidem).\" sanofi-aventis, Bridgewater, NJ.[6] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84[7] \"Product Information. Trikafta (elexacaftor/ivacaftor/tezacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[8] \"Product Information. Kalydeco (ivacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[9] \"Product Information. Orkambi (ivacaftor-lumacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[10] \"Product Information. Symdeko 4-Week (ivacaftor-tezacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.", "alternatives_a": "Guar gum, Pramlintide, Alogliptin, Rosuvastatin, Empagliflozin, Dulaglutide, Exenatide, Miglitol, Albiglutide, Rosiglitazone, Ertugliflozin, More", "alternatives_b": "Nitric Oxide, Doxapram, Elexacaftor", "updated_at": 1767369485}, {"id": 97036, "ingredient1": "Ivacaftor", "ingredient2": "Nefazodone", "severity": "Major", "effect": "Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of ivacaftor, which is primarily metabolized by the isoenzyme.", "source": "DDInter", "management_text": "For ivacaftor -The ivacaftor dose should be reduced from 1 tablet or 1 packet of oral granules twice a day to 1 tablet or 1 packet of oral granules twice a week (i.e., every 3 to 4 days) during coadministration with potent CYP450 3A4 inhibitors. For example, a patient taking ivacaftor 150 mg tablet twice a day should reduce their ivacaftor dose to a 150 mg tablet twice a week and a patient taking ivacaftor 50 mg oral granule packet twice a day should reduce their ivacaftor dose to 50 mg oral granule packet twice a week, etc.", "mechanism_text": "Metabolism", "recommendation": "For ivacaftor -The ivacaftor dose should be reduced from 1 tablet or 1 packet of oral granules twice a day to 1 tablet or 1 packet of oral granules twice a week (i.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97140/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Symdeko 4-Week (ivacaftor-tezacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[3] \"Product Information. Trikafta (elexacaftor/ivacaftor/tezacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[4] Cerner Multum, Inc. \"Australian Product Information.\" O 0[5] \"Product Information. Kalydeco (ivacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[6] \"Product Information. Orkambi (ivacaftor-lumacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[7] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[8] \"Product Information. VFEND (voriconazole).\" Pfizer U.S. Pharmaceuticals, New York, NY.[9] \"Product Information. Trikafta (elexacaftor/ivacaftor/tezacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[10] \"Product Information. Kalydeco (ivacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[11] \"Product Information. Orkambi (ivacaftor-lumacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[12] \"Product Information. Symdeko 4-Week (ivacaftor-tezacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.", "alternatives_a": "Sertraline, Maprotiline, Fluoxetine, Milnacipran, Vortioxetine, Levomilnacipran, Doxepin, Duloxetine, Isocarboxazid, Amoxapine, Imipramine, More", "alternatives_b": "Nitric Oxide, Doxapram, Elexacaftor, Lumacaftor", "updated_at": 1767369485}, {"id": 97037, "ingredient1": "Ivacaftor", "ingredient2": "Nelfinavir", "severity": "Major", "effect": "Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of ivacaftor, which is primarily metabolized by the isoenzyme.", "source": "DDInter", "management_text": "For ivacaftor -The ivacaftor dose should be reduced from 1 tablet or 1 packet of oral granules twice a day to 1 tablet or 1 packet of oral granules twice a week (i.e., every 3 to 4 days) during coadministration with potent CYP450 3A4 inhibitors. For example, a patient taking ivacaftor 150 mg tablet twice a day should reduce their ivacaftor dose to a 150 mg tablet twice a week and a patient taking ivacaftor 50 mg oral granule packet twice a day should reduce their ivacaftor dose to 50 mg oral granule packet twice a week, etc.", "mechanism_text": "Metabolism", "recommendation": "For ivacaftor -The ivacaftor dose should be reduced from 1 tablet or 1 packet of oral granules twice a day to 1 tablet or 1 packet of oral granules twice a week (i.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97141/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Symdeko 4-Week (ivacaftor-tezacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[3] \"Product Information. Trikafta (elexacaftor/ivacaftor/tezacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[4] Cerner Multum, Inc. \"Australian Product Information.\" O 0[5] \"Product Information. Kalydeco (ivacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[6] \"Product Information. Orkambi (ivacaftor-lumacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[7] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[8] \"Product Information. VFEND (voriconazole).\" Pfizer U.S. Pharmaceuticals, New York, NY.[9] \"Product Information. Trikafta (elexacaftor/ivacaftor/tezacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[10] \"Product Information. Kalydeco (ivacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[11] \"Product Information. Orkambi (ivacaftor-lumacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[12] \"Product Information. Symdeko 4-Week (ivacaftor-tezacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.", "alternatives_a": "Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Simeprevir, Cabotegravir, Valaciclovir, Zanamivir, Velpatasvir, Oseltamivir, Acyclovir, More", "alternatives_b": "Nitric Oxide, Doxapram, Elexacaftor", "updated_at": 1767369485}, {"id": 97038, "ingredient1": "Ivacaftor", "ingredient2": "Nevirapine", "severity": "Moderate", "effect": "Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of ivacaftor, which is primarily metabolized by the isoenzyme.", "source": "DDInter", "management_text": "The potential for diminished pharmacologic effects of ivacaftor-containing medications should be considered during coadministration with CYP450 3A4 inducers. Alternative treatments may be required if an interaction is suspected.", "mechanism_text": "Metabolism", "recommendation": "The potential for diminished pharmacologic effects of ivacaftor-containing medications should be considered during coadministration with CYP450 3A4 inducers.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97142/", "reference_text": "[1] \"Product Information. Symdeko 4-Week (ivacaftor-tezacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[2] \"Product Information. Orkambi (ivacaftor-lumacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[3] \"Product Information. Trikafta (elexacaftor/ivacaftor/tezacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[4] \"Product Information. Kalydeco (ivacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[5] \"Product Information. Trikafta (elexacaftor/ivacaftor/tezacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[6] \"Product Information. Kalydeco (ivacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[7] \"Product Information. Orkambi (ivacaftor-lumacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[8] \"Product Information. Symdeko 4-Week (ivacaftor-tezacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.", "alternatives_a": "Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Simeprevir, Cabotegravir, Valaciclovir, Zanamivir, Velpatasvir, Oseltamivir, Acyclovir, More", "alternatives_b": "Nitric Oxide, Doxapram, Elexacaftor, Lumacaftor", "updated_at": 1767369485}, {"id": 97039, "ingredient1": "Ivacaftor", "ingredient2": "Nicardipine", "severity": "Moderate", "effect": "Coadministration with ivacaftor may increase the plasma concentrations of drugs that are substrates of the CYP450 3A4 isoenzyme and/or P-glycoprotein (P-gp) efflux transporter. The mechanism is decreased clearance via these pathways due to inhibition by ivacaftor and its pharmacologically active M1 metabolite.", "source": "DDInter", "management_text": "Caution is advised when ivacaftor is used with drugs that are substrates of CYP450 3A4 and/or P-gp, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever ivacaftor is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when ivacaftor is used with drugs that are substrates of CYP450 3A4 and/or P-gp, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97143/", "reference_text": "[1] \"Product Information. Kalydeco (ivacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[2] Richter WO, Jacob BG, Schwandt P \"Interaction between fibre and lovastatin.\" Lancet 338 (1991): 706[3] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors.\" Clin Pharmacol Ther 64 (1998): 477-83[4] Kantola T, Kivisto KT, Neuvonen PJ \"Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid.\" Clin Pharmacol Ther 63 (1998): 397-402[5] \"Product Information. Mevacor (lovastatin).\" Merck & Co, Inc, West Point, PA.[6] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions.\" Br J Clin Pharmacol 46 (1998): 101-10[7] Neuvonen PJ, Backman JT, Niemi M \"Pharmacokinetic comparison of the potential over-the-counter statins simvastatin, lovastatin, fluvastatin and pravastatin.\" Clin Pharmacokinet 47 (2008): 463-74[8] Thompson PD, Clarkson P, Karas RH \"Statin-associated myopathy.\" JAMA 289 (2003): 1681-90[9] \"Product Information. Zocor (simvastatin).\" Merck & Co, Inc, West Point, PA.[10] \"Product Information. Trikafta (elexacaftor/ivacaftor/tezacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[11] \"Product Information. Kalydeco (ivacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[12] \"Product Information. Orkambi (ivacaftor-lumacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[13] \"Product Information. Symdeko 4-Week (ivacaftor-tezacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.", "alternatives_a": "Clevidipine", "alternatives_b": "Nitric Oxide, Doxapram, Elexacaftor", "updated_at": 1767369485}, {"id": 97040, "ingredient1": "Ivacaftor", "ingredient2": "Nilotinib", "severity": "Moderate", "effect": "Coadministration with inhibitors of CYP450 3A4 and/or P-glycoprotein may increase the plasma concentrations of nilotinib, which is a substrate of both the isoenzyme and the efflux transporter. Data are not available for nilotinib in combination with other CYP450 3A4 or P-glycoprotein inhibitors. Theoretically, a reverse interaction may also occur, since many CYP450 3A4 and P-glycoprotein inhibitors are also substrates, and nilotinib is an inhibitor of both.", "source": "DDInter", "management_text": "Caution is advised if nilotinib is prescribed in combination with CYP450 3A4 and/or P-glycoprotein inhibitors. Pharmacologic response to nilotinib should be monitored more closely whenever a CYP450 3A4 or P-glycoprotein inhibitor is added to or withdrawn from therapy, and the nilotinib dosage adjusted as necessary. Patients should have frequent ECGs and be monitored for arrhythmias when QT interval is prolonged. A QTc interval exceeding 480 msec will require suspension of nilotinib therapy and immediate action to correct any concomitant risk factors before resuming treatment. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope. Patients should also be monitored for altered efficacy and safety of the concomitant administered drug.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if nilotinib is prescribed in combination with CYP450 3A4 and/or P-glycoprotein inhibitors.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97144/", "reference_text": "[1] \"Product Information. Tasigna (nilotinib).\" Novartis Pharmaceuticals, East Hanover, NJ.[2] \"Product Information. Tasigna (nilotinib).\" Novartis Pharmaceuticals, East Hanover, NJ.[3] \"Product Information. Accolate (zafirlukast).\" Zeneca Pharmaceuticals, Wilmington, DE.", "alternatives_a": "Cabozantinib, Sunitinib, Regorafenib, Copanlisib, Ruxolitinib, Lenvatinib, Abemaciclib, Ponatinib, Neratinib, Vandetanib, Trametinib, More", "alternatives_b": "Nitric Oxide, Doxapram, Elexacaftor", "updated_at": 1767369485}, {"id": 97041, "ingredient1": "Ivacaftor", "ingredient2": "Nimodipine", "severity": "Moderate", "effect": "Coadministration with ivacaftor may increase the plasma concentrations of drugs that are substrates of the CYP450 3A4 isoenzyme and/or P-glycoprotein (P-gp) efflux transporter. The mechanism is decreased clearance via these pathways due to inhibition by ivacaftor and its pharmacologically active M1 metabolite.", "source": "DDInter", "management_text": "Caution is advised when ivacaftor is used with drugs that are substrates of CYP450 3A4 and/or P-gp, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever ivacaftor is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when ivacaftor is used with drugs that are substrates of CYP450 3A4 and/or P-gp, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97145/", "reference_text": "[1] \"Product Information. Kalydeco (ivacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[2] Richter WO, Jacob BG, Schwandt P \"Interaction between fibre and lovastatin.\" Lancet 338 (1991): 706[3] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors.\" Clin Pharmacol Ther 64 (1998): 477-83[4] Kantola T, Kivisto KT, Neuvonen PJ \"Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid.\" Clin Pharmacol Ther 63 (1998): 397-402[5] \"Product Information. Mevacor (lovastatin).\" Merck & Co, Inc, West Point, PA.[6] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions.\" Br J Clin Pharmacol 46 (1998): 101-10[7] Neuvonen PJ, Backman JT, Niemi M \"Pharmacokinetic comparison of the potential over-the-counter statins simvastatin, lovastatin, fluvastatin and pravastatin.\" Clin Pharmacokinet 47 (2008): 463-74[8] Thompson PD, Clarkson P, Karas RH \"Statin-associated myopathy.\" JAMA 289 (2003): 1681-90[9] \"Product Information. Zocor (simvastatin).\" Merck & Co, Inc, West Point, PA.[10] \"Product Information. Trikafta (elexacaftor/ivacaftor/tezacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[11] \"Product Information. Kalydeco (ivacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[12] \"Product Information. Orkambi (ivacaftor-lumacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[13] \"Product Information. Symdeko 4-Week (ivacaftor-tezacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.", "alternatives_a": "Clevidipine", "alternatives_b": "Nitric Oxide, Doxapram, Elexacaftor", "updated_at": 1767369485}, {"id": 97042, "ingredient1": "Ivacaftor", "ingredient2": "Nintedanib", "severity": "Moderate", "effect": "Coadministration with inhibitors of P-glycoprotein (P-gp) and CYP450 3A4 may increase the plasma concentrations of nintedanib, which is a substrate of the efflux transporter and a minor substrate of the isoenzyme.", "source": "DDInter", "management_text": "Caution is advised if nintedanib is prescribed in combination with P-gp and CYP450 3A4 inhibitors. Pharmacologic response to nintedanib should be monitored more closely whenever a CYP450 3A4/P-gp inhibitor is added to or withdrawn from therapy, and the nintedanib dosing adjusted or interrupted as necessary in accordance with the product labeling. Patients should be closely monitored for increased adverse effects such as liver enzyme and bilirubin elevations, diarrhea, nausea, vomiting, gastrointestinal perforation, bleeding, and arterial thromboembolic events (e.g., myocardial infarction).", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if nintedanib is prescribed in combination with P-gp and CYP450 3A4 inhibitors.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97146/", "reference_text": "[1] \"Product Information. Ofev (nintedanib).\" Boehringer Ingelheim, Ridgefield, CT.[2] \"Product Information. Ofev (nintedanib).\" Boehringer Ingelheim, Ridgefield, CT.", "alternatives_a": "Nitric Oxide, Doxapram, Elexacaftor", "alternatives_b": "Cabozantinib, Sunitinib, Regorafenib, Copanlisib, Ruxolitinib, Lenvatinib, Abemaciclib, Ponatinib, Neratinib, Vandetanib, Trametinib, More", "updated_at": 1767369485}, {"id": 97043, "ingredient1": "Ivacaftor", "ingredient2": "Nisoldipine", "severity": "Moderate", "effect": "Coadministration with ivacaftor may increase the plasma concentrations of drugs that are substrates of the CYP450 3A4 isoenzyme and/or P-glycoprotein (P-gp) efflux transporter. The mechanism is decreased clearance via these pathways due to inhibition by ivacaftor and its pharmacologically active M1 metabolite.", "source": "DDInter", "management_text": "Caution is advised when ivacaftor is used with drugs that are substrates of CYP450 3A4 and/or P-gp, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever ivacaftor is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when ivacaftor is used with drugs that are substrates of CYP450 3A4 and/or P-gp, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97147/", "reference_text": "[1] \"Product Information. Kalydeco (ivacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[2] Richter WO, Jacob BG, Schwandt P \"Interaction between fibre and lovastatin.\" Lancet 338 (1991): 706[3] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors.\" Clin Pharmacol Ther 64 (1998): 477-83[4] Kantola T, Kivisto KT, Neuvonen PJ \"Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid.\" Clin Pharmacol Ther 63 (1998): 397-402[5] \"Product Information. Mevacor (lovastatin).\" Merck & Co, Inc, West Point, PA.[6] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions.\" Br J Clin Pharmacol 46 (1998): 101-10[7] Neuvonen PJ, Backman JT, Niemi M \"Pharmacokinetic comparison of the potential over-the-counter statins simvastatin, lovastatin, fluvastatin and pravastatin.\" Clin Pharmacokinet 47 (2008): 463-74[8] Thompson PD, Clarkson P, Karas RH \"Statin-associated myopathy.\" JAMA 289 (2003): 1681-90[9] \"Product Information. Zocor (simvastatin).\" Merck & Co, Inc, West Point, PA.[10] \"Product Information. Trikafta (elexacaftor/ivacaftor/tezacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[11] \"Product Information. Kalydeco (ivacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[12] \"Product Information. Orkambi (ivacaftor-lumacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[13] \"Product Information. Symdeko 4-Week (ivacaftor-tezacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.", "alternatives_a": "Clevidipine", "alternatives_b": "Nitric Oxide, Doxapram, Elexacaftor, Lumacaftor", "updated_at": 1767369485}, {"id": 97044, "ingredient1": "Ivacaftor", "ingredient2": "Nitisinone", "severity": "Moderate", "effect": "Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of and exposure to, nitisinone. The proposed mechanism is inhibition of CYP450 3A4-mediated metabolism of nitisinone, which has been shown in in vitro studies to be metabolized by this isoenzyme.", "source": "DDInter", "management_text": "Until more information is available, caution is advised if nitisinone is used concomitantly with CYP450 3A4 inhibitors. Pharmacologic response to nitisinone should be monitored whenever a CYP450 3A4 inhibitor is added to or withdrawn from therapy, and the nitisinone dosage adjusted as necessary. Patients should be monitored for the development of adverse effects.", "mechanism_text": "Metabolism", "recommendation": "Until more information is available, caution is advised if nitisinone is used concomitantly with CYP450 3A4 inhibitors.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97148/", "reference_text": "[1] Cerner Multum, Inc. \"Australian Product Information.\" O 0[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[4] Gunston GD, Mehta U \"Potentially serious drug interactions with grapefruit juice.\" S Afr Med J 90 (2000): 41[5] Bailey DG, Arnold JMO, Spence JD \"Grapefruit juice and drugs - how significant is the interaction.\" Clin Pharmacokinet 26 (1994): 91-8[6] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[7] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions.\" Br J Clin Pharmacol 46 (1998): 101-10[8] Libersa CC, Brique SA, Motte KB, et al. \"Dramatic inhibition of amiodarone metabolism induced by grapefruit juice.\" Br J Clin Pharmacol 49 (2000): 373-8[9] Bailey DG, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit juice felodipine interaction: Effect of naringin and 6',7'-dihydroxybergamottin in humans.\" Clin Pharmacol Ther 64 (1998): 248-56[10] Jonkman JH, Sollie FA, Sauter R, Steinijans VW \"The influence of caffeine on the steady-state pharmacokinetics of theophylline.\" Clin Pharmacol Ther 49 (1991): 248-55[11] Ozdemir M, Aktan Y, Boydag BS, Cingi MI, Musmul A \"Interaction between grapefruit juice and diazepam in humans.\" Eur J Drug Metab Pharmacokinet 23 (1998): 55-9[12] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin.\" Clin Pharmacol Ther 66 (1999): 118-27[13] Bailey DG, Arnold JM, Munoz C, Spence JD \"Grapefruit juice--felodipine interaction: mechanism, predictability, and effect of naringin.\" Clin Pharmacol Ther 53 (1993): 637-42[14] Sigusch H, Hippius M, Henschel L, Kaufmann K, Hoffmann A \"Influence of grapefruit juice on the pharmacokinetics of a slow release nifedipine formulation.\" Pharmazie 49 (1994): 522-4[15] Eagling VA, Profit L, Back DJ \"Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-I protease inhibitor saquinavir by grapefruit juice components.\" Br J Clin Pharmacol 48 (1999): 543-52[16] Damkier P, Hansen LL, Brosen K \"Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine.\" Br J Clin Pharmacol 48 (1999): 829-38[17] Min DI, Ku YM, Geraets DR, Lee HC \"Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers.\" J Clin Pharmacol 36 (1996): 469-76[18] Zaidenstein R, Soback S, Gips M, Avni B, Dishi V, Weissgarten Y, Golik A, Scapa E \"Effect of grapefruit juice on the pharmacokinetics of losartan and its active metabolite E3174 in healthy volunteers.\" Ther Drug Monit 23 (2001): 369-73[19] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84[20] Lee AJ, Chan WK, Harralson AF, Buffum J, Bui BCC \"The effects of grapefruit juice on sertraline metabolism: An in vitro and in vivo study.\" Clin Ther 21 (1999): 1890-9[21] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors.\" Clin Pharmacol Ther 64 (1998): 477-83[22] Garg SK, Kumar N, Bhargava VK, Prabhakar SK \"Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy.\" Clin Pharmacol Ther 64 (1998): 286-8[23] Fuhr U, Maier-Bruggemann A, Blume H, et al. \"Grapefruit juice increases oral nimodipine bioavailability.\" Int J Clin Pharmacol Ther 36 (1998): 126-32[24] Sato J, Nakata H, Owada E, Kikuta T, Umetsu M, Ito K \"Influence of usual intake of dietary caffeine on single-dose kinetics of theophylline in healthy human subjects.\" Eur J Clin Pharmacol 44 (1993): 295-8[25] Edgar B, Bailey D, Bergstrand R, et al \"Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics on felodipine and its potential clinical relevance.\" Eur J Clin Pharmacol 42 (1992): 313-7[26] Kantola T, Kivisto KT, Neuvonen PJ \"Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid.\" Clin Pharmacol Ther 63 (1998): 397-402[27] Dresser GK, Spence JD, Bailey DG \"Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition.\" Clin Pharmacokinet 38 (2000): 41-57[28] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[29] Takanaga H, Ohnishi A, Maatsuo H, et al. \"Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model.\" Br J Clin Pharmacol 49 (2000): 49-58[30] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS \"Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice.\" Br J Clin Pharmacol 42 (1996): p662[31] Bailey DG, Arnold JM, Strong HA, Munoz C, Spence JD \"Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics.\" Clin Pharmacol Ther 54 (1993): 589-94[32] Josefsson M, Zackrisson AL, Ahlner J \"Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers.\" Eur J Clin Pharmacol 51 (1996): 189-93[33] Majeed A, Kareem A \"Effect of grapefruit juice on cyclosporine pharmacokinetics.\" Pediatr Nephrol 10 (1996): 395[34] Flanagan D \"Understanding the grapefruit-drug interaction.\" Gen Dent 53 (2005): 282-5; quiz 286[35] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ \"Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice.\" Clin Pharmacol Ther 58 (1995): 127-31[36] Gunston GD, Mehta U \"Potentially serious drug interactions with grapefruit juice.\" S Afr Med J 90 (2000): 41[37] Bailey DG, Arnold JMO, Spence JD \"Grapefruit juice and drugs - how significant is the interaction.\" Clin Pharmacokinet 26 (1994): 91-8[38] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[39] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions.\" Br J Clin Pharmacol 46 (1998): 101-10[40] Libersa CC, Brique SA, Motte KB, et al. \"Dramatic inhibition of amiodarone metabolism induced by grapefruit juice.\" Br J Clin Pharmacol 49 (2000): 373-8[41] Bailey DG, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit juice felodipine interaction: Effect of naringin and 6',7'-dihydroxybergamottin in humans.\" Clin Pharmacol Ther 64 (1998): 248-56[42] Jonkman JH, Sollie FA, Sauter R, Steinijans VW \"The influence of caffeine on the steady-state pharmacokinetics of theophylline.\" Clin Pharmacol Ther 49 (1991): 248-55[43] Ozdemir M, Aktan Y, Boydag BS, Cingi MI, Musmul A \"Interaction between grapefruit juice and diazepam in humans.\" Eur J Drug Metab Pharmacokinet 23 (1998): 55-9[44] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin.\" Clin Pharmacol Ther 66 (1999): 118-27[45] Bailey DG, Arnold JM, Munoz C, Spence JD \"Grapefruit juice--felodipine interaction: mechanism, predictability, and effect of naringin.\" Clin Pharmacol Ther 53 (1993): 637-42[46] Sigusch H, Hippius M, Henschel L, Kaufmann K, Hoffmann A \"Influence of grapefruit juice on the pharmacokinetics of a slow release nifedipine formulation.\" Pharmazie 49 (1994): 522-4[47] Eagling VA, Profit L, Back DJ \"Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-I protease inhibitor saquinavir by grapefruit juice components.\" Br J Clin Pharmacol 48 (1999): 543-52[48] Damkier P, Hansen LL, Brosen K \"Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine.\" Br J Clin Pharmacol 48 (1999): 829-38[49] Min DI, Ku YM, Geraets DR, Lee HC \"Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers.\" J Clin Pharmacol 36 (1996): 469-76[50] Zaidenstein R, Soback S, Gips M, Avni B, Dishi V, Weissgarten Y, Golik A, Scapa E \"Effect of grapefruit juice on the pharmacokinetics of losartan and its active metabolite E3174 in healthy volunteers.\" Ther Drug Monit 23 (2001): 369-73[51] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84[52] Lee AJ, Chan WK, Harralson AF, Buffum J, Bui BCC \"The effects of grapefruit juice on sertraline metabolism: An in vitro and in vivo study.\" Clin Ther 21 (1999): 1890-9[53] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors.\" Clin Pharmacol Ther 64 (1998): 477-83[54] Garg SK, Kumar N, Bhargava VK, Prabhakar SK \"Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy.\" Clin Pharmacol Ther 64 (1998): 286-8[55] Fuhr U, Maier-Bruggemann A, Blume H, et al. \"Grapefruit juice increases oral nimodipine bioavailability.\" Int J Clin Pharmacol Ther 36 (1998): 126-32[56] Sato J, Nakata H, Owada E, Kikuta T, Umetsu M, Ito K \"Influence of usual intake of dietary caffeine on single-dose kinetics of theophylline in healthy human subjects.\" Eur J Clin Pharmacol 44 (1993): 295-8[57] Edgar B, Bailey D, Bergstrand R, et al \"Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics on felodipine and its potential clinical relevance.\" Eur J Clin Pharmacol 42 (1992): 313-7[58] Kantola T, Kivisto KT, Neuvonen PJ \"Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid.\" Clin Pharmacol Ther 63 (1998): 397-402[59] Dresser GK, Spence JD, Bailey DG \"Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition.\" Clin Pharmacokinet 38 (2000): 41-57[60] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[61] Takanaga H, Ohnishi A, Maatsuo H, et al. \"Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model.\" Br J Clin Pharmacol 49 (2000): 49-58[62] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS \"Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice.\" Br J Clin Pharmacol 42 (1996): p662[63] Bailey DG, Arnold JM, Strong HA, Munoz C, Spence JD \"Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics.\" Clin Pharmacol Ther 54 (1993): 589-94[64] Josefsson M, Zackrisson AL, Ahlner J \"Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers.\" Eur J Clin Pharmacol 51 (1996): 189-93[65] Majeed A, Kareem A \"Effect of grapefruit juice on cyclosporine pharmacokinetics.\" Pediatr Nephrol 10 (1996): 395[66] Flanagan D \"Understanding the grapefruit-drug interaction.\" Gen Dent 53 (2005): 282-5; quiz 286[67] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ \"Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice.\" Clin Pharmacol Ther 58 (1995): 127-31", "alternatives_a": "Teduglutide, Fosdenopterin, Miglustat, Imiglucerase, Asfotase alfa, Glycerol phenylbutyrate, Pegvaliase, Triethylenetetramine, Sapropterin, Zinc acetate, Phenylbutyric acid, More", "alternatives_b": "Nitric Oxide, Doxapram, Elexacaftor", "updated_at": 1767369485}, {"id": 97045, "ingredient1": "Elexacaftor", "ingredient2": "Norethisterone", "severity": "Moderate", "effect": "Concomitant use of hormonal contraceptives and ivacaftor/tezacaftor/elexacaftor (IVA/TEZ/ELX) may increase the risk for rash events.", "source": "DDInter", "management_text": "Monitor for rash in patients taking both medications. Consider interrupting IVA/TEZ/ELX and hormonal contraceptives in patients who develop rash. Once the rash clears, IVA/TEZ/ELX may be restarted without the hormonal contraceptives. If rash does not recur, resumption of hormonal contraceptives can be considered.", "mechanism_text": "Synergism", "recommendation": "Monitor for rash in patients taking both medications.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97149/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Trikafta (elexacaftor/ivacaftor/tezacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[3] Gunston GD, Mehta U \"Potentially serious drug interactions with grapefruit juice.\" S Afr Med J 90 (2000): 41[4] Fuhr U, Maier-Bruggemann A, Blume H, et al. \"Grapefruit juice increases oral nimodipine bioavailability.\" Int J Clin Pharmacol Ther 36 (1998): 126-32[5] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[6] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[7] Takanaga H, Ohnishi A, Maatsuo H, et al. \"Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model.\" Br J Clin Pharmacol 49 (2000): 49-58[8] Jonkman JH, Sollie FA, Sauter R, Steinijans VW \"The influence of caffeine on the steady-state pharmacokinetics of theophylline.\" Clin Pharmacol Ther 49 (1991): 248-55[9] Ozdemir M, Aktan Y, Boydag BS, Cingi MI, Musmul A \"Interaction between grapefruit juice and diazepam in humans.\" Eur J Drug Metab Pharmacokinet 23 (1998): 55-9[10] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS \"Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice.\" Br J Clin Pharmacol 42 (1996): p662[11] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin.\" Clin Pharmacol Ther 66 (1999): 118-27[12] Bailey DG, Arnold JM, Strong HA, Munoz C, Spence JD \"Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics.\" Clin Pharmacol Ther 54 (1993): 589-94[13] Sigusch H, Hippius M, Henschel L, Kaufmann K, Hoffmann A \"Influence of grapefruit juice on the pharmacokinetics of a slow release nifedipine formulation.\" Pharmazie 49 (1994): 522-4[14] Bailey DG, Arnold JM, Munoz C, Spence JD \"Grapefruit juice--felodipine interaction: mechanism, predictability, and effect of naringin.\" Clin Pharmacol Ther 53 (1993): 637-42[15] Zaidenstein R, Soback S, Gips M, Avni B, Dishi V, Weissgarten Y, Golik A, Scapa E \"Effect of grapefruit juice on the pharmacokinetics of losartan and its active metabolite E3174 in healthy volunteers.\" Ther Drug Monit 23 (2001): 369-73[16] Josefsson M, Zackrisson AL, Ahlner J \"Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers.\" Eur J Clin Pharmacol 51 (1996): 189-93[17] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84[18] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors.\" Clin Pharmacol Ther 64 (1998): 477-83[19] Lee AJ, Chan WK, Harralson AF, Buffum J, Bui BCC \"The effects of grapefruit juice on sertraline metabolism: An in vitro and in vivo study.\" Clin Ther 21 (1999): 1890-9[20] Majeed A, Kareem A \"Effect of grapefruit juice on cyclosporine pharmacokinetics.\" Pediatr Nephrol 10 (1996): 395[21] Flanagan D \"Understanding the grapefruit-drug interaction.\" Gen Dent 53 (2005): 282-5; quiz 286[22] Garg SK, Kumar N, Bhargava VK, Prabhakar SK \"Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy.\" Clin Pharmacol Ther 64 (1998): 286-8[23] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ \"Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice.\" Clin Pharmacol Ther 58 (1995): 127-31[24] Sato J, Nakata H, Owada E, Kikuta T, Umetsu M, Ito K \"Influence of usual intake of dietary caffeine on single-dose kinetics of theophylline in healthy human subjects.\" Eur J Clin Pharmacol 44 (1993): 295-8[25] Dresser GK, Spence JD, Bailey DG \"Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition.\" Clin Pharmacokinet 38 (2000): 41-57[26] Bailey DG, Arnold JMO, Spence JD \"Grapefruit juice and drugs - how significant is the interaction.\" Clin Pharmacokinet 26 (1994): 91-8[27] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions.\" Br J Clin Pharmacol 46 (1998): 101-10[28] Libersa CC, Brique SA, Motte KB, et al. \"Dramatic inhibition of amiodarone metabolism induced by grapefruit juice.\" Br J Clin Pharmacol 49 (2000): 373-8[29] Bailey DG, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit juice felodipine interaction: Effect of naringin and 6',7'-dihydroxybergamottin in humans.\" Clin Pharmacol Ther 64 (1998): 248-56[30] Eagling VA, Profit L, Back DJ \"Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-I protease inhibitor saquinavir by grapefruit juice components.\" Br J Clin Pharmacol 48 (1999): 543-52[31] Damkier P, Hansen LL, Brosen K \"Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine.\" Br J Clin Pharmacol 48 (1999): 829-38[32] Min DI, Ku YM, Geraets DR, Lee HC \"Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers.\" J Clin Pharmacol 36 (1996): 469-76[33] Edgar B, Bailey D, Bergstrand R, et al \"Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics on felodipine and its potential clinical relevance.\" Eur J Clin Pharmacol 42 (1992): 313-7[34] Kantola T, Kivisto KT, Neuvonen PJ \"Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid.\" Clin Pharmacol Ther 63 (1998): 397-402[35] \"Product Information. Trikafta (elexacaftor/ivacaftor/tezacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[36] \"Product Information. Kalydeco (ivacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[37] \"Product Information. Orkambi (ivacaftor-lumacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[38] \"Product Information. Symdeko 4-Week (ivacaftor-tezacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.", "alternatives_a": "Nafarelin, Octreotide, Elagolix, Cetrorelix, Pasireotide, Estradiol, Ganirelix, Relugolix, Lanreotide, Gonadorelin, Ulipristal, More", "alternatives_b": "Nitric Oxide, Doxapram, Ivacaftor", "updated_at": 1767369485}, {"id": 97046, "ingredient1": "Elexacaftor", "ingredient2": "Norgestrel", "severity": "Moderate", "effect": "Concomitant use of hormonal contraceptives and ivacaftor/tezacaftor/elexacaftor (IVA/TEZ/ELX) may increase the risk for rash events.", "source": "DDInter", "management_text": "Monitor for rash in patients taking both medications. Consider interrupting IVA/TEZ/ELX and hormonal contraceptives in patients who develop rash. Once the rash clears, IVA/TEZ/ELX may be restarted without the hormonal contraceptives. If rash does not recur, resumption of hormonal contraceptives can be considered.", "mechanism_text": "Synergism", "recommendation": "Monitor for rash in patients taking both medications.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97150/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Trikafta (elexacaftor/ivacaftor/tezacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[3] Gunston GD, Mehta U \"Potentially serious drug interactions with grapefruit juice.\" S Afr Med J 90 (2000): 41[4] Fuhr U, Maier-Bruggemann A, Blume H, et al. \"Grapefruit juice increases oral nimodipine bioavailability.\" Int J Clin Pharmacol Ther 36 (1998): 126-32[5] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[6] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[7] Takanaga H, Ohnishi A, Maatsuo H, et al. \"Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model.\" Br J Clin Pharmacol 49 (2000): 49-58[8] Jonkman JH, Sollie FA, Sauter R, Steinijans VW \"The influence of caffeine on the steady-state pharmacokinetics of theophylline.\" Clin Pharmacol Ther 49 (1991): 248-55[9] Ozdemir M, Aktan Y, Boydag BS, Cingi MI, Musmul A \"Interaction between grapefruit juice and diazepam in humans.\" Eur J Drug Metab Pharmacokinet 23 (1998): 55-9[10] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS \"Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice.\" Br J Clin Pharmacol 42 (1996): p662[11] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin.\" Clin Pharmacol Ther 66 (1999): 118-27[12] Bailey DG, Arnold JM, Strong HA, Munoz C, Spence JD \"Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics.\" Clin Pharmacol Ther 54 (1993): 589-94[13] Sigusch H, Hippius M, Henschel L, Kaufmann K, Hoffmann A \"Influence of grapefruit juice on the pharmacokinetics of a slow release nifedipine formulation.\" Pharmazie 49 (1994): 522-4[14] Bailey DG, Arnold JM, Munoz C, Spence JD \"Grapefruit juice--felodipine interaction: mechanism, predictability, and effect of naringin.\" Clin Pharmacol Ther 53 (1993): 637-42[15] Zaidenstein R, Soback S, Gips M, Avni B, Dishi V, Weissgarten Y, Golik A, Scapa E \"Effect of grapefruit juice on the pharmacokinetics of losartan and its active metabolite E3174 in healthy volunteers.\" Ther Drug Monit 23 (2001): 369-73[16] Josefsson M, Zackrisson AL, Ahlner J \"Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers.\" Eur J Clin Pharmacol 51 (1996): 189-93[17] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84[18] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors.\" Clin Pharmacol Ther 64 (1998): 477-83[19] Lee AJ, Chan WK, Harralson AF, Buffum J, Bui BCC \"The effects of grapefruit juice on sertraline metabolism: An in vitro and in vivo study.\" Clin Ther 21 (1999): 1890-9[20] Majeed A, Kareem A \"Effect of grapefruit juice on cyclosporine pharmacokinetics.\" Pediatr Nephrol 10 (1996): 395[21] Flanagan D \"Understanding the grapefruit-drug interaction.\" Gen Dent 53 (2005): 282-5; quiz 286[22] Garg SK, Kumar N, Bhargava VK, Prabhakar SK \"Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy.\" Clin Pharmacol Ther 64 (1998): 286-8[23] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ \"Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice.\" Clin Pharmacol Ther 58 (1995): 127-31[24] Sato J, Nakata H, Owada E, Kikuta T, Umetsu M, Ito K \"Influence of usual intake of dietary caffeine on single-dose kinetics of theophylline in healthy human subjects.\" Eur J Clin Pharmacol 44 (1993): 295-8[25] Dresser GK, Spence JD, Bailey DG \"Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition.\" Clin Pharmacokinet 38 (2000): 41-57[26] Bailey DG, Arnold JMO, Spence JD \"Grapefruit juice and drugs - how significant is the interaction.\" Clin Pharmacokinet 26 (1994): 91-8[27] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions.\" Br J Clin Pharmacol 46 (1998): 101-10[28] Libersa CC, Brique SA, Motte KB, et al. \"Dramatic inhibition of amiodarone metabolism induced by grapefruit juice.\" Br J Clin Pharmacol 49 (2000): 373-8[29] Bailey DG, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit juice felodipine interaction: Effect of naringin and 6',7'-dihydroxybergamottin in humans.\" Clin Pharmacol Ther 64 (1998): 248-56[30] Eagling VA, Profit L, Back DJ \"Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-I protease inhibitor saquinavir by grapefruit juice components.\" Br J Clin Pharmacol 48 (1999): 543-52[31] Damkier P, Hansen LL, Brosen K \"Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine.\" Br J Clin Pharmacol 48 (1999): 829-38[32] Min DI, Ku YM, Geraets DR, Lee HC \"Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers.\" J Clin Pharmacol 36 (1996): 469-76[33] Edgar B, Bailey D, Bergstrand R, et al \"Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics on felodipine and its potential clinical relevance.\" Eur J Clin Pharmacol 42 (1992): 313-7[34] Kantola T, Kivisto KT, Neuvonen PJ \"Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid.\" Clin Pharmacol Ther 63 (1998): 397-402[35] \"Product Information. Trikafta (elexacaftor/ivacaftor/tezacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[36] \"Product Information. Kalydeco (ivacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[37] \"Product Information. Orkambi (ivacaftor-lumacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[38] \"Product Information. Symdeko 4-Week (ivacaftor-tezacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.", "alternatives_a": "Progesterone, Megestrol acetate, Norgestimate, Etynodiol, Estradiol, Desogestrel, Dienogest, Ulipristal, Norelgestromin, Megestrol acetate, Norgestimate, More", "alternatives_b": "Nitric Oxide, Doxapram, Ivacaftor", "updated_at": 1767369485}, {"id": 97047, "ingredient1": "Ivacaftor", "ingredient2": "Olaparib", "severity": "Moderate", "effect": "Based on in vitro inhibition data, coadministration with olaparib may increase the plasma concentrations of drugs that are substrates of CYP450 3A4 (e.g., cisapride, ergot alkaloids, fentanyl, lovastatin, oral midazolam, pimozide, quetiapine, simvastatin, triazolam, vinca alkaloids), P-gp (e.g., colchicine, dabigatran, digoxin), breast cancer resistance protein (BCRP) (e.g., rosuvastatin), OATP1B1 (e.g., eluxadoline, glyburide, repaglinide, statins, valsartan), or organic cation transporter 1 or 2 (OCT1, OCT2) (e.g., metformin). The proposed mechanism is decreased clearance due to inhibition of the corresponding metabolizing enzyme and/or efflux/uptake transporter by olaparib.", "source": "DDInter", "management_text": "Caution is advised if olaparib must be used concomitantly with drugs that are substrates of the affected enzymes or transporters, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever olaparib is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if olaparib must be used concomitantly with drugs that are substrates of the affected enzymes or transporters, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97151/", "reference_text": "[1] Cerner Multum, Inc. \"Australian Product Information.\" O 0[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Lynparza (olaparib).\" Astra-Zeneca Pharmaceuticals, Wilmington, DE.[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ \"Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice.\" Clin Pharmacol Ther 58 (1995): 127-31[7] Kupferschmidt HHT, Ha HR, Ziegler WH, Meier PJ, Krahenbuhl S \"Interaction between grapefruit juice and midazolam in humans.\" Clin Pharmacol Ther 58 (1995): 20-8[8] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[9] \"Product Information. Valium (diazepam).\" Roche Laboratories, Nutley, NJ.[10] \"Product Information. Xanax (alprazolam).\" Pharmacia and Upjohn, Kalamazoo, MI.[11] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[12] \"Product Information. Halcion (triazolam).\" Pharmacia and Upjohn, Kalamazoo, MI.", "alternatives_a": "Nitric Oxide, Doxapram, Elexacaftor", "alternatives_b": "Pertuzumab, Oxaliplatin, Bortezomib, Tisagenlecleucel, Aminolevulinic acid, Omacetaxine mepesuccinate, Altretamine, Tagraxofusp, Ixazomib, Enasidenib, Porfimer sodium, More", "updated_at": 1767369485}, {"id": 97048, "ingredient1": "Elexacaftor", "ingredient2": "Olmesartan", "severity": "Moderate", "effect": "Coadministration with elexacaftor may increase the plasma concentrations of drugs that are substrates of the organic anion transporting polypeptides (OATP) 1B1 and 1B3. The proposed mechanism, based on in vitro data, involves decreased metabolic clearance due to inhibition of OATP 1B1- and 1B3-mediated hepatic uptake by elexacaftor and its metabolite. The clinical relevance is unknown.", "source": "DDInter", "management_text": "Caution is advised when elexacaftor is used concurrently with drugs that are known OATP 1B1 and 1B3 substrates, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever elexacaftor is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when elexacaftor is used concurrently with drugs that are known OATP 1B1 and 1B3 substrates, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97152/", "reference_text": "[1] \"Product Information. Trikafta (elexacaftor/ivacaftor/tezacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[2] \"Product Information. Diovan (valsartan).\" Novartis Pharmaceuticals, East Hanover, NJ.[3] \"Product Information. Cozaar (losartan).\" Merck & Co, Inc, West Point, PA.[4] \"Product Information. Trikafta (elexacaftor/ivacaftor/tezacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[5] \"Product Information. Kalydeco (ivacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[6] \"Product Information. Orkambi (ivacaftor-lumacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[7] \"Product Information. Symdeko 4-Week (ivacaftor-tezacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.", "alternatives_a": "Amlodipine, Irbesartan, Hydrochlorothiazide, Losartan, Azilsartan medoxomil, Nebivolol, Telmisartan, Candesartan, Sacubitril, Aliskiren, Eprosartan, More", "alternatives_b": "Nitric Oxide, Doxapram, Ivacaftor, Lumacaftor", "updated_at": 1767369485}, {"id": 97049, "ingredient1": "Ivacaftor", "ingredient2": "Osilodrostat", "severity": "Moderate", "effect": "Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of osilodrostat, which is partially metabolized by the isoenzyme.", "source": "DDInter", "management_text": "Caution is advised when osilodrostat is coadministered with CYP450 3A4 inhibitors. Dosage adjustments may be required based on clinical response and tolerance. Patients should have regular monitoring of 24-hour urine free cortisol and serum or plasma cortisol during treatment, as well as regular evaluations for signs and symptoms of hypocortisolism such as nausea, vomiting, abdominal pain, loss of appetite, fatigue, dizziness, hypotension, abnormal electrolyte levels, and hypoglycemia. Decrease dosing or temporarily discontinue osilodrostat if patients experience symptoms of hypocortisolism or if urine free cortisol levels fall below the target range or there is a rapid decrease in cortisol levels. Stop osilodrostat and administer exogenous glucocorticoid replacement therapy if patients have symptoms of adrenal insufficiency and serum or plasma cortisol levels are below target range. Osilodrostat therapy may be restarted at a lower dosage when symptoms have resolved and cortisol values are within target range.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when osilodrostat is coadministered with CYP450 3A4 inhibitors.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97153/", "reference_text": "[1] \"Product Information. Isturisa (osilodrostat).\" Recordati Rare Diseases Inc, Lebanon, NJ.[2] \"Product Information. Accolate (zafirlukast).\" Zeneca Pharmaceuticals, Wilmington, DE.", "alternatives_a": "Nitric Oxide, Doxapram, Elexacaftor", "alternatives_b": "", "updated_at": 1767369485}, {"id": 97050, "ingredient1": "Ivacaftor", "ingredient2": "Osimertinib", "severity": "Moderate", "effect": "Coadministration with osimertinib may alter the plasma concentrations of drugs that are primarily metabolized by CYP450 3A4. In vitro, osimertinib has been shown to be a competitive inhibitor as well as inducer of CYP450 3A4.", "source": "DDInter", "management_text": "Concomitant use of osimertinib and sensitive CYP450 3A4 substrates or substrates with narrow therapeutic ranges should generally be avoided. These drugs include, but are not limited to: alfentanil, cisapride, colchicine, cyclosporine, fentanyl, ivacaftor, lovastatin, simvastatin, oral midazolam, triazolam, pimozide, quinidine, sildenafil, ergot derivatives, macrolide immunosuppressants, and vinca alkaloids.", "mechanism_text": "Metabolism", "recommendation": "Concomitant use of osimertinib and sensitive CYP450 3A4 substrates or substrates with narrow therapeutic ranges should generally be avoided.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97154/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Tagrisso (osimertinib).\" Astra-Zeneca Pharmaceuticals, Wilmington, DE.", "alternatives_a": "Nitric Oxide, Doxapram, Elexacaftor", "alternatives_b": "Cabozantinib, Sunitinib, Regorafenib, Copanlisib, Ruxolitinib, Lenvatinib, Abemaciclib, Ponatinib, Neratinib, Vandetanib, Trametinib, More", "updated_at": 1767369485}, {"id": 97051, "ingredient1": "Ivacaftor", "ingredient2": "Oxcarbazepine", "severity": "Moderate", "effect": "Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of ivacaftor, which is primarily metabolized by the isoenzyme.", "source": "DDInter", "management_text": "The potential for diminished pharmacologic effects of ivacaftor-containing medications should be considered during coadministration with CYP450 3A4 inducers. Alternative treatments may be required if an interaction is suspected.", "mechanism_text": "Metabolism", "recommendation": "The potential for diminished pharmacologic effects of ivacaftor-containing medications should be considered during coadministration with CYP450 3A4 inducers.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97155/", "reference_text": "[1] \"Product Information. Symdeko 4-Week (ivacaftor-tezacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[2] \"Product Information. Orkambi (ivacaftor-lumacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[3] \"Product Information. Trikafta (elexacaftor/ivacaftor/tezacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[4] \"Product Information. Kalydeco (ivacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[5] \"Product Information. Trikafta (elexacaftor/ivacaftor/tezacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[6] \"Product Information. Kalydeco (ivacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[7] \"Product Information. Orkambi (ivacaftor-lumacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[8] \"Product Information. Symdeko 4-Week (ivacaftor-tezacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.", "alternatives_a": "Brivaracetam, Topiramate, Ezogabine, Lamotrigine, Lacosamide, Levetiracetam, Tiagabine, Ethotoin, Paramethadione, Perampanel, Vigabatrin, More", "alternatives_b": "Nitric Oxide, Doxapram, Elexacaftor, Lumacaftor", "updated_at": 1767369485}, {"id": 97052, "ingredient1": "Ivacaftor", "ingredient2": "Oxycodone", "severity": "Moderate", "effect": "Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of oxycodone, which is primarily metabolized by the isoenzyme. Increased oxycodone concentrations could increase or prolong adverse drug effects and may cause potentially fatal respiratory depression. Itraconazole, telithromycin and voriconazole are considered potent inhibitors of CYP450 3A4.", "source": "DDInter", "management_text": "Caution may be advisable when oxycodone is prescribed with weak CYP450 3A4 inhibitors. The risk of overdose may be increased following the initiation of a CYP450 3A4 inhibitor in patients already receiving oxycodone. Patients should be closely monitored for signs and symptoms of sedation, respiratory depression, and hypotension. Following discontinuation of the CYP450 3A4 inhibitor, patients should be monitored for reduced efficacy of oxycodone or development of withdrawal symptoms due to reduced plasma oxycodone levels.", "mechanism_text": "Metabolism", "recommendation": "Caution may be advisable when oxycodone is prescribed with weak CYP450 3A4 inhibitors.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97156/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] \"Product Information. OxyContin (oxycodone).\" Purdue Frederick Company, Norwalk, CT.[4] Nieminen TH, Hagelberg NM, Saari TI, et al \"Grapefruit juice enhances the exposure to oral oxycodone.\" Basic Clin Pharmacol Toxicol 107 (2010): 782-8", "alternatives_a": "Codeine, Oliceridine, Oxymorphone, Tapentadol, Meperidine, Butorphanol, Acetaminophen, Hydromorphone, Dezocine, Opium, Dextropropoxyphene, More", "alternatives_b": "Doxapram, Elexacaftor", "updated_at": 1767369485}, {"id": 97053, "ingredient1": "Ivacaftor", "ingredient2": "Ozanimod", "severity": "Major", "effect": "Coadministration with breast cancer resistance protein (BCRP) inhibitors may increase the exposure of the active metabolites of ozanimod and the risk of adverse effects. Coadministration with cyclosporine, a BCRP inhibitor, did not alter the AUC of ozanimod, but it did double the exposure of the minor active metabolites of ozanimod, RP101988 and RP101075 which are direct precursors of the major active metabolite CC112273.", "source": "DDInter", "management_text": "According to the manufacturer, coadministration of ozanimod with BCRP inhibitors is not recommended.", "mechanism_text": "Others", "recommendation": "According to the manufacturer, coadministration of ozanimod with BCRP inhibitors is not recommended.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97157/", "reference_text": "[1] Cerner Multum, Inc. \"Australian Product Information.\" O 0[2] \"Product Information. Zeposia (ozanimod).\" Celgene Corporation, Summit, NJ.[3] \"Product Information. Zeposia (ozanimod).\" Celgene Corporation, Summit, NJ.", "alternatives_a": "Nitric Oxide, Elexacaftor", "alternatives_b": "Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Abatacept, More", "updated_at": 1767369485}, {"id": 97054, "ingredient1": "Ivacaftor", "ingredient2": "Palbociclib", "severity": "Moderate", "effect": "Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of ivacaftor, which is primarily metabolized by the isoenzyme. The interaction occurs to a greater extent when ivacaftor is administered as monotherapy than when administered in combination with lumacaftor, a potent CYP450 3A4 inducer.", "source": "DDInter", "management_text": "Caution is advised if ivacaftor is used with CYP450 3A4 inhibitors. A dosage adjustment for ivacaftor may be required if undue adverse effects occur.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if ivacaftor is used with CYP450 3A4 inhibitors.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97158/", "reference_text": "[1] \"Product Information. Kalydeco (ivacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[2] \"Product Information. Orkambi (ivacaftor-lumacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[3] \"Product Information. Accolate (zafirlukast).\" Zeneca Pharmaceuticals, Wilmington, DE.[4] \"Product Information. Trikafta (elexacaftor/ivacaftor/tezacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[5] \"Product Information. Kalydeco (ivacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[6] \"Product Information. Orkambi (ivacaftor-lumacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[7] \"Product Information. Symdeko 4-Week (ivacaftor-tezacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.", "alternatives_a": "Nitric Oxide, Doxapram, Elexacaftor", "alternatives_b": "Cabozantinib, Sunitinib, Regorafenib, Copanlisib, Ruxolitinib, Lenvatinib, Abemaciclib, Ponatinib, Neratinib, Vandetanib, Trametinib, More", "updated_at": 1767369485}, {"id": 97055, "ingredient1": "Ivacaftor", "ingredient2": "Panobinostat", "severity": "Moderate", "effect": "Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of panobinostat, which is partially metabolized by the isoenzyme.", "source": "DDInter", "management_text": "Caution is advised when panobinostat is prescribed with CYP450 3A4 inhibitors. Patients should be monitored for adverse effects such as nausea, vomiting, diarrhea, anorexia, peripheral edema, cardiotoxicity, ECG abnormalities, electrolyte disturbances, bleeding complications, hepatotoxicity and myelosuppression, and the dosage of panobinostat adjusted as necessary in accordance with the product labeling.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when panobinostat is prescribed with CYP450 3A4 inhibitors.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97159/", "reference_text": "[1] Hamberg P, Woo MM, Chen LC, et al. \"Effect of ketoconazole-mediated CYP3A4 inhibition on clinical pharmacokinetics of panobinostat (LBH589), an orally active histone deacetylase inhibitor.\" Cancer Chemother Pharmacol 68 (2011): 805-13[2] \"Product Information. Farydak (panobinostat).\" Novartis Pharmaceuticals, East Hanover, NJ.[3] \"Product Information. Accolate (zafirlukast).\" Zeneca Pharmaceuticals, Wilmington, DE.[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Farydak (panobinostat).\" Novartis Pharmaceuticals, East Hanover, NJ.", "alternatives_a": "Pertuzumab, Oxaliplatin, Bortezomib, Tisagenlecleucel, Aminolevulinic acid, Omacetaxine mepesuccinate, Altretamine, Tagraxofusp, Ixazomib, Enasidenib, Porfimer sodium, More", "alternatives_b": "Nitric Oxide, Doxapram, Elexacaftor", "updated_at": 1767369485}, {"id": 97056, "ingredient1": "Ivacaftor", "ingredient2": "Pazopanib", "severity": "Moderate", "effect": "Coadministration with ivacaftor may increase the plasma concentrations of drugs that are substrates of the CYP450 3A4 isoenzyme and/or P-glycoprotein (P-gp) efflux transporter. The mechanism is decreased clearance via these pathways due to inhibition by ivacaftor and its pharmacologically active M1 metabolite.", "source": "DDInter", "management_text": "Caution is advised when ivacaftor is used with drugs that are substrates of CYP450 3A4 and/or P-gp, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever ivacaftor is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when ivacaftor is used with drugs that are substrates of CYP450 3A4 and/or P-gp, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97160/", "reference_text": "[1] \"Product Information. Kalydeco (ivacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[2] Richter WO, Jacob BG, Schwandt P \"Interaction between fibre and lovastatin.\" Lancet 338 (1991): 706[3] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors.\" Clin Pharmacol Ther 64 (1998): 477-83[4] Kantola T, Kivisto KT, Neuvonen PJ \"Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid.\" Clin Pharmacol Ther 63 (1998): 397-402[5] \"Product Information. Mevacor (lovastatin).\" Merck & Co, Inc, West Point, PA.[6] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions.\" Br J Clin Pharmacol 46 (1998): 101-10[7] Neuvonen PJ, Backman JT, Niemi M \"Pharmacokinetic comparison of the potential over-the-counter statins simvastatin, lovastatin, fluvastatin and pravastatin.\" Clin Pharmacokinet 47 (2008): 463-74[8] Thompson PD, Clarkson P, Karas RH \"Statin-associated myopathy.\" JAMA 289 (2003): 1681-90[9] \"Product Information. Zocor (simvastatin).\" Merck & Co, Inc, West Point, PA.[10] \"Product Information. Trikafta (elexacaftor/ivacaftor/tezacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[11] \"Product Information. Kalydeco (ivacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[12] \"Product Information. Orkambi (ivacaftor-lumacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[13] \"Product Information. Symdeko 4-Week (ivacaftor-tezacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.", "alternatives_a": "Cabozantinib, Sunitinib, Regorafenib, Copanlisib, Ruxolitinib, Lenvatinib, Abemaciclib, Ponatinib, Neratinib, Vandetanib, Trametinib, More", "alternatives_b": "Nitric Oxide, Doxapram, Elexacaftor, Lumacaftor", "updated_at": 1767369485}, {"id": 97057, "ingredient1": "Ivacaftor", "ingredient2": "Pegaspargase", "severity": "Moderate", "effect": "Concomitant use of asparaginase with other hepatotoxic agents may potentiate the risk of liver injury. Hepatomegaly, acute severe hepatotoxicity, and fatal liver failure have been reported with asparaginase treatment in adults. Also, asparaginase may increase the toxicity of drugs bound to plasma proteins or metabolized by the liver.", "source": "DDInter", "management_text": "The risk of additive hepatotoxicity should be considered when asparaginase is used with other hepatotoxic agents (e.g., alcohol, androgens, antituberculosis agents, azole antifungal agents, ACE inhibitors, macrolide antibiotics, nonsteroidal anti-inflammatory agents, nucleoside reverse transcriptase inhibitors, sulfonamides, thiazolidinediones, and statins). Liver function tests should be monitored at regular intervals during asparaginase treatment with or without other hepatotoxic drugs. Patients should be advised to seek medical attention if they experience potential symptoms of hepatotoxicity such as right upper quadrant pain, increasing abdominal size, fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, dark urine, pale stools, and jaundice.", "mechanism_text": "Synergism", "recommendation": "The risk of additive hepatotoxicity should be considered when asparaginase is used with other hepatotoxic agents (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97161/", "reference_text": "[1] \"Product Information. Oncaspar (pegaspargase).\" Rhone-Poulenc Rorer, Collegeville, PA.[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] Bodmer M, Sulz M, Stadlmann S, Droll A, Terracciano L, Krahenbuhl S \"Fatal liver failure in an adult patient with acute lymphoblastic leukemia following treatment with L-asparaginase.\" Digestion 74 (2006): epub[4] Cerner Multum, Inc \"ANVISA Bulrio Eletrnico. Available from: URL: http://www.anvisa.gov.br/datavisa/fila_bula/index.asp.\" O 0 (2015):[5] \"Product Information. Elspar (asparaginase).\" Merck & Co, Inc, West Point, PA.[6] Christ TN, Stock W, Knoebel RW \"Incidence of asparaginase-related hepatotoxicity, pancreatitis, and thrombotic events in adults with acute lymphoblastic leukemia treated with a pediatric-inspired regimen.\" J Oncol Pharm Pract 24 (2018): 299-308[7] Lu G, Karur V, Herrington JD, Walker MG \"Successful treatment of pegaspargase-induced acute hepatotoxicity with vitamin B complex and L-carnitine\" Proc (Bayl Univ Med Cent) 29 (2016): 46-7[8] Jenkins R, Perlin E \"Severe hepatotoxicity from Escherichia coli L-asparaginase.\" J Natl Med Assoc 79 (1987): 775-9[9] \"Product Information. Asparlas (calaspargase pegol).\" Servier, Boston, MA.[10] Burke PW, Aldoss I, Lunning MA, et.al \"High-grade PEGylated asparaginase-related hepatotoxicity occurrence in a pediatric-inspired adult acute lymphoblastic leukemia regimen does not necessarily predict recurrent hepatotoxicity in subsequent cycles.\" Blood 122 (2013): 2671[11] \"Product Information. Erwinaze (asparaginase Erwinia chrysanthemi).\" EUSA Pharma, Newtown, PA.[12] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[13] Al-Nawakil C, Willems L, Mauprivez C, et.al \"Successful treatment of l-asparaginase-induced severe acute hepatotoxicity using mitochondrial cofactors.\" Leuk Lymphoma 55 (2014): 1670-4", "alternatives_a": "Pertuzumab, Oxaliplatin, Bortezomib, Tisagenlecleucel, Aminolevulinic acid, Omacetaxine mepesuccinate, Altretamine, Tagraxofusp, Ixazomib, Enasidenib, Porfimer sodium, More", "alternatives_b": "Nitric Oxide, Doxapram, Elexacaftor, Lumacaftor", "updated_at": 1767369485}, {"id": 97058, "ingredient1": "Ivacaftor", "ingredient2": "Peginterferon beta-1a", "severity": "Moderate", "effect": "Coadministration of beta interferons with other agents known to induce hepatotoxicity may potentiate the risk of liver injury. Use of beta interferons has been associated with rare cases of liver injury, including autoimmune hepatitis and severe liver damage leading to hepatic failure, some of which required transplantation.", "source": "DDInter", "management_text": "The risk of hepatic injury should be considered when beta interferons are used with other potentially hepatotoxic agents (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; other interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; nucleoside reverse transcriptase inhibitors; proteasome inhibitors; retinoids; sulfonamides; tamoxifen; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice). Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice.", "mechanism_text": "Synergism", "recommendation": "The risk of hepatic injury should be considered when beta interferons are used with other potentially hepatotoxic agents (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97162/", "reference_text": "[1] \"Product Information. Plegridy (peginterferon beta-1a).\" Biogen Idec Inc, Cambridge, MA.[2] \"Product Information. Betaseron (interferon beta-1b).\" Berlex, Richmond, CA.[3] \"Product Information. Rebif (interferon beta-1a).\" Serono Laboratories Inc, Norwell, MA.[4] \"Product Information. Avonex (interferon beta-1a).\" Biogen, Cambridge, MA.", "alternatives_a": "Nitric Oxide, Doxapram, Elexacaftor, Lumacaftor", "alternatives_b": "Interferon alfa-n1, Oprelvekin, Sipuleucel-T, Elapegademase, Peginterferon alfa-2a, Ropeginterferon alfa-2b, Interferon alfacon-1, Sargramostim, Histamine, Aldesleukin, Pegademase, More", "updated_at": 1767369485}, {"id": 97059, "ingredient1": "Ivacaftor", "ingredient2": "Pemigatinib", "severity": "Moderate", "effect": "Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of pemigatinib, which is primarily metabolized by the isoenzyme in vitro. Increased exposure to pemigatinib may increase the incidence and severity of serious adverse reactions such as abdominal pain, acute kidney injury, cholangitis, cholangitis infective, diarrhea, failure to thrive, hypercalcemia, hyponatremia, pleural effusion, pyrexia, small intestinal obstruction, and urinary tract infection.", "source": "DDInter", "management_text": "Caution is advised if pemigatinib is coadministered with CYP450 3A4 inhibitors. Dosage adjustments may be required based on clinical response and tolerance.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if pemigatinib is coadministered with CYP450 3A4 inhibitors.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97163/", "reference_text": "[1] \"Product Information. Pemazyre (pemigatinib).\" Incyte Corporation, Wilmington, DE.[2] \"Product Information. Pemazyre (pemigatinib).\" Incyte Corporation, Wilmington, DE.[3] \"Product Information. Accolate (zafirlukast).\" Zeneca Pharmaceuticals, Wilmington, DE.", "alternatives_a": "Nitric Oxide, Doxapram, Elexacaftor", "alternatives_b": "Cabozantinib, Sunitinib, Regorafenib, Copanlisib, Ruxolitinib, Lenvatinib, Abemaciclib, Ponatinib, Neratinib, Vandetanib, Trametinib, More", "updated_at": 1767369485}, {"id": 97060, "ingredient1": "Ivacaftor", "ingredient2": "Pentobarbital", "severity": "Moderate", "effect": "Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of ivacaftor, which is primarily metabolized by the isoenzyme.", "source": "DDInter", "management_text": "The potential for diminished pharmacologic effects of ivacaftor-containing medications should be considered during coadministration with CYP450 3A4 inducers. Alternative treatments may be required if an interaction is suspected.", "mechanism_text": "Metabolism", "recommendation": "The potential for diminished pharmacologic effects of ivacaftor-containing medications should be considered during coadministration with CYP450 3A4 inducers.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97164/", "reference_text": "[1] \"Product Information. Symdeko 4-Week (ivacaftor-tezacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[2] \"Product Information. Orkambi (ivacaftor-lumacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[3] \"Product Information. Trikafta (elexacaftor/ivacaftor/tezacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[4] \"Product Information. Kalydeco (ivacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[5] \"Product Information. Trikafta (elexacaftor/ivacaftor/tezacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[6] \"Product Information. Kalydeco (ivacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[7] \"Product Information. Orkambi (ivacaftor-lumacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[8] \"Product Information. Symdeko 4-Week (ivacaftor-tezacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.", "alternatives_a": "Flurazepam, Methohexital, Zaleplon, Dichloralphenazone, Valerian, Temazepam, Chloral hydrate, Quazepam, Paraldehyde, Ramelteon, Ethchlorvynol, More", "alternatives_b": "Nitric Oxide, Doxapram, Elexacaftor, Lumacaftor", "updated_at": 1767369485}, {"id": 97061, "ingredient1": "Ivacaftor", "ingredient2": "Pexidartinib", "severity": "Major", "effect": "Serious cases of hepatotoxicity, some fatal, have occurred in patients treated with pexidartinib. Concomitant use of other potentially hepatotoxic agents may potentiate the risk of liver injury. The mechanism of hepatotoxicity is unknown, its occurrence cannot be predicted, and it is unknown whether liver injury occurs in the absence of increased transaminases.", "source": "DDInter", "management_text": "The use of pexidartinib with other potentially hepatotoxic agents should be avoided. Patients treated with pexidartinib should have liver function tests, including AST, ALT, total bilirubin, direct bilirubin, ALP, and gamma-glutamyl transferase (GGT), prior to initiation of pexidartinib, weekly for the first 8 weeks, every 2 weeks for the next month, and every 3 months thereafter. Pexidartinib therapy may require a dosage reduction, to be withheld, or permanently discontinued based on the severity of the hepatotoxicity. A recurrence of increased serum transaminases, bilirubin, or ALP may occur upon rechallenge with a reduced dose of pexidartinib. Liver function tests should be performed weekly for the first month after rechallenge. Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice.", "mechanism_text": "Synergism", "recommendation": "The use of pexidartinib with other potentially hepatotoxic agents should be avoided.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97165/", "reference_text": "[1] \"Product Information. Turalio (pexidartinib).\" Daiichi Sankyo, Inc., Parsippany, NJ.[2] \"Product Information. Turalio (pexidartinib).\" Daiichi Sankyo, Inc., Parsippany, NJ.", "alternatives_a": "Nitric Oxide, Doxapram, Elexacaftor", "alternatives_b": "Cabozantinib, Sunitinib, Regorafenib, Copanlisib, Ruxolitinib, Lenvatinib, Abemaciclib, Ponatinib, Neratinib, Vandetanib, Trametinib, More", "updated_at": 1767369485}, {"id": 97062, "ingredient1": "Ivacaftor", "ingredient2": "Phenylbutazone", "severity": "Moderate", "effect": "Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of ivacaftor, which is primarily metabolized by the isoenzyme.", "source": "DDInter", "management_text": "The potential for diminished pharmacologic effects of ivacaftor-containing medications should be considered during coadministration with CYP450 3A4 inducers. Alternative treatments may be required if an interaction is suspected.", "mechanism_text": "Metabolism", "recommendation": "The potential for diminished pharmacologic effects of ivacaftor-containing medications should be considered during coadministration with CYP450 3A4 inducers.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97166/", "reference_text": "[1] \"Product Information. Symdeko 4-Week (ivacaftor-tezacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[2] \"Product Information. Orkambi (ivacaftor-lumacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[3] \"Product Information. Trikafta (elexacaftor/ivacaftor/tezacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[4] \"Product Information. Kalydeco (ivacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[5] \"Product Information. Trikafta (elexacaftor/ivacaftor/tezacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[6] \"Product Information. Kalydeco (ivacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[7] \"Product Information. Orkambi (ivacaftor-lumacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[8] \"Product Information. Symdeko 4-Week (ivacaftor-tezacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.", "alternatives_a": "Acetylsalicylic acid, Fenoprofen, Rabeprazole, Meclofenamic acid, Ketorolac, Misoprostol, Ketoprofen, Glucosamine, Oxaprozin, Chondroitin sulfate, Nabumetone, More", "alternatives_b": "Nitric Oxide, Doxapram, Elexacaftor, Lumacaftor", "updated_at": 1767369485}, {"id": 97063, "ingredient1": "Ivacaftor", "ingredient2": "Phenytoin", "severity": "Major", "effect": "Coadministration with potent inducers of CYP450 3A4 may significantly decrease the plasma concentrations of ivacaftor, which is primarily metabolized by the isoenzyme.", "source": "DDInter", "management_text": "Concomitant use of ivacaftor-containing medications with potent CYP450 3A4 inducers is not recommended.", "mechanism_text": "Metabolism", "recommendation": "Concomitant use of ivacaftor-containing medications with potent CYP450 3A4 inducers is not recommended.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97167/", "reference_text": "[1] \"Product Information. Orkambi (ivacaftor-lumacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] \"Product Information. Symdeko 4-Week (ivacaftor-tezacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[4] \"Product Information. Trikafta (elexacaftor/ivacaftor/tezacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[5] \"Product Information. Kalydeco (ivacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[6] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[7] Patel S, Robinson R, Burk M \"Hypertensive crisis associated with St. John's Wort.\" Am J Med 112 (2002): 507-8[8] \"Product Information. Trikafta (elexacaftor/ivacaftor/tezacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[9] \"Product Information. Kalydeco (ivacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[10] \"Product Information. Orkambi (ivacaftor-lumacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[11] \"Product Information. Symdeko 4-Week (ivacaftor-tezacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.", "alternatives_a": "Brivaracetam, Topiramate, Ezogabine, Lamotrigine, Lacosamide, Levetiracetam, Tiagabine, Ethotoin, Paramethadione, Perampanel, Vigabatrin, More", "alternatives_b": "Nitric Oxide, Doxapram, Elexacaftor", "updated_at": 1767369485}, {"id": 97064, "ingredient1": "Ivacaftor", "ingredient2": "Pimavanserin", "severity": "Moderate", "effect": "Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of pimavanserin, which is primarily metabolized by the isoenzyme. High plasma levels of pimavanserin may increase the risk of QT interval prolongation, which has been associated with ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Caution is advised when pimavanserin is used with CYP450 3A4 inhibitors. Patients should be monitored for adverse effects such as peripheral edema and QT prolongation, and the pimavanserin dosage adjusted as necessary.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when pimavanserin is used with CYP450 3A4 inhibitors.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97168/", "reference_text": "[1] \"Product Information. Nuplazid (pimavanserin).\" Accelis Pharma, East Windsor, NJ.[2] \"Product Information. Accolate (zafirlukast).\" Zeneca Pharmaceuticals, Wilmington, DE.", "alternatives_a": "Fluphenazine, Thiothixene, Risperidone, Amisulpride, Quetiapine, Prochlorperazine, Promazine, Thioridazine, Trifluoperazine, Paliperidone, Chlorpromazine, More", "alternatives_b": "Nitric Oxide, Doxapram, Elexacaftor", "updated_at": 1767369485}, {"id": 97065, "ingredient1": "Ivacaftor", "ingredient2": "Pimecrolimus (topical)", "severity": "Minor", "effect": "Theoretically, coadministration with CYP450 3A inhibitors may increase the plasma concentrations of pimecrolimus, which has been shown in vitro to undergo metabolism by this subfamily of hepatic microsomal enzymes. Although clinically significant drug interactions are not expected due to minimal systemic absorption of topically administered pimecrolimus, the possibility cannot be ruled out.", "source": "DDInter", "management_text": "-", "mechanism_text": "Metabolism", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97169/", "reference_text": "[1] \"Product Information. Elidel (pimecrolimus topical).\" Novartis Pharmaceuticals, East Hanover, NJ.", "alternatives_a": "Nitric Oxide, Doxapram, Elexacaftor, Lumacaftor", "alternatives_b": "", "updated_at": 1767369485}, {"id": 97066, "ingredient1": "Ivacaftor", "ingredient2": "Pimozide", "severity": "Major", "effect": "Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of pimozide, which is partially metabolized by the isoenzyme. The use of pimozide has been associated with dose-related prolongation of the QT interval, thus elevated plasma levels of the drug may potentiate the risk of ventricular arrhythmias such as ventricular tachycardia and torsade de pointes as well as cardiac arrest and sudden death.", "source": "DDInter", "management_text": "Given the potential for serious and life-threatening adverse cardiac events associated with increased plasma levels of pimozide, concomitant use with potent CYP450 3A4 inhibitors such as itraconazole, ketoconazole, posaconazole, voriconazole, clarithromycin, telithromycin, conivaptan, idelalisib, nefazodone, cobicistat, delavirdine, and most protease inhibitors is considered contraindicated. Some authorities consider concomitant administration of lurasidone and itraconazole to be contraindicated during and for 2 weeks after treatment with itraconazole. With respect to less potent CYP450 3A4 inhibitors, the manufacturers recommend that they also not be used with pimozide.", "mechanism_text": "Metabolism", "recommendation": "Given the potential for serious and life-threatening adverse cardiac events associated with increased plasma levels of pimozide, concomitant use with potent CYP450 3A4 inhibitors such as itraconazole, ketoconazole, posaconazole, voriconazole, clarithromycin, telithromycin, conivaptan, idelalisib, nefazodone, cobicistat, delavirdine, and most protease inhibitors is considered contraindicated.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97170/", "reference_text": "[1] \"Product Information. Sporanox (itraconazole).\" Janssen Pharmaceutica, Titusville, NJ.[2] Glassman AH, Bigger JT Jr \"Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death.\" Am J Psychiatry 158 (2001): 1774-82[3] Flockhart DA, Drici MD, Kerbusch T, et al \"Studies on the mechanism of a fatal clarithromycin-pimozide interaction in a patient with tourette syndrome.\" J Clin Psychopharmacol 20 (2000): 317-24[4] Mangum EM, Graham KK \"Lopinavir-Ritonavir: a new protease inhibitor.\" Pharmacotherapy 21 (2001): 1352-63[5] Desta Z, Kerbusch T, Flockhart DA \"Effect of clarithromycin on the pharmacokinetics and pharmacodynamics of pimozide in healthy poor and extensive metabolizers of cytochrome P450 2D6 (CYP2D6).\" Clin Pharmacol Ther 65 (1999): 10-20[6] Cerner Multum, Inc. \"Australian Product Information.\" O 0[7] \"Product Information. Orap Tablets (pimozide).\" Gate Pharmaceuticals, Sellersville, PA.[8] Dresser GK, Spence JD, Bailey DG \"Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition.\" Clin Pharmacokinet 38 (2000): 41-57[9] Krahenbuhl S, Sauter B, Kupferschmidt H, Krause M, Wyss PA, Meier PJ \"Case report: reversible QT prolongation with torsades de pointes in a patient with pimozide intoxication.\" Am J Med Sci 309 (1995): 315-6[10] Dresser GK, Spence JD, Bailey DG \"Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition.\" Clin Pharmacokinet 38 (2000): 41-57[11] \"Product Information. Orap Tablets (pimozide).\" Gate Pharmaceuticals, Sellersville, PA.", "alternatives_a": "Fluphenazine, Thiothixene, Risperidone, Amisulpride, Quetiapine, Prochlorperazine, Promazine, Thioridazine, Trifluoperazine, Paliperidone, Chlorpromazine, More", "alternatives_b": "Nitric Oxide, Doxapram, Elexacaftor, Lumacaftor", "updated_at": 1767369485}, {"id": 97067, "ingredient1": "Ivacaftor", "ingredient2": "Pirfenidone", "severity": "Moderate", "effect": "Coadministration with ivacaftor may increase the plasma concentrations of drugs that are substrates of the CYP450 2C9 isoenzyme. The proposed mechanism, based on in vitro data, involves decreased metabolic clearance due to inhibition of CYP450 2C9 by ivacaftor.", "source": "DDInter", "management_text": "Caution is advised when ivacaftor is used concurrently with drugs that are known CYP450 2C9 substrates, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever ivacaftor is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when ivacaftor is used concurrently with drugs that are known CYP450 2C9 substrates, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97171/", "reference_text": "[1] \"Product Information. Trikafta (elexacaftor/ivacaftor/tezacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[2] \"Product Information. Symdeko 4-Week (ivacaftor-tezacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[3] \"Product Information. Orkambi (ivacaftor-lumacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[4] \"Product Information. Kalydeco (ivacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[5] \"Product Information. Ambien (zolpidem).\" sanofi-aventis, Bridgewater, NJ.[6] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84[7] \"Product Information. Trikafta (elexacaftor/ivacaftor/tezacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[8] \"Product Information. Kalydeco (ivacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[9] \"Product Information. Orkambi (ivacaftor-lumacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[10] \"Product Information. Symdeko 4-Week (ivacaftor-tezacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.", "alternatives_a": "Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Abatacept, More", "alternatives_b": "Nitric Oxide, Doxapram, Elexacaftor, Lumacaftor", "updated_at": 1767369485}, {"id": 97068, "ingredient1": "Ivacaftor", "ingredient2": "Piroxicam", "severity": "Moderate", "effect": "Coadministration with ivacaftor may increase the plasma concentrations of drugs that are substrates of the CYP450 2C9 isoenzyme. The proposed mechanism, based on in vitro data, involves decreased metabolic clearance due to inhibition of CYP450 2C9 by ivacaftor.", "source": "DDInter", "management_text": "Caution is advised when ivacaftor is used concurrently with drugs that are known CYP450 2C9 substrates, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever ivacaftor is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when ivacaftor is used concurrently with drugs that are known CYP450 2C9 substrates, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97172/", "reference_text": "[1] \"Product Information. Trikafta (elexacaftor/ivacaftor/tezacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[2] \"Product Information. Symdeko 4-Week (ivacaftor-tezacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[3] \"Product Information. Orkambi (ivacaftor-lumacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[4] \"Product Information. Kalydeco (ivacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[5] \"Product Information. Ambien (zolpidem).\" sanofi-aventis, Bridgewater, NJ.[6] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84[7] \"Product Information. Trikafta (elexacaftor/ivacaftor/tezacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[8] \"Product Information. Kalydeco (ivacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[9] \"Product Information. Orkambi (ivacaftor-lumacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[10] \"Product Information. Symdeko 4-Week (ivacaftor-tezacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.", "alternatives_a": "Fenoprofen, Rabeprazole, Meclofenamic acid, Ketorolac, Misoprostol, Ketoprofen, Glucosamine, Oxaprozin, Chondroitin sulfate, Nabumetone, Rofecoxib, More", "alternatives_b": "Nitric Oxide, Doxapram, Elexacaftor, Lumacaftor", "updated_at": 1767369485}, {"id": 97069, "ingredient1": "Elexacaftor", "ingredient2": "Pitavastatin", "severity": "Moderate", "effect": "Coadministration with elexacaftor may increase the plasma concentrations of drugs that are substrates of the organic anion transporting polypeptides (OATP) 1B1 and 1B3. The proposed mechanism, based on in vitro data, involves decreased metabolic clearance due to inhibition of OATP 1B1- and 1B3-mediated hepatic uptake by elexacaftor and its metabolite. The clinical relevance is unknown.", "source": "DDInter", "management_text": "Caution is advised when elexacaftor is used concurrently with drugs that are known OATP 1B1 and 1B3 substrates, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever elexacaftor is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when elexacaftor is used concurrently with drugs that are known OATP 1B1 and 1B3 substrates, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97173/", "reference_text": "[1] \"Product Information. Trikafta (elexacaftor/ivacaftor/tezacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[2] \"Product Information. Diovan (valsartan).\" Novartis Pharmaceuticals, East Hanover, NJ.[3] \"Product Information. Cozaar (losartan).\" Merck & Co, Inc, West Point, PA.[4] \"Product Information. Trikafta (elexacaftor/ivacaftor/tezacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[5] \"Product Information. Kalydeco (ivacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[6] \"Product Information. Orkambi (ivacaftor-lumacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[7] \"Product Information. Symdeko 4-Week (ivacaftor-tezacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.", "alternatives_a": "Gemfibrozil, Fenofibric acid, Mipomersen, Evinacumab, Evolocumab, Dextrothyroxine, Probucol, Cholestyramine, Clofibrate, Colestipol, Niacin, More", "alternatives_b": "Nitric Oxide, Doxapram, Ivacaftor, Lumacaftor", "updated_at": 1767369485}, {"id": 97070, "ingredient1": "Ivacaftor", "ingredient2": "Polatuzumab vedotin", "severity": "Moderate", "effect": "Coadministration with inhibitors of CYP450 3A4 may increase exposure to unconjugated monomethyl auristatin E (MMAE), the anti-mitotic and cytotoxic component of polatuzumab vedotin. MMAE is a substrate for CYP450 3A4.", "source": "DDInter", "management_text": "Caution is advised when polatuzumab vedotin is used concomitantly with CYP450 3A4 inhibitors. Patients should be monitored for development or exacerbation of toxicities such as peripheral neuropathy, myelosuppression, opportunistic infections, tumor lysis syndrome and hepatotoxicity, and the dosing of polatuzumab vedotin adjusted or withheld as necessary in accordance with the product labeling.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when polatuzumab vedotin is used concomitantly with CYP450 3A4 inhibitors.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97174/", "reference_text": "[1] \"Product Information. Polivy (polatuzumab vedotin).\" Genentech, South San Francisco, CA.", "alternatives_a": "Nitric Oxide, Doxapram, Elexacaftor", "alternatives_b": "Pertuzumab, Cetuximab, Avelumab, Panitumumab, Obinutuzumab, Bevacizumab, Necitumumab, Dostarlimab, Ramucirumab, Atezolizumab, Amivantamab, More", "updated_at": 1767369485}, {"id": 97071, "ingredient1": "Ivacaftor", "ingredient2": "Posaconazole", "severity": "Major", "effect": "Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of ivacaftor, which is primarily metabolized by the isoenzyme.", "source": "DDInter", "management_text": "For ivacaftor -The ivacaftor dose should be reduced from 1 tablet or 1 packet of oral granules twice a day to 1 tablet or 1 packet of oral granules twice a week (i.e., every 3 to 4 days) during coadministration with potent CYP450 3A4 inhibitors. For example, a patient taking ivacaftor 150 mg tablet twice a day should reduce their ivacaftor dose to a 150 mg tablet twice a week and a patient taking ivacaftor 50 mg oral granule packet twice a day should reduce their ivacaftor dose to 50 mg oral granule packet twice a week, etc.", "mechanism_text": "Metabolism", "recommendation": "For ivacaftor -The ivacaftor dose should be reduced from 1 tablet or 1 packet of oral granules twice a day to 1 tablet or 1 packet of oral granules twice a week (i.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97175/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Symdeko 4-Week (ivacaftor-tezacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[3] \"Product Information. Trikafta (elexacaftor/ivacaftor/tezacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[4] Cerner Multum, Inc. \"Australian Product Information.\" O 0[5] \"Product Information. Kalydeco (ivacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[6] \"Product Information. Orkambi (ivacaftor-lumacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[7] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[8] \"Product Information. VFEND (voriconazole).\" Pfizer U.S. Pharmaceuticals, New York, NY.[9] \"Product Information. Trikafta (elexacaftor/ivacaftor/tezacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[10] \"Product Information. Kalydeco (ivacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[11] \"Product Information. Orkambi (ivacaftor-lumacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[12] \"Product Information. Symdeko 4-Week (ivacaftor-tezacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.", "alternatives_a": "Caspofungin, Micafungin, Amphotericin B, Oteseconazole, Flucytosine, Anidulafungin", "alternatives_b": "Nitric Oxide, Doxapram, Elexacaftor", "updated_at": 1767369485}, {"id": 97072, "ingredient1": "Ivacaftor", "ingredient2": "Pralsetinib", "severity": "Moderate", "effect": "Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of pralsetinib, which is primarily metabolized by the isoenzyme.", "source": "DDInter", "management_text": "Caution is advised when pralsetinib is used with CYP450 3A inhibitors. Monitor closely for adverse effects whenever a CYP450 3A4 inhibitor is added to therapy. Alternative treatments may be required if an interaction is suspected.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when pralsetinib is used with CYP450 3A inhibitors.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97176/", "reference_text": "[1] \"Product Information. Gavreto (pralsetinib).\" Blueprint Medicines Corporation, Cambridge, MA.[2] \"Product Information. Gavreto (pralsetinib).\" Blueprint Medicines Corporation, Cambridge, MA.", "alternatives_a": "Nitric Oxide, Doxapram, Elexacaftor", "alternatives_b": "Cabozantinib, Sunitinib, Regorafenib, Copanlisib, Ruxolitinib, Lenvatinib, Abemaciclib, Ponatinib, Neratinib, Vandetanib, Trametinib, More", "updated_at": 1767369485}, {"id": 97073, "ingredient1": "Elexacaftor", "ingredient2": "Pravastatin", "severity": "Moderate", "effect": "Coadministration with elexacaftor may increase the plasma concentrations of drugs that are substrates of the organic anion transporting polypeptides (OATP) 1B1 and 1B3. The proposed mechanism, based on in vitro data, involves decreased metabolic clearance due to inhibition of OATP 1B1- and 1B3-mediated hepatic uptake by elexacaftor and its metabolite. The clinical relevance is unknown.", "source": "DDInter", "management_text": "Caution is advised when elexacaftor is used concurrently with drugs that are known OATP 1B1 and 1B3 substrates, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever elexacaftor is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when elexacaftor is used concurrently with drugs that are known OATP 1B1 and 1B3 substrates, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97177/", "reference_text": "[1] \"Product Information. Trikafta (elexacaftor/ivacaftor/tezacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[2] \"Product Information. Diovan (valsartan).\" Novartis Pharmaceuticals, East Hanover, NJ.[3] \"Product Information. Cozaar (losartan).\" Merck & Co, Inc, West Point, PA.[4] \"Product Information. Trikafta (elexacaftor/ivacaftor/tezacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[5] \"Product Information. Kalydeco (ivacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[6] \"Product Information. Orkambi (ivacaftor-lumacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[7] \"Product Information. Symdeko 4-Week (ivacaftor-tezacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.", "alternatives_a": "Gemfibrozil, Fenofibric acid, Mipomersen, Evinacumab, Evolocumab, Dextrothyroxine, Probucol, Cholestyramine, Clofibrate, Colestipol, Niacin, More", "alternatives_b": "Nitric Oxide, Doxapram, Ivacaftor, Lumacaftor", "updated_at": 1767369485}, {"id": 97074, "ingredient1": "Ivacaftor", "ingredient2": "Prednisolone", "severity": "Moderate", "effect": "Coadministration with ivacaftor may increase the plasma concentrations of drugs that are substrates of the CYP450 3A4 isoenzyme and/or P-glycoprotein (P-gp) efflux transporter. The mechanism is decreased clearance via these pathways due to inhibition by ivacaftor and its pharmacologically active M1 metabolite.", "source": "DDInter", "management_text": "Caution is advised when ivacaftor is used with drugs that are substrates of CYP450 3A4 and/or P-gp, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever ivacaftor is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when ivacaftor is used with drugs that are substrates of CYP450 3A4 and/or P-gp, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97178/", "reference_text": "[1] \"Product Information. Kalydeco (ivacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[2] Richter WO, Jacob BG, Schwandt P \"Interaction between fibre and lovastatin.\" Lancet 338 (1991): 706[3] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors.\" Clin Pharmacol Ther 64 (1998): 477-83[4] Kantola T, Kivisto KT, Neuvonen PJ \"Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid.\" Clin Pharmacol Ther 63 (1998): 397-402[5] \"Product Information. Mevacor (lovastatin).\" Merck & Co, Inc, West Point, PA.[6] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions.\" Br J Clin Pharmacol 46 (1998): 101-10[7] Neuvonen PJ, Backman JT, Niemi M \"Pharmacokinetic comparison of the potential over-the-counter statins simvastatin, lovastatin, fluvastatin and pravastatin.\" Clin Pharmacokinet 47 (2008): 463-74[8] Thompson PD, Clarkson P, Karas RH \"Statin-associated myopathy.\" JAMA 289 (2003): 1681-90[9] \"Product Information. Zocor (simvastatin).\" Merck & Co, Inc, West Point, PA.[10] \"Product Information. Trikafta (elexacaftor/ivacaftor/tezacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[11] \"Product Information. Kalydeco (ivacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[12] \"Product Information. Orkambi (ivacaftor-lumacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[13] \"Product Information. Symdeko 4-Week (ivacaftor-tezacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.", "alternatives_a": "Mometasone furoate, Amcinonide, Fluocinolone acetonide, Hydrocortisone butyrate, Fluticasone, Fluocinonide, Fluorometholone, Clobetasol, Beclomethasone dipropionate, Fluocinolone acetonide, Fluorometholone, More", "alternatives_b": "Nitric Oxide, Doxapram, Elexacaftor", "updated_at": 1767369485}, {"id": 97075, "ingredient1": "Ivacaftor", "ingredient2": "Prednisone", "severity": "Moderate", "effect": "Coadministration with ivacaftor may increase the plasma concentrations of drugs that are substrates of the CYP450 3A4 isoenzyme and/or P-glycoprotein (P-gp) efflux transporter. The mechanism is decreased clearance via these pathways due to inhibition by ivacaftor and its pharmacologically active M1 metabolite.", "source": "DDInter", "management_text": "Caution is advised when ivacaftor is used with drugs that are substrates of CYP450 3A4 and/or P-gp, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever ivacaftor is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when ivacaftor is used with drugs that are substrates of CYP450 3A4 and/or P-gp, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97179/", "reference_text": "[1] \"Product Information. Kalydeco (ivacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[2] Richter WO, Jacob BG, Schwandt P \"Interaction between fibre and lovastatin.\" Lancet 338 (1991): 706[3] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors.\" Clin Pharmacol Ther 64 (1998): 477-83[4] Kantola T, Kivisto KT, Neuvonen PJ \"Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid.\" Clin Pharmacol Ther 63 (1998): 397-402[5] \"Product Information. Mevacor (lovastatin).\" Merck & Co, Inc, West Point, PA.[6] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions.\" Br J Clin Pharmacol 46 (1998): 101-10[7] Neuvonen PJ, Backman JT, Niemi M \"Pharmacokinetic comparison of the potential over-the-counter statins simvastatin, lovastatin, fluvastatin and pravastatin.\" Clin Pharmacokinet 47 (2008): 463-74[8] Thompson PD, Clarkson P, Karas RH \"Statin-associated myopathy.\" JAMA 289 (2003): 1681-90[9] \"Product Information. Zocor (simvastatin).\" Merck & Co, Inc, West Point, PA.[10] \"Product Information. Trikafta (elexacaftor/ivacaftor/tezacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[11] \"Product Information. Kalydeco (ivacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[12] \"Product Information. Orkambi (ivacaftor-lumacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[13] \"Product Information. Symdeko 4-Week (ivacaftor-tezacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.", "alternatives_a": "Cromoglicic acid, Olsalazine, Sulfasalazine, Balsalazide, Beclomethasone dipropionate, Mesalazine, Deflazacort", "alternatives_b": "Nitric Oxide, Doxapram, Elexacaftor", "updated_at": 1767369485}, {"id": 97076, "ingredient1": "Ivacaftor", "ingredient2": "Primidone", "severity": "Major", "effect": "Coadministration with potent inducers of CYP450 3A4 may significantly decrease the plasma concentrations of ivacaftor, which is primarily metabolized by the isoenzyme.", "source": "DDInter", "management_text": "Concomitant use of ivacaftor-containing medications with potent CYP450 3A4 inducers is not recommended.", "mechanism_text": "Metabolism", "recommendation": "Concomitant use of ivacaftor-containing medications with potent CYP450 3A4 inducers is not recommended.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97180/", "reference_text": "[1] \"Product Information. Orkambi (ivacaftor-lumacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] \"Product Information. Symdeko 4-Week (ivacaftor-tezacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[4] \"Product Information. Trikafta (elexacaftor/ivacaftor/tezacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[5] \"Product Information. Kalydeco (ivacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[6] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[7] Patel S, Robinson R, Burk M \"Hypertensive crisis associated with St. John's Wort.\" Am J Med 112 (2002): 507-8[8] \"Product Information. Trikafta (elexacaftor/ivacaftor/tezacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[9] \"Product Information. Kalydeco (ivacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[10] \"Product Information. Orkambi (ivacaftor-lumacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[11] \"Product Information. Symdeko 4-Week (ivacaftor-tezacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.", "alternatives_a": "Flurazepam, Methohexital, Zaleplon, Dichloralphenazone, Valerian, Temazepam, Chloral hydrate, Quazepam, Paraldehyde, Ramelteon, Ethchlorvynol, More", "alternatives_b": "Nitric Oxide, Doxapram, Elexacaftor", "updated_at": 1767369485}, {"id": 97077, "ingredient1": "Ivacaftor", "ingredient2": "Prucalopride", "severity": "Minor", "effect": "Coadministration with inhibitors of P-glycoprotein (P-gp) may increase the plasma concentrations of prucalopride, which is thought to be a weak substrate of the efflux transporter.", "source": "DDInter", "management_text": "-", "mechanism_text": "Others", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97181/", "reference_text": "[1] Cerner Multum, Inc. \"Australian Product Information.\" O 0[2] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid.\"[3] \"Product Information. Resotran (prucalopride).\" Janssen Pharmaceuticals, Titusville, NJ.[4] Cerner Multum, Inc. \"Australian Product Information.\" O 0[5] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid.\"[6] \"Product Information. Resotran (prucalopride).\" Janssen Pharmaceuticals, Titusville, NJ.[7] \"Product Information. Mavyret (glecaprevir-pibrentasvir).\" Abbott Pharmaceutical, Abbott Park, IL.", "alternatives_a": "Alvimopan, Sorbitol, Tegaserod, Bisacodyl, Lactulose, Methylnaltrexone, Lactitol, Sodium phosphate, monobasic, Magnesium oxide, Sodium sulfate, Linaclotide, More", "alternatives_b": "Nitric Oxide, Doxapram, Elexacaftor, Lumacaftor", "updated_at": 1767369485}, {"id": 97078, "ingredient1": "Ivacaftor", "ingredient2": "Quinidine", "severity": "Moderate", "effect": "Coadministration with ivacaftor may increase the plasma concentrations of drugs that are substrates of the CYP450 3A4 isoenzyme and/or P-glycoprotein (P-gp) efflux transporter. The mechanism is decreased clearance via these pathways due to inhibition by ivacaftor and its pharmacologically active M1 metabolite.", "source": "DDInter", "management_text": "Caution is advised when ivacaftor is used with drugs that are substrates of CYP450 3A4 and/or P-gp, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever ivacaftor is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when ivacaftor is used with drugs that are substrates of CYP450 3A4 and/or P-gp, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97182/", "reference_text": "[1] \"Product Information. Kalydeco (ivacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[2] Richter WO, Jacob BG, Schwandt P \"Interaction between fibre and lovastatin.\" Lancet 338 (1991): 706[3] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors.\" Clin Pharmacol Ther 64 (1998): 477-83[4] Kantola T, Kivisto KT, Neuvonen PJ \"Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid.\" Clin Pharmacol Ther 63 (1998): 397-402[5] \"Product Information. Mevacor (lovastatin).\" Merck & Co, Inc, West Point, PA.[6] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions.\" Br J Clin Pharmacol 46 (1998): 101-10[7] Neuvonen PJ, Backman JT, Niemi M \"Pharmacokinetic comparison of the potential over-the-counter statins simvastatin, lovastatin, fluvastatin and pravastatin.\" Clin Pharmacokinet 47 (2008): 463-74[8] Thompson PD, Clarkson P, Karas RH \"Statin-associated myopathy.\" JAMA 289 (2003): 1681-90[9] \"Product Information. Zocor (simvastatin).\" Merck & Co, Inc, West Point, PA.[10] \"Product Information. Trikafta (elexacaftor/ivacaftor/tezacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[11] \"Product Information. Kalydeco (ivacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[12] \"Product Information. Orkambi (ivacaftor-lumacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[13] \"Product Information. Symdeko 4-Week (ivacaftor-tezacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.", "alternatives_a": "Propafenone, Tocainide, Procainamide, Flecainide, Mexiletine, Bretylium, Moricizine, Ibutilide", "alternatives_b": "Nitric Oxide, Doxapram, Elexacaftor, Lumacaftor", "updated_at": 1767369485}, {"id": 97079, "ingredient1": "Ivacaftor", "ingredient2": "Ranolazine", "severity": "Moderate", "effect": "Coadministration with inhibitors of the P-glycoprotein (P-gp) efflux transporter may increase the oral bioavailability of ranolazine, which has been shown in vitro to be a substrate of P-gp. Ranolazine can prolong the QT interval in a dose-dependent manner, thus increased plasma levels may potentiate the risk of ventricular arrhythmias including ventricular fibrillation and torsade de pointes.", "source": "DDInter", "management_text": "Caution is advised if ranolazine is prescribed in combination with P-gp inhibitors. Pharmacologic response to ranolazine should be monitored more closely whenever a P-gp inhibitor is added to or withdrawn from therapy, and the ranolazine dosage adjusted as necessary. Patients should be advised to seek medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, palpitations, or syncope.", "mechanism_text": "Absorption", "recommendation": "Caution is advised if ranolazine is prescribed in combination with P-gp inhibitors.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97183/", "reference_text": "[1] \"Product Information. Ranexa (ranolazine).\" Calmoseptine Inc, Huntington Beach, CA.[2] \"Product Information. Ranexa (ranolazine).\" Calmoseptine Inc, Huntington Beach, CA.", "alternatives_a": "Adenosine, Regadenoson, Alprostadil, Ubidecarenone", "alternatives_b": "Nitric Oxide, Doxapram, Elexacaftor", "updated_at": 1767369485}, {"id": 97080, "ingredient1": "Ivacaftor", "ingredient2": "Relugolix", "severity": "Major", "effect": "Coadministration with inhibitors of the P-glycoprotein (P-gp) efflux transporter may increase the plasma concentrations of relugolix, particularly when the inhibitors are given orally. Relugolix is a substrate for intestinal P-gp.", "source": "DDInter", "management_text": "Concomitant use of relugolix with orally administered P-gp inhibitors should generally be avoided. If coadministration is required, the manufacturer recommends taking relugolix first and separating the dosing by at least 6 hours. Patients should be monitored more frequently for adverse effects. Alternatively, treatment with relugolix may be interrupted for up to two weeks if a short course of treatment with a P-gp inhibitor is necessary.", "mechanism_text": "Absorption", "recommendation": "Concomitant use of relugolix with orally administered P-gp inhibitors should generally be avoided.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97184/", "reference_text": "[1] \"Product Information. Orgovyx (relugolix).\" Myovant Sciences, Inc., Brisbane, CA.[2] \"Product Information. Juxtapid (lomitapide).\" Aegerion Pharmaceuticals Inc, Cambridge, MA.", "alternatives_a": "Nitric Oxide, Doxapram, Elexacaftor", "alternatives_b": "Norethisterone, Nafarelin, Octreotide, Cetrorelix, Pasireotide, Ganirelix, Lanreotide, Gonadorelin, Darolutamide, Anastrozole, Fulvestrant, More", "updated_at": 1767369485}, {"id": 97081, "ingredient1": "Ivacaftor", "ingredient2": "Remdesivir", "severity": "Moderate", "effect": "Concomitant use of remdesivir with other agents that are known to induce hepatotoxicity may theoretically increase the risk of liver injury. Data from investigational use and clinical studies suggest that remdesivir may be associated with hepatotoxic effects.", "source": "DDInter", "management_text": "Until more information is available, concomitant use of remdesivir with known hepatotoxic drugs should be avoided when possible. Liver function should be evaluated prior to starting remdesivir and monitored during treatment as clinically appropriate. Remdesivir should not be initiated in patients with ALT greater than or equal to 5 times the upper limit of normal (ULN) at baseline. Likewise, remdesivir should be discontinued immediately if ALT increases to 5 times ULN or greater during treatment (may be restarted when ALT falls below 5 times ULN), or if ALT elevation is accompanied by signs or symptoms of liver inflammation or increasing conjugated bilirubin, alkaline phosphatase, or INR.", "mechanism_text": "Synergism", "recommendation": "Until more information is available, concomitant use of remdesivir with known hepatotoxic drugs should be avoided when possible.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97185/", "reference_text": "[1] Gilead Sciences, Inc \"About Remdesivir. Available from: URL: https://www.gilead.com/purpose/advancing-global-health/covid-19/about-remdesivir.\" ([2020]):[2] US Food and Drug Administration \"Fact sheet for health care providers emergency use authorization (EUA) of remdesivir (GS-5734TM) Available from: URL: https://www.fda.gov/media/137566/download.\" ([2020, May 1]]):[3] European Medicines Agency \"Summary on compassionate use. Remdesivir Gilead. Available from: URL: https://www.ema.europa.eu/en/documents/other/summary-compassionate-use-remdesivir-gilead_en.pdf.\" ([2020 Apr 03]):[4] Cerner Multum, Inc. \"Australian Product Information.\" O 0[5] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0", "alternatives_a": "Nitric Oxide, Doxapram, Elexacaftor", "alternatives_b": "Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Simeprevir, Cabotegravir, Valaciclovir, Zanamivir, Velpatasvir, Oseltamivir, Acyclovir, More", "updated_at": 1767369485}, {"id": 97082, "ingredient1": "Elexacaftor", "ingredient2": "Repaglinide", "severity": "Moderate", "effect": "Coadministration with elexacaftor may increase the plasma concentrations of drugs that are substrates of the organic anion transporting polypeptides (OATP) 1B1 and 1B3. The proposed mechanism, based on in vitro data, involves decreased metabolic clearance due to inhibition of OATP 1B1- and 1B3-mediated hepatic uptake by elexacaftor and its metabolite. The clinical relevance is unknown.", "source": "DDInter", "management_text": "Caution is advised when elexacaftor is used concurrently with drugs that are known OATP 1B1 and 1B3 substrates, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever elexacaftor is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when elexacaftor is used concurrently with drugs that are known OATP 1B1 and 1B3 substrates, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97186/", "reference_text": "[1] \"Product Information. Trikafta (elexacaftor/ivacaftor/tezacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[2] \"Product Information. Diovan (valsartan).\" Novartis Pharmaceuticals, East Hanover, NJ.[3] \"Product Information. Cozaar (losartan).\" Merck & Co, Inc, West Point, PA.[4] \"Product Information. Trikafta (elexacaftor/ivacaftor/tezacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[5] \"Product Information. Kalydeco (ivacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[6] \"Product Information. Orkambi (ivacaftor-lumacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[7] \"Product Information. Symdeko 4-Week (ivacaftor-tezacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.", "alternatives_a": "Glipizide, Acetohexamide, Guar gum, Pramlintide, Alogliptin, Tolazamide, Dulaglutide, Exenatide, Tolbutamide, Miglitol, Glimepiride, More", "alternatives_b": "Nitric Oxide, Doxapram, Ivacaftor", "updated_at": 1767369485}, {"id": 97083, "ingredient1": "Elexacaftor", "ingredient2": "Revefenacin", "severity": "Moderate", "effect": "Coadministration of revefenacin with inhibitors of organic anion transporting polypeptide (OATP) 1B1 and/or 1B3 may increase systemic exposure to its active metabolite, which has been reported to be a substrate of the hepatic uptake transporters.", "source": "DDInter", "management_text": "Concomitant use of revefenacin with OATP 1B1 and/or 1B3 inhibitors is not recommended.", "mechanism_text": "Metabolism", "recommendation": "Concomitant use of revefenacin with OATP 1B1 and/or 1B3 inhibitors is not recommended.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97187/", "reference_text": "[1] \"Product Information. Yupelri (revefenacin).\" Mylan Specialty, Morgantown, WV.[2] \"Product Information. Nexletol (bempedoic acid).\" Esperion Therapeutics, Ann Arbor, MI.[3] \"Product Information. Nexlizet (bempedoic acid-ezetimibe).\" Esperion Therapeutics, Ann Arbor, MI.[4] \"Product Information. Yupelri (revefenacin).\" Mylan Specialty, Morgantown, WV.[5] \"Product Information. Nexletol (bempedoic acid).\" Esperion Therapeutics, Ann Arbor, MI.[6] \"Product Information. Nexlizet (bempedoic acid-ezetimibe).\" Esperion Therapeutics, Ann Arbor, MI.[7] \"Product Information. Mavyret (glecaprevir-pibrentasvir).\" Abbott Pharmaceutical, Abbott Park, IL.", "alternatives_a": "Ciclesonide, Umeclidinium, Mometasone furoate, Budesonide, Glycopyrronium, Aclidinium, Flunisolide, Fluticasone, Ipratropium, Cromoglicic acid, Betamethasone, More", "alternatives_b": "Nitric Oxide, Doxapram, Ivacaftor, Lumacaftor", "updated_at": 1767369485}, {"id": 97084, "ingredient1": "Ivacaftor", "ingredient2": "Ribociclib", "severity": "Major", "effect": "Coadministration with moderate inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of ivacaftor, which is primarily metabolized by the isoenzyme.", "source": "DDInter", "management_text": "Please consult manufacturer's product labeling for complete dosing information. For ivacaftor - The frequency of dosing should be reduced to 1 tablet or packet once a day when coadministered with moderate CYP450 3A4 inhibitors. Patients should continue to receive the same tablet or oral granule packet strength, but instead of dosing twice a day, the frequency should be reduced to once a day.", "mechanism_text": "Metabolism", "recommendation": "Please consult manufacturer's product labeling for complete dosing information.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97188/", "reference_text": "[1] \"Product Information. Kalydeco (ivacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[2] \"Product Information. Symdeko 4-Week (ivacaftor-tezacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] \"Product Information. Orkambi (ivacaftor-lumacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[5] \"Product Information. Trikafta (elexacaftor/ivacaftor/tezacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[6] \"Product Information. Trikafta (elexacaftor/ivacaftor/tezacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[7] \"Product Information. Kalydeco (ivacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[8] \"Product Information. Orkambi (ivacaftor-lumacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[9] \"Product Information. Symdeko 4-Week (ivacaftor-tezacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.", "alternatives_a": "Nitric Oxide, Doxapram, Elexacaftor", "alternatives_b": "Cabozantinib, Sunitinib, Regorafenib, Copanlisib, Ruxolitinib, Lenvatinib, Abemaciclib, Ponatinib, Neratinib, Vandetanib, Trametinib, More", "updated_at": 1767369485}, {"id": 97085, "ingredient1": "Ivacaftor", "ingredient2": "Rifabutin", "severity": "Major", "effect": "Coadministration with potent inducers of CYP450 3A4 may significantly decrease the plasma concentrations of ivacaftor, which is primarily metabolized by the isoenzyme.", "source": "DDInter", "management_text": "Concomitant use of ivacaftor-containing medications with potent CYP450 3A4 inducers is not recommended.", "mechanism_text": "Metabolism", "recommendation": "Concomitant use of ivacaftor-containing medications with potent CYP450 3A4 inducers is not recommended.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97189/", "reference_text": "[1] \"Product Information. Orkambi (ivacaftor-lumacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] \"Product Information. Symdeko 4-Week (ivacaftor-tezacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[4] \"Product Information. Trikafta (elexacaftor/ivacaftor/tezacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[5] \"Product Information. Kalydeco (ivacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[6] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[7] Patel S, Robinson R, Burk M \"Hypertensive crisis associated with St. John's Wort.\" Am J Med 112 (2002): 507-8[8] \"Product Information. Trikafta (elexacaftor/ivacaftor/tezacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[9] \"Product Information. Kalydeco (ivacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[10] \"Product Information. Orkambi (ivacaftor-lumacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[11] \"Product Information. Symdeko 4-Week (ivacaftor-tezacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.", "alternatives_a": "Capreomycin, Pyrazinamide, Rifamycin, Streptomycin, Trimethoprim, Cycloserine, Ethambutol, Pyridoxine, Ethionamide, Pretomanid, Aminosalicylic acid, More", "alternatives_b": "Nitric Oxide, Doxapram, Elexacaftor", "updated_at": 1767369485}, {"id": 97086, "ingredient1": "Ivacaftor", "ingredient2": "Rifampicin", "severity": "Major", "effect": "Coadministration with potent inducers of CYP450 3A4 may significantly decrease the plasma concentrations of ivacaftor, which is primarily metabolized by the isoenzyme.", "source": "DDInter", "management_text": "Concomitant use of ivacaftor-containing medications with potent CYP450 3A4 inducers is not recommended.", "mechanism_text": "Metabolism", "recommendation": "Concomitant use of ivacaftor-containing medications with potent CYP450 3A4 inducers is not recommended.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97190/", "reference_text": "[1] \"Product Information. Orkambi (ivacaftor-lumacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] \"Product Information. Symdeko 4-Week (ivacaftor-tezacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[4] \"Product Information. Trikafta (elexacaftor/ivacaftor/tezacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[5] \"Product Information. Kalydeco (ivacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[6] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[7] Patel S, Robinson R, Burk M \"Hypertensive crisis associated with St. John's Wort.\" Am J Med 112 (2002): 507-8[8] \"Product Information. Trikafta (elexacaftor/ivacaftor/tezacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[9] \"Product Information. Kalydeco (ivacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[10] \"Product Information. Orkambi (ivacaftor-lumacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[11] \"Product Information. Symdeko 4-Week (ivacaftor-tezacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.", "alternatives_a": "Capreomycin, Pyrazinamide, Rifamycin, Streptomycin, Trimethoprim, Cycloserine, Ethambutol, Pyridoxine, Ethionamide, Pretomanid, Aminosalicylic acid", "alternatives_b": "Nitric Oxide, Doxapram, Lumacaftor", "updated_at": 1767369485}, {"id": 97087, "ingredient1": "Ivacaftor", "ingredient2": "Rifapentine", "severity": "Major", "effect": "Coadministration with potent inducers of CYP450 3A4 may significantly decrease the plasma concentrations of ivacaftor, which is primarily metabolized by the isoenzyme.", "source": "DDInter", "management_text": "Concomitant use of ivacaftor-containing medications with potent CYP450 3A4 inducers is not recommended.", "mechanism_text": "Metabolism", "recommendation": "Concomitant use of ivacaftor-containing medications with potent CYP450 3A4 inducers is not recommended.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97191/", "reference_text": "[1] \"Product Information. Orkambi (ivacaftor-lumacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] \"Product Information. Symdeko 4-Week (ivacaftor-tezacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[4] \"Product Information. Trikafta (elexacaftor/ivacaftor/tezacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[5] \"Product Information. Kalydeco (ivacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[6] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[7] Patel S, Robinson R, Burk M \"Hypertensive crisis associated with St. John's Wort.\" Am J Med 112 (2002): 507-8[8] \"Product Information. Trikafta (elexacaftor/ivacaftor/tezacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[9] \"Product Information. Kalydeco (ivacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[10] \"Product Information. Orkambi (ivacaftor-lumacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[11] \"Product Information. Symdeko 4-Week (ivacaftor-tezacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.", "alternatives_a": "Capreomycin, Pyrazinamide, Rifamycin, Streptomycin, Trimethoprim, Cycloserine, Ethambutol, Pyridoxine, Ethionamide, Pretomanid, Aminosalicylic acid", "alternatives_b": "Nitric Oxide, Doxapram, Elexacaftor, Lumacaftor", "updated_at": 1767369485}, {"id": 97088, "ingredient1": "Elexacaftor", "ingredient2": "Rifaximin", "severity": "Moderate", "effect": "Coadministration with elexacaftor may increase the plasma concentrations of drugs that are substrates of the organic anion transporting polypeptides (OATP) 1B1 and 1B3. The proposed mechanism, based on in vitro data, involves decreased metabolic clearance due to inhibition of OATP 1B1- and 1B3-mediated hepatic uptake by elexacaftor and its metabolite. The clinical relevance is unknown.", "source": "DDInter", "management_text": "Caution is advised when elexacaftor is used concurrently with drugs that are known OATP 1B1 and 1B3 substrates, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever elexacaftor is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when elexacaftor is used concurrently with drugs that are known OATP 1B1 and 1B3 substrates, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97192/", "reference_text": "[1] \"Product Information. Trikafta (elexacaftor/ivacaftor/tezacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[2] \"Product Information. Diovan (valsartan).\" Novartis Pharmaceuticals, East Hanover, NJ.[3] \"Product Information. Cozaar (losartan).\" Merck & Co, Inc, West Point, PA.[4] \"Product Information. Trikafta (elexacaftor/ivacaftor/tezacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[5] \"Product Information. Kalydeco (ivacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[6] \"Product Information. Orkambi (ivacaftor-lumacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[7] \"Product Information. Symdeko 4-Week (ivacaftor-tezacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.", "alternatives_a": "Rifamycin, Kanamycin, Amphotericin B, Miconazole, Polymyxin B, Nystatin, Vancomycin, Streptomycin, Fidaxomicin, Paromomycin, Neomycin, More", "alternatives_b": "Nitric Oxide, Doxapram, Ivacaftor, Lumacaftor", "updated_at": 1767369485}, {"id": 97089, "ingredient1": "Ivacaftor", "ingredient2": "Rilpivirine", "severity": "Moderate", "effect": "Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of rilpivirine, which is primarily metabolized by the isoenzyme.", "source": "DDInter", "management_text": "Caution and clinical monitoring may be advisable if CYP450 3A4 inhibitors are coadministered with rilpivirine.", "mechanism_text": "Metabolism", "recommendation": "Caution and clinical monitoring may be advisable if CYP450 3A4 inhibitors are coadministered with rilpivirine.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97193/", "reference_text": "[1] Cerner Multum, Inc. \"Canadian Product Information.\" O 0 (2015):[2] \"Product Information. Edurant (rilpivirine).\" Tibotec Pharmaceuticals, Titusville, NJ.[3] Cerner Multum, Inc. \"Australian Product Information.\" O 0[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] Cerner Multum, Inc. \"Canadian Product Information.\" O 0 (2015):[6] \"Product Information. Edurant (rilpivirine).\" Tibotec Pharmaceuticals, Titusville, NJ.", "alternatives_a": "Nitric Oxide, Doxapram, Elexacaftor", "alternatives_b": "Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Simeprevir, Cabotegravir, Valaciclovir, Zanamivir, Velpatasvir, Oseltamivir, Acyclovir, More", "updated_at": 1767369485}, {"id": 97090, "ingredient1": "Ivacaftor", "ingredient2": "Rimegepant", "severity": "Moderate", "effect": "Coadministration with inhibitors of P-glycoprotein (P-gp) and/or breast cancer resistance protein (BCRP) may significantly increase the plasma concentrations of rimegepant. The proposed mechanism is decreased clearance due to inhibition of P-gp- and/or BCRP-mediated metabolism of rimegepant.", "source": "DDInter", "management_text": "Coadministration of rimegepant with P-gp and/or BCRP inhibitors should be avoided.", "mechanism_text": "Metabolism", "recommendation": "Coadministration of rimegepant with P-gp and/or BCRP inhibitors should be avoided.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97194/", "reference_text": "[1] \"Product Information. Nurtec ODT (rimegepant).\" Biohaven Pharmaceuticals, New Haven, CT.[2] \"Product Information. Venclexta (venetoclax).\" AbbVie US LLC, North Chicago, IL.[3] \"Product Information. Nurtec ODT (rimegepant).\" Biohaven Pharmaceuticals, New Haven, CT.", "alternatives_a": "Nitric Oxide, Doxapram, Elexacaftor", "alternatives_b": "Frovatriptan, Eptinezumab, Lasmiditan, Rizatriptan, Naratriptan, Galcanezumab, Zolmitriptan, Sumatriptan, Erenumab, Clonidine, Almotriptan, Fremanezumab", "updated_at": 1767369485}, {"id": 97091, "ingredient1": "Ivacaftor", "ingredient2": "Riociguat", "severity": "Moderate", "effect": "Coadministration with potent inhibitors of CYP450 3A4 or moderate to potent inhibitors of P-glycoprotein (P-gp) or breast cancer resistant protein (BCRP) may increase the plasma concentrations of riociguat, which is partially metabolized by CYP450 3A and also a substrate of the P-gp and BCRP efflux transporters. Increased levels of riociguat may increase the risk for hypotension.", "source": "DDInter", "management_text": "Caution is advised when riociguat is prescribed with potent CYP450 3A4 inhibitors or moderate to potent P-gp or BCRP inhibitors. Patients should be monitored for signs and symptoms of hypotension, and the dosage of riociguat adjusted if necessary.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when riociguat is prescribed with potent CYP450 3A4 inhibitors or moderate to potent P-gp or BCRP inhibitors.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97195/", "reference_text": "[1] Cerner Multum, Inc. \"Australian Product Information.\" O 0[2] \"Product Information. Adempas (riociguat).\" Bayer Pharmaceutical Inc, West Haven, CT.[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] \"Product Information. Adempas (riociguat).\" Bayer Pharmaceutical Inc, West Haven, CT.", "alternatives_a": "Nitric Oxide, Doxapram, Elexacaftor", "alternatives_b": "Metyrosine", "updated_at": 1767369485}, {"id": 97092, "ingredient1": "Ivacaftor", "ingredient2": "Ripretinib", "severity": "Moderate", "effect": "Coadministration of CYP450 3A4 inhibitors with ripretinib may increase the plasma concentrations and the risk of adverse effects (e.g., palmar-plantar erythrodysesthesia, hypertension, cardiac dysfunction, arthralgia/myalgia) of ripretinib and its active metabolite (DP-5439). The proposed mechanism is inhibition of CYP450 3A4, the isoenzyme responsible for the metabolic clearance of ripretinib and DP-5439.", "source": "DDInter", "management_text": "Caution is recommended when ripretinib is used concomitantly with a CYP450 3A4 inhibitor. Clinical and laboratory monitoring should be considered whenever a CYP450 3A4 inhibitor is added to or withdrawn from therapy with ripretinib, and the dosage adjusted as necessary. Patients should be monitored for development of adverse effects.", "mechanism_text": "Metabolism", "recommendation": "Caution is recommended when ripretinib is used concomitantly with a CYP450 3A4 inhibitor.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97196/", "reference_text": "[1] Cerner Multum, Inc. \"Australian Product Information.\" O 0[2] \"Product Information. Qinlock (ripretinib).\" Deciphera Pharmaceuticals, Waltham, MA.[3] Gunston GD, Mehta U \"Potentially serious drug interactions with grapefruit juice.\" S Afr Med J 90 (2000): 41[4] Bailey DG, Arnold JMO, Spence JD \"Grapefruit juice and drugs - how significant is the interaction.\" Clin Pharmacokinet 26 (1994): 91-8[5] Fuhr U, Maier-Bruggemann A, Blume H, et al. \"Grapefruit juice increases oral nimodipine bioavailability.\" Int J Clin Pharmacol Ther 36 (1998): 126-32[6] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[7] Libersa CC, Brique SA, Motte KB, et al. \"Dramatic inhibition of amiodarone metabolism induced by grapefruit juice.\" Br J Clin Pharmacol 49 (2000): 373-8[8] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions.\" Br J Clin Pharmacol 46 (1998): 101-10[9] Bailey DG, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit juice felodipine interaction: Effect of naringin and 6',7'-dihydroxybergamottin in humans.\" Clin Pharmacol Ther 64 (1998): 248-56[10] Takanaga H, Ohnishi A, Maatsuo H, et al. \"Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model.\" Br J Clin Pharmacol 49 (2000): 49-58[11] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[12] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS \"Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice.\" Br J Clin Pharmacol 42 (1996): p662[13] Eagling VA, Profit L, Back DJ \"Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-I protease inhibitor saquinavir by grapefruit juice components.\" Br J Clin Pharmacol 48 (1999): 543-52[14] Bailey DG, Arnold JM, Strong HA, Munoz C, Spence JD \"Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics.\" Clin Pharmacol Ther 54 (1993): 589-94[15] Damkier P, Hansen LL, Brosen K \"Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine.\" Br J Clin Pharmacol 48 (1999): 829-38[16] Min DI, Ku YM, Geraets DR, Lee HC \"Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers.\" J Clin Pharmacol 36 (1996): 469-76[17] Josefsson M, Zackrisson AL, Ahlner J \"Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers.\" Eur J Clin Pharmacol 51 (1996): 189-93[18] Majeed A, Kareem A \"Effect of grapefruit juice on cyclosporine pharmacokinetics.\" Pediatr Nephrol 10 (1996): 395[19] Flanagan D \"Understanding the grapefruit-drug interaction.\" Gen Dent 53 (2005): 282-5; quiz 286[20] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ \"Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice.\" Clin Pharmacol Ther 58 (1995): 127-31[21] Jonkman JH, Sollie FA, Sauter R, Steinijans VW \"The influence of caffeine on the steady-state pharmacokinetics of theophylline.\" Clin Pharmacol Ther 49 (1991): 248-55[22] Ozdemir M, Aktan Y, Boydag BS, Cingi MI, Musmul A \"Interaction between grapefruit juice and diazepam in humans.\" Eur J Drug Metab Pharmacokinet 23 (1998): 55-9[23] Edgar B, Bailey D, Bergstrand R, et al \"Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics on felodipine and its potential clinical relevance.\" Eur J Clin Pharmacol 42 (1992): 313-7[24] Kantola T, Kivisto KT, Neuvonen PJ \"Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid.\" Clin Pharmacol Ther 63 (1998): 397-402[25] Lee AJ, Chan WK, Harralson AF, Buffum J, Bui BCC \"The effects of grapefruit juice on sertraline metabolism: An in vitro and in vivo study.\" Clin Ther 21 (1999): 1890-9[26] Sato J, Nakata H, Owada E, Kikuta T, Umetsu M, Ito K \"Influence of usual intake of dietary caffeine on single-dose kinetics of theophylline in healthy human subjects.\" Eur J Clin Pharmacol 44 (1993): 295-8[27] Dresser GK, Spence JD, Bailey DG \"Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition.\" Clin Pharmacokinet 38 (2000): 41-57[28] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin.\" Clin Pharmacol Ther 66 (1999): 118-27[29] Sigusch H, Hippius M, Henschel L, Kaufmann K, Hoffmann A \"Influence of grapefruit juice on the pharmacokinetics of a slow release nifedipine formulation.\" Pharmazie 49 (1994): 522-4[30] Bailey DG, Arnold JM, Munoz C, Spence JD \"Grapefruit juice--felodipine interaction: mechanism, predictability, and effect of naringin.\" Clin Pharmacol Ther 53 (1993): 637-42[31] Zaidenstein R, Soback S, Gips M, Avni B, Dishi V, Weissgarten Y, Golik A, Scapa E \"Effect of grapefruit juice on the pharmacokinetics of losartan and its active metabolite E3174 in healthy volunteers.\" Ther Drug Monit 23 (2001): 369-73[32] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84[33] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors.\" Clin Pharmacol Ther 64 (1998): 477-83[34] Garg SK, Kumar N, Bhargava VK, Prabhakar SK \"Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy.\" Clin Pharmacol Ther 64 (1998): 286-8", "alternatives_a": "Nitric Oxide, Doxapram, Elexacaftor", "alternatives_b": "Cabozantinib, Sunitinib, Regorafenib, Copanlisib, Ruxolitinib, Lenvatinib, Abemaciclib, Ponatinib, Neratinib, Vandetanib, Trametinib, More", "updated_at": 1767369485}, {"id": 97093, "ingredient1": "Ivacaftor", "ingredient2": "Ritonavir", "severity": "Major", "effect": "Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of ivacaftor, which is primarily metabolized by the isoenzyme.", "source": "DDInter", "management_text": "For ivacaftor -The ivacaftor dose should be reduced from 1 tablet or 1 packet of oral granules twice a day to 1 tablet or 1 packet of oral granules twice a week (i.e., every 3 to 4 days) during coadministration with potent CYP450 3A4 inhibitors. For example, a patient taking ivacaftor 150 mg tablet twice a day should reduce their ivacaftor dose to a 150 mg tablet twice a week and a patient taking ivacaftor 50 mg oral granule packet twice a day should reduce their ivacaftor dose to 50 mg oral granule packet twice a week, etc.", "mechanism_text": "Metabolism", "recommendation": "For ivacaftor -The ivacaftor dose should be reduced from 1 tablet or 1 packet of oral granules twice a day to 1 tablet or 1 packet of oral granules twice a week (i.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97197/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Symdeko 4-Week (ivacaftor-tezacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[3] \"Product Information. Trikafta (elexacaftor/ivacaftor/tezacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[4] Cerner Multum, Inc. \"Australian Product Information.\" O 0[5] \"Product Information. Kalydeco (ivacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[6] \"Product Information. Orkambi (ivacaftor-lumacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[7] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[8] \"Product Information. VFEND (voriconazole).\" Pfizer U.S. Pharmaceuticals, New York, NY.[9] \"Product Information. Trikafta (elexacaftor/ivacaftor/tezacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[10] \"Product Information. Kalydeco (ivacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[11] \"Product Information. Orkambi (ivacaftor-lumacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[12] \"Product Information. Symdeko 4-Week (ivacaftor-tezacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.", "alternatives_a": "Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Simeprevir, Cabotegravir, Valaciclovir, Zanamivir, Velpatasvir, Oseltamivir, Acyclovir, More", "alternatives_b": "Nitric Oxide, Doxapram, Elexacaftor", "updated_at": 1767369485}, {"id": 97094, "ingredient1": "Ivacaftor", "ingredient2": "Rivaroxaban", "severity": "Moderate", "effect": "Coadministration with weak or moderate dual inhibitors of CYP450 3A4 and P-glycoprotein (P-gp) may increase the plasma concentrations of rivaroxaban, which is a substrate of both the isoenzyme and efflux transporter.", "source": "DDInter", "management_text": "In patients with CrCl of 15 to less than 80 mL/min, the use of rivaroxaban with weak or moderate dual inhibitors of CYP450 3A4 and P-gp should only be considered if the potential benefits justify the increased risk of bleeding complications. Patients should be routinely evaluated for signs and symptoms suggesting blood loss such as a drop in hemoglobin and/or hematocrit, hypotension, or fetal distress (in pregnant women). Renal function should also be assessed periodically, and treatment with rivaroxaban discontinued if acute renal failure develops. Due to the lack of clinical data, rivaroxaban is not recommended in patients with CrCl below 30 mL/min when used for the prophylaxis of deep vein thrombosis and in patients with CrCl below 15 mL/min when used for reducing the risk of stroke and systemic embolism in nonvalvular atrial fibrillation.", "mechanism_text": "Metabolism", "recommendation": "In patients with CrCl of 15 to less than 80 mL/min, the use of rivaroxaban with weak or moderate dual inhibitors of CYP450 3A4 and P-gp should only be considered if the potential benefits justify the increased risk of bleeding complications.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97198/", "reference_text": "[1] \"Product Information. Xarelto (rivaroxaban).\" Bayer Inc, Toronto, IA.[2] Hooks MA \"Tacrolimus, a new immunosuppressant--a review of the literature.\" Ann Pharmacother 28 (1994): 501-11[3] \"Product Information. Prograf (tacrolimus).\" Fujisawa, Deerfield, IL.", "alternatives_a": "Clopidogrel, Iloprost, Lepirudin, Acenocoumarol, Urokinase, Cangrelor, Dipyridamole, Caplacizumab, Argatroban, Prasugrel, Desirudin, More", "alternatives_b": "Nitric Oxide, Doxapram, Elexacaftor", "updated_at": 1767369485}, {"id": 97095, "ingredient1": "Ivacaftor", "ingredient2": "Romidepsin", "severity": "Moderate", "effect": "Coadministration with inhibitors of P-glycoprotein (P-gp) may increase the plasma concentrations of romidepsin, which is a substrate of the efflux transporter. Although there are no formal drug interaction studies, the interaction may increase the risk of hematologic toxicities such as anemia, leukopenia, and thrombocytopenia as well as electrocardiographic changes such as QT interval prolongation and T-wave and ST-segment changes.", "source": "DDInter", "management_text": "Caution is advised if romidepsin is prescribed in combination with P-gp inhibitors. Pharmacologic response to romidepsin should be monitored more closely whenever a P-gp inhibitor is added to or withdrawn from therapy, and the romidepsin dosage adjusted as necessary. Patients should have complete blood cell counts, electrocardiograms, and serum electrolyte levels performed at baseline and regular intervals as recommended in the product labeling. Patients should be advised to seek medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Absorption", "recommendation": "Caution is advised if romidepsin is prescribed in combination with P-gp inhibitors.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97199/", "reference_text": "[1] \"Product Information. Istodax (romidepsin).\" Gloucester Pharmaceuticals, Cambridge, MA.", "alternatives_a": "Pertuzumab, Oxaliplatin, Bortezomib, Tisagenlecleucel, Aminolevulinic acid, Omacetaxine mepesuccinate, Altretamine, Tagraxofusp, Ixazomib, Enasidenib, Porfimer sodium, More", "alternatives_b": "Nitric Oxide, Doxapram, Elexacaftor", "updated_at": 1767369485}, {"id": 97096, "ingredient1": "Elexacaftor", "ingredient2": "Rosuvastatin", "severity": "Moderate", "effect": "Coadministration with elexacaftor may increase the plasma concentrations of drugs that are substrates of the organic anion transporting polypeptides (OATP) 1B1 and 1B3. The proposed mechanism, based on in vitro data, involves decreased metabolic clearance due to inhibition of OATP 1B1- and 1B3-mediated hepatic uptake by elexacaftor and its metabolite. The clinical relevance is unknown.", "source": "DDInter", "management_text": "Caution is advised when elexacaftor is used concurrently with drugs that are known OATP 1B1 and 1B3 substrates, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever elexacaftor is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when elexacaftor is used concurrently with drugs that are known OATP 1B1 and 1B3 substrates, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97200/", "reference_text": "[1] \"Product Information. Trikafta (elexacaftor/ivacaftor/tezacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[2] \"Product Information. Diovan (valsartan).\" Novartis Pharmaceuticals, East Hanover, NJ.[3] \"Product Information. Cozaar (losartan).\" Merck & Co, Inc, West Point, PA.[4] \"Product Information. Trikafta (elexacaftor/ivacaftor/tezacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[5] \"Product Information. Kalydeco (ivacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[6] \"Product Information. Orkambi (ivacaftor-lumacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[7] \"Product Information. Symdeko 4-Week (ivacaftor-tezacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.", "alternatives_a": "Amlodipine, Ramipril, Lisinopril, Perindopril, Acetylsalicylic acid, Niacin, Bempedoic acid, Indapamide, Fenofibrate, Gemfibrozil, Fenofibric acid, More", "alternatives_b": "Nitric Oxide, Doxapram, Ivacaftor, Lumacaftor", "updated_at": 1767369485}, {"id": 97097, "ingredient1": "Ivacaftor", "ingredient2": "Rucaparib", "severity": "Moderate", "effect": "Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of ivacaftor, which is primarily metabolized by the isoenzyme. The interaction occurs to a greater extent when ivacaftor is administered as monotherapy than when administered in combination with lumacaftor, a potent CYP450 3A4 inducer.", "source": "DDInter", "management_text": "Caution is advised if ivacaftor is used with CYP450 3A4 inhibitors. A dosage adjustment for ivacaftor may be required if undue adverse effects occur.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if ivacaftor is used with CYP450 3A4 inhibitors.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97201/", "reference_text": "[1] \"Product Information. Kalydeco (ivacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[2] \"Product Information. Orkambi (ivacaftor-lumacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[3] \"Product Information. Accolate (zafirlukast).\" Zeneca Pharmaceuticals, Wilmington, DE.[4] \"Product Information. Trikafta (elexacaftor/ivacaftor/tezacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[5] \"Product Information. Kalydeco (ivacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[6] \"Product Information. Orkambi (ivacaftor-lumacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[7] \"Product Information. Symdeko 4-Week (ivacaftor-tezacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.", "alternatives_a": "Nitric Oxide, Doxapram, Elexacaftor", "alternatives_b": "Pertuzumab, Oxaliplatin, Bortezomib, Tisagenlecleucel, Aminolevulinic acid, Omacetaxine mepesuccinate, Altretamine, Tagraxofusp, Ixazomib, Enasidenib, Porfimer sodium, More", "updated_at": 1767369485}, {"id": 97098, "ingredient1": "Ivacaftor", "ingredient2": "Rufinamide", "severity": "Moderate", "effect": "Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of ivacaftor, which is primarily metabolized by the isoenzyme.", "source": "DDInter", "management_text": "The potential for diminished pharmacologic effects of ivacaftor-containing medications should be considered during coadministration with CYP450 3A4 inducers. Alternative treatments may be required if an interaction is suspected.", "mechanism_text": "Metabolism", "recommendation": "The potential for diminished pharmacologic effects of ivacaftor-containing medications should be considered during coadministration with CYP450 3A4 inducers.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97202/", "reference_text": "[1] \"Product Information. Symdeko 4-Week (ivacaftor-tezacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[2] \"Product Information. Orkambi (ivacaftor-lumacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[3] \"Product Information. Trikafta (elexacaftor/ivacaftor/tezacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[4] \"Product Information. Kalydeco (ivacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[5] \"Product Information. Trikafta (elexacaftor/ivacaftor/tezacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[6] \"Product Information. Kalydeco (ivacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[7] \"Product Information. Orkambi (ivacaftor-lumacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[8] \"Product Information. Symdeko 4-Week (ivacaftor-tezacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.", "alternatives_a": "Brivaracetam, Topiramate, Ezogabine, Lamotrigine, Lacosamide, Levetiracetam, Tiagabine, Ethotoin, Paramethadione, Perampanel, Vigabatrin, More", "alternatives_b": "Nitric Oxide, Doxapram, Elexacaftor, Lumacaftor", "updated_at": 1767369485}, {"id": 97099, "ingredient1": "Ivacaftor", "ingredient2": "Saquinavir", "severity": "Major", "effect": "Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of ivacaftor, which is primarily metabolized by the isoenzyme.", "source": "DDInter", "management_text": "For ivacaftor -The ivacaftor dose should be reduced from 1 tablet or 1 packet of oral granules twice a day to 1 tablet or 1 packet of oral granules twice a week (i.e., every 3 to 4 days) during coadministration with potent CYP450 3A4 inhibitors. For example, a patient taking ivacaftor 150 mg tablet twice a day should reduce their ivacaftor dose to a 150 mg tablet twice a week and a patient taking ivacaftor 50 mg oral granule packet twice a day should reduce their ivacaftor dose to 50 mg oral granule packet twice a week, etc.", "mechanism_text": "Metabolism", "recommendation": "For ivacaftor -The ivacaftor dose should be reduced from 1 tablet or 1 packet of oral granules twice a day to 1 tablet or 1 packet of oral granules twice a week (i.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97203/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Symdeko 4-Week (ivacaftor-tezacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[3] \"Product Information. Trikafta (elexacaftor/ivacaftor/tezacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[4] Cerner Multum, Inc. \"Australian Product Information.\" O 0[5] \"Product Information. Kalydeco (ivacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[6] \"Product Information. Orkambi (ivacaftor-lumacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[7] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[8] \"Product Information. VFEND (voriconazole).\" Pfizer U.S. Pharmaceuticals, New York, NY.[9] \"Product Information. Trikafta (elexacaftor/ivacaftor/tezacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[10] \"Product Information. Kalydeco (ivacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[11] \"Product Information. Orkambi (ivacaftor-lumacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[12] \"Product Information. Symdeko 4-Week (ivacaftor-tezacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.", "alternatives_a": "Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Simeprevir, Cabotegravir, Valaciclovir, Zanamivir, Velpatasvir, Oseltamivir, Acyclovir, More", "alternatives_b": "Nitric Oxide, Doxapram, Elexacaftor", "updated_at": 1767369485}, {"id": 97100, "ingredient1": "Ivacaftor", "ingredient2": "Secobarbital", "severity": "Moderate", "effect": "Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of ivacaftor, which is primarily metabolized by the isoenzyme.", "source": "DDInter", "management_text": "The potential for diminished pharmacologic effects of ivacaftor-containing medications should be considered during coadministration with CYP450 3A4 inducers. Alternative treatments may be required if an interaction is suspected.", "mechanism_text": "Metabolism", "recommendation": "The potential for diminished pharmacologic effects of ivacaftor-containing medications should be considered during coadministration with CYP450 3A4 inducers.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97204/", "reference_text": "[1] \"Product Information. Symdeko 4-Week (ivacaftor-tezacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[2] \"Product Information. Orkambi (ivacaftor-lumacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[3] \"Product Information. Trikafta (elexacaftor/ivacaftor/tezacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[4] \"Product Information. Kalydeco (ivacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[5] \"Product Information. Trikafta (elexacaftor/ivacaftor/tezacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[6] \"Product Information. Kalydeco (ivacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[7] \"Product Information. Orkambi (ivacaftor-lumacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[8] \"Product Information. Symdeko 4-Week (ivacaftor-tezacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.", "alternatives_a": "Flurazepam, Methohexital, Zaleplon, Dichloralphenazone, Valerian, Temazepam, Chloral hydrate, Quazepam, Paraldehyde, Ramelteon, Ethchlorvynol, More", "alternatives_b": "Nitric Oxide, Doxapram, Elexacaftor, Lumacaftor", "updated_at": 1767369485}, {"id": 97101, "ingredient1": "Elexacaftor", "ingredient2": "Selexipag", "severity": "Moderate", "effect": "Coadministration with elexacaftor may increase the plasma concentrations of drugs that are substrates of the organic anion transporting polypeptides (OATP) 1B1 and 1B3. The proposed mechanism, based on in vitro data, involves decreased metabolic clearance due to inhibition of OATP 1B1- and 1B3-mediated hepatic uptake by elexacaftor and its metabolite. The clinical relevance is unknown.", "source": "DDInter", "management_text": "Caution is advised when elexacaftor is used concurrently with drugs that are known OATP 1B1 and 1B3 substrates, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever elexacaftor is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when elexacaftor is used concurrently with drugs that are known OATP 1B1 and 1B3 substrates, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97205/", "reference_text": "[1] \"Product Information. Trikafta (elexacaftor/ivacaftor/tezacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[2] \"Product Information. Diovan (valsartan).\" Novartis Pharmaceuticals, East Hanover, NJ.[3] \"Product Information. Cozaar (losartan).\" Merck & Co, Inc, West Point, PA.[4] \"Product Information. Trikafta (elexacaftor/ivacaftor/tezacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[5] \"Product Information. Kalydeco (ivacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[6] \"Product Information. Orkambi (ivacaftor-lumacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[7] \"Product Information. Symdeko 4-Week (ivacaftor-tezacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.", "alternatives_a": "Ticagrelor, Betrixaban, Apixaban, Cilostazol, Rivaroxaban, Clopidogrel, Iloprost, Lepirudin, Acenocoumarol, Urokinase, Cangrelor, More", "alternatives_b": "Nitric Oxide, Doxapram, Ivacaftor, Lumacaftor", "updated_at": 1767369485}, {"id": 97102, "ingredient1": "Ivacaftor", "ingredient2": "Selpercatinib", "severity": "Moderate", "effect": "Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of ivacaftor, which is primarily metabolized by the isoenzyme. The interaction occurs to a greater extent when ivacaftor is administered as monotherapy than when administered in combination with lumacaftor, a potent CYP450 3A4 inducer.", "source": "DDInter", "management_text": "Caution is advised if ivacaftor is used with CYP450 3A4 inhibitors. A dosage adjustment for ivacaftor may be required if undue adverse effects occur.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if ivacaftor is used with CYP450 3A4 inhibitors.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97206/", "reference_text": "[1] \"Product Information. Kalydeco (ivacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[2] \"Product Information. Orkambi (ivacaftor-lumacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[3] \"Product Information. Accolate (zafirlukast).\" Zeneca Pharmaceuticals, Wilmington, DE.[4] \"Product Information. Trikafta (elexacaftor/ivacaftor/tezacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[5] \"Product Information. Kalydeco (ivacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[6] \"Product Information. Orkambi (ivacaftor-lumacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[7] \"Product Information. Symdeko 4-Week (ivacaftor-tezacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.", "alternatives_a": "Nitric Oxide, Doxapram, Elexacaftor", "alternatives_b": "Cabozantinib, Sunitinib, Regorafenib, Copanlisib, Ruxolitinib, Lenvatinib, Abemaciclib, Ponatinib, Neratinib, Vandetanib, Trametinib, More", "updated_at": 1767369485}, {"id": 97103, "ingredient1": "Ivacaftor", "ingredient2": "Selumetinib", "severity": "Moderate", "effect": "Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of selumetinib, which is primarily metabolized by CYP450 3A4 and to a lesser extent by CYP450 2C19, 1A2, 2C9, 2E1, and 3A5. Selumetinib also undergoes glucuronidation by UGT1A1 and UGT1A3. Increased exposures to selumetinib and N-desmethyl selumetinib may increase the risk and/or severity of serious adverse effects such as cardiomyopathy (decrease in left ventricular ejection fraction by 10% or more below baseline), ocular toxicity (blurred vision, photophobia, cataracts, ocular hypertension, retinal pigment epithelial detachment, retinal vein occlusion), gastrointestinal toxicity (diarrhea, colitis), skin toxicity (dermatitis acneiform, maculopapular rash, eczema), and musculoskeletal toxicity (creatine phosphokinase elevations, myalgia, rhabdomyolysis).", "source": "DDInter", "management_text": "Caution is advised when selumetinib is coadministered with CYP450 3A4 inhibitors. Dosage adjustments may be required based on clinical response and tolerance. Please refer to the product labeling for specific guidelines on dosing adjustments.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when selumetinib is coadministered with CYP450 3A4 inhibitors.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97207/", "reference_text": "[1] \"Multum Information Services, Inc. Expert Review Panel\"[2] \"Multum Information Services, Inc. Expert Review Panel\"[3] \"Product Information. Accolate (zafirlukast).\" Zeneca Pharmaceuticals, Wilmington, DE.", "alternatives_a": "Nitric Oxide, Doxapram, Elexacaftor", "alternatives_b": "Cabozantinib, Sunitinib, Regorafenib, Copanlisib, Ruxolitinib, Lenvatinib, Abemaciclib, Ponatinib, Neratinib, Vandetanib, Trametinib, More", "updated_at": 1767369485}, {"id": 97104, "ingredient1": "Ivacaftor", "ingredient2": "Sildenafil", "severity": "Moderate", "effect": "Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of sildenafil, which is primarily metabolized by the isoenzyme. The possibility of prolonged and/or increased pharmacologic effects of sildenafil should be considered.", "source": "DDInter", "management_text": "Caution is advised if sildenafil is coadministered with CYP450 3A4 inhibitors. Dosage adjustments may be appropriate for sildenafil whenever a CYP450 3A4 inhibitor is added to or withdrawn from therapy based on efficacy and side effects. Patients should be advised to promptly notify their physician if they experience pain or tightness in the chest or jaw, irregular heartbeat, nausea, shortness of breath, visual disturbances, syncope, or prolonged erection (greater than 4 hours).", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if sildenafil is coadministered with CYP450 3A4 inhibitors.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97208/", "reference_text": "[1] \"Product Information. Revatio (sildenafil).\" Pfizer U.S. Pharmaceuticals Group, New York, NY.[2] \"Product Information. Viagra (sildenafil).\" Pfizer US Pharmaceuticals, New York, NY.[3] Warrington JS, Shader RI, vonMoltke LL, Greenblatt DJ \"In vitro biotransformation of sildenafil (Viagra): Identification of human cytochromes and potential drug interactions.\" Drug Metab Disposition 28 (2000): 392-7[4] Hyland R, Roe GH, Jones BC, Smith DA \"Identification of the cytochrome P450 enzymes involved in the N-demethylation of sildenafil.\" Br J Clin Pharmaacol 51 (2001): 239-48[5] Jetter A, Kinzig-Schippers M, Walchner-Bonjean M, et al. \"Effects of grapefruit juice on the pharmacokinetics of sildenafil.\" Clin Pharmacol Ther 71 (2002): 21-29", "alternatives_a": "Tamsulosin, Tinidazole, Ascorbic acid, Hydroflumethiazide, Chlorothiazide, Metronidazole, Simeprevir, Rosuvastatin, Sulfadiazine, Lactic acid, Methazolamide, More", "alternatives_b": "Doxapram, Elexacaftor", "updated_at": 1767369485}, {"id": 97105, "ingredient1": "Ivacaftor", "ingredient2": "Silodosin", "severity": "Moderate", "effect": "Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of silodosin, which is primarily metabolized by the isoenzyme.", "source": "DDInter", "management_text": "Caution is advised if silodosin is prescribed in combination with inhibitors of CYP450 3A4. Pharmacologic response to silodosin should be monitored more closely whenever a CYP450 3A4 inhibitor is added to or withdrawn from therapy, and the silodosin dosage adjusted as necessary. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if silodosin is prescribed in combination with inhibitors of CYP450 3A4.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97209/", "reference_text": "[1] \"Product Information. Rapaflo (silodosin).\" Watson Pharmaceuticals, Corona, CA.[2] \"Product Information. Rapaflo (silodosin).\" Watson Pharmaceuticals, Corona, CA.", "alternatives_a": "Tamsulosin, Finasteride, Terazosin", "alternatives_b": "Nitric Oxide, Doxapram, Elexacaftor", "updated_at": 1767369485}, {"id": 97106, "ingredient1": "Elexacaftor", "ingredient2": "Simeprevir", "severity": "Moderate", "effect": "Coadministration with elexacaftor may increase the plasma concentrations of drugs that are substrates of the organic anion transporting polypeptides (OATP) 1B1 and 1B3. The proposed mechanism, based on in vitro data, involves decreased metabolic clearance due to inhibition of OATP 1B1- and 1B3-mediated hepatic uptake by elexacaftor and its metabolite. The clinical relevance is unknown.", "source": "DDInter", "management_text": "Caution is advised when elexacaftor is used concurrently with drugs that are known OATP 1B1 and 1B3 substrates, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever elexacaftor is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when elexacaftor is used concurrently with drugs that are known OATP 1B1 and 1B3 substrates, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97210/", "reference_text": "[1] \"Product Information. Trikafta (elexacaftor/ivacaftor/tezacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[2] \"Product Information. Diovan (valsartan).\" Novartis Pharmaceuticals, East Hanover, NJ.[3] \"Product Information. Cozaar (losartan).\" Merck & Co, Inc, West Point, PA.[4] \"Product Information. Trikafta (elexacaftor/ivacaftor/tezacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[5] \"Product Information. Kalydeco (ivacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[6] \"Product Information. Orkambi (ivacaftor-lumacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[7] \"Product Information. Symdeko 4-Week (ivacaftor-tezacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.", "alternatives_a": "Tamsulosin, Tinidazole, Ascorbic acid, Hydroflumethiazide, Chlorothiazide, Metronidazole, Sulfadiazine, Lactic acid, Mitapivat, Methazolamide, Amphotericin B, More", "alternatives_b": "Nitric Oxide, Doxapram, Ivacaftor", "updated_at": 1767369485}, {"id": 97107, "ingredient1": "Elexacaftor", "ingredient2": "Simvastatin", "severity": "Moderate", "effect": "Coadministration with elexacaftor may increase the plasma concentrations of drugs that are substrates of the organic anion transporting polypeptides (OATP) 1B1 and 1B3. The proposed mechanism, based on in vitro data, involves decreased metabolic clearance due to inhibition of OATP 1B1- and 1B3-mediated hepatic uptake by elexacaftor and its metabolite. The clinical relevance is unknown.", "source": "DDInter", "management_text": "Caution is advised when elexacaftor is used concurrently with drugs that are known OATP 1B1 and 1B3 substrates, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever elexacaftor is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when elexacaftor is used concurrently with drugs that are known OATP 1B1 and 1B3 substrates, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97211/", "reference_text": "[1] \"Product Information. Trikafta (elexacaftor/ivacaftor/tezacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[2] \"Product Information. Diovan (valsartan).\" Novartis Pharmaceuticals, East Hanover, NJ.[3] \"Product Information. Cozaar (losartan).\" Merck & Co, Inc, West Point, PA.[4] \"Product Information. Trikafta (elexacaftor/ivacaftor/tezacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[5] \"Product Information. Kalydeco (ivacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[6] \"Product Information. Orkambi (ivacaftor-lumacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[7] \"Product Information. Symdeko 4-Week (ivacaftor-tezacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.", "alternatives_a": "Glipizide, Acetohexamide, Guar gum, Pramlintide, Alogliptin, Tolazamide, Dulaglutide, Exenatide, Tolbutamide, Miglitol, Glimepiride, More", "alternatives_b": "Nitric Oxide, Doxapram", "updated_at": 1767369485}, {"id": 97108, "ingredient1": "Ivacaftor", "ingredient2": "Siponimod", "severity": "Moderate", "effect": "Coadministration with ivacaftor may increase the plasma concentrations of drugs that are substrates of the CYP450 2C9 isoenzyme. The proposed mechanism, based on in vitro data, involves decreased metabolic clearance due to inhibition of CYP450 2C9 by ivacaftor.", "source": "DDInter", "management_text": "Caution is advised when ivacaftor is used concurrently with drugs that are known CYP450 2C9 substrates, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever ivacaftor is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when ivacaftor is used concurrently with drugs that are known CYP450 2C9 substrates, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97212/", "reference_text": "[1] \"Product Information. Trikafta (elexacaftor/ivacaftor/tezacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[2] \"Product Information. Symdeko 4-Week (ivacaftor-tezacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[3] \"Product Information. Orkambi (ivacaftor-lumacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[4] \"Product Information. Kalydeco (ivacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[5] \"Product Information. Ambien (zolpidem).\" sanofi-aventis, Bridgewater, NJ.[6] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84[7] \"Product Information. Trikafta (elexacaftor/ivacaftor/tezacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[8] \"Product Information. Kalydeco (ivacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[9] \"Product Information. Orkambi (ivacaftor-lumacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[10] \"Product Information. Symdeko 4-Week (ivacaftor-tezacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.", "alternatives_a": "Nitric Oxide, Doxapram, Elexacaftor", "alternatives_b": "Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Abatacept, More", "updated_at": 1767369485}, {"id": 97109, "ingredient1": "Ivacaftor", "ingredient2": "Sirolimus", "severity": "Moderate", "effect": "Coadministration with ivacaftor may increase the plasma concentrations of drugs that are substrates of the CYP450 3A4 isoenzyme and/or P-glycoprotein (P-gp) efflux transporter. The mechanism is decreased clearance via these pathways due to inhibition by ivacaftor and its pharmacologically active M1 metabolite.", "source": "DDInter", "management_text": "Caution is advised when ivacaftor is used with drugs that are substrates of CYP450 3A4 and/or P-gp, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever ivacaftor is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when ivacaftor is used with drugs that are substrates of CYP450 3A4 and/or P-gp, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97213/", "reference_text": "[1] \"Product Information. Kalydeco (ivacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[2] Richter WO, Jacob BG, Schwandt P \"Interaction between fibre and lovastatin.\" Lancet 338 (1991): 706[3] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors.\" Clin Pharmacol Ther 64 (1998): 477-83[4] Kantola T, Kivisto KT, Neuvonen PJ \"Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid.\" Clin Pharmacol Ther 63 (1998): 397-402[5] \"Product Information. Mevacor (lovastatin).\" Merck & Co, Inc, West Point, PA.[6] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions.\" Br J Clin Pharmacol 46 (1998): 101-10[7] Neuvonen PJ, Backman JT, Niemi M \"Pharmacokinetic comparison of the potential over-the-counter statins simvastatin, lovastatin, fluvastatin and pravastatin.\" Clin Pharmacokinet 47 (2008): 463-74[8] Thompson PD, Clarkson P, Karas RH \"Statin-associated myopathy.\" JAMA 289 (2003): 1681-90[9] \"Product Information. Zocor (simvastatin).\" Merck & Co, Inc, West Point, PA.[10] \"Product Information. Trikafta (elexacaftor/ivacaftor/tezacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[11] \"Product Information. Kalydeco (ivacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[12] \"Product Information. Orkambi (ivacaftor-lumacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[13] \"Product Information. Symdeko 4-Week (ivacaftor-tezacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.", "alternatives_a": "Alteplase, Ascorbic acid, Vitamin A, Potassium Iodide, Acetylcysteine, Nandrolone, Heparin, Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, More", "alternatives_b": "Nitric Oxide, Doxapram, Elexacaftor", "updated_at": 1767369485}, {"id": 97110, "ingredient1": "Ivacaftor", "ingredient2": "Solifenacin", "severity": "Moderate", "effect": "Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of solifenacin, which is primarily metabolized by the isoenzyme.", "source": "DDInter", "management_text": "Pharmacologic response to solifenacin should be monitored more closely whenever a CYP450 3A4 inhibitor is added to or withdrawn from therapy, and the solifenacin dosage adjusted if necessary. Patients should be advised to contact their physician if they experience undue adverse effects of solifenacin such as severe abdominal pain or constipation for 3 or more days. Patients should seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitations, irregular heartbeat, shortness of breath, or syncope.", "mechanism_text": "Metabolism", "recommendation": "Pharmacologic response to solifenacin should be monitored more closely whenever a CYP450 3A4 inhibitor is added to or withdrawn from therapy, and the solifenacin dosage adjusted if necessary.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97214/", "reference_text": "[1] \"Product Information. VESIcare (solifenacin).\" GlaxoSmithKline, Research Triangle Park, NC.[2] \"Product Information. Accolate (zafirlukast).\" Zeneca Pharmaceuticals, Wilmington, DE.", "alternatives_a": "Apomorphine, Pentosan polysulfate, Calcium chloride, Phenazopyridine, Alprostadil, Trospium, Acetohydroxamic acid, Yohimbine, Flavoxate, Avanafil, Papaverine, More", "alternatives_b": "Nitric Oxide, Doxapram, Elexacaftor, Lumacaftor", "updated_at": 1767369485}, {"id": 97111, "ingredient1": "Ivacaftor", "ingredient2": "Somapacitan", "severity": "Moderate", "effect": "Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of ivacaftor, which is primarily metabolized by the isoenzyme.", "source": "DDInter", "management_text": "The potential for diminished pharmacologic effects of ivacaftor-containing medications should be considered during coadministration with CYP450 3A4 inducers. Alternative treatments may be required if an interaction is suspected.", "mechanism_text": "Metabolism", "recommendation": "The potential for diminished pharmacologic effects of ivacaftor-containing medications should be considered during coadministration with CYP450 3A4 inducers.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97215/", "reference_text": "[1] \"Product Information. Symdeko 4-Week (ivacaftor-tezacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[2] \"Product Information. Orkambi (ivacaftor-lumacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[3] \"Product Information. Trikafta (elexacaftor/ivacaftor/tezacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[4] \"Product Information. Kalydeco (ivacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[5] \"Product Information. Trikafta (elexacaftor/ivacaftor/tezacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[6] \"Product Information. Kalydeco (ivacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[7] \"Product Information. Orkambi (ivacaftor-lumacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[8] \"Product Information. Symdeko 4-Week (ivacaftor-tezacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.", "alternatives_a": "Nitric Oxide, Doxapram, Elexacaftor, Lumacaftor", "alternatives_b": "Corticotropin, Mecasermin, Sermorelin, Tesamorelin, Thyrotropin alfa, Tetracosactide, Mecasermin rinfabate, Pegvisomant", "updated_at": 1767369485}, {"id": 97112, "ingredient1": "Ivacaftor", "ingredient2": "Somatrem", "severity": "Moderate", "effect": "Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of ivacaftor, which is primarily metabolized by the isoenzyme.", "source": "DDInter", "management_text": "The potential for diminished pharmacologic effects of ivacaftor-containing medications should be considered during coadministration with CYP450 3A4 inducers. Alternative treatments may be required if an interaction is suspected.", "mechanism_text": "Metabolism", "recommendation": "The potential for diminished pharmacologic effects of ivacaftor-containing medications should be considered during coadministration with CYP450 3A4 inducers.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97216/", "reference_text": "[1] \"Product Information. Symdeko 4-Week (ivacaftor-tezacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[2] \"Product Information. Orkambi (ivacaftor-lumacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[3] \"Product Information. Trikafta (elexacaftor/ivacaftor/tezacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[4] \"Product Information. Kalydeco (ivacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[5] \"Product Information. Trikafta (elexacaftor/ivacaftor/tezacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[6] \"Product Information. Kalydeco (ivacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[7] \"Product Information. Orkambi (ivacaftor-lumacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[8] \"Product Information. Symdeko 4-Week (ivacaftor-tezacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.", "alternatives_a": "Nitric Oxide, Doxapram, Elexacaftor, Lumacaftor", "alternatives_b": "Corticotropin, Mecasermin, Sermorelin, Tesamorelin, Thyrotropin alfa, Tetracosactide, Mecasermin rinfabate, Pegvisomant", "updated_at": 1767369485}, {"id": 97113, "ingredient1": "Ivacaftor", "ingredient2": "Somatotropin", "severity": "Moderate", "effect": "Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of ivacaftor, which is primarily metabolized by the isoenzyme.", "source": "DDInter", "management_text": "The potential for diminished pharmacologic effects of ivacaftor-containing medications should be considered during coadministration with CYP450 3A4 inducers. Alternative treatments may be required if an interaction is suspected.", "mechanism_text": "Metabolism", "recommendation": "The potential for diminished pharmacologic effects of ivacaftor-containing medications should be considered during coadministration with CYP450 3A4 inducers.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97217/", "reference_text": "[1] \"Product Information. Symdeko 4-Week (ivacaftor-tezacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[2] \"Product Information. Orkambi (ivacaftor-lumacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[3] \"Product Information. Trikafta (elexacaftor/ivacaftor/tezacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[4] \"Product Information. Kalydeco (ivacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[5] \"Product Information. Trikafta (elexacaftor/ivacaftor/tezacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[6] \"Product Information. Kalydeco (ivacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[7] \"Product Information. Orkambi (ivacaftor-lumacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[8] \"Product Information. Symdeko 4-Week (ivacaftor-tezacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.", "alternatives_a": "Corticotropin, Mecasermin, Sermorelin, Tesamorelin, Thyrotropin alfa, Tetracosactide, Mecasermin rinfabate, Pegvisomant", "alternatives_b": "Nitric Oxide, Doxapram, Elexacaftor, Lumacaftor", "updated_at": 1767369485}, {"id": 97114, "ingredient1": "Ivacaftor", "ingredient2": "Sonidegib", "severity": "Moderate", "effect": "Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of sonidegib, which is primarily metabolized by the isoenzyme.", "source": "DDInter", "management_text": "Caution is advised when sonidegib is prescribed with CYP450 3A4 inhibitors. Patients should be monitored for potentially increased adverse reactions, particularly musculoskeletal toxicity, and sonidegib treatment interrupted or discontinued accordingly.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when sonidegib is prescribed with CYP450 3A4 inhibitors.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97218/", "reference_text": "[1] \"Product Information. Odomzo (sonidegib).\" Novartis Pharmaceuticals, East Hanover, NJ.[2] \"Product Information. Accolate (zafirlukast).\" Zeneca Pharmaceuticals, Wilmington, DE.[3] \"Product Information. Odomzo (sonidegib).\" Novartis Pharmaceuticals, East Hanover, NJ.", "alternatives_a": "Nitric Oxide, Doxapram, Elexacaftor", "alternatives_b": "Pertuzumab, Oxaliplatin, Bortezomib, Tisagenlecleucel, Aminolevulinic acid, Omacetaxine mepesuccinate, Altretamine, Tagraxofusp, Ixazomib, Enasidenib, Porfimer sodium, More", "updated_at": 1767369485}, {"id": 97115, "ingredient1": "Ivacaftor", "ingredient2": "St. John's Wort", "severity": "Major", "effect": "Coadministration with potent inducers of CYP450 3A4 may significantly decrease the plasma concentrations of ivacaftor, which is primarily metabolized by the isoenzyme.", "source": "DDInter", "management_text": "Concomitant use of ivacaftor-containing medications with potent CYP450 3A4 inducers is not recommended.", "mechanism_text": "Metabolism", "recommendation": "Concomitant use of ivacaftor-containing medications with potent CYP450 3A4 inducers is not recommended.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97219/", "reference_text": "[1] \"Product Information. Orkambi (ivacaftor-lumacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] \"Product Information. Symdeko 4-Week (ivacaftor-tezacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[4] \"Product Information. Trikafta (elexacaftor/ivacaftor/tezacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[5] \"Product Information. Kalydeco (ivacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[6] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[7] Patel S, Robinson R, Burk M \"Hypertensive crisis associated with St. John's Wort.\" Am J Med 112 (2002): 507-8[8] \"Product Information. Trikafta (elexacaftor/ivacaftor/tezacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[9] \"Product Information. Kalydeco (ivacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[10] \"Product Information. Orkambi (ivacaftor-lumacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[11] \"Product Information. Symdeko 4-Week (ivacaftor-tezacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.", "alternatives_a": "Sertraline, Maprotiline, Fluoxetine, Milnacipran, Vortioxetine, Levomilnacipran, Doxepin, Duloxetine, Isocarboxazid, Amoxapine, Imipramine, More", "alternatives_b": "Nitric Oxide, Doxapram, Elexacaftor, Lumacaftor", "updated_at": 1767369485}, {"id": 97116, "ingredient1": "Ivacaftor", "ingredient2": "Stiripentol", "severity": "Moderate", "effect": "Coadministration with inhibitors of CYP450 1A2 and/or 3A4 may increase the plasma concentrations of stiripentol, which has been shown in vitro to undergo phase I metabolism via these pathways. Conversely, many of these inhibitors are also substrates of CYP450 1A2 and/or 3A4, and coadministration with stiripentol may alter their plasma concentrations as well. Stiripentol is both an inhibitor and inducer of CYP450 1A2 and 3A4 in vitro.", "source": "DDInter", "management_text": "Caution is advised when stiripentol is used with inhibitors of CYP450 1A2 and/or 3A4 that are also substrates of these enzymatic pathways. Patients should be monitored for potentially increased adverse effects of stiripentol such as anorexia, nausea, vomiting, weight loss, somnolence, dizziness, confusion, difficulty concentrating, ataxia, hypotonia, tremor, hyperkinesia, dysarthria, suicidal ideation/behavior, neutropenia, and thrombocytopenia. In addition, clinical and laboratory monitoring may be appropriate for concomitant drugs whenever stiripentol is added to or withdrawn from therapy. Dosage adjustments or alternative treatments may be required if an interaction is suspected.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when stiripentol is used with inhibitors of CYP450 1A2 and/or 3A4 that are also substrates of these enzymatic pathways.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97220/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Diacomit (stiripentol).\" Biocodex Inc, Creswell, OR.[3] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid.\"[4] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[5] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid.\"[6] \"Product Information. Diacomit (stiripentol).\" Biocodex Inc, Creswell, OR.", "alternatives_a": "Nitric Oxide, Doxapram, Elexacaftor", "alternatives_b": "Brivaracetam, Topiramate, Ezogabine, Lamotrigine, Lacosamide, Levetiracetam, Tiagabine, Ethotoin, Paramethadione, Perampanel, Vigabatrin, More", "updated_at": 1767369485}, {"id": 97117, "ingredient1": "Ivacaftor", "ingredient2": "Sulfamethoxazole", "severity": "Moderate", "effect": "Coadministration with ivacaftor may increase the plasma concentrations of drugs that are substrates of the CYP450 2C9 isoenzyme. The proposed mechanism, based on in vitro data, involves decreased metabolic clearance due to inhibition of CYP450 2C9 by ivacaftor.", "source": "DDInter", "management_text": "Caution is advised when ivacaftor is used concurrently with drugs that are known CYP450 2C9 substrates, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever ivacaftor is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when ivacaftor is used concurrently with drugs that are known CYP450 2C9 substrates, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97221/", "reference_text": "[1] \"Product Information. Trikafta (elexacaftor/ivacaftor/tezacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[2] \"Product Information. Symdeko 4-Week (ivacaftor-tezacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[3] \"Product Information. Orkambi (ivacaftor-lumacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[4] \"Product Information. Kalydeco (ivacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[5] \"Product Information. Ambien (zolpidem).\" sanofi-aventis, Bridgewater, NJ.[6] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84[7] \"Product Information. Trikafta (elexacaftor/ivacaftor/tezacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[8] \"Product Information. Kalydeco (ivacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[9] \"Product Information. Orkambi (ivacaftor-lumacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[10] \"Product Information. Symdeko 4-Week (ivacaftor-tezacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.", "alternatives_a": "Capreomycin, Pyrazinamide, Rifamycin, Streptomycin, Trimethoprim, Cycloserine, Ethambutol, Pyridoxine, Ethionamide, Pretomanid, Aminosalicylic acid, More", "alternatives_b": "Nitric Oxide, Doxapram, Elexacaftor, Lumacaftor", "updated_at": 1767369485}, {"id": 97118, "ingredient1": "Ivacaftor", "ingredient2": "Sulfinpyrazone", "severity": "Moderate", "effect": "Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of ivacaftor, which is primarily metabolized by the isoenzyme.", "source": "DDInter", "management_text": "The potential for diminished pharmacologic effects of ivacaftor-containing medications should be considered during coadministration with CYP450 3A4 inducers. Alternative treatments may be required if an interaction is suspected.", "mechanism_text": "Metabolism", "recommendation": "The potential for diminished pharmacologic effects of ivacaftor-containing medications should be considered during coadministration with CYP450 3A4 inducers.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97222/", "reference_text": "[1] \"Product Information. Symdeko 4-Week (ivacaftor-tezacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[2] \"Product Information. Orkambi (ivacaftor-lumacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[3] \"Product Information. Trikafta (elexacaftor/ivacaftor/tezacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[4] \"Product Information. Kalydeco (ivacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[5] \"Product Information. Trikafta (elexacaftor/ivacaftor/tezacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[6] \"Product Information. Kalydeco (ivacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[7] \"Product Information. Orkambi (ivacaftor-lumacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[8] \"Product Information. Symdeko 4-Week (ivacaftor-tezacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.", "alternatives_a": "Pegloticase, Febuxostat, Rasburicase, Probenecid, Allopurinol", "alternatives_b": "Nitric Oxide, Doxapram, Elexacaftor, Lumacaftor", "updated_at": 1767369485}, {"id": 97119, "ingredient1": "Ivacaftor", "ingredient2": "Suvorexant", "severity": "Moderate", "effect": "Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of suvorexant, which is primarily metabolized by the isoenzyme.", "source": "DDInter", "management_text": "Caution is advised if suvorexant is prescribed with inhibitors of CYP450 3A4. Patients should be monitored for excessive sedation and other side effects, and the suvorexant dosage adjusted as necessary.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if suvorexant is prescribed with inhibitors of CYP450 3A4.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97223/", "reference_text": "[1] Cerner Multum, Inc. \"Australian Product Information.\" O 0[2] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[3] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[4] Gunston GD, Mehta U \"Potentially serious drug interactions with grapefruit juice.\" S Afr Med J 90 (2000): 41[5] Bailey DG, Arnold JMO, Spence JD \"Grapefruit juice and drugs - how significant is the interaction.\" Clin Pharmacokinet 26 (1994): 91-8[6] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[7] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions.\" Br J Clin Pharmacol 46 (1998): 101-10[8] Libersa CC, Brique SA, Motte KB, et al. \"Dramatic inhibition of amiodarone metabolism induced by grapefruit juice.\" Br J Clin Pharmacol 49 (2000): 373-8[9] Bailey DG, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit juice felodipine interaction: Effect of naringin and 6',7'-dihydroxybergamottin in humans.\" Clin Pharmacol Ther 64 (1998): 248-56[10] Jonkman JH, Sollie FA, Sauter R, Steinijans VW \"The influence of caffeine on the steady-state pharmacokinetics of theophylline.\" Clin Pharmacol Ther 49 (1991): 248-55[11] Ozdemir M, Aktan Y, Boydag BS, Cingi MI, Musmul A \"Interaction between grapefruit juice and diazepam in humans.\" Eur J Drug Metab Pharmacokinet 23 (1998): 55-9[12] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin.\" Clin Pharmacol Ther 66 (1999): 118-27[13] Bailey DG, Arnold JM, Munoz C, Spence JD \"Grapefruit juice--felodipine interaction: mechanism, predictability, and effect of naringin.\" Clin Pharmacol Ther 53 (1993): 637-42[14] Sigusch H, Hippius M, Henschel L, Kaufmann K, Hoffmann A \"Influence of grapefruit juice on the pharmacokinetics of a slow release nifedipine formulation.\" Pharmazie 49 (1994): 522-4[15] Eagling VA, Profit L, Back DJ \"Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-I protease inhibitor saquinavir by grapefruit juice components.\" Br J Clin Pharmacol 48 (1999): 543-52[16] Damkier P, Hansen LL, Brosen K \"Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine.\" Br J Clin Pharmacol 48 (1999): 829-38[17] Min DI, Ku YM, Geraets DR, Lee HC \"Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers.\" J Clin Pharmacol 36 (1996): 469-76[18] Zaidenstein R, Soback S, Gips M, Avni B, Dishi V, Weissgarten Y, Golik A, Scapa E \"Effect of grapefruit juice on the pharmacokinetics of losartan and its active metabolite E3174 in healthy volunteers.\" Ther Drug Monit 23 (2001): 369-73[19] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84[20] Lee AJ, Chan WK, Harralson AF, Buffum J, Bui BCC \"The effects of grapefruit juice on sertraline metabolism: An in vitro and in vivo study.\" Clin Ther 21 (1999): 1890-9[21] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors.\" Clin Pharmacol Ther 64 (1998): 477-83[22] Garg SK, Kumar N, Bhargava VK, Prabhakar SK \"Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy.\" Clin Pharmacol Ther 64 (1998): 286-8[23] Fuhr U, Maier-Bruggemann A, Blume H, et al. \"Grapefruit juice increases oral nimodipine bioavailability.\" Int J Clin Pharmacol Ther 36 (1998): 126-32[24] Sato J, Nakata H, Owada E, Kikuta T, Umetsu M, Ito K \"Influence of usual intake of dietary caffeine on single-dose kinetics of theophylline in healthy human subjects.\" Eur J Clin Pharmacol 44 (1993): 295-8[25] Edgar B, Bailey D, Bergstrand R, et al \"Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics on felodipine and its potential clinical relevance.\" Eur J Clin Pharmacol 42 (1992): 313-7[26] Kantola T, Kivisto KT, Neuvonen PJ \"Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid.\" Clin Pharmacol Ther 63 (1998): 397-402[27] Dresser GK, Spence JD, Bailey DG \"Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition.\" Clin Pharmacokinet 38 (2000): 41-57[28] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[29] Takanaga H, Ohnishi A, Maatsuo H, et al. \"Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model.\" Br J Clin Pharmacol 49 (2000): 49-58[30] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS \"Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice.\" Br J Clin Pharmacol 42 (1996): p662[31] Bailey DG, Arnold JM, Strong HA, Munoz C, Spence JD \"Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics.\" Clin Pharmacol Ther 54 (1993): 589-94[32] Josefsson M, Zackrisson AL, Ahlner J \"Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers.\" Eur J Clin Pharmacol 51 (1996): 189-93[33] Majeed A, Kareem A \"Effect of grapefruit juice on cyclosporine pharmacokinetics.\" Pediatr Nephrol 10 (1996): 395[34] Flanagan D \"Understanding the grapefruit-drug interaction.\" Gen Dent 53 (2005): 282-5; quiz 286[35] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ \"Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice.\" Clin Pharmacol Ther 58 (1995): 127-31", "alternatives_a": "Nitric Oxide, Doxapram, Elexacaftor", "alternatives_b": "Flurazepam, Methohexital, Zaleplon, Dichloralphenazone, Valerian, Temazepam, Chloral hydrate, Quazepam, Paraldehyde, Ramelteon, Ethchlorvynol, More", "updated_at": 1767369485}, {"id": 97120, "ingredient1": "Ivacaftor", "ingredient2": "Tacrolimus", "severity": "Moderate", "effect": "Coadministration with ivacaftor may increase the plasma concentrations of drugs that are substrates of the CYP450 3A4 isoenzyme and/or P-glycoprotein (P-gp) efflux transporter. The mechanism is decreased clearance via these pathways due to inhibition by ivacaftor and its pharmacologically active M1 metabolite.", "source": "DDInter", "management_text": "Caution is advised when ivacaftor is used with drugs that are substrates of CYP450 3A4 and/or P-gp, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever ivacaftor is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when ivacaftor is used with drugs that are substrates of CYP450 3A4 and/or P-gp, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97224/", "reference_text": "[1] \"Product Information. Kalydeco (ivacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[2] Richter WO, Jacob BG, Schwandt P \"Interaction between fibre and lovastatin.\" Lancet 338 (1991): 706[3] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors.\" Clin Pharmacol Ther 64 (1998): 477-83[4] Kantola T, Kivisto KT, Neuvonen PJ \"Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid.\" Clin Pharmacol Ther 63 (1998): 397-402[5] \"Product Information. Mevacor (lovastatin).\" Merck & Co, Inc, West Point, PA.[6] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions.\" Br J Clin Pharmacol 46 (1998): 101-10[7] Neuvonen PJ, Backman JT, Niemi M \"Pharmacokinetic comparison of the potential over-the-counter statins simvastatin, lovastatin, fluvastatin and pravastatin.\" Clin Pharmacokinet 47 (2008): 463-74[8] Thompson PD, Clarkson P, Karas RH \"Statin-associated myopathy.\" JAMA 289 (2003): 1681-90[9] \"Product Information. Zocor (simvastatin).\" Merck & Co, Inc, West Point, PA.[10] \"Product Information. Trikafta (elexacaftor/ivacaftor/tezacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[11] \"Product Information. Kalydeco (ivacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[12] \"Product Information. Orkambi (ivacaftor-lumacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[13] \"Product Information. Symdeko 4-Week (ivacaftor-tezacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.", "alternatives_a": "Minoxidil, Deoxycholic acid, Calcium gluconate, Magnesium sulfate, Glycopyrronium, Pimecrolimus, Aminobenzoic acid, Finasteride, Caffeine, Cromoglicic acid, Abrocitinib, More", "alternatives_b": "Nitric Oxide, Doxapram, Elexacaftor", "updated_at": 1767369485}, {"id": 97121, "ingredient1": "Ivacaftor", "ingredient2": "Tadalafil", "severity": "Moderate", "effect": "Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of tadalafil, which is primarily metabolized by the isoenzyme. The possibility of prolonged and/or increased pharmacologic effects of tadalafil should be considered.", "source": "DDInter", "management_text": "Caution is advised if tadalafil is prescribed with CYP450 3A4 inhibitors. Dosage adjustments may be appropriate for tadalafil whenever a CYP450 3A4 inhibitor is added to or withdrawn from therapy based on efficacy and side effects. Tadalafil labeling recommends that the dosage not exceed 10 mg once every 72 hours in patients treated concomitantly with a potent CYP450 3A4 inhibitor, such as erythromycin, itraconazole, ketoconazole, protease inhibitors, and nefazodone. Patients should be advised to promptly notify their physician if they experience potential symptoms of PDE5 inhibitor toxicity such as pain or tightness in the chest or jaw, irregular heartbeat, nausea, shortness of breath, visual disturbances, syncope, or prolonged erection (greater than 4 hours).", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if tadalafil is prescribed with CYP450 3A4 inhibitors.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97225/", "reference_text": "[1] \"Product Information. Cialis (tadalafil).\" Lilly, Eli and Company, Indianapolis, IN.[2] \"Product Information. Cialis (tadalafil).\" Lilly, Eli and Company, Indianapolis, IN.[3] \"Product Information. Adcirca (tadalafil).\" United Therapeutics Corporation, Silver Spring, MD.", "alternatives_a": "Apomorphine, Pentosan polysulfate, Calcium chloride, Phenazopyridine, Alprostadil, Trospium, Acetohydroxamic acid, Yohimbine, Flavoxate, Avanafil, Papaverine, More", "alternatives_b": "Nitric Oxide, Doxapram, Elexacaftor, Lumacaftor", "updated_at": 1767369485}, {"id": 97122, "ingredient1": "Ivacaftor", "ingredient2": "Talazoparib", "severity": "Moderate", "effect": "Coadministration with inhibitors of P-glycoprotein (P-gp) and/or breast cancer resistance protein (BCRP) may increase the plasma concentrations of talazoparib, which has been shown in vitro to be a substrate of both efflux membrane transporters.", "source": "DDInter", "management_text": "No initial dosage adjustment is recommended by the manufacturer when talazoparib is coadministered with inhibitors of BCRP and/or P-gp other than amiodarone, carvedilol, clarithromycin, itraconazole, or verapamil. However, patients should be closely monitored for adverse effects such as myelosuppression and myelodysplastic syndrome/acute myeloid leukemia, and dosage adjustments made or treatment withheld as needed in accordance with the product labeling.", "mechanism_text": "Distribution", "recommendation": "No initial dosage adjustment is recommended by the manufacturer when talazoparib is coadministered with inhibitors of BCRP and/or P-gp other than amiodarone, carvedilol, clarithromycin, itraconazole, or verapamil.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97226/", "reference_text": "[1] \"Product Information. Talzenna (talazoparib).\" Pfizer U.S. Pharmaceuticals Group, New York, NY.", "alternatives_a": "Nitric Oxide, Doxapram, Elexacaftor, Lumacaftor", "alternatives_b": "Pertuzumab, Oxaliplatin, Bortezomib, Tisagenlecleucel, Aminolevulinic acid, Omacetaxine mepesuccinate, Altretamine, Tagraxofusp, Ixazomib, Enasidenib, Porfimer sodium, More", "updated_at": 1767369485}, {"id": 97123, "ingredient1": "Ivacaftor", "ingredient2": "Tamoxifen", "severity": "Moderate", "effect": "Coadministration with ivacaftor may increase the plasma concentrations of drugs that are substrates of the CYP450 2C9 isoenzyme. The proposed mechanism, based on in vitro data, involves decreased metabolic clearance due to inhibition of CYP450 2C9 by ivacaftor.", "source": "DDInter", "management_text": "Caution is advised when ivacaftor is used concurrently with drugs that are known CYP450 2C9 substrates, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever ivacaftor is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when ivacaftor is used concurrently with drugs that are known CYP450 2C9 substrates, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97227/", "reference_text": "[1] \"Product Information. Trikafta (elexacaftor/ivacaftor/tezacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[2] \"Product Information. Symdeko 4-Week (ivacaftor-tezacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[3] \"Product Information. Orkambi (ivacaftor-lumacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[4] \"Product Information. Kalydeco (ivacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[5] \"Product Information. Ambien (zolpidem).\" sanofi-aventis, Bridgewater, NJ.[6] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84[7] \"Product Information. Trikafta (elexacaftor/ivacaftor/tezacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[8] \"Product Information. Kalydeco (ivacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[9] \"Product Information. Orkambi (ivacaftor-lumacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[10] \"Product Information. Symdeko 4-Week (ivacaftor-tezacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.", "alternatives_a": "Darolutamide, Anastrozole, Fulvestrant, Abarelix, Flutamide, Degarelix, Nilutamide, Exemestane", "alternatives_b": "Nitric Oxide, Doxapram, Elexacaftor, Lumacaftor", "updated_at": 1767369485}, {"id": 97124, "ingredient1": "Ivacaftor", "ingredient2": "Tasimelteon", "severity": "Moderate", "effect": "Coadministration with inhibitors of CYP450 1A2 and/or 3A4 may increase the plasma concentrations of tasimelteon, which is primarily metabolized by these isoenzymes.", "source": "DDInter", "management_text": "Caution is advised if tasimelteon is prescribed in combination with inhibitors of CYP450 1A2 and/or 3A4. Patients should be monitored for excessive sedation and other side effects.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if tasimelteon is prescribed in combination with inhibitors of CYP450 1A2 and/or 3A4.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97228/", "reference_text": "[1] \"Product Information. Hetlioz (tasimelteon).\" Vanda Pharmaceuticals Inc, Rockville, MD.[2] \"Product Information. Hetlioz (tasimelteon).\" Vanda Pharmaceuticals Inc, Rockville, MD.", "alternatives_a": "Nitric Oxide, Doxapram, Elexacaftor", "alternatives_b": "Flurazepam, Methohexital, Zaleplon, Dichloralphenazone, Valerian, Temazepam, Chloral hydrate, Quazepam, Paraldehyde, Ramelteon, Ethchlorvynol, More", "updated_at": 1767369485}, {"id": 97125, "ingredient1": "Ivacaftor", "ingredient2": "Tazemetostat", "severity": "Moderate", "effect": "Coadministration with CYP450 3A4 inhibitors may increase the plasma concentrations of tazemetostat, which is primarily metabolized by the isoenzyme. Clinically, this interaction may result in an increased risk of the frequency or severity of adverse reactions due to tazemetostat such as hemorrhage, pleural effusion, skin infection, dyspnea, pain, and respiratory distress. Data are not available for other, less potent inhibitors.", "source": "DDInter", "management_text": "Caution and clinical monitoring is recommended with the concomitant use of tazemetostat with CYP450 3A4 inhibitors. Patients should be advised to notify their health care professional if they experience signs or symptoms of possible tazemetostat-related adverse effects including secondary malignancies, hemorrhage, pleural effusion, skin infection, dyspnea, pain, and respiratory distress.", "mechanism_text": "Metabolism", "recommendation": "Caution and clinical monitoring is recommended with the concomitant use of tazemetostat with CYP450 3A4 inhibitors.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97229/", "reference_text": "[1] \"Product Information. Tazverik (tazemetostat).\" Epizyme, Inc, Cambridge, MA.[2] \"Product Information. Tazverik (tazemetostat).\" Epizyme, Inc, Cambridge, MA.[3] \"Product Information. Accolate (zafirlukast).\" Zeneca Pharmaceuticals, Wilmington, DE.", "alternatives_a": "Nitric Oxide, Doxapram, Elexacaftor", "alternatives_b": "Pertuzumab, Oxaliplatin, Bortezomib, Tisagenlecleucel, Aminolevulinic acid, Omacetaxine mepesuccinate, Altretamine, Tagraxofusp, Ixazomib, Enasidenib, Porfimer sodium, More", "updated_at": 1767369485}, {"id": 97126, "ingredient1": "Ivacaftor", "ingredient2": "Telaprevir", "severity": "Major", "effect": "Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of ivacaftor, which is primarily metabolized by the isoenzyme.", "source": "DDInter", "management_text": "For ivacaftor -The ivacaftor dose should be reduced from 1 tablet or 1 packet of oral granules twice a day to 1 tablet or 1 packet of oral granules twice a week (i.e., every 3 to 4 days) during coadministration with potent CYP450 3A4 inhibitors. For example, a patient taking ivacaftor 150 mg tablet twice a day should reduce their ivacaftor dose to a 150 mg tablet twice a week and a patient taking ivacaftor 50 mg oral granule packet twice a day should reduce their ivacaftor dose to 50 mg oral granule packet twice a week, etc.", "mechanism_text": "Metabolism", "recommendation": "For ivacaftor -The ivacaftor dose should be reduced from 1 tablet or 1 packet of oral granules twice a day to 1 tablet or 1 packet of oral granules twice a week (i.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97230/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Symdeko 4-Week (ivacaftor-tezacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[3] \"Product Information. Trikafta (elexacaftor/ivacaftor/tezacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[4] Cerner Multum, Inc. \"Australian Product Information.\" O 0[5] \"Product Information. Kalydeco (ivacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[6] \"Product Information. Orkambi (ivacaftor-lumacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[7] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[8] \"Product Information. VFEND (voriconazole).\" Pfizer U.S. Pharmaceuticals, New York, NY.[9] \"Product Information. Trikafta (elexacaftor/ivacaftor/tezacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[10] \"Product Information. Kalydeco (ivacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[11] \"Product Information. Orkambi (ivacaftor-lumacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[12] \"Product Information. Symdeko 4-Week (ivacaftor-tezacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.", "alternatives_a": "Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Simeprevir, Cabotegravir, Valaciclovir, Zanamivir, Velpatasvir, Oseltamivir, Acyclovir, More", "alternatives_b": "Nitric Oxide, Doxapram, Elexacaftor, Lumacaftor", "updated_at": 1767369485}, {"id": 97127, "ingredient1": "Ivacaftor", "ingredient2": "Telithromycin", "severity": "Major", "effect": "Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of ivacaftor, which is primarily metabolized by the isoenzyme.", "source": "DDInter", "management_text": "For ivacaftor -The ivacaftor dose should be reduced from 1 tablet or 1 packet of oral granules twice a day to 1 tablet or 1 packet of oral granules twice a week (i.e., every 3 to 4 days) during coadministration with potent CYP450 3A4 inhibitors. For example, a patient taking ivacaftor 150 mg tablet twice a day should reduce their ivacaftor dose to a 150 mg tablet twice a week and a patient taking ivacaftor 50 mg oral granule packet twice a day should reduce their ivacaftor dose to 50 mg oral granule packet twice a week, etc.", "mechanism_text": "Metabolism", "recommendation": "For ivacaftor -The ivacaftor dose should be reduced from 1 tablet or 1 packet of oral granules twice a day to 1 tablet or 1 packet of oral granules twice a week (i.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97231/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Symdeko 4-Week (ivacaftor-tezacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[3] \"Product Information. Trikafta (elexacaftor/ivacaftor/tezacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[4] Cerner Multum, Inc. \"Australian Product Information.\" O 0[5] \"Product Information. Kalydeco (ivacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[6] \"Product Information. Orkambi (ivacaftor-lumacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[7] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[8] \"Product Information. VFEND (voriconazole).\" Pfizer U.S. Pharmaceuticals, New York, NY.[9] \"Product Information. Trikafta (elexacaftor/ivacaftor/tezacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[10] \"Product Information. Kalydeco (ivacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[11] \"Product Information. Orkambi (ivacaftor-lumacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[12] \"Product Information. Symdeko 4-Week (ivacaftor-tezacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.", "alternatives_a": "Dirithromycin, Lincomycin, Azithromycin, Clindamycin", "alternatives_b": "Nitric Oxide, Doxapram, Elexacaftor", "updated_at": 1767369485}, {"id": 97128, "ingredient1": "Ivacaftor", "ingredient2": "Telotristat ethyl", "severity": "Moderate", "effect": "Coadministration with telotristat ethyl may decrease the plasma concentrations of drugs that are substrates of CYP450 3A4 and/or 2B6 isoenzymes. The proposed mechanism is accelerated clearance due to induction of CYP450 3A4 and/or 2B6 (in vitro) isoenzymes by telotristat ethyl.", "source": "DDInter", "management_text": "When drugs that are known substrates of CYP450 3A4 and/or 2B6 are coadministered with telotristat ethyl, the possibility of a diminished therapeutic response to those drugs should be considered. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs, particularly those with a narrow therapeutic range, whenever telotristat ethyl is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "When drugs that are known substrates of CYP450 3A4 and/or 2B6 are coadministered with telotristat ethyl, the possibility of a diminished therapeutic response to those drugs should be considered.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97232/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Xermelo (telotristat ethyl).\" Lexicon Pharmaceuticals, Inc., The Woodlands, TX.[3] \"Product Information. Xermelo (telotristat ethyl).\" Lexicon Pharmaceuticals, Inc., The Woodlands, TX.", "alternatives_a": "Nitric Oxide, Doxapram, Elexacaftor, Lumacaftor", "alternatives_b": "", "updated_at": 1767369485}, {"id": 97129, "ingredient1": "Ivacaftor", "ingredient2": "Temsirolimus", "severity": "Moderate", "effect": "Coadministration of temsirolimus with inhibitors of CYP450 3A4 may increase the plasma concentrations of sirolimus, a major active metabolite of temsirolimus and known substrate of CYP450 3A4.", "source": "DDInter", "management_text": "Caution is advised if temsirolimus is prescribed in combination with CYP450 3A4 inhibitors. Pharmacologic response to temsirolimus should be monitored more closely whenever a CYP450 3A4 inhibitor is added to or withdrawn from therapy, and the temsirolimus dosage adjusted as necessary.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if temsirolimus is prescribed in combination with CYP450 3A4 inhibitors.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97233/", "reference_text": "[1] \"Product Information. Torisel (temsirolimus).\" Wyeth-Ayerst Laboratories, Philadelphia, PA.[2] \"Product Information. Torisel (temsirolimus).\" Wyeth-Ayerst Laboratories, Philadelphia, PA.", "alternatives_a": "Cabozantinib, Sunitinib, Regorafenib, Copanlisib, Ruxolitinib, Lenvatinib, Abemaciclib, Ponatinib, Neratinib, Vandetanib, Trametinib, More", "alternatives_b": "Nitric Oxide, Doxapram, Elexacaftor", "updated_at": 1767369485}, {"id": 97130, "ingredient1": "Ivacaftor", "ingredient2": "Terfenadine", "severity": "Moderate", "effect": "Coadministration with ivacaftor may increase the plasma concentrations of drugs that are substrates of the CYP450 3A4 isoenzyme and/or P-glycoprotein (P-gp) efflux transporter. The mechanism is decreased clearance via these pathways due to inhibition by ivacaftor and its pharmacologically active M1 metabolite.", "source": "DDInter", "management_text": "Caution is advised when ivacaftor is used with drugs that are substrates of CYP450 3A4 and/or P-gp, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever ivacaftor is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when ivacaftor is used with drugs that are substrates of CYP450 3A4 and/or P-gp, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97234/", "reference_text": "[1] \"Product Information. Kalydeco (ivacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[2] Richter WO, Jacob BG, Schwandt P \"Interaction between fibre and lovastatin.\" Lancet 338 (1991): 706[3] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors.\" Clin Pharmacol Ther 64 (1998): 477-83[4] Kantola T, Kivisto KT, Neuvonen PJ \"Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid.\" Clin Pharmacol Ther 63 (1998): 397-402[5] \"Product Information. Mevacor (lovastatin).\" Merck & Co, Inc, West Point, PA.[6] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions.\" Br J Clin Pharmacol 46 (1998): 101-10[7] Neuvonen PJ, Backman JT, Niemi M \"Pharmacokinetic comparison of the potential over-the-counter statins simvastatin, lovastatin, fluvastatin and pravastatin.\" Clin Pharmacokinet 47 (2008): 463-74[8] Thompson PD, Clarkson P, Karas RH \"Statin-associated myopathy.\" JAMA 289 (2003): 1681-90[9] \"Product Information. Zocor (simvastatin).\" Merck & Co, Inc, West Point, PA.[10] \"Product Information. Trikafta (elexacaftor/ivacaftor/tezacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[11] \"Product Information. Kalydeco (ivacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[12] \"Product Information. Orkambi (ivacaftor-lumacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[13] \"Product Information. Symdeko 4-Week (ivacaftor-tezacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.", "alternatives_a": "Ketotifen, Mepyramine, Levocetirizine, Chlorcyclizine, Cetirizine, Acrivastine, Triprolidine, Tripelennamine, Azelastine, Dexbrompheniramine, Promethazine, More", "alternatives_b": "Nitric Oxide, Doxapram, Elexacaftor, Lumacaftor", "updated_at": 1767369485}, {"id": 97131, "ingredient1": "Ivacaftor", "ingredient2": "Teriflunomide", "severity": "Major", "effect": "The recent, concomitant, or subsequent use (without the recommended leflunomide washout period or procedure) of other agents known to induce hepatotoxicity may potentiate the risk of liver injury associated with leflunomide. The risk is thought to extend to teriflunomide, its principal active metabolite, because recommended dosages of both result in a similar range of plasma concentrations of teriflunomide.", "source": "DDInter", "management_text": "Caution is advised if leflunomide or teriflunomide must be used in patients who are currently receiving or have recently received treatment with other hepatotoxic agents (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; nucleoside reverse transcriptase inhibitors; proteasome inhibitors; retinoids; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice), and vice versa. Liver enzymes and bilirubin should be measured prior to initiation of leflunomide/teriflunomide therapy and at least monthly for the first six months of treatment and every 6 to 8 weeks thereafter. Patients with preexisting liver disease or elevated baseline liver enzymes (i.e., ALT greater than two times ULN) should not receive leflunomide or teriflunomide. Patients who develop elevated serum ALT greater than three times ULN while receiving these medications should discontinue treatment and be given washout procedures with cholestyramine or activated charcoal to accelerate elimination of leflunomide's active metabolite from plasma, which otherwise may take up to two years. Follow-up monitoring should be conducted at least weekly until the ALT value is within normal range, and washout procedures repeated as necessary. All patients treated with leflunomide or teriflunomide should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if leflunomide or teriflunomide must be used in patients who are currently receiving or have recently received treatment with other hepatotoxic agents (e.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97235/", "reference_text": "[1] EMEA \"EMEA public statement on leflunomide (ARAVA) - severe and serious hepatic reactions. Available from URL: http://www.eudra.org/emea.html.\" ([1999 Sept 2]):[2] \"Product Information. Arava (leflunomide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[3] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"", "alternatives_a": "Nitric Oxide, Doxapram, Elexacaftor, Lumacaftor", "alternatives_b": "Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Abatacept, More", "updated_at": 1767369485}, {"id": 97132, "ingredient1": "Ivacaftor", "ingredient2": "Tioguanine", "severity": "Moderate", "effect": "The concomitant or sequential use of other agents known to induce hepatotoxicity may potentiate the risk of liver injury associated with thioguanine. A high risk of liver toxicity characterized by vascular endothelial damage has been reported with long-term continuous use of thioguanine, particularly in children receiving the drug as part of maintenance therapy for acute lymphoblastic leukemia and in other conditions associated with continuous use.", "source": "DDInter", "management_text": "The risk of hepatic injury should be considered when thioguanine is used with other potentially hepatotoxic agents (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; nucleoside reverse transcriptase inhibitors; proteasome inhibitors; retinoids; sulfonamides; tamoxifen; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice). Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice. Baseline and regular monitoring of hepatic function is recommended. Thioguanine therapy should be discontinued if there is evidence of toxic hepatitis or biliary stasis, as reversal of signs and symptoms of liver toxicity have been reported upon withdrawal. Early indications of liver toxicity are signs associated with portal hypertension such as thrombocytopenia out of proportion with neutropenia and splenomegaly. Elevations of liver enzymes have also been reported, but do not always occur.", "mechanism_text": "Synergism", "recommendation": "The risk of hepatic injury should be considered when thioguanine is used with other potentially hepatotoxic agents (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97236/", "reference_text": "[1] \"Product Information. Aubagio (teriflunomide).\" Genzyme Corporation, Cambridge, MA.[2] \"Product Information. Tabloid (thioguanine).\" Prasco Laboratories, Cincinnati, OH.", "alternatives_a": "Fluorouracil, Pemetrexed, Mercaptopurine, Cladribine, Trifluridine, Floxuridine, Gemcitabine, Nelarabine, Cytarabine, Pralatrexate, Fludarabine, More", "alternatives_b": "Nitric Oxide, Doxapram, Elexacaftor, Lumacaftor", "updated_at": 1767369485}, {"id": 97133, "ingredient1": "Ivacaftor", "ingredient2": "Ticagrelor", "severity": "Moderate", "effect": "Coadministration with ticagrelor may increase the plasma concentrations of drugs that are primarily metabolized by the CYP450 3A4 isoenzyme. The mechanism is reduced clearance due to inhibition of CYP450 3A4 by ticagrelor, which is a mild inhibitor. The interaction may be significant for sensitive CYP450 3A4 substrates or those that demonstrate a narrow therapeutic index.", "source": "DDInter", "management_text": "Concomitant use of ticagrelor with sensitive CYP450 3A4 substrates or those that demonstrate a narrow therapeutic index (e.g., cisapride, ergot alkaloids, colchicine, fentanyl, macrolide immunosuppressants, midazolam, pimozide, triazolam, vinca alkaloids) is not recommended.", "mechanism_text": "Metabolism", "recommendation": "Concomitant use of ticagrelor with sensitive CYP450 3A4 substrates or those that demonstrate a narrow therapeutic index (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97237/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Brilinta (ticagrelor).\" Astra-Zeneca Pharmaceuticals, Wilmington, DE.", "alternatives_a": "Clopidogrel, Iloprost, Lepirudin, Acenocoumarol, Urokinase, Cangrelor, Dipyridamole, Caplacizumab, Argatroban, Prasugrel, Desirudin, More", "alternatives_b": "Nitric Oxide, Doxapram, Elexacaftor", "updated_at": 1767369485}, {"id": 97134, "ingredient1": "Ivacaftor", "ingredient2": "Tipranavir", "severity": "Moderate", "effect": "Coadministration with ivacaftor may increase the plasma concentrations of drugs that are substrates of the CYP450 3A4 isoenzyme and/or P-glycoprotein (P-gp) efflux transporter. The mechanism is decreased clearance via these pathways due to inhibition by ivacaftor and its pharmacologically active M1 metabolite.", "source": "DDInter", "management_text": "Caution is advised when ivacaftor is used with drugs that are substrates of CYP450 3A4 and/or P-gp, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever ivacaftor is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when ivacaftor is used with drugs that are substrates of CYP450 3A4 and/or P-gp, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97238/", "reference_text": "[1] \"Product Information. Kalydeco (ivacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[2] Richter WO, Jacob BG, Schwandt P \"Interaction between fibre and lovastatin.\" Lancet 338 (1991): 706[3] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors.\" Clin Pharmacol Ther 64 (1998): 477-83[4] Kantola T, Kivisto KT, Neuvonen PJ \"Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid.\" Clin Pharmacol Ther 63 (1998): 397-402[5] \"Product Information. Mevacor (lovastatin).\" Merck & Co, Inc, West Point, PA.[6] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions.\" Br J Clin Pharmacol 46 (1998): 101-10[7] Neuvonen PJ, Backman JT, Niemi M \"Pharmacokinetic comparison of the potential over-the-counter statins simvastatin, lovastatin, fluvastatin and pravastatin.\" Clin Pharmacokinet 47 (2008): 463-74[8] Thompson PD, Clarkson P, Karas RH \"Statin-associated myopathy.\" JAMA 289 (2003): 1681-90[9] \"Product Information. Zocor (simvastatin).\" Merck & Co, Inc, West Point, PA.[10] \"Product Information. Trikafta (elexacaftor/ivacaftor/tezacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[11] \"Product Information. Kalydeco (ivacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[12] \"Product Information. Orkambi (ivacaftor-lumacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[13] \"Product Information. Symdeko 4-Week (ivacaftor-tezacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.", "alternatives_a": "Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Simeprevir, Cabotegravir, Valaciclovir, Zanamivir, Velpatasvir, Oseltamivir, Acyclovir, More", "alternatives_b": "Nitric Oxide, Doxapram, Elexacaftor", "updated_at": 1767369485}, {"id": 97135, "ingredient1": "Ivacaftor", "ingredient2": "Tolazamide", "severity": "Moderate", "effect": "Coadministration with ivacaftor may increase the plasma concentrations of drugs that are substrates of the CYP450 2C9 isoenzyme. The proposed mechanism, based on in vitro data, involves decreased metabolic clearance due to inhibition of CYP450 2C9 by ivacaftor.", "source": "DDInter", "management_text": "Caution is advised when ivacaftor is used concurrently with drugs that are known CYP450 2C9 substrates, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever ivacaftor is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when ivacaftor is used concurrently with drugs that are known CYP450 2C9 substrates, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97239/", "reference_text": "[1] \"Product Information. Trikafta (elexacaftor/ivacaftor/tezacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[2] \"Product Information. Symdeko 4-Week (ivacaftor-tezacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[3] \"Product Information. Orkambi (ivacaftor-lumacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[4] \"Product Information. Kalydeco (ivacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[5] \"Product Information. Ambien (zolpidem).\" sanofi-aventis, Bridgewater, NJ.[6] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84[7] \"Product Information. Trikafta (elexacaftor/ivacaftor/tezacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[8] \"Product Information. Kalydeco (ivacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[9] \"Product Information. Orkambi (ivacaftor-lumacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[10] \"Product Information. Symdeko 4-Week (ivacaftor-tezacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.", "alternatives_a": "Guar gum, Pramlintide, Alogliptin, Rosuvastatin, Empagliflozin, Dulaglutide, Exenatide, Miglitol, Albiglutide, Rosiglitazone, Ertugliflozin, More", "alternatives_b": "Nitric Oxide, Doxapram, Elexacaftor", "updated_at": 1767369485}, {"id": 97136, "ingredient1": "Ivacaftor", "ingredient2": "Tolbutamide", "severity": "Moderate", "effect": "Coadministration with ivacaftor may increase the plasma concentrations of drugs that are substrates of the CYP450 2C9 isoenzyme. The proposed mechanism, based on in vitro data, involves decreased metabolic clearance due to inhibition of CYP450 2C9 by ivacaftor.", "source": "DDInter", "management_text": "Caution is advised when ivacaftor is used concurrently with drugs that are known CYP450 2C9 substrates, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever ivacaftor is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when ivacaftor is used concurrently with drugs that are known CYP450 2C9 substrates, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97240/", "reference_text": "[1] \"Product Information. Trikafta (elexacaftor/ivacaftor/tezacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[2] \"Product Information. Symdeko 4-Week (ivacaftor-tezacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[3] \"Product Information. Orkambi (ivacaftor-lumacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[4] \"Product Information. Kalydeco (ivacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[5] \"Product Information. Ambien (zolpidem).\" sanofi-aventis, Bridgewater, NJ.[6] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84[7] \"Product Information. Trikafta (elexacaftor/ivacaftor/tezacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[8] \"Product Information. Kalydeco (ivacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[9] \"Product Information. Orkambi (ivacaftor-lumacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[10] \"Product Information. Symdeko 4-Week (ivacaftor-tezacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.", "alternatives_a": "Sorbitol, Caffeine, Edrophonium, Indocyanine green, Inulin, Hexaminolevulinate, Secretin human, Galactose, Corticorelin, Macimorelin, Methacholine, More", "alternatives_b": "Nitric Oxide, Doxapram, Elexacaftor", "updated_at": 1767369485}, {"id": 97137, "ingredient1": "Ivacaftor", "ingredient2": "Tolterodine", "severity": "Moderate", "effect": "Coadministration with drugs that are inhibitors of CYP450 3A4 may increase the plasma concentrations of tolterodine, which is partially metabolized by the isoenzyme. The possibility of prolonged and/or increased pharmacologic effects of tolterodine should be considered. Although tolterodine is primarily metabolized by CYP450 2D6, there is some evidence that CYP450 3A4 may play a minor role, thus any alteration in its activity levels could conceivably affect the metabolism of tolterodine.", "source": "DDInter", "management_text": "The manufacturer recommends a maximum tolterodine dosage of 1 mg twice daily in patients receiving concomitant CYP450 3A4 inhibitors. Close clinical and laboratory monitoring is advised whenever a CYP450 3A4 inhibitor is added to or withdrawn from therapy. Patients should be advised to notify their physician if they experience an irregular heartbeat, severe blurry vision, difficulty urinating, dry mouth, headache, drowsiness, dizziness, or GI upset.", "mechanism_text": "Metabolism", "recommendation": "The manufacturer recommends a maximum tolterodine dosage of 1 mg twice daily in patients receiving concomitant CYP450 3A4 inhibitors.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97241/", "reference_text": "[1] \"Product Information. Detrol (tolterodine).\" Pharmacia and Upjohn, Kalamazoo, MI.[2] Brynne N, Forslund C, Hallen B, Gustafsson LL, Bertilsson L \"Ketoconazole inhibits the metabolism of tolterodine in subjects with deficient CYP2D6 activity.\" Br J Clin Pharmacol 48 (1999): 564-72", "alternatives_a": "Apomorphine, Pentosan polysulfate, Calcium chloride, Phenazopyridine, Alprostadil, Trospium, Acetohydroxamic acid, Yohimbine, Flavoxate, Avanafil, Papaverine, More", "alternatives_b": "Nitric Oxide, Doxapram, Elexacaftor, Lumacaftor", "updated_at": 1767369485}, {"id": 97138, "ingredient1": "Ivacaftor", "ingredient2": "Tolvaptan", "severity": "Moderate", "effect": "Coadministration with inhibitors of P-glycoprotein (P-gp) may increase the oral bioavailability of tolvaptan, which has been shown in vitro to be a substrate of the efflux transporter.", "source": "DDInter", "management_text": "Caution is advised if tolvaptan is prescribed in combination with P-glycoprotein inhibitors, especially potent ones such as amiodarone, cyclosporine, or quinidine. Serum sodium concentration and neurologic status should be closely monitored, and the tolvaptan dosage adjusted accordingly. Too rapid correction of hyponatremia increases the risk of osmotic demyelination syndrome, which is associated with dysarthria, mutism, dysphagia, lethargy, affective changes, spastic quadriparesis, seizures, coma, and death. Discontinuation or interruption of tolvaptan therapy should be considered in patients who develop too rapid a rise in serum sodium.", "mechanism_text": "Absorption", "recommendation": "Caution is advised if tolvaptan is prescribed in combination with P-glycoprotein inhibitors, especially potent ones such as amiodarone, cyclosporine, or quinidine.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97242/", "reference_text": "[1] \"Product Information. Samsca (tolvaptan).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[2] \"Product Information. Venclexta (venetoclax).\" AbbVie US LLC, North Chicago, IL.[3] \"Product Information. Samsca (tolvaptan).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.", "alternatives_a": "Nitric Oxide, Doxapram, Elexacaftor", "alternatives_b": "", "updated_at": 1767369485}, {"id": 97139, "ingredient1": "Ivacaftor", "ingredient2": "Toremifene", "severity": "Moderate", "effect": "Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of toremifene, which is primarily metabolized by the isoenzyme. Because toremifene is associated with dose- and concentration-dependent prolongation of the QT interval, increased levels may potentiate the risk of ventricular arrhythmias such as torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Clinical and laboratory monitoring for altered efficacy and safety of toremifene may be appropriate whenever a CYP450 3A inhibitor is added to or withdrawn from therapy. Complete blood counts, electrolyte levels (calcium, magnesium, potassium), and liver function tests should be obtained periodically. Patients should be advised to contact their physician if they experience vaginal bleeding or potential signs of blood clots such as chest pain, shortness of breath, sudden loss of vision, and pain, redness or swelling in an extremity. Patients should seek immediate medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, palpitations, or syncope.", "mechanism_text": "Metabolism", "recommendation": "Clinical and laboratory monitoring for altered efficacy and safety of toremifene may be appropriate whenever a CYP450 3A inhibitor is added to or withdrawn from therapy.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97243/", "reference_text": "[1] \"Product Information. Fareston (toremifene).\" Schering Laboratories, Kenilworth, NJ.[2] \"Product Information. Accolate (zafirlukast).\" Zeneca Pharmaceuticals, Wilmington, DE.[3] \"Product Information. Fareston (toremifene).\" Schering Laboratories, Kenilworth, NJ.[4] Therapeutic Research Faculty \"Natural Medicines Comprehensive Database. Available from: URL: http://www.naturaldatabase.com.\" ([1995-2008...]):", "alternatives_a": "Darolutamide, Anastrozole, Fulvestrant, Abarelix, Flutamide, Degarelix, Nilutamide, Exemestane", "alternatives_b": "Nitric Oxide, Doxapram, Elexacaftor", "updated_at": 1767369485}, {"id": 97140, "ingredient1": "Ivacaftor", "ingredient2": "Torasemide", "severity": "Moderate", "effect": "Coadministration with inhibitors of CYP450 2C9 may increase the plasma concentrations of torsemide. The interaction has not been evaluated in pharmacokinetic studies; however, torsemide has been shown to undergo metabolism by CYP450 2C9.", "source": "DDInter", "management_text": "Caution is advised when torsemide is prescribed with CYP450 2C9 inhibitors. Patients should be monitored for potentially increased adverse effects such as dehydration, hypotension, electrolyte imbalances, hyperglycemia, tinnitus, and hearing loss.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when torsemide is prescribed with CYP450 2C9 inhibitors.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97244/", "reference_text": "[1] Vormfelde SV, Engelhardt S, Zirk A, et al. \"CYP2C9 polymorphisms and the interindividual variability in pharmacokinetics and pharmacodynamics of the loop diuretic drug torsemide.\" Clin Pharmacol Ther 76 (2004): 557-66[2] Miners JO, Rees DLP, Valente L, Veronese ME, Birkett DJ \"Human hepatic cytochrome p450 2c9 catalyzes the rate-limiting pathway of torsemide metabolism.\" J Pharmacol Exp Ther 272 (1995): 1076-81[3] \"Product Information. Demedex (torsemide).\" Boehringer Mannheim, Gaithersburg, MD.[4] Miners JO, Birkett DJ \"Cytochrome P4502C9: an enzyme of major importance in human drug metabolism.\" Br J Clin Pharmacol 45 (1998): 525-38[5] \"Product Information. Accolate (zafirlukast).\" Zeneca Pharmaceuticals, Wilmington, DE.", "alternatives_a": "Furosemide, Bumetanide, Etacrynic acid, Tamsulosin, Tinidazole, Ascorbic acid, Hydroflumethiazide, Chlorothiazide, Metronidazole, Simeprevir, Rosuvastatin, More", "alternatives_b": "Nitric Oxide, Doxapram, Elexacaftor, Lumacaftor", "updated_at": 1767369485}, {"id": 97141, "ingredient1": "Ivacaftor", "ingredient2": "Trabectedin", "severity": "Moderate", "effect": "Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of trabectedin, which is primarily metabolized by the isoenzyme. Coadministration of trabectedin with other agents known to induce hepatotoxicity may potentiate the risk of liver injury. Reversible, acute increases in alanine aminotransferase (ALT) and aspartate aminotransferase (AST) have occurred frequently in patients treated with trabectedin alone or with pegylated liposomal doxorubicin in clinical trials.", "source": "DDInter", "management_text": "Caution is advised when trabectedin is prescribed with CYP450 3A4 inhibitors that are also potentially hepatotoxic (e.g., azole antifungal agents; bicalutamide; cyclosporine (high dosages); dronedarone; macrolide antibiotics; protein kinase inhibitors; zafirlukast). Patients should be monitored for toxicities such as myelosuppression, rhabdomyolysis, hepatotoxicity, and cardiomyopathy, and the trabectedin dosage adjusted accordingly or treatment discontinued as necessary. Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice. Monitoring of alkaline phosphatase, bilirubin, AST, and ALT should occur regularly during trabectedin treatment in accordance with the product labeling, or as often as necessary when clinical symptoms develop. Trabectedin must not be used in patients with elevated bilirubin at the time of initiation of cycle. Elevated liver function tests should be managed with treatment interruption, dosage reduction, or permanent discontinuation depending on the severity and duration of abnormality.", "mechanism_text": "Metabolism, Synergism", "recommendation": "Caution is advised when trabectedin is prescribed with CYP450 3A4 inhibitors that are also potentially hepatotoxic (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97245/", "reference_text": "[1] Machiels JP, Staddon A, Herremans C, et al. \"Impact of cytochrome P450 3A4 inducer and inhibitor on the pharmacokinetics of trabectedin in patients with advanced malignancies: open-label, multicenter studies.\" Cancer Chemother Pharmacol 74 (2014): 729-37[2] \"Product Information. Yondelis (trabectedin).\" Janssen Pharmaceuticals, Titusville, NJ.[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] \"Product Information. Accolate (zafirlukast).\" Zeneca Pharmaceuticals, Wilmington, DE.[5] \"Product Information. Yondelis (trabectedin).\" Janssen Pharmaceuticals, Titusville, NJ.[6] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0", "alternatives_a": "Topotecan, Teniposide, Paclitaxel", "alternatives_b": "Nitric Oxide, Doxapram, Elexacaftor", "updated_at": 1767369485}, {"id": 97142, "ingredient1": "Ivacaftor", "ingredient2": "Triazolam", "severity": "Moderate", "effect": "Coadministration with ivacaftor may increase the plasma concentrations of drugs that are substrates of the CYP450 3A4 isoenzyme and/or P-glycoprotein (P-gp) efflux transporter. The mechanism is decreased clearance via these pathways due to inhibition by ivacaftor and its pharmacologically active M1 metabolite.", "source": "DDInter", "management_text": "Caution is advised when ivacaftor is used with drugs that are substrates of CYP450 3A4 and/or P-gp, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever ivacaftor is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when ivacaftor is used with drugs that are substrates of CYP450 3A4 and/or P-gp, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97246/", "reference_text": "[1] \"Product Information. Kalydeco (ivacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[2] Richter WO, Jacob BG, Schwandt P \"Interaction between fibre and lovastatin.\" Lancet 338 (1991): 706[3] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors.\" Clin Pharmacol Ther 64 (1998): 477-83[4] Kantola T, Kivisto KT, Neuvonen PJ \"Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid.\" Clin Pharmacol Ther 63 (1998): 397-402[5] \"Product Information. Mevacor (lovastatin).\" Merck & Co, Inc, West Point, PA.[6] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions.\" Br J Clin Pharmacol 46 (1998): 101-10[7] Neuvonen PJ, Backman JT, Niemi M \"Pharmacokinetic comparison of the potential over-the-counter statins simvastatin, lovastatin, fluvastatin and pravastatin.\" Clin Pharmacokinet 47 (2008): 463-74[8] Thompson PD, Clarkson P, Karas RH \"Statin-associated myopathy.\" JAMA 289 (2003): 1681-90[9] \"Product Information. Zocor (simvastatin).\" Merck & Co, Inc, West Point, PA.[10] \"Product Information. Trikafta (elexacaftor/ivacaftor/tezacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[11] \"Product Information. Kalydeco (ivacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[12] \"Product Information. Orkambi (ivacaftor-lumacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[13] \"Product Information. Symdeko 4-Week (ivacaftor-tezacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.", "alternatives_a": "Flurazepam, Methohexital, Zaleplon, Dichloralphenazone, Valerian, Temazepam, Chloral hydrate, Quazepam, Paraldehyde, Ramelteon, Ethchlorvynol, More", "alternatives_b": "Nitric Oxide, Doxapram, Elexacaftor", "updated_at": 1767369485}, {"id": 97143, "ingredient1": "Ivacaftor", "ingredient2": "Troglitazone", "severity": "Moderate", "effect": "Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of ivacaftor, which is primarily metabolized by the isoenzyme.", "source": "DDInter", "management_text": "The potential for diminished pharmacologic effects of ivacaftor-containing medications should be considered during coadministration with CYP450 3A4 inducers. Alternative treatments may be required if an interaction is suspected.", "mechanism_text": "Metabolism", "recommendation": "The potential for diminished pharmacologic effects of ivacaftor-containing medications should be considered during coadministration with CYP450 3A4 inducers.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97247/", "reference_text": "[1] \"Product Information. Symdeko 4-Week (ivacaftor-tezacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[2] \"Product Information. Orkambi (ivacaftor-lumacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[3] \"Product Information. Trikafta (elexacaftor/ivacaftor/tezacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[4] \"Product Information. Kalydeco (ivacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[5] \"Product Information. Trikafta (elexacaftor/ivacaftor/tezacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[6] \"Product Information. Kalydeco (ivacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[7] \"Product Information. Orkambi (ivacaftor-lumacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[8] \"Product Information. Symdeko 4-Week (ivacaftor-tezacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.", "alternatives_a": "Guar gum, Pramlintide, Alogliptin, Rosuvastatin, Empagliflozin, Dulaglutide, Exenatide, Miglitol, Albiglutide, Rosiglitazone, Ertugliflozin, More", "alternatives_b": "Nitric Oxide, Doxapram, Elexacaftor, Lumacaftor", "updated_at": 1767369485}, {"id": 97144, "ingredient1": "Ivacaftor", "ingredient2": "Troleandomycin", "severity": "Major", "effect": "Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of ivacaftor, which is primarily metabolized by the isoenzyme.", "source": "DDInter", "management_text": "For ivacaftor -The ivacaftor dose should be reduced from 1 tablet or 1 packet of oral granules twice a day to 1 tablet or 1 packet of oral granules twice a week (i.e., every 3 to 4 days) during coadministration with potent CYP450 3A4 inhibitors. For example, a patient taking ivacaftor 150 mg tablet twice a day should reduce their ivacaftor dose to a 150 mg tablet twice a week and a patient taking ivacaftor 50 mg oral granule packet twice a day should reduce their ivacaftor dose to 50 mg oral granule packet twice a week, etc.", "mechanism_text": "Metabolism", "recommendation": "For ivacaftor -The ivacaftor dose should be reduced from 1 tablet or 1 packet of oral granules twice a day to 1 tablet or 1 packet of oral granules twice a week (i.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97248/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Symdeko 4-Week (ivacaftor-tezacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[3] \"Product Information. Trikafta (elexacaftor/ivacaftor/tezacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[4] Cerner Multum, Inc. \"Australian Product Information.\" O 0[5] \"Product Information. Kalydeco (ivacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[6] \"Product Information. Orkambi (ivacaftor-lumacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[7] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[8] \"Product Information. VFEND (voriconazole).\" Pfizer U.S. Pharmaceuticals, New York, NY.[9] \"Product Information. Trikafta (elexacaftor/ivacaftor/tezacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[10] \"Product Information. Kalydeco (ivacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[11] \"Product Information. Orkambi (ivacaftor-lumacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[12] \"Product Information. Symdeko 4-Week (ivacaftor-tezacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.", "alternatives_a": "Nitric Oxide, Doxapram, Elexacaftor, Lumacaftor", "alternatives_b": "Dirithromycin, Lincomycin, Azithromycin, Clindamycin", "updated_at": 1767369485}, {"id": 97145, "ingredient1": "Ivacaftor", "ingredient2": "Tucatinib", "severity": "Major", "effect": "Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of ivacaftor, which is primarily metabolized by the isoenzyme.", "source": "DDInter", "management_text": "For ivacaftor -The ivacaftor dose should be reduced from 1 tablet or 1 packet of oral granules twice a day to 1 tablet or 1 packet of oral granules twice a week (i.e., every 3 to 4 days) during coadministration with potent CYP450 3A4 inhibitors. For example, a patient taking ivacaftor 150 mg tablet twice a day should reduce their ivacaftor dose to a 150 mg tablet twice a week and a patient taking ivacaftor 50 mg oral granule packet twice a day should reduce their ivacaftor dose to 50 mg oral granule packet twice a week, etc.", "mechanism_text": "Metabolism", "recommendation": "For ivacaftor -The ivacaftor dose should be reduced from 1 tablet or 1 packet of oral granules twice a day to 1 tablet or 1 packet of oral granules twice a week (i.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97249/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Symdeko 4-Week (ivacaftor-tezacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[3] \"Product Information. Trikafta (elexacaftor/ivacaftor/tezacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[4] Cerner Multum, Inc. \"Australian Product Information.\" O 0[5] \"Product Information. Kalydeco (ivacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[6] \"Product Information. Orkambi (ivacaftor-lumacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[7] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[8] \"Product Information. VFEND (voriconazole).\" Pfizer U.S. Pharmaceuticals, New York, NY.[9] \"Product Information. Trikafta (elexacaftor/ivacaftor/tezacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[10] \"Product Information. Kalydeco (ivacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[11] \"Product Information. Orkambi (ivacaftor-lumacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[12] \"Product Information. Symdeko 4-Week (ivacaftor-tezacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.", "alternatives_a": "Nitric Oxide, Doxapram, Elexacaftor", "alternatives_b": "Cabozantinib, Sunitinib, Regorafenib, Copanlisib, Ruxolitinib, Lenvatinib, Abemaciclib, Ponatinib, Neratinib, Vandetanib, Trametinib, More", "updated_at": 1767369485}, {"id": 97146, "ingredient1": "Ivacaftor", "ingredient2": "Ubrogepant", "severity": "Moderate", "effect": "Coadministration with moderate or weak inhibitors of CYP450 3A4 may increase the plasma concentrations of ubrogepant, which is primarily metabolized by the isoenzyme.", "source": "DDInter", "management_text": "The manufacturer recommends an initial ubrogepant dose of 50 mg when coadministered with moderate or weak CYP450 3A4 inhibitors. If needed, a second ubrogepant dose should be avoided within 24 hours of the initial dose when used with moderate CYP450 3A4 inhibitors.", "mechanism_text": "Metabolism", "recommendation": "The manufacturer recommends an initial ubrogepant dose of 50 mg when coadministered with moderate or weak CYP450 3A4 inhibitors.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97250/", "reference_text": "[1] \"Product Information. Ubrelvy (ubrogepant).\" Allergan Inc, Irvine, CA.[2] \"Product Information. Ubrelvy (ubrogepant).\" Allergan Inc, Irvine, CA.", "alternatives_a": "Nitric Oxide, Doxapram, Elexacaftor", "alternatives_b": "Frovatriptan, Eptinezumab, Lasmiditan, Rizatriptan, Naratriptan, Galcanezumab, Zolmitriptan, Sumatriptan, Erenumab, Clonidine, Almotriptan, Fremanezumab", "updated_at": 1767369485}, {"id": 97147, "ingredient1": "Ivacaftor", "ingredient2": "Valdecoxib", "severity": "Moderate", "effect": "Coadministration with ivacaftor may increase the plasma concentrations of drugs that are substrates of the CYP450 2C9 isoenzyme. The proposed mechanism, based on in vitro data, involves decreased metabolic clearance due to inhibition of CYP450 2C9 by ivacaftor.", "source": "DDInter", "management_text": "Caution is advised when ivacaftor is used concurrently with drugs that are known CYP450 2C9 substrates, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever ivacaftor is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when ivacaftor is used concurrently with drugs that are known CYP450 2C9 substrates, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97251/", "reference_text": "[1] \"Product Information. Trikafta (elexacaftor/ivacaftor/tezacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[2] \"Product Information. Symdeko 4-Week (ivacaftor-tezacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[3] \"Product Information. Orkambi (ivacaftor-lumacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[4] \"Product Information. Kalydeco (ivacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[5] \"Product Information. Ambien (zolpidem).\" sanofi-aventis, Bridgewater, NJ.[6] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84[7] \"Product Information. Trikafta (elexacaftor/ivacaftor/tezacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[8] \"Product Information. Kalydeco (ivacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[9] \"Product Information. Orkambi (ivacaftor-lumacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[10] \"Product Information. Symdeko 4-Week (ivacaftor-tezacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.", "alternatives_a": "Fenoprofen, Rabeprazole, Meclofenamic acid, Ketorolac, Misoprostol, Ketoprofen, Glucosamine, Oxaprozin, Chondroitin sulfate, Nabumetone, Rofecoxib, More", "alternatives_b": "Nitric Oxide, Doxapram, Elexacaftor", "updated_at": 1767369485}, {"id": 97148, "ingredient1": "Elexacaftor", "ingredient2": "Valsartan", "severity": "Moderate", "effect": "Coadministration with elexacaftor may increase the plasma concentrations of drugs that are substrates of the organic anion transporting polypeptides (OATP) 1B1 and 1B3. The proposed mechanism, based on in vitro data, involves decreased metabolic clearance due to inhibition of OATP 1B1- and 1B3-mediated hepatic uptake by elexacaftor and its metabolite. The clinical relevance is unknown.", "source": "DDInter", "management_text": "Caution is advised when elexacaftor is used concurrently with drugs that are known OATP 1B1 and 1B3 substrates, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever elexacaftor is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when elexacaftor is used concurrently with drugs that are known OATP 1B1 and 1B3 substrates, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97252/", "reference_text": "[1] \"Product Information. Trikafta (elexacaftor/ivacaftor/tezacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[2] \"Product Information. Diovan (valsartan).\" Novartis Pharmaceuticals, East Hanover, NJ.[3] \"Product Information. Cozaar (losartan).\" Merck & Co, Inc, West Point, PA.[4] \"Product Information. Trikafta (elexacaftor/ivacaftor/tezacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[5] \"Product Information. Kalydeco (ivacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[6] \"Product Information. Orkambi (ivacaftor-lumacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[7] \"Product Information. Symdeko 4-Week (ivacaftor-tezacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.", "alternatives_a": "Amlodipine, Irbesartan, Hydrochlorothiazide, Losartan, Azilsartan medoxomil, Nebivolol, Telmisartan, Candesartan, Sacubitril, Aliskiren, Eprosartan, More", "alternatives_b": "Nitric Oxide, Doxapram, Ivacaftor, Lumacaftor", "updated_at": 1767369485}, {"id": 97149, "ingredient1": "Ivacaftor", "ingredient2": "Vardenafil", "severity": "Moderate", "effect": "Coadministration with inhibitors of CYP450 3A4 and/or 2C9 may increase the plasma concentrations of vardenafil, which is primarily metabolized by the former and secondarily by the latter. The possibility of prolonged and/or increased pharmacologic effects of vardenafil should be considered.", "source": "DDInter", "management_text": "Dosage adjustments may be appropriate for vardenafil whenever a CYP450 3A4 and/or 2C9 inhibitor is added to or withdrawn from therapy based on efficacy and patient tolerance. The manufacturer recommends that an initial vardenafil dosage of 2.5 to 5 mg be used in patients treated concomitantly with a potent CYP450 3A4 inhibitor such as erythromycin, itraconazole, ketoconazole, indinavir, and ritonavir.", "mechanism_text": "Metabolism", "recommendation": "Dosage adjustments may be appropriate for vardenafil whenever a CYP450 3A4 and/or 2C9 inhibitor is added to or withdrawn from therapy based on efficacy and patient tolerance.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97253/", "reference_text": "[1] \"Product Information. Levitra (vardenafil).\" Bayer, West Haven, CT.[2] \"Product Information. Accolate (zafirlukast).\" Zeneca Pharmaceuticals, Wilmington, DE.[3] Gunston GD, Mehta U \"Potentially serious drug interactions with grapefruit juice.\" S Afr Med J 90 (2000): 41[4] Fuhr U, Maier-Bruggemann A, Blume H, et al. \"Grapefruit juice increases oral nimodipine bioavailability.\" Int J Clin Pharmacol Ther 36 (1998): 126-32[5] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[6] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[7] Takanaga H, Ohnishi A, Maatsuo H, et al. \"Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model.\" Br J Clin Pharmacol 49 (2000): 49-58[8] Jonkman JH, Sollie FA, Sauter R, Steinijans VW \"The influence of caffeine on the steady-state pharmacokinetics of theophylline.\" Clin Pharmacol Ther 49 (1991): 248-55[9] Ozdemir M, Aktan Y, Boydag BS, Cingi MI, Musmul A \"Interaction between grapefruit juice and diazepam in humans.\" Eur J Drug Metab Pharmacokinet 23 (1998): 55-9[10] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS \"Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice.\" Br J Clin Pharmacol 42 (1996): p662[11] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin.\" Clin Pharmacol Ther 66 (1999): 118-27[12] Bailey DG, Arnold JM, Strong HA, Munoz C, Spence JD \"Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics.\" Clin Pharmacol Ther 54 (1993): 589-94[13] Sigusch H, Hippius M, Henschel L, Kaufmann K, Hoffmann A \"Influence of grapefruit juice on the pharmacokinetics of a slow release nifedipine formulation.\" Pharmazie 49 (1994): 522-4[14] Bailey DG, Arnold JM, Munoz C, Spence JD \"Grapefruit juice--felodipine interaction: mechanism, predictability, and effect of naringin.\" Clin Pharmacol Ther 53 (1993): 637-42[15] Zaidenstein R, Soback S, Gips M, Avni B, Dishi V, Weissgarten Y, Golik A, Scapa E \"Effect of grapefruit juice on the pharmacokinetics of losartan and its active metabolite E3174 in healthy volunteers.\" Ther Drug Monit 23 (2001): 369-73[16] Josefsson M, Zackrisson AL, Ahlner J \"Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers.\" Eur J Clin Pharmacol 51 (1996): 189-93[17] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84[18] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors.\" Clin Pharmacol Ther 64 (1998): 477-83[19] Lee AJ, Chan WK, Harralson AF, Buffum J, Bui BCC \"The effects of grapefruit juice on sertraline metabolism: An in vitro and in vivo study.\" Clin Ther 21 (1999): 1890-9[20] Majeed A, Kareem A \"Effect of grapefruit juice on cyclosporine pharmacokinetics.\" Pediatr Nephrol 10 (1996): 395[21] Flanagan D \"Understanding the grapefruit-drug interaction.\" Gen Dent 53 (2005): 282-5; quiz 286[22] Garg SK, Kumar N, Bhargava VK, Prabhakar SK \"Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy.\" Clin Pharmacol Ther 64 (1998): 286-8[23] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ \"Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice.\" Clin Pharmacol Ther 58 (1995): 127-31[24] Sato J, Nakata H, Owada E, Kikuta T, Umetsu M, Ito K \"Influence of usual intake of dietary caffeine on single-dose kinetics of theophylline in healthy human subjects.\" Eur J Clin Pharmacol 44 (1993): 295-8[25] Dresser GK, Spence JD, Bailey DG \"Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition.\" Clin Pharmacokinet 38 (2000): 41-57[26] Bailey DG, Arnold JMO, Spence JD \"Grapefruit juice and drugs - how significant is the interaction.\" Clin Pharmacokinet 26 (1994): 91-8[27] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions.\" Br J Clin Pharmacol 46 (1998): 101-10[28] Libersa CC, Brique SA, Motte KB, et al. \"Dramatic inhibition of amiodarone metabolism induced by grapefruit juice.\" Br J Clin Pharmacol 49 (2000): 373-8[29] Bailey DG, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit juice felodipine interaction: Effect of naringin and 6',7'-dihydroxybergamottin in humans.\" Clin Pharmacol Ther 64 (1998): 248-56[30] Eagling VA, Profit L, Back DJ \"Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-I protease inhibitor saquinavir by grapefruit juice components.\" Br J Clin Pharmacol 48 (1999): 543-52[31] Damkier P, Hansen LL, Brosen K \"Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine.\" Br J Clin Pharmacol 48 (1999): 829-38[32] Min DI, Ku YM, Geraets DR, Lee HC \"Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers.\" J Clin Pharmacol 36 (1996): 469-76[33] Edgar B, Bailey D, Bergstrand R, et al \"Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics on felodipine and its potential clinical relevance.\" Eur J Clin Pharmacol 42 (1992): 313-7[34] Kantola T, Kivisto KT, Neuvonen PJ \"Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid.\" Clin Pharmacol Ther 63 (1998): 397-402", "alternatives_a": "Apomorphine, Pentosan polysulfate, Calcium chloride, Phenazopyridine, Alprostadil, Trospium, Acetohydroxamic acid, Yohimbine, Flavoxate, Avanafil, Papaverine, More", "alternatives_b": "Nitric Oxide, Doxapram, Elexacaftor", "updated_at": 1767369485}, {"id": 97150, "ingredient1": "Ivacaftor", "ingredient2": "Vemurafenib", "severity": "Moderate", "effect": "Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of ivacaftor, which is primarily metabolized by the isoenzyme.", "source": "DDInter", "management_text": "The potential for diminished pharmacologic effects of ivacaftor-containing medications should be considered during coadministration with CYP450 3A4 inducers. Alternative treatments may be required if an interaction is suspected.", "mechanism_text": "Metabolism", "recommendation": "The potential for diminished pharmacologic effects of ivacaftor-containing medications should be considered during coadministration with CYP450 3A4 inducers.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97254/", "reference_text": "[1] \"Product Information. Symdeko 4-Week (ivacaftor-tezacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[2] \"Product Information. Orkambi (ivacaftor-lumacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[3] \"Product Information. Trikafta (elexacaftor/ivacaftor/tezacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[4] \"Product Information. Kalydeco (ivacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[5] \"Product Information. Trikafta (elexacaftor/ivacaftor/tezacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[6] \"Product Information. Kalydeco (ivacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[7] \"Product Information. Orkambi (ivacaftor-lumacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[8] \"Product Information. Symdeko 4-Week (ivacaftor-tezacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.", "alternatives_a": "Nitric Oxide, Doxapram, Elexacaftor", "alternatives_b": "Tamsulosin, Tinidazole, Ascorbic acid, Hydroflumethiazide, Chlorothiazide, Metronidazole, Simeprevir, Rosuvastatin, Sulfadiazine, Lactic acid, Methazolamide, More", "updated_at": 1767369485}, {"id": 97151, "ingredient1": "Ivacaftor", "ingredient2": "Venetoclax", "severity": "Major", "effect": "Coadministration with P-glycoprotein (P-gp) inhibitors may increase the plasma concentrations of venetoclax, which is a substrate of this efflux transporter.", "source": "DDInter", "management_text": "Concomitant use of venetoclax with P-gp inhibitors should generally be avoided. If coadministration is required, the manufacturer recommends that venetoclax dosage be reduced by at least 50%. The dosage used prior to initiating the P-gp inhibitor may be resumed 2 to 3 days after discontinuation of the inhibitor.", "mechanism_text": "Absorption", "recommendation": "Concomitant use of venetoclax with P-gp inhibitors should generally be avoided.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97255/", "reference_text": "[1] \"Product Information. Venclexta (venetoclax).\" AbbVie US LLC, North Chicago, IL.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] Cerner Multum, Inc. \"Australian Product Information.\" O 0[4] \"Product Information. Venclexta (venetoclax).\" AbbVie US LLC, North Chicago, IL.[5] \"Product Information. Mavyret (glecaprevir-pibrentasvir).\" Abbott Pharmaceutical, Abbott Park, IL.", "alternatives_a": "Nitric Oxide, Doxapram, Elexacaftor", "alternatives_b": "Pertuzumab, Oxaliplatin, Bortezomib, Tisagenlecleucel, Aminolevulinic acid, Omacetaxine mepesuccinate, Altretamine, Tagraxofusp, Ixazomib, Enasidenib, Porfimer sodium, More", "updated_at": 1767369485}, {"id": 97152, "ingredient1": "Ivacaftor", "ingredient2": "Venlafaxine", "severity": "Moderate", "effect": "Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of venlafaxine and its metabolite, O-desmethylvenlafaxine (ODV). The possibility of prolonged and/or increased pharmacologic effects of venlafaxine should be considered. Although venlafaxine is primarily metabolized by CYP450 2D6, there is some evidence that CYP450 3A4 may play a minor role, thus any alteration in its activity levels could conceivably affect the metabolism of venlafaxine. The interaction may be of greater concern in patients who are CYP450 2D6-deficient, or so-called poor metabolizers of CYP450 2D6 (approximately 7% of Caucasians and less than 2% of Asians and individuals of African descent).", "source": "DDInter", "management_text": "Caution is recommended when venlafaxine is used with CYP450 3A4 inhibitors.", "mechanism_text": "Metabolism", "recommendation": "Caution is recommended when venlafaxine is used with CYP450 3A4 inhibitors.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97256/", "reference_text": "[1] \"Product Information. Effexor (venlafaxine).\" Wyeth-Ayerst Laboratories, Philadelphia, PA.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] Cerner Multum, Inc. \"Australian Product Information.\" O 0[4] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[5] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[6] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[7] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[8] Gunston GD, Mehta U \"Potentially serious drug interactions with grapefruit juice.\" S Afr Med J 90 (2000): 41[9] Bailey DG, Arnold JMO, Spence JD \"Grapefruit juice and drugs - how significant is the interaction.\" Clin Pharmacokinet 26 (1994): 91-8[10] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[11] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions.\" Br J Clin Pharmacol 46 (1998): 101-10[12] Libersa CC, Brique SA, Motte KB, et al. \"Dramatic inhibition of amiodarone metabolism induced by grapefruit juice.\" Br J Clin Pharmacol 49 (2000): 373-8[13] Bailey DG, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit juice felodipine interaction: Effect of naringin and 6',7'-dihydroxybergamottin in humans.\" Clin Pharmacol Ther 64 (1998): 248-56[14] Jonkman JH, Sollie FA, Sauter R, Steinijans VW \"The influence of caffeine on the steady-state pharmacokinetics of theophylline.\" Clin Pharmacol Ther 49 (1991): 248-55[15] Ozdemir M, Aktan Y, Boydag BS, Cingi MI, Musmul A \"Interaction between grapefruit juice and diazepam in humans.\" Eur J Drug Metab Pharmacokinet 23 (1998): 55-9[16] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin.\" Clin Pharmacol Ther 66 (1999): 118-27[17] Bailey DG, Arnold JM, Munoz C, Spence JD \"Grapefruit juice--felodipine interaction: mechanism, predictability, and effect of naringin.\" Clin Pharmacol Ther 53 (1993): 637-42[18] Sigusch H, Hippius M, Henschel L, Kaufmann K, Hoffmann A \"Influence of grapefruit juice on the pharmacokinetics of a slow release nifedipine formulation.\" Pharmazie 49 (1994): 522-4[19] Eagling VA, Profit L, Back DJ \"Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-I protease inhibitor saquinavir by grapefruit juice components.\" Br J Clin Pharmacol 48 (1999): 543-52[20] Damkier P, Hansen LL, Brosen K \"Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine.\" Br J Clin Pharmacol 48 (1999): 829-38[21] Min DI, Ku YM, Geraets DR, Lee HC \"Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers.\" J Clin Pharmacol 36 (1996): 469-76[22] Zaidenstein R, Soback S, Gips M, Avni B, Dishi V, Weissgarten Y, Golik A, Scapa E \"Effect of grapefruit juice on the pharmacokinetics of losartan and its active metabolite E3174 in healthy volunteers.\" Ther Drug Monit 23 (2001): 369-73[23] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84[24] Lee AJ, Chan WK, Harralson AF, Buffum J, Bui BCC \"The effects of grapefruit juice on sertraline metabolism: An in vitro and in vivo study.\" Clin Ther 21 (1999): 1890-9[25] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors.\" Clin Pharmacol Ther 64 (1998): 477-83[26] Garg SK, Kumar N, Bhargava VK, Prabhakar SK \"Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy.\" Clin Pharmacol Ther 64 (1998): 286-8[27] Fuhr U, Maier-Bruggemann A, Blume H, et al. \"Grapefruit juice increases oral nimodipine bioavailability.\" Int J Clin Pharmacol Ther 36 (1998): 126-32[28] Sato J, Nakata H, Owada E, Kikuta T, Umetsu M, Ito K \"Influence of usual intake of dietary caffeine on single-dose kinetics of theophylline in healthy human subjects.\" Eur J Clin Pharmacol 44 (1993): 295-8[29] Edgar B, Bailey D, Bergstrand R, et al \"Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics on felodipine and its potential clinical relevance.\" Eur J Clin Pharmacol 42 (1992): 313-7[30] Kantola T, Kivisto KT, Neuvonen PJ \"Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid.\" Clin Pharmacol Ther 63 (1998): 397-402[31] Dresser GK, Spence JD, Bailey DG \"Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition.\" Clin Pharmacokinet 38 (2000): 41-57[32] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[33] Takanaga H, Ohnishi A, Maatsuo H, et al. \"Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model.\" Br J Clin Pharmacol 49 (2000): 49-58[34] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS \"Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice.\" Br J Clin Pharmacol 42 (1996): p662[35] Bailey DG, Arnold JM, Strong HA, Munoz C, Spence JD \"Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics.\" Clin Pharmacol Ther 54 (1993): 589-94[36] Josefsson M, Zackrisson AL, Ahlner J \"Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers.\" Eur J Clin Pharmacol 51 (1996): 189-93[37] Majeed A, Kareem A \"Effect of grapefruit juice on cyclosporine pharmacokinetics.\" Pediatr Nephrol 10 (1996): 395[38] Flanagan D \"Understanding the grapefruit-drug interaction.\" Gen Dent 53 (2005): 282-5; quiz 286[39] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ \"Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice.\" Clin Pharmacol Ther 58 (1995): 127-31", "alternatives_a": "Sertraline, Maprotiline, Fluoxetine, Milnacipran, Vortioxetine, Levomilnacipran, Doxepin, Duloxetine, Isocarboxazid, Amoxapine, Imipramine, More", "alternatives_b": "Nitric Oxide, Doxapram, Elexacaftor, Lumacaftor", "updated_at": 1767369485}, {"id": 97153, "ingredient1": "Ivacaftor", "ingredient2": "Vilazodone", "severity": "Moderate", "effect": "Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of vilazodone, which is primarily metabolized by the isoenzyme.", "source": "DDInter", "management_text": "When used with moderate CYP450 3A4 inhibitors, the maintenance dosage of vilazodone should be reduced to 20 mg/day in patients who develop intolerable adverse events.", "mechanism_text": "Metabolism", "recommendation": "When used with moderate CYP450 3A4 inhibitors, the maintenance dosage of vilazodone should be reduced to 20 mg/day in patients who develop intolerable adverse events.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97257/", "reference_text": "[1] \"Product Information. Viibryd (vilazodone).\" Trovis Pharmaceuticals LLC, New Haven, CT.[2] \"Product Information. Viibryd (vilazodone).\" Trovis Pharmaceuticals LLC, New Haven, CT.[3] Gunston GD, Mehta U \"Potentially serious drug interactions with grapefruit juice.\" S Afr Med J 90 (2000): 41[4] Bailey DG, Arnold JMO, Spence JD \"Grapefruit juice and drugs - how significant is the interaction.\" Clin Pharmacokinet 26 (1994): 91-8[5] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[6] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions.\" Br J Clin Pharmacol 46 (1998): 101-10[7] Libersa CC, Brique SA, Motte KB, et al. \"Dramatic inhibition of amiodarone metabolism induced by grapefruit juice.\" Br J Clin Pharmacol 49 (2000): 373-8[8] Bailey DG, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit juice felodipine interaction: Effect of naringin and 6',7'-dihydroxybergamottin in humans.\" Clin Pharmacol Ther 64 (1998): 248-56[9] Jonkman JH, Sollie FA, Sauter R, Steinijans VW \"The influence of caffeine on the steady-state pharmacokinetics of theophylline.\" Clin Pharmacol Ther 49 (1991): 248-55[10] Ozdemir M, Aktan Y, Boydag BS, Cingi MI, Musmul A \"Interaction between grapefruit juice and diazepam in humans.\" Eur J Drug Metab Pharmacokinet 23 (1998): 55-9[11] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin.\" Clin Pharmacol Ther 66 (1999): 118-27[12] Bailey DG, Arnold JM, Munoz C, Spence JD \"Grapefruit juice--felodipine interaction: mechanism, predictability, and effect of naringin.\" Clin Pharmacol Ther 53 (1993): 637-42[13] Sigusch H, Hippius M, Henschel L, Kaufmann K, Hoffmann A \"Influence of grapefruit juice on the pharmacokinetics of a slow release nifedipine formulation.\" Pharmazie 49 (1994): 522-4[14] Eagling VA, Profit L, Back DJ \"Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-I protease inhibitor saquinavir by grapefruit juice components.\" Br J Clin Pharmacol 48 (1999): 543-52[15] Damkier P, Hansen LL, Brosen K \"Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine.\" Br J Clin Pharmacol 48 (1999): 829-38[16] Min DI, Ku YM, Geraets DR, Lee HC \"Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers.\" J Clin Pharmacol 36 (1996): 469-76[17] Zaidenstein R, Soback S, Gips M, Avni B, Dishi V, Weissgarten Y, Golik A, Scapa E \"Effect of grapefruit juice on the pharmacokinetics of losartan and its active metabolite E3174 in healthy volunteers.\" Ther Drug Monit 23 (2001): 369-73[18] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84[19] Lee AJ, Chan WK, Harralson AF, Buffum J, Bui BCC \"The effects of grapefruit juice on sertraline metabolism: An in vitro and in vivo study.\" Clin Ther 21 (1999): 1890-9[20] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors.\" Clin Pharmacol Ther 64 (1998): 477-83[21] Garg SK, Kumar N, Bhargava VK, Prabhakar SK \"Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy.\" Clin Pharmacol Ther 64 (1998): 286-8[22] Fuhr U, Maier-Bruggemann A, Blume H, et al. \"Grapefruit juice increases oral nimodipine bioavailability.\" Int J Clin Pharmacol Ther 36 (1998): 126-32[23] Sato J, Nakata H, Owada E, Kikuta T, Umetsu M, Ito K \"Influence of usual intake of dietary caffeine on single-dose kinetics of theophylline in healthy human subjects.\" Eur J Clin Pharmacol 44 (1993): 295-8[24] Edgar B, Bailey D, Bergstrand R, et al \"Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics on felodipine and its potential clinical relevance.\" Eur J Clin Pharmacol 42 (1992): 313-7[25] Kantola T, Kivisto KT, Neuvonen PJ \"Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid.\" Clin Pharmacol Ther 63 (1998): 397-402[26] Dresser GK, Spence JD, Bailey DG \"Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition.\" Clin Pharmacokinet 38 (2000): 41-57[27] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[28] Takanaga H, Ohnishi A, Maatsuo H, et al. \"Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model.\" Br J Clin Pharmacol 49 (2000): 49-58[29] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS \"Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice.\" Br J Clin Pharmacol 42 (1996): p662[30] Bailey DG, Arnold JM, Strong HA, Munoz C, Spence JD \"Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics.\" Clin Pharmacol Ther 54 (1993): 589-94[31] Josefsson M, Zackrisson AL, Ahlner J \"Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers.\" Eur J Clin Pharmacol 51 (1996): 189-93[32] Majeed A, Kareem A \"Effect of grapefruit juice on cyclosporine pharmacokinetics.\" Pediatr Nephrol 10 (1996): 395[33] Flanagan D \"Understanding the grapefruit-drug interaction.\" Gen Dent 53 (2005): 282-5; quiz 286[34] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ \"Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice.\" Clin Pharmacol Ther 58 (1995): 127-31", "alternatives_a": "Sertraline, Maprotiline, Fluoxetine, Milnacipran, Vortioxetine, Levomilnacipran, Doxepin, Duloxetine, Isocarboxazid, Amoxapine, Imipramine, More", "alternatives_b": "Nitric Oxide, Doxapram, Elexacaftor", "updated_at": 1767369485}, {"id": 97154, "ingredient1": "Ivacaftor", "ingredient2": "Vinblastine", "severity": "Moderate", "effect": "Coadministration with ivacaftor may increase the plasma concentrations of drugs that are substrates of the CYP450 3A4 isoenzyme and/or P-glycoprotein (P-gp) efflux transporter. The mechanism is decreased clearance via these pathways due to inhibition by ivacaftor and its pharmacologically active M1 metabolite.", "source": "DDInter", "management_text": "Caution is advised when ivacaftor is used with drugs that are substrates of CYP450 3A4 and/or P-gp, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever ivacaftor is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when ivacaftor is used with drugs that are substrates of CYP450 3A4 and/or P-gp, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97258/", "reference_text": "[1] \"Product Information. Kalydeco (ivacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[2] Richter WO, Jacob BG, Schwandt P \"Interaction between fibre and lovastatin.\" Lancet 338 (1991): 706[3] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors.\" Clin Pharmacol Ther 64 (1998): 477-83[4] Kantola T, Kivisto KT, Neuvonen PJ \"Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid.\" Clin Pharmacol Ther 63 (1998): 397-402[5] \"Product Information. Mevacor (lovastatin).\" Merck & Co, Inc, West Point, PA.[6] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions.\" Br J Clin Pharmacol 46 (1998): 101-10[7] Neuvonen PJ, Backman JT, Niemi M \"Pharmacokinetic comparison of the potential over-the-counter statins simvastatin, lovastatin, fluvastatin and pravastatin.\" Clin Pharmacokinet 47 (2008): 463-74[8] Thompson PD, Clarkson P, Karas RH \"Statin-associated myopathy.\" JAMA 289 (2003): 1681-90[9] \"Product Information. Zocor (simvastatin).\" Merck & Co, Inc, West Point, PA.[10] \"Product Information. Trikafta (elexacaftor/ivacaftor/tezacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[11] \"Product Information. Kalydeco (ivacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[12] \"Product Information. Orkambi (ivacaftor-lumacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[13] \"Product Information. Symdeko 4-Week (ivacaftor-tezacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.", "alternatives_a": "Topotecan, Teniposide, Paclitaxel", "alternatives_b": "Nitric Oxide, Doxapram, Elexacaftor, Lumacaftor", "updated_at": 1767369485}, {"id": 97155, "ingredient1": "Ivacaftor", "ingredient2": "Vincristine", "severity": "Moderate", "effect": "Coadministration with ivacaftor may increase the plasma concentrations of drugs that are substrates of the CYP450 3A4 isoenzyme and/or P-glycoprotein (P-gp) efflux transporter. The mechanism is decreased clearance via these pathways due to inhibition by ivacaftor and its pharmacologically active M1 metabolite.", "source": "DDInter", "management_text": "Caution is advised when ivacaftor is used with drugs that are substrates of CYP450 3A4 and/or P-gp, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever ivacaftor is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when ivacaftor is used with drugs that are substrates of CYP450 3A4 and/or P-gp, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97259/", "reference_text": "[1] \"Product Information. Kalydeco (ivacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[2] Richter WO, Jacob BG, Schwandt P \"Interaction between fibre and lovastatin.\" Lancet 338 (1991): 706[3] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors.\" Clin Pharmacol Ther 64 (1998): 477-83[4] Kantola T, Kivisto KT, Neuvonen PJ \"Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid.\" Clin Pharmacol Ther 63 (1998): 397-402[5] \"Product Information. Mevacor (lovastatin).\" Merck & Co, Inc, West Point, PA.[6] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions.\" Br J Clin Pharmacol 46 (1998): 101-10[7] Neuvonen PJ, Backman JT, Niemi M \"Pharmacokinetic comparison of the potential over-the-counter statins simvastatin, lovastatin, fluvastatin and pravastatin.\" Clin Pharmacokinet 47 (2008): 463-74[8] Thompson PD, Clarkson P, Karas RH \"Statin-associated myopathy.\" JAMA 289 (2003): 1681-90[9] \"Product Information. Zocor (simvastatin).\" Merck & Co, Inc, West Point, PA.[10] \"Product Information. Trikafta (elexacaftor/ivacaftor/tezacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[11] \"Product Information. Kalydeco (ivacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[12] \"Product Information. Orkambi (ivacaftor-lumacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[13] \"Product Information. Symdeko 4-Week (ivacaftor-tezacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.", "alternatives_a": "Topotecan, Teniposide, Paclitaxel", "alternatives_b": "Nitric Oxide, Doxapram, Elexacaftor, Lumacaftor", "updated_at": 1767369485}, {"id": 97156, "ingredient1": "Ivacaftor", "ingredient2": "Vincristine (liposome)", "severity": "Moderate", "effect": "Coadministration with ivacaftor may increase the plasma concentrations of drugs that are substrates of the CYP450 3A4 isoenzyme and/or P-glycoprotein (P-gp) efflux transporter. The mechanism is decreased clearance via these pathways due to inhibition by ivacaftor and its pharmacologically active M1 metabolite.", "source": "DDInter", "management_text": "Caution is advised when ivacaftor is used with drugs that are substrates of CYP450 3A4 and/or P-gp, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever ivacaftor is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when ivacaftor is used with drugs that are substrates of CYP450 3A4 and/or P-gp, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97260/", "reference_text": "[1] \"Product Information. Kalydeco (ivacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[2] Richter WO, Jacob BG, Schwandt P \"Interaction between fibre and lovastatin.\" Lancet 338 (1991): 706[3] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors.\" Clin Pharmacol Ther 64 (1998): 477-83[4] Kantola T, Kivisto KT, Neuvonen PJ \"Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid.\" Clin Pharmacol Ther 63 (1998): 397-402[5] \"Product Information. Mevacor (lovastatin).\" Merck & Co, Inc, West Point, PA.[6] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions.\" Br J Clin Pharmacol 46 (1998): 101-10[7] Neuvonen PJ, Backman JT, Niemi M \"Pharmacokinetic comparison of the potential over-the-counter statins simvastatin, lovastatin, fluvastatin and pravastatin.\" Clin Pharmacokinet 47 (2008): 463-74[8] Thompson PD, Clarkson P, Karas RH \"Statin-associated myopathy.\" JAMA 289 (2003): 1681-90[9] \"Product Information. Zocor (simvastatin).\" Merck & Co, Inc, West Point, PA.[10] \"Product Information. Trikafta (elexacaftor/ivacaftor/tezacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[11] \"Product Information. Kalydeco (ivacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[12] \"Product Information. Orkambi (ivacaftor-lumacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[13] \"Product Information. Symdeko 4-Week (ivacaftor-tezacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.", "alternatives_a": "Topotecan, Teniposide, Paclitaxel", "alternatives_b": "Nitric Oxide, Doxapram, Elexacaftor, Lumacaftor", "updated_at": 1767369485}, {"id": 97157, "ingredient1": "Ivacaftor", "ingredient2": "Vinorelbine", "severity": "Moderate", "effect": "Coadministration with ivacaftor may increase the plasma concentrations of drugs that are substrates of the CYP450 3A4 isoenzyme and/or P-glycoprotein (P-gp) efflux transporter. The mechanism is decreased clearance via these pathways due to inhibition by ivacaftor and its pharmacologically active M1 metabolite.", "source": "DDInter", "management_text": "Caution is advised when ivacaftor is used with drugs that are substrates of CYP450 3A4 and/or P-gp, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever ivacaftor is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when ivacaftor is used with drugs that are substrates of CYP450 3A4 and/or P-gp, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97261/", "reference_text": "[1] \"Product Information. Kalydeco (ivacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[2] Richter WO, Jacob BG, Schwandt P \"Interaction between fibre and lovastatin.\" Lancet 338 (1991): 706[3] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors.\" Clin Pharmacol Ther 64 (1998): 477-83[4] Kantola T, Kivisto KT, Neuvonen PJ \"Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid.\" Clin Pharmacol Ther 63 (1998): 397-402[5] \"Product Information. Mevacor (lovastatin).\" Merck & Co, Inc, West Point, PA.[6] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions.\" Br J Clin Pharmacol 46 (1998): 101-10[7] Neuvonen PJ, Backman JT, Niemi M \"Pharmacokinetic comparison of the potential over-the-counter statins simvastatin, lovastatin, fluvastatin and pravastatin.\" Clin Pharmacokinet 47 (2008): 463-74[8] Thompson PD, Clarkson P, Karas RH \"Statin-associated myopathy.\" JAMA 289 (2003): 1681-90[9] \"Product Information. Zocor (simvastatin).\" Merck & Co, Inc, West Point, PA.[10] \"Product Information. Trikafta (elexacaftor/ivacaftor/tezacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[11] \"Product Information. Kalydeco (ivacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[12] \"Product Information. Orkambi (ivacaftor-lumacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[13] \"Product Information. Symdeko 4-Week (ivacaftor-tezacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.", "alternatives_a": "Topotecan, Teniposide, Paclitaxel", "alternatives_b": "Nitric Oxide, Doxapram, Elexacaftor, Lumacaftor", "updated_at": 1767369485}, {"id": 97158, "ingredient1": "Ivacaftor", "ingredient2": "Voriconazole", "severity": "Major", "effect": "Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of ivacaftor, which is primarily metabolized by the isoenzyme.", "source": "DDInter", "management_text": "For ivacaftor -The ivacaftor dose should be reduced from 1 tablet or 1 packet of oral granules twice a day to 1 tablet or 1 packet of oral granules twice a week (i.e., every 3 to 4 days) during coadministration with potent CYP450 3A4 inhibitors. For example, a patient taking ivacaftor 150 mg tablet twice a day should reduce their ivacaftor dose to a 150 mg tablet twice a week and a patient taking ivacaftor 50 mg oral granule packet twice a day should reduce their ivacaftor dose to 50 mg oral granule packet twice a week, etc.", "mechanism_text": "Metabolism", "recommendation": "For ivacaftor -The ivacaftor dose should be reduced from 1 tablet or 1 packet of oral granules twice a day to 1 tablet or 1 packet of oral granules twice a week (i.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97262/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Symdeko 4-Week (ivacaftor-tezacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[3] \"Product Information. Trikafta (elexacaftor/ivacaftor/tezacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[4] Cerner Multum, Inc. \"Australian Product Information.\" O 0[5] \"Product Information. Kalydeco (ivacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[6] \"Product Information. Orkambi (ivacaftor-lumacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[7] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[8] \"Product Information. VFEND (voriconazole).\" Pfizer U.S. Pharmaceuticals, New York, NY.[9] \"Product Information. Trikafta (elexacaftor/ivacaftor/tezacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[10] \"Product Information. Kalydeco (ivacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[11] \"Product Information. Orkambi (ivacaftor-lumacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[12] \"Product Information. Symdeko 4-Week (ivacaftor-tezacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.", "alternatives_a": "Caspofungin, Micafungin, Amphotericin B, Oteseconazole, Flucytosine, Anidulafungin", "alternatives_b": "Nitric Oxide, Doxapram, Elexacaftor", "updated_at": 1767369485}, {"id": 97159, "ingredient1": "Ivacaftor", "ingredient2": "Voxelotor", "severity": "Major", "effect": "Coadministration with moderate inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of ivacaftor, which is primarily metabolized by the isoenzyme.", "source": "DDInter", "management_text": "Please consult manufacturer's product labeling for complete dosing information. For ivacaftor - The frequency of dosing should be reduced to 1 tablet or packet once a day when coadministered with moderate CYP450 3A4 inhibitors. Patients should continue to receive the same tablet or oral granule packet strength, but instead of dosing twice a day, the frequency should be reduced to once a day.", "mechanism_text": "Metabolism", "recommendation": "Please consult manufacturer's product labeling for complete dosing information.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97263/", "reference_text": "[1] \"Product Information. Kalydeco (ivacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[2] \"Product Information. Symdeko 4-Week (ivacaftor-tezacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] \"Product Information. Orkambi (ivacaftor-lumacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[5] \"Product Information. Trikafta (elexacaftor/ivacaftor/tezacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[6] \"Product Information. Trikafta (elexacaftor/ivacaftor/tezacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[7] \"Product Information. Kalydeco (ivacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[8] \"Product Information. Orkambi (ivacaftor-lumacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[9] \"Product Information. Symdeko 4-Week (ivacaftor-tezacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.", "alternatives_a": "Nitric Oxide, Doxapram, Elexacaftor", "alternatives_b": "Hemin, Conestat alfa, Betibeglogene autotemcel, Hyaluronidase, Streptokinase, Human C1-esterase inhibitor, Crizanlizumab, Lanadelumab, Icatibant", "updated_at": 1767369485}, {"id": 97160, "ingredient1": "Ivacaftor", "ingredient2": "Warfarin", "severity": "Moderate", "effect": "Coadministration with ivacaftor may theoretically increase the plasma concentrations of warfarin. The proposed mechanism is inhibition of CYP450 2C9-mediated metabolism of warfarin, which is primarily metabolized by the isoenzyme. The clinical significance of this potential interaction is unknown.", "source": "DDInter", "management_text": "Caution is warranted and monitoring of INR is recommended when coadministration of warfarin and ivacaftor is required. Patients should be advised to promptly report any signs of bleeding to their physician, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, increased menstrual flow, vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or brown urine, or red or black stools.", "mechanism_text": "Metabolism", "recommendation": "Caution is warranted and monitoring of INR is recommended when coadministration of warfarin and ivacaftor is required.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97264/", "reference_text": "[1] \"Product Information. Symdeko 4-Week (ivacaftor-tezacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[2] Cerner Multum, Inc. \"Canadian Product Information.\" O 0 (2015):[3] \"Product Information. Kalydeco (ivacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[4] Cerner Multum, Inc. \"Australian Product Information.\" O 0[5] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[6] \"Product Information. Trikafta (elexacaftor/ivacaftor/tezacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[7] \"Product Information. Kalydeco (ivacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[8] \"Product Information. Orkambi (ivacaftor-lumacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[9] \"Product Information. Symdeko 4-Week (ivacaftor-tezacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[10] Bodiford AB, Kessler FO, Fermo JD, Ragucci KR \"Elevated international normalized ratio with the consumption of grapefruit and use of warfarin.\" SAGE Open Med Case Rep 0 (2013): 1-3[11] Guo LQ, Yamazoe Y \"Inhibition of cytochrome P450 by furanocoumarins in grapefruit juice and herbal medicines.\" Acta Pharmacol Sin 25 (2004): 129-36[12] Kempin SJ \"Warfarin resistance caused by broccoli.\" N Engl J Med 308 (1983): 1229-30[13] Lee M, Schwartz RN, Sharifi R \"Warfarin resistance and vitamin K.\" Ann Intern Med 94 (1981): 140-1[14] Brandin H, Myrberg O, Rundlof T, Arvidsson AK, Brenning G \"Adverse effects by artificial grapefruit seed extract products in patients on warfarin therapy.\" Eur J Clin Pharmacol 63 (2007): 565-70[15] Sullivan DM, Ford MA, Boyden TW \"Grapefruit juice and the response to warfarin.\" Am J Health Syst Pharm 55 (1998): 1581-3[16] Harrell CC, Kline SS \"Vitamin K-supplemented snacks containing olestra: Implication for patients taking warfarin.\" Jama J Am Med Assn 282 (1999): 1133-4[17] Grant P \"Warfarin and cranberry juice: an interaction?\" J Heart Valve Dis 13 (2004): 25-6[18] Kazmier FJ, Spittell JA Jr \"Coumarin drug interactions.\" Mayo Clin Proc 45 (1970): 249-55[19] Ge B, Zhang Z, Zuo Z \"Updates on the clinical evidenced herb-warfarin interactions.\" Evid Based Complement Alternat Med 2014 (2014): 957362[20] Kuykendall JR, Houle MD, Rhodes RS \"Possible warfarin failure due to interaction with smokeless tobacco.\" Ann Pharmacother 38 (2004): 595-7[21] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[22] Zallman JA, Lee DP, Jeffrey PL \"Liquid nutrition as a cause of warfarin resistance.\" Am J Hosp Pharm 38 (1981): 1174[23] Watson AJ, Pegg M, Green JR \"Enteral feeds may antagonise warfarin.\" Br Med J 288 (1984): 557[24] Monterrey-Rodriguez J \"Interaction between warfarin and mango fruit.\" Ann Pharmacother 36 (2002): 940-1[25] MHRA. Mediciines and Healthcare products Regulatory Agency. Committee on Safety of Medicines \"Possible interaction between warfarin and cranberry juice. Available from: URL: http://medicines.mhra.gov.uk/ourwork/monitorsafequalmed/currentproblems/currentproblems.htm.\" ([2003 Sept]):[26] Karlson B, Leijd B, Hellstrom K \"On the influence of vitamin K-rich vegetables and wine on the effectiveness of warfarin treatment.\" Acta Med Scand 220 (1986): 347-50[27] Griffiths AP, Beddall A, Pegler S \"Fatal haemopericardium and gastrointestinal haemorrhage due to possible interaction of cranberry juice with warfarin.\" J R Soc Health 128 (2008): 324-6[28] Roberts D, Flanagan P \"Case report: Cranberry juice and warfarin.\" Home Healthc Nurse 29 (2011): 92-7[29] O'Reilly RA, Rytand DA \"\"Resistance\" to warfarin due to unrecognized vitamin K supplementation.\" N Engl J Med 303 (1980): 160-1[30] Parr MD, Record KE, Griffith GL, et al \"Effect of enteral nutrition on warfarin therapy.\" Clin Pharm 1 (1982): 274-6[31] Andersen P, Godal HC \"Predictable reduction in anticoagulant activity of warfarin by small amounts of vitamin K.\" Acta Med Scand 198 (1975): 269-70[32] Cambria-Kiely JA \"Effect of soy milk on warfarin efficacy.\" Ann Pharmacother 36 (2002): 1893-6[33] Howard PA, Hannaman KN \"Warfarin resistance linked to enteral nutrition products.\" J Am Diet Assoc 85 (1985): 713-5[34] Rindone JP, Murphy TW \"Warfarin-cranberry juice interaction resulting in profound hypoprothrombinemia and bleeding.\" Am J Ther 13 (2006): 283-4[35] Suvarna R, Pirmohamed M, Henderson L \"Possible interaction between warfarin and cranberry juice.\" BMJ 327 (2003): 1454[36] Beckey NP, Korman LB, Parra D \"Effect of the moderate consumption of olestra in patients receiving long-term warfarin therapy.\" Pharmacotherapy 19 (1999): 1075-9[37] Westfall LK \"An unrecognized cause of warfarin resistance.\" Drug Intell Clin Pharm 15 (1981): 131[38] Walker FB \"Myocardial infarction after diet-induced warfarin resistance.\" Arch Intern Med 144 (1984): 2089-90[39] Pedersen FM, Hamberg O, Hess K, Ovesen L \"The effect of dietary vitamin K on warfarin-induced anticoagulation.\" J Intern Med 229 (1991): 517-20[40] Griffith LD, Olvey SE, Triplett WC \"Increasing prothrombin times in a warfarin-treated patient upon withdrawal of ensure plus.\" Crit Care Med 10 (1982): 799-800[41] Wells PS, Holbrook AM, Crowther NR, Hirsh J \"Interactions of warfarin with drugs and food.\" Ann Intern Med 121 (1994): 676-83[42] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare \"Centro de informacin online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[43] Chow WH, Chow TC, Tse TM, Tai YT, Lee WT \"Anticoagulation instability with life-threatening complication after dietary modification.\" Postgrad Med J 66 (1990): 855-7[44] Hamann GL, Campbell JD, George CM \"Warfarin-cranberry juice interaction.\" Ann Pharmacother 45 (2011): e17[45] MacLeod SM, Sellers EM \"Pharmacodynamic and pharmacokinetic drug interactions with coumarin anticoagulants.\" Drugs 11 (1976): 461-70[46] Jarvis S, Li C, Bogle RG \"Possible interaction between pomegranate juice and warfarin.\" Emerg Med J 27 (2010): 74-5", "alternatives_a": "Clopidogrel, Iloprost, Lepirudin, Acenocoumarol, Urokinase, Cangrelor, Dipyridamole, Caplacizumab, Argatroban, Prasugrel, Desirudin, More", "alternatives_b": "Nitric Oxide, Doxapram, Elexacaftor", "updated_at": 1767369485}, {"id": 97161, "ingredient1": "Ivacaftor", "ingredient2": "Zafirlukast", "severity": "Moderate", "effect": "Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of ivacaftor, which is primarily metabolized by the isoenzyme. The interaction occurs to a greater extent when ivacaftor is administered as monotherapy than when administered in combination with lumacaftor, a potent CYP450 3A4 inducer.", "source": "DDInter", "management_text": "Caution is advised if ivacaftor is used with CYP450 3A4 inhibitors. A dosage adjustment for ivacaftor may be required if undue adverse effects occur.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if ivacaftor is used with CYP450 3A4 inhibitors.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97265/", "reference_text": "[1] \"Product Information. Kalydeco (ivacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[2] \"Product Information. Orkambi (ivacaftor-lumacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[3] \"Product Information. Accolate (zafirlukast).\" Zeneca Pharmaceuticals, Wilmington, DE.[4] \"Product Information. Trikafta (elexacaftor/ivacaftor/tezacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[5] \"Product Information. Kalydeco (ivacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[6] \"Product Information. Orkambi (ivacaftor-lumacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[7] \"Product Information. Symdeko 4-Week (ivacaftor-tezacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.", "alternatives_a": "Theophylline, Omalizumab, Tezepelumab, Mercaptopurine, Aminophylline, Benralizumab, Caffeine, Reslizumab, Dyphylline, Oxtriphylline, Mepolizumab, More", "alternatives_b": "Nitric Oxide, Doxapram, Elexacaftor", "updated_at": 1767369485}, {"id": 97162, "ingredient1": "Ivacaftor", "ingredient2": "Zanubrutinib", "severity": "Moderate", "effect": "Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of zanubrutinib, which is primarily metabolized by the isoenzyme.", "source": "DDInter", "management_text": "Caution is advised when zanubrutinib is used with CYP450 3A4 inhibitors. Patients should be monitored for increased adverse effects such as rash, diarrhea, constipation, cough, hemorrhage, infection, cytopenias, and atrial fibrillation or flutter, and the zanubrutinib dosage adjusted as necessary.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when zanubrutinib is used with CYP450 3A4 inhibitors.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97266/", "reference_text": "[1] \"Product Information. Brukinsa (zanubrutinib).\" BeiGene USA, Inc, San Mateo, CA.[2] \"Product Information. Juxtapid (lomitapide).\" Aegerion Pharmaceuticals Inc, Cambridge, MA.[3] \"Product Information. Brukinsa (zanubrutinib).\" BeiGene USA, Inc, San Mateo, CA.", "alternatives_a": "Nitric Oxide, Doxapram, Elexacaftor", "alternatives_b": "Cabozantinib, Sunitinib, Regorafenib, Copanlisib, Ruxolitinib, Lenvatinib, Abemaciclib, Ponatinib, Neratinib, Vandetanib, Trametinib, More", "updated_at": 1767369485}, {"id": 97163, "ingredient1": "Ivacaftor", "ingredient2": "Zileuton", "severity": "Moderate", "effect": "Coadministration with ivacaftor may increase the plasma concentrations of drugs that are substrates of the CYP450 2C9 isoenzyme. The proposed mechanism, based on in vitro data, involves decreased metabolic clearance due to inhibition of CYP450 2C9 by ivacaftor.", "source": "DDInter", "management_text": "Caution is advised when ivacaftor is used concurrently with drugs that are known CYP450 2C9 substrates, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever ivacaftor is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when ivacaftor is used concurrently with drugs that are known CYP450 2C9 substrates, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97267/", "reference_text": "[1] \"Product Information. Trikafta (elexacaftor/ivacaftor/tezacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[2] \"Product Information. Symdeko 4-Week (ivacaftor-tezacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[3] \"Product Information. Orkambi (ivacaftor-lumacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[4] \"Product Information. Kalydeco (ivacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[5] \"Product Information. Ambien (zolpidem).\" sanofi-aventis, Bridgewater, NJ.[6] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84[7] \"Product Information. Trikafta (elexacaftor/ivacaftor/tezacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[8] \"Product Information. Kalydeco (ivacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[9] \"Product Information. Orkambi (ivacaftor-lumacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[10] \"Product Information. Symdeko 4-Week (ivacaftor-tezacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.", "alternatives_a": "Nitric Oxide, Doxapram, Elexacaftor, Lumacaftor", "alternatives_b": "", "updated_at": 1767369485}, {"id": 97164, "ingredient1": "Ivacaftor", "ingredient2": "Zolpidem", "severity": "Moderate", "effect": "Coadministration with ivacaftor may increase the plasma concentrations of drugs that are substrates of the CYP450 2C9 isoenzyme. The proposed mechanism, based on in vitro data, involves decreased metabolic clearance due to inhibition of CYP450 2C9 by ivacaftor.", "source": "DDInter", "management_text": "Caution is advised when ivacaftor is used concurrently with drugs that are known CYP450 2C9 substrates, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever ivacaftor is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when ivacaftor is used concurrently with drugs that are known CYP450 2C9 substrates, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97268/", "reference_text": "[1] \"Product Information. Trikafta (elexacaftor/ivacaftor/tezacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[2] \"Product Information. Symdeko 4-Week (ivacaftor-tezacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[3] \"Product Information. Orkambi (ivacaftor-lumacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[4] \"Product Information. Kalydeco (ivacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[5] \"Product Information. Ambien (zolpidem).\" sanofi-aventis, Bridgewater, NJ.[6] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84[7] \"Product Information. Trikafta (elexacaftor/ivacaftor/tezacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[8] \"Product Information. Kalydeco (ivacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[9] \"Product Information. Orkambi (ivacaftor-lumacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[10] \"Product Information. Symdeko 4-Week (ivacaftor-tezacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.", "alternatives_a": "Flurazepam, Methohexital, Zaleplon, Dichloralphenazone, Valerian, Temazepam, Chloral hydrate, Quazepam, Paraldehyde, Ramelteon, Ethchlorvynol, More", "alternatives_b": "Nitric Oxide, Doxapram, Elexacaftor", "updated_at": 1767369485}, {"id": 97165, "ingredient1": "Aminoglutethimide", "ingredient2": "Eliglustat", "severity": "Moderate", "effect": "Coadministration with inducers of CYP450 3A4 and/or P-glycoprotein (P-gp) may decrease the plasma concentrations of eliglustat, which is primarily metabolized by CYP450 2D6 and, to a lesser extent, CYP450 3A4. Eliglustat is also a substrate of P-gp efflux transporter.", "source": "DDInter", "management_text": "Patients receiving eliglustat with CYP450 3A4 inducers should be monitored for potentially diminished pharmacologic response to eliglustat. Concomitant use should be avoided if an interaction is suspected.", "mechanism_text": "Metabolism", "recommendation": "Patients receiving eliglustat with CYP450 3A4 inducers should be monitored for potentially diminished pharmacologic response to eliglustat.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97269/", "reference_text": "[1] \"Product Information. Cerdelga (eliglustat).\" Genzyme Corporation, Cambridge, MA.[2] \"Product Information. Cerdelga (eliglustat).\" Genzyme Corporation, Cambridge, MA.", "alternatives_a": "Darolutamide, Anastrozole, Letrozole, Toremifene, Fulvestrant, Abarelix, Flutamide, Degarelix, Nilutamide, Exemestane", "alternatives_b": "Teduglutide, Fosdenopterin, Miglustat, Imiglucerase, Asfotase alfa, Glycerol phenylbutyrate, Pegvaliase, Triethylenetetramine, Sapropterin, Zinc acetate, Phenylbutyric acid, More", "updated_at": 1767369485}, {"id": 97166, "ingredient1": "Amoxapine", "ingredient2": "Eliglustat", "severity": "Moderate", "effect": "Coadministration with eliglustat may increase the plasma concentrations of drugs that are primarily metabolized by CYP450 2D6.", "source": "DDInter", "management_text": "Caution is advised if eliglustat is used concomitantly with medications that undergo metabolism primarily by CYP450 2D6, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever eliglustat is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if eliglustat is used concomitantly with medications that undergo metabolism primarily by CYP450 2D6, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97270/", "reference_text": "[1] \"Product Information. Cerdelga (eliglustat).\" Genzyme Corporation, Cambridge, MA.[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] \"Product Information. Cerdelga (eliglustat).\" Genzyme Corporation, Cambridge, MA.[5] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[6] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[7] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[8] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.", "alternatives_a": "Phenelzine, Citalopram, Tranylcypromine, Desvenlafaxine, Isocarboxazid, Oxitriptan, Tryptophan, Milnacipran, Levomilnacipran, Vilazodone, Esketamine, More", "alternatives_b": "Teduglutide, Lonafarnib, Fosdenopterin, Miglustat, Imiglucerase, Asfotase alfa, Pegvaliase, Triethylenetetramine, Sapropterin, Zinc acetate, Phenylbutyric acid, More", "updated_at": 1767369485}, {"id": 97167, "ingredient1": "Amprenavir", "ingredient2": "Eliglustat", "severity": "Major", "effect": "Coadministration with moderate inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of eliglustat, which is primarily metabolized by CYP450 2D6 and, to a lesser extent, CYP450 3A4. Eliglustat at substantially elevated plasma concentrations is predicted to cause prolongation of the PR, QTc and QRS cardiac intervals, which may increase the risk of bradycardia, atrioventricular block, cardiac arrest, and serious ventricular arrhythmias such as torsade de pointes.", "source": "DDInter", "management_text": "The use of eliglustat in combination with one or more drugs that may result in moderate inhibition of CYP450 3A4 and moderate to potent inhibition of CYP450 2D6 is considered contraindicated in CYP450 2D6 extensive metabolizers (EMs) and intermediate metabolizers (IMs). In the absence of a concomitant CYP450 2D6 inhibitor, eliglustat may be prescribed at a reduced dosage of 84 mg once daily to EMs treated with a moderate CYP450 3A4 inhibitor. However, eliglustat should not be used with a moderate CYP450 3A4 inhibitor in CYP450 2D6 IMs or poor metabolizers (PMs). Moderate CYP450 3A4 inhibitors include aprepitant, ciprofloxacin, clotrimazole, crizotinib, darunavir, diltiazem, dronedarone, fluconazole, fusidic acid, imatinib, isavuconazonium, miconazole, mifepristone, netupitant, quinupristin-dalfopristin, ranolazine, stiripentol, and verapamil. Potent and moderate CYP450 2D6 inhibitors include abiraterone, bupropion, celecoxib, cimetidine, cinacalcet, clobazam, darifenacin, diphenhydramine, duloxetine, fluoxetine, methotrimeprazine, mirabegron, paroxetine, propoxyphene, quinidine, ranolazine, sertraline, stiripentol, and terbinafine.", "mechanism_text": "Metabolism", "recommendation": "The use of eliglustat in combination with one or more drugs that may result in moderate inhibition of CYP450 3A4 and moderate to potent inhibition of CYP450 2D6 is considered contraindicated in CYP450 2D6 extensive metabolizers (EMs) and intermediate metabolizers (IMs).", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97271/", "reference_text": "[1] \"Product Information. Cerdelga (eliglustat).\" Genzyme Corporation, Cambridge, MA.[2] \"Product Information. Cerdelga (eliglustat).\" Genzyme Corporation, Cambridge, MA.", "alternatives_a": "Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Simeprevir, Cabotegravir, Valaciclovir, Zanamivir, Velpatasvir, Rilpivirine, Dolutegravir, More", "alternatives_b": "Teduglutide, Fosdenopterin, Miglustat, Imiglucerase, Asfotase alfa, Glycerol phenylbutyrate, Pegvaliase, Triethylenetetramine, Sapropterin, Zinc acetate, Phenylbutyric acid, More", "updated_at": 1767369485}, {"id": 97168, "ingredient1": "Eliglustat", "ingredient2": "Artesunate", "severity": "Moderate", "effect": "Coadministration with eliglustat may increase the plasma concentrations of drugs that are substrates of the P-glycoprotein (P-gp) transporter. The proposed mechanism is decreased clearance in the intestine, liver, and/or kidney due to inhibition of P-glycoprotein-mediated drug efflux by eliglustat.", "source": "DDInter", "management_text": "Caution is advised when eliglustat is used concurrently with drugs that are known P-gp substrates, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever eliglustat is added to or withdrawn from therapy.", "mechanism_text": "Others", "recommendation": "Caution is advised when eliglustat is used concurrently with drugs that are known P-gp substrates, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97272/", "reference_text": "[1] \"Product Information. Cerdelga (eliglustat).\" Genzyme Corporation, Cambridge, MA.[2] \"Product Information. Cerdelga (eliglustat).\" Genzyme Corporation, Cambridge, MA.", "alternatives_a": "Teduglutide, Fosdenopterin, Miglustat, Imiglucerase, Asfotase alfa, Glycerol phenylbutyrate, Pegvaliase, Triethylenetetramine, Sapropterin, Zinc acetate, Phenylbutyric acid, More", "alternatives_b": "Mefloquine, Lumefantrine, Artemether, Pyrimethamine, Tafenoquine, Atovaquone, Hydroxychloroquine, Halofantrine, Quinine, Primaquine, Proguanil, More", "updated_at": 1767369485}, {"id": 97169, "ingredient1": "Eliglustat", "ingredient2": "Bepridil", "severity": "Major", "effect": "Class IA (e.g., disopyramide, quinidine, procainamide) and class III (e.g., amiodarone, dofetilide, sotalol) antiarrhythmic agents can cause dose-related prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Coadministration of class IA or class III antiarrhythmic agents with other drugs that can prolong the QT interval should preferably be avoided unless benefits are anticipated to outweigh the risks. Caution and clinical monitoring are recommended if concomitant use is required. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Coadministration of class IA or class III antiarrhythmic agents with other drugs that can prolong the QT interval should preferably be avoided unless benefits are anticipated to outweigh the risks.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97273/", "reference_text": "[1] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[2] Yamreudeewong W, DeBisschop M, Martin L, Lower D \"Potentially Significant Drug Interactions of Class III Antiarrhythmic Drugs.\" Drug Saf 26 (2003): 421-38[3] \"Product Information. Norpace (disopyramide).\" Searle, Skokie, IL.[4] Cerner Multum, Inc. \"Australian Product Information.\" O 0[5] \"Product Information. Betapace (sotalol).\" Berlex, Richmond, CA.[6] \"Product Information. Procan SR (procainamide).\" Parke-Davis, Morris Plains, NJ.[7] Maxa JL, Hebeler RF, Adeeko MA \"Torsades de pointes following concurrent amiodarone and levofloxacin therapy.\" Proc (Bayl Univ Med Cent) 19 (2006): 345-6[8] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[9] \"Product Information. Cordarone (amiodarone).\" Wyeth-Ayerst Laboratories, Philadelphia, PA.[10] EMA. European Medicines Agency. European Union \"EMA - List of medicines under additional monitoring. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000366.jsp&mid=WC0b01ac058067c852\" ([2013 - ]):[11] \"Product Information. Vascor (bepridil).\" McNeil Pharmaceutical, Raritan, NJ.[12] \"Product Information. Quiniglute (quinidine).\" Berlex, Richmond, CA.[13] Trujillo TC, Nolan PE \"Antiarrhythmic agents - Drug interactions of clinical significance.\" Drug Safety 23 (2000): 509-32[14] Gunston GD, Mehta U \"Potentially serious drug interactions with grapefruit juice.\" S Afr Med J 90 (2000): 41[15] Bailey DG, Arnold JMO, Spence JD \"Grapefruit juice and drugs - how significant is the interaction.\" Clin Pharmacokinet 26 (1994): 91-8[16] Fuhr U, Maier-Bruggemann A, Blume H, et al. \"Grapefruit juice increases oral nimodipine bioavailability.\" Int J Clin Pharmacol Ther 36 (1998): 126-32[17] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[18] Libersa CC, Brique SA, Motte KB, et al. \"Dramatic inhibition of amiodarone metabolism induced by grapefruit juice.\" Br J Clin Pharmacol 49 (2000): 373-8[19] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions.\" Br J Clin Pharmacol 46 (1998): 101-10[20] Bailey DG, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit juice felodipine interaction: Effect of naringin and 6',7'-dihydroxybergamottin in humans.\" Clin Pharmacol Ther 64 (1998): 248-56[21] Takanaga H, Ohnishi A, Maatsuo H, et al. \"Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model.\" Br J Clin Pharmacol 49 (2000): 49-58[22] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[23] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS \"Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice.\" Br J Clin Pharmacol 42 (1996): p662[24] Eagling VA, Profit L, Back DJ \"Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-I protease inhibitor saquinavir by grapefruit juice components.\" Br J Clin Pharmacol 48 (1999): 543-52[25] Bailey DG, Arnold JM, Strong HA, Munoz C, Spence JD \"Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics.\" Clin Pharmacol Ther 54 (1993): 589-94[26] Damkier P, Hansen LL, Brosen K \"Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine.\" Br J Clin Pharmacol 48 (1999): 829-38[27] Min DI, Ku YM, Geraets DR, Lee HC \"Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers.\" J Clin Pharmacol 36 (1996): 469-76[28] Josefsson M, Zackrisson AL, Ahlner J \"Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers.\" Eur J Clin Pharmacol 51 (1996): 189-93[29] Majeed A, Kareem A \"Effect of grapefruit juice on cyclosporine pharmacokinetics.\" Pediatr Nephrol 10 (1996): 395[30] Flanagan D \"Understanding the grapefruit-drug interaction.\" Gen Dent 53 (2005): 282-5; quiz 286[31] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ \"Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice.\" Clin Pharmacol Ther 58 (1995): 127-31[32] Jonkman JH, Sollie FA, Sauter R, Steinijans VW \"The influence of caffeine on the steady-state pharmacokinetics of theophylline.\" Clin Pharmacol Ther 49 (1991): 248-55[33] Ozdemir M, Aktan Y, Boydag BS, Cingi MI, Musmul A \"Interaction between grapefruit juice and diazepam in humans.\" Eur J Drug Metab Pharmacokinet 23 (1998): 55-9[34] Edgar B, Bailey D, Bergstrand R, et al \"Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics on felodipine and its potential clinical relevance.\" Eur J Clin Pharmacol 42 (1992): 313-7[35] Kantola T, Kivisto KT, Neuvonen PJ \"Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid.\" Clin Pharmacol Ther 63 (1998): 397-402[36] Lee AJ, Chan WK, Harralson AF, Buffum J, Bui BCC \"The effects of grapefruit juice on sertraline metabolism: An in vitro and in vivo study.\" Clin Ther 21 (1999): 1890-9[37] Sato J, Nakata H, Owada E, Kikuta T, Umetsu M, Ito K \"Influence of usual intake of dietary caffeine on single-dose kinetics of theophylline in healthy human subjects.\" Eur J Clin Pharmacol 44 (1993): 295-8[38] Dresser GK, Spence JD, Bailey DG \"Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition.\" Clin Pharmacokinet 38 (2000): 41-57[39] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin.\" Clin Pharmacol Ther 66 (1999): 118-27[40] Sigusch H, Hippius M, Henschel L, Kaufmann K, Hoffmann A \"Influence of grapefruit juice on the pharmacokinetics of a slow release nifedipine formulation.\" Pharmazie 49 (1994): 522-4[41] Bailey DG, Arnold JM, Munoz C, Spence JD \"Grapefruit juice--felodipine interaction: mechanism, predictability, and effect of naringin.\" Clin Pharmacol Ther 53 (1993): 637-42[42] Zaidenstein R, Soback S, Gips M, Avni B, Dishi V, Weissgarten Y, Golik A, Scapa E \"Effect of grapefruit juice on the pharmacokinetics of losartan and its active metabolite E3174 in healthy volunteers.\" Ther Drug Monit 23 (2001): 369-73[43] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84[44] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors.\" Clin Pharmacol Ther 64 (1998): 477-83[45] Garg SK, Kumar N, Bhargava VK, Prabhakar SK \"Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy.\" Clin Pharmacol Ther 64 (1998): 286-8", "alternatives_a": "Teduglutide, Fosdenopterin, Miglustat, Imiglucerase, Asfotase alfa, Glycerol phenylbutyrate, Pegvaliase, Triethylenetetramine, Sapropterin, Zinc acetate, Phenylbutyric acid, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 97170, "ingredient1": "Eliglustat", "ingredient2": "Berotralstat", "severity": "Major", "effect": "Coadministration of berotralstat with drugs that are both inhibitors of the efflux transporters P-glycoprotein (P-gp) and/or breast cancer resistance protein (BCRP) as well as substrates of the isoenzyme CYP450 3A4 may lead to an increase in the plasma concentrations and effects of both drugs. Berotralstat is a substrate of both P-gp and BCRP. Increased plasma concentrations of berotralstat may increase the risk of adverse effects, including the potential for QT prolongation. Berotralstat may cause concentration-dependent prolongation of the Fridericia-corrected QT interval (QTcF). In addition, berotralstat is considered a moderate CYP450 3A4 inhibitor and has been reported in drug interaction studies to increase the peak plasma concentration (Cmax) and systemic exposure (AUC) of sensitive CYP450 3A4 substrate midazolam by approximately 1.5-fold and 2.25-fold, respectively.", "source": "DDInter", "management_text": "The dosage of berotralstat should be reduced to 110 mg once daily in patients requiring chronic coadministration with drugs that are both inhibitors of P-gp or BCRP as well as substrates of CYP450 3A4, such as cyclosporine. Patients should be advised to contact their physician if they experience any undue adverse effects from their medications. Patients should seek prompt medical attention if they experience symptoms that could indicated the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitations, irregular heartbeat, shortness of breath, or syncope.", "mechanism_text": "Metabolism", "recommendation": "The dosage of berotralstat should be reduced to 110 mg once daily in patients requiring chronic coadministration with drugs that are both inhibitors of P-gp or BCRP as well as substrates of CYP450 3A4, such as cyclosporine.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97274/", "reference_text": "[1] \"Product Information. Orladeyo (berotralstat).\" BioCryst Pharmaceuticals Inc, Durham, NC.[2] \"Product Information. Intelence (etravirine).\" Ortho Biotech Inc, Bridgewater, NJ.", "alternatives_a": "Teduglutide, Fosdenopterin, Miglustat, Imiglucerase, Asfotase alfa, Glycerol phenylbutyrate, Pegvaliase, Triethylenetetramine, Sapropterin, Zinc acetate, Phenylbutyric acid, More", "alternatives_b": "Hemin, Conestat alfa, Betibeglogene autotemcel, Hyaluronidase, Streptokinase, Human C1-esterase inhibitor, Crizanlizumab, Lanadelumab, Icatibant", "updated_at": 1767369485}, {"id": 97171, "ingredient1": "Eliglustat", "ingredient2": "Boceprevir", "severity": "Major", "effect": "Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of eliglustat, which is primarily metabolized by CYP450 2D6 and, to a lesser extent, CYP450 3A4. Eliglustat at substantially elevated plasma concentrations is predicted to cause prolongation of the PR, QTc and QRS cardiac intervals, which may increase the risk of bradycardia, atrioventricular block, cardiac arrest, and serious ventricular arrhythmias such as torsade de pointes.", "source": "DDInter", "management_text": "The use of eliglustat with a potent CYP450 3A4 inhibitor is considered contraindicated in CYP450 2D6 poor metabolizers (PMs) and intermediate metabolizers (IMs). The contraindication is extended to extensive metabolizers (EMs) when a moderate or potent CYP450 2D6 inhibitor is given concomitantly with a moderate or potent CYP450 3A4 inhibitor. In the absence of a concomitant CYP450 2D6 inhibitor, eliglustat may be prescribed at a reduced dosage of 84 mg once daily to EMs treated with a potent CYP450 3A4 inhibitor. Potent CYP450 3A4 inhibitors include itraconazole, ketoconazole, posaconazole, voriconazole, conivaptan, ceritinib, idelalisib, mibefradil, nefazodone, cobicistat, delavirdine, protease inhibitors, and ketolide and certain macrolide antibiotics. Potent and moderate CYP450 2D6 inhibitors include abiraterone, bupropion, celecoxib, cimetidine, cinacalcet, clobazam, darifenacin, diphenhydramine, dronedarone, duloxetine, flecainide, fluoxetine, methotrimeprazine, mirabegron, paroxetine, propafenone, propoxyphene, quinidine, ranolazine, sertraline, and terbinafine. Some drugs such as cobicistat, delavirdine, mibefradil, and ritonavir are dual CYP450 3A4 and 2D6 inhibitors, and they should not be used with eliglustat in any patient regardless of their CYP450 2D6 metabolizer status.", "mechanism_text": "Metabolism", "recommendation": "The use of eliglustat with a potent CYP450 3A4 inhibitor is considered contraindicated in CYP450 2D6 poor metabolizers (PMs) and intermediate metabolizers (IMs).", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97275/", "reference_text": "[1] Cerner Multum, Inc. \"Australian Product Information.\" O 0[2] \"Product Information. Sporanox (itraconazole).\" Janssen Pharmaceutica, Titusville, NJ.[3] \"Product Information. Cerdelga (eliglustat).\" Genzyme Corporation, Cambridge, MA.[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] \"Product Information. Cerdelga (eliglustat).\" Genzyme Corporation, Cambridge, MA.[6] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[7] \"Product Information. VFEND (voriconazole).\" Pfizer U.S. Pharmaceuticals, New York, NY.", "alternatives_a": "Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Simeprevir, Cabotegravir, Valaciclovir, Zanamivir, Velpatasvir, Rilpivirine, Dolutegravir, More", "alternatives_b": "Teduglutide, Fosdenopterin, Miglustat, Imiglucerase, Asfotase alfa, Glycerol phenylbutyrate, Pegvaliase, Triethylenetetramine, Sapropterin, Zinc acetate, Phenylbutyric acid, More", "updated_at": 1767369485}, {"id": 97172, "ingredient1": "Eliglustat", "ingredient2": "Butabarbital", "severity": "Moderate", "effect": "Coadministration with inducers of CYP450 3A4 and/or P-glycoprotein (P-gp) may decrease the plasma concentrations of eliglustat, which is primarily metabolized by CYP450 2D6 and, to a lesser extent, CYP450 3A4. Eliglustat is also a substrate of P-gp efflux transporter.", "source": "DDInter", "management_text": "Patients receiving eliglustat with CYP450 3A4 inducers should be monitored for potentially diminished pharmacologic response to eliglustat. Concomitant use should be avoided if an interaction is suspected.", "mechanism_text": "Metabolism", "recommendation": "Patients receiving eliglustat with CYP450 3A4 inducers should be monitored for potentially diminished pharmacologic response to eliglustat.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97276/", "reference_text": "[1] \"Product Information. Cerdelga (eliglustat).\" Genzyme Corporation, Cambridge, MA.[2] \"Product Information. Cerdelga (eliglustat).\" Genzyme Corporation, Cambridge, MA.", "alternatives_a": "Triazolam, Flurazepam, Methohexital, Zolpidem, Zaleplon, Dichloralphenazone, Valerian, Temazepam, Chloral hydrate, Quazepam, Paraldehyde, More", "alternatives_b": "Teduglutide, Fosdenopterin, Miglustat, Imiglucerase, Asfotase alfa, Glycerol phenylbutyrate, Pegvaliase, Triethylenetetramine, Sapropterin, Zinc acetate, Phenylbutyric acid, More", "updated_at": 1767369485}, {"id": 97173, "ingredient1": "Eliglustat", "ingredient2": "Chlorpromazine", "severity": "Moderate", "effect": "Coadministration with eliglustat may increase the plasma concentrations of drugs that are primarily metabolized by CYP450 2D6.", "source": "DDInter", "management_text": "Caution is advised if eliglustat is used concomitantly with medications that undergo metabolism primarily by CYP450 2D6, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever eliglustat is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if eliglustat is used concomitantly with medications that undergo metabolism primarily by CYP450 2D6, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97277/", "reference_text": "[1] \"Product Information. Cerdelga (eliglustat).\" Genzyme Corporation, Cambridge, MA.[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] \"Product Information. Cerdelga (eliglustat).\" Genzyme Corporation, Cambridge, MA.[5] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[6] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[7] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[8] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.", "alternatives_a": "Quetiapine, Asenapine, Promazine, Prochlorperazine, Thiothixene, Pimavanserin, Lumateperone, Ziprasidone, Olanzapine, Trifluoperazine, Amisulpride, More", "alternatives_b": "Teduglutide, Lonafarnib, Fosdenopterin, Miglustat, Imiglucerase, Asfotase alfa, Pegvaliase, Triethylenetetramine, Sapropterin, Zinc acetate, Phenylbutyric acid, More", "updated_at": 1767369485}, {"id": 97174, "ingredient1": "Eliglustat", "ingredient2": "Clotrimazole", "severity": "Major", "effect": "Coadministration with moderate inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of eliglustat, which is primarily metabolized by CYP450 2D6 and, to a lesser extent, CYP450 3A4. Eliglustat at substantially elevated plasma concentrations is predicted to cause prolongation of the PR, QTc and QRS cardiac intervals, which may increase the risk of bradycardia, atrioventricular block, cardiac arrest, and serious ventricular arrhythmias such as torsade de pointes.", "source": "DDInter", "management_text": "The use of eliglustat in combination with one or more drugs that may result in moderate inhibition of CYP450 3A4 and moderate to potent inhibition of CYP450 2D6 is considered contraindicated in CYP450 2D6 extensive metabolizers (EMs) and intermediate metabolizers (IMs). In the absence of a concomitant CYP450 2D6 inhibitor, eliglustat may be prescribed at a reduced dosage of 84 mg once daily to EMs treated with a moderate CYP450 3A4 inhibitor. However, eliglustat should not be used with a moderate CYP450 3A4 inhibitor in CYP450 2D6 IMs or poor metabolizers (PMs). Moderate CYP450 3A4 inhibitors include aprepitant, ciprofloxacin, clotrimazole, crizotinib, darunavir, diltiazem, dronedarone, fluconazole, fusidic acid, imatinib, isavuconazonium, miconazole, mifepristone, netupitant, quinupristin-dalfopristin, ranolazine, stiripentol, and verapamil. Potent and moderate CYP450 2D6 inhibitors include abiraterone, bupropion, celecoxib, cimetidine, cinacalcet, clobazam, darifenacin, diphenhydramine, duloxetine, fluoxetine, methotrimeprazine, mirabegron, paroxetine, propoxyphene, quinidine, ranolazine, sertraline, stiripentol, and terbinafine.", "mechanism_text": "Metabolism", "recommendation": "The use of eliglustat in combination with one or more drugs that may result in moderate inhibition of CYP450 3A4 and moderate to potent inhibition of CYP450 2D6 is considered contraindicated in CYP450 2D6 extensive metabolizers (EMs) and intermediate metabolizers (IMs).", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97278/", "reference_text": "[1] \"Product Information. Cerdelga (eliglustat).\" Genzyme Corporation, Cambridge, MA.[2] \"Product Information. Cerdelga (eliglustat).\" Genzyme Corporation, Cambridge, MA.", "alternatives_a": "Salicylic acid, Selenium Sulfide, Thiabendazole, Nystatin, Ciclopirox, Econazole, Flucytosine, Tioconazole, Chlorphenesin, Tetracycline, Acetylsalicylic acid, More", "alternatives_b": "Teduglutide, Fosdenopterin, Miglustat, Imiglucerase, Asfotase alfa, Glycerol phenylbutyrate, Pegvaliase, Triethylenetetramine, Sapropterin, Zinc acetate, Phenylbutyric acid, More", "updated_at": 1767369485}, {"id": 97175, "ingredient1": "Eliglustat", "ingredient2": "Daunorubicin (liposomal)", "severity": "Moderate", "effect": "Coadministration with inhibitors of P-glycoprotein (P-gp) may increase the plasma concentrations of daunorubicin and idarubicin, both of which are substrates of the efflux transporter also known as ABCB1 or MDR1. The interaction has been studied with cyclosporine, a potent P-gp inhibitor, in attempt to overcome multidrug resistance in MDR1-overexpressing tumors.", "source": "DDInter", "management_text": "Caution is advised if daunorubicin or idarubicin is prescribed in combination with a P-gp inhibitor. Patients should be closely monitored for increased adverse effects including cardiotoxicity and myelosuppression.", "mechanism_text": "Absorption", "recommendation": "Caution is advised if daunorubicin or idarubicin is prescribed in combination with a P-gp inhibitor.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97279/", "reference_text": "[1] \"Product Information. Daunoxome (daunorubicin liposomal).\" Nexstar Pharmaceuticals Inc, Boulder, CO.[2] \"Product Information. Idamycin (idarubicin).\" Pharmacia and Upjohn, Kalamazoo, MI.[3] \"Multum Information Services, Inc. Expert Review Panel\"[4] \"Product Information. Cerubidine (daunorubicin).\" Wyeth-Ayerst Laboratories, Philadelphia, PA.[5] \"Product Information. Incivek (telaprevir).\" Vertex Pharmaceuticals, Cambridge, MA.", "alternatives_a": "Valrubicin, Plicamycin, Ixabepilone, Bleomycin, Mitomycin, Dactinomycin, Pertuzumab, Olaparib, Oxaliplatin, Bortezomib, Tisagenlecleucel, More", "alternatives_b": "Teduglutide, Lonafarnib, Fosdenopterin, Miglustat, Imiglucerase, Asfotase alfa, Glycerol phenylbutyrate, Pegvaliase, Triethylenetetramine, Sapropterin, Zinc acetate, More", "updated_at": 1767369485}, {"id": 97176, "ingredient1": "Eliglustat", "ingredient2": "Dexfenfluramine", "severity": "Moderate", "effect": "Coadministration with eliglustat may increase the plasma concentrations of drugs that are primarily metabolized by CYP450 2D6.", "source": "DDInter", "management_text": "Caution is advised if eliglustat is used concomitantly with medications that undergo metabolism primarily by CYP450 2D6, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever eliglustat is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if eliglustat is used concomitantly with medications that undergo metabolism primarily by CYP450 2D6, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97280/", "reference_text": "[1] \"Product Information. Cerdelga (eliglustat).\" Genzyme Corporation, Cambridge, MA.[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] \"Product Information. Cerdelga (eliglustat).\" Genzyme Corporation, Cambridge, MA.[5] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[6] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[7] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[8] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.", "alternatives_a": "Naltrexone, Ephedrine, Phentermine, Orlistat, Lorcaserin, Sibutramine, Diethylpropion, Mazindol", "alternatives_b": "Teduglutide, Lonafarnib, Fosdenopterin, Miglustat, Imiglucerase, Asfotase alfa, Pegvaliase, Triethylenetetramine, Sapropterin, Zinc acetate, Phenylbutyric acid, More", "updated_at": 1767369485}, {"id": 97177, "ingredient1": "Eliglustat", "ingredient2": "Doxorubicin (liposomal)", "severity": "Moderate", "effect": "Coadministration with eliglustat may increase the plasma concentrations of drugs that are substrates of the P-glycoprotein (P-gp) transporter. The proposed mechanism is decreased clearance in the intestine, liver, and/or kidney due to inhibition of P-glycoprotein-mediated drug efflux by eliglustat.", "source": "DDInter", "management_text": "Caution is advised when eliglustat is used concurrently with drugs that are known P-gp substrates, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever eliglustat is added to or withdrawn from therapy.", "mechanism_text": "Others", "recommendation": "Caution is advised when eliglustat is used concurrently with drugs that are known P-gp substrates, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97281/", "reference_text": "[1] \"Product Information. Cerdelga (eliglustat).\" Genzyme Corporation, Cambridge, MA.[2] \"Product Information. Cerdelga (eliglustat).\" Genzyme Corporation, Cambridge, MA.", "alternatives_a": "Valrubicin, Plicamycin, Ixabepilone, Bleomycin, Mitomycin, Dactinomycin", "alternatives_b": "Lipoic acid, Triheptanoin, Teduglutide, Fosdenopterin, Triethylenetetramine, Miglustat, Sapropterin, Zinc acetate, Nitisinone, Levocarnitine, Laronidase, More", "updated_at": 1767369485}, {"id": 97178, "ingredient1": "Eliglustat", "ingredient2": "Echinacea", "severity": "Moderate", "effect": "Coadministration with echinacea may alter the plasma concentrations and therapeutic effects of drugs that are substrates of CYP450 3A4. Echinacea appears to inhibit intestinal CYP450 3A4, which would lead to an increase in oral midazolam (a sensitive 3A4 substrate) bioavailability; however, plasma levels of midazolam following oral administration do not appear to be affected by echinacea. In contrast, it appears that echinacea may also induce hepatic CYP450 3A4; thereby increasing the hepatic clearance of drugs that are substrates of CYP450 3A4.", "source": "DDInter", "management_text": "In general, patients should be advised to consult their healthcare provider before using any herbal or alternative medicines. If echinacea is prescribed with a drug that is a CYP450 3A4 substrate, the possibility of an altered (increased or decreased) therapeutic response should be considered. Patients should be monitored more closely following the addition or withdrawal of echinacea and the dosage of the CYP450 3A4 substrate adjusted as necessary.", "mechanism_text": "Metabolism", "recommendation": "In general, patients should be advised to consult their healthcare provider before using any herbal or alternative medicines.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97282/", "reference_text": "[1] Gorski JC, Huang SM, Pinto A, et al. \"The effect of echinacea (Echinacea purpurea root) on cytochrome P450 activity in vivo.\" Clin Pharmacol Ther 75 (2004): 89-100[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "Teduglutide, Fosdenopterin, Miglustat, Imiglucerase, Asfotase alfa, Glycerol phenylbutyrate, Pegvaliase, Triethylenetetramine, Sapropterin, Zinc acetate, Phenylbutyric acid, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 97179, "ingredient1": "Encorafenib", "ingredient2": "Eliglustat", "severity": "Moderate", "effect": "Coadministration with encorafenib may theoretically increase the plasma concentrations of drugs that are substrates of P-glycoprotein (P-gp), breast cancer resistance protein (BCRP), organic cation transporter (OCT2), organic anion transporter (OAT1, OAT3), or organic anion transporting polypeptide (OATP1B1, OATP1B3). The proposed mechanism is decreased clearance due to inhibition of the corresponding transporter by encorafenib.", "source": "DDInter", "management_text": "Caution is advised if encorafenib must be used concomitantly with drugs that are substrates of the affected transporters, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever encorafenib is added to or withdrawn from therapy.", "mechanism_text": "Excretion", "recommendation": "Caution is advised if encorafenib must be used concomitantly with drugs that are substrates of the affected transporters, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97283/", "reference_text": "[1] \"Product Information. Braftovi (encorafenib).\" Array BioPharma Inc., Boulder, CO.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Braftovi (encorafenib).\" Array BioPharma Inc., Boulder, CO.[4] \"Product Information. Lonsurf (tipiracil-trifluridine).\" Taiho Oncology, Inc., Princeton, NJ.", "alternatives_a": "Teduglutide, Fosdenopterin, Miglustat, Imiglucerase, Asfotase alfa, Glycerol phenylbutyrate, Pegvaliase, Triethylenetetramine, Sapropterin, Zinc acetate, Phenylbutyric acid, More", "alternatives_b": "Acalabrutinib, Tepotinib, Avapritinib, Selumetinib, Vandetanib, Capmatinib, Ibrutinib, Tivozanib, Zanubrutinib, Axitinib, Sunitinib, More", "updated_at": 1767369485}, {"id": 97180, "ingredient1": "Enzalutamide", "ingredient2": "Eliglustat", "severity": "Major", "effect": "Coadministration with potent inducers of CYP450 3A4 and/or P-glycoprotein (P-gp) may significantly decrease the plasma concentrations of eliglustat, which is primarily metabolized by CYP450 2D6 and, to a lesser extent, CYP450 3A4. Eliglustat is also a substrate of P-gp efflux transporter.", "source": "DDInter", "management_text": "Concomitant use of eliglustat with potent CYP450 3A4 or P-gp inducers should generally be avoided due to the potential for significantly reduced efficacy.", "mechanism_text": "Metabolism", "recommendation": "Concomitant use of eliglustat with potent CYP450 3A4 or P-gp inducers should generally be avoided due to the potential for significantly reduced efficacy.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97284/", "reference_text": "[1] Cerner Multum, Inc. \"Australian Product Information.\" O 0[2] \"Product Information. Cerdelga (eliglustat).\" Genzyme Corporation, Cambridge, MA.[3] \"Product Information. Cerdelga (eliglustat).\" Genzyme Corporation, Cambridge, MA.[4] \"Product Information. Cerdelga (eliglustat).\" Genzyme Corporation, Cambridge, MA.[5] \"Product Information. Trikafta (elexacaftor/ivacaftor/tezacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[6] \"Product Information. Kalydeco (ivacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[7] \"Product Information. Orkambi (ivacaftor-lumacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[8] \"Product Information. Symdeko 4-Week (ivacaftor-tezacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.", "alternatives_a": "Darolutamide, Anastrozole, Letrozole, Toremifene, Fulvestrant, Abarelix, Flutamide, Degarelix, Nilutamide, Exemestane", "alternatives_b": "Lipoic acid, Triheptanoin, Teduglutide, Fosdenopterin, Triethylenetetramine, Miglustat, Sapropterin, Zinc acetate, Levocarnitine, Laronidase, Imiglucerase, More", "updated_at": 1767369485}, {"id": 97181, "ingredient1": "Epirubicin", "ingredient2": "Eliglustat", "severity": "Moderate", "effect": "Coadministration with eliglustat may increase the plasma concentrations of drugs that are substrates of the P-glycoprotein (P-gp) transporter. The proposed mechanism is decreased clearance in the intestine, liver, and/or kidney due to inhibition of P-glycoprotein-mediated drug efflux by eliglustat.", "source": "DDInter", "management_text": "Caution is advised when eliglustat is used concurrently with drugs that are known P-gp substrates, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever eliglustat is added to or withdrawn from therapy.", "mechanism_text": "Others", "recommendation": "Caution is advised when eliglustat is used concurrently with drugs that are known P-gp substrates, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97285/", "reference_text": "[1] \"Product Information. Cerdelga (eliglustat).\" Genzyme Corporation, Cambridge, MA.[2] \"Product Information. Cerdelga (eliglustat).\" Genzyme Corporation, Cambridge, MA.", "alternatives_a": "Valrubicin, Plicamycin, Ixabepilone, Bleomycin, Mitomycin, Dactinomycin", "alternatives_b": "Teduglutide, Fosdenopterin, Miglustat, Imiglucerase, Asfotase alfa, Glycerol phenylbutyrate, Pegvaliase, Triethylenetetramine, Sapropterin, Zinc acetate, Phenylbutyric acid, More", "updated_at": 1767369485}, {"id": 97182, "ingredient1": "Erdafitinib", "ingredient2": "Eliglustat", "severity": "Moderate", "effect": "Coadministration with erdafitinib may increase the plasma concentrations of drugs that are substrates of the P-glycoprotein (P-gp) efflux transporter, resulting in increased toxicity of these drugs. In vitro, erdafitinib has been shown to be an inhibitor of P-gp.", "source": "DDInter", "management_text": "Concomitant use of erdafitinib and P-gp substrates should generally be avoided. If concomitant use is required, administer erdafitinib at least 6 hours before or after administration of P-gp substrates with narrow therapeutic ranges.", "mechanism_text": "Distribution", "recommendation": "Concomitant use of erdafitinib and P-gp substrates should generally be avoided.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97286/", "reference_text": "[1] \"Product Information. Balversa (erdafitinib).\" Janssen Products, LP, Horsham, PA.", "alternatives_a": "Teduglutide, Lonafarnib, Fosdenopterin, Miglustat, Imiglucerase, Asfotase alfa, Glycerol phenylbutyrate, Pegvaliase, Triethylenetetramine, Sapropterin, Zinc acetate, More", "alternatives_b": "Acalabrutinib, Tepotinib, Avapritinib, Selumetinib, Vandetanib, Capmatinib, Ibrutinib, Tivozanib, Zanubrutinib, Axitinib, Sunitinib, More", "updated_at": 1767369485}, {"id": 97183, "ingredient1": "Erlotinib", "ingredient2": "Eliglustat", "severity": "Moderate", "effect": "Coadministration with eliglustat may increase the plasma concentrations of drugs that are substrates of the P-glycoprotein (P-gp) transporter. The proposed mechanism is decreased clearance in the intestine, liver, and/or kidney due to inhibition of P-glycoprotein-mediated drug efflux by eliglustat.", "source": "DDInter", "management_text": "Caution is advised when eliglustat is used concurrently with drugs that are known P-gp substrates, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever eliglustat is added to or withdrawn from therapy.", "mechanism_text": "Others", "recommendation": "Caution is advised when eliglustat is used concurrently with drugs that are known P-gp substrates, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97287/", "reference_text": "[1] \"Product Information. Cerdelga (eliglustat).\" Genzyme Corporation, Cambridge, MA.[2] \"Product Information. Cerdelga (eliglustat).\" Genzyme Corporation, Cambridge, MA.", "alternatives_a": "Acalabrutinib, Tepotinib, Avapritinib, Selumetinib, Vandetanib, Capmatinib, Ibrutinib, Tivozanib, Zanubrutinib, Axitinib, Sunitinib, More", "alternatives_b": "Teduglutide, Fosdenopterin, Miglustat, Imiglucerase, Asfotase alfa, Glycerol phenylbutyrate, Pegvaliase, Triethylenetetramine, Sapropterin, Zinc acetate, Phenylbutyric acid, More", "updated_at": 1767369485}, {"id": 97184, "ingredient1": "Eslicarbazepine", "ingredient2": "Eliglustat", "severity": "Moderate", "effect": "Coadministration with inducers of CYP450 3A4 and/or P-glycoprotein (P-gp) may decrease the plasma concentrations of eliglustat, which is primarily metabolized by CYP450 2D6 and, to a lesser extent, CYP450 3A4. Eliglustat is also a substrate of P-gp efflux transporter.", "source": "DDInter", "management_text": "Patients receiving eliglustat with CYP450 3A4 inducers should be monitored for potentially diminished pharmacologic response to eliglustat. Concomitant use should be avoided if an interaction is suspected.", "mechanism_text": "Metabolism", "recommendation": "Patients receiving eliglustat with CYP450 3A4 inducers should be monitored for potentially diminished pharmacologic response to eliglustat.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97288/", "reference_text": "[1] \"Product Information. Cerdelga (eliglustat).\" Genzyme Corporation, Cambridge, MA.[2] \"Product Information. Cerdelga (eliglustat).\" Genzyme Corporation, Cambridge, MA.", "alternatives_a": "Teduglutide, Fosdenopterin, Miglustat, Imiglucerase, Asfotase alfa, Glycerol phenylbutyrate, Pegvaliase, Triethylenetetramine, Sapropterin, Zinc acetate, Phenylbutyric acid, More", "alternatives_b": "Brivaracetam, Topiramate, Ezogabine, Lamotrigine, Ethosuximide, Lacosamide, Levetiracetam, Tiagabine, Ethotoin, Clonazepam, Paramethadione, More", "updated_at": 1767369485}, {"id": 97185, "ingredient1": "Etoposide", "ingredient2": "Eliglustat", "severity": "Moderate", "effect": "Coadministration with eliglustat may increase the plasma concentrations of drugs that are substrates of the P-glycoprotein (P-gp) transporter. The proposed mechanism is decreased clearance in the intestine, liver, and/or kidney due to inhibition of P-glycoprotein-mediated drug efflux by eliglustat.", "source": "DDInter", "management_text": "Caution is advised when eliglustat is used concurrently with drugs that are known P-gp substrates, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever eliglustat is added to or withdrawn from therapy.", "mechanism_text": "Others", "recommendation": "Caution is advised when eliglustat is used concurrently with drugs that are known P-gp substrates, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97289/", "reference_text": "[1] \"Product Information. Cerdelga (eliglustat).\" Genzyme Corporation, Cambridge, MA.[2] \"Product Information. Cerdelga (eliglustat).\" Genzyme Corporation, Cambridge, MA.", "alternatives_a": "Teniposide, Trabectedin, Cabazitaxel, Irinotecan", "alternatives_b": "Teduglutide, Fosdenopterin, Miglustat, Imiglucerase, Asfotase alfa, Glycerol phenylbutyrate, Pegvaliase, Triethylenetetramine, Sapropterin, Zinc acetate, Phenylbutyric acid, More", "updated_at": 1767369485}, {"id": 97186, "ingredient1": "Etravirine", "ingredient2": "Eliglustat", "severity": "Moderate", "effect": "Coadministration with inducers of CYP450 3A4 and/or P-glycoprotein (P-gp) may decrease the plasma concentrations of eliglustat, which is primarily metabolized by CYP450 2D6 and, to a lesser extent, CYP450 3A4. Eliglustat is also a substrate of P-gp efflux transporter.", "source": "DDInter", "management_text": "Patients receiving eliglustat with CYP450 3A4 inducers should be monitored for potentially diminished pharmacologic response to eliglustat. Concomitant use should be avoided if an interaction is suspected.", "mechanism_text": "Metabolism", "recommendation": "Patients receiving eliglustat with CYP450 3A4 inducers should be monitored for potentially diminished pharmacologic response to eliglustat.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97290/", "reference_text": "[1] \"Product Information. Cerdelga (eliglustat).\" Genzyme Corporation, Cambridge, MA.[2] \"Product Information. Cerdelga (eliglustat).\" Genzyme Corporation, Cambridge, MA.", "alternatives_a": "Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Simeprevir, Cabotegravir, Valaciclovir, Zanamivir, Velpatasvir, Rilpivirine, Dolutegravir, More", "alternatives_b": "Teduglutide, Fosdenopterin, Miglustat, Imiglucerase, Asfotase alfa, Glycerol phenylbutyrate, Pegvaliase, Triethylenetetramine, Sapropterin, Zinc acetate, Phenylbutyric acid, More", "updated_at": 1767369485}, {"id": 97187, "ingredient1": "Everolimus", "ingredient2": "Eliglustat", "severity": "Moderate", "effect": "Coadministration with inhibitors of CYP450 3A4 and/or P-glycoprotein may increase the blood concentrations of everolimus following oral administration. Everolimus is a substrate of both the CYP450 3A4 isoenzyme and P-glycoprotein drug efflux transporter, thus their inhibition in the intestine can enhance the absorption of everolimus.", "source": "DDInter", "management_text": "The possibility of prolonged and/or increased pharmacologic effects of everolimus therapy should be considered during coadministration with CYP450 3A4 and/or P-glycoprotein inhibitors, including adverse effects such as pneumonitis, stomatitis, infection, dyspnea, diarrhea, anemia, leucopenia, thrombocytopenia, hyperglycemia, and hyperlipidemia. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate whenever a CYP450 3A4 inhibitor is added to or withdrawn from therapy.", "mechanism_text": "Absorption", "recommendation": "The possibility of prolonged and/or increased pharmacologic effects of everolimus therapy should be considered during coadministration with CYP450 3A4 and/or P-glycoprotein inhibitors, including adverse effects such as pneumonitis, stomatitis, infection, dyspnea, diarrhea, anemia, leucopenia, thrombocytopenia, hyperglycemia, and hyperlipidemia.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97291/", "reference_text": "[1] \"Product Information. Afinitor (everolimus).\" Novartis Pharmaceuticals, East Hanover, NJ.[2] \"Product Information. Afinitor (everolimus).\" Novartis Pharmaceuticals, East Hanover, NJ.[3] \"Product Information. Afinitor (everolimus).\" Novartis Pharmaceuticals, East Hanover, NJ.[4] \"Product Information. Mavyret (glecaprevir-pibrentasvir).\" Abbott Pharmaceutical, Abbott Park, IL.", "alternatives_a": "Acalabrutinib, Tepotinib, Avapritinib, Selumetinib, Vandetanib, Capmatinib, Ibrutinib, Tivozanib, Zanubrutinib, Axitinib, Sunitinib, More", "alternatives_b": "Lipoic acid, Triheptanoin, Teduglutide, Fosdenopterin, Triethylenetetramine, Miglustat, Sapropterin, Nitisinone, Levocarnitine, Laronidase, Imiglucerase, More", "updated_at": 1767369485}, {"id": 97188, "ingredient1": "Fedratinib", "ingredient2": "Eliglustat", "severity": "Major", "effect": "Coadministration with inhibitors of CYP450 2D6 may significantly increase the plasma concentrations of eliglustat, which is primarily metabolized by CYP450 2D6 and, to a lesser extent, CYP450 3A4. Eliglustat at substantially elevated plasma concentrations is predicted to cause prolongation of the PR, QTc and QRS cardiac intervals, which may increase the risk of bradycardia, atrioventricular block, cardiac arrest, and serious ventricular arrhythmias such as torsade de pointes.", "source": "DDInter", "management_text": "The use of eliglustat in combination with one or more drugs that may result in moderate or potent inhibition of both CYP450 2D6 and 3A4 is considered contraindicated in CYP450 2D6 intermediate metabolizers (IMs) and extensive metabolizers (EMs). In the absence of a concomitant CYP450 3A4 inhibitor, eliglustat may be prescribed at a reduced dosage of 84 mg once daily to IMs and EMs treated with a potent or moderate CYP450 2D6 inhibitor. Poor metabolizers are not affected by CYP450 2D6 inhibition (since they already have minimal functional levels of the isoenzyme) and may also receive the reduced dosage of eliglustat, so long as they are not treated with a CYP450 3A4 inhibitor.", "mechanism_text": "Metabolism", "recommendation": "The use of eliglustat in combination with one or more drugs that may result in moderate or potent inhibition of both CYP450 2D6 and 3A4 is considered contraindicated in CYP450 2D6 intermediate metabolizers (IMs) and extensive metabolizers (EMs).", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97292/", "reference_text": "[1] \"Product Information. Cerdelga (eliglustat).\" Genzyme Corporation, Cambridge, MA.[2] \"Product Information. Cerdelga (eliglustat).\" Genzyme Corporation, Cambridge, MA.", "alternatives_a": "Teduglutide, Fosdenopterin, Miglustat, Imiglucerase, Asfotase alfa, Glycerol phenylbutyrate, Pegvaliase, Triethylenetetramine, Sapropterin, Zinc acetate, Phenylbutyric acid, More", "alternatives_b": "Acalabrutinib, Tepotinib, Avapritinib, Selumetinib, Vandetanib, Capmatinib, Ibrutinib, Tivozanib, Zanubrutinib, Axitinib, Sunitinib, More", "updated_at": 1767369485}, {"id": 97189, "ingredient1": "Felbamate", "ingredient2": "Eliglustat", "severity": "Moderate", "effect": "Coadministration with inducers of CYP450 3A4 and/or P-glycoprotein (P-gp) may decrease the plasma concentrations of eliglustat, which is primarily metabolized by CYP450 2D6 and, to a lesser extent, CYP450 3A4. Eliglustat is also a substrate of P-gp efflux transporter.", "source": "DDInter", "management_text": "Patients receiving eliglustat with CYP450 3A4 inducers should be monitored for potentially diminished pharmacologic response to eliglustat. Concomitant use should be avoided if an interaction is suspected.", "mechanism_text": "Metabolism", "recommendation": "Patients receiving eliglustat with CYP450 3A4 inducers should be monitored for potentially diminished pharmacologic response to eliglustat.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97293/", "reference_text": "[1] \"Product Information. Cerdelga (eliglustat).\" Genzyme Corporation, Cambridge, MA.[2] \"Product Information. Cerdelga (eliglustat).\" Genzyme Corporation, Cambridge, MA.", "alternatives_a": "Brivaracetam, Topiramate, Ezogabine, Lamotrigine, Ethosuximide, Lacosamide, Levetiracetam, Tiagabine, Ethotoin, Clonazepam, Paramethadione, More", "alternatives_b": "Teduglutide, Fosdenopterin, Miglustat, Imiglucerase, Asfotase alfa, Glycerol phenylbutyrate, Pegvaliase, Triethylenetetramine, Sapropterin, Zinc acetate, Phenylbutyric acid, More", "updated_at": 1767369485}, {"id": 97190, "ingredient1": "Fenfluramine", "ingredient2": "Eliglustat", "severity": "Moderate", "effect": "Coadministration with eliglustat may increase the plasma concentrations of drugs that are primarily metabolized by CYP450 2D6.", "source": "DDInter", "management_text": "Caution is advised if eliglustat is used concomitantly with medications that undergo metabolism primarily by CYP450 2D6, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever eliglustat is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if eliglustat is used concomitantly with medications that undergo metabolism primarily by CYP450 2D6, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97294/", "reference_text": "[1] \"Product Information. Cerdelga (eliglustat).\" Genzyme Corporation, Cambridge, MA.[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] \"Product Information. Cerdelga (eliglustat).\" Genzyme Corporation, Cambridge, MA.[5] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[6] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[7] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[8] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.", "alternatives_a": "Naltrexone, Ephedrine, Phentermine, Orlistat, Lorcaserin, Sibutramine, Diethylpropion, Mazindol, Brivaracetam, Topiramate, Ezogabine, More", "alternatives_b": "Teduglutide, Lonafarnib, Fosdenopterin, Miglustat, Imiglucerase, Asfotase alfa, Pegvaliase, Triethylenetetramine, Sapropterin, Zinc acetate, Phenylbutyric acid, More", "updated_at": 1767369485}, {"id": 97191, "ingredient1": "Fexofenadine", "ingredient2": "Eliglustat", "severity": "Moderate", "effect": "Coadministration with eliglustat may increase the plasma concentrations of drugs that are substrates of the P-glycoprotein (P-gp) transporter. The proposed mechanism is decreased clearance in the intestine, liver, and/or kidney due to inhibition of P-glycoprotein-mediated drug efflux by eliglustat.", "source": "DDInter", "management_text": "Caution is advised when eliglustat is used concurrently with drugs that are known P-gp substrates, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever eliglustat is added to or withdrawn from therapy.", "mechanism_text": "Others", "recommendation": "Caution is advised when eliglustat is used concurrently with drugs that are known P-gp substrates, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97295/", "reference_text": "[1] \"Product Information. Cerdelga (eliglustat).\" Genzyme Corporation, Cambridge, MA.[2] \"Product Information. Cerdelga (eliglustat).\" Genzyme Corporation, Cambridge, MA.", "alternatives_a": "Ketotifen, Mepyramine, Levocetirizine, Chlorcyclizine, Cetirizine, Acrivastine, Triprolidine, Tripelennamine, Azelastine, Dexbrompheniramine, Clemastine, More", "alternatives_b": "Teduglutide, Fosdenopterin, Miglustat, Imiglucerase, Asfotase alfa, Glycerol phenylbutyrate, Pegvaliase, Triethylenetetramine, Sapropterin, Zinc acetate, Phenylbutyric acid, More", "updated_at": 1767369485}, {"id": 97192, "ingredient1": "Fidaxomicin", "ingredient2": "Eliglustat", "severity": "Minor", "effect": "Coadministration with inhibitors of P-glycoprotein (P-gp) may increase the plasma concentrations of fidaxomicin and its main metabolite, OP-1118, both of which are substrates of the intestinal efflux transporter. Theoretically, concentrations of fidaxomicin and OP-1118 may also be decreased at the site of action (i.e., gastrointestinal tract) due to P-gp inhibition.", "source": "DDInter", "management_text": "-", "mechanism_text": "Absorption", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97296/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] \"Product Information. Dificid (fidaxomicin).\" Optimer Pharmaceuticals, San Diego, CA.[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Dificid (fidaxomicin).\" Optimer Pharmaceuticals, San Diego, CA.[7] \"Product Information. Mavyret (glecaprevir-pibrentasvir).\" Abbott Pharmaceutical, Abbott Park, IL.", "alternatives_a": "Rifamycin, Kanamycin, Amphotericin B, Polymyxin B, Nystatin, Vancomycin, Streptomycin, Paromomycin, Neomycin", "alternatives_b": "Teduglutide, Lonafarnib, Fosdenopterin, Miglustat, Imiglucerase, Asfotase alfa, Glycerol phenylbutyrate, Pegvaliase, Triethylenetetramine, Sapropterin, Zinc acetate, More", "updated_at": 1767369485}, {"id": 97193, "ingredient1": "Flecainide", "ingredient2": "Eliglustat", "severity": "Major", "effect": "Coadministration with inhibitors of CYP450 2D6 may significantly increase the plasma concentrations of eliglustat, which is primarily metabolized by CYP450 2D6 and, to a lesser extent, CYP450 3A4. Eliglustat at substantially elevated plasma concentrations is predicted to cause prolongation of the PR, QTc and QRS cardiac intervals, which may increase the risk of bradycardia, atrioventricular block, cardiac arrest, and serious ventricular arrhythmias such as torsade de pointes.", "source": "DDInter", "management_text": "The use of eliglustat in combination with one or more drugs that may result in moderate or potent inhibition of both CYP450 2D6 and 3A4 is considered contraindicated in CYP450 2D6 intermediate metabolizers (IMs) and extensive metabolizers (EMs). In the absence of a concomitant CYP450 3A4 inhibitor, eliglustat may be prescribed at a reduced dosage of 84 mg once daily to IMs and EMs treated with a potent or moderate CYP450 2D6 inhibitor. Poor metabolizers are not affected by CYP450 2D6 inhibition (since they already have minimal functional levels of the isoenzyme) and may also receive the reduced dosage of eliglustat, so long as they are not treated with a CYP450 3A4 inhibitor.", "mechanism_text": "Metabolism", "recommendation": "The use of eliglustat in combination with one or more drugs that may result in moderate or potent inhibition of both CYP450 2D6 and 3A4 is considered contraindicated in CYP450 2D6 intermediate metabolizers (IMs) and extensive metabolizers (EMs).", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97297/", "reference_text": "[1] \"Product Information. Cerdelga (eliglustat).\" Genzyme Corporation, Cambridge, MA.[2] \"Product Information. Cerdelga (eliglustat).\" Genzyme Corporation, Cambridge, MA.", "alternatives_a": "Lidocaine, Moricizine, Bretylium, Tocainide", "alternatives_b": "Teduglutide, Lonafarnib, Fosdenopterin, Miglustat, Imiglucerase, Asfotase alfa, Pegvaliase, Triethylenetetramine, Sapropterin, Zinc acetate, Phenylbutyric acid, More", "updated_at": 1767369485}, {"id": 97194, "ingredient1": "Fluconazole", "ingredient2": "Eliglustat", "severity": "Major", "effect": "Coadministration with moderate inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of eliglustat, which is primarily metabolized by CYP450 2D6 and, to a lesser extent, CYP450 3A4. Eliglustat at substantially elevated plasma concentrations is predicted to cause prolongation of the PR, QTc and QRS cardiac intervals, which may increase the risk of bradycardia, atrioventricular block, cardiac arrest, and serious ventricular arrhythmias such as torsade de pointes.", "source": "DDInter", "management_text": "The use of eliglustat in combination with one or more drugs that may result in moderate inhibition of CYP450 3A4 and moderate to potent inhibition of CYP450 2D6 is considered contraindicated in CYP450 2D6 extensive metabolizers (EMs) and intermediate metabolizers (IMs). In the absence of a concomitant CYP450 2D6 inhibitor, eliglustat may be prescribed at a reduced dosage of 84 mg once daily to EMs treated with a moderate CYP450 3A4 inhibitor. However, eliglustat should not be used with a moderate CYP450 3A4 inhibitor in CYP450 2D6 IMs or poor metabolizers (PMs). Moderate CYP450 3A4 inhibitors include aprepitant, ciprofloxacin, clotrimazole, crizotinib, darunavir, diltiazem, dronedarone, fluconazole, fusidic acid, imatinib, isavuconazonium, miconazole, mifepristone, netupitant, quinupristin-dalfopristin, ranolazine, stiripentol, and verapamil. Potent and moderate CYP450 2D6 inhibitors include abiraterone, bupropion, celecoxib, cimetidine, cinacalcet, clobazam, darifenacin, diphenhydramine, duloxetine, fluoxetine, methotrimeprazine, mirabegron, paroxetine, propoxyphene, quinidine, ranolazine, sertraline, stiripentol, and terbinafine.", "mechanism_text": "Metabolism", "recommendation": "The use of eliglustat in combination with one or more drugs that may result in moderate inhibition of CYP450 3A4 and moderate to potent inhibition of CYP450 2D6 is considered contraindicated in CYP450 2D6 extensive metabolizers (EMs) and intermediate metabolizers (IMs).", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97298/", "reference_text": "[1] \"Product Information. Cerdelga (eliglustat).\" Genzyme Corporation, Cambridge, MA.[2] \"Product Information. Cerdelga (eliglustat).\" Genzyme Corporation, Cambridge, MA.", "alternatives_a": "Tinidazole, Tetracycline, Cefepime, Norfloxacin, Metronidazole, Cefuroxime, Secnidazole, Cefixime, Azithromycin, Amikacin, Levofloxacin, More", "alternatives_b": "Teduglutide, Fosdenopterin, Miglustat, Imiglucerase, Asfotase alfa, Glycerol phenylbutyrate, Pegvaliase, Triethylenetetramine, Sapropterin, Zinc acetate, Phenylbutyric acid, More", "updated_at": 1767369485}, {"id": 97195, "ingredient1": "Fluoxetine", "ingredient2": "Eliglustat", "severity": "Major", "effect": "Coadministration with inhibitors of CYP450 2D6 may significantly increase the plasma concentrations of eliglustat, which is primarily metabolized by CYP450 2D6 and, to a lesser extent, CYP450 3A4. Eliglustat at substantially elevated plasma concentrations is predicted to cause prolongation of the PR, QTc and QRS cardiac intervals, which may increase the risk of bradycardia, atrioventricular block, cardiac arrest, and serious ventricular arrhythmias such as torsade de pointes.", "source": "DDInter", "management_text": "The use of eliglustat in combination with one or more drugs that may result in moderate or potent inhibition of both CYP450 2D6 and 3A4 is considered contraindicated in CYP450 2D6 intermediate metabolizers (IMs) and extensive metabolizers (EMs). In the absence of a concomitant CYP450 3A4 inhibitor, eliglustat may be prescribed at a reduced dosage of 84 mg once daily to IMs and EMs treated with a potent or moderate CYP450 2D6 inhibitor. Poor metabolizers are not affected by CYP450 2D6 inhibition (since they already have minimal functional levels of the isoenzyme) and may also receive the reduced dosage of eliglustat, so long as they are not treated with a CYP450 3A4 inhibitor.", "mechanism_text": "Metabolism", "recommendation": "The use of eliglustat in combination with one or more drugs that may result in moderate or potent inhibition of both CYP450 2D6 and 3A4 is considered contraindicated in CYP450 2D6 intermediate metabolizers (IMs) and extensive metabolizers (EMs).", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97299/", "reference_text": "[1] \"Product Information. Cerdelga (eliglustat).\" Genzyme Corporation, Cambridge, MA.[2] \"Product Information. Cerdelga (eliglustat).\" Genzyme Corporation, Cambridge, MA.", "alternatives_a": "Phenelzine, Citalopram, Tranylcypromine, Desvenlafaxine, Isocarboxazid, Oxitriptan, Tryptophan, Milnacipran, Levomilnacipran, Vilazodone, Esketamine, More", "alternatives_b": "Teduglutide, Lonafarnib, Fosdenopterin, Miglustat, Imiglucerase, Asfotase alfa, Pegvaliase, Triethylenetetramine, Sapropterin, Zinc acetate, Phenylbutyric acid, More", "updated_at": 1767369485}, {"id": 97196, "ingredient1": "Fluphenazine", "ingredient2": "Eliglustat", "severity": "Moderate", "effect": "Coadministration with eliglustat may increase the plasma concentrations of drugs that are primarily metabolized by CYP450 2D6.", "source": "DDInter", "management_text": "Caution is advised if eliglustat is used concomitantly with medications that undergo metabolism primarily by CYP450 2D6, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever eliglustat is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if eliglustat is used concomitantly with medications that undergo metabolism primarily by CYP450 2D6, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97300/", "reference_text": "[1] \"Product Information. Cerdelga (eliglustat).\" Genzyme Corporation, Cambridge, MA.[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] \"Product Information. Cerdelga (eliglustat).\" Genzyme Corporation, Cambridge, MA.[5] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[6] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[7] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[8] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.", "alternatives_a": "Quetiapine, Asenapine, Promazine, Prochlorperazine, Thiothixene, Pimavanserin, Lumateperone, Ziprasidone, Olanzapine, Trifluoperazine, Amisulpride, More", "alternatives_b": "Teduglutide, Lonafarnib, Fosdenopterin, Miglustat, Imiglucerase, Asfotase alfa, Pegvaliase, Triethylenetetramine, Sapropterin, Zinc acetate, Phenylbutyric acid, More", "updated_at": 1767369485}, {"id": 97197, "ingredient1": "Ginkgo biloba", "ingredient2": "Eliglustat", "severity": "Moderate", "effect": "Coadministration with weak inhibitors of CYP450 3A4 may increase the plasma concentrations of eliglustat, which is primarily metabolized by CYP450 2D6 and, to a lesser extent, CYP450 3A4. Eliglustat at substantially elevated plasma concentrations is predicted to cause prolongation of the PR, QTc and QRS cardiac intervals, which may increase the risk of bradycardia, atrioventricular block, cardiac arrest, and serious ventricular arrhythmias such as torsade de pointes.", "source": "DDInter", "management_text": "Concomitant use of eliglustat with weak CYP450 3A4 inhibitors such as chloramphenicol, cyclosporine, danazol, dasatinib, ethinyl estradiol, fluvoxamine, goldenseal, isoniazid, ivacaftor, lapatinib, lomitapide, nifedipine, nilotinib, palbociclib, pazopanib, suvorexant, ticagrelor, and zafirlukast is not recommended in CYP450 2D6 poor metabolizers. No dosage adjustment for eliglustat is necessary when used with weak CYP450 3A4 inhibitors in extensive or intermediate metabolizers.", "mechanism_text": "Metabolism", "recommendation": "Concomitant use of eliglustat with weak CYP450 3A4 inhibitors such as chloramphenicol, cyclosporine, danazol, dasatinib, ethinyl estradiol, fluvoxamine, goldenseal, isoniazid, ivacaftor, lapatinib, lomitapide, nifedipine, nilotinib, palbociclib, pazopanib, suvorexant, ticagrelor, and zafirlukast is not recommended in CYP450 2D6 poor metabolizers.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97301/", "reference_text": "[1] \"Product Information. Cerdelga (eliglustat).\" Genzyme Corporation, Cambridge, MA.[2] \"Product Information. Cerdelga (eliglustat).\" Genzyme Corporation, Cambridge, MA.", "alternatives_a": "Memantine, Rivastigmine, Tacrine, Aducanumab", "alternatives_b": "Teduglutide, Lonafarnib, Fosdenopterin, Miglustat, Imiglucerase, Asfotase alfa, Glycerol phenylbutyrate, Pegvaliase, Triethylenetetramine, Sapropterin, Zinc acetate, More", "updated_at": 1767369485}, {"id": 97198, "ingredient1": "Givosiran", "ingredient2": "Eliglustat", "severity": "Major", "effect": "Coadministration with inhibitors of CYP450 2D6 may significantly increase the plasma concentrations of eliglustat, which is primarily metabolized by CYP450 2D6 and, to a lesser extent, CYP450 3A4. Eliglustat at substantially elevated plasma concentrations is predicted to cause prolongation of the PR, QTc and QRS cardiac intervals, which may increase the risk of bradycardia, atrioventricular block, cardiac arrest, and serious ventricular arrhythmias such as torsade de pointes.", "source": "DDInter", "management_text": "The use of eliglustat in combination with one or more drugs that may result in moderate or potent inhibition of both CYP450 2D6 and 3A4 is considered contraindicated in CYP450 2D6 intermediate metabolizers (IMs) and extensive metabolizers (EMs). In the absence of a concomitant CYP450 3A4 inhibitor, eliglustat may be prescribed at a reduced dosage of 84 mg once daily to IMs and EMs treated with a potent or moderate CYP450 2D6 inhibitor. Poor metabolizers are not affected by CYP450 2D6 inhibition (since they already have minimal functional levels of the isoenzyme) and may also receive the reduced dosage of eliglustat, so long as they are not treated with a CYP450 3A4 inhibitor.", "mechanism_text": "Metabolism", "recommendation": "The use of eliglustat in combination with one or more drugs that may result in moderate or potent inhibition of both CYP450 2D6 and 3A4 is considered contraindicated in CYP450 2D6 intermediate metabolizers (IMs) and extensive metabolizers (EMs).", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97302/", "reference_text": "[1] \"Product Information. Cerdelga (eliglustat).\" Genzyme Corporation, Cambridge, MA.[2] \"Product Information. Cerdelga (eliglustat).\" Genzyme Corporation, Cambridge, MA.", "alternatives_a": "Teduglutide, Lonafarnib, Fosdenopterin, Miglustat, Imiglucerase, Asfotase alfa, Glycerol phenylbutyrate, Pegvaliase, Triethylenetetramine, Sapropterin, Zinc acetate, More", "alternatives_b": "Teduglutide, Fosdenopterin, Miglustat, Imiglucerase, Asfotase alfa, Pegvaliase, Triethylenetetramine, Sapropterin, Zinc acetate, Phenylbutyric acid, Agalsidase beta, More", "updated_at": 1767369485}, {"id": 97199, "ingredient1": "Glasdegib", "ingredient2": "Eliglustat", "severity": "Moderate", "effect": "Coadministration with glasdegib may increase the plasma concentrations of drugs that are substrates of the P-glycoprotein (P-gp) and/or breast cancer resistance protein (BCRP) efflux transporters.", "source": "DDInter", "management_text": "Caution is advised if glasdegib is coadministered with drugs that are substrates of P-gp and/or BCRP, particularly those with a narrow therapeutic range. Clinical and laboratory monitoring should be considered whenever glasdegib is added to or withdrawn from therapy with these drugs, and dosages adjusted as necessary. Patients should be monitored for the development of adverse effects.", "mechanism_text": "Absorption", "recommendation": "Caution is advised if glasdegib is coadministered with drugs that are substrates of P-gp and/or BCRP, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97303/", "reference_text": "[1] \"Product Information. Daurismo (glasdegib).\" Pfizer U.S. Pharmaceuticals Group, New York, NY.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Daurismo (glasdegib).\" Pfizer U.S. Pharmaceuticals Group, New York, NY.", "alternatives_a": "Teduglutide, Fosdenopterin, Miglustat, Imiglucerase, Asfotase alfa, Pegvaliase, Triethylenetetramine, Sapropterin, Zinc acetate, Phenylbutyric acid, Agalsidase beta, More", "alternatives_b": "Pertuzumab, Olaparib, Oxaliplatin, Bortezomib, Tisagenlecleucel, Aminolevulinic acid, Omacetaxine mepesuccinate, Altretamine, Tagraxofusp, Pegaspargase, Ixazomib, More", "updated_at": 1767369485}, {"id": 97200, "ingredient1": "Glycerol phenylbutyrate", "ingredient2": "Eliglustat", "severity": "Moderate", "effect": "Coadministration of glycerol phenylbutyrate may lead to increased concentrations of CYP450 2D6 substrates. The proposed mechanism is inhibition of CYP450 2D6 by phenylbutyrate, the active moiety of glycerol phenylbutyrate, which has been shown to be an in vitro inhibitor of this isoenzyme.", "source": "DDInter", "management_text": "Caution is recommended if glycerol phenylbutyrate is administered with medicines that are substrates of CYP450 2D6, such as codeine, dextromethorphan, and some beta blockers (including metoprolol, carvedilol, labetalol, propranolol, and nebivolol). Dosage adjustments as well as clinical and laboratory monitoring may be appropriate.", "mechanism_text": "Metabolism", "recommendation": "Caution is recommended if glycerol phenylbutyrate is administered with medicines that are substrates of CYP450 2D6, such as codeine, dextromethorphan, and some beta blockers (including metoprolol, carvedilol, labetalol, propranolol, and nebivolol).", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97304/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Ravicti (glycerol phenylbutyrate).\" Hyperion Therapeutics Inc, South San Francisco, CA.", "alternatives_a": "Teduglutide, Fosdenopterin, Miglustat, Imiglucerase, Asfotase alfa, Pegvaliase, Triethylenetetramine, Sapropterin, Zinc acetate, Phenylbutyric acid, Agalsidase beta, More", "alternatives_b": "Teduglutide, Fosdenopterin, Miglustat, Imiglucerase, Asfotase alfa, Glycerol phenylbutyrate, Pegvaliase, Triethylenetetramine, Sapropterin, Zinc acetate, Phenylbutyric acid, More", "updated_at": 1767369485}, {"id": 97201, "ingredient1": "Goldenseal", "ingredient2": "Eliglustat", "severity": "Moderate", "effect": "Coadministration with weak inhibitors of CYP450 3A4 may increase the plasma concentrations of eliglustat, which is primarily metabolized by CYP450 2D6 and, to a lesser extent, CYP450 3A4. Eliglustat at substantially elevated plasma concentrations is predicted to cause prolongation of the PR, QTc and QRS cardiac intervals, which may increase the risk of bradycardia, atrioventricular block, cardiac arrest, and serious ventricular arrhythmias such as torsade de pointes.", "source": "DDInter", "management_text": "Concomitant use of eliglustat with weak CYP450 3A4 inhibitors such as chloramphenicol, cyclosporine, danazol, dasatinib, ethinyl estradiol, fluvoxamine, goldenseal, isoniazid, ivacaftor, lapatinib, lomitapide, nifedipine, nilotinib, palbociclib, pazopanib, suvorexant, ticagrelor, and zafirlukast is not recommended in CYP450 2D6 poor metabolizers. No dosage adjustment for eliglustat is necessary when used with weak CYP450 3A4 inhibitors in extensive or intermediate metabolizers.", "mechanism_text": "Metabolism", "recommendation": "Concomitant use of eliglustat with weak CYP450 3A4 inhibitors such as chloramphenicol, cyclosporine, danazol, dasatinib, ethinyl estradiol, fluvoxamine, goldenseal, isoniazid, ivacaftor, lapatinib, lomitapide, nifedipine, nilotinib, palbociclib, pazopanib, suvorexant, ticagrelor, and zafirlukast is not recommended in CYP450 2D6 poor metabolizers.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97305/", "reference_text": "[1] \"Product Information. Cerdelga (eliglustat).\" Genzyme Corporation, Cambridge, MA.[2] \"Product Information. Cerdelga (eliglustat).\" Genzyme Corporation, Cambridge, MA.", "alternatives_a": "Teduglutide, Fosdenopterin, Miglustat, Imiglucerase, Asfotase alfa, Glycerol phenylbutyrate, Pegvaliase, Triethylenetetramine, Sapropterin, Zinc acetate, Phenylbutyric acid, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 97202, "ingredient1": "Grepafloxacin", "ingredient2": "Eliglustat", "severity": "Moderate", "effect": "Coadministration with weak inhibitors of CYP450 3A4 may increase the plasma concentrations of eliglustat, which is primarily metabolized by CYP450 2D6 and, to a lesser extent, CYP450 3A4. Eliglustat at substantially elevated plasma concentrations is predicted to cause prolongation of the PR, QTc and QRS cardiac intervals, which may increase the risk of bradycardia, atrioventricular block, cardiac arrest, and serious ventricular arrhythmias such as torsade de pointes.", "source": "DDInter", "management_text": "Concomitant use of eliglustat with weak CYP450 3A4 inhibitors such as chloramphenicol, cyclosporine, danazol, dasatinib, ethinyl estradiol, fluvoxamine, goldenseal, isoniazid, ivacaftor, lapatinib, lomitapide, nifedipine, nilotinib, palbociclib, pazopanib, suvorexant, ticagrelor, and zafirlukast is not recommended in CYP450 2D6 poor metabolizers. No dosage adjustment for eliglustat is necessary when used with weak CYP450 3A4 inhibitors in extensive or intermediate metabolizers.", "mechanism_text": "Metabolism", "recommendation": "Concomitant use of eliglustat with weak CYP450 3A4 inhibitors such as chloramphenicol, cyclosporine, danazol, dasatinib, ethinyl estradiol, fluvoxamine, goldenseal, isoniazid, ivacaftor, lapatinib, lomitapide, nifedipine, nilotinib, palbociclib, pazopanib, suvorexant, ticagrelor, and zafirlukast is not recommended in CYP450 2D6 poor metabolizers.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97306/", "reference_text": "[1] \"Product Information. Cerdelga (eliglustat).\" Genzyme Corporation, Cambridge, MA.[2] \"Product Information. Cerdelga (eliglustat).\" Genzyme Corporation, Cambridge, MA.", "alternatives_a": "Enoxacin, Gatifloxacin, Norfloxacin, Levofloxacin, Nalidixic acid, Gemifloxacin, Lomefloxacin, Moxifloxacin, Cinoxacin, Trovafloxacin, Delafloxacin, More", "alternatives_b": "Teduglutide, Fosdenopterin, Miglustat, Imiglucerase, Asfotase alfa, Glycerol phenylbutyrate, Pegvaliase, Triethylenetetramine, Sapropterin, Phenylbutyric acid, Agalsidase beta, More", "updated_at": 1767369485}, {"id": 97203, "ingredient1": "Griseofulvin", "ingredient2": "Eliglustat", "severity": "Moderate", "effect": "Coadministration with inducers of CYP450 3A4 and/or P-glycoprotein (P-gp) may decrease the plasma concentrations of eliglustat, which is primarily metabolized by CYP450 2D6 and, to a lesser extent, CYP450 3A4. Eliglustat is also a substrate of P-gp efflux transporter.", "source": "DDInter", "management_text": "Patients receiving eliglustat with CYP450 3A4 inducers should be monitored for potentially diminished pharmacologic response to eliglustat. Concomitant use should be avoided if an interaction is suspected.", "mechanism_text": "Metabolism", "recommendation": "Patients receiving eliglustat with CYP450 3A4 inducers should be monitored for potentially diminished pharmacologic response to eliglustat.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97307/", "reference_text": "[1] \"Product Information. Cerdelga (eliglustat).\" Genzyme Corporation, Cambridge, MA.[2] \"Product Information. Cerdelga (eliglustat).\" Genzyme Corporation, Cambridge, MA.", "alternatives_a": "Salicylic acid, Selenium Sulfide, Thiabendazole, Nystatin, Ciclopirox, Econazole, Flucytosine, Tioconazole, Chlorphenesin", "alternatives_b": "Teduglutide, Fosdenopterin, Miglustat, Imiglucerase, Asfotase alfa, Glycerol phenylbutyrate, Pegvaliase, Triethylenetetramine, Sapropterin, Zinc acetate, Phenylbutyric acid, More", "updated_at": 1767369485}, {"id": 97204, "ingredient1": "Haloperidol", "ingredient2": "Eliglustat", "severity": "Moderate", "effect": "Coadministration with eliglustat may increase the plasma concentrations of drugs that are primarily metabolized by CYP450 2D6.", "source": "DDInter", "management_text": "Caution is advised if eliglustat is used concomitantly with medications that undergo metabolism primarily by CYP450 2D6, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever eliglustat is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if eliglustat is used concomitantly with medications that undergo metabolism primarily by CYP450 2D6, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97308/", "reference_text": "[1] \"Product Information. Cerdelga (eliglustat).\" Genzyme Corporation, Cambridge, MA.[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] \"Product Information. Cerdelga (eliglustat).\" Genzyme Corporation, Cambridge, MA.[5] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[6] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[7] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[8] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.", "alternatives_a": "Quetiapine, Asenapine, Promazine, Prochlorperazine, Thiothixene, Pimavanserin, Lumateperone, Ziprasidone, Olanzapine, Trifluoperazine, Amisulpride, More", "alternatives_b": "Lipoic acid, Triheptanoin, Teduglutide, Fosdenopterin, Triethylenetetramine, Miglustat, Sapropterin, Zinc acetate, Nitisinone, Levocarnitine, Laronidase, More", "updated_at": 1767369485}, {"id": 97205, "ingredient1": "Ibutilide", "ingredient2": "Eliglustat", "severity": "Major", "effect": "Like other class III antiarrhythmic agents, ibutilide can cause dose-related QT interval prolongation. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Caution is recommended if ibutilide is used in combination with other drugs that can prolong the QT interval. Ibutilide should only be administered in a setting of continuous ECG monitoring and by personnel trained in identification and treatment of acute ventricular arrhythmias, particularly polymorphic ventricular tachycardia such as torsade de pointes.", "mechanism_text": "Synergism", "recommendation": "Caution is recommended if ibutilide is used in combination with other drugs that can prolong the QT interval.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97309/", "reference_text": "[1] Cerner Multum, Inc. \"Australian Product Information.\" O 0[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Corvert (ibutilide).\" Pharmacia and Upjohn, Kalamazoo, MI.[4] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"", "alternatives_a": "Lidocaine, Moricizine, Bretylium, Tocainide", "alternatives_b": "Teduglutide, Lonafarnib, Fosdenopterin, Miglustat, Imiglucerase, Asfotase alfa, Glycerol phenylbutyrate, Pegvaliase, Triethylenetetramine, Sapropterin, Zinc acetate, More", "updated_at": 1767369485}, {"id": 97206, "ingredient1": "Idarubicin", "ingredient2": "Eliglustat", "severity": "Moderate", "effect": "Coadministration with inhibitors of P-glycoprotein (P-gp) may increase the plasma concentrations of daunorubicin and idarubicin, both of which are substrates of the efflux transporter also known as ABCB1 or MDR1. The interaction has been studied with cyclosporine, a potent P-gp inhibitor, in attempt to overcome multidrug resistance in MDR1-overexpressing tumors.", "source": "DDInter", "management_text": "Caution is advised if daunorubicin or idarubicin is prescribed in combination with a P-gp inhibitor. Patients should be closely monitored for increased adverse effects including cardiotoxicity and myelosuppression.", "mechanism_text": "Absorption", "recommendation": "Caution is advised if daunorubicin or idarubicin is prescribed in combination with a P-gp inhibitor.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97310/", "reference_text": "[1] \"Product Information. Daunoxome (daunorubicin liposomal).\" Nexstar Pharmaceuticals Inc, Boulder, CO.[2] \"Product Information. Idamycin (idarubicin).\" Pharmacia and Upjohn, Kalamazoo, MI.[3] \"Multum Information Services, Inc. Expert Review Panel\"[4] \"Product Information. Cerubidine (daunorubicin).\" Wyeth-Ayerst Laboratories, Philadelphia, PA.[5] \"Product Information. Incivek (telaprevir).\" Vertex Pharmaceuticals, Cambridge, MA.", "alternatives_a": "Valrubicin, Plicamycin, Ixabepilone, Bleomycin, Mitomycin, Dactinomycin", "alternatives_b": "Teduglutide, Lonafarnib, Fosdenopterin, Miglustat, Imiglucerase, Asfotase alfa, Glycerol phenylbutyrate, Pegvaliase, Triethylenetetramine, Sapropterin, Zinc acetate, More", "updated_at": 1767369485}, {"id": 97207, "ingredient1": "Idelalisib", "ingredient2": "Eliglustat", "severity": "Major", "effect": "Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of eliglustat, which is primarily metabolized by CYP450 2D6 and, to a lesser extent, CYP450 3A4. Eliglustat at substantially elevated plasma concentrations is predicted to cause prolongation of the PR, QTc and QRS cardiac intervals, which may increase the risk of bradycardia, atrioventricular block, cardiac arrest, and serious ventricular arrhythmias such as torsade de pointes.", "source": "DDInter", "management_text": "The use of eliglustat with a potent CYP450 3A4 inhibitor is considered contraindicated in CYP450 2D6 poor metabolizers (PMs) and intermediate metabolizers (IMs). The contraindication is extended to extensive metabolizers (EMs) when a moderate or potent CYP450 2D6 inhibitor is given concomitantly with a moderate or potent CYP450 3A4 inhibitor. In the absence of a concomitant CYP450 2D6 inhibitor, eliglustat may be prescribed at a reduced dosage of 84 mg once daily to EMs treated with a potent CYP450 3A4 inhibitor. Potent CYP450 3A4 inhibitors include itraconazole, ketoconazole, posaconazole, voriconazole, conivaptan, ceritinib, idelalisib, mibefradil, nefazodone, cobicistat, delavirdine, protease inhibitors, and ketolide and certain macrolide antibiotics. Potent and moderate CYP450 2D6 inhibitors include abiraterone, bupropion, celecoxib, cimetidine, cinacalcet, clobazam, darifenacin, diphenhydramine, dronedarone, duloxetine, flecainide, fluoxetine, methotrimeprazine, mirabegron, paroxetine, propafenone, propoxyphene, quinidine, ranolazine, sertraline, and terbinafine. Some drugs such as cobicistat, delavirdine, mibefradil, and ritonavir are dual CYP450 3A4 and 2D6 inhibitors, and they should not be used with eliglustat in any patient regardless of their CYP450 2D6 metabolizer status.", "mechanism_text": "Metabolism", "recommendation": "The use of eliglustat with a potent CYP450 3A4 inhibitor is considered contraindicated in CYP450 2D6 poor metabolizers (PMs) and intermediate metabolizers (IMs).", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97311/", "reference_text": "[1] Cerner Multum, Inc. \"Australian Product Information.\" O 0[2] \"Product Information. Sporanox (itraconazole).\" Janssen Pharmaceutica, Titusville, NJ.[3] \"Product Information. Cerdelga (eliglustat).\" Genzyme Corporation, Cambridge, MA.[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] \"Product Information. Cerdelga (eliglustat).\" Genzyme Corporation, Cambridge, MA.[6] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[7] \"Product Information. VFEND (voriconazole).\" Pfizer U.S. Pharmaceuticals, New York, NY.", "alternatives_a": "Lipoic acid, Triheptanoin, Teduglutide, Fosdenopterin, Triethylenetetramine, Miglustat, Sapropterin, Zinc acetate, Levocarnitine, Laronidase, Imiglucerase, More", "alternatives_b": "Acalabrutinib, Tepotinib, Avapritinib, Selumetinib, Vandetanib, Capmatinib, Ibrutinib, Tivozanib, Zanubrutinib, Axitinib, Sunitinib, More", "updated_at": 1767369485}, {"id": 97208, "ingredient1": "Iloperidone", "ingredient2": "Eliglustat", "severity": "Moderate", "effect": "Coadministration with eliglustat may increase the plasma concentrations of drugs that are primarily metabolized by CYP450 2D6.", "source": "DDInter", "management_text": "Caution is advised if eliglustat is used concomitantly with medications that undergo metabolism primarily by CYP450 2D6, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever eliglustat is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if eliglustat is used concomitantly with medications that undergo metabolism primarily by CYP450 2D6, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97312/", "reference_text": "[1] \"Product Information. Cerdelga (eliglustat).\" Genzyme Corporation, Cambridge, MA.[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] \"Product Information. Cerdelga (eliglustat).\" Genzyme Corporation, Cambridge, MA.[5] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[6] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[7] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[8] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.", "alternatives_a": "Quetiapine, Asenapine, Promazine, Prochlorperazine, Thiothixene, Pimavanserin, Lumateperone, Ziprasidone, Olanzapine, Trifluoperazine, Amisulpride, More", "alternatives_b": "Teduglutide, Fosdenopterin, Miglustat, Imiglucerase, Asfotase alfa, Pegvaliase, Triethylenetetramine, Sapropterin, Zinc acetate, Phenylbutyric acid, Agalsidase beta, More", "updated_at": 1767369485}, {"id": 97209, "ingredient1": "Imatinib", "ingredient2": "Eliglustat", "severity": "Major", "effect": "Coadministration with moderate inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of eliglustat, which is primarily metabolized by CYP450 2D6 and, to a lesser extent, CYP450 3A4. Eliglustat at substantially elevated plasma concentrations is predicted to cause prolongation of the PR, QTc and QRS cardiac intervals, which may increase the risk of bradycardia, atrioventricular block, cardiac arrest, and serious ventricular arrhythmias such as torsade de pointes.", "source": "DDInter", "management_text": "The use of eliglustat in combination with one or more drugs that may result in moderate inhibition of CYP450 3A4 and moderate to potent inhibition of CYP450 2D6 is considered contraindicated in CYP450 2D6 extensive metabolizers (EMs) and intermediate metabolizers (IMs). In the absence of a concomitant CYP450 2D6 inhibitor, eliglustat may be prescribed at a reduced dosage of 84 mg once daily to EMs treated with a moderate CYP450 3A4 inhibitor. However, eliglustat should not be used with a moderate CYP450 3A4 inhibitor in CYP450 2D6 IMs or poor metabolizers (PMs). Moderate CYP450 3A4 inhibitors include aprepitant, ciprofloxacin, clotrimazole, crizotinib, darunavir, diltiazem, dronedarone, fluconazole, fusidic acid, imatinib, isavuconazonium, miconazole, mifepristone, netupitant, quinupristin-dalfopristin, ranolazine, stiripentol, and verapamil. Potent and moderate CYP450 2D6 inhibitors include abiraterone, bupropion, celecoxib, cimetidine, cinacalcet, clobazam, darifenacin, diphenhydramine, duloxetine, fluoxetine, methotrimeprazine, mirabegron, paroxetine, propoxyphene, quinidine, ranolazine, sertraline, stiripentol, and terbinafine.", "mechanism_text": "Metabolism", "recommendation": "The use of eliglustat in combination with one or more drugs that may result in moderate inhibition of CYP450 3A4 and moderate to potent inhibition of CYP450 2D6 is considered contraindicated in CYP450 2D6 extensive metabolizers (EMs) and intermediate metabolizers (IMs).", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97313/", "reference_text": "[1] \"Product Information. Cerdelga (eliglustat).\" Genzyme Corporation, Cambridge, MA.[2] \"Product Information. Cerdelga (eliglustat).\" Genzyme Corporation, Cambridge, MA.", "alternatives_a": "Acalabrutinib, Tepotinib, Avapritinib, Selumetinib, Vandetanib, Capmatinib, Ibrutinib, Tivozanib, Zanubrutinib, Axitinib, Sunitinib, More", "alternatives_b": "Lipoic acid, Triheptanoin, Teduglutide, Fosdenopterin, Triethylenetetramine, Miglustat, Sapropterin, Zinc acetate, Levocarnitine, Laronidase, Imiglucerase, More", "updated_at": 1767369485}, {"id": 97210, "ingredient1": "Imipramine", "ingredient2": "Eliglustat", "severity": "Moderate", "effect": "Coadministration with eliglustat may increase the plasma concentrations of drugs that are primarily metabolized by CYP450 2D6.", "source": "DDInter", "management_text": "Caution is advised if eliglustat is used concomitantly with medications that undergo metabolism primarily by CYP450 2D6, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever eliglustat is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if eliglustat is used concomitantly with medications that undergo metabolism primarily by CYP450 2D6, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97314/", "reference_text": "[1] \"Product Information. Cerdelga (eliglustat).\" Genzyme Corporation, Cambridge, MA.[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] \"Product Information. Cerdelga (eliglustat).\" Genzyme Corporation, Cambridge, MA.[5] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[6] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[7] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[8] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.", "alternatives_a": "Phenelzine, Citalopram, Tranylcypromine, Desvenlafaxine, Isocarboxazid, Oxitriptan, Tryptophan, Milnacipran, Levomilnacipran, Vilazodone, Esketamine, More", "alternatives_b": "Lipoic acid, Triheptanoin, Teduglutide, Fosdenopterin, Triethylenetetramine, Miglustat, Sapropterin, Zinc acetate, Nitisinone, Laronidase, Imiglucerase, More", "updated_at": 1767369485}, {"id": 97211, "ingredient1": "Indacaterol", "ingredient2": "Eliglustat", "severity": "Minor", "effect": "Coadministration with inhibitors of CYP450 3A4 and/or P-glycoprotein may increase the systemic exposure to indacaterol following oral inhalation, as it is a substrate of both the isoenzyme and efflux transporter.", "source": "DDInter", "management_text": "-", "mechanism_text": "Metabolism", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97315/", "reference_text": "[1] \"Product Information. Arcapta Neohaler (indacaterol).\" Novartis Pharmaceuticals, East Hanover, NJ.", "alternatives_a": "Formoterol, Cromoglicic acid, Ipratropium, Isoprenaline, Tiotropium, Beclomethasone dipropionate, Terbutaline, Budesonide, Glycopyrronium, Aclidinium, Mometasone, More", "alternatives_b": "Teduglutide, Fosdenopterin, Miglustat, Imiglucerase, Asfotase alfa, Glycerol phenylbutyrate, Pegvaliase, Triethylenetetramine, Sapropterin, Zinc acetate, Phenylbutyric acid, More", "updated_at": 1767369485}, {"id": 97212, "ingredient1": "Indinavir", "ingredient2": "Eliglustat", "severity": "Major", "effect": "Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of eliglustat, which is primarily metabolized by CYP450 2D6 and, to a lesser extent, CYP450 3A4. Eliglustat at substantially elevated plasma concentrations is predicted to cause prolongation of the PR, QTc and QRS cardiac intervals, which may increase the risk of bradycardia, atrioventricular block, cardiac arrest, and serious ventricular arrhythmias such as torsade de pointes.", "source": "DDInter", "management_text": "The use of eliglustat with a potent CYP450 3A4 inhibitor is considered contraindicated in CYP450 2D6 poor metabolizers (PMs) and intermediate metabolizers (IMs). The contraindication is extended to extensive metabolizers (EMs) when a moderate or potent CYP450 2D6 inhibitor is given concomitantly with a moderate or potent CYP450 3A4 inhibitor. In the absence of a concomitant CYP450 2D6 inhibitor, eliglustat may be prescribed at a reduced dosage of 84 mg once daily to EMs treated with a potent CYP450 3A4 inhibitor. Potent CYP450 3A4 inhibitors include itraconazole, ketoconazole, posaconazole, voriconazole, conivaptan, ceritinib, idelalisib, mibefradil, nefazodone, cobicistat, delavirdine, protease inhibitors, and ketolide and certain macrolide antibiotics. Potent and moderate CYP450 2D6 inhibitors include abiraterone, bupropion, celecoxib, cimetidine, cinacalcet, clobazam, darifenacin, diphenhydramine, dronedarone, duloxetine, flecainide, fluoxetine, methotrimeprazine, mirabegron, paroxetine, propafenone, propoxyphene, quinidine, ranolazine, sertraline, and terbinafine. Some drugs such as cobicistat, delavirdine, mibefradil, and ritonavir are dual CYP450 3A4 and 2D6 inhibitors, and they should not be used with eliglustat in any patient regardless of their CYP450 2D6 metabolizer status.", "mechanism_text": "Metabolism", "recommendation": "The use of eliglustat with a potent CYP450 3A4 inhibitor is considered contraindicated in CYP450 2D6 poor metabolizers (PMs) and intermediate metabolizers (IMs).", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97316/", "reference_text": "[1] Cerner Multum, Inc. \"Australian Product Information.\" O 0[2] \"Product Information. Sporanox (itraconazole).\" Janssen Pharmaceutica, Titusville, NJ.[3] \"Product Information. Cerdelga (eliglustat).\" Genzyme Corporation, Cambridge, MA.[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] \"Product Information. Cerdelga (eliglustat).\" Genzyme Corporation, Cambridge, MA.[6] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[7] \"Product Information. VFEND (voriconazole).\" Pfizer U.S. Pharmaceuticals, New York, NY.", "alternatives_a": "Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Simeprevir, Cabotegravir, Valaciclovir, Zanamivir, Velpatasvir, Rilpivirine, Dolutegravir, More", "alternatives_b": "Teduglutide, Fosdenopterin, Miglustat, Imiglucerase, Asfotase alfa, Glycerol phenylbutyrate, Pegvaliase, Triethylenetetramine, Sapropterin, Zinc acetate, Phenylbutyric acid, More", "updated_at": 1767369485}, {"id": 97213, "ingredient1": "Isavuconazonium", "ingredient2": "Eliglustat", "severity": "Major", "effect": "Coadministration with moderate inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of eliglustat, which is primarily metabolized by CYP450 2D6 and, to a lesser extent, CYP450 3A4. Eliglustat at substantially elevated plasma concentrations is predicted to cause prolongation of the PR, QTc and QRS cardiac intervals, which may increase the risk of bradycardia, atrioventricular block, cardiac arrest, and serious ventricular arrhythmias such as torsade de pointes.", "source": "DDInter", "management_text": "The use of eliglustat in combination with one or more drugs that may result in moderate inhibition of CYP450 3A4 and moderate to potent inhibition of CYP450 2D6 is considered contraindicated in CYP450 2D6 extensive metabolizers (EMs) and intermediate metabolizers (IMs). In the absence of a concomitant CYP450 2D6 inhibitor, eliglustat may be prescribed at a reduced dosage of 84 mg once daily to EMs treated with a moderate CYP450 3A4 inhibitor. However, eliglustat should not be used with a moderate CYP450 3A4 inhibitor in CYP450 2D6 IMs or poor metabolizers (PMs). Moderate CYP450 3A4 inhibitors include aprepitant, ciprofloxacin, clotrimazole, crizotinib, darunavir, diltiazem, dronedarone, fluconazole, fusidic acid, imatinib, isavuconazonium, miconazole, mifepristone, netupitant, quinupristin-dalfopristin, ranolazine, stiripentol, and verapamil. Potent and moderate CYP450 2D6 inhibitors include abiraterone, bupropion, celecoxib, cimetidine, cinacalcet, clobazam, darifenacin, diphenhydramine, duloxetine, fluoxetine, methotrimeprazine, mirabegron, paroxetine, propoxyphene, quinidine, ranolazine, sertraline, stiripentol, and terbinafine.", "mechanism_text": "Metabolism", "recommendation": "The use of eliglustat in combination with one or more drugs that may result in moderate inhibition of CYP450 3A4 and moderate to potent inhibition of CYP450 2D6 is considered contraindicated in CYP450 2D6 extensive metabolizers (EMs) and intermediate metabolizers (IMs).", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97317/", "reference_text": "[1] \"Product Information. Cerdelga (eliglustat).\" Genzyme Corporation, Cambridge, MA.[2] \"Product Information. Cerdelga (eliglustat).\" Genzyme Corporation, Cambridge, MA.", "alternatives_a": "Teduglutide, Fosdenopterin, Miglustat, Imiglucerase, Asfotase alfa, Glycerol phenylbutyrate, Pegvaliase, Triethylenetetramine, Sapropterin, Zinc acetate, Phenylbutyric acid, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 97214, "ingredient1": "Isoniazid", "ingredient2": "Eliglustat", "severity": "Moderate", "effect": "Coadministration with weak inhibitors of CYP450 3A4 may increase the plasma concentrations of eliglustat, which is primarily metabolized by CYP450 2D6 and, to a lesser extent, CYP450 3A4. Eliglustat at substantially elevated plasma concentrations is predicted to cause prolongation of the PR, QTc and QRS cardiac intervals, which may increase the risk of bradycardia, atrioventricular block, cardiac arrest, and serious ventricular arrhythmias such as torsade de pointes.", "source": "DDInter", "management_text": "Concomitant use of eliglustat with weak CYP450 3A4 inhibitors such as chloramphenicol, cyclosporine, danazol, dasatinib, ethinyl estradiol, fluvoxamine, goldenseal, isoniazid, ivacaftor, lapatinib, lomitapide, nifedipine, nilotinib, palbociclib, pazopanib, suvorexant, ticagrelor, and zafirlukast is not recommended in CYP450 2D6 poor metabolizers. No dosage adjustment for eliglustat is necessary when used with weak CYP450 3A4 inhibitors in extensive or intermediate metabolizers.", "mechanism_text": "Metabolism", "recommendation": "Concomitant use of eliglustat with weak CYP450 3A4 inhibitors such as chloramphenicol, cyclosporine, danazol, dasatinib, ethinyl estradiol, fluvoxamine, goldenseal, isoniazid, ivacaftor, lapatinib, lomitapide, nifedipine, nilotinib, palbociclib, pazopanib, suvorexant, ticagrelor, and zafirlukast is not recommended in CYP450 2D6 poor metabolizers.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97318/", "reference_text": "[1] \"Product Information. Cerdelga (eliglustat).\" Genzyme Corporation, Cambridge, MA.[2] \"Product Information. Cerdelga (eliglustat).\" Genzyme Corporation, Cambridge, MA.", "alternatives_a": "Capreomycin, Pyrazinamide, Rifamycin, Bedaquiline, Sulfamethoxazole, Streptomycin, Trimethoprim, Cycloserine, Ethambutol, Pyridoxine, Ethionamide, More", "alternatives_b": "Teduglutide, Fosdenopterin, Miglustat, Imiglucerase, Asfotase alfa, Glycerol phenylbutyrate, Pegvaliase, Triethylenetetramine, Sapropterin, Zinc acetate, Phenylbutyric acid, More", "updated_at": 1767369485}, {"id": 97215, "ingredient1": "Itraconazole", "ingredient2": "Eliglustat", "severity": "Major", "effect": "Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of eliglustat, which is primarily metabolized by CYP450 2D6 and, to a lesser extent, CYP450 3A4. Eliglustat at substantially elevated plasma concentrations is predicted to cause prolongation of the PR, QTc and QRS cardiac intervals, which may increase the risk of bradycardia, atrioventricular block, cardiac arrest, and serious ventricular arrhythmias such as torsade de pointes.", "source": "DDInter", "management_text": "The use of eliglustat with a potent CYP450 3A4 inhibitor is considered contraindicated in CYP450 2D6 poor metabolizers (PMs) and intermediate metabolizers (IMs). The contraindication is extended to extensive metabolizers (EMs) when a moderate or potent CYP450 2D6 inhibitor is given concomitantly with a moderate or potent CYP450 3A4 inhibitor. In the absence of a concomitant CYP450 2D6 inhibitor, eliglustat may be prescribed at a reduced dosage of 84 mg once daily to EMs treated with a potent CYP450 3A4 inhibitor. Potent CYP450 3A4 inhibitors include itraconazole, ketoconazole, posaconazole, voriconazole, conivaptan, ceritinib, idelalisib, mibefradil, nefazodone, cobicistat, delavirdine, protease inhibitors, and ketolide and certain macrolide antibiotics. Potent and moderate CYP450 2D6 inhibitors include abiraterone, bupropion, celecoxib, cimetidine, cinacalcet, clobazam, darifenacin, diphenhydramine, dronedarone, duloxetine, flecainide, fluoxetine, methotrimeprazine, mirabegron, paroxetine, propafenone, propoxyphene, quinidine, ranolazine, sertraline, and terbinafine. Some drugs such as cobicistat, delavirdine, mibefradil, and ritonavir are dual CYP450 3A4 and 2D6 inhibitors, and they should not be used with eliglustat in any patient regardless of their CYP450 2D6 metabolizer status.", "mechanism_text": "Metabolism", "recommendation": "The use of eliglustat with a potent CYP450 3A4 inhibitor is considered contraindicated in CYP450 2D6 poor metabolizers (PMs) and intermediate metabolizers (IMs).", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97319/", "reference_text": "[1] Cerner Multum, Inc. \"Australian Product Information.\" O 0[2] \"Product Information. Sporanox (itraconazole).\" Janssen Pharmaceutica, Titusville, NJ.[3] \"Product Information. Cerdelga (eliglustat).\" Genzyme Corporation, Cambridge, MA.[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] \"Product Information. Cerdelga (eliglustat).\" Genzyme Corporation, Cambridge, MA.[6] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[7] \"Product Information. VFEND (voriconazole).\" Pfizer U.S. Pharmaceuticals, New York, NY.", "alternatives_a": "Caspofungin, Micafungin, Amphotericin B, Oteseconazole, Flucytosine, Anidulafungin", "alternatives_b": "Teduglutide, Fosdenopterin, Miglustat, Imiglucerase, Asfotase alfa, Glycerol phenylbutyrate, Pegvaliase, Triethylenetetramine, Sapropterin, Zinc acetate, Phenylbutyric acid, More", "updated_at": 1767369485}, {"id": 97216, "ingredient1": "Eliglustat", "ingredient2": "Ivosidenib", "severity": "Moderate", "effect": "Coadministration with inducers of CYP450 3A4 and/or P-glycoprotein (P-gp) may decrease the plasma concentrations of eliglustat, which is primarily metabolized by CYP450 2D6 and, to a lesser extent, CYP450 3A4. Eliglustat is also a substrate of P-gp efflux transporter.", "source": "DDInter", "management_text": "Patients receiving eliglustat with CYP450 3A4 inducers should be monitored for potentially diminished pharmacologic response to eliglustat. Concomitant use should be avoided if an interaction is suspected.", "mechanism_text": "Metabolism", "recommendation": "Patients receiving eliglustat with CYP450 3A4 inducers should be monitored for potentially diminished pharmacologic response to eliglustat.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97320/", "reference_text": "[1] \"Product Information. Cerdelga (eliglustat).\" Genzyme Corporation, Cambridge, MA.[2] \"Product Information. Cerdelga (eliglustat).\" Genzyme Corporation, Cambridge, MA.", "alternatives_a": "Teduglutide, Fosdenopterin, Miglustat, Imiglucerase, Asfotase alfa, Glycerol phenylbutyrate, Pegvaliase, Triethylenetetramine, Sapropterin, Zinc acetate, Phenylbutyric acid, More", "alternatives_b": "Pertuzumab, Olaparib, Oxaliplatin, Bortezomib, Tisagenlecleucel, Aminolevulinic acid, Omacetaxine mepesuccinate, Altretamine, Tagraxofusp, Pegaspargase, Ixazomib, More", "updated_at": 1767369485}, {"id": 97217, "ingredient1": "Eliglustat", "ingredient2": "Ketoconazole", "severity": "Major", "effect": "Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of eliglustat, which is primarily metabolized by CYP450 2D6 and, to a lesser extent, CYP450 3A4. Eliglustat at substantially elevated plasma concentrations is predicted to cause prolongation of the PR, QTc and QRS cardiac intervals, which may increase the risk of bradycardia, atrioventricular block, cardiac arrest, and serious ventricular arrhythmias such as torsade de pointes.", "source": "DDInter", "management_text": "The use of eliglustat with a potent CYP450 3A4 inhibitor is considered contraindicated in CYP450 2D6 poor metabolizers (PMs) and intermediate metabolizers (IMs). The contraindication is extended to extensive metabolizers (EMs) when a moderate or potent CYP450 2D6 inhibitor is given concomitantly with a moderate or potent CYP450 3A4 inhibitor. In the absence of a concomitant CYP450 2D6 inhibitor, eliglustat may be prescribed at a reduced dosage of 84 mg once daily to EMs treated with a potent CYP450 3A4 inhibitor. Potent CYP450 3A4 inhibitors include itraconazole, ketoconazole, posaconazole, voriconazole, conivaptan, ceritinib, idelalisib, mibefradil, nefazodone, cobicistat, delavirdine, protease inhibitors, and ketolide and certain macrolide antibiotics. Potent and moderate CYP450 2D6 inhibitors include abiraterone, bupropion, celecoxib, cimetidine, cinacalcet, clobazam, darifenacin, diphenhydramine, dronedarone, duloxetine, flecainide, fluoxetine, methotrimeprazine, mirabegron, paroxetine, propafenone, propoxyphene, quinidine, ranolazine, sertraline, and terbinafine. Some drugs such as cobicistat, delavirdine, mibefradil, and ritonavir are dual CYP450 3A4 and 2D6 inhibitors, and they should not be used with eliglustat in any patient regardless of their CYP450 2D6 metabolizer status.", "mechanism_text": "Metabolism", "recommendation": "The use of eliglustat with a potent CYP450 3A4 inhibitor is considered contraindicated in CYP450 2D6 poor metabolizers (PMs) and intermediate metabolizers (IMs).", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97321/", "reference_text": "[1] Cerner Multum, Inc. \"Australian Product Information.\" O 0[2] \"Product Information. Sporanox (itraconazole).\" Janssen Pharmaceutica, Titusville, NJ.[3] \"Product Information. Cerdelga (eliglustat).\" Genzyme Corporation, Cambridge, MA.[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] \"Product Information. Cerdelga (eliglustat).\" Genzyme Corporation, Cambridge, MA.[6] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[7] \"Product Information. VFEND (voriconazole).\" Pfizer U.S. Pharmaceuticals, New York, NY.", "alternatives_a": "Tinidazole, Ascorbic acid, Hydroflumethiazide, Chlorothiazide, Metronidazole, Simeprevir, Rosuvastatin, Sulfadiazine, Lactic acid, Methazolamide, Amphotericin B, More", "alternatives_b": "Teduglutide, Fosdenopterin, Miglustat, Imiglucerase, Asfotase alfa, Glycerol phenylbutyrate, Pegvaliase, Triethylenetetramine, Sapropterin, Zinc acetate, Phenylbutyric acid, More", "updated_at": 1767369485}, {"id": 97218, "ingredient1": "Eliglustat", "ingredient2": "Lapatinib", "severity": "Moderate", "effect": "Coadministration with weak inhibitors of CYP450 3A4 may increase the plasma concentrations of eliglustat, which is primarily metabolized by CYP450 2D6 and, to a lesser extent, CYP450 3A4. Eliglustat at substantially elevated plasma concentrations is predicted to cause prolongation of the PR, QTc and QRS cardiac intervals, which may increase the risk of bradycardia, atrioventricular block, cardiac arrest, and serious ventricular arrhythmias such as torsade de pointes.", "source": "DDInter", "management_text": "Concomitant use of eliglustat with weak CYP450 3A4 inhibitors such as chloramphenicol, cyclosporine, danazol, dasatinib, ethinyl estradiol, fluvoxamine, goldenseal, isoniazid, ivacaftor, lapatinib, lomitapide, nifedipine, nilotinib, palbociclib, pazopanib, suvorexant, ticagrelor, and zafirlukast is not recommended in CYP450 2D6 poor metabolizers. No dosage adjustment for eliglustat is necessary when used with weak CYP450 3A4 inhibitors in extensive or intermediate metabolizers.", "mechanism_text": "Metabolism", "recommendation": "Concomitant use of eliglustat with weak CYP450 3A4 inhibitors such as chloramphenicol, cyclosporine, danazol, dasatinib, ethinyl estradiol, fluvoxamine, goldenseal, isoniazid, ivacaftor, lapatinib, lomitapide, nifedipine, nilotinib, palbociclib, pazopanib, suvorexant, ticagrelor, and zafirlukast is not recommended in CYP450 2D6 poor metabolizers.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97322/", "reference_text": "[1] \"Product Information. Cerdelga (eliglustat).\" Genzyme Corporation, Cambridge, MA.[2] \"Product Information. Cerdelga (eliglustat).\" Genzyme Corporation, Cambridge, MA.", "alternatives_a": "Acalabrutinib, Tepotinib, Avapritinib, Selumetinib, Vandetanib, Capmatinib, Ibrutinib, Tivozanib, Zanubrutinib, Axitinib, Sunitinib, More", "alternatives_b": "Lipoic acid, Triheptanoin, Teduglutide, Fosdenopterin, Triethylenetetramine, Miglustat, Sapropterin, Zinc acetate, Levocarnitine, Laronidase, Imiglucerase, More", "updated_at": 1767369485}, {"id": 97219, "ingredient1": "Eliglustat", "ingredient2": "Larotrectinib", "severity": "Moderate", "effect": "Coadministration with weak inhibitors of CYP450 3A4 may increase the plasma concentrations of eliglustat, which is primarily metabolized by CYP450 2D6 and, to a lesser extent, CYP450 3A4. Eliglustat at substantially elevated plasma concentrations is predicted to cause prolongation of the PR, QTc and QRS cardiac intervals, which may increase the risk of bradycardia, atrioventricular block, cardiac arrest, and serious ventricular arrhythmias such as torsade de pointes.", "source": "DDInter", "management_text": "Concomitant use of eliglustat with weak CYP450 3A4 inhibitors such as chloramphenicol, cyclosporine, danazol, dasatinib, ethinyl estradiol, fluvoxamine, goldenseal, isoniazid, ivacaftor, lapatinib, lomitapide, nifedipine, nilotinib, palbociclib, pazopanib, suvorexant, ticagrelor, and zafirlukast is not recommended in CYP450 2D6 poor metabolizers. No dosage adjustment for eliglustat is necessary when used with weak CYP450 3A4 inhibitors in extensive or intermediate metabolizers.", "mechanism_text": "Metabolism", "recommendation": "Concomitant use of eliglustat with weak CYP450 3A4 inhibitors such as chloramphenicol, cyclosporine, danazol, dasatinib, ethinyl estradiol, fluvoxamine, goldenseal, isoniazid, ivacaftor, lapatinib, lomitapide, nifedipine, nilotinib, palbociclib, pazopanib, suvorexant, ticagrelor, and zafirlukast is not recommended in CYP450 2D6 poor metabolizers.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97323/", "reference_text": "[1] \"Product Information. Cerdelga (eliglustat).\" Genzyme Corporation, Cambridge, MA.[2] \"Product Information. Cerdelga (eliglustat).\" Genzyme Corporation, Cambridge, MA.", "alternatives_a": "Lipoic acid, Triheptanoin, Teduglutide, Fosdenopterin, Triethylenetetramine, Miglustat, Sapropterin, Zinc acetate, Levocarnitine, Laronidase, Imiglucerase, More", "alternatives_b": "Acalabrutinib, Tepotinib, Avapritinib, Selumetinib, Vandetanib, Capmatinib, Ibrutinib, Tivozanib, Zanubrutinib, Axitinib, Sunitinib, More", "updated_at": 1767369485}, {"id": 97220, "ingredient1": "Eliglustat", "ingredient2": "Lasmiditan", "severity": "Moderate", "effect": "Coadministration with lasmiditan may increase the plasma concentrations of drugs that are substrates of the P-glycoprotein (P-gp) and/or breast cancer resistance protein (BCRP) transporters. The proposed mechanism, based on in vitro data, involves decreased clearance due to inhibition of P-gp and BCRP by lasmiditan.", "source": "DDInter", "management_text": "Concomitant use of lasmiditan with drugs that are P-gp and/or BCRP substrates should be avoided when possible. If coadministration is required, patients should be carefully monitored for increased adverse reactions of these drugs and dosing adjusted as necessary.", "mechanism_text": "Distribution", "recommendation": "Concomitant use of lasmiditan with drugs that are P-gp and/or BCRP substrates should be avoided when possible.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97324/", "reference_text": "[1] \"Product Information. Reyvow (lasmiditan).\" Lilly, Eli and Company, Indianapolis, IN.", "alternatives_a": "Teduglutide, Lonafarnib, Fosdenopterin, Miglustat, Imiglucerase, Asfotase alfa, Glycerol phenylbutyrate, Pegvaliase, Triethylenetetramine, Sapropterin, Zinc acetate, More", "alternatives_b": "Frovatriptan, Dihydroergotamine, Rimegepant, Eptinezumab, Atogepant, Eletriptan, Rizatriptan, Ergotamine, Clonidine, Naratriptan, Galcanezumab, More", "updated_at": 1767369485}, {"id": 97221, "ingredient1": "Eliglustat", "ingredient2": "Lefamulin", "severity": "Moderate", "effect": "When administered orally, lefamulin may increase the plasma concentrations of drugs that are primarily metabolized by CYP450 3A4. Based on interaction with midazolam, a sensitive CYP450 3A4 substrate, lefamulin may be a moderate CYP450 3A4 inhibitor. When oral midazolam was administered concomitantly with and at 2 or 4 hours after administration of lefamulin tablets, mean midazolam peak plasma concentration (Cmax) and systemic exposure (AUC) increased by approximately 100% and 200%, respectively.", "source": "DDInter", "management_text": "Caution is advised when oral lefamulin is used with drugs that undergo metabolism via CYP450 3A4, particularly sensitive CYP450 3A4 substrates or those that demonstrate a narrow therapeutic index (e.g., ergot alkaloids, colchicine, fentanyl, macrolide immunosuppressants, midazolam, triazolam, vardenafil, vinca alkaloids). Dosage adjustments as well as clinical and laboratory monitoring may be appropriate whenever oral lefamulin is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when oral lefamulin is used with drugs that undergo metabolism via CYP450 3A4, particularly sensitive CYP450 3A4 substrates or those that demonstrate a narrow therapeutic index (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97325/", "reference_text": "[1] \"Product Information. Xenleta (lefamulin).\" Nabriva Therapeutics US, Inc., King of Prussia, PA.[2] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[3] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[4] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[5] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[6] \"Product Information. Xenleta (lefamulin).\" Nabriva Therapeutics US, Inc., King of Prussia, PA.", "alternatives_a": "Lipoic acid, Triheptanoin, Teduglutide, Fosdenopterin, Triethylenetetramine, Miglustat, Sapropterin, Zinc acetate, Levocarnitine, Laronidase, Imiglucerase, More", "alternatives_b": "Tinidazole, Linezolid, Bacitracin, Oritavancin, Polymyxin B, Daptomycin, Vancomycin, Metronidazole, Telavancin, Methenamine, Spectinomycin, More", "updated_at": 1767369485}, {"id": 97222, "ingredient1": "Eliglustat", "ingredient2": "Lemborexant", "severity": "Moderate", "effect": "Coadministration with weak inhibitors of CYP450 3A4 may increase the plasma concentrations of eliglustat, which is primarily metabolized by CYP450 2D6 and, to a lesser extent, CYP450 3A4. Eliglustat at substantially elevated plasma concentrations is predicted to cause prolongation of the PR, QTc and QRS cardiac intervals, which may increase the risk of bradycardia, atrioventricular block, cardiac arrest, and serious ventricular arrhythmias such as torsade de pointes.", "source": "DDInter", "management_text": "Concomitant use of eliglustat with weak CYP450 3A4 inhibitors such as chloramphenicol, cyclosporine, danazol, dasatinib, ethinyl estradiol, fluvoxamine, goldenseal, isoniazid, ivacaftor, lapatinib, lomitapide, nifedipine, nilotinib, palbociclib, pazopanib, suvorexant, ticagrelor, and zafirlukast is not recommended in CYP450 2D6 poor metabolizers. No dosage adjustment for eliglustat is necessary when used with weak CYP450 3A4 inhibitors in extensive or intermediate metabolizers.", "mechanism_text": "Metabolism", "recommendation": "Concomitant use of eliglustat with weak CYP450 3A4 inhibitors such as chloramphenicol, cyclosporine, danazol, dasatinib, ethinyl estradiol, fluvoxamine, goldenseal, isoniazid, ivacaftor, lapatinib, lomitapide, nifedipine, nilotinib, palbociclib, pazopanib, suvorexant, ticagrelor, and zafirlukast is not recommended in CYP450 2D6 poor metabolizers.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97326/", "reference_text": "[1] \"Product Information. Cerdelga (eliglustat).\" Genzyme Corporation, Cambridge, MA.[2] \"Product Information. Cerdelga (eliglustat).\" Genzyme Corporation, Cambridge, MA.", "alternatives_a": "Lipoic acid, Triheptanoin, Teduglutide, Fosdenopterin, Triethylenetetramine, Miglustat, Sapropterin, Zinc acetate, Levocarnitine, Laronidase, Imiglucerase, More", "alternatives_b": "Triazolam, Flurazepam, Methohexital, Zolpidem, Zaleplon, Dichloralphenazone, Valerian, Temazepam, Chloral hydrate, Quazepam, Paraldehyde, More", "updated_at": 1767369485}, {"id": 97223, "ingredient1": "Eliglustat", "ingredient2": "Lenalidomide", "severity": "Moderate", "effect": "Coadministration with eliglustat may increase the plasma concentrations of drugs that are substrates of the P-glycoprotein (P-gp) transporter. The proposed mechanism is decreased clearance in the intestine, liver, and/or kidney due to inhibition of P-glycoprotein-mediated drug efflux by eliglustat.", "source": "DDInter", "management_text": "Caution is advised when eliglustat is used concurrently with drugs that are known P-gp substrates, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever eliglustat is added to or withdrawn from therapy.", "mechanism_text": "Others", "recommendation": "Caution is advised when eliglustat is used concurrently with drugs that are known P-gp substrates, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97327/", "reference_text": "[1] \"Product Information. Cerdelga (eliglustat).\" Genzyme Corporation, Cambridge, MA.[2] \"Product Information. Cerdelga (eliglustat).\" Genzyme Corporation, Cambridge, MA.", "alternatives_a": "Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Methotrexate, More", "alternatives_b": "Teduglutide, Lonafarnib, Fosdenopterin, Miglustat, Imiglucerase, Asfotase alfa, Glycerol phenylbutyrate, Pegvaliase, Triethylenetetramine, Sapropterin, Zinc acetate, More", "updated_at": 1767369485}, {"id": 97224, "ingredient1": "Eliglustat", "ingredient2": "Letermovir", "severity": "Major", "effect": "Coadministration with moderate inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of eliglustat, which is primarily metabolized by CYP450 2D6 and, to a lesser extent, CYP450 3A4. Eliglustat at substantially elevated plasma concentrations is predicted to cause prolongation of the PR, QTc and QRS cardiac intervals, which may increase the risk of bradycardia, atrioventricular block, cardiac arrest, and serious ventricular arrhythmias such as torsade de pointes.", "source": "DDInter", "management_text": "The use of eliglustat in combination with one or more drugs that may result in moderate inhibition of CYP450 3A4 and moderate to potent inhibition of CYP450 2D6 is considered contraindicated in CYP450 2D6 extensive metabolizers (EMs) and intermediate metabolizers (IMs). In the absence of a concomitant CYP450 2D6 inhibitor, eliglustat may be prescribed at a reduced dosage of 84 mg once daily to EMs treated with a moderate CYP450 3A4 inhibitor. However, eliglustat should not be used with a moderate CYP450 3A4 inhibitor in CYP450 2D6 IMs or poor metabolizers (PMs). Moderate CYP450 3A4 inhibitors include aprepitant, ciprofloxacin, clotrimazole, crizotinib, darunavir, diltiazem, dronedarone, fluconazole, fusidic acid, imatinib, isavuconazonium, miconazole, mifepristone, netupitant, quinupristin-dalfopristin, ranolazine, stiripentol, and verapamil. Potent and moderate CYP450 2D6 inhibitors include abiraterone, bupropion, celecoxib, cimetidine, cinacalcet, clobazam, darifenacin, diphenhydramine, duloxetine, fluoxetine, methotrimeprazine, mirabegron, paroxetine, propoxyphene, quinidine, ranolazine, sertraline, stiripentol, and terbinafine.", "mechanism_text": "Metabolism", "recommendation": "The use of eliglustat in combination with one or more drugs that may result in moderate inhibition of CYP450 3A4 and moderate to potent inhibition of CYP450 2D6 is considered contraindicated in CYP450 2D6 extensive metabolizers (EMs) and intermediate metabolizers (IMs).", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97328/", "reference_text": "[1] \"Product Information. Cerdelga (eliglustat).\" Genzyme Corporation, Cambridge, MA.[2] \"Product Information. Cerdelga (eliglustat).\" Genzyme Corporation, Cambridge, MA.", "alternatives_a": "Teduglutide, Fosdenopterin, Miglustat, Imiglucerase, Asfotase alfa, Glycerol phenylbutyrate, Pegvaliase, Triethylenetetramine, Sapropterin, Zinc acetate, Phenylbutyric acid, More", "alternatives_b": "Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Simeprevir, Cabotegravir, Valaciclovir, Zanamivir, Velpatasvir, Rilpivirine, Dolutegravir, More", "updated_at": 1767369485}, {"id": 97225, "ingredient1": "Eliglustat", "ingredient2": "Levamlodipine", "severity": "Moderate", "effect": "Coadministration with weak inhibitors of CYP450 3A4 may increase the plasma concentrations of eliglustat, which is primarily metabolized by CYP450 2D6 and, to a lesser extent, CYP450 3A4. Eliglustat at substantially elevated plasma concentrations is predicted to cause prolongation of the PR, QTc and QRS cardiac intervals, which may increase the risk of bradycardia, atrioventricular block, cardiac arrest, and serious ventricular arrhythmias such as torsade de pointes.", "source": "DDInter", "management_text": "Concomitant use of eliglustat with weak CYP450 3A4 inhibitors such as chloramphenicol, cyclosporine, danazol, dasatinib, ethinyl estradiol, fluvoxamine, goldenseal, isoniazid, ivacaftor, lapatinib, lomitapide, nifedipine, nilotinib, palbociclib, pazopanib, suvorexant, ticagrelor, and zafirlukast is not recommended in CYP450 2D6 poor metabolizers. No dosage adjustment for eliglustat is necessary when used with weak CYP450 3A4 inhibitors in extensive or intermediate metabolizers.", "mechanism_text": "Metabolism", "recommendation": "Concomitant use of eliglustat with weak CYP450 3A4 inhibitors such as chloramphenicol, cyclosporine, danazol, dasatinib, ethinyl estradiol, fluvoxamine, goldenseal, isoniazid, ivacaftor, lapatinib, lomitapide, nifedipine, nilotinib, palbociclib, pazopanib, suvorexant, ticagrelor, and zafirlukast is not recommended in CYP450 2D6 poor metabolizers.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97329/", "reference_text": "[1] \"Product Information. Cerdelga (eliglustat).\" Genzyme Corporation, Cambridge, MA.[2] \"Product Information. Cerdelga (eliglustat).\" Genzyme Corporation, Cambridge, MA.", "alternatives_a": "Teduglutide, Lonafarnib, Fosdenopterin, Miglustat, Imiglucerase, Asfotase alfa, Glycerol phenylbutyrate, Pegvaliase, Triethylenetetramine, Sapropterin, Zinc acetate, More", "alternatives_b": "Felodipine, Nisoldipine, Nicardipine, Isradipine, Clevidipine, Nimodipine", "updated_at": 1767369485}, {"id": 97226, "ingredient1": "Eliglustat", "ingredient2": "Lomitapide", "severity": "Moderate", "effect": "Coadministration with weak inhibitors of CYP450 3A4 may increase the plasma concentrations of eliglustat, which is primarily metabolized by CYP450 2D6 and, to a lesser extent, CYP450 3A4. Eliglustat at substantially elevated plasma concentrations is predicted to cause prolongation of the PR, QTc and QRS cardiac intervals, which may increase the risk of bradycardia, atrioventricular block, cardiac arrest, and serious ventricular arrhythmias such as torsade de pointes.", "source": "DDInter", "management_text": "Concomitant use of eliglustat with weak CYP450 3A4 inhibitors such as chloramphenicol, cyclosporine, danazol, dasatinib, ethinyl estradiol, fluvoxamine, goldenseal, isoniazid, ivacaftor, lapatinib, lomitapide, nifedipine, nilotinib, palbociclib, pazopanib, suvorexant, ticagrelor, and zafirlukast is not recommended in CYP450 2D6 poor metabolizers. No dosage adjustment for eliglustat is necessary when used with weak CYP450 3A4 inhibitors in extensive or intermediate metabolizers.", "mechanism_text": "Metabolism", "recommendation": "Concomitant use of eliglustat with weak CYP450 3A4 inhibitors such as chloramphenicol, cyclosporine, danazol, dasatinib, ethinyl estradiol, fluvoxamine, goldenseal, isoniazid, ivacaftor, lapatinib, lomitapide, nifedipine, nilotinib, palbociclib, pazopanib, suvorexant, ticagrelor, and zafirlukast is not recommended in CYP450 2D6 poor metabolizers.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97330/", "reference_text": "[1] \"Product Information. Cerdelga (eliglustat).\" Genzyme Corporation, Cambridge, MA.[2] \"Product Information. Cerdelga (eliglustat).\" Genzyme Corporation, Cambridge, MA.", "alternatives_a": "Cholestyramine, Rosuvastatin, Fenofibrate, Mipomersen, Evinacumab, Dextrothyroxine, Simvastatin, Probucol, Cerivastatin, Ezetimibe, Niacin, More", "alternatives_b": "Teduglutide, Fosdenopterin, Miglustat, Imiglucerase, Asfotase alfa, Glycerol phenylbutyrate, Pegvaliase, Triethylenetetramine, Sapropterin, Zinc acetate, Phenylbutyric acid, More", "updated_at": 1767369485}, {"id": 97227, "ingredient1": "Eliglustat", "ingredient2": "Lonafarnib", "severity": "Major", "effect": "Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of eliglustat, which is primarily metabolized by CYP450 2D6 and, to a lesser extent, CYP450 3A4. Eliglustat at substantially elevated plasma concentrations is predicted to cause prolongation of the PR, QTc and QRS cardiac intervals, which may increase the risk of bradycardia, atrioventricular block, cardiac arrest, and serious ventricular arrhythmias such as torsade de pointes.", "source": "DDInter", "management_text": "The use of eliglustat with a potent CYP450 3A4 inhibitor is considered contraindicated in CYP450 2D6 poor metabolizers (PMs) and intermediate metabolizers (IMs). The contraindication is extended to extensive metabolizers (EMs) when a moderate or potent CYP450 2D6 inhibitor is given concomitantly with a moderate or potent CYP450 3A4 inhibitor. In the absence of a concomitant CYP450 2D6 inhibitor, eliglustat may be prescribed at a reduced dosage of 84 mg once daily to EMs treated with a potent CYP450 3A4 inhibitor. Potent CYP450 3A4 inhibitors include itraconazole, ketoconazole, posaconazole, voriconazole, conivaptan, ceritinib, idelalisib, mibefradil, nefazodone, cobicistat, delavirdine, protease inhibitors, and ketolide and certain macrolide antibiotics. Potent and moderate CYP450 2D6 inhibitors include abiraterone, bupropion, celecoxib, cimetidine, cinacalcet, clobazam, darifenacin, diphenhydramine, dronedarone, duloxetine, flecainide, fluoxetine, methotrimeprazine, mirabegron, paroxetine, propafenone, propoxyphene, quinidine, ranolazine, sertraline, and terbinafine. Some drugs such as cobicistat, delavirdine, mibefradil, and ritonavir are dual CYP450 3A4 and 2D6 inhibitors, and they should not be used with eliglustat in any patient regardless of their CYP450 2D6 metabolizer status.", "mechanism_text": "Metabolism", "recommendation": "The use of eliglustat with a potent CYP450 3A4 inhibitor is considered contraindicated in CYP450 2D6 poor metabolizers (PMs) and intermediate metabolizers (IMs).", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97331/", "reference_text": "[1] Cerner Multum, Inc. \"Australian Product Information.\" O 0[2] \"Product Information. Sporanox (itraconazole).\" Janssen Pharmaceutica, Titusville, NJ.[3] \"Product Information. Cerdelga (eliglustat).\" Genzyme Corporation, Cambridge, MA.[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] \"Product Information. Cerdelga (eliglustat).\" Genzyme Corporation, Cambridge, MA.[6] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[7] \"Product Information. VFEND (voriconazole).\" Pfizer U.S. Pharmaceuticals, New York, NY.", "alternatives_a": "Teduglutide, Fosdenopterin, Miglustat, Imiglucerase, Asfotase alfa, Pegvaliase, Triethylenetetramine, Sapropterin, Zinc acetate, Phenylbutyric acid, Agalsidase beta, More", "alternatives_b": "Teduglutide, Lonafarnib, Fosdenopterin, Miglustat, Imiglucerase, Asfotase alfa, Pegvaliase, Triethylenetetramine, Sapropterin, Zinc acetate, Phenylbutyric acid, More", "updated_at": 1767369485}, {"id": 97228, "ingredient1": "Eliglustat", "ingredient2": "Lorlatinib", "severity": "Moderate", "effect": "Coadministration with inducers of CYP450 3A4 and/or P-glycoprotein (P-gp) may decrease the plasma concentrations of eliglustat, which is primarily metabolized by CYP450 2D6 and, to a lesser extent, CYP450 3A4. Eliglustat is also a substrate of P-gp efflux transporter.", "source": "DDInter", "management_text": "Patients receiving eliglustat with CYP450 3A4 inducers should be monitored for potentially diminished pharmacologic response to eliglustat. Concomitant use should be avoided if an interaction is suspected.", "mechanism_text": "Metabolism", "recommendation": "Patients receiving eliglustat with CYP450 3A4 inducers should be monitored for potentially diminished pharmacologic response to eliglustat.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97332/", "reference_text": "[1] \"Product Information. Cerdelga (eliglustat).\" Genzyme Corporation, Cambridge, MA.[2] \"Product Information. Cerdelga (eliglustat).\" Genzyme Corporation, Cambridge, MA.", "alternatives_a": "Teduglutide, Fosdenopterin, Miglustat, Imiglucerase, Asfotase alfa, Glycerol phenylbutyrate, Pegvaliase, Triethylenetetramine, Sapropterin, Zinc acetate, Phenylbutyric acid, More", "alternatives_b": "Acalabrutinib, Tepotinib, Avapritinib, Selumetinib, Vandetanib, Capmatinib, Ibrutinib, Tivozanib, Zanubrutinib, Axitinib, Sunitinib, More", "updated_at": 1767369485}, {"id": 97229, "ingredient1": "Eliglustat", "ingredient2": "Lusutrombopag", "severity": "Moderate", "effect": "Coadministration with eliglustat may increase the plasma concentrations of drugs that are substrates of the P-glycoprotein (P-gp) transporter. The proposed mechanism is decreased clearance in the intestine, liver, and/or kidney due to inhibition of P-glycoprotein-mediated drug efflux by eliglustat.", "source": "DDInter", "management_text": "Caution is advised when eliglustat is used concurrently with drugs that are known P-gp substrates, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever eliglustat is added to or withdrawn from therapy.", "mechanism_text": "Others", "recommendation": "Caution is advised when eliglustat is used concurrently with drugs that are known P-gp substrates, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97333/", "reference_text": "[1] \"Product Information. Cerdelga (eliglustat).\" Genzyme Corporation, Cambridge, MA.[2] \"Product Information. Cerdelga (eliglustat).\" Genzyme Corporation, Cambridge, MA.", "alternatives_a": "Teduglutide, Lonafarnib, Fosdenopterin, Miglustat, Imiglucerase, Asfotase alfa, Glycerol phenylbutyrate, Pegvaliase, Triethylenetetramine, Sapropterin, Zinc acetate, More", "alternatives_b": "Eltrombopag, Romiplostim, Avatrombopag, Emicizumab, Coagulation factor VIIa Recombinant Human, Coagulation factor X human, Phylloquinone, Anti-inhibitor coagulant complex, Antihemophilic factor, human recombinant, Fibrinogen human, Epinephrine, Coagulation Factor IX Human", "updated_at": 1767369485}, {"id": 97230, "ingredient1": "Eliglustat", "ingredient2": "Maprotiline", "severity": "Moderate", "effect": "Coadministration with eliglustat may increase the plasma concentrations of drugs that are primarily metabolized by CYP450 2D6.", "source": "DDInter", "management_text": "Caution is advised if eliglustat is used concomitantly with medications that undergo metabolism primarily by CYP450 2D6, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever eliglustat is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if eliglustat is used concomitantly with medications that undergo metabolism primarily by CYP450 2D6, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97334/", "reference_text": "[1] \"Product Information. Cerdelga (eliglustat).\" Genzyme Corporation, Cambridge, MA.[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] \"Product Information. Cerdelga (eliglustat).\" Genzyme Corporation, Cambridge, MA.[5] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[6] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[7] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[8] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.", "alternatives_a": "Phenelzine, Citalopram, Tranylcypromine, Desvenlafaxine, Isocarboxazid, Oxitriptan, Tryptophan, Milnacipran, Levomilnacipran, Vilazodone, Esketamine, More", "alternatives_b": "Teduglutide, Lonafarnib, Fosdenopterin, Miglustat, Imiglucerase, Asfotase alfa, Pegvaliase, Triethylenetetramine, Sapropterin, Zinc acetate, Phenylbutyric acid, More", "updated_at": 1767369485}, {"id": 97231, "ingredient1": "Eliglustat", "ingredient2": "Maraviroc", "severity": "Moderate", "effect": "Coadministration with inhibitors of the CYP450 3A4 isoenzyme and/or P-glycoprotein efflux transporter may increase the plasma concentrations of maraviroc, which is a substrate of both.", "source": "DDInter", "management_text": "Caution is advised when maraviroc is used with inhibitors of CYP450 3A4 and/or P-glycoprotein. Dosage adjustment for maraviroc may be necessary if an interaction is suspected.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when maraviroc is used with inhibitors of CYP450 3A4 and/or P-glycoprotein.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97335/", "reference_text": "[1] \"Product Information. Selzentry (maraviroc).\" Pfizer U.S. Pharmaceuticals Group, New York, NY.[2] \"Product Information. Selzentry (maraviroc).\" Pfizer U.S. Pharmaceuticals Group, New York, NY.", "alternatives_a": "Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Simeprevir, Cabotegravir, Valaciclovir, Zanamivir, Velpatasvir, Rilpivirine, Dolutegravir, More", "alternatives_b": "Teduglutide, Fosdenopterin, Miglustat, Imiglucerase, Asfotase alfa, Glycerol phenylbutyrate, Pegvaliase, Triethylenetetramine, Sapropterin, Zinc acetate, Phenylbutyric acid, More", "updated_at": 1767369485}, {"id": 97232, "ingredient1": "Eliglustat", "ingredient2": "Meclizine", "severity": "Moderate", "effect": "Coadministration with eliglustat may increase the plasma concentrations of drugs that are primarily metabolized by CYP450 2D6.", "source": "DDInter", "management_text": "Caution is advised if eliglustat is used concomitantly with medications that undergo metabolism primarily by CYP450 2D6, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever eliglustat is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if eliglustat is used concomitantly with medications that undergo metabolism primarily by CYP450 2D6, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97336/", "reference_text": "[1] \"Product Information. Cerdelga (eliglustat).\" Genzyme Corporation, Cambridge, MA.[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] \"Product Information. Cerdelga (eliglustat).\" Genzyme Corporation, Cambridge, MA.[5] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[6] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[7] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[8] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.", "alternatives_a": "Ketotifen, Mepyramine, Levocetirizine, Chlorcyclizine, Cetirizine, Acrivastine, Triprolidine, Tripelennamine, Azelastine, Dexbrompheniramine, Clemastine, More", "alternatives_b": "Teduglutide, Lonafarnib, Fosdenopterin, Miglustat, Imiglucerase, Asfotase alfa, Pegvaliase, Triethylenetetramine, Sapropterin, Zinc acetate, Phenylbutyric acid, More", "updated_at": 1767369485}, {"id": 97233, "ingredient1": "Eliglustat", "ingredient2": "Methylphenobarbital", "severity": "Moderate", "effect": "Coadministration with inducers of CYP450 3A4 and/or P-glycoprotein (P-gp) may decrease the plasma concentrations of eliglustat, which is primarily metabolized by CYP450 2D6 and, to a lesser extent, CYP450 3A4. Eliglustat is also a substrate of P-gp efflux transporter.", "source": "DDInter", "management_text": "Patients receiving eliglustat with CYP450 3A4 inducers should be monitored for potentially diminished pharmacologic response to eliglustat. Concomitant use should be avoided if an interaction is suspected.", "mechanism_text": "Metabolism", "recommendation": "Patients receiving eliglustat with CYP450 3A4 inducers should be monitored for potentially diminished pharmacologic response to eliglustat.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97337/", "reference_text": "[1] \"Product Information. Cerdelga (eliglustat).\" Genzyme Corporation, Cambridge, MA.[2] \"Product Information. Cerdelga (eliglustat).\" Genzyme Corporation, Cambridge, MA.", "alternatives_a": "Brivaracetam, Topiramate, Ezogabine, Lamotrigine, Ethosuximide, Lacosamide, Levetiracetam, Tiagabine, Ethotoin, Clonazepam, Paramethadione, More", "alternatives_b": "Teduglutide, Fosdenopterin, Miglustat, Imiglucerase, Asfotase alfa, Glycerol phenylbutyrate, Pegvaliase, Triethylenetetramine, Sapropterin, Zinc acetate, Phenylbutyric acid, More", "updated_at": 1767369485}, {"id": 97234, "ingredient1": "Eliglustat", "ingredient2": "Mesoridazine", "severity": "Moderate", "effect": "Coadministration with eliglustat may increase the plasma concentrations of drugs that are primarily metabolized by CYP450 2D6.", "source": "DDInter", "management_text": "Caution is advised if eliglustat is used concomitantly with medications that undergo metabolism primarily by CYP450 2D6, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever eliglustat is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if eliglustat is used concomitantly with medications that undergo metabolism primarily by CYP450 2D6, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97338/", "reference_text": "[1] \"Product Information. Cerdelga (eliglustat).\" Genzyme Corporation, Cambridge, MA.[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] \"Product Information. Cerdelga (eliglustat).\" Genzyme Corporation, Cambridge, MA.[5] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[6] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[7] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[8] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.", "alternatives_a": "Quetiapine, Asenapine, Promazine, Prochlorperazine, Thiothixene, Pimavanserin, Lumateperone, Ziprasidone, Olanzapine, Trifluoperazine, Amisulpride, More", "alternatives_b": "Teduglutide, Lonafarnib, Fosdenopterin, Miglustat, Imiglucerase, Asfotase alfa, Pegvaliase, Triethylenetetramine, Sapropterin, Zinc acetate, Phenylbutyric acid, More", "updated_at": 1767369485}, {"id": 97235, "ingredient1": "Eliglustat", "ingredient2": "Metamfetamine", "severity": "Moderate", "effect": "Coadministration with eliglustat may increase the plasma concentrations of drugs that are primarily metabolized by CYP450 2D6.", "source": "DDInter", "management_text": "Caution is advised if eliglustat is used concomitantly with medications that undergo metabolism primarily by CYP450 2D6, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever eliglustat is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if eliglustat is used concomitantly with medications that undergo metabolism primarily by CYP450 2D6, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97339/", "reference_text": "[1] \"Product Information. Cerdelga (eliglustat).\" Genzyme Corporation, Cambridge, MA.[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] \"Product Information. Cerdelga (eliglustat).\" Genzyme Corporation, Cambridge, MA.[5] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[6] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[7] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[8] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.", "alternatives_a": "Pemoline, Lisdexamfetamine, Solriamfetol, Caffeine, Methylphenidate, Dexmethylphenidate, Dextroamphetamine, Citicoline", "alternatives_b": "Teduglutide, Lonafarnib, Fosdenopterin, Miglustat, Imiglucerase, Asfotase alfa, Pegvaliase, Triethylenetetramine, Sapropterin, Zinc acetate, Phenylbutyric acid, More", "updated_at": 1767369485}, {"id": 97236, "ingredient1": "Eliglustat", "ingredient2": "Methotrimeprazine", "severity": "Major", "effect": "Coadministration with inhibitors of CYP450 2D6 may significantly increase the plasma concentrations of eliglustat, which is primarily metabolized by CYP450 2D6 and, to a lesser extent, CYP450 3A4. Eliglustat at substantially elevated plasma concentrations is predicted to cause prolongation of the PR, QTc and QRS cardiac intervals, which may increase the risk of bradycardia, atrioventricular block, cardiac arrest, and serious ventricular arrhythmias such as torsade de pointes.", "source": "DDInter", "management_text": "The use of eliglustat in combination with one or more drugs that may result in moderate or potent inhibition of both CYP450 2D6 and 3A4 is considered contraindicated in CYP450 2D6 intermediate metabolizers (IMs) and extensive metabolizers (EMs). In the absence of a concomitant CYP450 3A4 inhibitor, eliglustat may be prescribed at a reduced dosage of 84 mg once daily to IMs and EMs treated with a potent or moderate CYP450 2D6 inhibitor. Poor metabolizers are not affected by CYP450 2D6 inhibition (since they already have minimal functional levels of the isoenzyme) and may also receive the reduced dosage of eliglustat, so long as they are not treated with a CYP450 3A4 inhibitor.", "mechanism_text": "Metabolism", "recommendation": "The use of eliglustat in combination with one or more drugs that may result in moderate or potent inhibition of both CYP450 2D6 and 3A4 is considered contraindicated in CYP450 2D6 intermediate metabolizers (IMs) and extensive metabolizers (EMs).", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97340/", "reference_text": "[1] \"Product Information. Cerdelga (eliglustat).\" Genzyme Corporation, Cambridge, MA.[2] \"Product Information. Cerdelga (eliglustat).\" Genzyme Corporation, Cambridge, MA.", "alternatives_a": "Quetiapine, Asenapine, Promazine, Prochlorperazine, Thiothixene, Pimavanserin, Lumateperone, Ziprasidone, Olanzapine, Trifluoperazine, Amisulpride, More", "alternatives_b": "Teduglutide, Lonafarnib, Fosdenopterin, Miglustat, Imiglucerase, Asfotase alfa, Pegvaliase, Triethylenetetramine, Sapropterin, Zinc acetate, Phenylbutyric acid, More", "updated_at": 1767369485}, {"id": 97237, "ingredient1": "Eliglustat", "ingredient2": "Metoclopramide", "severity": "Moderate", "effect": "Coadministration with eliglustat may increase the plasma concentrations of drugs that are primarily metabolized by CYP450 2D6.", "source": "DDInter", "management_text": "Caution is advised if eliglustat is used concomitantly with medications that undergo metabolism primarily by CYP450 2D6, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever eliglustat is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if eliglustat is used concomitantly with medications that undergo metabolism primarily by CYP450 2D6, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97341/", "reference_text": "[1] \"Product Information. Cerdelga (eliglustat).\" Genzyme Corporation, Cambridge, MA.[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] \"Product Information. Cerdelga (eliglustat).\" Genzyme Corporation, Cambridge, MA.[5] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[6] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[7] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[8] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.", "alternatives_a": "Cisapride", "alternatives_b": "Teduglutide, Lonafarnib, Fosdenopterin, Miglustat, Imiglucerase, Asfotase alfa, Pegvaliase, Triethylenetetramine, Sapropterin, Zinc acetate, Phenylbutyric acid, More", "updated_at": 1767369485}, {"id": 97238, "ingredient1": "Eliglustat", "ingredient2": "Metoprolol", "severity": "Moderate", "effect": "Coadministration with eliglustat may increase the plasma concentrations of drugs that are primarily metabolized by CYP450 2D6.", "source": "DDInter", "management_text": "Caution is advised if eliglustat is used concomitantly with medications that undergo metabolism primarily by CYP450 2D6, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever eliglustat is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if eliglustat is used concomitantly with medications that undergo metabolism primarily by CYP450 2D6, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97342/", "reference_text": "[1] \"Product Information. Cerdelga (eliglustat).\" Genzyme Corporation, Cambridge, MA.[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] \"Product Information. Cerdelga (eliglustat).\" Genzyme Corporation, Cambridge, MA.[5] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[6] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[7] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[8] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.", "alternatives_a": "Felodipine, Bisoprolol, Ivabradine, Acetylsalicylic acid, Atenolol, Acebutolol, Labetalol, Nadolol, Esmolol, Betaxolol, Penbutolol, More", "alternatives_b": "Teduglutide, Lonafarnib, Fosdenopterin, Miglustat, Imiglucerase, Asfotase alfa, Pegvaliase, Triethylenetetramine, Sapropterin, Zinc acetate, Phenylbutyric acid, More", "updated_at": 1767369485}, {"id": 97239, "ingredient1": "Eliglustat", "ingredient2": "Metreleptin", "severity": "Moderate", "effect": "Coadministration with inducers of CYP450 3A4 and/or P-glycoprotein (P-gp) may decrease the plasma concentrations of eliglustat, which is primarily metabolized by CYP450 2D6 and, to a lesser extent, CYP450 3A4. Eliglustat is also a substrate of P-gp efflux transporter.", "source": "DDInter", "management_text": "Patients receiving eliglustat with CYP450 3A4 inducers should be monitored for potentially diminished pharmacologic response to eliglustat. Concomitant use should be avoided if an interaction is suspected.", "mechanism_text": "Metabolism", "recommendation": "Patients receiving eliglustat with CYP450 3A4 inducers should be monitored for potentially diminished pharmacologic response to eliglustat.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97343/", "reference_text": "[1] \"Product Information. Cerdelga (eliglustat).\" Genzyme Corporation, Cambridge, MA.[2] \"Product Information. Cerdelga (eliglustat).\" Genzyme Corporation, Cambridge, MA.", "alternatives_a": "Teduglutide, Fosdenopterin, Miglustat, Imiglucerase, Asfotase alfa, Glycerol phenylbutyrate, Pegvaliase, Triethylenetetramine, Sapropterin, Zinc acetate, Phenylbutyric acid, More", "alternatives_b": "Teduglutide, Fosdenopterin, Miglustat, Imiglucerase, Asfotase alfa, Pegvaliase, Triethylenetetramine, Sapropterin, Zinc acetate, Phenylbutyric acid, Agalsidase beta, More", "updated_at": 1767369485}, {"id": 97240, "ingredient1": "Eliglustat", "ingredient2": "Mexiletine", "severity": "Moderate", "effect": "Coadministration with eliglustat may increase the plasma concentrations of drugs that are primarily metabolized by CYP450 2D6.", "source": "DDInter", "management_text": "Caution is advised if eliglustat is used concomitantly with medications that undergo metabolism primarily by CYP450 2D6, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever eliglustat is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if eliglustat is used concomitantly with medications that undergo metabolism primarily by CYP450 2D6, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97344/", "reference_text": "[1] \"Product Information. Cerdelga (eliglustat).\" Genzyme Corporation, Cambridge, MA.[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] \"Product Information. Cerdelga (eliglustat).\" Genzyme Corporation, Cambridge, MA.[5] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[6] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[7] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[8] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.", "alternatives_a": "Lidocaine, Moricizine, Bretylium, Tocainide", "alternatives_b": "Teduglutide, Lonafarnib, Fosdenopterin, Miglustat, Imiglucerase, Asfotase alfa, Pegvaliase, Triethylenetetramine, Sapropterin, Zinc acetate, Phenylbutyric acid, More", "updated_at": 1767369485}, {"id": 97241, "ingredient1": "Eliglustat", "ingredient2": "Miconazole", "severity": "Major", "effect": "Coadministration with moderate inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of eliglustat, which is primarily metabolized by CYP450 2D6 and, to a lesser extent, CYP450 3A4. Eliglustat at substantially elevated plasma concentrations is predicted to cause prolongation of the PR, QTc and QRS cardiac intervals, which may increase the risk of bradycardia, atrioventricular block, cardiac arrest, and serious ventricular arrhythmias such as torsade de pointes.", "source": "DDInter", "management_text": "The use of eliglustat in combination with one or more drugs that may result in moderate inhibition of CYP450 3A4 and moderate to potent inhibition of CYP450 2D6 is considered contraindicated in CYP450 2D6 extensive metabolizers (EMs) and intermediate metabolizers (IMs). In the absence of a concomitant CYP450 2D6 inhibitor, eliglustat may be prescribed at a reduced dosage of 84 mg once daily to EMs treated with a moderate CYP450 3A4 inhibitor. However, eliglustat should not be used with a moderate CYP450 3A4 inhibitor in CYP450 2D6 IMs or poor metabolizers (PMs). Moderate CYP450 3A4 inhibitors include aprepitant, ciprofloxacin, clotrimazole, crizotinib, darunavir, diltiazem, dronedarone, fluconazole, fusidic acid, imatinib, isavuconazonium, miconazole, mifepristone, netupitant, quinupristin-dalfopristin, ranolazine, stiripentol, and verapamil. Potent and moderate CYP450 2D6 inhibitors include abiraterone, bupropion, celecoxib, cimetidine, cinacalcet, clobazam, darifenacin, diphenhydramine, duloxetine, fluoxetine, methotrimeprazine, mirabegron, paroxetine, propoxyphene, quinidine, ranolazine, sertraline, stiripentol, and terbinafine.", "mechanism_text": "Metabolism", "recommendation": "The use of eliglustat in combination with one or more drugs that may result in moderate inhibition of CYP450 3A4 and moderate to potent inhibition of CYP450 2D6 is considered contraindicated in CYP450 2D6 extensive metabolizers (EMs) and intermediate metabolizers (IMs).", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97345/", "reference_text": "[1] \"Product Information. Cerdelga (eliglustat).\" Genzyme Corporation, Cambridge, MA.[2] \"Product Information. Cerdelga (eliglustat).\" Genzyme Corporation, Cambridge, MA.", "alternatives_a": "Rifamycin, Kanamycin, Amphotericin B, Polymyxin B, Nystatin, Vancomycin, Streptomycin, Paromomycin, Neomycin, Caspofungin, Micafungin, More", "alternatives_b": "Teduglutide, Fosdenopterin, Miglustat, Imiglucerase, Asfotase alfa, Glycerol phenylbutyrate, Pegvaliase, Triethylenetetramine, Sapropterin, Zinc acetate, Phenylbutyric acid, More", "updated_at": 1767369485}, {"id": 97242, "ingredient1": "Eliglustat", "ingredient2": "Mifepristone", "severity": "Major", "effect": "Coadministration with moderate inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of eliglustat, which is primarily metabolized by CYP450 2D6 and, to a lesser extent, CYP450 3A4. Eliglustat at substantially elevated plasma concentrations is predicted to cause prolongation of the PR, QTc and QRS cardiac intervals, which may increase the risk of bradycardia, atrioventricular block, cardiac arrest, and serious ventricular arrhythmias such as torsade de pointes.", "source": "DDInter", "management_text": "The use of eliglustat in combination with one or more drugs that may result in moderate inhibition of CYP450 3A4 and moderate to potent inhibition of CYP450 2D6 is considered contraindicated in CYP450 2D6 extensive metabolizers (EMs) and intermediate metabolizers (IMs). In the absence of a concomitant CYP450 2D6 inhibitor, eliglustat may be prescribed at a reduced dosage of 84 mg once daily to EMs treated with a moderate CYP450 3A4 inhibitor. However, eliglustat should not be used with a moderate CYP450 3A4 inhibitor in CYP450 2D6 IMs or poor metabolizers (PMs). Moderate CYP450 3A4 inhibitors include aprepitant, ciprofloxacin, clotrimazole, crizotinib, darunavir, diltiazem, dronedarone, fluconazole, fusidic acid, imatinib, isavuconazonium, miconazole, mifepristone, netupitant, quinupristin-dalfopristin, ranolazine, stiripentol, and verapamil. Potent and moderate CYP450 2D6 inhibitors include abiraterone, bupropion, celecoxib, cimetidine, cinacalcet, clobazam, darifenacin, diphenhydramine, duloxetine, fluoxetine, methotrimeprazine, mirabegron, paroxetine, propoxyphene, quinidine, ranolazine, sertraline, stiripentol, and terbinafine.", "mechanism_text": "Metabolism", "recommendation": "The use of eliglustat in combination with one or more drugs that may result in moderate inhibition of CYP450 3A4 and moderate to potent inhibition of CYP450 2D6 is considered contraindicated in CYP450 2D6 extensive metabolizers (EMs) and intermediate metabolizers (IMs).", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97346/", "reference_text": "[1] \"Product Information. Cerdelga (eliglustat).\" Genzyme Corporation, Cambridge, MA.[2] \"Product Information. Cerdelga (eliglustat).\" Genzyme Corporation, Cambridge, MA.", "alternatives_a": "Ulipristal, Ospemifene, Raloxifene, Bazedoxifene, Prasterone", "alternatives_b": "Teduglutide, Fosdenopterin, Miglustat, Imiglucerase, Asfotase alfa, Glycerol phenylbutyrate, Pegvaliase, Triethylenetetramine, Sapropterin, Zinc acetate, Phenylbutyric acid, More", "updated_at": 1767369485}, {"id": 97243, "ingredient1": "Eliglustat", "ingredient2": "Mirabegron", "severity": "Major", "effect": "Coadministration with inhibitors of CYP450 2D6 may significantly increase the plasma concentrations of eliglustat, which is primarily metabolized by CYP450 2D6 and, to a lesser extent, CYP450 3A4. Eliglustat at substantially elevated plasma concentrations is predicted to cause prolongation of the PR, QTc and QRS cardiac intervals, which may increase the risk of bradycardia, atrioventricular block, cardiac arrest, and serious ventricular arrhythmias such as torsade de pointes.", "source": "DDInter", "management_text": "The use of eliglustat in combination with one or more drugs that may result in moderate or potent inhibition of both CYP450 2D6 and 3A4 is considered contraindicated in CYP450 2D6 intermediate metabolizers (IMs) and extensive metabolizers (EMs). In the absence of a concomitant CYP450 3A4 inhibitor, eliglustat may be prescribed at a reduced dosage of 84 mg once daily to IMs and EMs treated with a potent or moderate CYP450 2D6 inhibitor. Poor metabolizers are not affected by CYP450 2D6 inhibition (since they already have minimal functional levels of the isoenzyme) and may also receive the reduced dosage of eliglustat, so long as they are not treated with a CYP450 3A4 inhibitor.", "mechanism_text": "Metabolism", "recommendation": "The use of eliglustat in combination with one or more drugs that may result in moderate or potent inhibition of both CYP450 2D6 and 3A4 is considered contraindicated in CYP450 2D6 intermediate metabolizers (IMs) and extensive metabolizers (EMs).", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97347/", "reference_text": "[1] \"Product Information. Cerdelga (eliglustat).\" Genzyme Corporation, Cambridge, MA.[2] \"Product Information. Cerdelga (eliglustat).\" Genzyme Corporation, Cambridge, MA.", "alternatives_a": "Vardenafil, Tadalafil, Ammonium chloride, Apomorphine, Yohimbine, Papaverine, Oxybutynin, Dimethyl sulfoxide, Pentosan polysulfate, Calcium chloride, Trospium, More", "alternatives_b": "Teduglutide, Fosdenopterin, Miglustat, Imiglucerase, Asfotase alfa, Pegvaliase, Triethylenetetramine, Sapropterin, Zinc acetate, Phenylbutyric acid, Agalsidase beta, More", "updated_at": 1767369485}, {"id": 97244, "ingredient1": "Eliglustat", "ingredient2": "Mirtazapine", "severity": "Moderate", "effect": "Coadministration of mirtazapine with drugs that inhibit one or more of its metabolic pathways may result in increased plasma concentrations of mirtazapine. In vitro data from human liver microsomes indicate that CYP450 2D6 and 1A2 are involved in the formation of the 8-hydroxy metabolite, while CYP450 3A4 is primarily responsible for the formation of the N-desmethyl and N-oxide metabolites.", "source": "DDInter", "management_text": "The possibility of prolonged and/or increased pharmacologic effects of mirtazapine should be considered during coadministration of drugs that inhibit CYP450 1A2, 2D6 and/or 3A4. Therapeutic response to mirtazapine should be monitored more closely following initiation, discontinuation, or dosing change of CYP450 inhibitors, and the mirtazapine dosage adjusted as necessary.", "mechanism_text": "Metabolism", "recommendation": "The possibility of prolonged and/or increased pharmacologic effects of mirtazapine should be considered during coadministration of drugs that inhibit CYP450 1A2, 2D6 and/or 3A4.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97348/", "reference_text": "[1] Sitsen JM, Maris FA, Timmer CJ \"Concomitant use of mirtazapine and cimetidine: a drug-drug interaction study in healthy male subjects.\" Eur J Clin Pharmacol 56 (2000): 389-94[2] \"Product Information. Remeron (mirtazapine).\" Organon, West Orange, NJ.[3] Stormer E, von Moltke LL, Shader RI, Greenblatt DJ \"Metabolism of the antidepressant mirtazapine in vitro: contribution of cytochromes P-450 1A2, 2D6, and 3A4\" Drug Metab Dispos 28 (2000): 1168-75[4] Okubo M, Murayama N, Miura J, Chiba Y, Yamazaki H \"Effects of cytochrome P450 2D6 and 3A5 genotypes and possible coadministered medicines on the metabolic clearance of antidepressant mirtazapine in Japanese patients.\" Biochem Pharmacol 93 (2015): 104-9[5] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[6] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[7] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[8] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.", "alternatives_a": "Phenelzine, Citalopram, Tranylcypromine, Desvenlafaxine, Isocarboxazid, Oxitriptan, Tryptophan, Milnacipran, Levomilnacipran, Vilazodone, Esketamine, More", "alternatives_b": "Lipoic acid, Triheptanoin, Teduglutide, Fosdenopterin, Triethylenetetramine, Miglustat, Sapropterin, Zinc acetate, Nitisinone, Laronidase, Imiglucerase, More", "updated_at": 1767369485}, {"id": 97245, "ingredient1": "Eliglustat", "ingredient2": "Mitotane", "severity": "Major", "effect": "Coadministration with potent inducers of CYP450 3A4 and/or P-glycoprotein (P-gp) may significantly decrease the plasma concentrations of eliglustat, which is primarily metabolized by CYP450 2D6 and, to a lesser extent, CYP450 3A4. Eliglustat is also a substrate of P-gp efflux transporter.", "source": "DDInter", "management_text": "Concomitant use of eliglustat with potent CYP450 3A4 or P-gp inducers should generally be avoided due to the potential for significantly reduced efficacy.", "mechanism_text": "Metabolism", "recommendation": "Concomitant use of eliglustat with potent CYP450 3A4 or P-gp inducers should generally be avoided due to the potential for significantly reduced efficacy.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97349/", "reference_text": "[1] Cerner Multum, Inc. \"Australian Product Information.\" O 0[2] \"Product Information. Cerdelga (eliglustat).\" Genzyme Corporation, Cambridge, MA.[3] \"Product Information. Cerdelga (eliglustat).\" Genzyme Corporation, Cambridge, MA.[4] \"Product Information. Cerdelga (eliglustat).\" Genzyme Corporation, Cambridge, MA.[5] \"Product Information. Trikafta (elexacaftor/ivacaftor/tezacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[6] \"Product Information. Kalydeco (ivacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[7] \"Product Information. Orkambi (ivacaftor-lumacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[8] \"Product Information. Symdeko 4-Week (ivacaftor-tezacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.", "alternatives_a": "Pertuzumab, Olaparib, Oxaliplatin, Bortezomib, Tisagenlecleucel, Aminolevulinic acid, Omacetaxine mepesuccinate, Altretamine, Tagraxofusp, Pegaspargase, Ixazomib, More", "alternatives_b": "Teduglutide, Fosdenopterin, Miglustat, Imiglucerase, Asfotase alfa, Glycerol phenylbutyrate, Pegvaliase, Triethylenetetramine, Sapropterin, Zinc acetate, Phenylbutyric acid, More", "updated_at": 1767369485}, {"id": 97246, "ingredient1": "Eliglustat", "ingredient2": "Mitoxantrone", "severity": "Moderate", "effect": "Coadministration with inhibitors of P-glycoprotein (P-gp) may increase the plasma concentrations of mitoxantrone, which is a substrate of the efflux transporter also known as ABCB1 or MDR1. The interaction has been studied with cyclosporine, a potent P-gp inhibitor.", "source": "DDInter", "management_text": "Caution is advised if mitoxantrone is prescribed in combination with a P-gp inhibitor. Patients should be closely monitored for increased adverse effects including cardiotoxicity and myelosuppression.", "mechanism_text": "Others", "recommendation": "Caution is advised if mitoxantrone is prescribed in combination with a P-gp inhibitor.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97350/", "reference_text": "[1] \"Product Information. Novantrone (mitoxantrone).\" Immunex Corporation, Seattle, WA.[2] \"Multum Information Services, Inc. Expert Review Panel\"[3] \"Product Information. Novantrone (mitoxantrone).\" Immunex Corporation, Seattle, WA.[4] \"Multum Information Services, Inc. Expert Review Panel\"[5] \"Product Information. Mavyret (glecaprevir-pibrentasvir).\" Abbott Pharmaceutical, Abbott Park, IL.", "alternatives_a": "Valrubicin, Plicamycin, Ixabepilone, Bleomycin, Mitomycin, Dactinomycin", "alternatives_b": "Teduglutide, Lonafarnib, Fosdenopterin, Miglustat, Imiglucerase, Asfotase alfa, Glycerol phenylbutyrate, Pegvaliase, Triethylenetetramine, Sapropterin, Zinc acetate, More", "updated_at": 1767369485}, {"id": 97247, "ingredient1": "Eliglustat", "ingredient2": "Modafinil", "severity": "Moderate", "effect": "Coadministration with inducers of CYP450 3A4 and/or P-glycoprotein (P-gp) may decrease the plasma concentrations of eliglustat, which is primarily metabolized by CYP450 2D6 and, to a lesser extent, CYP450 3A4. Eliglustat is also a substrate of P-gp efflux transporter.", "source": "DDInter", "management_text": "Patients receiving eliglustat with CYP450 3A4 inducers should be monitored for potentially diminished pharmacologic response to eliglustat. Concomitant use should be avoided if an interaction is suspected.", "mechanism_text": "Metabolism", "recommendation": "Patients receiving eliglustat with CYP450 3A4 inducers should be monitored for potentially diminished pharmacologic response to eliglustat.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97351/", "reference_text": "[1] \"Product Information. Cerdelga (eliglustat).\" Genzyme Corporation, Cambridge, MA.[2] \"Product Information. Cerdelga (eliglustat).\" Genzyme Corporation, Cambridge, MA.", "alternatives_a": "Pemoline, Lisdexamfetamine, Solriamfetol, Caffeine, Methylphenidate, Dexmethylphenidate, Dextroamphetamine, Citicoline", "alternatives_b": "Teduglutide, Fosdenopterin, Miglustat, Imiglucerase, Asfotase alfa, Glycerol phenylbutyrate, Pegvaliase, Triethylenetetramine, Sapropterin, Zinc acetate, Phenylbutyric acid, More", "updated_at": 1767369485}, {"id": 97248, "ingredient1": "Eliglustat", "ingredient2": "Nafcillin", "severity": "Moderate", "effect": "Coadministration with inducers of CYP450 3A4 and/or P-glycoprotein (P-gp) may decrease the plasma concentrations of eliglustat, which is primarily metabolized by CYP450 2D6 and, to a lesser extent, CYP450 3A4. Eliglustat is also a substrate of P-gp efflux transporter.", "source": "DDInter", "management_text": "Patients receiving eliglustat with CYP450 3A4 inducers should be monitored for potentially diminished pharmacologic response to eliglustat. Concomitant use should be avoided if an interaction is suspected.", "mechanism_text": "Metabolism", "recommendation": "Patients receiving eliglustat with CYP450 3A4 inducers should be monitored for potentially diminished pharmacologic response to eliglustat.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97352/", "reference_text": "[1] \"Product Information. Cerdelga (eliglustat).\" Genzyme Corporation, Cambridge, MA.[2] \"Product Information. Cerdelga (eliglustat).\" Genzyme Corporation, Cambridge, MA.", "alternatives_a": "Sulbactam, Oxacillin, Dicloxacillin, Piperacillin, Meticillin, Carbenicillin, Bacampicillin, Ticarcillin, Mezlocillin, Tazobactam, Cloxacillin, More", "alternatives_b": "Teduglutide, Fosdenopterin, Miglustat, Imiglucerase, Asfotase alfa, Glycerol phenylbutyrate, Pegvaliase, Triethylenetetramine, Sapropterin, Zinc acetate, Phenylbutyric acid, More", "updated_at": 1767369485}, {"id": 97249, "ingredient1": "Eliglustat", "ingredient2": "Naldemedine", "severity": "Moderate", "effect": "Coadministration with moderate inhibitors of CYP450 3A4 and/or moderate or potent inhibitors of P-glycoprotein (P-gp) may increase the plasma concentrations of naldemedine, which is primarily metabolized by CYP450 3A4 to nor-naldemedine and to a minor extent by UGT1A3 to naldemedine 3-G. Both metabolites have demonstrated antagonistic activity for opioid receptors, but with less potency than the parent drug.", "source": "DDInter", "management_text": "Caution is advised during concomitant use of naldemedine with moderate inhibitors of CYP450 3A4 and/or moderate or potent inhibitors of P-glycoprotein (P-gp). Patients should be closely monitored for potential opioid withdrawal symptoms as well as other adverse effects of naldemedine.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised during concomitant use of naldemedine with moderate inhibitors of CYP450 3A4 and/or moderate or potent inhibitors of P-glycoprotein (P-gp).", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97353/", "reference_text": "[1] \"Product Information. Symproic (naldemedine).\" Shionogi USA Inc, Florham Park, NJ.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Symproic (naldemedine).\" Shionogi USA Inc, Florham Park, NJ.", "alternatives_a": "Teduglutide, Fosdenopterin, Miglustat, Imiglucerase, Asfotase alfa, Glycerol phenylbutyrate, Pegvaliase, Triethylenetetramine, Sapropterin, Zinc acetate, Phenylbutyric acid, More", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Bisacodyl, Lactulose, Methylnaltrexone, Lactitol, Sodium phosphate, monobasic, Magnesium oxide, Sodium sulfate, Linaclotide, More", "updated_at": 1767369485}, {"id": 97250, "ingredient1": "Eliglustat", "ingredient2": "Naloxegol", "severity": "Minor", "effect": "Coadministration with inhibitors of P-glycoprotein (P-gp) and/or weak inhibitors of CYP450 3A4 may increase the plasma concentrations of naloxegol, which is a substrate of both the efflux transporter and the isoenzyme.", "source": "DDInter", "management_text": "-", "mechanism_text": "Metabolism, Absorption", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97354/", "reference_text": "[1] \"Product Information. Movantik (naloxegol).\" Astra-Zeneca Pharmaceuticals, Wilmington, DE.[2] \"Product Information. Movantik (naloxegol).\" Astra-Zeneca Pharmaceuticals, Wilmington, DE.[3] \"Product Information. Movantik (naloxegol).\" Astra-Zeneca Pharmaceuticals, Wilmington, DE.[4] \"Product Information. Mavyret (glecaprevir-pibrentasvir).\" Abbott Pharmaceutical, Abbott Park, IL.", "alternatives_a": "Teduglutide, Fosdenopterin, Miglustat, Imiglucerase, Asfotase alfa, Glycerol phenylbutyrate, Triethylenetetramine, Sapropterin, Zinc acetate, Phenylbutyric acid, Agalsidase beta, More", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Bisacodyl, Lactulose, Methylnaltrexone, Lactitol, Sodium phosphate, monobasic, Magnesium oxide, Sodium sulfate, Linaclotide, More", "updated_at": 1767369485}, {"id": 97251, "ingredient1": "Eliglustat", "ingredient2": "Nebivolol", "severity": "Moderate", "effect": "Coadministration with eliglustat may increase the plasma concentrations of drugs that are primarily metabolized by CYP450 2D6.", "source": "DDInter", "management_text": "Caution is advised if eliglustat is used concomitantly with medications that undergo metabolism primarily by CYP450 2D6, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever eliglustat is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if eliglustat is used concomitantly with medications that undergo metabolism primarily by CYP450 2D6, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97355/", "reference_text": "[1] \"Product Information. Cerdelga (eliglustat).\" Genzyme Corporation, Cambridge, MA.[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] \"Product Information. Cerdelga (eliglustat).\" Genzyme Corporation, Cambridge, MA.[5] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[6] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[7] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[8] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.", "alternatives_a": "Felodipine, Bisoprolol, Ivabradine, Acetylsalicylic acid, Atenolol, Valsartan, Irbesartan, Hydrochlorothiazide, Losartan, Olmesartan, Azilsartan medoxomil, More", "alternatives_b": "Teduglutide, Lonafarnib, Fosdenopterin, Miglustat, Imiglucerase, Asfotase alfa, Pegvaliase, Triethylenetetramine, Sapropterin, Zinc acetate, Phenylbutyric acid, More", "updated_at": 1767369485}, {"id": 97252, "ingredient1": "Eliglustat", "ingredient2": "Nefazodone", "severity": "Major", "effect": "Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of eliglustat, which is primarily metabolized by CYP450 2D6 and, to a lesser extent, CYP450 3A4. Eliglustat at substantially elevated plasma concentrations is predicted to cause prolongation of the PR, QTc and QRS cardiac intervals, which may increase the risk of bradycardia, atrioventricular block, cardiac arrest, and serious ventricular arrhythmias such as torsade de pointes.", "source": "DDInter", "management_text": "The use of eliglustat with a potent CYP450 3A4 inhibitor is considered contraindicated in CYP450 2D6 poor metabolizers (PMs) and intermediate metabolizers (IMs). The contraindication is extended to extensive metabolizers (EMs) when a moderate or potent CYP450 2D6 inhibitor is given concomitantly with a moderate or potent CYP450 3A4 inhibitor. In the absence of a concomitant CYP450 2D6 inhibitor, eliglustat may be prescribed at a reduced dosage of 84 mg once daily to EMs treated with a potent CYP450 3A4 inhibitor. Potent CYP450 3A4 inhibitors include itraconazole, ketoconazole, posaconazole, voriconazole, conivaptan, ceritinib, idelalisib, mibefradil, nefazodone, cobicistat, delavirdine, protease inhibitors, and ketolide and certain macrolide antibiotics. Potent and moderate CYP450 2D6 inhibitors include abiraterone, bupropion, celecoxib, cimetidine, cinacalcet, clobazam, darifenacin, diphenhydramine, dronedarone, duloxetine, flecainide, fluoxetine, methotrimeprazine, mirabegron, paroxetine, propafenone, propoxyphene, quinidine, ranolazine, sertraline, and terbinafine. Some drugs such as cobicistat, delavirdine, mibefradil, and ritonavir are dual CYP450 3A4 and 2D6 inhibitors, and they should not be used with eliglustat in any patient regardless of their CYP450 2D6 metabolizer status.", "mechanism_text": "Metabolism", "recommendation": "The use of eliglustat with a potent CYP450 3A4 inhibitor is considered contraindicated in CYP450 2D6 poor metabolizers (PMs) and intermediate metabolizers (IMs).", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97356/", "reference_text": "[1] Cerner Multum, Inc. \"Australian Product Information.\" O 0[2] \"Product Information. Sporanox (itraconazole).\" Janssen Pharmaceutica, Titusville, NJ.[3] \"Product Information. Cerdelga (eliglustat).\" Genzyme Corporation, Cambridge, MA.[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] \"Product Information. Cerdelga (eliglustat).\" Genzyme Corporation, Cambridge, MA.[6] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[7] \"Product Information. VFEND (voriconazole).\" Pfizer U.S. Pharmaceuticals, New York, NY.", "alternatives_a": "Phenelzine, Citalopram, Tranylcypromine, Desvenlafaxine, Isocarboxazid, Oxitriptan, Tryptophan, Milnacipran, Levomilnacipran, Vilazodone, Esketamine, More", "alternatives_b": "Teduglutide, Fosdenopterin, Miglustat, Imiglucerase, Asfotase alfa, Pegvaliase, Triethylenetetramine, Sapropterin, Zinc acetate, Phenylbutyric acid, Agalsidase beta, More", "updated_at": 1767369485}, {"id": 97253, "ingredient1": "Eliglustat", "ingredient2": "Nelfinavir", "severity": "Major", "effect": "Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of eliglustat, which is primarily metabolized by CYP450 2D6 and, to a lesser extent, CYP450 3A4. Eliglustat at substantially elevated plasma concentrations is predicted to cause prolongation of the PR, QTc and QRS cardiac intervals, which may increase the risk of bradycardia, atrioventricular block, cardiac arrest, and serious ventricular arrhythmias such as torsade de pointes.", "source": "DDInter", "management_text": "The use of eliglustat with a potent CYP450 3A4 inhibitor is considered contraindicated in CYP450 2D6 poor metabolizers (PMs) and intermediate metabolizers (IMs). The contraindication is extended to extensive metabolizers (EMs) when a moderate or potent CYP450 2D6 inhibitor is given concomitantly with a moderate or potent CYP450 3A4 inhibitor. In the absence of a concomitant CYP450 2D6 inhibitor, eliglustat may be prescribed at a reduced dosage of 84 mg once daily to EMs treated with a potent CYP450 3A4 inhibitor. Potent CYP450 3A4 inhibitors include itraconazole, ketoconazole, posaconazole, voriconazole, conivaptan, ceritinib, idelalisib, mibefradil, nefazodone, cobicistat, delavirdine, protease inhibitors, and ketolide and certain macrolide antibiotics. Potent and moderate CYP450 2D6 inhibitors include abiraterone, bupropion, celecoxib, cimetidine, cinacalcet, clobazam, darifenacin, diphenhydramine, dronedarone, duloxetine, flecainide, fluoxetine, methotrimeprazine, mirabegron, paroxetine, propafenone, propoxyphene, quinidine, ranolazine, sertraline, and terbinafine. Some drugs such as cobicistat, delavirdine, mibefradil, and ritonavir are dual CYP450 3A4 and 2D6 inhibitors, and they should not be used with eliglustat in any patient regardless of their CYP450 2D6 metabolizer status.", "mechanism_text": "Metabolism", "recommendation": "The use of eliglustat with a potent CYP450 3A4 inhibitor is considered contraindicated in CYP450 2D6 poor metabolizers (PMs) and intermediate metabolizers (IMs).", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97357/", "reference_text": "[1] Cerner Multum, Inc. \"Australian Product Information.\" O 0[2] \"Product Information. Sporanox (itraconazole).\" Janssen Pharmaceutica, Titusville, NJ.[3] \"Product Information. Cerdelga (eliglustat).\" Genzyme Corporation, Cambridge, MA.[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] \"Product Information. Cerdelga (eliglustat).\" Genzyme Corporation, Cambridge, MA.[6] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[7] \"Product Information. VFEND (voriconazole).\" Pfizer U.S. Pharmaceuticals, New York, NY.", "alternatives_a": "Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Simeprevir, Cabotegravir, Valaciclovir, Zanamivir, Velpatasvir, Rilpivirine, Dolutegravir, More", "alternatives_b": "Teduglutide, Fosdenopterin, Miglustat, Imiglucerase, Asfotase alfa, Glycerol phenylbutyrate, Pegvaliase, Triethylenetetramine, Sapropterin, Zinc acetate, Phenylbutyric acid, More", "updated_at": 1767369485}, {"id": 97254, "ingredient1": "Eliglustat", "ingredient2": "Nevirapine", "severity": "Moderate", "effect": "Coadministration with inducers of CYP450 3A4 and/or P-glycoprotein (P-gp) may decrease the plasma concentrations of eliglustat, which is primarily metabolized by CYP450 2D6 and, to a lesser extent, CYP450 3A4. Eliglustat is also a substrate of P-gp efflux transporter.", "source": "DDInter", "management_text": "Patients receiving eliglustat with CYP450 3A4 inducers should be monitored for potentially diminished pharmacologic response to eliglustat. Concomitant use should be avoided if an interaction is suspected.", "mechanism_text": "Metabolism", "recommendation": "Patients receiving eliglustat with CYP450 3A4 inducers should be monitored for potentially diminished pharmacologic response to eliglustat.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97358/", "reference_text": "[1] \"Product Information. Cerdelga (eliglustat).\" Genzyme Corporation, Cambridge, MA.[2] \"Product Information. Cerdelga (eliglustat).\" Genzyme Corporation, Cambridge, MA.", "alternatives_a": "Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Simeprevir, Cabotegravir, Valaciclovir, Zanamivir, Velpatasvir, Rilpivirine, Dolutegravir, More", "alternatives_b": "Teduglutide, Fosdenopterin, Miglustat, Imiglucerase, Asfotase alfa, Glycerol phenylbutyrate, Pegvaliase, Triethylenetetramine, Sapropterin, Zinc acetate, Phenylbutyric acid, More", "updated_at": 1767369485}, {"id": 97255, "ingredient1": "Eliglustat", "ingredient2": "Nilotinib", "severity": "Moderate", "effect": "Coadministration with weak inhibitors of CYP450 3A4 may increase the plasma concentrations of eliglustat, which is primarily metabolized by CYP450 2D6 and, to a lesser extent, CYP450 3A4. Eliglustat at substantially elevated plasma concentrations is predicted to cause prolongation of the PR, QTc and QRS cardiac intervals, which may increase the risk of bradycardia, atrioventricular block, cardiac arrest, and serious ventricular arrhythmias such as torsade de pointes.", "source": "DDInter", "management_text": "Concomitant use of eliglustat with weak CYP450 3A4 inhibitors such as chloramphenicol, cyclosporine, danazol, dasatinib, ethinyl estradiol, fluvoxamine, goldenseal, isoniazid, ivacaftor, lapatinib, lomitapide, nifedipine, nilotinib, palbociclib, pazopanib, suvorexant, ticagrelor, and zafirlukast is not recommended in CYP450 2D6 poor metabolizers. No dosage adjustment for eliglustat is necessary when used with weak CYP450 3A4 inhibitors in extensive or intermediate metabolizers.", "mechanism_text": "Metabolism", "recommendation": "Concomitant use of eliglustat with weak CYP450 3A4 inhibitors such as chloramphenicol, cyclosporine, danazol, dasatinib, ethinyl estradiol, fluvoxamine, goldenseal, isoniazid, ivacaftor, lapatinib, lomitapide, nifedipine, nilotinib, palbociclib, pazopanib, suvorexant, ticagrelor, and zafirlukast is not recommended in CYP450 2D6 poor metabolizers.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97359/", "reference_text": "[1] \"Product Information. Cerdelga (eliglustat).\" Genzyme Corporation, Cambridge, MA.[2] \"Product Information. Cerdelga (eliglustat).\" Genzyme Corporation, Cambridge, MA.", "alternatives_a": "Acalabrutinib, Tepotinib, Avapritinib, Selumetinib, Vandetanib, Capmatinib, Ibrutinib, Tivozanib, Zanubrutinib, Axitinib, Sunitinib, More", "alternatives_b": "Teduglutide, Fosdenopterin, Miglustat, Imiglucerase, Asfotase alfa, Glycerol phenylbutyrate, Pegvaliase, Triethylenetetramine, Sapropterin, Zinc acetate, Phenylbutyric acid, More", "updated_at": 1767369485}, {"id": 97256, "ingredient1": "Eliglustat", "ingredient2": "Nortriptyline", "severity": "Moderate", "effect": "Coadministration with eliglustat may increase the plasma concentrations of drugs that are primarily metabolized by CYP450 2D6.", "source": "DDInter", "management_text": "Caution is advised if eliglustat is used concomitantly with medications that undergo metabolism primarily by CYP450 2D6, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever eliglustat is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if eliglustat is used concomitantly with medications that undergo metabolism primarily by CYP450 2D6, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97360/", "reference_text": "[1] \"Product Information. Cerdelga (eliglustat).\" Genzyme Corporation, Cambridge, MA.[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] \"Product Information. Cerdelga (eliglustat).\" Genzyme Corporation, Cambridge, MA.[5] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[6] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[7] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[8] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.", "alternatives_a": "Phenelzine, Citalopram, Tranylcypromine, Desvenlafaxine, Isocarboxazid, Oxitriptan, Tryptophan, Milnacipran, Levomilnacipran, Vilazodone, Esketamine, More", "alternatives_b": "Teduglutide, Lonafarnib, Fosdenopterin, Miglustat, Imiglucerase, Asfotase alfa, Pegvaliase, Triethylenetetramine, Sapropterin, Zinc acetate, Phenylbutyric acid, More", "updated_at": 1767369485}, {"id": 97257, "ingredient1": "Eliglustat", "ingredient2": "Oliceridine", "severity": "Major", "effect": "Coadministration with moderate or potent inhibitors of CYP450 2D6 and/or 3A4 may increase the plasma concentrations and adverse opioid effects of oliceridine, which is primarily metabolized by both isoenzymes in vitro. In addition, oliceridine concentrations may decrease following discontinuation of a concomitant moderate or potent CYP450 2D6 or 3A4 inhibitor, possibly resulting in decreased opioid efficacy or withdrawal syndrome. The effect of a CYP450 2D6 inhibitor on the pharmacokinetics of oliceridine has not been studied. However, it may be similar to that reported in CYP450 2D6 poor metabolizers, whose plasma clearance of oliceridine is reduced by approximately 50% compared to those who are nonpoor CYP450 2D6 metabolizers.", "source": "DDInter", "management_text": "Caution is recommended if oliceridine is used in combination with moderate or potent inhibitors of CYP450 2D6 or 3A4. If concomitant use is considered necessary, patients may require less frequent dosing of oliceridine and should be closely monitored for respiratory depression, sedation, and QT prolongation. If a moderate or potent CYP450 2D6 or 3A4 inhibitor is discontinued, an increase of the oliceridine dosage may be considered while monitoring for signs of opioid withdrawal until stable drug effects are achieved.", "mechanism_text": "Metabolism", "recommendation": "Caution is recommended if oliceridine is used in combination with moderate or potent inhibitors of CYP450 2D6 or 3A4.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97361/", "reference_text": "[1] \"Product Information. Olinvyk (oliceridine).\" Trevena Inc, Chesterbrook, PA.[2] \"Product Information. Olinvyk (oliceridine).\" Trevena Inc, Chesterbrook, PA.[3] Gunston GD, Mehta U \"Potentially serious drug interactions with grapefruit juice.\" S Afr Med J 90 (2000): 41[4] Bailey DG, Arnold JMO, Spence JD \"Grapefruit juice and drugs - how significant is the interaction.\" Clin Pharmacokinet 26 (1994): 91-8[5] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[6] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions.\" Br J Clin Pharmacol 46 (1998): 101-10[7] Libersa CC, Brique SA, Motte KB, et al. \"Dramatic inhibition of amiodarone metabolism induced by grapefruit juice.\" Br J Clin Pharmacol 49 (2000): 373-8[8] Bailey DG, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit juice felodipine interaction: Effect of naringin and 6',7'-dihydroxybergamottin in humans.\" Clin Pharmacol Ther 64 (1998): 248-56[9] Jonkman JH, Sollie FA, Sauter R, Steinijans VW \"The influence of caffeine on the steady-state pharmacokinetics of theophylline.\" Clin Pharmacol Ther 49 (1991): 248-55[10] Ozdemir M, Aktan Y, Boydag BS, Cingi MI, Musmul A \"Interaction between grapefruit juice and diazepam in humans.\" Eur J Drug Metab Pharmacokinet 23 (1998): 55-9[11] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin.\" Clin Pharmacol Ther 66 (1999): 118-27[12] Bailey DG, Arnold JM, Munoz C, Spence JD \"Grapefruit juice--felodipine interaction: mechanism, predictability, and effect of naringin.\" Clin Pharmacol Ther 53 (1993): 637-42[13] Sigusch H, Hippius M, Henschel L, Kaufmann K, Hoffmann A \"Influence of grapefruit juice on the pharmacokinetics of a slow release nifedipine formulation.\" Pharmazie 49 (1994): 522-4[14] Eagling VA, Profit L, Back DJ \"Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-I protease inhibitor saquinavir by grapefruit juice components.\" Br J Clin Pharmacol 48 (1999): 543-52[15] Damkier P, Hansen LL, Brosen K \"Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine.\" Br J Clin Pharmacol 48 (1999): 829-38[16] Min DI, Ku YM, Geraets DR, Lee HC \"Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers.\" J Clin Pharmacol 36 (1996): 469-76[17] Zaidenstein R, Soback S, Gips M, Avni B, Dishi V, Weissgarten Y, Golik A, Scapa E \"Effect of grapefruit juice on the pharmacokinetics of losartan and its active metabolite E3174 in healthy volunteers.\" Ther Drug Monit 23 (2001): 369-73[18] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84[19] Lee AJ, Chan WK, Harralson AF, Buffum J, Bui BCC \"The effects of grapefruit juice on sertraline metabolism: An in vitro and in vivo study.\" Clin Ther 21 (1999): 1890-9[20] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors.\" Clin Pharmacol Ther 64 (1998): 477-83[21] Garg SK, Kumar N, Bhargava VK, Prabhakar SK \"Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy.\" Clin Pharmacol Ther 64 (1998): 286-8[22] Fuhr U, Maier-Bruggemann A, Blume H, et al. \"Grapefruit juice increases oral nimodipine bioavailability.\" Int J Clin Pharmacol Ther 36 (1998): 126-32[23] Sato J, Nakata H, Owada E, Kikuta T, Umetsu M, Ito K \"Influence of usual intake of dietary caffeine on single-dose kinetics of theophylline in healthy human subjects.\" Eur J Clin Pharmacol 44 (1993): 295-8[24] Edgar B, Bailey D, Bergstrand R, et al \"Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics on felodipine and its potential clinical relevance.\" Eur J Clin Pharmacol 42 (1992): 313-7[25] Kantola T, Kivisto KT, Neuvonen PJ \"Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid.\" Clin Pharmacol Ther 63 (1998): 397-402[26] Dresser GK, Spence JD, Bailey DG \"Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition.\" Clin Pharmacokinet 38 (2000): 41-57[27] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[28] Takanaga H, Ohnishi A, Maatsuo H, et al. \"Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model.\" Br J Clin Pharmacol 49 (2000): 49-58[29] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS \"Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice.\" Br J Clin Pharmacol 42 (1996): p662[30] Bailey DG, Arnold JM, Strong HA, Munoz C, Spence JD \"Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics.\" Clin Pharmacol Ther 54 (1993): 589-94[31] Josefsson M, Zackrisson AL, Ahlner J \"Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers.\" Eur J Clin Pharmacol 51 (1996): 189-93[32] Majeed A, Kareem A \"Effect of grapefruit juice on cyclosporine pharmacokinetics.\" Pediatr Nephrol 10 (1996): 395[33] Flanagan D \"Understanding the grapefruit-drug interaction.\" Gen Dent 53 (2005): 282-5; quiz 286[34] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ \"Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice.\" Clin Pharmacol Ther 58 (1995): 127-31", "alternatives_a": "Lipoic acid, Triheptanoin, Teduglutide, Fosdenopterin, Triethylenetetramine, Miglustat, Sapropterin, Zinc acetate, Nitisinone, Levocarnitine, Laronidase, More", "alternatives_b": "Naltrexone, Oxymorphone, Oxycodone, Methadone, Pentazocine, Buprenorphine, Butorphanol, Fentanyl, Ibuprofen, Nalbuphine, Acetaminophen, More", "updated_at": 1767369485}, {"id": 97258, "ingredient1": "Eliglustat", "ingredient2": "Oxcarbazepine", "severity": "Moderate", "effect": "Coadministration with inducers of CYP450 3A4 and/or P-glycoprotein (P-gp) may decrease the plasma concentrations of eliglustat, which is primarily metabolized by CYP450 2D6 and, to a lesser extent, CYP450 3A4. Eliglustat is also a substrate of P-gp efflux transporter.", "source": "DDInter", "management_text": "Patients receiving eliglustat with CYP450 3A4 inducers should be monitored for potentially diminished pharmacologic response to eliglustat. Concomitant use should be avoided if an interaction is suspected.", "mechanism_text": "Metabolism", "recommendation": "Patients receiving eliglustat with CYP450 3A4 inducers should be monitored for potentially diminished pharmacologic response to eliglustat.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97362/", "reference_text": "[1] \"Product Information. Cerdelga (eliglustat).\" Genzyme Corporation, Cambridge, MA.[2] \"Product Information. Cerdelga (eliglustat).\" Genzyme Corporation, Cambridge, MA.", "alternatives_a": "Brivaracetam, Topiramate, Ezogabine, Lamotrigine, Ethosuximide, Lacosamide, Levetiracetam, Tiagabine, Ethotoin, Clonazepam, Paramethadione, More", "alternatives_b": "Teduglutide, Fosdenopterin, Miglustat, Imiglucerase, Asfotase alfa, Glycerol phenylbutyrate, Pegvaliase, Triethylenetetramine, Sapropterin, Zinc acetate, Phenylbutyric acid, More", "updated_at": 1767369485}, {"id": 97259, "ingredient1": "Eliglustat", "ingredient2": "Paclitaxel (protein-bound)", "severity": "Moderate", "effect": "Coadministration with eliglustat may increase the plasma concentrations of drugs that are substrates of the P-glycoprotein (P-gp) transporter. The proposed mechanism is decreased clearance in the intestine, liver, and/or kidney due to inhibition of P-glycoprotein-mediated drug efflux by eliglustat.", "source": "DDInter", "management_text": "Caution is advised when eliglustat is used concurrently with drugs that are known P-gp substrates, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever eliglustat is added to or withdrawn from therapy.", "mechanism_text": "Others", "recommendation": "Caution is advised when eliglustat is used concurrently with drugs that are known P-gp substrates, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97363/", "reference_text": "[1] \"Product Information. Cerdelga (eliglustat).\" Genzyme Corporation, Cambridge, MA.[2] \"Product Information. Cerdelga (eliglustat).\" Genzyme Corporation, Cambridge, MA.", "alternatives_a": "Teduglutide, Fosdenopterin, Miglustat, Imiglucerase, Asfotase alfa, Glycerol phenylbutyrate, Pegvaliase, Triethylenetetramine, Sapropterin, Zinc acetate, Phenylbutyric acid, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 97260, "ingredient1": "Eliglustat", "ingredient2": "Palbociclib", "severity": "Moderate", "effect": "Coadministration with weak inhibitors of CYP450 3A4 may increase the plasma concentrations of eliglustat, which is primarily metabolized by CYP450 2D6 and, to a lesser extent, CYP450 3A4. Eliglustat at substantially elevated plasma concentrations is predicted to cause prolongation of the PR, QTc and QRS cardiac intervals, which may increase the risk of bradycardia, atrioventricular block, cardiac arrest, and serious ventricular arrhythmias such as torsade de pointes.", "source": "DDInter", "management_text": "Concomitant use of eliglustat with weak CYP450 3A4 inhibitors such as chloramphenicol, cyclosporine, danazol, dasatinib, ethinyl estradiol, fluvoxamine, goldenseal, isoniazid, ivacaftor, lapatinib, lomitapide, nifedipine, nilotinib, palbociclib, pazopanib, suvorexant, ticagrelor, and zafirlukast is not recommended in CYP450 2D6 poor metabolizers. No dosage adjustment for eliglustat is necessary when used with weak CYP450 3A4 inhibitors in extensive or intermediate metabolizers.", "mechanism_text": "Metabolism", "recommendation": "Concomitant use of eliglustat with weak CYP450 3A4 inhibitors such as chloramphenicol, cyclosporine, danazol, dasatinib, ethinyl estradiol, fluvoxamine, goldenseal, isoniazid, ivacaftor, lapatinib, lomitapide, nifedipine, nilotinib, palbociclib, pazopanib, suvorexant, ticagrelor, and zafirlukast is not recommended in CYP450 2D6 poor metabolizers.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97364/", "reference_text": "[1] \"Product Information. Cerdelga (eliglustat).\" Genzyme Corporation, Cambridge, MA.[2] \"Product Information. Cerdelga (eliglustat).\" Genzyme Corporation, Cambridge, MA.", "alternatives_a": "Teduglutide, Fosdenopterin, Miglustat, Imiglucerase, Asfotase alfa, Glycerol phenylbutyrate, Pegvaliase, Triethylenetetramine, Sapropterin, Zinc acetate, Phenylbutyric acid, More", "alternatives_b": "Acalabrutinib, Tepotinib, Avapritinib, Selumetinib, Vandetanib, Capmatinib, Ibrutinib, Tivozanib, Zanubrutinib, Axitinib, Sunitinib, More", "updated_at": 1767369485}, {"id": 97261, "ingredient1": "Eliglustat", "ingredient2": "Panobinostat", "severity": "Major", "effect": "Coadministration with inhibitors of CYP450 2D6 may significantly increase the plasma concentrations of eliglustat, which is primarily metabolized by CYP450 2D6 and, to a lesser extent, CYP450 3A4. Eliglustat at substantially elevated plasma concentrations is predicted to cause prolongation of the PR, QTc and QRS cardiac intervals, which may increase the risk of bradycardia, atrioventricular block, cardiac arrest, and serious ventricular arrhythmias such as torsade de pointes.", "source": "DDInter", "management_text": "The use of eliglustat in combination with one or more drugs that may result in moderate or potent inhibition of both CYP450 2D6 and 3A4 is considered contraindicated in CYP450 2D6 intermediate metabolizers (IMs) and extensive metabolizers (EMs). In the absence of a concomitant CYP450 3A4 inhibitor, eliglustat may be prescribed at a reduced dosage of 84 mg once daily to IMs and EMs treated with a potent or moderate CYP450 2D6 inhibitor. Poor metabolizers are not affected by CYP450 2D6 inhibition (since they already have minimal functional levels of the isoenzyme) and may also receive the reduced dosage of eliglustat, so long as they are not treated with a CYP450 3A4 inhibitor.", "mechanism_text": "Metabolism", "recommendation": "The use of eliglustat in combination with one or more drugs that may result in moderate or potent inhibition of both CYP450 2D6 and 3A4 is considered contraindicated in CYP450 2D6 intermediate metabolizers (IMs) and extensive metabolizers (EMs).", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97365/", "reference_text": "[1] \"Product Information. Cerdelga (eliglustat).\" Genzyme Corporation, Cambridge, MA.[2] \"Product Information. Cerdelga (eliglustat).\" Genzyme Corporation, Cambridge, MA.", "alternatives_a": "Pertuzumab, Olaparib, Oxaliplatin, Bortezomib, Tisagenlecleucel, Aminolevulinic acid, Omacetaxine mepesuccinate, Altretamine, Tagraxofusp, Pegaspargase, Ixazomib, More", "alternatives_b": "Lipoic acid, Triheptanoin, Teduglutide, Fosdenopterin, Triethylenetetramine, Miglustat, Sapropterin, Zinc acetate, Nitisinone, Levocarnitine, Laronidase, More", "updated_at": 1767369485}, {"id": 97262, "ingredient1": "Eliglustat", "ingredient2": "Paroxetine", "severity": "Major", "effect": "Coadministration with inhibitors of CYP450 2D6 may significantly increase the plasma concentrations of eliglustat, which is primarily metabolized by CYP450 2D6 and, to a lesser extent, CYP450 3A4. Eliglustat at substantially elevated plasma concentrations is predicted to cause prolongation of the PR, QTc and QRS cardiac intervals, which may increase the risk of bradycardia, atrioventricular block, cardiac arrest, and serious ventricular arrhythmias such as torsade de pointes.", "source": "DDInter", "management_text": "The use of eliglustat in combination with one or more drugs that may result in moderate or potent inhibition of both CYP450 2D6 and 3A4 is considered contraindicated in CYP450 2D6 intermediate metabolizers (IMs) and extensive metabolizers (EMs). In the absence of a concomitant CYP450 3A4 inhibitor, eliglustat may be prescribed at a reduced dosage of 84 mg once daily to IMs and EMs treated with a potent or moderate CYP450 2D6 inhibitor. Poor metabolizers are not affected by CYP450 2D6 inhibition (since they already have minimal functional levels of the isoenzyme) and may also receive the reduced dosage of eliglustat, so long as they are not treated with a CYP450 3A4 inhibitor.", "mechanism_text": "Metabolism", "recommendation": "The use of eliglustat in combination with one or more drugs that may result in moderate or potent inhibition of both CYP450 2D6 and 3A4 is considered contraindicated in CYP450 2D6 intermediate metabolizers (IMs) and extensive metabolizers (EMs).", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97366/", "reference_text": "[1] \"Product Information. Cerdelga (eliglustat).\" Genzyme Corporation, Cambridge, MA.[2] \"Product Information. Cerdelga (eliglustat).\" Genzyme Corporation, Cambridge, MA.", "alternatives_a": "Phenelzine, Citalopram, Tranylcypromine, Desvenlafaxine, Isocarboxazid, Oxitriptan, Tryptophan, Milnacipran, Levomilnacipran, Vilazodone, Esketamine, More", "alternatives_b": "Teduglutide, Lonafarnib, Fosdenopterin, Miglustat, Imiglucerase, Asfotase alfa, Pegvaliase, Triethylenetetramine, Sapropterin, Zinc acetate, Phenylbutyric acid, More", "updated_at": 1767369485}, {"id": 97263, "ingredient1": "Eliglustat", "ingredient2": "Pazopanib", "severity": "Moderate", "effect": "Coadministration with weak inhibitors of CYP450 3A4 may increase the plasma concentrations of eliglustat, which is primarily metabolized by CYP450 2D6 and, to a lesser extent, CYP450 3A4. Eliglustat at substantially elevated plasma concentrations is predicted to cause prolongation of the PR, QTc and QRS cardiac intervals, which may increase the risk of bradycardia, atrioventricular block, cardiac arrest, and serious ventricular arrhythmias such as torsade de pointes.", "source": "DDInter", "management_text": "Concomitant use of eliglustat with weak CYP450 3A4 inhibitors such as chloramphenicol, cyclosporine, danazol, dasatinib, ethinyl estradiol, fluvoxamine, goldenseal, isoniazid, ivacaftor, lapatinib, lomitapide, nifedipine, nilotinib, palbociclib, pazopanib, suvorexant, ticagrelor, and zafirlukast is not recommended in CYP450 2D6 poor metabolizers. No dosage adjustment for eliglustat is necessary when used with weak CYP450 3A4 inhibitors in extensive or intermediate metabolizers.", "mechanism_text": "Metabolism", "recommendation": "Concomitant use of eliglustat with weak CYP450 3A4 inhibitors such as chloramphenicol, cyclosporine, danazol, dasatinib, ethinyl estradiol, fluvoxamine, goldenseal, isoniazid, ivacaftor, lapatinib, lomitapide, nifedipine, nilotinib, palbociclib, pazopanib, suvorexant, ticagrelor, and zafirlukast is not recommended in CYP450 2D6 poor metabolizers.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97367/", "reference_text": "[1] \"Product Information. Cerdelga (eliglustat).\" Genzyme Corporation, Cambridge, MA.[2] \"Product Information. Cerdelga (eliglustat).\" Genzyme Corporation, Cambridge, MA.", "alternatives_a": "Acalabrutinib, Tepotinib, Avapritinib, Selumetinib, Vandetanib, Capmatinib, Ibrutinib, Tivozanib, Zanubrutinib, Axitinib, Sunitinib, More", "alternatives_b": "Teduglutide, Fosdenopterin, Miglustat, Imiglucerase, Asfotase alfa, Glycerol phenylbutyrate, Pegvaliase, Triethylenetetramine, Sapropterin, Zinc acetate, Phenylbutyric acid, More", "updated_at": 1767369485}, {"id": 97264, "ingredient1": "Eliglustat", "ingredient2": "Pentobarbital", "severity": "Moderate", "effect": "Coadministration with inducers of CYP450 3A4 and/or P-glycoprotein (P-gp) may decrease the plasma concentrations of eliglustat, which is primarily metabolized by CYP450 2D6 and, to a lesser extent, CYP450 3A4. Eliglustat is also a substrate of P-gp efflux transporter.", "source": "DDInter", "management_text": "Patients receiving eliglustat with CYP450 3A4 inducers should be monitored for potentially diminished pharmacologic response to eliglustat. Concomitant use should be avoided if an interaction is suspected.", "mechanism_text": "Metabolism", "recommendation": "Patients receiving eliglustat with CYP450 3A4 inducers should be monitored for potentially diminished pharmacologic response to eliglustat.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97368/", "reference_text": "[1] \"Product Information. Cerdelga (eliglustat).\" Genzyme Corporation, Cambridge, MA.[2] \"Product Information. Cerdelga (eliglustat).\" Genzyme Corporation, Cambridge, MA.", "alternatives_a": "Triazolam, Flurazepam, Methohexital, Zolpidem, Zaleplon, Dichloralphenazone, Valerian, Temazepam, Chloral hydrate, Quazepam, Paraldehyde, More", "alternatives_b": "Teduglutide, Fosdenopterin, Miglustat, Imiglucerase, Asfotase alfa, Glycerol phenylbutyrate, Pegvaliase, Triethylenetetramine, Sapropterin, Zinc acetate, Phenylbutyric acid, More", "updated_at": 1767369485}, {"id": 97265, "ingredient1": "Eliglustat", "ingredient2": "Perphenazine", "severity": "Moderate", "effect": "Coadministration with eliglustat may increase the plasma concentrations of drugs that are primarily metabolized by CYP450 2D6.", "source": "DDInter", "management_text": "Caution is advised if eliglustat is used concomitantly with medications that undergo metabolism primarily by CYP450 2D6, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever eliglustat is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if eliglustat is used concomitantly with medications that undergo metabolism primarily by CYP450 2D6, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97369/", "reference_text": "[1] \"Product Information. Cerdelga (eliglustat).\" Genzyme Corporation, Cambridge, MA.[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] \"Product Information. Cerdelga (eliglustat).\" Genzyme Corporation, Cambridge, MA.[5] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[6] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[7] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[8] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.", "alternatives_a": "Quetiapine, Asenapine, Promazine, Prochlorperazine, Thiothixene, Pimavanserin, Lumateperone, Ziprasidone, Olanzapine, Trifluoperazine, Amisulpride, More", "alternatives_b": "Teduglutide, Lonafarnib, Fosdenopterin, Miglustat, Imiglucerase, Asfotase alfa, Pegvaliase, Triethylenetetramine, Sapropterin, Zinc acetate, Phenylbutyric acid, More", "updated_at": 1767369485}, {"id": 97266, "ingredient1": "Eliglustat", "ingredient2": "Pexidartinib", "severity": "Moderate", "effect": "Coadministration with inducers of CYP450 3A4 and/or P-glycoprotein (P-gp) may decrease the plasma concentrations of eliglustat, which is primarily metabolized by CYP450 2D6 and, to a lesser extent, CYP450 3A4. Eliglustat is also a substrate of P-gp efflux transporter.", "source": "DDInter", "management_text": "Patients receiving eliglustat with CYP450 3A4 inducers should be monitored for potentially diminished pharmacologic response to eliglustat. Concomitant use should be avoided if an interaction is suspected.", "mechanism_text": "Metabolism", "recommendation": "Patients receiving eliglustat with CYP450 3A4 inducers should be monitored for potentially diminished pharmacologic response to eliglustat.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97370/", "reference_text": "[1] \"Product Information. Cerdelga (eliglustat).\" Genzyme Corporation, Cambridge, MA.[2] \"Product Information. Cerdelga (eliglustat).\" Genzyme Corporation, Cambridge, MA.", "alternatives_a": "Teduglutide, Fosdenopterin, Miglustat, Imiglucerase, Asfotase alfa, Glycerol phenylbutyrate, Pegvaliase, Triethylenetetramine, Sapropterin, Zinc acetate, Phenylbutyric acid, More", "alternatives_b": "Acalabrutinib, Tepotinib, Avapritinib, Selumetinib, Vandetanib, Capmatinib, Ibrutinib, Tivozanib, Zanubrutinib, Axitinib, Sunitinib, More", "updated_at": 1767369485}, {"id": 97267, "ingredient1": "Eliglustat", "ingredient2": "Phenylbutazone", "severity": "Moderate", "effect": "Coadministration with inducers of CYP450 3A4 and/or P-glycoprotein (P-gp) may decrease the plasma concentrations of eliglustat, which is primarily metabolized by CYP450 2D6 and, to a lesser extent, CYP450 3A4. Eliglustat is also a substrate of P-gp efflux transporter.", "source": "DDInter", "management_text": "Patients receiving eliglustat with CYP450 3A4 inducers should be monitored for potentially diminished pharmacologic response to eliglustat. Concomitant use should be avoided if an interaction is suspected.", "mechanism_text": "Metabolism", "recommendation": "Patients receiving eliglustat with CYP450 3A4 inducers should be monitored for potentially diminished pharmacologic response to eliglustat.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97371/", "reference_text": "[1] \"Product Information. Cerdelga (eliglustat).\" Genzyme Corporation, Cambridge, MA.[2] \"Product Information. Cerdelga (eliglustat).\" Genzyme Corporation, Cambridge, MA.", "alternatives_a": "Acetylsalicylic acid, Rabeprazole, Ketoprofen, Diclofenac, Piroxicam, Rofecoxib, Sulindac, Meclofenamic acid, Etodolac, Ketorolac, Misoprostol, More", "alternatives_b": "Teduglutide, Fosdenopterin, Miglustat, Imiglucerase, Asfotase alfa, Glycerol phenylbutyrate, Pegvaliase, Triethylenetetramine, Sapropterin, Zinc acetate, Phenylbutyric acid, More", "updated_at": 1767369485}, {"id": 97268, "ingredient1": "Eliglustat", "ingredient2": "Phenytoin", "severity": "Major", "effect": "Coadministration with potent inducers of CYP450 3A4 and/or P-glycoprotein (P-gp) may significantly decrease the plasma concentrations of eliglustat, which is primarily metabolized by CYP450 2D6 and, to a lesser extent, CYP450 3A4. Eliglustat is also a substrate of P-gp efflux transporter.", "source": "DDInter", "management_text": "Concomitant use of eliglustat with potent CYP450 3A4 or P-gp inducers should generally be avoided due to the potential for significantly reduced efficacy.", "mechanism_text": "Metabolism", "recommendation": "Concomitant use of eliglustat with potent CYP450 3A4 or P-gp inducers should generally be avoided due to the potential for significantly reduced efficacy.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97372/", "reference_text": "[1] Cerner Multum, Inc. \"Australian Product Information.\" O 0[2] \"Product Information. Cerdelga (eliglustat).\" Genzyme Corporation, Cambridge, MA.[3] \"Product Information. Cerdelga (eliglustat).\" Genzyme Corporation, Cambridge, MA.[4] \"Product Information. Cerdelga (eliglustat).\" Genzyme Corporation, Cambridge, MA.[5] \"Product Information. Trikafta (elexacaftor/ivacaftor/tezacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[6] \"Product Information. Kalydeco (ivacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[7] \"Product Information. Orkambi (ivacaftor-lumacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[8] \"Product Information. Symdeko 4-Week (ivacaftor-tezacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.", "alternatives_a": "Brivaracetam, Topiramate, Ezogabine, Lamotrigine, Ethosuximide, Lacosamide, Levetiracetam, Tiagabine, Ethotoin, Clonazepam, Paramethadione, More", "alternatives_b": "Teduglutide, Fosdenopterin, Miglustat, Imiglucerase, Asfotase alfa, Glycerol phenylbutyrate, Pegvaliase, Triethylenetetramine, Sapropterin, Zinc acetate, Phenylbutyric acid, More", "updated_at": 1767369485}, {"id": 97269, "ingredient1": "Eliglustat", "ingredient2": "Pimozide", "severity": "Major", "effect": "Coadministration with inhibitors of CYP450 2D6 may increase the plasma concentrations of pimozide, which is partially metabolized by the isoenzyme. The use of pimozide has been associated with dose-related prolongation of the QT interval, thus elevated plasma levels of the drug may potentiate the risk of ventricular arrhythmias such as ventricular tachycardia and torsade de pointes as well as cardiac arrest and sudden death.", "source": "DDInter", "management_text": "Due to the narrow therapeutic index of pimozide, concomitant use of pimozide in combination with moderate inhibitors of CYP450 2D6 should preferably be avoided if possible. Otherwise, close monitoring for the development of electrocardiographic abnormalities, extrapyramidal reactions (i.e., acute dystonic reactions, tardive dyskinesia, akathisia, Parkinson-like symptoms), and hypotension is recommended if concurrent use is required. Patients should be advised to seek medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitations, irregular heartbeat, shortness of breath, or syncope. The manufacturers consider the use of pimozide with potent CYP450 2D6 inhibitors such as fluoxetine, paroxetine, and quinidine to be contraindicated.", "mechanism_text": "Metabolism", "recommendation": "Due to the narrow therapeutic index of pimozide, concomitant use of pimozide in combination with moderate inhibitors of CYP450 2D6 should preferably be avoided if possible.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97373/", "reference_text": "[1] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[2] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid.\"[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] Cerner Multum, Inc. \"Australian Product Information.\" O 0[5] \"Product Information. Orap Tablets (pimozide).\" Gate Pharmaceuticals, Sellersville, PA.[6] Dresser GK, Spence JD, Bailey DG \"Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition.\" Clin Pharmacokinet 38 (2000): 41-57[7] \"Product Information. Orap Tablets (pimozide).\" Gate Pharmaceuticals, Sellersville, PA.", "alternatives_a": "Quetiapine, Asenapine, Promazine, Prochlorperazine, Thiothixene, Pimavanserin, Lumateperone, Ziprasidone, Olanzapine, Trifluoperazine, Amisulpride, More", "alternatives_b": "Teduglutide, Fosdenopterin, Miglustat, Imiglucerase, Asfotase alfa, Pegvaliase, Triethylenetetramine, Sapropterin, Zinc acetate, Phenylbutyric acid, Agalsidase beta, More", "updated_at": 1767369485}, {"id": 97270, "ingredient1": "Eliglustat", "ingredient2": "Pirfenidone", "severity": "Moderate", "effect": "Coadministration with moderate or potent inhibitors of CYP450 2C9, 2C19, 2D6, and/or 2E1 may increase the plasma concentrations of pirfenidone, especially when used in addition to a moderate or potent CYP450 1A2 inhibitor. Pirfenidone is primarily (70% to 80%) metabolized by CYP450 1A2, with minor contribution from CYP450 2C9, 2C19, 2D6, and 2E1.", "source": "DDInter", "management_text": "Concomitant use of pirfenidone with moderate or potent inhibitors of CYP450 2C9, 2C19, 2D6, and/or 2E1 in addition to a moderate or potent inhibitor of CYP450 1A2 (e.g., certain fluoroquinolones, oral contraceptives, deferasirox, methoxsalen, mexiletine, thiabendazole, ticlopidine, zileuton) should be avoided. No particular precaution is necessary if pirfenidone and CYP450 2C9, 2C19, 2D6, and/or 2E1 inhibitors are coadministered without a moderate or potent CYP450 1A2 inhibitor.", "mechanism_text": "Metabolism", "recommendation": "Concomitant use of pirfenidone with moderate or potent inhibitors of CYP450 2C9, 2C19, 2D6, and/or 2E1 in addition to a moderate or potent inhibitor of CYP450 1A2 (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97374/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Esbriet (pirfenidone).\" Intermune Inc, Brisbane, CA.[3] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[4] \"Product Information. VFEND (voriconazole).\" Pfizer U.S. Pharmaceuticals, New York, NY.[5] \"Product Information. Esbriet (pirfenidone).\" Intermune Inc, Brisbane, CA.[6] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0", "alternatives_a": "Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Methotrexate, More", "alternatives_b": "Lipoic acid, Triheptanoin, Teduglutide, Fosdenopterin, Triethylenetetramine, Miglustat, Sapropterin, Zinc acetate, Levocarnitine, Laronidase, Imiglucerase, More", "updated_at": 1767369485}, {"id": 97271, "ingredient1": "Eliglustat", "ingredient2": "Pitolisant", "severity": "Moderate", "effect": "Coadministration with inhibitors of CYP450 2D6 may increase plasma concentrations of pitolisant. The proposed mechanism is decreased clearance of pitolisant due to inhibition of its metabolism via this isoenzyme. Clinically, high plasma levels of pitolisant may increase the risk of QT interval prolongation, which has been associated with ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Caution and clinical monitoring are recommended if pitolisant is used in combination with CYP450 2D6 inhibitors. Patients should be monitored for clinical response and increased adverse effects such as headache, insomnia, nausea, anxiety, increased heart rate, QT prolongation, hallucinations, abdominal pain, upper respiratory tract infections and musculoskeletal pain, and the dosage of pitolisant adjusted as necessary in accordance with the product labeling.", "mechanism_text": "Metabolism", "recommendation": "Caution and clinical monitoring are recommended if pitolisant is used in combination with CYP450 2D6 inhibitors.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97375/", "reference_text": "[1] \"Product Information. Wakix (pitolisant).\" Harmony Biosciences, LLC, Plymouth Meeting, PA.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[4] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[5] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[6] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.", "alternatives_a": "Lipoic acid, Triheptanoin, Teduglutide, Fosdenopterin, Triethylenetetramine, Miglustat, Sapropterin, Zinc acetate, Levocarnitine, Laronidase, Imiglucerase, More", "alternatives_b": "Valbenazine, Dalfampridine, Sodium oxybate, Riluzole, Inotersen, Amifampridine, Deutetrabenazine, Tafamidis", "updated_at": 1767369485}, {"id": 97272, "ingredient1": "Eliglustat", "ingredient2": "Posaconazole", "severity": "Major", "effect": "Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of eliglustat, which is primarily metabolized by CYP450 2D6 and, to a lesser extent, CYP450 3A4. Eliglustat at substantially elevated plasma concentrations is predicted to cause prolongation of the PR, QTc and QRS cardiac intervals, which may increase the risk of bradycardia, atrioventricular block, cardiac arrest, and serious ventricular arrhythmias such as torsade de pointes.", "source": "DDInter", "management_text": "The use of eliglustat with a potent CYP450 3A4 inhibitor is considered contraindicated in CYP450 2D6 poor metabolizers (PMs) and intermediate metabolizers (IMs). The contraindication is extended to extensive metabolizers (EMs) when a moderate or potent CYP450 2D6 inhibitor is given concomitantly with a moderate or potent CYP450 3A4 inhibitor. In the absence of a concomitant CYP450 2D6 inhibitor, eliglustat may be prescribed at a reduced dosage of 84 mg once daily to EMs treated with a potent CYP450 3A4 inhibitor. Potent CYP450 3A4 inhibitors include itraconazole, ketoconazole, posaconazole, voriconazole, conivaptan, ceritinib, idelalisib, mibefradil, nefazodone, cobicistat, delavirdine, protease inhibitors, and ketolide and certain macrolide antibiotics. Potent and moderate CYP450 2D6 inhibitors include abiraterone, bupropion, celecoxib, cimetidine, cinacalcet, clobazam, darifenacin, diphenhydramine, dronedarone, duloxetine, flecainide, fluoxetine, methotrimeprazine, mirabegron, paroxetine, propafenone, propoxyphene, quinidine, ranolazine, sertraline, and terbinafine. Some drugs such as cobicistat, delavirdine, mibefradil, and ritonavir are dual CYP450 3A4 and 2D6 inhibitors, and they should not be used with eliglustat in any patient regardless of their CYP450 2D6 metabolizer status.", "mechanism_text": "Metabolism", "recommendation": "The use of eliglustat with a potent CYP450 3A4 inhibitor is considered contraindicated in CYP450 2D6 poor metabolizers (PMs) and intermediate metabolizers (IMs).", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97376/", "reference_text": "[1] Cerner Multum, Inc. \"Australian Product Information.\" O 0[2] \"Product Information. Sporanox (itraconazole).\" Janssen Pharmaceutica, Titusville, NJ.[3] \"Product Information. Cerdelga (eliglustat).\" Genzyme Corporation, Cambridge, MA.[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] \"Product Information. Cerdelga (eliglustat).\" Genzyme Corporation, Cambridge, MA.[6] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[7] \"Product Information. VFEND (voriconazole).\" Pfizer U.S. Pharmaceuticals, New York, NY.", "alternatives_a": "Caspofungin, Micafungin, Amphotericin B, Oteseconazole, Flucytosine, Anidulafungin", "alternatives_b": "Teduglutide, Fosdenopterin, Miglustat, Imiglucerase, Asfotase alfa, Glycerol phenylbutyrate, Pegvaliase, Triethylenetetramine, Sapropterin, Zinc acetate, Phenylbutyric acid, More", "updated_at": 1767369485}, {"id": 97273, "ingredient1": "Eliglustat", "ingredient2": "Primidone", "severity": "Major", "effect": "Coadministration with potent inducers of CYP450 3A4 and/or P-glycoprotein (P-gp) may significantly decrease the plasma concentrations of eliglustat, which is primarily metabolized by CYP450 2D6 and, to a lesser extent, CYP450 3A4. Eliglustat is also a substrate of P-gp efflux transporter.", "source": "DDInter", "management_text": "Concomitant use of eliglustat with potent CYP450 3A4 or P-gp inducers should generally be avoided due to the potential for significantly reduced efficacy.", "mechanism_text": "Metabolism", "recommendation": "Concomitant use of eliglustat with potent CYP450 3A4 or P-gp inducers should generally be avoided due to the potential for significantly reduced efficacy.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97377/", "reference_text": "[1] Cerner Multum, Inc. \"Australian Product Information.\" O 0[2] \"Product Information. Cerdelga (eliglustat).\" Genzyme Corporation, Cambridge, MA.[3] \"Product Information. Cerdelga (eliglustat).\" Genzyme Corporation, Cambridge, MA.[4] \"Product Information. Cerdelga (eliglustat).\" Genzyme Corporation, Cambridge, MA.[5] \"Product Information. Trikafta (elexacaftor/ivacaftor/tezacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[6] \"Product Information. Kalydeco (ivacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[7] \"Product Information. Orkambi (ivacaftor-lumacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[8] \"Product Information. Symdeko 4-Week (ivacaftor-tezacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.", "alternatives_a": "Triazolam, Flurazepam, Methohexital, Zolpidem, Zaleplon, Dichloralphenazone, Valerian, Temazepam, Chloral hydrate, Quazepam, Paraldehyde, More", "alternatives_b": "Lipoic acid, Triheptanoin, Teduglutide, Fosdenopterin, Triethylenetetramine, Miglustat, Sapropterin, Zinc acetate, Levocarnitine, Laronidase, Imiglucerase, More", "updated_at": 1767369485}, {"id": 97274, "ingredient1": "Eliglustat", "ingredient2": "Procainamide", "severity": "Major", "effect": "Class IA (e.g., disopyramide, quinidine, procainamide) and class III (e.g., amiodarone, dofetilide, sotalol) antiarrhythmic agents can cause dose-related prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Coadministration of class IA or class III antiarrhythmic agents with other drugs that can prolong the QT interval should preferably be avoided unless benefits are anticipated to outweigh the risks. Caution and clinical monitoring are recommended if concomitant use is required. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Coadministration of class IA or class III antiarrhythmic agents with other drugs that can prolong the QT interval should preferably be avoided unless benefits are anticipated to outweigh the risks.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97378/", "reference_text": "[1] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[2] Yamreudeewong W, DeBisschop M, Martin L, Lower D \"Potentially Significant Drug Interactions of Class III Antiarrhythmic Drugs.\" Drug Saf 26 (2003): 421-38[3] \"Product Information. Norpace (disopyramide).\" Searle, Skokie, IL.[4] Cerner Multum, Inc. \"Australian Product Information.\" O 0[5] \"Product Information. Betapace (sotalol).\" Berlex, Richmond, CA.[6] \"Product Information. Procan SR (procainamide).\" Parke-Davis, Morris Plains, NJ.[7] Maxa JL, Hebeler RF, Adeeko MA \"Torsades de pointes following concurrent amiodarone and levofloxacin therapy.\" Proc (Bayl Univ Med Cent) 19 (2006): 345-6[8] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[9] \"Product Information. Cordarone (amiodarone).\" Wyeth-Ayerst Laboratories, Philadelphia, PA.[10] EMA. European Medicines Agency. European Union \"EMA - List of medicines under additional monitoring. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000366.jsp&mid=WC0b01ac058067c852\" ([2013 - ]):[11] \"Product Information. Vascor (bepridil).\" McNeil Pharmaceutical, Raritan, NJ.[12] \"Product Information. Quiniglute (quinidine).\" Berlex, Richmond, CA.[13] Trujillo TC, Nolan PE \"Antiarrhythmic agents - Drug interactions of clinical significance.\" Drug Safety 23 (2000): 509-32[14] Gunston GD, Mehta U \"Potentially serious drug interactions with grapefruit juice.\" S Afr Med J 90 (2000): 41[15] Bailey DG, Arnold JMO, Spence JD \"Grapefruit juice and drugs - how significant is the interaction.\" Clin Pharmacokinet 26 (1994): 91-8[16] Fuhr U, Maier-Bruggemann A, Blume H, et al. \"Grapefruit juice increases oral nimodipine bioavailability.\" Int J Clin Pharmacol Ther 36 (1998): 126-32[17] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[18] Libersa CC, Brique SA, Motte KB, et al. \"Dramatic inhibition of amiodarone metabolism induced by grapefruit juice.\" Br J Clin Pharmacol 49 (2000): 373-8[19] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions.\" Br J Clin Pharmacol 46 (1998): 101-10[20] Bailey DG, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit juice felodipine interaction: Effect of naringin and 6',7'-dihydroxybergamottin in humans.\" Clin Pharmacol Ther 64 (1998): 248-56[21] Takanaga H, Ohnishi A, Maatsuo H, et al. \"Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model.\" Br J Clin Pharmacol 49 (2000): 49-58[22] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[23] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS \"Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice.\" Br J Clin Pharmacol 42 (1996): p662[24] Eagling VA, Profit L, Back DJ \"Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-I protease inhibitor saquinavir by grapefruit juice components.\" Br J Clin Pharmacol 48 (1999): 543-52[25] Bailey DG, Arnold JM, Strong HA, Munoz C, Spence JD \"Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics.\" Clin Pharmacol Ther 54 (1993): 589-94[26] Damkier P, Hansen LL, Brosen K \"Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine.\" Br J Clin Pharmacol 48 (1999): 829-38[27] Min DI, Ku YM, Geraets DR, Lee HC \"Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers.\" J Clin Pharmacol 36 (1996): 469-76[28] Josefsson M, Zackrisson AL, Ahlner J \"Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers.\" Eur J Clin Pharmacol 51 (1996): 189-93[29] Majeed A, Kareem A \"Effect of grapefruit juice on cyclosporine pharmacokinetics.\" Pediatr Nephrol 10 (1996): 395[30] Flanagan D \"Understanding the grapefruit-drug interaction.\" Gen Dent 53 (2005): 282-5; quiz 286[31] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ \"Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice.\" Clin Pharmacol Ther 58 (1995): 127-31[32] Jonkman JH, Sollie FA, Sauter R, Steinijans VW \"The influence of caffeine on the steady-state pharmacokinetics of theophylline.\" Clin Pharmacol Ther 49 (1991): 248-55[33] Ozdemir M, Aktan Y, Boydag BS, Cingi MI, Musmul A \"Interaction between grapefruit juice and diazepam in humans.\" Eur J Drug Metab Pharmacokinet 23 (1998): 55-9[34] Edgar B, Bailey D, Bergstrand R, et al \"Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics on felodipine and its potential clinical relevance.\" Eur J Clin Pharmacol 42 (1992): 313-7[35] Kantola T, Kivisto KT, Neuvonen PJ \"Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid.\" Clin Pharmacol Ther 63 (1998): 397-402[36] Lee AJ, Chan WK, Harralson AF, Buffum J, Bui BCC \"The effects of grapefruit juice on sertraline metabolism: An in vitro and in vivo study.\" Clin Ther 21 (1999): 1890-9[37] Sato J, Nakata H, Owada E, Kikuta T, Umetsu M, Ito K \"Influence of usual intake of dietary caffeine on single-dose kinetics of theophylline in healthy human subjects.\" Eur J Clin Pharmacol 44 (1993): 295-8[38] Dresser GK, Spence JD, Bailey DG \"Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition.\" Clin Pharmacokinet 38 (2000): 41-57[39] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin.\" Clin Pharmacol Ther 66 (1999): 118-27[40] Sigusch H, Hippius M, Henschel L, Kaufmann K, Hoffmann A \"Influence of grapefruit juice on the pharmacokinetics of a slow release nifedipine formulation.\" Pharmazie 49 (1994): 522-4[41] Bailey DG, Arnold JM, Munoz C, Spence JD \"Grapefruit juice--felodipine interaction: mechanism, predictability, and effect of naringin.\" Clin Pharmacol Ther 53 (1993): 637-42[42] Zaidenstein R, Soback S, Gips M, Avni B, Dishi V, Weissgarten Y, Golik A, Scapa E \"Effect of grapefruit juice on the pharmacokinetics of losartan and its active metabolite E3174 in healthy volunteers.\" Ther Drug Monit 23 (2001): 369-73[43] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84[44] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors.\" Clin Pharmacol Ther 64 (1998): 477-83[45] Garg SK, Kumar N, Bhargava VK, Prabhakar SK \"Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy.\" Clin Pharmacol Ther 64 (1998): 286-8", "alternatives_a": "Lidocaine, Moricizine, Bretylium, Tocainide", "alternatives_b": "Teduglutide, Lonafarnib, Fosdenopterin, Miglustat, Imiglucerase, Asfotase alfa, Glycerol phenylbutyrate, Pegvaliase, Triethylenetetramine, Sapropterin, Zinc acetate, More", "updated_at": 1767369485}, {"id": 97275, "ingredient1": "Eliglustat", "ingredient2": "Promethazine", "severity": "Moderate", "effect": "Coadministration with eliglustat may increase the plasma concentrations of drugs that are primarily metabolized by CYP450 2D6.", "source": "DDInter", "management_text": "Caution is advised if eliglustat is used concomitantly with medications that undergo metabolism primarily by CYP450 2D6, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever eliglustat is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if eliglustat is used concomitantly with medications that undergo metabolism primarily by CYP450 2D6, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97379/", "reference_text": "[1] \"Product Information. Cerdelga (eliglustat).\" Genzyme Corporation, Cambridge, MA.[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] \"Product Information. Cerdelga (eliglustat).\" Genzyme Corporation, Cambridge, MA.[5] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[6] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[7] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[8] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.", "alternatives_a": "Ketotifen, Mepyramine, Levocetirizine, Chlorcyclizine, Cetirizine, Acrivastine, Triprolidine, Tripelennamine, Azelastine, Dexbrompheniramine, Clemastine, More", "alternatives_b": "Teduglutide, Lonafarnib, Fosdenopterin, Miglustat, Imiglucerase, Asfotase alfa, Pegvaliase, Triethylenetetramine, Sapropterin, Zinc acetate, Phenylbutyric acid, More", "updated_at": 1767369485}, {"id": 97276, "ingredient1": "Eliglustat", "ingredient2": "Propafenone", "severity": "Major", "effect": "Coadministration with inhibitors of CYP450 2D6 may significantly increase the plasma concentrations of eliglustat, which is primarily metabolized by CYP450 2D6 and, to a lesser extent, CYP450 3A4. Eliglustat at substantially elevated plasma concentrations is predicted to cause prolongation of the PR, QTc and QRS cardiac intervals, which may increase the risk of bradycardia, atrioventricular block, cardiac arrest, and serious ventricular arrhythmias such as torsade de pointes.", "source": "DDInter", "management_text": "The use of eliglustat in combination with one or more drugs that may result in moderate or potent inhibition of both CYP450 2D6 and 3A4 is considered contraindicated in CYP450 2D6 intermediate metabolizers (IMs) and extensive metabolizers (EMs). In the absence of a concomitant CYP450 3A4 inhibitor, eliglustat may be prescribed at a reduced dosage of 84 mg once daily to IMs and EMs treated with a potent or moderate CYP450 2D6 inhibitor. Poor metabolizers are not affected by CYP450 2D6 inhibition (since they already have minimal functional levels of the isoenzyme) and may also receive the reduced dosage of eliglustat, so long as they are not treated with a CYP450 3A4 inhibitor.", "mechanism_text": "Metabolism", "recommendation": "The use of eliglustat in combination with one or more drugs that may result in moderate or potent inhibition of both CYP450 2D6 and 3A4 is considered contraindicated in CYP450 2D6 intermediate metabolizers (IMs) and extensive metabolizers (EMs).", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97380/", "reference_text": "[1] \"Product Information. Cerdelga (eliglustat).\" Genzyme Corporation, Cambridge, MA.[2] \"Product Information. Cerdelga (eliglustat).\" Genzyme Corporation, Cambridge, MA.", "alternatives_a": "Lidocaine, Moricizine, Bretylium, Tocainide", "alternatives_b": "Teduglutide, Fosdenopterin, Miglustat, Imiglucerase, Asfotase alfa, Pegvaliase, Triethylenetetramine, Sapropterin, Zinc acetate, Phenylbutyric acid, Agalsidase beta, More", "updated_at": 1767369485}, {"id": 97277, "ingredient1": "Eliglustat", "ingredient2": "Dextropropoxyphene", "severity": "Major", "effect": "Coadministration with inhibitors of CYP450 2D6 may significantly increase the plasma concentrations of eliglustat, which is primarily metabolized by CYP450 2D6 and, to a lesser extent, CYP450 3A4. Eliglustat at substantially elevated plasma concentrations is predicted to cause prolongation of the PR, QTc and QRS cardiac intervals, which may increase the risk of bradycardia, atrioventricular block, cardiac arrest, and serious ventricular arrhythmias such as torsade de pointes.", "source": "DDInter", "management_text": "The use of eliglustat in combination with one or more drugs that may result in moderate or potent inhibition of both CYP450 2D6 and 3A4 is considered contraindicated in CYP450 2D6 intermediate metabolizers (IMs) and extensive metabolizers (EMs). In the absence of a concomitant CYP450 3A4 inhibitor, eliglustat may be prescribed at a reduced dosage of 84 mg once daily to IMs and EMs treated with a potent or moderate CYP450 2D6 inhibitor. Poor metabolizers are not affected by CYP450 2D6 inhibition (since they already have minimal functional levels of the isoenzyme) and may also receive the reduced dosage of eliglustat, so long as they are not treated with a CYP450 3A4 inhibitor.", "mechanism_text": "Metabolism", "recommendation": "The use of eliglustat in combination with one or more drugs that may result in moderate or potent inhibition of both CYP450 2D6 and 3A4 is considered contraindicated in CYP450 2D6 intermediate metabolizers (IMs) and extensive metabolizers (EMs).", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97381/", "reference_text": "[1] \"Product Information. Cerdelga (eliglustat).\" Genzyme Corporation, Cambridge, MA.[2] \"Product Information. Cerdelga (eliglustat).\" Genzyme Corporation, Cambridge, MA.", "alternatives_a": "Naltrexone, Oxymorphone, Oxycodone, Methadone, Pentazocine, Buprenorphine, Butorphanol, Fentanyl, Ibuprofen, Nalbuphine, Acetaminophen, More", "alternatives_b": "Teduglutide, Lonafarnib, Fosdenopterin, Miglustat, Imiglucerase, Asfotase alfa, Pegvaliase, Triethylenetetramine, Sapropterin, Zinc acetate, Phenylbutyric acid, More", "updated_at": 1767369485}, {"id": 97278, "ingredient1": "Eliglustat", "ingredient2": "Propranolol", "severity": "Moderate", "effect": "Coadministration with eliglustat may increase the plasma concentrations of drugs that are primarily metabolized by CYP450 2D6.", "source": "DDInter", "management_text": "Caution is advised if eliglustat is used concomitantly with medications that undergo metabolism primarily by CYP450 2D6, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever eliglustat is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if eliglustat is used concomitantly with medications that undergo metabolism primarily by CYP450 2D6, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97382/", "reference_text": "[1] \"Product Information. Cerdelga (eliglustat).\" Genzyme Corporation, Cambridge, MA.[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] \"Product Information. Cerdelga (eliglustat).\" Genzyme Corporation, Cambridge, MA.[5] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[6] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[7] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[8] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.", "alternatives_a": "Felodipine, Bisoprolol, Ivabradine, Acetylsalicylic acid, Atenolol, Acebutolol, Labetalol, Nadolol, Esmolol, Betaxolol, Penbutolol, More", "alternatives_b": "Teduglutide, Fosdenopterin, Miglustat, Imiglucerase, Asfotase alfa, Pegvaliase, Triethylenetetramine, Sapropterin, Zinc acetate, Phenylbutyric acid, Agalsidase beta, More", "updated_at": 1767369485}, {"id": 97279, "ingredient1": "Eliglustat", "ingredient2": "Protriptyline", "severity": "Moderate", "effect": "Coadministration with eliglustat may increase the plasma concentrations of drugs that are primarily metabolized by CYP450 2D6.", "source": "DDInter", "management_text": "Caution is advised if eliglustat is used concomitantly with medications that undergo metabolism primarily by CYP450 2D6, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever eliglustat is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if eliglustat is used concomitantly with medications that undergo metabolism primarily by CYP450 2D6, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97383/", "reference_text": "[1] \"Product Information. Cerdelga (eliglustat).\" Genzyme Corporation, Cambridge, MA.[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] \"Product Information. Cerdelga (eliglustat).\" Genzyme Corporation, Cambridge, MA.[5] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[6] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[7] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[8] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.", "alternatives_a": "Phenelzine, Citalopram, Tranylcypromine, Desvenlafaxine, Isocarboxazid, Oxitriptan, Tryptophan, Milnacipran, Levomilnacipran, Vilazodone, Esketamine, More", "alternatives_b": "Teduglutide, Lonafarnib, Fosdenopterin, Miglustat, Imiglucerase, Asfotase alfa, Pegvaliase, Triethylenetetramine, Sapropterin, Zinc acetate, Phenylbutyric acid, More", "updated_at": 1767369485}, {"id": 97280, "ingredient1": "Eliglustat", "ingredient2": "Prucalopride", "severity": "Minor", "effect": "Coadministration with inhibitors of P-glycoprotein (P-gp) may increase the plasma concentrations of prucalopride, which is thought to be a weak substrate of the efflux transporter.", "source": "DDInter", "management_text": "-", "mechanism_text": "Others", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97384/", "reference_text": "[1] Cerner Multum, Inc. \"Australian Product Information.\" O 0[2] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid.\"[3] \"Product Information. Resotran (prucalopride).\" Janssen Pharmaceuticals, Titusville, NJ.[4] Cerner Multum, Inc. \"Australian Product Information.\" O 0[5] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid.\"[6] \"Product Information. Resotran (prucalopride).\" Janssen Pharmaceuticals, Titusville, NJ.[7] \"Product Information. Mavyret (glecaprevir-pibrentasvir).\" Abbott Pharmaceutical, Abbott Park, IL.", "alternatives_a": "Alvimopan, Sorbitol, Tegaserod, Bisacodyl, Lactulose, Methylnaltrexone, Lactitol, Sodium phosphate, monobasic, Magnesium oxide, Sodium sulfate, Linaclotide, More", "alternatives_b": "Teduglutide, Lonafarnib, Fosdenopterin, Miglustat, Imiglucerase, Asfotase alfa, Glycerol phenylbutyrate, Pegvaliase, Triethylenetetramine, Sapropterin, Zinc acetate, More", "updated_at": 1767369485}, {"id": 97281, "ingredient1": "Eliglustat", "ingredient2": "Quinidine", "severity": "Major", "effect": "Coadministration with inhibitors of CYP450 2D6 may significantly increase the plasma concentrations of eliglustat, which is primarily metabolized by CYP450 2D6 and, to a lesser extent, CYP450 3A4. Eliglustat at substantially elevated plasma concentrations is predicted to cause prolongation of the PR, QTc and QRS cardiac intervals, which may increase the risk of bradycardia, atrioventricular block, cardiac arrest, and serious ventricular arrhythmias such as torsade de pointes.", "source": "DDInter", "management_text": "The use of eliglustat in combination with one or more drugs that may result in moderate or potent inhibition of both CYP450 2D6 and 3A4 is considered contraindicated in CYP450 2D6 intermediate metabolizers (IMs) and extensive metabolizers (EMs). In the absence of a concomitant CYP450 3A4 inhibitor, eliglustat may be prescribed at a reduced dosage of 84 mg once daily to IMs and EMs treated with a potent or moderate CYP450 2D6 inhibitor. Poor metabolizers are not affected by CYP450 2D6 inhibition (since they already have minimal functional levels of the isoenzyme) and may also receive the reduced dosage of eliglustat, so long as they are not treated with a CYP450 3A4 inhibitor.", "mechanism_text": "Metabolism", "recommendation": "The use of eliglustat in combination with one or more drugs that may result in moderate or potent inhibition of both CYP450 2D6 and 3A4 is considered contraindicated in CYP450 2D6 intermediate metabolizers (IMs) and extensive metabolizers (EMs).", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97385/", "reference_text": "[1] \"Product Information. Cerdelga (eliglustat).\" Genzyme Corporation, Cambridge, MA.[2] \"Product Information. Cerdelga (eliglustat).\" Genzyme Corporation, Cambridge, MA.", "alternatives_a": "Lidocaine, Moricizine, Bretylium, Tocainide", "alternatives_b": "Teduglutide, Fosdenopterin, Miglustat, Imiglucerase, Asfotase alfa, Pegvaliase, Triethylenetetramine, Sapropterin, Zinc acetate, Phenylbutyric acid, Agalsidase beta, More", "updated_at": 1767369485}, {"id": 97282, "ingredient1": "Eliglustat", "ingredient2": "Ranolazine", "severity": "Major", "effect": "Coadministration with inhibitors of CYP450 2D6 may significantly increase the plasma concentrations of eliglustat, which is primarily metabolized by CYP450 2D6 and, to a lesser extent, CYP450 3A4. Eliglustat at substantially elevated plasma concentrations is predicted to cause prolongation of the PR, QTc and QRS cardiac intervals, which may increase the risk of bradycardia, atrioventricular block, cardiac arrest, and serious ventricular arrhythmias such as torsade de pointes.", "source": "DDInter", "management_text": "The use of eliglustat in combination with one or more drugs that may result in moderate or potent inhibition of both CYP450 2D6 and 3A4 is considered contraindicated in CYP450 2D6 intermediate metabolizers (IMs) and extensive metabolizers (EMs). In the absence of a concomitant CYP450 3A4 inhibitor, eliglustat may be prescribed at a reduced dosage of 84 mg once daily to IMs and EMs treated with a potent or moderate CYP450 2D6 inhibitor. Poor metabolizers are not affected by CYP450 2D6 inhibition (since they already have minimal functional levels of the isoenzyme) and may also receive the reduced dosage of eliglustat, so long as they are not treated with a CYP450 3A4 inhibitor.", "mechanism_text": "Metabolism", "recommendation": "The use of eliglustat in combination with one or more drugs that may result in moderate or potent inhibition of both CYP450 2D6 and 3A4 is considered contraindicated in CYP450 2D6 intermediate metabolizers (IMs) and extensive metabolizers (EMs).", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97386/", "reference_text": "[1] \"Product Information. Cerdelga (eliglustat).\" Genzyme Corporation, Cambridge, MA.[2] \"Product Information. Cerdelga (eliglustat).\" Genzyme Corporation, Cambridge, MA.", "alternatives_a": "Alprostadil, Indomethacin, Ibuprofen, Ubidecarenone, Ivabradine, Adenosine, Regadenoson", "alternatives_b": "Lipoic acid, Triheptanoin, Teduglutide, Fosdenopterin, Triethylenetetramine, Miglustat, Sapropterin, Zinc acetate, Levocarnitine, Laronidase, Imiglucerase, More", "updated_at": 1767369485}, {"id": 97283, "ingredient1": "Eliglustat", "ingredient2": "Relugolix", "severity": "Major", "effect": "Coadministration with inhibitors of the P-glycoprotein (P-gp) efflux transporter may increase the plasma concentrations of relugolix, particularly when the inhibitors are given orally. Relugolix is a substrate for intestinal P-gp.", "source": "DDInter", "management_text": "Concomitant use of relugolix with orally administered P-gp inhibitors should generally be avoided. If coadministration is required, the manufacturer recommends taking relugolix first and separating the dosing by at least 6 hours. Patients should be monitored more frequently for adverse effects. Alternatively, treatment with relugolix may be interrupted for up to two weeks if a short course of treatment with a P-gp inhibitor is necessary.", "mechanism_text": "Absorption", "recommendation": "Concomitant use of relugolix with orally administered P-gp inhibitors should generally be avoided.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97387/", "reference_text": "[1] \"Product Information. Orgovyx (relugolix).\" Myovant Sciences, Inc., Brisbane, CA.[2] \"Product Information. Juxtapid (lomitapide).\" Aegerion Pharmaceuticals Inc, Cambridge, MA.", "alternatives_a": "Teduglutide, Fosdenopterin, Miglustat, Imiglucerase, Asfotase alfa, Pegvaliase, Triethylenetetramine, Sapropterin, Zinc acetate, Phenylbutyric acid, Agalsidase beta, More", "alternatives_b": "Norethisterone, Nafarelin, Octreotide, Cetrorelix, Pasireotide, Estradiol, Ganirelix, Lanreotide, Gonadorelin, Darolutamide, Anastrozole, More", "updated_at": 1767369485}, {"id": 97284, "ingredient1": "Eliglustat", "ingredient2": "Ribociclib", "severity": "Major", "effect": "Coadministration with moderate inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of eliglustat, which is primarily metabolized by CYP450 2D6 and, to a lesser extent, CYP450 3A4. Eliglustat at substantially elevated plasma concentrations is predicted to cause prolongation of the PR, QTc and QRS cardiac intervals, which may increase the risk of bradycardia, atrioventricular block, cardiac arrest, and serious ventricular arrhythmias such as torsade de pointes.", "source": "DDInter", "management_text": "The use of eliglustat in combination with one or more drugs that may result in moderate inhibition of CYP450 3A4 and moderate to potent inhibition of CYP450 2D6 is considered contraindicated in CYP450 2D6 extensive metabolizers (EMs) and intermediate metabolizers (IMs). In the absence of a concomitant CYP450 2D6 inhibitor, eliglustat may be prescribed at a reduced dosage of 84 mg once daily to EMs treated with a moderate CYP450 3A4 inhibitor. However, eliglustat should not be used with a moderate CYP450 3A4 inhibitor in CYP450 2D6 IMs or poor metabolizers (PMs). Moderate CYP450 3A4 inhibitors include aprepitant, ciprofloxacin, clotrimazole, crizotinib, darunavir, diltiazem, dronedarone, fluconazole, fusidic acid, imatinib, isavuconazonium, miconazole, mifepristone, netupitant, quinupristin-dalfopristin, ranolazine, stiripentol, and verapamil. Potent and moderate CYP450 2D6 inhibitors include abiraterone, bupropion, celecoxib, cimetidine, cinacalcet, clobazam, darifenacin, diphenhydramine, duloxetine, fluoxetine, methotrimeprazine, mirabegron, paroxetine, propoxyphene, quinidine, ranolazine, sertraline, stiripentol, and terbinafine.", "mechanism_text": "Metabolism", "recommendation": "The use of eliglustat in combination with one or more drugs that may result in moderate inhibition of CYP450 3A4 and moderate to potent inhibition of CYP450 2D6 is considered contraindicated in CYP450 2D6 extensive metabolizers (EMs) and intermediate metabolizers (IMs).", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97388/", "reference_text": "[1] \"Product Information. Cerdelga (eliglustat).\" Genzyme Corporation, Cambridge, MA.[2] \"Product Information. Cerdelga (eliglustat).\" Genzyme Corporation, Cambridge, MA.", "alternatives_a": "Lipoic acid, Triheptanoin, Teduglutide, Fosdenopterin, Triethylenetetramine, Miglustat, Sapropterin, Zinc acetate, Levocarnitine, Laronidase, Imiglucerase, More", "alternatives_b": "Acalabrutinib, Tepotinib, Avapritinib, Selumetinib, Vandetanib, Capmatinib, Ibrutinib, Tivozanib, Zanubrutinib, Axitinib, Sunitinib, More", "updated_at": 1767369485}, {"id": 97285, "ingredient1": "Eliglustat", "ingredient2": "Rifabutin", "severity": "Major", "effect": "Coadministration with potent inducers of CYP450 3A4 and/or P-glycoprotein (P-gp) may significantly decrease the plasma concentrations of eliglustat, which is primarily metabolized by CYP450 2D6 and, to a lesser extent, CYP450 3A4. Eliglustat is also a substrate of P-gp efflux transporter.", "source": "DDInter", "management_text": "Concomitant use of eliglustat with potent CYP450 3A4 or P-gp inducers should generally be avoided due to the potential for significantly reduced efficacy.", "mechanism_text": "Metabolism", "recommendation": "Concomitant use of eliglustat with potent CYP450 3A4 or P-gp inducers should generally be avoided due to the potential for significantly reduced efficacy.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97389/", "reference_text": "[1] Cerner Multum, Inc. \"Australian Product Information.\" O 0[2] \"Product Information. Cerdelga (eliglustat).\" Genzyme Corporation, Cambridge, MA.[3] \"Product Information. Cerdelga (eliglustat).\" Genzyme Corporation, Cambridge, MA.[4] \"Product Information. Cerdelga (eliglustat).\" Genzyme Corporation, Cambridge, MA.[5] \"Product Information. Trikafta (elexacaftor/ivacaftor/tezacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[6] \"Product Information. Kalydeco (ivacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[7] \"Product Information. Orkambi (ivacaftor-lumacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[8] \"Product Information. Symdeko 4-Week (ivacaftor-tezacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.", "alternatives_a": "Capreomycin, Pyrazinamide, Rifamycin, Bedaquiline, Sulfamethoxazole, Streptomycin, Trimethoprim, Cycloserine, Ethambutol, Pyridoxine, Ethionamide, More", "alternatives_b": "Teduglutide, Fosdenopterin, Miglustat, Imiglucerase, Asfotase alfa, Glycerol phenylbutyrate, Pegvaliase, Triethylenetetramine, Sapropterin, Zinc acetate, Phenylbutyric acid, More", "updated_at": 1767369485}, {"id": 97286, "ingredient1": "Eliglustat", "ingredient2": "Rifampicin", "severity": "Major", "effect": "Coadministration with potent inducers of CYP450 3A4 and/or P-glycoprotein (P-gp) may significantly decrease the plasma concentrations of eliglustat, which is primarily metabolized by CYP450 2D6 and, to a lesser extent, CYP450 3A4. Eliglustat is also a substrate of P-gp efflux transporter.", "source": "DDInter", "management_text": "Concomitant use of eliglustat with potent CYP450 3A4 or P-gp inducers should generally be avoided due to the potential for significantly reduced efficacy.", "mechanism_text": "Metabolism", "recommendation": "Concomitant use of eliglustat with potent CYP450 3A4 or P-gp inducers should generally be avoided due to the potential for significantly reduced efficacy.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97390/", "reference_text": "[1] Cerner Multum, Inc. \"Australian Product Information.\" O 0[2] \"Product Information. Cerdelga (eliglustat).\" Genzyme Corporation, Cambridge, MA.[3] \"Product Information. Cerdelga (eliglustat).\" Genzyme Corporation, Cambridge, MA.[4] \"Product Information. Cerdelga (eliglustat).\" Genzyme Corporation, Cambridge, MA.[5] \"Product Information. Trikafta (elexacaftor/ivacaftor/tezacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[6] \"Product Information. Kalydeco (ivacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[7] \"Product Information. Orkambi (ivacaftor-lumacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[8] \"Product Information. Symdeko 4-Week (ivacaftor-tezacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.", "alternatives_a": "Capreomycin, Pyrazinamide, Rifamycin, Bedaquiline, Sulfamethoxazole, Streptomycin, Trimethoprim, Cycloserine, Ethambutol, Pyridoxine, Ethionamide, More", "alternatives_b": "Teduglutide, Fosdenopterin, Miglustat, Imiglucerase, Asfotase alfa, Glycerol phenylbutyrate, Pegvaliase, Triethylenetetramine, Sapropterin, Zinc acetate, Phenylbutyric acid, More", "updated_at": 1767369485}, {"id": 97287, "ingredient1": "Eliglustat", "ingredient2": "Rifapentine", "severity": "Major", "effect": "Coadministration with potent inducers of CYP450 3A4 and/or P-glycoprotein (P-gp) may significantly decrease the plasma concentrations of eliglustat, which is primarily metabolized by CYP450 2D6 and, to a lesser extent, CYP450 3A4. Eliglustat is also a substrate of P-gp efflux transporter.", "source": "DDInter", "management_text": "Concomitant use of eliglustat with potent CYP450 3A4 or P-gp inducers should generally be avoided due to the potential for significantly reduced efficacy.", "mechanism_text": "Metabolism", "recommendation": "Concomitant use of eliglustat with potent CYP450 3A4 or P-gp inducers should generally be avoided due to the potential for significantly reduced efficacy.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97391/", "reference_text": "[1] Cerner Multum, Inc. \"Australian Product Information.\" O 0[2] \"Product Information. Cerdelga (eliglustat).\" Genzyme Corporation, Cambridge, MA.[3] \"Product Information. Cerdelga (eliglustat).\" Genzyme Corporation, Cambridge, MA.[4] \"Product Information. Cerdelga (eliglustat).\" Genzyme Corporation, Cambridge, MA.[5] \"Product Information. Trikafta (elexacaftor/ivacaftor/tezacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[6] \"Product Information. Kalydeco (ivacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[7] \"Product Information. Orkambi (ivacaftor-lumacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[8] \"Product Information. Symdeko 4-Week (ivacaftor-tezacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.", "alternatives_a": "Capreomycin, Pyrazinamide, Rifamycin, Bedaquiline, Sulfamethoxazole, Streptomycin, Trimethoprim, Cycloserine, Ethambutol, Pyridoxine, Ethionamide, More", "alternatives_b": "Teduglutide, Fosdenopterin, Miglustat, Imiglucerase, Asfotase alfa, Glycerol phenylbutyrate, Pegvaliase, Triethylenetetramine, Sapropterin, Zinc acetate, Phenylbutyric acid, More", "updated_at": 1767369485}, {"id": 97288, "ingredient1": "Eliglustat", "ingredient2": "Rifaximin", "severity": "Moderate", "effect": "Coadministration with eliglustat may increase the plasma concentrations of drugs that are substrates of the P-glycoprotein (P-gp) transporter. The proposed mechanism is decreased clearance in the intestine, liver, and/or kidney due to inhibition of P-glycoprotein-mediated drug efflux by eliglustat.", "source": "DDInter", "management_text": "Caution is advised when eliglustat is used concurrently with drugs that are known P-gp substrates, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever eliglustat is added to or withdrawn from therapy.", "mechanism_text": "Others", "recommendation": "Caution is advised when eliglustat is used concurrently with drugs that are known P-gp substrates, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97392/", "reference_text": "[1] \"Product Information. Cerdelga (eliglustat).\" Genzyme Corporation, Cambridge, MA.[2] \"Product Information. Cerdelga (eliglustat).\" Genzyme Corporation, Cambridge, MA.", "alternatives_a": "Rifamycin, Kanamycin, Amphotericin B, Polymyxin B, Nystatin, Vancomycin, Streptomycin, Paromomycin, Neomycin, Tetracycline, Mupirocin, More", "alternatives_b": "Teduglutide, Fosdenopterin, Miglustat, Imiglucerase, Asfotase alfa, Glycerol phenylbutyrate, Pegvaliase, Triethylenetetramine, Sapropterin, Zinc acetate, Phenylbutyric acid, More", "updated_at": 1767369485}, {"id": 97289, "ingredient1": "Eliglustat", "ingredient2": "Ripretinib", "severity": "Moderate", "effect": "Coadministration with inhibitors of P-glycoprotein (P-gp) may increase the plasma concentrations of ripretinib and its active metabolite, DP-5439. In vitro studies indicate that ripretinib and DP-5439 are substrates of the P-gp efflux transporter.", "source": "DDInter", "management_text": "Until more information is available, caution is recommended when ripretinib is used concomitantly with drugs that are inhibitors of P-gp. Clinical and laboratory monitoring should be considered whenever a P-gp inhibitor is added to or withdrawn from therapy with ripretinib, and the dosage adjusted as necessary. Patients should be monitored for development of adverse effects such as nausea, vomiting, constipation, diarrhea, alopecia, arthralgia, myalgia, hypertension, cardiac dysfunction, and palmar-plantar erythrodysesthesia.", "mechanism_text": "Absorption", "recommendation": "Until more information is available, caution is recommended when ripretinib is used concomitantly with drugs that are inhibitors of P-gp.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97393/", "reference_text": "[1] Cerner Multum, Inc. \"Australian Product Information.\" O 0[2] \"Product Information. Qinlock (ripretinib).\" Deciphera Pharmaceuticals, Waltham, MA.[3] Cerner Multum, Inc. \"Australian Product Information.\" O 0[4] \"Product Information. Qinlock (ripretinib).\" Deciphera Pharmaceuticals, Waltham, MA.[5] \"Product Information. Mavyret (glecaprevir-pibrentasvir).\" Abbott Pharmaceutical, Abbott Park, IL.[6] Gunston GD, Mehta U \"Potentially serious drug interactions with grapefruit juice.\" S Afr Med J 90 (2000): 41[7] Bailey DG, Arnold JMO, Spence JD \"Grapefruit juice and drugs - how significant is the interaction.\" Clin Pharmacokinet 26 (1994): 91-8[8] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[9] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions.\" Br J Clin Pharmacol 46 (1998): 101-10[10] Libersa CC, Brique SA, Motte KB, et al. \"Dramatic inhibition of amiodarone metabolism induced by grapefruit juice.\" Br J Clin Pharmacol 49 (2000): 373-8[11] Bailey DG, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit juice felodipine interaction: Effect of naringin and 6',7'-dihydroxybergamottin in humans.\" Clin Pharmacol Ther 64 (1998): 248-56[12] Jonkman JH, Sollie FA, Sauter R, Steinijans VW \"The influence of caffeine on the steady-state pharmacokinetics of theophylline.\" Clin Pharmacol Ther 49 (1991): 248-55[13] Ozdemir M, Aktan Y, Boydag BS, Cingi MI, Musmul A \"Interaction between grapefruit juice and diazepam in humans.\" Eur J Drug Metab Pharmacokinet 23 (1998): 55-9[14] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin.\" Clin Pharmacol Ther 66 (1999): 118-27[15] Bailey DG, Arnold JM, Munoz C, Spence JD \"Grapefruit juice--felodipine interaction: mechanism, predictability, and effect of naringin.\" Clin Pharmacol Ther 53 (1993): 637-42[16] Sigusch H, Hippius M, Henschel L, Kaufmann K, Hoffmann A \"Influence of grapefruit juice on the pharmacokinetics of a slow release nifedipine formulation.\" Pharmazie 49 (1994): 522-4[17] Eagling VA, Profit L, Back DJ \"Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-I protease inhibitor saquinavir by grapefruit juice components.\" Br J Clin Pharmacol 48 (1999): 543-52[18] Damkier P, Hansen LL, Brosen K \"Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine.\" Br J Clin Pharmacol 48 (1999): 829-38[19] Min DI, Ku YM, Geraets DR, Lee HC \"Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers.\" J Clin Pharmacol 36 (1996): 469-76[20] Zaidenstein R, Soback S, Gips M, Avni B, Dishi V, Weissgarten Y, Golik A, Scapa E \"Effect of grapefruit juice on the pharmacokinetics of losartan and its active metabolite E3174 in healthy volunteers.\" Ther Drug Monit 23 (2001): 369-73[21] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84[22] Lee AJ, Chan WK, Harralson AF, Buffum J, Bui BCC \"The effects of grapefruit juice on sertraline metabolism: An in vitro and in vivo study.\" Clin Ther 21 (1999): 1890-9[23] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors.\" Clin Pharmacol Ther 64 (1998): 477-83[24] Garg SK, Kumar N, Bhargava VK, Prabhakar SK \"Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy.\" Clin Pharmacol Ther 64 (1998): 286-8[25] Fuhr U, Maier-Bruggemann A, Blume H, et al. \"Grapefruit juice increases oral nimodipine bioavailability.\" Int J Clin Pharmacol Ther 36 (1998): 126-32[26] Sato J, Nakata H, Owada E, Kikuta T, Umetsu M, Ito K \"Influence of usual intake of dietary caffeine on single-dose kinetics of theophylline in healthy human subjects.\" Eur J Clin Pharmacol 44 (1993): 295-8[27] Edgar B, Bailey D, Bergstrand R, et al \"Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics on felodipine and its potential clinical relevance.\" Eur J Clin Pharmacol 42 (1992): 313-7[28] Kantola T, Kivisto KT, Neuvonen PJ \"Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid.\" Clin Pharmacol Ther 63 (1998): 397-402[29] Dresser GK, Spence JD, Bailey DG \"Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition.\" Clin Pharmacokinet 38 (2000): 41-57[30] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[31] Takanaga H, Ohnishi A, Maatsuo H, et al. \"Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model.\" Br J Clin Pharmacol 49 (2000): 49-58[32] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS \"Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice.\" Br J Clin Pharmacol 42 (1996): p662[33] Bailey DG, Arnold JM, Strong HA, Munoz C, Spence JD \"Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics.\" Clin Pharmacol Ther 54 (1993): 589-94[34] Josefsson M, Zackrisson AL, Ahlner J \"Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers.\" Eur J Clin Pharmacol 51 (1996): 189-93[35] Majeed A, Kareem A \"Effect of grapefruit juice on cyclosporine pharmacokinetics.\" Pediatr Nephrol 10 (1996): 395[36] Flanagan D \"Understanding the grapefruit-drug interaction.\" Gen Dent 53 (2005): 282-5; quiz 286[37] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ \"Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice.\" Clin Pharmacol Ther 58 (1995): 127-31", "alternatives_a": "Teduglutide, Fosdenopterin, Miglustat, Imiglucerase, Asfotase alfa, Pegvaliase, Triethylenetetramine, Sapropterin, Zinc acetate, Phenylbutyric acid, Agalsidase beta, More", "alternatives_b": "Acalabrutinib, Tepotinib, Avapritinib, Selumetinib, Vandetanib, Capmatinib, Ibrutinib, Tivozanib, Zanubrutinib, Axitinib, Sunitinib, More", "updated_at": 1767369485}, {"id": 97290, "ingredient1": "Eliglustat", "ingredient2": "Risperidone", "severity": "Moderate", "effect": "Coadministration with eliglustat may increase the plasma concentrations of drugs that are primarily metabolized by CYP450 2D6.", "source": "DDInter", "management_text": "Caution is advised if eliglustat is used concomitantly with medications that undergo metabolism primarily by CYP450 2D6, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever eliglustat is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if eliglustat is used concomitantly with medications that undergo metabolism primarily by CYP450 2D6, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97394/", "reference_text": "[1] \"Product Information. Cerdelga (eliglustat).\" Genzyme Corporation, Cambridge, MA.[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] \"Product Information. Cerdelga (eliglustat).\" Genzyme Corporation, Cambridge, MA.[5] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[6] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[7] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[8] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.", "alternatives_a": "Quetiapine, Asenapine, Promazine, Prochlorperazine, Thiothixene, Pimavanserin, Lumateperone, Ziprasidone, Olanzapine, Trifluoperazine, Amisulpride, More", "alternatives_b": "Teduglutide, Lonafarnib, Fosdenopterin, Miglustat, Imiglucerase, Asfotase alfa, Pegvaliase, Triethylenetetramine, Sapropterin, Zinc acetate, Phenylbutyric acid, More", "updated_at": 1767369485}, {"id": 97291, "ingredient1": "Eliglustat", "ingredient2": "Ritonavir", "severity": "Major", "effect": "Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of eliglustat, which is primarily metabolized by CYP450 2D6 and, to a lesser extent, CYP450 3A4. Eliglustat at substantially elevated plasma concentrations is predicted to cause prolongation of the PR, QTc and QRS cardiac intervals, which may increase the risk of bradycardia, atrioventricular block, cardiac arrest, and serious ventricular arrhythmias such as torsade de pointes.", "source": "DDInter", "management_text": "The use of eliglustat with a potent CYP450 3A4 inhibitor is considered contraindicated in CYP450 2D6 poor metabolizers (PMs) and intermediate metabolizers (IMs). The contraindication is extended to extensive metabolizers (EMs) when a moderate or potent CYP450 2D6 inhibitor is given concomitantly with a moderate or potent CYP450 3A4 inhibitor. In the absence of a concomitant CYP450 2D6 inhibitor, eliglustat may be prescribed at a reduced dosage of 84 mg once daily to EMs treated with a potent CYP450 3A4 inhibitor. Potent CYP450 3A4 inhibitors include itraconazole, ketoconazole, posaconazole, voriconazole, conivaptan, ceritinib, idelalisib, mibefradil, nefazodone, cobicistat, delavirdine, protease inhibitors, and ketolide and certain macrolide antibiotics. Potent and moderate CYP450 2D6 inhibitors include abiraterone, bupropion, celecoxib, cimetidine, cinacalcet, clobazam, darifenacin, diphenhydramine, dronedarone, duloxetine, flecainide, fluoxetine, methotrimeprazine, mirabegron, paroxetine, propafenone, propoxyphene, quinidine, ranolazine, sertraline, and terbinafine. Some drugs such as cobicistat, delavirdine, mibefradil, and ritonavir are dual CYP450 3A4 and 2D6 inhibitors, and they should not be used with eliglustat in any patient regardless of their CYP450 2D6 metabolizer status.", "mechanism_text": "Metabolism", "recommendation": "The use of eliglustat with a potent CYP450 3A4 inhibitor is considered contraindicated in CYP450 2D6 poor metabolizers (PMs) and intermediate metabolizers (IMs).", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97395/", "reference_text": "[1] Cerner Multum, Inc. \"Australian Product Information.\" O 0[2] \"Product Information. Sporanox (itraconazole).\" Janssen Pharmaceutica, Titusville, NJ.[3] \"Product Information. Cerdelga (eliglustat).\" Genzyme Corporation, Cambridge, MA.[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] \"Product Information. Cerdelga (eliglustat).\" Genzyme Corporation, Cambridge, MA.[6] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[7] \"Product Information. VFEND (voriconazole).\" Pfizer U.S. Pharmaceuticals, New York, NY.", "alternatives_a": "Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Simeprevir, Cabotegravir, Valaciclovir, Zanamivir, Velpatasvir, Rilpivirine, Dolutegravir, More", "alternatives_b": "Lipoic acid, Triheptanoin, Teduglutide, Fosdenopterin, Triethylenetetramine, Miglustat, Sapropterin, Zinc acetate, Laronidase, Imiglucerase, Metreleptin, More", "updated_at": 1767369485}, {"id": 97292, "ingredient1": "Eliglustat", "ingredient2": "Rivaroxaban", "severity": "Moderate", "effect": "Coadministration with eliglustat may increase the plasma concentrations of drugs that are substrates of the P-glycoprotein (P-gp) transporter. The proposed mechanism is decreased clearance in the intestine, liver, and/or kidney due to inhibition of P-glycoprotein-mediated drug efflux by eliglustat.", "source": "DDInter", "management_text": "Caution is advised when eliglustat is used concurrently with drugs that are known P-gp substrates, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever eliglustat is added to or withdrawn from therapy.", "mechanism_text": "Others", "recommendation": "Caution is advised when eliglustat is used concurrently with drugs that are known P-gp substrates, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97396/", "reference_text": "[1] \"Product Information. Cerdelga (eliglustat).\" Genzyme Corporation, Cambridge, MA.[2] \"Product Information. Cerdelga (eliglustat).\" Genzyme Corporation, Cambridge, MA.", "alternatives_a": "Clopidogrel, Iloprost, Lepirudin, Acenocoumarol, Urokinase, Cangrelor, Dipyridamole, Warfarin, Caplacizumab, Argatroban, Prasugrel, More", "alternatives_b": "Teduglutide, Fosdenopterin, Miglustat, Imiglucerase, Asfotase alfa, Glycerol phenylbutyrate, Pegvaliase, Triethylenetetramine, Sapropterin, Zinc acetate, Phenylbutyric acid, More", "updated_at": 1767369485}, {"id": 97293, "ingredient1": "Eliglustat", "ingredient2": "Rolapitant", "severity": "Major", "effect": "Coadministration with inhibitors of CYP450 2D6 may significantly increase the plasma concentrations of eliglustat, which is primarily metabolized by CYP450 2D6 and, to a lesser extent, CYP450 3A4. Eliglustat at substantially elevated plasma concentrations is predicted to cause prolongation of the PR, QTc and QRS cardiac intervals, which may increase the risk of bradycardia, atrioventricular block, cardiac arrest, and serious ventricular arrhythmias such as torsade de pointes.", "source": "DDInter", "management_text": "The use of eliglustat in combination with one or more drugs that may result in moderate or potent inhibition of both CYP450 2D6 and 3A4 is considered contraindicated in CYP450 2D6 intermediate metabolizers (IMs) and extensive metabolizers (EMs). In the absence of a concomitant CYP450 3A4 inhibitor, eliglustat may be prescribed at a reduced dosage of 84 mg once daily to IMs and EMs treated with a potent or moderate CYP450 2D6 inhibitor. Poor metabolizers are not affected by CYP450 2D6 inhibition (since they already have minimal functional levels of the isoenzyme) and may also receive the reduced dosage of eliglustat, so long as they are not treated with a CYP450 3A4 inhibitor.", "mechanism_text": "Metabolism", "recommendation": "The use of eliglustat in combination with one or more drugs that may result in moderate or potent inhibition of both CYP450 2D6 and 3A4 is considered contraindicated in CYP450 2D6 intermediate metabolizers (IMs) and extensive metabolizers (EMs).", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97397/", "reference_text": "[1] \"Product Information. Cerdelga (eliglustat).\" Genzyme Corporation, Cambridge, MA.[2] \"Product Information. Cerdelga (eliglustat).\" Genzyme Corporation, Cambridge, MA.", "alternatives_a": "Teduglutide, Lonafarnib, Fosdenopterin, Miglustat, Imiglucerase, Asfotase alfa, Glycerol phenylbutyrate, Pegvaliase, Triethylenetetramine, Sapropterin, Zinc acetate, More", "alternatives_b": "Nabilone, Granisetron, Scopolamine, Dronabinol, Dolasetron, Ondansetron, Palonosetron", "updated_at": 1767369485}, {"id": 97294, "ingredient1": "Eliglustat", "ingredient2": "Romidepsin", "severity": "Moderate", "effect": "Coadministration with inhibitors of P-glycoprotein (P-gp) may increase the plasma concentrations of romidepsin, which is a substrate of the efflux transporter. Although there are no formal drug interaction studies, the interaction may increase the risk of hematologic toxicities such as anemia, leukopenia, and thrombocytopenia as well as electrocardiographic changes such as QT interval prolongation and T-wave and ST-segment changes.", "source": "DDInter", "management_text": "Caution is advised if romidepsin is prescribed in combination with P-gp inhibitors. Pharmacologic response to romidepsin should be monitored more closely whenever a P-gp inhibitor is added to or withdrawn from therapy, and the romidepsin dosage adjusted as necessary. Patients should have complete blood cell counts, electrocardiograms, and serum electrolyte levels performed at baseline and regular intervals as recommended in the product labeling. Patients should be advised to seek medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Absorption", "recommendation": "Caution is advised if romidepsin is prescribed in combination with P-gp inhibitors.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97398/", "reference_text": "[1] \"Product Information. Istodax (romidepsin).\" Gloucester Pharmaceuticals, Cambridge, MA.", "alternatives_a": "Pertuzumab, Olaparib, Oxaliplatin, Bortezomib, Tisagenlecleucel, Aminolevulinic acid, Omacetaxine mepesuccinate, Altretamine, Tagraxofusp, Pegaspargase, Ixazomib, More", "alternatives_b": "Teduglutide, Fosdenopterin, Miglustat, Imiglucerase, Asfotase alfa, Pegvaliase, Triethylenetetramine, Sapropterin, Zinc acetate, Agalsidase beta, Givosiran, More", "updated_at": 1767369485}, {"id": 97295, "ingredient1": "Eliglustat", "ingredient2": "Rucaparib", "severity": "Moderate", "effect": "Coadministration with weak inhibitors of CYP450 3A4 may increase the plasma concentrations of eliglustat, which is primarily metabolized by CYP450 2D6 and, to a lesser extent, CYP450 3A4. Eliglustat at substantially elevated plasma concentrations is predicted to cause prolongation of the PR, QTc and QRS cardiac intervals, which may increase the risk of bradycardia, atrioventricular block, cardiac arrest, and serious ventricular arrhythmias such as torsade de pointes.", "source": "DDInter", "management_text": "Concomitant use of eliglustat with weak CYP450 3A4 inhibitors such as chloramphenicol, cyclosporine, danazol, dasatinib, ethinyl estradiol, fluvoxamine, goldenseal, isoniazid, ivacaftor, lapatinib, lomitapide, nifedipine, nilotinib, palbociclib, pazopanib, suvorexant, ticagrelor, and zafirlukast is not recommended in CYP450 2D6 poor metabolizers. No dosage adjustment for eliglustat is necessary when used with weak CYP450 3A4 inhibitors in extensive or intermediate metabolizers.", "mechanism_text": "Metabolism", "recommendation": "Concomitant use of eliglustat with weak CYP450 3A4 inhibitors such as chloramphenicol, cyclosporine, danazol, dasatinib, ethinyl estradiol, fluvoxamine, goldenseal, isoniazid, ivacaftor, lapatinib, lomitapide, nifedipine, nilotinib, palbociclib, pazopanib, suvorexant, ticagrelor, and zafirlukast is not recommended in CYP450 2D6 poor metabolizers.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97399/", "reference_text": "[1] \"Product Information. Cerdelga (eliglustat).\" Genzyme Corporation, Cambridge, MA.[2] \"Product Information. Cerdelga (eliglustat).\" Genzyme Corporation, Cambridge, MA.", "alternatives_a": "Teduglutide, Fosdenopterin, Miglustat, Imiglucerase, Asfotase alfa, Glycerol phenylbutyrate, Pegvaliase, Triethylenetetramine, Sapropterin, Zinc acetate, Phenylbutyric acid, More", "alternatives_b": "Pertuzumab, Olaparib, Oxaliplatin, Bortezomib, Tisagenlecleucel, Aminolevulinic acid, Omacetaxine mepesuccinate, Altretamine, Tagraxofusp, Pegaspargase, Ixazomib, More", "updated_at": 1767369485}, {"id": 97296, "ingredient1": "Eliglustat", "ingredient2": "Rufinamide", "severity": "Moderate", "effect": "Coadministration with inducers of CYP450 3A4 and/or P-glycoprotein (P-gp) may decrease the plasma concentrations of eliglustat, which is primarily metabolized by CYP450 2D6 and, to a lesser extent, CYP450 3A4. Eliglustat is also a substrate of P-gp efflux transporter.", "source": "DDInter", "management_text": "Patients receiving eliglustat with CYP450 3A4 inducers should be monitored for potentially diminished pharmacologic response to eliglustat. Concomitant use should be avoided if an interaction is suspected.", "mechanism_text": "Metabolism", "recommendation": "Patients receiving eliglustat with CYP450 3A4 inducers should be monitored for potentially diminished pharmacologic response to eliglustat.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97400/", "reference_text": "[1] \"Product Information. Cerdelga (eliglustat).\" Genzyme Corporation, Cambridge, MA.[2] \"Product Information. Cerdelga (eliglustat).\" Genzyme Corporation, Cambridge, MA.", "alternatives_a": "Brivaracetam, Topiramate, Ezogabine, Lamotrigine, Ethosuximide, Lacosamide, Levetiracetam, Tiagabine, Ethotoin, Clonazepam, Paramethadione, More", "alternatives_b": "Teduglutide, Fosdenopterin, Miglustat, Imiglucerase, Asfotase alfa, Glycerol phenylbutyrate, Pegvaliase, Triethylenetetramine, Sapropterin, Zinc acetate, Phenylbutyric acid, More", "updated_at": 1767369485}, {"id": 97297, "ingredient1": "Eliglustat", "ingredient2": "Saquinavir", "severity": "Major", "effect": "Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of eliglustat, which is primarily metabolized by CYP450 2D6 and, to a lesser extent, CYP450 3A4. Eliglustat at substantially elevated plasma concentrations is predicted to cause prolongation of the PR, QTc and QRS cardiac intervals, which may increase the risk of bradycardia, atrioventricular block, cardiac arrest, and serious ventricular arrhythmias such as torsade de pointes.", "source": "DDInter", "management_text": "The use of eliglustat with a potent CYP450 3A4 inhibitor is considered contraindicated in CYP450 2D6 poor metabolizers (PMs) and intermediate metabolizers (IMs). The contraindication is extended to extensive metabolizers (EMs) when a moderate or potent CYP450 2D6 inhibitor is given concomitantly with a moderate or potent CYP450 3A4 inhibitor. In the absence of a concomitant CYP450 2D6 inhibitor, eliglustat may be prescribed at a reduced dosage of 84 mg once daily to EMs treated with a potent CYP450 3A4 inhibitor. Potent CYP450 3A4 inhibitors include itraconazole, ketoconazole, posaconazole, voriconazole, conivaptan, ceritinib, idelalisib, mibefradil, nefazodone, cobicistat, delavirdine, protease inhibitors, and ketolide and certain macrolide antibiotics. Potent and moderate CYP450 2D6 inhibitors include abiraterone, bupropion, celecoxib, cimetidine, cinacalcet, clobazam, darifenacin, diphenhydramine, dronedarone, duloxetine, flecainide, fluoxetine, methotrimeprazine, mirabegron, paroxetine, propafenone, propoxyphene, quinidine, ranolazine, sertraline, and terbinafine. Some drugs such as cobicistat, delavirdine, mibefradil, and ritonavir are dual CYP450 3A4 and 2D6 inhibitors, and they should not be used with eliglustat in any patient regardless of their CYP450 2D6 metabolizer status.", "mechanism_text": "Metabolism", "recommendation": "The use of eliglustat with a potent CYP450 3A4 inhibitor is considered contraindicated in CYP450 2D6 poor metabolizers (PMs) and intermediate metabolizers (IMs).", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97401/", "reference_text": "[1] Cerner Multum, Inc. \"Australian Product Information.\" O 0[2] \"Product Information. Sporanox (itraconazole).\" Janssen Pharmaceutica, Titusville, NJ.[3] \"Product Information. Cerdelga (eliglustat).\" Genzyme Corporation, Cambridge, MA.[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] \"Product Information. Cerdelga (eliglustat).\" Genzyme Corporation, Cambridge, MA.[6] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[7] \"Product Information. VFEND (voriconazole).\" Pfizer U.S. Pharmaceuticals, New York, NY.", "alternatives_a": "Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Simeprevir, Cabotegravir, Valaciclovir, Zanamivir, Velpatasvir, Rilpivirine, Dolutegravir, More", "alternatives_b": "Teduglutide, Fosdenopterin, Miglustat, Imiglucerase, Asfotase alfa, Glycerol phenylbutyrate, Pegvaliase, Triethylenetetramine, Sapropterin, Zinc acetate, Phenylbutyric acid, More", "updated_at": 1767369485}, {"id": 97298, "ingredient1": "Eliglustat", "ingredient2": "Sarecycline", "severity": "Moderate", "effect": "Coadministration with sarecycline may increase the plasma concentrations of drugs that are substrates of the P-glycoprotein (P-gp) transporter. The proposed mechanism is decreased clearance in the intestine, kidney, and/or liver due to inhibition of P-gp-mediated efflux by sarecycline.", "source": "DDInter", "management_text": "Caution is advised when sarecycline is used concurrently with drugs that are P-gp substrates, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever sarecycline is added to or withdrawn from therapy.", "mechanism_text": "Others", "recommendation": "Caution is advised when sarecycline is used concurrently with drugs that are P-gp substrates, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97402/", "reference_text": "[1] \"Product Information. Seysara (sarecycline).\" Allergan Inc, Irvine, CA.", "alternatives_a": "Teduglutide, Lonafarnib, Fosdenopterin, Miglustat, Imiglucerase, Asfotase alfa, Glycerol phenylbutyrate, Pegvaliase, Triethylenetetramine, Sapropterin, Phenylbutyric acid, More", "alternatives_b": "Tetracycline, Minocycline, Oxytetracycline, Doxycycline, Omadacycline, Eravacycline, Demeclocycline, Tigecycline", "updated_at": 1767369485}, {"id": 97299, "ingredient1": "Eliglustat", "ingredient2": "Secobarbital", "severity": "Moderate", "effect": "Coadministration with inducers of CYP450 3A4 and/or P-glycoprotein (P-gp) may decrease the plasma concentrations of eliglustat, which is primarily metabolized by CYP450 2D6 and, to a lesser extent, CYP450 3A4. Eliglustat is also a substrate of P-gp efflux transporter.", "source": "DDInter", "management_text": "Patients receiving eliglustat with CYP450 3A4 inducers should be monitored for potentially diminished pharmacologic response to eliglustat. Concomitant use should be avoided if an interaction is suspected.", "mechanism_text": "Metabolism", "recommendation": "Patients receiving eliglustat with CYP450 3A4 inducers should be monitored for potentially diminished pharmacologic response to eliglustat.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97403/", "reference_text": "[1] \"Product Information. Cerdelga (eliglustat).\" Genzyme Corporation, Cambridge, MA.[2] \"Product Information. Cerdelga (eliglustat).\" Genzyme Corporation, Cambridge, MA.", "alternatives_a": "Triazolam, Flurazepam, Methohexital, Zolpidem, Zaleplon, Dichloralphenazone, Valerian, Temazepam, Chloral hydrate, Quazepam, Paraldehyde, More", "alternatives_b": "Teduglutide, Fosdenopterin, Miglustat, Imiglucerase, Asfotase alfa, Glycerol phenylbutyrate, Pegvaliase, Triethylenetetramine, Sapropterin, Zinc acetate, Phenylbutyric acid, More", "updated_at": 1767369485}, {"id": 97300, "ingredient1": "Eliglustat", "ingredient2": "Selpercatinib", "severity": "Moderate", "effect": "Coadministration with weak inhibitors of CYP450 3A4 may increase the plasma concentrations of eliglustat, which is primarily metabolized by CYP450 2D6 and, to a lesser extent, CYP450 3A4. Eliglustat at substantially elevated plasma concentrations is predicted to cause prolongation of the PR, QTc and QRS cardiac intervals, which may increase the risk of bradycardia, atrioventricular block, cardiac arrest, and serious ventricular arrhythmias such as torsade de pointes.", "source": "DDInter", "management_text": "Concomitant use of eliglustat with weak CYP450 3A4 inhibitors such as chloramphenicol, cyclosporine, danazol, dasatinib, ethinyl estradiol, fluvoxamine, goldenseal, isoniazid, ivacaftor, lapatinib, lomitapide, nifedipine, nilotinib, palbociclib, pazopanib, suvorexant, ticagrelor, and zafirlukast is not recommended in CYP450 2D6 poor metabolizers. No dosage adjustment for eliglustat is necessary when used with weak CYP450 3A4 inhibitors in extensive or intermediate metabolizers.", "mechanism_text": "Metabolism", "recommendation": "Concomitant use of eliglustat with weak CYP450 3A4 inhibitors such as chloramphenicol, cyclosporine, danazol, dasatinib, ethinyl estradiol, fluvoxamine, goldenseal, isoniazid, ivacaftor, lapatinib, lomitapide, nifedipine, nilotinib, palbociclib, pazopanib, suvorexant, ticagrelor, and zafirlukast is not recommended in CYP450 2D6 poor metabolizers.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97404/", "reference_text": "[1] \"Product Information. Cerdelga (eliglustat).\" Genzyme Corporation, Cambridge, MA.[2] \"Product Information. Cerdelga (eliglustat).\" Genzyme Corporation, Cambridge, MA.", "alternatives_a": "Lipoic acid, Triheptanoin, Teduglutide, Fosdenopterin, Triethylenetetramine, Miglustat, Sapropterin, Zinc acetate, Levocarnitine, Laronidase, Imiglucerase, More", "alternatives_b": "Acalabrutinib, Tepotinib, Avapritinib, Selumetinib, Vandetanib, Capmatinib, Ibrutinib, Tivozanib, Zanubrutinib, Axitinib, Sunitinib, More", "updated_at": 1767369485}, {"id": 97301, "ingredient1": "Eliglustat", "ingredient2": "Sertraline", "severity": "Major", "effect": "Coadministration with inhibitors of CYP450 2D6 may significantly increase the plasma concentrations of eliglustat, which is primarily metabolized by CYP450 2D6 and, to a lesser extent, CYP450 3A4. Eliglustat at substantially elevated plasma concentrations is predicted to cause prolongation of the PR, QTc and QRS cardiac intervals, which may increase the risk of bradycardia, atrioventricular block, cardiac arrest, and serious ventricular arrhythmias such as torsade de pointes.", "source": "DDInter", "management_text": "The use of eliglustat in combination with one or more drugs that may result in moderate or potent inhibition of both CYP450 2D6 and 3A4 is considered contraindicated in CYP450 2D6 intermediate metabolizers (IMs) and extensive metabolizers (EMs). In the absence of a concomitant CYP450 3A4 inhibitor, eliglustat may be prescribed at a reduced dosage of 84 mg once daily to IMs and EMs treated with a potent or moderate CYP450 2D6 inhibitor. Poor metabolizers are not affected by CYP450 2D6 inhibition (since they already have minimal functional levels of the isoenzyme) and may also receive the reduced dosage of eliglustat, so long as they are not treated with a CYP450 3A4 inhibitor.", "mechanism_text": "Metabolism", "recommendation": "The use of eliglustat in combination with one or more drugs that may result in moderate or potent inhibition of both CYP450 2D6 and 3A4 is considered contraindicated in CYP450 2D6 intermediate metabolizers (IMs) and extensive metabolizers (EMs).", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97405/", "reference_text": "[1] \"Product Information. Cerdelga (eliglustat).\" Genzyme Corporation, Cambridge, MA.[2] \"Product Information. Cerdelga (eliglustat).\" Genzyme Corporation, Cambridge, MA.", "alternatives_a": "Phenelzine, Citalopram, Tranylcypromine, Desvenlafaxine, Isocarboxazid, Oxitriptan, Tryptophan, Milnacipran, Levomilnacipran, Vilazodone, Esketamine, More", "alternatives_b": "Teduglutide, Lonafarnib, Fosdenopterin, Miglustat, Imiglucerase, Asfotase alfa, Pegvaliase, Triethylenetetramine, Sapropterin, Zinc acetate, Phenylbutyric acid, More", "updated_at": 1767369485}, {"id": 97302, "ingredient1": "Eliglustat", "ingredient2": "Silodosin", "severity": "Moderate", "effect": "Coadministration with eliglustat may increase the plasma concentrations of drugs that are substrates of the P-glycoprotein (P-gp) transporter. The proposed mechanism is decreased clearance in the intestine, liver, and/or kidney due to inhibition of P-glycoprotein-mediated drug efflux by eliglustat.", "source": "DDInter", "management_text": "Caution is advised when eliglustat is used concurrently with drugs that are known P-gp substrates, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever eliglustat is added to or withdrawn from therapy.", "mechanism_text": "Others", "recommendation": "Caution is advised when eliglustat is used concurrently with drugs that are known P-gp substrates, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97406/", "reference_text": "[1] \"Product Information. Cerdelga (eliglustat).\" Genzyme Corporation, Cambridge, MA.[2] \"Product Information. Cerdelga (eliglustat).\" Genzyme Corporation, Cambridge, MA.", "alternatives_a": "Terazosin, Alfuzosin, Tadalafil, Finasteride, Dutasteride, Solifenacin", "alternatives_b": "Teduglutide, Fosdenopterin, Miglustat, Imiglucerase, Asfotase alfa, Pegvaliase, Triethylenetetramine, Sapropterin, Zinc acetate, Phenylbutyric acid, Agalsidase beta, More", "updated_at": 1767369485}, {"id": 97303, "ingredient1": "Eliglustat", "ingredient2": "Sirolimus", "severity": "Moderate", "effect": "Coadministration with eliglustat may increase the plasma concentrations of drugs that are substrates of the P-glycoprotein (P-gp) transporter. The proposed mechanism is decreased clearance in the intestine, liver, and/or kidney due to inhibition of P-glycoprotein-mediated drug efflux by eliglustat.", "source": "DDInter", "management_text": "Caution is advised when eliglustat is used concurrently with drugs that are known P-gp substrates, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever eliglustat is added to or withdrawn from therapy.", "mechanism_text": "Others", "recommendation": "Caution is advised when eliglustat is used concurrently with drugs that are known P-gp substrates, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97407/", "reference_text": "[1] \"Product Information. Cerdelga (eliglustat).\" Genzyme Corporation, Cambridge, MA.[2] \"Product Information. Cerdelga (eliglustat).\" Genzyme Corporation, Cambridge, MA.", "alternatives_a": "Alteplase, Ascorbic acid, Vitamin A, Potassium Iodide, Acetylcysteine, Nandrolone, Heparin, Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, More", "alternatives_b": "Lipoic acid, Triheptanoin, Teduglutide, Fosdenopterin, Triethylenetetramine, Miglustat, Sapropterin, Nitisinone, Levocarnitine, Laronidase, Imiglucerase, More", "updated_at": 1767369485}, {"id": 97304, "ingredient1": "Eliglustat", "ingredient2": "Somapacitan", "severity": "Moderate", "effect": "Coadministration with inducers of CYP450 3A4 and/or P-glycoprotein (P-gp) may decrease the plasma concentrations of eliglustat, which is primarily metabolized by CYP450 2D6 and, to a lesser extent, CYP450 3A4. Eliglustat is also a substrate of P-gp efflux transporter.", "source": "DDInter", "management_text": "Patients receiving eliglustat with CYP450 3A4 inducers should be monitored for potentially diminished pharmacologic response to eliglustat. Concomitant use should be avoided if an interaction is suspected.", "mechanism_text": "Metabolism", "recommendation": "Patients receiving eliglustat with CYP450 3A4 inducers should be monitored for potentially diminished pharmacologic response to eliglustat.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97408/", "reference_text": "[1] \"Product Information. Cerdelga (eliglustat).\" Genzyme Corporation, Cambridge, MA.[2] \"Product Information. Cerdelga (eliglustat).\" Genzyme Corporation, Cambridge, MA.", "alternatives_a": "Teduglutide, Fosdenopterin, Miglustat, Imiglucerase, Asfotase alfa, Glycerol phenylbutyrate, Pegvaliase, Triethylenetetramine, Sapropterin, Zinc acetate, Phenylbutyric acid, More", "alternatives_b": "Corticotropin, Mecasermin, Sermorelin, Tesamorelin, Thyrotropin alfa, Tetracosactide, Mecasermin rinfabate, Pegvisomant", "updated_at": 1767369485}, {"id": 97305, "ingredient1": "Eliglustat", "ingredient2": "Somatrem", "severity": "Moderate", "effect": "Coadministration with inducers of CYP450 3A4 and/or P-glycoprotein (P-gp) may decrease the plasma concentrations of eliglustat, which is primarily metabolized by CYP450 2D6 and, to a lesser extent, CYP450 3A4. Eliglustat is also a substrate of P-gp efflux transporter.", "source": "DDInter", "management_text": "Patients receiving eliglustat with CYP450 3A4 inducers should be monitored for potentially diminished pharmacologic response to eliglustat. Concomitant use should be avoided if an interaction is suspected.", "mechanism_text": "Metabolism", "recommendation": "Patients receiving eliglustat with CYP450 3A4 inducers should be monitored for potentially diminished pharmacologic response to eliglustat.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97409/", "reference_text": "[1] \"Product Information. Cerdelga (eliglustat).\" Genzyme Corporation, Cambridge, MA.[2] \"Product Information. Cerdelga (eliglustat).\" Genzyme Corporation, Cambridge, MA.", "alternatives_a": "Teduglutide, Fosdenopterin, Miglustat, Imiglucerase, Asfotase alfa, Glycerol phenylbutyrate, Pegvaliase, Triethylenetetramine, Sapropterin, Zinc acetate, Phenylbutyric acid, More", "alternatives_b": "Corticotropin, Mecasermin, Sermorelin, Tesamorelin, Thyrotropin alfa, Tetracosactide, Mecasermin rinfabate, Pegvisomant", "updated_at": 1767369485}, {"id": 97306, "ingredient1": "Eliglustat", "ingredient2": "Somatotropin", "severity": "Moderate", "effect": "Coadministration with inducers of CYP450 3A4 and/or P-glycoprotein (P-gp) may decrease the plasma concentrations of eliglustat, which is primarily metabolized by CYP450 2D6 and, to a lesser extent, CYP450 3A4. Eliglustat is also a substrate of P-gp efflux transporter.", "source": "DDInter", "management_text": "Patients receiving eliglustat with CYP450 3A4 inducers should be monitored for potentially diminished pharmacologic response to eliglustat. Concomitant use should be avoided if an interaction is suspected.", "mechanism_text": "Metabolism", "recommendation": "Patients receiving eliglustat with CYP450 3A4 inducers should be monitored for potentially diminished pharmacologic response to eliglustat.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97410/", "reference_text": "[1] \"Product Information. Cerdelga (eliglustat).\" Genzyme Corporation, Cambridge, MA.[2] \"Product Information. Cerdelga (eliglustat).\" Genzyme Corporation, Cambridge, MA.", "alternatives_a": "Corticotropin, Mecasermin, Sermorelin, Tesamorelin, Thyrotropin alfa, Tetracosactide, Mecasermin rinfabate, Pegvisomant", "alternatives_b": "Teduglutide, Fosdenopterin, Miglustat, Imiglucerase, Asfotase alfa, Glycerol phenylbutyrate, Pegvaliase, Triethylenetetramine, Sapropterin, Zinc acetate, Phenylbutyric acid, More", "updated_at": 1767369485}, {"id": 97307, "ingredient1": "Eliglustat", "ingredient2": "Sotalol", "severity": "Major", "effect": "Class IA (e.g., disopyramide, quinidine, procainamide) and class III (e.g., amiodarone, dofetilide, sotalol) antiarrhythmic agents can cause dose-related prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Coadministration of class IA or class III antiarrhythmic agents with other drugs that can prolong the QT interval should preferably be avoided unless benefits are anticipated to outweigh the risks. Caution and clinical monitoring are recommended if concomitant use is required. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Coadministration of class IA or class III antiarrhythmic agents with other drugs that can prolong the QT interval should preferably be avoided unless benefits are anticipated to outweigh the risks.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97411/", "reference_text": "[1] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[2] Yamreudeewong W, DeBisschop M, Martin L, Lower D \"Potentially Significant Drug Interactions of Class III Antiarrhythmic Drugs.\" Drug Saf 26 (2003): 421-38[3] \"Product Information. Norpace (disopyramide).\" Searle, Skokie, IL.[4] Cerner Multum, Inc. \"Australian Product Information.\" O 0[5] \"Product Information. Betapace (sotalol).\" Berlex, Richmond, CA.[6] \"Product Information. Procan SR (procainamide).\" Parke-Davis, Morris Plains, NJ.[7] Maxa JL, Hebeler RF, Adeeko MA \"Torsades de pointes following concurrent amiodarone and levofloxacin therapy.\" Proc (Bayl Univ Med Cent) 19 (2006): 345-6[8] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[9] \"Product Information. Cordarone (amiodarone).\" Wyeth-Ayerst Laboratories, Philadelphia, PA.[10] EMA. European Medicines Agency. European Union \"EMA - List of medicines under additional monitoring. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000366.jsp&mid=WC0b01ac058067c852\" ([2013 - ]):[11] \"Product Information. Vascor (bepridil).\" McNeil Pharmaceutical, Raritan, NJ.[12] \"Product Information. Quiniglute (quinidine).\" Berlex, Richmond, CA.[13] Trujillo TC, Nolan PE \"Antiarrhythmic agents - Drug interactions of clinical significance.\" Drug Safety 23 (2000): 509-32[14] Gunston GD, Mehta U \"Potentially serious drug interactions with grapefruit juice.\" S Afr Med J 90 (2000): 41[15] Bailey DG, Arnold JMO, Spence JD \"Grapefruit juice and drugs - how significant is the interaction.\" Clin Pharmacokinet 26 (1994): 91-8[16] Fuhr U, Maier-Bruggemann A, Blume H, et al. \"Grapefruit juice increases oral nimodipine bioavailability.\" Int J Clin Pharmacol Ther 36 (1998): 126-32[17] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[18] Libersa CC, Brique SA, Motte KB, et al. \"Dramatic inhibition of amiodarone metabolism induced by grapefruit juice.\" Br J Clin Pharmacol 49 (2000): 373-8[19] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions.\" Br J Clin Pharmacol 46 (1998): 101-10[20] Bailey DG, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit juice felodipine interaction: Effect of naringin and 6',7'-dihydroxybergamottin in humans.\" Clin Pharmacol Ther 64 (1998): 248-56[21] Takanaga H, Ohnishi A, Maatsuo H, et al. \"Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model.\" Br J Clin Pharmacol 49 (2000): 49-58[22] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[23] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS \"Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice.\" Br J Clin Pharmacol 42 (1996): p662[24] Eagling VA, Profit L, Back DJ \"Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-I protease inhibitor saquinavir by grapefruit juice components.\" Br J Clin Pharmacol 48 (1999): 543-52[25] Bailey DG, Arnold JM, Strong HA, Munoz C, Spence JD \"Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics.\" Clin Pharmacol Ther 54 (1993): 589-94[26] Damkier P, Hansen LL, Brosen K \"Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine.\" Br J Clin Pharmacol 48 (1999): 829-38[27] Min DI, Ku YM, Geraets DR, Lee HC \"Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers.\" J Clin Pharmacol 36 (1996): 469-76[28] Josefsson M, Zackrisson AL, Ahlner J \"Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers.\" Eur J Clin Pharmacol 51 (1996): 189-93[29] Majeed A, Kareem A \"Effect of grapefruit juice on cyclosporine pharmacokinetics.\" Pediatr Nephrol 10 (1996): 395[30] Flanagan D \"Understanding the grapefruit-drug interaction.\" Gen Dent 53 (2005): 282-5; quiz 286[31] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ \"Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice.\" Clin Pharmacol Ther 58 (1995): 127-31[32] Jonkman JH, Sollie FA, Sauter R, Steinijans VW \"The influence of caffeine on the steady-state pharmacokinetics of theophylline.\" Clin Pharmacol Ther 49 (1991): 248-55[33] Ozdemir M, Aktan Y, Boydag BS, Cingi MI, Musmul A \"Interaction between grapefruit juice and diazepam in humans.\" Eur J Drug Metab Pharmacokinet 23 (1998): 55-9[34] Edgar B, Bailey D, Bergstrand R, et al \"Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics on felodipine and its potential clinical relevance.\" Eur J Clin Pharmacol 42 (1992): 313-7[35] Kantola T, Kivisto KT, Neuvonen PJ \"Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid.\" Clin Pharmacol Ther 63 (1998): 397-402[36] Lee AJ, Chan WK, Harralson AF, Buffum J, Bui BCC \"The effects of grapefruit juice on sertraline metabolism: An in vitro and in vivo study.\" Clin Ther 21 (1999): 1890-9[37] Sato J, Nakata H, Owada E, Kikuta T, Umetsu M, Ito K \"Influence of usual intake of dietary caffeine on single-dose kinetics of theophylline in healthy human subjects.\" Eur J Clin Pharmacol 44 (1993): 295-8[38] Dresser GK, Spence JD, Bailey DG \"Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition.\" Clin Pharmacokinet 38 (2000): 41-57[39] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin.\" Clin Pharmacol Ther 66 (1999): 118-27[40] Sigusch H, Hippius M, Henschel L, Kaufmann K, Hoffmann A \"Influence of grapefruit juice on the pharmacokinetics of a slow release nifedipine formulation.\" Pharmazie 49 (1994): 522-4[41] Bailey DG, Arnold JM, Munoz C, Spence JD \"Grapefruit juice--felodipine interaction: mechanism, predictability, and effect of naringin.\" Clin Pharmacol Ther 53 (1993): 637-42[42] Zaidenstein R, Soback S, Gips M, Avni B, Dishi V, Weissgarten Y, Golik A, Scapa E \"Effect of grapefruit juice on the pharmacokinetics of losartan and its active metabolite E3174 in healthy volunteers.\" Ther Drug Monit 23 (2001): 369-73[43] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84[44] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors.\" Clin Pharmacol Ther 64 (1998): 477-83[45] Garg SK, Kumar N, Bhargava VK, Prabhakar SK \"Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy.\" Clin Pharmacol Ther 64 (1998): 286-8", "alternatives_a": "Acebutolol, Labetalol, Nadolol, Esmolol, Betaxolol, Penbutolol, Bisoprolol, Carteolol, Pindolol, Atenolol, Acebutolol, More", "alternatives_b": "Teduglutide, Lonafarnib, Fosdenopterin, Miglustat, Imiglucerase, Asfotase alfa, Glycerol phenylbutyrate, Pegvaliase, Triethylenetetramine, Sapropterin, Zinc acetate, More", "updated_at": 1767369485}, {"id": 97308, "ingredient1": "Eliglustat", "ingredient2": "St. John's Wort", "severity": "Major", "effect": "Coadministration with potent inducers of CYP450 3A4 and/or P-glycoprotein (P-gp) may significantly decrease the plasma concentrations of eliglustat, which is primarily metabolized by CYP450 2D6 and, to a lesser extent, CYP450 3A4. Eliglustat is also a substrate of P-gp efflux transporter.", "source": "DDInter", "management_text": "Concomitant use of eliglustat with potent CYP450 3A4 or P-gp inducers should generally be avoided due to the potential for significantly reduced efficacy.", "mechanism_text": "Metabolism", "recommendation": "Concomitant use of eliglustat with potent CYP450 3A4 or P-gp inducers should generally be avoided due to the potential for significantly reduced efficacy.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97412/", "reference_text": "[1] Cerner Multum, Inc. \"Australian Product Information.\" O 0[2] \"Product Information. Cerdelga (eliglustat).\" Genzyme Corporation, Cambridge, MA.[3] \"Product Information. Cerdelga (eliglustat).\" Genzyme Corporation, Cambridge, MA.[4] \"Product Information. Cerdelga (eliglustat).\" Genzyme Corporation, Cambridge, MA.[5] \"Product Information. Trikafta (elexacaftor/ivacaftor/tezacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[6] \"Product Information. Kalydeco (ivacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[7] \"Product Information. Orkambi (ivacaftor-lumacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[8] \"Product Information. Symdeko 4-Week (ivacaftor-tezacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.", "alternatives_a": "Phenelzine, Citalopram, Tranylcypromine, Desvenlafaxine, Isocarboxazid, Oxitriptan, Tryptophan, Milnacipran, Levomilnacipran, Vilazodone, Esketamine, More", "alternatives_b": "Teduglutide, Fosdenopterin, Miglustat, Imiglucerase, Asfotase alfa, Glycerol phenylbutyrate, Pegvaliase, Triethylenetetramine, Sapropterin, Zinc acetate, Phenylbutyric acid, More", "updated_at": 1767369485}, {"id": 97309, "ingredient1": "Eliglustat", "ingredient2": "Stiripentol", "severity": "Major", "effect": "Coadministration with inhibitors of CYP450 2D6 may significantly increase the plasma concentrations of eliglustat, which is primarily metabolized by CYP450 2D6 and, to a lesser extent, CYP450 3A4. Eliglustat at substantially elevated plasma concentrations is predicted to cause prolongation of the PR, QTc and QRS cardiac intervals, which may increase the risk of bradycardia, atrioventricular block, cardiac arrest, and serious ventricular arrhythmias such as torsade de pointes.", "source": "DDInter", "management_text": "The use of eliglustat in combination with one or more drugs that may result in moderate or potent inhibition of both CYP450 2D6 and 3A4 is considered contraindicated in CYP450 2D6 intermediate metabolizers (IMs) and extensive metabolizers (EMs). In the absence of a concomitant CYP450 3A4 inhibitor, eliglustat may be prescribed at a reduced dosage of 84 mg once daily to IMs and EMs treated with a potent or moderate CYP450 2D6 inhibitor. Poor metabolizers are not affected by CYP450 2D6 inhibition (since they already have minimal functional levels of the isoenzyme) and may also receive the reduced dosage of eliglustat, so long as they are not treated with a CYP450 3A4 inhibitor.", "mechanism_text": "Metabolism", "recommendation": "The use of eliglustat in combination with one or more drugs that may result in moderate or potent inhibition of both CYP450 2D6 and 3A4 is considered contraindicated in CYP450 2D6 intermediate metabolizers (IMs) and extensive metabolizers (EMs).", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97413/", "reference_text": "[1] \"Product Information. Cerdelga (eliglustat).\" Genzyme Corporation, Cambridge, MA.[2] \"Product Information. Cerdelga (eliglustat).\" Genzyme Corporation, Cambridge, MA.", "alternatives_a": "Teduglutide, Lonafarnib, Fosdenopterin, Miglustat, Imiglucerase, Asfotase alfa, Pegvaliase, Triethylenetetramine, Sapropterin, Zinc acetate, Phenylbutyric acid, More", "alternatives_b": "Brivaracetam, Topiramate, Ezogabine, Lamotrigine, Ethosuximide, Lacosamide, Levetiracetam, Tiagabine, Ethotoin, Clonazepam, Paramethadione, More", "updated_at": 1767369485}, {"id": 97310, "ingredient1": "Eliglustat", "ingredient2": "Sulfinpyrazone", "severity": "Moderate", "effect": "Coadministration with inducers of CYP450 3A4 and/or P-glycoprotein (P-gp) may decrease the plasma concentrations of eliglustat, which is primarily metabolized by CYP450 2D6 and, to a lesser extent, CYP450 3A4. Eliglustat is also a substrate of P-gp efflux transporter.", "source": "DDInter", "management_text": "Patients receiving eliglustat with CYP450 3A4 inducers should be monitored for potentially diminished pharmacologic response to eliglustat. Concomitant use should be avoided if an interaction is suspected.", "mechanism_text": "Metabolism", "recommendation": "Patients receiving eliglustat with CYP450 3A4 inducers should be monitored for potentially diminished pharmacologic response to eliglustat.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97414/", "reference_text": "[1] \"Product Information. Cerdelga (eliglustat).\" Genzyme Corporation, Cambridge, MA.[2] \"Product Information. Cerdelga (eliglustat).\" Genzyme Corporation, Cambridge, MA.", "alternatives_a": "Lesinurad, Febuxostat, Pegloticase, Rasburicase, Probenecid, Allopurinol", "alternatives_b": "Teduglutide, Fosdenopterin, Miglustat, Imiglucerase, Asfotase alfa, Glycerol phenylbutyrate, Pegvaliase, Triethylenetetramine, Sapropterin, Zinc acetate, Phenylbutyric acid, More", "updated_at": 1767369485}, {"id": 97311, "ingredient1": "Eliglustat", "ingredient2": "Suvorexant", "severity": "Moderate", "effect": "Coadministration with weak inhibitors of CYP450 3A4 may increase the plasma concentrations of eliglustat, which is primarily metabolized by CYP450 2D6 and, to a lesser extent, CYP450 3A4. Eliglustat at substantially elevated plasma concentrations is predicted to cause prolongation of the PR, QTc and QRS cardiac intervals, which may increase the risk of bradycardia, atrioventricular block, cardiac arrest, and serious ventricular arrhythmias such as torsade de pointes.", "source": "DDInter", "management_text": "Concomitant use of eliglustat with weak CYP450 3A4 inhibitors such as chloramphenicol, cyclosporine, danazol, dasatinib, ethinyl estradiol, fluvoxamine, goldenseal, isoniazid, ivacaftor, lapatinib, lomitapide, nifedipine, nilotinib, palbociclib, pazopanib, suvorexant, ticagrelor, and zafirlukast is not recommended in CYP450 2D6 poor metabolizers. No dosage adjustment for eliglustat is necessary when used with weak CYP450 3A4 inhibitors in extensive or intermediate metabolizers.", "mechanism_text": "Metabolism", "recommendation": "Concomitant use of eliglustat with weak CYP450 3A4 inhibitors such as chloramphenicol, cyclosporine, danazol, dasatinib, ethinyl estradiol, fluvoxamine, goldenseal, isoniazid, ivacaftor, lapatinib, lomitapide, nifedipine, nilotinib, palbociclib, pazopanib, suvorexant, ticagrelor, and zafirlukast is not recommended in CYP450 2D6 poor metabolizers.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97415/", "reference_text": "[1] \"Product Information. Cerdelga (eliglustat).\" Genzyme Corporation, Cambridge, MA.[2] \"Product Information. Cerdelga (eliglustat).\" Genzyme Corporation, Cambridge, MA.", "alternatives_a": "Triazolam, Flurazepam, Methohexital, Zolpidem, Zaleplon, Dichloralphenazone, Valerian, Temazepam, Chloral hydrate, Quazepam, Paraldehyde, More", "alternatives_b": "Teduglutide, Fosdenopterin, Miglustat, Imiglucerase, Asfotase alfa, Glycerol phenylbutyrate, Pegvaliase, Triethylenetetramine, Sapropterin, Zinc acetate, Phenylbutyric acid, More", "updated_at": 1767369485}, {"id": 97312, "ingredient1": "Eliglustat", "ingredient2": "Talazoparib", "severity": "Moderate", "effect": "Coadministration with inhibitors of P-glycoprotein (P-gp) and/or breast cancer resistance protein (BCRP) may increase the plasma concentrations of talazoparib, which has been shown in vitro to be a substrate of both efflux membrane transporters.", "source": "DDInter", "management_text": "No initial dosage adjustment is recommended by the manufacturer when talazoparib is coadministered with inhibitors of BCRP and/or P-gp other than amiodarone, carvedilol, clarithromycin, itraconazole, or verapamil. However, patients should be closely monitored for adverse effects such as myelosuppression and myelodysplastic syndrome/acute myeloid leukemia, and dosage adjustments made or treatment withheld as needed in accordance with the product labeling.", "mechanism_text": "Distribution", "recommendation": "No initial dosage adjustment is recommended by the manufacturer when talazoparib is coadministered with inhibitors of BCRP and/or P-gp other than amiodarone, carvedilol, clarithromycin, itraconazole, or verapamil.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97416/", "reference_text": "[1] \"Product Information. Talzenna (talazoparib).\" Pfizer U.S. Pharmaceuticals Group, New York, NY.", "alternatives_a": "Teduglutide, Lonafarnib, Fosdenopterin, Miglustat, Imiglucerase, Asfotase alfa, Glycerol phenylbutyrate, Pegvaliase, Triethylenetetramine, Sapropterin, Zinc acetate, More", "alternatives_b": "Pertuzumab, Olaparib, Oxaliplatin, Bortezomib, Tisagenlecleucel, Aminolevulinic acid, Omacetaxine mepesuccinate, Altretamine, Tagraxofusp, Pegaspargase, Ixazomib, More", "updated_at": 1767369485}, {"id": 97313, "ingredient1": "Eliglustat", "ingredient2": "Tamoxifen", "severity": "Major", "effect": "Chronic coadministration of potent or moderate CYP450 2D6 inhibitors including certain antidepressants may reduce the effectiveness of tamoxifen. The proposed mechanism is inhibition of tamoxifen bioactivation via CYP450 2D6 to endoxifen (4-hydroxy-N-desmethyltamoxifen), the active metabolite that may be responsible for much of tamoxifen's antiestrogenic activity.", "source": "DDInter", "management_text": "Based on available data, patients treated with tamoxifen should avoid the chronic use of potent CYP450 2D6 inhibitors such as fluoxetine, paroxetine, and quinidine whenever possible, and preferably also moderate inhibitors such as bupropion, duloxetine, and sertraline. If an antidepressant is required during treatment with tamoxifen, agents such as desvenlafaxine, fluvoxamine, milnacipran, levomilnacipran, mirtazapine, and venlafaxine may be considered, since they have mild to no effects on CYP450 2D6. Alternatively, aromatase inhibitors such as anastrozole, exemestane, and letrozole may be appropriate substitutes for tamoxifen in certain patients. Alternatively, aromatase inhibitors such as anastrozole, exemestane, and letrozole may be appropriate substitutes for tamoxifen in certain patients.", "mechanism_text": "Metabolism", "recommendation": "Based on available data, patients treated with tamoxifen should avoid the chronic use of potent CYP450 2D6 inhibitors such as fluoxetine, paroxetine, and quinidine whenever possible, and preferably also moderate inhibitors such as bupropion, duloxetine, and sertraline.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97417/", "reference_text": "[1] Goetz MP, Rae JM, Suman VJ, et al. \"Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes.\" J Clin Oncol 23 (2005): 9312-8[2] Schroth W, Antoniadou L, Fritz P, et al. \"Breast cancer treatment outcome with adjuvant tamoxifen relative to patient CYP2D6 and CYP2C19 genotypes.\" J Clin Oncol 25 (2007): 5187-93[3] Stearns V, Johnson MD, Rae JM, et al. \"Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine.\" J Natl Cancer Inst 95 (2003): 1758-64[4] Desta Z, Flockhart DA \"Germline pharmacogenetics of tamoxifen response: have we learned enough?\" J Clin Oncol 25 (2007): 5147-9[5] Jordan VC, Collins MM, Rowsby L, Prestwich G \"A monohydroxylated metabolite of tamoxifen with potent antioestrogenic activity.\" J Endocrinol 75 (1977): 305-16[6] Henry NL, Stearns V, Flockhart DA, Hayes DF, Riba M \"Drug interactions and pharmacogenomics in the treatment of breast cancer and depression.\" Am J Psychiatry 165 (2008): 1251-5[7] Jin Y, Desta Z, Stearns V, et al. \"CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment.\" J Natl Cancer Inst 97 (2005): 30-9[8] Lash TL, Pedersen L, Cronin-Fenton D, et al \"Tamoxifen's protection against breast cancer recurrence is not reduced by concurrent use of the SSRI citalopram.\" Br J Cancer 99 (2008): 616-21[9] Wegman P, Elingarami S, Carstensen J, Stal O, Nordenskjold B, Wingren S \"Genetic variants of CYP3A5, CYP2D6, SULT1A1, UGT2B15 and tamoxifen response in postmenopausal patients with breast cancer.\" Breast Cancer Res 9 (2007): R7[10] Ponzone R, Biglia N, Sismondi P \"Re: Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine.\" J Natl Cancer Inst 96 (2004): 883-4; author reply 884-5[11] Johnson MD, Zuo H, Lee KH, et al. \"Pharmacological characterization of 4-hydroxy-N-desmethyl tamoxifen, a novel active metabolite of tamoxifen.\" Breast Cancer Res Treat 85 (2004): 151-9[12] McCaffrey P \"Genetics and drug interactions affect tamoxifen metabolism.\" Lancet Oncol 6 (2005): 72[13] Coller JK, Krebsfaenger N, Klein K, et al. \"The influence of CYP2B6, CYP2C9 and CYP2D6 genotypes on the formation of the potent antioestrogen Z-4-hydroxy-tamoxifen in human liver.\" Br J Clin Pharmacol 54 (2002): 157-167[14] Young D \"Genetics examined in tamoxifen's effectiveness: recurrence warning urged for labeling.\" Am J Health Syst Pharm 63 (2006): 2286, 2296[15] Lehmann D, Nelsen J, Ramanath V, Newman N, Duggan D, Smith A \"Lack of attenuation in the antitumor effect of tamoxifen by chronic CYP isoform inhibition.\" J Clin Pharmacol 44 (2004): 861-5[16] Dehal SS, Kupfer D \"CYP2D6 catalyzes tamoxifen 4-hydroxylation in human liver.\" Cancer Res 57 (1997): 3402-6[17] Rochat B \"Role of cytochrome p450 activity in the fate of anticancer agents and in drug resistance : focus on tamoxifen, Paclitaxel and imatinib metabolism.\" Clin Pharmacokinet 44 (2005): 349-66[18] Bonanni B, Macis D, Maisonneuve P, et al. \"Polymorphism in the CYP2D6 tamoxifen-metabolizing gene influences clinical effect but not hot flashes: data from the Italian Tamoxifen Trial.\" J Clin Oncol 24 (2006): 3708-9[19] Borgna JL, Rochefort H \"Hydroxylated metabolites of tamoxifen are formed in vivo and bound to estrogen receptor in target tissues.\" J Biol Chem 256 (1981): 859-68[20] Crewe HK, Lennard MS, Tucker GT, Woods FR, Haddock RE \"The effect of selective serotonin re-uptake inhibitors on cytochrome P4502D6 (CYP2D6) activity in human liver microsomes.\" Br J Clin Pharmacol 34 (1992): 262-5[21] Desta Z, Ward BA, Soukhova NV, Flockhart DA \"Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6.\" J Pharmacol Exp Ther (2004):[22] Brauch H, Murdter TE, Eichelbaum M, Schwab M \"Pharmacogenomics of tamoxifen therapy.\" Clin Chem 55 (2009): 1770-82[23] Crewe HK, Notley LM, Wunsch RM, Lennard MS, Gillam EM \"Metabolism of tamoxifen by recombinant human cytochrome P450 enzymes: formation of the 4-hydroxy, 4'-hydroxy and N-desmethyl metabolites and isomerization of trans-4-hydroxytamoxifen.\" Drug Metab Dispos 30 (2002): 869-74[24] Goetz MP, Kamal A, Ames MM \"Tamoxifen Pharmacogenomics: The Role of CYP2D6 as a Predictor of Drug Response.\" Clin Pharmacol Ther (2007):[25] Wegman P, Vainikka L, Stal O, et al \"Genotype of metabolic enzymes and the benefit of tamoxifen in postmenopausal breast cancer patients.\" Breast Cancer Res 7 (2005): R284-90[26] Ratliff B, Dietze EC, Bean GR, Moore C, Wanko S, Seewaldt VL \"Re: Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine.\" J Natl Cancer Inst 96 (2004): 883; author reply 884-5[27] Amchin J, Ereshefsky L, Zarycranski W, Taylor K, Albano D, Klockowski PM \"Effect of venlafaxine versus fluoxetine on metabolism of dextromethorphan, a CYP2D6 probe.\" J Clin Pharmacol 41 (2001): 443-51[28] Lim HS, Ju Lee H, Seok Lee K, Sook Lee E, Jang IJ, Ro J \"Clinical implications of CYP2D6 genotypes predictive of tamoxifen pharmacokinetics in metastatic breast cancer.\" J Clin Oncol 25 (2007): 3837-45[29] Dezentje VO, Guchelaar HJ, Nortier JW, van de Velde CJ, Gelderblom H \"Clinical implications of CYP2D6 genotyping in tamoxifen treatment for breast cancer.\" Clin Cancer Res 15 (2009): 15-21[30] Goetz MP, Loprinzi CL \"A hot flash on tamoxifen metabolism.\" J Natl Cancer Inst 95 (2003): 1734-5[31] Gaston C, Kolesar J \"Clinical Significance of CYP2D6 Polymorphisms and Tamoxifen in Women with Breast Cancer.\" Clin Adv Hematol Oncol 6 (2008): 825-33[32] Borges S, Desta Z, Li L, et al. \"Quantitative effect of CYP2D6 genotype and inhibitors on tamoxifen metabolism: Implication for optimization of breast cancer treatment.\" Clin Pharmacol Ther 80 (2006): 61-74[33] Jordan VC \"Metabolites of tamoxifen in animals and man: identification, pharmacology, and significance.\" Breast Cancer Res Treat 2 (1982): 123-38[34] Aubert RE, Stanek EJ, Yao J, et al \"Increased risk of breast cancer recurrence in women initiating tamoxifen with CYP2D6 inhibitors. Available from: URL: https://www.medcoresearch.com/community/oncology/tamoxifen.\" ([2009 May 30]):[35] Therapeutic Research Faculty \"Natural Medicines Comprehensive Database. Available from: URL: http://www.naturaldatabase.com.\" ([1995-2008...]):", "alternatives_a": "Darolutamide, Anastrozole, Letrozole, Toremifene, Fulvestrant, Abarelix, Flutamide, Degarelix, Nilutamide, Exemestane", "alternatives_b": "Lipoic acid, Triheptanoin, Teduglutide, Fosdenopterin, Triethylenetetramine, Miglustat, Sapropterin, Zinc acetate, Levocarnitine, Laronidase, Imiglucerase, More", "updated_at": 1767369485}, {"id": 97314, "ingredient1": "Eliglustat", "ingredient2": "Tazemetostat", "severity": "Moderate", "effect": "Coadministration with inducers of CYP450 3A4 and/or P-glycoprotein (P-gp) may decrease the plasma concentrations of eliglustat, which is primarily metabolized by CYP450 2D6 and, to a lesser extent, CYP450 3A4. Eliglustat is also a substrate of P-gp efflux transporter.", "source": "DDInter", "management_text": "Patients receiving eliglustat with CYP450 3A4 inducers should be monitored for potentially diminished pharmacologic response to eliglustat. Concomitant use should be avoided if an interaction is suspected.", "mechanism_text": "Metabolism", "recommendation": "Patients receiving eliglustat with CYP450 3A4 inducers should be monitored for potentially diminished pharmacologic response to eliglustat.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97418/", "reference_text": "[1] \"Product Information. Cerdelga (eliglustat).\" Genzyme Corporation, Cambridge, MA.[2] \"Product Information. Cerdelga (eliglustat).\" Genzyme Corporation, Cambridge, MA.", "alternatives_a": "Lipoic acid, Triheptanoin, Teduglutide, Fosdenopterin, Triethylenetetramine, Miglustat, Sapropterin, Zinc acetate, Levocarnitine, Laronidase, Imiglucerase, More", "alternatives_b": "Pertuzumab, Olaparib, Oxaliplatin, Bortezomib, Tisagenlecleucel, Aminolevulinic acid, Omacetaxine mepesuccinate, Altretamine, Tagraxofusp, Pegaspargase, Ixazomib, More", "updated_at": 1767369485}, {"id": 97315, "ingredient1": "Eliglustat", "ingredient2": "Telaprevir", "severity": "Major", "effect": "Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of eliglustat, which is primarily metabolized by CYP450 2D6 and, to a lesser extent, CYP450 3A4. Eliglustat at substantially elevated plasma concentrations is predicted to cause prolongation of the PR, QTc and QRS cardiac intervals, which may increase the risk of bradycardia, atrioventricular block, cardiac arrest, and serious ventricular arrhythmias such as torsade de pointes.", "source": "DDInter", "management_text": "The use of eliglustat with a potent CYP450 3A4 inhibitor is considered contraindicated in CYP450 2D6 poor metabolizers (PMs) and intermediate metabolizers (IMs). The contraindication is extended to extensive metabolizers (EMs) when a moderate or potent CYP450 2D6 inhibitor is given concomitantly with a moderate or potent CYP450 3A4 inhibitor. In the absence of a concomitant CYP450 2D6 inhibitor, eliglustat may be prescribed at a reduced dosage of 84 mg once daily to EMs treated with a potent CYP450 3A4 inhibitor. Potent CYP450 3A4 inhibitors include itraconazole, ketoconazole, posaconazole, voriconazole, conivaptan, ceritinib, idelalisib, mibefradil, nefazodone, cobicistat, delavirdine, protease inhibitors, and ketolide and certain macrolide antibiotics. Potent and moderate CYP450 2D6 inhibitors include abiraterone, bupropion, celecoxib, cimetidine, cinacalcet, clobazam, darifenacin, diphenhydramine, dronedarone, duloxetine, flecainide, fluoxetine, methotrimeprazine, mirabegron, paroxetine, propafenone, propoxyphene, quinidine, ranolazine, sertraline, and terbinafine. Some drugs such as cobicistat, delavirdine, mibefradil, and ritonavir are dual CYP450 3A4 and 2D6 inhibitors, and they should not be used with eliglustat in any patient regardless of their CYP450 2D6 metabolizer status.", "mechanism_text": "Metabolism", "recommendation": "The use of eliglustat with a potent CYP450 3A4 inhibitor is considered contraindicated in CYP450 2D6 poor metabolizers (PMs) and intermediate metabolizers (IMs).", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97419/", "reference_text": "[1] Cerner Multum, Inc. \"Australian Product Information.\" O 0[2] \"Product Information. Sporanox (itraconazole).\" Janssen Pharmaceutica, Titusville, NJ.[3] \"Product Information. Cerdelga (eliglustat).\" Genzyme Corporation, Cambridge, MA.[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] \"Product Information. Cerdelga (eliglustat).\" Genzyme Corporation, Cambridge, MA.[6] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[7] \"Product Information. VFEND (voriconazole).\" Pfizer U.S. Pharmaceuticals, New York, NY.", "alternatives_a": "Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Simeprevir, Cabotegravir, Valaciclovir, Zanamivir, Velpatasvir, Rilpivirine, Dolutegravir, More", "alternatives_b": "Teduglutide, Fosdenopterin, Miglustat, Imiglucerase, Asfotase alfa, Glycerol phenylbutyrate, Pegvaliase, Triethylenetetramine, Sapropterin, Zinc acetate, Phenylbutyric acid, More", "updated_at": 1767369485}, {"id": 97316, "ingredient1": "Eliglustat", "ingredient2": "Telithromycin", "severity": "Major", "effect": "Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of eliglustat, which is primarily metabolized by CYP450 2D6 and, to a lesser extent, CYP450 3A4. Eliglustat at substantially elevated plasma concentrations is predicted to cause prolongation of the PR, QTc and QRS cardiac intervals, which may increase the risk of bradycardia, atrioventricular block, cardiac arrest, and serious ventricular arrhythmias such as torsade de pointes.", "source": "DDInter", "management_text": "The use of eliglustat with a potent CYP450 3A4 inhibitor is considered contraindicated in CYP450 2D6 poor metabolizers (PMs) and intermediate metabolizers (IMs). The contraindication is extended to extensive metabolizers (EMs) when a moderate or potent CYP450 2D6 inhibitor is given concomitantly with a moderate or potent CYP450 3A4 inhibitor. In the absence of a concomitant CYP450 2D6 inhibitor, eliglustat may be prescribed at a reduced dosage of 84 mg once daily to EMs treated with a potent CYP450 3A4 inhibitor. Potent CYP450 3A4 inhibitors include itraconazole, ketoconazole, posaconazole, voriconazole, conivaptan, ceritinib, idelalisib, mibefradil, nefazodone, cobicistat, delavirdine, protease inhibitors, and ketolide and certain macrolide antibiotics. Potent and moderate CYP450 2D6 inhibitors include abiraterone, bupropion, celecoxib, cimetidine, cinacalcet, clobazam, darifenacin, diphenhydramine, dronedarone, duloxetine, flecainide, fluoxetine, methotrimeprazine, mirabegron, paroxetine, propafenone, propoxyphene, quinidine, ranolazine, sertraline, and terbinafine. Some drugs such as cobicistat, delavirdine, mibefradil, and ritonavir are dual CYP450 3A4 and 2D6 inhibitors, and they should not be used with eliglustat in any patient regardless of their CYP450 2D6 metabolizer status.", "mechanism_text": "Metabolism", "recommendation": "The use of eliglustat with a potent CYP450 3A4 inhibitor is considered contraindicated in CYP450 2D6 poor metabolizers (PMs) and intermediate metabolizers (IMs).", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97420/", "reference_text": "[1] Cerner Multum, Inc. \"Australian Product Information.\" O 0[2] \"Product Information. Sporanox (itraconazole).\" Janssen Pharmaceutica, Titusville, NJ.[3] \"Product Information. Cerdelga (eliglustat).\" Genzyme Corporation, Cambridge, MA.[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] \"Product Information. Cerdelga (eliglustat).\" Genzyme Corporation, Cambridge, MA.[6] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[7] \"Product Information. VFEND (voriconazole).\" Pfizer U.S. Pharmaceuticals, New York, NY.", "alternatives_a": "Dirithromycin, Lincomycin, Azithromycin, Clindamycin", "alternatives_b": "Teduglutide, Fosdenopterin, Miglustat, Imiglucerase, Asfotase alfa, Glycerol phenylbutyrate, Pegvaliase, Triethylenetetramine, Sapropterin, Zinc acetate, Phenylbutyric acid, More", "updated_at": 1767369485}, {"id": 97317, "ingredient1": "Eliglustat", "ingredient2": "Telotristat ethyl", "severity": "Moderate", "effect": "Coadministration with telotristat ethyl may decrease the plasma concentrations of drugs that are substrates of CYP450 3A4 and/or 2B6 isoenzymes. The proposed mechanism is accelerated clearance due to induction of CYP450 3A4 and/or 2B6 (in vitro) isoenzymes by telotristat ethyl.", "source": "DDInter", "management_text": "When drugs that are known substrates of CYP450 3A4 and/or 2B6 are coadministered with telotristat ethyl, the possibility of a diminished therapeutic response to those drugs should be considered. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs, particularly those with a narrow therapeutic range, whenever telotristat ethyl is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "When drugs that are known substrates of CYP450 3A4 and/or 2B6 are coadministered with telotristat ethyl, the possibility of a diminished therapeutic response to those drugs should be considered.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97421/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Xermelo (telotristat ethyl).\" Lexicon Pharmaceuticals, Inc., The Woodlands, TX.[3] \"Product Information. Xermelo (telotristat ethyl).\" Lexicon Pharmaceuticals, Inc., The Woodlands, TX.", "alternatives_a": "Teduglutide, Fosdenopterin, Miglustat, Imiglucerase, Asfotase alfa, Glycerol phenylbutyrate, Pegvaliase, Triethylenetetramine, Sapropterin, Zinc acetate, Phenylbutyric acid, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 97318, "ingredient1": "Eliglustat", "ingredient2": "Terbinafine", "severity": "Major", "effect": "Coadministration with inhibitors of CYP450 2D6 may significantly increase the plasma concentrations of eliglustat, which is primarily metabolized by CYP450 2D6 and, to a lesser extent, CYP450 3A4. Eliglustat at substantially elevated plasma concentrations is predicted to cause prolongation of the PR, QTc and QRS cardiac intervals, which may increase the risk of bradycardia, atrioventricular block, cardiac arrest, and serious ventricular arrhythmias such as torsade de pointes.", "source": "DDInter", "management_text": "The use of eliglustat in combination with one or more drugs that may result in moderate or potent inhibition of both CYP450 2D6 and 3A4 is considered contraindicated in CYP450 2D6 intermediate metabolizers (IMs) and extensive metabolizers (EMs). In the absence of a concomitant CYP450 3A4 inhibitor, eliglustat may be prescribed at a reduced dosage of 84 mg once daily to IMs and EMs treated with a potent or moderate CYP450 2D6 inhibitor. Poor metabolizers are not affected by CYP450 2D6 inhibition (since they already have minimal functional levels of the isoenzyme) and may also receive the reduced dosage of eliglustat, so long as they are not treated with a CYP450 3A4 inhibitor.", "mechanism_text": "Metabolism", "recommendation": "The use of eliglustat in combination with one or more drugs that may result in moderate or potent inhibition of both CYP450 2D6 and 3A4 is considered contraindicated in CYP450 2D6 intermediate metabolizers (IMs) and extensive metabolizers (EMs).", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97422/", "reference_text": "[1] \"Product Information. Cerdelga (eliglustat).\" Genzyme Corporation, Cambridge, MA.[2] \"Product Information. Cerdelga (eliglustat).\" Genzyme Corporation, Cambridge, MA.", "alternatives_a": "Salicylic acid, Selenium Sulfide, Thiabendazole, Nystatin, Ciclopirox, Econazole, Flucytosine, Tioconazole, Chlorphenesin", "alternatives_b": "Teduglutide, Lonafarnib, Fosdenopterin, Miglustat, Imiglucerase, Asfotase alfa, Glycerol phenylbutyrate, Pegvaliase, Triethylenetetramine, Sapropterin, Zinc acetate, More", "updated_at": 1767369485}, {"id": 97319, "ingredient1": "Eliglustat", "ingredient2": "Terfenadine", "severity": "Moderate", "effect": "Coadministration with eliglustat may increase the plasma concentrations of drugs that are substrates of the P-glycoprotein (P-gp) transporter. The proposed mechanism is decreased clearance in the intestine, liver, and/or kidney due to inhibition of P-glycoprotein-mediated drug efflux by eliglustat.", "source": "DDInter", "management_text": "Caution is advised when eliglustat is used concurrently with drugs that are known P-gp substrates, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever eliglustat is added to or withdrawn from therapy.", "mechanism_text": "Others", "recommendation": "Caution is advised when eliglustat is used concurrently with drugs that are known P-gp substrates, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97423/", "reference_text": "[1] \"Product Information. Cerdelga (eliglustat).\" Genzyme Corporation, Cambridge, MA.[2] \"Product Information. Cerdelga (eliglustat).\" Genzyme Corporation, Cambridge, MA.", "alternatives_a": "Ketotifen, Mepyramine, Levocetirizine, Chlorcyclizine, Cetirizine, Acrivastine, Triprolidine, Tripelennamine, Azelastine, Dexbrompheniramine, Clemastine, More", "alternatives_b": "Teduglutide, Fosdenopterin, Miglustat, Imiglucerase, Asfotase alfa, Glycerol phenylbutyrate, Pegvaliase, Triethylenetetramine, Sapropterin, Zinc acetate, Phenylbutyric acid, More", "updated_at": 1767369485}, {"id": 97320, "ingredient1": "Eliglustat", "ingredient2": "Tetrabenazine", "severity": "Moderate", "effect": "Coadministration with eliglustat may increase the plasma concentrations of drugs that are primarily metabolized by CYP450 2D6.", "source": "DDInter", "management_text": "Caution is advised if eliglustat is used concomitantly with medications that undergo metabolism primarily by CYP450 2D6, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever eliglustat is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if eliglustat is used concomitantly with medications that undergo metabolism primarily by CYP450 2D6, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97424/", "reference_text": "[1] \"Product Information. Cerdelga (eliglustat).\" Genzyme Corporation, Cambridge, MA.[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] \"Product Information. Cerdelga (eliglustat).\" Genzyme Corporation, Cambridge, MA.[5] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[6] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[7] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[8] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.", "alternatives_a": "Valbenazine, Dalfampridine, Sodium oxybate, Riluzole, Inotersen, Amifampridine, Deutetrabenazine, Tafamidis", "alternatives_b": "Teduglutide, Lonafarnib, Fosdenopterin, Miglustat, Imiglucerase, Asfotase alfa, Pegvaliase, Triethylenetetramine, Sapropterin, Zinc acetate, Phenylbutyric acid, More", "updated_at": 1767369485}, {"id": 97321, "ingredient1": "Eliglustat", "ingredient2": "Thioridazine", "severity": "Major", "effect": "Coadministration with inhibitors of CYP450 2D6 may increase the plasma concentrations of thioridazine and its two active metabolites, mesoridazine and sulforidazine, all of which are substrates of the isoenzyme.", "source": "DDInter", "management_text": "The use of thioridazine with drugs that inhibit CYP450 2D6 is considered contraindicated. Depending on the elimination half-life of these drugs, a considerable waiting period may be appropriate following their discontinuation before thioridazine is initiated. For example, the manufacturer of fluoxetine recommends that thioridazine not be administered within 5 weeks after discontinuing fluoxetine because of the drug's long half-life.", "mechanism_text": "Metabolism", "recommendation": "The use of thioridazine with drugs that inhibit CYP450 2D6 is considered contraindicated.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97425/", "reference_text": "[1] Glassman AH, Bigger JT Jr \"Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death.\" Am J Psychiatry 158 (2001): 1774-82[2] Greendyke RM, Gulya A \"Effect of pindolol administration on serum levels of thioridazine, haloperidol, phenytoin, and phenobarbital.\" J Clin Psychiatry 49 (1988): 105-7[3] Carrillo JA, Ramos SI, Herraiz AG, Llerena A, Agundez JAG, Berecz R, Duran M, Benitez J \"Pharmacokinetic interaction of fluvoxamine and thioridazine in schizophrenic patients.\" J Clin Psychopharmacol 19 (1999): 494-9[4] Abernethy DR, Greenblatt DJ, Steel K, Shader RI \"Impairment of hepatic drug oxidation by propoxyphene.\" Ann Intern Med 97 (1982): 223-4[5] Fletcher GF, Kazamias TM \"Cardiotoxic effects of Mellaril: conduction disturbances and supraventricular arrhythmias.\" Am Heart J 78 (1969): 135-8[6] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[7] \"Product Information. Mellaril (thioridazine).\" Sandoz Pharmaceuticals Corporation, East Hanover, NJ.[8] \"Product Information. Prozac (fluoxetine).\" Dista Products Company, Indianapolis, IN.[9] Silver JM, Yudofsky SC, Kogan M, Katz BL \"Elevation of thioridazine plasma levels by propranolol.\" Am J Psychiatry 143 (1986): 1290-2[10] Hartigan-Go K, Bateman DN, Nyberg G, Martensson E, Thomas SHL \"Concentration-related pharmacodynamic effects of thioridazine and its metabolites in humans.\" Clin Pharmacol Ther 60 (1996): 543-53[11] Greendyke RM, Kanter DR \"Plasma propranolol levels and their effect on plasma thioridazine and haloperidol concentrations.\" J Clin Psychopharmacol 7 (1987): 178-82[12] Thomas M, Maconochie JG, Fletcher E \"The dilemma of the prolonged QT interval in early drug studies.\" Br J Clin Pharmacol 41 (1996): 77-81[13] Cerner Multum, Inc. \"Australian Product Information.\" O 0[14] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[15] \"Product Information. Gleevec (imatinib mesylate).\" Novartis Pharmaceuticals, East Hanover, NJ.", "alternatives_a": "Quetiapine, Asenapine, Promazine, Prochlorperazine, Thiothixene, Pimavanserin, Lumateperone, Ziprasidone, Olanzapine, Trifluoperazine, Amisulpride, More", "alternatives_b": "Teduglutide, Lonafarnib, Fosdenopterin, Miglustat, Imiglucerase, Asfotase alfa, Pegvaliase, Triethylenetetramine, Sapropterin, Zinc acetate, Phenylbutyric acid, More", "updated_at": 1767369485}, {"id": 97322, "ingredient1": "Eliglustat", "ingredient2": "Ticagrelor", "severity": "Moderate", "effect": "Coadministration with weak inhibitors of CYP450 3A4 may increase the plasma concentrations of eliglustat, which is primarily metabolized by CYP450 2D6 and, to a lesser extent, CYP450 3A4. Eliglustat at substantially elevated plasma concentrations is predicted to cause prolongation of the PR, QTc and QRS cardiac intervals, which may increase the risk of bradycardia, atrioventricular block, cardiac arrest, and serious ventricular arrhythmias such as torsade de pointes.", "source": "DDInter", "management_text": "Concomitant use of eliglustat with weak CYP450 3A4 inhibitors such as chloramphenicol, cyclosporine, danazol, dasatinib, ethinyl estradiol, fluvoxamine, goldenseal, isoniazid, ivacaftor, lapatinib, lomitapide, nifedipine, nilotinib, palbociclib, pazopanib, suvorexant, ticagrelor, and zafirlukast is not recommended in CYP450 2D6 poor metabolizers. No dosage adjustment for eliglustat is necessary when used with weak CYP450 3A4 inhibitors in extensive or intermediate metabolizers.", "mechanism_text": "Metabolism", "recommendation": "Concomitant use of eliglustat with weak CYP450 3A4 inhibitors such as chloramphenicol, cyclosporine, danazol, dasatinib, ethinyl estradiol, fluvoxamine, goldenseal, isoniazid, ivacaftor, lapatinib, lomitapide, nifedipine, nilotinib, palbociclib, pazopanib, suvorexant, ticagrelor, and zafirlukast is not recommended in CYP450 2D6 poor metabolizers.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97426/", "reference_text": "[1] \"Product Information. Cerdelga (eliglustat).\" Genzyme Corporation, Cambridge, MA.[2] \"Product Information. Cerdelga (eliglustat).\" Genzyme Corporation, Cambridge, MA.", "alternatives_a": "Clopidogrel, Iloprost, Lepirudin, Acenocoumarol, Urokinase, Cangrelor, Dipyridamole, Warfarin, Caplacizumab, Argatroban, Prasugrel, More", "alternatives_b": "Teduglutide, Fosdenopterin, Miglustat, Imiglucerase, Asfotase alfa, Glycerol phenylbutyrate, Pegvaliase, Triethylenetetramine, Sapropterin, Zinc acetate, Phenylbutyric acid, More", "updated_at": 1767369485}, {"id": 97323, "ingredient1": "Eliglustat", "ingredient2": "Timolol", "severity": "Moderate", "effect": "Coadministration with eliglustat may increase the plasma concentrations of drugs that are primarily metabolized by CYP450 2D6.", "source": "DDInter", "management_text": "Caution is advised if eliglustat is used concomitantly with medications that undergo metabolism primarily by CYP450 2D6, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever eliglustat is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if eliglustat is used concomitantly with medications that undergo metabolism primarily by CYP450 2D6, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97427/", "reference_text": "[1] \"Product Information. Cerdelga (eliglustat).\" Genzyme Corporation, Cambridge, MA.[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] \"Product Information. Cerdelga (eliglustat).\" Genzyme Corporation, Cambridge, MA.[5] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[6] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[7] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[8] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.", "alternatives_a": "Acebutolol, Labetalol, Nadolol, Esmolol, Betaxolol, Penbutolol, Bisoprolol, Carteolol, Pindolol, Atenolol, Neostigmine, More", "alternatives_b": "Teduglutide, Lonafarnib, Fosdenopterin, Miglustat, Imiglucerase, Asfotase alfa, Pegvaliase, Triethylenetetramine, Sapropterin, Zinc acetate, Phenylbutyric acid, More", "updated_at": 1767369485}, {"id": 97324, "ingredient1": "Eliglustat", "ingredient2": "Tipranavir", "severity": "Moderate", "effect": "Coadministration with eliglustat may increase the plasma concentrations of drugs that are substrates of the P-glycoprotein (P-gp) transporter. The proposed mechanism is decreased clearance in the intestine, liver, and/or kidney due to inhibition of P-glycoprotein-mediated drug efflux by eliglustat.", "source": "DDInter", "management_text": "Caution is advised when eliglustat is used concurrently with drugs that are known P-gp substrates, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever eliglustat is added to or withdrawn from therapy.", "mechanism_text": "Others", "recommendation": "Caution is advised when eliglustat is used concurrently with drugs that are known P-gp substrates, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97428/", "reference_text": "[1] \"Product Information. Cerdelga (eliglustat).\" Genzyme Corporation, Cambridge, MA.[2] \"Product Information. Cerdelga (eliglustat).\" Genzyme Corporation, Cambridge, MA.", "alternatives_a": "Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Simeprevir, Cabotegravir, Valaciclovir, Zanamivir, Velpatasvir, Rilpivirine, Dolutegravir, More", "alternatives_b": "Teduglutide, Fosdenopterin, Miglustat, Imiglucerase, Asfotase alfa, Glycerol phenylbutyrate, Pegvaliase, Triethylenetetramine, Sapropterin, Zinc acetate, Phenylbutyric acid, More", "updated_at": 1767369485}, {"id": 97325, "ingredient1": "Eliglustat", "ingredient2": "Tolterodine", "severity": "Minor", "effect": "Coadministration with drugs that are inhibitors of CYP450 2D6 may increase the plasma concentrations of tolterodine, which is primarily metabolized by this isoenzyme in patients that are extensive metabolizers, or EMs (approximately 93% of Caucasians and more than 98% of Asians and individuals of African descent). Moreover, since the active 5-hydroxymethyl metabolite (5-HM) generated by CYP450 2D6 is equipotent compared with tolterodine, and the sum of unbound serum concentrations of tolterodine and 5-HM are only 25% higher during the interaction, little alteration in the overall pharmacologic activity would be expected. Thus, dosage reductions should not be necessary.", "source": "DDInter", "management_text": "-", "mechanism_text": "Metabolism", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97429/", "reference_text": "[1] Brynne N, Svanstrom C, AbergWistedt A, Hallen B, Bertilsson L \"Fluoxetine inhibits the metabolism of tolterodin-pharmacokinetic implications and proposed clinical relevance.\" Br J Clin Pharmacol 48 (1999): 553-63[2] \"Product Information. Detrol (tolterodine).\" Pharmacia and Upjohn, Kalamazoo, MI.", "alternatives_a": "Vardenafil, Tadalafil, Ammonium chloride, Apomorphine, Yohimbine, Papaverine, Oxybutynin, Dimethyl sulfoxide, Pentosan polysulfate, Calcium chloride, Trospium, More", "alternatives_b": "Teduglutide, Fosdenopterin, Miglustat, Imiglucerase, Asfotase alfa, Pegvaliase, Triethylenetetramine, Sapropterin, Zinc acetate, Phenylbutyric acid, Agalsidase beta, More", "updated_at": 1767369485}, {"id": 97326, "ingredient1": "Eliglustat", "ingredient2": "Tolvaptan", "severity": "Moderate", "effect": "Coadministration with inhibitors of P-glycoprotein (P-gp) may increase the oral bioavailability of tolvaptan, which has been shown in vitro to be a substrate of the efflux transporter.", "source": "DDInter", "management_text": "Caution is advised if tolvaptan is prescribed in combination with P-glycoprotein inhibitors, especially potent ones such as amiodarone, cyclosporine, or quinidine. Serum sodium concentration and neurologic status should be closely monitored, and the tolvaptan dosage adjusted accordingly. Too rapid correction of hyponatremia increases the risk of osmotic demyelination syndrome, which is associated with dysarthria, mutism, dysphagia, lethargy, affective changes, spastic quadriparesis, seizures, coma, and death. Discontinuation or interruption of tolvaptan therapy should be considered in patients who develop too rapid a rise in serum sodium.", "mechanism_text": "Absorption", "recommendation": "Caution is advised if tolvaptan is prescribed in combination with P-glycoprotein inhibitors, especially potent ones such as amiodarone, cyclosporine, or quinidine.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97430/", "reference_text": "[1] \"Product Information. Samsca (tolvaptan).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[2] \"Product Information. Venclexta (venetoclax).\" AbbVie US LLC, North Chicago, IL.[3] \"Product Information. Samsca (tolvaptan).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.", "alternatives_a": "Teduglutide, Fosdenopterin, Miglustat, Imiglucerase, Asfotase alfa, Glycerol phenylbutyrate, Pegvaliase, Triethylenetetramine, Sapropterin, Zinc acetate, Phenylbutyric acid, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 97327, "ingredient1": "Eliglustat", "ingredient2": "Topotecan", "severity": "Moderate", "effect": "Coadministration with eliglustat may increase the plasma concentrations of drugs that are substrates of the P-glycoprotein (P-gp) transporter. The proposed mechanism is decreased clearance in the intestine, liver, and/or kidney due to inhibition of P-glycoprotein-mediated drug efflux by eliglustat.", "source": "DDInter", "management_text": "Caution is advised when eliglustat is used concurrently with drugs that are known P-gp substrates, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever eliglustat is added to or withdrawn from therapy.", "mechanism_text": "Others", "recommendation": "Caution is advised when eliglustat is used concurrently with drugs that are known P-gp substrates, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97431/", "reference_text": "[1] \"Product Information. Cerdelga (eliglustat).\" Genzyme Corporation, Cambridge, MA.[2] \"Product Information. Cerdelga (eliglustat).\" Genzyme Corporation, Cambridge, MA.", "alternatives_a": "Teniposide, Trabectedin, Cabazitaxel, Irinotecan", "alternatives_b": "Teduglutide, Fosdenopterin, Miglustat, Imiglucerase, Asfotase alfa, Glycerol phenylbutyrate, Pegvaliase, Triethylenetetramine, Sapropterin, Zinc acetate, Phenylbutyric acid, More", "updated_at": 1767369485}, {"id": 97328, "ingredient1": "Eliglustat", "ingredient2": "Trazodone", "severity": "Moderate", "effect": "Coadministration with eliglustat may increase the plasma concentrations of drugs that are primarily metabolized by CYP450 2D6.", "source": "DDInter", "management_text": "Caution is advised if eliglustat is used concomitantly with medications that undergo metabolism primarily by CYP450 2D6, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever eliglustat is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if eliglustat is used concomitantly with medications that undergo metabolism primarily by CYP450 2D6, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97432/", "reference_text": "[1] \"Product Information. Cerdelga (eliglustat).\" Genzyme Corporation, Cambridge, MA.[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] \"Product Information. Cerdelga (eliglustat).\" Genzyme Corporation, Cambridge, MA.[5] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[6] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[7] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[8] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.", "alternatives_a": "Phenelzine, Citalopram, Tranylcypromine, Desvenlafaxine, Isocarboxazid, Oxitriptan, Tryptophan, Milnacipran, Levomilnacipran, Vilazodone, Esketamine, More", "alternatives_b": "Teduglutide, Fosdenopterin, Miglustat, Imiglucerase, Asfotase alfa, Pegvaliase, Triethylenetetramine, Sapropterin, Zinc acetate, Phenylbutyric acid, Agalsidase beta, More", "updated_at": 1767369485}, {"id": 97329, "ingredient1": "Eliglustat", "ingredient2": "Trimipramine", "severity": "Moderate", "effect": "Coadministration with eliglustat may increase the plasma concentrations of drugs that are primarily metabolized by CYP450 2D6.", "source": "DDInter", "management_text": "Caution is advised if eliglustat is used concomitantly with medications that undergo metabolism primarily by CYP450 2D6, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever eliglustat is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if eliglustat is used concomitantly with medications that undergo metabolism primarily by CYP450 2D6, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97433/", "reference_text": "[1] \"Product Information. Cerdelga (eliglustat).\" Genzyme Corporation, Cambridge, MA.[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] \"Product Information. Cerdelga (eliglustat).\" Genzyme Corporation, Cambridge, MA.[5] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[6] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[7] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[8] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.", "alternatives_a": "Phenelzine, Citalopram, Tranylcypromine, Desvenlafaxine, Isocarboxazid, Oxitriptan, Tryptophan, Milnacipran, Levomilnacipran, Vilazodone, Esketamine, More", "alternatives_b": "Teduglutide, Lonafarnib, Fosdenopterin, Miglustat, Imiglucerase, Asfotase alfa, Pegvaliase, Triethylenetetramine, Sapropterin, Zinc acetate, Phenylbutyric acid, More", "updated_at": 1767369485}, {"id": 97330, "ingredient1": "Eliglustat", "ingredient2": "Troglitazone", "severity": "Moderate", "effect": "Coadministration with inducers of CYP450 3A4 and/or P-glycoprotein (P-gp) may decrease the plasma concentrations of eliglustat, which is primarily metabolized by CYP450 2D6 and, to a lesser extent, CYP450 3A4. Eliglustat is also a substrate of P-gp efflux transporter.", "source": "DDInter", "management_text": "Patients receiving eliglustat with CYP450 3A4 inducers should be monitored for potentially diminished pharmacologic response to eliglustat. Concomitant use should be avoided if an interaction is suspected.", "mechanism_text": "Metabolism", "recommendation": "Patients receiving eliglustat with CYP450 3A4 inducers should be monitored for potentially diminished pharmacologic response to eliglustat.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97434/", "reference_text": "[1] \"Product Information. Cerdelga (eliglustat).\" Genzyme Corporation, Cambridge, MA.[2] \"Product Information. Cerdelga (eliglustat).\" Genzyme Corporation, Cambridge, MA.", "alternatives_a": "Glipizide, Acetohexamide, Guar gum, Pramlintide, Alogliptin, Rosuvastatin, Tolazamide, Empagliflozin, Dulaglutide, Exenatide, Tolbutamide, More", "alternatives_b": "Teduglutide, Fosdenopterin, Miglustat, Imiglucerase, Asfotase alfa, Glycerol phenylbutyrate, Pegvaliase, Triethylenetetramine, Sapropterin, Zinc acetate, Phenylbutyric acid, More", "updated_at": 1767369485}, {"id": 97331, "ingredient1": "Eliglustat", "ingredient2": "Troleandomycin", "severity": "Major", "effect": "Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of eliglustat, which is primarily metabolized by CYP450 2D6 and, to a lesser extent, CYP450 3A4. Eliglustat at substantially elevated plasma concentrations is predicted to cause prolongation of the PR, QTc and QRS cardiac intervals, which may increase the risk of bradycardia, atrioventricular block, cardiac arrest, and serious ventricular arrhythmias such as torsade de pointes.", "source": "DDInter", "management_text": "The use of eliglustat with a potent CYP450 3A4 inhibitor is considered contraindicated in CYP450 2D6 poor metabolizers (PMs) and intermediate metabolizers (IMs). The contraindication is extended to extensive metabolizers (EMs) when a moderate or potent CYP450 2D6 inhibitor is given concomitantly with a moderate or potent CYP450 3A4 inhibitor. In the absence of a concomitant CYP450 2D6 inhibitor, eliglustat may be prescribed at a reduced dosage of 84 mg once daily to EMs treated with a potent CYP450 3A4 inhibitor. Potent CYP450 3A4 inhibitors include itraconazole, ketoconazole, posaconazole, voriconazole, conivaptan, ceritinib, idelalisib, mibefradil, nefazodone, cobicistat, delavirdine, protease inhibitors, and ketolide and certain macrolide antibiotics. Potent and moderate CYP450 2D6 inhibitors include abiraterone, bupropion, celecoxib, cimetidine, cinacalcet, clobazam, darifenacin, diphenhydramine, dronedarone, duloxetine, flecainide, fluoxetine, methotrimeprazine, mirabegron, paroxetine, propafenone, propoxyphene, quinidine, ranolazine, sertraline, and terbinafine. Some drugs such as cobicistat, delavirdine, mibefradil, and ritonavir are dual CYP450 3A4 and 2D6 inhibitors, and they should not be used with eliglustat in any patient regardless of their CYP450 2D6 metabolizer status.", "mechanism_text": "Metabolism", "recommendation": "The use of eliglustat with a potent CYP450 3A4 inhibitor is considered contraindicated in CYP450 2D6 poor metabolizers (PMs) and intermediate metabolizers (IMs).", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97435/", "reference_text": "[1] Cerner Multum, Inc. \"Australian Product Information.\" O 0[2] \"Product Information. Sporanox (itraconazole).\" Janssen Pharmaceutica, Titusville, NJ.[3] \"Product Information. Cerdelga (eliglustat).\" Genzyme Corporation, Cambridge, MA.[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] \"Product Information. Cerdelga (eliglustat).\" Genzyme Corporation, Cambridge, MA.[6] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[7] \"Product Information. VFEND (voriconazole).\" Pfizer U.S. Pharmaceuticals, New York, NY.", "alternatives_a": "Teduglutide, Fosdenopterin, Miglustat, Imiglucerase, Asfotase alfa, Glycerol phenylbutyrate, Pegvaliase, Triethylenetetramine, Sapropterin, Zinc acetate, Phenylbutyric acid, More", "alternatives_b": "Dirithromycin, Lincomycin, Azithromycin, Clindamycin", "updated_at": 1767369485}, {"id": 97332, "ingredient1": "Eliglustat", "ingredient2": "Tucatinib", "severity": "Major", "effect": "Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of eliglustat, which is primarily metabolized by CYP450 2D6 and, to a lesser extent, CYP450 3A4. Eliglustat at substantially elevated plasma concentrations is predicted to cause prolongation of the PR, QTc and QRS cardiac intervals, which may increase the risk of bradycardia, atrioventricular block, cardiac arrest, and serious ventricular arrhythmias such as torsade de pointes.", "source": "DDInter", "management_text": "The use of eliglustat with a potent CYP450 3A4 inhibitor is considered contraindicated in CYP450 2D6 poor metabolizers (PMs) and intermediate metabolizers (IMs). The contraindication is extended to extensive metabolizers (EMs) when a moderate or potent CYP450 2D6 inhibitor is given concomitantly with a moderate or potent CYP450 3A4 inhibitor. In the absence of a concomitant CYP450 2D6 inhibitor, eliglustat may be prescribed at a reduced dosage of 84 mg once daily to EMs treated with a potent CYP450 3A4 inhibitor. Potent CYP450 3A4 inhibitors include itraconazole, ketoconazole, posaconazole, voriconazole, conivaptan, ceritinib, idelalisib, mibefradil, nefazodone, cobicistat, delavirdine, protease inhibitors, and ketolide and certain macrolide antibiotics. Potent and moderate CYP450 2D6 inhibitors include abiraterone, bupropion, celecoxib, cimetidine, cinacalcet, clobazam, darifenacin, diphenhydramine, dronedarone, duloxetine, flecainide, fluoxetine, methotrimeprazine, mirabegron, paroxetine, propafenone, propoxyphene, quinidine, ranolazine, sertraline, and terbinafine. Some drugs such as cobicistat, delavirdine, mibefradil, and ritonavir are dual CYP450 3A4 and 2D6 inhibitors, and they should not be used with eliglustat in any patient regardless of their CYP450 2D6 metabolizer status.", "mechanism_text": "Metabolism", "recommendation": "The use of eliglustat with a potent CYP450 3A4 inhibitor is considered contraindicated in CYP450 2D6 poor metabolizers (PMs) and intermediate metabolizers (IMs).", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97436/", "reference_text": "[1] Cerner Multum, Inc. \"Australian Product Information.\" O 0[2] \"Product Information. Sporanox (itraconazole).\" Janssen Pharmaceutica, Titusville, NJ.[3] \"Product Information. Cerdelga (eliglustat).\" Genzyme Corporation, Cambridge, MA.[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] \"Product Information. Cerdelga (eliglustat).\" Genzyme Corporation, Cambridge, MA.[6] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[7] \"Product Information. VFEND (voriconazole).\" Pfizer U.S. Pharmaceuticals, New York, NY.", "alternatives_a": "Lipoic acid, Triheptanoin, Teduglutide, Fosdenopterin, Triethylenetetramine, Miglustat, Sapropterin, Zinc acetate, Levocarnitine, Laronidase, Imiglucerase, More", "alternatives_b": "Acalabrutinib, Tepotinib, Avapritinib, Selumetinib, Vandetanib, Capmatinib, Ibrutinib, Tivozanib, Zanubrutinib, Axitinib, Sunitinib, More", "updated_at": 1767369485}, {"id": 97333, "ingredient1": "Eliglustat", "ingredient2": "Ubrogepant", "severity": "Moderate", "effect": "Coadministration with breast cancer resistance protein (BCRP) and/or P-glycoprotein (P-gp) only inhibitors may increase the exposure of ubrogepant, which is a substrate of these transporters.", "source": "DDInter", "management_text": "The manufacturer recommends an initial ubrogepant dose of 50 mg when coadministered with BCRP and/or P-gp only inhibitors. If needed, a second 50 mg dose of ubrogepant may be administered at least 2 hours after the initial dose.", "mechanism_text": "Distribution", "recommendation": "The manufacturer recommends an initial ubrogepant dose of 50 mg when coadministered with BCRP and/or P-gp only inhibitors.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97437/", "reference_text": "[1] \"Product Information. Ubrelvy (ubrogepant).\" Allergan Inc, Irvine, CA.[2] \"Product Information. Mavyret (glecaprevir-pibrentasvir).\" Abbott Pharmaceutical, Abbott Park, IL.[3] \"Product Information. Ubrelvy (ubrogepant).\" Allergan Inc, Irvine, CA.", "alternatives_a": "Teduglutide, Fosdenopterin, Miglustat, Imiglucerase, Asfotase alfa, Pegvaliase, Triethylenetetramine, Sapropterin, Zinc acetate, Phenylbutyric acid, Agalsidase beta, More", "alternatives_b": "Frovatriptan, Dihydroergotamine, Rimegepant, Eptinezumab, Atogepant, Eletriptan, Rizatriptan, Ergotamine, Clonidine, Naratriptan, Galcanezumab, More", "updated_at": 1767369485}, {"id": 97334, "ingredient1": "Eliglustat", "ingredient2": "Vemurafenib", "severity": "Moderate", "effect": "Coadministration with inducers of CYP450 3A4 and/or P-glycoprotein (P-gp) may decrease the plasma concentrations of eliglustat, which is primarily metabolized by CYP450 2D6 and, to a lesser extent, CYP450 3A4. Eliglustat is also a substrate of P-gp efflux transporter.", "source": "DDInter", "management_text": "Patients receiving eliglustat with CYP450 3A4 inducers should be monitored for potentially diminished pharmacologic response to eliglustat. Concomitant use should be avoided if an interaction is suspected.", "mechanism_text": "Metabolism", "recommendation": "Patients receiving eliglustat with CYP450 3A4 inducers should be monitored for potentially diminished pharmacologic response to eliglustat.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97438/", "reference_text": "[1] \"Product Information. Cerdelga (eliglustat).\" Genzyme Corporation, Cambridge, MA.[2] \"Product Information. Cerdelga (eliglustat).\" Genzyme Corporation, Cambridge, MA.", "alternatives_a": "Tinidazole, Ascorbic acid, Hydroflumethiazide, Chlorothiazide, Metronidazole, Simeprevir, Rosuvastatin, Sulfadiazine, Lactic acid, Methazolamide, Amphotericin B, More", "alternatives_b": "Teduglutide, Fosdenopterin, Miglustat, Imiglucerase, Asfotase alfa, Glycerol phenylbutyrate, Pegvaliase, Triethylenetetramine, Sapropterin, Zinc acetate, Phenylbutyric acid, More", "updated_at": 1767369485}, {"id": 97335, "ingredient1": "Eliglustat", "ingredient2": "Venetoclax", "severity": "Major", "effect": "Coadministration with moderate inhibitors of CYP450 3A4 may increase the plasma concentrations of venetoclax, which is a substrate of the isoenzyme.", "source": "DDInter", "management_text": "Concomitant use of venetoclax with moderate CYP450 3A4 inhibitors should generally be avoided. If coadministration is required, the manufacturer recommends that venetoclax dosage be reduced by at least 50%. The dosage used prior to initiating the CYP450 3A4 inhibitor may be resumed 2 to 3 days after discontinuation of the inhibitor.", "mechanism_text": "Metabolism", "recommendation": "Concomitant use of venetoclax with moderate CYP450 3A4 inhibitors should generally be avoided.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97439/", "reference_text": "[1] \"Product Information. Venclexta (venetoclax).\" AbbVie US LLC, North Chicago, IL.[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] \"Product Information. Venclexta (venetoclax).\" AbbVie US LLC, North Chicago, IL.", "alternatives_a": "Teduglutide, Fosdenopterin, Miglustat, Imiglucerase, Asfotase alfa, Glycerol phenylbutyrate, Pegvaliase, Triethylenetetramine, Sapropterin, Zinc acetate, Phenylbutyric acid, More", "alternatives_b": "Pertuzumab, Olaparib, Oxaliplatin, Bortezomib, Tisagenlecleucel, Aminolevulinic acid, Omacetaxine mepesuccinate, Altretamine, Tagraxofusp, Pegaspargase, Ixazomib, More", "updated_at": 1767369485}, {"id": 97336, "ingredient1": "Eliglustat", "ingredient2": "Vinblastine", "severity": "Moderate", "effect": "Coadministration with eliglustat may increase the plasma concentrations of drugs that are substrates of the P-glycoprotein (P-gp) transporter. The proposed mechanism is decreased clearance in the intestine, liver, and/or kidney due to inhibition of P-glycoprotein-mediated drug efflux by eliglustat.", "source": "DDInter", "management_text": "Caution is advised when eliglustat is used concurrently with drugs that are known P-gp substrates, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever eliglustat is added to or withdrawn from therapy.", "mechanism_text": "Others", "recommendation": "Caution is advised when eliglustat is used concurrently with drugs that are known P-gp substrates, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97440/", "reference_text": "[1] \"Product Information. Cerdelga (eliglustat).\" Genzyme Corporation, Cambridge, MA.[2] \"Product Information. Cerdelga (eliglustat).\" Genzyme Corporation, Cambridge, MA.", "alternatives_a": "Teniposide, Trabectedin, Cabazitaxel, Irinotecan", "alternatives_b": "Teduglutide, Fosdenopterin, Miglustat, Imiglucerase, Asfotase alfa, Pegvaliase, Triethylenetetramine, Sapropterin, Zinc acetate, Phenylbutyric acid, Agalsidase beta, More", "updated_at": 1767369485}, {"id": 97337, "ingredient1": "Eliglustat", "ingredient2": "Vincristine", "severity": "Moderate", "effect": "Coadministration with eliglustat may increase the plasma concentrations of drugs that are substrates of the P-glycoprotein (P-gp) transporter. The proposed mechanism is decreased clearance in the intestine, liver, and/or kidney due to inhibition of P-glycoprotein-mediated drug efflux by eliglustat.", "source": "DDInter", "management_text": "Caution is advised when eliglustat is used concurrently with drugs that are known P-gp substrates, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever eliglustat is added to or withdrawn from therapy.", "mechanism_text": "Others", "recommendation": "Caution is advised when eliglustat is used concurrently with drugs that are known P-gp substrates, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97441/", "reference_text": "[1] \"Product Information. Cerdelga (eliglustat).\" Genzyme Corporation, Cambridge, MA.[2] \"Product Information. Cerdelga (eliglustat).\" Genzyme Corporation, Cambridge, MA.", "alternatives_a": "Teniposide, Trabectedin, Cabazitaxel, Irinotecan", "alternatives_b": "Teduglutide, Fosdenopterin, Miglustat, Imiglucerase, Asfotase alfa, Pegvaliase, Triethylenetetramine, Sapropterin, Zinc acetate, Phenylbutyric acid, Agalsidase beta, More", "updated_at": 1767369485}, {"id": 97338, "ingredient1": "Eliglustat", "ingredient2": "Vincristine (liposome)", "severity": "Moderate", "effect": "Coadministration with eliglustat may increase the plasma concentrations of drugs that are substrates of the P-glycoprotein (P-gp) transporter. The proposed mechanism is decreased clearance in the intestine, liver, and/or kidney due to inhibition of P-glycoprotein-mediated drug efflux by eliglustat.", "source": "DDInter", "management_text": "Caution is advised when eliglustat is used concurrently with drugs that are known P-gp substrates, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever eliglustat is added to or withdrawn from therapy.", "mechanism_text": "Others", "recommendation": "Caution is advised when eliglustat is used concurrently with drugs that are known P-gp substrates, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97442/", "reference_text": "[1] \"Product Information. Cerdelga (eliglustat).\" Genzyme Corporation, Cambridge, MA.[2] \"Product Information. Cerdelga (eliglustat).\" Genzyme Corporation, Cambridge, MA.", "alternatives_a": "Teniposide, Trabectedin, Cabazitaxel, Irinotecan", "alternatives_b": "Teduglutide, Fosdenopterin, Miglustat, Imiglucerase, Asfotase alfa, Glycerol phenylbutyrate, Pegvaliase, Triethylenetetramine, Sapropterin, Zinc acetate, Phenylbutyric acid, More", "updated_at": 1767369485}, {"id": 97339, "ingredient1": "Eliglustat", "ingredient2": "Vinorelbine", "severity": "Moderate", "effect": "Coadministration with eliglustat may increase the plasma concentrations of drugs that are substrates of the P-glycoprotein (P-gp) transporter. The proposed mechanism is decreased clearance in the intestine, liver, and/or kidney due to inhibition of P-glycoprotein-mediated drug efflux by eliglustat.", "source": "DDInter", "management_text": "Caution is advised when eliglustat is used concurrently with drugs that are known P-gp substrates, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever eliglustat is added to or withdrawn from therapy.", "mechanism_text": "Others", "recommendation": "Caution is advised when eliglustat is used concurrently with drugs that are known P-gp substrates, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97443/", "reference_text": "[1] \"Product Information. Cerdelga (eliglustat).\" Genzyme Corporation, Cambridge, MA.[2] \"Product Information. Cerdelga (eliglustat).\" Genzyme Corporation, Cambridge, MA.", "alternatives_a": "Teniposide, Trabectedin, Cabazitaxel, Irinotecan", "alternatives_b": "Teduglutide, Fosdenopterin, Miglustat, Imiglucerase, Asfotase alfa, Pegvaliase, Triethylenetetramine, Sapropterin, Zinc acetate, Phenylbutyric acid, Agalsidase beta, More", "updated_at": 1767369485}, {"id": 97340, "ingredient1": "Eliglustat", "ingredient2": "Voriconazole", "severity": "Major", "effect": "Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of eliglustat, which is primarily metabolized by CYP450 2D6 and, to a lesser extent, CYP450 3A4. Eliglustat at substantially elevated plasma concentrations is predicted to cause prolongation of the PR, QTc and QRS cardiac intervals, which may increase the risk of bradycardia, atrioventricular block, cardiac arrest, and serious ventricular arrhythmias such as torsade de pointes.", "source": "DDInter", "management_text": "The use of eliglustat with a potent CYP450 3A4 inhibitor is considered contraindicated in CYP450 2D6 poor metabolizers (PMs) and intermediate metabolizers (IMs). The contraindication is extended to extensive metabolizers (EMs) when a moderate or potent CYP450 2D6 inhibitor is given concomitantly with a moderate or potent CYP450 3A4 inhibitor. In the absence of a concomitant CYP450 2D6 inhibitor, eliglustat may be prescribed at a reduced dosage of 84 mg once daily to EMs treated with a potent CYP450 3A4 inhibitor. Potent CYP450 3A4 inhibitors include itraconazole, ketoconazole, posaconazole, voriconazole, conivaptan, ceritinib, idelalisib, mibefradil, nefazodone, cobicistat, delavirdine, protease inhibitors, and ketolide and certain macrolide antibiotics. Potent and moderate CYP450 2D6 inhibitors include abiraterone, bupropion, celecoxib, cimetidine, cinacalcet, clobazam, darifenacin, diphenhydramine, dronedarone, duloxetine, flecainide, fluoxetine, methotrimeprazine, mirabegron, paroxetine, propafenone, propoxyphene, quinidine, ranolazine, sertraline, and terbinafine. Some drugs such as cobicistat, delavirdine, mibefradil, and ritonavir are dual CYP450 3A4 and 2D6 inhibitors, and they should not be used with eliglustat in any patient regardless of their CYP450 2D6 metabolizer status.", "mechanism_text": "Metabolism", "recommendation": "The use of eliglustat with a potent CYP450 3A4 inhibitor is considered contraindicated in CYP450 2D6 poor metabolizers (PMs) and intermediate metabolizers (IMs).", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97444/", "reference_text": "[1] Cerner Multum, Inc. \"Australian Product Information.\" O 0[2] \"Product Information. Sporanox (itraconazole).\" Janssen Pharmaceutica, Titusville, NJ.[3] \"Product Information. Cerdelga (eliglustat).\" Genzyme Corporation, Cambridge, MA.[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] \"Product Information. Cerdelga (eliglustat).\" Genzyme Corporation, Cambridge, MA.[6] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[7] \"Product Information. VFEND (voriconazole).\" Pfizer U.S. Pharmaceuticals, New York, NY.", "alternatives_a": "Caspofungin, Micafungin, Amphotericin B, Oteseconazole, Flucytosine, Anidulafungin", "alternatives_b": "Teduglutide, Fosdenopterin, Miglustat, Imiglucerase, Asfotase alfa, Glycerol phenylbutyrate, Pegvaliase, Triethylenetetramine, Sapropterin, Zinc acetate, Phenylbutyric acid, More", "updated_at": 1767369485}, {"id": 97341, "ingredient1": "Eliglustat", "ingredient2": "Vortioxetine", "severity": "Moderate", "effect": "Coadministration with eliglustat may increase the plasma concentrations of drugs that are primarily metabolized by CYP450 2D6.", "source": "DDInter", "management_text": "Caution is advised if eliglustat is used concomitantly with medications that undergo metabolism primarily by CYP450 2D6, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever eliglustat is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if eliglustat is used concomitantly with medications that undergo metabolism primarily by CYP450 2D6, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97445/", "reference_text": "[1] \"Product Information. Cerdelga (eliglustat).\" Genzyme Corporation, Cambridge, MA.[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] \"Product Information. Cerdelga (eliglustat).\" Genzyme Corporation, Cambridge, MA.[5] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[6] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[7] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[8] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.", "alternatives_a": "Teduglutide, Lonafarnib, Fosdenopterin, Miglustat, Imiglucerase, Asfotase alfa, Pegvaliase, Triethylenetetramine, Sapropterin, Zinc acetate, Phenylbutyric acid, More", "alternatives_b": "Phenelzine, Citalopram, Tranylcypromine, Desvenlafaxine, Isocarboxazid, Oxitriptan, Tryptophan, Milnacipran, Levomilnacipran, Vilazodone, Esketamine, More", "updated_at": 1767369485}, {"id": 97342, "ingredient1": "Eliglustat", "ingredient2": "Voxelotor", "severity": "Major", "effect": "Coadministration with moderate inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of eliglustat, which is primarily metabolized by CYP450 2D6 and, to a lesser extent, CYP450 3A4. Eliglustat at substantially elevated plasma concentrations is predicted to cause prolongation of the PR, QTc and QRS cardiac intervals, which may increase the risk of bradycardia, atrioventricular block, cardiac arrest, and serious ventricular arrhythmias such as torsade de pointes.", "source": "DDInter", "management_text": "The use of eliglustat in combination with one or more drugs that may result in moderate inhibition of CYP450 3A4 and moderate to potent inhibition of CYP450 2D6 is considered contraindicated in CYP450 2D6 extensive metabolizers (EMs) and intermediate metabolizers (IMs). In the absence of a concomitant CYP450 2D6 inhibitor, eliglustat may be prescribed at a reduced dosage of 84 mg once daily to EMs treated with a moderate CYP450 3A4 inhibitor. However, eliglustat should not be used with a moderate CYP450 3A4 inhibitor in CYP450 2D6 IMs or poor metabolizers (PMs). Moderate CYP450 3A4 inhibitors include aprepitant, ciprofloxacin, clotrimazole, crizotinib, darunavir, diltiazem, dronedarone, fluconazole, fusidic acid, imatinib, isavuconazonium, miconazole, mifepristone, netupitant, quinupristin-dalfopristin, ranolazine, stiripentol, and verapamil. Potent and moderate CYP450 2D6 inhibitors include abiraterone, bupropion, celecoxib, cimetidine, cinacalcet, clobazam, darifenacin, diphenhydramine, duloxetine, fluoxetine, methotrimeprazine, mirabegron, paroxetine, propoxyphene, quinidine, ranolazine, sertraline, stiripentol, and terbinafine.", "mechanism_text": "Metabolism", "recommendation": "The use of eliglustat in combination with one or more drugs that may result in moderate inhibition of CYP450 3A4 and moderate to potent inhibition of CYP450 2D6 is considered contraindicated in CYP450 2D6 extensive metabolizers (EMs) and intermediate metabolizers (IMs).", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97446/", "reference_text": "[1] \"Product Information. Cerdelga (eliglustat).\" Genzyme Corporation, Cambridge, MA.[2] \"Product Information. Cerdelga (eliglustat).\" Genzyme Corporation, Cambridge, MA.", "alternatives_a": "Teduglutide, Fosdenopterin, Miglustat, Imiglucerase, Asfotase alfa, Glycerol phenylbutyrate, Pegvaliase, Triethylenetetramine, Sapropterin, Zinc acetate, Phenylbutyric acid, More", "alternatives_b": "Hemin, Conestat alfa, Betibeglogene autotemcel, Hyaluronidase, Streptokinase, Human C1-esterase inhibitor, Crizanlizumab, Lanadelumab, Icatibant", "updated_at": 1767369485}, {"id": 97343, "ingredient1": "Eliglustat", "ingredient2": "Zafirlukast", "severity": "Moderate", "effect": "Coadministration with weak inhibitors of CYP450 3A4 may increase the plasma concentrations of eliglustat, which is primarily metabolized by CYP450 2D6 and, to a lesser extent, CYP450 3A4. Eliglustat at substantially elevated plasma concentrations is predicted to cause prolongation of the PR, QTc and QRS cardiac intervals, which may increase the risk of bradycardia, atrioventricular block, cardiac arrest, and serious ventricular arrhythmias such as torsade de pointes.", "source": "DDInter", "management_text": "Concomitant use of eliglustat with weak CYP450 3A4 inhibitors such as chloramphenicol, cyclosporine, danazol, dasatinib, ethinyl estradiol, fluvoxamine, goldenseal, isoniazid, ivacaftor, lapatinib, lomitapide, nifedipine, nilotinib, palbociclib, pazopanib, suvorexant, ticagrelor, and zafirlukast is not recommended in CYP450 2D6 poor metabolizers. No dosage adjustment for eliglustat is necessary when used with weak CYP450 3A4 inhibitors in extensive or intermediate metabolizers.", "mechanism_text": "Metabolism", "recommendation": "Concomitant use of eliglustat with weak CYP450 3A4 inhibitors such as chloramphenicol, cyclosporine, danazol, dasatinib, ethinyl estradiol, fluvoxamine, goldenseal, isoniazid, ivacaftor, lapatinib, lomitapide, nifedipine, nilotinib, palbociclib, pazopanib, suvorexant, ticagrelor, and zafirlukast is not recommended in CYP450 2D6 poor metabolizers.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97447/", "reference_text": "[1] \"Product Information. Cerdelga (eliglustat).\" Genzyme Corporation, Cambridge, MA.[2] \"Product Information. Cerdelga (eliglustat).\" Genzyme Corporation, Cambridge, MA.", "alternatives_a": "Theophylline, Omalizumab, Tezepelumab, Mercaptopurine, Aminophylline, Benralizumab, Caffeine, Reslizumab, Montelukast, Dyphylline, Oxtriphylline, More", "alternatives_b": "Teduglutide, Fosdenopterin, Miglustat, Imiglucerase, Asfotase alfa, Glycerol phenylbutyrate, Pegvaliase, Triethylenetetramine, Sapropterin, Zinc acetate, Phenylbutyric acid, More", "updated_at": 1767369485}, {"id": 97344, "ingredient1": "Eliglustat", "ingredient2": "Zileuton", "severity": "Moderate", "effect": "Coadministration with weak inhibitors of CYP450 3A4 may increase the plasma concentrations of eliglustat, which is primarily metabolized by CYP450 2D6 and, to a lesser extent, CYP450 3A4. Eliglustat at substantially elevated plasma concentrations is predicted to cause prolongation of the PR, QTc and QRS cardiac intervals, which may increase the risk of bradycardia, atrioventricular block, cardiac arrest, and serious ventricular arrhythmias such as torsade de pointes.", "source": "DDInter", "management_text": "Concomitant use of eliglustat with weak CYP450 3A4 inhibitors such as chloramphenicol, cyclosporine, danazol, dasatinib, ethinyl estradiol, fluvoxamine, goldenseal, isoniazid, ivacaftor, lapatinib, lomitapide, nifedipine, nilotinib, palbociclib, pazopanib, suvorexant, ticagrelor, and zafirlukast is not recommended in CYP450 2D6 poor metabolizers. No dosage adjustment for eliglustat is necessary when used with weak CYP450 3A4 inhibitors in extensive or intermediate metabolizers.", "mechanism_text": "Metabolism", "recommendation": "Concomitant use of eliglustat with weak CYP450 3A4 inhibitors such as chloramphenicol, cyclosporine, danazol, dasatinib, ethinyl estradiol, fluvoxamine, goldenseal, isoniazid, ivacaftor, lapatinib, lomitapide, nifedipine, nilotinib, palbociclib, pazopanib, suvorexant, ticagrelor, and zafirlukast is not recommended in CYP450 2D6 poor metabolizers.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97448/", "reference_text": "[1] \"Product Information. Cerdelga (eliglustat).\" Genzyme Corporation, Cambridge, MA.[2] \"Product Information. Cerdelga (eliglustat).\" Genzyme Corporation, Cambridge, MA.", "alternatives_a": "Teduglutide, Fosdenopterin, Miglustat, Imiglucerase, Asfotase alfa, Glycerol phenylbutyrate, Pegvaliase, Triethylenetetramine, Sapropterin, Zinc acetate, Phenylbutyric acid, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 97345, "ingredient1": "Aminoglutethimide", "ingredient2": "Theophylline", "severity": "Moderate", "effect": "Aminoglutethimide may significantly reduce theophylline serum concentrations by increasing theophylline clearance. The mechanism is induction of CYP450 3A4 hepatic microsomal enzymes.", "source": "DDInter", "management_text": "The patient should be monitored for clinical and laboratory evidence of altered theophylline response when aminoglutethimide is added, discontinued, or the dosage is changed. Patients should be advised to notify their physician if they experience a worsening of their respiratory symptoms during concurrent therapy.", "mechanism_text": "Metabolism", "recommendation": "The patient should be monitored for clinical and laboratory evidence of altered theophylline response when aminoglutethimide is added, discontinued, or the dosage is changed.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97449/", "reference_text": "[1] Lonning PE, Kvinnsland S, Bakke OM \"Effect of aminoglutethimide on antipyrine, theophylline, and digitoxin disposition in breast cancer.\" Clin Pharmacol Ther 36 (1984): 796-802", "alternatives_a": "Omalizumab, Tezepelumab, Mercaptopurine, Benralizumab, Caffeine, Reslizumab, Dyphylline, Mepolizumab, Roflumilast, Pentoxifylline, Zafirlukast, Bromotheophylline", "alternatives_b": "Darolutamide, Tamoxifen, Anastrozole, Letrozole, Toremifene, Fulvestrant, Abarelix, Enzalutamide, Relugolix, Bicalutamide, Degarelix, More", "updated_at": 1767369485}, {"id": 97346, "ingredient1": "Theophylline", "ingredient2": "Atracurium", "severity": "Moderate", "effect": "Methylxanthines may antagonize the effects of neuromuscular blockers. The mechanism is unknown. In patients stabilized on aminophylline, resistance to pancuronium has been reported.", "source": "DDInter", "management_text": "The patient should be monitored for adequate neuromuscular blockade and the dosage adjusted, if necessary.", "mechanism_text": "Antagonism", "recommendation": "The patient should be monitored for adequate neuromuscular blockade and the dosage adjusted, if necessary.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97450/", "reference_text": "[1] Doll DC, Rosenberg H \"Antagonism of neuromuscular blockage by theophylline.\" Anesth Analg 58 (1979): 139-40[2] Azar I, Kumar D, Betcher AM \"Resistance to pancuronium in an asthmatic patient treated with aminophylline and steroids.\" Can Anaesth Soc J 29 (1982): 280-2[3] Daller JA, Erstad B, Rosado L, Otto C, Putnam CW \"Aminophylline antagonizes the neuromuscular blockade of pancuronium but not vecuronium.\" Crit Care Med 19 (1991): 983-5", "alternatives_a": "Omalizumab, Tezepelumab, Mercaptopurine, Benralizumab, Caffeine, Reslizumab, Montelukast, Mepolizumab, Roflumilast, Pentoxifylline, Zafirlukast, Bromotheophylline", "alternatives_b": "Botulinum toxin type A", "updated_at": 1767369485}, {"id": 97347, "ingredient1": "Butabarbital", "ingredient2": "Theophylline", "severity": "Moderate", "effect": "Barbiturates may decrease serum levels and therapeutic effects of the methylxanthines. The mechanism is barbiturate induction of CYP450 3A4 and 1A2 hepatic metabolism of methylxanthines.", "source": "DDInter", "management_text": "Close observation for clinical and laboratory evidence of decreased methylxanthine effect is indicated if these drugs must be used together. Patients should be advised to notify their physician if they experience a worsening of their respiratory symptoms.", "mechanism_text": "Metabolism", "recommendation": "Close observation for clinical and laboratory evidence of decreased methylxanthine effect is indicated if these drugs must be used together.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97451/", "reference_text": "[1] Dahlqvist R, Steiner E, Koike Y, von Bahr C, Lind M, Billing B \"Induction of theophylline metabolism by pentobarbital.\" Ther Drug Monit 11 (1989): 408-10[2] Bukowskyj M, Nakatsu K, Munt PW \"Theophylline reassessed.\" Ann Intern Med 101 (1984): 63-73[3] Upton RA \"Pharmacokinetic interactions between theophylline and other medication (Part I).\" Clin Pharmacokinet 20 (1991): 66-80[4] Landay RA, Gonzalez MA, Taylor JC \"Effect of phenobarbital on theophylline disposition.\" J Allergy Clin Immunol 62 (1978): 27-9", "alternatives_a": "Suvorexant, Chloral hydrate, Nitrazepam, Paraldehyde, Propiomazine, Ramelteon, Meprobamate, Scopolamine, Eszopiclone, Dexmedetomidine, Lemborexant, More", "alternatives_b": "Omalizumab, Tezepelumab, Mercaptopurine, Benralizumab, Caffeine, Reslizumab, Dyphylline, Mepolizumab, Roflumilast, Pentoxifylline, Zafirlukast, Bromotheophylline", "updated_at": 1767369485}, {"id": 97348, "ingredient1": "Carteolol", "ingredient2": "Theophylline", "severity": "Major", "effect": "The pharmacologic effects of theophyllines and beta-blockers are opposite. Nonselective and high doses of cardioselective beta-blockers may cause severe or fatal bronchospasm by opposing theophylline-induced bronchodilation. Ophthalmic beta-blockers undergo significant systemic absorption and may also interact. In addition, propranolol and other beta-blockers may reduce the CYP450 hepatic metabolism of theophylline, and serum theophylline levels may be increased.", "source": "DDInter", "management_text": "Oral and ophthalmic nonselective beta-blockers (e.g., carteolol, carvedilol, levobunolol, metipranolol, nadolol, oxprenolol, penbutolol, pindolol, propranolol, sotalol, and timolol) are considered contraindicated in patients with bronchospastic diseases. Cardioselective beta-blockers should generally be avoided, or used with extreme caution if no other alternatives are available and the benefits outweigh the risks of potentially severe bronchospasm. If patients do receive this combination, they should be closely monitored for increased serum theophylline levels but decreased bronchodilatory effectiveness.", "mechanism_text": "Antagonism", "recommendation": "Oral and ophthalmic nonselective beta-blockers (e.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97452/", "reference_text": "[1] Upton RA \"Pharmacokinetic interactions between theophylline and other medication (Part II).\" Clin Pharmacokinet 20 (1991): 135-50[2] Mue S, Sasaki T, Shibahara S, et alT \"Influence of metoprolol on hemodynamics and respiratory function in asthmatic patients.\" Int J Clin Pharmacol Biopharm 17 (1979): 346-50[3] Lombardi TP, Bertino JS, Goldberg A, Middleton E, Slaughter RL \"The effects of a beta-2 selective adrenergic agonist and a beta- nonselective antagonist on theophylline clearance.\" J Clin Pharmacol 27 (1987): 523-9[4] Horvath JS, Woolcock AJ, Tiller DJ, Donnelly P, Armstrong J, Caterson R \"A comparison of metoprolol and propranolol on blood pressure and respiratory function in patients with hypertension.\" Aust N Z J Med 8 (1978): 1-6[5] Conrad KA, Nyman DW \"Effects of metoprolol and propranolol on theophylline elimination.\" Clin Pharmacol Ther 28 (1980): 463-7", "alternatives_a": "Omalizumab, Tezepelumab, Mercaptopurine, Benralizumab, Caffeine, Reslizumab, Montelukast, Mepolizumab, Roflumilast, Zafirlukast, Bromotheophylline", "alternatives_b": "Apraclonidine, Methazolamide, Neostigmine, Pilocarpine, Physostigmine, Acetylcholine, Diclofenamide, Bimatoprost, Travoprost, Acetazolamide, Brinzolamide, More", "updated_at": 1767369485}, {"id": 97349, "ingredient1": "Activated charcoal", "ingredient2": "Theophylline", "severity": "Moderate", "effect": "Charcoal may reduce the absorption of many drugs and can absorb enterohepatically circulated drugs. Clinical utility may be the reduction either of the effects or of the toxicity of many drugs. Activated charcoal may adsorb any therapeutic agents administered while it is in the gastrointestinal tract.", "source": "DDInter", "management_text": "The regular ingestion of charcoal should be avoided by patients requiring maintenance medications. If concomitant use is necessary, the dosage or route of administration may need to be altered.", "mechanism_text": "Absorption", "recommendation": "The regular ingestion of charcoal should be avoided by patients requiring maintenance medications.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97453/", "reference_text": "[1] Naveau S, Bonhomme L, Preaux N, Chaput JC \"A pure charcoal suspension for colonoscopic tattoo.\" Gastrointest Endosc 37 (1991): 624-5[2] Ilkhanipour K, Yealy DM, Krenzelok EP \"Activated charcoal surface area and its role in multiple-dose charcoal therapy.\" Am J Emerg Med 11 (1993): 583-5[3] Reed MD \"Oral activated charcoal therapy.\" Am J Emerg Med 6 (1988): 318[4] Neuvonen PJ \"Clinical pharmacokinetics of oral activated charcoal in acute intoxications.\" Clin Pharmacokinet 7 (1982): 465-89[5] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[6] Kivisto KT, Neuvonen PJ \"The effect of cholestyramine and activated charcoal on glipizide absorption.\" Br J Clin Pharmacol 30 (1990): 733-6[7] Glab WN, Corby DG, Decker WJ, Coldiron VR \"Decreased absorption of propoxyphene by activated charcoal.\" J Toxicol Clin Toxicol 19 (1982): 129-38[8] Watson WA \"Factors influencing the clinical efficacy of activated charcoal.\" Drug Intell Clin Pharm 21 (1987): 160-6[9] Howard CE, Roberts RS, Ely DS, Moye RA \"Use of multiple-dose activated charcoal in phenytoin toxicity.\" Ann Pharmacother 28 (1994): 201-3[10] Herrington AM, Clifton GD \"Toxicology and management of acute drug ingestions in adults.\" Pharmacotherapy 15 (1995): 182-200[11] Scheufler E, Bos I \"Influence of peroral charcoal on pharmacokinetics and intestinal toxicity of intravenously given methotrexate.\" Arch Int Pharmacodyn Ther 261 (1983): 180-5[12] Gadgil SD, Damle SR, Advani SH, Vaidya AB \"Effect of activated charcoal on the pharmacokinetics of high-dose methotrexate.\" Cancer Treat Rep 66 (1982): 1169-71[13] Bonuccelli U, Piccini P, Del Dotto P, Pavese N, D'Antonio P, Muratorio A \"Apomorphine test in de novo Parkinson's disease.\" Funct Neurol 7 (1992): 295-8[14] Park GD, Spector R, Goldberg MJ, Johnson GF \"Expanded role of charcoal therapy in the poisoned and overdosed patient.\" Arch Intern Med 146 (1986): 969-73[15] Knadler MP, Bergstrom RF, Callaghan JT, Obermeyer BD, Rubin A \"Absorption studies of the H2-blocker nizatidine.\" Clin Pharmacol Ther 42 (1987): 514-20[16] Dolgin JG, Nix DE, Sanchez J, Watson WA \"Pharmacokinetic simulation of the effect of multiple-dose activated charcoal in phenytoin poisoning: report of two pediatric cases.\" DICP 25 (1991): 646-9[17] Wakabayashi Y, Maruyama S, Hachimura K, Ohwada T \"Activated charcoal interrupts enteroenteric circulation of phenobarbital.\" J Toxicol Clin Toxicol 32 (1994): 419-24[18] Decker WJ, Shpall RA, Corby DG \"Inhibition of aspirin absorption by activated charcoal and apomorphine.\" Clin Pharmacol Ther 10 (1969): 710-3[19] Chernish SM, Wolen RL, Rodda BE \"Adsorption of propoxyphene hydrochloride by activated charcoal.\" Clin Toxicol 5 (1972): 317-29[20] Orisakwe OE \"Activated charcoal: is failure to use it negligence or ignorance?\" South Med J 87 (1994): 165-8[21] Wing LM, Miners JO, Birkett DJ, et al \"Lidocaine disposition: sex differences and effects of cimetidine.\" Clin Pharmacol Ther 35 (1984): 695-701[22] Saetta JP \"Gastric decontaminating procedures: is it time to call a stop?\" J R Soc Med 86 (1993): 396-9[23] Rowden AM, Spoor JE, Bertino JS, Jr \"The effect of activated charcoal on phenytoin pharmacokinetics.\" Ann Emerg Med 19 (1990): 1144-7[24] Farrar HC, Herold DA, Reed MD \"Acute valproic acid intoxication: enhanced drug clearance with oral-activated charcoal.\" Crit Care Med 21 (1993): 299-301[25] Karkkainen S, Neuvonen PJ \"Effect of oral charcoal and urine pH on dextropropoxyphene pharmacokinetics.\" Int J Clin Pharmacol Ther Toxicol 23 (1985): 219-25", "alternatives_a": "Omalizumab, Tezepelumab, Mercaptopurine, Benralizumab, Caffeine, Reslizumab, Montelukast, Mepolizumab, Roflumilast, Pentoxifylline, Zafirlukast, Bromotheophylline", "alternatives_b": "Pectin, Kaolin, Attapulgite", "updated_at": 1767369485}, {"id": 97350, "ingredient1": "Cinoxacin", "ingredient2": "Theophylline", "severity": "Moderate", "effect": "Some fluoroquinolones have been shown to decrease the hepatic metabolism of theophyllines. The mechanism is inhibition of CYP450 1A2 hepatic metabolism. Patients with chronic obstructive pulmonary disease, congestive heart failure, or cirrhosis may have slower theophylline clearance rates; therefore, they may be at greater risk of developing theophylline toxicity. This drug combination may increase the risk of seizures, especially in the elderly. Interpatient variability of this effect makes it prudent to monitor patients who may not tolerate a small increase in theophylline levels during concurrent fluoroquinolone therapy.", "source": "DDInter", "management_text": "Interpatient variability of this effect makes it prudent to monitor patients who may not tolerate a small increase in theophylline levels. Levofloxacin, sparfloxacin, and lomefloxacin have been reported to cause minor or no changes in theophylline levels and may be considered as alternatives. Patients should be advised to report any signs of theophylline toxicity including nausea, vomiting, diarrhea, headache, restlessness, insomnia, seizures, or irregular heartbeat to their physicians.", "mechanism_text": "Metabolism", "recommendation": "Interpatient variability of this effect makes it prudent to monitor patients who may not tolerate a small increase in theophylline levels.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97454/", "reference_text": "[1] Davis RL, Kelly HW, Quenzer RW, Standefer J, Steinberg B, Gallegos J \"Effect of norfloxacin on theophyllin metabolism.\" Antimicrob Agents Chemother 33 (1989): 212-4[2] Grasela TH, Dreis MW \"An evaluation of the quinolone-theophylline interaction using the Food and Drug Administration spontaneous reporting system.\" Arch Intern Med 152 (1992): 617-21[3] Wijnands WJ, Vree TB \"Interaction between the fluoroquinolones and the bronchodilator theophylline.\" J Antimicrob Chemother 22 (1988): 109-14[4] Ho G, Tierney MG, Dales RE \"Evaluation of the effect of norfloxacin on the pharmacokinetics of theophylline.\" Clin Pharmacol Ther 44 (1988): 35-8[5] Bowles SK, Popovski Z, Rybak MJ, Beckman HB, Edwards DJ \"Effect of norfloxacin on theophylline pharmacokinetics at steady state.\" Antimicrob Agents Chemother 32 (1988): 510-12[6] Gregoire SL, Grasela TH Jr, Freer JP, Tack KJ, Schentag JJ \"Inhibition of theophylline clearance by coadministered ofloxacin without alteraction of theophylline effects.\" Antimicrob Agents Chemother 31 (1987): 375-8[7] Upton RA \"Pharmacokinetic interactions between theophylline and other medication (Part I).\" Clin Pharmacokinet 20 (1991): 66-80[8] Sano M, Yamamoto I, Ueda J, Yoskikawa E, Yamashina H, Goto M \"Comparative pharmacokinetics of theophylline following two fluoroquinolones co-administration.\" Eur J Clin Pharmacol 32 (1987): 431-2[9] Segev S. Rehavi M, Rubinstein E \"Quinolones, theophylline, and diclofenac interactions with the gamma-aminobutyric acid receptor.\" Antimicrob Agents Chemother 32 (1988): 1624-6[10] Wijnands WJ, Vree TB, Baars AM, van Herwaarden CL \"Steady-state kinetics of the quinolone derivatives ofloxacin, enoxacin, ciprofloxacin and pefloxacin during maintneance treatment with theophylline.\" Drugs 34 (1987): 159-69[11] Raoof S, Wollschlager C, Khan FA \"Ciprofloxacin increases serum levels of theophylline.\" Am J Med 82 (1987): 115-8[12] Covelli HD, Knodel AR, Heppner BT \"Predisposing factors to apparent theophylline-induced seizures.\" Ann Allergy 54 (1985): 411-5[13] \"Product Information. Cinobac (cinoxacin).\" Oclassen Pharmaceuticals Inc, San Rafael, CA.[14] Ball P \"Ciprofloxacin: an overview of adverse experiences.\" J Antimicrob Chemother 18 (1986): 187-93[15] Green L, Clark J \"Fluoroquinolones and theophylline toxicity: norfloxacin.\" JAMA 262 (1989): 2383[16] Hooper DC, Wolfson JS \"The fluoroquinolones: pharmacology, clinical uses, and toxicities in humans.\" Antimicrob Agents Chemother 28 (1985): 716-21", "alternatives_a": "Omalizumab, Tezepelumab, Benralizumab, Caffeine, Reslizumab, Montelukast, Dyphylline, Mepolizumab, Roflumilast, Pentoxifylline, Zafirlukast, Bromotheophylline", "alternatives_b": "Gatifloxacin, Levofloxacin, Gemifloxacin, Lomefloxacin, Trovafloxacin, Delafloxacin, Sparfloxacin", "updated_at": 1767369485}, {"id": 97351, "ingredient1": "Demeclocycline", "ingredient2": "Theophylline", "severity": "Moderate", "effect": "Coadministration of a tetracycline may decrease theophylline plasma clearance and increase theophylline levels. Data are available for minocycline, tetracycline, and doxycycline, but are conflicting in some cases. This interaction appears to be more problematic if a tetracycline is administered for more than five days. Patients with chronic obstructive pulmonary disease, congestive heart failure, or cirrhosis may have slower theophylline clearance rates; therefore, they may be at greater risk of developing theophylline toxicity.", "source": "DDInter", "management_text": "If these drugs are given concurrently, close clinical and laboratory monitoring of response and tolerance is recommended. Patients should be advised to notify their physician if they experience any signs of theophylline toxicity including nausea, vomiting, diarrhea, headache, restlessness, insomnia, seizures, or irregular heartbeats. It may be necessary to reduce theophylline dosage.", "mechanism_text": "Metabolism", "recommendation": "If these drugs are given concurrently, close clinical and laboratory monitoring of response and tolerance is recommended.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97455/", "reference_text": "[1] McCormack JP, Reid SE, Lawson LM \"Theophylline toxicity induced by tetracycline.\" Clin Pharm 9 (1990): 546-9[2] Gotz VP, Ryerson GG \"Evaluation of tetracycline on theophylline disposition in patients with chronic obstructive airways disease.\" Drug Intell Clin Pharm 20 (1986): 694-6[3] Upton RA \"Pharmacokinetic interactions between theophylline and other medication (Part I).\" Clin Pharmacokinet 20 (1991): 66-80[4] \"Product Information. Achromycin (tetracycline).\" Lederle Laboratories, Wayne, NJ.[5] \"Product Information. Declomycin (demeclocycline).\" Lederle Laboratories, Wayne, NJ.", "alternatives_a": "Omalizumab, Tezepelumab, Mercaptopurine, Benralizumab, Caffeine, Reslizumab, Montelukast, Dyphylline, Mepolizumab, Roflumilast, Pentoxifylline, More", "alternatives_b": "Tigecycline, Sarecycline, Omadacycline, Eravacycline, Mupirocin, Rifamycin, Bacitracin, Chloramphenicol, Rifaximin, Gentamicin, Neomycin", "updated_at": 1767369485}, {"id": 97352, "ingredient1": "Doxacurium", "ingredient2": "Theophylline", "severity": "Moderate", "effect": "Methylxanthines may antagonize the effects of neuromuscular blockers. The mechanism is unknown. In patients stabilized on aminophylline, resistance to pancuronium has been reported.", "source": "DDInter", "management_text": "The patient should be monitored for adequate neuromuscular blockade and the dosage adjusted, if necessary.", "mechanism_text": "Antagonism", "recommendation": "The patient should be monitored for adequate neuromuscular blockade and the dosage adjusted, if necessary.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97456/", "reference_text": "[1] Doll DC, Rosenberg H \"Antagonism of neuromuscular blockage by theophylline.\" Anesth Analg 58 (1979): 139-40[2] Azar I, Kumar D, Betcher AM \"Resistance to pancuronium in an asthmatic patient treated with aminophylline and steroids.\" Can Anaesth Soc J 29 (1982): 280-2[3] Daller JA, Erstad B, Rosado L, Otto C, Putnam CW \"Aminophylline antagonizes the neuromuscular blockade of pancuronium but not vecuronium.\" Crit Care Med 19 (1991): 983-5", "alternatives_a": "Omalizumab, Tezepelumab, Mercaptopurine, Benralizumab, Caffeine, Reslizumab, Montelukast, Mepolizumab, Roflumilast, Pentoxifylline, Zafirlukast, Bromotheophylline", "alternatives_b": "Botulinum toxin type A", "updated_at": 1767369485}, {"id": 97353, "ingredient1": "Echinacea", "ingredient2": "Theophylline", "severity": "Moderate", "effect": "Coadministration with echinacea may increase the plasma concentrations and the risk of adverse effects of drugs that are substrates of CYP450 1A2. The proposed mechanism is decreased clearance due to echinacea-mediated inhibition of CYP450 1A2.", "source": "DDInter", "management_text": "Caution is advised if echinacea is used concomitantly with drugs that are substrates of CYP450 1A2, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring should be considered whenever echinacea is added to or withdrawn from therapy with these drugs. Patients should be monitored for the development of adverse effects.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if echinacea is used concomitantly with drugs that are substrates of CYP450 1A2, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97457/", "reference_text": "[1] Gorski JC, Huang SM, Pinto A, et al. \"The effect of echinacea (Echinacea purpurea root) on cytochrome P450 activity in vivo.\" Clin Pharmacol Ther 75 (2004): 89-100", "alternatives_a": "Tezepelumab, Mercaptopurine, Aminophylline, Benralizumab, Reslizumab, Dyphylline, Oxtriphylline, Mepolizumab, Zafirlukast, Bromotheophylline", "alternatives_b": "", "updated_at": 1767369485}, {"id": 97354, "ingredient1": "Emapalumab", "ingredient2": "Theophylline", "severity": "Moderate", "effect": "Plasma concentrations of drugs that are CYP450 substrates may decrease following the initiation of interleukin (IL) inhibitors, tumor necrosis factor (TNF) blockers, or interferon (IFN) inhibitors in patients with chronic inflammatory diseases. Because the formation of hepatic CYP450 enzymes is down-regulated during infection and chronic inflammation by increased levels of certain cytokines (e.g., interleukins-1, -6, and -10; tumor necrosis factor alpha; interferons), treatment targeting these cytokines may restore or normalize CYP450 enzyme levels resulting in increased metabolism of these drugs.", "source": "DDInter", "management_text": "Caution is advised when treatments targeting cytokines such as interleukins, tumor necrosis factors, or interferons are prescribed to patients receiving concomitant drugs that are CYP450 substrates, particularly those with narrow therapeutic ranges (e.g., antiarrhythmics, anticonvulsants, immunosuppressants, theophylline) or sensitive substrates where decreases in plasma levels may be significant or undesirable (e.g., oral contraceptives, statins, benzodiazepines, opioids). Clinical and/or laboratory monitoring should be considered following the initiation or withdrawal of such treatments, and the dosage(s) of the CYP450 substrate(s) adjusted accordingly. The effects of IL inhibitors, TNF blockers, and IFN inhibitors on CYP450 activities may persist for several weeks after stopping therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when treatments targeting cytokines such as interleukins, tumor necrosis factors, or interferons are prescribed to patients receiving concomitant drugs that are CYP450 substrates, particularly those with narrow therapeutic ranges (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97458/", "reference_text": "[1] \"Product Information. Skyrizi (risankizumab).\" AbbVie US LLC, North Chicago, IL.[2] \"Product Information. Cosentyx (secukinumab).\" Novartis Pharmaceuticals, East Hanover, NJ.[3] \"Product Information. Ilaris (canakinumab).\" Novartis Pharmaceuticals, East Hanover, NJ.[4] \"Product Information. Gamifant (emapalumab).\" Sobi Inc, Ardmore, PA.[5] \"Product Information. Kevzara (sarilumab).\" sanofi-aventis, Bridgewater, NJ.[6] \"Product Information. Simponi (golimumab).\" Centocor Inc, Malvern, PA.[7] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[8] \"Product Information. Sylvant (siltuximab).\" Janssen Biotech, Inc., Horsham, PA, PA.[9] \"Product Information. Stelara (ustekinumab).\" Centocor Inc, Malvern, PA.[10] \"Product Information. Ilumya (tildrakizumab).\" Merck & Company Inc, Whitehouse Station, NJ.[11] \"Product Information. Actemra (tocilizumab).\" Genentech, South San Francisco, CA.[12] \"Product Information. Amevive (alefacept).\" Biogen, Cambridge, MA.[13] \"Product Information. Remicade (infliximab).\" Centocor Inc, Malvern, PA.[14] \"Product Information. Taltz Autoinjector (ixekizumab).\" Eli Lilly and Company, Indianapolis, IN.[15] \"Product Information. Arcalyst (rilonacept).\" Regeneron Pharmaceuticals Inc, Tarrytown, NY.[16] Ace LN, Jaffe JM, Kunka RL \"Effect of food and an antacid on quinidine bioavailability.\" Biopharm Drug Dispos 4 (1983): 183-90[17] Min DI, Ku YM, Geraets DR, Lee HC \"Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers.\" J Clin Pharmacol 36 (1996): 469-76[18] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[19] Ha HR, Chen J, Leuenberger PM, Freiburghaus AU, Follah F \"In vitro inhibition of midazolam and quinidine metabolism by flavonoids.\" Eur J Clin Pharmacol 48 (1995): 367-71", "alternatives_a": "Omalizumab, Tezepelumab, Mercaptopurine, Benralizumab, Caffeine, Reslizumab, Montelukast, Dyphylline, Mepolizumab, Roflumilast, Pentoxifylline, More", "alternatives_b": "Cyclosporine, Antithymocyte immunoglobulin (rabbit), Anifrolumab, Ravulizumab, Diroximel fumarate, Abatacept, Upadacitinib, Siponimod, Apremilast, Inebilizumab, Cladribine, More", "updated_at": 1767369485}, {"id": 97355, "ingredient1": "Enoxacin", "ingredient2": "Theophylline", "severity": "Major", "effect": "Enoxacin has been shown to reduce theophylline clearance by up to 75%. The mechanism is inhibition of CYP450 1A2 hepatic metabolism. Theophylline serum levels increase 1.5 to 3.0 times when enoxacin is administered concurrently. Patients with chronic obstructive pulmonary disease, congestive heart failure, or cirrhosis may have slower theophylline clearance rates; therefore, they may be at greater risk of developing theophylline toxicity.", "source": "DDInter", "management_text": "If possible, enoxacin therapy should be avoided in patients receiving theophylline. Levofloxacin, sparfloxacin, moxifloxacin, gatifloxacin, trovafloxacin, and lomefloxacin have been reported to cause minor or no changes in theophylline levels and may be considered as alternatives. If enoxacin is given concomitantly with theophylline, the theophylline dosage should be reduced approximately 50% or more, and theophylline serum levels should be closely monitored. Patients should be advised to report any signs of theophylline toxicity including nausea, vomiting, diarrhea, headache, restlessness, insomnia, seizures, or irregular heartbeats to their physician.", "mechanism_text": "Metabolism", "recommendation": "If possible, enoxacin therapy should be avoided in patients receiving theophylline.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97459/", "reference_text": "[1] Wijnands WJ, Vree TB, Baars AM, van Herwaarden CL \"Steady-state kinetics of the quinolone derivatives ofloxacin, enoxacin, ciprofloxacin and pefloxacin during maintneance treatment with theophylline.\" Drugs 34 (1987): 159-69[2] Rogge MC, Solomon WR, Sedman AJ, et al \"The theophylline-enoxacin interaction. I: effect of enoxacin dose size on theophylline disposition.\" Clin Pharmacol Ther 44 (1988): 579-87[3] Takagi K, Hasegawa T, Ogura Y, et al \"Comparative studies on interaction between theophylline and quinolones.\" J Asthma 25 (1988): 63-70[4] Wijnands WJ, Vree TB \"Interaction between the fluoroquinolones and the bronchodilator theophylline.\" J Antimicrob Chemother 22 (1988): 109-14[5] Sijnands WJ, Vree TB, Baars AM, Van Herwaarden CL \"Steady-state kinetics of the quinolone derivatives ofloxacin, enoxacin, ciprofloxacin and pefloxacin during maintenance treatment with theopylline.\" Drugs 34 (1987): 159-69[6] Harris JM \"Drug interaction affecting theophylline clearance.\" J Pediatr 116 (1990): 838-9[7] Sorgel F, Mahr G, Granneman GR, et al \"Effects of 2 quinolone antibacterials, temafloxacin and enoxacin, on theophylline pharmacokinetics.\" Clin Pharmacokinet 22 (1992): 65-74[8] Wijnands GJ, Vree TB, Janssen TJ, Guelen PJ \"Drug-drug interactions affecting fluoroquinolones.\" Am J Med 87 (1989): s47-51[9] Beckmann J, Elsaber W, Gundert-Remy U, Hertrampf R \"Enoxacin: a potent inhibitor of theophylline metabolism.\" Eur J Clin Pharmacol 33 (1987): 227-30[10] Rogge MC, Solomon WR, Sedman AJ, et al \"The theophylline-enoxacin interaction. II: Changes in the disposition of theophylline and its metabolites during intermittent administration of enoxacin.\" Clin Pharmacol Ther 46 (1989): 420-8[11] Takagi K, Hasegawa T, Yamaki K, et al \"Interaction between theophylline and enoxacin.\" Int J Clin Pharmacol Ther Toxicol 26 (1988): 288-92[12] Sano M, Kawakatsu K, Yamamoto I, et al \"Inhibitory effect of enoxacin, ofloxacin and norfloxacin on renal excretion of theophylline in humans.\" Eur J Clin Pharmacol 36 (1989): 323-4[13] Koup JR, Toothaker RD, Posvar E, et al \"Theophylline dosage adjustment during enoxacin coadministration.\" Antimicrob Agents Chemother 34 (1990): 803-7[14] Sana M, Kawakatsu K, Ohkita C, et al \"Effects of enoxacin, ofloxacin and norfloxacin on theophylline disposition in humans.\" Eur J Clin Pharmacol 35 (1988): 161-5[15] Hardman JG, Gilman AG, Limbird LE eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 9th ed.\" New York, NY: McGraw-Hill (1995):[16] Upton RA \"Pharmacokinetic interactions between theophylline and other medication (Part I).\" Clin Pharmacokinet 20 (1991): 66-80[17] Sano M, Kawakatsu K, Yamamoto I, et al \"Inhibitory effect of enoxacin, ofloxacin and norfloxacin on renal excretion of theophylline in humans.\" Eur J Clin Pharmacol 36 (1989): 323-4[18] Wijnands WJ, Van Herwaarden CL \"Enoxacin raises plasma theophylline concentrations.\" Lancet 2 (1984): 108-9[19] Wijnands WJ, Vree TB, van Herwaarden CL \"Enoxacin decreases the clearance of theophylline in man.\" Br J Clin Pharmacol 20 (1985): 583-8", "alternatives_a": "Omalizumab, Tezepelumab, Benralizumab, Reslizumab, Montelukast, Dyphylline, Mepolizumab, Zafirlukast, Bromotheophylline", "alternatives_b": "Gatifloxacin, Levofloxacin, Gemifloxacin, Lomefloxacin, Trovafloxacin, Delafloxacin, Sparfloxacin", "updated_at": 1767369485}, {"id": 97356, "ingredient1": "Ephedrine", "ingredient2": "Theophylline", "severity": "Minor", "effect": "Ephedrine-theophylline or ephedrine-dyphylline combinations are used for the treatment of asthma but the efficacy of the combination has been questioned. This combination may lead to increased xanthine side effects. The mechanism is unknown, but may be related to synergistic pharmacologic effects. Patients using this combination should be closely monitored for side effects such as nausea, vomiting, tachycardia, nervousness, or insomnia. If side effects are noted, the dosage of the xanthine may need to be decreased.", "source": "DDInter", "management_text": "-", "mechanism_text": "Synergism", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97460/", "reference_text": "[1] Badiei B, Faciane J, Sly M \"Effect of throphylline, ephedrine and theri combination upon exercise-induced airway obstruction.\" Ann Allergy 35 (1975): 32-6[2] Weinberger M, Bronsky E, Bensch GW, Bock GN, Yecies JJ \"Interaction of ephedrine and theophylline.\" Clin Pharmacol Ther 17 (1975): 585-92[3] Tinkelman DG, Avner SE \"Ephedrine therapy in asthmatic children. Clinical tolerance and absence of side effects.\" JAMA 237 (1977): 553-7[4] Weinberger MM, Brousky EA \"Evaluation of oral bronchodilator therapy in asthmatic children: bronchodilators in asthmatic children.\" J Pediatr 84 (1974): 421-7[5] Sims JA, doPico GA, Reed CE \"Bronchodilating effect of oral theophylline-ephedrine combination.\" J Allergy Clin Immunol 62 (1978): 15-21", "alternatives_a": "Omalizumab, Tezepelumab, Mercaptopurine, Benralizumab, Caffeine, Reslizumab, Montelukast, Mepolizumab, Roflumilast, Pentoxifylline, Zafirlukast, Bromotheophylline", "alternatives_b": "Ketorolac, Homatropine, Atropine, Scopolamine, Methscopolamine, Tropicamide, Phenylephrine, Ciclesonide, Mupirocin, Mometasone furoate, Mometasone, More", "updated_at": 1767369485}, {"id": 97357, "ingredient1": "Ephedrine (nasal)", "ingredient2": "Theophylline", "severity": "Minor", "effect": "Ephedrine-theophylline or ephedrine-dyphylline combinations are used for the treatment of asthma but the efficacy of the combination has been questioned. This combination may lead to increased xanthine side effects. The mechanism is unknown, but may be related to synergistic pharmacologic effects. Patients using this combination should be closely monitored for side effects such as nausea, vomiting, tachycardia, nervousness, or insomnia. If side effects are noted, the dosage of the xanthine may need to be decreased.", "source": "DDInter", "management_text": "-", "mechanism_text": "Synergism", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97461/", "reference_text": "[1] Badiei B, Faciane J, Sly M \"Effect of throphylline, ephedrine and theri combination upon exercise-induced airway obstruction.\" Ann Allergy 35 (1975): 32-6[2] Weinberger M, Bronsky E, Bensch GW, Bock GN, Yecies JJ \"Interaction of ephedrine and theophylline.\" Clin Pharmacol Ther 17 (1975): 585-92[3] Tinkelman DG, Avner SE \"Ephedrine therapy in asthmatic children. Clinical tolerance and absence of side effects.\" JAMA 237 (1977): 553-7[4] Weinberger MM, Brousky EA \"Evaluation of oral bronchodilator therapy in asthmatic children: bronchodilators in asthmatic children.\" J Pediatr 84 (1974): 421-7[5] Sims JA, doPico GA, Reed CE \"Bronchodilating effect of oral theophylline-ephedrine combination.\" J Allergy Clin Immunol 62 (1978): 15-21", "alternatives_a": "Omalizumab, Tezepelumab, Mercaptopurine, Benralizumab, Caffeine, Reslizumab, Montelukast, Mepolizumab, Roflumilast, Pentoxifylline, Zafirlukast, Bromotheophylline", "alternatives_b": "Ketorolac, Homatropine, Atropine, Scopolamine, Methscopolamine, Tropicamide, Phenylephrine, Ciclesonide, Mupirocin, Mometasone furoate, Mometasone, More", "updated_at": 1767369485}, {"id": 97358, "ingredient1": "Esmolol", "ingredient2": "Theophylline", "severity": "Major", "effect": "The pharmacologic effects of theophyllines and beta-blockers are opposite. Nonselective and high doses of cardioselective beta-blockers may cause severe or fatal bronchospasm by opposing theophylline-induced bronchodilation. Ophthalmic beta-blockers undergo significant systemic absorption and may also interact. In addition, propranolol and other beta-blockers may reduce the CYP450 hepatic metabolism of theophylline, and serum theophylline levels may be increased.", "source": "DDInter", "management_text": "Oral and ophthalmic nonselective beta-blockers (e.g., carteolol, carvedilol, levobunolol, metipranolol, nadolol, oxprenolol, penbutolol, pindolol, propranolol, sotalol, and timolol) are considered contraindicated in patients with bronchospastic diseases. Cardioselective beta-blockers should generally be avoided, or used with extreme caution if no other alternatives are available and the benefits outweigh the risks of potentially severe bronchospasm. If patients do receive this combination, they should be closely monitored for increased serum theophylline levels but decreased bronchodilatory effectiveness.", "mechanism_text": "Antagonism", "recommendation": "Oral and ophthalmic nonselective beta-blockers (e.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97462/", "reference_text": "[1] Upton RA \"Pharmacokinetic interactions between theophylline and other medication (Part II).\" Clin Pharmacokinet 20 (1991): 135-50[2] Mue S, Sasaki T, Shibahara S, et alT \"Influence of metoprolol on hemodynamics and respiratory function in asthmatic patients.\" Int J Clin Pharmacol Biopharm 17 (1979): 346-50[3] Lombardi TP, Bertino JS, Goldberg A, Middleton E, Slaughter RL \"The effects of a beta-2 selective adrenergic agonist and a beta- nonselective antagonist on theophylline clearance.\" J Clin Pharmacol 27 (1987): 523-9[4] Horvath JS, Woolcock AJ, Tiller DJ, Donnelly P, Armstrong J, Caterson R \"A comparison of metoprolol and propranolol on blood pressure and respiratory function in patients with hypertension.\" Aust N Z J Med 8 (1978): 1-6[5] Conrad KA, Nyman DW \"Effects of metoprolol and propranolol on theophylline elimination.\" Clin Pharmacol Ther 28 (1980): 463-7", "alternatives_a": "Omalizumab, Tezepelumab, Mercaptopurine, Benralizumab, Caffeine, Reslizumab, Montelukast, Mepolizumab, Roflumilast, Zafirlukast, Bromotheophylline", "alternatives_b": "", "updated_at": 1767369485}, {"id": 97359, "ingredient1": "Esomeprazole", "ingredient2": "Theophylline", "severity": "Moderate", "effect": "Proton pump inhibitors may increase the rate of theophylline absorption from sustained-release formulations. Chronic use of proton pump inhibitors produce sustained hypochlorhydria, which may enhance peristalsis in the small intestine and antiperistalsis in the proximal colon where theophylline is absorbed.", "source": "DDInter", "management_text": "In patients treated with proton pump inhibitors, the possibility of an enhanced pharmacologic response to sustained-release theophylline should be considered. Patients should be closely monitored for development of toxicity, particularly those with theophylline levels in the upper range of normal. Patients should be advised to report any signs of theophylline toxicity including nausea, vomiting, diarrhea, headache, restlessness, insomnia, or irregular heartbeat to their physicians.", "mechanism_text": "Absorption", "recommendation": "In patients treated with proton pump inhibitors, the possibility of an enhanced pharmacologic response to sustained-release theophylline should be considered.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97463/", "reference_text": "[1] Sommers DK, van Wyk M, Snyman JR, Moncrieff J \"The effects of omeprazole-induced hypochlorhydria on absorption of theophylline from a sustained-release formulation.\" Eur J Clin Pharmacol 43 (1992): 141-3[2] Sato J, Nakata H, Owada E, Kikuta T, Umetsu M, Ito K \"Influence of usual intake of dietary caffeine on single-dose kinetics of theophylline in healthy human subjects.\" Eur J Clin Pharmacol 44 (1993): 295-8[3] Jonkman JH, Sollie FA, Sauter R, Steinijans VW \"The influence of caffeine on the steady-state pharmacokinetics of theophylline.\" Clin Pharmacol Ther 49 (1991): 248-55[4] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67", "alternatives_a": "Omalizumab, Tezepelumab, Mercaptopurine, Aminophylline, Benralizumab, Caffeine, Reslizumab, Montelukast, Dyphylline, Oxtriphylline, Mepolizumab, More", "alternatives_b": "Tinidazole, Levofloxacin, Dexlansoprazole, Misoprostol, Bismuth subcitrate potassium, Rifabutin, Vonoprazan, Amoxicillin, Fenoprofen, Meclofenamic acid, Ketorolac, More", "updated_at": 1767369485}, {"id": 97360, "ingredient1": "Estazolam", "ingredient2": "Theophylline", "severity": "Minor", "effect": "Methylxanthines may antagonize the sedative effects of benzodiazepines. Aminophylline in particular has been demonstrated to attenuate the sedative effects of diazepam. The mechanism of this interaction may be related to competitive binding to intracerebral adenosine receptors.", "source": "DDInter", "management_text": "-", "mechanism_text": "Antagonism", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97464/", "reference_text": "[1] Tuncok Y, Akpinar O, Guven H, Akkoclu A \"The effects of theophylline on serum alprazolam levels.\" Int J Clin Pharmacol Ther 32 (1994): 642-5[2] Gallen JS \"Aminophylline reversal of midazolam sedation.\" Anesth Analg 69 (1989): 268[3] Bonfiglio MF, Dasta JF \"Clinical significance of the benzodiazepine-theophylline interaction.\" Pharmacotherapy 11 (1991): 85-7[4] Upton RA \"Pharmacokinetic interactions between theophylline and other medication (Part II).\" Clin Pharmacokinet 20 (1991): 135-50[5] Stirt JA \"Aminophylline is a diazepam antagonist.\" Anesth Analg 60 (1981): 767-8[6] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[7] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[8] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[9] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Omalizumab, Tezepelumab, Mercaptopurine, Benralizumab, Caffeine, Reslizumab, Montelukast, Mepolizumab, Roflumilast, Zafirlukast, Bromotheophylline", "alternatives_b": "Suvorexant, Chloral hydrate, Nitrazepam, Paraldehyde, Propiomazine, Ramelteon, Meprobamate, Scopolamine, Eszopiclone, Dexmedetomidine, Lemborexant, More", "updated_at": 1767369485}, {"id": 97361, "ingredient1": "Etanercept", "ingredient2": "Theophylline", "severity": "Moderate", "effect": "Plasma concentrations of drugs that are CYP450 substrates may decrease following the initiation of interleukin (IL) inhibitors, tumor necrosis factor (TNF) blockers, or interferon (IFN) inhibitors in patients with chronic inflammatory diseases. Because the formation of hepatic CYP450 enzymes is down-regulated during infection and chronic inflammation by increased levels of certain cytokines (e.g., interleukins-1, -6, and -10; tumor necrosis factor alpha; interferons), treatment targeting these cytokines may restore or normalize CYP450 enzyme levels resulting in increased metabolism of these drugs.", "source": "DDInter", "management_text": "Caution is advised when treatments targeting cytokines such as interleukins, tumor necrosis factors, or interferons are prescribed to patients receiving concomitant drugs that are CYP450 substrates, particularly those with narrow therapeutic ranges (e.g., antiarrhythmics, anticonvulsants, immunosuppressants, theophylline) or sensitive substrates where decreases in plasma levels may be significant or undesirable (e.g., oral contraceptives, statins, benzodiazepines, opioids). Clinical and/or laboratory monitoring should be considered following the initiation or withdrawal of such treatments, and the dosage(s) of the CYP450 substrate(s) adjusted accordingly. The effects of IL inhibitors, TNF blockers, and IFN inhibitors on CYP450 activities may persist for several weeks after stopping therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when treatments targeting cytokines such as interleukins, tumor necrosis factors, or interferons are prescribed to patients receiving concomitant drugs that are CYP450 substrates, particularly those with narrow therapeutic ranges (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97465/", "reference_text": "[1] \"Product Information. Skyrizi (risankizumab).\" AbbVie US LLC, North Chicago, IL.[2] \"Product Information. Cosentyx (secukinumab).\" Novartis Pharmaceuticals, East Hanover, NJ.[3] \"Product Information. Ilaris (canakinumab).\" Novartis Pharmaceuticals, East Hanover, NJ.[4] \"Product Information. Gamifant (emapalumab).\" Sobi Inc, Ardmore, PA.[5] \"Product Information. Kevzara (sarilumab).\" sanofi-aventis, Bridgewater, NJ.[6] \"Product Information. Simponi (golimumab).\" Centocor Inc, Malvern, PA.[7] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[8] \"Product Information. Sylvant (siltuximab).\" Janssen Biotech, Inc., Horsham, PA, PA.[9] \"Product Information. Stelara (ustekinumab).\" Centocor Inc, Malvern, PA.[10] \"Product Information. Ilumya (tildrakizumab).\" Merck & Company Inc, Whitehouse Station, NJ.[11] \"Product Information. Actemra (tocilizumab).\" Genentech, South San Francisco, CA.[12] \"Product Information. Amevive (alefacept).\" Biogen, Cambridge, MA.[13] \"Product Information. Remicade (infliximab).\" Centocor Inc, Malvern, PA.[14] \"Product Information. Taltz Autoinjector (ixekizumab).\" Eli Lilly and Company, Indianapolis, IN.[15] \"Product Information. Arcalyst (rilonacept).\" Regeneron Pharmaceuticals Inc, Tarrytown, NY.[16] Ace LN, Jaffe JM, Kunka RL \"Effect of food and an antacid on quinidine bioavailability.\" Biopharm Drug Dispos 4 (1983): 183-90[17] Min DI, Ku YM, Geraets DR, Lee HC \"Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers.\" J Clin Pharmacol 36 (1996): 469-76[18] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[19] Ha HR, Chen J, Leuenberger PM, Freiburghaus AU, Follah F \"In vitro inhibition of midazolam and quinidine metabolism by flavonoids.\" Eur J Clin Pharmacol 48 (1995): 367-71", "alternatives_a": "Cyclosporine, Antithymocyte immunoglobulin (rabbit), Anifrolumab, Ravulizumab, Diroximel fumarate, Abatacept, Upadacitinib, Siponimod, Apremilast, Inebilizumab, Cladribine, More", "alternatives_b": "Omalizumab, Tezepelumab, Benralizumab, Caffeine, Reslizumab, Montelukast, Dyphylline, Mepolizumab, Pentoxifylline, Bromotheophylline", "updated_at": 1767369485}, {"id": 97362, "ingredient1": "Ethotoin", "ingredient2": "Theophylline", "severity": "Moderate", "effect": "Phenytoin has been reported to increase the clearance of theophylline by 40% to 50%, presumably by enhancing the hepatic CYP450 metabolism of theophylline. Also, coadministration of theophylline has been reported to lower serum phenytoin concentrations. Other hydantoins and hepatically metabolized methylxanthines may also interact.", "source": "DDInter", "management_text": "Management consists of monitoring clinical response and serum concentrations of both drugs and adjusting dosages as necessary. Patients should be advised to report loss of seizure control or worsening of respiratory symptoms to their physician.", "mechanism_text": "Metabolism", "recommendation": "Management consists of monitoring clinical response and serum concentrations of both drugs and adjusting dosages as necessary.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97466/", "reference_text": "[1] Miller M, Cosgriff J, Kwong T, Morken DA \"Influence of phenytoin on theophylline clearance.\" Clin Pharmacol Ther 35 (1984): 666-9[2] Upton RA \"Pharmacokinetic interactions between theophylline and other medication (Part I).\" Clin Pharmacokinet 20 (1991): 66-80[3] Sklar SJ, Wagner \"Enhanced theophylline clearance secondary to phenytoin therapy.\" Drug Intell Clin Pharm 19 (1985): 34-6[4] Crowley JJ, Cusack BJ, Jue SG, et al \"Cigarette smoking and theophylline metabolism: effects of phenytoin.\" Clin Pharmacol Ther 42 (1987): 334-40[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[7] Fleisher D, Sheth N, Kou JH \"Phenytoin interaction with enteral feedings administered through nasogastric tubes.\" JPEN J Parenter Enteral Nutr 14 (1990): 513-6[8] Krueger KA, Garnett WR, Comstock TJ, Fitzsimmons WE, Karnes HT, Pellock JM \"Effect of two administration schedules of an enteral nutrient formula on phenytoin bioavailability.\" Epilepsia 28 (1987): 706-12[9] Haley CJ, Nelson J \"Phenytoin-enteral feeding interaction.\" DICP 23 (1989): 796-8[10] Faraji B, Yu PP \"Serum phenytoin levels of patients on gastrostomy tube feeding.\" J Neurosci Nurs 30 (1998): 55-9[11] Au Yeung SC, Ensom MH \"Phenytoin and enteral feedings: does evidence support an interaction?\" Ann Pharmacother 34 (2000): 896-905[12] Sandor P, Sellers EM, Dumbrell M, Khouw V \"Effect of short- and long-term alcohol use on phenytoin kinetics in chronic alcoholics.\" Clin Pharmacol Ther 30 (1981): 390-7[13] Ozuna J, Friel P \"Effect of enteral tube feeding on serum phenytoin levels.\" J Neurosurg Nurs 16 (1984): 289-91[14] Guidry JR, Eastwood TF, Curry SC \"Phenytoin absorption in volunteers receiving selected enteral feedings.\" West J Med 150 (1989): 659-61[15] Marvel ME, Bertino JS \"Comparative effects of an elemental and a complex enteral feeding formulation on the absorption of phenytoin suspension.\" JPEN J Parenter Enteral Nutr 15 (1991): 316-8[16] \"Product Information. Dilantin (phenytoin).\" Parke-Davis, Morris Plains, NJ.[17] Doak KK, Haas CE, Dunnigan KJ, et al. \"Bioavailability of phenytoin acid and phenytoin sodium with enteral feedings.\" Pharmacotherapy 18 (1998): 637-45[18] Rodman DP, Stevenson TL, Ray TR \"Phenytoin malabsorption after jejunostomy tube delivery.\" Pharmacotherapy 15 (1995): 801-5[19] Sellers EM, Holloway MR \"Drug kinetics and alcohol ingestion.\" Clin Pharmacokinet 3 (1978): 440-52[20] Holtz L, Milton J, Sturek JK \"Compatibility of medications with enteral feedings.\" JPEN J Parenter Enteral Nutr 11 (1987): 183-6", "alternatives_a": "Omalizumab, Tezepelumab, Mercaptopurine, Benralizumab, Caffeine, Reslizumab, Montelukast, Dyphylline, Mepolizumab, Roflumilast, Pentoxifylline, More", "alternatives_b": "Brivaracetam, Topiramate, Ezogabine, Cenobamate, Lamotrigine, Ethosuximide, Lacosamide, Levetiracetam, Tiagabine, Oxcarbazepine, Rufinamide, More", "updated_at": 1767369485}, {"id": 97363, "ingredient1": "Etonogestrel", "ingredient2": "Theophylline", "severity": "Moderate", "effect": "The coadministration with contraceptive steroids may increase the plasma concentrations of theophylline and other methylxanthines. The proposed mechanism is inhibition of methylxanthine metabolism via hepatic microsomal enzymes, of which estrogens and progestins are also substrates.", "source": "DDInter", "management_text": "Caution is advised during concomitant therapy with methylxanthines and hormonal contraceptives. Serum theophylline levels and pharmacologic response should be monitored and the dosage adjusted accordingly, particularly following initiation or discontinuation of hormonal contraceptives in patients who are stabilized on their theophylline regimen. Patients should be advised to notify their physician if they experience signs and symptoms of theophylline toxicity such as nausea, vomiting, diarrhea, headache, restlessness, insomnia, and irregular heartbeat.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised during concomitant therapy with methylxanthines and hormonal contraceptives.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97467/", "reference_text": "[1] Gardner MJ, Tornatore KM, Jusko WJ, Kanarkowski R \"Effects of tobacco smoking and oral contraceptive use on theophylline disposition.\" Br J Clin Pharmacol 16 (1983): 271-80[2] Tornatore KM, Kanarkowski R, McCarthy TL, et al \"Effect of chronic oral contraceptive steroids on theophylline disposition.\" Eur J Clin Pharmacol 23 (1982): 129-34[3] Roberts RK, Grice J, McGuffie, Heilbronn L \"Oral contraceptive steroids impair the elimination of theophylline.\" J Lab Clin Med 101 (1983): 821-25[4] Gunston GD, Mehta U \"Potentially serious drug interactions with grapefruit juice.\" S Afr Med J 90 (2000): 41[5] Bailey DG, Arnold JMO, Spence JD \"Grapefruit juice and drugs - how significant is the interaction.\" Clin Pharmacokinet 26 (1994): 91-8[6] Fuhr U, Maier-Bruggemann A, Blume H, et al. \"Grapefruit juice increases oral nimodipine bioavailability.\" Int J Clin Pharmacol Ther 36 (1998): 126-32[7] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[8] Libersa CC, Brique SA, Motte KB, et al. \"Dramatic inhibition of amiodarone metabolism induced by grapefruit juice.\" Br J Clin Pharmacol 49 (2000): 373-8[9] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions.\" Br J Clin Pharmacol 46 (1998): 101-10[10] Bailey DG, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit juice felodipine interaction: Effect of naringin and 6',7'-dihydroxybergamottin in humans.\" Clin Pharmacol Ther 64 (1998): 248-56[11] Takanaga H, Ohnishi A, Maatsuo H, et al. \"Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model.\" Br J Clin Pharmacol 49 (2000): 49-58[12] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[13] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS \"Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice.\" Br J Clin Pharmacol 42 (1996): p662[14] Eagling VA, Profit L, Back DJ \"Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-I protease inhibitor saquinavir by grapefruit juice components.\" Br J Clin Pharmacol 48 (1999): 543-52[15] Bailey DG, Arnold JM, Strong HA, Munoz C, Spence JD \"Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics.\" Clin Pharmacol Ther 54 (1993): 589-94[16] Damkier P, Hansen LL, Brosen K \"Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine.\" Br J Clin Pharmacol 48 (1999): 829-38[17] Min DI, Ku YM, Geraets DR, Lee HC \"Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers.\" J Clin Pharmacol 36 (1996): 469-76[18] Josefsson M, Zackrisson AL, Ahlner J \"Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers.\" Eur J Clin Pharmacol 51 (1996): 189-93[19] Majeed A, Kareem A \"Effect of grapefruit juice on cyclosporine pharmacokinetics.\" Pediatr Nephrol 10 (1996): 395[20] Flanagan D \"Understanding the grapefruit-drug interaction.\" Gen Dent 53 (2005): 282-5; quiz 286[21] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ \"Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice.\" Clin Pharmacol Ther 58 (1995): 127-31[22] Jonkman JH, Sollie FA, Sauter R, Steinijans VW \"The influence of caffeine on the steady-state pharmacokinetics of theophylline.\" Clin Pharmacol Ther 49 (1991): 248-55[23] Ozdemir M, Aktan Y, Boydag BS, Cingi MI, Musmul A \"Interaction between grapefruit juice and diazepam in humans.\" Eur J Drug Metab Pharmacokinet 23 (1998): 55-9[24] Edgar B, Bailey D, Bergstrand R, et al \"Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics on felodipine and its potential clinical relevance.\" Eur J Clin Pharmacol 42 (1992): 313-7[25] Kantola T, Kivisto KT, Neuvonen PJ \"Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid.\" Clin Pharmacol Ther 63 (1998): 397-402[26] Lee AJ, Chan WK, Harralson AF, Buffum J, Bui BCC \"The effects of grapefruit juice on sertraline metabolism: An in vitro and in vivo study.\" Clin Ther 21 (1999): 1890-9[27] Sato J, Nakata H, Owada E, Kikuta T, Umetsu M, Ito K \"Influence of usual intake of dietary caffeine on single-dose kinetics of theophylline in healthy human subjects.\" Eur J Clin Pharmacol 44 (1993): 295-8[28] Dresser GK, Spence JD, Bailey DG \"Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition.\" Clin Pharmacokinet 38 (2000): 41-57[29] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin.\" Clin Pharmacol Ther 66 (1999): 118-27[30] Sigusch H, Hippius M, Henschel L, Kaufmann K, Hoffmann A \"Influence of grapefruit juice on the pharmacokinetics of a slow release nifedipine formulation.\" Pharmazie 49 (1994): 522-4[31] Bailey DG, Arnold JM, Munoz C, Spence JD \"Grapefruit juice--felodipine interaction: mechanism, predictability, and effect of naringin.\" Clin Pharmacol Ther 53 (1993): 637-42[32] Zaidenstein R, Soback S, Gips M, Avni B, Dishi V, Weissgarten Y, Golik A, Scapa E \"Effect of grapefruit juice on the pharmacokinetics of losartan and its active metabolite E3174 in healthy volunteers.\" Ther Drug Monit 23 (2001): 369-73[33] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84[34] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors.\" Clin Pharmacol Ther 64 (1998): 477-83[35] Garg SK, Kumar N, Bhargava VK, Prabhakar SK \"Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy.\" Clin Pharmacol Ther 64 (1998): 286-8", "alternatives_a": "Omalizumab, Tezepelumab, Mercaptopurine, Benralizumab, Caffeine, Reslizumab, Montelukast, Dyphylline, Mepolizumab, Roflumilast, Pentoxifylline, More", "alternatives_b": "Megestrol acetate, Ulipristal, Estetrol, Medroxyprogesterone acetate", "updated_at": 1767369485}, {"id": 97364, "ingredient1": "Febuxostat", "ingredient2": "Theophylline", "severity": "Moderate", "effect": "Coadministration with febuxostat may alter the pharmacokinetics of theophylline. The proposed mechanism is inhibition of xanthine oxidase by febuxostat.", "source": "DDInter", "management_text": "No dosage adjustment is necessary for theophylline when coadministered with febuxostat, but caution is advised. Because the safety of long-term exposure to 1-methylxanthine is unknown, this should be taken into consideration when deciding to use the combination.", "mechanism_text": "Metabolism", "recommendation": "No dosage adjustment is necessary for theophylline when coadministered with febuxostat, but caution is advised.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97468/", "reference_text": "[1] \"Product Information. Uloric (febuxostat).\" Takeda Pharmaceuticals America, Lincolnshire, IL.", "alternatives_a": "Omalizumab, Tezepelumab, Benralizumab, Caffeine, Reslizumab, Montelukast, Mepolizumab, Roflumilast, Pentoxifylline, Zafirlukast, Bromotheophylline", "alternatives_b": "Lesinurad, Pegloticase, Colchicine, Rasburicase, Probenecid", "updated_at": 1767369485}, {"id": 97365, "ingredient1": "Felodipine", "ingredient2": "Theophylline", "severity": "Minor", "effect": "In one study, concurrent administration of theophylline and felodipine led to an 18% reduction in theophylline area under the plasma-time concentration curve. Presumably, decreased absorption of theophylline is the cause. If theophylline and felodipine are given together, theophylline levels and patient response should be monitored and the dosage adjusted as needed. Patients should be advised to notify their physician if they experience worsening of their respiratory symptoms.", "source": "DDInter", "management_text": "-", "mechanism_text": "Absorption", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97469/", "reference_text": "[1] Bratel T, Billing B, Dahlqvist R \"Felodipine reduces the absorption of theophylline in man.\" Eur J Clin Pharmacol 36 (1989): 481-5[2] Upton RA \"Pharmacokinetic interactions between theophylline and other medication (Part II).\" Clin Pharmacokinet 20 (1991): 135-50[3] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[4] Bailey DG, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit juice felodipine interaction: Effect of naringin and 6',7'-dihydroxybergamottin in humans.\" Clin Pharmacol Ther 64 (1998): 248-56[5] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[6] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions.\" Br J Clin Pharmacol 46 (1998): 101-10[7] \"Product Information. Procardia (nifedipine).\" Pfizer US Pharmaceuticals, New York, NY.[8] Takanaga H, Ohnishi A, Maatsuo H, et al. \"Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model.\" Br J Clin Pharmacol 49 (2000): 49-58[9] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84[10] Edgar B, Bailey D, Bergstrand R, Johnsson G, Regardh CG \"Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics of felodipine--and its potential clinical relevance.\" Eur J Clin Pharmacol 42 (1992): 313-7[11] Bailey DG, Arnold JMO, Spence JD \"Grapefruit juice and drugs - how significant is the interaction.\" Clin Pharmacokinet 26 (1994): 91-8[12] Josefsson M, Zackrisson AL, Ahlner J \"Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers.\" Eur J Clin Pharmacol 51 (1996): 189-93[13] Fuhr U, Muller-Peltzer H, Kern R, et al. \"Effects of grapefruit juice and smoking on verapamil concentrations in steady state.\" Eur J Clin Pharmacol 58 (2002): 45-53[14] Gunston GD, Mehta U \"Potentially serious drug interactions with grapefruit juice.\" S Afr Med J 90 (2000): 41[15] Fuhr U, Maier-Bruggemann A, Blume H, et al. \"Grapefruit juice increases oral nimodipine bioavailability.\" Int J Clin Pharmacol Ther 36 (1998): 126-32[16] \"Product Information. Sular (nisoldipine).\" Zeneca Pharmaceuticals, Wilmington, DE.[17] Ho PC, Ghose K, Saville D, Wanwimolruk S \"Effect of grapefruit juice on pharmacokinetics and pharmacodynamics of verapamil enantiomers in healthy volunteers.\" Eur J Clin Pharmacol 56 (2000): 693-8[18] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[19] Bailey DG, Arnold JM, Strong HA, Munoz C, Spence JD \"Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics.\" Clin Pharmacol Ther 54 (1993): 589-94[20] Bailey DG, Arnold JM, Munoz C, Spence JD \"Grapefruit juice--felodipine interaction: mechanism, predictability, and effect of naringin.\" Clin Pharmacol Ther 53 (1993): 637-42[21] \"Product Information. Plendil (felodipine).\" Merck & Co, Inc, West Point, PA.", "alternatives_a": "Omalizumab, Tezepelumab, Mercaptopurine, Benralizumab, Caffeine, Reslizumab, Dyphylline, Mepolizumab, Roflumilast, Zafirlukast, Bromotheophylline", "alternatives_b": "Ivabradine, Nicardipine, Isradipine, Clevidipine, Levamlodipine, Nimodipine, Moexipril, Perindopril, Benazepril, Trandolapril, Fosinopril, Indapamide", "updated_at": 1767369485}, {"id": 97366, "ingredient1": "Fluconazole", "ingredient2": "Theophylline", "severity": "Moderate", "effect": "The concurrent use of fluconazole may increase the serum concentrations of theophylline in some patients. The mechanism is unknown. Toxicity could occur in patients whose theophylline levels are at the upper end of the therapeutic range.", "source": "DDInter", "management_text": "Clinical and laboratory monitoring is warranted if these agents are given concurrently. Dose adjustments are recommended if an interaction is suspected. Patients receiving this combination should be advised to report any signs of theophylline toxicity including nausea, vomiting, diarrhea, headache, restlessness, insomnia, or irregular heartbeat to their doctor.", "mechanism_text": "Synergism", "recommendation": "Clinical and laboratory monitoring is warranted if these agents are given concurrently.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97470/", "reference_text": "[1] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[2] Konishi H, Morita K, Yamaji A \"Effect of fluconazole on theophylline disposition in humans.\" Eur J Clin Pharmacol 46 (1994): 309-12[3] \"Product Information. Diflucan (fluconazole).\" Roerig Division, New York, NY.[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] Tett S, Carey D, Lee H-S \"Drug interactions with fluconazole.\" Med J Aust 156 (1992): 365", "alternatives_a": "Tinidazole, Cefepime, Secnidazole, Cefixime, Levofloxacin, Micafungin, Caspofungin, Itraconazole, Miconazole, Posaconazole, Oteseconazole, More", "alternatives_b": "Omalizumab, Tezepelumab, Benralizumab, Caffeine, Reslizumab, Dyphylline, Oxtriphylline, Mepolizumab, Roflumilast, Bromotheophylline", "updated_at": 1767369485}, {"id": 97367, "ingredient1": "Fludrocortisone", "ingredient2": "Theophylline", "severity": "Moderate", "effect": "The concomitant use of theophylline and corticosteroids may theoretically increase the risk of hypokalemia due to additive potassium-lowering effects. Additionally, theophylline serum concentrations may be altered.", "source": "DDInter", "management_text": "Monitoring for altered efficacy and safety of theophylline and altered serum potassium and theophylline concentrations is advisable when these drugs are coadministered. Patients should be advised to notify their physician if they experience signs of hypokalemia (e.g., weakness, lethargy, and muscle pains or cramps), worsening respiratory symptoms, or signs of theophylline toxicity (e.g., nausea, vomiting, diarrhea, headache, restlessness, insomnia, or irregular heartbeat).", "mechanism_text": "Synergism", "recommendation": "Monitoring for altered efficacy and safety of theophylline and altered serum potassium and theophylline concentrations is advisable when these drugs are coadministered.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97471/", "reference_text": "[1] Fergusson RJ, Scott CM, Rafferty P, Gaddie J \"Effect of prednisolone on theophylline pharmacokinetics in patients with chronic airflow obstruction.\" Thorax 42 (1987): 195-8[2] Buchanan N, Hurwitz S, Butler P \"Asthma - a possible interaction between hydrocortisone and theophylline.\" S Afr Med J 56 (1979): 1147-8[3] Leavengood DC, Bunker-Soler AL, Nelson HS \"The effect of corticosteroids on theophylline metabolism.\" Ann Allergy 50 (1983): 249-51[4] Elvey SM, Saccar CL, Rocci ML, Mansmann HC, Martynec DM, Kester MB \"The effect of corticosteroids on theophylline metabolim in asthmatic children.\" Ann Allergy 56 (1986): 520[5] Tatsis G, Orphanidou D, Douratsos D, et al \"The effect of steroids on theophylline absorption.\" J Int Med Res 19 (1991): 326-9[6] Anderson JL, Ayres JW, Hall CA \"Potential pharmacokinetic interaction between theophylline and prednisone.\" Clin Pharm 3 (1984): 187-8", "alternatives_a": "Omalizumab, Tezepelumab, Mercaptopurine, Benralizumab, Caffeine, Reslizumab, Montelukast, Dyphylline, Oxtriphylline, Mepolizumab, Pentoxifylline, More", "alternatives_b": "Fluocinolone acetonide, Indomethacin, Fluocinolone acetonide, Fluorometholone, Deflazacort", "updated_at": 1767369485}, {"id": 97368, "ingredient1": "Fluphenazine", "ingredient2": "Theophylline", "severity": "Moderate", "effect": "The risk of seizures may be increased during coadministration of fluphenazine with any substance that can reduce the seizure threshold, such as aminophylline, antidepressants, antipsychotics, opioids, carbapenems, etc. These agents are often individually epileptogenic and may have additive effects when combined. Many of these agents also exhibit CNS- and/or respiratory-depressant effects, which may be enhanced during their concomitant use with fluphenazine.", "source": "DDInter", "management_text": "Caution is advised if fluphenazine is administered with any substance that can reduce the seizure threshold, particularly in the elderly and in patients with epilepsy, a history of seizures, or other risk factors for seizures (e.g., head trauma, brain tumor, metabolic disorders, alcohol and drug withdrawal, CNS infections). Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if fluphenazine is administered with any substance that can reduce the seizure threshold, particularly in the elderly and in patients with epilepsy, a history of seizures, or other risk factors for seizures (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97472/", "reference_text": "[1] Cerner Multum, Inc. \"Australian Product Information.\" O 0[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0", "alternatives_a": "Omalizumab, Tezepelumab, Mercaptopurine, Benralizumab, Caffeine, Reslizumab, Montelukast, Dyphylline, Mepolizumab, Roflumilast, Pentoxifylline, More", "alternatives_b": "Thiothixene, Amisulpride, Quetiapine, Promazine, Prochlorperazine, Thioridazine, Lumateperone, Pimozide, Trifluoperazine, Cariprazine, Paliperidone, More", "updated_at": 1767369485}, {"id": 97369, "ingredient1": "Flurazepam", "ingredient2": "Theophylline", "severity": "Minor", "effect": "Methylxanthines may antagonize the sedative effects of benzodiazepines. Aminophylline in particular has been demonstrated to attenuate the sedative effects of diazepam. The mechanism of this interaction may be related to competitive binding to intracerebral adenosine receptors.", "source": "DDInter", "management_text": "-", "mechanism_text": "Antagonism", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97473/", "reference_text": "[1] Tuncok Y, Akpinar O, Guven H, Akkoclu A \"The effects of theophylline on serum alprazolam levels.\" Int J Clin Pharmacol Ther 32 (1994): 642-5[2] Gallen JS \"Aminophylline reversal of midazolam sedation.\" Anesth Analg 69 (1989): 268[3] Bonfiglio MF, Dasta JF \"Clinical significance of the benzodiazepine-theophylline interaction.\" Pharmacotherapy 11 (1991): 85-7[4] Upton RA \"Pharmacokinetic interactions between theophylline and other medication (Part II).\" Clin Pharmacokinet 20 (1991): 135-50[5] Stirt JA \"Aminophylline is a diazepam antagonist.\" Anesth Analg 60 (1981): 767-8[6] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[7] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[8] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[9] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Omalizumab, Tezepelumab, Mercaptopurine, Benralizumab, Caffeine, Reslizumab, Mepolizumab, Roflumilast, Pentoxifylline, Zafirlukast, Bromotheophylline", "alternatives_b": "Suvorexant, Chloral hydrate, Nitrazepam, Paraldehyde, Propiomazine, Ramelteon, Meprobamate, Scopolamine, Eszopiclone, Dexmedetomidine, Lemborexant, More", "updated_at": 1767369485}, {"id": 97370, "ingredient1": "Flutamide", "ingredient2": "Theophylline", "severity": "Moderate", "effect": "Coadministration with flutamide may increase the plasma concentrations and the risk of toxicity of theophylline. The proposed mechanism may involve inhibition of CYP450 1A2, which is the principal enzyme responsible for the metabolism of theophylline and the conversion of flutamide to its active metabolite hydroxyflutamide. Patients with chronic obstructive pulmonary disease, congestive heart failure, or cirrhosis may have slower theophylline clearance rates; therefore, they may be at greater risk of developing theophylline toxicity.", "source": "DDInter", "management_text": "Caution is advised if flutamide is used concomitantly with theophylline. Dosage adjustments as well as clinical and laboratory monitoring should be considered whenever flutamide is added to or withdrawn from therapy with theophylline. Patients should be advised to notify their doctor if they experience any signs of theophylline toxicity including nausea, vomiting, diarrhea, headache, restlessness, insomnia, or seizures.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if flutamide is used concomitantly with theophylline.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97474/", "reference_text": "[1] Shet MS, McPhaul M, Fisher CW, Stallings NR, Estabrook RW \"Metabolism of the antiandrogenic drug (Flutamide) by human CYP1A2.\" Drug Metab Dispos 25 (1997): 1298-303[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] Sato J, Nakata H, Owada E, Kikuta T, Umetsu M, Ito K \"Influence of usual intake of dietary caffeine on single-dose kinetics of theophylline in healthy human subjects.\" Eur J Clin Pharmacol 44 (1993): 295-8[5] Jonkman JH, Sollie FA, Sauter R, Steinijans VW \"The influence of caffeine on the steady-state pharmacokinetics of theophylline.\" Clin Pharmacol Ther 49 (1991): 248-55[6] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67", "alternatives_a": "Omalizumab, Tezepelumab, Mercaptopurine, Aminophylline, Benralizumab, Caffeine, Reslizumab, Montelukast, Dyphylline, Oxtriphylline, Mepolizumab, More", "alternatives_b": "Darolutamide, Tamoxifen, Anastrozole, Letrozole, Toremifene, Fulvestrant, Abarelix, Enzalutamide, Relugolix, Bicalutamide, Degarelix, More", "updated_at": 1767369485}, {"id": 97371, "ingredient1": "Fluvoxamine", "ingredient2": "Theophylline", "severity": "Major", "effect": "Coadministration with fluvoxamine may significantly increase the serum concentrations of theophylline and the associated risk of toxicity. The mechanism is fluvoxamine inhibition of theophylline metabolism via CYP450 1A2.", "source": "DDInter", "management_text": "The use of theophylline or its salts in combination with fluvoxamine should generally be avoided. If coadministration is required, a reduction of theophylline dosage by one-half to two-thirds should be considered. Pharmacologic response and serum levels should be closely monitored following initiation, discontinuation or change of dosage of fluvoxamine, and the theophylline dosage adjusted accordingly. Patients should be advised to contact their physician if they experience signs and symptoms suggestive of theophylline toxicity such as nausea, vomiting, diarrhea, anorexia, headache, tremor, irritability, confusion, insomnia, seizure, palpitation, and arrhythmia. Other selective serotonin reuptake inhibitors including citalopram, escitalopram, fluoxetine, paroxetine, and sertraline do not significantly inhibit CYP450 1A2 and may be safer alternatives in theophylline-treated patients.", "mechanism_text": "Metabolism", "recommendation": "The use of theophylline or its salts in combination with fluvoxamine should generally be avoided.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97475/", "reference_text": "[1] Orlando R, Padrini R, Perazzi M, De Martin S, Piccoli P, Palatini P \"Liver dysfunction markedly decreases the inhibition of cytochrome P450 1A2-mediated theophylline metabolism by fluvoxamine.\" Clin Pharmacol Ther 79 (2006): 489-99[2] Brosen K, Skjelbo E, Rasmussen BB, Poulsen HE, Loft S \"Fluvoxamine is a potent inhibitor of cytochrome P4501A2.\" Biochem Pharmacol 45 (1993): 1211-4[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] Devane CL, Markowitz JS, Hardesty SJ, Mundy S, Gill HS \"Fluvoxamine-induced theophylline toxicity.\" Am J Psychiatry 154 (1997): 1317-8[5] Sperber AD \"Toxic interaction between fluvoxamine and sustained release theophylline in an 11-year-old boy.\" Drug Saf 6 (1991): 460-2[6] Rasmussen BB, Jeppesen U, Gaist D, Brosen K \"Griseofulvin and fluvoxamine interactions with the metabolism of theophylline.\" Ther Drug Monit 19 (1997): 56-62[7] Nemeroff CB, Devane CL, Pollock BG \"Newer antidepressants and the cytochrome p450 system.\" Am J Psychiatry 153 (1996): 311-20[8] van den Brekel AM, Harriington L \"Toxic effects of theophylline caused by fluoxamine.\" CMAJ 151 (1994): 1289-90[9] Rasmussen BB, Maenpaa J, Pelkonen O, et al \"Selective serotonin reuptake inhibitors and theophylline metabolism in human liver microsomes: potent inhibition by fluvoxamine.\" Br J Clin Pharmacol 39 (1995): 151-9[10] Yao C, Kunze KL, Kharasch ED, et al. \"Fluvoxamine-theophylline interaction: Gap between in vitro and in vivo inhibition constants toward cytochrome P4501A2.\" Clin Pharmacol Ther 70 (2001): 415-24[11] \"Product Information. Luvox (fluvoxamine).\" Solvay Pharmaceuticals Inc, Marietta, GA.[12] Hardman JG, Gilman AG, Limbird LE eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 9th ed.\" New York, NY: McGraw-Hill (1995):[13] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[14] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[15] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.", "alternatives_a": "Maprotiline, Vortioxetine, Milnacipran, Levomilnacipran, Doxepin, Duloxetine, Isocarboxazid, Amoxapine, Imipramine, Esketamine, Phenelzine, More", "alternatives_b": "Omalizumab, Tezepelumab, Mercaptopurine, Benralizumab, Reslizumab, Dyphylline, Mepolizumab, Zafirlukast, Bromotheophylline", "updated_at": 1767369485}, {"id": 97372, "ingredient1": "Fosphenytoin", "ingredient2": "Theophylline", "severity": "Moderate", "effect": "Phenytoin has been reported to increase the clearance of theophylline by 40% to 50%, presumably by enhancing the hepatic CYP450 metabolism of theophylline. Also, coadministration of theophylline has been reported to lower serum phenytoin concentrations. Other hydantoins and hepatically metabolized methylxanthines may also interact.", "source": "DDInter", "management_text": "Management consists of monitoring clinical response and serum concentrations of both drugs and adjusting dosages as necessary. Patients should be advised to report loss of seizure control or worsening of respiratory symptoms to their physician.", "mechanism_text": "Metabolism", "recommendation": "Management consists of monitoring clinical response and serum concentrations of both drugs and adjusting dosages as necessary.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97476/", "reference_text": "[1] Miller M, Cosgriff J, Kwong T, Morken DA \"Influence of phenytoin on theophylline clearance.\" Clin Pharmacol Ther 35 (1984): 666-9[2] Upton RA \"Pharmacokinetic interactions between theophylline and other medication (Part I).\" Clin Pharmacokinet 20 (1991): 66-80[3] Sklar SJ, Wagner \"Enhanced theophylline clearance secondary to phenytoin therapy.\" Drug Intell Clin Pharm 19 (1985): 34-6[4] Crowley JJ, Cusack BJ, Jue SG, et al \"Cigarette smoking and theophylline metabolism: effects of phenytoin.\" Clin Pharmacol Ther 42 (1987): 334-40[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[7] Fleisher D, Sheth N, Kou JH \"Phenytoin interaction with enteral feedings administered through nasogastric tubes.\" JPEN J Parenter Enteral Nutr 14 (1990): 513-6[8] Krueger KA, Garnett WR, Comstock TJ, Fitzsimmons WE, Karnes HT, Pellock JM \"Effect of two administration schedules of an enteral nutrient formula on phenytoin bioavailability.\" Epilepsia 28 (1987): 706-12[9] Haley CJ, Nelson J \"Phenytoin-enteral feeding interaction.\" DICP 23 (1989): 796-8[10] Faraji B, Yu PP \"Serum phenytoin levels of patients on gastrostomy tube feeding.\" J Neurosci Nurs 30 (1998): 55-9[11] Au Yeung SC, Ensom MH \"Phenytoin and enteral feedings: does evidence support an interaction?\" Ann Pharmacother 34 (2000): 896-905[12] Sandor P, Sellers EM, Dumbrell M, Khouw V \"Effect of short- and long-term alcohol use on phenytoin kinetics in chronic alcoholics.\" Clin Pharmacol Ther 30 (1981): 390-7[13] Ozuna J, Friel P \"Effect of enteral tube feeding on serum phenytoin levels.\" J Neurosurg Nurs 16 (1984): 289-91[14] Guidry JR, Eastwood TF, Curry SC \"Phenytoin absorption in volunteers receiving selected enteral feedings.\" West J Med 150 (1989): 659-61[15] Marvel ME, Bertino JS \"Comparative effects of an elemental and a complex enteral feeding formulation on the absorption of phenytoin suspension.\" JPEN J Parenter Enteral Nutr 15 (1991): 316-8[16] \"Product Information. Dilantin (phenytoin).\" Parke-Davis, Morris Plains, NJ.[17] Doak KK, Haas CE, Dunnigan KJ, et al. \"Bioavailability of phenytoin acid and phenytoin sodium with enteral feedings.\" Pharmacotherapy 18 (1998): 637-45[18] Rodman DP, Stevenson TL, Ray TR \"Phenytoin malabsorption after jejunostomy tube delivery.\" Pharmacotherapy 15 (1995): 801-5[19] Sellers EM, Holloway MR \"Drug kinetics and alcohol ingestion.\" Clin Pharmacokinet 3 (1978): 440-52[20] Holtz L, Milton J, Sturek JK \"Compatibility of medications with enteral feedings.\" JPEN J Parenter Enteral Nutr 11 (1987): 183-6", "alternatives_a": "Omalizumab, Tezepelumab, Mercaptopurine, Benralizumab, Caffeine, Reslizumab, Dyphylline, Mepolizumab, Pentoxifylline, Zafirlukast, Bromotheophylline", "alternatives_b": "Brivaracetam, Topiramate, Ezogabine, Cenobamate, Lamotrigine, Ethosuximide, Lacosamide, Levetiracetam, Tiagabine, Oxcarbazepine, Rufinamide, More", "updated_at": 1767369485}, {"id": 97373, "ingredient1": "Fostamatinib", "ingredient2": "Theophylline", "severity": "Moderate", "effect": "Coadministration with fostamatinib may increase the plasma concentrations of drugs that are substrates of the CYP450 3A4 isoenzyme and/or P-glycoprotein (P-gp) transporter. The proposed mechanism is decreased clearance in the intestine and/or liver due to inhibition of CYP450 3A4-mediated metabolism and P-gp-mediated efflux by fostamatinib.", "source": "DDInter", "management_text": "Caution is advised when fostamatinib is used concurrently with drugs that are known substrates of CYP450 3A4 and/or P-gp, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever fostamatinib is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when fostamatinib is used concurrently with drugs that are known substrates of CYP450 3A4 and/or P-gp, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97477/", "reference_text": "[1] \"Product Information. Tavalisse (fostamatinib).\" Rigel Pharmaceuticals, South San Francisco, CA.", "alternatives_a": "Omalizumab, Tezepelumab, Mercaptopurine, Aminophylline, Benralizumab, Caffeine, Reslizumab, Dyphylline, Oxtriphylline, Mepolizumab, Pentoxifylline, Bromotheophylline", "alternatives_b": "Eltrombopag, Romiplostim, Avatrombopag, Emicizumab, Coagulation factor VIIa Recombinant Human, Coagulation factor X human, Phylloquinone, Lusutrombopag, Anti-inhibitor coagulant complex, Antihemophilic factor, human recombinant, Fibrinogen human, Coagulation Factor IX Human", "updated_at": 1767369485}, {"id": 97374, "ingredient1": "Furosemide", "ingredient2": "Theophylline", "severity": "Minor", "effect": "Furosemide has reportedly increased, decreased, or not affected serum theophylline levels. The mechanism and clinical significance is unknown. Dosage adjustments may be required if an interaction is suspected.", "source": "DDInter", "management_text": "-", "mechanism_text": "Others", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97478/", "reference_text": "[1] Conlon PF, Grambau GR, Johnson CE, Weg JG \"Effect of intravenous furosemide on serum theophylline concentration.\" Am J Hosp Pharm 38 (1981): 1345-7[2] Sigurd B, Olesen KH \"The supra-additive natriuretic effect addition of theophylline ethylenediamine and bumetanide in congestive heart failure. Permutation trial tests in patients in long-term treatment with bumetanide.\" Am Heart J 94 (1977): 168-74[3] Toback JW, Gilman ME \"Theophylline-furosemide inactivation?\" Pediatrics 71 (1983): 140-1[4] Upton RA \"Pharmacokinetic interactions between theophylline and other medication (Part II).\" Clin Pharmacokinet 20 (1991): 135-50[5] Carpentiere G, Marino S, Castello F \"Furosemide and theophylline.\" Ann Intern Med 103 (1985): 957", "alternatives_a": "Omalizumab, Tezepelumab, Benralizumab, Caffeine, Reslizumab, Dyphylline, Oxtriphylline, Mepolizumab, Roflumilast, Bromotheophylline", "alternatives_b": "Trichlormethiazide, Chlorthalidone, Bendroflumethiazide, Etacrynic acid, Tinidazole, Ascorbic acid, Hydroflumethiazide, Chlorothiazide, Simeprevir, Rosuvastatin, Sulfadiazine, More", "updated_at": 1767369485}, {"id": 97375, "ingredient1": "Ginkgo biloba", "ingredient2": "Theophylline", "severity": "Moderate", "effect": "Certain preparations of ginkgo biloba have been reported to induce seizures. There may be a theoretical risk of increased seizure potential when used with other agents that can lower the seizure threshold such as selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, and theophylline. Ginkgo products may contain varying amounts of 4'-O-methylpyridoxine (ginkgotoxin), a known neurotoxin found primarily in ginkgo biloba seeds but also detected in lesser amounts in the leaves. In vivo, 4'-O-methylpyridoxine competes with vitamin B6, which causes an indirect inhibition of glutamate decarboxylase and subsequent decrease in the formation of gamma-aminobutyric acid (GABA) in the brain. There have been published case reports of generalized convulsions and vomiting within several hours after ingestion of large amounts of ginkgo nuts/seeds, including in young children and healthy individuals with no known personal or family history of epilepsy.", "source": "DDInter", "management_text": "Patients should consult a healthcare provider before taking any herbal or alternative medicine. Because of inconsistencies in formulation and potency of commercial herbal preparations, there is no way to verify without laboratory testing if and in what quantity 4'-O-methylpyridoxine may be present in a given ginkgo preparation. Patients treated with agents that can lower the seizure threshold should preferably avoid the use of products containing ginkgo biloba.", "mechanism_text": "Synergism", "recommendation": "Patients should consult a healthcare provider before taking any herbal or alternative medicine.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97479/", "reference_text": "[1] Kajiyama Y, Fujii K, Takeuchi H, Manabe Y \"Ginkgo seed poisoning.\" Pediatrics 109 (2002): 325-7[2] Granger AS \"Ginkgo biloba precipitating epileptic seizures.\" Age Ageing 30 (2001): 523-5[3] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[4] Gregory PJ \"Seizure associated with Ginkgo biloba?.\" Ann Intern Med 134 (2001): 344[5] Harms SL, Garrard J, Schwinghammer P, Eberly LE, Chang Y, Leppik IE \"Ginkgo biloba use in nursing home elderly with epilepsy or seizure disorder.\" Epilepsia 47 (2006): 323-9[6] Spinella M \"Herbal medicines and epilepsy: the potential for benefit and adverse effects.\" Epilepsy Behav 2 (2001): 524-32[7] Miwa H, Iijima M, Tanaka S, Mizuno Y \"Generalized convulsions after consuming a large amount of Gingko nuts.\" Epilepsia 42 (2001): 280-1[8] Kupiec T, Raj V \"Fatal seizures due to potential herb-drug interactions with Ginkgo biloba.\" J Anal Toxicol 29 (2005): 755-8", "alternatives_a": "Omalizumab, Tezepelumab, Mercaptopurine, Benralizumab, Caffeine, Reslizumab, Montelukast, Dyphylline, Mepolizumab, Roflumilast, Pentoxifylline, More", "alternatives_b": "Rivastigmine, Galantamine, Donepezil, Memantine, Aducanumab", "updated_at": 1767369485}, {"id": 97376, "ingredient1": "Givosiran", "ingredient2": "Theophylline", "severity": "Moderate", "effect": "Coadministration with givosiran may increase the plasma concentrations and the risk of adverse effects of drugs that are substrates of CYP450 1A2 and/or CYP450 2D6. The proposed mechanism is decreased clearance due to givosiran-mediated inhibition of CYP450 1A2 and 2D6 isoenzymes.", "source": "DDInter", "management_text": "Caution and monitoring are recommended when givosiran is given with drugs that are substrates of CYP450 1A2 and/or 2D6. Concomitant use should generally be avoided with CYP450 1A2 or 2D6 substrates that have a narrow therapeutic range where minimal concentration changes may lead to serious or life-threatening toxicities. If concomitant use is unavoidable, the dosage of the CYP450 1A2 or 2D6 substrate should be reduced according to approved product labeling or clinical response and tolerance. Dosage adjustments as well as clinical and laboratory monitoring should be considered whenever givosiran is added to or withdrawn from therapy with these drugs.", "mechanism_text": "Metabolism", "recommendation": "Caution and monitoring are recommended when givosiran is given with drugs that are substrates of CYP450 1A2 and/or 2D6.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97480/", "reference_text": "[1] \"Product Information. Givlaari (givosiran).\" Alnylam Pharmaceuticals, Cambridge, MA.", "alternatives_a": "Omalizumab, Tezepelumab, Mercaptopurine, Aminophylline, Benralizumab, Reslizumab, Montelukast, Dyphylline, Oxtriphylline, Mepolizumab, Zafirlukast, Bromotheophylline", "alternatives_b": "Teduglutide, Lonafarnib, Fosdenopterin, Miglustat, Imiglucerase, Asfotase alfa, Glycerol phenylbutyrate, Pegvaliase, Triethylenetetramine, Sapropterin, Zinc acetate, More", "updated_at": 1767369485}, {"id": 97377, "ingredient1": "Golimumab", "ingredient2": "Theophylline", "severity": "Moderate", "effect": "Plasma concentrations of drugs that are CYP450 substrates may decrease following the initiation of interleukin (IL) inhibitors, tumor necrosis factor (TNF) blockers, or interferon (IFN) inhibitors in patients with chronic inflammatory diseases. Because the formation of hepatic CYP450 enzymes is down-regulated during infection and chronic inflammation by increased levels of certain cytokines (e.g., interleukins-1, -6, and -10; tumor necrosis factor alpha; interferons), treatment targeting these cytokines may restore or normalize CYP450 enzyme levels resulting in increased metabolism of these drugs.", "source": "DDInter", "management_text": "Caution is advised when treatments targeting cytokines such as interleukins, tumor necrosis factors, or interferons are prescribed to patients receiving concomitant drugs that are CYP450 substrates, particularly those with narrow therapeutic ranges (e.g., antiarrhythmics, anticonvulsants, immunosuppressants, theophylline) or sensitive substrates where decreases in plasma levels may be significant or undesirable (e.g., oral contraceptives, statins, benzodiazepines, opioids). Clinical and/or laboratory monitoring should be considered following the initiation or withdrawal of such treatments, and the dosage(s) of the CYP450 substrate(s) adjusted accordingly. The effects of IL inhibitors, TNF blockers, and IFN inhibitors on CYP450 activities may persist for several weeks after stopping therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when treatments targeting cytokines such as interleukins, tumor necrosis factors, or interferons are prescribed to patients receiving concomitant drugs that are CYP450 substrates, particularly those with narrow therapeutic ranges (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97481/", "reference_text": "[1] \"Product Information. Skyrizi (risankizumab).\" AbbVie US LLC, North Chicago, IL.[2] \"Product Information. Cosentyx (secukinumab).\" Novartis Pharmaceuticals, East Hanover, NJ.[3] \"Product Information. Ilaris (canakinumab).\" Novartis Pharmaceuticals, East Hanover, NJ.[4] \"Product Information. Gamifant (emapalumab).\" Sobi Inc, Ardmore, PA.[5] \"Product Information. Kevzara (sarilumab).\" sanofi-aventis, Bridgewater, NJ.[6] \"Product Information. Simponi (golimumab).\" Centocor Inc, Malvern, PA.[7] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[8] \"Product Information. Sylvant (siltuximab).\" Janssen Biotech, Inc., Horsham, PA, PA.[9] \"Product Information. Stelara (ustekinumab).\" Centocor Inc, Malvern, PA.[10] \"Product Information. Ilumya (tildrakizumab).\" Merck & Company Inc, Whitehouse Station, NJ.[11] \"Product Information. Actemra (tocilizumab).\" Genentech, South San Francisco, CA.[12] \"Product Information. Amevive (alefacept).\" Biogen, Cambridge, MA.[13] \"Product Information. Remicade (infliximab).\" Centocor Inc, Malvern, PA.[14] \"Product Information. Taltz Autoinjector (ixekizumab).\" Eli Lilly and Company, Indianapolis, IN.[15] \"Product Information. Arcalyst (rilonacept).\" Regeneron Pharmaceuticals Inc, Tarrytown, NY.[16] Ace LN, Jaffe JM, Kunka RL \"Effect of food and an antacid on quinidine bioavailability.\" Biopharm Drug Dispos 4 (1983): 183-90[17] Min DI, Ku YM, Geraets DR, Lee HC \"Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers.\" J Clin Pharmacol 36 (1996): 469-76[18] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[19] Ha HR, Chen J, Leuenberger PM, Freiburghaus AU, Follah F \"In vitro inhibition of midazolam and quinidine metabolism by flavonoids.\" Eur J Clin Pharmacol 48 (1995): 367-71", "alternatives_a": "Omalizumab, Tezepelumab, Benralizumab, Caffeine, Reslizumab, Montelukast, Dyphylline, Mepolizumab, Pentoxifylline, Bromotheophylline", "alternatives_b": "Cyclosporine, Antithymocyte immunoglobulin (rabbit), Anifrolumab, Ravulizumab, Diroximel fumarate, Abatacept, Upadacitinib, Siponimod, Apremilast, Inebilizumab, Cladribine, More", "updated_at": 1767369485}, {"id": 97378, "ingredient1": "Grepafloxacin", "ingredient2": "Theophylline", "severity": "Moderate", "effect": "The coadministration with grepafloxacin may increase the serum concentrations of theophylline. The mechanism is grepafloxacin inhibition of CYP450 1A2, the isoenzyme primarily responsible for the metabolic clearance of theophylline.", "source": "DDInter", "management_text": "A 50% reduction in theophylline maintenance dosage is recommended during grepafloxacin treatment, and serum theophylline levels should be monitored to further guide any therapy adjustments. Patients should be advised to notify their physician if they experience possible signs of theophylline toxicity such as nausea, vomiting, diarrhea, headache, restlessness, insomnia, seizures, or irregular heartbeats.", "mechanism_text": "Metabolism", "recommendation": "A 50% reduction in theophylline maintenance dosage is recommended during grepafloxacin treatment, and serum theophylline levels should be monitored to further guide any therapy adjustments.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97482/", "reference_text": "[1] Efthymiopoulos C, Bramer SL, Maroli A, Blum B \"Theophylline and warfarin interaction studies with grepafloxacin.\" Clin Pharmacokinet 33(Suppl 1) (1997): 39-46[2] \"Product Information. Raxar (grepafloxacin).\" Glaxo Wellcome, Research Triangle Park, NC.", "alternatives_a": "Omalizumab, Tezepelumab, Benralizumab, Reslizumab, Montelukast, Dyphylline, Mepolizumab, Pentoxifylline, Zafirlukast, Bromotheophylline", "alternatives_b": "Gatifloxacin, Levofloxacin, Gemifloxacin, Lomefloxacin, Trovafloxacin, Delafloxacin, Sparfloxacin", "updated_at": 1767369485}, {"id": 97379, "ingredient1": "Guselkumab", "ingredient2": "Theophylline", "severity": "Moderate", "effect": "Plasma concentrations of drugs that are CYP450 substrates may decrease following the initiation of interleukin (IL) inhibitors, tumor necrosis factor (TNF) blockers, or interferon (IFN) inhibitors in patients with chronic inflammatory diseases. Because the formation of hepatic CYP450 enzymes is down-regulated during infection and chronic inflammation by increased levels of certain cytokines (e.g., interleukins-1, -6, and -10; tumor necrosis factor alpha; interferons), treatment targeting these cytokines may restore or normalize CYP450 enzyme levels resulting in increased metabolism of these drugs.", "source": "DDInter", "management_text": "Caution is advised when treatments targeting cytokines such as interleukins, tumor necrosis factors, or interferons are prescribed to patients receiving concomitant drugs that are CYP450 substrates, particularly those with narrow therapeutic ranges (e.g., antiarrhythmics, anticonvulsants, immunosuppressants, theophylline) or sensitive substrates where decreases in plasma levels may be significant or undesirable (e.g., oral contraceptives, statins, benzodiazepines, opioids). Clinical and/or laboratory monitoring should be considered following the initiation or withdrawal of such treatments, and the dosage(s) of the CYP450 substrate(s) adjusted accordingly. The effects of IL inhibitors, TNF blockers, and IFN inhibitors on CYP450 activities may persist for several weeks after stopping therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when treatments targeting cytokines such as interleukins, tumor necrosis factors, or interferons are prescribed to patients receiving concomitant drugs that are CYP450 substrates, particularly those with narrow therapeutic ranges (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97483/", "reference_text": "[1] \"Product Information. Skyrizi (risankizumab).\" AbbVie US LLC, North Chicago, IL.[2] \"Product Information. Cosentyx (secukinumab).\" Novartis Pharmaceuticals, East Hanover, NJ.[3] \"Product Information. Ilaris (canakinumab).\" Novartis Pharmaceuticals, East Hanover, NJ.[4] \"Product Information. Gamifant (emapalumab).\" Sobi Inc, Ardmore, PA.[5] \"Product Information. Kevzara (sarilumab).\" sanofi-aventis, Bridgewater, NJ.[6] \"Product Information. Simponi (golimumab).\" Centocor Inc, Malvern, PA.[7] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[8] \"Product Information. Sylvant (siltuximab).\" Janssen Biotech, Inc., Horsham, PA, PA.[9] \"Product Information. Stelara (ustekinumab).\" Centocor Inc, Malvern, PA.[10] \"Product Information. Ilumya (tildrakizumab).\" Merck & Company Inc, Whitehouse Station, NJ.[11] \"Product Information. Actemra (tocilizumab).\" Genentech, South San Francisco, CA.[12] \"Product Information. Amevive (alefacept).\" Biogen, Cambridge, MA.[13] \"Product Information. Remicade (infliximab).\" Centocor Inc, Malvern, PA.[14] \"Product Information. Taltz Autoinjector (ixekizumab).\" Eli Lilly and Company, Indianapolis, IN.[15] \"Product Information. Arcalyst (rilonacept).\" Regeneron Pharmaceuticals Inc, Tarrytown, NY.[16] Ace LN, Jaffe JM, Kunka RL \"Effect of food and an antacid on quinidine bioavailability.\" Biopharm Drug Dispos 4 (1983): 183-90[17] Min DI, Ku YM, Geraets DR, Lee HC \"Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers.\" J Clin Pharmacol 36 (1996): 469-76[18] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[19] Ha HR, Chen J, Leuenberger PM, Freiburghaus AU, Follah F \"In vitro inhibition of midazolam and quinidine metabolism by flavonoids.\" Eur J Clin Pharmacol 48 (1995): 367-71", "alternatives_a": "Omalizumab, Tezepelumab, Mercaptopurine, Benralizumab, Caffeine, Reslizumab, Montelukast, Dyphylline, Mepolizumab, Pentoxifylline, Zafirlukast, Bromotheophylline", "alternatives_b": "Cyclosporine, Antithymocyte immunoglobulin (rabbit), Anifrolumab, Ravulizumab, Diroximel fumarate, Abatacept, Upadacitinib, Siponimod, Apremilast, Inebilizumab, Cladribine, More", "updated_at": 1767369485}, {"id": 97380, "ingredient1": "Halazepam", "ingredient2": "Theophylline", "severity": "Minor", "effect": "Methylxanthines may antagonize the sedative effects of benzodiazepines. Aminophylline in particular has been demonstrated to attenuate the sedative effects of diazepam. The mechanism of this interaction may be related to competitive binding to intracerebral adenosine receptors.", "source": "DDInter", "management_text": "-", "mechanism_text": "Antagonism", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97484/", "reference_text": "[1] Tuncok Y, Akpinar O, Guven H, Akkoclu A \"The effects of theophylline on serum alprazolam levels.\" Int J Clin Pharmacol Ther 32 (1994): 642-5[2] Gallen JS \"Aminophylline reversal of midazolam sedation.\" Anesth Analg 69 (1989): 268[3] Bonfiglio MF, Dasta JF \"Clinical significance of the benzodiazepine-theophylline interaction.\" Pharmacotherapy 11 (1991): 85-7[4] Upton RA \"Pharmacokinetic interactions between theophylline and other medication (Part II).\" Clin Pharmacokinet 20 (1991): 135-50[5] Stirt JA \"Aminophylline is a diazepam antagonist.\" Anesth Analg 60 (1981): 767-8[6] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[7] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[8] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[9] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Omalizumab, Tezepelumab, Mercaptopurine, Benralizumab, Caffeine, Reslizumab, Montelukast, Mepolizumab, Roflumilast, Pentoxifylline, Zafirlukast, Bromotheophylline", "alternatives_b": "Meprobamate, Buspirone", "updated_at": 1767369485}, {"id": 97381, "ingredient1": "Halothane", "ingredient2": "Theophylline", "severity": "Major", "effect": "The administration of halothane following theophylline administration has been reported to result in ventricular tachycardia and, in one case, ventricular fibrillation. Halothane increases the arrhythmogenic potential of catecholamines. Theophylline appears to enhance the release of catecholamines.", "source": "DDInter", "management_text": "This combination should be avoided if possible. Halothane may interact in a similar manner with other methylxanthines.", "mechanism_text": "Synergism", "recommendation": "This combination should be avoided if possible.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97485/", "reference_text": "[1] Roizen MF, Stevens WC \"Multiform ventricular tachycardia due to the interaction of aminophylline and halothane.\" Anesth Analg 57 (1978): 738-41[2] Richards W, Thompson J, Lewis G, et al \"Cardiac arrest associated with halothane anesthesia in a patient receiving theophylline.\" Ann Allergy 61 (1988): 83-4", "alternatives_a": "Omalizumab, Tezepelumab, Mercaptopurine, Benralizumab, Caffeine, Reslizumab, Montelukast, Mepolizumab, Roflumilast, Pentoxifylline, Zafirlukast, Bromotheophylline", "alternatives_b": "Alfentanil, Remifentanil, Sodium oxybate, Isoflurane, Nitrous oxide, Desflurane, Sufentanil, Enflurane, Esketamine, Sevoflurane, Etomidate", "updated_at": 1767369485}, {"id": 97382, "ingredient1": "Indacaterol", "ingredient2": "Theophylline", "severity": "Moderate", "effect": "Concomitant use of beta-2 adrenergic agonists with theophylline may increase the risk and/or severity of hypokalemia and adverse cardiovascular effects such as palpitation, tachycardia, and blood pressure elevation. Adverse events, especially hypokalemia, may be more likely with systemic or nebulized formulations of beta-2 agonists or high dosages of theophylline. Beta-2 agonists can cause clinically significant but usually transient decreases in serum potassium concentrations, while hypokalemia associated with theophylline often occurs in toxicity. Pharmacokinetically, some beta-2 agonists given systemically may decrease the plasma concentrations of theophylline.", "source": "DDInter", "management_text": "Although theophylline and beta-2 agonists are commonly used together to produce bronchodilation, it may be appropriate to monitor patient response as well as serum potassium level, blood pressure and heart rate during coadministration, especially if the beta-2 agonist is administered systemically or by nebulizer. Close monitoring is particularly important in patients with severe asthma, since the potential increases in blood pressure and heart rate may have more serious consequences in the presence of hypoxemia or hypercapnia due to increased myocardial oxygen consumption. Patients should be advised to notify their physician if they experience worsening of their respiratory condition or potential signs and symptoms of hypokalemia such as fatigue, weakness, myalgia, muscle cramps, numbness, tingling, abdominal pain, constipation, palpitation, and irregular heartbeat.", "mechanism_text": "Synergism", "recommendation": "Although theophylline and beta-2 agonists are commonly used together to produce bronchodilation, it may be appropriate to monitor patient response as well as serum potassium level, blood pressure and heart rate during coadministration, especially if the beta-2 agonist is administered systemically or by nebulizer.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97486/", "reference_text": "[1] Garty M, Paul-Keslin L, Ilfeld DN, et al \"Increased theophylline clearance in asthmatic patients due to terbutaline.\" Eur J Clin Pharmacol 36 (1989): 25-8[2] Amirav I, Amitai Y, Avital A, Godfrey S \"Enhancement of theophylline clearance by intravenous albuterol.\" Chest 94 (1988): 444-5[3] \"Product Information. Striverdi Respimat (olodaterol).\" Boehringer Ingelheim, Ridgefield, CT.[4] Cusack BJ, Nielson CP, Morgan ME, Vestal RE \"Additive effect of theophylline on the cardiac response to isoproterenol.\" Clin Pharmacol Ther 41 (1987): 289-96[5] Griffith JA, Kozloski GD \"Isoproterenol-theophylline interaction: possible potentiation by other drugs.\" Clin Pharm 9 (1990): 54-7[6] Conrad KA, Woodworth JR \"Orciprenaline does not alter theophylline elimination.\" Br J Clin Pharmacol 12 (1981): 756-7[7] Flatt A, Burgess C, Windom H, Beasley R, Purdie G, Crane J \"The cardiovascular effects of inhaled fenoterol alone and during treatment with oral theophylline.\" Chest 96 (1989): 1317-20[8] Smith SR, Kendall MJ \"Potentiation of the adverse effects of intravenous terbutaline by oral theophylline.\" Br J Clin Pharmacol 21 (1986): 451-3[9] Danzinger Y, Garty M, Volwitz B, Ilfeld D, Varsano I, Rosenfeld JB \"Reduction of serum theophylline levels by terbutaline in children with asthma.\" Clin Pharmacol Ther 37 (1985): 469-71[10] O'Rourke PP, Crone RK \"Effect of isoproterenol on measured theophylline levels.\" Crit Care Med 12 (1984): 373-5[11] Whyte KF, Reid C, Addis GJ, Whitesmith R, Reid JL \"Salbutamol induced hypokalaemia: the effect of theophylline alone and in combination with adrenaline.\" Br J Clin Pharmacol 25 (1988): 571-8[12] Coleman JJ, Vollmer WM, Barker AF, et al \"Cardiac arrhythmias during the combined use of beta-adrenergic agonist drugs and theophylline.\" Chest 90 (1986): 45-51[13] Kelly HW \"Controversies in asthma therapy with theophylline and the beta2-adrenergic agonists.\" Clin Pharm 3 (1984): 386-95[14] Amitai Y, Glustein J, Godfrey S \"Enhancement of theophylline clearance by oral albuterol.\" Chest 102 (1992): 786-9[15] \"Product Information. Brovana (arformoterol).\" Sepracor Inc, Marlborough, MA.[16] \"Interactions between methyl xanthines and beta adrenergic agonists.\" FDA Drug Bull 11 (1981): 19-20[17] Chow OK, Fung KP \"Slow-release terbutaline and theophylline for the long-term therapy of children with asthma: a Latin square and factorial study of drug effects and interactions.\" Pediatrics 84 (1989): 119-25[18] Hemstreet MP, Miles MV, Rutland RO \"Effect of intravenous isoproterenol on theophylline kinetics.\" J Allergy Clin Immunol 69 (1982): 360-4[19] Upton RA \"Pharmacokinetic interactions between theophylline and other medication (Part I).\" Clin Pharmacokinet 20 (1991): 66-80[20] Rachelefsky GS, Katz RM, Mickey MR Jr, Siegel SC \"Metaproterenol and theophylline in asthmatic children.\" Ann Allergy 45 (1980): 207-12[21] Josephson GW, Kennedy HL, MacKenzie EJ, Gibson G \"Cardiac dysrhythmias during the treatment of acute asthma. A comparison of two treatment regimens by a double blind protocol.\" Chest 78 (1980): 429-35[22] Dawson KP, Fergusson DM \"Effects of oral theophylline and oral salbutamol in the treatment of asthma.\" Arch Dis Child 57 (1982): 674-6[23] Jonkman JH, Borgstrom L, van der Boon WJ, de Noord OE \"Theophylline-terbutaline, a steady state study on possible pharmacokinetic interactions with special reference to chronopharmacokinetic aspects.\" Br J Clin Pharmacol 26 (1988): 285-93[24] Deenstra M, Haalboom JR, Struyvenberg A \"Decrease of plasma potassium due to inhalation of beta-2 agonists: absence of an additional effect of intravenous theophylline.\" Eur J Clin Invest 18 (1988): 162-5[25] \"Product Information. Arcapta Neohaler (indacaterol).\" Novartis Pharmaceuticals, East Hanover, NJ.[26] Lombardi TP, Bertino JS, Goldberg A, Middleton E, Slaughter RL \"The effects of a beta-2 selective adrenergic agonist and a beta- nonselective antagonist on theophylline clearance.\" J Clin Pharmacol 27 (1987): 523-9", "alternatives_a": "Omalizumab, Tezepelumab, Mercaptopurine, Benralizumab, Caffeine, Reslizumab, Montelukast, Mepolizumab, Roflumilast, Pentoxifylline, Zafirlukast, Bromotheophylline", "alternatives_b": "Mometasone furoate, Umeclidinium, Aclidinium, Mometasone, Glycopyrronium, Ipratropium, Beclomethasone dipropionate", "updated_at": 1767369485}, {"id": 97383, "ingredient1": "Infliximab", "ingredient2": "Theophylline", "severity": "Moderate", "effect": "Plasma concentrations of drugs that are CYP450 substrates may decrease following the initiation of interleukin (IL) inhibitors, tumor necrosis factor (TNF) blockers, or interferon (IFN) inhibitors in patients with chronic inflammatory diseases. Because the formation of hepatic CYP450 enzymes is down-regulated during infection and chronic inflammation by increased levels of certain cytokines (e.g., interleukins-1, -6, and -10; tumor necrosis factor alpha; interferons), treatment targeting these cytokines may restore or normalize CYP450 enzyme levels resulting in increased metabolism of these drugs.", "source": "DDInter", "management_text": "Caution is advised when treatments targeting cytokines such as interleukins, tumor necrosis factors, or interferons are prescribed to patients receiving concomitant drugs that are CYP450 substrates, particularly those with narrow therapeutic ranges (e.g., antiarrhythmics, anticonvulsants, immunosuppressants, theophylline) or sensitive substrates where decreases in plasma levels may be significant or undesirable (e.g., oral contraceptives, statins, benzodiazepines, opioids). Clinical and/or laboratory monitoring should be considered following the initiation or withdrawal of such treatments, and the dosage(s) of the CYP450 substrate(s) adjusted accordingly. The effects of IL inhibitors, TNF blockers, and IFN inhibitors on CYP450 activities may persist for several weeks after stopping therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when treatments targeting cytokines such as interleukins, tumor necrosis factors, or interferons are prescribed to patients receiving concomitant drugs that are CYP450 substrates, particularly those with narrow therapeutic ranges (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97487/", "reference_text": "[1] \"Product Information. Skyrizi (risankizumab).\" AbbVie US LLC, North Chicago, IL.[2] \"Product Information. Cosentyx (secukinumab).\" Novartis Pharmaceuticals, East Hanover, NJ.[3] \"Product Information. Ilaris (canakinumab).\" Novartis Pharmaceuticals, East Hanover, NJ.[4] \"Product Information. Gamifant (emapalumab).\" Sobi Inc, Ardmore, PA.[5] \"Product Information. Kevzara (sarilumab).\" sanofi-aventis, Bridgewater, NJ.[6] \"Product Information. Simponi (golimumab).\" Centocor Inc, Malvern, PA.[7] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[8] \"Product Information. Sylvant (siltuximab).\" Janssen Biotech, Inc., Horsham, PA, PA.[9] \"Product Information. Stelara (ustekinumab).\" Centocor Inc, Malvern, PA.[10] \"Product Information. Ilumya (tildrakizumab).\" Merck & Company Inc, Whitehouse Station, NJ.[11] \"Product Information. Actemra (tocilizumab).\" Genentech, South San Francisco, CA.[12] \"Product Information. Amevive (alefacept).\" Biogen, Cambridge, MA.[13] \"Product Information. Remicade (infliximab).\" Centocor Inc, Malvern, PA.[14] \"Product Information. Taltz Autoinjector (ixekizumab).\" Eli Lilly and Company, Indianapolis, IN.[15] \"Product Information. Arcalyst (rilonacept).\" Regeneron Pharmaceuticals Inc, Tarrytown, NY.[16] Ace LN, Jaffe JM, Kunka RL \"Effect of food and an antacid on quinidine bioavailability.\" Biopharm Drug Dispos 4 (1983): 183-90[17] Min DI, Ku YM, Geraets DR, Lee HC \"Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers.\" J Clin Pharmacol 36 (1996): 469-76[18] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[19] Ha HR, Chen J, Leuenberger PM, Freiburghaus AU, Follah F \"In vitro inhibition of midazolam and quinidine metabolism by flavonoids.\" Eur J Clin Pharmacol 48 (1995): 367-71", "alternatives_a": "Cyclosporine, Antithymocyte immunoglobulin (rabbit), Anifrolumab, Ravulizumab, Diroximel fumarate, Abatacept, Upadacitinib, Siponimod, Apremilast, Inebilizumab, Cladribine, More", "alternatives_b": "Omalizumab, Tezepelumab, Benralizumab, Caffeine, Reslizumab, Montelukast, Dyphylline, Mepolizumab, Pentoxifylline, Bromotheophylline", "updated_at": 1767369485}, {"id": 97384, "ingredient1": "Interferon alfa-2a, Recombinant", "ingredient2": "Theophylline", "severity": "Moderate", "effect": "The coadministration with interferons has been associated with decreases in clearance and increases in plasma concentration and elimination half-life of theophylline. The mechanism is unknown but may be related to interferon-induced suppression of hepatic CYP450 enzymes, particularly, CYP450 1A2.", "source": "DDInter", "management_text": "Caution is advised if theophylline or other methylxanthines are administered with an interferon. Pharmacologic response and serum theophylline levels should be monitored and the dosage adjusted accordingly, particularly following initiation or discontinuation of interferon therapy in patients who are stabilized on their methylxanthine regimen. Patients should be advised to contact their physician if they experience signs and symptoms of theophylline toxicity such as nausea, vomiting, diarrhea, headache, restlessness, insomnia, or irregular heartbeat.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if theophylline or other methylxanthines are administered with an interferon.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97488/", "reference_text": "[1] \"Product Information. Intron A (interferon alfa-2b).\" Schering Laboratories, Kenilworth, NJ.[2] Sakai H, Okamoto T, Kikkawa Y \"Suppression of hepatic drug metabolism by the interferon inducer polyriboinosinic acid:polyribocitidylic acid.\" J Pharmacol Exp Ther 263 (1992): 381-6[3] Jonkman JH, Nicholson KG, Farrow PR, et al \"Effects of alpha-interferon on theophylline pharmacokinetics and metabolism.\" Br J Clin Pharmacol 27 (1989): 795-802[4] Kramer P, Tsuru M, Cook CE, et al \"Effect of influenza vaccine on warfarin anticoagulation.\" Clin Pharmacol Ther 35 (1984): 416-8[5] Upton RA \"Pharmacokinetic interactions between theophylline and other medication (Part II).\" Clin Pharmacokinet 20 (1991): 135-50[6] Okuno H, Takasu M, Kano H, Seki T, Shiozaki Y, Inoue K \"Depression of drug-metabolizing activity in the human liver by interferon-beta.\" Hepatology 17 (1993): 65-9[7] Williams SJ, Baird-Lambert JA, Farrell GC \"Inhibition of theophylline metabolism by interferon.\" Lancet 10/24/87 (1987): 939-41[8] Cerner Multum, Inc. \"Australian Product Information.\" O 0[9] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0", "alternatives_a": "Omalizumab, Tezepelumab, Benralizumab, Caffeine, Reslizumab, Montelukast, Dyphylline, Mepolizumab, Pentoxifylline, Bromotheophylline", "alternatives_b": "", "updated_at": 1767369485}, {"id": 97385, "ingredient1": "Interferon alfa-2b", "ingredient2": "Theophylline", "severity": "Moderate", "effect": "The coadministration with interferons has been associated with decreases in clearance and increases in plasma concentration and elimination half-life of theophylline. The mechanism is unknown but may be related to interferon-induced suppression of hepatic CYP450 enzymes, particularly, CYP450 1A2.", "source": "DDInter", "management_text": "Caution is advised if theophylline or other methylxanthines are administered with an interferon. Pharmacologic response and serum theophylline levels should be monitored and the dosage adjusted accordingly, particularly following initiation or discontinuation of interferon therapy in patients who are stabilized on their methylxanthine regimen. Patients should be advised to contact their physician if they experience signs and symptoms of theophylline toxicity such as nausea, vomiting, diarrhea, headache, restlessness, insomnia, or irregular heartbeat.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if theophylline or other methylxanthines are administered with an interferon.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97489/", "reference_text": "[1] \"Product Information. Intron A (interferon alfa-2b).\" Schering Laboratories, Kenilworth, NJ.[2] Sakai H, Okamoto T, Kikkawa Y \"Suppression of hepatic drug metabolism by the interferon inducer polyriboinosinic acid:polyribocitidylic acid.\" J Pharmacol Exp Ther 263 (1992): 381-6[3] Jonkman JH, Nicholson KG, Farrow PR, et al \"Effects of alpha-interferon on theophylline pharmacokinetics and metabolism.\" Br J Clin Pharmacol 27 (1989): 795-802[4] Kramer P, Tsuru M, Cook CE, et al \"Effect of influenza vaccine on warfarin anticoagulation.\" Clin Pharmacol Ther 35 (1984): 416-8[5] Upton RA \"Pharmacokinetic interactions between theophylline and other medication (Part II).\" Clin Pharmacokinet 20 (1991): 135-50[6] Okuno H, Takasu M, Kano H, Seki T, Shiozaki Y, Inoue K \"Depression of drug-metabolizing activity in the human liver by interferon-beta.\" Hepatology 17 (1993): 65-9[7] Williams SJ, Baird-Lambert JA, Farrell GC \"Inhibition of theophylline metabolism by interferon.\" Lancet 10/24/87 (1987): 939-41[8] Cerner Multum, Inc. \"Australian Product Information.\" O 0[9] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0", "alternatives_a": "Oprelvekin, Sipuleucel-T, Elapegademase, Sargramostim, Histamine, Aldesleukin, Pegademase, Pegfilgrastim, Filgrastim, Glatiramer", "alternatives_b": "Omalizumab, Tezepelumab, Benralizumab, Caffeine, Reslizumab, Montelukast, Dyphylline, Mepolizumab, Pentoxifylline, Bromotheophylline", "updated_at": 1767369485}, {"id": 97386, "ingredient1": "Interferon alfa-n1", "ingredient2": "Theophylline", "severity": "Moderate", "effect": "The coadministration with interferons has been associated with decreases in clearance and increases in plasma concentration and elimination half-life of theophylline. The mechanism is unknown but may be related to interferon-induced suppression of hepatic CYP450 enzymes, particularly, CYP450 1A2.", "source": "DDInter", "management_text": "Caution is advised if theophylline or other methylxanthines are administered with an interferon. Pharmacologic response and serum theophylline levels should be monitored and the dosage adjusted accordingly, particularly following initiation or discontinuation of interferon therapy in patients who are stabilized on their methylxanthine regimen. Patients should be advised to contact their physician if they experience signs and symptoms of theophylline toxicity such as nausea, vomiting, diarrhea, headache, restlessness, insomnia, or irregular heartbeat.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if theophylline or other methylxanthines are administered with an interferon.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97490/", "reference_text": "[1] \"Product Information. Intron A (interferon alfa-2b).\" Schering Laboratories, Kenilworth, NJ.[2] Sakai H, Okamoto T, Kikkawa Y \"Suppression of hepatic drug metabolism by the interferon inducer polyriboinosinic acid:polyribocitidylic acid.\" J Pharmacol Exp Ther 263 (1992): 381-6[3] Jonkman JH, Nicholson KG, Farrow PR, et al \"Effects of alpha-interferon on theophylline pharmacokinetics and metabolism.\" Br J Clin Pharmacol 27 (1989): 795-802[4] Kramer P, Tsuru M, Cook CE, et al \"Effect of influenza vaccine on warfarin anticoagulation.\" Clin Pharmacol Ther 35 (1984): 416-8[5] Upton RA \"Pharmacokinetic interactions between theophylline and other medication (Part II).\" Clin Pharmacokinet 20 (1991): 135-50[6] Okuno H, Takasu M, Kano H, Seki T, Shiozaki Y, Inoue K \"Depression of drug-metabolizing activity in the human liver by interferon-beta.\" Hepatology 17 (1993): 65-9[7] Williams SJ, Baird-Lambert JA, Farrell GC \"Inhibition of theophylline metabolism by interferon.\" Lancet 10/24/87 (1987): 939-41[8] Cerner Multum, Inc. \"Australian Product Information.\" O 0[9] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0", "alternatives_a": "Oprelvekin, Sipuleucel-T, Elapegademase, Sargramostim, Histamine, Aldesleukin, Pegademase, Pegfilgrastim, Filgrastim, Glatiramer", "alternatives_b": "Omalizumab, Tezepelumab, Mercaptopurine, Benralizumab, Caffeine, Reslizumab, Montelukast, Dyphylline, Mepolizumab, Pentoxifylline, Bromotheophylline", "updated_at": 1767369485}, {"id": 97387, "ingredient1": "Interferon alfa-n3", "ingredient2": "Theophylline", "severity": "Moderate", "effect": "The coadministration with interferons has been associated with decreases in clearance and increases in plasma concentration and elimination half-life of theophylline. The mechanism is unknown but may be related to interferon-induced suppression of hepatic CYP450 enzymes, particularly, CYP450 1A2.", "source": "DDInter", "management_text": "Caution is advised if theophylline or other methylxanthines are administered with an interferon. Pharmacologic response and serum theophylline levels should be monitored and the dosage adjusted accordingly, particularly following initiation or discontinuation of interferon therapy in patients who are stabilized on their methylxanthine regimen. Patients should be advised to contact their physician if they experience signs and symptoms of theophylline toxicity such as nausea, vomiting, diarrhea, headache, restlessness, insomnia, or irregular heartbeat.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if theophylline or other methylxanthines are administered with an interferon.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97491/", "reference_text": "[1] \"Product Information. Intron A (interferon alfa-2b).\" Schering Laboratories, Kenilworth, NJ.[2] Sakai H, Okamoto T, Kikkawa Y \"Suppression of hepatic drug metabolism by the interferon inducer polyriboinosinic acid:polyribocitidylic acid.\" J Pharmacol Exp Ther 263 (1992): 381-6[3] Jonkman JH, Nicholson KG, Farrow PR, et al \"Effects of alpha-interferon on theophylline pharmacokinetics and metabolism.\" Br J Clin Pharmacol 27 (1989): 795-802[4] Kramer P, Tsuru M, Cook CE, et al \"Effect of influenza vaccine on warfarin anticoagulation.\" Clin Pharmacol Ther 35 (1984): 416-8[5] Upton RA \"Pharmacokinetic interactions between theophylline and other medication (Part II).\" Clin Pharmacokinet 20 (1991): 135-50[6] Okuno H, Takasu M, Kano H, Seki T, Shiozaki Y, Inoue K \"Depression of drug-metabolizing activity in the human liver by interferon-beta.\" Hepatology 17 (1993): 65-9[7] Williams SJ, Baird-Lambert JA, Farrell GC \"Inhibition of theophylline metabolism by interferon.\" Lancet 10/24/87 (1987): 939-41[8] Cerner Multum, Inc. \"Australian Product Information.\" O 0[9] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0", "alternatives_a": "Omalizumab, Tezepelumab, Mercaptopurine, Benralizumab, Caffeine, Reslizumab, Montelukast, Dyphylline, Mepolizumab, Roflumilast, Pentoxifylline, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 97388, "ingredient1": "Interferon alfacon-1", "ingredient2": "Theophylline", "severity": "Moderate", "effect": "The coadministration with interferons has been associated with decreases in clearance and increases in plasma concentration and elimination half-life of theophylline. The mechanism is unknown but may be related to interferon-induced suppression of hepatic CYP450 enzymes, particularly, CYP450 1A2.", "source": "DDInter", "management_text": "Caution is advised if theophylline or other methylxanthines are administered with an interferon. Pharmacologic response and serum theophylline levels should be monitored and the dosage adjusted accordingly, particularly following initiation or discontinuation of interferon therapy in patients who are stabilized on their methylxanthine regimen. Patients should be advised to contact their physician if they experience signs and symptoms of theophylline toxicity such as nausea, vomiting, diarrhea, headache, restlessness, insomnia, or irregular heartbeat.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if theophylline or other methylxanthines are administered with an interferon.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97492/", "reference_text": "[1] \"Product Information. Intron A (interferon alfa-2b).\" Schering Laboratories, Kenilworth, NJ.[2] Sakai H, Okamoto T, Kikkawa Y \"Suppression of hepatic drug metabolism by the interferon inducer polyriboinosinic acid:polyribocitidylic acid.\" J Pharmacol Exp Ther 263 (1992): 381-6[3] Jonkman JH, Nicholson KG, Farrow PR, et al \"Effects of alpha-interferon on theophylline pharmacokinetics and metabolism.\" Br J Clin Pharmacol 27 (1989): 795-802[4] Kramer P, Tsuru M, Cook CE, et al \"Effect of influenza vaccine on warfarin anticoagulation.\" Clin Pharmacol Ther 35 (1984): 416-8[5] Upton RA \"Pharmacokinetic interactions between theophylline and other medication (Part II).\" Clin Pharmacokinet 20 (1991): 135-50[6] Okuno H, Takasu M, Kano H, Seki T, Shiozaki Y, Inoue K \"Depression of drug-metabolizing activity in the human liver by interferon-beta.\" Hepatology 17 (1993): 65-9[7] Williams SJ, Baird-Lambert JA, Farrell GC \"Inhibition of theophylline metabolism by interferon.\" Lancet 10/24/87 (1987): 939-41[8] Cerner Multum, Inc. \"Australian Product Information.\" O 0[9] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0", "alternatives_a": "Oprelvekin, Sipuleucel-T, Elapegademase, Sargramostim, Histamine, Aldesleukin, Pegademase, Pegfilgrastim, Filgrastim, Glatiramer", "alternatives_b": "Omalizumab, Tezepelumab, Mercaptopurine, Benralizumab, Caffeine, Reslizumab, Montelukast, Dyphylline, Mepolizumab, Pentoxifylline, Bromotheophylline", "updated_at": 1767369485}, {"id": 97389, "ingredient1": "Interferon beta-1a", "ingredient2": "Theophylline", "severity": "Moderate", "effect": "The coadministration with interferons has been associated with decreases in clearance and increases in plasma concentration and elimination half-life of theophylline. The mechanism is unknown but may be related to interferon-induced suppression of hepatic CYP450 enzymes, particularly, CYP450 1A2.", "source": "DDInter", "management_text": "Caution is advised if theophylline or other methylxanthines are administered with an interferon. Pharmacologic response and serum theophylline levels should be monitored and the dosage adjusted accordingly, particularly following initiation or discontinuation of interferon therapy in patients who are stabilized on their methylxanthine regimen. Patients should be advised to contact their physician if they experience signs and symptoms of theophylline toxicity such as nausea, vomiting, diarrhea, headache, restlessness, insomnia, or irregular heartbeat.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if theophylline or other methylxanthines are administered with an interferon.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97493/", "reference_text": "[1] \"Product Information. Intron A (interferon alfa-2b).\" Schering Laboratories, Kenilworth, NJ.[2] Sakai H, Okamoto T, Kikkawa Y \"Suppression of hepatic drug metabolism by the interferon inducer polyriboinosinic acid:polyribocitidylic acid.\" J Pharmacol Exp Ther 263 (1992): 381-6[3] Jonkman JH, Nicholson KG, Farrow PR, et al \"Effects of alpha-interferon on theophylline pharmacokinetics and metabolism.\" Br J Clin Pharmacol 27 (1989): 795-802[4] Kramer P, Tsuru M, Cook CE, et al \"Effect of influenza vaccine on warfarin anticoagulation.\" Clin Pharmacol Ther 35 (1984): 416-8[5] Upton RA \"Pharmacokinetic interactions between theophylline and other medication (Part II).\" Clin Pharmacokinet 20 (1991): 135-50[6] Okuno H, Takasu M, Kano H, Seki T, Shiozaki Y, Inoue K \"Depression of drug-metabolizing activity in the human liver by interferon-beta.\" Hepatology 17 (1993): 65-9[7] Williams SJ, Baird-Lambert JA, Farrell GC \"Inhibition of theophylline metabolism by interferon.\" Lancet 10/24/87 (1987): 939-41[8] Cerner Multum, Inc. \"Australian Product Information.\" O 0[9] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0", "alternatives_a": "Oprelvekin, Sipuleucel-T, Elapegademase, Sargramostim, Histamine, Aldesleukin, Pegademase, Pegfilgrastim, Filgrastim, Glatiramer", "alternatives_b": "Omalizumab, Tezepelumab, Benralizumab, Caffeine, Reslizumab, Montelukast, Dyphylline, Mepolizumab, Roflumilast, Pentoxifylline, Bromotheophylline", "updated_at": 1767369485}, {"id": 97390, "ingredient1": "Interferon beta-1b", "ingredient2": "Theophylline", "severity": "Moderate", "effect": "The coadministration with interferons has been associated with decreases in clearance and increases in plasma concentration and elimination half-life of theophylline. The mechanism is unknown but may be related to interferon-induced suppression of hepatic CYP450 enzymes, particularly, CYP450 1A2.", "source": "DDInter", "management_text": "Caution is advised if theophylline or other methylxanthines are administered with an interferon. Pharmacologic response and serum theophylline levels should be monitored and the dosage adjusted accordingly, particularly following initiation or discontinuation of interferon therapy in patients who are stabilized on their methylxanthine regimen. Patients should be advised to contact their physician if they experience signs and symptoms of theophylline toxicity such as nausea, vomiting, diarrhea, headache, restlessness, insomnia, or irregular heartbeat.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if theophylline or other methylxanthines are administered with an interferon.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97494/", "reference_text": "[1] \"Product Information. Intron A (interferon alfa-2b).\" Schering Laboratories, Kenilworth, NJ.[2] Sakai H, Okamoto T, Kikkawa Y \"Suppression of hepatic drug metabolism by the interferon inducer polyriboinosinic acid:polyribocitidylic acid.\" J Pharmacol Exp Ther 263 (1992): 381-6[3] Jonkman JH, Nicholson KG, Farrow PR, et al \"Effects of alpha-interferon on theophylline pharmacokinetics and metabolism.\" Br J Clin Pharmacol 27 (1989): 795-802[4] Kramer P, Tsuru M, Cook CE, et al \"Effect of influenza vaccine on warfarin anticoagulation.\" Clin Pharmacol Ther 35 (1984): 416-8[5] Upton RA \"Pharmacokinetic interactions between theophylline and other medication (Part II).\" Clin Pharmacokinet 20 (1991): 135-50[6] Okuno H, Takasu M, Kano H, Seki T, Shiozaki Y, Inoue K \"Depression of drug-metabolizing activity in the human liver by interferon-beta.\" Hepatology 17 (1993): 65-9[7] Williams SJ, Baird-Lambert JA, Farrell GC \"Inhibition of theophylline metabolism by interferon.\" Lancet 10/24/87 (1987): 939-41[8] Cerner Multum, Inc. \"Australian Product Information.\" O 0[9] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0", "alternatives_a": "Oprelvekin, Sipuleucel-T, Elapegademase, Sargramostim, Histamine, Aldesleukin, Pegademase, Pegfilgrastim, Filgrastim, Glatiramer", "alternatives_b": "Omalizumab, Tezepelumab, Benralizumab, Caffeine, Reslizumab, Montelukast, Dyphylline, Mepolizumab, Roflumilast, Pentoxifylline, Bromotheophylline", "updated_at": 1767369485}, {"id": 97391, "ingredient1": "Interferon gamma-1b", "ingredient2": "Theophylline", "severity": "Moderate", "effect": "The coadministration with interferons has been associated with decreases in clearance and increases in plasma concentration and elimination half-life of theophylline. The mechanism is unknown but may be related to interferon-induced suppression of hepatic CYP450 enzymes, particularly, CYP450 1A2.", "source": "DDInter", "management_text": "Caution is advised if theophylline or other methylxanthines are administered with an interferon. Pharmacologic response and serum theophylline levels should be monitored and the dosage adjusted accordingly, particularly following initiation or discontinuation of interferon therapy in patients who are stabilized on their methylxanthine regimen. Patients should be advised to contact their physician if they experience signs and symptoms of theophylline toxicity such as nausea, vomiting, diarrhea, headache, restlessness, insomnia, or irregular heartbeat.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if theophylline or other methylxanthines are administered with an interferon.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97495/", "reference_text": "[1] \"Product Information. Intron A (interferon alfa-2b).\" Schering Laboratories, Kenilworth, NJ.[2] Sakai H, Okamoto T, Kikkawa Y \"Suppression of hepatic drug metabolism by the interferon inducer polyriboinosinic acid:polyribocitidylic acid.\" J Pharmacol Exp Ther 263 (1992): 381-6[3] Jonkman JH, Nicholson KG, Farrow PR, et al \"Effects of alpha-interferon on theophylline pharmacokinetics and metabolism.\" Br J Clin Pharmacol 27 (1989): 795-802[4] Kramer P, Tsuru M, Cook CE, et al \"Effect of influenza vaccine on warfarin anticoagulation.\" Clin Pharmacol Ther 35 (1984): 416-8[5] Upton RA \"Pharmacokinetic interactions between theophylline and other medication (Part II).\" Clin Pharmacokinet 20 (1991): 135-50[6] Okuno H, Takasu M, Kano H, Seki T, Shiozaki Y, Inoue K \"Depression of drug-metabolizing activity in the human liver by interferon-beta.\" Hepatology 17 (1993): 65-9[7] Williams SJ, Baird-Lambert JA, Farrell GC \"Inhibition of theophylline metabolism by interferon.\" Lancet 10/24/87 (1987): 939-41[8] Cerner Multum, Inc. \"Australian Product Information.\" O 0[9] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0", "alternatives_a": "Omalizumab, Tezepelumab, Mercaptopurine, Benralizumab, Caffeine, Reslizumab, Montelukast, Dyphylline, Mepolizumab, Pentoxifylline, Zafirlukast, Bromotheophylline", "alternatives_b": "", "updated_at": 1767369485}, {"id": 97392, "ingredient1": "Iohexol", "ingredient2": "Theophylline", "severity": "Major", "effect": "Intrathecal administration of iodinated contrast media may induce seizures. Although clinical data are generally lacking, there may be a theoretical risk of increased seizure potential when used with selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), and/or any substance that can reduce the seizure threshold (e.g., carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, theophylline). These agents are often individually epileptogenic and may have additive effects when combined.", "source": "DDInter", "management_text": "Drugs that can lower the seizure threshold should preferably be withheld for at least 48 hours prior to and 24 hours following intrathecal administration of iodinated contrast media, provided that temporary interruption of therapy does not pose an undue risk to the patient. Otherwise, close monitoring is advised during and after contrast administration.", "mechanism_text": "Synergism", "recommendation": "Drugs that can lower the seizure threshold should preferably be withheld for at least 48 hours prior to and 24 hours following intrathecal administration of iodinated contrast media, provided that temporary interruption of therapy does not pose an undue risk to the patient.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97496/", "reference_text": "[1] \"Product Information. Amipaque (metrizamide)\" Nycomed Inc, Princeton, NJ.[2] Hindmarsh T, Grepe A, Widen L \"Metrizamide-phenothiazine interaction: report of a case with seizures following myelography.\" Acta Radiol Diagn (Stockh) 16 (1975): 129-35[3] \"Product Information. Omnipaque 180 (iohexol).\" Amersham Health, Princeton, NJ.[4] \"Product Information. Osmovist 240 (iotrolan).\" Berlex Canada Inc, Lachine, QC.[5] \"Product Information. Isovue-M-200 (iopamidol).\" Bracco Diagnostics Inc, Princeton, NJ.", "alternatives_a": "Omalizumab, Tezepelumab, Mercaptopurine, Benralizumab, Caffeine, Reslizumab, Montelukast, Dyphylline, Mepolizumab, Roflumilast, Pentoxifylline, More", "alternatives_b": "Ioxilan, Iodipamide, Ioversol, Iodamide, Iodixanol, Tyropanoic acid, Ethiodized oil, Iopanoic acid, Iopodic acid, Iothalamic acid, Ioxaglic acid, More", "updated_at": 1767369485}, {"id": 97393, "ingredient1": "Iopamidol", "ingredient2": "Theophylline", "severity": "Major", "effect": "Intrathecal administration of iodinated contrast media may induce seizures. Although clinical data are generally lacking, there may be a theoretical risk of increased seizure potential when used with selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), and/or any substance that can reduce the seizure threshold (e.g., carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, theophylline). These agents are often individually epileptogenic and may have additive effects when combined.", "source": "DDInter", "management_text": "Drugs that can lower the seizure threshold should preferably be withheld for at least 48 hours prior to and 24 hours following intrathecal administration of iodinated contrast media, provided that temporary interruption of therapy does not pose an undue risk to the patient. Otherwise, close monitoring is advised during and after contrast administration.", "mechanism_text": "Synergism", "recommendation": "Drugs that can lower the seizure threshold should preferably be withheld for at least 48 hours prior to and 24 hours following intrathecal administration of iodinated contrast media, provided that temporary interruption of therapy does not pose an undue risk to the patient.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97497/", "reference_text": "[1] \"Product Information. Amipaque (metrizamide)\" Nycomed Inc, Princeton, NJ.[2] Hindmarsh T, Grepe A, Widen L \"Metrizamide-phenothiazine interaction: report of a case with seizures following myelography.\" Acta Radiol Diagn (Stockh) 16 (1975): 129-35[3] \"Product Information. Omnipaque 180 (iohexol).\" Amersham Health, Princeton, NJ.[4] \"Product Information. Osmovist 240 (iotrolan).\" Berlex Canada Inc, Lachine, QC.[5] \"Product Information. Isovue-M-200 (iopamidol).\" Bracco Diagnostics Inc, Princeton, NJ.", "alternatives_a": "Omalizumab, Tezepelumab, Mercaptopurine, Benralizumab, Caffeine, Reslizumab, Montelukast, Dyphylline, Mepolizumab, Roflumilast, Pentoxifylline, More", "alternatives_b": "Ioxilan, Iodipamide, Ioversol, Iodamide, Iodixanol, Tyropanoic acid, Ethiodized oil, Iopanoic acid, Iopodic acid, Iothalamic acid, Ioxaglic acid, More", "updated_at": 1767369485}, {"id": 97394, "ingredient1": "Isoetharine", "ingredient2": "Theophylline", "severity": "Moderate", "effect": "Concomitant use of beta-2 adrenergic agonists with theophylline may increase the risk and/or severity of hypokalemia and adverse cardiovascular effects such as palpitation, tachycardia, and blood pressure elevation. Adverse events, especially hypokalemia, may be more likely with systemic or nebulized formulations of beta-2 agonists or high dosages of theophylline. Beta-2 agonists can cause clinically significant but usually transient decreases in serum potassium concentrations, while hypokalemia associated with theophylline often occurs in toxicity. Pharmacokinetically, some beta-2 agonists given systemically may decrease the plasma concentrations of theophylline.", "source": "DDInter", "management_text": "Although theophylline and beta-2 agonists are commonly used together to produce bronchodilation, it may be appropriate to monitor patient response as well as serum potassium level, blood pressure and heart rate during coadministration, especially if the beta-2 agonist is administered systemically or by nebulizer. Close monitoring is particularly important in patients with severe asthma, since the potential increases in blood pressure and heart rate may have more serious consequences in the presence of hypoxemia or hypercapnia due to increased myocardial oxygen consumption. Patients should be advised to notify their physician if they experience worsening of their respiratory condition or potential signs and symptoms of hypokalemia such as fatigue, weakness, myalgia, muscle cramps, numbness, tingling, abdominal pain, constipation, palpitation, and irregular heartbeat.", "mechanism_text": "Synergism", "recommendation": "Although theophylline and beta-2 agonists are commonly used together to produce bronchodilation, it may be appropriate to monitor patient response as well as serum potassium level, blood pressure and heart rate during coadministration, especially if the beta-2 agonist is administered systemically or by nebulizer.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97498/", "reference_text": "[1] Garty M, Paul-Keslin L, Ilfeld DN, et al \"Increased theophylline clearance in asthmatic patients due to terbutaline.\" Eur J Clin Pharmacol 36 (1989): 25-8[2] Amirav I, Amitai Y, Avital A, Godfrey S \"Enhancement of theophylline clearance by intravenous albuterol.\" Chest 94 (1988): 444-5[3] \"Product Information. Striverdi Respimat (olodaterol).\" Boehringer Ingelheim, Ridgefield, CT.[4] Cusack BJ, Nielson CP, Morgan ME, Vestal RE \"Additive effect of theophylline on the cardiac response to isoproterenol.\" Clin Pharmacol Ther 41 (1987): 289-96[5] Griffith JA, Kozloski GD \"Isoproterenol-theophylline interaction: possible potentiation by other drugs.\" Clin Pharm 9 (1990): 54-7[6] Conrad KA, Woodworth JR \"Orciprenaline does not alter theophylline elimination.\" Br J Clin Pharmacol 12 (1981): 756-7[7] Flatt A, Burgess C, Windom H, Beasley R, Purdie G, Crane J \"The cardiovascular effects of inhaled fenoterol alone and during treatment with oral theophylline.\" Chest 96 (1989): 1317-20[8] Smith SR, Kendall MJ \"Potentiation of the adverse effects of intravenous terbutaline by oral theophylline.\" Br J Clin Pharmacol 21 (1986): 451-3[9] Danzinger Y, Garty M, Volwitz B, Ilfeld D, Varsano I, Rosenfeld JB \"Reduction of serum theophylline levels by terbutaline in children with asthma.\" Clin Pharmacol Ther 37 (1985): 469-71[10] O'Rourke PP, Crone RK \"Effect of isoproterenol on measured theophylline levels.\" Crit Care Med 12 (1984): 373-5[11] Whyte KF, Reid C, Addis GJ, Whitesmith R, Reid JL \"Salbutamol induced hypokalaemia: the effect of theophylline alone and in combination with adrenaline.\" Br J Clin Pharmacol 25 (1988): 571-8[12] Coleman JJ, Vollmer WM, Barker AF, et al \"Cardiac arrhythmias during the combined use of beta-adrenergic agonist drugs and theophylline.\" Chest 90 (1986): 45-51[13] Kelly HW \"Controversies in asthma therapy with theophylline and the beta2-adrenergic agonists.\" Clin Pharm 3 (1984): 386-95[14] Amitai Y, Glustein J, Godfrey S \"Enhancement of theophylline clearance by oral albuterol.\" Chest 102 (1992): 786-9[15] \"Product Information. Brovana (arformoterol).\" Sepracor Inc, Marlborough, MA.[16] \"Interactions between methyl xanthines and beta adrenergic agonists.\" FDA Drug Bull 11 (1981): 19-20[17] Chow OK, Fung KP \"Slow-release terbutaline and theophylline for the long-term therapy of children with asthma: a Latin square and factorial study of drug effects and interactions.\" Pediatrics 84 (1989): 119-25[18] Hemstreet MP, Miles MV, Rutland RO \"Effect of intravenous isoproterenol on theophylline kinetics.\" J Allergy Clin Immunol 69 (1982): 360-4[19] Upton RA \"Pharmacokinetic interactions between theophylline and other medication (Part I).\" Clin Pharmacokinet 20 (1991): 66-80[20] Rachelefsky GS, Katz RM, Mickey MR Jr, Siegel SC \"Metaproterenol and theophylline in asthmatic children.\" Ann Allergy 45 (1980): 207-12[21] Josephson GW, Kennedy HL, MacKenzie EJ, Gibson G \"Cardiac dysrhythmias during the treatment of acute asthma. A comparison of two treatment regimens by a double blind protocol.\" Chest 78 (1980): 429-35[22] Dawson KP, Fergusson DM \"Effects of oral theophylline and oral salbutamol in the treatment of asthma.\" Arch Dis Child 57 (1982): 674-6[23] Jonkman JH, Borgstrom L, van der Boon WJ, de Noord OE \"Theophylline-terbutaline, a steady state study on possible pharmacokinetic interactions with special reference to chronopharmacokinetic aspects.\" Br J Clin Pharmacol 26 (1988): 285-93[24] Deenstra M, Haalboom JR, Struyvenberg A \"Decrease of plasma potassium due to inhalation of beta-2 agonists: absence of an additional effect of intravenous theophylline.\" Eur J Clin Invest 18 (1988): 162-5[25] \"Product Information. Arcapta Neohaler (indacaterol).\" Novartis Pharmaceuticals, East Hanover, NJ.[26] Lombardi TP, Bertino JS, Goldberg A, Middleton E, Slaughter RL \"The effects of a beta-2 selective adrenergic agonist and a beta- nonselective antagonist on theophylline clearance.\" J Clin Pharmacol 27 (1987): 523-9", "alternatives_a": "Omalizumab, Tezepelumab, Mercaptopurine, Benralizumab, Caffeine, Reslizumab, Montelukast, Mepolizumab, Roflumilast, Pentoxifylline, Zafirlukast, Bromotheophylline", "alternatives_b": "", "updated_at": 1767369485}, {"id": 97395, "ingredient1": "Isoniazid", "ingredient2": "Theophylline", "severity": "Moderate", "effect": "Theophylline serum concentrations may be gradually increased by concomitant isoniazid administration. The mechanism is thought to involve isoniazid-induced inhibition of the CYP450 3A4 and 1A2 hepatic metabolism of theophylline.", "source": "DDInter", "management_text": "Clinical monitoring of patient response and tolerance and serum theophylline levels is recommended when isoniazid is added. Patients should be advised to report any signs of theophylline toxicity to their caregiver, including nausea, vomiting, diarrhea, headache, restlessness, insomnia, or irregular heartbeat.", "mechanism_text": "Metabolism", "recommendation": "Clinical monitoring of patient response and tolerance and serum theophylline levels is recommended when isoniazid is added.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97499/", "reference_text": "[1] Dal Negro R, Turco P, Trevisan F, De Conti F \"Rifampicin-isoniazid and delayed elimination of theophylline: a case report.\" Int J Clin Pharmacol Res 8 (1988): 275-7[2] Hoglund P, Nilsson LG, Paulson O \"Interaction between isoniazid and theophylline.\" Eur J Respir Dis 70 (1987): 110-6[3] Upton RA \"Pharmacokinetic interactions between theophylline and other medication (Part I).\" Clin Pharmacokinet 20 (1991): 66-80[4] Torrent J, Izquierdo I, Cabezas R, Jane F \"Theophylline-isoniazid interaction.\" DICP 23 (1989): 143-5[5] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[6] Self TH, Chrisman CR, Baciewicz AM, Bronze MS \"Isoniazid drug and food interactions.\" Am J Med Sci 317 (1999): 304-11[7] Uragoda CG, Kottegoda SR \"Adverse reactions to isoniazid on ingestion of fish with a high histamine content.\" Tubercle 58 (1977): 83-9[8] \"Product Information. INH (isoniazid).\" Ciba Pharmaceuticals, Summit, NJ.[9] Smith CK, Durack DT \"Isoniazid and reaction to cheese.\" Ann Intern Med 88 (1978): 520-1[10] Dimartini A \"Isoniazid, tricyclics and the ''cheese reaction''.\" Int Clin Psychopharmacol 10 (1995): 197-8", "alternatives_a": "Omalizumab, Tezepelumab, Mercaptopurine, Benralizumab, Caffeine, Reslizumab, Dyphylline, Mepolizumab, Pentoxifylline, Bromotheophylline", "alternatives_b": "Capreomycin, Pyrazinamide, Rifamycin, Bedaquiline, Sulfamethoxazole, Rifapentine, Streptomycin, Trimethoprim, Cycloserine, Rifabutin, Ethambutol, More", "updated_at": 1767369485}, {"id": 97396, "ingredient1": "Isoprenaline", "ingredient2": "Theophylline", "severity": "Moderate", "effect": "Concomitant use of beta-2 adrenergic agonists with theophylline may increase the risk and/or severity of hypokalemia and adverse cardiovascular effects such as palpitation, tachycardia, and blood pressure elevation. Adverse events, especially hypokalemia, may be more likely with systemic or nebulized formulations of beta-2 agonists or high dosages of theophylline. Beta-2 agonists can cause clinically significant but usually transient decreases in serum potassium concentrations, while hypokalemia associated with theophylline often occurs in toxicity. Pharmacokinetically, some beta-2 agonists given systemically may decrease the plasma concentrations of theophylline.", "source": "DDInter", "management_text": "Although theophylline and beta-2 agonists are commonly used together to produce bronchodilation, it may be appropriate to monitor patient response as well as serum potassium level, blood pressure and heart rate during coadministration, especially if the beta-2 agonist is administered systemically or by nebulizer. Close monitoring is particularly important in patients with severe asthma, since the potential increases in blood pressure and heart rate may have more serious consequences in the presence of hypoxemia or hypercapnia due to increased myocardial oxygen consumption. Patients should be advised to notify their physician if they experience worsening of their respiratory condition or potential signs and symptoms of hypokalemia such as fatigue, weakness, myalgia, muscle cramps, numbness, tingling, abdominal pain, constipation, palpitation, and irregular heartbeat.", "mechanism_text": "Synergism", "recommendation": "Although theophylline and beta-2 agonists are commonly used together to produce bronchodilation, it may be appropriate to monitor patient response as well as serum potassium level, blood pressure and heart rate during coadministration, especially if the beta-2 agonist is administered systemically or by nebulizer.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97500/", "reference_text": "[1] Garty M, Paul-Keslin L, Ilfeld DN, et al \"Increased theophylline clearance in asthmatic patients due to terbutaline.\" Eur J Clin Pharmacol 36 (1989): 25-8[2] Amirav I, Amitai Y, Avital A, Godfrey S \"Enhancement of theophylline clearance by intravenous albuterol.\" Chest 94 (1988): 444-5[3] \"Product Information. Striverdi Respimat (olodaterol).\" Boehringer Ingelheim, Ridgefield, CT.[4] Cusack BJ, Nielson CP, Morgan ME, Vestal RE \"Additive effect of theophylline on the cardiac response to isoproterenol.\" Clin Pharmacol Ther 41 (1987): 289-96[5] Griffith JA, Kozloski GD \"Isoproterenol-theophylline interaction: possible potentiation by other drugs.\" Clin Pharm 9 (1990): 54-7[6] Conrad KA, Woodworth JR \"Orciprenaline does not alter theophylline elimination.\" Br J Clin Pharmacol 12 (1981): 756-7[7] Flatt A, Burgess C, Windom H, Beasley R, Purdie G, Crane J \"The cardiovascular effects of inhaled fenoterol alone and during treatment with oral theophylline.\" Chest 96 (1989): 1317-20[8] Smith SR, Kendall MJ \"Potentiation of the adverse effects of intravenous terbutaline by oral theophylline.\" Br J Clin Pharmacol 21 (1986): 451-3[9] Danzinger Y, Garty M, Volwitz B, Ilfeld D, Varsano I, Rosenfeld JB \"Reduction of serum theophylline levels by terbutaline in children with asthma.\" Clin Pharmacol Ther 37 (1985): 469-71[10] O'Rourke PP, Crone RK \"Effect of isoproterenol on measured theophylline levels.\" Crit Care Med 12 (1984): 373-5[11] Whyte KF, Reid C, Addis GJ, Whitesmith R, Reid JL \"Salbutamol induced hypokalaemia: the effect of theophylline alone and in combination with adrenaline.\" Br J Clin Pharmacol 25 (1988): 571-8[12] Coleman JJ, Vollmer WM, Barker AF, et al \"Cardiac arrhythmias during the combined use of beta-adrenergic agonist drugs and theophylline.\" Chest 90 (1986): 45-51[13] Kelly HW \"Controversies in asthma therapy with theophylline and the beta2-adrenergic agonists.\" Clin Pharm 3 (1984): 386-95[14] Amitai Y, Glustein J, Godfrey S \"Enhancement of theophylline clearance by oral albuterol.\" Chest 102 (1992): 786-9[15] \"Product Information. Brovana (arformoterol).\" Sepracor Inc, Marlborough, MA.[16] \"Interactions between methyl xanthines and beta adrenergic agonists.\" FDA Drug Bull 11 (1981): 19-20[17] Chow OK, Fung KP \"Slow-release terbutaline and theophylline for the long-term therapy of children with asthma: a Latin square and factorial study of drug effects and interactions.\" Pediatrics 84 (1989): 119-25[18] Hemstreet MP, Miles MV, Rutland RO \"Effect of intravenous isoproterenol on theophylline kinetics.\" J Allergy Clin Immunol 69 (1982): 360-4[19] Upton RA \"Pharmacokinetic interactions between theophylline and other medication (Part I).\" Clin Pharmacokinet 20 (1991): 66-80[20] Rachelefsky GS, Katz RM, Mickey MR Jr, Siegel SC \"Metaproterenol and theophylline in asthmatic children.\" Ann Allergy 45 (1980): 207-12[21] Josephson GW, Kennedy HL, MacKenzie EJ, Gibson G \"Cardiac dysrhythmias during the treatment of acute asthma. A comparison of two treatment regimens by a double blind protocol.\" Chest 78 (1980): 429-35[22] Dawson KP, Fergusson DM \"Effects of oral theophylline and oral salbutamol in the treatment of asthma.\" Arch Dis Child 57 (1982): 674-6[23] Jonkman JH, Borgstrom L, van der Boon WJ, de Noord OE \"Theophylline-terbutaline, a steady state study on possible pharmacokinetic interactions with special reference to chronopharmacokinetic aspects.\" Br J Clin Pharmacol 26 (1988): 285-93[24] Deenstra M, Haalboom JR, Struyvenberg A \"Decrease of plasma potassium due to inhalation of beta-2 agonists: absence of an additional effect of intravenous theophylline.\" Eur J Clin Invest 18 (1988): 162-5[25] \"Product Information. Arcapta Neohaler (indacaterol).\" Novartis Pharmaceuticals, East Hanover, NJ.[26] Lombardi TP, Bertino JS, Goldberg A, Middleton E, Slaughter RL \"The effects of a beta-2 selective adrenergic agonist and a beta- nonselective antagonist on theophylline clearance.\" J Clin Pharmacol 27 (1987): 523-9", "alternatives_a": "Omalizumab, Tezepelumab, Mercaptopurine, Benralizumab, Caffeine, Reslizumab, Montelukast, Mepolizumab, Roflumilast, Pentoxifylline, Zafirlukast, Bromotheophylline", "alternatives_b": "Dobutamine, Norepinephrine, Midodrine, Amrinone, Droxidopa, Angiotensin II, Milrinone, Arbutamine, Phenylephrine, Fenoldopam, Metaraminol, More", "updated_at": 1767369485}, {"id": 97397, "ingredient1": "Theophylline", "ingredient2": "Ixekizumab", "severity": "Moderate", "effect": "Plasma concentrations of drugs that are CYP450 substrates may decrease following the initiation of interleukin (IL) inhibitors, tumor necrosis factor (TNF) blockers, or interferon (IFN) inhibitors in patients with chronic inflammatory diseases. Because the formation of hepatic CYP450 enzymes is down-regulated during infection and chronic inflammation by increased levels of certain cytokines (e.g., interleukins-1, -6, and -10; tumor necrosis factor alpha; interferons), treatment targeting these cytokines may restore or normalize CYP450 enzyme levels resulting in increased metabolism of these drugs.", "source": "DDInter", "management_text": "Caution is advised when treatments targeting cytokines such as interleukins, tumor necrosis factors, or interferons are prescribed to patients receiving concomitant drugs that are CYP450 substrates, particularly those with narrow therapeutic ranges (e.g., antiarrhythmics, anticonvulsants, immunosuppressants, theophylline) or sensitive substrates where decreases in plasma levels may be significant or undesirable (e.g., oral contraceptives, statins, benzodiazepines, opioids). Clinical and/or laboratory monitoring should be considered following the initiation or withdrawal of such treatments, and the dosage(s) of the CYP450 substrate(s) adjusted accordingly. The effects of IL inhibitors, TNF blockers, and IFN inhibitors on CYP450 activities may persist for several weeks after stopping therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when treatments targeting cytokines such as interleukins, tumor necrosis factors, or interferons are prescribed to patients receiving concomitant drugs that are CYP450 substrates, particularly those with narrow therapeutic ranges (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97501/", "reference_text": "[1] \"Product Information. Skyrizi (risankizumab).\" AbbVie US LLC, North Chicago, IL.[2] \"Product Information. Cosentyx (secukinumab).\" Novartis Pharmaceuticals, East Hanover, NJ.[3] \"Product Information. Ilaris (canakinumab).\" Novartis Pharmaceuticals, East Hanover, NJ.[4] \"Product Information. Gamifant (emapalumab).\" Sobi Inc, Ardmore, PA.[5] \"Product Information. Kevzara (sarilumab).\" sanofi-aventis, Bridgewater, NJ.[6] \"Product Information. Simponi (golimumab).\" Centocor Inc, Malvern, PA.[7] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[8] \"Product Information. Sylvant (siltuximab).\" Janssen Biotech, Inc., Horsham, PA, PA.[9] \"Product Information. Stelara (ustekinumab).\" Centocor Inc, Malvern, PA.[10] \"Product Information. Ilumya (tildrakizumab).\" Merck & Company Inc, Whitehouse Station, NJ.[11] \"Product Information. Actemra (tocilizumab).\" Genentech, South San Francisco, CA.[12] \"Product Information. Amevive (alefacept).\" Biogen, Cambridge, MA.[13] \"Product Information. Remicade (infliximab).\" Centocor Inc, Malvern, PA.[14] \"Product Information. Taltz Autoinjector (ixekizumab).\" Eli Lilly and Company, Indianapolis, IN.[15] \"Product Information. Arcalyst (rilonacept).\" Regeneron Pharmaceuticals Inc, Tarrytown, NY.[16] Ace LN, Jaffe JM, Kunka RL \"Effect of food and an antacid on quinidine bioavailability.\" Biopharm Drug Dispos 4 (1983): 183-90[17] Min DI, Ku YM, Geraets DR, Lee HC \"Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers.\" J Clin Pharmacol 36 (1996): 469-76[18] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[19] Ha HR, Chen J, Leuenberger PM, Freiburghaus AU, Follah F \"In vitro inhibition of midazolam and quinidine metabolism by flavonoids.\" Eur J Clin Pharmacol 48 (1995): 367-71", "alternatives_a": "Omalizumab, Tezepelumab, Mercaptopurine, Benralizumab, Caffeine, Reslizumab, Montelukast, Dyphylline, Mepolizumab, Pentoxifylline, Zafirlukast, Bromotheophylline", "alternatives_b": "Cyclosporine, Antithymocyte immunoglobulin (rabbit), Anifrolumab, Ravulizumab, Diroximel fumarate, Abatacept, Upadacitinib, Siponimod, Apremilast, Inebilizumab, Cladribine, More", "updated_at": 1767369485}, {"id": 97398, "ingredient1": "Theophylline", "ingredient2": "Ketamine", "severity": "Moderate", "effect": "Cases of extensor-type seizures have been reported in four asthmatic patients who received aminophylline following induction of anesthesia with ketamine. Causality was not clearly determined due to the presence of other anesthetics. Animal studies suggest that the mechanism of this interaction may involve a lowering of the seizure threshold. Theophylline, dyphylline, and oxtriphylline may also interact.", "source": "DDInter", "management_text": "If aminophylline and ketamine must be used concomitantly, caution should be exercised.", "mechanism_text": "Others", "recommendation": "If aminophylline and ketamine must be used concomitantly, caution should be exercised.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97502/", "reference_text": "[1] Hirshman CA, Krieger W, Littlejohn G, Lee R, Julien R \"Ketamine-aminophylline-induced decrease in seizure threshold.\" Anesthesiology 56 (1982): 464-7[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] \"Product Information. Ketalar (ketamine).\" JHP Pharmaceuticals, Saddle River, NJ.[4] Peltoniemi MA, Saari TI, Hagelberg NM, Laine K, Neuvonen PJ, Olkkola KT \"S-ketamine concentrations are greatly increased by grapefruit juice.\" Eur J Clin Pharmacol 68 (2012): 979-86[5] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0", "alternatives_a": "Omalizumab, Tezepelumab, Mercaptopurine, Benralizumab, Caffeine, Reslizumab, Montelukast, Mepolizumab, Roflumilast, Pentoxifylline, Zafirlukast, Bromotheophylline", "alternatives_b": "Alfentanil, Remifentanil, Sodium oxybate, Isoflurane, Nitrous oxide, Desflurane, Sufentanil, Enflurane, Esketamine, Sevoflurane, Etomidate", "updated_at": 1767369485}, {"id": 97399, "ingredient1": "Theophylline", "ingredient2": "Ketoconazole", "severity": "Minor", "effect": "Coadministration of ketoconazole with a slow-release preparation of theophylline has been reported to decrease serum theophylline concentration. The mechanism may be related to decreased absorption. Ketoconazole has not been shown to interfere with the pharmacokinetics of intravenous theophylline. Theophylline dosages should be adjusted if necessary. Patients should be monitored for altered efficacy of theophylline if ketoconazole is added to their regimen.", "source": "DDInter", "management_text": "-", "mechanism_text": "Absorption", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97503/", "reference_text": "[1] Brown MW, Maldonado AL, Meredith CG, Speeg KV \"Effect of ketoconazole on hepatic oxidative drug metabolism.\" Clin Pharmacol Ther 37 (1985): 290-7[2] Heusner JJ, Dukes GE, Rollins DE, et al \"Effect of chronically administered ketoconazole on the elimination of theophylline in man.\" Drug Intell Clin Pharm 21 (1987): 514-7", "alternatives_a": "Omalizumab, Tezepelumab, Mercaptopurine, Benralizumab, Caffeine, Reslizumab, Dyphylline, Mepolizumab, Pentoxifylline, Zafirlukast, Bromotheophylline", "alternatives_b": "Tinidazole, Ascorbic acid, Hydroflumethiazide, Chlorothiazide, Simeprevir, Rosuvastatin, Sulfadiazine, Lactic acid, Mitapivat, Methazolamide, Clindamycin, More", "updated_at": 1767369485}, {"id": 97400, "ingredient1": "Theophylline", "ingredient2": "Labetalol", "severity": "Major", "effect": "The pharmacologic effects of theophyllines and beta-blockers are opposite. Nonselective and high doses of cardioselective beta-blockers may cause severe or fatal bronchospasm by opposing theophylline-induced bronchodilation. Ophthalmic beta-blockers undergo significant systemic absorption and may also interact. In addition, propranolol and other beta-blockers may reduce the CYP450 hepatic metabolism of theophylline, and serum theophylline levels may be increased.", "source": "DDInter", "management_text": "Oral and ophthalmic nonselective beta-blockers (e.g., carteolol, carvedilol, levobunolol, metipranolol, nadolol, oxprenolol, penbutolol, pindolol, propranolol, sotalol, and timolol) are considered contraindicated in patients with bronchospastic diseases. Cardioselective beta-blockers should generally be avoided, or used with extreme caution if no other alternatives are available and the benefits outweigh the risks of potentially severe bronchospasm. If patients do receive this combination, they should be closely monitored for increased serum theophylline levels but decreased bronchodilatory effectiveness.", "mechanism_text": "Antagonism", "recommendation": "Oral and ophthalmic nonselective beta-blockers (e.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97504/", "reference_text": "[1] Upton RA \"Pharmacokinetic interactions between theophylline and other medication (Part II).\" Clin Pharmacokinet 20 (1991): 135-50[2] Mue S, Sasaki T, Shibahara S, et alT \"Influence of metoprolol on hemodynamics and respiratory function in asthmatic patients.\" Int J Clin Pharmacol Biopharm 17 (1979): 346-50[3] Lombardi TP, Bertino JS, Goldberg A, Middleton E, Slaughter RL \"The effects of a beta-2 selective adrenergic agonist and a beta- nonselective antagonist on theophylline clearance.\" J Clin Pharmacol 27 (1987): 523-9[4] Horvath JS, Woolcock AJ, Tiller DJ, Donnelly P, Armstrong J, Caterson R \"A comparison of metoprolol and propranolol on blood pressure and respiratory function in patients with hypertension.\" Aust N Z J Med 8 (1978): 1-6[5] Conrad KA, Nyman DW \"Effects of metoprolol and propranolol on theophylline elimination.\" Clin Pharmacol Ther 28 (1980): 463-7", "alternatives_a": "Omalizumab, Tezepelumab, Mercaptopurine, Benralizumab, Caffeine, Reslizumab, Montelukast, Mepolizumab, Roflumilast, Zafirlukast, Bromotheophylline", "alternatives_b": "", "updated_at": 1767369485}, {"id": 97401, "ingredient1": "Theophylline", "ingredient2": "Lansoprazole", "severity": "Minor", "effect": "Lansoprazole may cause a minor decrease in the area under the plasma concentration-time curve of theophylline and related drugs. This effect appears to be small (approximately a 13% decrease in one study) and may be related either to a reduction in absorption or to enhanced clearance caused by induction of hepatic enzymes by lansoprazole. Dosage adjustment is not believed to be necessary. However, close observation for evidence of altered methylxanthine effect is recommended.", "source": "DDInter", "management_text": "-", "mechanism_text": "Metabolism", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97505/", "reference_text": "[1] Kokufu T, Ihara N, Sugioka N, Koyama H, Ohta T, Mori S, Nakajima K \"Effects of lansoprazole on pharmacokinetics and metabolism of theophylline.\" Eur J Clin Pharmacol 48 (1995): 391-5[2] Granneman GR, Karol MD, Locke CS \"Pharmacokinetic interaction between lansoprazole and theophylline.\" Ther Drug Monit 17 (1995): 460-4[3] Ko JW, Jang IJ, Shin JG, Nam SK, Shin SG, Flockhart DA \"Theophylline pharmacokinetics are not altered by lansoprazole in CYP2C19 poor metabolizers.\" Clin Pharmacol Ther 65 (1999): 606-14[4] \"Product Information. Prevacid (lansoprazole).\" TAP Pharmaceuticals Inc, Deerfield, IL.", "alternatives_a": "Omalizumab, Tezepelumab, Benralizumab, Caffeine, Reslizumab, Dyphylline, Mepolizumab, Roflumilast, Bromotheophylline", "alternatives_b": "Tinidazole, Levofloxacin, Dexlansoprazole, Misoprostol, Bismuth subcitrate potassium, Rifabutin, Vonoprazan, Amoxicillin", "updated_at": 1767369485}, {"id": 97402, "ingredient1": "Theophylline", "ingredient2": "Larotrectinib", "severity": "Moderate", "effect": "Coadministration with larotrectinib may increase the plasma concentrations of drugs that are substrates of the CYP450 3A4 isoenzyme.", "source": "DDInter", "management_text": "Caution is advised when larotrectinib is used concomitantly with drugs that are substrates of CYP450 3A4, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever larotrectinib is added to or withdrawn from therapy. Patients should be monitored for the development of adverse effects. Some authorities recommend avoiding concomitant use of larotrectinib and sensitive CYP450 3A4 substrates or substrates with narrow therapeutic ranges. These drugs include, but are not limited to: alfentanil, cisapride, colchicine, cyclosporine, fentanyl, ivacaftor, lovastatin, simvastatin, oral midazolam, triazolam, pimozide, quinidine, sildenafil, ergot derivatives, macrolide immunosuppressants, and vinca alkaloids.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when larotrectinib is used concomitantly with drugs that are substrates of CYP450 3A4, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97506/", "reference_text": "[1] \"Product Information. Vitrakvi (larotrectinib).\" Bayer Pharmaceutical Inc, West Haven, CT.[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] \"Product Information. Vitrakvi (larotrectinib).\" Bayer Pharmaceutical Inc, West Haven, CT.", "alternatives_a": "Omalizumab, Tezepelumab, Mercaptopurine, Aminophylline, Benralizumab, Caffeine, Reslizumab, Dyphylline, Oxtriphylline, Mepolizumab, Roflumilast, More", "alternatives_b": "Entrectinib, Imatinib, Dabrafenib, Asciminib, Acalabrutinib, Dacomitinib, Pexidartinib, Tepotinib, Fedratinib, Avapritinib, Bosutinib, More", "updated_at": 1767369485}, {"id": 97403, "ingredient1": "Theophylline", "ingredient2": "Lefamulin", "severity": "Moderate", "effect": "When administered orally, lefamulin may increase the plasma concentrations of drugs that are primarily metabolized by CYP450 3A4. Based on interaction with midazolam, a sensitive CYP450 3A4 substrate, lefamulin may be a moderate CYP450 3A4 inhibitor. When oral midazolam was administered concomitantly with and at 2 or 4 hours after administration of lefamulin tablets, mean midazolam peak plasma concentration (Cmax) and systemic exposure (AUC) increased by approximately 100% and 200%, respectively.", "source": "DDInter", "management_text": "Caution is advised when oral lefamulin is used with drugs that undergo metabolism via CYP450 3A4, particularly sensitive CYP450 3A4 substrates or those that demonstrate a narrow therapeutic index (e.g., ergot alkaloids, colchicine, fentanyl, macrolide immunosuppressants, midazolam, triazolam, vardenafil, vinca alkaloids). Dosage adjustments as well as clinical and laboratory monitoring may be appropriate whenever oral lefamulin is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when oral lefamulin is used with drugs that undergo metabolism via CYP450 3A4, particularly sensitive CYP450 3A4 substrates or those that demonstrate a narrow therapeutic index (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97507/", "reference_text": "[1] \"Product Information. Xenleta (lefamulin).\" Nabriva Therapeutics US, Inc., King of Prussia, PA.[2] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[3] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[4] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[5] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[6] \"Product Information. Xenleta (lefamulin).\" Nabriva Therapeutics US, Inc., King of Prussia, PA.", "alternatives_a": "Omalizumab, Tezepelumab, Mercaptopurine, Aminophylline, Benralizumab, Caffeine, Reslizumab, Dyphylline, Oxtriphylline, Mepolizumab, Pentoxifylline, Bromotheophylline", "alternatives_b": "Tinidazole, Linezolid, Bacitracin, Oritavancin, Polymyxin B, Daptomycin, Vancomycin, Telavancin, Methenamine, Spectinomycin, Nitrofurantoin, More", "updated_at": 1767369485}, {"id": 97404, "ingredient1": "Theophylline", "ingredient2": "Levosalbutamol", "severity": "Moderate", "effect": "Concomitant use of beta-2 adrenergic agonists with theophylline may increase the risk and/or severity of hypokalemia and adverse cardiovascular effects such as palpitation, tachycardia, and blood pressure elevation. Adverse events, especially hypokalemia, may be more likely with systemic or nebulized formulations of beta-2 agonists or high dosages of theophylline. Beta-2 agonists can cause clinically significant but usually transient decreases in serum potassium concentrations, while hypokalemia associated with theophylline often occurs in toxicity. Pharmacokinetically, some beta-2 agonists given systemically may decrease the plasma concentrations of theophylline.", "source": "DDInter", "management_text": "Although theophylline and beta-2 agonists are commonly used together to produce bronchodilation, it may be appropriate to monitor patient response as well as serum potassium level, blood pressure and heart rate during coadministration, especially if the beta-2 agonist is administered systemically or by nebulizer. Close monitoring is particularly important in patients with severe asthma, since the potential increases in blood pressure and heart rate may have more serious consequences in the presence of hypoxemia or hypercapnia due to increased myocardial oxygen consumption. Patients should be advised to notify their physician if they experience worsening of their respiratory condition or potential signs and symptoms of hypokalemia such as fatigue, weakness, myalgia, muscle cramps, numbness, tingling, abdominal pain, constipation, palpitation, and irregular heartbeat.", "mechanism_text": "Synergism", "recommendation": "Although theophylline and beta-2 agonists are commonly used together to produce bronchodilation, it may be appropriate to monitor patient response as well as serum potassium level, blood pressure and heart rate during coadministration, especially if the beta-2 agonist is administered systemically or by nebulizer.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97508/", "reference_text": "[1] Garty M, Paul-Keslin L, Ilfeld DN, et al \"Increased theophylline clearance in asthmatic patients due to terbutaline.\" Eur J Clin Pharmacol 36 (1989): 25-8[2] Amirav I, Amitai Y, Avital A, Godfrey S \"Enhancement of theophylline clearance by intravenous albuterol.\" Chest 94 (1988): 444-5[3] \"Product Information. Striverdi Respimat (olodaterol).\" Boehringer Ingelheim, Ridgefield, CT.[4] Cusack BJ, Nielson CP, Morgan ME, Vestal RE \"Additive effect of theophylline on the cardiac response to isoproterenol.\" Clin Pharmacol Ther 41 (1987): 289-96[5] Griffith JA, Kozloski GD \"Isoproterenol-theophylline interaction: possible potentiation by other drugs.\" Clin Pharm 9 (1990): 54-7[6] Conrad KA, Woodworth JR \"Orciprenaline does not alter theophylline elimination.\" Br J Clin Pharmacol 12 (1981): 756-7[7] Flatt A, Burgess C, Windom H, Beasley R, Purdie G, Crane J \"The cardiovascular effects of inhaled fenoterol alone and during treatment with oral theophylline.\" Chest 96 (1989): 1317-20[8] Smith SR, Kendall MJ \"Potentiation of the adverse effects of intravenous terbutaline by oral theophylline.\" Br J Clin Pharmacol 21 (1986): 451-3[9] Danzinger Y, Garty M, Volwitz B, Ilfeld D, Varsano I, Rosenfeld JB \"Reduction of serum theophylline levels by terbutaline in children with asthma.\" Clin Pharmacol Ther 37 (1985): 469-71[10] O'Rourke PP, Crone RK \"Effect of isoproterenol on measured theophylline levels.\" Crit Care Med 12 (1984): 373-5[11] Whyte KF, Reid C, Addis GJ, Whitesmith R, Reid JL \"Salbutamol induced hypokalaemia: the effect of theophylline alone and in combination with adrenaline.\" Br J Clin Pharmacol 25 (1988): 571-8[12] Coleman JJ, Vollmer WM, Barker AF, et al \"Cardiac arrhythmias during the combined use of beta-adrenergic agonist drugs and theophylline.\" Chest 90 (1986): 45-51[13] Kelly HW \"Controversies in asthma therapy with theophylline and the beta2-adrenergic agonists.\" Clin Pharm 3 (1984): 386-95[14] Amitai Y, Glustein J, Godfrey S \"Enhancement of theophylline clearance by oral albuterol.\" Chest 102 (1992): 786-9[15] \"Product Information. Brovana (arformoterol).\" Sepracor Inc, Marlborough, MA.[16] \"Interactions between methyl xanthines and beta adrenergic agonists.\" FDA Drug Bull 11 (1981): 19-20[17] Chow OK, Fung KP \"Slow-release terbutaline and theophylline for the long-term therapy of children with asthma: a Latin square and factorial study of drug effects and interactions.\" Pediatrics 84 (1989): 119-25[18] Hemstreet MP, Miles MV, Rutland RO \"Effect of intravenous isoproterenol on theophylline kinetics.\" J Allergy Clin Immunol 69 (1982): 360-4[19] Upton RA \"Pharmacokinetic interactions between theophylline and other medication (Part I).\" Clin Pharmacokinet 20 (1991): 66-80[20] Rachelefsky GS, Katz RM, Mickey MR Jr, Siegel SC \"Metaproterenol and theophylline in asthmatic children.\" Ann Allergy 45 (1980): 207-12[21] Josephson GW, Kennedy HL, MacKenzie EJ, Gibson G \"Cardiac dysrhythmias during the treatment of acute asthma. A comparison of two treatment regimens by a double blind protocol.\" Chest 78 (1980): 429-35[22] Dawson KP, Fergusson DM \"Effects of oral theophylline and oral salbutamol in the treatment of asthma.\" Arch Dis Child 57 (1982): 674-6[23] Jonkman JH, Borgstrom L, van der Boon WJ, de Noord OE \"Theophylline-terbutaline, a steady state study on possible pharmacokinetic interactions with special reference to chronopharmacokinetic aspects.\" Br J Clin Pharmacol 26 (1988): 285-93[24] Deenstra M, Haalboom JR, Struyvenberg A \"Decrease of plasma potassium due to inhalation of beta-2 agonists: absence of an additional effect of intravenous theophylline.\" Eur J Clin Invest 18 (1988): 162-5[25] \"Product Information. Arcapta Neohaler (indacaterol).\" Novartis Pharmaceuticals, East Hanover, NJ.[26] Lombardi TP, Bertino JS, Goldberg A, Middleton E, Slaughter RL \"The effects of a beta-2 selective adrenergic agonist and a beta- nonselective antagonist on theophylline clearance.\" J Clin Pharmacol 27 (1987): 523-9", "alternatives_a": "Omalizumab, Tezepelumab, Mercaptopurine, Benralizumab, Caffeine, Reslizumab, Montelukast, Mepolizumab, Roflumilast, Pentoxifylline, Zafirlukast, Bromotheophylline", "alternatives_b": "", "updated_at": 1767369485}, {"id": 97405, "ingredient1": "Theophylline", "ingredient2": "Levobetaxolol (ophthalmic)", "severity": "Major", "effect": "The pharmacologic effects of theophyllines and beta-blockers are opposite. Nonselective and high doses of cardioselective beta-blockers may cause severe or fatal bronchospasm by opposing theophylline-induced bronchodilation. Ophthalmic beta-blockers undergo significant systemic absorption and may also interact. In addition, propranolol and other beta-blockers may reduce the CYP450 hepatic metabolism of theophylline, and serum theophylline levels may be increased.", "source": "DDInter", "management_text": "Oral and ophthalmic nonselective beta-blockers (e.g., carteolol, carvedilol, levobunolol, metipranolol, nadolol, oxprenolol, penbutolol, pindolol, propranolol, sotalol, and timolol) are considered contraindicated in patients with bronchospastic diseases. Cardioselective beta-blockers should generally be avoided, or used with extreme caution if no other alternatives are available and the benefits outweigh the risks of potentially severe bronchospasm. If patients do receive this combination, they should be closely monitored for increased serum theophylline levels but decreased bronchodilatory effectiveness.", "mechanism_text": "Antagonism", "recommendation": "Oral and ophthalmic nonselective beta-blockers (e.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97509/", "reference_text": "[1] Upton RA \"Pharmacokinetic interactions between theophylline and other medication (Part II).\" Clin Pharmacokinet 20 (1991): 135-50[2] Mue S, Sasaki T, Shibahara S, et alT \"Influence of metoprolol on hemodynamics and respiratory function in asthmatic patients.\" Int J Clin Pharmacol Biopharm 17 (1979): 346-50[3] Lombardi TP, Bertino JS, Goldberg A, Middleton E, Slaughter RL \"The effects of a beta-2 selective adrenergic agonist and a beta- nonselective antagonist on theophylline clearance.\" J Clin Pharmacol 27 (1987): 523-9[4] Horvath JS, Woolcock AJ, Tiller DJ, Donnelly P, Armstrong J, Caterson R \"A comparison of metoprolol and propranolol on blood pressure and respiratory function in patients with hypertension.\" Aust N Z J Med 8 (1978): 1-6[5] Conrad KA, Nyman DW \"Effects of metoprolol and propranolol on theophylline elimination.\" Clin Pharmacol Ther 28 (1980): 463-7", "alternatives_a": "Omalizumab, Tezepelumab, Mercaptopurine, Benralizumab, Caffeine, Reslizumab, Montelukast, Mepolizumab, Roflumilast, Pentoxifylline, Zafirlukast, Bromotheophylline", "alternatives_b": "", "updated_at": 1767369485}, {"id": 97406, "ingredient1": "Theophylline", "ingredient2": "Levobunolol (ophthalmic)", "severity": "Major", "effect": "The pharmacologic effects of theophyllines and beta-blockers are opposite. Nonselective and high doses of cardioselective beta-blockers may cause severe or fatal bronchospasm by opposing theophylline-induced bronchodilation. Ophthalmic beta-blockers undergo significant systemic absorption and may also interact. In addition, propranolol and other beta-blockers may reduce the CYP450 hepatic metabolism of theophylline, and serum theophylline levels may be increased.", "source": "DDInter", "management_text": "Oral and ophthalmic nonselective beta-blockers (e.g., carteolol, carvedilol, levobunolol, metipranolol, nadolol, oxprenolol, penbutolol, pindolol, propranolol, sotalol, and timolol) are considered contraindicated in patients with bronchospastic diseases. Cardioselective beta-blockers should generally be avoided, or used with extreme caution if no other alternatives are available and the benefits outweigh the risks of potentially severe bronchospasm. If patients do receive this combination, they should be closely monitored for increased serum theophylline levels but decreased bronchodilatory effectiveness.", "mechanism_text": "Antagonism", "recommendation": "Oral and ophthalmic nonselective beta-blockers (e.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97510/", "reference_text": "[1] Upton RA \"Pharmacokinetic interactions between theophylline and other medication (Part II).\" Clin Pharmacokinet 20 (1991): 135-50[2] Mue S, Sasaki T, Shibahara S, et alT \"Influence of metoprolol on hemodynamics and respiratory function in asthmatic patients.\" Int J Clin Pharmacol Biopharm 17 (1979): 346-50[3] Lombardi TP, Bertino JS, Goldberg A, Middleton E, Slaughter RL \"The effects of a beta-2 selective adrenergic agonist and a beta- nonselective antagonist on theophylline clearance.\" J Clin Pharmacol 27 (1987): 523-9[4] Horvath JS, Woolcock AJ, Tiller DJ, Donnelly P, Armstrong J, Caterson R \"A comparison of metoprolol and propranolol on blood pressure and respiratory function in patients with hypertension.\" Aust N Z J Med 8 (1978): 1-6[5] Conrad KA, Nyman DW \"Effects of metoprolol and propranolol on theophylline elimination.\" Clin Pharmacol Ther 28 (1980): 463-7", "alternatives_a": "Omalizumab, Tezepelumab, Mercaptopurine, Benralizumab, Caffeine, Reslizumab, Montelukast, Mepolizumab, Roflumilast, Pentoxifylline, Zafirlukast, Bromotheophylline", "alternatives_b": "Apraclonidine, Methazolamide, Neostigmine, Pilocarpine, Physostigmine, Acetylcholine, Diclofenamide, Bimatoprost, Travoprost, Acetazolamide, Brinzolamide, More", "updated_at": 1767369485}, {"id": 97407, "ingredient1": "Theophylline", "ingredient2": "Levocetirizine", "severity": "Minor", "effect": "Coadministration with theophylline may decrease the clearance of cetirizine. The mechanism of interaction is unknown.", "source": "DDInter", "management_text": "-", "mechanism_text": "Metabolism", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97511/", "reference_text": "[1] \"Product Information. Zyrtec (cetirizine).\" Pfizer US Pharmaceuticals, New York, NY.[2] Sato J, Nakata H, Owada E, Kikuta T, Umetsu M, Ito K \"Influence of usual intake of dietary caffeine on single-dose kinetics of theophylline in healthy human subjects.\" Eur J Clin Pharmacol 44 (1993): 295-8[3] Jonkman JH, Sollie FA, Sauter R, Steinijans VW \"The influence of caffeine on the steady-state pharmacokinetics of theophylline.\" Clin Pharmacol Ther 49 (1991): 248-55[4] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[5] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[6] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[7] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[8] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.", "alternatives_a": "Omalizumab, Tezepelumab, Mercaptopurine, Aminophylline, Benralizumab, Caffeine, Reslizumab, Montelukast, Dyphylline, Oxtriphylline, Mepolizumab, More", "alternatives_b": "Mepyramine, Chlorcyclizine, Acrivastine, Triprolidine, Tripelennamine, Azelastine, Dexbrompheniramine, Clemastine, Doxylamine, Meclizine, Cyclizine, More", "updated_at": 1767369485}, {"id": 97408, "ingredient1": "Theophylline", "ingredient2": "Levonorgestrel", "severity": "Moderate", "effect": "The coadministration with contraceptive steroids may increase the plasma concentrations of theophylline and other methylxanthines. The proposed mechanism is inhibition of methylxanthine metabolism via hepatic microsomal enzymes, of which estrogens and progestins are also substrates.", "source": "DDInter", "management_text": "Caution is advised during concomitant therapy with methylxanthines and hormonal contraceptives. Serum theophylline levels and pharmacologic response should be monitored and the dosage adjusted accordingly, particularly following initiation or discontinuation of hormonal contraceptives in patients who are stabilized on their theophylline regimen. Patients should be advised to notify their physician if they experience signs and symptoms of theophylline toxicity such as nausea, vomiting, diarrhea, headache, restlessness, insomnia, and irregular heartbeat.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised during concomitant therapy with methylxanthines and hormonal contraceptives.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97512/", "reference_text": "[1] Gardner MJ, Tornatore KM, Jusko WJ, Kanarkowski R \"Effects of tobacco smoking and oral contraceptive use on theophylline disposition.\" Br J Clin Pharmacol 16 (1983): 271-80[2] Tornatore KM, Kanarkowski R, McCarthy TL, et al \"Effect of chronic oral contraceptive steroids on theophylline disposition.\" Eur J Clin Pharmacol 23 (1982): 129-34[3] Roberts RK, Grice J, McGuffie, Heilbronn L \"Oral contraceptive steroids impair the elimination of theophylline.\" J Lab Clin Med 101 (1983): 821-25[4] Gunston GD, Mehta U \"Potentially serious drug interactions with grapefruit juice.\" S Afr Med J 90 (2000): 41[5] Bailey DG, Arnold JMO, Spence JD \"Grapefruit juice and drugs - how significant is the interaction.\" Clin Pharmacokinet 26 (1994): 91-8[6] Fuhr U, Maier-Bruggemann A, Blume H, et al. \"Grapefruit juice increases oral nimodipine bioavailability.\" Int J Clin Pharmacol Ther 36 (1998): 126-32[7] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[8] Libersa CC, Brique SA, Motte KB, et al. \"Dramatic inhibition of amiodarone metabolism induced by grapefruit juice.\" Br J Clin Pharmacol 49 (2000): 373-8[9] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions.\" Br J Clin Pharmacol 46 (1998): 101-10[10] Bailey DG, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit juice felodipine interaction: Effect of naringin and 6',7'-dihydroxybergamottin in humans.\" Clin Pharmacol Ther 64 (1998): 248-56[11] Takanaga H, Ohnishi A, Maatsuo H, et al. \"Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model.\" Br J Clin Pharmacol 49 (2000): 49-58[12] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[13] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS \"Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice.\" Br J Clin Pharmacol 42 (1996): p662[14] Eagling VA, Profit L, Back DJ \"Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-I protease inhibitor saquinavir by grapefruit juice components.\" Br J Clin Pharmacol 48 (1999): 543-52[15] Bailey DG, Arnold JM, Strong HA, Munoz C, Spence JD \"Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics.\" Clin Pharmacol Ther 54 (1993): 589-94[16] Damkier P, Hansen LL, Brosen K \"Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine.\" Br J Clin Pharmacol 48 (1999): 829-38[17] Min DI, Ku YM, Geraets DR, Lee HC \"Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers.\" J Clin Pharmacol 36 (1996): 469-76[18] Josefsson M, Zackrisson AL, Ahlner J \"Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers.\" Eur J Clin Pharmacol 51 (1996): 189-93[19] Majeed A, Kareem A \"Effect of grapefruit juice on cyclosporine pharmacokinetics.\" Pediatr Nephrol 10 (1996): 395[20] Flanagan D \"Understanding the grapefruit-drug interaction.\" Gen Dent 53 (2005): 282-5; quiz 286[21] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ \"Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice.\" Clin Pharmacol Ther 58 (1995): 127-31[22] Jonkman JH, Sollie FA, Sauter R, Steinijans VW \"The influence of caffeine on the steady-state pharmacokinetics of theophylline.\" Clin Pharmacol Ther 49 (1991): 248-55[23] Ozdemir M, Aktan Y, Boydag BS, Cingi MI, Musmul A \"Interaction between grapefruit juice and diazepam in humans.\" Eur J Drug Metab Pharmacokinet 23 (1998): 55-9[24] Edgar B, Bailey D, Bergstrand R, et al \"Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics on felodipine and its potential clinical relevance.\" Eur J Clin Pharmacol 42 (1992): 313-7[25] Kantola T, Kivisto KT, Neuvonen PJ \"Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid.\" Clin Pharmacol Ther 63 (1998): 397-402[26] Lee AJ, Chan WK, Harralson AF, Buffum J, Bui BCC \"The effects of grapefruit juice on sertraline metabolism: An in vitro and in vivo study.\" Clin Ther 21 (1999): 1890-9[27] Sato J, Nakata H, Owada E, Kikuta T, Umetsu M, Ito K \"Influence of usual intake of dietary caffeine on single-dose kinetics of theophylline in healthy human subjects.\" Eur J Clin Pharmacol 44 (1993): 295-8[28] Dresser GK, Spence JD, Bailey DG \"Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition.\" Clin Pharmacokinet 38 (2000): 41-57[29] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin.\" Clin Pharmacol Ther 66 (1999): 118-27[30] Sigusch H, Hippius M, Henschel L, Kaufmann K, Hoffmann A \"Influence of grapefruit juice on the pharmacokinetics of a slow release nifedipine formulation.\" Pharmazie 49 (1994): 522-4[31] Bailey DG, Arnold JM, Munoz C, Spence JD \"Grapefruit juice--felodipine interaction: mechanism, predictability, and effect of naringin.\" Clin Pharmacol Ther 53 (1993): 637-42[32] Zaidenstein R, Soback S, Gips M, Avni B, Dishi V, Weissgarten Y, Golik A, Scapa E \"Effect of grapefruit juice on the pharmacokinetics of losartan and its active metabolite E3174 in healthy volunteers.\" Ther Drug Monit 23 (2001): 369-73[33] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84[34] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors.\" Clin Pharmacol Ther 64 (1998): 477-83[35] Garg SK, Kumar N, Bhargava VK, Prabhakar SK \"Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy.\" Clin Pharmacol Ther 64 (1998): 286-8", "alternatives_a": "Omalizumab, Tezepelumab, Mercaptopurine, Benralizumab, Caffeine, Reslizumab, Dyphylline, Mepolizumab, Roflumilast, Pentoxifylline, Zafirlukast, Bromotheophylline", "alternatives_b": "Megestrol acetate, Ulipristal, Estetrol, Medroxyprogesterone acetate, Megestrol acetate, Progesterone, Medroxyprogesterone acetate", "updated_at": 1767369485}, {"id": 97409, "ingredient1": "Theophylline", "ingredient2": "Levothyroxine", "severity": "Moderate", "effect": "The metabolism of theophylline is directly related to thyroid function. Theophylline clearance is decreased in hypothyroid patients and increased in hyperthyroid patients. Toxicity or subtherapeutic levels may occur. Similar interactions may occur with other methylxanthines.", "source": "DDInter", "management_text": "When thyroid hormone dosage is instituted, discontinued, or changed, close observation for altered theophylline effect and serum concentrations is recommended. Patients should be advised to notify their physician if they experience a worsening of their respiratory symptoms, or any signs of theophylline toxicity including nausea, vomiting, diarrhea, headache, restlessness, insomnia, or irregular heartbeats.", "mechanism_text": "Others", "recommendation": "When thyroid hormone dosage is instituted, discontinued, or changed, close observation for altered theophylline effect and serum concentrations is recommended.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97513/", "reference_text": "[1] Bauman JH, Teichman S, Wible DA \"Increased theophylline clearance in a patient with hyperthyroidism.\" Ann Allergy 52 (1984): 94-6[2] Vozeh S, Otten M, Staub JJ, Follath F \"Influence of thyroid function on theophylline kinetics.\" Clin Pharmacol Ther 36 (1984): 634-40[3] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[4] \"Product Information. Armour thyroid (thyroid desiccated).\" Forest Pharmaceuticals, St. Louis, MO.[5] \"Product Information. Synthroid (levothyroxine).\" Abbott Pharmaceutical, Abbott Park, IL.", "alternatives_a": "Omalizumab, Tezepelumab, Benralizumab, Caffeine, Reslizumab, Dyphylline, Mepolizumab, Roflumilast, Bromotheophylline", "alternatives_b": "", "updated_at": 1767369485}, {"id": 97410, "ingredient1": "Theophylline", "ingredient2": "Lindane", "severity": "Moderate", "effect": "Lindane penetrates human skin and has the potential to cause central nervous system toxicity. Seizures have been reported after excessive use or oral ingestion of lindane. There may be a theoretical risk of increased seizure potential when lindane is used with selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), and/or any substance that can reduce the seizure threshold (e.g., carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, theophylline).", "source": "DDInter", "management_text": "Caution is advised if lindane is used with any substance that can reduce the seizure threshold, particularly in the very young or the elderly and in patients with epilepsy, a history of seizures, or other risk factors for seizures (e.g., head trauma, brain tumor, metabolic disorders, alcohol and drug withdrawal, CNS infections). Lindane should be used according to recommended dosage and directions for application.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if lindane is used with any substance that can reduce the seizure threshold, particularly in the very young or the elderly and in patients with epilepsy, a history of seizures, or other risk factors for seizures (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97514/", "reference_text": "[1] Cox R, Krupnick J, Bush N, Houpt A \"Seizures caused by concomitant use of lindane and dextroamphetamine in a child with attention deficit hyperactivity disorder.\" J Miss State Med Assoc 41 (2000): 690-2[2] Matsuoka LY \"Convulsions following application of gamma benzene hexachloride.\" J Am Acad Dermatol 5 (1981): 98-9[3] \"Product Information. Kwell (lindane).\" Reed and Carnrick, Jersey City, NJ.[4] Telch J, Jarvis DA \"Acute intoxication with lindane (gamma benzene hexachloride).\" Can Med Assoc J 126 (1982): 662-3[5] Pramanik AK, Hansen RC \"Transcutaneous gamma benzene hexachloride absorption and toxicity in infants and children.\" Arch Dermatol 115 (1979): 1224-5[6] Ramchander V, Cameron ES, Reid HF \"Lindane toxicity in an infant.\" West Indian Med J 40 (1991): 41-3[7] Tenenbein M \"Seizures after lindane therapy.\" J Am Geriatr Soc 39 (1991): 394-5[8] Solomon BA, Haut SR, Carr EM, Shalita AR \"Neurotoxic reaction to lindane in an HIV-seropositive patient: an old medication's new problem.\" J Fam Pract 40 (1995): 291-6[9] Munk ZM, Nantel A \"Acute lindane poisoning with development of muscle necrosis.\" Can Med Assoc J 117 (1977): 1050-4", "alternatives_a": "Omalizumab, Tezepelumab, Mercaptopurine, Benralizumab, Caffeine, Reslizumab, Montelukast, Dyphylline, Mepolizumab, Roflumilast, Pentoxifylline, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 97411, "ingredient1": "Theophylline", "ingredient2": "Liothyronine", "severity": "Moderate", "effect": "The metabolism of theophylline is directly related to thyroid function. Theophylline clearance is decreased in hypothyroid patients and increased in hyperthyroid patients. Toxicity or subtherapeutic levels may occur. Similar interactions may occur with other methylxanthines.", "source": "DDInter", "management_text": "When thyroid hormone dosage is instituted, discontinued, or changed, close observation for altered theophylline effect and serum concentrations is recommended. Patients should be advised to notify their physician if they experience a worsening of their respiratory symptoms, or any signs of theophylline toxicity including nausea, vomiting, diarrhea, headache, restlessness, insomnia, or irregular heartbeats.", "mechanism_text": "Others", "recommendation": "When thyroid hormone dosage is instituted, discontinued, or changed, close observation for altered theophylline effect and serum concentrations is recommended.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97515/", "reference_text": "[1] Bauman JH, Teichman S, Wible DA \"Increased theophylline clearance in a patient with hyperthyroidism.\" Ann Allergy 52 (1984): 94-6[2] Vozeh S, Otten M, Staub JJ, Follath F \"Influence of thyroid function on theophylline kinetics.\" Clin Pharmacol Ther 36 (1984): 634-40[3] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[4] \"Product Information. Armour thyroid (thyroid desiccated).\" Forest Pharmaceuticals, St. Louis, MO.[5] \"Product Information. Synthroid (levothyroxine).\" Abbott Pharmaceutical, Abbott Park, IL.", "alternatives_a": "Omalizumab, Tezepelumab, Mercaptopurine, Benralizumab, Caffeine, Reslizumab, Dyphylline, Mepolizumab, Roflumilast, Pentoxifylline, Zafirlukast, Bromotheophylline", "alternatives_b": "", "updated_at": 1767369485}, {"id": 97412, "ingredient1": "Theophylline", "ingredient2": "Liotrix", "severity": "Moderate", "effect": "The metabolism of theophylline is directly related to thyroid function. Theophylline clearance is decreased in hypothyroid patients and increased in hyperthyroid patients. Toxicity or subtherapeutic levels may occur. Similar interactions may occur with other methylxanthines.", "source": "DDInter", "management_text": "When thyroid hormone dosage is instituted, discontinued, or changed, close observation for altered theophylline effect and serum concentrations is recommended. Patients should be advised to notify their physician if they experience a worsening of their respiratory symptoms, or any signs of theophylline toxicity including nausea, vomiting, diarrhea, headache, restlessness, insomnia, or irregular heartbeats.", "mechanism_text": "Others", "recommendation": "When thyroid hormone dosage is instituted, discontinued, or changed, close observation for altered theophylline effect and serum concentrations is recommended.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97516/", "reference_text": "[1] Bauman JH, Teichman S, Wible DA \"Increased theophylline clearance in a patient with hyperthyroidism.\" Ann Allergy 52 (1984): 94-6[2] Vozeh S, Otten M, Staub JJ, Follath F \"Influence of thyroid function on theophylline kinetics.\" Clin Pharmacol Ther 36 (1984): 634-40[3] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[4] \"Product Information. Armour thyroid (thyroid desiccated).\" Forest Pharmaceuticals, St. Louis, MO.[5] \"Product Information. Synthroid (levothyroxine).\" Abbott Pharmaceutical, Abbott Park, IL.", "alternatives_a": "Omalizumab, Tezepelumab, Mercaptopurine, Benralizumab, Caffeine, Reslizumab, Montelukast, Dyphylline, Mepolizumab, Roflumilast, Pentoxifylline, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 97413, "ingredient1": "Theophylline", "ingredient2": "Lithium carbonate", "severity": "Moderate", "effect": "Theophylline may decrease plasma lithium levels by increasing renal elimination of lithium. The magnitude of the decrease may be sufficient to result in loss of therapeutic control. Also, when lithium is added to a stable theophylline regimen, higher initial lithium dosage may be necessary.", "source": "DDInter", "management_text": "The patient should be closely monitored for altered theophylline or lithium effect when either of these drugs is added to or discontinued from a stable regimen.", "mechanism_text": "Excretion", "recommendation": "The patient should be closely monitored for altered theophylline or lithium effect when either of these drugs is added to or discontinued from a stable regimen.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97517/", "reference_text": "[1] Thomsen K, Schou M \"Renal lithium excretion in man.\" Am J Psychol 215 (1968): 823-7[2] Perry PJ, Calloway RA, Cook BL, Smith RE \"Theophylline precipitated alterations of lithium clearance.\" Acta Psychiatr Scand 69 (1984): 528-37[3] Sierles FS, Ossowski MG \"Concurrent use of theophylline and lithium in a patient with chronic obstructive lung disease and bipolar disorder.\" Am J Psychiatry 139 (1982): 117-8[4] Cook BL, Smith RE, Perry PJ, Calloway RA \"Theophylline-lithium interaction.\" J Clin Psychiatry 46 (1985): 278-9[5] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[6] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[7] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[8] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.", "alternatives_a": "Omalizumab, Tezepelumab, Mercaptopurine, Benralizumab, Reslizumab, Montelukast, Dyphylline, Mepolizumab, Roflumilast, Pentoxifylline, Zafirlukast, Bromotheophylline", "alternatives_b": "", "updated_at": 1767369485}, {"id": 97414, "ingredient1": "Theophylline", "ingredient2": "Lorazepam", "severity": "Minor", "effect": "Methylxanthines may antagonize the sedative effects of benzodiazepines. Aminophylline in particular has been demonstrated to attenuate the sedative effects of diazepam. The mechanism of this interaction may be related to competitive binding to intracerebral adenosine receptors.", "source": "DDInter", "management_text": "-", "mechanism_text": "Antagonism", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97518/", "reference_text": "[1] Tuncok Y, Akpinar O, Guven H, Akkoclu A \"The effects of theophylline on serum alprazolam levels.\" Int J Clin Pharmacol Ther 32 (1994): 642-5[2] Gallen JS \"Aminophylline reversal of midazolam sedation.\" Anesth Analg 69 (1989): 268[3] Bonfiglio MF, Dasta JF \"Clinical significance of the benzodiazepine-theophylline interaction.\" Pharmacotherapy 11 (1991): 85-7[4] Upton RA \"Pharmacokinetic interactions between theophylline and other medication (Part II).\" Clin Pharmacokinet 20 (1991): 135-50[5] Stirt JA \"Aminophylline is a diazepam antagonist.\" Anesth Analg 60 (1981): 767-8[6] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[7] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[8] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[9] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Meprobamate, Buspirone", "alternatives_b": "Omalizumab, Tezepelumab, Benralizumab, Caffeine, Reslizumab, Mepolizumab, Roflumilast, Bromotheophylline", "updated_at": 1767369485}, {"id": 97415, "ingredient1": "Theophylline", "ingredient2": "Mephenytoin", "severity": "Moderate", "effect": "Phenytoin has been reported to increase the clearance of theophylline by 40% to 50%, presumably by enhancing the hepatic CYP450 metabolism of theophylline. Also, coadministration of theophylline has been reported to lower serum phenytoin concentrations. Other hydantoins and hepatically metabolized methylxanthines may also interact.", "source": "DDInter", "management_text": "Management consists of monitoring clinical response and serum concentrations of both drugs and adjusting dosages as necessary. Patients should be advised to report loss of seizure control or worsening of respiratory symptoms to their physician.", "mechanism_text": "Metabolism", "recommendation": "Management consists of monitoring clinical response and serum concentrations of both drugs and adjusting dosages as necessary.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97519/", "reference_text": "[1] Miller M, Cosgriff J, Kwong T, Morken DA \"Influence of phenytoin on theophylline clearance.\" Clin Pharmacol Ther 35 (1984): 666-9[2] Upton RA \"Pharmacokinetic interactions between theophylline and other medication (Part I).\" Clin Pharmacokinet 20 (1991): 66-80[3] Sklar SJ, Wagner \"Enhanced theophylline clearance secondary to phenytoin therapy.\" Drug Intell Clin Pharm 19 (1985): 34-6[4] Crowley JJ, Cusack BJ, Jue SG, et al \"Cigarette smoking and theophylline metabolism: effects of phenytoin.\" Clin Pharmacol Ther 42 (1987): 334-40[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[7] Fleisher D, Sheth N, Kou JH \"Phenytoin interaction with enteral feedings administered through nasogastric tubes.\" JPEN J Parenter Enteral Nutr 14 (1990): 513-6[8] Krueger KA, Garnett WR, Comstock TJ, Fitzsimmons WE, Karnes HT, Pellock JM \"Effect of two administration schedules of an enteral nutrient formula on phenytoin bioavailability.\" Epilepsia 28 (1987): 706-12[9] Haley CJ, Nelson J \"Phenytoin-enteral feeding interaction.\" DICP 23 (1989): 796-8[10] Faraji B, Yu PP \"Serum phenytoin levels of patients on gastrostomy tube feeding.\" J Neurosci Nurs 30 (1998): 55-9[11] Au Yeung SC, Ensom MH \"Phenytoin and enteral feedings: does evidence support an interaction?\" Ann Pharmacother 34 (2000): 896-905[12] Sandor P, Sellers EM, Dumbrell M, Khouw V \"Effect of short- and long-term alcohol use on phenytoin kinetics in chronic alcoholics.\" Clin Pharmacol Ther 30 (1981): 390-7[13] Ozuna J, Friel P \"Effect of enteral tube feeding on serum phenytoin levels.\" J Neurosurg Nurs 16 (1984): 289-91[14] Guidry JR, Eastwood TF, Curry SC \"Phenytoin absorption in volunteers receiving selected enteral feedings.\" West J Med 150 (1989): 659-61[15] Marvel ME, Bertino JS \"Comparative effects of an elemental and a complex enteral feeding formulation on the absorption of phenytoin suspension.\" JPEN J Parenter Enteral Nutr 15 (1991): 316-8[16] \"Product Information. Dilantin (phenytoin).\" Parke-Davis, Morris Plains, NJ.[17] Doak KK, Haas CE, Dunnigan KJ, et al. \"Bioavailability of phenytoin acid and phenytoin sodium with enteral feedings.\" Pharmacotherapy 18 (1998): 637-45[18] Rodman DP, Stevenson TL, Ray TR \"Phenytoin malabsorption after jejunostomy tube delivery.\" Pharmacotherapy 15 (1995): 801-5[19] Sellers EM, Holloway MR \"Drug kinetics and alcohol ingestion.\" Clin Pharmacokinet 3 (1978): 440-52[20] Holtz L, Milton J, Sturek JK \"Compatibility of medications with enteral feedings.\" JPEN J Parenter Enteral Nutr 11 (1987): 183-6", "alternatives_a": "Omalizumab, Tezepelumab, Mercaptopurine, Benralizumab, Caffeine, Reslizumab, Montelukast, Dyphylline, Mepolizumab, Roflumilast, Pentoxifylline, More", "alternatives_b": "Brivaracetam, Topiramate, Ezogabine, Cenobamate, Lamotrigine, Ethosuximide, Lacosamide, Levetiracetam, Tiagabine, Oxcarbazepine, Rufinamide, More", "updated_at": 1767369485}, {"id": 97416, "ingredient1": "Theophylline", "ingredient2": "Methylphenobarbital", "severity": "Moderate", "effect": "Barbiturates may decrease serum levels and therapeutic effects of the methylxanthines. The mechanism is barbiturate induction of CYP450 3A4 and 1A2 hepatic metabolism of methylxanthines.", "source": "DDInter", "management_text": "Close observation for clinical and laboratory evidence of decreased methylxanthine effect is indicated if these drugs must be used together. Patients should be advised to notify their physician if they experience a worsening of their respiratory symptoms.", "mechanism_text": "Metabolism", "recommendation": "Close observation for clinical and laboratory evidence of decreased methylxanthine effect is indicated if these drugs must be used together.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97520/", "reference_text": "[1] Dahlqvist R, Steiner E, Koike Y, von Bahr C, Lind M, Billing B \"Induction of theophylline metabolism by pentobarbital.\" Ther Drug Monit 11 (1989): 408-10[2] Bukowskyj M, Nakatsu K, Munt PW \"Theophylline reassessed.\" Ann Intern Med 101 (1984): 63-73[3] Upton RA \"Pharmacokinetic interactions between theophylline and other medication (Part I).\" Clin Pharmacokinet 20 (1991): 66-80[4] Landay RA, Gonzalez MA, Taylor JC \"Effect of phenobarbital on theophylline disposition.\" J Allergy Clin Immunol 62 (1978): 27-9", "alternatives_a": "Omalizumab, Tezepelumab, Mercaptopurine, Benralizumab, Caffeine, Reslizumab, Dyphylline, Mepolizumab, Roflumilast, Pentoxifylline, Zafirlukast, Bromotheophylline", "alternatives_b": "Brivaracetam, Topiramate, Ezogabine, Cenobamate, Lamotrigine, Ethosuximide, Lacosamide, Levetiracetam, Tiagabine, Oxcarbazepine, Rufinamide, More", "updated_at": 1767369485}, {"id": 97417, "ingredient1": "Theophylline", "ingredient2": "Orciprenaline", "severity": "Moderate", "effect": "Concomitant use of beta-2 adrenergic agonists with theophylline may increase the risk and/or severity of hypokalemia and adverse cardiovascular effects such as palpitation, tachycardia, and blood pressure elevation. Adverse events, especially hypokalemia, may be more likely with systemic or nebulized formulations of beta-2 agonists or high dosages of theophylline. Beta-2 agonists can cause clinically significant but usually transient decreases in serum potassium concentrations, while hypokalemia associated with theophylline often occurs in toxicity. Pharmacokinetically, some beta-2 agonists given systemically may decrease the plasma concentrations of theophylline.", "source": "DDInter", "management_text": "Although theophylline and beta-2 agonists are commonly used together to produce bronchodilation, it may be appropriate to monitor patient response as well as serum potassium level, blood pressure and heart rate during coadministration, especially if the beta-2 agonist is administered systemically or by nebulizer. Close monitoring is particularly important in patients with severe asthma, since the potential increases in blood pressure and heart rate may have more serious consequences in the presence of hypoxemia or hypercapnia due to increased myocardial oxygen consumption. Patients should be advised to notify their physician if they experience worsening of their respiratory condition or potential signs and symptoms of hypokalemia such as fatigue, weakness, myalgia, muscle cramps, numbness, tingling, abdominal pain, constipation, palpitation, and irregular heartbeat.", "mechanism_text": "Synergism", "recommendation": "Although theophylline and beta-2 agonists are commonly used together to produce bronchodilation, it may be appropriate to monitor patient response as well as serum potassium level, blood pressure and heart rate during coadministration, especially if the beta-2 agonist is administered systemically or by nebulizer.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97521/", "reference_text": "[1] Garty M, Paul-Keslin L, Ilfeld DN, et al \"Increased theophylline clearance in asthmatic patients due to terbutaline.\" Eur J Clin Pharmacol 36 (1989): 25-8[2] Amirav I, Amitai Y, Avital A, Godfrey S \"Enhancement of theophylline clearance by intravenous albuterol.\" Chest 94 (1988): 444-5[3] \"Product Information. Striverdi Respimat (olodaterol).\" Boehringer Ingelheim, Ridgefield, CT.[4] Cusack BJ, Nielson CP, Morgan ME, Vestal RE \"Additive effect of theophylline on the cardiac response to isoproterenol.\" Clin Pharmacol Ther 41 (1987): 289-96[5] Griffith JA, Kozloski GD \"Isoproterenol-theophylline interaction: possible potentiation by other drugs.\" Clin Pharm 9 (1990): 54-7[6] Conrad KA, Woodworth JR \"Orciprenaline does not alter theophylline elimination.\" Br J Clin Pharmacol 12 (1981): 756-7[7] Flatt A, Burgess C, Windom H, Beasley R, Purdie G, Crane J \"The cardiovascular effects of inhaled fenoterol alone and during treatment with oral theophylline.\" Chest 96 (1989): 1317-20[8] Smith SR, Kendall MJ \"Potentiation of the adverse effects of intravenous terbutaline by oral theophylline.\" Br J Clin Pharmacol 21 (1986): 451-3[9] Danzinger Y, Garty M, Volwitz B, Ilfeld D, Varsano I, Rosenfeld JB \"Reduction of serum theophylline levels by terbutaline in children with asthma.\" Clin Pharmacol Ther 37 (1985): 469-71[10] O'Rourke PP, Crone RK \"Effect of isoproterenol on measured theophylline levels.\" Crit Care Med 12 (1984): 373-5[11] Whyte KF, Reid C, Addis GJ, Whitesmith R, Reid JL \"Salbutamol induced hypokalaemia: the effect of theophylline alone and in combination with adrenaline.\" Br J Clin Pharmacol 25 (1988): 571-8[12] Coleman JJ, Vollmer WM, Barker AF, et al \"Cardiac arrhythmias during the combined use of beta-adrenergic agonist drugs and theophylline.\" Chest 90 (1986): 45-51[13] Kelly HW \"Controversies in asthma therapy with theophylline and the beta2-adrenergic agonists.\" Clin Pharm 3 (1984): 386-95[14] Amitai Y, Glustein J, Godfrey S \"Enhancement of theophylline clearance by oral albuterol.\" Chest 102 (1992): 786-9[15] \"Product Information. Brovana (arformoterol).\" Sepracor Inc, Marlborough, MA.[16] \"Interactions between methyl xanthines and beta adrenergic agonists.\" FDA Drug Bull 11 (1981): 19-20[17] Chow OK, Fung KP \"Slow-release terbutaline and theophylline for the long-term therapy of children with asthma: a Latin square and factorial study of drug effects and interactions.\" Pediatrics 84 (1989): 119-25[18] Hemstreet MP, Miles MV, Rutland RO \"Effect of intravenous isoproterenol on theophylline kinetics.\" J Allergy Clin Immunol 69 (1982): 360-4[19] Upton RA \"Pharmacokinetic interactions between theophylline and other medication (Part I).\" Clin Pharmacokinet 20 (1991): 66-80[20] Rachelefsky GS, Katz RM, Mickey MR Jr, Siegel SC \"Metaproterenol and theophylline in asthmatic children.\" Ann Allergy 45 (1980): 207-12[21] Josephson GW, Kennedy HL, MacKenzie EJ, Gibson G \"Cardiac dysrhythmias during the treatment of acute asthma. A comparison of two treatment regimens by a double blind protocol.\" Chest 78 (1980): 429-35[22] Dawson KP, Fergusson DM \"Effects of oral theophylline and oral salbutamol in the treatment of asthma.\" Arch Dis Child 57 (1982): 674-6[23] Jonkman JH, Borgstrom L, van der Boon WJ, de Noord OE \"Theophylline-terbutaline, a steady state study on possible pharmacokinetic interactions with special reference to chronopharmacokinetic aspects.\" Br J Clin Pharmacol 26 (1988): 285-93[24] Deenstra M, Haalboom JR, Struyvenberg A \"Decrease of plasma potassium due to inhalation of beta-2 agonists: absence of an additional effect of intravenous theophylline.\" Eur J Clin Invest 18 (1988): 162-5[25] \"Product Information. Arcapta Neohaler (indacaterol).\" Novartis Pharmaceuticals, East Hanover, NJ.[26] Lombardi TP, Bertino JS, Goldberg A, Middleton E, Slaughter RL \"The effects of a beta-2 selective adrenergic agonist and a beta- nonselective antagonist on theophylline clearance.\" J Clin Pharmacol 27 (1987): 523-9", "alternatives_a": "Omalizumab, Tezepelumab, Mercaptopurine, Benralizumab, Caffeine, Reslizumab, Montelukast, Mepolizumab, Roflumilast, Pentoxifylline, Zafirlukast, Bromotheophylline", "alternatives_b": "Mometasone furoate, Umeclidinium, Aclidinium, Mometasone, Glycopyrronium, Ipratropium, Beclomethasone dipropionate", "updated_at": 1767369485}, {"id": 97418, "ingredient1": "Theophylline", "ingredient2": "Methimazole", "severity": "Moderate", "effect": "Clearance of theophylline and related agents depends upon thyroid function. In the hyperthyroid state, clearance may be enhanced. In the hypothyroid state, clearance may be reduced. Theophylline clearance may decrease and the risk of toxicity may increase when hyperthyroid patients become euthyroid.", "source": "DDInter", "management_text": "The patient and theophylline levels should be closely monitored while achieving a euthyroid state and when an antithyroid agent is added, discontinued, or the dosage is changed. Theophylline dosage adjustments may be required. Patients should be advised to notify their physician if they experience a worsening of their respiratory symptoms, or any signs of theophylline toxicity including nausea, vomiting, diarrhea, headache, restlessness, insomnia, seizures, or irregular heartbeats.", "mechanism_text": "Others", "recommendation": "The patient and theophylline levels should be closely monitored while achieving a euthyroid state and when an antithyroid agent is added, discontinued, or the dosage is changed.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97522/", "reference_text": "[1] Aderka D, Shavit G, Garfinkel D, et al \"Life-threatening theophylline intoxication in a hypothyroid patient.\" Respiration 44 (1983): 77-80[2] Bauman JH, Teichman S, Wible DA \"Increased theophylline clearance in a patient with hyperthyroidism.\" Ann Allergy 52 (1984): 94-6[3] \"Product Information. Tapazole (methimazole).\" King Pharmaceuticals Inc, Bristol, TN.", "alternatives_a": "Omalizumab, Tezepelumab, Mercaptopurine, Benralizumab, Caffeine, Reslizumab, Dyphylline, Mepolizumab, Roflumilast, Pentoxifylline, Zafirlukast, Bromotheophylline", "alternatives_b": "Potassium perchlorate", "updated_at": 1767369485}, {"id": 97419, "ingredient1": "Theophylline", "ingredient2": "Methohexital", "severity": "Moderate", "effect": "Barbiturates may decrease serum levels and therapeutic effects of the methylxanthines. The mechanism is barbiturate induction of CYP450 3A4 and 1A2 hepatic metabolism of methylxanthines.", "source": "DDInter", "management_text": "Close observation for clinical and laboratory evidence of decreased methylxanthine effect is indicated if these drugs must be used together. Patients should be advised to notify their physician if they experience a worsening of their respiratory symptoms.", "mechanism_text": "Metabolism", "recommendation": "Close observation for clinical and laboratory evidence of decreased methylxanthine effect is indicated if these drugs must be used together.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97523/", "reference_text": "[1] Dahlqvist R, Steiner E, Koike Y, von Bahr C, Lind M, Billing B \"Induction of theophylline metabolism by pentobarbital.\" Ther Drug Monit 11 (1989): 408-10[2] Bukowskyj M, Nakatsu K, Munt PW \"Theophylline reassessed.\" Ann Intern Med 101 (1984): 63-73[3] Upton RA \"Pharmacokinetic interactions between theophylline and other medication (Part I).\" Clin Pharmacokinet 20 (1991): 66-80[4] Landay RA, Gonzalez MA, Taylor JC \"Effect of phenobarbital on theophylline disposition.\" J Allergy Clin Immunol 62 (1978): 27-9", "alternatives_a": "Omalizumab, Tezepelumab, Mercaptopurine, Benralizumab, Caffeine, Reslizumab, Montelukast, Dyphylline, Mepolizumab, Roflumilast, Pentoxifylline, More", "alternatives_b": "Suvorexant, Chloral hydrate, Nitrazepam, Paraldehyde, Propiomazine, Ramelteon, Meprobamate, Scopolamine, Eszopiclone, Dexmedetomidine, Lemborexant, More", "updated_at": 1767369485}, {"id": 97420, "ingredient1": "Theophylline", "ingredient2": "Methotrexate", "severity": "Moderate", "effect": "Methotrexate may reduce oral theophylline clearance. The mechanism has not been described. Patients who are maintained on theophylline may exhibit toxicity if methotrexate is added to the regimen.", "source": "DDInter", "management_text": "The clinician should observe closely for alterations in theophylline serum levels and signs of toxicity. Patients should be advised to report any signs of theophylline toxicity including nausea, vomiting, diarrhea, headache, restlessness, insomnia, or irregular heartbeat.", "mechanism_text": "Metabolism", "recommendation": "The clinician should observe closely for alterations in theophylline serum levels and signs of toxicity.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97524/", "reference_text": "[1] Glynn-Barnhart A, Szefler S, Cott G \"Effect of methotrexate on prednisolone and theophylline pharmacokinetics.\" Clin Pharmacol Ther 47 (1990): 130[2] Nesher G, Mates M, Zevin S \"Effect of caffeine consumption on efficacy of methotrexate in rheumatoid arthritis.\" Arthritis Rheum 48 (2003): 571-572[3] Sato J, Nakata H, Owada E, Kikuta T, Umetsu M, Ito K \"Influence of usual intake of dietary caffeine on single-dose kinetics of theophylline in healthy human subjects.\" Eur J Clin Pharmacol 44 (1993): 295-8[4] Jonkman JH, Sollie FA, Sauter R, Steinijans VW \"The influence of caffeine on the steady-state pharmacokinetics of theophylline.\" Clin Pharmacol Ther 49 (1991): 248-55[5] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67", "alternatives_a": "Omalizumab, Tezepelumab, Aminophylline, Benralizumab, Reslizumab, Dyphylline, Oxtriphylline, Mepolizumab, Bromotheophylline", "alternatives_b": "Cyclosporine, Antithymocyte immunoglobulin (rabbit), Anifrolumab, Ravulizumab, Diroximel fumarate, Abatacept, Upadacitinib, Siponimod, Apremilast, Inebilizumab, Cladribine, More", "updated_at": 1767369485}, {"id": 97421, "ingredient1": "Theophylline", "ingredient2": "Methylprednisolone", "severity": "Moderate", "effect": "The concomitant use of theophylline and corticosteroids may theoretically increase the risk of hypokalemia due to additive potassium-lowering effects. Additionally, theophylline serum concentrations may be altered.", "source": "DDInter", "management_text": "Monitoring for altered efficacy and safety of theophylline and altered serum potassium and theophylline concentrations is advisable when these drugs are coadministered. Patients should be advised to notify their physician if they experience signs of hypokalemia (e.g., weakness, lethargy, and muscle pains or cramps), worsening respiratory symptoms, or signs of theophylline toxicity (e.g., nausea, vomiting, diarrhea, headache, restlessness, insomnia, or irregular heartbeat).", "mechanism_text": "Synergism", "recommendation": "Monitoring for altered efficacy and safety of theophylline and altered serum potassium and theophylline concentrations is advisable when these drugs are coadministered.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97525/", "reference_text": "[1] Fergusson RJ, Scott CM, Rafferty P, Gaddie J \"Effect of prednisolone on theophylline pharmacokinetics in patients with chronic airflow obstruction.\" Thorax 42 (1987): 195-8[2] Buchanan N, Hurwitz S, Butler P \"Asthma - a possible interaction between hydrocortisone and theophylline.\" S Afr Med J 56 (1979): 1147-8[3] Leavengood DC, Bunker-Soler AL, Nelson HS \"The effect of corticosteroids on theophylline metabolism.\" Ann Allergy 50 (1983): 249-51[4] Elvey SM, Saccar CL, Rocci ML, Mansmann HC, Martynec DM, Kester MB \"The effect of corticosteroids on theophylline metabolim in asthmatic children.\" Ann Allergy 56 (1986): 520[5] Tatsis G, Orphanidou D, Douratsos D, et al \"The effect of steroids on theophylline absorption.\" J Int Med Res 19 (1991): 326-9[6] Anderson JL, Ayres JW, Hall CA \"Potential pharmacokinetic interaction between theophylline and prednisone.\" Clin Pharm 3 (1984): 187-8", "alternatives_a": "Omalizumab, Tezepelumab, Benralizumab, Caffeine, Reslizumab, Dyphylline, Oxtriphylline, Mepolizumab, Zafirlukast, Bromotheophylline", "alternatives_b": "Clindamycin, Vitamin A, Isotretinoin, Chloramphenicol, Fluorometholone, Tretinoin, Dapsone, Azelaic acid, Adapalene, Deflazacort, Fluocinolone acetonide, More", "updated_at": 1767369485}, {"id": 97422, "ingredient1": "Theophylline", "ingredient2": "Metipranolol (ophthalmic)", "severity": "Major", "effect": "The pharmacologic effects of theophyllines and beta-blockers are opposite. Nonselective and high doses of cardioselective beta-blockers may cause severe or fatal bronchospasm by opposing theophylline-induced bronchodilation. Ophthalmic beta-blockers undergo significant systemic absorption and may also interact. In addition, propranolol and other beta-blockers may reduce the CYP450 hepatic metabolism of theophylline, and serum theophylline levels may be increased.", "source": "DDInter", "management_text": "Oral and ophthalmic nonselective beta-blockers (e.g., carteolol, carvedilol, levobunolol, metipranolol, nadolol, oxprenolol, penbutolol, pindolol, propranolol, sotalol, and timolol) are considered contraindicated in patients with bronchospastic diseases. Cardioselective beta-blockers should generally be avoided, or used with extreme caution if no other alternatives are available and the benefits outweigh the risks of potentially severe bronchospasm. If patients do receive this combination, they should be closely monitored for increased serum theophylline levels but decreased bronchodilatory effectiveness.", "mechanism_text": "Antagonism", "recommendation": "Oral and ophthalmic nonselective beta-blockers (e.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97526/", "reference_text": "[1] Upton RA \"Pharmacokinetic interactions between theophylline and other medication (Part II).\" Clin Pharmacokinet 20 (1991): 135-50[2] Mue S, Sasaki T, Shibahara S, et alT \"Influence of metoprolol on hemodynamics and respiratory function in asthmatic patients.\" Int J Clin Pharmacol Biopharm 17 (1979): 346-50[3] Lombardi TP, Bertino JS, Goldberg A, Middleton E, Slaughter RL \"The effects of a beta-2 selective adrenergic agonist and a beta- nonselective antagonist on theophylline clearance.\" J Clin Pharmacol 27 (1987): 523-9[4] Horvath JS, Woolcock AJ, Tiller DJ, Donnelly P, Armstrong J, Caterson R \"A comparison of metoprolol and propranolol on blood pressure and respiratory function in patients with hypertension.\" Aust N Z J Med 8 (1978): 1-6[5] Conrad KA, Nyman DW \"Effects of metoprolol and propranolol on theophylline elimination.\" Clin Pharmacol Ther 28 (1980): 463-7", "alternatives_a": "Omalizumab, Tezepelumab, Mercaptopurine, Benralizumab, Caffeine, Reslizumab, Montelukast, Mepolizumab, Roflumilast, Pentoxifylline, Zafirlukast, Bromotheophylline", "alternatives_b": "Sulbactam, Oxacillin, Dicloxacillin, Piperacillin, Meticillin, Carbenicillin, Bacampicillin, Ticarcillin, Mezlocillin, Tazobactam, Cloxacillin, More", "updated_at": 1767369485}, {"id": 97423, "ingredient1": "Theophylline", "ingredient2": "Metocurine", "severity": "Moderate", "effect": "Methylxanthines may antagonize the effects of neuromuscular blockers. The mechanism is unknown. In patients stabilized on aminophylline, resistance to pancuronium has been reported.", "source": "DDInter", "management_text": "The patient should be monitored for adequate neuromuscular blockade and the dosage adjusted, if necessary.", "mechanism_text": "Antagonism", "recommendation": "The patient should be monitored for adequate neuromuscular blockade and the dosage adjusted, if necessary.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97527/", "reference_text": "[1] Doll DC, Rosenberg H \"Antagonism of neuromuscular blockage by theophylline.\" Anesth Analg 58 (1979): 139-40[2] Azar I, Kumar D, Betcher AM \"Resistance to pancuronium in an asthmatic patient treated with aminophylline and steroids.\" Can Anaesth Soc J 29 (1982): 280-2[3] Daller JA, Erstad B, Rosado L, Otto C, Putnam CW \"Aminophylline antagonizes the neuromuscular blockade of pancuronium but not vecuronium.\" Crit Care Med 19 (1991): 983-5", "alternatives_a": "Omalizumab, Tezepelumab, Mercaptopurine, Benralizumab, Caffeine, Reslizumab, Montelukast, Mepolizumab, Roflumilast, Pentoxifylline, Zafirlukast, Bromotheophylline", "alternatives_b": "", "updated_at": 1767369485}, {"id": 97424, "ingredient1": "Theophylline", "ingredient2": "Metoprolol", "severity": "Major", "effect": "The pharmacologic effects of theophyllines and beta-blockers are opposite. Nonselective and high doses of cardioselective beta-blockers may cause severe or fatal bronchospasm by opposing theophylline-induced bronchodilation. Ophthalmic beta-blockers undergo significant systemic absorption and may also interact. In addition, propranolol and other beta-blockers may reduce the CYP450 hepatic metabolism of theophylline, and serum theophylline levels may be increased.", "source": "DDInter", "management_text": "Oral and ophthalmic nonselective beta-blockers (e.g., carteolol, carvedilol, levobunolol, metipranolol, nadolol, oxprenolol, penbutolol, pindolol, propranolol, sotalol, and timolol) are considered contraindicated in patients with bronchospastic diseases. Cardioselective beta-blockers should generally be avoided, or used with extreme caution if no other alternatives are available and the benefits outweigh the risks of potentially severe bronchospasm. If patients do receive this combination, they should be closely monitored for increased serum theophylline levels but decreased bronchodilatory effectiveness.", "mechanism_text": "Antagonism", "recommendation": "Oral and ophthalmic nonselective beta-blockers (e.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97528/", "reference_text": "[1] Upton RA \"Pharmacokinetic interactions between theophylline and other medication (Part II).\" Clin Pharmacokinet 20 (1991): 135-50[2] Mue S, Sasaki T, Shibahara S, et alT \"Influence of metoprolol on hemodynamics and respiratory function in asthmatic patients.\" Int J Clin Pharmacol Biopharm 17 (1979): 346-50[3] Lombardi TP, Bertino JS, Goldberg A, Middleton E, Slaughter RL \"The effects of a beta-2 selective adrenergic agonist and a beta- nonselective antagonist on theophylline clearance.\" J Clin Pharmacol 27 (1987): 523-9[4] Horvath JS, Woolcock AJ, Tiller DJ, Donnelly P, Armstrong J, Caterson R \"A comparison of metoprolol and propranolol on blood pressure and respiratory function in patients with hypertension.\" Aust N Z J Med 8 (1978): 1-6[5] Conrad KA, Nyman DW \"Effects of metoprolol and propranolol on theophylline elimination.\" Clin Pharmacol Ther 28 (1980): 463-7", "alternatives_a": "Ivabradine", "alternatives_b": "Omalizumab, Tezepelumab, Benralizumab, Caffeine, Reslizumab, Mepolizumab, Roflumilast, Bromotheophylline", "updated_at": 1767369485}, {"id": 97425, "ingredient1": "Theophylline", "ingredient2": "Metreleptin", "severity": "Moderate", "effect": "Treatment with metreleptin, a recombinant analog of human leptin, may affect the pharmacokinetics of drugs that are primarily metabolized by CYP450 isoenzymes.", "source": "DDInter", "management_text": "Caution is advised when metreleptin is prescribed to patients receiving drugs with a narrow therapeutic index that are substrates of CYP450 isoenzymes, such as macrolide immunosuppressants, oral contraceptives, cyclosporine, theophylline, and warfarin. Clinical and laboratory monitoring are recommended following the initiation, discontinuation or change of dosage of metreleptin, and the individual dosage of the concomitant agents adjusted as needed.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when metreleptin is prescribed to patients receiving drugs with a narrow therapeutic index that are substrates of CYP450 isoenzymes, such as macrolide immunosuppressants, oral contraceptives, cyclosporine, theophylline, and warfarin.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97529/", "reference_text": "[1] \"Product Information. Myalept (metreleptin).\" Bristol-Myers Squibb, Princeton, NJ.[2] Gunston GD, Mehta U \"Potentially serious drug interactions with grapefruit juice.\" S Afr Med J 90 (2000): 41[3] Bailey DG, Arnold JMO, Spence JD \"Grapefruit juice and drugs - how significant is the interaction.\" Clin Pharmacokinet 26 (1994): 91-8[4] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[5] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions.\" Br J Clin Pharmacol 46 (1998): 101-10[6] Libersa CC, Brique SA, Motte KB, et al. \"Dramatic inhibition of amiodarone metabolism induced by grapefruit juice.\" Br J Clin Pharmacol 49 (2000): 373-8[7] Bailey DG, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit juice felodipine interaction: Effect of naringin and 6',7'-dihydroxybergamottin in humans.\" Clin Pharmacol Ther 64 (1998): 248-56[8] Jonkman JH, Sollie FA, Sauter R, Steinijans VW \"The influence of caffeine on the steady-state pharmacokinetics of theophylline.\" Clin Pharmacol Ther 49 (1991): 248-55[9] Ozdemir M, Aktan Y, Boydag BS, Cingi MI, Musmul A \"Interaction between grapefruit juice and diazepam in humans.\" Eur J Drug Metab Pharmacokinet 23 (1998): 55-9[10] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin.\" Clin Pharmacol Ther 66 (1999): 118-27[11] Bailey DG, Arnold JM, Munoz C, Spence JD \"Grapefruit juice--felodipine interaction: mechanism, predictability, and effect of naringin.\" Clin Pharmacol Ther 53 (1993): 637-42[12] Sigusch H, Hippius M, Henschel L, Kaufmann K, Hoffmann A \"Influence of grapefruit juice on the pharmacokinetics of a slow release nifedipine formulation.\" Pharmazie 49 (1994): 522-4[13] Eagling VA, Profit L, Back DJ \"Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-I protease inhibitor saquinavir by grapefruit juice components.\" Br J Clin Pharmacol 48 (1999): 543-52[14] Damkier P, Hansen LL, Brosen K \"Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine.\" Br J Clin Pharmacol 48 (1999): 829-38[15] Min DI, Ku YM, Geraets DR, Lee HC \"Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers.\" J Clin Pharmacol 36 (1996): 469-76[16] Zaidenstein R, Soback S, Gips M, Avni B, Dishi V, Weissgarten Y, Golik A, Scapa E \"Effect of grapefruit juice on the pharmacokinetics of losartan and its active metabolite E3174 in healthy volunteers.\" Ther Drug Monit 23 (2001): 369-73[17] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84[18] Lee AJ, Chan WK, Harralson AF, Buffum J, Bui BCC \"The effects of grapefruit juice on sertraline metabolism: An in vitro and in vivo study.\" Clin Ther 21 (1999): 1890-9[19] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors.\" Clin Pharmacol Ther 64 (1998): 477-83[20] Garg SK, Kumar N, Bhargava VK, Prabhakar SK \"Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy.\" Clin Pharmacol Ther 64 (1998): 286-8[21] Fuhr U, Maier-Bruggemann A, Blume H, et al. \"Grapefruit juice increases oral nimodipine bioavailability.\" Int J Clin Pharmacol Ther 36 (1998): 126-32[22] Sato J, Nakata H, Owada E, Kikuta T, Umetsu M, Ito K \"Influence of usual intake of dietary caffeine on single-dose kinetics of theophylline in healthy human subjects.\" Eur J Clin Pharmacol 44 (1993): 295-8[23] Edgar B, Bailey D, Bergstrand R, et al \"Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics on felodipine and its potential clinical relevance.\" Eur J Clin Pharmacol 42 (1992): 313-7[24] Kantola T, Kivisto KT, Neuvonen PJ \"Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid.\" Clin Pharmacol Ther 63 (1998): 397-402[25] Dresser GK, Spence JD, Bailey DG \"Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition.\" Clin Pharmacokinet 38 (2000): 41-57[26] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[27] Takanaga H, Ohnishi A, Maatsuo H, et al. \"Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model.\" Br J Clin Pharmacol 49 (2000): 49-58[28] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS \"Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice.\" Br J Clin Pharmacol 42 (1996): p662[29] Bailey DG, Arnold JM, Strong HA, Munoz C, Spence JD \"Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics.\" Clin Pharmacol Ther 54 (1993): 589-94[30] Josefsson M, Zackrisson AL, Ahlner J \"Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers.\" Eur J Clin Pharmacol 51 (1996): 189-93[31] Majeed A, Kareem A \"Effect of grapefruit juice on cyclosporine pharmacokinetics.\" Pediatr Nephrol 10 (1996): 395[32] Flanagan D \"Understanding the grapefruit-drug interaction.\" Gen Dent 53 (2005): 282-5; quiz 286[33] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ \"Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice.\" Clin Pharmacol Ther 58 (1995): 127-31[34] Schubert W, Eriksson U, Edgar B, Cullberg G, Hedner T \"Flavonoids in grapefruit juice inhibit the in vitro hepatic metabolism of 17B-estradiol.\" Eur J Drug Metab Pharmacokinet 20 (1995): 219-24[35] Weber A, Jager R, Borner A, et al. \"Can grapefruit juice influence ethinyl estradiol bioavailability?\" Contraception 53 (1996): 41-7", "alternatives_a": "Omalizumab, Tezepelumab, Mercaptopurine, Benralizumab, Caffeine, Reslizumab, Montelukast, Dyphylline, Mepolizumab, Roflumilast, Pentoxifylline, More", "alternatives_b": "Teduglutide, Lonafarnib, Fosdenopterin, Miglustat, Imiglucerase, Asfotase alfa, Glycerol phenylbutyrate, Pegvaliase, Triethylenetetramine, Sapropterin, Zinc acetate, More", "updated_at": 1767369485}, {"id": 97426, "ingredient1": "Theophylline", "ingredient2": "Mexiletine", "severity": "Major", "effect": "Coadministration with mexiletine may increase the serum concentrations of theophylline. The proposed mechanism is inhibition of the CYP450 1A2-mediated metabolism of theophylline by mexiletine.", "source": "DDInter", "management_text": "Caution is advised when theophylline is used with mexiletine. Close monitoring of serum theophylline levels is recommended, particularly following the addition, discontinuation or change of dosage of mexiletine, and the theophylline dosage adjusted accordingly. Patients should be advised to notify their physician if they experience signs of theophylline toxicity such as nausea, vomiting, diarrhea, headache, restlessness, insomnia, seizures, palpitations, and cardiac arrhythmia.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when theophylline is used with mexiletine.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97530/", "reference_text": "[1] Ueno K, Miyai K, Kato M, et al \"Mechanism of interaction between theophylline and mexiletine.\" DICP 25 (1991): 727-30[2] Katz A, Buskila D, Sukenik S \"Oral mexiletine-theophylline interaction.\" Int J Cardiol 17 (1987): 227-8[3] Stoysich AM, Mohiuddin SM, Destache CJ, et al \"Influence of mexiletine on the pharmacokinetics of theophylline in healthy volunteers.\" J Clin Pharmacol 31 (1991): 354-7[4] Stanley R, Comer T, Taylor JL, Saliba D \"Mexiletine-theophylline interaction.\" Am J Med 86 (1989): 733-4[5] Kessler KM, Interian A, Cox M, et al \"Proarrhythmia related to a kinetic and dynamic interaction of mexiletine and theophylline.\" Am Heart J 117 (1989): 964-6[6] Ueno K, Miyai K, Seki T, Kawaguchi Y \"Interaction between theophylline and mexiletine.\" DICP 24 (1990): 471-2[7] Hurwitz A, Vacek JL, Botteron GW, et al \"Mexiletine effects on theophylline disposition.\" Clin Pharmacol Ther 50 (1991): 299-307[8] Upton RA \"Pharmacokinetic interactions between theophylline and other medication (Part II).\" Clin Pharmacokinet 20 (1991): 135-50[9] Loi CM, Wei X, Vestal RE \"Inhibition of theophylline metabolism by mexiletine in young male and female nonsmokers.\" Clin Pharmacol Ther 49 (1991): 571-80", "alternatives_a": "Omalizumab, Tezepelumab, Mercaptopurine, Benralizumab, Caffeine, Reslizumab, Dyphylline, Mepolizumab, Zafirlukast, Bromotheophylline", "alternatives_b": "Dronedarone, Procainamide, Flecainide, Dofetilide, Bretylium, Ibutilide", "updated_at": 1767369485}, {"id": 97427, "ingredient1": "Theophylline", "ingredient2": "Midazolam", "severity": "Minor", "effect": "Methylxanthines may antagonize the sedative effects of benzodiazepines. Aminophylline in particular has been demonstrated to attenuate the sedative effects of diazepam. The mechanism of this interaction may be related to competitive binding to intracerebral adenosine receptors.", "source": "DDInter", "management_text": "-", "mechanism_text": "Antagonism", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97531/", "reference_text": "[1] Tuncok Y, Akpinar O, Guven H, Akkoclu A \"The effects of theophylline on serum alprazolam levels.\" Int J Clin Pharmacol Ther 32 (1994): 642-5[2] Gallen JS \"Aminophylline reversal of midazolam sedation.\" Anesth Analg 69 (1989): 268[3] Bonfiglio MF, Dasta JF \"Clinical significance of the benzodiazepine-theophylline interaction.\" Pharmacotherapy 11 (1991): 85-7[4] Upton RA \"Pharmacokinetic interactions between theophylline and other medication (Part II).\" Clin Pharmacokinet 20 (1991): 135-50[5] Stirt JA \"Aminophylline is a diazepam antagonist.\" Anesth Analg 60 (1981): 767-8[6] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[7] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[8] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[9] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Omalizumab, Tezepelumab, Mercaptopurine, Benralizumab, Caffeine, Reslizumab, Montelukast, Mepolizumab, Roflumilast, Pentoxifylline, Zafirlukast, Bromotheophylline", "alternatives_b": "Suvorexant, Chloral hydrate, Nitrazepam, Paraldehyde, Propiomazine, Ramelteon, Meprobamate, Scopolamine, Eszopiclone, Dexmedetomidine, Lemborexant, More", "updated_at": 1767369485}, {"id": 97428, "ingredient1": "Theophylline", "ingredient2": "Mivacurium", "severity": "Moderate", "effect": "Methylxanthines may antagonize the effects of neuromuscular blockers. The mechanism is unknown. In patients stabilized on aminophylline, resistance to pancuronium has been reported.", "source": "DDInter", "management_text": "The patient should be monitored for adequate neuromuscular blockade and the dosage adjusted, if necessary.", "mechanism_text": "Antagonism", "recommendation": "The patient should be monitored for adequate neuromuscular blockade and the dosage adjusted, if necessary.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97532/", "reference_text": "[1] Doll DC, Rosenberg H \"Antagonism of neuromuscular blockage by theophylline.\" Anesth Analg 58 (1979): 139-40[2] Azar I, Kumar D, Betcher AM \"Resistance to pancuronium in an asthmatic patient treated with aminophylline and steroids.\" Can Anaesth Soc J 29 (1982): 280-2[3] Daller JA, Erstad B, Rosado L, Otto C, Putnam CW \"Aminophylline antagonizes the neuromuscular blockade of pancuronium but not vecuronium.\" Crit Care Med 19 (1991): 983-5", "alternatives_a": "Omalizumab, Tezepelumab, Mercaptopurine, Benralizumab, Caffeine, Reslizumab, Montelukast, Mepolizumab, Roflumilast, Pentoxifylline, Zafirlukast, Bromotheophylline", "alternatives_b": "Botulinum toxin type A", "updated_at": 1767369485}, {"id": 97429, "ingredient1": "Theophylline", "ingredient2": "Moricizine", "severity": "Minor", "effect": "Moricizine may increase the plasma clearance of theophylline by 46% to 68% and decrease theophylline half-life by 20% to 34%. Conversely, theophylline toxicity may occur when moricizine is discontinued. The mechanism is unknown, but may be related to hepatic enzyme induction. Management consists of monitoring the patient for theophylline efficacy, checking levels if indicated, and adjusting theophylline dosage accordingly. Patients should be advised to notify their physician if they experience a worsening of their respiratory symptoms.", "source": "DDInter", "management_text": "-", "mechanism_text": "Metabolism", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97533/", "reference_text": "[1] Upton RA \"Pharmacokinetic interactions between theophylline and other medication (Part II).\" Clin Pharmacokinet 20 (1991): 135-50[2] Pieniaszek HJ Jr, Davidson AF, Benedek IH \"Effect of moricizine on the pharmacokinetics of single-dose theophylline in healthy subjects.\" Ther Drug Monit 15 (1993): 199-203[3] Siddoway LA, Schwartz SL, Barbey JT, Woosley RL \"Clinical pharmacokinetics of moricizine.\" Am J Cardiol 65 (1990): d21-5; disc. D68-71", "alternatives_a": "Omalizumab, Tezepelumab, Mercaptopurine, Benralizumab, Caffeine, Reslizumab, Montelukast, Dyphylline, Mepolizumab, Roflumilast, Pentoxifylline, More", "alternatives_b": "Dronedarone, Procainamide, Flecainide, Dofetilide, Bretylium, Ibutilide", "updated_at": 1767369485}, {"id": 97430, "ingredient1": "Theophylline", "ingredient2": "Mycophenolate mofetil", "severity": "Minor", "effect": "In vitro studies have shown that mycophenolic acid in concentrations up to 100 mcg/mL decreases protein binding of theophylline from 53% to 45%. The clinical significance of this interaction is unknown. Decreased protein binding theoretically could lead to increased plasma theophylline concentrations. However, clinical toxicity has not been reported. It may be appropriate to monitor more closely patients receiving theophylline or other methylxanthine derivatives with mycophenolic acid products. Patients should be advised to contact their physician if they experience potential symptoms of theophylline toxicity such as nausea, vomiting, diarrhea, headache, restlessness, insomnia, and irregular heartbeat.", "source": "DDInter", "management_text": "-", "mechanism_text": "Distribution", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97534/", "reference_text": "[1] \"Product Information. CellCept (mycophenolate mofetil).\" Roche Laboratories, Nutley, NJ.[2] \"Product Information. Myfortic (mycophenolic acid).\" Novartis Pharmaceuticals, East Hanover, NJ.", "alternatives_a": "Omalizumab, Tezepelumab, Mercaptopurine, Benralizumab, Caffeine, Reslizumab, Montelukast, Dyphylline, Mepolizumab, Pentoxifylline, Zafirlukast, Bromotheophylline", "alternatives_b": "", "updated_at": 1767369485}, {"id": 97431, "ingredient1": "Theophylline", "ingredient2": "Mycophenolic acid", "severity": "Minor", "effect": "In vitro studies have shown that mycophenolic acid in concentrations up to 100 mcg/mL decreases protein binding of theophylline from 53% to 45%. The clinical significance of this interaction is unknown. Decreased protein binding theoretically could lead to increased plasma theophylline concentrations. However, clinical toxicity has not been reported. It may be appropriate to monitor more closely patients receiving theophylline or other methylxanthine derivatives with mycophenolic acid products. Patients should be advised to contact their physician if they experience potential symptoms of theophylline toxicity such as nausea, vomiting, diarrhea, headache, restlessness, insomnia, and irregular heartbeat.", "source": "DDInter", "management_text": "-", "mechanism_text": "Distribution", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97535/", "reference_text": "[1] \"Product Information. CellCept (mycophenolate mofetil).\" Roche Laboratories, Nutley, NJ.[2] \"Product Information. Myfortic (mycophenolic acid).\" Novartis Pharmaceuticals, East Hanover, NJ.", "alternatives_a": "Omalizumab, Tezepelumab, Mercaptopurine, Benralizumab, Caffeine, Reslizumab, Montelukast, Dyphylline, Mepolizumab, Pentoxifylline, Zafirlukast, Bromotheophylline", "alternatives_b": "Cyclosporine, Antithymocyte immunoglobulin (rabbit), Anifrolumab, Ravulizumab, Diroximel fumarate, Abatacept, Upadacitinib, Siponimod, Apremilast, Inebilizumab, Cladribine, More", "updated_at": 1767369485}, {"id": 97432, "ingredient1": "Theophylline", "ingredient2": "Nadolol", "severity": "Major", "effect": "The pharmacologic effects of theophyllines and beta-blockers are opposite. Nonselective and high doses of cardioselective beta-blockers may cause severe or fatal bronchospasm by opposing theophylline-induced bronchodilation. Ophthalmic beta-blockers undergo significant systemic absorption and may also interact. In addition, propranolol and other beta-blockers may reduce the CYP450 hepatic metabolism of theophylline, and serum theophylline levels may be increased.", "source": "DDInter", "management_text": "Oral and ophthalmic nonselective beta-blockers (e.g., carteolol, carvedilol, levobunolol, metipranolol, nadolol, oxprenolol, penbutolol, pindolol, propranolol, sotalol, and timolol) are considered contraindicated in patients with bronchospastic diseases. Cardioselective beta-blockers should generally be avoided, or used with extreme caution if no other alternatives are available and the benefits outweigh the risks of potentially severe bronchospasm. If patients do receive this combination, they should be closely monitored for increased serum theophylline levels but decreased bronchodilatory effectiveness.", "mechanism_text": "Antagonism", "recommendation": "Oral and ophthalmic nonselective beta-blockers (e.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97536/", "reference_text": "[1] Upton RA \"Pharmacokinetic interactions between theophylline and other medication (Part II).\" Clin Pharmacokinet 20 (1991): 135-50[2] Mue S, Sasaki T, Shibahara S, et alT \"Influence of metoprolol on hemodynamics and respiratory function in asthmatic patients.\" Int J Clin Pharmacol Biopharm 17 (1979): 346-50[3] Lombardi TP, Bertino JS, Goldberg A, Middleton E, Slaughter RL \"The effects of a beta-2 selective adrenergic agonist and a beta- nonselective antagonist on theophylline clearance.\" J Clin Pharmacol 27 (1987): 523-9[4] Horvath JS, Woolcock AJ, Tiller DJ, Donnelly P, Armstrong J, Caterson R \"A comparison of metoprolol and propranolol on blood pressure and respiratory function in patients with hypertension.\" Aust N Z J Med 8 (1978): 1-6[5] Conrad KA, Nyman DW \"Effects of metoprolol and propranolol on theophylline elimination.\" Clin Pharmacol Ther 28 (1980): 463-7", "alternatives_a": "Omalizumab, Tezepelumab, Mercaptopurine, Benralizumab, Caffeine, Reslizumab, Mepolizumab, Roflumilast, Zafirlukast, Bromotheophylline", "alternatives_b": "", "updated_at": 1767369485}, {"id": 97433, "ingredient1": "Theophylline", "ingredient2": "Nalidixic acid", "severity": "Moderate", "effect": "Some fluoroquinolones have been shown to decrease the hepatic metabolism of theophyllines. The mechanism is inhibition of CYP450 1A2 hepatic metabolism. Patients with chronic obstructive pulmonary disease, congestive heart failure, or cirrhosis may have slower theophylline clearance rates; therefore, they may be at greater risk of developing theophylline toxicity. This drug combination may increase the risk of seizures, especially in the elderly. Interpatient variability of this effect makes it prudent to monitor patients who may not tolerate a small increase in theophylline levels during concurrent fluoroquinolone therapy.", "source": "DDInter", "management_text": "Interpatient variability of this effect makes it prudent to monitor patients who may not tolerate a small increase in theophylline levels. Levofloxacin, sparfloxacin, and lomefloxacin have been reported to cause minor or no changes in theophylline levels and may be considered as alternatives. Patients should be advised to report any signs of theophylline toxicity including nausea, vomiting, diarrhea, headache, restlessness, insomnia, seizures, or irregular heartbeat to their physicians.", "mechanism_text": "Metabolism", "recommendation": "Interpatient variability of this effect makes it prudent to monitor patients who may not tolerate a small increase in theophylline levels.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97537/", "reference_text": "[1] Davis RL, Kelly HW, Quenzer RW, Standefer J, Steinberg B, Gallegos J \"Effect of norfloxacin on theophyllin metabolism.\" Antimicrob Agents Chemother 33 (1989): 212-4[2] Grasela TH, Dreis MW \"An evaluation of the quinolone-theophylline interaction using the Food and Drug Administration spontaneous reporting system.\" Arch Intern Med 152 (1992): 617-21[3] Wijnands WJ, Vree TB \"Interaction between the fluoroquinolones and the bronchodilator theophylline.\" J Antimicrob Chemother 22 (1988): 109-14[4] Ho G, Tierney MG, Dales RE \"Evaluation of the effect of norfloxacin on the pharmacokinetics of theophylline.\" Clin Pharmacol Ther 44 (1988): 35-8[5] Bowles SK, Popovski Z, Rybak MJ, Beckman HB, Edwards DJ \"Effect of norfloxacin on theophylline pharmacokinetics at steady state.\" Antimicrob Agents Chemother 32 (1988): 510-12[6] Gregoire SL, Grasela TH Jr, Freer JP, Tack KJ, Schentag JJ \"Inhibition of theophylline clearance by coadministered ofloxacin without alteraction of theophylline effects.\" Antimicrob Agents Chemother 31 (1987): 375-8[7] Upton RA \"Pharmacokinetic interactions between theophylline and other medication (Part I).\" Clin Pharmacokinet 20 (1991): 66-80[8] Sano M, Yamamoto I, Ueda J, Yoskikawa E, Yamashina H, Goto M \"Comparative pharmacokinetics of theophylline following two fluoroquinolones co-administration.\" Eur J Clin Pharmacol 32 (1987): 431-2[9] Segev S. Rehavi M, Rubinstein E \"Quinolones, theophylline, and diclofenac interactions with the gamma-aminobutyric acid receptor.\" Antimicrob Agents Chemother 32 (1988): 1624-6[10] Wijnands WJ, Vree TB, Baars AM, van Herwaarden CL \"Steady-state kinetics of the quinolone derivatives ofloxacin, enoxacin, ciprofloxacin and pefloxacin during maintneance treatment with theophylline.\" Drugs 34 (1987): 159-69[11] Raoof S, Wollschlager C, Khan FA \"Ciprofloxacin increases serum levels of theophylline.\" Am J Med 82 (1987): 115-8[12] Covelli HD, Knodel AR, Heppner BT \"Predisposing factors to apparent theophylline-induced seizures.\" Ann Allergy 54 (1985): 411-5[13] \"Product Information. Cinobac (cinoxacin).\" Oclassen Pharmaceuticals Inc, San Rafael, CA.[14] Ball P \"Ciprofloxacin: an overview of adverse experiences.\" J Antimicrob Chemother 18 (1986): 187-93[15] Green L, Clark J \"Fluoroquinolones and theophylline toxicity: norfloxacin.\" JAMA 262 (1989): 2383[16] Hooper DC, Wolfson JS \"The fluoroquinolones: pharmacology, clinical uses, and toxicities in humans.\" Antimicrob Agents Chemother 28 (1985): 716-21", "alternatives_a": "Omalizumab, Tezepelumab, Benralizumab, Reslizumab, Montelukast, Dyphylline, Oxtriphylline, Mepolizumab, Roflumilast, Pentoxifylline, Zafirlukast, Bromotheophylline", "alternatives_b": "Gatifloxacin, Levofloxacin, Gemifloxacin, Lomefloxacin, Trovafloxacin, Delafloxacin, Sparfloxacin", "updated_at": 1767369485}, {"id": 97434, "ingredient1": "Theophylline", "ingredient2": "Nebivolol", "severity": "Major", "effect": "The pharmacologic effects of theophyllines and beta-blockers are opposite. Nonselective and high doses of cardioselective beta-blockers may cause severe or fatal bronchospasm by opposing theophylline-induced bronchodilation. Ophthalmic beta-blockers undergo significant systemic absorption and may also interact. In addition, propranolol and other beta-blockers may reduce the CYP450 hepatic metabolism of theophylline, and serum theophylline levels may be increased.", "source": "DDInter", "management_text": "Oral and ophthalmic nonselective beta-blockers (e.g., carteolol, carvedilol, levobunolol, metipranolol, nadolol, oxprenolol, penbutolol, pindolol, propranolol, sotalol, and timolol) are considered contraindicated in patients with bronchospastic diseases. Cardioselective beta-blockers should generally be avoided, or used with extreme caution if no other alternatives are available and the benefits outweigh the risks of potentially severe bronchospasm. If patients do receive this combination, they should be closely monitored for increased serum theophylline levels but decreased bronchodilatory effectiveness.", "mechanism_text": "Antagonism", "recommendation": "Oral and ophthalmic nonselective beta-blockers (e.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97538/", "reference_text": "[1] Upton RA \"Pharmacokinetic interactions between theophylline and other medication (Part II).\" Clin Pharmacokinet 20 (1991): 135-50[2] Mue S, Sasaki T, Shibahara S, et alT \"Influence of metoprolol on hemodynamics and respiratory function in asthmatic patients.\" Int J Clin Pharmacol Biopharm 17 (1979): 346-50[3] Lombardi TP, Bertino JS, Goldberg A, Middleton E, Slaughter RL \"The effects of a beta-2 selective adrenergic agonist and a beta- nonselective antagonist on theophylline clearance.\" J Clin Pharmacol 27 (1987): 523-9[4] Horvath JS, Woolcock AJ, Tiller DJ, Donnelly P, Armstrong J, Caterson R \"A comparison of metoprolol and propranolol on blood pressure and respiratory function in patients with hypertension.\" Aust N Z J Med 8 (1978): 1-6[5] Conrad KA, Nyman DW \"Effects of metoprolol and propranolol on theophylline elimination.\" Clin Pharmacol Ther 28 (1980): 463-7", "alternatives_a": "Omalizumab, Tezepelumab, Mercaptopurine, Benralizumab, Caffeine, Reslizumab, Montelukast, Mepolizumab, Roflumilast, Zafirlukast, Bromotheophylline", "alternatives_b": "Ivabradine, Olmesartan, Azilsartan medoxomil, Telmisartan, Candesartan, Sacubitril, Aliskiren, Eprosartan", "updated_at": 1767369485}, {"id": 97435, "ingredient1": "Theophylline", "ingredient2": "Nefazodone", "severity": "Moderate", "effect": "Coadministration with nefazodone may increase the plasma concentrations of drugs that are substrates of the CYP450 3A4 isoenzyme. The mechanism is decreased clearance due to inhibition of CYP450 3A4 activity by nefazodone.", "source": "DDInter", "management_text": "Caution is advised if nefazodone must be used concomitantly with medications that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range. A lower initial dosage, as well as clinical and laboratory monitoring, may be appropriate for some drugs.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if nefazodone must be used concomitantly with medications that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97539/", "reference_text": "[1] \"Product Information. Serzone (nefazodone).\" Bristol-Myers Squibb, Princeton, NJ.[2] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[3] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[4] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[5] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.", "alternatives_a": "Omalizumab, Tezepelumab, Mercaptopurine, Aminophylline, Benralizumab, Caffeine, Reslizumab, Dyphylline, Oxtriphylline, Mepolizumab, Roflumilast, More", "alternatives_b": "Maprotiline, Vortioxetine, Milnacipran, Levomilnacipran, Doxepin, Duloxetine, Isocarboxazid, Amoxapine, Imipramine, Esketamine, Phenelzine, More", "updated_at": 1767369485}, {"id": 97436, "ingredient1": "Theophylline", "ingredient2": "Nelfinavir", "severity": "Moderate", "effect": "Coadministration with nelfinavir may increase the plasma concentrations of drugs that are substrates of the CYP450 3A4 isoenzyme. The mechanism is decreased clearance due to inhibition of CYP450 3A4 activity by nelfinavir.", "source": "DDInter", "management_text": "Caution is advised if nelfinavir must be used concurrently with medications that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever nelfinavir is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if nelfinavir must be used concurrently with medications that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97540/", "reference_text": "[1] \"Product Information. Viracept (nelfinavir).\" Agouron Pharma Inc, La Jolla, CA.", "alternatives_a": "Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Amprenavir, Simeprevir, Valaciclovir, Zanamivir, Cabotegravir, Telaprevir, More", "alternatives_b": "Omalizumab, Tezepelumab, Mercaptopurine, Aminophylline, Benralizumab, Caffeine, Reslizumab, Montelukast, Dyphylline, Oxtriphylline, Mepolizumab, More", "updated_at": 1767369485}, {"id": 97437, "ingredient1": "Theophylline", "ingredient2": "Nisoldipine", "severity": "Minor", "effect": "Limited and controversial data suggest the following: either there is no significant interaction between theophylline and dihydropyridine calcium channel blockers, or theophylline serum levels increase after the addition of dihydropyridine calcium channel blockers. Data are available for nifedipine. Theophylline dosage should be reduced if necessary, and plasma levels should be checked when clinically necessary and appropriate. Patients should be advised to report any signs of theophylline toxicity including nausea, vomiting, diarrhea, headache, restlessness, insomnia, or irregular heartbeat to their physician.", "source": "DDInter", "management_text": "-", "mechanism_text": "Others", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97541/", "reference_text": "[1] Parrillo SJ, Venditto M \"Elevated theophylline blood levels from institution of nifedipine therapy.\" Ann Emerg Med 13 (1984): 216-7[2] Harrod CS \"Theophylline toxicity and nifedipine.\" Ann Intern Med 106 (1987): 480[3] Upton RA \"Pharmacokinetic interactions between theophylline and other medication (Part II).\" Clin Pharmacokinet 20 (1991): 135-50[4] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[5] Bailey DG, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit juice felodipine interaction: Effect of naringin and 6',7'-dihydroxybergamottin in humans.\" Clin Pharmacol Ther 64 (1998): 248-56[6] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[7] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions.\" Br J Clin Pharmacol 46 (1998): 101-10[8] \"Product Information. Procardia (nifedipine).\" Pfizer US Pharmaceuticals, New York, NY.[9] Takanaga H, Ohnishi A, Maatsuo H, et al. \"Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model.\" Br J Clin Pharmacol 49 (2000): 49-58[10] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84[11] Edgar B, Bailey D, Bergstrand R, Johnsson G, Regardh CG \"Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics of felodipine--and its potential clinical relevance.\" Eur J Clin Pharmacol 42 (1992): 313-7[12] Bailey DG, Arnold JMO, Spence JD \"Grapefruit juice and drugs - how significant is the interaction.\" Clin Pharmacokinet 26 (1994): 91-8[13] Josefsson M, Zackrisson AL, Ahlner J \"Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers.\" Eur J Clin Pharmacol 51 (1996): 189-93[14] Fuhr U, Muller-Peltzer H, Kern R, et al. \"Effects of grapefruit juice and smoking on verapamil concentrations in steady state.\" Eur J Clin Pharmacol 58 (2002): 45-53[15] Gunston GD, Mehta U \"Potentially serious drug interactions with grapefruit juice.\" S Afr Med J 90 (2000): 41[16] Fuhr U, Maier-Bruggemann A, Blume H, et al. \"Grapefruit juice increases oral nimodipine bioavailability.\" Int J Clin Pharmacol Ther 36 (1998): 126-32[17] \"Product Information. Sular (nisoldipine).\" Zeneca Pharmaceuticals, Wilmington, DE.[18] Ho PC, Ghose K, Saville D, Wanwimolruk S \"Effect of grapefruit juice on pharmacokinetics and pharmacodynamics of verapamil enantiomers in healthy volunteers.\" Eur J Clin Pharmacol 56 (2000): 693-8[19] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[20] Bailey DG, Arnold JM, Strong HA, Munoz C, Spence JD \"Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics.\" Clin Pharmacol Ther 54 (1993): 589-94[21] Bailey DG, Arnold JM, Munoz C, Spence JD \"Grapefruit juice--felodipine interaction: mechanism, predictability, and effect of naringin.\" Clin Pharmacol Ther 53 (1993): 637-42[22] \"Product Information. Plendil (felodipine).\" Merck & Co, Inc, West Point, PA.", "alternatives_a": "Omalizumab, Tezepelumab, Mercaptopurine, Benralizumab, Caffeine, Reslizumab, Dyphylline, Mepolizumab, Roflumilast, Zafirlukast, Bromotheophylline", "alternatives_b": "Nicardipine, Isradipine, Clevidipine, Levamlodipine, Nimodipine", "updated_at": 1767369485}, {"id": 97438, "ingredient1": "Theophylline", "ingredient2": "Nizatidine", "severity": "Moderate", "effect": "Cimetidine may increase theophylline plasma concentrations by as much as 70%. The mechanism is related to inhibition of liver CYP450 enzymes responsible for theophylline metabolism. Patients with chronic obstructive pulmonary disease, congestive heart failure, or cirrhosis may have slower theophylline clearance rates; therefore, they may be at greater risk of developing theophylline toxicity.", "source": "DDInter", "management_text": "Clinical monitoring of patient response, tolerance, and laboratory theophylline serum concentrations is recommended. Patients should be advised to report any signs of theophylline toxicity including nausea, vomiting, diarrhea, headache, restlessness, insomnia, or irregular heartbeat to their physician.", "mechanism_text": "Metabolism", "recommendation": "Clinical monitoring of patient response, tolerance, and laboratory theophylline serum concentrations is recommended.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97542/", "reference_text": "[1] Schwartz JI, Bachmann KA, Bond LW, Mahajan VK \"Impact of cimetidine on the pharmacokinetics of the theophylline.\" Clin Pharm 1 (1982): 534-8[2] Jackson JE, Powell JR, Wandell M, Bentley J, Dorr R \"Cimetidine decreases theophylline clearance.\" Am Rev Respir Dis 123 (1981): 615-7[3] Anderson JR, Poklis A, Slavin RG \"A fatal case of theophylline intoxication.\" Arch Intern Med 143 (1983): 559-60[4] Weinberger MM, Smith G, Milavetz G, Hendeles L \"Decreased clearance of theophylline due to cimetidine .\" N Engl J Med 304 (1981): 672[5] Skinner MH, Lenert L, Blaschke TF \"Theophylline toxicity subsequent to ranitidine administration: a possible drug-drug interaction.\" Am J Med 86 (1989): 129-32[6] Bauman JH, Kimelblatt BJ, Caraccio TR, Silverman HM, Simon GI, Beck GJ \"Cimetidine-theophylline interaction: report of four patients.\" Ann Allergy 48 (1982): 100-2[7] Lofgren RP, Gilbertson RA \"Cimetidine and theophylline.\" Ann Intern Med 96 (1982): 378[8] Powell JR, Rogers JF, Wargin WA, Cross RE, Eshelman FN \"Inhibition of theophylline clearance by cimetidine but not ranitidine.\" Arch Intern Med 144 (1984): 484-6[9] Kelly HW, Powell JR, Donohue JF \"Ranitidine at very large doses does not inhibit theophylline elimination.\" Clin Pharmacol Ther 39 (1986): 577-81[10] Bachmann K, Sullivan TJ, Reese JH, Jauregui L, Miller K, Scott M, Yeh KC, Stepanavage M, King JD, Schwartz J \"Controlled study of the putative interaction between famotidine and theophylline in patients with chronic obstructive pulmonary disease.\" J Clin Pharmacol 35 (1995): 529-35[11] Kelly HW \"Lack of evidence for reduction of theophylline clearance by ranitidine.\" Am J Med 86 (1989): 629-32[12] Hegman GW, Gilbert RP \"Ranitidine-theophylline interaction--fact or fiction?\" Ann Pharmacother 25 (1991): 21-5[13] Fernandes E, Melewicz FM \"Ranitidine and theophylline.\" Ann Intern Med 100 (1984): 459[14] Reitberg DP, Bernhard H, Schentag JJ \"Alteration of theophylline clearance and half-life by cimetidine in normal volunteers.\" Ann Intern Med 95 (1981): 582-5[15] Bachmann KA, Sullivan TJ, Jauregui L, Reese J, Miller K, Levine L \"Drug interactions of h-2-receptor antagonists.\" Scand J Gastroenterol 29 (1994): 14-9[16] Kehoe WA, Sands CD, Long LF, et al \"Effect of ranitidine on theophylline metabolism in healthy Koreans living in China.\" Ann Pharmacother 30 (1996): 133-7[17] Boehning W \"Effect of cimetidine and ranitidine on plasma theophylline in patients with chronic obstructive airways disease treated with theophylline and corticosteroids.\" Eur J Clin Pharmacol 38 (1990): 43-5[18] Campbell MA, Plachetka JR, Jackson JE, Moon JF, Finley PR \"Cimetidine decreases theophylline clearance.\" Ann Intern Med 95 (1981): 68-9[19] Loi CM, Parker BM, Cusack BJ, Vestal RE \"Aging and drug interactions .3. individual and combined effects of cimetidine and ciprofloxacin on theophylline metabolism in healthy male and female nonsmokers.\" J Pharmacol Exp Ther 280 (1997): 627-37[20] Ohashi K, Sakamoto K, Sudo T, Tateishi T, Fujimura A, Shiga T, Ebihara A \"Effects of diltiazem and cimetidine on theophylline oxidative metabolism.\" J Clin Pharmacol 33 (1993): 1233-7[21] Pride M, Deamer RL \"Over-the-counter cimetidine and theophylline interaction.\" Am Fam Physician 52 (1995): 2180[22] Verdiani P, Di Carlo S, Baronti A \"Famotidine effects on theophylline pharmacokinetics in subjects affected by COPD: comparison with cimetidine and placebo.\" Chest 94 (1988): 807-10[23] Boehning W \"Effect of cimetidine and ranitidine on plasma theophylline in patients with chronic obstructive airways disease treated with theophylline and corticosteroids.\" Eur J Clin Pharmacol 38 (1990): 43-5[24] Hardman JG, Gilman AG, Limbird LE eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 9th ed.\" New York, NY: McGraw-Hill (1995):[25] Roy AK, Cuda MP, Levine RA \"Induction of theophylline toxicity and inhibition of clearance rates by ranitidine.\" Am J Med 85 (1988): 525-7[26] Fenje PC, Isles AF, Baltodano A, MacLeod SM, Soldin S \"Interaction of cimetidine and theophylline in two infants.\" Can Med Assoc J 126 (1982): 1178[27] Upton RA \"Pharmacokinetic interactions between theophylline and other medication (Part II).\" Clin Pharmacokinet 20 (1991): 135-50[28] Dal Negro R, Pomari C, Turco P \"Famotidine and theophylline pharmacokinetics. An unexpected cimetidine-like interaction in patients with chronic obstructive pulmonary disease.\" Clin Pharmacokinet 24 (1993): 255-8[29] Hsu K, Garton A, Sproule BJ, Tam YK, Leggatt D, Herbert FA \"The influence of orally administered cimetidine and theophylline on the elimination of each drug in patients with chronic airways obstruction.\" Am Rev Respir Dis 130 (1984): 740-3[30] Lin JH, Chremos AN, Chiou R, Yeh KC, Williams R \"Comparative effect of famotidine and cimetidine on the pharmacokinetics of theophylline in normal volunteers.\" Br J Clin Pharmacol 24 (1987): 669-72", "alternatives_a": "Omalizumab, Tezepelumab, Mercaptopurine, Benralizumab, Caffeine, Reslizumab, Dyphylline, Mepolizumab, Roflumilast, Bromotheophylline", "alternatives_b": "Tinidazole, Levofloxacin, Dexlansoprazole, Misoprostol, Bismuth subcitrate potassium, Rifabutin, Vonoprazan, Amoxicillin", "updated_at": 1767369485}, {"id": 97439, "ingredient1": "Theophylline", "ingredient2": "Norfloxacin", "severity": "Moderate", "effect": "Some fluoroquinolones have been shown to decrease the hepatic metabolism of theophyllines. The mechanism is inhibition of CYP450 1A2 hepatic metabolism. Patients with chronic obstructive pulmonary disease, congestive heart failure, or cirrhosis may have slower theophylline clearance rates; therefore, they may be at greater risk of developing theophylline toxicity. This drug combination may increase the risk of seizures, especially in the elderly. Interpatient variability of this effect makes it prudent to monitor patients who may not tolerate a small increase in theophylline levels during concurrent fluoroquinolone therapy.", "source": "DDInter", "management_text": "Interpatient variability of this effect makes it prudent to monitor patients who may not tolerate a small increase in theophylline levels. Levofloxacin, sparfloxacin, and lomefloxacin have been reported to cause minor or no changes in theophylline levels and may be considered as alternatives. Patients should be advised to report any signs of theophylline toxicity including nausea, vomiting, diarrhea, headache, restlessness, insomnia, seizures, or irregular heartbeat to their physicians.", "mechanism_text": "Metabolism", "recommendation": "Interpatient variability of this effect makes it prudent to monitor patients who may not tolerate a small increase in theophylline levels.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97543/", "reference_text": "[1] Davis RL, Kelly HW, Quenzer RW, Standefer J, Steinberg B, Gallegos J \"Effect of norfloxacin on theophyllin metabolism.\" Antimicrob Agents Chemother 33 (1989): 212-4[2] Grasela TH, Dreis MW \"An evaluation of the quinolone-theophylline interaction using the Food and Drug Administration spontaneous reporting system.\" Arch Intern Med 152 (1992): 617-21[3] Wijnands WJ, Vree TB \"Interaction between the fluoroquinolones and the bronchodilator theophylline.\" J Antimicrob Chemother 22 (1988): 109-14[4] Ho G, Tierney MG, Dales RE \"Evaluation of the effect of norfloxacin on the pharmacokinetics of theophylline.\" Clin Pharmacol Ther 44 (1988): 35-8[5] Bowles SK, Popovski Z, Rybak MJ, Beckman HB, Edwards DJ \"Effect of norfloxacin on theophylline pharmacokinetics at steady state.\" Antimicrob Agents Chemother 32 (1988): 510-12[6] Gregoire SL, Grasela TH Jr, Freer JP, Tack KJ, Schentag JJ \"Inhibition of theophylline clearance by coadministered ofloxacin without alteraction of theophylline effects.\" Antimicrob Agents Chemother 31 (1987): 375-8[7] Upton RA \"Pharmacokinetic interactions between theophylline and other medication (Part I).\" Clin Pharmacokinet 20 (1991): 66-80[8] Sano M, Yamamoto I, Ueda J, Yoskikawa E, Yamashina H, Goto M \"Comparative pharmacokinetics of theophylline following two fluoroquinolones co-administration.\" Eur J Clin Pharmacol 32 (1987): 431-2[9] Segev S. Rehavi M, Rubinstein E \"Quinolones, theophylline, and diclofenac interactions with the gamma-aminobutyric acid receptor.\" Antimicrob Agents Chemother 32 (1988): 1624-6[10] Wijnands WJ, Vree TB, Baars AM, van Herwaarden CL \"Steady-state kinetics of the quinolone derivatives ofloxacin, enoxacin, ciprofloxacin and pefloxacin during maintneance treatment with theophylline.\" Drugs 34 (1987): 159-69[11] Raoof S, Wollschlager C, Khan FA \"Ciprofloxacin increases serum levels of theophylline.\" Am J Med 82 (1987): 115-8[12] Covelli HD, Knodel AR, Heppner BT \"Predisposing factors to apparent theophylline-induced seizures.\" Ann Allergy 54 (1985): 411-5[13] \"Product Information. Cinobac (cinoxacin).\" Oclassen Pharmaceuticals Inc, San Rafael, CA.[14] Ball P \"Ciprofloxacin: an overview of adverse experiences.\" J Antimicrob Chemother 18 (1986): 187-93[15] Green L, Clark J \"Fluoroquinolones and theophylline toxicity: norfloxacin.\" JAMA 262 (1989): 2383[16] Hooper DC, Wolfson JS \"The fluoroquinolones: pharmacology, clinical uses, and toxicities in humans.\" Antimicrob Agents Chemother 28 (1985): 716-21", "alternatives_a": "Omalizumab, Tezepelumab, Benralizumab, Reslizumab, Dyphylline, Mepolizumab, Roflumilast, Pentoxifylline, Zafirlukast, Bromotheophylline", "alternatives_b": "Tinidazole, Cefepime, Secnidazole, Cefixime, Levofloxacin, Gatifloxacin, Rifamycin, Kanamycin, Lomefloxacin, Ampicillin, Netilmicin, More", "updated_at": 1767369485}, {"id": 97440, "ingredient1": "Theophylline", "ingredient2": "Norgestrel", "severity": "Moderate", "effect": "The coadministration with contraceptive steroids may increase the plasma concentrations of theophylline and other methylxanthines. The proposed mechanism is inhibition of methylxanthine metabolism via hepatic microsomal enzymes, of which estrogens and progestins are also substrates.", "source": "DDInter", "management_text": "Caution is advised during concomitant therapy with methylxanthines and hormonal contraceptives. Serum theophylline levels and pharmacologic response should be monitored and the dosage adjusted accordingly, particularly following initiation or discontinuation of hormonal contraceptives in patients who are stabilized on their theophylline regimen. Patients should be advised to notify their physician if they experience signs and symptoms of theophylline toxicity such as nausea, vomiting, diarrhea, headache, restlessness, insomnia, and irregular heartbeat.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised during concomitant therapy with methylxanthines and hormonal contraceptives.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97544/", "reference_text": "[1] Gardner MJ, Tornatore KM, Jusko WJ, Kanarkowski R \"Effects of tobacco smoking and oral contraceptive use on theophylline disposition.\" Br J Clin Pharmacol 16 (1983): 271-80[2] Tornatore KM, Kanarkowski R, McCarthy TL, et al \"Effect of chronic oral contraceptive steroids on theophylline disposition.\" Eur J Clin Pharmacol 23 (1982): 129-34[3] Roberts RK, Grice J, McGuffie, Heilbronn L \"Oral contraceptive steroids impair the elimination of theophylline.\" J Lab Clin Med 101 (1983): 821-25[4] Gunston GD, Mehta U \"Potentially serious drug interactions with grapefruit juice.\" S Afr Med J 90 (2000): 41[5] Bailey DG, Arnold JMO, Spence JD \"Grapefruit juice and drugs - how significant is the interaction.\" Clin Pharmacokinet 26 (1994): 91-8[6] Fuhr U, Maier-Bruggemann A, Blume H, et al. \"Grapefruit juice increases oral nimodipine bioavailability.\" Int J Clin Pharmacol Ther 36 (1998): 126-32[7] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[8] Libersa CC, Brique SA, Motte KB, et al. \"Dramatic inhibition of amiodarone metabolism induced by grapefruit juice.\" Br J Clin Pharmacol 49 (2000): 373-8[9] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions.\" Br J Clin Pharmacol 46 (1998): 101-10[10] Bailey DG, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit juice felodipine interaction: Effect of naringin and 6',7'-dihydroxybergamottin in humans.\" Clin Pharmacol Ther 64 (1998): 248-56[11] Takanaga H, Ohnishi A, Maatsuo H, et al. \"Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model.\" Br J Clin Pharmacol 49 (2000): 49-58[12] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[13] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS \"Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice.\" Br J Clin Pharmacol 42 (1996): p662[14] Eagling VA, Profit L, Back DJ \"Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-I protease inhibitor saquinavir by grapefruit juice components.\" Br J Clin Pharmacol 48 (1999): 543-52[15] Bailey DG, Arnold JM, Strong HA, Munoz C, Spence JD \"Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics.\" Clin Pharmacol Ther 54 (1993): 589-94[16] Damkier P, Hansen LL, Brosen K \"Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine.\" Br J Clin Pharmacol 48 (1999): 829-38[17] Min DI, Ku YM, Geraets DR, Lee HC \"Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers.\" J Clin Pharmacol 36 (1996): 469-76[18] Josefsson M, Zackrisson AL, Ahlner J \"Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers.\" Eur J Clin Pharmacol 51 (1996): 189-93[19] Majeed A, Kareem A \"Effect of grapefruit juice on cyclosporine pharmacokinetics.\" Pediatr Nephrol 10 (1996): 395[20] Flanagan D \"Understanding the grapefruit-drug interaction.\" Gen Dent 53 (2005): 282-5; quiz 286[21] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ \"Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice.\" Clin Pharmacol Ther 58 (1995): 127-31[22] Jonkman JH, Sollie FA, Sauter R, Steinijans VW \"The influence of caffeine on the steady-state pharmacokinetics of theophylline.\" Clin Pharmacol Ther 49 (1991): 248-55[23] Ozdemir M, Aktan Y, Boydag BS, Cingi MI, Musmul A \"Interaction between grapefruit juice and diazepam in humans.\" Eur J Drug Metab Pharmacokinet 23 (1998): 55-9[24] Edgar B, Bailey D, Bergstrand R, et al \"Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics on felodipine and its potential clinical relevance.\" Eur J Clin Pharmacol 42 (1992): 313-7[25] Kantola T, Kivisto KT, Neuvonen PJ \"Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid.\" Clin Pharmacol Ther 63 (1998): 397-402[26] Lee AJ, Chan WK, Harralson AF, Buffum J, Bui BCC \"The effects of grapefruit juice on sertraline metabolism: An in vitro and in vivo study.\" Clin Ther 21 (1999): 1890-9[27] Sato J, Nakata H, Owada E, Kikuta T, Umetsu M, Ito K \"Influence of usual intake of dietary caffeine on single-dose kinetics of theophylline in healthy human subjects.\" Eur J Clin Pharmacol 44 (1993): 295-8[28] Dresser GK, Spence JD, Bailey DG \"Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition.\" Clin Pharmacokinet 38 (2000): 41-57[29] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin.\" Clin Pharmacol Ther 66 (1999): 118-27[30] Sigusch H, Hippius M, Henschel L, Kaufmann K, Hoffmann A \"Influence of grapefruit juice on the pharmacokinetics of a slow release nifedipine formulation.\" Pharmazie 49 (1994): 522-4[31] Bailey DG, Arnold JM, Munoz C, Spence JD \"Grapefruit juice--felodipine interaction: mechanism, predictability, and effect of naringin.\" Clin Pharmacol Ther 53 (1993): 637-42[32] Zaidenstein R, Soback S, Gips M, Avni B, Dishi V, Weissgarten Y, Golik A, Scapa E \"Effect of grapefruit juice on the pharmacokinetics of losartan and its active metabolite E3174 in healthy volunteers.\" Ther Drug Monit 23 (2001): 369-73[33] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84[34] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors.\" Clin Pharmacol Ther 64 (1998): 477-83[35] Garg SK, Kumar N, Bhargava VK, Prabhakar SK \"Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy.\" Clin Pharmacol Ther 64 (1998): 286-8", "alternatives_a": "Omalizumab, Tezepelumab, Mercaptopurine, Benralizumab, Caffeine, Reslizumab, Montelukast, Dyphylline, Mepolizumab, Roflumilast, Pentoxifylline, More", "alternatives_b": "Megestrol acetate, Progesterone, Medroxyprogesterone acetate, Megestrol acetate, Ulipristal, Estetrol, Medroxyprogesterone acetate", "updated_at": 1767369485}, {"id": 97441, "ingredient1": "Theophylline", "ingredient2": "Obeticholic acid", "severity": "Moderate", "effect": "Coadministration with obeticholic acid may increase the plasma concentrations of drugs that are substrates of the CYP450 1A2 isoenzyme. The mechanism is decreased clearance due to inhibition of CYP450 1A2 activity by obeticholic acid and its glycine and taurine conjugates.", "source": "DDInter", "management_text": "Caution is advised when obeticholic acid is prescribed with drugs that undergo metabolism by CYP450 1A2, particularly those with a narrow therapeutic range such as theophylline or tizanidine. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever obeticholic acid is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when obeticholic acid is prescribed with drugs that undergo metabolism by CYP450 1A2, particularly those with a narrow therapeutic range such as theophylline or tizanidine.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97545/", "reference_text": "[1] \"Product Information. Ocaliva (obeticholic acid).\" Intercept Pharmaceuticals, Inc., New York, NY.", "alternatives_a": "Omalizumab, Tezepelumab, Mercaptopurine, Benralizumab, Reslizumab, Montelukast, Dyphylline, Mepolizumab, Zafirlukast, Bromotheophylline", "alternatives_b": "Maralixibat, Ursodeoxycholic acid, Cholic Acid, Odevixibat, Chenodeoxycholic acid", "updated_at": 1767369485}, {"id": 97442, "ingredient1": "Theophylline", "ingredient2": "Ofloxacin", "severity": "Moderate", "effect": "Some fluoroquinolones have been shown to decrease the hepatic metabolism of theophyllines. The mechanism is inhibition of CYP450 1A2 hepatic metabolism. Patients with chronic obstructive pulmonary disease, congestive heart failure, or cirrhosis may have slower theophylline clearance rates; therefore, they may be at greater risk of developing theophylline toxicity. This drug combination may increase the risk of seizures, especially in the elderly. Interpatient variability of this effect makes it prudent to monitor patients who may not tolerate a small increase in theophylline levels during concurrent fluoroquinolone therapy.", "source": "DDInter", "management_text": "Interpatient variability of this effect makes it prudent to monitor patients who may not tolerate a small increase in theophylline levels. Levofloxacin, sparfloxacin, and lomefloxacin have been reported to cause minor or no changes in theophylline levels and may be considered as alternatives. Patients should be advised to report any signs of theophylline toxicity including nausea, vomiting, diarrhea, headache, restlessness, insomnia, seizures, or irregular heartbeat to their physicians.", "mechanism_text": "Metabolism", "recommendation": "Interpatient variability of this effect makes it prudent to monitor patients who may not tolerate a small increase in theophylline levels.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97546/", "reference_text": "[1] Davis RL, Kelly HW, Quenzer RW, Standefer J, Steinberg B, Gallegos J \"Effect of norfloxacin on theophyllin metabolism.\" Antimicrob Agents Chemother 33 (1989): 212-4[2] Grasela TH, Dreis MW \"An evaluation of the quinolone-theophylline interaction using the Food and Drug Administration spontaneous reporting system.\" Arch Intern Med 152 (1992): 617-21[3] Wijnands WJ, Vree TB \"Interaction between the fluoroquinolones and the bronchodilator theophylline.\" J Antimicrob Chemother 22 (1988): 109-14[4] Ho G, Tierney MG, Dales RE \"Evaluation of the effect of norfloxacin on the pharmacokinetics of theophylline.\" Clin Pharmacol Ther 44 (1988): 35-8[5] Bowles SK, Popovski Z, Rybak MJ, Beckman HB, Edwards DJ \"Effect of norfloxacin on theophylline pharmacokinetics at steady state.\" Antimicrob Agents Chemother 32 (1988): 510-12[6] Gregoire SL, Grasela TH Jr, Freer JP, Tack KJ, Schentag JJ \"Inhibition of theophylline clearance by coadministered ofloxacin without alteraction of theophylline effects.\" Antimicrob Agents Chemother 31 (1987): 375-8[7] Upton RA \"Pharmacokinetic interactions between theophylline and other medication (Part I).\" Clin Pharmacokinet 20 (1991): 66-80[8] Sano M, Yamamoto I, Ueda J, Yoskikawa E, Yamashina H, Goto M \"Comparative pharmacokinetics of theophylline following two fluoroquinolones co-administration.\" Eur J Clin Pharmacol 32 (1987): 431-2[9] Segev S. Rehavi M, Rubinstein E \"Quinolones, theophylline, and diclofenac interactions with the gamma-aminobutyric acid receptor.\" Antimicrob Agents Chemother 32 (1988): 1624-6[10] Wijnands WJ, Vree TB, Baars AM, van Herwaarden CL \"Steady-state kinetics of the quinolone derivatives ofloxacin, enoxacin, ciprofloxacin and pefloxacin during maintneance treatment with theophylline.\" Drugs 34 (1987): 159-69[11] Raoof S, Wollschlager C, Khan FA \"Ciprofloxacin increases serum levels of theophylline.\" Am J Med 82 (1987): 115-8[12] Covelli HD, Knodel AR, Heppner BT \"Predisposing factors to apparent theophylline-induced seizures.\" Ann Allergy 54 (1985): 411-5[13] \"Product Information. Cinobac (cinoxacin).\" Oclassen Pharmaceuticals Inc, San Rafael, CA.[14] Ball P \"Ciprofloxacin: an overview of adverse experiences.\" J Antimicrob Chemother 18 (1986): 187-93[15] Green L, Clark J \"Fluoroquinolones and theophylline toxicity: norfloxacin.\" JAMA 262 (1989): 2383[16] Hooper DC, Wolfson JS \"The fluoroquinolones: pharmacology, clinical uses, and toxicities in humans.\" Antimicrob Agents Chemother 28 (1985): 716-21", "alternatives_a": "Omalizumab, Tezepelumab, Benralizumab, Caffeine, Reslizumab, Dyphylline, Mepolizumab, Roflumilast, Bromotheophylline", "alternatives_b": "Gatifloxacin, Levofloxacin, Gemifloxacin, Lomefloxacin, Trovafloxacin, Delafloxacin, Sparfloxacin, Tinidazole, Cefepime, Secnidazole, Cefixime, More", "updated_at": 1767369485}, {"id": 97443, "ingredient1": "Theophylline", "ingredient2": "Olaparib", "severity": "Moderate", "effect": "Coadministration with olaparib may decrease the plasma concentrations and therapeutic effects of drugs that are substrates of CYP450 1A2 and/or 2B6. The proposed mechanism, based on in vitro data, is increased clearance due to olaparib-mediated induction of CYP450 1A2 and/or 2B6.", "source": "DDInter", "management_text": "Caution is advised if olaparib is used concomitantly with drugs that are substrates of CYP450 1A2 and/or 2B6. Pharmacologic response and serum levels should be monitored more closely whenever olaparib is added to or withdrawn from therapy with these drugs. Dosage adjustments may be required if an interaction is suspected.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if olaparib is used concomitantly with drugs that are substrates of CYP450 1A2 and/or 2B6.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97547/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] EMA. European Medicines Agency. European Union \"EMA - List of medicines under additional monitoring. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000366.jsp&mid=WC0b01ac058067c852\" ([2013 - ]):[4] \"Product Information. Lynparza (olaparib).\" Astra-Zeneca Pharmaceuticals, Wilmington, DE.[5] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[6] Cerner Multum, Inc. \"Australian Product Information.\" O 0[7] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[8] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[9] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[10] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.", "alternatives_a": "Omalizumab, Tezepelumab, Aminophylline, Benralizumab, Reslizumab, Montelukast, Dyphylline, Oxtriphylline, Mepolizumab, Bromotheophylline", "alternatives_b": "Pertuzumab, Oxaliplatin, Bortezomib, Tisagenlecleucel, Aminolevulinic acid, Omacetaxine mepesuccinate, Tazemetostat, Altretamine, Tagraxofusp, Pegaspargase, Ixazomib, More", "updated_at": 1767369485}, {"id": 97444, "ingredient1": "Theophylline", "ingredient2": "Olodaterol", "severity": "Moderate", "effect": "Concomitant use of beta-2 adrenergic agonists with theophylline may increase the risk and/or severity of hypokalemia and adverse cardiovascular effects such as palpitation, tachycardia, and blood pressure elevation. Adverse events, especially hypokalemia, may be more likely with systemic or nebulized formulations of beta-2 agonists or high dosages of theophylline. Beta-2 agonists can cause clinically significant but usually transient decreases in serum potassium concentrations, while hypokalemia associated with theophylline often occurs in toxicity. Pharmacokinetically, some beta-2 agonists given systemically may decrease the plasma concentrations of theophylline.", "source": "DDInter", "management_text": "Although theophylline and beta-2 agonists are commonly used together to produce bronchodilation, it may be appropriate to monitor patient response as well as serum potassium level, blood pressure and heart rate during coadministration, especially if the beta-2 agonist is administered systemically or by nebulizer. Close monitoring is particularly important in patients with severe asthma, since the potential increases in blood pressure and heart rate may have more serious consequences in the presence of hypoxemia or hypercapnia due to increased myocardial oxygen consumption. Patients should be advised to notify their physician if they experience worsening of their respiratory condition or potential signs and symptoms of hypokalemia such as fatigue, weakness, myalgia, muscle cramps, numbness, tingling, abdominal pain, constipation, palpitation, and irregular heartbeat.", "mechanism_text": "Synergism", "recommendation": "Although theophylline and beta-2 agonists are commonly used together to produce bronchodilation, it may be appropriate to monitor patient response as well as serum potassium level, blood pressure and heart rate during coadministration, especially if the beta-2 agonist is administered systemically or by nebulizer.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97548/", "reference_text": "[1] Garty M, Paul-Keslin L, Ilfeld DN, et al \"Increased theophylline clearance in asthmatic patients due to terbutaline.\" Eur J Clin Pharmacol 36 (1989): 25-8[2] Amirav I, Amitai Y, Avital A, Godfrey S \"Enhancement of theophylline clearance by intravenous albuterol.\" Chest 94 (1988): 444-5[3] \"Product Information. Striverdi Respimat (olodaterol).\" Boehringer Ingelheim, Ridgefield, CT.[4] Cusack BJ, Nielson CP, Morgan ME, Vestal RE \"Additive effect of theophylline on the cardiac response to isoproterenol.\" Clin Pharmacol Ther 41 (1987): 289-96[5] Griffith JA, Kozloski GD \"Isoproterenol-theophylline interaction: possible potentiation by other drugs.\" Clin Pharm 9 (1990): 54-7[6] Conrad KA, Woodworth JR \"Orciprenaline does not alter theophylline elimination.\" Br J Clin Pharmacol 12 (1981): 756-7[7] Flatt A, Burgess C, Windom H, Beasley R, Purdie G, Crane J \"The cardiovascular effects of inhaled fenoterol alone and during treatment with oral theophylline.\" Chest 96 (1989): 1317-20[8] Smith SR, Kendall MJ \"Potentiation of the adverse effects of intravenous terbutaline by oral theophylline.\" Br J Clin Pharmacol 21 (1986): 451-3[9] Danzinger Y, Garty M, Volwitz B, Ilfeld D, Varsano I, Rosenfeld JB \"Reduction of serum theophylline levels by terbutaline in children with asthma.\" Clin Pharmacol Ther 37 (1985): 469-71[10] O'Rourke PP, Crone RK \"Effect of isoproterenol on measured theophylline levels.\" Crit Care Med 12 (1984): 373-5[11] Whyte KF, Reid C, Addis GJ, Whitesmith R, Reid JL \"Salbutamol induced hypokalaemia: the effect of theophylline alone and in combination with adrenaline.\" Br J Clin Pharmacol 25 (1988): 571-8[12] Coleman JJ, Vollmer WM, Barker AF, et al \"Cardiac arrhythmias during the combined use of beta-adrenergic agonist drugs and theophylline.\" Chest 90 (1986): 45-51[13] Kelly HW \"Controversies in asthma therapy with theophylline and the beta2-adrenergic agonists.\" Clin Pharm 3 (1984): 386-95[14] Amitai Y, Glustein J, Godfrey S \"Enhancement of theophylline clearance by oral albuterol.\" Chest 102 (1992): 786-9[15] \"Product Information. Brovana (arformoterol).\" Sepracor Inc, Marlborough, MA.[16] \"Interactions between methyl xanthines and beta adrenergic agonists.\" FDA Drug Bull 11 (1981): 19-20[17] Chow OK, Fung KP \"Slow-release terbutaline and theophylline for the long-term therapy of children with asthma: a Latin square and factorial study of drug effects and interactions.\" Pediatrics 84 (1989): 119-25[18] Hemstreet MP, Miles MV, Rutland RO \"Effect of intravenous isoproterenol on theophylline kinetics.\" J Allergy Clin Immunol 69 (1982): 360-4[19] Upton RA \"Pharmacokinetic interactions between theophylline and other medication (Part I).\" Clin Pharmacokinet 20 (1991): 66-80[20] Rachelefsky GS, Katz RM, Mickey MR Jr, Siegel SC \"Metaproterenol and theophylline in asthmatic children.\" Ann Allergy 45 (1980): 207-12[21] Josephson GW, Kennedy HL, MacKenzie EJ, Gibson G \"Cardiac dysrhythmias during the treatment of acute asthma. A comparison of two treatment regimens by a double blind protocol.\" Chest 78 (1980): 429-35[22] Dawson KP, Fergusson DM \"Effects of oral theophylline and oral salbutamol in the treatment of asthma.\" Arch Dis Child 57 (1982): 674-6[23] Jonkman JH, Borgstrom L, van der Boon WJ, de Noord OE \"Theophylline-terbutaline, a steady state study on possible pharmacokinetic interactions with special reference to chronopharmacokinetic aspects.\" Br J Clin Pharmacol 26 (1988): 285-93[24] Deenstra M, Haalboom JR, Struyvenberg A \"Decrease of plasma potassium due to inhalation of beta-2 agonists: absence of an additional effect of intravenous theophylline.\" Eur J Clin Invest 18 (1988): 162-5[25] \"Product Information. Arcapta Neohaler (indacaterol).\" Novartis Pharmaceuticals, East Hanover, NJ.[26] Lombardi TP, Bertino JS, Goldberg A, Middleton E, Slaughter RL \"The effects of a beta-2 selective adrenergic agonist and a beta- nonselective antagonist on theophylline clearance.\" J Clin Pharmacol 27 (1987): 523-9", "alternatives_a": "Omalizumab, Tezepelumab, Mercaptopurine, Benralizumab, Caffeine, Reslizumab, Montelukast, Mepolizumab, Roflumilast, Pentoxifylline, Zafirlukast, Bromotheophylline", "alternatives_b": "Mometasone furoate, Umeclidinium, Aclidinium, Mometasone, Glycopyrronium, Ipratropium, Beclomethasone dipropionate", "updated_at": 1767369485}, {"id": 97445, "ingredient1": "Theophylline", "ingredient2": "Osilodrostat", "severity": "Moderate", "effect": "Coadministration with osilodrostat may increase the plasma concentrations of drugs that are metabolized by CYP450 1A2 and/or 2C19. Osilodrostat has been shown to be a moderate inhibitor of CYP450 1A2 and a mild to borderline moderate inhibitor of CYP450 2C19.", "source": "DDInter", "management_text": "Caution is advised when osilodrostat is used concurrently with drugs that are substrates of CYP450 1A2 and/or 2C19, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever osilodrostat is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when osilodrostat is used concurrently with drugs that are substrates of CYP450 1A2 and/or 2C19, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97549/", "reference_text": "[1] \"Product Information. Isturisa (osilodrostat).\" Recordati Rare Diseases Inc, Lebanon, NJ.", "alternatives_a": "Omalizumab, Tezepelumab, Mercaptopurine, Aminophylline, Benralizumab, Reslizumab, Montelukast, Dyphylline, Oxtriphylline, Mepolizumab, Bromotheophylline", "alternatives_b": "", "updated_at": 1767369485}, {"id": 97446, "ingredient1": "Theophylline", "ingredient2": "Osimertinib", "severity": "Moderate", "effect": "Coadministration with osimertinib may decrease the plasma concentrations of drugs that are primarily metabolized by CYP450 1A2. In vitro, osimertinib has been shown to be an inducer of the isoenzyme.", "source": "DDInter", "management_text": "Caution is advised when osimertinib is prescribed with drugs that undergo metabolism by CYP450 1A2. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever osimertinib is added to or withdrawn from therapy. Sensitive CYP450 1A2 substrates or substrates with narrow therapeutic ranges (e.g., theophylline) should preferably be avoided with osimertinib, if possible.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when osimertinib is prescribed with drugs that undergo metabolism by CYP450 1A2.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97550/", "reference_text": "[1] \"Product Information. Tagrisso (osimertinib).\" Astra-Zeneca Pharmaceuticals, Wilmington, DE.", "alternatives_a": "Omalizumab, Tezepelumab, Mercaptopurine, Aminophylline, Benralizumab, Reslizumab, Montelukast, Dyphylline, Oxtriphylline, Mepolizumab, Pentoxifylline, Bromotheophylline", "alternatives_b": "Entrectinib, Imatinib, Dabrafenib, Asciminib, Acalabrutinib, Dacomitinib, Pexidartinib, Tepotinib, Fedratinib, Avapritinib, Bosutinib, More", "updated_at": 1767369485}, {"id": 97447, "ingredient1": "Theophylline", "ingredient2": "Oxazepam", "severity": "Minor", "effect": "Methylxanthines may antagonize the sedative effects of benzodiazepines. Aminophylline in particular has been demonstrated to attenuate the sedative effects of diazepam. The mechanism of this interaction may be related to competitive binding to intracerebral adenosine receptors.", "source": "DDInter", "management_text": "-", "mechanism_text": "Antagonism", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97551/", "reference_text": "[1] Tuncok Y, Akpinar O, Guven H, Akkoclu A \"The effects of theophylline on serum alprazolam levels.\" Int J Clin Pharmacol Ther 32 (1994): 642-5[2] Gallen JS \"Aminophylline reversal of midazolam sedation.\" Anesth Analg 69 (1989): 268[3] Bonfiglio MF, Dasta JF \"Clinical significance of the benzodiazepine-theophylline interaction.\" Pharmacotherapy 11 (1991): 85-7[4] Upton RA \"Pharmacokinetic interactions between theophylline and other medication (Part II).\" Clin Pharmacokinet 20 (1991): 135-50[5] Stirt JA \"Aminophylline is a diazepam antagonist.\" Anesth Analg 60 (1981): 767-8[6] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[7] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[8] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[9] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Omalizumab, Tezepelumab, Mercaptopurine, Benralizumab, Caffeine, Reslizumab, Mepolizumab, Roflumilast, Pentoxifylline, Zafirlukast, Bromotheophylline", "alternatives_b": "Meprobamate, Buspirone", "updated_at": 1767369485}, {"id": 97448, "ingredient1": "Theophylline", "ingredient2": "Oxytetracycline", "severity": "Moderate", "effect": "Coadministration of a tetracycline may decrease theophylline plasma clearance and increase theophylline levels. Data are available for minocycline, tetracycline, and doxycycline, but are conflicting in some cases. This interaction appears to be more problematic if a tetracycline is administered for more than five days. Patients with chronic obstructive pulmonary disease, congestive heart failure, or cirrhosis may have slower theophylline clearance rates; therefore, they may be at greater risk of developing theophylline toxicity.", "source": "DDInter", "management_text": "If these drugs are given concurrently, close clinical and laboratory monitoring of response and tolerance is recommended. Patients should be advised to notify their physician if they experience any signs of theophylline toxicity including nausea, vomiting, diarrhea, headache, restlessness, insomnia, seizures, or irregular heartbeats. It may be necessary to reduce theophylline dosage.", "mechanism_text": "Metabolism", "recommendation": "If these drugs are given concurrently, close clinical and laboratory monitoring of response and tolerance is recommended.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97552/", "reference_text": "[1] McCormack JP, Reid SE, Lawson LM \"Theophylline toxicity induced by tetracycline.\" Clin Pharm 9 (1990): 546-9[2] Gotz VP, Ryerson GG \"Evaluation of tetracycline on theophylline disposition in patients with chronic obstructive airways disease.\" Drug Intell Clin Pharm 20 (1986): 694-6[3] Upton RA \"Pharmacokinetic interactions between theophylline and other medication (Part I).\" Clin Pharmacokinet 20 (1991): 66-80[4] \"Product Information. Achromycin (tetracycline).\" Lederle Laboratories, Wayne, NJ.[5] \"Product Information. Declomycin (demeclocycline).\" Lederle Laboratories, Wayne, NJ.", "alternatives_a": "Omalizumab, Tezepelumab, Mercaptopurine, Benralizumab, Caffeine, Reslizumab, Montelukast, Dyphylline, Mepolizumab, Roflumilast, Pentoxifylline, More", "alternatives_b": "Tigecycline, Sarecycline, Omadacycline, Eravacycline, Gatifloxacin, Rifamycin, Kanamycin, Lomefloxacin, Ampicillin, Netilmicin, Polymyxin B, More", "updated_at": 1767369485}, {"id": 97449, "ingredient1": "Theophylline", "ingredient2": "Pancuronium", "severity": "Moderate", "effect": "Methylxanthines may antagonize the effects of neuromuscular blockers. The mechanism is unknown. In patients stabilized on aminophylline, resistance to pancuronium has been reported.", "source": "DDInter", "management_text": "The patient should be monitored for adequate neuromuscular blockade and the dosage adjusted, if necessary.", "mechanism_text": "Antagonism", "recommendation": "The patient should be monitored for adequate neuromuscular blockade and the dosage adjusted, if necessary.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97553/", "reference_text": "[1] Doll DC, Rosenberg H \"Antagonism of neuromuscular blockage by theophylline.\" Anesth Analg 58 (1979): 139-40[2] Azar I, Kumar D, Betcher AM \"Resistance to pancuronium in an asthmatic patient treated with aminophylline and steroids.\" Can Anaesth Soc J 29 (1982): 280-2[3] Daller JA, Erstad B, Rosado L, Otto C, Putnam CW \"Aminophylline antagonizes the neuromuscular blockade of pancuronium but not vecuronium.\" Crit Care Med 19 (1991): 983-5", "alternatives_a": "Omalizumab, Tezepelumab, Mercaptopurine, Benralizumab, Caffeine, Reslizumab, Montelukast, Mepolizumab, Roflumilast, Pentoxifylline, Zafirlukast, Bromotheophylline", "alternatives_b": "Botulinum toxin type A", "updated_at": 1767369485}, {"id": 97450, "ingredient1": "Theophylline", "ingredient2": "Pantoprazole", "severity": "Moderate", "effect": "Proton pump inhibitors may increase the rate of theophylline absorption from sustained-release formulations. Chronic use of proton pump inhibitors produce sustained hypochlorhydria, which may enhance peristalsis in the small intestine and antiperistalsis in the proximal colon where theophylline is absorbed.", "source": "DDInter", "management_text": "In patients treated with proton pump inhibitors, the possibility of an enhanced pharmacologic response to sustained-release theophylline should be considered. Patients should be closely monitored for development of toxicity, particularly those with theophylline levels in the upper range of normal. Patients should be advised to report any signs of theophylline toxicity including nausea, vomiting, diarrhea, headache, restlessness, insomnia, or irregular heartbeat to their physicians.", "mechanism_text": "Absorption", "recommendation": "In patients treated with proton pump inhibitors, the possibility of an enhanced pharmacologic response to sustained-release theophylline should be considered.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97554/", "reference_text": "[1] Sommers DK, van Wyk M, Snyman JR, Moncrieff J \"The effects of omeprazole-induced hypochlorhydria on absorption of theophylline from a sustained-release formulation.\" Eur J Clin Pharmacol 43 (1992): 141-3[2] Sato J, Nakata H, Owada E, Kikuta T, Umetsu M, Ito K \"Influence of usual intake of dietary caffeine on single-dose kinetics of theophylline in healthy human subjects.\" Eur J Clin Pharmacol 44 (1993): 295-8[3] Jonkman JH, Sollie FA, Sauter R, Steinijans VW \"The influence of caffeine on the steady-state pharmacokinetics of theophylline.\" Clin Pharmacol Ther 49 (1991): 248-55[4] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67", "alternatives_a": "Tinidazole, Levofloxacin, Dexlansoprazole, Misoprostol, Bismuth subcitrate potassium, Rifabutin, Vonoprazan, Amoxicillin", "alternatives_b": "Omalizumab, Tezepelumab, Benralizumab, Caffeine, Reslizumab, Dyphylline, Oxtriphylline, Mepolizumab, Roflumilast, Bromotheophylline", "updated_at": 1767369485}, {"id": 97451, "ingredient1": "Theophylline", "ingredient2": "Peginterferon alfa-2a", "severity": "Moderate", "effect": "The coadministration with interferons has been associated with decreases in clearance and increases in plasma concentration and elimination half-life of theophylline. The mechanism is unknown but may be related to interferon-induced suppression of hepatic CYP450 enzymes, particularly, CYP450 1A2.", "source": "DDInter", "management_text": "Caution is advised if theophylline or other methylxanthines are administered with an interferon. Pharmacologic response and serum theophylline levels should be monitored and the dosage adjusted accordingly, particularly following initiation or discontinuation of interferon therapy in patients who are stabilized on their methylxanthine regimen. Patients should be advised to contact their physician if they experience signs and symptoms of theophylline toxicity such as nausea, vomiting, diarrhea, headache, restlessness, insomnia, or irregular heartbeat.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if theophylline or other methylxanthines are administered with an interferon.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97555/", "reference_text": "[1] \"Product Information. Intron A (interferon alfa-2b).\" Schering Laboratories, Kenilworth, NJ.[2] Sakai H, Okamoto T, Kikkawa Y \"Suppression of hepatic drug metabolism by the interferon inducer polyriboinosinic acid:polyribocitidylic acid.\" J Pharmacol Exp Ther 263 (1992): 381-6[3] Jonkman JH, Nicholson KG, Farrow PR, et al \"Effects of alpha-interferon on theophylline pharmacokinetics and metabolism.\" Br J Clin Pharmacol 27 (1989): 795-802[4] Kramer P, Tsuru M, Cook CE, et al \"Effect of influenza vaccine on warfarin anticoagulation.\" Clin Pharmacol Ther 35 (1984): 416-8[5] Upton RA \"Pharmacokinetic interactions between theophylline and other medication (Part II).\" Clin Pharmacokinet 20 (1991): 135-50[6] Okuno H, Takasu M, Kano H, Seki T, Shiozaki Y, Inoue K \"Depression of drug-metabolizing activity in the human liver by interferon-beta.\" Hepatology 17 (1993): 65-9[7] Williams SJ, Baird-Lambert JA, Farrell GC \"Inhibition of theophylline metabolism by interferon.\" Lancet 10/24/87 (1987): 939-41[8] Cerner Multum, Inc. \"Australian Product Information.\" O 0[9] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0", "alternatives_a": "Oprelvekin, Sipuleucel-T, Elapegademase, Sargramostim, Histamine, Aldesleukin, Pegademase, Pegfilgrastim, Filgrastim, Glatiramer", "alternatives_b": "Omalizumab, Tezepelumab, Mercaptopurine, Benralizumab, Caffeine, Reslizumab, Montelukast, Dyphylline, Mepolizumab, Pentoxifylline, Bromotheophylline", "updated_at": 1767369485}, {"id": 97452, "ingredient1": "Theophylline", "ingredient2": "Peginterferon alfa-2b", "severity": "Moderate", "effect": "The coadministration with interferons has been associated with decreases in clearance and increases in plasma concentration and elimination half-life of theophylline. The mechanism is unknown but may be related to interferon-induced suppression of hepatic CYP450 enzymes, particularly, CYP450 1A2.", "source": "DDInter", "management_text": "Caution is advised if theophylline or other methylxanthines are administered with an interferon. Pharmacologic response and serum theophylline levels should be monitored and the dosage adjusted accordingly, particularly following initiation or discontinuation of interferon therapy in patients who are stabilized on their methylxanthine regimen. Patients should be advised to contact their physician if they experience signs and symptoms of theophylline toxicity such as nausea, vomiting, diarrhea, headache, restlessness, insomnia, or irregular heartbeat.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if theophylline or other methylxanthines are administered with an interferon.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97556/", "reference_text": "[1] \"Product Information. Intron A (interferon alfa-2b).\" Schering Laboratories, Kenilworth, NJ.[2] Sakai H, Okamoto T, Kikkawa Y \"Suppression of hepatic drug metabolism by the interferon inducer polyriboinosinic acid:polyribocitidylic acid.\" J Pharmacol Exp Ther 263 (1992): 381-6[3] Jonkman JH, Nicholson KG, Farrow PR, et al \"Effects of alpha-interferon on theophylline pharmacokinetics and metabolism.\" Br J Clin Pharmacol 27 (1989): 795-802[4] Kramer P, Tsuru M, Cook CE, et al \"Effect of influenza vaccine on warfarin anticoagulation.\" Clin Pharmacol Ther 35 (1984): 416-8[5] Upton RA \"Pharmacokinetic interactions between theophylline and other medication (Part II).\" Clin Pharmacokinet 20 (1991): 135-50[6] Okuno H, Takasu M, Kano H, Seki T, Shiozaki Y, Inoue K \"Depression of drug-metabolizing activity in the human liver by interferon-beta.\" Hepatology 17 (1993): 65-9[7] Williams SJ, Baird-Lambert JA, Farrell GC \"Inhibition of theophylline metabolism by interferon.\" Lancet 10/24/87 (1987): 939-41[8] Cerner Multum, Inc. \"Australian Product Information.\" O 0[9] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0", "alternatives_a": "Oprelvekin, Sipuleucel-T, Elapegademase, Sargramostim, Histamine, Aldesleukin, Pegademase, Pegfilgrastim, Filgrastim, Glatiramer", "alternatives_b": "Omalizumab, Tezepelumab, Mercaptopurine, Benralizumab, Caffeine, Reslizumab, Montelukast, Dyphylline, Mepolizumab, Pentoxifylline, Bromotheophylline", "updated_at": 1767369485}, {"id": 97453, "ingredient1": "Theophylline", "ingredient2": "Peginterferon beta-1a", "severity": "Moderate", "effect": "The coadministration with interferons has been associated with decreases in clearance and increases in plasma concentration and elimination half-life of theophylline. The mechanism is unknown but may be related to interferon-induced suppression of hepatic CYP450 enzymes, particularly, CYP450 1A2.", "source": "DDInter", "management_text": "Caution is advised if theophylline or other methylxanthines are administered with an interferon. Pharmacologic response and serum theophylline levels should be monitored and the dosage adjusted accordingly, particularly following initiation or discontinuation of interferon therapy in patients who are stabilized on their methylxanthine regimen. Patients should be advised to contact their physician if they experience signs and symptoms of theophylline toxicity such as nausea, vomiting, diarrhea, headache, restlessness, insomnia, or irregular heartbeat.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if theophylline or other methylxanthines are administered with an interferon.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97557/", "reference_text": "[1] \"Product Information. Intron A (interferon alfa-2b).\" Schering Laboratories, Kenilworth, NJ.[2] Sakai H, Okamoto T, Kikkawa Y \"Suppression of hepatic drug metabolism by the interferon inducer polyriboinosinic acid:polyribocitidylic acid.\" J Pharmacol Exp Ther 263 (1992): 381-6[3] Jonkman JH, Nicholson KG, Farrow PR, et al \"Effects of alpha-interferon on theophylline pharmacokinetics and metabolism.\" Br J Clin Pharmacol 27 (1989): 795-802[4] Kramer P, Tsuru M, Cook CE, et al \"Effect of influenza vaccine on warfarin anticoagulation.\" Clin Pharmacol Ther 35 (1984): 416-8[5] Upton RA \"Pharmacokinetic interactions between theophylline and other medication (Part II).\" Clin Pharmacokinet 20 (1991): 135-50[6] Okuno H, Takasu M, Kano H, Seki T, Shiozaki Y, Inoue K \"Depression of drug-metabolizing activity in the human liver by interferon-beta.\" Hepatology 17 (1993): 65-9[7] Williams SJ, Baird-Lambert JA, Farrell GC \"Inhibition of theophylline metabolism by interferon.\" Lancet 10/24/87 (1987): 939-41[8] Cerner Multum, Inc. \"Australian Product Information.\" O 0[9] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0", "alternatives_a": "Omalizumab, Tezepelumab, Benralizumab, Caffeine, Reslizumab, Montelukast, Dyphylline, Mepolizumab, Roflumilast, Pentoxifylline, Bromotheophylline", "alternatives_b": "Oprelvekin, Sipuleucel-T, Elapegademase, Sargramostim, Histamine, Aldesleukin, Pegademase, Pegfilgrastim, Filgrastim, Glatiramer", "updated_at": 1767369485}, {"id": 97454, "ingredient1": "Theophylline", "ingredient2": "Penbutolol", "severity": "Major", "effect": "The pharmacologic effects of theophyllines and beta-blockers are opposite. Nonselective and high doses of cardioselective beta-blockers may cause severe or fatal bronchospasm by opposing theophylline-induced bronchodilation. Ophthalmic beta-blockers undergo significant systemic absorption and may also interact. In addition, propranolol and other beta-blockers may reduce the CYP450 hepatic metabolism of theophylline, and serum theophylline levels may be increased.", "source": "DDInter", "management_text": "Oral and ophthalmic nonselective beta-blockers (e.g., carteolol, carvedilol, levobunolol, metipranolol, nadolol, oxprenolol, penbutolol, pindolol, propranolol, sotalol, and timolol) are considered contraindicated in patients with bronchospastic diseases. Cardioselective beta-blockers should generally be avoided, or used with extreme caution if no other alternatives are available and the benefits outweigh the risks of potentially severe bronchospasm. If patients do receive this combination, they should be closely monitored for increased serum theophylline levels but decreased bronchodilatory effectiveness.", "mechanism_text": "Antagonism", "recommendation": "Oral and ophthalmic nonselective beta-blockers (e.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97558/", "reference_text": "[1] Upton RA \"Pharmacokinetic interactions between theophylline and other medication (Part II).\" Clin Pharmacokinet 20 (1991): 135-50[2] Mue S, Sasaki T, Shibahara S, et alT \"Influence of metoprolol on hemodynamics and respiratory function in asthmatic patients.\" Int J Clin Pharmacol Biopharm 17 (1979): 346-50[3] Lombardi TP, Bertino JS, Goldberg A, Middleton E, Slaughter RL \"The effects of a beta-2 selective adrenergic agonist and a beta- nonselective antagonist on theophylline clearance.\" J Clin Pharmacol 27 (1987): 523-9[4] Horvath JS, Woolcock AJ, Tiller DJ, Donnelly P, Armstrong J, Caterson R \"A comparison of metoprolol and propranolol on blood pressure and respiratory function in patients with hypertension.\" Aust N Z J Med 8 (1978): 1-6[5] Conrad KA, Nyman DW \"Effects of metoprolol and propranolol on theophylline elimination.\" Clin Pharmacol Ther 28 (1980): 463-7", "alternatives_a": "Omalizumab, Tezepelumab, Mercaptopurine, Benralizumab, Caffeine, Reslizumab, Montelukast, Mepolizumab, Roflumilast, Zafirlukast, Bromotheophylline", "alternatives_b": "", "updated_at": 1767369485}, {"id": 97455, "ingredient1": "Theophylline", "ingredient2": "Pentobarbital", "severity": "Moderate", "effect": "Barbiturates may decrease serum levels and therapeutic effects of the methylxanthines. The mechanism is barbiturate induction of CYP450 3A4 and 1A2 hepatic metabolism of methylxanthines.", "source": "DDInter", "management_text": "Close observation for clinical and laboratory evidence of decreased methylxanthine effect is indicated if these drugs must be used together. Patients should be advised to notify their physician if they experience a worsening of their respiratory symptoms.", "mechanism_text": "Metabolism", "recommendation": "Close observation for clinical and laboratory evidence of decreased methylxanthine effect is indicated if these drugs must be used together.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97559/", "reference_text": "[1] Dahlqvist R, Steiner E, Koike Y, von Bahr C, Lind M, Billing B \"Induction of theophylline metabolism by pentobarbital.\" Ther Drug Monit 11 (1989): 408-10[2] Bukowskyj M, Nakatsu K, Munt PW \"Theophylline reassessed.\" Ann Intern Med 101 (1984): 63-73[3] Upton RA \"Pharmacokinetic interactions between theophylline and other medication (Part I).\" Clin Pharmacokinet 20 (1991): 66-80[4] Landay RA, Gonzalez MA, Taylor JC \"Effect of phenobarbital on theophylline disposition.\" J Allergy Clin Immunol 62 (1978): 27-9", "alternatives_a": "Omalizumab, Tezepelumab, Mercaptopurine, Benralizumab, Caffeine, Reslizumab, Dyphylline, Mepolizumab, Roflumilast, Pentoxifylline, Zafirlukast, Bromotheophylline", "alternatives_b": "Suvorexant, Chloral hydrate, Nitrazepam, Paraldehyde, Propiomazine, Ramelteon, Meprobamate, Scopolamine, Eszopiclone, Dexmedetomidine, Lemborexant, More", "updated_at": 1767369485}, {"id": 97456, "ingredient1": "Theophylline", "ingredient2": "Pentoxifylline", "severity": "Moderate", "effect": "Coadministration with pentoxifylline may increase the serum concentrations of theophylline. The mechanism of interaction has not been described, but may involve competitive metabolism as both drugs are methylxanthine derivatives.", "source": "DDInter", "management_text": "Caution is advised if theophylline preparations are used in combination with pentoxifylline. Serum theophylline concentrations should be monitored more closely following the initiation, discontinuation or change of dosage of pentoxifylline, and the theophylline dosage adjusted as necessary.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if theophylline preparations are used in combination with pentoxifylline.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97560/", "reference_text": "[1] Cohen IA, Johnson CE, Wesolowicz L, Converse-Swastek K \"Effect of pentoxifylline and its metabolites on three theophylline assays.\" Clin Pharm 7 (1988): 457-61[2] \"Product Information. Trental (pentoxifylline).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[3] Cummings DM, Rocci ML Jr, Green P, Saccar C \"Interference potential of pentoxifylline and its major metabolite with theophylline assays.\" Am J Hosp Pharm 42 (1985): 2717-8[4] Ellison MJ, Horner RD, Willis SE, Cummings DM \"Influence of pentoxifylline on steady-state theophylline serum concentrations from sustained-release formulations.\" Pharmacotherapy 10 (1990): 383-6", "alternatives_a": "Omalizumab, Tezepelumab, Mercaptopurine, Benralizumab, Caffeine, Reslizumab, Dyphylline, Mepolizumab, Roflumilast, Pentoxifylline, Zafirlukast, Bromotheophylline", "alternatives_b": "Cyclandelate, Tolazoline, Phenoxybenzamine, Phentolamine, Isoxsuprine, Theophylline, Omalizumab, Tezepelumab, Mercaptopurine, Benralizumab, Reslizumab, More", "updated_at": 1767369485}, {"id": 97457, "ingredient1": "Theophylline", "ingredient2": "Phenytoin", "severity": "Moderate", "effect": "Phenytoin has been reported to increase the clearance of theophylline by 40% to 50%, presumably by enhancing the hepatic CYP450 metabolism of theophylline. Also, coadministration of theophylline has been reported to lower serum phenytoin concentrations. Other hydantoins and hepatically metabolized methylxanthines may also interact.", "source": "DDInter", "management_text": "Management consists of monitoring clinical response and serum concentrations of both drugs and adjusting dosages as necessary. Patients should be advised to report loss of seizure control or worsening of respiratory symptoms to their physician.", "mechanism_text": "Metabolism", "recommendation": "Management consists of monitoring clinical response and serum concentrations of both drugs and adjusting dosages as necessary.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97561/", "reference_text": "[1] Miller M, Cosgriff J, Kwong T, Morken DA \"Influence of phenytoin on theophylline clearance.\" Clin Pharmacol Ther 35 (1984): 666-9[2] Upton RA \"Pharmacokinetic interactions between theophylline and other medication (Part I).\" Clin Pharmacokinet 20 (1991): 66-80[3] Sklar SJ, Wagner \"Enhanced theophylline clearance secondary to phenytoin therapy.\" Drug Intell Clin Pharm 19 (1985): 34-6[4] Crowley JJ, Cusack BJ, Jue SG, et al \"Cigarette smoking and theophylline metabolism: effects of phenytoin.\" Clin Pharmacol Ther 42 (1987): 334-40[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[7] Fleisher D, Sheth N, Kou JH \"Phenytoin interaction with enteral feedings administered through nasogastric tubes.\" JPEN J Parenter Enteral Nutr 14 (1990): 513-6[8] Krueger KA, Garnett WR, Comstock TJ, Fitzsimmons WE, Karnes HT, Pellock JM \"Effect of two administration schedules of an enteral nutrient formula on phenytoin bioavailability.\" Epilepsia 28 (1987): 706-12[9] Haley CJ, Nelson J \"Phenytoin-enteral feeding interaction.\" DICP 23 (1989): 796-8[10] Faraji B, Yu PP \"Serum phenytoin levels of patients on gastrostomy tube feeding.\" J Neurosci Nurs 30 (1998): 55-9[11] Au Yeung SC, Ensom MH \"Phenytoin and enteral feedings: does evidence support an interaction?\" Ann Pharmacother 34 (2000): 896-905[12] Sandor P, Sellers EM, Dumbrell M, Khouw V \"Effect of short- and long-term alcohol use on phenytoin kinetics in chronic alcoholics.\" Clin Pharmacol Ther 30 (1981): 390-7[13] Ozuna J, Friel P \"Effect of enteral tube feeding on serum phenytoin levels.\" J Neurosurg Nurs 16 (1984): 289-91[14] Guidry JR, Eastwood TF, Curry SC \"Phenytoin absorption in volunteers receiving selected enteral feedings.\" West J Med 150 (1989): 659-61[15] Marvel ME, Bertino JS \"Comparative effects of an elemental and a complex enteral feeding formulation on the absorption of phenytoin suspension.\" JPEN J Parenter Enteral Nutr 15 (1991): 316-8[16] \"Product Information. Dilantin (phenytoin).\" Parke-Davis, Morris Plains, NJ.[17] Doak KK, Haas CE, Dunnigan KJ, et al. \"Bioavailability of phenytoin acid and phenytoin sodium with enteral feedings.\" Pharmacotherapy 18 (1998): 637-45[18] Rodman DP, Stevenson TL, Ray TR \"Phenytoin malabsorption after jejunostomy tube delivery.\" Pharmacotherapy 15 (1995): 801-5[19] Sellers EM, Holloway MR \"Drug kinetics and alcohol ingestion.\" Clin Pharmacokinet 3 (1978): 440-52[20] Holtz L, Milton J, Sturek JK \"Compatibility of medications with enteral feedings.\" JPEN J Parenter Enteral Nutr 11 (1987): 183-6", "alternatives_a": "Brivaracetam, Topiramate, Ezogabine, Cenobamate, Lamotrigine, Ethosuximide, Lacosamide, Levetiracetam, Tiagabine, Oxcarbazepine, Rufinamide, More", "alternatives_b": "Omalizumab, Tezepelumab, Mercaptopurine, Benralizumab, Caffeine, Reslizumab, Dyphylline, Mepolizumab, Pentoxifylline, Zafirlukast, Bromotheophylline", "updated_at": 1767369485}, {"id": 97458, "ingredient1": "Theophylline", "ingredient2": "Pindolol", "severity": "Major", "effect": "The pharmacologic effects of theophyllines and beta-blockers are opposite. Nonselective and high doses of cardioselective beta-blockers may cause severe or fatal bronchospasm by opposing theophylline-induced bronchodilation. Ophthalmic beta-blockers undergo significant systemic absorption and may also interact. In addition, propranolol and other beta-blockers may reduce the CYP450 hepatic metabolism of theophylline, and serum theophylline levels may be increased.", "source": "DDInter", "management_text": "Oral and ophthalmic nonselective beta-blockers (e.g., carteolol, carvedilol, levobunolol, metipranolol, nadolol, oxprenolol, penbutolol, pindolol, propranolol, sotalol, and timolol) are considered contraindicated in patients with bronchospastic diseases. Cardioselective beta-blockers should generally be avoided, or used with extreme caution if no other alternatives are available and the benefits outweigh the risks of potentially severe bronchospasm. If patients do receive this combination, they should be closely monitored for increased serum theophylline levels but decreased bronchodilatory effectiveness.", "mechanism_text": "Antagonism", "recommendation": "Oral and ophthalmic nonselective beta-blockers (e.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97562/", "reference_text": "[1] Upton RA \"Pharmacokinetic interactions between theophylline and other medication (Part II).\" Clin Pharmacokinet 20 (1991): 135-50[2] Mue S, Sasaki T, Shibahara S, et alT \"Influence of metoprolol on hemodynamics and respiratory function in asthmatic patients.\" Int J Clin Pharmacol Biopharm 17 (1979): 346-50[3] Lombardi TP, Bertino JS, Goldberg A, Middleton E, Slaughter RL \"The effects of a beta-2 selective adrenergic agonist and a beta- nonselective antagonist on theophylline clearance.\" J Clin Pharmacol 27 (1987): 523-9[4] Horvath JS, Woolcock AJ, Tiller DJ, Donnelly P, Armstrong J, Caterson R \"A comparison of metoprolol and propranolol on blood pressure and respiratory function in patients with hypertension.\" Aust N Z J Med 8 (1978): 1-6[5] Conrad KA, Nyman DW \"Effects of metoprolol and propranolol on theophylline elimination.\" Clin Pharmacol Ther 28 (1980): 463-7", "alternatives_a": "Omalizumab, Tezepelumab, Mercaptopurine, Benralizumab, Caffeine, Reslizumab, Montelukast, Mepolizumab, Roflumilast, Zafirlukast, Bromotheophylline", "alternatives_b": "", "updated_at": 1767369485}, {"id": 97459, "ingredient1": "Theophylline", "ingredient2": "Pipecuronium", "severity": "Moderate", "effect": "Methylxanthines may antagonize the effects of neuromuscular blockers. The mechanism is unknown. In patients stabilized on aminophylline, resistance to pancuronium has been reported.", "source": "DDInter", "management_text": "The patient should be monitored for adequate neuromuscular blockade and the dosage adjusted, if necessary.", "mechanism_text": "Antagonism", "recommendation": "The patient should be monitored for adequate neuromuscular blockade and the dosage adjusted, if necessary.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97563/", "reference_text": "[1] Doll DC, Rosenberg H \"Antagonism of neuromuscular blockage by theophylline.\" Anesth Analg 58 (1979): 139-40[2] Azar I, Kumar D, Betcher AM \"Resistance to pancuronium in an asthmatic patient treated with aminophylline and steroids.\" Can Anaesth Soc J 29 (1982): 280-2[3] Daller JA, Erstad B, Rosado L, Otto C, Putnam CW \"Aminophylline antagonizes the neuromuscular blockade of pancuronium but not vecuronium.\" Crit Care Med 19 (1991): 983-5", "alternatives_a": "Omalizumab, Tezepelumab, Mercaptopurine, Benralizumab, Caffeine, Reslizumab, Montelukast, Mepolizumab, Roflumilast, Pentoxifylline, Zafirlukast, Bromotheophylline", "alternatives_b": "Botulinum toxin type A", "updated_at": 1767369485}, {"id": 97460, "ingredient1": "Theophylline", "ingredient2": "Pirbuterol", "severity": "Moderate", "effect": "Concomitant use of beta-2 adrenergic agonists with theophylline may increase the risk and/or severity of hypokalemia and adverse cardiovascular effects such as palpitation, tachycardia, and blood pressure elevation. Adverse events, especially hypokalemia, may be more likely with systemic or nebulized formulations of beta-2 agonists or high dosages of theophylline. Beta-2 agonists can cause clinically significant but usually transient decreases in serum potassium concentrations, while hypokalemia associated with theophylline often occurs in toxicity. Pharmacokinetically, some beta-2 agonists given systemically may decrease the plasma concentrations of theophylline.", "source": "DDInter", "management_text": "Although theophylline and beta-2 agonists are commonly used together to produce bronchodilation, it may be appropriate to monitor patient response as well as serum potassium level, blood pressure and heart rate during coadministration, especially if the beta-2 agonist is administered systemically or by nebulizer. Close monitoring is particularly important in patients with severe asthma, since the potential increases in blood pressure and heart rate may have more serious consequences in the presence of hypoxemia or hypercapnia due to increased myocardial oxygen consumption. Patients should be advised to notify their physician if they experience worsening of their respiratory condition or potential signs and symptoms of hypokalemia such as fatigue, weakness, myalgia, muscle cramps, numbness, tingling, abdominal pain, constipation, palpitation, and irregular heartbeat.", "mechanism_text": "Synergism", "recommendation": "Although theophylline and beta-2 agonists are commonly used together to produce bronchodilation, it may be appropriate to monitor patient response as well as serum potassium level, blood pressure and heart rate during coadministration, especially if the beta-2 agonist is administered systemically or by nebulizer.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97564/", "reference_text": "[1] Garty M, Paul-Keslin L, Ilfeld DN, et al \"Increased theophylline clearance in asthmatic patients due to terbutaline.\" Eur J Clin Pharmacol 36 (1989): 25-8[2] Amirav I, Amitai Y, Avital A, Godfrey S \"Enhancement of theophylline clearance by intravenous albuterol.\" Chest 94 (1988): 444-5[3] \"Product Information. Striverdi Respimat (olodaterol).\" Boehringer Ingelheim, Ridgefield, CT.[4] Cusack BJ, Nielson CP, Morgan ME, Vestal RE \"Additive effect of theophylline on the cardiac response to isoproterenol.\" Clin Pharmacol Ther 41 (1987): 289-96[5] Griffith JA, Kozloski GD \"Isoproterenol-theophylline interaction: possible potentiation by other drugs.\" Clin Pharm 9 (1990): 54-7[6] Conrad KA, Woodworth JR \"Orciprenaline does not alter theophylline elimination.\" Br J Clin Pharmacol 12 (1981): 756-7[7] Flatt A, Burgess C, Windom H, Beasley R, Purdie G, Crane J \"The cardiovascular effects of inhaled fenoterol alone and during treatment with oral theophylline.\" Chest 96 (1989): 1317-20[8] Smith SR, Kendall MJ \"Potentiation of the adverse effects of intravenous terbutaline by oral theophylline.\" Br J Clin Pharmacol 21 (1986): 451-3[9] Danzinger Y, Garty M, Volwitz B, Ilfeld D, Varsano I, Rosenfeld JB \"Reduction of serum theophylline levels by terbutaline in children with asthma.\" Clin Pharmacol Ther 37 (1985): 469-71[10] O'Rourke PP, Crone RK \"Effect of isoproterenol on measured theophylline levels.\" Crit Care Med 12 (1984): 373-5[11] Whyte KF, Reid C, Addis GJ, Whitesmith R, Reid JL \"Salbutamol induced hypokalaemia: the effect of theophylline alone and in combination with adrenaline.\" Br J Clin Pharmacol 25 (1988): 571-8[12] Coleman JJ, Vollmer WM, Barker AF, et al \"Cardiac arrhythmias during the combined use of beta-adrenergic agonist drugs and theophylline.\" Chest 90 (1986): 45-51[13] Kelly HW \"Controversies in asthma therapy with theophylline and the beta2-adrenergic agonists.\" Clin Pharm 3 (1984): 386-95[14] Amitai Y, Glustein J, Godfrey S \"Enhancement of theophylline clearance by oral albuterol.\" Chest 102 (1992): 786-9[15] \"Product Information. Brovana (arformoterol).\" Sepracor Inc, Marlborough, MA.[16] \"Interactions between methyl xanthines and beta adrenergic agonists.\" FDA Drug Bull 11 (1981): 19-20[17] Chow OK, Fung KP \"Slow-release terbutaline and theophylline for the long-term therapy of children with asthma: a Latin square and factorial study of drug effects and interactions.\" Pediatrics 84 (1989): 119-25[18] Hemstreet MP, Miles MV, Rutland RO \"Effect of intravenous isoproterenol on theophylline kinetics.\" J Allergy Clin Immunol 69 (1982): 360-4[19] Upton RA \"Pharmacokinetic interactions between theophylline and other medication (Part I).\" Clin Pharmacokinet 20 (1991): 66-80[20] Rachelefsky GS, Katz RM, Mickey MR Jr, Siegel SC \"Metaproterenol and theophylline in asthmatic children.\" Ann Allergy 45 (1980): 207-12[21] Josephson GW, Kennedy HL, MacKenzie EJ, Gibson G \"Cardiac dysrhythmias during the treatment of acute asthma. A comparison of two treatment regimens by a double blind protocol.\" Chest 78 (1980): 429-35[22] Dawson KP, Fergusson DM \"Effects of oral theophylline and oral salbutamol in the treatment of asthma.\" Arch Dis Child 57 (1982): 674-6[23] Jonkman JH, Borgstrom L, van der Boon WJ, de Noord OE \"Theophylline-terbutaline, a steady state study on possible pharmacokinetic interactions with special reference to chronopharmacokinetic aspects.\" Br J Clin Pharmacol 26 (1988): 285-93[24] Deenstra M, Haalboom JR, Struyvenberg A \"Decrease of plasma potassium due to inhalation of beta-2 agonists: absence of an additional effect of intravenous theophylline.\" Eur J Clin Invest 18 (1988): 162-5[25] \"Product Information. Arcapta Neohaler (indacaterol).\" Novartis Pharmaceuticals, East Hanover, NJ.[26] Lombardi TP, Bertino JS, Goldberg A, Middleton E, Slaughter RL \"The effects of a beta-2 selective adrenergic agonist and a beta- nonselective antagonist on theophylline clearance.\" J Clin Pharmacol 27 (1987): 523-9", "alternatives_a": "Omalizumab, Tezepelumab, Mercaptopurine, Benralizumab, Caffeine, Reslizumab, Mepolizumab, Roflumilast, Pentoxifylline, Bromotheophylline", "alternatives_b": "Mometasone furoate, Umeclidinium, Aclidinium, Mometasone, Glycopyrronium, Ipratropium, Beclomethasone dipropionate", "updated_at": 1767369485}, {"id": 97461, "ingredient1": "Theophylline", "ingredient2": "Prednisolone", "severity": "Moderate", "effect": "The concomitant use of theophylline and corticosteroids may theoretically increase the risk of hypokalemia due to additive potassium-lowering effects. Additionally, theophylline serum concentrations may be altered.", "source": "DDInter", "management_text": "Monitoring for altered efficacy and safety of theophylline and altered serum potassium and theophylline concentrations is advisable when these drugs are coadministered. Patients should be advised to notify their physician if they experience signs of hypokalemia (e.g., weakness, lethargy, and muscle pains or cramps), worsening respiratory symptoms, or signs of theophylline toxicity (e.g., nausea, vomiting, diarrhea, headache, restlessness, insomnia, or irregular heartbeat).", "mechanism_text": "Synergism", "recommendation": "Monitoring for altered efficacy and safety of theophylline and altered serum potassium and theophylline concentrations is advisable when these drugs are coadministered.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97565/", "reference_text": "[1] Fergusson RJ, Scott CM, Rafferty P, Gaddie J \"Effect of prednisolone on theophylline pharmacokinetics in patients with chronic airflow obstruction.\" Thorax 42 (1987): 195-8[2] Buchanan N, Hurwitz S, Butler P \"Asthma - a possible interaction between hydrocortisone and theophylline.\" S Afr Med J 56 (1979): 1147-8[3] Leavengood DC, Bunker-Soler AL, Nelson HS \"The effect of corticosteroids on theophylline metabolism.\" Ann Allergy 50 (1983): 249-51[4] Elvey SM, Saccar CL, Rocci ML, Mansmann HC, Martynec DM, Kester MB \"The effect of corticosteroids on theophylline metabolim in asthmatic children.\" Ann Allergy 56 (1986): 520[5] Tatsis G, Orphanidou D, Douratsos D, et al \"The effect of steroids on theophylline absorption.\" J Int Med Res 19 (1991): 326-9[6] Anderson JL, Ayres JW, Hall CA \"Potential pharmacokinetic interaction between theophylline and prednisone.\" Clin Pharm 3 (1984): 187-8", "alternatives_a": "Omalizumab, Tezepelumab, Benralizumab, Caffeine, Reslizumab, Dyphylline, Oxtriphylline, Mepolizumab, Bromotheophylline", "alternatives_b": "Mometasone furoate, Amcinonide, Fluocinolone acetonide, Hydrocortisone butyrate, Fluocinonide, Fluorometholone, Clobetasol, Beclomethasone dipropionate, Indomethacin, Fluocinolone acetonide, Fluorometholone, More", "updated_at": 1767369485}, {"id": 97462, "ingredient1": "Theophylline", "ingredient2": "Prednisone", "severity": "Moderate", "effect": "The concomitant use of theophylline and corticosteroids may theoretically increase the risk of hypokalemia due to additive potassium-lowering effects. Additionally, theophylline serum concentrations may be altered.", "source": "DDInter", "management_text": "Monitoring for altered efficacy and safety of theophylline and altered serum potassium and theophylline concentrations is advisable when these drugs are coadministered. Patients should be advised to notify their physician if they experience signs of hypokalemia (e.g., weakness, lethargy, and muscle pains or cramps), worsening respiratory symptoms, or signs of theophylline toxicity (e.g., nausea, vomiting, diarrhea, headache, restlessness, insomnia, or irregular heartbeat).", "mechanism_text": "Synergism", "recommendation": "Monitoring for altered efficacy and safety of theophylline and altered serum potassium and theophylline concentrations is advisable when these drugs are coadministered.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97566/", "reference_text": "[1] Fergusson RJ, Scott CM, Rafferty P, Gaddie J \"Effect of prednisolone on theophylline pharmacokinetics in patients with chronic airflow obstruction.\" Thorax 42 (1987): 195-8[2] Buchanan N, Hurwitz S, Butler P \"Asthma - a possible interaction between hydrocortisone and theophylline.\" S Afr Med J 56 (1979): 1147-8[3] Leavengood DC, Bunker-Soler AL, Nelson HS \"The effect of corticosteroids on theophylline metabolism.\" Ann Allergy 50 (1983): 249-51[4] Elvey SM, Saccar CL, Rocci ML, Mansmann HC, Martynec DM, Kester MB \"The effect of corticosteroids on theophylline metabolim in asthmatic children.\" Ann Allergy 56 (1986): 520[5] Tatsis G, Orphanidou D, Douratsos D, et al \"The effect of steroids on theophylline absorption.\" J Int Med Res 19 (1991): 326-9[6] Anderson JL, Ayres JW, Hall CA \"Potential pharmacokinetic interaction between theophylline and prednisone.\" Clin Pharm 3 (1984): 187-8", "alternatives_a": "Omalizumab, Tezepelumab, Benralizumab, Caffeine, Reslizumab, Dyphylline, Oxtriphylline, Mepolizumab, Bromotheophylline", "alternatives_b": "Olsalazine, Sulfasalazine, Balsalazide, Beclomethasone dipropionate, Mesalazine, Deflazacort", "updated_at": 1767369485}, {"id": 97463, "ingredient1": "Theophylline", "ingredient2": "Primidone", "severity": "Moderate", "effect": "Barbiturates may decrease serum levels and therapeutic effects of the methylxanthines. The mechanism is barbiturate induction of CYP450 3A4 and 1A2 hepatic metabolism of methylxanthines.", "source": "DDInter", "management_text": "Close observation for clinical and laboratory evidence of decreased methylxanthine effect is indicated if these drugs must be used together. Patients should be advised to notify their physician if they experience a worsening of their respiratory symptoms.", "mechanism_text": "Metabolism", "recommendation": "Close observation for clinical and laboratory evidence of decreased methylxanthine effect is indicated if these drugs must be used together.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97567/", "reference_text": "[1] Dahlqvist R, Steiner E, Koike Y, von Bahr C, Lind M, Billing B \"Induction of theophylline metabolism by pentobarbital.\" Ther Drug Monit 11 (1989): 408-10[2] Bukowskyj M, Nakatsu K, Munt PW \"Theophylline reassessed.\" Ann Intern Med 101 (1984): 63-73[3] Upton RA \"Pharmacokinetic interactions between theophylline and other medication (Part I).\" Clin Pharmacokinet 20 (1991): 66-80[4] Landay RA, Gonzalez MA, Taylor JC \"Effect of phenobarbital on theophylline disposition.\" J Allergy Clin Immunol 62 (1978): 27-9", "alternatives_a": "Omalizumab, Tezepelumab, Mercaptopurine, Benralizumab, Caffeine, Reslizumab, Dyphylline, Mepolizumab, Roflumilast, Zafirlukast, Bromotheophylline", "alternatives_b": "Suvorexant, Chloral hydrate, Nitrazepam, Paraldehyde, Propiomazine, Ramelteon, Meprobamate, Scopolamine, Eszopiclone, Dexmedetomidine, Lemborexant, More", "updated_at": 1767369485}, {"id": 97464, "ingredient1": "Theophylline", "ingredient2": "Propafenone", "severity": "Moderate", "effect": "Propafenone may inhibit the clearance of theophyllines. The exact mechanism is not known. Serum theophylline concentration and the risk of toxicity may be increased. Patients with chronic obstructive pulmonary disease, congestive heart failure, or cirrhosis may have slower theophylline clearance rates; therefore, they may be at greater risk of developing theophylline toxicity. Also, the clinician should be aware of the risk that bronchospasm may be induced or exacerbated by propafenone. These drugs may have antagonistic pharmacologic effects on the patient's airways.", "source": "DDInter", "management_text": "If these drugs are given concurrently, close clinical and laboratory monitoring of response and tolerance is recommended. Patients should be advised to notify their physician if they experience a worsening of their respiratory symptoms or any signs of theophylline toxicity including nausea, vomiting, diarrhea, headache, restlessness, insomnia, seizures, or irregular heartbeats. It may be necessary to reduce theophylline dosage.", "mechanism_text": "Metabolism", "recommendation": "If these drugs are given concurrently, close clinical and laboratory monitoring of response and tolerance is recommended.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97568/", "reference_text": "[1] Lee BL, Dohrmann ML \"Theophylline toxicity after propafenone treatment: evidence for drug interaction.\" Clin Pharmacol Ther 51 (1992): 353-5[2] Spinler SA, Gammaitoni A, Charland SL, Hurwitz J \"Propafenone-theophylline interaction.\" Pharmacotherapy 13 (1993): 68-71", "alternatives_a": "Omalizumab, Tezepelumab, Mercaptopurine, Benralizumab, Caffeine, Reslizumab, Dyphylline, Mepolizumab, Pentoxifylline, Zafirlukast, Bromotheophylline", "alternatives_b": "Dronedarone, Procainamide, Flecainide, Dofetilide, Bretylium, Ibutilide", "updated_at": 1767369485}, {"id": 97465, "ingredient1": "Theophylline", "ingredient2": "Propranolol", "severity": "Major", "effect": "The pharmacologic effects of theophyllines and beta-blockers are opposite. Nonselective and high doses of cardioselective beta-blockers may cause severe or fatal bronchospasm by opposing theophylline-induced bronchodilation. Ophthalmic beta-blockers undergo significant systemic absorption and may also interact. In addition, propranolol and other beta-blockers may reduce the CYP450 hepatic metabolism of theophylline, and serum theophylline levels may be increased.", "source": "DDInter", "management_text": "Oral and ophthalmic nonselective beta-blockers (e.g., carteolol, carvedilol, levobunolol, metipranolol, nadolol, oxprenolol, penbutolol, pindolol, propranolol, sotalol, and timolol) are considered contraindicated in patients with bronchospastic diseases. Cardioselective beta-blockers should generally be avoided, or used with extreme caution if no other alternatives are available and the benefits outweigh the risks of potentially severe bronchospasm. If patients do receive this combination, they should be closely monitored for increased serum theophylline levels but decreased bronchodilatory effectiveness.", "mechanism_text": "Antagonism", "recommendation": "Oral and ophthalmic nonselective beta-blockers (e.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97569/", "reference_text": "[1] Upton RA \"Pharmacokinetic interactions between theophylline and other medication (Part II).\" Clin Pharmacokinet 20 (1991): 135-50[2] Mue S, Sasaki T, Shibahara S, et alT \"Influence of metoprolol on hemodynamics and respiratory function in asthmatic patients.\" Int J Clin Pharmacol Biopharm 17 (1979): 346-50[3] Lombardi TP, Bertino JS, Goldberg A, Middleton E, Slaughter RL \"The effects of a beta-2 selective adrenergic agonist and a beta- nonselective antagonist on theophylline clearance.\" J Clin Pharmacol 27 (1987): 523-9[4] Horvath JS, Woolcock AJ, Tiller DJ, Donnelly P, Armstrong J, Caterson R \"A comparison of metoprolol and propranolol on blood pressure and respiratory function in patients with hypertension.\" Aust N Z J Med 8 (1978): 1-6[5] Conrad KA, Nyman DW \"Effects of metoprolol and propranolol on theophylline elimination.\" Clin Pharmacol Ther 28 (1980): 463-7", "alternatives_a": "Omalizumab, Tezepelumab, Mercaptopurine, Benralizumab, Caffeine, Reslizumab, Mepolizumab, Roflumilast, Zafirlukast, Bromotheophylline", "alternatives_b": "Ivabradine", "updated_at": 1767369485}, {"id": 97466, "ingredient1": "Theophylline", "ingredient2": "Propylthiouracil", "severity": "Moderate", "effect": "Clearance of theophylline and related agents depends upon thyroid function. In the hyperthyroid state, clearance may be enhanced. In the hypothyroid state, clearance may be reduced. Theophylline clearance may decrease and the risk of toxicity may increase when hyperthyroid patients become euthyroid.", "source": "DDInter", "management_text": "The patient and theophylline levels should be closely monitored while achieving a euthyroid state and when an antithyroid agent is added, discontinued, or the dosage is changed. Theophylline dosage adjustments may be required. Patients should be advised to notify their physician if they experience a worsening of their respiratory symptoms, or any signs of theophylline toxicity including nausea, vomiting, diarrhea, headache, restlessness, insomnia, seizures, or irregular heartbeats.", "mechanism_text": "Others", "recommendation": "The patient and theophylline levels should be closely monitored while achieving a euthyroid state and when an antithyroid agent is added, discontinued, or the dosage is changed.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97570/", "reference_text": "[1] Aderka D, Shavit G, Garfinkel D, et al \"Life-threatening theophylline intoxication in a hypothyroid patient.\" Respiration 44 (1983): 77-80[2] Bauman JH, Teichman S, Wible DA \"Increased theophylline clearance in a patient with hyperthyroidism.\" Ann Allergy 52 (1984): 94-6[3] \"Product Information. Tapazole (methimazole).\" King Pharmaceuticals Inc, Bristol, TN.", "alternatives_a": "Omalizumab, Tezepelumab, Mercaptopurine, Benralizumab, Caffeine, Reslizumab, Montelukast, Dyphylline, Mepolizumab, Roflumilast, Pentoxifylline, More", "alternatives_b": "Potassium perchlorate", "updated_at": 1767369485}, {"id": 97467, "ingredient1": "Theophylline", "ingredient2": "Quazepam", "severity": "Minor", "effect": "Methylxanthines may antagonize the sedative effects of benzodiazepines. Aminophylline in particular has been demonstrated to attenuate the sedative effects of diazepam. The mechanism of this interaction may be related to competitive binding to intracerebral adenosine receptors.", "source": "DDInter", "management_text": "-", "mechanism_text": "Antagonism", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97571/", "reference_text": "[1] Tuncok Y, Akpinar O, Guven H, Akkoclu A \"The effects of theophylline on serum alprazolam levels.\" Int J Clin Pharmacol Ther 32 (1994): 642-5[2] Gallen JS \"Aminophylline reversal of midazolam sedation.\" Anesth Analg 69 (1989): 268[3] Bonfiglio MF, Dasta JF \"Clinical significance of the benzodiazepine-theophylline interaction.\" Pharmacotherapy 11 (1991): 85-7[4] Upton RA \"Pharmacokinetic interactions between theophylline and other medication (Part II).\" Clin Pharmacokinet 20 (1991): 135-50[5] Stirt JA \"Aminophylline is a diazepam antagonist.\" Anesth Analg 60 (1981): 767-8[6] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[7] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[8] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[9] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Omalizumab, Tezepelumab, Mercaptopurine, Benralizumab, Caffeine, Reslizumab, Mepolizumab, Roflumilast, Pentoxifylline, Zafirlukast, Bromotheophylline", "alternatives_b": "Suvorexant, Chloral hydrate, Nitrazepam, Paraldehyde, Propiomazine, Ramelteon, Meprobamate, Scopolamine, Eszopiclone, Dexmedetomidine, Lemborexant, More", "updated_at": 1767369485}, {"id": 97468, "ingredient1": "Theophylline", "ingredient2": "Quinine", "severity": "Moderate", "effect": "Coadministration of theophylline and quinine has resulted in slightly decreased serum concentrations of theophylline and increased concentrations of quinine. The mechanism of interaction has not been established.", "source": "DDInter", "management_text": "Caution is advised during concomitant use of theophylline and quinine. Serum theophylline levels should be monitored frequently to ensure therapeutic concentrations, and patients should be monitored for adverse reactions associated with quinine such as hematologic toxicities and cardiac arrhythmias including torsade de pointes and atrial fibrillation. Patients should be advised to contact their physician if they experience increased side effects such as headache, flushing, sweating, nausea, vomiting, diarrhea, abdominal pain, tinnitus, dizziness, vertigo, hearing impairment, blurred vision, vision impairment, and irregular heart rhythm.", "mechanism_text": "Others", "recommendation": "Caution is advised during concomitant use of theophylline and quinine.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97572/", "reference_text": "[1] \"Product Information. Qualaquin (quinine).\" AR Scientific Inc, Philadelphia, PA.[2] Sato J, Nakata H, Owada E, Kikuta T, Umetsu M, Ito K \"Influence of usual intake of dietary caffeine on single-dose kinetics of theophylline in healthy human subjects.\" Eur J Clin Pharmacol 44 (1993): 295-8[3] Jonkman JH, Sollie FA, Sauter R, Steinijans VW \"The influence of caffeine on the steady-state pharmacokinetics of theophylline.\" Clin Pharmacol Ther 49 (1991): 248-55[4] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[5] \"Product Information. Qualaquin (quinine).\" AR Scientific Inc, Philadelphia, PA.[6] Ho PC, Chalcroft SC, Coville PF, Wanwimolruk S \"Grapefruit juice has no effect on quinine pharmacokinetics.\" Eur J Clin Pharmacol 55 (1999): 393-8[7] Zhang H, Coville PF, Walker RJ, Miners JO, Birkett DJ, Wanwimolruk S \"Evidence for involvement of human CYP3A in the 3-hydroxylation of quinine.\" Br J Clin Pharmacol 43 (1997): 245-52[8] Mirghani RA, Yasar U, Zheng T, et al \"Enzyme kinetics for the formation of 3-hydroxyquinine and three new metabolites of quinine in vitro; 3-hydroxylation by CYP3A4 is indeed the major metabolic pathway.\" Drug Metab Dispos 30 (2002): 1368-71[9] Hermans K, Stockman D, Van den Branden F \"Grapefruit and tonic: a deadly combination in a patient with the long QT syndrome.\" Am J Med 114 (2003): 511-2", "alternatives_a": "Omalizumab, Tezepelumab, Mercaptopurine, Aminophylline, Benralizumab, Caffeine, Reslizumab, Montelukast, Dyphylline, Oxtriphylline, Mepolizumab, More", "alternatives_b": "Risdiplam, Collagenase clostridium histolyticum, Onasemnogene abeparvovec, Hyaluronic acid, Artesunate, Mefloquine, Lumefantrine, Artemether, Pyrimethamine, Tafenoquine, Atovaquone, More", "updated_at": 1767369485}, {"id": 97469, "ingredient1": "Theophylline", "ingredient2": "Ranitidine (bismuth citrate)", "severity": "Moderate", "effect": "Cimetidine may increase theophylline plasma concentrations by as much as 70%. The mechanism is related to inhibition of liver CYP450 enzymes responsible for theophylline metabolism. Patients with chronic obstructive pulmonary disease, congestive heart failure, or cirrhosis may have slower theophylline clearance rates; therefore, they may be at greater risk of developing theophylline toxicity.", "source": "DDInter", "management_text": "Clinical monitoring of patient response, tolerance, and laboratory theophylline serum concentrations is recommended. Patients should be advised to report any signs of theophylline toxicity including nausea, vomiting, diarrhea, headache, restlessness, insomnia, or irregular heartbeat to their physician.", "mechanism_text": "Metabolism", "recommendation": "Clinical monitoring of patient response, tolerance, and laboratory theophylline serum concentrations is recommended.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97573/", "reference_text": "[1] Schwartz JI, Bachmann KA, Bond LW, Mahajan VK \"Impact of cimetidine on the pharmacokinetics of the theophylline.\" Clin Pharm 1 (1982): 534-8[2] Jackson JE, Powell JR, Wandell M, Bentley J, Dorr R \"Cimetidine decreases theophylline clearance.\" Am Rev Respir Dis 123 (1981): 615-7[3] Anderson JR, Poklis A, Slavin RG \"A fatal case of theophylline intoxication.\" Arch Intern Med 143 (1983): 559-60[4] Weinberger MM, Smith G, Milavetz G, Hendeles L \"Decreased clearance of theophylline due to cimetidine .\" N Engl J Med 304 (1981): 672[5] Skinner MH, Lenert L, Blaschke TF \"Theophylline toxicity subsequent to ranitidine administration: a possible drug-drug interaction.\" Am J Med 86 (1989): 129-32[6] Bauman JH, Kimelblatt BJ, Caraccio TR, Silverman HM, Simon GI, Beck GJ \"Cimetidine-theophylline interaction: report of four patients.\" Ann Allergy 48 (1982): 100-2[7] Lofgren RP, Gilbertson RA \"Cimetidine and theophylline.\" Ann Intern Med 96 (1982): 378[8] Powell JR, Rogers JF, Wargin WA, Cross RE, Eshelman FN \"Inhibition of theophylline clearance by cimetidine but not ranitidine.\" Arch Intern Med 144 (1984): 484-6[9] Kelly HW, Powell JR, Donohue JF \"Ranitidine at very large doses does not inhibit theophylline elimination.\" Clin Pharmacol Ther 39 (1986): 577-81[10] Bachmann K, Sullivan TJ, Reese JH, Jauregui L, Miller K, Scott M, Yeh KC, Stepanavage M, King JD, Schwartz J \"Controlled study of the putative interaction between famotidine and theophylline in patients with chronic obstructive pulmonary disease.\" J Clin Pharmacol 35 (1995): 529-35[11] Kelly HW \"Lack of evidence for reduction of theophylline clearance by ranitidine.\" Am J Med 86 (1989): 629-32[12] Hegman GW, Gilbert RP \"Ranitidine-theophylline interaction--fact or fiction?\" Ann Pharmacother 25 (1991): 21-5[13] Fernandes E, Melewicz FM \"Ranitidine and theophylline.\" Ann Intern Med 100 (1984): 459[14] Reitberg DP, Bernhard H, Schentag JJ \"Alteration of theophylline clearance and half-life by cimetidine in normal volunteers.\" Ann Intern Med 95 (1981): 582-5[15] Bachmann KA, Sullivan TJ, Jauregui L, Reese J, Miller K, Levine L \"Drug interactions of h-2-receptor antagonists.\" Scand J Gastroenterol 29 (1994): 14-9[16] Kehoe WA, Sands CD, Long LF, et al \"Effect of ranitidine on theophylline metabolism in healthy Koreans living in China.\" Ann Pharmacother 30 (1996): 133-7[17] Boehning W \"Effect of cimetidine and ranitidine on plasma theophylline in patients with chronic obstructive airways disease treated with theophylline and corticosteroids.\" Eur J Clin Pharmacol 38 (1990): 43-5[18] Campbell MA, Plachetka JR, Jackson JE, Moon JF, Finley PR \"Cimetidine decreases theophylline clearance.\" Ann Intern Med 95 (1981): 68-9[19] Loi CM, Parker BM, Cusack BJ, Vestal RE \"Aging and drug interactions .3. individual and combined effects of cimetidine and ciprofloxacin on theophylline metabolism in healthy male and female nonsmokers.\" J Pharmacol Exp Ther 280 (1997): 627-37[20] Ohashi K, Sakamoto K, Sudo T, Tateishi T, Fujimura A, Shiga T, Ebihara A \"Effects of diltiazem and cimetidine on theophylline oxidative metabolism.\" J Clin Pharmacol 33 (1993): 1233-7[21] Pride M, Deamer RL \"Over-the-counter cimetidine and theophylline interaction.\" Am Fam Physician 52 (1995): 2180[22] Verdiani P, Di Carlo S, Baronti A \"Famotidine effects on theophylline pharmacokinetics in subjects affected by COPD: comparison with cimetidine and placebo.\" Chest 94 (1988): 807-10[23] Boehning W \"Effect of cimetidine and ranitidine on plasma theophylline in patients with chronic obstructive airways disease treated with theophylline and corticosteroids.\" Eur J Clin Pharmacol 38 (1990): 43-5[24] Hardman JG, Gilman AG, Limbird LE eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 9th ed.\" New York, NY: McGraw-Hill (1995):[25] Roy AK, Cuda MP, Levine RA \"Induction of theophylline toxicity and inhibition of clearance rates by ranitidine.\" Am J Med 85 (1988): 525-7[26] Fenje PC, Isles AF, Baltodano A, MacLeod SM, Soldin S \"Interaction of cimetidine and theophylline in two infants.\" Can Med Assoc J 126 (1982): 1178[27] Upton RA \"Pharmacokinetic interactions between theophylline and other medication (Part II).\" Clin Pharmacokinet 20 (1991): 135-50[28] Dal Negro R, Pomari C, Turco P \"Famotidine and theophylline pharmacokinetics. An unexpected cimetidine-like interaction in patients with chronic obstructive pulmonary disease.\" Clin Pharmacokinet 24 (1993): 255-8[29] Hsu K, Garton A, Sproule BJ, Tam YK, Leggatt D, Herbert FA \"The influence of orally administered cimetidine and theophylline on the elimination of each drug in patients with chronic airways obstruction.\" Am Rev Respir Dis 130 (1984): 740-3[30] Lin JH, Chremos AN, Chiou R, Yeh KC, Williams R \"Comparative effect of famotidine and cimetidine on the pharmacokinetics of theophylline in normal volunteers.\" Br J Clin Pharmacol 24 (1987): 669-72", "alternatives_a": "Omalizumab, Tezepelumab, Mercaptopurine, Benralizumab, Caffeine, Reslizumab, Montelukast, Dyphylline, Mepolizumab, Roflumilast, Pentoxifylline, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 97470, "ingredient1": "Theophylline", "ingredient2": "Rapacuronium", "severity": "Moderate", "effect": "Methylxanthines may antagonize the effects of neuromuscular blockers. The mechanism is unknown. In patients stabilized on aminophylline, resistance to pancuronium has been reported.", "source": "DDInter", "management_text": "The patient should be monitored for adequate neuromuscular blockade and the dosage adjusted, if necessary.", "mechanism_text": "Antagonism", "recommendation": "The patient should be monitored for adequate neuromuscular blockade and the dosage adjusted, if necessary.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97574/", "reference_text": "[1] Doll DC, Rosenberg H \"Antagonism of neuromuscular blockage by theophylline.\" Anesth Analg 58 (1979): 139-40[2] Azar I, Kumar D, Betcher AM \"Resistance to pancuronium in an asthmatic patient treated with aminophylline and steroids.\" Can Anaesth Soc J 29 (1982): 280-2[3] Daller JA, Erstad B, Rosado L, Otto C, Putnam CW \"Aminophylline antagonizes the neuromuscular blockade of pancuronium but not vecuronium.\" Crit Care Med 19 (1991): 983-5", "alternatives_a": "Omalizumab, Tezepelumab, Mercaptopurine, Benralizumab, Caffeine, Reslizumab, Montelukast, Mepolizumab, Roflumilast, Pentoxifylline, Zafirlukast, Bromotheophylline", "alternatives_b": "", "updated_at": 1767369485}, {"id": 97471, "ingredient1": "Theophylline", "ingredient2": "Regadenoson", "severity": "Moderate", "effect": "INTERVAL: Methylxanthines (e.g., caffeine, theophylline) are nonspecific, competitive antagonists of adenosine receptors. As such, they may interfere with the pharmacologic effects of adenosine and other adenosine receptor agonists such as dipyridamole and regadenoson. There have been case reports of patients receiving theophylline who required higher than normal dosages of adenosine for the treatment of paroxysmal supraventricular tachycardia.", "source": "DDInter", "management_text": "Clinicians should be aware that adenosine and other adenosine receptor agonists may be less effective in the presence of methylxanthines. Methylxanthines including caffeine should be withheld for 12 to 24 hours (or five half-lives) prior to administration of adenosine receptor agonists for myocardial perfusion imaging. However, parenteral aminophylline should be readily available for treating severe or persistent adverse reactions to adenosine receptor agonists such as bronchospasm or chest pain.", "mechanism_text": "Antagonism", "recommendation": "Clinicians should be aware that adenosine and other adenosine receptor agonists may be less effective in the presence of methylxanthines.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97575/", "reference_text": "[1] \"Product Information. Persantine (dipyridamole).\" Boehringer-Ingelheim, Ridgefield, CT.[2] Smits P, Schouten J, Thien T \"Respiratory stimulant effects of adenosine in man after caffeine and enprofylline.\" Br J Clin Pharmacol 24 (1987): 816-9[3] Ranhosky A, Kempthorne-Rawson J, the Intravenous Dipyridamole Thallium Imaging Study Group \"The safety of intravenous dipyridamole thallium myocardial perfusion imaging.\" Circulation 81 (1990): 1205-9[4] Minton NA, Henry JA \"Pharmacodynamic interactions between infused adenosine and oral theophylline.\" Hum Exp Toxicol 10 (1991): 411-8[5] \"Product Information. Adenoscan (adenosine).\" Fujisawa, Deerfield, IL.[6] Conti CR \"Adenosine: clinical pharmacology and applications.\" Clin Cardiol 14 (1991): 91-3[7] \"Product Information. Lexiscan (regadenoson).\" Astellas Pharma US, Inc, Deerfield, IL.[8] Smits P, Aengevaeren WR, Corstens FH, Thien T \"Caffeine reduces dipyridamole-induced myocardial ischemia.\" J Nucl Med 30 (1989): 1723-6[9] \"Product Information. Adenocard (adenosine).\" Fujisawa, Deerfield, IL.[10] \"Product Information. Lexiscan (regadenoson).\" Astellas Pharma US, Inc, Deerfield, IL.", "alternatives_a": "Omalizumab, Tezepelumab, Mercaptopurine, Benralizumab, Reslizumab, Montelukast, Mepolizumab, Roflumilast, Pentoxifylline, Zafirlukast, Bromotheophylline", "alternatives_b": "Alprostadil, Indomethacin, Ranolazine, Ivabradine, Ubidecarenone", "updated_at": 1767369485}, {"id": 97472, "ingredient1": "Theophylline", "ingredient2": "Remimazolam", "severity": "Minor", "effect": "Methylxanthines may antagonize the sedative effects of benzodiazepines. Aminophylline in particular has been demonstrated to attenuate the sedative effects of diazepam. The mechanism of this interaction may be related to competitive binding to intracerebral adenosine receptors.", "source": "DDInter", "management_text": "-", "mechanism_text": "Antagonism", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97576/", "reference_text": "[1] Tuncok Y, Akpinar O, Guven H, Akkoclu A \"The effects of theophylline on serum alprazolam levels.\" Int J Clin Pharmacol Ther 32 (1994): 642-5[2] Gallen JS \"Aminophylline reversal of midazolam sedation.\" Anesth Analg 69 (1989): 268[3] Bonfiglio MF, Dasta JF \"Clinical significance of the benzodiazepine-theophylline interaction.\" Pharmacotherapy 11 (1991): 85-7[4] Upton RA \"Pharmacokinetic interactions between theophylline and other medication (Part II).\" Clin Pharmacokinet 20 (1991): 135-50[5] Stirt JA \"Aminophylline is a diazepam antagonist.\" Anesth Analg 60 (1981): 767-8[6] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[7] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[8] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[9] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Omalizumab, Tezepelumab, Mercaptopurine, Benralizumab, Caffeine, Reslizumab, Montelukast, Mepolizumab, Roflumilast, Pentoxifylline, Zafirlukast, Bromotheophylline", "alternatives_b": "Suvorexant, Chloral hydrate, Nitrazepam, Paraldehyde, Propiomazine, Ramelteon, Meprobamate, Scopolamine, Eszopiclone, Dexmedetomidine, Lemborexant, More", "updated_at": 1767369485}, {"id": 97473, "ingredient1": "Theophylline", "ingredient2": "Rifampicin", "severity": "Moderate", "effect": "Rifampin may decrease the plasma concentrations of theophyllines by inducing CYP450 3A4 and 1A2 hepatic metabolism.", "source": "DDInter", "management_text": "While receiving rifampin, patients should be monitored for changes in theophylline serum concentrations or inadequate response to theophylline. Patients should be advised to notify their physician if they experience a worsening of their respiratory symptoms. Dosages should be adjusted as necessary.", "mechanism_text": "Metabolism", "recommendation": "While receiving rifampin, patients should be monitored for changes in theophylline serum concentrations or inadequate response to theophylline.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97577/", "reference_text": "[1] Strayhorn VA, Baciewicz AM, Self TH \"Update on rifampin drug interactions, III.\" Arch Intern Med 157 (1997): 2453-8[2] Dal Negro R, Turco P, Trevisan F, De Conti F \"Rifampicin-isoniazid and delayed elimination of theophylline: a case report.\" Int J Clin Pharmacol Res 8 (1988): 275-7[3] Venkatesan K \"Pharmacokinetic drug interactions with rifampicin.\" Clin Pharmacokinet 22 (1992): 47-65[4] Borcherding SM, Baciewicz AM, Self TH \"Update on rifampin drug interactions.\" Arch Intern Med 152 (1992): 711-6[5] Boyce EG, Dukes GE, Rollins DE, Sudds TW \"The effect of rifampin on theophylline kinetics.\" J Clin Pharmacol 26 (1986): 696-9[6] Upton RA \"Pharmacokinetic interactions between theophylline and other medication (Part I).\" Clin Pharmacokinet 20 (1991): 66-80[7] Boyce EG, Dukes GE, Rollins DE, Sudds TW \"The effect of rifampin on theophylline kinetics.\" Clin Pharmacol Ther 37 (1985): 183[8] Powell-Jackson PR, Jamieson AP, Gray BJ, et al \"Effect of rifampicin administration on theophyllin pharmacokinetics in humans.\" Am Rev Respir Dis 131 (1985): 939-40", "alternatives_a": "Omalizumab, Tezepelumab, Mercaptopurine, Benralizumab, Caffeine, Reslizumab, Dyphylline, Mepolizumab, Pentoxifylline, Zafirlukast, Bromotheophylline", "alternatives_b": "Capreomycin, Pyrazinamide, Rifamycin, Bedaquiline, Sulfamethoxazole, Rifapentine, Streptomycin, Trimethoprim, Cycloserine, Rifabutin, Ethambutol, More", "updated_at": 1767369485}, {"id": 97474, "ingredient1": "Theophylline", "ingredient2": "Rilonacept", "severity": "Moderate", "effect": "Plasma concentrations of drugs that are CYP450 substrates may decrease following the initiation of interleukin (IL) inhibitors, tumor necrosis factor (TNF) blockers, or interferon (IFN) inhibitors in patients with chronic inflammatory diseases. Because the formation of hepatic CYP450 enzymes is down-regulated during infection and chronic inflammation by increased levels of certain cytokines (e.g., interleukins-1, -6, and -10; tumor necrosis factor alpha; interferons), treatment targeting these cytokines may restore or normalize CYP450 enzyme levels resulting in increased metabolism of these drugs.", "source": "DDInter", "management_text": "Caution is advised when treatments targeting cytokines such as interleukins, tumor necrosis factors, or interferons are prescribed to patients receiving concomitant drugs that are CYP450 substrates, particularly those with narrow therapeutic ranges (e.g., antiarrhythmics, anticonvulsants, immunosuppressants, theophylline) or sensitive substrates where decreases in plasma levels may be significant or undesirable (e.g., oral contraceptives, statins, benzodiazepines, opioids). Clinical and/or laboratory monitoring should be considered following the initiation or withdrawal of such treatments, and the dosage(s) of the CYP450 substrate(s) adjusted accordingly. The effects of IL inhibitors, TNF blockers, and IFN inhibitors on CYP450 activities may persist for several weeks after stopping therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when treatments targeting cytokines such as interleukins, tumor necrosis factors, or interferons are prescribed to patients receiving concomitant drugs that are CYP450 substrates, particularly those with narrow therapeutic ranges (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97578/", "reference_text": "[1] \"Product Information. Skyrizi (risankizumab).\" AbbVie US LLC, North Chicago, IL.[2] \"Product Information. Cosentyx (secukinumab).\" Novartis Pharmaceuticals, East Hanover, NJ.[3] \"Product Information. Ilaris (canakinumab).\" Novartis Pharmaceuticals, East Hanover, NJ.[4] \"Product Information. Gamifant (emapalumab).\" Sobi Inc, Ardmore, PA.[5] \"Product Information. Kevzara (sarilumab).\" sanofi-aventis, Bridgewater, NJ.[6] \"Product Information. Simponi (golimumab).\" Centocor Inc, Malvern, PA.[7] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[8] \"Product Information. Sylvant (siltuximab).\" Janssen Biotech, Inc., Horsham, PA, PA.[9] \"Product Information. Stelara (ustekinumab).\" Centocor Inc, Malvern, PA.[10] \"Product Information. Ilumya (tildrakizumab).\" Merck & Company Inc, Whitehouse Station, NJ.[11] \"Product Information. Actemra (tocilizumab).\" Genentech, South San Francisco, CA.[12] \"Product Information. Amevive (alefacept).\" Biogen, Cambridge, MA.[13] \"Product Information. Remicade (infliximab).\" Centocor Inc, Malvern, PA.[14] \"Product Information. Taltz Autoinjector (ixekizumab).\" Eli Lilly and Company, Indianapolis, IN.[15] \"Product Information. Arcalyst (rilonacept).\" Regeneron Pharmaceuticals Inc, Tarrytown, NY.[16] Ace LN, Jaffe JM, Kunka RL \"Effect of food and an antacid on quinidine bioavailability.\" Biopharm Drug Dispos 4 (1983): 183-90[17] Min DI, Ku YM, Geraets DR, Lee HC \"Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers.\" J Clin Pharmacol 36 (1996): 469-76[18] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[19] Ha HR, Chen J, Leuenberger PM, Freiburghaus AU, Follah F \"In vitro inhibition of midazolam and quinidine metabolism by flavonoids.\" Eur J Clin Pharmacol 48 (1995): 367-71", "alternatives_a": "Omalizumab, Tezepelumab, Benralizumab, Caffeine, Reslizumab, Montelukast, Dyphylline, Mepolizumab, Pentoxifylline, Zafirlukast, Bromotheophylline", "alternatives_b": "Cyclosporine, Antithymocyte immunoglobulin (rabbit), Anifrolumab, Ravulizumab, Diroximel fumarate, Abatacept, Upadacitinib, Siponimod, Apremilast, Inebilizumab, Cladribine, More", "updated_at": 1767369485}, {"id": 97475, "ingredient1": "Theophylline", "ingredient2": "Riluzole", "severity": "Minor", "effect": "According to the manufacturer, riluzole serum concentrations may theoretically be increased by concurrent theophylline and aminophylline. The proposed mechanism is metabolic inhibition. The clinical significance of this interaction is not known. The patient should be monitored for altered clinical effect. Dosage adjustments may be necessary if an interaction is suspected.", "source": "DDInter", "management_text": "-", "mechanism_text": "Metabolism", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97579/", "reference_text": "[1] \"Product Information. Rilutek (riluzole).\" Rhone-Poulenc Rorer, Collegeville, PA.", "alternatives_a": "Omalizumab, Tezepelumab, Mercaptopurine, Benralizumab, Reslizumab, Montelukast, Dyphylline, Oxtriphylline, Mepolizumab, Roflumilast, Pentoxifylline, More", "alternatives_b": "Dextromethorphan, Valbenazine, Dalfampridine, Sodium oxybate, Tetrabenazine, Inotersen, Pitolisant, Amifampridine, Deutetrabenazine, Tafamidis", "updated_at": 1767369485}, {"id": 97476, "ingredient1": "Theophylline", "ingredient2": "Riociguat", "severity": "Major", "effect": "Coadministration of riociguat with phosphodiesterase (PDE) inhibitors may cause significant hypotension. The mechanism involves peripheral vasodilation secondary to enhanced levels of cyclic guanosine monophosphate (cGMP) in vascular smooth muscle cells, as PDE inhibitors prevent degradation of cGMP while riociguat promotes its synthesis by stimulating soluble guanylate cyclase (sGC), an enzyme in the cardiopulmonary system that binds with nitric oxide (NO) to catalyze the synthesis of cGMP. Riociguat does not affect the pharmacokinetics of sildenafil.", "source": "DDInter", "management_text": "Concomitant use of riociguat with PDE inhibitors, including specific PDE-5 inhibitors (e.g., avanafil, sildenafil, tadalafil, vardenafil) or nonspecific PDE inhibitors (e.g., dipyridamole, theophylline), is considered contraindicated. Riociguat should be discontinued at least 24 hours before administering a PDE-5 inhibitor, and avoidance of riociguat administration within 24 hours after sildenafil or within 48 hours after tadalafil is recommended. Limited data exists for other PDE inhibitors.", "mechanism_text": "Others", "recommendation": "Concomitant use of riociguat with PDE inhibitors, including specific PDE-5 inhibitors (e.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97580/", "reference_text": "[1] \"Product Information. Adempas (riociguat).\" Bayer Pharmaceutical Inc, West Haven, CT.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] Cerner Multum, Inc. \"Australian Product Information.\" O 0[4] \"Product Information. Adempas (riociguat).\" Bayer Pharmaceutical Inc, West Haven, CT.", "alternatives_a": "Omalizumab, Tezepelumab, Mercaptopurine, Benralizumab, Caffeine, Reslizumab, Montelukast, Mepolizumab, Roflumilast, Pentoxifylline, Zafirlukast, Bromotheophylline", "alternatives_b": "Macitentan, Metyrosine, Tadalafil, Bosentan, Ambrisentan", "updated_at": 1767369485}, {"id": 97477, "ingredient1": "Theophylline", "ingredient2": "Ritodrine", "severity": "Moderate", "effect": "Concomitant use of beta-2 adrenergic agonists with theophylline may increase the risk and/or severity of hypokalemia and adverse cardiovascular effects such as palpitation, tachycardia, and blood pressure elevation. Adverse events, especially hypokalemia, may be more likely with systemic or nebulized formulations of beta-2 agonists or high dosages of theophylline. Beta-2 agonists can cause clinically significant but usually transient decreases in serum potassium concentrations, while hypokalemia associated with theophylline often occurs in toxicity. Pharmacokinetically, some beta-2 agonists given systemically may decrease the plasma concentrations of theophylline.", "source": "DDInter", "management_text": "Although theophylline and beta-2 agonists are commonly used together to produce bronchodilation, it may be appropriate to monitor patient response as well as serum potassium level, blood pressure and heart rate during coadministration, especially if the beta-2 agonist is administered systemically or by nebulizer. Close monitoring is particularly important in patients with severe asthma, since the potential increases in blood pressure and heart rate may have more serious consequences in the presence of hypoxemia or hypercapnia due to increased myocardial oxygen consumption. Patients should be advised to notify their physician if they experience worsening of their respiratory condition or potential signs and symptoms of hypokalemia such as fatigue, weakness, myalgia, muscle cramps, numbness, tingling, abdominal pain, constipation, palpitation, and irregular heartbeat.", "mechanism_text": "Synergism", "recommendation": "Although theophylline and beta-2 agonists are commonly used together to produce bronchodilation, it may be appropriate to monitor patient response as well as serum potassium level, blood pressure and heart rate during coadministration, especially if the beta-2 agonist is administered systemically or by nebulizer.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97581/", "reference_text": "[1] Garty M, Paul-Keslin L, Ilfeld DN, et al \"Increased theophylline clearance in asthmatic patients due to terbutaline.\" Eur J Clin Pharmacol 36 (1989): 25-8[2] Amirav I, Amitai Y, Avital A, Godfrey S \"Enhancement of theophylline clearance by intravenous albuterol.\" Chest 94 (1988): 444-5[3] \"Product Information. Striverdi Respimat (olodaterol).\" Boehringer Ingelheim, Ridgefield, CT.[4] Cusack BJ, Nielson CP, Morgan ME, Vestal RE \"Additive effect of theophylline on the cardiac response to isoproterenol.\" Clin Pharmacol Ther 41 (1987): 289-96[5] Griffith JA, Kozloski GD \"Isoproterenol-theophylline interaction: possible potentiation by other drugs.\" Clin Pharm 9 (1990): 54-7[6] Conrad KA, Woodworth JR \"Orciprenaline does not alter theophylline elimination.\" Br J Clin Pharmacol 12 (1981): 756-7[7] Flatt A, Burgess C, Windom H, Beasley R, Purdie G, Crane J \"The cardiovascular effects of inhaled fenoterol alone and during treatment with oral theophylline.\" Chest 96 (1989): 1317-20[8] Smith SR, Kendall MJ \"Potentiation of the adverse effects of intravenous terbutaline by oral theophylline.\" Br J Clin Pharmacol 21 (1986): 451-3[9] Danzinger Y, Garty M, Volwitz B, Ilfeld D, Varsano I, Rosenfeld JB \"Reduction of serum theophylline levels by terbutaline in children with asthma.\" Clin Pharmacol Ther 37 (1985): 469-71[10] O'Rourke PP, Crone RK \"Effect of isoproterenol on measured theophylline levels.\" Crit Care Med 12 (1984): 373-5[11] Whyte KF, Reid C, Addis GJ, Whitesmith R, Reid JL \"Salbutamol induced hypokalaemia: the effect of theophylline alone and in combination with adrenaline.\" Br J Clin Pharmacol 25 (1988): 571-8[12] Coleman JJ, Vollmer WM, Barker AF, et al \"Cardiac arrhythmias during the combined use of beta-adrenergic agonist drugs and theophylline.\" Chest 90 (1986): 45-51[13] Kelly HW \"Controversies in asthma therapy with theophylline and the beta2-adrenergic agonists.\" Clin Pharm 3 (1984): 386-95[14] Amitai Y, Glustein J, Godfrey S \"Enhancement of theophylline clearance by oral albuterol.\" Chest 102 (1992): 786-9[15] \"Product Information. Brovana (arformoterol).\" Sepracor Inc, Marlborough, MA.[16] \"Interactions between methyl xanthines and beta adrenergic agonists.\" FDA Drug Bull 11 (1981): 19-20[17] Chow OK, Fung KP \"Slow-release terbutaline and theophylline for the long-term therapy of children with asthma: a Latin square and factorial study of drug effects and interactions.\" Pediatrics 84 (1989): 119-25[18] Hemstreet MP, Miles MV, Rutland RO \"Effect of intravenous isoproterenol on theophylline kinetics.\" J Allergy Clin Immunol 69 (1982): 360-4[19] Upton RA \"Pharmacokinetic interactions between theophylline and other medication (Part I).\" Clin Pharmacokinet 20 (1991): 66-80[20] Rachelefsky GS, Katz RM, Mickey MR Jr, Siegel SC \"Metaproterenol and theophylline in asthmatic children.\" Ann Allergy 45 (1980): 207-12[21] Josephson GW, Kennedy HL, MacKenzie EJ, Gibson G \"Cardiac dysrhythmias during the treatment of acute asthma. A comparison of two treatment regimens by a double blind protocol.\" Chest 78 (1980): 429-35[22] Dawson KP, Fergusson DM \"Effects of oral theophylline and oral salbutamol in the treatment of asthma.\" Arch Dis Child 57 (1982): 674-6[23] Jonkman JH, Borgstrom L, van der Boon WJ, de Noord OE \"Theophylline-terbutaline, a steady state study on possible pharmacokinetic interactions with special reference to chronopharmacokinetic aspects.\" Br J Clin Pharmacol 26 (1988): 285-93[24] Deenstra M, Haalboom JR, Struyvenberg A \"Decrease of plasma potassium due to inhalation of beta-2 agonists: absence of an additional effect of intravenous theophylline.\" Eur J Clin Invest 18 (1988): 162-5[25] \"Product Information. Arcapta Neohaler (indacaterol).\" Novartis Pharmaceuticals, East Hanover, NJ.[26] Lombardi TP, Bertino JS, Goldberg A, Middleton E, Slaughter RL \"The effects of a beta-2 selective adrenergic agonist and a beta- nonselective antagonist on theophylline clearance.\" J Clin Pharmacol 27 (1987): 523-9", "alternatives_a": "Omalizumab, Tezepelumab, Mercaptopurine, Benralizumab, Caffeine, Reslizumab, Montelukast, Mepolizumab, Roflumilast, Pentoxifylline, Zafirlukast, Bromotheophylline", "alternatives_b": "Bremelanotide, Flibanserin, Cabergoline, Black cohosh, Bromocriptine", "updated_at": 1767369485}, {"id": 97478, "ingredient1": "Theophylline", "ingredient2": "Ritonavir", "severity": "Moderate", "effect": "The coadministration with ritonavir may decrease the plasma concentrations of theophylline. The proposed mechanism is ritonavir induction of CYP450 1A2, the isoenzyme responsible for the metabolic clearance of theophylline.", "source": "DDInter", "management_text": "During coadministration with ritonavir, the possibility of a diminished therapeutic response to theophylline should be considered. Dosage adjustment as well as clinical and laboratory monitoring may be appropriate whenever ritonavir is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "During coadministration with ritonavir, the possibility of a diminished therapeutic response to theophylline should be considered.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97582/", "reference_text": "[1] \"Product Information. Norvir (ritonavir).\" Abbott Pharmaceutical, Abbott Park, IL.[2] Hsu A, Granneman GR, Witt G, Cavanaugh JH, Leonard J \"Assessment of multiple doses of ritonavir on the pharmacokinetics of theophylline.\" Int Conf AIDS 11 (1996): 89(ab.no.mo.b.1200)[3] \"Product Information. Kaletra (lopinavir-ritonavir)\" Abbott Pharmaceutical, Abbott Park, IL.[4] \"Product Information. Norvir (ritonavir).\" Abbott Pharmaceutical, Abbott Park, IL.", "alternatives_a": "Omalizumab, Tezepelumab, Mercaptopurine, Benralizumab, Caffeine, Reslizumab, Dyphylline, Mepolizumab, Roflumilast, Pentoxifylline, Bromotheophylline", "alternatives_b": "Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Amprenavir, Simeprevir, Valaciclovir, Zanamivir, Cabotegravir, Telaprevir, More", "updated_at": 1767369485}, {"id": 97479, "ingredient1": "Theophylline", "ingredient2": "Rocuronium", "severity": "Moderate", "effect": "Methylxanthines may antagonize the effects of neuromuscular blockers. The mechanism is unknown. In patients stabilized on aminophylline, resistance to pancuronium has been reported.", "source": "DDInter", "management_text": "The patient should be monitored for adequate neuromuscular blockade and the dosage adjusted, if necessary.", "mechanism_text": "Antagonism", "recommendation": "The patient should be monitored for adequate neuromuscular blockade and the dosage adjusted, if necessary.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97583/", "reference_text": "[1] Doll DC, Rosenberg H \"Antagonism of neuromuscular blockage by theophylline.\" Anesth Analg 58 (1979): 139-40[2] Azar I, Kumar D, Betcher AM \"Resistance to pancuronium in an asthmatic patient treated with aminophylline and steroids.\" Can Anaesth Soc J 29 (1982): 280-2[3] Daller JA, Erstad B, Rosado L, Otto C, Putnam CW \"Aminophylline antagonizes the neuromuscular blockade of pancuronium but not vecuronium.\" Crit Care Med 19 (1991): 983-5", "alternatives_a": "Omalizumab, Tezepelumab, Mercaptopurine, Benralizumab, Caffeine, Reslizumab, Montelukast, Mepolizumab, Roflumilast, Pentoxifylline, Zafirlukast, Bromotheophylline", "alternatives_b": "Botulinum toxin type A", "updated_at": 1767369485}, {"id": 97480, "ingredient1": "Theophylline", "ingredient2": "Rofecoxib", "severity": "Moderate", "effect": "The coadministration with rofecoxib may increase the plasma concentrations of theophylline. The proposed mechanism is rofecoxib inhibition of CYP450 1A2, the isoenzyme primarily responsible for the metabolic clearance of theophylline.", "source": "DDInter", "management_text": "Caution is advised during coadministration of theophylline with rofecoxib. Theophylline plasma levels should be closely monitored and the dosage adjusted accordingly, particularly following initiation, discontinuation or change of dosage of rofecoxib therapy in patients who are stabilized on their theophylline regimen. Patients should be advised to notify their physician if they experience signs of theophylline toxicity such as nausea, vomiting, diarrhea, headache, restlessness, insomnia, seizures, palpitations, and cardiac arrhythmia.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised during coadministration of theophylline with rofecoxib.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97584/", "reference_text": "[1] \"Product Information. Vioxx (rofecoxib).\" Merck & Co, Inc, West Point, PA.", "alternatives_a": "Omalizumab, Tezepelumab, Benralizumab, Caffeine, Reslizumab, Dyphylline, Mepolizumab, Roflumilast, Bromotheophylline", "alternatives_b": "Fenoprofen, Meclofenamic acid, Ketorolac, Phenylbutazone, Mefenamic acid, Misoprostol, Indomethacin, Ketoprofen, Glucosamine, Oxaprozin, Piroxicam, More", "updated_at": 1767369485}, {"id": 97481, "ingredient1": "Theophylline", "ingredient2": "Roflumilast", "severity": "Minor", "effect": "Coadministration with theophylline may increase the systemic exposure to roflumilast and its pharmacologically active N-oxide metabolite.", "source": "DDInter", "management_text": "-", "mechanism_text": "Others", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97585/", "reference_text": "[1] \"Product Information. Daxas (roflumilast).\" Nycomed Inc, Princeton, NJ.[2] \"Product Information. Daliresp (roflumilast).\" Astra-Zeneca Pharmaceuticals, Wilmington, DE.[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] \"Product Information. Daxas (roflumilast).\" Nycomed Inc, Princeton, NJ.[6] \"Product Information. Daliresp (roflumilast).\" Astra-Zeneca Pharmaceuticals, Wilmington, DE.", "alternatives_a": "Omalizumab, Tezepelumab, Benralizumab, Caffeine, Reslizumab, Montelukast, Dyphylline, Mepolizumab, Roflumilast, Pentoxifylline, Zafirlukast, Bromotheophylline", "alternatives_b": "Theophylline, Omalizumab, Tezepelumab, Mercaptopurine, Benralizumab, Reslizumab, Dyphylline, Oxtriphylline, Mepolizumab, Bromotheophylline", "updated_at": 1767369485}, {"id": 97482, "ingredient1": "Theophylline", "ingredient2": "Ropivacaine", "severity": "Minor", "effect": "Ropivacaine serum concentrations may increase when given with drugs metabolized by the cytochrome P-450 isoenzyme 1A2. The theorized mechanism is via competitive inhibition. Information is only available from in vitro studies. Theophylline and mexiletine, drugs metabolized by CYP450 1A2, may participate in this interaction.", "source": "DDInter", "management_text": "-", "mechanism_text": "Metabolism", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97586/", "reference_text": "[1] \"Product Information. Naropin (ropivacaine).\" Astra USA, Westborough, MA.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0", "alternatives_a": "Omalizumab, Tezepelumab, Mercaptopurine, Aminophylline, Benralizumab, Reslizumab, Montelukast, Dyphylline, Oxtriphylline, Mepolizumab, Roflumilast, More", "alternatives_b": "Chloroprocaine, Bupivacaine, Levobupivacaine, Tetracaine, Mepivacaine, Procaine, Prilocaine, Articaine, Etidocaine", "updated_at": 1767369485}, {"id": 97483, "ingredient1": "Theophylline", "ingredient2": "Rucaparib", "severity": "Moderate", "effect": "Coadministration with rucaparib may increase the plasma concentrations and the risk of adverse effects of drugs that are substrates of CYP450 1A2. The proposed mechanism is decreased clearance due to rucaparib-mediated inhibition of CYP450 1A2.", "source": "DDInter", "management_text": "Caution is advised if rucaparib is used concomitantly with drugs that are substrates of CYP450 1A2, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring should be considered whenever rucaparib is added to or withdrawn from therapy with these drugs. Patients should be monitored for the development of adverse effects.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if rucaparib is used concomitantly with drugs that are substrates of CYP450 1A2, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97587/", "reference_text": "[1] EMA. European Medicines Agency. European Union \"EMA - List of medicines under additional monitoring. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000366.jsp&mid=WC0b01ac058067c852\" ([2013 - ]):", "alternatives_a": "Omalizumab, Tezepelumab, Mercaptopurine, Aminophylline, Benralizumab, Reslizumab, Dyphylline, Oxtriphylline, Mepolizumab, Bromotheophylline", "alternatives_b": "Pertuzumab, Oxaliplatin, Bortezomib, Tisagenlecleucel, Aminolevulinic acid, Omacetaxine mepesuccinate, Tazemetostat, Altretamine, Tagraxofusp, Pegaspargase, Ixazomib, More", "updated_at": 1767369485}, {"id": 97484, "ingredient1": "Theophylline", "ingredient2": "Salmeterol", "severity": "Moderate", "effect": "Concomitant use of beta-2 adrenergic agonists with theophylline may increase the risk and/or severity of hypokalemia and adverse cardiovascular effects such as palpitation, tachycardia, and blood pressure elevation. Adverse events, especially hypokalemia, may be more likely with systemic or nebulized formulations of beta-2 agonists or high dosages of theophylline. Beta-2 agonists can cause clinically significant but usually transient decreases in serum potassium concentrations, while hypokalemia associated with theophylline often occurs in toxicity. Pharmacokinetically, some beta-2 agonists given systemically may decrease the plasma concentrations of theophylline.", "source": "DDInter", "management_text": "Although theophylline and beta-2 agonists are commonly used together to produce bronchodilation, it may be appropriate to monitor patient response as well as serum potassium level, blood pressure and heart rate during coadministration, especially if the beta-2 agonist is administered systemically or by nebulizer. Close monitoring is particularly important in patients with severe asthma, since the potential increases in blood pressure and heart rate may have more serious consequences in the presence of hypoxemia or hypercapnia due to increased myocardial oxygen consumption. Patients should be advised to notify their physician if they experience worsening of their respiratory condition or potential signs and symptoms of hypokalemia such as fatigue, weakness, myalgia, muscle cramps, numbness, tingling, abdominal pain, constipation, palpitation, and irregular heartbeat.", "mechanism_text": "Synergism", "recommendation": "Although theophylline and beta-2 agonists are commonly used together to produce bronchodilation, it may be appropriate to monitor patient response as well as serum potassium level, blood pressure and heart rate during coadministration, especially if the beta-2 agonist is administered systemically or by nebulizer.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97588/", "reference_text": "[1] Garty M, Paul-Keslin L, Ilfeld DN, et al \"Increased theophylline clearance in asthmatic patients due to terbutaline.\" Eur J Clin Pharmacol 36 (1989): 25-8[2] Amirav I, Amitai Y, Avital A, Godfrey S \"Enhancement of theophylline clearance by intravenous albuterol.\" Chest 94 (1988): 444-5[3] \"Product Information. Striverdi Respimat (olodaterol).\" Boehringer Ingelheim, Ridgefield, CT.[4] Cusack BJ, Nielson CP, Morgan ME, Vestal RE \"Additive effect of theophylline on the cardiac response to isoproterenol.\" Clin Pharmacol Ther 41 (1987): 289-96[5] Griffith JA, Kozloski GD \"Isoproterenol-theophylline interaction: possible potentiation by other drugs.\" Clin Pharm 9 (1990): 54-7[6] Conrad KA, Woodworth JR \"Orciprenaline does not alter theophylline elimination.\" Br J Clin Pharmacol 12 (1981): 756-7[7] Flatt A, Burgess C, Windom H, Beasley R, Purdie G, Crane J \"The cardiovascular effects of inhaled fenoterol alone and during treatment with oral theophylline.\" Chest 96 (1989): 1317-20[8] Smith SR, Kendall MJ \"Potentiation of the adverse effects of intravenous terbutaline by oral theophylline.\" Br J Clin Pharmacol 21 (1986): 451-3[9] Danzinger Y, Garty M, Volwitz B, Ilfeld D, Varsano I, Rosenfeld JB \"Reduction of serum theophylline levels by terbutaline in children with asthma.\" Clin Pharmacol Ther 37 (1985): 469-71[10] O'Rourke PP, Crone RK \"Effect of isoproterenol on measured theophylline levels.\" Crit Care Med 12 (1984): 373-5[11] Whyte KF, Reid C, Addis GJ, Whitesmith R, Reid JL \"Salbutamol induced hypokalaemia: the effect of theophylline alone and in combination with adrenaline.\" Br J Clin Pharmacol 25 (1988): 571-8[12] Coleman JJ, Vollmer WM, Barker AF, et al \"Cardiac arrhythmias during the combined use of beta-adrenergic agonist drugs and theophylline.\" Chest 90 (1986): 45-51[13] Kelly HW \"Controversies in asthma therapy with theophylline and the beta2-adrenergic agonists.\" Clin Pharm 3 (1984): 386-95[14] Amitai Y, Glustein J, Godfrey S \"Enhancement of theophylline clearance by oral albuterol.\" Chest 102 (1992): 786-9[15] \"Product Information. Brovana (arformoterol).\" Sepracor Inc, Marlborough, MA.[16] \"Interactions between methyl xanthines and beta adrenergic agonists.\" FDA Drug Bull 11 (1981): 19-20[17] Chow OK, Fung KP \"Slow-release terbutaline and theophylline for the long-term therapy of children with asthma: a Latin square and factorial study of drug effects and interactions.\" Pediatrics 84 (1989): 119-25[18] Hemstreet MP, Miles MV, Rutland RO \"Effect of intravenous isoproterenol on theophylline kinetics.\" J Allergy Clin Immunol 69 (1982): 360-4[19] Upton RA \"Pharmacokinetic interactions between theophylline and other medication (Part I).\" Clin Pharmacokinet 20 (1991): 66-80[20] Rachelefsky GS, Katz RM, Mickey MR Jr, Siegel SC \"Metaproterenol and theophylline in asthmatic children.\" Ann Allergy 45 (1980): 207-12[21] Josephson GW, Kennedy HL, MacKenzie EJ, Gibson G \"Cardiac dysrhythmias during the treatment of acute asthma. A comparison of two treatment regimens by a double blind protocol.\" Chest 78 (1980): 429-35[22] Dawson KP, Fergusson DM \"Effects of oral theophylline and oral salbutamol in the treatment of asthma.\" Arch Dis Child 57 (1982): 674-6[23] Jonkman JH, Borgstrom L, van der Boon WJ, de Noord OE \"Theophylline-terbutaline, a steady state study on possible pharmacokinetic interactions with special reference to chronopharmacokinetic aspects.\" Br J Clin Pharmacol 26 (1988): 285-93[24] Deenstra M, Haalboom JR, Struyvenberg A \"Decrease of plasma potassium due to inhalation of beta-2 agonists: absence of an additional effect of intravenous theophylline.\" Eur J Clin Invest 18 (1988): 162-5[25] \"Product Information. Arcapta Neohaler (indacaterol).\" Novartis Pharmaceuticals, East Hanover, NJ.[26] Lombardi TP, Bertino JS, Goldberg A, Middleton E, Slaughter RL \"The effects of a beta-2 selective adrenergic agonist and a beta- nonselective antagonist on theophylline clearance.\" J Clin Pharmacol 27 (1987): 523-9", "alternatives_a": "Omalizumab, Tezepelumab, Mercaptopurine, Benralizumab, Caffeine, Reslizumab, Mepolizumab, Roflumilast, Bromotheophylline", "alternatives_b": "Mometasone furoate, Umeclidinium, Aclidinium, Mometasone, Glycopyrronium, Ipratropium, Beclomethasone dipropionate", "updated_at": 1767369485}, {"id": 97485, "ingredient1": "Theophylline", "ingredient2": "Sarilumab", "severity": "Moderate", "effect": "Plasma concentrations of drugs that are CYP450 substrates may decrease following the initiation of interleukin (IL) inhibitors, tumor necrosis factor (TNF) blockers, or interferon (IFN) inhibitors in patients with chronic inflammatory diseases. Because the formation of hepatic CYP450 enzymes is down-regulated during infection and chronic inflammation by increased levels of certain cytokines (e.g., interleukins-1, -6, and -10; tumor necrosis factor alpha; interferons), treatment targeting these cytokines may restore or normalize CYP450 enzyme levels resulting in increased metabolism of these drugs.", "source": "DDInter", "management_text": "Caution is advised when treatments targeting cytokines such as interleukins, tumor necrosis factors, or interferons are prescribed to patients receiving concomitant drugs that are CYP450 substrates, particularly those with narrow therapeutic ranges (e.g., antiarrhythmics, anticonvulsants, immunosuppressants, theophylline) or sensitive substrates where decreases in plasma levels may be significant or undesirable (e.g., oral contraceptives, statins, benzodiazepines, opioids). Clinical and/or laboratory monitoring should be considered following the initiation or withdrawal of such treatments, and the dosage(s) of the CYP450 substrate(s) adjusted accordingly. The effects of IL inhibitors, TNF blockers, and IFN inhibitors on CYP450 activities may persist for several weeks after stopping therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when treatments targeting cytokines such as interleukins, tumor necrosis factors, or interferons are prescribed to patients receiving concomitant drugs that are CYP450 substrates, particularly those with narrow therapeutic ranges (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97589/", "reference_text": "[1] \"Product Information. Skyrizi (risankizumab).\" AbbVie US LLC, North Chicago, IL.[2] \"Product Information. Cosentyx (secukinumab).\" Novartis Pharmaceuticals, East Hanover, NJ.[3] \"Product Information. Ilaris (canakinumab).\" Novartis Pharmaceuticals, East Hanover, NJ.[4] \"Product Information. Gamifant (emapalumab).\" Sobi Inc, Ardmore, PA.[5] \"Product Information. Kevzara (sarilumab).\" sanofi-aventis, Bridgewater, NJ.[6] \"Product Information. Simponi (golimumab).\" Centocor Inc, Malvern, PA.[7] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[8] \"Product Information. Sylvant (siltuximab).\" Janssen Biotech, Inc., Horsham, PA, PA.[9] \"Product Information. Stelara (ustekinumab).\" Centocor Inc, Malvern, PA.[10] \"Product Information. Ilumya (tildrakizumab).\" Merck & Company Inc, Whitehouse Station, NJ.[11] \"Product Information. Actemra (tocilizumab).\" Genentech, South San Francisco, CA.[12] \"Product Information. Amevive (alefacept).\" Biogen, Cambridge, MA.[13] \"Product Information. Remicade (infliximab).\" Centocor Inc, Malvern, PA.[14] \"Product Information. Taltz Autoinjector (ixekizumab).\" Eli Lilly and Company, Indianapolis, IN.[15] \"Product Information. Arcalyst (rilonacept).\" Regeneron Pharmaceuticals Inc, Tarrytown, NY.[16] Ace LN, Jaffe JM, Kunka RL \"Effect of food and an antacid on quinidine bioavailability.\" Biopharm Drug Dispos 4 (1983): 183-90[17] Min DI, Ku YM, Geraets DR, Lee HC \"Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers.\" J Clin Pharmacol 36 (1996): 469-76[18] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[19] Ha HR, Chen J, Leuenberger PM, Freiburghaus AU, Follah F \"In vitro inhibition of midazolam and quinidine metabolism by flavonoids.\" Eur J Clin Pharmacol 48 (1995): 367-71", "alternatives_a": "Omalizumab, Tezepelumab, Mercaptopurine, Benralizumab, Caffeine, Reslizumab, Montelukast, Dyphylline, Mepolizumab, Pentoxifylline, Zafirlukast, Bromotheophylline", "alternatives_b": "Cyclosporine, Antithymocyte immunoglobulin (rabbit), Anifrolumab, Ravulizumab, Diroximel fumarate, Abatacept, Upadacitinib, Siponimod, Apremilast, Inebilizumab, Cladribine, More", "updated_at": 1767369485}, {"id": 97486, "ingredient1": "Theophylline", "ingredient2": "Satralizumab", "severity": "Moderate", "effect": "Plasma concentrations of drugs that are CYP450 substrates may decrease following the initiation of interleukin (IL) inhibitors, tumor necrosis factor (TNF) blockers, or interferon (IFN) inhibitors in patients with chronic inflammatory diseases. Because the formation of hepatic CYP450 enzymes is down-regulated during infection and chronic inflammation by increased levels of certain cytokines (e.g., interleukins-1, -6, and -10; tumor necrosis factor alpha; interferons), treatment targeting these cytokines may restore or normalize CYP450 enzyme levels resulting in increased metabolism of these drugs.", "source": "DDInter", "management_text": "Caution is advised when treatments targeting cytokines such as interleukins, tumor necrosis factors, or interferons are prescribed to patients receiving concomitant drugs that are CYP450 substrates, particularly those with narrow therapeutic ranges (e.g., antiarrhythmics, anticonvulsants, immunosuppressants, theophylline) or sensitive substrates where decreases in plasma levels may be significant or undesirable (e.g., oral contraceptives, statins, benzodiazepines, opioids). Clinical and/or laboratory monitoring should be considered following the initiation or withdrawal of such treatments, and the dosage(s) of the CYP450 substrate(s) adjusted accordingly. The effects of IL inhibitors, TNF blockers, and IFN inhibitors on CYP450 activities may persist for several weeks after stopping therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when treatments targeting cytokines such as interleukins, tumor necrosis factors, or interferons are prescribed to patients receiving concomitant drugs that are CYP450 substrates, particularly those with narrow therapeutic ranges (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97590/", "reference_text": "[1] \"Product Information. Skyrizi (risankizumab).\" AbbVie US LLC, North Chicago, IL.[2] \"Product Information. Cosentyx (secukinumab).\" Novartis Pharmaceuticals, East Hanover, NJ.[3] \"Product Information. Ilaris (canakinumab).\" Novartis Pharmaceuticals, East Hanover, NJ.[4] \"Product Information. Gamifant (emapalumab).\" Sobi Inc, Ardmore, PA.[5] \"Product Information. Kevzara (sarilumab).\" sanofi-aventis, Bridgewater, NJ.[6] \"Product Information. Simponi (golimumab).\" Centocor Inc, Malvern, PA.[7] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[8] \"Product Information. Sylvant (siltuximab).\" Janssen Biotech, Inc., Horsham, PA, PA.[9] \"Product Information. Stelara (ustekinumab).\" Centocor Inc, Malvern, PA.[10] \"Product Information. Ilumya (tildrakizumab).\" Merck & Company Inc, Whitehouse Station, NJ.[11] \"Product Information. Actemra (tocilizumab).\" Genentech, South San Francisco, CA.[12] \"Product Information. Amevive (alefacept).\" Biogen, Cambridge, MA.[13] \"Product Information. Remicade (infliximab).\" Centocor Inc, Malvern, PA.[14] \"Product Information. Taltz Autoinjector (ixekizumab).\" Eli Lilly and Company, Indianapolis, IN.[15] \"Product Information. Arcalyst (rilonacept).\" Regeneron Pharmaceuticals Inc, Tarrytown, NY.[16] Ace LN, Jaffe JM, Kunka RL \"Effect of food and an antacid on quinidine bioavailability.\" Biopharm Drug Dispos 4 (1983): 183-90[17] Min DI, Ku YM, Geraets DR, Lee HC \"Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers.\" J Clin Pharmacol 36 (1996): 469-76[18] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[19] Ha HR, Chen J, Leuenberger PM, Freiburghaus AU, Follah F \"In vitro inhibition of midazolam and quinidine metabolism by flavonoids.\" Eur J Clin Pharmacol 48 (1995): 367-71", "alternatives_a": "Omalizumab, Tezepelumab, Mercaptopurine, Benralizumab, Caffeine, Reslizumab, Montelukast, Dyphylline, Mepolizumab, Pentoxifylline, Zafirlukast, Bromotheophylline", "alternatives_b": "Cyclosporine, Antithymocyte immunoglobulin (rabbit), Anifrolumab, Ravulizumab, Diroximel fumarate, Abatacept, Upadacitinib, Siponimod, Apremilast, Inebilizumab, Cladribine, More", "updated_at": 1767369485}, {"id": 97487, "ingredient1": "Theophylline", "ingredient2": "Secobarbital", "severity": "Moderate", "effect": "Barbiturates may decrease serum levels and therapeutic effects of the methylxanthines. The mechanism is barbiturate induction of CYP450 3A4 and 1A2 hepatic metabolism of methylxanthines.", "source": "DDInter", "management_text": "Close observation for clinical and laboratory evidence of decreased methylxanthine effect is indicated if these drugs must be used together. Patients should be advised to notify their physician if they experience a worsening of their respiratory symptoms.", "mechanism_text": "Metabolism", "recommendation": "Close observation for clinical and laboratory evidence of decreased methylxanthine effect is indicated if these drugs must be used together.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97591/", "reference_text": "[1] Dahlqvist R, Steiner E, Koike Y, von Bahr C, Lind M, Billing B \"Induction of theophylline metabolism by pentobarbital.\" Ther Drug Monit 11 (1989): 408-10[2] Bukowskyj M, Nakatsu K, Munt PW \"Theophylline reassessed.\" Ann Intern Med 101 (1984): 63-73[3] Upton RA \"Pharmacokinetic interactions between theophylline and other medication (Part I).\" Clin Pharmacokinet 20 (1991): 66-80[4] Landay RA, Gonzalez MA, Taylor JC \"Effect of phenobarbital on theophylline disposition.\" J Allergy Clin Immunol 62 (1978): 27-9", "alternatives_a": "Omalizumab, Tezepelumab, Mercaptopurine, Benralizumab, Caffeine, Reslizumab, Dyphylline, Mepolizumab, Roflumilast, Pentoxifylline, Zafirlukast, Bromotheophylline", "alternatives_b": "Suvorexant, Chloral hydrate, Nitrazepam, Paraldehyde, Propiomazine, Ramelteon, Meprobamate, Scopolamine, Eszopiclone, Dexmedetomidine, Lemborexant, More", "updated_at": 1767369485}, {"id": 97488, "ingredient1": "Theophylline", "ingredient2": "Secukinumab", "severity": "Moderate", "effect": "Plasma concentrations of drugs that are CYP450 substrates may decrease following the initiation of interleukin (IL) inhibitors, tumor necrosis factor (TNF) blockers, or interferon (IFN) inhibitors in patients with chronic inflammatory diseases. Because the formation of hepatic CYP450 enzymes is down-regulated during infection and chronic inflammation by increased levels of certain cytokines (e.g., interleukins-1, -6, and -10; tumor necrosis factor alpha; interferons), treatment targeting these cytokines may restore or normalize CYP450 enzyme levels resulting in increased metabolism of these drugs.", "source": "DDInter", "management_text": "Caution is advised when treatments targeting cytokines such as interleukins, tumor necrosis factors, or interferons are prescribed to patients receiving concomitant drugs that are CYP450 substrates, particularly those with narrow therapeutic ranges (e.g., antiarrhythmics, anticonvulsants, immunosuppressants, theophylline) or sensitive substrates where decreases in plasma levels may be significant or undesirable (e.g., oral contraceptives, statins, benzodiazepines, opioids). Clinical and/or laboratory monitoring should be considered following the initiation or withdrawal of such treatments, and the dosage(s) of the CYP450 substrate(s) adjusted accordingly. The effects of IL inhibitors, TNF blockers, and IFN inhibitors on CYP450 activities may persist for several weeks after stopping therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when treatments targeting cytokines such as interleukins, tumor necrosis factors, or interferons are prescribed to patients receiving concomitant drugs that are CYP450 substrates, particularly those with narrow therapeutic ranges (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97592/", "reference_text": "[1] \"Product Information. Skyrizi (risankizumab).\" AbbVie US LLC, North Chicago, IL.[2] \"Product Information. Cosentyx (secukinumab).\" Novartis Pharmaceuticals, East Hanover, NJ.[3] \"Product Information. Ilaris (canakinumab).\" Novartis Pharmaceuticals, East Hanover, NJ.[4] \"Product Information. Gamifant (emapalumab).\" Sobi Inc, Ardmore, PA.[5] \"Product Information. Kevzara (sarilumab).\" sanofi-aventis, Bridgewater, NJ.[6] \"Product Information. Simponi (golimumab).\" Centocor Inc, Malvern, PA.[7] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[8] \"Product Information. Sylvant (siltuximab).\" Janssen Biotech, Inc., Horsham, PA, PA.[9] \"Product Information. Stelara (ustekinumab).\" Centocor Inc, Malvern, PA.[10] \"Product Information. Ilumya (tildrakizumab).\" Merck & Company Inc, Whitehouse Station, NJ.[11] \"Product Information. Actemra (tocilizumab).\" Genentech, South San Francisco, CA.[12] \"Product Information. Amevive (alefacept).\" Biogen, Cambridge, MA.[13] \"Product Information. Remicade (infliximab).\" Centocor Inc, Malvern, PA.[14] \"Product Information. Taltz Autoinjector (ixekizumab).\" Eli Lilly and Company, Indianapolis, IN.[15] \"Product Information. Arcalyst (rilonacept).\" Regeneron Pharmaceuticals Inc, Tarrytown, NY.[16] Ace LN, Jaffe JM, Kunka RL \"Effect of food and an antacid on quinidine bioavailability.\" Biopharm Drug Dispos 4 (1983): 183-90[17] Min DI, Ku YM, Geraets DR, Lee HC \"Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers.\" J Clin Pharmacol 36 (1996): 469-76[18] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[19] Ha HR, Chen J, Leuenberger PM, Freiburghaus AU, Follah F \"In vitro inhibition of midazolam and quinidine metabolism by flavonoids.\" Eur J Clin Pharmacol 48 (1995): 367-71", "alternatives_a": "Omalizumab, Tezepelumab, Mercaptopurine, Benralizumab, Caffeine, Reslizumab, Montelukast, Dyphylline, Mepolizumab, Pentoxifylline, Zafirlukast, Bromotheophylline", "alternatives_b": "Cyclosporine, Antithymocyte immunoglobulin (rabbit), Anifrolumab, Ravulizumab, Diroximel fumarate, Abatacept, Upadacitinib, Siponimod, Apremilast, Inebilizumab, Cladribine, More", "updated_at": 1767369485}, {"id": 97489, "ingredient1": "Theophylline", "ingredient2": "Sildenafil", "severity": "Minor", "effect": "Because sildenafil is a phosphodiesterase inhibitor, it is possible that the effects of other phosphodiesterase inhibitors, such as theophylline and dipyridamole can be altered. The clinical significance is unknown.", "source": "DDInter", "management_text": "-", "mechanism_text": "Others", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97593/", "reference_text": "[1] \"Viagra/theophylline, dipyridamole interaction study requested by EMEA.\" F-D-C Reports -- \"The Pink Sheet\" 60 (1998): 19[2] Sato J, Nakata H, Owada E, Kikuta T, Umetsu M, Ito K \"Influence of usual intake of dietary caffeine on single-dose kinetics of theophylline in healthy human subjects.\" Eur J Clin Pharmacol 44 (1993): 295-8[3] Jonkman JH, Sollie FA, Sauter R, Steinijans VW \"The influence of caffeine on the steady-state pharmacokinetics of theophylline.\" Clin Pharmacol Ther 49 (1991): 248-55[4] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[5] Jetter A, Kinzig-Schippers M, Walchner-Bonjean M, et al. \"Effects of grapefruit juice on the pharmacokinetics of sildenafil.\" Clin Pharmacol Ther 71 (2002): 21-29", "alternatives_a": "Tinidazole, Ascorbic acid, Hydroflumethiazide, Chlorothiazide, Simeprevir, Rosuvastatin, Sulfadiazine, Lactic acid, Mitapivat, Methazolamide, Clindamycin, More", "alternatives_b": "Omalizumab, Tezepelumab, Aminophylline, Benralizumab, Caffeine, Reslizumab, Dyphylline, Oxtriphylline, Mepolizumab, Roflumilast, Bromotheophylline", "updated_at": 1767369485}, {"id": 97490, "ingredient1": "Theophylline", "ingredient2": "Siltuximab", "severity": "Moderate", "effect": "Plasma concentrations of drugs that are CYP450 substrates may decrease following the initiation of interleukin (IL) inhibitors, tumor necrosis factor (TNF) blockers, or interferon (IFN) inhibitors in patients with chronic inflammatory diseases. Because the formation of hepatic CYP450 enzymes is down-regulated during infection and chronic inflammation by increased levels of certain cytokines (e.g., interleukins-1, -6, and -10; tumor necrosis factor alpha; interferons), treatment targeting these cytokines may restore or normalize CYP450 enzyme levels resulting in increased metabolism of these drugs.", "source": "DDInter", "management_text": "Caution is advised when treatments targeting cytokines such as interleukins, tumor necrosis factors, or interferons are prescribed to patients receiving concomitant drugs that are CYP450 substrates, particularly those with narrow therapeutic ranges (e.g., antiarrhythmics, anticonvulsants, immunosuppressants, theophylline) or sensitive substrates where decreases in plasma levels may be significant or undesirable (e.g., oral contraceptives, statins, benzodiazepines, opioids). Clinical and/or laboratory monitoring should be considered following the initiation or withdrawal of such treatments, and the dosage(s) of the CYP450 substrate(s) adjusted accordingly. The effects of IL inhibitors, TNF blockers, and IFN inhibitors on CYP450 activities may persist for several weeks after stopping therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when treatments targeting cytokines such as interleukins, tumor necrosis factors, or interferons are prescribed to patients receiving concomitant drugs that are CYP450 substrates, particularly those with narrow therapeutic ranges (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97594/", "reference_text": "[1] \"Product Information. Skyrizi (risankizumab).\" AbbVie US LLC, North Chicago, IL.[2] \"Product Information. Cosentyx (secukinumab).\" Novartis Pharmaceuticals, East Hanover, NJ.[3] \"Product Information. Ilaris (canakinumab).\" Novartis Pharmaceuticals, East Hanover, NJ.[4] \"Product Information. Gamifant (emapalumab).\" Sobi Inc, Ardmore, PA.[5] \"Product Information. Kevzara (sarilumab).\" sanofi-aventis, Bridgewater, NJ.[6] \"Product Information. Simponi (golimumab).\" Centocor Inc, Malvern, PA.[7] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[8] \"Product Information. Sylvant (siltuximab).\" Janssen Biotech, Inc., Horsham, PA, PA.[9] \"Product Information. Stelara (ustekinumab).\" Centocor Inc, Malvern, PA.[10] \"Product Information. Ilumya (tildrakizumab).\" Merck & Company Inc, Whitehouse Station, NJ.[11] \"Product Information. Actemra (tocilizumab).\" Genentech, South San Francisco, CA.[12] \"Product Information. Amevive (alefacept).\" Biogen, Cambridge, MA.[13] \"Product Information. Remicade (infliximab).\" Centocor Inc, Malvern, PA.[14] \"Product Information. Taltz Autoinjector (ixekizumab).\" Eli Lilly and Company, Indianapolis, IN.[15] \"Product Information. Arcalyst (rilonacept).\" Regeneron Pharmaceuticals Inc, Tarrytown, NY.[16] Ace LN, Jaffe JM, Kunka RL \"Effect of food and an antacid on quinidine bioavailability.\" Biopharm Drug Dispos 4 (1983): 183-90[17] Min DI, Ku YM, Geraets DR, Lee HC \"Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers.\" J Clin Pharmacol 36 (1996): 469-76[18] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[19] Ha HR, Chen J, Leuenberger PM, Freiburghaus AU, Follah F \"In vitro inhibition of midazolam and quinidine metabolism by flavonoids.\" Eur J Clin Pharmacol 48 (1995): 367-71", "alternatives_a": "Omalizumab, Tezepelumab, Mercaptopurine, Benralizumab, Caffeine, Reslizumab, Montelukast, Dyphylline, Mepolizumab, Pentoxifylline, Zafirlukast, Bromotheophylline", "alternatives_b": "Cyclosporine, Antithymocyte immunoglobulin (rabbit), Anifrolumab, Ravulizumab, Diroximel fumarate, Abatacept, Upadacitinib, Siponimod, Apremilast, Inebilizumab, Cladribine, More", "updated_at": 1767369485}, {"id": 97491, "ingredient1": "Theophylline", "ingredient2": "Sirolimus", "severity": "Moderate", "effect": "Coadministration of sirolimus or tacrolimus with other drugs that are also metabolized by CYP450 3A4 may result in elevated plasma concentrations of the macrolide immunosuppressant and/or the coadministered drug(s). The mechanism is decreased drug clearance due to competitive inhibition of CYP450 3A4 activity.", "source": "DDInter", "management_text": "Pharmacologic responses and/or plasma drug levels should be monitored more closely whenever a macrolide immunosuppressant or another substrate of CYP450 3A4 is added to or withdrawn from therapy, and the dosage(s) adjusted as necessary.", "mechanism_text": "Metabolism", "recommendation": "Pharmacologic responses and/or plasma drug levels should be monitored more closely whenever a macrolide immunosuppressant or another substrate of CYP450 3A4 is added to or withdrawn from therapy, and the dosage(s) adjusted as necessary.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97595/", "reference_text": "[1] \"Product Information. Prograf (tacrolimus).\" Fujisawa, Deerfield, IL.[2] \"Product Information. Rapamune (sirolimus)\" Wyeth-Ayerst Laboratories, Philadelphia, PA.[3] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[4] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[5] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[6] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[7] \"Product Information. Torisel (temsirolimus).\" Wyeth-Ayerst Laboratories, Philadelphia, PA.", "alternatives_a": "Omalizumab, Tezepelumab, Mercaptopurine, Aminophylline, Benralizumab, Caffeine, Reslizumab, Dyphylline, Oxtriphylline, Mepolizumab, Zafirlukast, Bromotheophylline", "alternatives_b": "Alteplase, Ascorbic acid, Vitamin A, Potassium Iodide, Cyclosporine, Nandrolone, Cyclosporine, Antithymocyte immunoglobulin (rabbit), Anifrolumab, Ravulizumab, Diroximel fumarate, More", "updated_at": 1767369485}, {"id": 97492, "ingredient1": "Theophylline", "ingredient2": "Somapacitan", "severity": "Moderate", "effect": "Coadministration with human growth hormone may decrease the plasma concentrations of drugs that are metabolized by CYP450 3A4.", "source": "DDInter", "management_text": "Caution is advised when human growth hormone is used concurrently with drugs that are known CYP450 3A4 substrates, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever human growth hormone is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when human growth hormone is used concurrently with drugs that are known CYP450 3A4 substrates, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97596/", "reference_text": "[1] Cerner Multum, Inc. \"Australian Product Information.\" O 0[2] \"Product Information. Zorbtive (somatropin).\" Serono Laboratories Inc, Rockland, MA.[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] \"Product Information. Humatrope (somatropin).\" Lilly, Eli and Company, Indianapolis, IN.", "alternatives_a": "Omalizumab, Tezepelumab, Mercaptopurine, Aminophylline, Benralizumab, Caffeine, Reslizumab, Dyphylline, Oxtriphylline, Mepolizumab, Pentoxifylline, More", "alternatives_b": "Mecasermin, Sermorelin, Tesamorelin, Thyrotropin alfa, Mecasermin rinfabate, Pegvisomant", "updated_at": 1767369485}, {"id": 97493, "ingredient1": "Theophylline", "ingredient2": "Somatrem", "severity": "Moderate", "effect": "Coadministration with human growth hormone may decrease the plasma concentrations of drugs that are metabolized by CYP450 3A4.", "source": "DDInter", "management_text": "Caution is advised when human growth hormone is used concurrently with drugs that are known CYP450 3A4 substrates, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever human growth hormone is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when human growth hormone is used concurrently with drugs that are known CYP450 3A4 substrates, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97597/", "reference_text": "[1] Cerner Multum, Inc. \"Australian Product Information.\" O 0[2] \"Product Information. Zorbtive (somatropin).\" Serono Laboratories Inc, Rockland, MA.[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] \"Product Information. Humatrope (somatropin).\" Lilly, Eli and Company, Indianapolis, IN.", "alternatives_a": "Omalizumab, Tezepelumab, Mercaptopurine, Aminophylline, Benralizumab, Caffeine, Reslizumab, Dyphylline, Oxtriphylline, Mepolizumab, Pentoxifylline, More", "alternatives_b": "Mecasermin, Sermorelin, Tesamorelin, Thyrotropin alfa, Mecasermin rinfabate, Pegvisomant", "updated_at": 1767369485}, {"id": 97494, "ingredient1": "Theophylline", "ingredient2": "Somatotropin", "severity": "Moderate", "effect": "Coadministration with human growth hormone may decrease the plasma concentrations of drugs that are metabolized by CYP450 3A4.", "source": "DDInter", "management_text": "Caution is advised when human growth hormone is used concurrently with drugs that are known CYP450 3A4 substrates, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever human growth hormone is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when human growth hormone is used concurrently with drugs that are known CYP450 3A4 substrates, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97598/", "reference_text": "[1] Cerner Multum, Inc. \"Australian Product Information.\" O 0[2] \"Product Information. Zorbtive (somatropin).\" Serono Laboratories Inc, Rockland, MA.[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] \"Product Information. Humatrope (somatropin).\" Lilly, Eli and Company, Indianapolis, IN.", "alternatives_a": "Mecasermin, Sermorelin, Tesamorelin, Thyrotropin alfa, Mecasermin rinfabate, Pegvisomant", "alternatives_b": "Omalizumab, Tezepelumab, Mercaptopurine, Aminophylline, Benralizumab, Caffeine, Reslizumab, Dyphylline, Oxtriphylline, Mepolizumab, Pentoxifylline, More", "updated_at": 1767369485}, {"id": 97495, "ingredient1": "Theophylline", "ingredient2": "Sotalol", "severity": "Major", "effect": "The pharmacologic effects of theophyllines and beta-blockers are opposite. Nonselective and high doses of cardioselective beta-blockers may cause severe or fatal bronchospasm by opposing theophylline-induced bronchodilation. Ophthalmic beta-blockers undergo significant systemic absorption and may also interact. In addition, propranolol and other beta-blockers may reduce the CYP450 hepatic metabolism of theophylline, and serum theophylline levels may be increased.", "source": "DDInter", "management_text": "Oral and ophthalmic nonselective beta-blockers (e.g., carteolol, carvedilol, levobunolol, metipranolol, nadolol, oxprenolol, penbutolol, pindolol, propranolol, sotalol, and timolol) are considered contraindicated in patients with bronchospastic diseases. Cardioselective beta-blockers should generally be avoided, or used with extreme caution if no other alternatives are available and the benefits outweigh the risks of potentially severe bronchospasm. If patients do receive this combination, they should be closely monitored for increased serum theophylline levels but decreased bronchodilatory effectiveness.", "mechanism_text": "Antagonism", "recommendation": "Oral and ophthalmic nonselective beta-blockers (e.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97599/", "reference_text": "[1] Upton RA \"Pharmacokinetic interactions between theophylline and other medication (Part II).\" Clin Pharmacokinet 20 (1991): 135-50[2] Mue S, Sasaki T, Shibahara S, et alT \"Influence of metoprolol on hemodynamics and respiratory function in asthmatic patients.\" Int J Clin Pharmacol Biopharm 17 (1979): 346-50[3] Lombardi TP, Bertino JS, Goldberg A, Middleton E, Slaughter RL \"The effects of a beta-2 selective adrenergic agonist and a beta- nonselective antagonist on theophylline clearance.\" J Clin Pharmacol 27 (1987): 523-9[4] Horvath JS, Woolcock AJ, Tiller DJ, Donnelly P, Armstrong J, Caterson R \"A comparison of metoprolol and propranolol on blood pressure and respiratory function in patients with hypertension.\" Aust N Z J Med 8 (1978): 1-6[5] Conrad KA, Nyman DW \"Effects of metoprolol and propranolol on theophylline elimination.\" Clin Pharmacol Ther 28 (1980): 463-7", "alternatives_a": "Omalizumab, Tezepelumab, Mercaptopurine, Benralizumab, Caffeine, Reslizumab, Mepolizumab, Roflumilast, Zafirlukast, Bromotheophylline", "alternatives_b": "Ivabradine", "updated_at": 1767369485}, {"id": 97496, "ingredient1": "Theophylline", "ingredient2": "St. John's Wort", "severity": "Moderate", "effect": "Coadministration with St. John's wort may decrease the serum concentrations of theophylline. The proposed mechanism is accelerated clearance of theophylline due to induction of hepatic CYP450 isoenzymes, namely 1A2, by constituents of St. John's wort.", "source": "DDInter", "management_text": "Patients should consult a healthcare provider before taking any herbal or alternative medicine. Pharmacologic response and serum theophylline levels should be monitored more closely whenever St. John's wort is added to or withdrawn from therapy, and the methylxanthine dosage adjusted as necessary. Patients should be advised to notify their physician if they experience loss of asthma control or worsening of respiratory symptoms.", "mechanism_text": "Metabolism", "recommendation": "Patients should consult a healthcare provider before taking any herbal or alternative medicine.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97600/", "reference_text": "[1] Nebel A, Schneider BJ, Baker RK, Kroll DJ \"Potential metabolic interaction between St. John's wort and theophylline.\" Ann Pharmacother 33 (1999): 502[2] Fugh-Berman A \"Herb-drug interactions.\" Lancet 355 (2000): 134-8[3] Izzo AA, Ernst E \"Interactions between herbal medicines and prescribed drugs: a systematic review.\" Drugs 61 (2001): 2163-75[4] Patel S, Robinson R, Burk M \"Hypertensive crisis associated with St. John's Wort.\" Am J Med 112 (2002): 507-8", "alternatives_a": "Omalizumab, Tezepelumab, Mercaptopurine, Benralizumab, Caffeine, Reslizumab, Dyphylline, Mepolizumab, Pentoxifylline, Zafirlukast, Bromotheophylline", "alternatives_b": "Maprotiline, Vortioxetine, Milnacipran, Levomilnacipran, Doxepin, Duloxetine, Isocarboxazid, Amoxapine, Imipramine, Esketamine, Phenelzine, More", "updated_at": 1767369485}, {"id": 97497, "ingredient1": "Theophylline", "ingredient2": "Stiripentol", "severity": "Moderate", "effect": "The concomitant administration of stiripentol may increase plasma concentrations and toxic effects of theophylline and caffeine. The mechanism is inhibition of CYP450 1A2 metabolism by stiripentol.", "source": "DDInter", "management_text": "The manufacturer recommends that concomitant use should be avoided.", "mechanism_text": "Metabolism", "recommendation": "The manufacturer recommends that concomitant use should be avoided.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97601/", "reference_text": "[1] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid.\"[2] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[3] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid.\"[4] \"Product Information. Diacomit (stiripentol).\" Biocodex Inc, Creswell, OR.", "alternatives_a": "Omalizumab, Tezepelumab, Mercaptopurine, Benralizumab, Reslizumab, Montelukast, Dyphylline, Mepolizumab, Roflumilast, Bromotheophylline", "alternatives_b": "Brivaracetam, Topiramate, Ezogabine, Cenobamate, Lamotrigine, Ethosuximide, Lacosamide, Levetiracetam, Tiagabine, Oxcarbazepine, Rufinamide, More", "updated_at": 1767369485}, {"id": 97498, "ingredient1": "Theophylline", "ingredient2": "Succinylcholine", "severity": "Moderate", "effect": "Methylxanthines may antagonize the effects of neuromuscular blockers. The mechanism is unknown. In patients stabilized on aminophylline, resistance to pancuronium has been reported.", "source": "DDInter", "management_text": "The patient should be monitored for adequate neuromuscular blockade and the dosage adjusted, if necessary.", "mechanism_text": "Antagonism", "recommendation": "The patient should be monitored for adequate neuromuscular blockade and the dosage adjusted, if necessary.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97602/", "reference_text": "[1] Doll DC, Rosenberg H \"Antagonism of neuromuscular blockage by theophylline.\" Anesth Analg 58 (1979): 139-40[2] Azar I, Kumar D, Betcher AM \"Resistance to pancuronium in an asthmatic patient treated with aminophylline and steroids.\" Can Anaesth Soc J 29 (1982): 280-2[3] Daller JA, Erstad B, Rosado L, Otto C, Putnam CW \"Aminophylline antagonizes the neuromuscular blockade of pancuronium but not vecuronium.\" Crit Care Med 19 (1991): 983-5", "alternatives_a": "Botulinum toxin type A", "alternatives_b": "Omalizumab, Tezepelumab, Mercaptopurine, Benralizumab, Caffeine, Reslizumab, Montelukast, Mepolizumab, Roflumilast, Pentoxifylline, Zafirlukast, Bromotheophylline", "updated_at": 1767369485}, {"id": 97499, "ingredient1": "Theophylline", "ingredient2": "Sucralfate", "severity": "Minor", "effect": "Limited clinical data suggest that sucralfate may inhibit the oral absorption of theophylline. The clinical significance of this interaction is unknown. Patients should be monitored for clinical and laboratory evidence of altered theophylline effect. Patients should be advised to take theophylline at least 2 hours before or 6 hours after sucralfate to minimize a potential interaction and to notify their physician if they experience a worsening of their respiratory symptoms.", "source": "DDInter", "management_text": "-", "mechanism_text": "Absorption", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97603/", "reference_text": "[1] \"Product Information. Carafate (sucralfate).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[2] Sato J, Nakata H, Owada E, Kikuta T, Umetsu M, Ito K \"Influence of usual intake of dietary caffeine on single-dose kinetics of theophylline in healthy human subjects.\" Eur J Clin Pharmacol 44 (1993): 295-8[3] Jonkman JH, Sollie FA, Sauter R, Steinijans VW \"The influence of caffeine on the steady-state pharmacokinetics of theophylline.\" Clin Pharmacol Ther 49 (1991): 248-55[4] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[5] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67", "alternatives_a": "Omalizumab, Tezepelumab, Mercaptopurine, Benralizumab, Caffeine, Reslizumab, Dyphylline, Oxtriphylline, Mepolizumab, Roflumilast, Pentoxifylline, Bromotheophylline", "alternatives_b": "Tinidazole, Levofloxacin, Dexlansoprazole, Misoprostol, Bismuth subcitrate potassium, Rifabutin, Vonoprazan, Amoxicillin", "updated_at": 1767369485}, {"id": 97500, "ingredient1": "Theophylline", "ingredient2": "Sulfinpyrazone", "severity": "Minor", "effect": "In one study, concomitant administration of sulfinpyrazone resulted in a 22% increase in total theophylline clearance. Changes noted in the elimination of theophylline included an increase in metabolism and a decrease in renal excretion. The clinical significance of this interaction is unknown. If sulfinpyrazone and theophylline are given together, clinical monitoring of patient response and serum theophylline levels is recommended. Patients should be advised to report worsening of their respiratory symptoms to their physician.", "source": "DDInter", "management_text": "-", "mechanism_text": "Excretion", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97604/", "reference_text": "[1] Upton RA \"Pharmacokinetic interactions between theophylline and other medication (Part II).\" Clin Pharmacokinet 20 (1991): 135-50[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] Birkett DJ, Miners JO, Attwood J \"Evidence for a dual action of sulphinpyrazone on drug metabolism in man: theophylline-sulphinpyrazone interactions.\" Br J Clin Pharmacol 15 (1983): 567-9", "alternatives_a": "Omalizumab, Tezepelumab, Mercaptopurine, Benralizumab, Caffeine, Reslizumab, Dyphylline, Mepolizumab, Roflumilast, Zafirlukast, Bromotheophylline", "alternatives_b": "Lesinurad, Pegloticase, Colchicine, Rasburicase, Probenecid", "updated_at": 1767369485}, {"id": 97501, "ingredient1": "Theophylline", "ingredient2": "Tacrine", "severity": "Moderate", "effect": "Tacrine may increase plasma theophylline levels twofold and increase the elimination half-life of theophylline. The mechanism is probably related to the fact that both agents are metabolized by CYP450 1A2. Other hepatically metabolized methylxanthines may also be affected.", "source": "DDInter", "management_text": "If tacrine and a theophylline must be used concomitantly, dosage reductions are recommended, as is close observation for evidence of altered clinical and laboratory effects. Patients should be advised to report any signs of theophylline toxicity including nausea, vomiting, diarrhea, headache, restlessness, insomnia, or irregular heartbeat to their physicians.", "mechanism_text": "Metabolism", "recommendation": "If tacrine and a theophylline must be used concomitantly, dosage reductions are recommended, as is close observation for evidence of altered clinical and laboratory effects.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97605/", "reference_text": "[1] \"Product Information. Cognex (tacrine).\" Parke-Davis, Morris Plains, NJ.", "alternatives_a": "Omalizumab, Tezepelumab, Mercaptopurine, Benralizumab, Caffeine, Reslizumab, Montelukast, Dyphylline, Mepolizumab, Roflumilast, Pentoxifylline, More", "alternatives_b": "Rivastigmine, Galantamine, Donepezil, Memantine, Aducanumab", "updated_at": 1767369485}, {"id": 97502, "ingredient1": "Theophylline", "ingredient2": "Tacrolimus", "severity": "Moderate", "effect": "Coadministration of sirolimus or tacrolimus with other drugs that are also metabolized by CYP450 3A4 may result in elevated plasma concentrations of the macrolide immunosuppressant and/or the coadministered drug(s). The mechanism is decreased drug clearance due to competitive inhibition of CYP450 3A4 activity.", "source": "DDInter", "management_text": "Pharmacologic responses and/or plasma drug levels should be monitored more closely whenever a macrolide immunosuppressant or another substrate of CYP450 3A4 is added to or withdrawn from therapy, and the dosage(s) adjusted as necessary.", "mechanism_text": "Metabolism", "recommendation": "Pharmacologic responses and/or plasma drug levels should be monitored more closely whenever a macrolide immunosuppressant or another substrate of CYP450 3A4 is added to or withdrawn from therapy, and the dosage(s) adjusted as necessary.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97606/", "reference_text": "[1] \"Product Information. Prograf (tacrolimus).\" Fujisawa, Deerfield, IL.[2] \"Product Information. Rapamune (sirolimus)\" Wyeth-Ayerst Laboratories, Philadelphia, PA.[3] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[4] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[5] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[6] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[7] \"Product Information. Torisel (temsirolimus).\" Wyeth-Ayerst Laboratories, Philadelphia, PA.", "alternatives_a": "Omalizumab, Tezepelumab, Aminophylline, Benralizumab, Caffeine, Reslizumab, Dyphylline, Oxtriphylline, Mepolizumab, Zafirlukast, Bromotheophylline", "alternatives_b": "Minoxidil, Deoxycholic acid, Calcium gluconate, Magnesium sulfate, Glycopyrronium, Pimecrolimus, Aminobenzoic acid, Ivermectin, Abrocitinib, Dupilumab, Tralokinumab, More", "updated_at": 1767369485}, {"id": 97503, "ingredient1": "Theophylline", "ingredient2": "Telithromycin", "severity": "Moderate", "effect": "INTERVAL: No clinically relevant pharmacokinetic interaction has been observed with telithromycin and theophylline administered as an extended-release formulation. However, simultaneous administration of theophylline and telithromycin may worsen gastrointestinal side effects such as nausea and vomiting, especially in female patients.", "source": "DDInter", "management_text": "Telithromycin and theophylline should be taken one hour apart to decrease the likelihood of gastrointestinal side effects.", "mechanism_text": "Synergism", "recommendation": "Telithromycin and theophylline should be taken one hour apart to decrease the likelihood of gastrointestinal side effects.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97607/", "reference_text": "[1] European Agency for the Evaluation of Medicinal Products. Committee for Proprietary Medicinal Products \"European Public Assessment Report Ketek (telithromycin) (Rev. 2) Available from: URL: http:www.emea.eu.int/humandocs/Humans/EPAR/Ketek/Ketek.htm.\" ([2001]):[2] \"Product Information. Ketek (telithromycin).\" Aventis Pharmaceuticals, Bridgewater, NJ.[3] Sato J, Nakata H, Owada E, Kikuta T, Umetsu M, Ito K \"Influence of usual intake of dietary caffeine on single-dose kinetics of theophylline in healthy human subjects.\" Eur J Clin Pharmacol 44 (1993): 295-8[4] Jonkman JH, Sollie FA, Sauter R, Steinijans VW \"The influence of caffeine on the steady-state pharmacokinetics of theophylline.\" Clin Pharmacol Ther 49 (1991): 248-55[5] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67", "alternatives_a": "Omalizumab, Tezepelumab, Mercaptopurine, Aminophylline, Benralizumab, Caffeine, Reslizumab, Dyphylline, Oxtriphylline, Mepolizumab, Roflumilast, More", "alternatives_b": "Lincomycin, Clindamycin", "updated_at": 1767369485}, {"id": 97504, "ingredient1": "Theophylline", "ingredient2": "Temazepam", "severity": "Minor", "effect": "Methylxanthines may antagonize the sedative effects of benzodiazepines. Aminophylline in particular has been demonstrated to attenuate the sedative effects of diazepam. The mechanism of this interaction may be related to competitive binding to intracerebral adenosine receptors.", "source": "DDInter", "management_text": "-", "mechanism_text": "Antagonism", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97608/", "reference_text": "[1] Tuncok Y, Akpinar O, Guven H, Akkoclu A \"The effects of theophylline on serum alprazolam levels.\" Int J Clin Pharmacol Ther 32 (1994): 642-5[2] Gallen JS \"Aminophylline reversal of midazolam sedation.\" Anesth Analg 69 (1989): 268[3] Bonfiglio MF, Dasta JF \"Clinical significance of the benzodiazepine-theophylline interaction.\" Pharmacotherapy 11 (1991): 85-7[4] Upton RA \"Pharmacokinetic interactions between theophylline and other medication (Part II).\" Clin Pharmacokinet 20 (1991): 135-50[5] Stirt JA \"Aminophylline is a diazepam antagonist.\" Anesth Analg 60 (1981): 767-8[6] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[7] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[8] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[9] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Suvorexant, Chloral hydrate, Nitrazepam, Paraldehyde, Propiomazine, Ramelteon, Meprobamate, Scopolamine, Eszopiclone, Dexmedetomidine, Lemborexant, More", "alternatives_b": "Omalizumab, Tezepelumab, Benralizumab, Caffeine, Reslizumab, Mepolizumab, Roflumilast, Bromotheophylline", "updated_at": 1767369485}, {"id": 97505, "ingredient1": "Theophylline", "ingredient2": "Temsirolimus", "severity": "Moderate", "effect": "Coadministration of sirolimus or tacrolimus with other drugs that are also metabolized by CYP450 3A4 may result in elevated plasma concentrations of the macrolide immunosuppressant and/or the coadministered drug(s). The mechanism is decreased drug clearance due to competitive inhibition of CYP450 3A4 activity.", "source": "DDInter", "management_text": "Pharmacologic responses and/or plasma drug levels should be monitored more closely whenever a macrolide immunosuppressant or another substrate of CYP450 3A4 is added to or withdrawn from therapy, and the dosage(s) adjusted as necessary.", "mechanism_text": "Metabolism", "recommendation": "Pharmacologic responses and/or plasma drug levels should be monitored more closely whenever a macrolide immunosuppressant or another substrate of CYP450 3A4 is added to or withdrawn from therapy, and the dosage(s) adjusted as necessary.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97609/", "reference_text": "[1] \"Product Information. Prograf (tacrolimus).\" Fujisawa, Deerfield, IL.[2] \"Product Information. Rapamune (sirolimus)\" Wyeth-Ayerst Laboratories, Philadelphia, PA.[3] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[4] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[5] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[6] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[7] \"Product Information. Torisel (temsirolimus).\" Wyeth-Ayerst Laboratories, Philadelphia, PA.", "alternatives_a": "Omalizumab, Tezepelumab, Mercaptopurine, Aminophylline, Benralizumab, Caffeine, Reslizumab, Montelukast, Dyphylline, Oxtriphylline, Mepolizumab, More", "alternatives_b": "Entrectinib, Imatinib, Dabrafenib, Asciminib, Acalabrutinib, Dacomitinib, Pexidartinib, Tepotinib, Fedratinib, Avapritinib, Bosutinib, More", "updated_at": 1767369485}, {"id": 97506, "ingredient1": "Theophylline", "ingredient2": "Terbinafine", "severity": "Moderate", "effect": "The coadministration of terbinafine and theophylline may result in elevated plasma concentrations of the latter. The exact mechanism is unknown but may involve inhibition of the CYP450 1A2 enzymatic pathway, which is responsible for the metabolism of theophylline and other methylxanthines such as caffeine, the clearance of which has also been found to be reduced (21%) by terbinafine.", "source": "DDInter", "management_text": "Given the narrow therapeutic index of theophylline, patients should be monitored closely during concomitant therapy with terbinafine. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate whenever terbinafine is added to or withdrawn from therapy. Due to the long elimination half-life of terbinafine, especially following prolonged use, potential drug interactions may be observed for several months after discontinuation of terbinafine therapy. Patients should be advised to report any signs of theophylline toxicity including nausea, vomiting, diarrhea, headache, restlessness, insomnia, or irregular heartbeat to their physicians.", "mechanism_text": "Metabolism", "recommendation": "Given the narrow therapeutic index of theophylline, patients should be monitored closely during concomitant therapy with terbinafine.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97610/", "reference_text": "[1] Trepanier EF, Nafziger AN, Amsden GW \"Effect of terbinafine on theophylline pharmacokinetics in healthy volunteers.\" Antimicrob Agents Chemother 42 (1998): 695-7[2] Wahllander A, Paumgartner G \"Effect of ketoconazole and terbinafine on the pharmacokinetics of caffeine in healthy volunteers.\" Eur J Clin Pharmacol 37 (1989): 279-83", "alternatives_a": "Omalizumab, Tezepelumab, Mercaptopurine, Benralizumab, Reslizumab, Dyphylline, Mepolizumab, Roflumilast, Pentoxifylline, Zafirlukast, Bromotheophylline", "alternatives_b": "Salicylic acid, Selenium Sulfide, Miconazole, Nystatin, Ciclopirox, Griseofulvin, Econazole, Flucytosine, Tioconazole, Clotrimazole, Chlorphenesin, Griseofulvin", "updated_at": 1767369485}, {"id": 97507, "ingredient1": "Theophylline", "ingredient2": "Terbutaline", "severity": "Moderate", "effect": "Concomitant use of beta-2 adrenergic agonists with theophylline may increase the risk and/or severity of hypokalemia and adverse cardiovascular effects such as palpitation, tachycardia, and blood pressure elevation. Adverse events, especially hypokalemia, may be more likely with systemic or nebulized formulations of beta-2 agonists or high dosages of theophylline. Beta-2 agonists can cause clinically significant but usually transient decreases in serum potassium concentrations, while hypokalemia associated with theophylline often occurs in toxicity. Pharmacokinetically, some beta-2 agonists given systemically may decrease the plasma concentrations of theophylline.", "source": "DDInter", "management_text": "Although theophylline and beta-2 agonists are commonly used together to produce bronchodilation, it may be appropriate to monitor patient response as well as serum potassium level, blood pressure and heart rate during coadministration, especially if the beta-2 agonist is administered systemically or by nebulizer. Close monitoring is particularly important in patients with severe asthma, since the potential increases in blood pressure and heart rate may have more serious consequences in the presence of hypoxemia or hypercapnia due to increased myocardial oxygen consumption. Patients should be advised to notify their physician if they experience worsening of their respiratory condition or potential signs and symptoms of hypokalemia such as fatigue, weakness, myalgia, muscle cramps, numbness, tingling, abdominal pain, constipation, palpitation, and irregular heartbeat.", "mechanism_text": "Synergism", "recommendation": "Although theophylline and beta-2 agonists are commonly used together to produce bronchodilation, it may be appropriate to monitor patient response as well as serum potassium level, blood pressure and heart rate during coadministration, especially if the beta-2 agonist is administered systemically or by nebulizer.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97611/", "reference_text": "[1] Garty M, Paul-Keslin L, Ilfeld DN, et al \"Increased theophylline clearance in asthmatic patients due to terbutaline.\" Eur J Clin Pharmacol 36 (1989): 25-8[2] Amirav I, Amitai Y, Avital A, Godfrey S \"Enhancement of theophylline clearance by intravenous albuterol.\" Chest 94 (1988): 444-5[3] \"Product Information. Striverdi Respimat (olodaterol).\" Boehringer Ingelheim, Ridgefield, CT.[4] Cusack BJ, Nielson CP, Morgan ME, Vestal RE \"Additive effect of theophylline on the cardiac response to isoproterenol.\" Clin Pharmacol Ther 41 (1987): 289-96[5] Griffith JA, Kozloski GD \"Isoproterenol-theophylline interaction: possible potentiation by other drugs.\" Clin Pharm 9 (1990): 54-7[6] Conrad KA, Woodworth JR \"Orciprenaline does not alter theophylline elimination.\" Br J Clin Pharmacol 12 (1981): 756-7[7] Flatt A, Burgess C, Windom H, Beasley R, Purdie G, Crane J \"The cardiovascular effects of inhaled fenoterol alone and during treatment with oral theophylline.\" Chest 96 (1989): 1317-20[8] Smith SR, Kendall MJ \"Potentiation of the adverse effects of intravenous terbutaline by oral theophylline.\" Br J Clin Pharmacol 21 (1986): 451-3[9] Danzinger Y, Garty M, Volwitz B, Ilfeld D, Varsano I, Rosenfeld JB \"Reduction of serum theophylline levels by terbutaline in children with asthma.\" Clin Pharmacol Ther 37 (1985): 469-71[10] O'Rourke PP, Crone RK \"Effect of isoproterenol on measured theophylline levels.\" Crit Care Med 12 (1984): 373-5[11] Whyte KF, Reid C, Addis GJ, Whitesmith R, Reid JL \"Salbutamol induced hypokalaemia: the effect of theophylline alone and in combination with adrenaline.\" Br J Clin Pharmacol 25 (1988): 571-8[12] Coleman JJ, Vollmer WM, Barker AF, et al \"Cardiac arrhythmias during the combined use of beta-adrenergic agonist drugs and theophylline.\" Chest 90 (1986): 45-51[13] Kelly HW \"Controversies in asthma therapy with theophylline and the beta2-adrenergic agonists.\" Clin Pharm 3 (1984): 386-95[14] Amitai Y, Glustein J, Godfrey S \"Enhancement of theophylline clearance by oral albuterol.\" Chest 102 (1992): 786-9[15] \"Product Information. Brovana (arformoterol).\" Sepracor Inc, Marlborough, MA.[16] \"Interactions between methyl xanthines and beta adrenergic agonists.\" FDA Drug Bull 11 (1981): 19-20[17] Chow OK, Fung KP \"Slow-release terbutaline and theophylline for the long-term therapy of children with asthma: a Latin square and factorial study of drug effects and interactions.\" Pediatrics 84 (1989): 119-25[18] Hemstreet MP, Miles MV, Rutland RO \"Effect of intravenous isoproterenol on theophylline kinetics.\" J Allergy Clin Immunol 69 (1982): 360-4[19] Upton RA \"Pharmacokinetic interactions between theophylline and other medication (Part I).\" Clin Pharmacokinet 20 (1991): 66-80[20] Rachelefsky GS, Katz RM, Mickey MR Jr, Siegel SC \"Metaproterenol and theophylline in asthmatic children.\" Ann Allergy 45 (1980): 207-12[21] Josephson GW, Kennedy HL, MacKenzie EJ, Gibson G \"Cardiac dysrhythmias during the treatment of acute asthma. A comparison of two treatment regimens by a double blind protocol.\" Chest 78 (1980): 429-35[22] Dawson KP, Fergusson DM \"Effects of oral theophylline and oral salbutamol in the treatment of asthma.\" Arch Dis Child 57 (1982): 674-6[23] Jonkman JH, Borgstrom L, van der Boon WJ, de Noord OE \"Theophylline-terbutaline, a steady state study on possible pharmacokinetic interactions with special reference to chronopharmacokinetic aspects.\" Br J Clin Pharmacol 26 (1988): 285-93[24] Deenstra M, Haalboom JR, Struyvenberg A \"Decrease of plasma potassium due to inhalation of beta-2 agonists: absence of an additional effect of intravenous theophylline.\" Eur J Clin Invest 18 (1988): 162-5[25] \"Product Information. Arcapta Neohaler (indacaterol).\" Novartis Pharmaceuticals, East Hanover, NJ.[26] Lombardi TP, Bertino JS, Goldberg A, Middleton E, Slaughter RL \"The effects of a beta-2 selective adrenergic agonist and a beta- nonselective antagonist on theophylline clearance.\" J Clin Pharmacol 27 (1987): 523-9", "alternatives_a": "Omalizumab, Tezepelumab, Mercaptopurine, Benralizumab, Caffeine, Reslizumab, Montelukast, Mepolizumab, Roflumilast, Pentoxifylline, Zafirlukast, Bromotheophylline", "alternatives_b": "Mometasone furoate, Umeclidinium, Aclidinium, Mometasone, Glycopyrronium, Ipratropium, Beclomethasone dipropionate", "updated_at": 1767369485}, {"id": 97508, "ingredient1": "Theophylline", "ingredient2": "Teriflunomide", "severity": "Moderate", "effect": "Coadministration with teriflunomide may decrease the plasma concentrations and therapeutic effects of drugs that are substrates of CYP450 1A2. The proposed mechanism is increased clearance due to teriflunomide-mediated induction of CYP450 1A2.", "source": "DDInter", "management_text": "Caution is advised if teriflunomide is used concomitantly with drugs that are substrates of CYP450 1A2. Dosage adjustments as well as clinical and laboratory monitoring should be considered whenever teriflunomide is added to or withdrawn from therapy with these drugs.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if teriflunomide is used concomitantly with drugs that are substrates of CYP450 1A2.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97612/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] \"Product Information. Aubagio (teriflunomide).\" Genzyme Corporation, Cambridge, MA.[4] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[5] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[6] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[7] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.", "alternatives_a": "Omalizumab, Tezepelumab, Aminophylline, Benralizumab, Reslizumab, Dyphylline, Oxtriphylline, Mepolizumab, Bromotheophylline", "alternatives_b": "Cyclosporine, Antithymocyte immunoglobulin (rabbit), Anifrolumab, Ravulizumab, Diroximel fumarate, Abatacept, Upadacitinib, Siponimod, Apremilast, Inebilizumab, Cladribine, More", "updated_at": 1767369485}, {"id": 97509, "ingredient1": "Theophylline", "ingredient2": "Thallous Chloride", "severity": "Moderate", "effect": "Coadministration of certain drugs may alter the myocardial uptake of thallous chloride Tl-201 and interfere with results of myocardial imaging studies. Drugs that increase or decrease coronary blood flow or potassium uptake may alter the biodistribution of thallous chloride Tl-201.", "source": "DDInter", "management_text": "Clinicians should be aware of possible diagnostic interference by these drugs.", "mechanism_text": "Others", "recommendation": "Clinicians should be aware of possible diagnostic interference by these drugs.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97613/", "reference_text": "[1] \"Product Information. Thallous Chloride Tl 201 (thallous chloride Tl-201).\" GE Healthcare, Princeton, NJ.[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] Nuclear Pharmacy Website. University of Arkansas for Medical Sciences. College of Pharmacy \"Drug - Radiopharmaceutical Interactions. Available from: URL: http://nuclearpharmacy.uams.edu/nicki.html#tl.\" ([cited Feb2015]):", "alternatives_a": "Omalizumab, Tezepelumab, Mercaptopurine, Aminophylline, Benralizumab, Caffeine, Reslizumab, Montelukast, Dyphylline, Oxtriphylline, Mepolizumab, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 97510, "ingredient1": "Theophylline", "ingredient2": "Thiabendazole", "severity": "Moderate", "effect": "Theophylline toxicity has been reported during concomitant administration of theophylline and thiabendazole. Decreases in clearance have been noted up to nine days after discontinuation of thiabendazole. The proposed mechanism is inhibition of hepatic metabolism by thiabendazole.", "source": "DDInter", "management_text": "Clinical monitoring of patient response and tolerance and serum theophylline levels is recommended. Patients should be advised to report any signs of theophylline toxicity including nausea, vomiting, diarrhea, headache, restlessness, insomnia, or irregular heartbeat to their physicians. The theophylline dosage may require reduction or alternatives agents could be considered during thiabenzole therapy.", "mechanism_text": "Metabolism", "recommendation": "Clinical monitoring of patient response and tolerance and serum theophylline levels is recommended.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97614/", "reference_text": "[1] Schneider D, Gannon R, Sweeney K, Shore E \"Theophylline and antiparasitic drug interactions: a case report and study of the influence of thiabendazole and mebendazole on theophylline pharmacokinetics in adult.\" Chest 97 (1990): 84-7[2] Lew G, Murray WE, Lane JR, Haeger E \"Theophylline-thiabendazole drug interaction.\" Clin Pharm 8 (1989): 225-7[3] Sugar AM, Kearns PJ, Haulk AA, Rushing JL \"Possible thiabendazole-induced theophylline toxicity.\" Am Rev Respir Dis 122 (1980): 501-3[4] Upton RA \"Pharmacokinetic interactions between theophylline and other medication (Part II).\" Clin Pharmacokinet 20 (1991): 135-50", "alternatives_a": "Omalizumab, Tezepelumab, Mercaptopurine, Benralizumab, Reslizumab, Montelukast, Dyphylline, Mepolizumab, Zafirlukast, Bromotheophylline", "alternatives_b": "Salicylic acid, Selenium Sulfide, Miconazole, Nystatin, Ciclopirox, Griseofulvin, Econazole, Flucytosine, Tioconazole, Clotrimazole, Chlorphenesin, More", "updated_at": 1767369485}, {"id": 97511, "ingredient1": "Thiopental", "ingredient2": "Theophylline", "severity": "Moderate", "effect": "Barbiturates may decrease serum levels and therapeutic effects of the methylxanthines. The mechanism is barbiturate induction of CYP450 3A4 and 1A2 hepatic metabolism of methylxanthines.", "source": "DDInter", "management_text": "Close observation for clinical and laboratory evidence of decreased methylxanthine effect is indicated if these drugs must be used together. Patients should be advised to notify their physician if they experience a worsening of their respiratory symptoms.", "mechanism_text": "Metabolism", "recommendation": "Close observation for clinical and laboratory evidence of decreased methylxanthine effect is indicated if these drugs must be used together.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97615/", "reference_text": "[1] Dahlqvist R, Steiner E, Koike Y, von Bahr C, Lind M, Billing B \"Induction of theophylline metabolism by pentobarbital.\" Ther Drug Monit 11 (1989): 408-10[2] Bukowskyj M, Nakatsu K, Munt PW \"Theophylline reassessed.\" Ann Intern Med 101 (1984): 63-73[3] Upton RA \"Pharmacokinetic interactions between theophylline and other medication (Part I).\" Clin Pharmacokinet 20 (1991): 66-80[4] Landay RA, Gonzalez MA, Taylor JC \"Effect of phenobarbital on theophylline disposition.\" J Allergy Clin Immunol 62 (1978): 27-9", "alternatives_a": "Omalizumab, Tezepelumab, Mercaptopurine, Benralizumab, Caffeine, Reslizumab, Montelukast, Dyphylline, Mepolizumab, Roflumilast, Pentoxifylline, More", "alternatives_b": "Alfentanil, Remifentanil, Sodium oxybate, Isoflurane, Nitrous oxide, Desflurane, Sufentanil, Enflurane, Esketamine, Sevoflurane, Etomidate, More", "updated_at": 1767369485}, {"id": 97512, "ingredient1": "Thyroid, porcine", "ingredient2": "Theophylline", "severity": "Moderate", "effect": "The metabolism of theophylline is directly related to thyroid function. Theophylline clearance is decreased in hypothyroid patients and increased in hyperthyroid patients. Toxicity or subtherapeutic levels may occur. Similar interactions may occur with other methylxanthines.", "source": "DDInter", "management_text": "When thyroid hormone dosage is instituted, discontinued, or changed, close observation for altered theophylline effect and serum concentrations is recommended. Patients should be advised to notify their physician if they experience a worsening of their respiratory symptoms, or any signs of theophylline toxicity including nausea, vomiting, diarrhea, headache, restlessness, insomnia, or irregular heartbeats.", "mechanism_text": "Others", "recommendation": "When thyroid hormone dosage is instituted, discontinued, or changed, close observation for altered theophylline effect and serum concentrations is recommended.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97616/", "reference_text": "[1] Bauman JH, Teichman S, Wible DA \"Increased theophylline clearance in a patient with hyperthyroidism.\" Ann Allergy 52 (1984): 94-6[2] Vozeh S, Otten M, Staub JJ, Follath F \"Influence of thyroid function on theophylline kinetics.\" Clin Pharmacol Ther 36 (1984): 634-40[3] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[4] \"Product Information. Armour thyroid (thyroid desiccated).\" Forest Pharmaceuticals, St. Louis, MO.[5] \"Product Information. Synthroid (levothyroxine).\" Abbott Pharmaceutical, Abbott Park, IL.", "alternatives_a": "Omalizumab, Tezepelumab, Mercaptopurine, Benralizumab, Caffeine, Reslizumab, Montelukast, Dyphylline, Mepolizumab, Roflumilast, Pentoxifylline, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 97513, "ingredient1": "Ticlopidine", "ingredient2": "Theophylline", "severity": "Moderate", "effect": "In one study, theophylline clearance was reduced by 37% and theophylline half-life increased by 42% during concomitant ticlopidine therapy. The exact mechanism of this interaction is not known, but ticlopidine probably interferes with theophylline metabolism.", "source": "DDInter", "management_text": "Theophylline levels and clinical response should be monitored when ticlopidine therapy is initiated or discontinued. Patients should be advised to report any signs of theophylline toxicity during concurrent therapy, including nausea, vomiting, diarrhea, headache, restlessness, insomnia, or irregular heartbeat to their physician.", "mechanism_text": "Metabolism", "recommendation": "Theophylline levels and clinical response should be monitored when ticlopidine therapy is initiated or discontinued.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97617/", "reference_text": "[1] Colli A, Buccino G, Cocciolo M, Parravicini R, Elli GM, Scaltrini G \"Ticlopidine-theophylline interaction.\" Clin Pharmacol Ther 41 (1987): 358-62[2] \"Product Information. Ticlid (ticlopidine).\" Syntex Laboratories Inc, Palo Alto, CA.", "alternatives_a": "Ticagrelor, Betrixaban, Apixaban, Cilostazol, Rivaroxaban, Iloprost, Lepirudin, Acenocoumarol, Urokinase, Cangrelor, Caplacizumab, More", "alternatives_b": "Omalizumab, Tezepelumab, Mercaptopurine, Benralizumab, Caffeine, Reslizumab, Dyphylline, Mepolizumab, Zafirlukast, Bromotheophylline", "updated_at": 1767369485}, {"id": 97514, "ingredient1": "Timolol", "ingredient2": "Theophylline", "severity": "Major", "effect": "The pharmacologic effects of theophyllines and beta-blockers are opposite. Nonselective and high doses of cardioselective beta-blockers may cause severe or fatal bronchospasm by opposing theophylline-induced bronchodilation. Ophthalmic beta-blockers undergo significant systemic absorption and may also interact. In addition, propranolol and other beta-blockers may reduce the CYP450 hepatic metabolism of theophylline, and serum theophylline levels may be increased.", "source": "DDInter", "management_text": "Oral and ophthalmic nonselective beta-blockers (e.g., carteolol, carvedilol, levobunolol, metipranolol, nadolol, oxprenolol, penbutolol, pindolol, propranolol, sotalol, and timolol) are considered contraindicated in patients with bronchospastic diseases. Cardioselective beta-blockers should generally be avoided, or used with extreme caution if no other alternatives are available and the benefits outweigh the risks of potentially severe bronchospasm. If patients do receive this combination, they should be closely monitored for increased serum theophylline levels but decreased bronchodilatory effectiveness.", "mechanism_text": "Antagonism", "recommendation": "Oral and ophthalmic nonselective beta-blockers (e.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97618/", "reference_text": "[1] Upton RA \"Pharmacokinetic interactions between theophylline and other medication (Part II).\" Clin Pharmacokinet 20 (1991): 135-50[2] Mue S, Sasaki T, Shibahara S, et alT \"Influence of metoprolol on hemodynamics and respiratory function in asthmatic patients.\" Int J Clin Pharmacol Biopharm 17 (1979): 346-50[3] Lombardi TP, Bertino JS, Goldberg A, Middleton E, Slaughter RL \"The effects of a beta-2 selective adrenergic agonist and a beta- nonselective antagonist on theophylline clearance.\" J Clin Pharmacol 27 (1987): 523-9[4] Horvath JS, Woolcock AJ, Tiller DJ, Donnelly P, Armstrong J, Caterson R \"A comparison of metoprolol and propranolol on blood pressure and respiratory function in patients with hypertension.\" Aust N Z J Med 8 (1978): 1-6[5] Conrad KA, Nyman DW \"Effects of metoprolol and propranolol on theophylline elimination.\" Clin Pharmacol Ther 28 (1980): 463-7", "alternatives_a": "Omalizumab, Tezepelumab, Mercaptopurine, Benralizumab, Caffeine, Reslizumab, Mepolizumab, Roflumilast, Zafirlukast, Bromotheophylline", "alternatives_b": "Apraclonidine, Methazolamide, Neostigmine, Pilocarpine, Physostigmine, Acetylcholine, Diclofenamide, Bimatoprost, Travoprost, Acetazolamide, Brinzolamide, More", "updated_at": 1767369485}, {"id": 97515, "ingredient1": "Tocainide", "ingredient2": "Theophylline", "severity": "Minor", "effect": "Tocainide causes a decrease in theophylline clearance. The result is an increase in serum theophylline concentrations and a mild increase in the serum half-life of theophylline. The mechanism of this interaction is not known. Tocainide may interact in a similar way with other xanthines. Management consists of monitoring clinical status during therapy and checking serum theophylline levels as necessary. Patients should be advised to report any signs of theophylline toxicity including nausea, vomiting, diarrhea, headache, restlessness, insomnia, or irregular heartbeat to their physician.", "source": "DDInter", "management_text": "-", "mechanism_text": "Metabolism", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97619/", "reference_text": "[1] Loi CM, Wei X, Parker BM, Korrapati MR, Vestal RE \"The effect of tocainide on theophylline metabolism.\" Br J Clin Pharmacol 35 (1993): 437-40[2] Loi C, Wei X, Parker B, Vestal R \"Effect of tocainide on theophylline elimination.\" Clin Pharmacol Ther 51 (1992): 155", "alternatives_a": "Omalizumab, Tezepelumab, Mercaptopurine, Benralizumab, Caffeine, Reslizumab, Montelukast, Dyphylline, Mepolizumab, Roflumilast, Pentoxifylline, More", "alternatives_b": "Dronedarone, Procainamide, Flecainide, Dofetilide, Bretylium, Ibutilide", "updated_at": 1767369485}, {"id": 97516, "ingredient1": "Tocilizumab", "ingredient2": "Theophylline", "severity": "Moderate", "effect": "Plasma concentrations of drugs that are CYP450 substrates may decrease following the initiation of interleukin (IL) inhibitors, tumor necrosis factor (TNF) blockers, or interferon (IFN) inhibitors in patients with chronic inflammatory diseases. Because the formation of hepatic CYP450 enzymes is down-regulated during infection and chronic inflammation by increased levels of certain cytokines (e.g., interleukins-1, -6, and -10; tumor necrosis factor alpha; interferons), treatment targeting these cytokines may restore or normalize CYP450 enzyme levels resulting in increased metabolism of these drugs.", "source": "DDInter", "management_text": "Caution is advised when treatments targeting cytokines such as interleukins, tumor necrosis factors, or interferons are prescribed to patients receiving concomitant drugs that are CYP450 substrates, particularly those with narrow therapeutic ranges (e.g., antiarrhythmics, anticonvulsants, immunosuppressants, theophylline) or sensitive substrates where decreases in plasma levels may be significant or undesirable (e.g., oral contraceptives, statins, benzodiazepines, opioids). Clinical and/or laboratory monitoring should be considered following the initiation or withdrawal of such treatments, and the dosage(s) of the CYP450 substrate(s) adjusted accordingly. The effects of IL inhibitors, TNF blockers, and IFN inhibitors on CYP450 activities may persist for several weeks after stopping therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when treatments targeting cytokines such as interleukins, tumor necrosis factors, or interferons are prescribed to patients receiving concomitant drugs that are CYP450 substrates, particularly those with narrow therapeutic ranges (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97620/", "reference_text": "[1] \"Product Information. Skyrizi (risankizumab).\" AbbVie US LLC, North Chicago, IL.[2] \"Product Information. Cosentyx (secukinumab).\" Novartis Pharmaceuticals, East Hanover, NJ.[3] \"Product Information. Ilaris (canakinumab).\" Novartis Pharmaceuticals, East Hanover, NJ.[4] \"Product Information. Gamifant (emapalumab).\" Sobi Inc, Ardmore, PA.[5] \"Product Information. Kevzara (sarilumab).\" sanofi-aventis, Bridgewater, NJ.[6] \"Product Information. Simponi (golimumab).\" Centocor Inc, Malvern, PA.[7] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[8] \"Product Information. Sylvant (siltuximab).\" Janssen Biotech, Inc., Horsham, PA, PA.[9] \"Product Information. Stelara (ustekinumab).\" Centocor Inc, Malvern, PA.[10] \"Product Information. Ilumya (tildrakizumab).\" Merck & Company Inc, Whitehouse Station, NJ.[11] \"Product Information. Actemra (tocilizumab).\" Genentech, South San Francisco, CA.[12] \"Product Information. Amevive (alefacept).\" Biogen, Cambridge, MA.[13] \"Product Information. Remicade (infliximab).\" Centocor Inc, Malvern, PA.[14] \"Product Information. Taltz Autoinjector (ixekizumab).\" Eli Lilly and Company, Indianapolis, IN.[15] \"Product Information. Arcalyst (rilonacept).\" Regeneron Pharmaceuticals Inc, Tarrytown, NY.[16] Ace LN, Jaffe JM, Kunka RL \"Effect of food and an antacid on quinidine bioavailability.\" Biopharm Drug Dispos 4 (1983): 183-90[17] Min DI, Ku YM, Geraets DR, Lee HC \"Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers.\" J Clin Pharmacol 36 (1996): 469-76[18] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[19] Ha HR, Chen J, Leuenberger PM, Freiburghaus AU, Follah F \"In vitro inhibition of midazolam and quinidine metabolism by flavonoids.\" Eur J Clin Pharmacol 48 (1995): 367-71", "alternatives_a": "Omalizumab, Tezepelumab, Mercaptopurine, Benralizumab, Caffeine, Reslizumab, Montelukast, Dyphylline, Mepolizumab, Pentoxifylline, Bromotheophylline", "alternatives_b": "Cyclosporine, Antithymocyte immunoglobulin (rabbit), Anifrolumab, Ravulizumab, Diroximel fumarate, Abatacept, Upadacitinib, Siponimod, Apremilast, Inebilizumab, Cladribine, More", "updated_at": 1767369485}, {"id": 97517, "ingredient1": "Triazolam", "ingredient2": "Theophylline", "severity": "Minor", "effect": "Methylxanthines may antagonize the sedative effects of benzodiazepines. Aminophylline in particular has been demonstrated to attenuate the sedative effects of diazepam. The mechanism of this interaction may be related to competitive binding to intracerebral adenosine receptors.", "source": "DDInter", "management_text": "-", "mechanism_text": "Antagonism", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97621/", "reference_text": "[1] Tuncok Y, Akpinar O, Guven H, Akkoclu A \"The effects of theophylline on serum alprazolam levels.\" Int J Clin Pharmacol Ther 32 (1994): 642-5[2] Gallen JS \"Aminophylline reversal of midazolam sedation.\" Anesth Analg 69 (1989): 268[3] Bonfiglio MF, Dasta JF \"Clinical significance of the benzodiazepine-theophylline interaction.\" Pharmacotherapy 11 (1991): 85-7[4] Upton RA \"Pharmacokinetic interactions between theophylline and other medication (Part II).\" Clin Pharmacokinet 20 (1991): 135-50[5] Stirt JA \"Aminophylline is a diazepam antagonist.\" Anesth Analg 60 (1981): 767-8[6] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[7] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[8] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[9] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Omalizumab, Tezepelumab, Mercaptopurine, Benralizumab, Caffeine, Reslizumab, Mepolizumab, Roflumilast, Pentoxifylline, Zafirlukast, Bromotheophylline", "alternatives_b": "Suvorexant, Chloral hydrate, Nitrazepam, Paraldehyde, Propiomazine, Ramelteon, Meprobamate, Scopolamine, Eszopiclone, Dexmedetomidine, Lemborexant, More", "updated_at": 1767369485}, {"id": 97518, "ingredient1": "Troleandomycin", "ingredient2": "Theophylline", "severity": "Moderate", "effect": "Coadministration with certain macrolide antibiotics may increase the serum concentrations of theophylline, which may result in toxicity. The proposed mechanism is macrolide inhibition of CYP450 3A4, the isoenzyme partially responsible for the metabolic clearance of theophylline.", "source": "DDInter", "management_text": "Pharmacologic response and serum theophylline levels should be monitored more closely whenever a macrolide antibiotic is added to or withdrawn from therapy, and the methylxanthine dosage adjusted as necessary.", "mechanism_text": "Metabolism", "recommendation": "Pharmacologic response and serum theophylline levels should be monitored more closely whenever a macrolide antibiotic is added to or withdrawn from therapy, and the methylxanthine dosage adjusted as necessary.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97622/", "reference_text": "[1] Upton RA \"Pharmacokinetic interactions between theophylline and other medication (Part I).\" Clin Pharmacokinet 20 (1991): 66-80[2] Amsden GW \"Erythromycin, clarithromycin, and azithromycin: are the differences real?\" Clin Ther 18 (1996): 56-72[3] Amsden GW \"Macrolides versus azalides: a drug interaction update.\" Ann Pharmacother 29 (1995): 906-17[4] Principi N, Esposito S \"Comparative tolerability of erythromycin and newer macrolide antibacterials in paediatric: Patients.\" Drug Safety 20 (1999): 25-41[5] Descotes J, Andre P, Evreux JC \"Pharmacokinetic drug interactions with macrolide antibiotics.\" J Antimicrob Chemother 15 (1985): 659-64[6] Rockwood RP, Embardo LS \"Theophylline, ciprofloxacin, erythromycin: a potentially harmful regimen.\" Ann Pharmacother 27 (1993): 651-2[7] von Rosenstiel NA, Adam D \"Macrolide antibacterials. Drug interactions of clinical significance.\" Drug Saf 13 (1995): 105-22[8] Reisz G, Pingleton SK, Melethil S, Ryan PB \"The effect of erythromycin on theophylline pharmacokinetics in chronic bronchitis.\" Am Rev Respir Dis 127 (1983): 581-4[9] Jonkman JH, Upton RA \"Pharmacokinetic drug interactions with theophylline.\" Clin Pharmacokinet 9 (1984): 309-34[10] Ludden TM \"Pharmacokinetic interactions of the macrolide antibiotics.\" Clin Pharmacokinet 10 (1985): 63-79[11] Hildebrandt R, Moller H, Gundert-Remy U \"Influence of theophylline on the renal clearance of erythromycin.\" Int J Clin Pharmacol Ther Toxicol 25 (1987): 601-4[12] May DC, Jarboe CH, Ellenburg DT, et al \"The effects of erythromycin on theophylline elimination in normal males.\" J Clin Pharmacol 22 (1982): 125-30[13] Gillum JG, Israel DS, Scott RB, Climo MW, Polk RE \"Effect of combination therapy with ciprofloxacin and clarithromycin on theophylline pharmacokinetics in healthy volunteers.\" Antimicrob Agents Chemother 40 (1996): 1715-6[14] Richer C, Mathieu M, Bah H, Thuillez C, Duroux P, Giudicelli JF \"Theophylline kinetics and ventilatory flow in bronchial asthma and chronic airflow obstruction: influence of erythromycin.\" Clin Pharmacol Ther 31 (1982): 579-86[15] Pfeifer HJ, Greenblatt DJ, Friedman P \"Effects of three antibiotics on theophylline kinetics.\" Clin Pharmacol Ther 26 (1979): 36-40[16] Prince RA, Wing DS, Weinberger MM, et al \"Effect of erythromycin on theophylline kinetics.\" J Allergy Clin Immunol 68 (1981): 427-31[17] Kozak PP, Cummins LH, Gillman SH \"Administration of erythromycin to patients on theophylline.\" J Allergy Clin Immunol 60 (1977): 149-51[18] Zarowitz BJ, Szefler SJ, Lasezkay GM \"Effect of erythromycin base on theophylline kinetics.\" Clin Pharmacol Ther 29 (1981): 601-5[19] Bachmann K, Nunlee M, Martin M, et al \"Changes in the steady-state pharmacokinetics of theophylline during treatment with dirithromycin.\" J Clin Pharmacol 30 (1990): 1001-5[20] Maddux MS, Leeds NH, Organek HW, Hasegawa GR, Bauman JL \"The effect of erythromycin on theophylline pharmacokinetics at steady state.\" Chest 81 (1982): 563-5[21] Pollak PT, Slayter KL \"Reduced serum theophylline concentrations after discontinuation of azithromycin: evidence for an unusual interaction.\" Pharmacotherapy 17 (1997): 827-9[22] Wiggins J, Arbab O, Ayres JG, Skinner C \"Elevated serum theophylline concentration following cessation of erythromycin treatment.\" Eur J Respir Dis 68 (1986): 298-300[23] Kamada AK, Hill MR, Brenner AM, Szefler SJ \"Effect of low-dose troleandomycin on theophylline clearance: implications for therapeutic drug monitoring.\" Pharmacotherapy 12 (1992): 98-102[24] Parish RA, Haulman NJ, Burns RM \"Interaction of theophylline with erythromycin base in a patient with seizure activity.\" Pediatrics 72 (1983): 828-30[25] Branigan TA, Robbins RA, Cady WJ, et al \"The effects of erythromycin on the absorption and disposition kinetics of theophylline.\" Eur J Clin Pharmacol 21 (1981): 115-20[26] Renton KW, Gray JD, Hung OR \"Depression of theophylline elimination by erythromycin.\" Clin Pharmacol Ther 30 (1981): 422-6[27] Bachmann K, Jauregui L, Sides G, Sullivan TJ \"Steady-state pharmacokinetics of theophylline in COPD patients treated with dirithromycin.\" J Clin Pharmacol 33 (1993): 861-5[28] Peters DH, Friedel HA, McTavish D \"Azithromycin: a review of its antimicrobial activity, pharmacokinetic properties and clinical efficacy.\" Drugs 44 (1992): 750-99[29] Iliopoulou A, Aldhous ME, Johnston A, Turner P \"Pharmacokinetic interaction between theophylline and erythromycin.\" Br J Clin Pharmacol 14 (1982): 495-9[30] Nahata M \"Drug interactions with azithromycin and the macrolides: an overview.\" J Antimicrob Chemother 37 Suppl C (1996): 133-42[31] Tenenbein M \"Theophylline toxicity due to drug interaction.\" J Emerg Med 7 (1989): 249-51[32] Paulsen O, Hoglund P, Nilsson LG, Bengtsson HI \"The interaction of erythromycin with theophylline.\" Eur J Clin Pharmacol 32 (1987): 493-8", "alternatives_a": "Omalizumab, Tezepelumab, Mercaptopurine, Benralizumab, Caffeine, Reslizumab, Montelukast, Dyphylline, Mepolizumab, Roflumilast, Pentoxifylline, More", "alternatives_b": "Lincomycin, Clindamycin", "updated_at": 1767369485}, {"id": 97519, "ingredient1": "Tubocurarine", "ingredient2": "Theophylline", "severity": "Moderate", "effect": "Methylxanthines may antagonize the effects of neuromuscular blockers. The mechanism is unknown. In patients stabilized on aminophylline, resistance to pancuronium has been reported.", "source": "DDInter", "management_text": "The patient should be monitored for adequate neuromuscular blockade and the dosage adjusted, if necessary.", "mechanism_text": "Antagonism", "recommendation": "The patient should be monitored for adequate neuromuscular blockade and the dosage adjusted, if necessary.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97623/", "reference_text": "[1] Doll DC, Rosenberg H \"Antagonism of neuromuscular blockage by theophylline.\" Anesth Analg 58 (1979): 139-40[2] Azar I, Kumar D, Betcher AM \"Resistance to pancuronium in an asthmatic patient treated with aminophylline and steroids.\" Can Anaesth Soc J 29 (1982): 280-2[3] Daller JA, Erstad B, Rosado L, Otto C, Putnam CW \"Aminophylline antagonizes the neuromuscular blockade of pancuronium but not vecuronium.\" Crit Care Med 19 (1991): 983-5", "alternatives_a": "Omalizumab, Tezepelumab, Mercaptopurine, Benralizumab, Caffeine, Reslizumab, Montelukast, Mepolizumab, Roflumilast, Pentoxifylline, Zafirlukast, Bromotheophylline", "alternatives_b": "Botulinum toxin type A", "updated_at": 1767369485}, {"id": 97520, "ingredient1": "Ustekinumab", "ingredient2": "Theophylline", "severity": "Moderate", "effect": "Plasma concentrations of drugs that are CYP450 substrates may decrease following the initiation of interleukin (IL) inhibitors, tumor necrosis factor (TNF) blockers, or interferon (IFN) inhibitors in patients with chronic inflammatory diseases. Because the formation of hepatic CYP450 enzymes is down-regulated during infection and chronic inflammation by increased levels of certain cytokines (e.g., interleukins-1, -6, and -10; tumor necrosis factor alpha; interferons), treatment targeting these cytokines may restore or normalize CYP450 enzyme levels resulting in increased metabolism of these drugs.", "source": "DDInter", "management_text": "Caution is advised when treatments targeting cytokines such as interleukins, tumor necrosis factors, or interferons are prescribed to patients receiving concomitant drugs that are CYP450 substrates, particularly those with narrow therapeutic ranges (e.g., antiarrhythmics, anticonvulsants, immunosuppressants, theophylline) or sensitive substrates where decreases in plasma levels may be significant or undesirable (e.g., oral contraceptives, statins, benzodiazepines, opioids). Clinical and/or laboratory monitoring should be considered following the initiation or withdrawal of such treatments, and the dosage(s) of the CYP450 substrate(s) adjusted accordingly. The effects of IL inhibitors, TNF blockers, and IFN inhibitors on CYP450 activities may persist for several weeks after stopping therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when treatments targeting cytokines such as interleukins, tumor necrosis factors, or interferons are prescribed to patients receiving concomitant drugs that are CYP450 substrates, particularly those with narrow therapeutic ranges (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97624/", "reference_text": "[1] \"Product Information. Skyrizi (risankizumab).\" AbbVie US LLC, North Chicago, IL.[2] \"Product Information. Cosentyx (secukinumab).\" Novartis Pharmaceuticals, East Hanover, NJ.[3] \"Product Information. Ilaris (canakinumab).\" Novartis Pharmaceuticals, East Hanover, NJ.[4] \"Product Information. Gamifant (emapalumab).\" Sobi Inc, Ardmore, PA.[5] \"Product Information. Kevzara (sarilumab).\" sanofi-aventis, Bridgewater, NJ.[6] \"Product Information. Simponi (golimumab).\" Centocor Inc, Malvern, PA.[7] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[8] \"Product Information. Sylvant (siltuximab).\" Janssen Biotech, Inc., Horsham, PA, PA.[9] \"Product Information. Stelara (ustekinumab).\" Centocor Inc, Malvern, PA.[10] \"Product Information. Ilumya (tildrakizumab).\" Merck & Company Inc, Whitehouse Station, NJ.[11] \"Product Information. Actemra (tocilizumab).\" Genentech, South San Francisco, CA.[12] \"Product Information. Amevive (alefacept).\" Biogen, Cambridge, MA.[13] \"Product Information. Remicade (infliximab).\" Centocor Inc, Malvern, PA.[14] \"Product Information. Taltz Autoinjector (ixekizumab).\" Eli Lilly and Company, Indianapolis, IN.[15] \"Product Information. Arcalyst (rilonacept).\" Regeneron Pharmaceuticals Inc, Tarrytown, NY.[16] Ace LN, Jaffe JM, Kunka RL \"Effect of food and an antacid on quinidine bioavailability.\" Biopharm Drug Dispos 4 (1983): 183-90[17] Min DI, Ku YM, Geraets DR, Lee HC \"Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers.\" J Clin Pharmacol 36 (1996): 469-76[18] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[19] Ha HR, Chen J, Leuenberger PM, Freiburghaus AU, Follah F \"In vitro inhibition of midazolam and quinidine metabolism by flavonoids.\" Eur J Clin Pharmacol 48 (1995): 367-71", "alternatives_a": "Omalizumab, Tezepelumab, Benralizumab, Caffeine, Reslizumab, Montelukast, Dyphylline, Mepolizumab, Pentoxifylline, Zafirlukast, Bromotheophylline", "alternatives_b": "Cyclosporine, Antithymocyte immunoglobulin (rabbit), Anifrolumab, Ravulizumab, Diroximel fumarate, Abatacept, Upadacitinib, Siponimod, Apremilast, Inebilizumab, Cladribine, More", "updated_at": 1767369485}, {"id": 97521, "ingredient1": "Vecuronium", "ingredient2": "Theophylline", "severity": "Moderate", "effect": "Methylxanthines may antagonize the effects of neuromuscular blockers. The mechanism is unknown. In patients stabilized on aminophylline, resistance to pancuronium has been reported.", "source": "DDInter", "management_text": "The patient should be monitored for adequate neuromuscular blockade and the dosage adjusted, if necessary.", "mechanism_text": "Antagonism", "recommendation": "The patient should be monitored for adequate neuromuscular blockade and the dosage adjusted, if necessary.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97625/", "reference_text": "[1] Doll DC, Rosenberg H \"Antagonism of neuromuscular blockage by theophylline.\" Anesth Analg 58 (1979): 139-40[2] Azar I, Kumar D, Betcher AM \"Resistance to pancuronium in an asthmatic patient treated with aminophylline and steroids.\" Can Anaesth Soc J 29 (1982): 280-2[3] Daller JA, Erstad B, Rosado L, Otto C, Putnam CW \"Aminophylline antagonizes the neuromuscular blockade of pancuronium but not vecuronium.\" Crit Care Med 19 (1991): 983-5", "alternatives_a": "Omalizumab, Tezepelumab, Mercaptopurine, Benralizumab, Caffeine, Reslizumab, Montelukast, Mepolizumab, Roflumilast, Pentoxifylline, Zafirlukast, Bromotheophylline", "alternatives_b": "Botulinum toxin type A", "updated_at": 1767369485}, {"id": 97522, "ingredient1": "Vemurafenib", "ingredient2": "Theophylline", "severity": "Moderate", "effect": "Coadministration with vemurafenib may increase the plasma concentrations of drugs that are substrates of the CYP450 1A2 and/or 2D6 isoenzymes. The mechanism is decreased clearance due to inhibition of CYP450 1A2 and 2D6 activity by vemurafenib. The interaction has been studied with caffeine and dextromethorphan, probe substrates for CYP450 1A2 and 2D6, respectively.", "source": "DDInter", "management_text": "Caution is advised if vemurafenib must be used concurrently with drugs that undergo metabolism by CYP450 1A2 and/or 2D6. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever vemurafenib is added to or withdrawn from therapy. Concomitant use of vemurafenib and substrates of CYP450 1A2 and/or 2D6 with a narrow therapeutic index (e.g., antiarrhythmics; theophylline) should be avoided if possible.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if vemurafenib must be used concurrently with drugs that undergo metabolism by CYP450 1A2 and/or 2D6.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97626/", "reference_text": "[1] \"Product Information. Zelboraf (vemurafenib).\" Genentech, South San Francisco, CA.", "alternatives_a": "Omalizumab, Tezepelumab, Mercaptopurine, Aminophylline, Benralizumab, Reslizumab, Dyphylline, Oxtriphylline, Mepolizumab, Zafirlukast, Bromotheophylline", "alternatives_b": "Tinidazole, Ascorbic acid, Hydroflumethiazide, Chlorothiazide, Simeprevir, Rosuvastatin, Sulfadiazine, Lactic acid, Mitapivat, Methazolamide, Clindamycin, More", "updated_at": 1767369485}, {"id": 97523, "ingredient1": "Voriconazole", "ingredient2": "Theophylline", "severity": "Moderate", "effect": "Coadministration with voriconazole may increase the plasma concentrations of drugs that are substrates of CYP450 2C19, 2C9, and/or 3A4. The mechanism is decreased clearance due to inhibition of those isoenzymes by voriconazole. Increased plasma levels and/or pharmacologic effects of drugs such as cyclosporine, sirolimus, tacrolimus (3A4 substrates), and warfarin (2C9 substrate) have been reported during coadministration with voriconazole.", "source": "DDInter", "management_text": "Caution is advised if voriconazole must be used concomitantly with medications that undergo metabolism by CYP450 2C19, 2C9 and/or 3A4, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever voriconazole is added to or withdrawn from therapy. The manufacturer specifically recommends that a dosage reduction be considered for benzodiazepines, statins, long-acting opiates, and vinca alkaloids that are metabolized by the affected isoenzymes when used with voriconazole.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if voriconazole must be used concomitantly with medications that undergo metabolism by CYP450 2C19, 2C9 and/or 3A4, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97627/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] \"Product Information. VFEND (voriconazole).\" Pfizer U.S. Pharmaceuticals, New York, NY.[4] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[5] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[6] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[7] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[8] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[9] \"Product Information. VFEND (voriconazole).\" Pfizer U.S. Pharmaceuticals, New York, NY.", "alternatives_a": "Omalizumab, Tezepelumab, Aminophylline, Benralizumab, Caffeine, Reslizumab, Dyphylline, Oxtriphylline, Mepolizumab, Roflumilast, Pentoxifylline, Bromotheophylline", "alternatives_b": "Micafungin, Caspofungin, Itraconazole, Miconazole, Posaconazole, Oteseconazole, Flucytosine, Anidulafungin", "updated_at": 1767369485}, {"id": 97524, "ingredient1": "Zafirlukast", "ingredient2": "Theophylline", "severity": "Moderate", "effect": "The coadministration of theophylline with zafirlukast may modestly reduce zafirlukast plasma concentrations. The mechanism is unknown.", "source": "DDInter", "management_text": "If there is any change in either drug's regimen, the patient should be observed for altered theophylline and zafirlukast effect, and theophylline levels should be monitored closely. Other methylxanthines may interact with zafirlukast in a similar manner.", "mechanism_text": "Others", "recommendation": "If there is any change in either drug's regimen, the patient should be observed for altered theophylline and zafirlukast effect, and theophylline levels should be monitored closely.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97628/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Katial RK, Stelzle RC, Bonner MW, Marino M, Cantilena LR, Smith LJ \"A drug interaction between zafirlukast and theophylline.\" Arch Intern Med 158 (1998): 1713-5[3] Cerner Multum, Inc. \"Australian Product Information.\" O 0[4] \"Product Information. Accolate (zafirlukast).\" Zeneca Pharmaceuticals, Wilmington, DE.[5] \"Product Information. Accolate (zafirlukast).\" Zeneca Pharmaceuticals, Wilmington, DE.", "alternatives_a": "Omalizumab, Tezepelumab, Mercaptopurine, Benralizumab, Caffeine, Reslizumab, Dyphylline, Mepolizumab, Roflumilast, Pentoxifylline, Zafirlukast, Bromotheophylline", "alternatives_b": "Theophylline, Omalizumab, Tezepelumab, Mercaptopurine, Benralizumab, Reslizumab, Dyphylline, Oxtriphylline, Mepolizumab, Bromotheophylline", "updated_at": 1767369485}, {"id": 97525, "ingredient1": "Zileuton", "ingredient2": "Theophylline", "severity": "Moderate", "effect": "Coadministration with zileuton may significantly increase the plasma concentrations of theophylline. The proposed mechanism is zileuton inhibition of theophylline metabolism via CYP450 1A2.", "source": "DDInter", "management_text": "Caution is advised if theophylline is prescribed in combination with zileuton, particularly in the elderly and patients with chronic obstructive pulmonary disease, congestive heart failure or cirrhosis, as these patients generally have lower theophylline clearance rates and may be particularly vulnerable to theophylline toxicity. When zileuton is initiated in patients receiving theophylline, the theophylline dosage should be reduced by approximately one-half and theophylline levels closely monitored. Similarly, when initiating therapy with theophylline in patients receiving zileuton, the maintenance dosage and/or dosing interval of theophylline should be adjusted accordingly and guided by serum theophylline levels. Patients should be advised to notify their physician if they experience signs and symptoms suggestive of theophylline toxicity such as nausea, vomiting, diarrhea, headache, tremor, irritability, insomnia, seizures, palpitation, or arrhythmia.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if theophylline is prescribed in combination with zileuton, particularly in the elderly and patients with chronic obstructive pulmonary disease, congestive heart failure or cirrhosis, as these patients generally have lower theophylline clearance rates and may be particularly vulnerable to theophylline toxicity.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97629/", "reference_text": "[1] \"Product Information. Zylo Filmtab (zileuton).\" Abbott Pharmaceutical, Abbott Park, IL.[2] Lau R \"Drug interactions with zileuton.\" Lancet 349 (1997): 1479-80[3] Granneman GR, Braeckman RA, Locke CS, Cavanaugh JH, Dube LM, Awni WM \"Effect of zileuton on theophylline pharmacokinetics.\" Clin Pharmacokinet 29(suppl 2 (1995): 77-83", "alternatives_a": "Omalizumab, Tezepelumab, Mercaptopurine, Benralizumab, Caffeine, Reslizumab, Montelukast, Dyphylline, Mepolizumab, Zafirlukast, Bromotheophylline", "alternatives_b": "", "updated_at": 1767369485}, {"id": 97526, "ingredient1": "Eltrombopag", "ingredient2": "Aluminum hydroxide", "severity": "Moderate", "effect": "INTERVAL: Products containing aluminum, calcium, iron, magnesium, zinc and other polyvalent cations such as antacids or mineral supplements can significantly reduce the gastrointestinal absorption of eltrombopag due to chelation.", "source": "DDInter", "management_text": "Eltrombopag should be taken on an empty stomach at least 2 hours before or 4 hours after oral medications that contain antacids (e.g., didanosine buffered tablets or pediatric oral solution), aluminum, calcium, iron, magnesium, zinc or other polyvalent cations.", "mechanism_text": "Absorption", "recommendation": "Eltrombopag should be taken on an empty stomach at least 2 hours before or 4 hours after oral medications that contain antacids (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97630/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Promacta (eltrombopag).\" GlaxoSmithKline, Research Triangle Park, NC.[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] \"Product Information. Promacta (eltrombopag).\" GlaxoSmithKline, Research Triangle Park, NC.", "alternatives_a": "Romiplostim, Fostamatinib, Avatrombopag, Emicizumab, Coagulation factor VIIa Recombinant Human, Coagulation factor X human, Phylloquinone, Lusutrombopag, Anti-inhibitor coagulant complex, Antihemophilic factor, human recombinant, Fibrinogen human, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 97527, "ingredient1": "Eltrombopag", "ingredient2": "Artesunate", "severity": "Moderate", "effect": "Coadministration with eltrombopag may increase the plasma concentrations of drugs that are substrates of the organic anion transporting polypeptide (OATP) 1B1 and/or breast cancer resistance protein (BCRP) transporters. The mechanism is decreased clearance due to inhibition of OATP1B1-mediated hepatic uptake and BCRP-mediated intestinal and hepatobiliary efflux by eltrombopag. The interaction has been demonstrated for rosuvastatin, a known substrate of both OATP 1B1 and BCRP.", "source": "DDInter", "management_text": "Caution is advised during concomitant use of eltrombopag with drugs that are substrates of the OATP1B1 and/or BCRP transporters, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever eltrombopag is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised during concomitant use of eltrombopag with drugs that are substrates of the OATP1B1 and/or BCRP transporters, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97631/", "reference_text": "[1] Allred AJ, Bowen CJ, Park JW, et al. \"Eltrombopag increases plasma rosuvastatin exposure in healthy volunteers.\" Br J Clin Pharmacol 72 (2011): 321-9[2] Kalliokoski A, Niemi M \"Impact of OATP transporters on pharmacokinetics.\" Br J Pharmacol 158 (2009): 693-705[3] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[4] \"Product Information. Promacta (eltrombopag).\" GlaxoSmithKline, Research Triangle Park, NC.[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[7] \"Product Information. Promacta (eltrombopag).\" GlaxoSmithKline, Research Triangle Park, NC.", "alternatives_a": "Romiplostim, Avatrombopag, Emicizumab, Coagulation factor VIIa Recombinant Human, Coagulation factor X human, Phylloquinone, Lusutrombopag, Anti-inhibitor coagulant complex, Antihemophilic factor, human recombinant, Fibrinogen human, Epinephrine, Coagulation Factor IX Human", "alternatives_b": "Mefloquine, Lumefantrine, Artemether, Pyrimethamine, Tafenoquine, Atovaquone, Hydroxychloroquine, Halofantrine, Quinine, Primaquine, Proguanil, More", "updated_at": 1767369485}, {"id": 97528, "ingredient1": "Eltrombopag", "ingredient2": "Attapulgite", "severity": "Moderate", "effect": "INTERVAL: Products containing aluminum, calcium, iron, magnesium, zinc and other polyvalent cations such as antacids or mineral supplements can significantly reduce the gastrointestinal absorption of eltrombopag due to chelation.", "source": "DDInter", "management_text": "Eltrombopag should be taken on an empty stomach at least 2 hours before or 4 hours after oral medications that contain antacids (e.g., didanosine buffered tablets or pediatric oral solution), aluminum, calcium, iron, magnesium, zinc or other polyvalent cations.", "mechanism_text": "Absorption", "recommendation": "Eltrombopag should be taken on an empty stomach at least 2 hours before or 4 hours after oral medications that contain antacids (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97632/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Promacta (eltrombopag).\" GlaxoSmithKline, Research Triangle Park, NC.[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] \"Product Information. Promacta (eltrombopag).\" GlaxoSmithKline, Research Triangle Park, NC.", "alternatives_a": "Pectin, Activated charcoal", "alternatives_b": "Romiplostim, Fostamatinib, Avatrombopag, Emicizumab, Coagulation factor VIIa Recombinant Human, Coagulation factor X human, Phylloquinone, Lusutrombopag, Anti-inhibitor coagulant complex, Antihemophilic factor, human recombinant, Fibrinogen human, More", "updated_at": 1767369485}, {"id": 97529, "ingredient1": "Eltrombopag", "ingredient2": "Bedaquiline", "severity": "Moderate", "effect": "Coadministration of bedaquiline with other agents known to induce hepatotoxicity may potentiate the risk of liver injury.", "source": "DDInter", "management_text": "The use of bedaquiline with other potentially hepatotoxic agents should be avoided whenever possible (e.g., acetaminophen; alcohol; androgens and anabolic steroids; other antituberculous agents; azole antifungal agents; ACE inhibitors; disulfiram; endothelin receptor antagonists; ketolide and macrolide antibiotics; interferons; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; nucleoside reverse transcriptase inhibitors; proteasome inhibitors; retinoids; sulfonamides; tamoxifen; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice), especially in patients with diminished hepatic reserve. Patients treated with bedaquiline should have serum ALT, AST, alkaline phosphatase, and bilirubin monitored at baseline and monthly during treatment, or as often as needed. An increase of serum aminotransferases to greater than 3 times ULN should be followed by repeat testing within 48 hours. Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice. Discontinue bedaquiline if aminotransferase elevations are accompanied by total bilirubin elevation greater than 2 times ULN, aminotransferase elevations are greater than 8 times ULN, or aminotransferase elevations persist beyond 2 weeks.", "mechanism_text": "Synergism", "recommendation": "The use of bedaquiline with other potentially hepatotoxic agents should be avoided whenever possible (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97633/", "reference_text": "[1] \"Product Information. Sirturo (bedaquiline).\" Janssen Pharmaceuticals, Titusville, NJ.[2] \"Product Information. Sirturo (bedaquiline).\" Janssen Pharmaceuticals, Titusville, NJ.[3] \"Product Information. Hivid (zalcitabine).\" Roche Laboratories, Nutley, NJ.", "alternatives_a": "Romiplostim, Avatrombopag, Emicizumab, Coagulation factor VIIa Recombinant Human, Coagulation factor X human, Phylloquinone, Lusutrombopag, Anti-inhibitor coagulant complex, Antihemophilic factor, human recombinant, Fibrinogen human, Epinephrine, Coagulation Factor IX Human", "alternatives_b": "Capreomycin, Pyrazinamide, Rifamycin, Sulfamethoxazole, Rifapentine, Streptomycin, Trimethoprim, Cycloserine, Rifabutin, Isoniazid, Ethambutol, More", "updated_at": 1767369485}, {"id": 97530, "ingredient1": "Eltrombopag", "ingredient2": "Berotralstat", "severity": "Major", "effect": "Coadministration with inhibitors of P-glycoprotein (P-gp) and/or breast cancer resistance protein (BCRP) may significantly increase the plasma concentrations of berotralstat. Berotralstat is a substrate of both P-gp and BCRP.", "source": "DDInter", "management_text": "The dosage of berotralstat should be reduced to 110 mg once daily in patients requiring chronic coadministration with P-gp and/or BCRP inhibitors. Patients should be advised to contact their physician if they experience undue adverse effects of berotralstat such as abdominal pain, vomiting, or diarrhea. Patients should seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitations, irregular heartbeat, shortness of breath, or syncope.", "mechanism_text": "Absorption", "recommendation": "The dosage of berotralstat should be reduced to 110 mg once daily in patients requiring chronic coadministration with P-gp and/or BCRP inhibitors.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97634/", "reference_text": "[1] \"Product Information. Orladeyo (berotralstat).\" BioCryst Pharmaceuticals Inc, Durham, NC.[2] Min DI, Ku YM, Geraets DR, Lee HC \"Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers.\" J Clin Pharmacol 36 (1996): 469-76[3] Ace LN, Jaffe JM, Kunka RL \"Effect of food and an antacid on quinidine bioavailability.\" Biopharm Drug Dispos 4 (1983): 183-90[4] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[5] Ha HR, Chen J, Leuenberger PM, Freiburghaus AU, Follah F \"In vitro inhibition of midazolam and quinidine metabolism by flavonoids.\" Eur J Clin Pharmacol 48 (1995): 367-71", "alternatives_a": "Romiplostim, Avatrombopag, Emicizumab, Coagulation factor VIIa Recombinant Human, Coagulation factor X human, Phylloquinone, Anti-inhibitor coagulant complex, Antihemophilic factor, human recombinant, Fibrinogen human, Epinephrine, Coagulation Factor IX Human", "alternatives_b": "Hemin, Voxelotor, Conestat alfa, Betibeglogene autotemcel, Hyaluronidase, Streptokinase, Human C1-esterase inhibitor, Crizanlizumab, Lanadelumab, Icatibant", "updated_at": 1767369485}, {"id": 97531, "ingredient1": "Eltrombopag", "ingredient2": "Boceprevir", "severity": "Minor", "effect": "Coadministration with eltrombopag may alter the pharmacokinetics of boceprevir. The clinical significance is unknown, although the potential for more substantial changes during multiple dosing of eltrombopag cannot be ruled out. Boceprevir did not have an effect on the plasma concentrations of eltrombopag.", "source": "DDInter", "management_text": "-", "mechanism_text": "Others", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97635/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] \"Product Information. Promacta (eltrombopag).\" GlaxoSmithKline, Research Triangle Park, NC.[5] \"Product Information. Victrelis (boceprevir).\" Schering-Plough Corporation, Kenilworth, NJ.", "alternatives_a": "Romiplostim, Emicizumab, Coagulation factor VIIa Recombinant Human, Coagulation factor X human, Phylloquinone, Anti-inhibitor coagulant complex, Antihemophilic factor, human recombinant, Fibrinogen human, Epinephrine, Coagulation Factor IX Human", "alternatives_b": "Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Amprenavir, Cabotegravir, Valaciclovir, Zanamivir, Lenacapavir, Telaprevir, More", "updated_at": 1767369485}, {"id": 97532, "ingredient1": "Eltrombopag", "ingredient2": "Calcium carbonate", "severity": "Moderate", "effect": "INTERVAL: Products containing aluminum, calcium, iron, magnesium, zinc and other polyvalent cations such as antacids or mineral supplements can significantly reduce the gastrointestinal absorption of eltrombopag due to chelation.", "source": "DDInter", "management_text": "Eltrombopag should be taken on an empty stomach at least 2 hours before or 4 hours after oral medications that contain antacids (e.g., didanosine buffered tablets or pediatric oral solution), aluminum, calcium, iron, magnesium, zinc or other polyvalent cations.", "mechanism_text": "Absorption", "recommendation": "Eltrombopag should be taken on an empty stomach at least 2 hours before or 4 hours after oral medications that contain antacids (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97636/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Promacta (eltrombopag).\" GlaxoSmithKline, Research Triangle Park, NC.[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] \"Product Information. Promacta (eltrombopag).\" GlaxoSmithKline, Research Triangle Park, NC.", "alternatives_a": "Romiplostim, Fostamatinib, Avatrombopag, Emicizumab, Coagulation factor VIIa Recombinant Human, Coagulation factor X human, Phylloquinone, Lusutrombopag, Anti-inhibitor coagulant complex, Antihemophilic factor, human recombinant, Fibrinogen human, More", "alternatives_b": "Calcium glucoheptonate, Calcium chloride, Ascorbic acid, Calcium chloride", "updated_at": 1767369485}, {"id": 97533, "ingredient1": "Eltrombopag", "ingredient2": "Calcium citrate", "severity": "Moderate", "effect": "INTERVAL: Products containing aluminum, calcium, iron, magnesium, zinc and other polyvalent cations such as antacids or mineral supplements can significantly reduce the gastrointestinal absorption of eltrombopag due to chelation.", "source": "DDInter", "management_text": "Eltrombopag should be taken on an empty stomach at least 2 hours before or 4 hours after oral medications that contain antacids (e.g., didanosine buffered tablets or pediatric oral solution), aluminum, calcium, iron, magnesium, zinc or other polyvalent cations.", "mechanism_text": "Absorption", "recommendation": "Eltrombopag should be taken on an empty stomach at least 2 hours before or 4 hours after oral medications that contain antacids (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97637/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Promacta (eltrombopag).\" GlaxoSmithKline, Research Triangle Park, NC.[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] \"Product Information. Promacta (eltrombopag).\" GlaxoSmithKline, Research Triangle Park, NC.", "alternatives_a": "Romiplostim, Fostamatinib, Avatrombopag, Emicizumab, Coagulation factor VIIa Recombinant Human, Coagulation factor X human, Phylloquinone, Lusutrombopag, Anti-inhibitor coagulant complex, Antihemophilic factor, human recombinant, Fibrinogen human, More", "alternatives_b": "Calcium glucoheptonate, Calcium chloride, Ascorbic acid, Calcium chloride", "updated_at": 1767369485}, {"id": 97534, "ingredient1": "Eltrombopag", "ingredient2": "Calcium glubionate anhydrous", "severity": "Moderate", "effect": "INTERVAL: Products containing aluminum, calcium, iron, magnesium, zinc and other polyvalent cations such as antacids or mineral supplements can significantly reduce the gastrointestinal absorption of eltrombopag due to chelation.", "source": "DDInter", "management_text": "Eltrombopag should be taken on an empty stomach at least 2 hours before or 4 hours after oral medications that contain antacids (e.g., didanosine buffered tablets or pediatric oral solution), aluminum, calcium, iron, magnesium, zinc or other polyvalent cations.", "mechanism_text": "Absorption", "recommendation": "Eltrombopag should be taken on an empty stomach at least 2 hours before or 4 hours after oral medications that contain antacids (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97638/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Promacta (eltrombopag).\" GlaxoSmithKline, Research Triangle Park, NC.[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] \"Product Information. Promacta (eltrombopag).\" GlaxoSmithKline, Research Triangle Park, NC.", "alternatives_a": "Romiplostim, Fostamatinib, Avatrombopag, Emicizumab, Coagulation factor VIIa Recombinant Human, Coagulation factor X human, Phylloquinone, Lusutrombopag, Anti-inhibitor coagulant complex, Antihemophilic factor, human recombinant, Fibrinogen human, More", "alternatives_b": "Calcium glucoheptonate, Calcium chloride", "updated_at": 1767369485}, {"id": 97535, "ingredient1": "Eltrombopag", "ingredient2": "Calcium gluconate", "severity": "Moderate", "effect": "INTERVAL: Products containing aluminum, calcium, iron, magnesium, zinc and other polyvalent cations such as antacids or mineral supplements can significantly reduce the gastrointestinal absorption of eltrombopag due to chelation.", "source": "DDInter", "management_text": "Eltrombopag should be taken on an empty stomach at least 2 hours before or 4 hours after oral medications that contain antacids (e.g., didanosine buffered tablets or pediatric oral solution), aluminum, calcium, iron, magnesium, zinc or other polyvalent cations.", "mechanism_text": "Absorption", "recommendation": "Eltrombopag should be taken on an empty stomach at least 2 hours before or 4 hours after oral medications that contain antacids (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97639/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Promacta (eltrombopag).\" GlaxoSmithKline, Research Triangle Park, NC.[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] \"Product Information. Promacta (eltrombopag).\" GlaxoSmithKline, Research Triangle Park, NC.", "alternatives_a": "Romiplostim, Fostamatinib, Avatrombopag, Emicizumab, Coagulation factor VIIa Recombinant Human, Coagulation factor X human, Phylloquinone, Lusutrombopag, Anti-inhibitor coagulant complex, Antihemophilic factor, human recombinant, Fibrinogen human, More", "alternatives_b": "Calcium glucoheptonate, Calcium chloride, Tacrolimus, Minoxidil, Deoxycholic acid, Pimecrolimus, Glycopyrronium, Aminobenzoic acid, Finasteride, Ivermectin, Caffeine, More", "updated_at": 1767369485}, {"id": 97536, "ingredient1": "Eltrombopag", "ingredient2": "Calcium glycerophosphate", "severity": "Moderate", "effect": "INTERVAL: Products containing aluminum, calcium, iron, magnesium, zinc and other polyvalent cations such as antacids or mineral supplements can significantly reduce the gastrointestinal absorption of eltrombopag due to chelation.", "source": "DDInter", "management_text": "Eltrombopag should be taken on an empty stomach at least 2 hours before or 4 hours after oral medications that contain antacids (e.g., didanosine buffered tablets or pediatric oral solution), aluminum, calcium, iron, magnesium, zinc or other polyvalent cations.", "mechanism_text": "Absorption", "recommendation": "Eltrombopag should be taken on an empty stomach at least 2 hours before or 4 hours after oral medications that contain antacids (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97640/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Promacta (eltrombopag).\" GlaxoSmithKline, Research Triangle Park, NC.[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] \"Product Information. Promacta (eltrombopag).\" GlaxoSmithKline, Research Triangle Park, NC.", "alternatives_a": "Romiplostim, Fostamatinib, Avatrombopag, Emicizumab, Coagulation factor VIIa Recombinant Human, Coagulation factor X human, Phylloquinone, Lusutrombopag, Anti-inhibitor coagulant complex, Antihemophilic factor, human recombinant, Fibrinogen human, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 97537, "ingredient1": "Eltrombopag", "ingredient2": "Calcium lactate", "severity": "Moderate", "effect": "INTERVAL: Products containing aluminum, calcium, iron, magnesium, zinc and other polyvalent cations such as antacids or mineral supplements can significantly reduce the gastrointestinal absorption of eltrombopag due to chelation.", "source": "DDInter", "management_text": "Eltrombopag should be taken on an empty stomach at least 2 hours before or 4 hours after oral medications that contain antacids (e.g., didanosine buffered tablets or pediatric oral solution), aluminum, calcium, iron, magnesium, zinc or other polyvalent cations.", "mechanism_text": "Absorption", "recommendation": "Eltrombopag should be taken on an empty stomach at least 2 hours before or 4 hours after oral medications that contain antacids (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97641/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Promacta (eltrombopag).\" GlaxoSmithKline, Research Triangle Park, NC.[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] \"Product Information. Promacta (eltrombopag).\" GlaxoSmithKline, Research Triangle Park, NC.", "alternatives_a": "Romiplostim, Fostamatinib, Avatrombopag, Emicizumab, Coagulation factor VIIa Recombinant Human, Coagulation factor X human, Phylloquinone, Lusutrombopag, Anti-inhibitor coagulant complex, Antihemophilic factor, human recombinant, Fibrinogen human, More", "alternatives_b": "Calcium glucoheptonate, Calcium chloride", "updated_at": 1767369485}, {"id": 97538, "ingredient1": "Iron", "ingredient2": "Eltrombopag", "severity": "Moderate", "effect": "INTERVAL: Products containing aluminum, calcium, iron, magnesium, zinc and other polyvalent cations such as antacids or mineral supplements can significantly reduce the gastrointestinal absorption of eltrombopag due to chelation.", "source": "DDInter", "management_text": "Eltrombopag should be taken on an empty stomach at least 2 hours before or 4 hours after oral medications that contain antacids (e.g., didanosine buffered tablets or pediatric oral solution), aluminum, calcium, iron, magnesium, zinc or other polyvalent cations.", "mechanism_text": "Absorption", "recommendation": "Eltrombopag should be taken on an empty stomach at least 2 hours before or 4 hours after oral medications that contain antacids (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97642/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Promacta (eltrombopag).\" GlaxoSmithKline, Research Triangle Park, NC.[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] \"Product Information. Promacta (eltrombopag).\" GlaxoSmithKline, Research Triangle Park, NC.", "alternatives_a": "Iron sucrose, Cyanocobalamin, Folic acid", "alternatives_b": "Romiplostim, Fostamatinib, Avatrombopag, Emicizumab, Coagulation factor VIIa Recombinant Human, Coagulation factor X human, Phylloquinone, Lusutrombopag, Anti-inhibitor coagulant complex, Antihemophilic factor, human recombinant, Fibrinogen human, More", "updated_at": 1767369485}, {"id": 97539, "ingredient1": "Eltrombopag", "ingredient2": "Cerivastatin", "severity": "Moderate", "effect": "Coadministration with eltrombopag may increase the plasma concentrations of HMG-CoA reductase inhibitors (statins). The proposed mechanism is decreased clearance due to eltrombopag inhibition of the OATP 1B1-mediated hepatic uptake of statins and/or their metabolites (e.g., simvastatin acid), with fluvastatin the least likely to be significantly affected. High levels of HMG-CoA reductase inhibitory activity in plasma is associated with an increased risk of musculoskeletal toxicity. Myopathy manifested as muscle pain and/or weakness associated with grossly elevated creatine kinase exceeding ten times the upper limit of normal has been reported occasionally.", "source": "DDInter", "management_text": "Lower statin dosages should be considered during coadministration with eltrombopag. In clinical trials with eltrombopag, a dosage reduction of rosuvastatin by 50% was recommended. No specific adjustment recommendations were given for the others. All patients receiving statin therapy should be advised to promptly report any unexplained muscle pain, tenderness or weakness, particularly if accompanied by fever, malaise and/or dark colored urine. Therapy should be discontinued if creatine kinase is markedly elevated in the absence of strenuous exercise or if myopathy is otherwise suspected or diagnosed.", "mechanism_text": "Excretion", "recommendation": "Lower statin dosages should be considered during coadministration with eltrombopag.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97643/", "reference_text": "[1] Allred AJ, Bowen CJ, Park JW, et al. \"Eltrombopag increases plasma rosuvastatin exposure in healthy volunteers.\" Br J Clin Pharmacol 72 (2011): 321-9[2] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[3] Cerner Multum, Inc. \"Australian Product Information.\" O 0[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] Kalliokoski A, Niemi M \"Impact of OATP transporters on pharmacokinetics.\" Br J Pharmacol 158 (2009): 693-705[6] \"Product Information. Promacta (eltrombopag).\" GlaxoSmithKline, Research Triangle Park, NC.[7] Richter WO, Jacob BG, Schwandt P \"Interaction between fibre and lovastatin.\" Lancet 338 (1991): 706[8] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors.\" Clin Pharmacol Ther 64 (1998): 477-83[9] Kantola T, Kivisto KT, Neuvonen PJ \"Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid.\" Clin Pharmacol Ther 63 (1998): 397-402[10] \"Product Information. Mevacor (lovastatin).\" Merck & Co, Inc, West Point, PA.[11] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions.\" Br J Clin Pharmacol 46 (1998): 101-10[12] Neuvonen PJ, Backman JT, Niemi M \"Pharmacokinetic comparison of the potential over-the-counter statins simvastatin, lovastatin, fluvastatin and pravastatin.\" Clin Pharmacokinet 47 (2008): 463-74[13] Thompson PD, Clarkson P, Karas RH \"Statin-associated myopathy.\" JAMA 289 (2003): 1681-90[14] \"Product Information. Zocor (simvastatin).\" Merck & Co, Inc, West Point, PA.[15] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[16] \"Product Information. Promacta (eltrombopag).\" GlaxoSmithKline, Research Triangle Park, NC.", "alternatives_a": "Gemfibrozil, Fenofibric acid, Evinacumab, Evolocumab, Probucol, Dextrothyroxine, Cholestyramine, Clofibrate, Colestipol, Niacin, Fenofibrate, More", "alternatives_b": "Romiplostim, Avatrombopag, Emicizumab, Coagulation factor VIIa Recombinant Human, Coagulation factor X human, Phylloquinone, Lusutrombopag, Anti-inhibitor coagulant complex, Antihemophilic factor, human recombinant, Fibrinogen human, Epinephrine, Coagulation Factor IX Human", "updated_at": 1767369485}, {"id": 97540, "ingredient1": "Eltrombopag", "ingredient2": "Chromium picolinate", "severity": "Moderate", "effect": "INTERVAL: Products containing aluminum, calcium, iron, magnesium, zinc and other polyvalent cations such as antacids or mineral supplements can significantly reduce the gastrointestinal absorption of eltrombopag due to chelation.", "source": "DDInter", "management_text": "Eltrombopag should be taken on an empty stomach at least 2 hours before or 4 hours after oral medications that contain antacids (e.g., didanosine buffered tablets or pediatric oral solution), aluminum, calcium, iron, magnesium, zinc or other polyvalent cations.", "mechanism_text": "Absorption", "recommendation": "Eltrombopag should be taken on an empty stomach at least 2 hours before or 4 hours after oral medications that contain antacids (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97644/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Promacta (eltrombopag).\" GlaxoSmithKline, Research Triangle Park, NC.[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] \"Product Information. Promacta (eltrombopag).\" GlaxoSmithKline, Research Triangle Park, NC.", "alternatives_a": "Romiplostim, Fostamatinib, Avatrombopag, Emicizumab, Coagulation factor VIIa Recombinant Human, Coagulation factor X human, Phylloquinone, Lusutrombopag, Anti-inhibitor coagulant complex, Antihemophilic factor, human recombinant, Fibrinogen human, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 97541, "ingredient1": "Eltrombopag", "ingredient2": "Copper gluconate", "severity": "Moderate", "effect": "INTERVAL: Products containing aluminum, calcium, iron, magnesium, zinc and other polyvalent cations such as antacids or mineral supplements can significantly reduce the gastrointestinal absorption of eltrombopag due to chelation.", "source": "DDInter", "management_text": "Eltrombopag should be taken on an empty stomach at least 2 hours before or 4 hours after oral medications that contain antacids (e.g., didanosine buffered tablets or pediatric oral solution), aluminum, calcium, iron, magnesium, zinc or other polyvalent cations.", "mechanism_text": "Absorption", "recommendation": "Eltrombopag should be taken on an empty stomach at least 2 hours before or 4 hours after oral medications that contain antacids (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97645/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Promacta (eltrombopag).\" GlaxoSmithKline, Research Triangle Park, NC.[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] \"Product Information. Promacta (eltrombopag).\" GlaxoSmithKline, Research Triangle Park, NC.", "alternatives_a": "Romiplostim, Fostamatinib, Avatrombopag, Emicizumab, Coagulation factor VIIa Recombinant Human, Coagulation factor X human, Phylloquinone, Lusutrombopag, Anti-inhibitor coagulant complex, Antihemophilic factor, human recombinant, Fibrinogen human, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 97542, "ingredient1": "Eltrombopag", "ingredient2": "Echinacea", "severity": "Moderate", "effect": "Coadministration with echinacea may increase the plasma concentrations and the risk of adverse effects of drugs that are substrates of CYP450 1A2. The proposed mechanism is decreased clearance due to echinacea-mediated inhibition of CYP450 1A2.", "source": "DDInter", "management_text": "Caution is advised if echinacea is used concomitantly with drugs that are substrates of CYP450 1A2, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring should be considered whenever echinacea is added to or withdrawn from therapy with these drugs. Patients should be monitored for the development of adverse effects.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if echinacea is used concomitantly with drugs that are substrates of CYP450 1A2, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97646/", "reference_text": "[1] Gorski JC, Huang SM, Pinto A, et al. \"The effect of echinacea (Echinacea purpurea root) on cytochrome P450 activity in vivo.\" Clin Pharmacol Ther 75 (2004): 89-100", "alternatives_a": "Romiplostim, Fostamatinib, Avatrombopag, Emicizumab, Coagulation factor VIIa Recombinant Human, Coagulation factor X human, Phylloquinone, Lusutrombopag, Anti-inhibitor coagulant complex, Antihemophilic factor, human recombinant, Fibrinogen human, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 97543, "ingredient1": "Eluxadoline", "ingredient2": "Eltrombopag", "severity": "Major", "effect": "Coadministration with inhibitors of organic anion transporting polypeptide (OATP) 1B1 may significantly increase the plasma concentrations of eluxadoline. Based on available data, inhibition of OATP1B1-mediated hepatic uptake appears to reduce both the hepatic first-pass extraction and systemic biliary clearance of eluxadoline.", "source": "DDInter", "management_text": "The recommended dosage of eluxadoline is 75 mg twice daily when used with OATP1B1 inhibitors. Patients should be monitored for adverse effects such as sedation, nausea, vomiting, constipation, abdominal pain, liver enzyme elevations, and pancreatitis.", "mechanism_text": "Metabolism", "recommendation": "The recommended dosage of eluxadoline is 75 mg twice daily when used with OATP1B1 inhibitors.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97647/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Davenport JM, Covington P, Bonifacio L, McIntyre G, Venitz J \"Effect of uptake transporters OAT3 and OATPIBI and efflux transporter MRP2 on the pharmacokinetics of eluxadoline.\" J Clin Pharmacol 55 (2015): 534-42[3] \"Product Information. Viberzi (eluxadoline).\" Actavis Pharma, Inc., Parsippany, NJ.[4] \"Product Information. Viberzi (eluxadoline).\" Actavis Pharma, Inc., Parsippany, NJ.[5] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[6] Cerner Multum, Inc. \"Australian Product Information.\" O 0[7] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[8] \"Product Information. Aptivus (tipranavir).\" Boehringer-Ingelheim, Ridgefield, CT.", "alternatives_a": "Romiplostim, Fostamatinib, Avatrombopag, Emicizumab, Coagulation factor VIIa Recombinant Human, Coagulation factor X human, Phylloquinone, Lusutrombopag, Anti-inhibitor coagulant complex, Antihemophilic factor, human recombinant, Fibrinogen human, More", "alternatives_b": "Morphine, Diphenoxylate, Opium, Difenoxin, Loperamide", "updated_at": 1767369485}, {"id": 97544, "ingredient1": "Enasidenib", "ingredient2": "Eltrombopag", "severity": "Moderate", "effect": "Based on in vitro data, coadministration with enasidenib may increase the plasma concentrations of drugs that are substrates of the transporters, organic anion transporting polypeptides (OATP) 1B1/1B3 and breast cancer resistance protein (BCRP). The proposed mechanism is decreased clearance due to enasidenib -mediated inhibition of OATP1B1/1B3 and BCRP transporters.", "source": "DDInter", "management_text": "Caution is advised when enasidenib is used concurrently with medications that are substrates of OATP 1B1/1B3 and/or BCRP, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever enasidenib is added to or withdrawn from therapy.", "mechanism_text": "Distribution", "recommendation": "Caution is advised when enasidenib is used concurrently with medications that are substrates of OATP 1B1/1B3 and/or BCRP, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97648/", "reference_text": "[1] \"Product Information. Idhifa (enasidenib).\" Celgene Corporation, Summit, NJ.[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] \"Product Information. Mavyret (glecaprevir-pibrentasvir).\" Abbott Pharmaceutical, Abbott Park, IL.", "alternatives_a": "Romiplostim, Fostamatinib, Avatrombopag, Emicizumab, Coagulation factor VIIa Recombinant Human, Coagulation factor X human, Phylloquinone, Anti-inhibitor coagulant complex, Antihemophilic factor, human recombinant, Fibrinogen human, Epinephrine, Coagulation Factor IX Human", "alternatives_b": "Pertuzumab, Olaparib, Oxaliplatin, Bortezomib, Tisagenlecleucel, Aminolevulinic acid, Omacetaxine mepesuccinate, Tazemetostat, Altretamine, Tagraxofusp, Ixazomib, More", "updated_at": 1767369485}, {"id": 97545, "ingredient1": "Encorafenib", "ingredient2": "Eltrombopag", "severity": "Moderate", "effect": "Coadministration with encorafenib may theoretically increase the plasma concentrations of drugs that are substrates of P-glycoprotein (P-gp), breast cancer resistance protein (BCRP), organic cation transporter (OCT2), organic anion transporter (OAT1, OAT3), or organic anion transporting polypeptide (OATP1B1, OATP1B3). The proposed mechanism is decreased clearance due to inhibition of the corresponding transporter by encorafenib.", "source": "DDInter", "management_text": "Caution is advised if encorafenib must be used concomitantly with drugs that are substrates of the affected transporters, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever encorafenib is added to or withdrawn from therapy.", "mechanism_text": "Excretion", "recommendation": "Caution is advised if encorafenib must be used concomitantly with drugs that are substrates of the affected transporters, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97649/", "reference_text": "[1] \"Product Information. Braftovi (encorafenib).\" Array BioPharma Inc., Boulder, CO.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Braftovi (encorafenib).\" Array BioPharma Inc., Boulder, CO.[4] \"Product Information. Lonsurf (tipiracil-trifluridine).\" Taiho Oncology, Inc., Princeton, NJ.", "alternatives_a": "Romiplostim, Fostamatinib, Avatrombopag, Emicizumab, Coagulation factor VIIa Recombinant Human, Coagulation factor X human, Phylloquinone, Anti-inhibitor coagulant complex, Antihemophilic factor, human recombinant, Fibrinogen human, Epinephrine, Coagulation Factor IX Human", "alternatives_b": "Dabrafenib, Asciminib, Acalabrutinib, Dacomitinib, Tepotinib, Fedratinib, Avapritinib, Bosutinib, Vemurafenib, Selumetinib, Vandetanib, More", "updated_at": 1767369485}, {"id": 97546, "ingredient1": "Entrectinib", "ingredient2": "Eltrombopag", "severity": "Moderate", "effect": "Coadministration with entrectinib may increase the plasma concentrations of drugs that are substrates of the breast cancer resistance protein (BCRP) transporter. The proposed mechanisms, based on in vitro data, is decreased clearance due to entrectinib-mediated inhibition of BCRP transport protein.", "source": "DDInter", "management_text": "Caution is advised when entrectinib is prescribed with drugs that are BCRP substrates, particularly those with a narrow therapeutic range such as methotrexate, mitoxantrone, topotecan, and lapatinib. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever entrectinib is added to or withdrawn from therapy.", "mechanism_text": "Others", "recommendation": "Caution is advised when entrectinib is prescribed with drugs that are BCRP substrates, particularly those with a narrow therapeutic range such as methotrexate, mitoxantrone, topotecan, and lapatinib.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97650/", "reference_text": "[1] \"Product Information. Rozlytrek (entrectinib).\" Genentech, South San Francisco, CA.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] Cerner Multum, Inc. \"Australian Product Information.\" O 0[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] \"Product Information. Rozlytrek (entrectinib).\" Genentech, South San Francisco, CA.", "alternatives_a": "Romiplostim, Avatrombopag, Emicizumab, Coagulation factor VIIa Recombinant Human, Coagulation factor X human, Phylloquinone, Anti-inhibitor coagulant complex, Antihemophilic factor, human recombinant, Fibrinogen human, Epinephrine, Coagulation Factor IX Human", "alternatives_b": "Dabrafenib, Asciminib, Acalabrutinib, Dacomitinib, Tepotinib, Fedratinib, Avapritinib, Bosutinib, Vemurafenib, Selumetinib, Vandetanib, More", "updated_at": 1767369485}, {"id": 97547, "ingredient1": "Epirubicin", "ingredient2": "Eltrombopag", "severity": "Moderate", "effect": "The concomitant or sequential use of epirubicin with agents known to induce hepatotoxicity may potentiate the risk of liver injury. Epirubicin undergoes elimination through the hepatobiliary system.", "source": "DDInter", "management_text": "Caution and clinical and laboratory monitoring for signs of liver injury are advisable before, during, or after use of epirubicin with other agents that are potentially hepatotoxic.", "mechanism_text": "Synergism", "recommendation": "Caution and clinical and laboratory monitoring for signs of liver injury are advisable before, during, or after use of epirubicin with other agents that are potentially hepatotoxic.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97651/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] \"Product Information. Ellence (epirubicin)\" Pharmacia and Upjohn, Kalamazoo, MI.[4] \"Product Information. Hivid (zalcitabine).\" Roche Laboratories, Nutley, NJ.", "alternatives_a": "Idarubicin, Valrubicin, Plicamycin, Ixabepilone, Bleomycin, Doxorubicin, Mitomycin, Daunorubicin, Dactinomycin", "alternatives_b": "Romiplostim, Avatrombopag, Emicizumab, Coagulation factor VIIa Recombinant Human, Coagulation factor X human, Phylloquinone, Lusutrombopag, Anti-inhibitor coagulant complex, Antihemophilic factor, human recombinant, Fibrinogen human, Epinephrine, Coagulation Factor IX Human", "updated_at": 1767369485}, {"id": 97548, "ingredient1": "Eltrombopag", "ingredient2": "Tetraferric tricitrate decahydrate", "severity": "Moderate", "effect": "INTERVAL: Products containing aluminum, calcium, iron, magnesium, zinc and other polyvalent cations such as antacids or mineral supplements can significantly reduce the gastrointestinal absorption of eltrombopag due to chelation.", "source": "DDInter", "management_text": "Eltrombopag should be taken on an empty stomach at least 2 hours before or 4 hours after oral medications that contain antacids (e.g., didanosine buffered tablets or pediatric oral solution), aluminum, calcium, iron, magnesium, zinc or other polyvalent cations.", "mechanism_text": "Absorption", "recommendation": "Eltrombopag should be taken on an empty stomach at least 2 hours before or 4 hours after oral medications that contain antacids (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97652/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Promacta (eltrombopag).\" GlaxoSmithKline, Research Triangle Park, NC.[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] \"Product Information. Promacta (eltrombopag).\" GlaxoSmithKline, Research Triangle Park, NC.", "alternatives_a": "Romiplostim, Fostamatinib, Avatrombopag, Emicizumab, Coagulation factor VIIa Recombinant Human, Coagulation factor X human, Phylloquinone, Lusutrombopag, Anti-inhibitor coagulant complex, Antihemophilic factor, human recombinant, Fibrinogen human, More", "alternatives_b": "Hydroxocobalamin, Fomepizole, Ipecac, Nitrous acid, Dexrazoxane, Oxygen, Lanthanum carbonate, Difelikefalin, Cobicistat, Deferoxamine, Levoleucovorin, More", "updated_at": 1767369485}, {"id": 97549, "ingredient1": "Ferrous fumarate", "ingredient2": "Eltrombopag", "severity": "Moderate", "effect": "INTERVAL: Products containing aluminum, calcium, iron, magnesium, zinc and other polyvalent cations such as antacids or mineral supplements can significantly reduce the gastrointestinal absorption of eltrombopag due to chelation.", "source": "DDInter", "management_text": "Eltrombopag should be taken on an empty stomach at least 2 hours before or 4 hours after oral medications that contain antacids (e.g., didanosine buffered tablets or pediatric oral solution), aluminum, calcium, iron, magnesium, zinc or other polyvalent cations.", "mechanism_text": "Absorption", "recommendation": "Eltrombopag should be taken on an empty stomach at least 2 hours before or 4 hours after oral medications that contain antacids (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97653/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Promacta (eltrombopag).\" GlaxoSmithKline, Research Triangle Park, NC.[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] \"Product Information. Promacta (eltrombopag).\" GlaxoSmithKline, Research Triangle Park, NC.", "alternatives_a": "Romiplostim, Fostamatinib, Avatrombopag, Emicizumab, Coagulation factor VIIa Recombinant Human, Coagulation factor X human, Phylloquinone, Lusutrombopag, Anti-inhibitor coagulant complex, Antihemophilic factor, human recombinant, Fibrinogen human, More", "alternatives_b": "Iron sucrose, Cyanocobalamin, Folic acid", "updated_at": 1767369485}, {"id": 97550, "ingredient1": "Ferrous gluconate", "ingredient2": "Eltrombopag", "severity": "Moderate", "effect": "INTERVAL: Products containing aluminum, calcium, iron, magnesium, zinc and other polyvalent cations such as antacids or mineral supplements can significantly reduce the gastrointestinal absorption of eltrombopag due to chelation.", "source": "DDInter", "management_text": "Eltrombopag should be taken on an empty stomach at least 2 hours before or 4 hours after oral medications that contain antacids (e.g., didanosine buffered tablets or pediatric oral solution), aluminum, calcium, iron, magnesium, zinc or other polyvalent cations.", "mechanism_text": "Absorption", "recommendation": "Eltrombopag should be taken on an empty stomach at least 2 hours before or 4 hours after oral medications that contain antacids (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97654/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Promacta (eltrombopag).\" GlaxoSmithKline, Research Triangle Park, NC.[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] \"Product Information. Promacta (eltrombopag).\" GlaxoSmithKline, Research Triangle Park, NC.", "alternatives_a": "Romiplostim, Fostamatinib, Avatrombopag, Emicizumab, Coagulation factor VIIa Recombinant Human, Coagulation factor X human, Phylloquinone, Lusutrombopag, Anti-inhibitor coagulant complex, Antihemophilic factor, human recombinant, Fibrinogen human, More", "alternatives_b": "Iron sucrose, Cyanocobalamin, Folic acid", "updated_at": 1767369485}, {"id": 97551, "ingredient1": "Ferrous sulfate anhydrous", "ingredient2": "Eltrombopag", "severity": "Moderate", "effect": "INTERVAL: Products containing aluminum, calcium, iron, magnesium, zinc and other polyvalent cations such as antacids or mineral supplements can significantly reduce the gastrointestinal absorption of eltrombopag due to chelation.", "source": "DDInter", "management_text": "Eltrombopag should be taken on an empty stomach at least 2 hours before or 4 hours after oral medications that contain antacids (e.g., didanosine buffered tablets or pediatric oral solution), aluminum, calcium, iron, magnesium, zinc or other polyvalent cations.", "mechanism_text": "Absorption", "recommendation": "Eltrombopag should be taken on an empty stomach at least 2 hours before or 4 hours after oral medications that contain antacids (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97655/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Promacta (eltrombopag).\" GlaxoSmithKline, Research Triangle Park, NC.[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] \"Product Information. Promacta (eltrombopag).\" GlaxoSmithKline, Research Triangle Park, NC.", "alternatives_a": "Romiplostim, Fostamatinib, Avatrombopag, Emicizumab, Coagulation factor VIIa Recombinant Human, Coagulation factor X human, Phylloquinone, Lusutrombopag, Anti-inhibitor coagulant complex, Antihemophilic factor, human recombinant, Fibrinogen human, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 97552, "ingredient1": "Fexofenadine", "ingredient2": "Eltrombopag", "severity": "Moderate", "effect": "Coadministration with eltrombopag may increase the plasma concentrations of drugs that are substrates of the organic anion transporting polypeptide (OATP) 1B1 and/or breast cancer resistance protein (BCRP) transporters. The mechanism is decreased clearance due to inhibition of OATP1B1-mediated hepatic uptake and BCRP-mediated intestinal and hepatobiliary efflux by eltrombopag. The interaction has been demonstrated for rosuvastatin, a known substrate of both OATP 1B1 and BCRP.", "source": "DDInter", "management_text": "Caution is advised during concomitant use of eltrombopag with drugs that are substrates of the OATP1B1 and/or BCRP transporters, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever eltrombopag is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised during concomitant use of eltrombopag with drugs that are substrates of the OATP1B1 and/or BCRP transporters, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97656/", "reference_text": "[1] Allred AJ, Bowen CJ, Park JW, et al. \"Eltrombopag increases plasma rosuvastatin exposure in healthy volunteers.\" Br J Clin Pharmacol 72 (2011): 321-9[2] Kalliokoski A, Niemi M \"Impact of OATP transporters on pharmacokinetics.\" Br J Pharmacol 158 (2009): 693-705[3] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[4] \"Product Information. Promacta (eltrombopag).\" GlaxoSmithKline, Research Triangle Park, NC.[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[7] \"Product Information. Promacta (eltrombopag).\" GlaxoSmithKline, Research Triangle Park, NC.", "alternatives_a": "Ketotifen, Mepyramine, Levocetirizine, Chlorcyclizine, Cetirizine, Acrivastine, Triprolidine, Tripelennamine, Azelastine, Dexbrompheniramine, Promethazine, More", "alternatives_b": "Romiplostim, Avatrombopag, Emicizumab, Coagulation factor VIIa Recombinant Human, Coagulation factor X human, Phylloquinone, Lusutrombopag, Anti-inhibitor coagulant complex, Antihemophilic factor, human recombinant, Fibrinogen human, Coagulation Factor IX Human", "updated_at": 1767369485}, {"id": 97553, "ingredient1": "Fluvastatin", "ingredient2": "Eltrombopag", "severity": "Moderate", "effect": "Coadministration with eltrombopag may increase the plasma concentrations of HMG-CoA reductase inhibitors (statins). The proposed mechanism is decreased clearance due to eltrombopag inhibition of the OATP 1B1-mediated hepatic uptake of statins and/or their metabolites (e.g., simvastatin acid), with fluvastatin the least likely to be significantly affected. High levels of HMG-CoA reductase inhibitory activity in plasma is associated with an increased risk of musculoskeletal toxicity. Myopathy manifested as muscle pain and/or weakness associated with grossly elevated creatine kinase exceeding ten times the upper limit of normal has been reported occasionally.", "source": "DDInter", "management_text": "Lower statin dosages should be considered during coadministration with eltrombopag. In clinical trials with eltrombopag, a dosage reduction of rosuvastatin by 50% was recommended. No specific adjustment recommendations were given for the others. All patients receiving statin therapy should be advised to promptly report any unexplained muscle pain, tenderness or weakness, particularly if accompanied by fever, malaise and/or dark colored urine. Therapy should be discontinued if creatine kinase is markedly elevated in the absence of strenuous exercise or if myopathy is otherwise suspected or diagnosed.", "mechanism_text": "Excretion", "recommendation": "Lower statin dosages should be considered during coadministration with eltrombopag.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97657/", "reference_text": "[1] Allred AJ, Bowen CJ, Park JW, et al. \"Eltrombopag increases plasma rosuvastatin exposure in healthy volunteers.\" Br J Clin Pharmacol 72 (2011): 321-9[2] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[3] Cerner Multum, Inc. \"Australian Product Information.\" O 0[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] Kalliokoski A, Niemi M \"Impact of OATP transporters on pharmacokinetics.\" Br J Pharmacol 158 (2009): 693-705[6] \"Product Information. Promacta (eltrombopag).\" GlaxoSmithKline, Research Triangle Park, NC.[7] Richter WO, Jacob BG, Schwandt P \"Interaction between fibre and lovastatin.\" Lancet 338 (1991): 706[8] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors.\" Clin Pharmacol Ther 64 (1998): 477-83[9] Kantola T, Kivisto KT, Neuvonen PJ \"Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid.\" Clin Pharmacol Ther 63 (1998): 397-402[10] \"Product Information. Mevacor (lovastatin).\" Merck & Co, Inc, West Point, PA.[11] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions.\" Br J Clin Pharmacol 46 (1998): 101-10[12] Neuvonen PJ, Backman JT, Niemi M \"Pharmacokinetic comparison of the potential over-the-counter statins simvastatin, lovastatin, fluvastatin and pravastatin.\" Clin Pharmacokinet 47 (2008): 463-74[13] Thompson PD, Clarkson P, Karas RH \"Statin-associated myopathy.\" JAMA 289 (2003): 1681-90[14] \"Product Information. Zocor (simvastatin).\" Merck & Co, Inc, West Point, PA.[15] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[16] \"Product Information. Promacta (eltrombopag).\" GlaxoSmithKline, Research Triangle Park, NC.", "alternatives_a": "Gemfibrozil, Fenofibric acid, Evinacumab, Evolocumab, Probucol, Dextrothyroxine, Cholestyramine, Clofibrate, Colestipol, Niacin, Fenofibrate, More", "alternatives_b": "Romiplostim, Avatrombopag, Emicizumab, Coagulation factor VIIa Recombinant Human, Coagulation factor X human, Phylloquinone, Lusutrombopag, Anti-inhibitor coagulant complex, Antihemophilic factor, human recombinant, Fibrinogen human, Coagulation Factor IX Human", "updated_at": 1767369485}, {"id": 97554, "ingredient1": "Glasdegib", "ingredient2": "Eltrombopag", "severity": "Moderate", "effect": "Coadministration with glasdegib may increase the plasma concentrations of drugs that are substrates of the P-glycoprotein (P-gp) and/or breast cancer resistance protein (BCRP) efflux transporters.", "source": "DDInter", "management_text": "Caution is advised if glasdegib is coadministered with drugs that are substrates of P-gp and/or BCRP, particularly those with a narrow therapeutic range. Clinical and laboratory monitoring should be considered whenever glasdegib is added to or withdrawn from therapy with these drugs, and dosages adjusted as necessary. Patients should be monitored for the development of adverse effects.", "mechanism_text": "Absorption", "recommendation": "Caution is advised if glasdegib is coadministered with drugs that are substrates of P-gp and/or BCRP, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97658/", "reference_text": "[1] \"Product Information. Daurismo (glasdegib).\" Pfizer U.S. Pharmaceuticals Group, New York, NY.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Daurismo (glasdegib).\" Pfizer U.S. Pharmaceuticals Group, New York, NY.", "alternatives_a": "Romiplostim, Fostamatinib, Avatrombopag, Emicizumab, Coagulation factor VIIa Recombinant Human, Coagulation factor X human, Phylloquinone, Anti-inhibitor coagulant complex, Antihemophilic factor, human recombinant, Fibrinogen human, Epinephrine, Coagulation Factor IX Human", "alternatives_b": "Pertuzumab, Olaparib, Oxaliplatin, Bortezomib, Tisagenlecleucel, Aminolevulinic acid, Omacetaxine mepesuccinate, Tazemetostat, Altretamine, Tagraxofusp, Ixazomib, More", "updated_at": 1767369485}, {"id": 97555, "ingredient1": "Glyburide", "ingredient2": "Eltrombopag", "severity": "Moderate", "effect": "Coadministration with eltrombopag may increase the plasma concentrations of drugs that are substrates of the organic anion transporting polypeptide (OATP) 1B1 and/or breast cancer resistance protein (BCRP) transporters. The mechanism is decreased clearance due to inhibition of OATP1B1-mediated hepatic uptake and BCRP-mediated intestinal and hepatobiliary efflux by eltrombopag. The interaction has been demonstrated for rosuvastatin, a known substrate of both OATP 1B1 and BCRP.", "source": "DDInter", "management_text": "Caution is advised during concomitant use of eltrombopag with drugs that are substrates of the OATP1B1 and/or BCRP transporters, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever eltrombopag is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised during concomitant use of eltrombopag with drugs that are substrates of the OATP1B1 and/or BCRP transporters, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97659/", "reference_text": "[1] Allred AJ, Bowen CJ, Park JW, et al. \"Eltrombopag increases plasma rosuvastatin exposure in healthy volunteers.\" Br J Clin Pharmacol 72 (2011): 321-9[2] Kalliokoski A, Niemi M \"Impact of OATP transporters on pharmacokinetics.\" Br J Pharmacol 158 (2009): 693-705[3] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[4] \"Product Information. Promacta (eltrombopag).\" GlaxoSmithKline, Research Triangle Park, NC.[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[7] \"Product Information. Promacta (eltrombopag).\" GlaxoSmithKline, Research Triangle Park, NC.", "alternatives_a": "Glipizide, Acetohexamide, Guar gum, Pramlintide, Alogliptin, Tolazamide, Empagliflozin, Dulaglutide, Exenatide, Tolbutamide, Miglitol, More", "alternatives_b": "Romiplostim, Avatrombopag, Emicizumab, Coagulation factor VIIa Recombinant Human, Coagulation factor X human, Phylloquinone, Lusutrombopag, Anti-inhibitor coagulant complex, Antihemophilic factor, human recombinant, Fibrinogen human, Coagulation Factor IX Human", "updated_at": 1767369485}, {"id": 97556, "ingredient1": "Idelalisib", "ingredient2": "Eltrombopag", "severity": "Moderate", "effect": "Coadministration of idelalisib with other agents known to induce hepatotoxicity may potentiate the risk of liver injury. The use of idelalisib has been associated with elevations in alanine aminotransferase (ALT) and aspartate aminotransferase (AST) greater than 5 times the upper limit of normal.", "source": "DDInter", "management_text": "The use of idelalisib with other potentially hepatotoxic agents should be avoided whenever possible (e.g., acetaminophen; alcohol; amiodarone; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; methotrexate; nonsteroidal anti-inflammatory agents; nucleoside reverse transcriptase inhibitors; proteasome inhibitors; retinoids; sulfonamides; tamoxifen; tetracyclines; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice). Patients treated with idelalisib should have serum ALT, AST, and bilirubin measured prior to initiation of treatment and regularly during treatment in accordance with the product labeling, and the dosing adjusted or interrupted as necessary.", "mechanism_text": "Synergism", "recommendation": "The use of idelalisib with other potentially hepatotoxic agents should be avoided whenever possible (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97660/", "reference_text": "[1] \"Product Information. Zydelig (idelalisib).\" Gilead Sciences, Foster City, CA.[2] \"Product Information. Hivid (zalcitabine).\" Roche Laboratories, Nutley, NJ.", "alternatives_a": "Romiplostim, Emicizumab, Coagulation factor VIIa Recombinant Human, Coagulation factor X human, Phylloquinone, Anti-inhibitor coagulant complex, Antihemophilic factor, human recombinant, Fibrinogen human, Epinephrine, Coagulation Factor IX Human", "alternatives_b": "Dabrafenib, Asciminib, Acalabrutinib, Dacomitinib, Tepotinib, Fedratinib, Avapritinib, Bosutinib, Vemurafenib, Selumetinib, Vandetanib, More", "updated_at": 1767369485}, {"id": 97557, "ingredient1": "Imatinib", "ingredient2": "Eltrombopag", "severity": "Moderate", "effect": "Coadministration with eltrombopag may increase the plasma concentrations of drugs that are substrates of the organic anion transporting polypeptide (OATP) 1B1 and/or breast cancer resistance protein (BCRP) transporters. The mechanism is decreased clearance due to inhibition of OATP1B1-mediated hepatic uptake and BCRP-mediated intestinal and hepatobiliary efflux by eltrombopag. The interaction has been demonstrated for rosuvastatin, a known substrate of both OATP 1B1 and BCRP.", "source": "DDInter", "management_text": "Caution is advised during concomitant use of eltrombopag with drugs that are substrates of the OATP1B1 and/or BCRP transporters, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever eltrombopag is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised during concomitant use of eltrombopag with drugs that are substrates of the OATP1B1 and/or BCRP transporters, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97661/", "reference_text": "[1] Allred AJ, Bowen CJ, Park JW, et al. \"Eltrombopag increases plasma rosuvastatin exposure in healthy volunteers.\" Br J Clin Pharmacol 72 (2011): 321-9[2] Kalliokoski A, Niemi M \"Impact of OATP transporters on pharmacokinetics.\" Br J Pharmacol 158 (2009): 693-705[3] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[4] \"Product Information. Promacta (eltrombopag).\" GlaxoSmithKline, Research Triangle Park, NC.[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[7] \"Product Information. Promacta (eltrombopag).\" GlaxoSmithKline, Research Triangle Park, NC.", "alternatives_a": "Dabrafenib, Asciminib, Acalabrutinib, Dacomitinib, Tepotinib, Fedratinib, Avapritinib, Bosutinib, Vemurafenib, Selumetinib, Vandetanib, More", "alternatives_b": "Romiplostim, Emicizumab, Coagulation factor VIIa Recombinant Human, Coagulation factor X human, Phylloquinone, Lusutrombopag, Anti-inhibitor coagulant complex, Antihemophilic factor, human recombinant, Fibrinogen human, Epinephrine, Coagulation Factor IX Human", "updated_at": 1767369485}, {"id": 97558, "ingredient1": "Interferon alfa-2a, Recombinant", "ingredient2": "Eltrombopag", "severity": "Major", "effect": "In chronic hepatitis C patients with advanced liver disease, coadministration of eltrombopag with interferon-based therapy may increase the risk of adverse reactions including potentially fatal hepatic decompensation and thromboembolic events.", "source": "DDInter", "management_text": "In chronic hepatitis C patients with poor liver function (albumin levels <=3.5 g/L or MELD score >=10) at baseline, eltrombopag should only be administered with interferon-based therapy after careful consideration of the potential benefits versus associated risks, and patients should be monitored closely for signs and symptoms of hepatic decompensation. Eltrombopag should be discontinued if antiviral therapy is withdrawn for hepatic decompensation.", "mechanism_text": "Others", "recommendation": "In chronic hepatitis C patients with poor liver function (albumin levels <=3.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97662/", "reference_text": "[1] \"Product Information. Promacta (eltrombopag).\" GlaxoSmithKline, Research Triangle Park, NC.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] Cerner Multum, Inc. \"Australian Product Information.\" O 0[4] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[5] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[6] \"Product Information. Promacta (eltrombopag).\" GlaxoSmithKline, Research Triangle Park, NC.", "alternatives_a": "Romiplostim, Fostamatinib, Avatrombopag, Emicizumab, Coagulation factor VIIa Recombinant Human, Coagulation factor X human, Phylloquinone, Lusutrombopag, Anti-inhibitor coagulant complex, Antihemophilic factor, human recombinant, Fibrinogen human, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 97559, "ingredient1": "Interferon alfa-2b", "ingredient2": "Eltrombopag", "severity": "Major", "effect": "In chronic hepatitis C patients with advanced liver disease, coadministration of eltrombopag with interferon-based therapy may increase the risk of adverse reactions including potentially fatal hepatic decompensation and thromboembolic events.", "source": "DDInter", "management_text": "In chronic hepatitis C patients with poor liver function (albumin levels <=3.5 g/L or MELD score >=10) at baseline, eltrombopag should only be administered with interferon-based therapy after careful consideration of the potential benefits versus associated risks, and patients should be monitored closely for signs and symptoms of hepatic decompensation. Eltrombopag should be discontinued if antiviral therapy is withdrawn for hepatic decompensation.", "mechanism_text": "Others", "recommendation": "In chronic hepatitis C patients with poor liver function (albumin levels <=3.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97663/", "reference_text": "[1] \"Product Information. Promacta (eltrombopag).\" GlaxoSmithKline, Research Triangle Park, NC.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] Cerner Multum, Inc. \"Australian Product Information.\" O 0[4] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[5] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[6] \"Product Information. Promacta (eltrombopag).\" GlaxoSmithKline, Research Triangle Park, NC.", "alternatives_a": "Oprelvekin, Sipuleucel-T, Elapegademase, Ropeginterferon alfa-2b, Sargramostim, Histamine, Aldesleukin, Pegademase, Pegfilgrastim, Filgrastim, Glatiramer", "alternatives_b": "Romiplostim, Fostamatinib, Avatrombopag, Emicizumab, Coagulation factor VIIa Recombinant Human, Coagulation factor X human, Phylloquinone, Lusutrombopag, Anti-inhibitor coagulant complex, Antihemophilic factor, human recombinant, Fibrinogen human, More", "updated_at": 1767369485}, {"id": 97560, "ingredient1": "Interferon alfa-n1", "ingredient2": "Eltrombopag", "severity": "Major", "effect": "In chronic hepatitis C patients with advanced liver disease, coadministration of eltrombopag with interferon-based therapy may increase the risk of adverse reactions including potentially fatal hepatic decompensation and thromboembolic events.", "source": "DDInter", "management_text": "In chronic hepatitis C patients with poor liver function (albumin levels <=3.5 g/L or MELD score >=10) at baseline, eltrombopag should only be administered with interferon-based therapy after careful consideration of the potential benefits versus associated risks, and patients should be monitored closely for signs and symptoms of hepatic decompensation. Eltrombopag should be discontinued if antiviral therapy is withdrawn for hepatic decompensation.", "mechanism_text": "Others", "recommendation": "In chronic hepatitis C patients with poor liver function (albumin levels <=3.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97664/", "reference_text": "[1] \"Product Information. Promacta (eltrombopag).\" GlaxoSmithKline, Research Triangle Park, NC.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] Cerner Multum, Inc. \"Australian Product Information.\" O 0[4] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[5] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[6] \"Product Information. Promacta (eltrombopag).\" GlaxoSmithKline, Research Triangle Park, NC.", "alternatives_a": "Oprelvekin, Sipuleucel-T, Elapegademase, Ropeginterferon alfa-2b, Sargramostim, Histamine, Aldesleukin, Pegademase, Pegfilgrastim, Filgrastim, Glatiramer", "alternatives_b": "Romiplostim, Fostamatinib, Emicizumab, Coagulation factor VIIa Recombinant Human, Coagulation factor X human, Phylloquinone, Lusutrombopag, Anti-inhibitor coagulant complex, Antihemophilic factor, human recombinant, Fibrinogen human, Epinephrine, Coagulation Factor IX Human", "updated_at": 1767369485}, {"id": 97561, "ingredient1": "Interferon alfacon-1", "ingredient2": "Eltrombopag", "severity": "Major", "effect": "In chronic hepatitis C patients with advanced liver disease, coadministration of eltrombopag with interferon-based therapy may increase the risk of adverse reactions including potentially fatal hepatic decompensation and thromboembolic events.", "source": "DDInter", "management_text": "In chronic hepatitis C patients with poor liver function (albumin levels <=3.5 g/L or MELD score >=10) at baseline, eltrombopag should only be administered with interferon-based therapy after careful consideration of the potential benefits versus associated risks, and patients should be monitored closely for signs and symptoms of hepatic decompensation. Eltrombopag should be discontinued if antiviral therapy is withdrawn for hepatic decompensation.", "mechanism_text": "Others", "recommendation": "In chronic hepatitis C patients with poor liver function (albumin levels <=3.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97665/", "reference_text": "[1] \"Product Information. Promacta (eltrombopag).\" GlaxoSmithKline, Research Triangle Park, NC.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] Cerner Multum, Inc. \"Australian Product Information.\" O 0[4] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[5] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[6] \"Product Information. Promacta (eltrombopag).\" GlaxoSmithKline, Research Triangle Park, NC.", "alternatives_a": "Oprelvekin, Sipuleucel-T, Elapegademase, Ropeginterferon alfa-2b, Sargramostim, Histamine, Aldesleukin, Pegademase, Pegfilgrastim, Filgrastim, Glatiramer", "alternatives_b": "Romiplostim, Fostamatinib, Emicizumab, Coagulation factor VIIa Recombinant Human, Coagulation factor X human, Phylloquinone, Lusutrombopag, Anti-inhibitor coagulant complex, Antihemophilic factor, human recombinant, Fibrinogen human, Epinephrine, Coagulation Factor IX Human", "updated_at": 1767369485}, {"id": 97562, "ingredient1": "Interferon beta-1a", "ingredient2": "Eltrombopag", "severity": "Moderate", "effect": "Coadministration of beta interferons with other agents known to induce hepatotoxicity may potentiate the risk of liver injury. Use of beta interferons has been associated with rare cases of liver injury, including autoimmune hepatitis and severe liver damage leading to hepatic failure, some of which required transplantation.", "source": "DDInter", "management_text": "The risk of hepatic injury should be considered when beta interferons are used with other potentially hepatotoxic agents (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; other interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; nucleoside reverse transcriptase inhibitors; proteasome inhibitors; retinoids; sulfonamides; tamoxifen; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice). Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice.", "mechanism_text": "Synergism", "recommendation": "The risk of hepatic injury should be considered when beta interferons are used with other potentially hepatotoxic agents (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97666/", "reference_text": "[1] \"Product Information. Plegridy (peginterferon beta-1a).\" Biogen Idec Inc, Cambridge, MA.[2] \"Product Information. Betaseron (interferon beta-1b).\" Berlex, Richmond, CA.[3] \"Product Information. Rebif (interferon beta-1a).\" Serono Laboratories Inc, Norwell, MA.[4] \"Product Information. Avonex (interferon beta-1a).\" Biogen, Cambridge, MA.", "alternatives_a": "Oprelvekin, Sipuleucel-T, Elapegademase, Ropeginterferon alfa-2b, Sargramostim, Histamine, Aldesleukin, Pegademase, Pegfilgrastim, Filgrastim, Glatiramer", "alternatives_b": "Romiplostim, Emicizumab, Coagulation factor VIIa Recombinant Human, Coagulation factor X human, Phylloquinone, Lusutrombopag, Anti-inhibitor coagulant complex, Antihemophilic factor, human recombinant, Fibrinogen human, Epinephrine, Coagulation Factor IX Human", "updated_at": 1767369485}, {"id": 97563, "ingredient1": "Interferon beta-1b", "ingredient2": "Eltrombopag", "severity": "Moderate", "effect": "Coadministration of beta interferons with other agents known to induce hepatotoxicity may potentiate the risk of liver injury. Use of beta interferons has been associated with rare cases of liver injury, including autoimmune hepatitis and severe liver damage leading to hepatic failure, some of which required transplantation.", "source": "DDInter", "management_text": "The risk of hepatic injury should be considered when beta interferons are used with other potentially hepatotoxic agents (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; other interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; nucleoside reverse transcriptase inhibitors; proteasome inhibitors; retinoids; sulfonamides; tamoxifen; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice). Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice.", "mechanism_text": "Synergism", "recommendation": "The risk of hepatic injury should be considered when beta interferons are used with other potentially hepatotoxic agents (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97667/", "reference_text": "[1] \"Product Information. Plegridy (peginterferon beta-1a).\" Biogen Idec Inc, Cambridge, MA.[2] \"Product Information. Betaseron (interferon beta-1b).\" Berlex, Richmond, CA.[3] \"Product Information. Rebif (interferon beta-1a).\" Serono Laboratories Inc, Norwell, MA.[4] \"Product Information. Avonex (interferon beta-1a).\" Biogen, Cambridge, MA.", "alternatives_a": "Oprelvekin, Sipuleucel-T, Elapegademase, Ropeginterferon alfa-2b, Sargramostim, Histamine, Aldesleukin, Pegademase, Pegfilgrastim, Filgrastim, Glatiramer", "alternatives_b": "Romiplostim, Emicizumab, Coagulation factor VIIa Recombinant Human, Coagulation factor X human, Phylloquinone, Lusutrombopag, Anti-inhibitor coagulant complex, Antihemophilic factor, human recombinant, Fibrinogen human, Epinephrine, Coagulation Factor IX Human", "updated_at": 1767369485}, {"id": 97564, "ingredient1": "Irinotecan", "ingredient2": "Eltrombopag", "severity": "Moderate", "effect": "Coadministration with eltrombopag may increase the plasma concentrations of drugs that are substrates of the organic anion transporting polypeptide (OATP) 1B1 and/or breast cancer resistance protein (BCRP) transporters. The mechanism is decreased clearance due to inhibition of OATP1B1-mediated hepatic uptake and BCRP-mediated intestinal and hepatobiliary efflux by eltrombopag. The interaction has been demonstrated for rosuvastatin, a known substrate of both OATP 1B1 and BCRP.", "source": "DDInter", "management_text": "Caution is advised during concomitant use of eltrombopag with drugs that are substrates of the OATP1B1 and/or BCRP transporters, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever eltrombopag is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised during concomitant use of eltrombopag with drugs that are substrates of the OATP1B1 and/or BCRP transporters, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97668/", "reference_text": "[1] Allred AJ, Bowen CJ, Park JW, et al. \"Eltrombopag increases plasma rosuvastatin exposure in healthy volunteers.\" Br J Clin Pharmacol 72 (2011): 321-9[2] Kalliokoski A, Niemi M \"Impact of OATP transporters on pharmacokinetics.\" Br J Pharmacol 158 (2009): 693-705[3] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[4] \"Product Information. Promacta (eltrombopag).\" GlaxoSmithKline, Research Triangle Park, NC.[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[7] \"Product Information. Promacta (eltrombopag).\" GlaxoSmithKline, Research Triangle Park, NC.", "alternatives_a": "Vincristine, Cabazitaxel, Vinblastine, Paclitaxel, Teniposide, Vinorelbine, Etoposide, Docetaxel", "alternatives_b": "Romiplostim, Avatrombopag, Emicizumab, Coagulation factor VIIa Recombinant Human, Coagulation factor X human, Phylloquinone, Lusutrombopag, Anti-inhibitor coagulant complex, Antihemophilic factor, human recombinant, Fibrinogen human, Epinephrine, Coagulation Factor IX Human", "updated_at": 1767369485}, {"id": 97565, "ingredient1": "Irinotecan (liposomal)", "ingredient2": "Eltrombopag", "severity": "Moderate", "effect": "Coadministration with eltrombopag may increase the plasma concentrations of drugs that are substrates of the organic anion transporting polypeptide (OATP) 1B1 and/or breast cancer resistance protein (BCRP) transporters. The mechanism is decreased clearance due to inhibition of OATP1B1-mediated hepatic uptake and BCRP-mediated intestinal and hepatobiliary efflux by eltrombopag. The interaction has been demonstrated for rosuvastatin, a known substrate of both OATP 1B1 and BCRP.", "source": "DDInter", "management_text": "Caution is advised during concomitant use of eltrombopag with drugs that are substrates of the OATP1B1 and/or BCRP transporters, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever eltrombopag is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised during concomitant use of eltrombopag with drugs that are substrates of the OATP1B1 and/or BCRP transporters, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97669/", "reference_text": "[1] Allred AJ, Bowen CJ, Park JW, et al. \"Eltrombopag increases plasma rosuvastatin exposure in healthy volunteers.\" Br J Clin Pharmacol 72 (2011): 321-9[2] Kalliokoski A, Niemi M \"Impact of OATP transporters on pharmacokinetics.\" Br J Pharmacol 158 (2009): 693-705[3] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[4] \"Product Information. Promacta (eltrombopag).\" GlaxoSmithKline, Research Triangle Park, NC.[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[7] \"Product Information. Promacta (eltrombopag).\" GlaxoSmithKline, Research Triangle Park, NC.", "alternatives_a": "Vincristine, Cabazitaxel, Vinblastine, Paclitaxel, Teniposide, Vinorelbine, Etoposide, Docetaxel", "alternatives_b": "Romiplostim, Avatrombopag, Emicizumab, Coagulation factor VIIa Recombinant Human, Coagulation factor X human, Phylloquinone, Lusutrombopag, Anti-inhibitor coagulant complex, Antihemophilic factor, human recombinant, Fibrinogen human, Epinephrine, Coagulation Factor IX Human", "updated_at": 1767369485}, {"id": 97566, "ingredient1": "Iron protein succinylate", "ingredient2": "Eltrombopag", "severity": "Moderate", "effect": "INTERVAL: Products containing aluminum, calcium, iron, magnesium, zinc and other polyvalent cations such as antacids or mineral supplements can significantly reduce the gastrointestinal absorption of eltrombopag due to chelation.", "source": "DDInter", "management_text": "Eltrombopag should be taken on an empty stomach at least 2 hours before or 4 hours after oral medications that contain antacids (e.g., didanosine buffered tablets or pediatric oral solution), aluminum, calcium, iron, magnesium, zinc or other polyvalent cations.", "mechanism_text": "Absorption", "recommendation": "Eltrombopag should be taken on an empty stomach at least 2 hours before or 4 hours after oral medications that contain antacids (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97670/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Promacta (eltrombopag).\" GlaxoSmithKline, Research Triangle Park, NC.[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] \"Product Information. Promacta (eltrombopag).\" GlaxoSmithKline, Research Triangle Park, NC.", "alternatives_a": "Romiplostim, Fostamatinib, Avatrombopag, Emicizumab, Coagulation factor VIIa Recombinant Human, Coagulation factor X human, Phylloquinone, Lusutrombopag, Anti-inhibitor coagulant complex, Antihemophilic factor, human recombinant, Fibrinogen human, More", "alternatives_b": "Iron sucrose, Cyanocobalamin, Folic acid", "updated_at": 1767369485}, {"id": 97567, "ingredient1": "Eltrombopag", "ingredient2": "Kaolin", "severity": "Moderate", "effect": "INTERVAL: Products containing aluminum, calcium, iron, magnesium, zinc and other polyvalent cations such as antacids or mineral supplements can significantly reduce the gastrointestinal absorption of eltrombopag due to chelation.", "source": "DDInter", "management_text": "Eltrombopag should be taken on an empty stomach at least 2 hours before or 4 hours after oral medications that contain antacids (e.g., didanosine buffered tablets or pediatric oral solution), aluminum, calcium, iron, magnesium, zinc or other polyvalent cations.", "mechanism_text": "Absorption", "recommendation": "Eltrombopag should be taken on an empty stomach at least 2 hours before or 4 hours after oral medications that contain antacids (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97671/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Promacta (eltrombopag).\" GlaxoSmithKline, Research Triangle Park, NC.[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] \"Product Information. Promacta (eltrombopag).\" GlaxoSmithKline, Research Triangle Park, NC.", "alternatives_a": "Pectin, Activated charcoal", "alternatives_b": "Romiplostim, Fostamatinib, Avatrombopag, Emicizumab, Coagulation factor VIIa Recombinant Human, Coagulation factor X human, Phylloquinone, Lusutrombopag, Anti-inhibitor coagulant complex, Antihemophilic factor, human recombinant, Fibrinogen human, More", "updated_at": 1767369485}, {"id": 97568, "ingredient1": "Eltrombopag", "ingredient2": "Lapatinib", "severity": "Moderate", "effect": "Coadministration with eltrombopag may increase the plasma concentrations of drugs that are substrates of the organic anion transporting polypeptide (OATP) 1B1 and/or breast cancer resistance protein (BCRP) transporters. The mechanism is decreased clearance due to inhibition of OATP1B1-mediated hepatic uptake and BCRP-mediated intestinal and hepatobiliary efflux by eltrombopag. The interaction has been demonstrated for rosuvastatin, a known substrate of both OATP 1B1 and BCRP.", "source": "DDInter", "management_text": "Caution is advised during concomitant use of eltrombopag with drugs that are substrates of the OATP1B1 and/or BCRP transporters, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever eltrombopag is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised during concomitant use of eltrombopag with drugs that are substrates of the OATP1B1 and/or BCRP transporters, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97672/", "reference_text": "[1] Allred AJ, Bowen CJ, Park JW, et al. \"Eltrombopag increases plasma rosuvastatin exposure in healthy volunteers.\" Br J Clin Pharmacol 72 (2011): 321-9[2] Kalliokoski A, Niemi M \"Impact of OATP transporters on pharmacokinetics.\" Br J Pharmacol 158 (2009): 693-705[3] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[4] \"Product Information. Promacta (eltrombopag).\" GlaxoSmithKline, Research Triangle Park, NC.[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[7] \"Product Information. Promacta (eltrombopag).\" GlaxoSmithKline, Research Triangle Park, NC.", "alternatives_a": "Dabrafenib, Asciminib, Acalabrutinib, Dacomitinib, Tepotinib, Fedratinib, Avapritinib, Bosutinib, Vemurafenib, Selumetinib, Vandetanib, More", "alternatives_b": "Romiplostim, Avatrombopag, Emicizumab, Coagulation factor VIIa Recombinant Human, Coagulation factor X human, Phylloquinone, Anti-inhibitor coagulant complex, Antihemophilic factor, human recombinant, Fibrinogen human, Epinephrine, Coagulation Factor IX Human", "updated_at": 1767369485}, {"id": 97569, "ingredient1": "Eltrombopag", "ingredient2": "Larotrectinib", "severity": "Moderate", "effect": "Coadministration with eltrombopag may increase the plasma concentrations of drugs that are substrates of the organic anion transporting polypeptide (OATP) 1B1 and/or breast cancer resistance protein (BCRP) transporters. The mechanism is decreased clearance due to inhibition of OATP1B1-mediated hepatic uptake and BCRP-mediated intestinal and hepatobiliary efflux by eltrombopag. The interaction has been demonstrated for rosuvastatin, a known substrate of both OATP 1B1 and BCRP.", "source": "DDInter", "management_text": "Caution is advised during concomitant use of eltrombopag with drugs that are substrates of the OATP1B1 and/or BCRP transporters, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever eltrombopag is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised during concomitant use of eltrombopag with drugs that are substrates of the OATP1B1 and/or BCRP transporters, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97673/", "reference_text": "[1] Allred AJ, Bowen CJ, Park JW, et al. \"Eltrombopag increases plasma rosuvastatin exposure in healthy volunteers.\" Br J Clin Pharmacol 72 (2011): 321-9[2] Kalliokoski A, Niemi M \"Impact of OATP transporters on pharmacokinetics.\" Br J Pharmacol 158 (2009): 693-705[3] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[4] \"Product Information. Promacta (eltrombopag).\" GlaxoSmithKline, Research Triangle Park, NC.[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[7] \"Product Information. Promacta (eltrombopag).\" GlaxoSmithKline, Research Triangle Park, NC.", "alternatives_a": "Romiplostim, Avatrombopag, Emicizumab, Coagulation factor VIIa Recombinant Human, Coagulation factor X human, Phylloquinone, Lusutrombopag, Anti-inhibitor coagulant complex, Antihemophilic factor, human recombinant, Fibrinogen human, Epinephrine, Coagulation Factor IX Human", "alternatives_b": "Dabrafenib, Asciminib, Acalabrutinib, Dacomitinib, Tepotinib, Fedratinib, Avapritinib, Bosutinib, Vemurafenib, Selumetinib, Vandetanib, More", "updated_at": 1767369485}, {"id": 97570, "ingredient1": "Eltrombopag", "ingredient2": "Lasmiditan", "severity": "Moderate", "effect": "Coadministration with lasmiditan may increase the plasma concentrations of drugs that are substrates of the P-glycoprotein (P-gp) and/or breast cancer resistance protein (BCRP) transporters. The proposed mechanism, based on in vitro data, involves decreased clearance due to inhibition of P-gp and BCRP by lasmiditan.", "source": "DDInter", "management_text": "Concomitant use of lasmiditan with drugs that are P-gp and/or BCRP substrates should be avoided when possible. If coadministration is required, patients should be carefully monitored for increased adverse reactions of these drugs and dosing adjusted as necessary.", "mechanism_text": "Distribution", "recommendation": "Concomitant use of lasmiditan with drugs that are P-gp and/or BCRP substrates should be avoided when possible.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97674/", "reference_text": "[1] \"Product Information. Reyvow (lasmiditan).\" Lilly, Eli and Company, Indianapolis, IN.", "alternatives_a": "Romiplostim, Fostamatinib, Avatrombopag, Emicizumab, Coagulation factor VIIa Recombinant Human, Coagulation factor X human, Phylloquinone, Anti-inhibitor coagulant complex, Antihemophilic factor, human recombinant, Fibrinogen human, Epinephrine, Coagulation Factor IX Human", "alternatives_b": "Frovatriptan, Dihydroergotamine, Eptinezumab, Eletriptan, Rizatriptan, Ergotamine, Clonidine, Naratriptan, Galcanezumab, Zolmitriptan, Sumatriptan, More", "updated_at": 1767369485}, {"id": 97571, "ingredient1": "Eltrombopag", "ingredient2": "Leflunomide", "severity": "Major", "effect": "The recent, concomitant, or subsequent use (without the recommended leflunomide washout period or procedure) of other agents known to induce hepatotoxicity may potentiate the risk of liver injury associated with leflunomide. The risk is thought to extend to teriflunomide, its principal active metabolite, because recommended dosages of both result in a similar range of plasma concentrations of teriflunomide.", "source": "DDInter", "management_text": "Caution is advised if leflunomide or teriflunomide must be used in patients who are currently receiving or have recently received treatment with other hepatotoxic agents (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; nucleoside reverse transcriptase inhibitors; proteasome inhibitors; retinoids; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice), and vice versa. Liver enzymes and bilirubin should be measured prior to initiation of leflunomide/teriflunomide therapy and at least monthly for the first six months of treatment and every 6 to 8 weeks thereafter. Patients with preexisting liver disease or elevated baseline liver enzymes (i.e., ALT greater than two times ULN) should not receive leflunomide or teriflunomide. Patients who develop elevated serum ALT greater than three times ULN while receiving these medications should discontinue treatment and be given washout procedures with cholestyramine or activated charcoal to accelerate elimination of leflunomide's active metabolite from plasma, which otherwise may take up to two years. Follow-up monitoring should be conducted at least weekly until the ALT value is within normal range, and washout procedures repeated as necessary. All patients treated with leflunomide or teriflunomide should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if leflunomide or teriflunomide must be used in patients who are currently receiving or have recently received treatment with other hepatotoxic agents (e.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97675/", "reference_text": "[1] EMEA \"EMEA public statement on leflunomide (ARAVA) - severe and serious hepatic reactions. Available from URL: http://www.eudra.org/emea.html.\" ([1999 Sept 2]):[2] \"Product Information. Arava (leflunomide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[3] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"", "alternatives_a": "Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Tacrolimus, More", "alternatives_b": "Romiplostim, Avatrombopag, Emicizumab, Coagulation factor VIIa Recombinant Human, Coagulation factor X human, Phylloquinone, Lusutrombopag, Anti-inhibitor coagulant complex, Antihemophilic factor, human recombinant, Fibrinogen human, Epinephrine, Coagulation Factor IX Human", "updated_at": 1767369485}, {"id": 97572, "ingredient1": "Eltrombopag", "ingredient2": "Lomitapide", "severity": "Major", "effect": "Coadministration of lomitapide with other agents known to induce hepatotoxicity may potentiate the risk of liver injury. Lomitapide can cause elevations in serum transaminases and hepatic steatosis. Clinical data suggest that hepatic fat accumulation is reversible after stopping treatment with lomitapide, although the long-term consequences are unknown.", "source": "DDInter", "management_text": "Caution is advised if lomitapide is used with other potentially hepatotoxic agents (e.g., acetaminophen; alcohol; amiodarone; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; methotrexate; nonsteroidal anti-inflammatory agents; nucleoside reverse transcriptase inhibitors; proteasome inhibitors; retinoids; tamoxifen; tetracyclines; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; other lipid-lowering medications such as fenofibrate, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice). Patients treated with lomitapide should have serum ALT, AST, alkaline phosphatase, and total bilirubin measured prior to initiation of treatment and regularly during treatment in accordance with the product labeling, and the dosing adjusted or interrupted as necessary. Since alcohol may increase levels of hepatic fat and induce or exacerbate liver injury, the manufacturer recommends that patients taking lomitapide not consume more than one alcoholic drink per day. Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if lomitapide is used with other potentially hepatotoxic agents (e.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97676/", "reference_text": "[1] \"Product Information. Juxtapid (lomitapide).\" Aegerion Pharmaceuticals Inc, Cambridge, MA.[2] \"Product Information. Juxtapid (lomitapide).\" Aegerion Pharmaceuticals Inc, Cambridge, MA.", "alternatives_a": "Romiplostim, Avatrombopag, Emicizumab, Coagulation factor VIIa Recombinant Human, Coagulation factor X human, Phylloquinone, Anti-inhibitor coagulant complex, Antihemophilic factor, human recombinant, Fibrinogen human, Epinephrine, Coagulation Factor IX Human", "alternatives_b": "Gemfibrozil, Fenofibric acid, Evinacumab, Evolocumab, Probucol, Dextrothyroxine, Cholestyramine, Clofibrate, Colestipol, Niacin, Fenofibrate, More", "updated_at": 1767369485}, {"id": 97573, "ingredient1": "Eltrombopag", "ingredient2": "Lorlatinib", "severity": "Moderate", "effect": "Coadministration with lorlatinib may decrease the plasma concentrations of drugs that are substrates of the uridine diphosphate glucuronosyl transferase (UGT) enzymes. The proposed mechanism involves decreased metabolic clearance due to induction of UGT by lorlatinib.", "source": "DDInter", "management_text": "Caution is advised when lorlatinib is used concurrently with drugs that are known UGT substrates, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever lorlatinib is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when lorlatinib is used concurrently with drugs that are known UGT substrates, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97677/", "reference_text": "[1] Cerner Multum, Inc. \"Australian Product Information.\" O 0[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Lorbrena (lorlatinib).\" Pfizer U.S. Pharmaceuticals Group, New York, NY.[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] \"Product Information. Lorbrena (lorlatinib).\" Pfizer U.S. Pharmaceuticals Group, New York, NY.", "alternatives_a": "Romiplostim, Avatrombopag, Emicizumab, Coagulation factor VIIa Recombinant Human, Coagulation factor X human, Phylloquinone, Lusutrombopag, Anti-inhibitor coagulant complex, Antihemophilic factor, human recombinant, Fibrinogen human, Epinephrine, Coagulation Factor IX Human", "alternatives_b": "Dabrafenib, Asciminib, Acalabrutinib, Dacomitinib, Tepotinib, Fedratinib, Avapritinib, Bosutinib, Vemurafenib, Selumetinib, Vandetanib, More", "updated_at": 1767369485}, {"id": 97574, "ingredient1": "Eltrombopag", "ingredient2": "Lovastatin", "severity": "Moderate", "effect": "Coadministration with eltrombopag may increase the plasma concentrations of HMG-CoA reductase inhibitors (statins). The proposed mechanism is decreased clearance due to eltrombopag inhibition of the OATP 1B1-mediated hepatic uptake of statins and/or their metabolites (e.g., simvastatin acid), with fluvastatin the least likely to be significantly affected. High levels of HMG-CoA reductase inhibitory activity in plasma is associated with an increased risk of musculoskeletal toxicity. Myopathy manifested as muscle pain and/or weakness associated with grossly elevated creatine kinase exceeding ten times the upper limit of normal has been reported occasionally.", "source": "DDInter", "management_text": "Lower statin dosages should be considered during coadministration with eltrombopag. In clinical trials with eltrombopag, a dosage reduction of rosuvastatin by 50% was recommended. No specific adjustment recommendations were given for the others. All patients receiving statin therapy should be advised to promptly report any unexplained muscle pain, tenderness or weakness, particularly if accompanied by fever, malaise and/or dark colored urine. Therapy should be discontinued if creatine kinase is markedly elevated in the absence of strenuous exercise or if myopathy is otherwise suspected or diagnosed.", "mechanism_text": "Excretion", "recommendation": "Lower statin dosages should be considered during coadministration with eltrombopag.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97678/", "reference_text": "[1] Allred AJ, Bowen CJ, Park JW, et al. \"Eltrombopag increases plasma rosuvastatin exposure in healthy volunteers.\" Br J Clin Pharmacol 72 (2011): 321-9[2] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[3] Cerner Multum, Inc. \"Australian Product Information.\" O 0[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] Kalliokoski A, Niemi M \"Impact of OATP transporters on pharmacokinetics.\" Br J Pharmacol 158 (2009): 693-705[6] \"Product Information. Promacta (eltrombopag).\" GlaxoSmithKline, Research Triangle Park, NC.[7] Richter WO, Jacob BG, Schwandt P \"Interaction between fibre and lovastatin.\" Lancet 338 (1991): 706[8] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors.\" Clin Pharmacol Ther 64 (1998): 477-83[9] Kantola T, Kivisto KT, Neuvonen PJ \"Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid.\" Clin Pharmacol Ther 63 (1998): 397-402[10] \"Product Information. Mevacor (lovastatin).\" Merck & Co, Inc, West Point, PA.[11] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions.\" Br J Clin Pharmacol 46 (1998): 101-10[12] Neuvonen PJ, Backman JT, Niemi M \"Pharmacokinetic comparison of the potential over-the-counter statins simvastatin, lovastatin, fluvastatin and pravastatin.\" Clin Pharmacokinet 47 (2008): 463-74[13] Thompson PD, Clarkson P, Karas RH \"Statin-associated myopathy.\" JAMA 289 (2003): 1681-90[14] \"Product Information. Zocor (simvastatin).\" Merck & Co, Inc, West Point, PA.[15] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[16] \"Product Information. Promacta (eltrombopag).\" GlaxoSmithKline, Research Triangle Park, NC.", "alternatives_a": "Gemfibrozil, Fenofibric acid, Evinacumab, Evolocumab, Probucol, Dextrothyroxine, Cholestyramine, Clofibrate, Colestipol, Niacin, Fenofibrate, More", "alternatives_b": "Romiplostim, Avatrombopag, Emicizumab, Coagulation factor VIIa Recombinant Human, Coagulation factor X human, Phylloquinone, Anti-inhibitor coagulant complex, Antihemophilic factor, human recombinant, Fibrinogen human, Coagulation Factor IX Human", "updated_at": 1767369485}, {"id": 97575, "ingredient1": "Eltrombopag", "ingredient2": "Lumateperone", "severity": "Moderate", "effect": "Coadministration of lumateperone with uridine diphosphate glucuronosyltransferase (UGT) inhibitors may increase the plasma concentrations of lumateperone, which is metabolized by the enzyme in vitro.", "source": "DDInter", "management_text": "The use of lumateperone with UGT inhibitors should be avoided.", "mechanism_text": "Metabolism", "recommendation": "The use of lumateperone with UGT inhibitors should be avoided.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97679/", "reference_text": "[1] \"Product Information. Caplyta (lumateperone).\" Intra-Cellular Therapies, Inc., New York, NY.[2] \"Product Information. Nexavar (sorafenib).\" Bayer Pharmaceutical Inc, West Haven, CT.[3] \"Product Information. Caplyta (lumateperone).\" Intra-Cellular Therapies, Inc., New York, NY.", "alternatives_a": "Fluphenazine, Haloperidol, Thiothixene, Risperidone, Amisulpride, Quetiapine, Prochlorperazine, Promazine, Thioridazine, Pimozide, Trifluoperazine, More", "alternatives_b": "Romiplostim, Avatrombopag, Emicizumab, Coagulation factor VIIa Recombinant Human, Coagulation factor X human, Phylloquinone, Lusutrombopag, Anti-inhibitor coagulant complex, Antihemophilic factor, human recombinant, Fibrinogen human, Coagulation Factor IX Human", "updated_at": 1767369485}, {"id": 97576, "ingredient1": "Eltrombopag", "ingredient2": "Lusutrombopag", "severity": "Moderate", "effect": "Coadministration with eltrombopag may increase the plasma concentrations of drugs that are substrates of the organic anion transporting polypeptide (OATP) 1B1 and/or breast cancer resistance protein (BCRP) transporters. The mechanism is decreased clearance due to inhibition of OATP1B1-mediated hepatic uptake and BCRP-mediated intestinal and hepatobiliary efflux by eltrombopag. The interaction has been demonstrated for rosuvastatin, a known substrate of both OATP 1B1 and BCRP.", "source": "DDInter", "management_text": "Caution is advised during concomitant use of eltrombopag with drugs that are substrates of the OATP1B1 and/or BCRP transporters, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever eltrombopag is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised during concomitant use of eltrombopag with drugs that are substrates of the OATP1B1 and/or BCRP transporters, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97680/", "reference_text": "[1] Allred AJ, Bowen CJ, Park JW, et al. \"Eltrombopag increases plasma rosuvastatin exposure in healthy volunteers.\" Br J Clin Pharmacol 72 (2011): 321-9[2] Kalliokoski A, Niemi M \"Impact of OATP transporters on pharmacokinetics.\" Br J Pharmacol 158 (2009): 693-705[3] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[4] \"Product Information. Promacta (eltrombopag).\" GlaxoSmithKline, Research Triangle Park, NC.[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[7] \"Product Information. Promacta (eltrombopag).\" GlaxoSmithKline, Research Triangle Park, NC.", "alternatives_a": "Romiplostim, Avatrombopag, Emicizumab, Coagulation factor VIIa Recombinant Human, Coagulation factor X human, Phylloquinone, Lusutrombopag, Anti-inhibitor coagulant complex, Antihemophilic factor, human recombinant, Fibrinogen human, Epinephrine, Coagulation Factor IX Human", "alternatives_b": "Eltrombopag, Romiplostim, Fostamatinib, Avatrombopag, Emicizumab, Coagulation factor VIIa Recombinant Human, Coagulation factor X human, Phylloquinone, Anti-inhibitor coagulant complex, Antihemophilic factor, human recombinant, Fibrinogen human, More", "updated_at": 1767369485}, {"id": 97577, "ingredient1": "Eltrombopag", "ingredient2": "Magaldrate", "severity": "Moderate", "effect": "INTERVAL: Products containing aluminum, calcium, iron, magnesium, zinc and other polyvalent cations such as antacids or mineral supplements can significantly reduce the gastrointestinal absorption of eltrombopag due to chelation.", "source": "DDInter", "management_text": "Eltrombopag should be taken on an empty stomach at least 2 hours before or 4 hours after oral medications that contain antacids (e.g., didanosine buffered tablets or pediatric oral solution), aluminum, calcium, iron, magnesium, zinc or other polyvalent cations.", "mechanism_text": "Absorption", "recommendation": "Eltrombopag should be taken on an empty stomach at least 2 hours before or 4 hours after oral medications that contain antacids (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97681/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Promacta (eltrombopag).\" GlaxoSmithKline, Research Triangle Park, NC.[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] \"Product Information. Promacta (eltrombopag).\" GlaxoSmithKline, Research Triangle Park, NC.", "alternatives_a": "Romiplostim, Fostamatinib, Avatrombopag, Emicizumab, Coagulation factor VIIa Recombinant Human, Coagulation factor X human, Phylloquinone, Lusutrombopag, Anti-inhibitor coagulant complex, Antihemophilic factor, human recombinant, Fibrinogen human, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 97578, "ingredient1": "Eltrombopag", "ingredient2": "Magnesium carbonate", "severity": "Moderate", "effect": "INTERVAL: Products containing aluminum, calcium, iron, magnesium, zinc and other polyvalent cations such as antacids or mineral supplements can significantly reduce the gastrointestinal absorption of eltrombopag due to chelation.", "source": "DDInter", "management_text": "Eltrombopag should be taken on an empty stomach at least 2 hours before or 4 hours after oral medications that contain antacids (e.g., didanosine buffered tablets or pediatric oral solution), aluminum, calcium, iron, magnesium, zinc or other polyvalent cations.", "mechanism_text": "Absorption", "recommendation": "Eltrombopag should be taken on an empty stomach at least 2 hours before or 4 hours after oral medications that contain antacids (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97682/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Promacta (eltrombopag).\" GlaxoSmithKline, Research Triangle Park, NC.[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] \"Product Information. Promacta (eltrombopag).\" GlaxoSmithKline, Research Triangle Park, NC.", "alternatives_a": "Romiplostim, Fostamatinib, Avatrombopag, Emicizumab, Coagulation factor VIIa Recombinant Human, Coagulation factor X human, Phylloquinone, Lusutrombopag, Anti-inhibitor coagulant complex, Antihemophilic factor, human recombinant, Fibrinogen human, More", "alternatives_b": "Hydroxocobalamin, Fomepizole, Ipecac, Nitrous acid, Dexrazoxane, Oxygen, Lanthanum carbonate, Difelikefalin, Cobicistat, Deferoxamine, Levoleucovorin, More", "updated_at": 1767369485}, {"id": 97579, "ingredient1": "Eltrombopag", "ingredient2": "Magnesium chloride", "severity": "Moderate", "effect": "INTERVAL: Products containing aluminum, calcium, iron, magnesium, zinc and other polyvalent cations such as antacids or mineral supplements can significantly reduce the gastrointestinal absorption of eltrombopag due to chelation.", "source": "DDInter", "management_text": "Eltrombopag should be taken on an empty stomach at least 2 hours before or 4 hours after oral medications that contain antacids (e.g., didanosine buffered tablets or pediatric oral solution), aluminum, calcium, iron, magnesium, zinc or other polyvalent cations.", "mechanism_text": "Absorption", "recommendation": "Eltrombopag should be taken on an empty stomach at least 2 hours before or 4 hours after oral medications that contain antacids (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97683/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Promacta (eltrombopag).\" GlaxoSmithKline, Research Triangle Park, NC.[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] \"Product Information. Promacta (eltrombopag).\" GlaxoSmithKline, Research Triangle Park, NC.", "alternatives_a": "Romiplostim, Fostamatinib, Avatrombopag, Emicizumab, Coagulation factor VIIa Recombinant Human, Coagulation factor X human, Phylloquinone, Lusutrombopag, Anti-inhibitor coagulant complex, Antihemophilic factor, human recombinant, Fibrinogen human, More", "alternatives_b": "Sodium chloride, Sodium sulfate, Calcium chloride, Potassium chloride, Sodium acetate, Arginine, Sodium glycerophosphate, Zinc chloride, Tromethamine, Sodium phosphate, monobasic, Sodium bicarbonate, More", "updated_at": 1767369485}, {"id": 97580, "ingredient1": "Eltrombopag", "ingredient2": "Magnesium citrate", "severity": "Moderate", "effect": "INTERVAL: Products containing aluminum, calcium, iron, magnesium, zinc and other polyvalent cations such as antacids or mineral supplements can significantly reduce the gastrointestinal absorption of eltrombopag due to chelation.", "source": "DDInter", "management_text": "Eltrombopag should be taken on an empty stomach at least 2 hours before or 4 hours after oral medications that contain antacids (e.g., didanosine buffered tablets or pediatric oral solution), aluminum, calcium, iron, magnesium, zinc or other polyvalent cations.", "mechanism_text": "Absorption", "recommendation": "Eltrombopag should be taken on an empty stomach at least 2 hours before or 4 hours after oral medications that contain antacids (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97684/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Promacta (eltrombopag).\" GlaxoSmithKline, Research Triangle Park, NC.[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] \"Product Information. Promacta (eltrombopag).\" GlaxoSmithKline, Research Triangle Park, NC.", "alternatives_a": "Romiplostim, Fostamatinib, Avatrombopag, Emicizumab, Coagulation factor VIIa Recombinant Human, Coagulation factor X human, Phylloquinone, Lusutrombopag, Anti-inhibitor coagulant complex, Antihemophilic factor, human recombinant, Fibrinogen human, More", "alternatives_b": "Sorbitol, Sulfamethizole, Sodium citrate, Mannitol, Sodium bicarbonate, Sodium chloride, Chlorhexidine, Neomycin, Sodium chloride, Sodium sulfate, Alvimopan, More", "updated_at": 1767369485}, {"id": 97581, "ingredient1": "Eltrombopag", "ingredient2": "Magnesium gluconate", "severity": "Moderate", "effect": "INTERVAL: Products containing aluminum, calcium, iron, magnesium, zinc and other polyvalent cations such as antacids or mineral supplements can significantly reduce the gastrointestinal absorption of eltrombopag due to chelation.", "source": "DDInter", "management_text": "Eltrombopag should be taken on an empty stomach at least 2 hours before or 4 hours after oral medications that contain antacids (e.g., didanosine buffered tablets or pediatric oral solution), aluminum, calcium, iron, magnesium, zinc or other polyvalent cations.", "mechanism_text": "Absorption", "recommendation": "Eltrombopag should be taken on an empty stomach at least 2 hours before or 4 hours after oral medications that contain antacids (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97685/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Promacta (eltrombopag).\" GlaxoSmithKline, Research Triangle Park, NC.[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] \"Product Information. Promacta (eltrombopag).\" GlaxoSmithKline, Research Triangle Park, NC.", "alternatives_a": "Romiplostim, Fostamatinib, Avatrombopag, Emicizumab, Coagulation factor VIIa Recombinant Human, Coagulation factor X human, Phylloquinone, Lusutrombopag, Anti-inhibitor coagulant complex, Antihemophilic factor, human recombinant, Fibrinogen human, More", "alternatives_b": "Sodium chloride, Sodium sulfate", "updated_at": 1767369485}, {"id": 97582, "ingredient1": "Eltrombopag", "ingredient2": "Magnesium glycinate", "severity": "Moderate", "effect": "INTERVAL: Products containing aluminum, calcium, iron, magnesium, zinc and other polyvalent cations such as antacids or mineral supplements can significantly reduce the gastrointestinal absorption of eltrombopag due to chelation.", "source": "DDInter", "management_text": "Eltrombopag should be taken on an empty stomach at least 2 hours before or 4 hours after oral medications that contain antacids (e.g., didanosine buffered tablets or pediatric oral solution), aluminum, calcium, iron, magnesium, zinc or other polyvalent cations.", "mechanism_text": "Absorption", "recommendation": "Eltrombopag should be taken on an empty stomach at least 2 hours before or 4 hours after oral medications that contain antacids (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97686/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Promacta (eltrombopag).\" GlaxoSmithKline, Research Triangle Park, NC.[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] \"Product Information. Promacta (eltrombopag).\" GlaxoSmithKline, Research Triangle Park, NC.", "alternatives_a": "Romiplostim, Fostamatinib, Avatrombopag, Emicizumab, Coagulation factor VIIa Recombinant Human, Coagulation factor X human, Phylloquinone, Lusutrombopag, Anti-inhibitor coagulant complex, Antihemophilic factor, human recombinant, Fibrinogen human, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 97583, "ingredient1": "Eltrombopag", "ingredient2": "Magnesium hydroxide", "severity": "Moderate", "effect": "INTERVAL: Products containing aluminum, calcium, iron, magnesium, zinc and other polyvalent cations such as antacids or mineral supplements can significantly reduce the gastrointestinal absorption of eltrombopag due to chelation.", "source": "DDInter", "management_text": "Eltrombopag should be taken on an empty stomach at least 2 hours before or 4 hours after oral medications that contain antacids (e.g., didanosine buffered tablets or pediatric oral solution), aluminum, calcium, iron, magnesium, zinc or other polyvalent cations.", "mechanism_text": "Absorption", "recommendation": "Eltrombopag should be taken on an empty stomach at least 2 hours before or 4 hours after oral medications that contain antacids (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97687/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Promacta (eltrombopag).\" GlaxoSmithKline, Research Triangle Park, NC.[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] \"Product Information. Promacta (eltrombopag).\" GlaxoSmithKline, Research Triangle Park, NC.", "alternatives_a": "Romiplostim, Fostamatinib, Avatrombopag, Emicizumab, Coagulation factor VIIa Recombinant Human, Coagulation factor X human, Phylloquinone, Lusutrombopag, Anti-inhibitor coagulant complex, Antihemophilic factor, human recombinant, Fibrinogen human, More", "alternatives_b": "Darifenacin, Vardenafil, Tadalafil, Ammonium chloride, Apomorphine, Yohimbine, Papaverine, Oxybutynin, Dimethyl sulfoxide, Pentosan polysulfate, Calcium chloride, More", "updated_at": 1767369485}, {"id": 97584, "ingredient1": "Eltrombopag", "ingredient2": "Magnesium sulfate", "severity": "Moderate", "effect": "INTERVAL: Products containing aluminum, calcium, iron, magnesium, zinc and other polyvalent cations such as antacids or mineral supplements can significantly reduce the gastrointestinal absorption of eltrombopag due to chelation.", "source": "DDInter", "management_text": "Eltrombopag should be taken on an empty stomach at least 2 hours before or 4 hours after oral medications that contain antacids (e.g., didanosine buffered tablets or pediatric oral solution), aluminum, calcium, iron, magnesium, zinc or other polyvalent cations.", "mechanism_text": "Absorption", "recommendation": "Eltrombopag should be taken on an empty stomach at least 2 hours before or 4 hours after oral medications that contain antacids (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97688/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Promacta (eltrombopag).\" GlaxoSmithKline, Research Triangle Park, NC.[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] \"Product Information. Promacta (eltrombopag).\" GlaxoSmithKline, Research Triangle Park, NC.", "alternatives_a": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Sodium phosphate, monobasic, Prucalopride, More", "alternatives_b": "Romiplostim, Fostamatinib, Avatrombopag, Emicizumab, Coagulation factor VIIa Recombinant Human, Coagulation factor X human, Phylloquinone, Lusutrombopag, Anti-inhibitor coagulant complex, Antihemophilic factor, human recombinant, Fibrinogen human, More", "updated_at": 1767369485}, {"id": 97585, "ingredient1": "Eltrombopag", "ingredient2": "Methotrexate", "severity": "Moderate", "effect": "Coadministration with eltrombopag may increase the plasma concentrations of drugs that are substrates of the organic anion transporting polypeptide (OATP) 1B1 and/or breast cancer resistance protein (BCRP) transporters. The mechanism is decreased clearance due to inhibition of OATP1B1-mediated hepatic uptake and BCRP-mediated intestinal and hepatobiliary efflux by eltrombopag. The interaction has been demonstrated for rosuvastatin, a known substrate of both OATP 1B1 and BCRP.", "source": "DDInter", "management_text": "Caution is advised during concomitant use of eltrombopag with drugs that are substrates of the OATP1B1 and/or BCRP transporters, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever eltrombopag is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised during concomitant use of eltrombopag with drugs that are substrates of the OATP1B1 and/or BCRP transporters, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97689/", "reference_text": "[1] Allred AJ, Bowen CJ, Park JW, et al. \"Eltrombopag increases plasma rosuvastatin exposure in healthy volunteers.\" Br J Clin Pharmacol 72 (2011): 321-9[2] Kalliokoski A, Niemi M \"Impact of OATP transporters on pharmacokinetics.\" Br J Pharmacol 158 (2009): 693-705[3] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[4] \"Product Information. Promacta (eltrombopag).\" GlaxoSmithKline, Research Triangle Park, NC.[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[7] \"Product Information. Promacta (eltrombopag).\" GlaxoSmithKline, Research Triangle Park, NC.", "alternatives_a": "Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Tacrolimus, More", "alternatives_b": "Romiplostim, Avatrombopag, Emicizumab, Coagulation factor VIIa Recombinant Human, Coagulation factor X human, Lusutrombopag, Anti-inhibitor coagulant complex, Antihemophilic factor, human recombinant, Fibrinogen human, Coagulation Factor IX Human", "updated_at": 1767369485}, {"id": 97586, "ingredient1": "Eltrombopag", "ingredient2": "Midostaurin", "severity": "Moderate", "effect": "Coadministration with midostaurin may increase the plasma concentrations and the risk of adverse effects of drugs that are substrates of P-glycoprotein (P-gp), breast cancer resistance protein (BCRP), and/or organic anion transporting polypeptide (OATP) 1B1 transporters. The proposed mechanism, based on in vitro data, is decreased clearance due to midostaurin-mediated inhibition of P-gp, BCRP, and/or OATP1B1 transport proteins.", "source": "DDInter", "management_text": "Caution is advised if midostaurin is used concomitantly with drugs that are substrates of P-gp, BCRP, and/or OATP1B1 transport proteins, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring should be considered whenever midostaurin is added to or withdrawn from therapy with these drugs. Patients should be monitored for the development of adverse effects.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if midostaurin is used concomitantly with drugs that are substrates of P-gp, BCRP, and/or OATP1B1 transport proteins, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97690/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Rydapt (midostaurin).\" Novartis Pharmaceuticals, East Hanover, NJ.", "alternatives_a": "Romiplostim, Avatrombopag, Emicizumab, Coagulation factor VIIa Recombinant Human, Coagulation factor X human, Phylloquinone, Anti-inhibitor coagulant complex, Antihemophilic factor, human recombinant, Fibrinogen human, Epinephrine, Coagulation Factor IX Human", "alternatives_b": "Dabrafenib, Asciminib, Acalabrutinib, Dacomitinib, Tepotinib, Fedratinib, Avapritinib, Bosutinib, Vemurafenib, Selumetinib, Vandetanib, More", "updated_at": 1767369485}, {"id": 97587, "ingredient1": "Eltrombopag", "ingredient2": "Mipomersen", "severity": "Major", "effect": "Coadministration of mipomersen with other agents known to induce hepatotoxicity may potentiate the risk of liver injury. Mipomersen can cause elevations in serum transaminases and hepatic steatosis.", "source": "DDInter", "management_text": "Caution is advised if mipomersen is used with other potentially hepatotoxic agents (e.g., acetaminophen; alcohol; amiodarone; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; kinase inhibitors; methotrexate; nonsteroidal anti-inflammatory agents; nucleoside reverse transcriptase inhibitors; proteasome inhibitors; retinoids; tamoxifen; tetracyclines; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; other lipid-lowering medications such as fenofibrate, lomitapide, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice). Mipomersen has not been studied with other LDL-lowering agents that can also increase hepatic fat, thus concomitant use is not recommended. Patients treated with mipomersen should have serum ALT, AST, alkaline phosphatase, and total bilirubin measured prior to initiation of treatment and regularly during treatment in accordance with the product labeling, and the dosing adjusted or interrupted as necessary. Since alcohol may increase levels of hepatic fat and induce or exacerbate liver injury, the manufacturer recommends that patients taking mipomersen not consume more than one alcoholic drink per day. Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if mipomersen is used with other potentially hepatotoxic agents (e.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97691/", "reference_text": "[1] \"Product Information. Kynamro (mipomersen).\" Genzyme Corporation, Cambridge, MA.[2] \"Product Information. Kynamro (mipomersen).\" Genzyme Corporation, Cambridge, MA.", "alternatives_a": "Gemfibrozil, Fenofibric acid, Evinacumab, Evolocumab, Probucol, Dextrothyroxine, Cholestyramine, Clofibrate, Colestipol, Niacin, Fenofibrate, More", "alternatives_b": "Romiplostim, Avatrombopag, Emicizumab, Coagulation factor VIIa Recombinant Human, Coagulation factor X human, Phylloquinone, Lusutrombopag, Anti-inhibitor coagulant complex, Antihemophilic factor, human recombinant, Fibrinogen human, Epinephrine, Coagulation Factor IX Human", "updated_at": 1767369485}, {"id": 97588, "ingredient1": "Eltrombopag", "ingredient2": "Mitoxantrone", "severity": "Moderate", "effect": "Coadministration with eltrombopag may increase the plasma concentrations of drugs that are substrates of the organic anion transporting polypeptide (OATP) 1B1 and/or breast cancer resistance protein (BCRP) transporters. The mechanism is decreased clearance due to inhibition of OATP1B1-mediated hepatic uptake and BCRP-mediated intestinal and hepatobiliary efflux by eltrombopag. The interaction has been demonstrated for rosuvastatin, a known substrate of both OATP 1B1 and BCRP.", "source": "DDInter", "management_text": "Caution is advised during concomitant use of eltrombopag with drugs that are substrates of the OATP1B1 and/or BCRP transporters, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever eltrombopag is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised during concomitant use of eltrombopag with drugs that are substrates of the OATP1B1 and/or BCRP transporters, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97692/", "reference_text": "[1] Allred AJ, Bowen CJ, Park JW, et al. \"Eltrombopag increases plasma rosuvastatin exposure in healthy volunteers.\" Br J Clin Pharmacol 72 (2011): 321-9[2] Kalliokoski A, Niemi M \"Impact of OATP transporters on pharmacokinetics.\" Br J Pharmacol 158 (2009): 693-705[3] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[4] \"Product Information. Promacta (eltrombopag).\" GlaxoSmithKline, Research Triangle Park, NC.[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[7] \"Product Information. Promacta (eltrombopag).\" GlaxoSmithKline, Research Triangle Park, NC.", "alternatives_a": "Idarubicin, Valrubicin, Plicamycin, Ixabepilone, Bleomycin, Doxorubicin, Mitomycin, Daunorubicin, Dactinomycin", "alternatives_b": "Romiplostim, Avatrombopag, Emicizumab, Coagulation factor VIIa Recombinant Human, Coagulation factor X human, Phylloquinone, Lusutrombopag, Anti-inhibitor coagulant complex, Antihemophilic factor, human recombinant, Fibrinogen human, Epinephrine, Coagulation Factor IX Human", "updated_at": 1767369485}, {"id": 97589, "ingredient1": "Eltrombopag", "ingredient2": "Naltrexone", "severity": "Moderate", "effect": "Coadministration of naltrexone with other agents known to induce hepatotoxicity may potentiate the risk of liver injury. Naltrexone, especially in larger than recommended doses (more than 50 mg/day), has been associated with hepatocellular injury, hepatitis, and elevations in liver transaminases and bilirubin. Other potential causative or contributory etiologies identified include preexisting alcoholic liver disease, hepatitis B and/or C infection, and concomitant usage of other hepatotoxic drugs.", "source": "DDInter", "management_text": "The use of naltrexone with other potentially hepatotoxic agents should be avoided whenever possible (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; nucleoside reverse transcriptase inhibitors; proteasome inhibitors; retinoids; sulfonamides; tamoxifen; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice). Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice. Periodic monitoring of hepatic function is advisable.", "mechanism_text": "Synergism", "recommendation": "The use of naltrexone with other potentially hepatotoxic agents should be avoided whenever possible (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97693/", "reference_text": "[1] \"Product Information. ReVia (naltrexone).\" DuPont Pharmaceuticals, Wilmington, DE.", "alternatives_a": "Oxymorphone, Oxycodone, Methadone, Pentazocine, Buprenorphine, Oliceridine, Morphine, Butorphanol, Fentanyl, Ibuprofen, Codeine, More", "alternatives_b": "Romiplostim, Avatrombopag, Emicizumab, Coagulation factor VIIa Recombinant Human, Coagulation factor X human, Phylloquinone, Lusutrombopag, Anti-inhibitor coagulant complex, Antihemophilic factor, human recombinant, Fibrinogen human, Epinephrine, Coagulation Factor IX Human", "updated_at": 1767369485}, {"id": 97590, "ingredient1": "Eltrombopag", "ingredient2": "Neratinib", "severity": "Moderate", "effect": "Coadministration with neratinib may increase the plasma concentrations and the risk of adverse effects of drugs that are substrates of the breast cancer resistance protein (BCRP) transporter, such as dabigatran, rosuvastatin, sulfasazine, and topotecan. The proposed mechanisms, based on in vitro data, is decreased clearance due to neratinib-mediated inhibition of BCRP transport protein. There are no clinical data regarding the use of neratinib with BCRP substrates.", "source": "DDInter", "management_text": "Caution is advised if neratinib is used concomitantly with drugs that are substrates of BCRP transport protein, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring should be considered whenever neratinib is added to or withdrawn from therapy with these drugs. Patients should be monitored for the development of adverse effects.", "mechanism_text": "Others", "recommendation": "Caution is advised if neratinib is used concomitantly with drugs that are substrates of BCRP transport protein, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97694/", "reference_text": "[1] Cerner Multum, Inc. \"Australian Product Information.\" O 0[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] Abbas R, Hug BA, Leister C, Burns J, Sonnichsen D \"Pharmacokinetics of oral neratinib during co-administration of ketoconazole in healthy subjects.\" Br J Clin Pharmacol 71 (2011): 522-7[4] \"Product Information. Nerlynx (neratinib).\" Puma Biotechnology, Inc., Los Angeles, CA.", "alternatives_a": "Romiplostim, Fostamatinib, Avatrombopag, Emicizumab, Coagulation factor VIIa Recombinant Human, Coagulation factor X human, Phylloquinone, Anti-inhibitor coagulant complex, Antihemophilic factor, human recombinant, Fibrinogen human, Epinephrine, Coagulation Factor IX Human", "alternatives_b": "Dabrafenib, Asciminib, Acalabrutinib, Dacomitinib, Tepotinib, Fedratinib, Avapritinib, Bosutinib, Vemurafenib, Selumetinib, Vandetanib, More", "updated_at": 1767369485}, {"id": 97591, "ingredient1": "Eltrombopag", "ingredient2": "Niraparib", "severity": "Moderate", "effect": "Coadministration with eltrombopag may increase the plasma concentrations of drugs that are substrates of the organic anion transporting polypeptide (OATP) 1B1 and/or breast cancer resistance protein (BCRP) transporters. The mechanism is decreased clearance due to inhibition of OATP1B1-mediated hepatic uptake and BCRP-mediated intestinal and hepatobiliary efflux by eltrombopag. The interaction has been demonstrated for rosuvastatin, a known substrate of both OATP 1B1 and BCRP.", "source": "DDInter", "management_text": "Caution is advised during concomitant use of eltrombopag with drugs that are substrates of the OATP1B1 and/or BCRP transporters, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever eltrombopag is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised during concomitant use of eltrombopag with drugs that are substrates of the OATP1B1 and/or BCRP transporters, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97695/", "reference_text": "[1] Allred AJ, Bowen CJ, Park JW, et al. \"Eltrombopag increases plasma rosuvastatin exposure in healthy volunteers.\" Br J Clin Pharmacol 72 (2011): 321-9[2] Kalliokoski A, Niemi M \"Impact of OATP transporters on pharmacokinetics.\" Br J Pharmacol 158 (2009): 693-705[3] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[4] \"Product Information. Promacta (eltrombopag).\" GlaxoSmithKline, Research Triangle Park, NC.[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[7] \"Product Information. Promacta (eltrombopag).\" GlaxoSmithKline, Research Triangle Park, NC.", "alternatives_a": "Romiplostim, Avatrombopag, Emicizumab, Coagulation factor VIIa Recombinant Human, Coagulation factor X human, Phylloquinone, Anti-inhibitor coagulant complex, Antihemophilic factor, human recombinant, Fibrinogen human, Epinephrine, Coagulation Factor IX Human", "alternatives_b": "Pertuzumab, Olaparib, Oxaliplatin, Bortezomib, Tisagenlecleucel, Aminolevulinic acid, Omacetaxine mepesuccinate, Tazemetostat, Altretamine, Tagraxofusp, Ixazomib, More", "updated_at": 1767369485}, {"id": 97592, "ingredient1": "Eltrombopag", "ingredient2": "Osimertinib", "severity": "Moderate", "effect": "Coadministration with osimertinib may increase the exposure of breast cancer resistance protein (BCRP) transporter substrates. In vitro studies have shown that osimertinib is a competitive inhibitor of BCRP.", "source": "DDInter", "management_text": "Caution is recommended if osimertinib is used in combination with drugs that are substrates of the BCRP transporter, particularly those with a narrow therapeutic index. Monitoring for signs and symptoms of increased exposure to the BCRP substrate should be considered whenever osimertinib is added to or withdrawn from therapy.", "mechanism_text": "Others", "recommendation": "Caution is recommended if osimertinib is used in combination with drugs that are substrates of the BCRP transporter, particularly those with a narrow therapeutic index.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97696/", "reference_text": "[1] Cerner Multum, Inc. \"Australian Product Information.\" O 0[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Tagrisso (osimertinib).\" Astra-Zeneca Pharmaceuticals, Wilmington, DE.", "alternatives_a": "Romiplostim, Avatrombopag, Emicizumab, Coagulation factor VIIa Recombinant Human, Coagulation factor X human, Phylloquinone, Anti-inhibitor coagulant complex, Antihemophilic factor, human recombinant, Fibrinogen human, Epinephrine, Coagulation Factor IX Human", "alternatives_b": "Dabrafenib, Asciminib, Acalabrutinib, Dacomitinib, Tepotinib, Fedratinib, Avapritinib, Bosutinib, Vemurafenib, Selumetinib, Vandetanib, More", "updated_at": 1767369485}, {"id": 97593, "ingredient1": "Eltrombopag", "ingredient2": "Ospemifene", "severity": "Moderate", "effect": "Ospemifene and its major metabolite, 4-hydroxyospemifene, may increase the plasma concentrations and the risk of adverse effects of drugs that are substrates of organic cation transporter (OCT)1, uridine diphosphate glucuronosyltransferase (UGT) 1A3, and/or UGT1A9. The proposed mechanism, based on in vitro data, is decreased clearance due to ospemifene-mediated inhibition of OCT1, UGT1A3, and/or UGT1A9.", "source": "DDInter", "management_text": "Until more information is available, caution is advised when ospemifene is used concomitantly with drugs that are substrates of OCT1, UGT1A3, and/or UGT1A9, particularly those with a narrow therapeutic range. Patients should be monitored for the development of adverse effects.", "mechanism_text": "Excretion", "recommendation": "Until more information is available, caution is advised when ospemifene is used concomitantly with drugs that are substrates of OCT1, UGT1A3, and/or UGT1A9, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97697/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Nexavar (sorafenib).\" Bayer Pharmaceutical Inc, West Haven, CT.[3] \"Product Information. Osphena (ospemifene).\" Shionogi USA Inc, Florham Park, NJ.", "alternatives_a": "Ulipristal, Danazol, Mifepristone, Raloxifene, Bazedoxifene, Prasterone", "alternatives_b": "Romiplostim, Fostamatinib, Avatrombopag, Emicizumab, Coagulation factor VIIa Recombinant Human, Coagulation factor X human, Phylloquinone, Lusutrombopag, Anti-inhibitor coagulant complex, Antihemophilic factor, human recombinant, Fibrinogen human, More", "updated_at": 1767369485}, {"id": 97594, "ingredient1": "Eltrombopag", "ingredient2": "Ozanimod", "severity": "Major", "effect": "Coadministration with breast cancer resistance protein (BCRP) inhibitors may increase the exposure of the active metabolites of ozanimod and the risk of adverse effects. Coadministration with cyclosporine, a BCRP inhibitor, did not alter the AUC of ozanimod, but it did double the exposure of the minor active metabolites of ozanimod, RP101988 and RP101075 which are direct precursors of the major active metabolite CC112273.", "source": "DDInter", "management_text": "According to the manufacturer, coadministration of ozanimod with BCRP inhibitors is not recommended.", "mechanism_text": "Others", "recommendation": "According to the manufacturer, coadministration of ozanimod with BCRP inhibitors is not recommended.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97698/", "reference_text": "[1] Cerner Multum, Inc. \"Australian Product Information.\" O 0[2] \"Product Information. Zeposia (ozanimod).\" Celgene Corporation, Summit, NJ.[3] \"Product Information. Zeposia (ozanimod).\" Celgene Corporation, Summit, NJ.", "alternatives_a": "Romiplostim, Fostamatinib, Avatrombopag, Emicizumab, Coagulation factor VIIa Recombinant Human, Coagulation factor X human, Phylloquinone, Lusutrombopag, Anti-inhibitor coagulant complex, Antihemophilic factor, human recombinant, Fibrinogen human, Coagulation Factor IX Human", "alternatives_b": "Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Tacrolimus, More", "updated_at": 1767369485}, {"id": 97595, "ingredient1": "Eltrombopag", "ingredient2": "Pegaspargase", "severity": "Moderate", "effect": "Concomitant use of asparaginase with other hepatotoxic agents may potentiate the risk of liver injury. Hepatomegaly, acute severe hepatotoxicity, and fatal liver failure have been reported with asparaginase treatment in adults. Also, asparaginase may increase the toxicity of drugs bound to plasma proteins or metabolized by the liver.", "source": "DDInter", "management_text": "The risk of additive hepatotoxicity should be considered when asparaginase is used with other hepatotoxic agents (e.g., alcohol, androgens, antituberculosis agents, azole antifungal agents, ACE inhibitors, macrolide antibiotics, nonsteroidal anti-inflammatory agents, nucleoside reverse transcriptase inhibitors, sulfonamides, thiazolidinediones, and statins). Liver function tests should be monitored at regular intervals during asparaginase treatment with or without other hepatotoxic drugs. Patients should be advised to seek medical attention if they experience potential symptoms of hepatotoxicity such as right upper quadrant pain, increasing abdominal size, fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, dark urine, pale stools, and jaundice.", "mechanism_text": "Synergism", "recommendation": "The risk of additive hepatotoxicity should be considered when asparaginase is used with other hepatotoxic agents (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97699/", "reference_text": "[1] \"Product Information. Oncaspar (pegaspargase).\" Rhone-Poulenc Rorer, Collegeville, PA.[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] Bodmer M, Sulz M, Stadlmann S, Droll A, Terracciano L, Krahenbuhl S \"Fatal liver failure in an adult patient with acute lymphoblastic leukemia following treatment with L-asparaginase.\" Digestion 74 (2006): epub[4] Cerner Multum, Inc \"ANVISA Bulrio Eletrnico. Available from: URL: http://www.anvisa.gov.br/datavisa/fila_bula/index.asp.\" O 0 (2015):[5] \"Product Information. Elspar (asparaginase).\" Merck & Co, Inc, West Point, PA.[6] Christ TN, Stock W, Knoebel RW \"Incidence of asparaginase-related hepatotoxicity, pancreatitis, and thrombotic events in adults with acute lymphoblastic leukemia treated with a pediatric-inspired regimen.\" J Oncol Pharm Pract 24 (2018): 299-308[7] Lu G, Karur V, Herrington JD, Walker MG \"Successful treatment of pegaspargase-induced acute hepatotoxicity with vitamin B complex and L-carnitine\" Proc (Bayl Univ Med Cent) 29 (2016): 46-7[8] Jenkins R, Perlin E \"Severe hepatotoxicity from Escherichia coli L-asparaginase.\" J Natl Med Assoc 79 (1987): 775-9[9] \"Product Information. Asparlas (calaspargase pegol).\" Servier, Boston, MA.[10] Burke PW, Aldoss I, Lunning MA, et.al \"High-grade PEGylated asparaginase-related hepatotoxicity occurrence in a pediatric-inspired adult acute lymphoblastic leukemia regimen does not necessarily predict recurrent hepatotoxicity in subsequent cycles.\" Blood 122 (2013): 2671[11] \"Product Information. Erwinaze (asparaginase Erwinia chrysanthemi).\" EUSA Pharma, Newtown, PA.[12] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[13] Al-Nawakil C, Willems L, Mauprivez C, et.al \"Successful treatment of l-asparaginase-induced severe acute hepatotoxicity using mitochondrial cofactors.\" Leuk Lymphoma 55 (2014): 1670-4", "alternatives_a": "Pertuzumab, Olaparib, Oxaliplatin, Bortezomib, Tisagenlecleucel, Aminolevulinic acid, Omacetaxine mepesuccinate, Tazemetostat, Altretamine, Tagraxofusp, Ixazomib, More", "alternatives_b": "Romiplostim, Fostamatinib, Avatrombopag, Emicizumab, Coagulation factor VIIa Recombinant Human, Coagulation factor X human, Phylloquinone, Lusutrombopag, Anti-inhibitor coagulant complex, Antihemophilic factor, human recombinant, Fibrinogen human, More", "updated_at": 1767369485}, {"id": 97596, "ingredient1": "Eltrombopag", "ingredient2": "Peginterferon alfa-2a", "severity": "Major", "effect": "In chronic hepatitis C patients with advanced liver disease, coadministration of eltrombopag with interferon-based therapy may increase the risk of adverse reactions including potentially fatal hepatic decompensation and thromboembolic events.", "source": "DDInter", "management_text": "In chronic hepatitis C patients with poor liver function (albumin levels <=3.5 g/L or MELD score >=10) at baseline, eltrombopag should only be administered with interferon-based therapy after careful consideration of the potential benefits versus associated risks, and patients should be monitored closely for signs and symptoms of hepatic decompensation. Eltrombopag should be discontinued if antiviral therapy is withdrawn for hepatic decompensation.", "mechanism_text": "Others", "recommendation": "In chronic hepatitis C patients with poor liver function (albumin levels <=3.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97700/", "reference_text": "[1] \"Product Information. Promacta (eltrombopag).\" GlaxoSmithKline, Research Triangle Park, NC.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] Cerner Multum, Inc. \"Australian Product Information.\" O 0[4] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[5] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[6] \"Product Information. Promacta (eltrombopag).\" GlaxoSmithKline, Research Triangle Park, NC.", "alternatives_a": "Oprelvekin, Sipuleucel-T, Elapegademase, Ropeginterferon alfa-2b, Sargramostim, Histamine, Aldesleukin, Pegademase, Pegfilgrastim, Filgrastim, Glatiramer", "alternatives_b": "Romiplostim, Fostamatinib, Avatrombopag, Emicizumab, Coagulation factor VIIa Recombinant Human, Coagulation factor X human, Phylloquinone, Lusutrombopag, Anti-inhibitor coagulant complex, Antihemophilic factor, human recombinant, Fibrinogen human, More", "updated_at": 1767369485}, {"id": 97597, "ingredient1": "Eltrombopag", "ingredient2": "Peginterferon alfa-2b", "severity": "Major", "effect": "In chronic hepatitis C patients with advanced liver disease, coadministration of eltrombopag with interferon-based therapy may increase the risk of adverse reactions including potentially fatal hepatic decompensation and thromboembolic events.", "source": "DDInter", "management_text": "In chronic hepatitis C patients with poor liver function (albumin levels <=3.5 g/L or MELD score >=10) at baseline, eltrombopag should only be administered with interferon-based therapy after careful consideration of the potential benefits versus associated risks, and patients should be monitored closely for signs and symptoms of hepatic decompensation. Eltrombopag should be discontinued if antiviral therapy is withdrawn for hepatic decompensation.", "mechanism_text": "Others", "recommendation": "In chronic hepatitis C patients with poor liver function (albumin levels <=3.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97701/", "reference_text": "[1] \"Product Information. Promacta (eltrombopag).\" GlaxoSmithKline, Research Triangle Park, NC.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] Cerner Multum, Inc. \"Australian Product Information.\" O 0[4] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[5] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[6] \"Product Information. Promacta (eltrombopag).\" GlaxoSmithKline, Research Triangle Park, NC.", "alternatives_a": "Oprelvekin, Sipuleucel-T, Elapegademase, Ropeginterferon alfa-2b, Sargramostim, Histamine, Aldesleukin, Pegademase, Pegfilgrastim, Filgrastim, Glatiramer", "alternatives_b": "Romiplostim, Fostamatinib, Avatrombopag, Emicizumab, Coagulation factor VIIa Recombinant Human, Coagulation factor X human, Phylloquinone, Lusutrombopag, Anti-inhibitor coagulant complex, Antihemophilic factor, human recombinant, Fibrinogen human, More", "updated_at": 1767369485}, {"id": 97598, "ingredient1": "Eltrombopag", "ingredient2": "Peginterferon beta-1a", "severity": "Moderate", "effect": "Coadministration of beta interferons with other agents known to induce hepatotoxicity may potentiate the risk of liver injury. Use of beta interferons has been associated with rare cases of liver injury, including autoimmune hepatitis and severe liver damage leading to hepatic failure, some of which required transplantation.", "source": "DDInter", "management_text": "The risk of hepatic injury should be considered when beta interferons are used with other potentially hepatotoxic agents (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; other interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; nucleoside reverse transcriptase inhibitors; proteasome inhibitors; retinoids; sulfonamides; tamoxifen; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice). Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice.", "mechanism_text": "Synergism", "recommendation": "The risk of hepatic injury should be considered when beta interferons are used with other potentially hepatotoxic agents (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97702/", "reference_text": "[1] \"Product Information. Plegridy (peginterferon beta-1a).\" Biogen Idec Inc, Cambridge, MA.[2] \"Product Information. Betaseron (interferon beta-1b).\" Berlex, Richmond, CA.[3] \"Product Information. Rebif (interferon beta-1a).\" Serono Laboratories Inc, Norwell, MA.[4] \"Product Information. Avonex (interferon beta-1a).\" Biogen, Cambridge, MA.", "alternatives_a": "Romiplostim, Emicizumab, Coagulation factor VIIa Recombinant Human, Coagulation factor X human, Phylloquinone, Lusutrombopag, Anti-inhibitor coagulant complex, Antihemophilic factor, human recombinant, Fibrinogen human, Epinephrine, Coagulation Factor IX Human", "alternatives_b": "Oprelvekin, Sipuleucel-T, Elapegademase, Ropeginterferon alfa-2b, Sargramostim, Histamine, Aldesleukin, Pegademase, Pegfilgrastim, Filgrastim, Glatiramer", "updated_at": 1767369485}, {"id": 97599, "ingredient1": "Eltrombopag", "ingredient2": "Pexidartinib", "severity": "Major", "effect": "Serious cases of hepatotoxicity, some fatal, have occurred in patients treated with pexidartinib. Concomitant use of other potentially hepatotoxic agents may potentiate the risk of liver injury. The mechanism of hepatotoxicity is unknown, its occurrence cannot be predicted, and it is unknown whether liver injury occurs in the absence of increased transaminases.", "source": "DDInter", "management_text": "The use of pexidartinib with other potentially hepatotoxic agents should be avoided. Patients treated with pexidartinib should have liver function tests, including AST, ALT, total bilirubin, direct bilirubin, ALP, and gamma-glutamyl transferase (GGT), prior to initiation of pexidartinib, weekly for the first 8 weeks, every 2 weeks for the next month, and every 3 months thereafter. Pexidartinib therapy may require a dosage reduction, to be withheld, or permanently discontinued based on the severity of the hepatotoxicity. A recurrence of increased serum transaminases, bilirubin, or ALP may occur upon rechallenge with a reduced dose of pexidartinib. Liver function tests should be performed weekly for the first month after rechallenge. Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice.", "mechanism_text": "Synergism", "recommendation": "The use of pexidartinib with other potentially hepatotoxic agents should be avoided.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97703/", "reference_text": "[1] \"Product Information. Turalio (pexidartinib).\" Daiichi Sankyo, Inc., Parsippany, NJ.[2] \"Product Information. Turalio (pexidartinib).\" Daiichi Sankyo, Inc., Parsippany, NJ.", "alternatives_a": "Romiplostim, Emicizumab, Coagulation factor VIIa Recombinant Human, Coagulation factor X human, Phylloquinone, Lusutrombopag, Anti-inhibitor coagulant complex, Antihemophilic factor, human recombinant, Fibrinogen human, Epinephrine, Coagulation Factor IX Human", "alternatives_b": "Dabrafenib, Asciminib, Acalabrutinib, Dacomitinib, Tepotinib, Fedratinib, Avapritinib, Bosutinib, Vemurafenib, Selumetinib, Vandetanib, More", "updated_at": 1767369485}, {"id": 97600, "ingredient1": "Eltrombopag", "ingredient2": "Pitavastatin", "severity": "Moderate", "effect": "Coadministration with eltrombopag may increase the plasma concentrations of HMG-CoA reductase inhibitors (statins). The proposed mechanism is decreased clearance due to eltrombopag inhibition of the OATP 1B1-mediated hepatic uptake of statins and/or their metabolites (e.g., simvastatin acid), with fluvastatin the least likely to be significantly affected. High levels of HMG-CoA reductase inhibitory activity in plasma is associated with an increased risk of musculoskeletal toxicity. Myopathy manifested as muscle pain and/or weakness associated with grossly elevated creatine kinase exceeding ten times the upper limit of normal has been reported occasionally.", "source": "DDInter", "management_text": "Lower statin dosages should be considered during coadministration with eltrombopag. In clinical trials with eltrombopag, a dosage reduction of rosuvastatin by 50% was recommended. No specific adjustment recommendations were given for the others. All patients receiving statin therapy should be advised to promptly report any unexplained muscle pain, tenderness or weakness, particularly if accompanied by fever, malaise and/or dark colored urine. Therapy should be discontinued if creatine kinase is markedly elevated in the absence of strenuous exercise or if myopathy is otherwise suspected or diagnosed.", "mechanism_text": "Excretion", "recommendation": "Lower statin dosages should be considered during coadministration with eltrombopag.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97704/", "reference_text": "[1] Allred AJ, Bowen CJ, Park JW, et al. \"Eltrombopag increases plasma rosuvastatin exposure in healthy volunteers.\" Br J Clin Pharmacol 72 (2011): 321-9[2] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[3] Cerner Multum, Inc. \"Australian Product Information.\" O 0[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] Kalliokoski A, Niemi M \"Impact of OATP transporters on pharmacokinetics.\" Br J Pharmacol 158 (2009): 693-705[6] \"Product Information. Promacta (eltrombopag).\" GlaxoSmithKline, Research Triangle Park, NC.[7] Richter WO, Jacob BG, Schwandt P \"Interaction between fibre and lovastatin.\" Lancet 338 (1991): 706[8] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors.\" Clin Pharmacol Ther 64 (1998): 477-83[9] Kantola T, Kivisto KT, Neuvonen PJ \"Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid.\" Clin Pharmacol Ther 63 (1998): 397-402[10] \"Product Information. Mevacor (lovastatin).\" Merck & Co, Inc, West Point, PA.[11] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions.\" Br J Clin Pharmacol 46 (1998): 101-10[12] Neuvonen PJ, Backman JT, Niemi M \"Pharmacokinetic comparison of the potential over-the-counter statins simvastatin, lovastatin, fluvastatin and pravastatin.\" Clin Pharmacokinet 47 (2008): 463-74[13] Thompson PD, Clarkson P, Karas RH \"Statin-associated myopathy.\" JAMA 289 (2003): 1681-90[14] \"Product Information. Zocor (simvastatin).\" Merck & Co, Inc, West Point, PA.[15] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[16] \"Product Information. Promacta (eltrombopag).\" GlaxoSmithKline, Research Triangle Park, NC.", "alternatives_a": "Romiplostim, Fostamatinib, Avatrombopag, Emicizumab, Coagulation factor VIIa Recombinant Human, Coagulation factor X human, Phylloquinone, Lusutrombopag, Anti-inhibitor coagulant complex, Antihemophilic factor, human recombinant, Fibrinogen human, More", "alternatives_b": "Gemfibrozil, Fenofibric acid, Evinacumab, Evolocumab, Probucol, Dextrothyroxine, Cholestyramine, Clofibrate, Colestipol, Niacin, Fenofibrate, More", "updated_at": 1767369485}, {"id": 97601, "ingredient1": "Eltrombopag", "ingredient2": "Pravastatin", "severity": "Moderate", "effect": "Coadministration with eltrombopag may increase the plasma concentrations of HMG-CoA reductase inhibitors (statins). The proposed mechanism is decreased clearance due to eltrombopag inhibition of the OATP 1B1-mediated hepatic uptake of statins and/or their metabolites (e.g., simvastatin acid), with fluvastatin the least likely to be significantly affected. High levels of HMG-CoA reductase inhibitory activity in plasma is associated with an increased risk of musculoskeletal toxicity. Myopathy manifested as muscle pain and/or weakness associated with grossly elevated creatine kinase exceeding ten times the upper limit of normal has been reported occasionally.", "source": "DDInter", "management_text": "Lower statin dosages should be considered during coadministration with eltrombopag. In clinical trials with eltrombopag, a dosage reduction of rosuvastatin by 50% was recommended. No specific adjustment recommendations were given for the others. All patients receiving statin therapy should be advised to promptly report any unexplained muscle pain, tenderness or weakness, particularly if accompanied by fever, malaise and/or dark colored urine. Therapy should be discontinued if creatine kinase is markedly elevated in the absence of strenuous exercise or if myopathy is otherwise suspected or diagnosed.", "mechanism_text": "Excretion", "recommendation": "Lower statin dosages should be considered during coadministration with eltrombopag.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97705/", "reference_text": "[1] Allred AJ, Bowen CJ, Park JW, et al. \"Eltrombopag increases plasma rosuvastatin exposure in healthy volunteers.\" Br J Clin Pharmacol 72 (2011): 321-9[2] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[3] Cerner Multum, Inc. \"Australian Product Information.\" O 0[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] Kalliokoski A, Niemi M \"Impact of OATP transporters on pharmacokinetics.\" Br J Pharmacol 158 (2009): 693-705[6] \"Product Information. Promacta (eltrombopag).\" GlaxoSmithKline, Research Triangle Park, NC.[7] Richter WO, Jacob BG, Schwandt P \"Interaction between fibre and lovastatin.\" Lancet 338 (1991): 706[8] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors.\" Clin Pharmacol Ther 64 (1998): 477-83[9] Kantola T, Kivisto KT, Neuvonen PJ \"Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid.\" Clin Pharmacol Ther 63 (1998): 397-402[10] \"Product Information. Mevacor (lovastatin).\" Merck & Co, Inc, West Point, PA.[11] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions.\" Br J Clin Pharmacol 46 (1998): 101-10[12] Neuvonen PJ, Backman JT, Niemi M \"Pharmacokinetic comparison of the potential over-the-counter statins simvastatin, lovastatin, fluvastatin and pravastatin.\" Clin Pharmacokinet 47 (2008): 463-74[13] Thompson PD, Clarkson P, Karas RH \"Statin-associated myopathy.\" JAMA 289 (2003): 1681-90[14] \"Product Information. Zocor (simvastatin).\" Merck & Co, Inc, West Point, PA.[15] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[16] \"Product Information. Promacta (eltrombopag).\" GlaxoSmithKline, Research Triangle Park, NC.", "alternatives_a": "Gemfibrozil, Fenofibric acid, Evinacumab, Evolocumab, Probucol, Dextrothyroxine, Cholestyramine, Clofibrate, Colestipol, Niacin, Fenofibrate, More", "alternatives_b": "Romiplostim, Fostamatinib, Avatrombopag, Emicizumab, Coagulation factor VIIa Recombinant Human, Coagulation factor X human, Lusutrombopag, Anti-inhibitor coagulant complex, Antihemophilic factor, human recombinant, Fibrinogen human, Coagulation Factor IX Human", "updated_at": 1767369485}, {"id": 97602, "ingredient1": "Eltrombopag", "ingredient2": "Remdesivir", "severity": "Moderate", "effect": "Concomitant use of remdesivir with other agents that are known to induce hepatotoxicity may theoretically increase the risk of liver injury. Data from investigational use and clinical studies suggest that remdesivir may be associated with hepatotoxic effects.", "source": "DDInter", "management_text": "Until more information is available, concomitant use of remdesivir with known hepatotoxic drugs should be avoided when possible. Liver function should be evaluated prior to starting remdesivir and monitored during treatment as clinically appropriate. Remdesivir should not be initiated in patients with ALT greater than or equal to 5 times the upper limit of normal (ULN) at baseline. Likewise, remdesivir should be discontinued immediately if ALT increases to 5 times ULN or greater during treatment (may be restarted when ALT falls below 5 times ULN), or if ALT elevation is accompanied by signs or symptoms of liver inflammation or increasing conjugated bilirubin, alkaline phosphatase, or INR.", "mechanism_text": "Synergism", "recommendation": "Until more information is available, concomitant use of remdesivir with known hepatotoxic drugs should be avoided when possible.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97706/", "reference_text": "[1] Gilead Sciences, Inc \"About Remdesivir. Available from: URL: https://www.gilead.com/purpose/advancing-global-health/covid-19/about-remdesivir.\" ([2020]):[2] US Food and Drug Administration \"Fact sheet for health care providers emergency use authorization (EUA) of remdesivir (GS-5734TM) Available from: URL: https://www.fda.gov/media/137566/download.\" ([2020, May 1]]):[3] European Medicines Agency \"Summary on compassionate use. Remdesivir Gilead. Available from: URL: https://www.ema.europa.eu/en/documents/other/summary-compassionate-use-remdesivir-gilead_en.pdf.\" ([2020 Apr 03]):[4] Cerner Multum, Inc. \"Australian Product Information.\" O 0[5] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0", "alternatives_a": "Romiplostim, Avatrombopag, Emicizumab, Coagulation factor VIIa Recombinant Human, Coagulation factor X human, Phylloquinone, Lusutrombopag, Anti-inhibitor coagulant complex, Antihemophilic factor, human recombinant, Fibrinogen human, Epinephrine, Coagulation Factor IX Human", "alternatives_b": "Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Amprenavir, Cabotegravir, Valaciclovir, Zanamivir, Lenacapavir, Telaprevir, More", "updated_at": 1767369485}, {"id": 97603, "ingredient1": "Eltrombopag", "ingredient2": "Repaglinide", "severity": "Moderate", "effect": "Coadministration with eltrombopag may increase the plasma concentrations of drugs that are substrates of the organic anion transporting polypeptide (OATP) 1B1 and/or breast cancer resistance protein (BCRP) transporters. The mechanism is decreased clearance due to inhibition of OATP1B1-mediated hepatic uptake and BCRP-mediated intestinal and hepatobiliary efflux by eltrombopag. The interaction has been demonstrated for rosuvastatin, a known substrate of both OATP 1B1 and BCRP.", "source": "DDInter", "management_text": "Caution is advised during concomitant use of eltrombopag with drugs that are substrates of the OATP1B1 and/or BCRP transporters, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever eltrombopag is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised during concomitant use of eltrombopag with drugs that are substrates of the OATP1B1 and/or BCRP transporters, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97707/", "reference_text": "[1] Allred AJ, Bowen CJ, Park JW, et al. \"Eltrombopag increases plasma rosuvastatin exposure in healthy volunteers.\" Br J Clin Pharmacol 72 (2011): 321-9[2] Kalliokoski A, Niemi M \"Impact of OATP transporters on pharmacokinetics.\" Br J Pharmacol 158 (2009): 693-705[3] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[4] \"Product Information. Promacta (eltrombopag).\" GlaxoSmithKline, Research Triangle Park, NC.[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[7] \"Product Information. Promacta (eltrombopag).\" GlaxoSmithKline, Research Triangle Park, NC.", "alternatives_a": "Glipizide, Acetohexamide, Guar gum, Pramlintide, Alogliptin, Tolazamide, Empagliflozin, Dulaglutide, Exenatide, Tolbutamide, Miglitol, More", "alternatives_b": "Romiplostim, Avatrombopag, Emicizumab, Coagulation factor VIIa Recombinant Human, Coagulation factor X human, Phylloquinone, Lusutrombopag, Anti-inhibitor coagulant complex, Antihemophilic factor, human recombinant, Fibrinogen human, Coagulation Factor IX Human", "updated_at": 1767369485}, {"id": 97604, "ingredient1": "Eltrombopag", "ingredient2": "Revefenacin", "severity": "Moderate", "effect": "Coadministration of revefenacin with inhibitors of organic anion transporting polypeptide (OATP) 1B1 and/or 1B3 may increase systemic exposure to its active metabolite, which has been reported to be a substrate of the hepatic uptake transporters.", "source": "DDInter", "management_text": "Concomitant use of revefenacin with OATP 1B1 and/or 1B3 inhibitors is not recommended.", "mechanism_text": "Metabolism", "recommendation": "Concomitant use of revefenacin with OATP 1B1 and/or 1B3 inhibitors is not recommended.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97708/", "reference_text": "[1] \"Product Information. Yupelri (revefenacin).\" Mylan Specialty, Morgantown, WV.[2] \"Product Information. Nexletol (bempedoic acid).\" Esperion Therapeutics, Ann Arbor, MI.[3] \"Product Information. Nexlizet (bempedoic acid-ezetimibe).\" Esperion Therapeutics, Ann Arbor, MI.[4] \"Product Information. Yupelri (revefenacin).\" Mylan Specialty, Morgantown, WV.[5] \"Product Information. Nexletol (bempedoic acid).\" Esperion Therapeutics, Ann Arbor, MI.[6] \"Product Information. Nexlizet (bempedoic acid-ezetimibe).\" Esperion Therapeutics, Ann Arbor, MI.[7] \"Product Information. Mavyret (glecaprevir-pibrentasvir).\" Abbott Pharmaceutical, Abbott Park, IL.", "alternatives_a": "Romiplostim, Fostamatinib, Avatrombopag, Emicizumab, Coagulation factor VIIa Recombinant Human, Coagulation factor X human, Phylloquinone, Lusutrombopag, Anti-inhibitor coagulant complex, Antihemophilic factor, human recombinant, Fibrinogen human, More", "alternatives_b": "Ciclesonide, Umeclidinium, Mometasone furoate, Budesonide, Glycopyrronium, Aclidinium, Flunisolide, Fluticasone, Ipratropium, Cromoglicic acid, Betamethasone, More", "updated_at": 1767369485}, {"id": 97605, "ingredient1": "Eltrombopag", "ingredient2": "Ribociclib", "severity": "Moderate", "effect": "Coadministration with ribociclib may increase the plasma concentrations and pharmacologic effects of drugs that are substrates of breast cancer resistance protein (BCRP), organic cation transporter-2 (OCT-2), multidrug and toxin extrusion 1 (MATE1), and/or bile salt efflux pump (BSEP) transporters. The proposed mechanism, based on in vitro data, is decreased clearance due to ribociclib-mediated inhibition of these transport proteins at clinically relevant concentrations.", "source": "DDInter", "management_text": "Caution is advised if ribociclib is used concomitantly with drugs that are substrates of BCRP, OCT-2, MATE1, and/or BSEP transport proteins, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring should be considered whenever ribociclib is added to or withdrawn from therapy with these drugs. Patients should be monitored for the development of adverse effects.", "mechanism_text": "Excretion", "recommendation": "Caution is advised if ribociclib is used concomitantly with drugs that are substrates of BCRP, OCT-2, MATE1, and/or BSEP transport proteins, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97709/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Kisqali (ribociclib).\" Novartis Pharmaceuticals, East Hanover, NJ.[3] \"Product Information. Kisqali (ribociclib).\" Novartis Pharmaceuticals, East Hanover, NJ.", "alternatives_a": "Romiplostim, Avatrombopag, Emicizumab, Coagulation factor VIIa Recombinant Human, Coagulation factor X human, Phylloquinone, Anti-inhibitor coagulant complex, Antihemophilic factor, human recombinant, Fibrinogen human, Epinephrine, Coagulation Factor IX Human", "alternatives_b": "Dabrafenib, Asciminib, Acalabrutinib, Dacomitinib, Tepotinib, Fedratinib, Avapritinib, Bosutinib, Vemurafenib, Selumetinib, Vandetanib, More", "updated_at": 1767369485}, {"id": 97606, "ingredient1": "Eltrombopag", "ingredient2": "Rifampicin", "severity": "Moderate", "effect": "Coadministration with eltrombopag may increase the plasma concentrations of drugs that are substrates of the organic anion transporting polypeptide (OATP) 1B1 and/or breast cancer resistance protein (BCRP) transporters. The mechanism is decreased clearance due to inhibition of OATP1B1-mediated hepatic uptake and BCRP-mediated intestinal and hepatobiliary efflux by eltrombopag. The interaction has been demonstrated for rosuvastatin, a known substrate of both OATP 1B1 and BCRP.", "source": "DDInter", "management_text": "Caution is advised during concomitant use of eltrombopag with drugs that are substrates of the OATP1B1 and/or BCRP transporters, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever eltrombopag is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised during concomitant use of eltrombopag with drugs that are substrates of the OATP1B1 and/or BCRP transporters, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97710/", "reference_text": "[1] Allred AJ, Bowen CJ, Park JW, et al. \"Eltrombopag increases plasma rosuvastatin exposure in healthy volunteers.\" Br J Clin Pharmacol 72 (2011): 321-9[2] Kalliokoski A, Niemi M \"Impact of OATP transporters on pharmacokinetics.\" Br J Pharmacol 158 (2009): 693-705[3] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[4] \"Product Information. Promacta (eltrombopag).\" GlaxoSmithKline, Research Triangle Park, NC.[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[7] \"Product Information. Promacta (eltrombopag).\" GlaxoSmithKline, Research Triangle Park, NC.", "alternatives_a": "Capreomycin, Pyrazinamide, Rifamycin, Sulfamethoxazole, Rifapentine, Streptomycin, Trimethoprim, Cycloserine, Rifabutin, Isoniazid, Ethambutol, More", "alternatives_b": "Romiplostim, Emicizumab, Coagulation factor VIIa Recombinant Human, Coagulation factor X human, Phylloquinone, Lusutrombopag, Anti-inhibitor coagulant complex, Antihemophilic factor, human recombinant, Fibrinogen human, Epinephrine, Coagulation Factor IX Human", "updated_at": 1767369485}, {"id": 97607, "ingredient1": "Eltrombopag", "ingredient2": "Rimegepant", "severity": "Moderate", "effect": "Coadministration with inhibitors of P-glycoprotein (P-gp) and/or breast cancer resistance protein (BCRP) may significantly increase the plasma concentrations of rimegepant. The proposed mechanism is decreased clearance due to inhibition of P-gp- and/or BCRP-mediated metabolism of rimegepant.", "source": "DDInter", "management_text": "Coadministration of rimegepant with P-gp and/or BCRP inhibitors should be avoided.", "mechanism_text": "Metabolism", "recommendation": "Coadministration of rimegepant with P-gp and/or BCRP inhibitors should be avoided.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97711/", "reference_text": "[1] \"Product Information. Nurtec ODT (rimegepant).\" Biohaven Pharmaceuticals, New Haven, CT.[2] \"Product Information. Venclexta (venetoclax).\" AbbVie US LLC, North Chicago, IL.[3] \"Product Information. Nurtec ODT (rimegepant).\" Biohaven Pharmaceuticals, New Haven, CT.", "alternatives_a": "Romiplostim, Fostamatinib, Avatrombopag, Emicizumab, Coagulation factor VIIa Recombinant Human, Coagulation factor X human, Phylloquinone, Lusutrombopag, Anti-inhibitor coagulant complex, Antihemophilic factor, human recombinant, Fibrinogen human, More", "alternatives_b": "Frovatriptan, Dihydroergotamine, Eptinezumab, Eletriptan, Rizatriptan, Ergotamine, Clonidine, Naratriptan, Galcanezumab, Zolmitriptan, Sumatriptan, More", "updated_at": 1767369485}, {"id": 97608, "ingredient1": "Eltrombopag", "ingredient2": "Rosuvastatin", "severity": "Moderate", "effect": "Coadministration with eltrombopag may increase the plasma concentrations of HMG-CoA reductase inhibitors (statins). The proposed mechanism is decreased clearance due to eltrombopag inhibition of the OATP 1B1-mediated hepatic uptake of statins and/or their metabolites (e.g., simvastatin acid), with fluvastatin the least likely to be significantly affected. High levels of HMG-CoA reductase inhibitory activity in plasma is associated with an increased risk of musculoskeletal toxicity. Myopathy manifested as muscle pain and/or weakness associated with grossly elevated creatine kinase exceeding ten times the upper limit of normal has been reported occasionally.", "source": "DDInter", "management_text": "Lower statin dosages should be considered during coadministration with eltrombopag. In clinical trials with eltrombopag, a dosage reduction of rosuvastatin by 50% was recommended. No specific adjustment recommendations were given for the others. All patients receiving statin therapy should be advised to promptly report any unexplained muscle pain, tenderness or weakness, particularly if accompanied by fever, malaise and/or dark colored urine. Therapy should be discontinued if creatine kinase is markedly elevated in the absence of strenuous exercise or if myopathy is otherwise suspected or diagnosed.", "mechanism_text": "Excretion", "recommendation": "Lower statin dosages should be considered during coadministration with eltrombopag.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97712/", "reference_text": "[1] Allred AJ, Bowen CJ, Park JW, et al. \"Eltrombopag increases plasma rosuvastatin exposure in healthy volunteers.\" Br J Clin Pharmacol 72 (2011): 321-9[2] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[3] Cerner Multum, Inc. \"Australian Product Information.\" O 0[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] Kalliokoski A, Niemi M \"Impact of OATP transporters on pharmacokinetics.\" Br J Pharmacol 158 (2009): 693-705[6] \"Product Information. Promacta (eltrombopag).\" GlaxoSmithKline, Research Triangle Park, NC.[7] Richter WO, Jacob BG, Schwandt P \"Interaction between fibre and lovastatin.\" Lancet 338 (1991): 706[8] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors.\" Clin Pharmacol Ther 64 (1998): 477-83[9] Kantola T, Kivisto KT, Neuvonen PJ \"Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid.\" Clin Pharmacol Ther 63 (1998): 397-402[10] \"Product Information. Mevacor (lovastatin).\" Merck & Co, Inc, West Point, PA.[11] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions.\" Br J Clin Pharmacol 46 (1998): 101-10[12] Neuvonen PJ, Backman JT, Niemi M \"Pharmacokinetic comparison of the potential over-the-counter statins simvastatin, lovastatin, fluvastatin and pravastatin.\" Clin Pharmacokinet 47 (2008): 463-74[13] Thompson PD, Clarkson P, Karas RH \"Statin-associated myopathy.\" JAMA 289 (2003): 1681-90[14] \"Product Information. Zocor (simvastatin).\" Merck & Co, Inc, West Point, PA.[15] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[16] \"Product Information. Promacta (eltrombopag).\" GlaxoSmithKline, Research Triangle Park, NC.", "alternatives_a": "Amlodipine, Ramipril, Lisinopril, Perindopril, Acetylsalicylic acid, Niacin, Bempedoic acid, Indapamide, Fenofibrate, Gemfibrozil, Fenofibric acid, More", "alternatives_b": "Romiplostim, Avatrombopag, Emicizumab, Coagulation factor VIIa Recombinant Human, Coagulation factor X human, Phylloquinone, Lusutrombopag, Anti-inhibitor coagulant complex, Antihemophilic factor, human recombinant, Fibrinogen human, Coagulation Factor IX Human", "updated_at": 1767369485}, {"id": 97609, "ingredient1": "Eltrombopag", "ingredient2": "Rucaparib", "severity": "Moderate", "effect": "Coadministration with rucaparib may increase the plasma concentrations and the risk of adverse effects of drugs that are substrates of breast cancer resistance protein (BCRP) (e.g., rosuvastatin) and/or uridine diphosphate glucuronosyltransferase (UGT) 1A1 (e.g., deferasirox).", "source": "DDInter", "management_text": "Caution is advised if rucaparib is used with drugs that are substrates of BCRP and/or UGT1A1, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring should be considered whenever rucaparib is added to or withdrawn from therapy with these drugs. Patients should be monitored for the development of adverse effects.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if rucaparib is used with drugs that are substrates of BCRP and/or UGT1A1, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97713/", "reference_text": "[1] EMA. European Medicines Agency. European Union \"EMA - List of medicines under additional monitoring. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000366.jsp&mid=WC0b01ac058067c852\" ([2013 - ]):[2] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[3] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[4] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[5] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.", "alternatives_a": "Romiplostim, Fostamatinib, Avatrombopag, Emicizumab, Coagulation factor VIIa Recombinant Human, Coagulation factor X human, Phylloquinone, Anti-inhibitor coagulant complex, Antihemophilic factor, human recombinant, Fibrinogen human, Epinephrine, Coagulation Factor IX Human", "alternatives_b": "Pertuzumab, Olaparib, Oxaliplatin, Bortezomib, Tisagenlecleucel, Aminolevulinic acid, Omacetaxine mepesuccinate, Tazemetostat, Altretamine, Tagraxofusp, Ixazomib, More", "updated_at": 1767369485}, {"id": 97610, "ingredient1": "Eltrombopag", "ingredient2": "Safinamide", "severity": "Moderate", "effect": "Coadministration with safinamide may increase the plasma concentrations of drugs that are substrates of the breast cancer resistance protein (BCRP) transporter. The proposed mechanism is decreased clearance due to intestinal BCRP-inhibition by safinamide.", "source": "DDInter", "management_text": "Caution is advised when safinamide is prescribed with drugs that are BCRP substrates, particularly those with a narrow therapeutic range such as methotrexate, topotecan, and irinotecan. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever safinamide is added to or withdrawn from therapy.", "mechanism_text": "Others", "recommendation": "Caution is advised when safinamide is prescribed with drugs that are BCRP substrates, particularly those with a narrow therapeutic range such as methotrexate, topotecan, and irinotecan.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97714/", "reference_text": "[1] \"Product Information. Xadago (safinamide).\" US WorldMeds LLC, Louisville , KY.[2] \"Product Information. Xadago (safinamide).\" US WorldMeds LLC, Louisville , KY.", "alternatives_a": "Romiplostim, Fostamatinib, Avatrombopag, Emicizumab, Coagulation factor VIIa Recombinant Human, Coagulation factor X human, Phylloquinone, Anti-inhibitor coagulant complex, Antihemophilic factor, human recombinant, Fibrinogen human, Epinephrine, Coagulation Factor IX Human", "alternatives_b": "Apomorphine, Ropinirole, Opicapone, Cabergoline, Rasagiline, Entacapone, Selegiline, Tolcapone, Rotigotine, Bromocriptine, Pergolide, More", "updated_at": 1767369485}, {"id": 97611, "ingredient1": "Eltrombopag", "ingredient2": "Selenium", "severity": "Moderate", "effect": "INTERVAL: Products containing aluminum, calcium, iron, magnesium, zinc and other polyvalent cations such as antacids or mineral supplements can significantly reduce the gastrointestinal absorption of eltrombopag due to chelation.", "source": "DDInter", "management_text": "Eltrombopag should be taken on an empty stomach at least 2 hours before or 4 hours after oral medications that contain antacids (e.g., didanosine buffered tablets or pediatric oral solution), aluminum, calcium, iron, magnesium, zinc or other polyvalent cations.", "mechanism_text": "Absorption", "recommendation": "Eltrombopag should be taken on an empty stomach at least 2 hours before or 4 hours after oral medications that contain antacids (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97715/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Promacta (eltrombopag).\" GlaxoSmithKline, Research Triangle Park, NC.[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] \"Product Information. Promacta (eltrombopag).\" GlaxoSmithKline, Research Triangle Park, NC.", "alternatives_a": "Romiplostim, Fostamatinib, Avatrombopag, Emicizumab, Coagulation factor VIIa Recombinant Human, Coagulation factor X human, Phylloquinone, Lusutrombopag, Anti-inhibitor coagulant complex, Antihemophilic factor, human recombinant, Fibrinogen human, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 97612, "ingredient1": "Eltrombopag", "ingredient2": "Simeprevir", "severity": "Moderate", "effect": "Coadministration with eltrombopag may increase the plasma concentrations of drugs that are substrates of the organic anion transporting polypeptide (OATP) 1B1 and/or breast cancer resistance protein (BCRP) transporters. The mechanism is decreased clearance due to inhibition of OATP1B1-mediated hepatic uptake and BCRP-mediated intestinal and hepatobiliary efflux by eltrombopag. The interaction has been demonstrated for rosuvastatin, a known substrate of both OATP 1B1 and BCRP.", "source": "DDInter", "management_text": "Caution is advised during concomitant use of eltrombopag with drugs that are substrates of the OATP1B1 and/or BCRP transporters, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever eltrombopag is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised during concomitant use of eltrombopag with drugs that are substrates of the OATP1B1 and/or BCRP transporters, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97716/", "reference_text": "[1] Allred AJ, Bowen CJ, Park JW, et al. \"Eltrombopag increases plasma rosuvastatin exposure in healthy volunteers.\" Br J Clin Pharmacol 72 (2011): 321-9[2] Kalliokoski A, Niemi M \"Impact of OATP transporters on pharmacokinetics.\" Br J Pharmacol 158 (2009): 693-705[3] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[4] \"Product Information. Promacta (eltrombopag).\" GlaxoSmithKline, Research Triangle Park, NC.[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[7] \"Product Information. Promacta (eltrombopag).\" GlaxoSmithKline, Research Triangle Park, NC.", "alternatives_a": "Romiplostim, Fostamatinib, Avatrombopag, Emicizumab, Coagulation factor VIIa Recombinant Human, Coagulation factor X human, Phylloquinone, Anti-inhibitor coagulant complex, Antihemophilic factor, human recombinant, Fibrinogen human, Epinephrine, Coagulation Factor IX Human", "alternatives_b": "Tamsulosin, Tinidazole, Ascorbic acid, Hydroflumethiazide, Chlorothiazide, Metronidazole, Sulfadiazine, Lactic acid, Mitapivat, Methazolamide, Amphotericin B, More", "updated_at": 1767369485}, {"id": 97613, "ingredient1": "Eltrombopag", "ingredient2": "Simvastatin", "severity": "Moderate", "effect": "Coadministration with eltrombopag may increase the plasma concentrations of HMG-CoA reductase inhibitors (statins). The proposed mechanism is decreased clearance due to eltrombopag inhibition of the OATP 1B1-mediated hepatic uptake of statins and/or their metabolites (e.g., simvastatin acid), with fluvastatin the least likely to be significantly affected. High levels of HMG-CoA reductase inhibitory activity in plasma is associated with an increased risk of musculoskeletal toxicity. Myopathy manifested as muscle pain and/or weakness associated with grossly elevated creatine kinase exceeding ten times the upper limit of normal has been reported occasionally.", "source": "DDInter", "management_text": "Lower statin dosages should be considered during coadministration with eltrombopag. In clinical trials with eltrombopag, a dosage reduction of rosuvastatin by 50% was recommended. No specific adjustment recommendations were given for the others. All patients receiving statin therapy should be advised to promptly report any unexplained muscle pain, tenderness or weakness, particularly if accompanied by fever, malaise and/or dark colored urine. Therapy should be discontinued if creatine kinase is markedly elevated in the absence of strenuous exercise or if myopathy is otherwise suspected or diagnosed.", "mechanism_text": "Excretion", "recommendation": "Lower statin dosages should be considered during coadministration with eltrombopag.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97717/", "reference_text": "[1] Allred AJ, Bowen CJ, Park JW, et al. \"Eltrombopag increases plasma rosuvastatin exposure in healthy volunteers.\" Br J Clin Pharmacol 72 (2011): 321-9[2] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[3] Cerner Multum, Inc. \"Australian Product Information.\" O 0[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] Kalliokoski A, Niemi M \"Impact of OATP transporters on pharmacokinetics.\" Br J Pharmacol 158 (2009): 693-705[6] \"Product Information. Promacta (eltrombopag).\" GlaxoSmithKline, Research Triangle Park, NC.[7] Richter WO, Jacob BG, Schwandt P \"Interaction between fibre and lovastatin.\" Lancet 338 (1991): 706[8] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors.\" Clin Pharmacol Ther 64 (1998): 477-83[9] Kantola T, Kivisto KT, Neuvonen PJ \"Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid.\" Clin Pharmacol Ther 63 (1998): 397-402[10] \"Product Information. Mevacor (lovastatin).\" Merck & Co, Inc, West Point, PA.[11] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions.\" Br J Clin Pharmacol 46 (1998): 101-10[12] Neuvonen PJ, Backman JT, Niemi M \"Pharmacokinetic comparison of the potential over-the-counter statins simvastatin, lovastatin, fluvastatin and pravastatin.\" Clin Pharmacokinet 47 (2008): 463-74[13] Thompson PD, Clarkson P, Karas RH \"Statin-associated myopathy.\" JAMA 289 (2003): 1681-90[14] \"Product Information. Zocor (simvastatin).\" Merck & Co, Inc, West Point, PA.[15] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[16] \"Product Information. Promacta (eltrombopag).\" GlaxoSmithKline, Research Triangle Park, NC.", "alternatives_a": "Glipizide, Acetohexamide, Guar gum, Pramlintide, Alogliptin, Tolazamide, Empagliflozin, Dulaglutide, Exenatide, Tolbutamide, Miglitol, More", "alternatives_b": "Romiplostim, Avatrombopag, Emicizumab, Coagulation factor VIIa Recombinant Human, Coagulation factor X human, Anti-inhibitor coagulant complex, Antihemophilic factor, human recombinant, Fibrinogen human, Coagulation Factor IX Human", "updated_at": 1767369485}, {"id": 97614, "ingredient1": "Eltrombopag", "ingredient2": "Sucralfate", "severity": "Moderate", "effect": "INTERVAL: Products containing aluminum, calcium, iron, magnesium, zinc and other polyvalent cations such as antacids or mineral supplements can significantly reduce the gastrointestinal absorption of eltrombopag due to chelation.", "source": "DDInter", "management_text": "Eltrombopag should be taken on an empty stomach at least 2 hours before or 4 hours after oral medications that contain antacids (e.g., didanosine buffered tablets or pediatric oral solution), aluminum, calcium, iron, magnesium, zinc or other polyvalent cations.", "mechanism_text": "Absorption", "recommendation": "Eltrombopag should be taken on an empty stomach at least 2 hours before or 4 hours after oral medications that contain antacids (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97718/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Promacta (eltrombopag).\" GlaxoSmithKline, Research Triangle Park, NC.[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] \"Product Information. Promacta (eltrombopag).\" GlaxoSmithKline, Research Triangle Park, NC.", "alternatives_a": "Tinidazole, Dexlansoprazole, Rabeprazole, Metronidazole, Vonoprazan, Amoxicillin, Pantoprazole, Misoprostol, Esomeprazole, Ranitidine, Levofloxacin, More", "alternatives_b": "Romiplostim, Fostamatinib, Avatrombopag, Emicizumab, Coagulation factor VIIa Recombinant Human, Coagulation factor X human, Lusutrombopag, Anti-inhibitor coagulant complex, Antihemophilic factor, human recombinant, Fibrinogen human, Coagulation Factor IX Human", "updated_at": 1767369485}, {"id": 97615, "ingredient1": "Eltrombopag", "ingredient2": "Sulfasalazine", "severity": "Moderate", "effect": "Coadministration with eltrombopag may increase the plasma concentrations of drugs that are substrates of the organic anion transporting polypeptide (OATP) 1B1 and/or breast cancer resistance protein (BCRP) transporters. The mechanism is decreased clearance due to inhibition of OATP1B1-mediated hepatic uptake and BCRP-mediated intestinal and hepatobiliary efflux by eltrombopag. The interaction has been demonstrated for rosuvastatin, a known substrate of both OATP 1B1 and BCRP.", "source": "DDInter", "management_text": "Caution is advised during concomitant use of eltrombopag with drugs that are substrates of the OATP1B1 and/or BCRP transporters, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever eltrombopag is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised during concomitant use of eltrombopag with drugs that are substrates of the OATP1B1 and/or BCRP transporters, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97719/", "reference_text": "[1] Allred AJ, Bowen CJ, Park JW, et al. \"Eltrombopag increases plasma rosuvastatin exposure in healthy volunteers.\" Br J Clin Pharmacol 72 (2011): 321-9[2] Kalliokoski A, Niemi M \"Impact of OATP transporters on pharmacokinetics.\" Br J Pharmacol 158 (2009): 693-705[3] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[4] \"Product Information. Promacta (eltrombopag).\" GlaxoSmithKline, Research Triangle Park, NC.[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[7] \"Product Information. Promacta (eltrombopag).\" GlaxoSmithKline, Research Triangle Park, NC.", "alternatives_a": "Tamsulosin, Tinidazole, Ascorbic acid, Hydroflumethiazide, Chlorothiazide, Metronidazole, Sulfadiazine, Lactic acid, Mitapivat, Methazolamide, Amphotericin B, More", "alternatives_b": "Romiplostim, Fostamatinib, Avatrombopag, Emicizumab, Coagulation factor VIIa Recombinant Human, Coagulation factor X human, Phylloquinone, Lusutrombopag, Anti-inhibitor coagulant complex, Antihemophilic factor, human recombinant, Fibrinogen human, More", "updated_at": 1767369485}, {"id": 97616, "ingredient1": "Eltrombopag", "ingredient2": "Tafamidis", "severity": "Moderate", "effect": "Based on in vitro data, coadministration with tafamidis may increase the plasma concentrations and the risk of toxicity of drugs that are substrates of the transport protein breast cancer resistance protein (BCRP) (e.g., methotrexate, rosuvastatin, imatinib), uridine diphosphate glucuronosyltransferase (UGT) 1A1 (e.g., bictegravir, irinotecan, raltegravir), and/or uptake transporters OAT1 and OAT3 (organic anion transporters) (e.g., bumetanide, furosemide, lamivudine, methotrexate, oseltamivir, tenofovir, ganciclovir, adefovir, cidofovir, zidovudine, zalcitabine) at clinically relevant concentrations. The proposed mechanism is decreased clearance due to tafamidis-mediated inhibition of the corresponding transport protein.", "source": "DDInter", "management_text": "Caution is advised if tafamidis is used concomitantly with drugs that are substrates of these transport proteins, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring should be considered whenever tafamidis is added to or withdrawn from therapy with these drugs. Patients should be monitored for the development of adverse effects.", "mechanism_text": "Excretion", "recommendation": "Caution is advised if tafamidis is used concomitantly with drugs that are substrates of these transport proteins, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97720/", "reference_text": "[1] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare \"Centro de informacin online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[2] \"Product Information. Vyndaqel (tafamidis).\" Pfizer U.S. Pharmaceuticals Group, New York, NY.[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] \"Product Information. Hivid (zalcitabine).\" Roche Laboratories, Nutley, NJ.", "alternatives_a": "Romiplostim, Fostamatinib, Avatrombopag, Emicizumab, Coagulation factor VIIa Recombinant Human, Coagulation factor X human, Phylloquinone, Anti-inhibitor coagulant complex, Antihemophilic factor, human recombinant, Fibrinogen human, Epinephrine, Coagulation Factor IX Human", "alternatives_b": "Dextromethorphan, Valbenazine, Dalfampridine, Sodium oxybate, Riluzole, Tetrabenazine, Inotersen, Pitolisant, Amifampridine, Deutetrabenazine", "updated_at": 1767369485}, {"id": 97617, "ingredient1": "Eltrombopag", "ingredient2": "Talazoparib", "severity": "Moderate", "effect": "Coadministration with inhibitors of breast cancer resistance protein (BCRP) may increase the plasma concentrations of talazoparib, which has been shown in vitro to be a substrate of this efflux membrane transporter. However, the effect of BCRP inhibitors on the pharmacokinetics of talazoparib has not been studied in vivo.", "source": "DDInter", "management_text": "Caution is recommended when talazoparib is coadministered with inhibitors of BCRP. Some authorities advise that concomitant use of talazoparib with potent BCRP inhibitors such as cyclosporine should be avoided (UK). Patients should be closely monitored for adverse effects such as myelosuppression and myelodysplastic syndrome/acute myeloid leukemia, and dosage adjustments made or treatment withheld as needed in accordance with the product labeling.", "mechanism_text": "Others", "recommendation": "Caution is recommended when talazoparib is coadministered with inhibitors of BCRP.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97721/", "reference_text": "[1] \"Product Information. Talzenna (talazoparib).\" Pfizer U.S. Pharmaceuticals Group, New York, NY.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0", "alternatives_a": "Romiplostim, Avatrombopag, Emicizumab, Coagulation factor VIIa Recombinant Human, Coagulation factor X human, Phylloquinone, Lusutrombopag, Anti-inhibitor coagulant complex, Antihemophilic factor, human recombinant, Fibrinogen human, Epinephrine, Coagulation Factor IX Human", "alternatives_b": "Pertuzumab, Olaparib, Oxaliplatin, Bortezomib, Tisagenlecleucel, Aminolevulinic acid, Omacetaxine mepesuccinate, Tazemetostat, Altretamine, Tagraxofusp, Ixazomib, More", "updated_at": 1767369485}, {"id": 97618, "ingredient1": "Eltrombopag", "ingredient2": "Tedizolid", "severity": "Moderate", "effect": "Coadministration with oral tedizolid may increase the plasma concentrations and the risk of adverse effects of orally administered drugs that are substrates of the breast cancer resistance protein (BCRP) transporter. The proposed mechanism is decreased clearance due to inhibition of BCRP-mediated intestinal efflux by tedizolid.", "source": "DDInter", "management_text": "Consider temporarily interrupting treatment with the BCRP substrate during treatment with tedizolid, especially for BCRP substrates with a narrow therapeutic index. If coadministration cannot be avoided, monitor for adverse reactions related to concomitantly administered BCRP substrate.", "mechanism_text": "Absorption", "recommendation": "Consider temporarily interrupting treatment with the BCRP substrate during treatment with tedizolid, especially for BCRP substrates with a narrow therapeutic index.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97722/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Sivextro (tedizolid).\" Cubist Pharmaceuticals Inc, Lexington, MA.[3] \"Product Information. Venclexta (venetoclax).\" AbbVie US LLC, North Chicago, IL.", "alternatives_a": "Romiplostim, Fostamatinib, Avatrombopag, Emicizumab, Coagulation factor VIIa Recombinant Human, Coagulation factor X human, Phylloquinone, Anti-inhibitor coagulant complex, Antihemophilic factor, human recombinant, Fibrinogen human, Epinephrine, Coagulation Factor IX Human", "alternatives_b": "Tinidazole, Linezolid, Bacitracin, Oritavancin, Polymyxin B, Daptomycin, Vancomycin, Metronidazole, Telavancin, Methenamine, Spectinomycin, More", "updated_at": 1767369485}, {"id": 97619, "ingredient1": "Eltrombopag", "ingredient2": "Teriflunomide", "severity": "Major", "effect": "The recent, concomitant, or subsequent use (without the recommended leflunomide washout period or procedure) of other agents known to induce hepatotoxicity may potentiate the risk of liver injury associated with leflunomide. The risk is thought to extend to teriflunomide, its principal active metabolite, because recommended dosages of both result in a similar range of plasma concentrations of teriflunomide.", "source": "DDInter", "management_text": "Caution is advised if leflunomide or teriflunomide must be used in patients who are currently receiving or have recently received treatment with other hepatotoxic agents (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; nucleoside reverse transcriptase inhibitors; proteasome inhibitors; retinoids; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice), and vice versa. Liver enzymes and bilirubin should be measured prior to initiation of leflunomide/teriflunomide therapy and at least monthly for the first six months of treatment and every 6 to 8 weeks thereafter. Patients with preexisting liver disease or elevated baseline liver enzymes (i.e., ALT greater than two times ULN) should not receive leflunomide or teriflunomide. Patients who develop elevated serum ALT greater than three times ULN while receiving these medications should discontinue treatment and be given washout procedures with cholestyramine or activated charcoal to accelerate elimination of leflunomide's active metabolite from plasma, which otherwise may take up to two years. Follow-up monitoring should be conducted at least weekly until the ALT value is within normal range, and washout procedures repeated as necessary. All patients treated with leflunomide or teriflunomide should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if leflunomide or teriflunomide must be used in patients who are currently receiving or have recently received treatment with other hepatotoxic agents (e.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97723/", "reference_text": "[1] EMEA \"EMEA public statement on leflunomide (ARAVA) - severe and serious hepatic reactions. Available from URL: http://www.eudra.org/emea.html.\" ([1999 Sept 2]):[2] \"Product Information. Arava (leflunomide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[3] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"", "alternatives_a": "Romiplostim, Avatrombopag, Emicizumab, Coagulation factor VIIa Recombinant Human, Coagulation factor X human, Phylloquinone, Anti-inhibitor coagulant complex, Antihemophilic factor, human recombinant, Fibrinogen human, Epinephrine, Coagulation Factor IX Human", "alternatives_b": "Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Tacrolimus, More", "updated_at": 1767369485}, {"id": 97620, "ingredient1": "Eltrombopag", "ingredient2": "Tioguanine", "severity": "Moderate", "effect": "The concomitant or sequential use of other agents known to induce hepatotoxicity may potentiate the risk of liver injury associated with thioguanine. A high risk of liver toxicity characterized by vascular endothelial damage has been reported with long-term continuous use of thioguanine, particularly in children receiving the drug as part of maintenance therapy for acute lymphoblastic leukemia and in other conditions associated with continuous use.", "source": "DDInter", "management_text": "The risk of hepatic injury should be considered when thioguanine is used with other potentially hepatotoxic agents (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; nucleoside reverse transcriptase inhibitors; proteasome inhibitors; retinoids; sulfonamides; tamoxifen; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice). Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice. Baseline and regular monitoring of hepatic function is recommended. Thioguanine therapy should be discontinued if there is evidence of toxic hepatitis or biliary stasis, as reversal of signs and symptoms of liver toxicity have been reported upon withdrawal. Early indications of liver toxicity are signs associated with portal hypertension such as thrombocytopenia out of proportion with neutropenia and splenomegaly. Elevations of liver enzymes have also been reported, but do not always occur.", "mechanism_text": "Synergism", "recommendation": "The risk of hepatic injury should be considered when thioguanine is used with other potentially hepatotoxic agents (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97724/", "reference_text": "[1] \"Product Information. Aubagio (teriflunomide).\" Genzyme Corporation, Cambridge, MA.[2] \"Product Information. Tabloid (thioguanine).\" Prasco Laboratories, Cincinnati, OH.", "alternatives_a": "Fluorouracil, Pemetrexed, Mercaptopurine, Trifluridine, Floxuridine, Gemcitabine, Nelarabine, Cytarabine, Pralatrexate, Fludarabine, Decitabine, More", "alternatives_b": "Romiplostim, Avatrombopag, Emicizumab, Coagulation factor VIIa Recombinant Human, Coagulation factor X human, Phylloquinone, Lusutrombopag, Anti-inhibitor coagulant complex, Antihemophilic factor, human recombinant, Fibrinogen human, Epinephrine, Coagulation Factor IX Human", "updated_at": 1767369485}, {"id": 97621, "ingredient1": "Eltrombopag", "ingredient2": "Topotecan", "severity": "Moderate", "effect": "Coadministration with eltrombopag may increase the plasma concentrations of drugs that are substrates of the organic anion transporting polypeptide (OATP) 1B1 and/or breast cancer resistance protein (BCRP) transporters. The mechanism is decreased clearance due to inhibition of OATP1B1-mediated hepatic uptake and BCRP-mediated intestinal and hepatobiliary efflux by eltrombopag. The interaction has been demonstrated for rosuvastatin, a known substrate of both OATP 1B1 and BCRP.", "source": "DDInter", "management_text": "Caution is advised during concomitant use of eltrombopag with drugs that are substrates of the OATP1B1 and/or BCRP transporters, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever eltrombopag is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised during concomitant use of eltrombopag with drugs that are substrates of the OATP1B1 and/or BCRP transporters, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97725/", "reference_text": "[1] Allred AJ, Bowen CJ, Park JW, et al. \"Eltrombopag increases plasma rosuvastatin exposure in healthy volunteers.\" Br J Clin Pharmacol 72 (2011): 321-9[2] Kalliokoski A, Niemi M \"Impact of OATP transporters on pharmacokinetics.\" Br J Pharmacol 158 (2009): 693-705[3] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[4] \"Product Information. Promacta (eltrombopag).\" GlaxoSmithKline, Research Triangle Park, NC.[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[7] \"Product Information. Promacta (eltrombopag).\" GlaxoSmithKline, Research Triangle Park, NC.", "alternatives_a": "Vincristine, Cabazitaxel, Vinblastine, Paclitaxel, Teniposide, Vinorelbine, Etoposide, Docetaxel", "alternatives_b": "Romiplostim, Avatrombopag, Emicizumab, Coagulation factor VIIa Recombinant Human, Coagulation factor X human, Phylloquinone, Lusutrombopag, Anti-inhibitor coagulant complex, Antihemophilic factor, human recombinant, Fibrinogen human, Epinephrine, Coagulation Factor IX Human", "updated_at": 1767369485}, {"id": 97622, "ingredient1": "Eltrombopag", "ingredient2": "Trabectedin", "severity": "Moderate", "effect": "Coadministration of trabectedin with other agents known to induce hepatotoxicity may potentiate the risk of liver injury.", "source": "DDInter", "management_text": "The risk of hepatic injury should be considered when trabectedin is used with other potentially hepatotoxic agents (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; nucleoside reverse transcriptase inhibitors; proteasome inhibitors; retinoids; sulfonamides; tamoxifen; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice). Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice. Monitoring of alkaline phosphatase, bilirubin, AST, and ALT should occur regularly during trabectedin treatment in accordance with the product labeling, or as often as necessary when clinical symptoms develop.", "mechanism_text": "Synergism", "recommendation": "The risk of hepatic injury should be considered when trabectedin is used with other potentially hepatotoxic agents (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97726/", "reference_text": "[1] \"Product Information. Yondelis (trabectedin).\" Janssen Pharmaceuticals, Titusville, NJ.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Yondelis (trabectedin).\" Janssen Pharmaceuticals, Titusville, NJ.[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0", "alternatives_a": "Vincristine, Cabazitaxel, Vinblastine, Paclitaxel, Teniposide, Vinorelbine, Etoposide, Docetaxel", "alternatives_b": "Romiplostim, Avatrombopag, Emicizumab, Coagulation factor VIIa Recombinant Human, Coagulation factor X human, Phylloquinone, Lusutrombopag, Anti-inhibitor coagulant complex, Antihemophilic factor, human recombinant, Fibrinogen human, Epinephrine, Coagulation Factor IX Human", "updated_at": 1767369485}, {"id": 97623, "ingredient1": "Eltrombopag", "ingredient2": "Tucatinib", "severity": "Moderate", "effect": "Coadministration with inhibitors of CYP450 2C8 may increase the plasma concentrations of tucatinib, which is primarily metabolized by the isoenzyme.", "source": "DDInter", "management_text": "Increased monitoring is advised if tucatinib is coadministered with CYP450 2C8 inhibitors. Dosage adjustments may be required based on clinical response and tolerance.", "mechanism_text": "Metabolism", "recommendation": "Increased monitoring is advised if tucatinib is coadministered with CYP450 2C8 inhibitors.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97727/", "reference_text": "[1] \"Product Information. Tukysa (tucatinib).\" Seattle Genetics Inc, Bothell, WA.[2] \"Product Information. Accolate (zafirlukast).\" Zeneca Pharmaceuticals, Wilmington, DE.", "alternatives_a": "Romiplostim, Emicizumab, Coagulation factor VIIa Recombinant Human, Coagulation factor X human, Phylloquinone, Anti-inhibitor coagulant complex, Antihemophilic factor, human recombinant, Fibrinogen human, Epinephrine, Coagulation Factor IX Human", "alternatives_b": "Dabrafenib, Asciminib, Acalabrutinib, Dacomitinib, Tepotinib, Fedratinib, Avapritinib, Bosutinib, Vemurafenib, Selumetinib, Vandetanib, More", "updated_at": 1767369485}, {"id": 97624, "ingredient1": "Eltrombopag", "ingredient2": "Ubrogepant", "severity": "Moderate", "effect": "Coadministration with breast cancer resistance protein (BCRP) and/or P-glycoprotein (P-gp) only inhibitors may increase the exposure of ubrogepant, which is a substrate of these transporters.", "source": "DDInter", "management_text": "The manufacturer recommends an initial ubrogepant dose of 50 mg when coadministered with BCRP and/or P-gp only inhibitors. If needed, a second 50 mg dose of ubrogepant may be administered at least 2 hours after the initial dose.", "mechanism_text": "Distribution", "recommendation": "The manufacturer recommends an initial ubrogepant dose of 50 mg when coadministered with BCRP and/or P-gp only inhibitors.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97728/", "reference_text": "[1] \"Product Information. Ubrelvy (ubrogepant).\" Allergan Inc, Irvine, CA.[2] \"Product Information. Mavyret (glecaprevir-pibrentasvir).\" Abbott Pharmaceutical, Abbott Park, IL.[3] \"Product Information. Ubrelvy (ubrogepant).\" Allergan Inc, Irvine, CA.", "alternatives_a": "Romiplostim, Avatrombopag, Emicizumab, Coagulation factor VIIa Recombinant Human, Coagulation factor X human, Phylloquinone, Lusutrombopag, Anti-inhibitor coagulant complex, Antihemophilic factor, human recombinant, Fibrinogen human, Epinephrine, Coagulation Factor IX Human", "alternatives_b": "Frovatriptan, Dihydroergotamine, Eptinezumab, Eletriptan, Rizatriptan, Ergotamine, Clonidine, Naratriptan, Galcanezumab, Zolmitriptan, Sumatriptan, More", "updated_at": 1767369485}, {"id": 97625, "ingredient1": "Eltrombopag", "ingredient2": "Zinc acetate", "severity": "Moderate", "effect": "INTERVAL: Products containing aluminum, calcium, iron, magnesium, zinc and other polyvalent cations such as antacids or mineral supplements can significantly reduce the gastrointestinal absorption of eltrombopag due to chelation.", "source": "DDInter", "management_text": "Eltrombopag should be taken on an empty stomach at least 2 hours before or 4 hours after oral medications that contain antacids (e.g., didanosine buffered tablets or pediatric oral solution), aluminum, calcium, iron, magnesium, zinc or other polyvalent cations.", "mechanism_text": "Absorption", "recommendation": "Eltrombopag should be taken on an empty stomach at least 2 hours before or 4 hours after oral medications that contain antacids (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97729/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Promacta (eltrombopag).\" GlaxoSmithKline, Research Triangle Park, NC.[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] \"Product Information. Promacta (eltrombopag).\" GlaxoSmithKline, Research Triangle Park, NC.", "alternatives_a": "Romiplostim, Fostamatinib, Avatrombopag, Emicizumab, Coagulation factor VIIa Recombinant Human, Coagulation factor X human, Phylloquinone, Lusutrombopag, Anti-inhibitor coagulant complex, Antihemophilic factor, human recombinant, Fibrinogen human, More", "alternatives_b": "Lidocaine, Diltiazem, Tetracaine, Fluocinolone acetonide, Hydrocortisone, Fluocinonide, Isosorbide dinitrate, Zinc chloride, Procaine, Prednisolone, Betamethasone, More", "updated_at": 1767369485}, {"id": 97626, "ingredient1": "Eltrombopag", "ingredient2": "Zinc gluconate", "severity": "Moderate", "effect": "INTERVAL: Products containing aluminum, calcium, iron, magnesium, zinc and other polyvalent cations such as antacids or mineral supplements can significantly reduce the gastrointestinal absorption of eltrombopag due to chelation.", "source": "DDInter", "management_text": "Eltrombopag should be taken on an empty stomach at least 2 hours before or 4 hours after oral medications that contain antacids (e.g., didanosine buffered tablets or pediatric oral solution), aluminum, calcium, iron, magnesium, zinc or other polyvalent cations.", "mechanism_text": "Absorption", "recommendation": "Eltrombopag should be taken on an empty stomach at least 2 hours before or 4 hours after oral medications that contain antacids (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97730/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Promacta (eltrombopag).\" GlaxoSmithKline, Research Triangle Park, NC.[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] \"Product Information. Promacta (eltrombopag).\" GlaxoSmithKline, Research Triangle Park, NC.", "alternatives_a": "Romiplostim, Fostamatinib, Avatrombopag, Emicizumab, Coagulation factor VIIa Recombinant Human, Coagulation factor X human, Phylloquinone, Lusutrombopag, Anti-inhibitor coagulant complex, Antihemophilic factor, human recombinant, Fibrinogen human, More", "alternatives_b": "Lidocaine, Diltiazem, Tetracaine, Fluocinolone acetonide, Hydrocortisone, Fluocinonide, Isosorbide dinitrate, Zinc chloride, Procaine, Prednisolone, Betamethasone, More", "updated_at": 1767369485}, {"id": 97627, "ingredient1": "Eltrombopag", "ingredient2": "Zinc sulfate", "severity": "Moderate", "effect": "INTERVAL: Products containing aluminum, calcium, iron, magnesium, zinc and other polyvalent cations such as antacids or mineral supplements can significantly reduce the gastrointestinal absorption of eltrombopag due to chelation.", "source": "DDInter", "management_text": "Eltrombopag should be taken on an empty stomach at least 2 hours before or 4 hours after oral medications that contain antacids (e.g., didanosine buffered tablets or pediatric oral solution), aluminum, calcium, iron, magnesium, zinc or other polyvalent cations.", "mechanism_text": "Absorption", "recommendation": "Eltrombopag should be taken on an empty stomach at least 2 hours before or 4 hours after oral medications that contain antacids (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97731/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Promacta (eltrombopag).\" GlaxoSmithKline, Research Triangle Park, NC.[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] \"Product Information. Promacta (eltrombopag).\" GlaxoSmithKline, Research Triangle Park, NC.", "alternatives_a": "Romiplostim, Fostamatinib, Avatrombopag, Emicizumab, Coagulation factor VIIa Recombinant Human, Coagulation factor X human, Phylloquinone, Lusutrombopag, Anti-inhibitor coagulant complex, Antihemophilic factor, human recombinant, Fibrinogen human, More", "alternatives_b": "Lidocaine, Diltiazem, Tetracaine, Fluocinolone acetonide, Hydrocortisone, Fluocinonide, Isosorbide dinitrate, Zinc chloride, Procaine, Prednisolone, Betamethasone, More", "updated_at": 1767369485}, {"id": 97628, "ingredient1": "Amoxapine", "ingredient2": "Eluxadoline", "severity": "Moderate", "effect": "The risk of constipation and serious constipation-related adverse reactions may be increased when eluxadoline is used with other drugs that are also associated with this adverse effect.", "source": "DDInter", "management_text": "Concomitant use of eluxadoline with other drugs that can cause constipation such as alosetron, anticholinergics, and opioids should generally be avoided. Loperamide may be used occasionally for acute management of severe diarrhea, but chronic use is not recommended, and it should be discontinued immediately if constipation occurs. Eluxadoline should also be discontinued if constipation occurs for more than 4 days.", "mechanism_text": "Synergism", "recommendation": "Concomitant use of eluxadoline with other drugs that can cause constipation such as alosetron, anticholinergics, and opioids should generally be avoided.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97732/", "reference_text": "[1] \"Product Information. Viberzi (eluxadoline).\" Actavis Pharma, Inc., Parsippany, NJ.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Viberzi (eluxadoline).\" Actavis Pharma, Inc., Parsippany, NJ.", "alternatives_a": "Citalopram, Sertraline, St. John's Wort, Milnacipran, Vortioxetine, Levomilnacipran, Duloxetine, Isocarboxazid, Viloxazine, Esketamine, Phenelzine, More", "alternatives_b": "Diphenoxylate, Difenoxin", "updated_at": 1767369485}, {"id": 97629, "ingredient1": "Amprenavir", "ingredient2": "Eluxadoline", "severity": "Moderate", "effect": "It is not known whether, and to what extent, eluxadoline may be metabolized by CYP450 isoenzymes and may interact with inhibitors of CYP450 isoenzymes.", "source": "DDInter", "management_text": "As a precautionary measure due to incomplete information on the metabolism of eluxadoline, the manufacturer recommends caution during coadministration with potent inhibitors of various CYP450 isoenzymes. Patients should be monitored for adverse effects such as sedation, nausea, vomiting, constipation, abdominal pain, liver enzyme elevations, and pancreatitis,", "mechanism_text": "Metabolism", "recommendation": "As a precautionary measure due to incomplete information on the metabolism of eluxadoline, the manufacturer recommends caution during coadministration with potent inhibitors of various CYP450 isoenzymes.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97733/", "reference_text": "[1] \"Product Information. Viberzi (eluxadoline).\" Actavis Pharma, Inc., Parsippany, NJ.[2] \"Product Information. Viberzi (eluxadoline).\" Actavis Pharma, Inc., Parsippany, NJ.[3] \"Product Information. Zokinvy (lonafarnib).\" Eiger BioPharmaceuticals, Palo Alto, CA.", "alternatives_a": "Lamivudine, Glecaprevir, Tenofovir alafenamide, Maraviroc, Cabotegravir, Valaciclovir, Zanamivir, Lenacapavir, Velpatasvir, Rilpivirine, Etravirine, More", "alternatives_b": "Opium, Diphenoxylate, Morphine, Difenoxin", "updated_at": 1767369485}, {"id": 97630, "ingredient1": "Eluxadoline", "ingredient2": "Artesunate", "severity": "Major", "effect": "Coadministration with inhibitors of organic anion transporting polypeptide (OATP) 1B1 may significantly increase the plasma concentrations of eluxadoline. Based on available data, inhibition of OATP1B1-mediated hepatic uptake appears to reduce both the hepatic first-pass extraction and systemic biliary clearance of eluxadoline.", "source": "DDInter", "management_text": "The recommended dosage of eluxadoline is 75 mg twice daily when used with OATP1B1 inhibitors. Patients should be monitored for adverse effects such as sedation, nausea, vomiting, constipation, abdominal pain, liver enzyme elevations, and pancreatitis.", "mechanism_text": "Metabolism", "recommendation": "The recommended dosage of eluxadoline is 75 mg twice daily when used with OATP1B1 inhibitors.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97734/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Davenport JM, Covington P, Bonifacio L, McIntyre G, Venitz J \"Effect of uptake transporters OAT3 and OATPIBI and efflux transporter MRP2 on the pharmacokinetics of eluxadoline.\" J Clin Pharmacol 55 (2015): 534-42[3] \"Product Information. Viberzi (eluxadoline).\" Actavis Pharma, Inc., Parsippany, NJ.[4] \"Product Information. Viberzi (eluxadoline).\" Actavis Pharma, Inc., Parsippany, NJ.[5] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[6] Cerner Multum, Inc. \"Australian Product Information.\" O 0[7] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[8] \"Product Information. Aptivus (tipranavir).\" Boehringer-Ingelheim, Ridgefield, CT.", "alternatives_a": "Morphine, Diphenoxylate, Opium, Difenoxin, Loperamide", "alternatives_b": "Mefloquine, Lumefantrine, Artemether, Pyrimethamine, Tafenoquine, Atovaquone, Hydroxychloroquine, Halofantrine, Quinine, Primaquine, Proguanil, More", "updated_at": 1767369485}, {"id": 97631, "ingredient1": "Eluxadoline", "ingredient2": "Astemizole", "severity": "Moderate", "effect": "It is not known whether, and to what extent, eluxadoline may inhibit CYP450 3A4 and may interact with substrates of the isoenzyme. In vitro studies have shown that eluxadoline is not an inhibitor of CYP450 3A4 at clinically relevant systemic concentrations, but they were not adequate to rule out inhibition of CYP450 3A4 in the gut by eluxadoline. Therefore, the potential for eluxadoline to increase plasma concentrations of oral drugs that are metabolized by CYP450 3A4 should be considered.", "source": "DDInter", "management_text": "Caution is advised when eluxadoline is used with sensitive CYP450 3A4 substrates or substrates with narrow therapeutic ranges. These drugs include, but are not limited to: cisapride, colchicine, cyclosporine, fentanyl, ivacaftor, lovastatin, simvastatin, oral midazolam, triazolam, pimozide, quinidine, sildenafil, ergot derivatives, and macrolide immunosuppressants.", "mechanism_text": "Others", "recommendation": "Caution is advised when eluxadoline is used with sensitive CYP450 3A4 substrates or substrates with narrow therapeutic ranges.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97735/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Viberzi (eluxadoline).\" Actavis Pharma, Inc., Parsippany, NJ.[3] \"Product Information. Viberzi (eluxadoline).\" Actavis Pharma, Inc., Parsippany, NJ.[4] Kupferschmidt HHT, Ha HR, Ziegler WH, Meier PJ, Krahenbuhl S \"Interaction between grapefruit juice and midazolam in humans.\" Clin Pharmacol Ther 58 (1995): 20-8[5] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ \"Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice.\" Clin Pharmacol Ther 58 (1995): 127-31[6] \"Product Information. Valium (diazepam).\" Roche Laboratories, Nutley, NJ.[7] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[8] \"Product Information. Halcion (triazolam).\" Pharmacia and Upjohn, Kalamazoo, MI.[9] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[10] \"Product Information. Xanax (alprazolam).\" Pharmacia and Upjohn, Kalamazoo, MI.", "alternatives_a": "Ketotifen, Levocetirizine, Cetirizine, Loratadine, Trimethobenzamide, Desloratadine, Azelastine", "alternatives_b": "Opium, Diphenoxylate, Difenoxin", "updated_at": 1767369485}, {"id": 97632, "ingredient1": "Eluxadoline", "ingredient2": "Azatadine", "severity": "Moderate", "effect": "The risk of constipation and serious constipation-related adverse reactions may be increased when eluxadoline is used with other drugs that are also associated with this adverse effect.", "source": "DDInter", "management_text": "Concomitant use of eluxadoline with other drugs that can cause constipation such as alosetron, anticholinergics, and opioids should generally be avoided. Loperamide may be used occasionally for acute management of severe diarrhea, but chronic use is not recommended, and it should be discontinued immediately if constipation occurs. Eluxadoline should also be discontinued if constipation occurs for more than 4 days.", "mechanism_text": "Synergism", "recommendation": "Concomitant use of eluxadoline with other drugs that can cause constipation such as alosetron, anticholinergics, and opioids should generally be avoided.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97736/", "reference_text": "[1] \"Product Information. Viberzi (eluxadoline).\" Actavis Pharma, Inc., Parsippany, NJ.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Viberzi (eluxadoline).\" Actavis Pharma, Inc., Parsippany, NJ.", "alternatives_a": "Ketotifen, Levocetirizine, Cetirizine, Loratadine, Trimethobenzamide, Desloratadine, Azelastine", "alternatives_b": "Diphenoxylate, Difenoxin", "updated_at": 1767369485}, {"id": 97633, "ingredient1": "Eluxadoline", "ingredient2": "Belladonna", "severity": "Moderate", "effect": "The risk of constipation and serious constipation-related adverse reactions may be increased when eluxadoline is used with other drugs that are also associated with this adverse effect.", "source": "DDInter", "management_text": "Concomitant use of eluxadoline with other drugs that can cause constipation such as alosetron, anticholinergics, and opioids should generally be avoided. Loperamide may be used occasionally for acute management of severe diarrhea, but chronic use is not recommended, and it should be discontinued immediately if constipation occurs. Eluxadoline should also be discontinued if constipation occurs for more than 4 days.", "mechanism_text": "Synergism", "recommendation": "Concomitant use of eluxadoline with other drugs that can cause constipation such as alosetron, anticholinergics, and opioids should generally be avoided.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97737/", "reference_text": "[1] \"Product Information. Viberzi (eluxadoline).\" Actavis Pharma, Inc., Parsippany, NJ.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Viberzi (eluxadoline).\" Actavis Pharma, Inc., Parsippany, NJ.", "alternatives_a": "Diphenoxylate, Difenoxin", "alternatives_b": "", "updated_at": 1767369485}, {"id": 97634, "ingredient1": "Eluxadoline", "ingredient2": "Boceprevir", "severity": "Moderate", "effect": "It is not known whether, and to what extent, eluxadoline may be metabolized by CYP450 isoenzymes and may interact with inhibitors of CYP450 isoenzymes.", "source": "DDInter", "management_text": "As a precautionary measure due to incomplete information on the metabolism of eluxadoline, the manufacturer recommends caution during coadministration with potent inhibitors of various CYP450 isoenzymes. Patients should be monitored for adverse effects such as sedation, nausea, vomiting, constipation, abdominal pain, liver enzyme elevations, and pancreatitis,", "mechanism_text": "Metabolism", "recommendation": "As a precautionary measure due to incomplete information on the metabolism of eluxadoline, the manufacturer recommends caution during coadministration with potent inhibitors of various CYP450 isoenzymes.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97738/", "reference_text": "[1] \"Product Information. Viberzi (eluxadoline).\" Actavis Pharma, Inc., Parsippany, NJ.[2] \"Product Information. Viberzi (eluxadoline).\" Actavis Pharma, Inc., Parsippany, NJ.[3] \"Product Information. Zokinvy (lonafarnib).\" Eiger BioPharmaceuticals, Palo Alto, CA.", "alternatives_a": "Lamivudine, Glecaprevir, Tenofovir alafenamide, Maraviroc, Cabotegravir, Valaciclovir, Zanamivir, Lenacapavir, Velpatasvir, Rilpivirine, Etravirine, More", "alternatives_b": "Opium, Diphenoxylate, Morphine, Difenoxin", "updated_at": 1767369485}, {"id": 97635, "ingredient1": "Eluxadoline", "ingredient2": "Cerivastatin", "severity": "Moderate", "effect": "Coadministration with eluxadoline may increase the plasma concentrations of drugs that are substrates of the organic anion transporting polypeptide (OATP) 1B1 and/or breast cancer resistance protein (BCRP) transporters. The mechanism is decreased clearance due to inhibition of OATP1B1-mediated hepatic uptake and BCRP-mediated intestinal and hepatobiliary efflux by eluxadoline.", "source": "DDInter", "management_text": "Caution is advised when eluxadoline is used concomitantly with drugs that are substrates of the OATP1B1 and/or BCRP transporters, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever eluxadoline is added to or withdrawn from therapy.", "mechanism_text": "Others", "recommendation": "Caution is advised when eluxadoline is used concomitantly with drugs that are substrates of the OATP1B1 and/or BCRP transporters, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97739/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Viberzi (eluxadoline).\" Actavis Pharma, Inc., Parsippany, NJ.[3] Richter WO, Jacob BG, Schwandt P \"Interaction between fibre and lovastatin.\" Lancet 338 (1991): 706[4] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors.\" Clin Pharmacol Ther 64 (1998): 477-83[5] Kantola T, Kivisto KT, Neuvonen PJ \"Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid.\" Clin Pharmacol Ther 63 (1998): 397-402[6] \"Product Information. Mevacor (lovastatin).\" Merck & Co, Inc, West Point, PA.[7] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions.\" Br J Clin Pharmacol 46 (1998): 101-10[8] Neuvonen PJ, Backman JT, Niemi M \"Pharmacokinetic comparison of the potential over-the-counter statins simvastatin, lovastatin, fluvastatin and pravastatin.\" Clin Pharmacokinet 47 (2008): 463-74[9] Thompson PD, Clarkson P, Karas RH \"Statin-associated myopathy.\" JAMA 289 (2003): 1681-90[10] \"Product Information. Zocor (simvastatin).\" Merck & Co, Inc, West Point, PA.[11] \"Product Information. Viberzi (eluxadoline).\" Actavis Pharma, Inc., Parsippany, NJ.", "alternatives_a": "Fenofibric acid, Mipomersen, Evinacumab, Evolocumab, Dextrothyroxine, Probucol, Cholestyramine, Clofibrate, Colestipol, Niacin, Lomitapide, More", "alternatives_b": "Morphine, Diphenoxylate, Opium, Difenoxin, Loperamide", "updated_at": 1767369485}, {"id": 97636, "ingredient1": "Eluxadoline", "ingredient2": "Chlorcyclizine", "severity": "Moderate", "effect": "The risk of constipation and serious constipation-related adverse reactions may be increased when eluxadoline is used with other drugs that are also associated with this adverse effect.", "source": "DDInter", "management_text": "Concomitant use of eluxadoline with other drugs that can cause constipation such as alosetron, anticholinergics, and opioids should generally be avoided. Loperamide may be used occasionally for acute management of severe diarrhea, but chronic use is not recommended, and it should be discontinued immediately if constipation occurs. Eluxadoline should also be discontinued if constipation occurs for more than 4 days.", "mechanism_text": "Synergism", "recommendation": "Concomitant use of eluxadoline with other drugs that can cause constipation such as alosetron, anticholinergics, and opioids should generally be avoided.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97740/", "reference_text": "[1] \"Product Information. Viberzi (eluxadoline).\" Actavis Pharma, Inc., Parsippany, NJ.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Viberzi (eluxadoline).\" Actavis Pharma, Inc., Parsippany, NJ.", "alternatives_a": "Ketotifen, Levocetirizine, Cetirizine, Loratadine, Trimethobenzamide, Desloratadine, Azelastine", "alternatives_b": "Diphenoxylate, Difenoxin", "updated_at": 1767369485}, {"id": 97637, "ingredient1": "Eluxadoline", "ingredient2": "Chlorpromazine", "severity": "Moderate", "effect": "The risk of constipation and serious constipation-related adverse reactions may be increased when eluxadoline is used with other drugs that are also associated with this adverse effect.", "source": "DDInter", "management_text": "Concomitant use of eluxadoline with other drugs that can cause constipation such as alosetron, anticholinergics, and opioids should generally be avoided. Loperamide may be used occasionally for acute management of severe diarrhea, but chronic use is not recommended, and it should be discontinued immediately if constipation occurs. Eluxadoline should also be discontinued if constipation occurs for more than 4 days.", "mechanism_text": "Synergism", "recommendation": "Concomitant use of eluxadoline with other drugs that can cause constipation such as alosetron, anticholinergics, and opioids should generally be avoided.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97741/", "reference_text": "[1] \"Product Information. Viberzi (eluxadoline).\" Actavis Pharma, Inc., Parsippany, NJ.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Viberzi (eluxadoline).\" Actavis Pharma, Inc., Parsippany, NJ.", "alternatives_a": "Asenapine, Pimavanserin, Ziprasidone, Lumateperone, Iloperidone, Amisulpride, Droperidol, Cariprazine, Brexpiprazole, Paliperidone, Lurasidone", "alternatives_b": "Diphenoxylate, Difenoxin", "updated_at": 1767369485}, {"id": 97638, "ingredient1": "Eluxadoline", "ingredient2": "Cisapride", "severity": "Moderate", "effect": "It is not known whether, and to what extent, eluxadoline may inhibit CYP450 3A4 and may interact with substrates of the isoenzyme. In vitro studies have shown that eluxadoline is not an inhibitor of CYP450 3A4 at clinically relevant systemic concentrations, but they were not adequate to rule out inhibition of CYP450 3A4 in the gut by eluxadoline. Therefore, the potential for eluxadoline to increase plasma concentrations of oral drugs that are metabolized by CYP450 3A4 should be considered.", "source": "DDInter", "management_text": "Caution is advised when eluxadoline is used with sensitive CYP450 3A4 substrates or substrates with narrow therapeutic ranges. These drugs include, but are not limited to: cisapride, colchicine, cyclosporine, fentanyl, ivacaftor, lovastatin, simvastatin, oral midazolam, triazolam, pimozide, quinidine, sildenafil, ergot derivatives, and macrolide immunosuppressants.", "mechanism_text": "Others", "recommendation": "Caution is advised when eluxadoline is used with sensitive CYP450 3A4 substrates or substrates with narrow therapeutic ranges.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97742/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Viberzi (eluxadoline).\" Actavis Pharma, Inc., Parsippany, NJ.[3] \"Product Information. Viberzi (eluxadoline).\" Actavis Pharma, Inc., Parsippany, NJ.[4] Kupferschmidt HHT, Ha HR, Ziegler WH, Meier PJ, Krahenbuhl S \"Interaction between grapefruit juice and midazolam in humans.\" Clin Pharmacol Ther 58 (1995): 20-8[5] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ \"Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice.\" Clin Pharmacol Ther 58 (1995): 127-31[6] \"Product Information. Valium (diazepam).\" Roche Laboratories, Nutley, NJ.[7] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[8] \"Product Information. Halcion (triazolam).\" Pharmacia and Upjohn, Kalamazoo, MI.[9] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[10] \"Product Information. Xanax (alprazolam).\" Pharmacia and Upjohn, Kalamazoo, MI.", "alternatives_a": "Metoclopramide", "alternatives_b": "Opium, Diphenoxylate, Difenoxin", "updated_at": 1767369485}, {"id": 97639, "ingredient1": "Eluxadoline", "ingredient2": "Cyclizine", "severity": "Moderate", "effect": "The risk of constipation and serious constipation-related adverse reactions may be increased when eluxadoline is used with other drugs that are also associated with this adverse effect.", "source": "DDInter", "management_text": "Concomitant use of eluxadoline with other drugs that can cause constipation such as alosetron, anticholinergics, and opioids should generally be avoided. Loperamide may be used occasionally for acute management of severe diarrhea, but chronic use is not recommended, and it should be discontinued immediately if constipation occurs. Eluxadoline should also be discontinued if constipation occurs for more than 4 days.", "mechanism_text": "Synergism", "recommendation": "Concomitant use of eluxadoline with other drugs that can cause constipation such as alosetron, anticholinergics, and opioids should generally be avoided.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97743/", "reference_text": "[1] \"Product Information. Viberzi (eluxadoline).\" Actavis Pharma, Inc., Parsippany, NJ.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Viberzi (eluxadoline).\" Actavis Pharma, Inc., Parsippany, NJ.", "alternatives_a": "Ketotifen, Levocetirizine, Cetirizine, Loratadine, Trimethobenzamide, Desloratadine, Azelastine", "alternatives_b": "Difenoxin", "updated_at": 1767369485}, {"id": 97640, "ingredient1": "Eluxadoline", "ingredient2": "Cyproheptadine", "severity": "Moderate", "effect": "The risk of constipation and serious constipation-related adverse reactions may be increased when eluxadoline is used with other drugs that are also associated with this adverse effect.", "source": "DDInter", "management_text": "Concomitant use of eluxadoline with other drugs that can cause constipation such as alosetron, anticholinergics, and opioids should generally be avoided. Loperamide may be used occasionally for acute management of severe diarrhea, but chronic use is not recommended, and it should be discontinued immediately if constipation occurs. Eluxadoline should also be discontinued if constipation occurs for more than 4 days.", "mechanism_text": "Synergism", "recommendation": "Concomitant use of eluxadoline with other drugs that can cause constipation such as alosetron, anticholinergics, and opioids should generally be avoided.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97744/", "reference_text": "[1] \"Product Information. Viberzi (eluxadoline).\" Actavis Pharma, Inc., Parsippany, NJ.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Viberzi (eluxadoline).\" Actavis Pharma, Inc., Parsippany, NJ.", "alternatives_a": "Ketotifen, Levocetirizine, Cetirizine, Loratadine, Trimethobenzamide, Desloratadine, Azelastine", "alternatives_b": "", "updated_at": 1767369485}, {"id": 97641, "ingredient1": "Eluxadoline", "ingredient2": "Dexbrompheniramine", "severity": "Moderate", "effect": "The risk of constipation and serious constipation-related adverse reactions may be increased when eluxadoline is used with other drugs that are also associated with this adverse effect.", "source": "DDInter", "management_text": "Concomitant use of eluxadoline with other drugs that can cause constipation such as alosetron, anticholinergics, and opioids should generally be avoided. Loperamide may be used occasionally for acute management of severe diarrhea, but chronic use is not recommended, and it should be discontinued immediately if constipation occurs. Eluxadoline should also be discontinued if constipation occurs for more than 4 days.", "mechanism_text": "Synergism", "recommendation": "Concomitant use of eluxadoline with other drugs that can cause constipation such as alosetron, anticholinergics, and opioids should generally be avoided.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97745/", "reference_text": "[1] \"Product Information. Viberzi (eluxadoline).\" Actavis Pharma, Inc., Parsippany, NJ.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Viberzi (eluxadoline).\" Actavis Pharma, Inc., Parsippany, NJ.", "alternatives_a": "Ketotifen, Levocetirizine, Cetirizine, Loratadine, Trimethobenzamide, Desloratadine, Azelastine", "alternatives_b": "", "updated_at": 1767369485}, {"id": 97642, "ingredient1": "Eluxadoline", "ingredient2": "Dezocine", "severity": "Moderate", "effect": "The risk of constipation and serious constipation-related adverse reactions may be increased when eluxadoline is used with other drugs that are also associated with this adverse effect.", "source": "DDInter", "management_text": "Concomitant use of eluxadoline with other drugs that can cause constipation such as alosetron, anticholinergics, and opioids should generally be avoided. Loperamide may be used occasionally for acute management of severe diarrhea, but chronic use is not recommended, and it should be discontinued immediately if constipation occurs. Eluxadoline should also be discontinued if constipation occurs for more than 4 days.", "mechanism_text": "Synergism", "recommendation": "Concomitant use of eluxadoline with other drugs that can cause constipation such as alosetron, anticholinergics, and opioids should generally be avoided.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97746/", "reference_text": "[1] \"Product Information. Viberzi (eluxadoline).\" Actavis Pharma, Inc., Parsippany, NJ.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Viberzi (eluxadoline).\" Actavis Pharma, Inc., Parsippany, NJ.", "alternatives_a": "Naltrexone, Acetaminophen, Ibuprofen, Celecoxib, Acetylsalicylic acid, Naloxone", "alternatives_b": "Loperamide", "updated_at": 1767369485}, {"id": 97643, "ingredient1": "Eluxadoline", "ingredient2": "Dimenhydrinate", "severity": "Moderate", "effect": "The risk of constipation and serious constipation-related adverse reactions may be increased when eluxadoline is used with other drugs that are also associated with this adverse effect.", "source": "DDInter", "management_text": "Concomitant use of eluxadoline with other drugs that can cause constipation such as alosetron, anticholinergics, and opioids should generally be avoided. Loperamide may be used occasionally for acute management of severe diarrhea, but chronic use is not recommended, and it should be discontinued immediately if constipation occurs. Eluxadoline should also be discontinued if constipation occurs for more than 4 days.", "mechanism_text": "Synergism", "recommendation": "Concomitant use of eluxadoline with other drugs that can cause constipation such as alosetron, anticholinergics, and opioids should generally be avoided.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97747/", "reference_text": "[1] \"Product Information. Viberzi (eluxadoline).\" Actavis Pharma, Inc., Parsippany, NJ.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Viberzi (eluxadoline).\" Actavis Pharma, Inc., Parsippany, NJ.", "alternatives_a": "Ketotifen, Levocetirizine, Cetirizine, Loratadine, Trimethobenzamide, Desloratadine, Azelastine", "alternatives_b": "", "updated_at": 1767369485}, {"id": 97644, "ingredient1": "Empagliflozin", "ingredient2": "Eluxadoline", "severity": "Moderate", "effect": "Coadministration with eluxadoline may increase the plasma concentrations of drugs that are substrates of the organic anion transporting polypeptide (OATP) 1B1 and/or breast cancer resistance protein (BCRP) transporters. The mechanism is decreased clearance due to inhibition of OATP1B1-mediated hepatic uptake and BCRP-mediated intestinal and hepatobiliary efflux by eluxadoline.", "source": "DDInter", "management_text": "Caution is advised when eluxadoline is used concomitantly with drugs that are substrates of the OATP1B1 and/or BCRP transporters, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever eluxadoline is added to or withdrawn from therapy.", "mechanism_text": "Others", "recommendation": "Caution is advised when eluxadoline is used concomitantly with drugs that are substrates of the OATP1B1 and/or BCRP transporters, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97748/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Viberzi (eluxadoline).\" Actavis Pharma, Inc., Parsippany, NJ.[3] Richter WO, Jacob BG, Schwandt P \"Interaction between fibre and lovastatin.\" Lancet 338 (1991): 706[4] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors.\" Clin Pharmacol Ther 64 (1998): 477-83[5] Kantola T, Kivisto KT, Neuvonen PJ \"Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid.\" Clin Pharmacol Ther 63 (1998): 397-402[6] \"Product Information. Mevacor (lovastatin).\" Merck & Co, Inc, West Point, PA.[7] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions.\" Br J Clin Pharmacol 46 (1998): 101-10[8] Neuvonen PJ, Backman JT, Niemi M \"Pharmacokinetic comparison of the potential over-the-counter statins simvastatin, lovastatin, fluvastatin and pravastatin.\" Clin Pharmacokinet 47 (2008): 463-74[9] Thompson PD, Clarkson P, Karas RH \"Statin-associated myopathy.\" JAMA 289 (2003): 1681-90[10] \"Product Information. Zocor (simvastatin).\" Merck & Co, Inc, West Point, PA.[11] \"Product Information. Viberzi (eluxadoline).\" Actavis Pharma, Inc., Parsippany, NJ.", "alternatives_a": "Glipizide, Acetohexamide, Guar gum, Pramlintide, Alogliptin, Tolazamide, Dulaglutide, Exenatide, Tolbutamide, Miglitol, Glimepiride, More", "alternatives_b": "Morphine, Diphenoxylate, Opium, Difenoxin, Loperamide", "updated_at": 1767369485}, {"id": 97645, "ingredient1": "Enoxacin", "ingredient2": "Eluxadoline", "severity": "Moderate", "effect": "It is not known whether, and to what extent, eluxadoline may be metabolized by CYP450 isoenzymes and may interact with inhibitors of CYP450 isoenzymes.", "source": "DDInter", "management_text": "As a precautionary measure due to incomplete information on the metabolism of eluxadoline, the manufacturer recommends caution during coadministration with potent inhibitors of various CYP450 isoenzymes. Patients should be monitored for adverse effects such as sedation, nausea, vomiting, constipation, abdominal pain, liver enzyme elevations, and pancreatitis,", "mechanism_text": "Metabolism", "recommendation": "As a precautionary measure due to incomplete information on the metabolism of eluxadoline, the manufacturer recommends caution during coadministration with potent inhibitors of various CYP450 isoenzymes.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97749/", "reference_text": "[1] \"Product Information. Viberzi (eluxadoline).\" Actavis Pharma, Inc., Parsippany, NJ.[2] \"Product Information. Viberzi (eluxadoline).\" Actavis Pharma, Inc., Parsippany, NJ.[3] \"Product Information. Zokinvy (lonafarnib).\" Eiger BioPharmaceuticals, Palo Alto, CA.", "alternatives_a": "Gatifloxacin, Norfloxacin, Levofloxacin, Nalidixic acid, Gemifloxacin, Lomefloxacin, Grepafloxacin, Moxifloxacin, Cinoxacin, Trovafloxacin, Delafloxacin, More", "alternatives_b": "Morphine, Diphenoxylate, Opium, Difenoxin, Loperamide", "updated_at": 1767369485}, {"id": 97646, "ingredient1": "Ergometrine", "ingredient2": "Eluxadoline", "severity": "Moderate", "effect": "It is not known whether, and to what extent, eluxadoline may inhibit CYP450 3A4 and may interact with substrates of the isoenzyme. In vitro studies have shown that eluxadoline is not an inhibitor of CYP450 3A4 at clinically relevant systemic concentrations, but they were not adequate to rule out inhibition of CYP450 3A4 in the gut by eluxadoline. Therefore, the potential for eluxadoline to increase plasma concentrations of oral drugs that are metabolized by CYP450 3A4 should be considered.", "source": "DDInter", "management_text": "Caution is advised when eluxadoline is used with sensitive CYP450 3A4 substrates or substrates with narrow therapeutic ranges. These drugs include, but are not limited to: cisapride, colchicine, cyclosporine, fentanyl, ivacaftor, lovastatin, simvastatin, oral midazolam, triazolam, pimozide, quinidine, sildenafil, ergot derivatives, and macrolide immunosuppressants.", "mechanism_text": "Others", "recommendation": "Caution is advised when eluxadoline is used with sensitive CYP450 3A4 substrates or substrates with narrow therapeutic ranges.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97750/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Viberzi (eluxadoline).\" Actavis Pharma, Inc., Parsippany, NJ.[3] \"Product Information. Viberzi (eluxadoline).\" Actavis Pharma, Inc., Parsippany, NJ.[4] Kupferschmidt HHT, Ha HR, Ziegler WH, Meier PJ, Krahenbuhl S \"Interaction between grapefruit juice and midazolam in humans.\" Clin Pharmacol Ther 58 (1995): 20-8[5] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ \"Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice.\" Clin Pharmacol Ther 58 (1995): 127-31[6] \"Product Information. Valium (diazepam).\" Roche Laboratories, Nutley, NJ.[7] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[8] \"Product Information. Halcion (triazolam).\" Pharmacia and Upjohn, Kalamazoo, MI.[9] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[10] \"Product Information. Xanax (alprazolam).\" Pharmacia and Upjohn, Kalamazoo, MI.", "alternatives_a": "Misoprostol, Dinoprostone, Oxytocin", "alternatives_b": "Morphine, Diphenoxylate, Opium, Difenoxin, Loperamide", "updated_at": 1767369485}, {"id": 97647, "ingredient1": "Ergotamine", "ingredient2": "Eluxadoline", "severity": "Moderate", "effect": "It is not known whether, and to what extent, eluxadoline may inhibit CYP450 3A4 and may interact with substrates of the isoenzyme. In vitro studies have shown that eluxadoline is not an inhibitor of CYP450 3A4 at clinically relevant systemic concentrations, but they were not adequate to rule out inhibition of CYP450 3A4 in the gut by eluxadoline. Therefore, the potential for eluxadoline to increase plasma concentrations of oral drugs that are metabolized by CYP450 3A4 should be considered.", "source": "DDInter", "management_text": "Caution is advised when eluxadoline is used with sensitive CYP450 3A4 substrates or substrates with narrow therapeutic ranges. These drugs include, but are not limited to: cisapride, colchicine, cyclosporine, fentanyl, ivacaftor, lovastatin, simvastatin, oral midazolam, triazolam, pimozide, quinidine, sildenafil, ergot derivatives, and macrolide immunosuppressants.", "mechanism_text": "Others", "recommendation": "Caution is advised when eluxadoline is used with sensitive CYP450 3A4 substrates or substrates with narrow therapeutic ranges.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97751/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Viberzi (eluxadoline).\" Actavis Pharma, Inc., Parsippany, NJ.[3] \"Product Information. Viberzi (eluxadoline).\" Actavis Pharma, Inc., Parsippany, NJ.[4] Kupferschmidt HHT, Ha HR, Ziegler WH, Meier PJ, Krahenbuhl S \"Interaction between grapefruit juice and midazolam in humans.\" Clin Pharmacol Ther 58 (1995): 20-8[5] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ \"Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice.\" Clin Pharmacol Ther 58 (1995): 127-31[6] \"Product Information. Valium (diazepam).\" Roche Laboratories, Nutley, NJ.[7] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[8] \"Product Information. Halcion (triazolam).\" Pharmacia and Upjohn, Kalamazoo, MI.[9] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[10] \"Product Information. Xanax (alprazolam).\" Pharmacia and Upjohn, Kalamazoo, MI.", "alternatives_a": "Frovatriptan, Rimegepant, Eptinezumab, Lasmiditan, Eletriptan, Rizatriptan, Naratriptan, Galcanezumab, Zolmitriptan, Sumatriptan, Erenumab, More", "alternatives_b": "Morphine, Diphenoxylate, Opium, Difenoxin, Loperamide", "updated_at": 1767369485}, {"id": 97648, "ingredient1": "Everolimus", "ingredient2": "Eluxadoline", "severity": "Moderate", "effect": "It is not known whether, and to what extent, eluxadoline may inhibit CYP450 3A4 and may interact with substrates of the isoenzyme. In vitro studies have shown that eluxadoline is not an inhibitor of CYP450 3A4 at clinically relevant systemic concentrations, but they were not adequate to rule out inhibition of CYP450 3A4 in the gut by eluxadoline. Therefore, the potential for eluxadoline to increase plasma concentrations of oral drugs that are metabolized by CYP450 3A4 should be considered.", "source": "DDInter", "management_text": "Caution is advised when eluxadoline is used with sensitive CYP450 3A4 substrates or substrates with narrow therapeutic ranges. These drugs include, but are not limited to: cisapride, colchicine, cyclosporine, fentanyl, ivacaftor, lovastatin, simvastatin, oral midazolam, triazolam, pimozide, quinidine, sildenafil, ergot derivatives, and macrolide immunosuppressants.", "mechanism_text": "Others", "recommendation": "Caution is advised when eluxadoline is used with sensitive CYP450 3A4 substrates or substrates with narrow therapeutic ranges.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97752/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Viberzi (eluxadoline).\" Actavis Pharma, Inc., Parsippany, NJ.[3] \"Product Information. Viberzi (eluxadoline).\" Actavis Pharma, Inc., Parsippany, NJ.[4] Kupferschmidt HHT, Ha HR, Ziegler WH, Meier PJ, Krahenbuhl S \"Interaction between grapefruit juice and midazolam in humans.\" Clin Pharmacol Ther 58 (1995): 20-8[5] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ \"Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice.\" Clin Pharmacol Ther 58 (1995): 127-31[6] \"Product Information. Valium (diazepam).\" Roche Laboratories, Nutley, NJ.[7] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[8] \"Product Information. Halcion (triazolam).\" Pharmacia and Upjohn, Kalamazoo, MI.[9] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[10] \"Product Information. Xanax (alprazolam).\" Pharmacia and Upjohn, Kalamazoo, MI.", "alternatives_a": "Entrectinib, Imatinib, Pralsetinib, Dabrafenib, Asciminib, Acalabrutinib, Dacomitinib, Pexidartinib, Pacritinib, Tepotinib, Fedratinib, More", "alternatives_b": "Morphine, Diphenoxylate, Opium, Difenoxin, Loperamide", "updated_at": 1767369485}, {"id": 97649, "ingredient1": "Fesoterodine", "ingredient2": "Eluxadoline", "severity": "Moderate", "effect": "The risk of constipation and serious constipation-related adverse reactions may be increased when eluxadoline is used with other drugs that are also associated with this adverse effect.", "source": "DDInter", "management_text": "Concomitant use of eluxadoline with other drugs that can cause constipation such as alosetron, anticholinergics, and opioids should generally be avoided. Loperamide may be used occasionally for acute management of severe diarrhea, but chronic use is not recommended, and it should be discontinued immediately if constipation occurs. Eluxadoline should also be discontinued if constipation occurs for more than 4 days.", "mechanism_text": "Synergism", "recommendation": "Concomitant use of eluxadoline with other drugs that can cause constipation such as alosetron, anticholinergics, and opioids should generally be avoided.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97753/", "reference_text": "[1] \"Product Information. Viberzi (eluxadoline).\" Actavis Pharma, Inc., Parsippany, NJ.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Viberzi (eluxadoline).\" Actavis Pharma, Inc., Parsippany, NJ.", "alternatives_a": "Apomorphine, Pentosan polysulfate, Calcium chloride, Phenazopyridine, Alprostadil, Mirabegron, Acetohydroxamic acid, Yohimbine, Avanafil, Papaverine, Vardenafil, More", "alternatives_b": "Loperamide, Diphenoxylate, Difenoxin", "updated_at": 1767369485}, {"id": 97650, "ingredient1": "Fexofenadine", "ingredient2": "Eluxadoline", "severity": "Moderate", "effect": "Coadministration with eluxadoline may increase the plasma concentrations of drugs that are substrates of the organic anion transporting polypeptide (OATP) 1B1 and/or breast cancer resistance protein (BCRP) transporters. The mechanism is decreased clearance due to inhibition of OATP1B1-mediated hepatic uptake and BCRP-mediated intestinal and hepatobiliary efflux by eluxadoline.", "source": "DDInter", "management_text": "Caution is advised when eluxadoline is used concomitantly with drugs that are substrates of the OATP1B1 and/or BCRP transporters, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever eluxadoline is added to or withdrawn from therapy.", "mechanism_text": "Others", "recommendation": "Caution is advised when eluxadoline is used concomitantly with drugs that are substrates of the OATP1B1 and/or BCRP transporters, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97754/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Viberzi (eluxadoline).\" Actavis Pharma, Inc., Parsippany, NJ.[3] Richter WO, Jacob BG, Schwandt P \"Interaction between fibre and lovastatin.\" Lancet 338 (1991): 706[4] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors.\" Clin Pharmacol Ther 64 (1998): 477-83[5] Kantola T, Kivisto KT, Neuvonen PJ \"Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid.\" Clin Pharmacol Ther 63 (1998): 397-402[6] \"Product Information. Mevacor (lovastatin).\" Merck & Co, Inc, West Point, PA.[7] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions.\" Br J Clin Pharmacol 46 (1998): 101-10[8] Neuvonen PJ, Backman JT, Niemi M \"Pharmacokinetic comparison of the potential over-the-counter statins simvastatin, lovastatin, fluvastatin and pravastatin.\" Clin Pharmacokinet 47 (2008): 463-74[9] Thompson PD, Clarkson P, Karas RH \"Statin-associated myopathy.\" JAMA 289 (2003): 1681-90[10] \"Product Information. Zocor (simvastatin).\" Merck & Co, Inc, West Point, PA.[11] \"Product Information. Viberzi (eluxadoline).\" Actavis Pharma, Inc., Parsippany, NJ.", "alternatives_a": "Ketotifen, Levocetirizine, Cetirizine, Loratadine, Trimethobenzamide, Desloratadine, Azelastine", "alternatives_b": "Opium, Diphenoxylate, Difenoxin", "updated_at": 1767369485}, {"id": 97651, "ingredient1": "Flavoxate", "ingredient2": "Eluxadoline", "severity": "Moderate", "effect": "The risk of constipation and serious constipation-related adverse reactions may be increased when eluxadoline is used with other drugs that are also associated with this adverse effect.", "source": "DDInter", "management_text": "Concomitant use of eluxadoline with other drugs that can cause constipation such as alosetron, anticholinergics, and opioids should generally be avoided. Loperamide may be used occasionally for acute management of severe diarrhea, but chronic use is not recommended, and it should be discontinued immediately if constipation occurs. Eluxadoline should also be discontinued if constipation occurs for more than 4 days.", "mechanism_text": "Synergism", "recommendation": "Concomitant use of eluxadoline with other drugs that can cause constipation such as alosetron, anticholinergics, and opioids should generally be avoided.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97755/", "reference_text": "[1] \"Product Information. Viberzi (eluxadoline).\" Actavis Pharma, Inc., Parsippany, NJ.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Viberzi (eluxadoline).\" Actavis Pharma, Inc., Parsippany, NJ.", "alternatives_a": "Apomorphine, Pentosan polysulfate, Calcium chloride, Phenazopyridine, Alprostadil, Mirabegron, Acetohydroxamic acid, Yohimbine, Avanafil, Papaverine, Vardenafil, More", "alternatives_b": "Diphenoxylate, Difenoxin", "updated_at": 1767369485}, {"id": 97652, "ingredient1": "Fluconazole", "ingredient2": "Eluxadoline", "severity": "Moderate", "effect": "It is not known whether, and to what extent, eluxadoline may be metabolized by CYP450 isoenzymes and may interact with inhibitors of CYP450 isoenzymes.", "source": "DDInter", "management_text": "As a precautionary measure due to incomplete information on the metabolism of eluxadoline, the manufacturer recommends caution during coadministration with potent inhibitors of various CYP450 isoenzymes. Patients should be monitored for adverse effects such as sedation, nausea, vomiting, constipation, abdominal pain, liver enzyme elevations, and pancreatitis,", "mechanism_text": "Metabolism", "recommendation": "As a precautionary measure due to incomplete information on the metabolism of eluxadoline, the manufacturer recommends caution during coadministration with potent inhibitors of various CYP450 isoenzymes.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97756/", "reference_text": "[1] \"Product Information. Viberzi (eluxadoline).\" Actavis Pharma, Inc., Parsippany, NJ.[2] \"Product Information. Viberzi (eluxadoline).\" Actavis Pharma, Inc., Parsippany, NJ.[3] \"Product Information. Zokinvy (lonafarnib).\" Eiger BioPharmaceuticals, Palo Alto, CA.", "alternatives_a": "Tinidazole, Tetracycline, Cefepime, Norfloxacin, Metronidazole, Cefuroxime, Secnidazole, Cefixime, Azithromycin, Amikacin, Levofloxacin, More", "alternatives_b": "Opium, Diphenoxylate, Difenoxin", "updated_at": 1767369485}, {"id": 97653, "ingredient1": "Fluoxetine", "ingredient2": "Eluxadoline", "severity": "Moderate", "effect": "It is not known whether, and to what extent, eluxadoline may be metabolized by CYP450 isoenzymes and may interact with inhibitors of CYP450 isoenzymes.", "source": "DDInter", "management_text": "As a precautionary measure due to incomplete information on the metabolism of eluxadoline, the manufacturer recommends caution during coadministration with potent inhibitors of various CYP450 isoenzymes. Patients should be monitored for adverse effects such as sedation, nausea, vomiting, constipation, abdominal pain, liver enzyme elevations, and pancreatitis,", "mechanism_text": "Metabolism", "recommendation": "As a precautionary measure due to incomplete information on the metabolism of eluxadoline, the manufacturer recommends caution during coadministration with potent inhibitors of various CYP450 isoenzymes.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97757/", "reference_text": "[1] \"Product Information. Viberzi (eluxadoline).\" Actavis Pharma, Inc., Parsippany, NJ.[2] \"Product Information. Viberzi (eluxadoline).\" Actavis Pharma, Inc., Parsippany, NJ.[3] \"Product Information. Zokinvy (lonafarnib).\" Eiger BioPharmaceuticals, Palo Alto, CA.", "alternatives_a": "Citalopram, Sertraline, St. John's Wort, Milnacipran, Vortioxetine, Levomilnacipran, Duloxetine, Isocarboxazid, Viloxazine, Esketamine, Phenelzine, More", "alternatives_b": "Diphenoxylate, Difenoxin", "updated_at": 1767369485}, {"id": 97654, "ingredient1": "Fluphenazine", "ingredient2": "Eluxadoline", "severity": "Moderate", "effect": "The risk of constipation and serious constipation-related adverse reactions may be increased when eluxadoline is used with other drugs that are also associated with this adverse effect.", "source": "DDInter", "management_text": "Concomitant use of eluxadoline with other drugs that can cause constipation such as alosetron, anticholinergics, and opioids should generally be avoided. Loperamide may be used occasionally for acute management of severe diarrhea, but chronic use is not recommended, and it should be discontinued immediately if constipation occurs. Eluxadoline should also be discontinued if constipation occurs for more than 4 days.", "mechanism_text": "Synergism", "recommendation": "Concomitant use of eluxadoline with other drugs that can cause constipation such as alosetron, anticholinergics, and opioids should generally be avoided.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97758/", "reference_text": "[1] \"Product Information. Viberzi (eluxadoline).\" Actavis Pharma, Inc., Parsippany, NJ.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Viberzi (eluxadoline).\" Actavis Pharma, Inc., Parsippany, NJ.", "alternatives_a": "Asenapine, Pimavanserin, Ziprasidone, Lumateperone, Iloperidone, Amisulpride, Droperidol, Cariprazine, Brexpiprazole, Paliperidone, Lurasidone", "alternatives_b": "Difenoxin", "updated_at": 1767369485}, {"id": 97655, "ingredient1": "Glyburide", "ingredient2": "Eluxadoline", "severity": "Moderate", "effect": "Coadministration with eluxadoline may increase the plasma concentrations of drugs that are substrates of the organic anion transporting polypeptide (OATP) 1B1 and/or breast cancer resistance protein (BCRP) transporters. The mechanism is decreased clearance due to inhibition of OATP1B1-mediated hepatic uptake and BCRP-mediated intestinal and hepatobiliary efflux by eluxadoline.", "source": "DDInter", "management_text": "Caution is advised when eluxadoline is used concomitantly with drugs that are substrates of the OATP1B1 and/or BCRP transporters, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever eluxadoline is added to or withdrawn from therapy.", "mechanism_text": "Others", "recommendation": "Caution is advised when eluxadoline is used concomitantly with drugs that are substrates of the OATP1B1 and/or BCRP transporters, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97759/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Viberzi (eluxadoline).\" Actavis Pharma, Inc., Parsippany, NJ.[3] Richter WO, Jacob BG, Schwandt P \"Interaction between fibre and lovastatin.\" Lancet 338 (1991): 706[4] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors.\" Clin Pharmacol Ther 64 (1998): 477-83[5] Kantola T, Kivisto KT, Neuvonen PJ \"Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid.\" Clin Pharmacol Ther 63 (1998): 397-402[6] \"Product Information. Mevacor (lovastatin).\" Merck & Co, Inc, West Point, PA.[7] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions.\" Br J Clin Pharmacol 46 (1998): 101-10[8] Neuvonen PJ, Backman JT, Niemi M \"Pharmacokinetic comparison of the potential over-the-counter statins simvastatin, lovastatin, fluvastatin and pravastatin.\" Clin Pharmacokinet 47 (2008): 463-74[9] Thompson PD, Clarkson P, Karas RH \"Statin-associated myopathy.\" JAMA 289 (2003): 1681-90[10] \"Product Information. Zocor (simvastatin).\" Merck & Co, Inc, West Point, PA.[11] \"Product Information. Viberzi (eluxadoline).\" Actavis Pharma, Inc., Parsippany, NJ.", "alternatives_a": "Glipizide, Acetohexamide, Guar gum, Pramlintide, Alogliptin, Tolazamide, Dulaglutide, Exenatide, Tolbutamide, Miglitol, Glimepiride, More", "alternatives_b": "Opium, Diphenoxylate, Difenoxin", "updated_at": 1767369485}, {"id": 97656, "ingredient1": "Glycopyrronium (topical)", "ingredient2": "Eluxadoline", "severity": "Moderate", "effect": "The risk of constipation and serious constipation-related adverse reactions may be increased when eluxadoline is used with other drugs that are also associated with this adverse effect.", "source": "DDInter", "management_text": "Concomitant use of eluxadoline with other drugs that can cause constipation such as alosetron, anticholinergics, and opioids should generally be avoided. Loperamide may be used occasionally for acute management of severe diarrhea, but chronic use is not recommended, and it should be discontinued immediately if constipation occurs. Eluxadoline should also be discontinued if constipation occurs for more than 4 days.", "mechanism_text": "Synergism", "recommendation": "Concomitant use of eluxadoline with other drugs that can cause constipation such as alosetron, anticholinergics, and opioids should generally be avoided.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97760/", "reference_text": "[1] \"Product Information. Viberzi (eluxadoline).\" Actavis Pharma, Inc., Parsippany, NJ.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Viberzi (eluxadoline).\" Actavis Pharma, Inc., Parsippany, NJ.", "alternatives_a": "Morphine, Diphenoxylate, Opium, Difenoxin, Loperamide", "alternatives_b": "", "updated_at": 1767369485}, {"id": 97657, "ingredient1": "Haloperidol", "ingredient2": "Eluxadoline", "severity": "Moderate", "effect": "The risk of constipation and serious constipation-related adverse reactions may be increased when eluxadoline is used with other drugs that are also associated with this adverse effect.", "source": "DDInter", "management_text": "Concomitant use of eluxadoline with other drugs that can cause constipation such as alosetron, anticholinergics, and opioids should generally be avoided. Loperamide may be used occasionally for acute management of severe diarrhea, but chronic use is not recommended, and it should be discontinued immediately if constipation occurs. Eluxadoline should also be discontinued if constipation occurs for more than 4 days.", "mechanism_text": "Synergism", "recommendation": "Concomitant use of eluxadoline with other drugs that can cause constipation such as alosetron, anticholinergics, and opioids should generally be avoided.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97761/", "reference_text": "[1] \"Product Information. Viberzi (eluxadoline).\" Actavis Pharma, Inc., Parsippany, NJ.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Viberzi (eluxadoline).\" Actavis Pharma, Inc., Parsippany, NJ.", "alternatives_a": "Asenapine, Pimavanserin, Ziprasidone, Lumateperone, Iloperidone, Amisulpride, Droperidol, Cariprazine, Brexpiprazole, Paliperidone, Lurasidone", "alternatives_b": "Diphenoxylate, Difenoxin", "updated_at": 1767369485}, {"id": 97658, "ingredient1": "Hydromorphone", "ingredient2": "Eluxadoline", "severity": "Moderate", "effect": "The risk of constipation and serious constipation-related adverse reactions may be increased when eluxadoline is used with other drugs that are also associated with this adverse effect.", "source": "DDInter", "management_text": "Concomitant use of eluxadoline with other drugs that can cause constipation such as alosetron, anticholinergics, and opioids should generally be avoided. Loperamide may be used occasionally for acute management of severe diarrhea, but chronic use is not recommended, and it should be discontinued immediately if constipation occurs. Eluxadoline should also be discontinued if constipation occurs for more than 4 days.", "mechanism_text": "Synergism", "recommendation": "Concomitant use of eluxadoline with other drugs that can cause constipation such as alosetron, anticholinergics, and opioids should generally be avoided.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97762/", "reference_text": "[1] \"Product Information. Viberzi (eluxadoline).\" Actavis Pharma, Inc., Parsippany, NJ.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Viberzi (eluxadoline).\" Actavis Pharma, Inc., Parsippany, NJ.", "alternatives_a": "Naltrexone, Acetaminophen, Ibuprofen, Celecoxib, Acetylsalicylic acid, Naloxone", "alternatives_b": "", "updated_at": 1767369485}, {"id": 97659, "ingredient1": "Hydroxyzine", "ingredient2": "Eluxadoline", "severity": "Moderate", "effect": "The risk of constipation and serious constipation-related adverse reactions may be increased when eluxadoline is used with other drugs that are also associated with this adverse effect.", "source": "DDInter", "management_text": "Concomitant use of eluxadoline with other drugs that can cause constipation such as alosetron, anticholinergics, and opioids should generally be avoided. Loperamide may be used occasionally for acute management of severe diarrhea, but chronic use is not recommended, and it should be discontinued immediately if constipation occurs. Eluxadoline should also be discontinued if constipation occurs for more than 4 days.", "mechanism_text": "Synergism", "recommendation": "Concomitant use of eluxadoline with other drugs that can cause constipation such as alosetron, anticholinergics, and opioids should generally be avoided.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97763/", "reference_text": "[1] \"Product Information. Viberzi (eluxadoline).\" Actavis Pharma, Inc., Parsippany, NJ.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Viberzi (eluxadoline).\" Actavis Pharma, Inc., Parsippany, NJ.", "alternatives_a": "Clobazam, Meprobamate, Alprazolam, Lorazepam, Chlordiazepoxide, Halazepam, Clorazepic acid, Buspirone, Diazepam, Oxazepam", "alternatives_b": "Diphenoxylate, Difenoxin", "updated_at": 1767369485}, {"id": 97660, "ingredient1": "Idelalisib", "ingredient2": "Eluxadoline", "severity": "Moderate", "effect": "It is not known whether, and to what extent, eluxadoline may be metabolized by CYP450 isoenzymes and may interact with inhibitors of CYP450 isoenzymes.", "source": "DDInter", "management_text": "As a precautionary measure due to incomplete information on the metabolism of eluxadoline, the manufacturer recommends caution during coadministration with potent inhibitors of various CYP450 isoenzymes. Patients should be monitored for adverse effects such as sedation, nausea, vomiting, constipation, abdominal pain, liver enzyme elevations, and pancreatitis,", "mechanism_text": "Metabolism", "recommendation": "As a precautionary measure due to incomplete information on the metabolism of eluxadoline, the manufacturer recommends caution during coadministration with potent inhibitors of various CYP450 isoenzymes.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97764/", "reference_text": "[1] \"Product Information. Viberzi (eluxadoline).\" Actavis Pharma, Inc., Parsippany, NJ.[2] \"Product Information. Viberzi (eluxadoline).\" Actavis Pharma, Inc., Parsippany, NJ.[3] \"Product Information. Zokinvy (lonafarnib).\" Eiger BioPharmaceuticals, Palo Alto, CA.", "alternatives_a": "Entrectinib, Imatinib, Pralsetinib, Dabrafenib, Asciminib, Acalabrutinib, Dacomitinib, Pexidartinib, Pacritinib, Tepotinib, Fedratinib, More", "alternatives_b": "Opium, Diphenoxylate, Morphine, Difenoxin", "updated_at": 1767369485}, {"id": 97661, "ingredient1": "Imipramine", "ingredient2": "Eluxadoline", "severity": "Moderate", "effect": "The risk of constipation and serious constipation-related adverse reactions may be increased when eluxadoline is used with other drugs that are also associated with this adverse effect.", "source": "DDInter", "management_text": "Concomitant use of eluxadoline with other drugs that can cause constipation such as alosetron, anticholinergics, and opioids should generally be avoided. Loperamide may be used occasionally for acute management of severe diarrhea, but chronic use is not recommended, and it should be discontinued immediately if constipation occurs. Eluxadoline should also be discontinued if constipation occurs for more than 4 days.", "mechanism_text": "Synergism", "recommendation": "Concomitant use of eluxadoline with other drugs that can cause constipation such as alosetron, anticholinergics, and opioids should generally be avoided.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97765/", "reference_text": "[1] \"Product Information. Viberzi (eluxadoline).\" Actavis Pharma, Inc., Parsippany, NJ.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Viberzi (eluxadoline).\" Actavis Pharma, Inc., Parsippany, NJ.", "alternatives_a": "Citalopram, Sertraline, St. John's Wort, Milnacipran, Vortioxetine, Levomilnacipran, Duloxetine, Isocarboxazid, Viloxazine, Esketamine, Phenelzine, More", "alternatives_b": "Diphenoxylate, Difenoxin", "updated_at": 1767369485}, {"id": 97662, "ingredient1": "Indinavir", "ingredient2": "Eluxadoline", "severity": "Moderate", "effect": "It is not known whether, and to what extent, eluxadoline may be metabolized by CYP450 isoenzymes and may interact with inhibitors of CYP450 isoenzymes.", "source": "DDInter", "management_text": "As a precautionary measure due to incomplete information on the metabolism of eluxadoline, the manufacturer recommends caution during coadministration with potent inhibitors of various CYP450 isoenzymes. Patients should be monitored for adverse effects such as sedation, nausea, vomiting, constipation, abdominal pain, liver enzyme elevations, and pancreatitis,", "mechanism_text": "Metabolism", "recommendation": "As a precautionary measure due to incomplete information on the metabolism of eluxadoline, the manufacturer recommends caution during coadministration with potent inhibitors of various CYP450 isoenzymes.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97766/", "reference_text": "[1] \"Product Information. Viberzi (eluxadoline).\" Actavis Pharma, Inc., Parsippany, NJ.[2] \"Product Information. Viberzi (eluxadoline).\" Actavis Pharma, Inc., Parsippany, NJ.[3] \"Product Information. Zokinvy (lonafarnib).\" Eiger BioPharmaceuticals, Palo Alto, CA.", "alternatives_a": "Lamivudine, Glecaprevir, Tenofovir alafenamide, Maraviroc, Cabotegravir, Valaciclovir, Zanamivir, Lenacapavir, Velpatasvir, Rilpivirine, Etravirine, More", "alternatives_b": "Opium, Diphenoxylate, Difenoxin", "updated_at": 1767369485}, {"id": 97663, "ingredient1": "Irinotecan", "ingredient2": "Eluxadoline", "severity": "Moderate", "effect": "Coadministration with eluxadoline may increase the plasma concentrations of drugs that are substrates of the organic anion transporting polypeptide (OATP) 1B1 and/or breast cancer resistance protein (BCRP) transporters. The mechanism is decreased clearance due to inhibition of OATP1B1-mediated hepatic uptake and BCRP-mediated intestinal and hepatobiliary efflux by eluxadoline.", "source": "DDInter", "management_text": "Caution is advised when eluxadoline is used concomitantly with drugs that are substrates of the OATP1B1 and/or BCRP transporters, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever eluxadoline is added to or withdrawn from therapy.", "mechanism_text": "Others", "recommendation": "Caution is advised when eluxadoline is used concomitantly with drugs that are substrates of the OATP1B1 and/or BCRP transporters, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97767/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Viberzi (eluxadoline).\" Actavis Pharma, Inc., Parsippany, NJ.[3] Richter WO, Jacob BG, Schwandt P \"Interaction between fibre and lovastatin.\" Lancet 338 (1991): 706[4] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors.\" Clin Pharmacol Ther 64 (1998): 477-83[5] Kantola T, Kivisto KT, Neuvonen PJ \"Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid.\" Clin Pharmacol Ther 63 (1998): 397-402[6] \"Product Information. Mevacor (lovastatin).\" Merck & Co, Inc, West Point, PA.[7] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions.\" Br J Clin Pharmacol 46 (1998): 101-10[8] Neuvonen PJ, Backman JT, Niemi M \"Pharmacokinetic comparison of the potential over-the-counter statins simvastatin, lovastatin, fluvastatin and pravastatin.\" Clin Pharmacokinet 47 (2008): 463-74[9] Thompson PD, Clarkson P, Karas RH \"Statin-associated myopathy.\" JAMA 289 (2003): 1681-90[10] \"Product Information. Zocor (simvastatin).\" Merck & Co, Inc, West Point, PA.[11] \"Product Information. Viberzi (eluxadoline).\" Actavis Pharma, Inc., Parsippany, NJ.", "alternatives_a": "Trabectedin, Cabazitaxel, Vinblastine, Paclitaxel, Vincristine, Topotecan, Teniposide, Vinorelbine, Etoposide, Docetaxel", "alternatives_b": "Opium, Diphenoxylate, Difenoxin", "updated_at": 1767369485}, {"id": 97664, "ingredient1": "Itraconazole", "ingredient2": "Eluxadoline", "severity": "Moderate", "effect": "It is not known whether, and to what extent, eluxadoline may be metabolized by CYP450 isoenzymes and may interact with inhibitors of CYP450 isoenzymes.", "source": "DDInter", "management_text": "As a precautionary measure due to incomplete information on the metabolism of eluxadoline, the manufacturer recommends caution during coadministration with potent inhibitors of various CYP450 isoenzymes. Patients should be monitored for adverse effects such as sedation, nausea, vomiting, constipation, abdominal pain, liver enzyme elevations, and pancreatitis,", "mechanism_text": "Metabolism", "recommendation": "As a precautionary measure due to incomplete information on the metabolism of eluxadoline, the manufacturer recommends caution during coadministration with potent inhibitors of various CYP450 isoenzymes.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97768/", "reference_text": "[1] \"Product Information. Viberzi (eluxadoline).\" Actavis Pharma, Inc., Parsippany, NJ.[2] \"Product Information. Viberzi (eluxadoline).\" Actavis Pharma, Inc., Parsippany, NJ.[3] \"Product Information. Zokinvy (lonafarnib).\" Eiger BioPharmaceuticals, Palo Alto, CA.", "alternatives_a": "Caspofungin, Micafungin, Amphotericin B, Miconazole, Oteseconazole, Flucytosine, Anidulafungin", "alternatives_b": "Opium, Diphenoxylate, Difenoxin", "updated_at": 1767369485}, {"id": 97665, "ingredient1": "Eluxadoline", "ingredient2": "Ketoconazole", "severity": "Moderate", "effect": "It is not known whether, and to what extent, eluxadoline may be metabolized by CYP450 isoenzymes and may interact with inhibitors of CYP450 isoenzymes.", "source": "DDInter", "management_text": "As a precautionary measure due to incomplete information on the metabolism of eluxadoline, the manufacturer recommends caution during coadministration with potent inhibitors of various CYP450 isoenzymes. Patients should be monitored for adverse effects such as sedation, nausea, vomiting, constipation, abdominal pain, liver enzyme elevations, and pancreatitis,", "mechanism_text": "Metabolism", "recommendation": "As a precautionary measure due to incomplete information on the metabolism of eluxadoline, the manufacturer recommends caution during coadministration with potent inhibitors of various CYP450 isoenzymes.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97769/", "reference_text": "[1] \"Product Information. Viberzi (eluxadoline).\" Actavis Pharma, Inc., Parsippany, NJ.[2] \"Product Information. Viberzi (eluxadoline).\" Actavis Pharma, Inc., Parsippany, NJ.[3] \"Product Information. Zokinvy (lonafarnib).\" Eiger BioPharmaceuticals, Palo Alto, CA.", "alternatives_a": "Tamsulosin, Tinidazole, Ascorbic acid, Hydroflumethiazide, Chlorothiazide, Metronidazole, Sulfadiazine, Lactic acid, Mitapivat, Methazolamide, Amphotericin B, More", "alternatives_b": "Opium, Diphenoxylate, Difenoxin", "updated_at": 1767369485}, {"id": 97666, "ingredient1": "Eluxadoline", "ingredient2": "Lapatinib", "severity": "Major", "effect": "Coadministration with inhibitors of organic anion transporting polypeptide (OATP) 1B1 may significantly increase the plasma concentrations of eluxadoline. Based on available data, inhibition of OATP1B1-mediated hepatic uptake appears to reduce both the hepatic first-pass extraction and systemic biliary clearance of eluxadoline.", "source": "DDInter", "management_text": "The recommended dosage of eluxadoline is 75 mg twice daily when used with OATP1B1 inhibitors. Patients should be monitored for adverse effects such as sedation, nausea, vomiting, constipation, abdominal pain, liver enzyme elevations, and pancreatitis.", "mechanism_text": "Metabolism", "recommendation": "The recommended dosage of eluxadoline is 75 mg twice daily when used with OATP1B1 inhibitors.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97770/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Davenport JM, Covington P, Bonifacio L, McIntyre G, Venitz J \"Effect of uptake transporters OAT3 and OATPIBI and efflux transporter MRP2 on the pharmacokinetics of eluxadoline.\" J Clin Pharmacol 55 (2015): 534-42[3] \"Product Information. Viberzi (eluxadoline).\" Actavis Pharma, Inc., Parsippany, NJ.[4] \"Product Information. Viberzi (eluxadoline).\" Actavis Pharma, Inc., Parsippany, NJ.[5] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[6] Cerner Multum, Inc. \"Australian Product Information.\" O 0[7] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[8] \"Product Information. Aptivus (tipranavir).\" Boehringer-Ingelheim, Ridgefield, CT.", "alternatives_a": "Entrectinib, Imatinib, Pralsetinib, Dabrafenib, Asciminib, Acalabrutinib, Dacomitinib, Pexidartinib, Pacritinib, Tepotinib, Fedratinib, More", "alternatives_b": "Opium, Diphenoxylate, Difenoxin", "updated_at": 1767369485}, {"id": 97667, "ingredient1": "Eluxadoline", "ingredient2": "Levacetylmethadol", "severity": "Moderate", "effect": "The risk of constipation and serious constipation-related adverse reactions may be increased when eluxadoline is used with other drugs that are also associated with this adverse effect.", "source": "DDInter", "management_text": "Concomitant use of eluxadoline with other drugs that can cause constipation such as alosetron, anticholinergics, and opioids should generally be avoided. Loperamide may be used occasionally for acute management of severe diarrhea, but chronic use is not recommended, and it should be discontinued immediately if constipation occurs. Eluxadoline should also be discontinued if constipation occurs for more than 4 days.", "mechanism_text": "Synergism", "recommendation": "Concomitant use of eluxadoline with other drugs that can cause constipation such as alosetron, anticholinergics, and opioids should generally be avoided.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97771/", "reference_text": "[1] \"Product Information. Viberzi (eluxadoline).\" Actavis Pharma, Inc., Parsippany, NJ.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Viberzi (eluxadoline).\" Actavis Pharma, Inc., Parsippany, NJ.", "alternatives_a": "Diamorphine, Acamprosate, Lofexidine, Naltrexone, Varenicline, Disulfiram, Nalmefene, Nicotine", "alternatives_b": "", "updated_at": 1767369485}, {"id": 97668, "ingredient1": "Eluxadoline", "ingredient2": "Levorphanol", "severity": "Moderate", "effect": "The risk of constipation and serious constipation-related adverse reactions may be increased when eluxadoline is used with other drugs that are also associated with this adverse effect.", "source": "DDInter", "management_text": "Concomitant use of eluxadoline with other drugs that can cause constipation such as alosetron, anticholinergics, and opioids should generally be avoided. Loperamide may be used occasionally for acute management of severe diarrhea, but chronic use is not recommended, and it should be discontinued immediately if constipation occurs. Eluxadoline should also be discontinued if constipation occurs for more than 4 days.", "mechanism_text": "Synergism", "recommendation": "Concomitant use of eluxadoline with other drugs that can cause constipation such as alosetron, anticholinergics, and opioids should generally be avoided.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97772/", "reference_text": "[1] \"Product Information. Viberzi (eluxadoline).\" Actavis Pharma, Inc., Parsippany, NJ.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Viberzi (eluxadoline).\" Actavis Pharma, Inc., Parsippany, NJ.", "alternatives_a": "", "alternatives_b": "", "updated_at": 1767369485}, {"id": 97669, "ingredient1": "Eluxadoline", "ingredient2": "Lovastatin", "severity": "Moderate", "effect": "Coadministration with eluxadoline may increase the plasma concentrations of drugs that are substrates of the organic anion transporting polypeptide (OATP) 1B1 and/or breast cancer resistance protein (BCRP) transporters. The mechanism is decreased clearance due to inhibition of OATP1B1-mediated hepatic uptake and BCRP-mediated intestinal and hepatobiliary efflux by eluxadoline.", "source": "DDInter", "management_text": "Caution is advised when eluxadoline is used concomitantly with drugs that are substrates of the OATP1B1 and/or BCRP transporters, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever eluxadoline is added to or withdrawn from therapy.", "mechanism_text": "Others", "recommendation": "Caution is advised when eluxadoline is used concomitantly with drugs that are substrates of the OATP1B1 and/or BCRP transporters, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97773/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Viberzi (eluxadoline).\" Actavis Pharma, Inc., Parsippany, NJ.[3] Richter WO, Jacob BG, Schwandt P \"Interaction between fibre and lovastatin.\" Lancet 338 (1991): 706[4] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors.\" Clin Pharmacol Ther 64 (1998): 477-83[5] Kantola T, Kivisto KT, Neuvonen PJ \"Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid.\" Clin Pharmacol Ther 63 (1998): 397-402[6] \"Product Information. Mevacor (lovastatin).\" Merck & Co, Inc, West Point, PA.[7] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions.\" Br J Clin Pharmacol 46 (1998): 101-10[8] Neuvonen PJ, Backman JT, Niemi M \"Pharmacokinetic comparison of the potential over-the-counter statins simvastatin, lovastatin, fluvastatin and pravastatin.\" Clin Pharmacokinet 47 (2008): 463-74[9] Thompson PD, Clarkson P, Karas RH \"Statin-associated myopathy.\" JAMA 289 (2003): 1681-90[10] \"Product Information. Zocor (simvastatin).\" Merck & Co, Inc, West Point, PA.[11] \"Product Information. Viberzi (eluxadoline).\" Actavis Pharma, Inc., Parsippany, NJ.", "alternatives_a": "Fenofibric acid, Mipomersen, Evinacumab, Evolocumab, Dextrothyroxine, Probucol, Cholestyramine, Clofibrate, Colestipol, Niacin, Lomitapide, More", "alternatives_b": "Opium, Diphenoxylate, Difenoxin", "updated_at": 1767369485}, {"id": 97670, "ingredient1": "Eluxadoline", "ingredient2": "Loxapine", "severity": "Moderate", "effect": "The risk of constipation and serious constipation-related adverse reactions may be increased when eluxadoline is used with other drugs that are also associated with this adverse effect.", "source": "DDInter", "management_text": "Concomitant use of eluxadoline with other drugs that can cause constipation such as alosetron, anticholinergics, and opioids should generally be avoided. Loperamide may be used occasionally for acute management of severe diarrhea, but chronic use is not recommended, and it should be discontinued immediately if constipation occurs. Eluxadoline should also be discontinued if constipation occurs for more than 4 days.", "mechanism_text": "Synergism", "recommendation": "Concomitant use of eluxadoline with other drugs that can cause constipation such as alosetron, anticholinergics, and opioids should generally be avoided.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97774/", "reference_text": "[1] \"Product Information. Viberzi (eluxadoline).\" Actavis Pharma, Inc., Parsippany, NJ.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Viberzi (eluxadoline).\" Actavis Pharma, Inc., Parsippany, NJ.", "alternatives_a": "Asenapine, Pimavanserin, Ziprasidone, Lumateperone, Iloperidone, Amisulpride, Droperidol, Cariprazine, Brexpiprazole, Paliperidone, Lurasidone", "alternatives_b": "Diphenoxylate, Difenoxin", "updated_at": 1767369485}, {"id": 97671, "ingredient1": "Eluxadoline", "ingredient2": "Maprotiline", "severity": "Moderate", "effect": "The risk of constipation and serious constipation-related adverse reactions may be increased when eluxadoline is used with other drugs that are also associated with this adverse effect.", "source": "DDInter", "management_text": "Concomitant use of eluxadoline with other drugs that can cause constipation such as alosetron, anticholinergics, and opioids should generally be avoided. Loperamide may be used occasionally for acute management of severe diarrhea, but chronic use is not recommended, and it should be discontinued immediately if constipation occurs. Eluxadoline should also be discontinued if constipation occurs for more than 4 days.", "mechanism_text": "Synergism", "recommendation": "Concomitant use of eluxadoline with other drugs that can cause constipation such as alosetron, anticholinergics, and opioids should generally be avoided.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97775/", "reference_text": "[1] \"Product Information. Viberzi (eluxadoline).\" Actavis Pharma, Inc., Parsippany, NJ.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Viberzi (eluxadoline).\" Actavis Pharma, Inc., Parsippany, NJ.", "alternatives_a": "Citalopram, Sertraline, St. John's Wort, Milnacipran, Vortioxetine, Levomilnacipran, Duloxetine, Isocarboxazid, Viloxazine, Esketamine, Phenelzine, More", "alternatives_b": "Diphenoxylate, Difenoxin", "updated_at": 1767369485}, {"id": 97672, "ingredient1": "Eluxadoline", "ingredient2": "Meclizine", "severity": "Moderate", "effect": "The risk of constipation and serious constipation-related adverse reactions may be increased when eluxadoline is used with other drugs that are also associated with this adverse effect.", "source": "DDInter", "management_text": "Concomitant use of eluxadoline with other drugs that can cause constipation such as alosetron, anticholinergics, and opioids should generally be avoided. Loperamide may be used occasionally for acute management of severe diarrhea, but chronic use is not recommended, and it should be discontinued immediately if constipation occurs. Eluxadoline should also be discontinued if constipation occurs for more than 4 days.", "mechanism_text": "Synergism", "recommendation": "Concomitant use of eluxadoline with other drugs that can cause constipation such as alosetron, anticholinergics, and opioids should generally be avoided.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97776/", "reference_text": "[1] \"Product Information. Viberzi (eluxadoline).\" Actavis Pharma, Inc., Parsippany, NJ.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Viberzi (eluxadoline).\" Actavis Pharma, Inc., Parsippany, NJ.", "alternatives_a": "Ketotifen, Levocetirizine, Cetirizine, Loratadine, Trimethobenzamide, Desloratadine, Azelastine", "alternatives_b": "Diphenoxylate, Difenoxin", "updated_at": 1767369485}, {"id": 97673, "ingredient1": "Eluxadoline", "ingredient2": "Mepenzolate", "severity": "Moderate", "effect": "The risk of constipation and serious constipation-related adverse reactions may be increased when eluxadoline is used with other drugs that are also associated with this adverse effect.", "source": "DDInter", "management_text": "Concomitant use of eluxadoline with other drugs that can cause constipation such as alosetron, anticholinergics, and opioids should generally be avoided. Loperamide may be used occasionally for acute management of severe diarrhea, but chronic use is not recommended, and it should be discontinued immediately if constipation occurs. Eluxadoline should also be discontinued if constipation occurs for more than 4 days.", "mechanism_text": "Synergism", "recommendation": "Concomitant use of eluxadoline with other drugs that can cause constipation such as alosetron, anticholinergics, and opioids should generally be avoided.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97777/", "reference_text": "[1] \"Product Information. Viberzi (eluxadoline).\" Actavis Pharma, Inc., Parsippany, NJ.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Viberzi (eluxadoline).\" Actavis Pharma, Inc., Parsippany, NJ.", "alternatives_a": "Papaverine, Isometheptene", "alternatives_b": "Diphenoxylate, Difenoxin", "updated_at": 1767369485}, {"id": 97674, "ingredient1": "Eluxadoline", "ingredient2": "Meperidine", "severity": "Moderate", "effect": "The risk of constipation and serious constipation-related adverse reactions may be increased when eluxadoline is used with other drugs that are also associated with this adverse effect.", "source": "DDInter", "management_text": "Concomitant use of eluxadoline with other drugs that can cause constipation such as alosetron, anticholinergics, and opioids should generally be avoided. Loperamide may be used occasionally for acute management of severe diarrhea, but chronic use is not recommended, and it should be discontinued immediately if constipation occurs. Eluxadoline should also be discontinued if constipation occurs for more than 4 days.", "mechanism_text": "Synergism", "recommendation": "Concomitant use of eluxadoline with other drugs that can cause constipation such as alosetron, anticholinergics, and opioids should generally be avoided.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97778/", "reference_text": "[1] \"Product Information. Viberzi (eluxadoline).\" Actavis Pharma, Inc., Parsippany, NJ.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Viberzi (eluxadoline).\" Actavis Pharma, Inc., Parsippany, NJ.", "alternatives_a": "Naltrexone, Acetaminophen, Ibuprofen, Celecoxib, Acetylsalicylic acid, Naloxone", "alternatives_b": "", "updated_at": 1767369485}, {"id": 97675, "ingredient1": "Eluxadoline", "ingredient2": "Mesoridazine", "severity": "Moderate", "effect": "The risk of constipation and serious constipation-related adverse reactions may be increased when eluxadoline is used with other drugs that are also associated with this adverse effect.", "source": "DDInter", "management_text": "Concomitant use of eluxadoline with other drugs that can cause constipation such as alosetron, anticholinergics, and opioids should generally be avoided. Loperamide may be used occasionally for acute management of severe diarrhea, but chronic use is not recommended, and it should be discontinued immediately if constipation occurs. Eluxadoline should also be discontinued if constipation occurs for more than 4 days.", "mechanism_text": "Synergism", "recommendation": "Concomitant use of eluxadoline with other drugs that can cause constipation such as alosetron, anticholinergics, and opioids should generally be avoided.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97779/", "reference_text": "[1] \"Product Information. Viberzi (eluxadoline).\" Actavis Pharma, Inc., Parsippany, NJ.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Viberzi (eluxadoline).\" Actavis Pharma, Inc., Parsippany, NJ.", "alternatives_a": "Asenapine, Pimavanserin, Ziprasidone, Lumateperone, Iloperidone, Amisulpride, Droperidol, Cariprazine, Brexpiprazole, Paliperidone, Lurasidone", "alternatives_b": "Diphenoxylate, Difenoxin", "updated_at": 1767369485}, {"id": 97676, "ingredient1": "Eluxadoline", "ingredient2": "Methdilazine", "severity": "Moderate", "effect": "The risk of constipation and serious constipation-related adverse reactions may be increased when eluxadoline is used with other drugs that are also associated with this adverse effect.", "source": "DDInter", "management_text": "Concomitant use of eluxadoline with other drugs that can cause constipation such as alosetron, anticholinergics, and opioids should generally be avoided. Loperamide may be used occasionally for acute management of severe diarrhea, but chronic use is not recommended, and it should be discontinued immediately if constipation occurs. Eluxadoline should also be discontinued if constipation occurs for more than 4 days.", "mechanism_text": "Synergism", "recommendation": "Concomitant use of eluxadoline with other drugs that can cause constipation such as alosetron, anticholinergics, and opioids should generally be avoided.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97780/", "reference_text": "[1] \"Product Information. Viberzi (eluxadoline).\" Actavis Pharma, Inc., Parsippany, NJ.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Viberzi (eluxadoline).\" Actavis Pharma, Inc., Parsippany, NJ.", "alternatives_a": "Ketotifen, Levocetirizine, Cetirizine, Loratadine, Trimethobenzamide, Desloratadine, Azelastine", "alternatives_b": "Diphenoxylate, Difenoxin", "updated_at": 1767369485}, {"id": 97677, "ingredient1": "Eluxadoline", "ingredient2": "Methotrexate", "severity": "Moderate", "effect": "Coadministration with eluxadoline may increase the plasma concentrations of drugs that are substrates of the organic anion transporting polypeptide (OATP) 1B1 and/or breast cancer resistance protein (BCRP) transporters. The mechanism is decreased clearance due to inhibition of OATP1B1-mediated hepatic uptake and BCRP-mediated intestinal and hepatobiliary efflux by eluxadoline.", "source": "DDInter", "management_text": "Caution is advised when eluxadoline is used concomitantly with drugs that are substrates of the OATP1B1 and/or BCRP transporters, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever eluxadoline is added to or withdrawn from therapy.", "mechanism_text": "Others", "recommendation": "Caution is advised when eluxadoline is used concomitantly with drugs that are substrates of the OATP1B1 and/or BCRP transporters, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97781/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Viberzi (eluxadoline).\" Actavis Pharma, Inc., Parsippany, NJ.[3] Richter WO, Jacob BG, Schwandt P \"Interaction between fibre and lovastatin.\" Lancet 338 (1991): 706[4] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors.\" Clin Pharmacol Ther 64 (1998): 477-83[5] Kantola T, Kivisto KT, Neuvonen PJ \"Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid.\" Clin Pharmacol Ther 63 (1998): 397-402[6] \"Product Information. Mevacor (lovastatin).\" Merck & Co, Inc, West Point, PA.[7] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions.\" Br J Clin Pharmacol 46 (1998): 101-10[8] Neuvonen PJ, Backman JT, Niemi M \"Pharmacokinetic comparison of the potential over-the-counter statins simvastatin, lovastatin, fluvastatin and pravastatin.\" Clin Pharmacokinet 47 (2008): 463-74[9] Thompson PD, Clarkson P, Karas RH \"Statin-associated myopathy.\" JAMA 289 (2003): 1681-90[10] \"Product Information. Zocor (simvastatin).\" Merck & Co, Inc, West Point, PA.[11] \"Product Information. Viberzi (eluxadoline).\" Actavis Pharma, Inc., Parsippany, NJ.", "alternatives_a": "Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Abatacept, More", "alternatives_b": "Opium, Diphenoxylate, Difenoxin", "updated_at": 1767369485}, {"id": 97678, "ingredient1": "Eluxadoline", "ingredient2": "Methotrimeprazine", "severity": "Moderate", "effect": "It is not known whether, and to what extent, eluxadoline may be metabolized by CYP450 isoenzymes and may interact with inhibitors of CYP450 isoenzymes.", "source": "DDInter", "management_text": "As a precautionary measure due to incomplete information on the metabolism of eluxadoline, the manufacturer recommends caution during coadministration with potent inhibitors of various CYP450 isoenzymes. Patients should be monitored for adverse effects such as sedation, nausea, vomiting, constipation, abdominal pain, liver enzyme elevations, and pancreatitis,", "mechanism_text": "Metabolism", "recommendation": "As a precautionary measure due to incomplete information on the metabolism of eluxadoline, the manufacturer recommends caution during coadministration with potent inhibitors of various CYP450 isoenzymes.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97782/", "reference_text": "[1] \"Product Information. Viberzi (eluxadoline).\" Actavis Pharma, Inc., Parsippany, NJ.[2] \"Product Information. Viberzi (eluxadoline).\" Actavis Pharma, Inc., Parsippany, NJ.[3] \"Product Information. Zokinvy (lonafarnib).\" Eiger BioPharmaceuticals, Palo Alto, CA.", "alternatives_a": "Asenapine, Pimavanserin, Ziprasidone, Lumateperone, Iloperidone, Amisulpride, Droperidol, Cariprazine, Brexpiprazole, Paliperidone, Lurasidone", "alternatives_b": "Diphenoxylate, Difenoxin", "updated_at": 1767369485}, {"id": 97679, "ingredient1": "Eluxadoline", "ingredient2": "Methscopolamine", "severity": "Moderate", "effect": "The risk of constipation and serious constipation-related adverse reactions may be increased when eluxadoline is used with other drugs that are also associated with this adverse effect.", "source": "DDInter", "management_text": "Concomitant use of eluxadoline with other drugs that can cause constipation such as alosetron, anticholinergics, and opioids should generally be avoided. Loperamide may be used occasionally for acute management of severe diarrhea, but chronic use is not recommended, and it should be discontinued immediately if constipation occurs. Eluxadoline should also be discontinued if constipation occurs for more than 4 days.", "mechanism_text": "Synergism", "recommendation": "Concomitant use of eluxadoline with other drugs that can cause constipation such as alosetron, anticholinergics, and opioids should generally be avoided.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97783/", "reference_text": "[1] \"Product Information. Viberzi (eluxadoline).\" Actavis Pharma, Inc., Parsippany, NJ.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Viberzi (eluxadoline).\" Actavis Pharma, Inc., Parsippany, NJ.", "alternatives_a": "Diphenoxylate, Difenoxin", "alternatives_b": "Tropicamide, Ephedrine, Ketorolac, Phenylephrine", "updated_at": 1767369485}, {"id": 97680, "ingredient1": "Eluxadoline", "ingredient2": "Methylergometrine", "severity": "Moderate", "effect": "It is not known whether, and to what extent, eluxadoline may inhibit CYP450 3A4 and may interact with substrates of the isoenzyme. In vitro studies have shown that eluxadoline is not an inhibitor of CYP450 3A4 at clinically relevant systemic concentrations, but they were not adequate to rule out inhibition of CYP450 3A4 in the gut by eluxadoline. Therefore, the potential for eluxadoline to increase plasma concentrations of oral drugs that are metabolized by CYP450 3A4 should be considered.", "source": "DDInter", "management_text": "Caution is advised when eluxadoline is used with sensitive CYP450 3A4 substrates or substrates with narrow therapeutic ranges. These drugs include, but are not limited to: cisapride, colchicine, cyclosporine, fentanyl, ivacaftor, lovastatin, simvastatin, oral midazolam, triazolam, pimozide, quinidine, sildenafil, ergot derivatives, and macrolide immunosuppressants.", "mechanism_text": "Others", "recommendation": "Caution is advised when eluxadoline is used with sensitive CYP450 3A4 substrates or substrates with narrow therapeutic ranges.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97784/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Viberzi (eluxadoline).\" Actavis Pharma, Inc., Parsippany, NJ.[3] \"Product Information. Viberzi (eluxadoline).\" Actavis Pharma, Inc., Parsippany, NJ.[4] Kupferschmidt HHT, Ha HR, Ziegler WH, Meier PJ, Krahenbuhl S \"Interaction between grapefruit juice and midazolam in humans.\" Clin Pharmacol Ther 58 (1995): 20-8[5] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ \"Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice.\" Clin Pharmacol Ther 58 (1995): 127-31[6] \"Product Information. Valium (diazepam).\" Roche Laboratories, Nutley, NJ.[7] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[8] \"Product Information. Halcion (triazolam).\" Pharmacia and Upjohn, Kalamazoo, MI.[9] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[10] \"Product Information. Xanax (alprazolam).\" Pharmacia and Upjohn, Kalamazoo, MI.", "alternatives_a": "Misoprostol, Dinoprostone, Oxytocin", "alternatives_b": "Morphine, Diphenoxylate, Opium, Difenoxin, Loperamide", "updated_at": 1767369485}, {"id": 97681, "ingredient1": "Eluxadoline", "ingredient2": "Methysergide", "severity": "Moderate", "effect": "It is not known whether, and to what extent, eluxadoline may inhibit CYP450 3A4 and may interact with substrates of the isoenzyme. In vitro studies have shown that eluxadoline is not an inhibitor of CYP450 3A4 at clinically relevant systemic concentrations, but they were not adequate to rule out inhibition of CYP450 3A4 in the gut by eluxadoline. Therefore, the potential for eluxadoline to increase plasma concentrations of oral drugs that are metabolized by CYP450 3A4 should be considered.", "source": "DDInter", "management_text": "Caution is advised when eluxadoline is used with sensitive CYP450 3A4 substrates or substrates with narrow therapeutic ranges. These drugs include, but are not limited to: cisapride, colchicine, cyclosporine, fentanyl, ivacaftor, lovastatin, simvastatin, oral midazolam, triazolam, pimozide, quinidine, sildenafil, ergot derivatives, and macrolide immunosuppressants.", "mechanism_text": "Others", "recommendation": "Caution is advised when eluxadoline is used with sensitive CYP450 3A4 substrates or substrates with narrow therapeutic ranges.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97785/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Viberzi (eluxadoline).\" Actavis Pharma, Inc., Parsippany, NJ.[3] \"Product Information. Viberzi (eluxadoline).\" Actavis Pharma, Inc., Parsippany, NJ.[4] Kupferschmidt HHT, Ha HR, Ziegler WH, Meier PJ, Krahenbuhl S \"Interaction between grapefruit juice and midazolam in humans.\" Clin Pharmacol Ther 58 (1995): 20-8[5] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ \"Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice.\" Clin Pharmacol Ther 58 (1995): 127-31[6] \"Product Information. Valium (diazepam).\" Roche Laboratories, Nutley, NJ.[7] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[8] \"Product Information. Halcion (triazolam).\" Pharmacia and Upjohn, Kalamazoo, MI.[9] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[10] \"Product Information. Xanax (alprazolam).\" Pharmacia and Upjohn, Kalamazoo, MI.", "alternatives_a": "Frovatriptan, Rimegepant, Eptinezumab, Lasmiditan, Eletriptan, Rizatriptan, Naratriptan, Galcanezumab, Zolmitriptan, Sumatriptan, Erenumab, More", "alternatives_b": "Morphine, Diphenoxylate, Opium, Difenoxin, Loperamide", "updated_at": 1767369485}, {"id": 97682, "ingredient1": "Eluxadoline", "ingredient2": "Midazolam", "severity": "Moderate", "effect": "It is not known whether, and to what extent, eluxadoline may inhibit CYP450 3A4 and may interact with substrates of the isoenzyme. In vitro studies have shown that eluxadoline is not an inhibitor of CYP450 3A4 at clinically relevant systemic concentrations, but they were not adequate to rule out inhibition of CYP450 3A4 in the gut by eluxadoline. Therefore, the potential for eluxadoline to increase plasma concentrations of oral drugs that are metabolized by CYP450 3A4 should be considered.", "source": "DDInter", "management_text": "Caution is advised when eluxadoline is used with sensitive CYP450 3A4 substrates or substrates with narrow therapeutic ranges. These drugs include, but are not limited to: cisapride, colchicine, cyclosporine, fentanyl, ivacaftor, lovastatin, simvastatin, oral midazolam, triazolam, pimozide, quinidine, sildenafil, ergot derivatives, and macrolide immunosuppressants.", "mechanism_text": "Others", "recommendation": "Caution is advised when eluxadoline is used with sensitive CYP450 3A4 substrates or substrates with narrow therapeutic ranges.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97786/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Viberzi (eluxadoline).\" Actavis Pharma, Inc., Parsippany, NJ.[3] \"Product Information. Viberzi (eluxadoline).\" Actavis Pharma, Inc., Parsippany, NJ.[4] Kupferschmidt HHT, Ha HR, Ziegler WH, Meier PJ, Krahenbuhl S \"Interaction between grapefruit juice and midazolam in humans.\" Clin Pharmacol Ther 58 (1995): 20-8[5] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ \"Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice.\" Clin Pharmacol Ther 58 (1995): 127-31[6] \"Product Information. Valium (diazepam).\" Roche Laboratories, Nutley, NJ.[7] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[8] \"Product Information. Halcion (triazolam).\" Pharmacia and Upjohn, Kalamazoo, MI.[9] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[10] \"Product Information. Xanax (alprazolam).\" Pharmacia and Upjohn, Kalamazoo, MI.", "alternatives_a": "Suvorexant, Flurazepam, Methohexital, Methylphenobarbital, Zolpidem, Pentobarbital, Zaleplon, Dichloralphenazone, Valerian, Temazepam, Butabarbital, More", "alternatives_b": "Loperamide, Diphenoxylate, Difenoxin", "updated_at": 1767369485}, {"id": 97683, "ingredient1": "Eluxadoline", "ingredient2": "Mifepristone", "severity": "Moderate", "effect": "It is not known whether, and to what extent, eluxadoline may be metabolized by CYP450 isoenzymes and may interact with inhibitors of CYP450 isoenzymes.", "source": "DDInter", "management_text": "As a precautionary measure due to incomplete information on the metabolism of eluxadoline, the manufacturer recommends caution during coadministration with potent inhibitors of various CYP450 isoenzymes. Patients should be monitored for adverse effects such as sedation, nausea, vomiting, constipation, abdominal pain, liver enzyme elevations, and pancreatitis,", "mechanism_text": "Metabolism", "recommendation": "As a precautionary measure due to incomplete information on the metabolism of eluxadoline, the manufacturer recommends caution during coadministration with potent inhibitors of various CYP450 isoenzymes.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97787/", "reference_text": "[1] \"Product Information. Viberzi (eluxadoline).\" Actavis Pharma, Inc., Parsippany, NJ.[2] \"Product Information. Viberzi (eluxadoline).\" Actavis Pharma, Inc., Parsippany, NJ.[3] \"Product Information. Zokinvy (lonafarnib).\" Eiger BioPharmaceuticals, Palo Alto, CA.", "alternatives_a": "Ulipristal, Danazol, Ospemifene, Raloxifene, Bazedoxifene, Prasterone", "alternatives_b": "Opium, Diphenoxylate, Difenoxin", "updated_at": 1767369485}, {"id": 97684, "ingredient1": "Eluxadoline", "ingredient2": "Molindone", "severity": "Moderate", "effect": "The risk of constipation and serious constipation-related adverse reactions may be increased when eluxadoline is used with other drugs that are also associated with this adverse effect.", "source": "DDInter", "management_text": "Concomitant use of eluxadoline with other drugs that can cause constipation such as alosetron, anticholinergics, and opioids should generally be avoided. Loperamide may be used occasionally for acute management of severe diarrhea, but chronic use is not recommended, and it should be discontinued immediately if constipation occurs. Eluxadoline should also be discontinued if constipation occurs for more than 4 days.", "mechanism_text": "Synergism", "recommendation": "Concomitant use of eluxadoline with other drugs that can cause constipation such as alosetron, anticholinergics, and opioids should generally be avoided.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97788/", "reference_text": "[1] \"Product Information. Viberzi (eluxadoline).\" Actavis Pharma, Inc., Parsippany, NJ.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Viberzi (eluxadoline).\" Actavis Pharma, Inc., Parsippany, NJ.", "alternatives_a": "Asenapine, Pimavanserin, Ziprasidone, Lumateperone, Iloperidone, Amisulpride, Droperidol, Cariprazine, Brexpiprazole, Paliperidone, Lurasidone", "alternatives_b": "Diphenoxylate, Difenoxin", "updated_at": 1767369485}, {"id": 97685, "ingredient1": "Eluxadoline", "ingredient2": "Morphine (liposomal)", "severity": "Moderate", "effect": "The risk of constipation and serious constipation-related adverse reactions may be increased when eluxadoline is used with other drugs that are also associated with this adverse effect.", "source": "DDInter", "management_text": "Concomitant use of eluxadoline with other drugs that can cause constipation such as alosetron, anticholinergics, and opioids should generally be avoided. Loperamide may be used occasionally for acute management of severe diarrhea, but chronic use is not recommended, and it should be discontinued immediately if constipation occurs. Eluxadoline should also be discontinued if constipation occurs for more than 4 days.", "mechanism_text": "Synergism", "recommendation": "Concomitant use of eluxadoline with other drugs that can cause constipation such as alosetron, anticholinergics, and opioids should generally be avoided.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97789/", "reference_text": "[1] \"Product Information. Viberzi (eluxadoline).\" Actavis Pharma, Inc., Parsippany, NJ.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Viberzi (eluxadoline).\" Actavis Pharma, Inc., Parsippany, NJ.", "alternatives_a": "Eluxadoline, Naltrexone, Acetaminophen, Ibuprofen, Celecoxib, Acetylsalicylic acid, Naloxone", "alternatives_b": "Diphenoxylate, Morphine, Difenoxin", "updated_at": 1767369485}, {"id": 97686, "ingredient1": "Eluxadoline", "ingredient2": "Nalbuphine", "severity": "Moderate", "effect": "The risk of constipation and serious constipation-related adverse reactions may be increased when eluxadoline is used with other drugs that are also associated with this adverse effect.", "source": "DDInter", "management_text": "Concomitant use of eluxadoline with other drugs that can cause constipation such as alosetron, anticholinergics, and opioids should generally be avoided. Loperamide may be used occasionally for acute management of severe diarrhea, but chronic use is not recommended, and it should be discontinued immediately if constipation occurs. Eluxadoline should also be discontinued if constipation occurs for more than 4 days.", "mechanism_text": "Synergism", "recommendation": "Concomitant use of eluxadoline with other drugs that can cause constipation such as alosetron, anticholinergics, and opioids should generally be avoided.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97790/", "reference_text": "[1] \"Product Information. Viberzi (eluxadoline).\" Actavis Pharma, Inc., Parsippany, NJ.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Viberzi (eluxadoline).\" Actavis Pharma, Inc., Parsippany, NJ.", "alternatives_a": "Naltrexone, Acetaminophen, Ibuprofen, Celecoxib, Acetylsalicylic acid, Naloxone", "alternatives_b": "", "updated_at": 1767369485}, {"id": 97687, "ingredient1": "Eluxadoline", "ingredient2": "Nefazodone", "severity": "Moderate", "effect": "It is not known whether, and to what extent, eluxadoline may be metabolized by CYP450 isoenzymes and may interact with inhibitors of CYP450 isoenzymes.", "source": "DDInter", "management_text": "As a precautionary measure due to incomplete information on the metabolism of eluxadoline, the manufacturer recommends caution during coadministration with potent inhibitors of various CYP450 isoenzymes. Patients should be monitored for adverse effects such as sedation, nausea, vomiting, constipation, abdominal pain, liver enzyme elevations, and pancreatitis,", "mechanism_text": "Metabolism", "recommendation": "As a precautionary measure due to incomplete information on the metabolism of eluxadoline, the manufacturer recommends caution during coadministration with potent inhibitors of various CYP450 isoenzymes.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97791/", "reference_text": "[1] \"Product Information. Viberzi (eluxadoline).\" Actavis Pharma, Inc., Parsippany, NJ.[2] \"Product Information. Viberzi (eluxadoline).\" Actavis Pharma, Inc., Parsippany, NJ.[3] \"Product Information. Zokinvy (lonafarnib).\" Eiger BioPharmaceuticals, Palo Alto, CA.", "alternatives_a": "Citalopram, Sertraline, St. John's Wort, Milnacipran, Vortioxetine, Levomilnacipran, Duloxetine, Isocarboxazid, Viloxazine, Esketamine, Phenelzine, More", "alternatives_b": "Diphenoxylate, Difenoxin", "updated_at": 1767369485}, {"id": 97688, "ingredient1": "Eluxadoline", "ingredient2": "Nelfinavir", "severity": "Moderate", "effect": "It is not known whether, and to what extent, eluxadoline may be metabolized by CYP450 isoenzymes and may interact with inhibitors of CYP450 isoenzymes.", "source": "DDInter", "management_text": "As a precautionary measure due to incomplete information on the metabolism of eluxadoline, the manufacturer recommends caution during coadministration with potent inhibitors of various CYP450 isoenzymes. Patients should be monitored for adverse effects such as sedation, nausea, vomiting, constipation, abdominal pain, liver enzyme elevations, and pancreatitis,", "mechanism_text": "Metabolism", "recommendation": "As a precautionary measure due to incomplete information on the metabolism of eluxadoline, the manufacturer recommends caution during coadministration with potent inhibitors of various CYP450 isoenzymes.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97792/", "reference_text": "[1] \"Product Information. Viberzi (eluxadoline).\" Actavis Pharma, Inc., Parsippany, NJ.[2] \"Product Information. Viberzi (eluxadoline).\" Actavis Pharma, Inc., Parsippany, NJ.[3] \"Product Information. Zokinvy (lonafarnib).\" Eiger BioPharmaceuticals, Palo Alto, CA.", "alternatives_a": "Lamivudine, Glecaprevir, Tenofovir alafenamide, Maraviroc, Cabotegravir, Valaciclovir, Zanamivir, Lenacapavir, Velpatasvir, Rilpivirine, Etravirine, More", "alternatives_b": "Opium, Diphenoxylate, Difenoxin", "updated_at": 1767369485}, {"id": 97689, "ingredient1": "Eluxadoline", "ingredient2": "Nortriptyline", "severity": "Moderate", "effect": "The risk of constipation and serious constipation-related adverse reactions may be increased when eluxadoline is used with other drugs that are also associated with this adverse effect.", "source": "DDInter", "management_text": "Concomitant use of eluxadoline with other drugs that can cause constipation such as alosetron, anticholinergics, and opioids should generally be avoided. Loperamide may be used occasionally for acute management of severe diarrhea, but chronic use is not recommended, and it should be discontinued immediately if constipation occurs. Eluxadoline should also be discontinued if constipation occurs for more than 4 days.", "mechanism_text": "Synergism", "recommendation": "Concomitant use of eluxadoline with other drugs that can cause constipation such as alosetron, anticholinergics, and opioids should generally be avoided.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97793/", "reference_text": "[1] \"Product Information. Viberzi (eluxadoline).\" Actavis Pharma, Inc., Parsippany, NJ.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Viberzi (eluxadoline).\" Actavis Pharma, Inc., Parsippany, NJ.", "alternatives_a": "Citalopram, Sertraline, St. John's Wort, Milnacipran, Vortioxetine, Levomilnacipran, Duloxetine, Isocarboxazid, Viloxazine, Esketamine, Phenelzine, More", "alternatives_b": "Diphenoxylate, Difenoxin", "updated_at": 1767369485}, {"id": 97690, "ingredient1": "Eluxadoline", "ingredient2": "Olanzapine", "severity": "Moderate", "effect": "The risk of constipation and serious constipation-related adverse reactions may be increased when eluxadoline is used with other drugs that are also associated with this adverse effect.", "source": "DDInter", "management_text": "Concomitant use of eluxadoline with other drugs that can cause constipation such as alosetron, anticholinergics, and opioids should generally be avoided. Loperamide may be used occasionally for acute management of severe diarrhea, but chronic use is not recommended, and it should be discontinued immediately if constipation occurs. Eluxadoline should also be discontinued if constipation occurs for more than 4 days.", "mechanism_text": "Synergism", "recommendation": "Concomitant use of eluxadoline with other drugs that can cause constipation such as alosetron, anticholinergics, and opioids should generally be avoided.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97794/", "reference_text": "[1] \"Product Information. Viberzi (eluxadoline).\" Actavis Pharma, Inc., Parsippany, NJ.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Viberzi (eluxadoline).\" Actavis Pharma, Inc., Parsippany, NJ.", "alternatives_a": "Asenapine, Pimavanserin, Ziprasidone, Lumateperone, Iloperidone, Amisulpride, Droperidol, Cariprazine, Brexpiprazole, Paliperidone, Lurasidone", "alternatives_b": "", "updated_at": 1767369485}, {"id": 97691, "ingredient1": "Eluxadoline", "ingredient2": "Olaparib", "severity": "Moderate", "effect": "Based on in vitro inhibition data, coadministration with olaparib may increase the plasma concentrations of drugs that are substrates of CYP450 3A4 (e.g., cisapride, ergot alkaloids, fentanyl, lovastatin, oral midazolam, pimozide, quetiapine, simvastatin, triazolam, vinca alkaloids), P-gp (e.g., colchicine, dabigatran, digoxin), breast cancer resistance protein (BCRP) (e.g., rosuvastatin), OATP1B1 (e.g., eluxadoline, glyburide, repaglinide, statins, valsartan), or organic cation transporter 1 or 2 (OCT1, OCT2) (e.g., metformin). The proposed mechanism is decreased clearance due to inhibition of the corresponding metabolizing enzyme and/or efflux/uptake transporter by olaparib.", "source": "DDInter", "management_text": "Caution is advised if olaparib must be used concomitantly with drugs that are substrates of the affected enzymes or transporters, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever olaparib is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if olaparib must be used concomitantly with drugs that are substrates of the affected enzymes or transporters, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97795/", "reference_text": "[1] Cerner Multum, Inc. \"Australian Product Information.\" O 0[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Lynparza (olaparib).\" Astra-Zeneca Pharmaceuticals, Wilmington, DE.[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ \"Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice.\" Clin Pharmacol Ther 58 (1995): 127-31[7] Kupferschmidt HHT, Ha HR, Ziegler WH, Meier PJ, Krahenbuhl S \"Interaction between grapefruit juice and midazolam in humans.\" Clin Pharmacol Ther 58 (1995): 20-8[8] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[9] \"Product Information. Valium (diazepam).\" Roche Laboratories, Nutley, NJ.[10] \"Product Information. Xanax (alprazolam).\" Pharmacia and Upjohn, Kalamazoo, MI.[11] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[12] \"Product Information. Halcion (triazolam).\" Pharmacia and Upjohn, Kalamazoo, MI.", "alternatives_a": "Pertuzumab, Oxaliplatin, Rucaparib, Bortezomib, Tisagenlecleucel, Aminolevulinic acid, Omacetaxine mepesuccinate, Tazemetostat, Altretamine, Tagraxofusp, Pegaspargase, More", "alternatives_b": "Opium, Loperamide, Diphenoxylate, Difenoxin", "updated_at": 1767369485}, {"id": 97692, "ingredient1": "Eluxadoline", "ingredient2": "Oliceridine", "severity": "Moderate", "effect": "The risk of constipation and serious constipation-related adverse reactions may be increased when eluxadoline is used with other drugs that are also associated with this adverse effect.", "source": "DDInter", "management_text": "Concomitant use of eluxadoline with other drugs that can cause constipation such as alosetron, anticholinergics, and opioids should generally be avoided. Loperamide may be used occasionally for acute management of severe diarrhea, but chronic use is not recommended, and it should be discontinued immediately if constipation occurs. Eluxadoline should also be discontinued if constipation occurs for more than 4 days.", "mechanism_text": "Synergism", "recommendation": "Concomitant use of eluxadoline with other drugs that can cause constipation such as alosetron, anticholinergics, and opioids should generally be avoided.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97796/", "reference_text": "[1] \"Product Information. Viberzi (eluxadoline).\" Actavis Pharma, Inc., Parsippany, NJ.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Viberzi (eluxadoline).\" Actavis Pharma, Inc., Parsippany, NJ.", "alternatives_a": "Naltrexone, Acetaminophen, Ibuprofen, Celecoxib, Acetylsalicylic acid, Naloxone", "alternatives_b": "", "updated_at": 1767369485}, {"id": 97693, "ingredient1": "Eluxadoline", "ingredient2": "Opium", "severity": "Moderate", "effect": "The risk of constipation and serious constipation-related adverse reactions may be increased when eluxadoline is used with other drugs that are also associated with this adverse effect.", "source": "DDInter", "management_text": "Concomitant use of eluxadoline with other drugs that can cause constipation such as alosetron, anticholinergics, and opioids should generally be avoided. Loperamide may be used occasionally for acute management of severe diarrhea, but chronic use is not recommended, and it should be discontinued immediately if constipation occurs. Eluxadoline should also be discontinued if constipation occurs for more than 4 days.", "mechanism_text": "Synergism", "recommendation": "Concomitant use of eluxadoline with other drugs that can cause constipation such as alosetron, anticholinergics, and opioids should generally be avoided.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97797/", "reference_text": "[1] \"Product Information. Viberzi (eluxadoline).\" Actavis Pharma, Inc., Parsippany, NJ.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Viberzi (eluxadoline).\" Actavis Pharma, Inc., Parsippany, NJ.", "alternatives_a": "Opium", "alternatives_b": "Eluxadoline, Naltrexone, Acetaminophen, Ibuprofen, Celecoxib, Acetylsalicylic acid, Naloxone", "updated_at": 1767369485}, {"id": 97694, "ingredient1": "Eluxadoline", "ingredient2": "Orphenadrine", "severity": "Moderate", "effect": "The risk of constipation and serious constipation-related adverse reactions may be increased when eluxadoline is used with other drugs that are also associated with this adverse effect.", "source": "DDInter", "management_text": "Concomitant use of eluxadoline with other drugs that can cause constipation such as alosetron, anticholinergics, and opioids should generally be avoided. Loperamide may be used occasionally for acute management of severe diarrhea, but chronic use is not recommended, and it should be discontinued immediately if constipation occurs. Eluxadoline should also be discontinued if constipation occurs for more than 4 days.", "mechanism_text": "Synergism", "recommendation": "Concomitant use of eluxadoline with other drugs that can cause constipation such as alosetron, anticholinergics, and opioids should generally be avoided.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97798/", "reference_text": "[1] \"Product Information. Viberzi (eluxadoline).\" Actavis Pharma, Inc., Parsippany, NJ.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Viberzi (eluxadoline).\" Actavis Pharma, Inc., Parsippany, NJ.", "alternatives_a": "Carisoprodol, Chlorzoxazone, Tizanidine, Baclofen, Methocarbamol, Chlormezanone", "alternatives_b": "Difenoxin", "updated_at": 1767369485}, {"id": 97695, "ingredient1": "Eluxadoline", "ingredient2": "Oxybutynin", "severity": "Moderate", "effect": "The risk of constipation and serious constipation-related adverse reactions may be increased when eluxadoline is used with other drugs that are also associated with this adverse effect.", "source": "DDInter", "management_text": "Concomitant use of eluxadoline with other drugs that can cause constipation such as alosetron, anticholinergics, and opioids should generally be avoided. Loperamide may be used occasionally for acute management of severe diarrhea, but chronic use is not recommended, and it should be discontinued immediately if constipation occurs. Eluxadoline should also be discontinued if constipation occurs for more than 4 days.", "mechanism_text": "Synergism", "recommendation": "Concomitant use of eluxadoline with other drugs that can cause constipation such as alosetron, anticholinergics, and opioids should generally be avoided.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97799/", "reference_text": "[1] \"Product Information. Viberzi (eluxadoline).\" Actavis Pharma, Inc., Parsippany, NJ.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Viberzi (eluxadoline).\" Actavis Pharma, Inc., Parsippany, NJ.", "alternatives_a": "Apomorphine, Pentosan polysulfate, Calcium chloride, Phenazopyridine, Alprostadil, Mirabegron, Acetohydroxamic acid, Yohimbine, Avanafil, Papaverine, Vardenafil, More", "alternatives_b": "Diphenoxylate, Difenoxin", "updated_at": 1767369485}, {"id": 97696, "ingredient1": "Eluxadoline", "ingredient2": "Oxycodone", "severity": "Moderate", "effect": "The risk of constipation and serious constipation-related adverse reactions may be increased when eluxadoline is used with other drugs that are also associated with this adverse effect.", "source": "DDInter", "management_text": "Concomitant use of eluxadoline with other drugs that can cause constipation such as alosetron, anticholinergics, and opioids should generally be avoided. Loperamide may be used occasionally for acute management of severe diarrhea, but chronic use is not recommended, and it should be discontinued immediately if constipation occurs. Eluxadoline should also be discontinued if constipation occurs for more than 4 days.", "mechanism_text": "Synergism", "recommendation": "Concomitant use of eluxadoline with other drugs that can cause constipation such as alosetron, anticholinergics, and opioids should generally be avoided.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97800/", "reference_text": "[1] \"Product Information. Viberzi (eluxadoline).\" Actavis Pharma, Inc., Parsippany, NJ.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Viberzi (eluxadoline).\" Actavis Pharma, Inc., Parsippany, NJ.", "alternatives_a": "Naltrexone, Acetaminophen, Ibuprofen, Celecoxib, Acetylsalicylic acid, Naloxone", "alternatives_b": "", "updated_at": 1767369485}, {"id": 97697, "ingredient1": "Eluxadoline", "ingredient2": "Oxymorphone", "severity": "Moderate", "effect": "The risk of constipation and serious constipation-related adverse reactions may be increased when eluxadoline is used with other drugs that are also associated with this adverse effect.", "source": "DDInter", "management_text": "Concomitant use of eluxadoline with other drugs that can cause constipation such as alosetron, anticholinergics, and opioids should generally be avoided. Loperamide may be used occasionally for acute management of severe diarrhea, but chronic use is not recommended, and it should be discontinued immediately if constipation occurs. Eluxadoline should also be discontinued if constipation occurs for more than 4 days.", "mechanism_text": "Synergism", "recommendation": "Concomitant use of eluxadoline with other drugs that can cause constipation such as alosetron, anticholinergics, and opioids should generally be avoided.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97801/", "reference_text": "[1] \"Product Information. Viberzi (eluxadoline).\" Actavis Pharma, Inc., Parsippany, NJ.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Viberzi (eluxadoline).\" Actavis Pharma, Inc., Parsippany, NJ.", "alternatives_a": "Naltrexone, Acetaminophen, Ibuprofen, Celecoxib, Acetylsalicylic acid, Naloxone", "alternatives_b": "", "updated_at": 1767369485}, {"id": 97698, "ingredient1": "Eluxadoline", "ingredient2": "Paroxetine", "severity": "Moderate", "effect": "It is not known whether, and to what extent, eluxadoline may be metabolized by CYP450 isoenzymes and may interact with inhibitors of CYP450 isoenzymes.", "source": "DDInter", "management_text": "As a precautionary measure due to incomplete information on the metabolism of eluxadoline, the manufacturer recommends caution during coadministration with potent inhibitors of various CYP450 isoenzymes. Patients should be monitored for adverse effects such as sedation, nausea, vomiting, constipation, abdominal pain, liver enzyme elevations, and pancreatitis,", "mechanism_text": "Metabolism", "recommendation": "As a precautionary measure due to incomplete information on the metabolism of eluxadoline, the manufacturer recommends caution during coadministration with potent inhibitors of various CYP450 isoenzymes.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97802/", "reference_text": "[1] \"Product Information. Viberzi (eluxadoline).\" Actavis Pharma, Inc., Parsippany, NJ.[2] \"Product Information. Viberzi (eluxadoline).\" Actavis Pharma, Inc., Parsippany, NJ.[3] \"Product Information. Zokinvy (lonafarnib).\" Eiger BioPharmaceuticals, Palo Alto, CA.", "alternatives_a": "Citalopram, Sertraline, St. John's Wort, Milnacipran, Vortioxetine, Levomilnacipran, Duloxetine, Isocarboxazid, Viloxazine, Esketamine, Phenelzine, More", "alternatives_b": "Diphenoxylate, Difenoxin", "updated_at": 1767369485}, {"id": 97699, "ingredient1": "Eluxadoline", "ingredient2": "Pentazocine", "severity": "Moderate", "effect": "The risk of constipation and serious constipation-related adverse reactions may be increased when eluxadoline is used with other drugs that are also associated with this adverse effect.", "source": "DDInter", "management_text": "Concomitant use of eluxadoline with other drugs that can cause constipation such as alosetron, anticholinergics, and opioids should generally be avoided. Loperamide may be used occasionally for acute management of severe diarrhea, but chronic use is not recommended, and it should be discontinued immediately if constipation occurs. Eluxadoline should also be discontinued if constipation occurs for more than 4 days.", "mechanism_text": "Synergism", "recommendation": "Concomitant use of eluxadoline with other drugs that can cause constipation such as alosetron, anticholinergics, and opioids should generally be avoided.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97803/", "reference_text": "[1] \"Product Information. Viberzi (eluxadoline).\" Actavis Pharma, Inc., Parsippany, NJ.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Viberzi (eluxadoline).\" Actavis Pharma, Inc., Parsippany, NJ.", "alternatives_a": "Naltrexone, Acetaminophen, Ibuprofen, Celecoxib, Acetylsalicylic acid, Naloxone", "alternatives_b": "", "updated_at": 1767369485}, {"id": 97700, "ingredient1": "Eluxadoline", "ingredient2": "Perphenazine", "severity": "Moderate", "effect": "The risk of constipation and serious constipation-related adverse reactions may be increased when eluxadoline is used with other drugs that are also associated with this adverse effect.", "source": "DDInter", "management_text": "Concomitant use of eluxadoline with other drugs that can cause constipation such as alosetron, anticholinergics, and opioids should generally be avoided. Loperamide may be used occasionally for acute management of severe diarrhea, but chronic use is not recommended, and it should be discontinued immediately if constipation occurs. Eluxadoline should also be discontinued if constipation occurs for more than 4 days.", "mechanism_text": "Synergism", "recommendation": "Concomitant use of eluxadoline with other drugs that can cause constipation such as alosetron, anticholinergics, and opioids should generally be avoided.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97804/", "reference_text": "[1] \"Product Information. Viberzi (eluxadoline).\" Actavis Pharma, Inc., Parsippany, NJ.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Viberzi (eluxadoline).\" Actavis Pharma, Inc., Parsippany, NJ.", "alternatives_a": "Asenapine, Pimavanserin, Ziprasidone, Lumateperone, Iloperidone, Amisulpride, Droperidol, Cariprazine, Brexpiprazole, Paliperidone, Lurasidone", "alternatives_b": "Diphenoxylate, Difenoxin", "updated_at": 1767369485}, {"id": 97701, "ingredient1": "Eluxadoline", "ingredient2": "Phenindamine", "severity": "Moderate", "effect": "The risk of constipation and serious constipation-related adverse reactions may be increased when eluxadoline is used with other drugs that are also associated with this adverse effect.", "source": "DDInter", "management_text": "Concomitant use of eluxadoline with other drugs that can cause constipation such as alosetron, anticholinergics, and opioids should generally be avoided. Loperamide may be used occasionally for acute management of severe diarrhea, but chronic use is not recommended, and it should be discontinued immediately if constipation occurs. Eluxadoline should also be discontinued if constipation occurs for more than 4 days.", "mechanism_text": "Synergism", "recommendation": "Concomitant use of eluxadoline with other drugs that can cause constipation such as alosetron, anticholinergics, and opioids should generally be avoided.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97805/", "reference_text": "[1] \"Product Information. Viberzi (eluxadoline).\" Actavis Pharma, Inc., Parsippany, NJ.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Viberzi (eluxadoline).\" Actavis Pharma, Inc., Parsippany, NJ.", "alternatives_a": "Ketotifen, Levocetirizine, Cetirizine, Loratadine, Trimethobenzamide, Desloratadine, Azelastine", "alternatives_b": "Diphenoxylate, Difenoxin", "updated_at": 1767369485}, {"id": 97702, "ingredient1": "Eluxadoline", "ingredient2": "Pimozide", "severity": "Moderate", "effect": "The risk of constipation and serious constipation-related adverse reactions may be increased when eluxadoline is used with other drugs that are also associated with this adverse effect.", "source": "DDInter", "management_text": "Concomitant use of eluxadoline with other drugs that can cause constipation such as alosetron, anticholinergics, and opioids should generally be avoided. Loperamide may be used occasionally for acute management of severe diarrhea, but chronic use is not recommended, and it should be discontinued immediately if constipation occurs. Eluxadoline should also be discontinued if constipation occurs for more than 4 days.", "mechanism_text": "Synergism", "recommendation": "Concomitant use of eluxadoline with other drugs that can cause constipation such as alosetron, anticholinergics, and opioids should generally be avoided.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97806/", "reference_text": "[1] \"Product Information. Viberzi (eluxadoline).\" Actavis Pharma, Inc., Parsippany, NJ.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Viberzi (eluxadoline).\" Actavis Pharma, Inc., Parsippany, NJ.", "alternatives_a": "Asenapine, Pimavanserin, Ziprasidone, Lumateperone, Iloperidone, Amisulpride, Droperidol, Cariprazine, Brexpiprazole, Paliperidone, Lurasidone", "alternatives_b": "Difenoxin", "updated_at": 1767369485}, {"id": 97703, "ingredient1": "Eluxadoline", "ingredient2": "Pitavastatin", "severity": "Moderate", "effect": "Coadministration with eluxadoline may increase the plasma concentrations of drugs that are substrates of the organic anion transporting polypeptide (OATP) 1B1 and/or breast cancer resistance protein (BCRP) transporters. The mechanism is decreased clearance due to inhibition of OATP1B1-mediated hepatic uptake and BCRP-mediated intestinal and hepatobiliary efflux by eluxadoline.", "source": "DDInter", "management_text": "Caution is advised when eluxadoline is used concomitantly with drugs that are substrates of the OATP1B1 and/or BCRP transporters, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever eluxadoline is added to or withdrawn from therapy.", "mechanism_text": "Others", "recommendation": "Caution is advised when eluxadoline is used concomitantly with drugs that are substrates of the OATP1B1 and/or BCRP transporters, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97807/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Viberzi (eluxadoline).\" Actavis Pharma, Inc., Parsippany, NJ.[3] Richter WO, Jacob BG, Schwandt P \"Interaction between fibre and lovastatin.\" Lancet 338 (1991): 706[4] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors.\" Clin Pharmacol Ther 64 (1998): 477-83[5] Kantola T, Kivisto KT, Neuvonen PJ \"Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid.\" Clin Pharmacol Ther 63 (1998): 397-402[6] \"Product Information. Mevacor (lovastatin).\" Merck & Co, Inc, West Point, PA.[7] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions.\" Br J Clin Pharmacol 46 (1998): 101-10[8] Neuvonen PJ, Backman JT, Niemi M \"Pharmacokinetic comparison of the potential over-the-counter statins simvastatin, lovastatin, fluvastatin and pravastatin.\" Clin Pharmacokinet 47 (2008): 463-74[9] Thompson PD, Clarkson P, Karas RH \"Statin-associated myopathy.\" JAMA 289 (2003): 1681-90[10] \"Product Information. Zocor (simvastatin).\" Merck & Co, Inc, West Point, PA.[11] \"Product Information. Viberzi (eluxadoline).\" Actavis Pharma, Inc., Parsippany, NJ.", "alternatives_a": "Fenofibric acid, Mipomersen, Evinacumab, Evolocumab, Dextrothyroxine, Probucol, Cholestyramine, Clofibrate, Colestipol, Niacin, Lomitapide, More", "alternatives_b": "Morphine, Diphenoxylate, Opium, Difenoxin, Loperamide", "updated_at": 1767369485}, {"id": 97704, "ingredient1": "Eluxadoline", "ingredient2": "Posaconazole", "severity": "Moderate", "effect": "It is not known whether, and to what extent, eluxadoline may be metabolized by CYP450 isoenzymes and may interact with inhibitors of CYP450 isoenzymes.", "source": "DDInter", "management_text": "As a precautionary measure due to incomplete information on the metabolism of eluxadoline, the manufacturer recommends caution during coadministration with potent inhibitors of various CYP450 isoenzymes. Patients should be monitored for adverse effects such as sedation, nausea, vomiting, constipation, abdominal pain, liver enzyme elevations, and pancreatitis,", "mechanism_text": "Metabolism", "recommendation": "As a precautionary measure due to incomplete information on the metabolism of eluxadoline, the manufacturer recommends caution during coadministration with potent inhibitors of various CYP450 isoenzymes.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97808/", "reference_text": "[1] \"Product Information. Viberzi (eluxadoline).\" Actavis Pharma, Inc., Parsippany, NJ.[2] \"Product Information. Viberzi (eluxadoline).\" Actavis Pharma, Inc., Parsippany, NJ.[3] \"Product Information. Zokinvy (lonafarnib).\" Eiger BioPharmaceuticals, Palo Alto, CA.", "alternatives_a": "Caspofungin, Micafungin, Amphotericin B, Miconazole, Oteseconazole, Flucytosine, Anidulafungin", "alternatives_b": "Opium, Diphenoxylate, Difenoxin", "updated_at": 1767369485}, {"id": 97705, "ingredient1": "Eluxadoline", "ingredient2": "Pravastatin", "severity": "Moderate", "effect": "Coadministration with eluxadoline may increase the plasma concentrations of drugs that are substrates of the organic anion transporting polypeptide (OATP) 1B1 and/or breast cancer resistance protein (BCRP) transporters. The mechanism is decreased clearance due to inhibition of OATP1B1-mediated hepatic uptake and BCRP-mediated intestinal and hepatobiliary efflux by eluxadoline.", "source": "DDInter", "management_text": "Caution is advised when eluxadoline is used concomitantly with drugs that are substrates of the OATP1B1 and/or BCRP transporters, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever eluxadoline is added to or withdrawn from therapy.", "mechanism_text": "Others", "recommendation": "Caution is advised when eluxadoline is used concomitantly with drugs that are substrates of the OATP1B1 and/or BCRP transporters, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97809/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Viberzi (eluxadoline).\" Actavis Pharma, Inc., Parsippany, NJ.[3] Richter WO, Jacob BG, Schwandt P \"Interaction between fibre and lovastatin.\" Lancet 338 (1991): 706[4] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors.\" Clin Pharmacol Ther 64 (1998): 477-83[5] Kantola T, Kivisto KT, Neuvonen PJ \"Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid.\" Clin Pharmacol Ther 63 (1998): 397-402[6] \"Product Information. Mevacor (lovastatin).\" Merck & Co, Inc, West Point, PA.[7] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions.\" Br J Clin Pharmacol 46 (1998): 101-10[8] Neuvonen PJ, Backman JT, Niemi M \"Pharmacokinetic comparison of the potential over-the-counter statins simvastatin, lovastatin, fluvastatin and pravastatin.\" Clin Pharmacokinet 47 (2008): 463-74[9] Thompson PD, Clarkson P, Karas RH \"Statin-associated myopathy.\" JAMA 289 (2003): 1681-90[10] \"Product Information. Zocor (simvastatin).\" Merck & Co, Inc, West Point, PA.[11] \"Product Information. Viberzi (eluxadoline).\" Actavis Pharma, Inc., Parsippany, NJ.", "alternatives_a": "Fenofibric acid, Mipomersen, Evinacumab, Evolocumab, Dextrothyroxine, Probucol, Cholestyramine, Clofibrate, Colestipol, Niacin, Lomitapide, More", "alternatives_b": "Opium, Diphenoxylate, Difenoxin", "updated_at": 1767369485}, {"id": 97706, "ingredient1": "Eluxadoline", "ingredient2": "Probenecid", "severity": "Minor", "effect": "Coadministration with probenecid may modestly increase the plasma concentrations of eluxadoline. The proposed mechanism is probenecid inhibition of multidrug resistance-associated protein 2 (MRP2) and organic anion transporter 3 (OAT3), which are involved in the hepatobiliary efflux and proximal tubular uptake of eluxadoline, respectively. These changes are not considered clinically significant.", "source": "DDInter", "management_text": "-", "mechanism_text": "Excretion", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97810/", "reference_text": "[1] \"Product Information. Viberzi (eluxadoline).\" Actavis Pharma, Inc., Parsippany, NJ.[2] Davenport JM, Covington P, Bonifacio L, McIntyre G, Venitz J \"Effect of uptake transporters OAT3 and OATPIBI and efflux transporter MRP2 on the pharmacokinetics of eluxadoline.\" J Clin Pharmacol 55 (2015): 534-42[3] \"Product Information. Viberzi (eluxadoline).\" Actavis Pharma, Inc., Parsippany, NJ.", "alternatives_a": "Lesinurad, Febuxostat, Pegloticase, Sulfinpyrazone, Rasburicase, Allopurinol, Tamsulosin, Tinidazole, Ascorbic acid, Hydroflumethiazide, Chlorothiazide, More", "alternatives_b": "Opium, Loperamide, Diphenoxylate, Difenoxin", "updated_at": 1767369485}, {"id": 97707, "ingredient1": "Eluxadoline", "ingredient2": "Procainamide", "severity": "Moderate", "effect": "The risk of constipation and serious constipation-related adverse reactions may be increased when eluxadoline is used with other drugs that are also associated with this adverse effect.", "source": "DDInter", "management_text": "Concomitant use of eluxadoline with other drugs that can cause constipation such as alosetron, anticholinergics, and opioids should generally be avoided. Loperamide may be used occasionally for acute management of severe diarrhea, but chronic use is not recommended, and it should be discontinued immediately if constipation occurs. Eluxadoline should also be discontinued if constipation occurs for more than 4 days.", "mechanism_text": "Synergism", "recommendation": "Concomitant use of eluxadoline with other drugs that can cause constipation such as alosetron, anticholinergics, and opioids should generally be avoided.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97811/", "reference_text": "[1] \"Product Information. Viberzi (eluxadoline).\" Actavis Pharma, Inc., Parsippany, NJ.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Viberzi (eluxadoline).\" Actavis Pharma, Inc., Parsippany, NJ.", "alternatives_a": "Amiodarone, Dronedarone, Tocainide, Lidocaine, Propafenone, Flecainide, Mexiletine, Dofetilide, Bretylium, Moricizine, Ibutilide", "alternatives_b": "Opium, Diphenoxylate, Morphine, Difenoxin", "updated_at": 1767369485}, {"id": 97708, "ingredient1": "Eluxadoline", "ingredient2": "Procyclidine", "severity": "Moderate", "effect": "The risk of constipation and serious constipation-related adverse reactions may be increased when eluxadoline is used with other drugs that are also associated with this adverse effect.", "source": "DDInter", "management_text": "Concomitant use of eluxadoline with other drugs that can cause constipation such as alosetron, anticholinergics, and opioids should generally be avoided. Loperamide may be used occasionally for acute management of severe diarrhea, but chronic use is not recommended, and it should be discontinued immediately if constipation occurs. Eluxadoline should also be discontinued if constipation occurs for more than 4 days.", "mechanism_text": "Synergism", "recommendation": "Concomitant use of eluxadoline with other drugs that can cause constipation such as alosetron, anticholinergics, and opioids should generally be avoided.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97812/", "reference_text": "[1] \"Product Information. Viberzi (eluxadoline).\" Actavis Pharma, Inc., Parsippany, NJ.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Viberzi (eluxadoline).\" Actavis Pharma, Inc., Parsippany, NJ.", "alternatives_a": "", "alternatives_b": "", "updated_at": 1767369485}, {"id": 97709, "ingredient1": "Eluxadoline", "ingredient2": "Promazine", "severity": "Moderate", "effect": "The risk of constipation and serious constipation-related adverse reactions may be increased when eluxadoline is used with other drugs that are also associated with this adverse effect.", "source": "DDInter", "management_text": "Concomitant use of eluxadoline with other drugs that can cause constipation such as alosetron, anticholinergics, and opioids should generally be avoided. Loperamide may be used occasionally for acute management of severe diarrhea, but chronic use is not recommended, and it should be discontinued immediately if constipation occurs. Eluxadoline should also be discontinued if constipation occurs for more than 4 days.", "mechanism_text": "Synergism", "recommendation": "Concomitant use of eluxadoline with other drugs that can cause constipation such as alosetron, anticholinergics, and opioids should generally be avoided.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97813/", "reference_text": "[1] \"Product Information. Viberzi (eluxadoline).\" Actavis Pharma, Inc., Parsippany, NJ.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Viberzi (eluxadoline).\" Actavis Pharma, Inc., Parsippany, NJ.", "alternatives_a": "Asenapine, Pimavanserin, Ziprasidone, Lumateperone, Iloperidone, Amisulpride, Droperidol, Cariprazine, Brexpiprazole, Paliperidone, Lurasidone", "alternatives_b": "Diphenoxylate, Difenoxin", "updated_at": 1767369485}, {"id": 97710, "ingredient1": "Eluxadoline", "ingredient2": "Promethazine", "severity": "Moderate", "effect": "The risk of constipation and serious constipation-related adverse reactions may be increased when eluxadoline is used with other drugs that are also associated with this adverse effect.", "source": "DDInter", "management_text": "Concomitant use of eluxadoline with other drugs that can cause constipation such as alosetron, anticholinergics, and opioids should generally be avoided. Loperamide may be used occasionally for acute management of severe diarrhea, but chronic use is not recommended, and it should be discontinued immediately if constipation occurs. Eluxadoline should also be discontinued if constipation occurs for more than 4 days.", "mechanism_text": "Synergism", "recommendation": "Concomitant use of eluxadoline with other drugs that can cause constipation such as alosetron, anticholinergics, and opioids should generally be avoided.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97814/", "reference_text": "[1] \"Product Information. Viberzi (eluxadoline).\" Actavis Pharma, Inc., Parsippany, NJ.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Viberzi (eluxadoline).\" Actavis Pharma, Inc., Parsippany, NJ.", "alternatives_a": "Ketotifen, Levocetirizine, Cetirizine, Loratadine, Trimethobenzamide, Desloratadine, Azelastine, Lidocaine, Tetracaine, Hydroxocobalamin, Fomepizole, More", "alternatives_b": "Diphenoxylate, Difenoxin", "updated_at": 1767369485}, {"id": 97711, "ingredient1": "Eluxadoline", "ingredient2": "Propantheline", "severity": "Moderate", "effect": "The risk of constipation and serious constipation-related adverse reactions may be increased when eluxadoline is used with other drugs that are also associated with this adverse effect.", "source": "DDInter", "management_text": "Concomitant use of eluxadoline with other drugs that can cause constipation such as alosetron, anticholinergics, and opioids should generally be avoided. Loperamide may be used occasionally for acute management of severe diarrhea, but chronic use is not recommended, and it should be discontinued immediately if constipation occurs. Eluxadoline should also be discontinued if constipation occurs for more than 4 days.", "mechanism_text": "Synergism", "recommendation": "Concomitant use of eluxadoline with other drugs that can cause constipation such as alosetron, anticholinergics, and opioids should generally be avoided.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97815/", "reference_text": "[1] \"Product Information. Viberzi (eluxadoline).\" Actavis Pharma, Inc., Parsippany, NJ.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Viberzi (eluxadoline).\" Actavis Pharma, Inc., Parsippany, NJ.", "alternatives_a": "Papaverine, Isometheptene", "alternatives_b": "Diphenoxylate, Difenoxin", "updated_at": 1767369485}, {"id": 97712, "ingredient1": "Eluxadoline", "ingredient2": "Propiomazine", "severity": "Moderate", "effect": "The risk of constipation and serious constipation-related adverse reactions may be increased when eluxadoline is used with other drugs that are also associated with this adverse effect.", "source": "DDInter", "management_text": "Concomitant use of eluxadoline with other drugs that can cause constipation such as alosetron, anticholinergics, and opioids should generally be avoided. Loperamide may be used occasionally for acute management of severe diarrhea, but chronic use is not recommended, and it should be discontinued immediately if constipation occurs. Eluxadoline should also be discontinued if constipation occurs for more than 4 days.", "mechanism_text": "Synergism", "recommendation": "Concomitant use of eluxadoline with other drugs that can cause constipation such as alosetron, anticholinergics, and opioids should generally be avoided.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97816/", "reference_text": "[1] \"Product Information. Viberzi (eluxadoline).\" Actavis Pharma, Inc., Parsippany, NJ.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Viberzi (eluxadoline).\" Actavis Pharma, Inc., Parsippany, NJ.", "alternatives_a": "Suvorexant, Flurazepam, Methohexital, Methylphenobarbital, Zolpidem, Pentobarbital, Zaleplon, Dichloralphenazone, Valerian, Temazepam, Butabarbital, More", "alternatives_b": "Diphenoxylate, Difenoxin", "updated_at": 1767369485}, {"id": 97713, "ingredient1": "Eluxadoline", "ingredient2": "Dextropropoxyphene", "severity": "Moderate", "effect": "The risk of constipation and serious constipation-related adverse reactions may be increased when eluxadoline is used with other drugs that are also associated with this adverse effect.", "source": "DDInter", "management_text": "Concomitant use of eluxadoline with other drugs that can cause constipation such as alosetron, anticholinergics, and opioids should generally be avoided. Loperamide may be used occasionally for acute management of severe diarrhea, but chronic use is not recommended, and it should be discontinued immediately if constipation occurs. Eluxadoline should also be discontinued if constipation occurs for more than 4 days.", "mechanism_text": "Synergism", "recommendation": "Concomitant use of eluxadoline with other drugs that can cause constipation such as alosetron, anticholinergics, and opioids should generally be avoided.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97817/", "reference_text": "[1] \"Product Information. Viberzi (eluxadoline).\" Actavis Pharma, Inc., Parsippany, NJ.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Viberzi (eluxadoline).\" Actavis Pharma, Inc., Parsippany, NJ.", "alternatives_a": "Naltrexone, Acetaminophen, Ibuprofen, Celecoxib, Acetylsalicylic acid, Naloxone", "alternatives_b": "", "updated_at": 1767369485}, {"id": 97714, "ingredient1": "Eluxadoline", "ingredient2": "Protriptyline", "severity": "Moderate", "effect": "The risk of constipation and serious constipation-related adverse reactions may be increased when eluxadoline is used with other drugs that are also associated with this adverse effect.", "source": "DDInter", "management_text": "Concomitant use of eluxadoline with other drugs that can cause constipation such as alosetron, anticholinergics, and opioids should generally be avoided. Loperamide may be used occasionally for acute management of severe diarrhea, but chronic use is not recommended, and it should be discontinued immediately if constipation occurs. Eluxadoline should also be discontinued if constipation occurs for more than 4 days.", "mechanism_text": "Synergism", "recommendation": "Concomitant use of eluxadoline with other drugs that can cause constipation such as alosetron, anticholinergics, and opioids should generally be avoided.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97818/", "reference_text": "[1] \"Product Information. Viberzi (eluxadoline).\" Actavis Pharma, Inc., Parsippany, NJ.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Viberzi (eluxadoline).\" Actavis Pharma, Inc., Parsippany, NJ.", "alternatives_a": "Citalopram, Sertraline, St. John's Wort, Milnacipran, Vortioxetine, Levomilnacipran, Duloxetine, Isocarboxazid, Viloxazine, Esketamine, Phenelzine, More", "alternatives_b": "Difenoxin", "updated_at": 1767369485}, {"id": 97715, "ingredient1": "Eluxadoline", "ingredient2": "Quetiapine", "severity": "Moderate", "effect": "The risk of constipation and serious constipation-related adverse reactions may be increased when eluxadoline is used with other drugs that are also associated with this adverse effect.", "source": "DDInter", "management_text": "Concomitant use of eluxadoline with other drugs that can cause constipation such as alosetron, anticholinergics, and opioids should generally be avoided. Loperamide may be used occasionally for acute management of severe diarrhea, but chronic use is not recommended, and it should be discontinued immediately if constipation occurs. Eluxadoline should also be discontinued if constipation occurs for more than 4 days.", "mechanism_text": "Synergism", "recommendation": "Concomitant use of eluxadoline with other drugs that can cause constipation such as alosetron, anticholinergics, and opioids should generally be avoided.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97819/", "reference_text": "[1] \"Product Information. Viberzi (eluxadoline).\" Actavis Pharma, Inc., Parsippany, NJ.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Viberzi (eluxadoline).\" Actavis Pharma, Inc., Parsippany, NJ.", "alternatives_a": "Asenapine, Pimavanserin, Ziprasidone, Lumateperone, Iloperidone, Amisulpride, Droperidol, Cariprazine, Brexpiprazole, Paliperidone, Lurasidone", "alternatives_b": "Diphenoxylate, Difenoxin", "updated_at": 1767369485}, {"id": 97716, "ingredient1": "Eluxadoline", "ingredient2": "Quinidine", "severity": "Moderate", "effect": "It is not known whether, and to what extent, eluxadoline may inhibit CYP450 3A4 and may interact with substrates of the isoenzyme. In vitro studies have shown that eluxadoline is not an inhibitor of CYP450 3A4 at clinically relevant systemic concentrations, but they were not adequate to rule out inhibition of CYP450 3A4 in the gut by eluxadoline. Therefore, the potential for eluxadoline to increase plasma concentrations of oral drugs that are metabolized by CYP450 3A4 should be considered.", "source": "DDInter", "management_text": "Caution is advised when eluxadoline is used with sensitive CYP450 3A4 substrates or substrates with narrow therapeutic ranges. These drugs include, but are not limited to: cisapride, colchicine, cyclosporine, fentanyl, ivacaftor, lovastatin, simvastatin, oral midazolam, triazolam, pimozide, quinidine, sildenafil, ergot derivatives, and macrolide immunosuppressants.", "mechanism_text": "Others", "recommendation": "Caution is advised when eluxadoline is used with sensitive CYP450 3A4 substrates or substrates with narrow therapeutic ranges.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97820/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Viberzi (eluxadoline).\" Actavis Pharma, Inc., Parsippany, NJ.[3] \"Product Information. Viberzi (eluxadoline).\" Actavis Pharma, Inc., Parsippany, NJ.[4] Kupferschmidt HHT, Ha HR, Ziegler WH, Meier PJ, Krahenbuhl S \"Interaction between grapefruit juice and midazolam in humans.\" Clin Pharmacol Ther 58 (1995): 20-8[5] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ \"Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice.\" Clin Pharmacol Ther 58 (1995): 127-31[6] \"Product Information. Valium (diazepam).\" Roche Laboratories, Nutley, NJ.[7] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[8] \"Product Information. Halcion (triazolam).\" Pharmacia and Upjohn, Kalamazoo, MI.[9] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[10] \"Product Information. Xanax (alprazolam).\" Pharmacia and Upjohn, Kalamazoo, MI.", "alternatives_a": "Amiodarone, Dronedarone, Tocainide, Lidocaine, Propafenone, Flecainide, Mexiletine, Dofetilide, Bretylium, Moricizine, Ibutilide", "alternatives_b": "Opium, Diphenoxylate, Difenoxin", "updated_at": 1767369485}, {"id": 97717, "ingredient1": "Eluxadoline", "ingredient2": "Remifentanil", "severity": "Moderate", "effect": "The risk of constipation and serious constipation-related adverse reactions may be increased when eluxadoline is used with other drugs that are also associated with this adverse effect.", "source": "DDInter", "management_text": "Concomitant use of eluxadoline with other drugs that can cause constipation such as alosetron, anticholinergics, and opioids should generally be avoided. Loperamide may be used occasionally for acute management of severe diarrhea, but chronic use is not recommended, and it should be discontinued immediately if constipation occurs. Eluxadoline should also be discontinued if constipation occurs for more than 4 days.", "mechanism_text": "Synergism", "recommendation": "Concomitant use of eluxadoline with other drugs that can cause constipation such as alosetron, anticholinergics, and opioids should generally be avoided.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97821/", "reference_text": "[1] \"Product Information. Viberzi (eluxadoline).\" Actavis Pharma, Inc., Parsippany, NJ.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Viberzi (eluxadoline).\" Actavis Pharma, Inc., Parsippany, NJ.", "alternatives_a": "Halothane, Thiopental, Sodium oxybate, Isoflurane, Methohexital, Nitrous oxide, Desflurane, Propofol, Enflurane, Esketamine, Sevoflurane, More", "alternatives_b": "Loperamide", "updated_at": 1767369485}, {"id": 97718, "ingredient1": "Eluxadoline", "ingredient2": "Repaglinide", "severity": "Moderate", "effect": "Coadministration with eluxadoline may increase the plasma concentrations of drugs that are substrates of the organic anion transporting polypeptide (OATP) 1B1 and/or breast cancer resistance protein (BCRP) transporters. The mechanism is decreased clearance due to inhibition of OATP1B1-mediated hepatic uptake and BCRP-mediated intestinal and hepatobiliary efflux by eluxadoline.", "source": "DDInter", "management_text": "Caution is advised when eluxadoline is used concomitantly with drugs that are substrates of the OATP1B1 and/or BCRP transporters, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever eluxadoline is added to or withdrawn from therapy.", "mechanism_text": "Others", "recommendation": "Caution is advised when eluxadoline is used concomitantly with drugs that are substrates of the OATP1B1 and/or BCRP transporters, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97822/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Viberzi (eluxadoline).\" Actavis Pharma, Inc., Parsippany, NJ.[3] Richter WO, Jacob BG, Schwandt P \"Interaction between fibre and lovastatin.\" Lancet 338 (1991): 706[4] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors.\" Clin Pharmacol Ther 64 (1998): 477-83[5] Kantola T, Kivisto KT, Neuvonen PJ \"Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid.\" Clin Pharmacol Ther 63 (1998): 397-402[6] \"Product Information. Mevacor (lovastatin).\" Merck & Co, Inc, West Point, PA.[7] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions.\" Br J Clin Pharmacol 46 (1998): 101-10[8] Neuvonen PJ, Backman JT, Niemi M \"Pharmacokinetic comparison of the potential over-the-counter statins simvastatin, lovastatin, fluvastatin and pravastatin.\" Clin Pharmacokinet 47 (2008): 463-74[9] Thompson PD, Clarkson P, Karas RH \"Statin-associated myopathy.\" JAMA 289 (2003): 1681-90[10] \"Product Information. Zocor (simvastatin).\" Merck & Co, Inc, West Point, PA.[11] \"Product Information. Viberzi (eluxadoline).\" Actavis Pharma, Inc., Parsippany, NJ.", "alternatives_a": "Glipizide, Acetohexamide, Guar gum, Pramlintide, Alogliptin, Tolazamide, Dulaglutide, Exenatide, Tolbutamide, Miglitol, Glimepiride, More", "alternatives_b": "Opium, Diphenoxylate, Difenoxin", "updated_at": 1767369485}, {"id": 97719, "ingredient1": "Eluxadoline", "ingredient2": "Revefenacin", "severity": "Moderate", "effect": "Coadministration of revefenacin with inhibitors of organic anion transporting polypeptide (OATP) 1B1 and/or 1B3 may increase systemic exposure to its active metabolite, which has been reported to be a substrate of the hepatic uptake transporters.", "source": "DDInter", "management_text": "Concomitant use of revefenacin with OATP 1B1 and/or 1B3 inhibitors is not recommended.", "mechanism_text": "Metabolism", "recommendation": "Concomitant use of revefenacin with OATP 1B1 and/or 1B3 inhibitors is not recommended.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97823/", "reference_text": "[1] \"Product Information. Yupelri (revefenacin).\" Mylan Specialty, Morgantown, WV.[2] \"Product Information. Nexletol (bempedoic acid).\" Esperion Therapeutics, Ann Arbor, MI.[3] \"Product Information. Nexlizet (bempedoic acid-ezetimibe).\" Esperion Therapeutics, Ann Arbor, MI.[4] \"Product Information. Yupelri (revefenacin).\" Mylan Specialty, Morgantown, WV.[5] \"Product Information. Nexletol (bempedoic acid).\" Esperion Therapeutics, Ann Arbor, MI.[6] \"Product Information. Nexlizet (bempedoic acid-ezetimibe).\" Esperion Therapeutics, Ann Arbor, MI.[7] \"Product Information. Mavyret (glecaprevir-pibrentasvir).\" Abbott Pharmaceutical, Abbott Park, IL.", "alternatives_a": "Morphine, Diphenoxylate, Opium, Difenoxin, Loperamide", "alternatives_b": "Ciclesonide, Mometasone furoate, Budesonide, Flunisolide, Fluticasone, Cromoglicic acid, Betamethasone, Nedocromil, Triamcinolone, Beclomethasone dipropionate", "updated_at": 1767369485}, {"id": 97720, "ingredient1": "Eluxadoline", "ingredient2": "Rifampicin", "severity": "Major", "effect": "Coadministration with inhibitors of organic anion transporting polypeptide (OATP) 1B1 may significantly increase the plasma concentrations of eluxadoline. Based on available data, inhibition of OATP1B1-mediated hepatic uptake appears to reduce both the hepatic first-pass extraction and systemic biliary clearance of eluxadoline.", "source": "DDInter", "management_text": "The recommended dosage of eluxadoline is 75 mg twice daily when used with OATP1B1 inhibitors. Patients should be monitored for adverse effects such as sedation, nausea, vomiting, constipation, abdominal pain, liver enzyme elevations, and pancreatitis.", "mechanism_text": "Metabolism", "recommendation": "The recommended dosage of eluxadoline is 75 mg twice daily when used with OATP1B1 inhibitors.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97824/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Davenport JM, Covington P, Bonifacio L, McIntyre G, Venitz J \"Effect of uptake transporters OAT3 and OATPIBI and efflux transporter MRP2 on the pharmacokinetics of eluxadoline.\" J Clin Pharmacol 55 (2015): 534-42[3] \"Product Information. Viberzi (eluxadoline).\" Actavis Pharma, Inc., Parsippany, NJ.[4] \"Product Information. Viberzi (eluxadoline).\" Actavis Pharma, Inc., Parsippany, NJ.[5] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[6] Cerner Multum, Inc. \"Australian Product Information.\" O 0[7] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[8] \"Product Information. Aptivus (tipranavir).\" Boehringer-Ingelheim, Ridgefield, CT.", "alternatives_a": "Capreomycin, Pyrazinamide, Rifamycin, Bedaquiline, Sulfamethoxazole, Rifapentine, Streptomycin, Trimethoprim, Cycloserine, Rifabutin, Isoniazid, More", "alternatives_b": "Opium, Loperamide, Diphenoxylate, Difenoxin", "updated_at": 1767369485}, {"id": 97721, "ingredient1": "Eluxadoline", "ingredient2": "Risperidone", "severity": "Moderate", "effect": "The risk of constipation and serious constipation-related adverse reactions may be increased when eluxadoline is used with other drugs that are also associated with this adverse effect.", "source": "DDInter", "management_text": "Concomitant use of eluxadoline with other drugs that can cause constipation such as alosetron, anticholinergics, and opioids should generally be avoided. Loperamide may be used occasionally for acute management of severe diarrhea, but chronic use is not recommended, and it should be discontinued immediately if constipation occurs. Eluxadoline should also be discontinued if constipation occurs for more than 4 days.", "mechanism_text": "Synergism", "recommendation": "Concomitant use of eluxadoline with other drugs that can cause constipation such as alosetron, anticholinergics, and opioids should generally be avoided.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97825/", "reference_text": "[1] \"Product Information. Viberzi (eluxadoline).\" Actavis Pharma, Inc., Parsippany, NJ.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Viberzi (eluxadoline).\" Actavis Pharma, Inc., Parsippany, NJ.", "alternatives_a": "Asenapine, Pimavanserin, Ziprasidone, Lumateperone, Iloperidone, Amisulpride, Droperidol, Cariprazine, Brexpiprazole, Paliperidone, Lurasidone", "alternatives_b": "Diphenoxylate, Difenoxin", "updated_at": 1767369485}, {"id": 97722, "ingredient1": "Eluxadoline", "ingredient2": "Ritonavir", "severity": "Major", "effect": "Coadministration with inhibitors of organic anion transporting polypeptide (OATP) 1B1 may significantly increase the plasma concentrations of eluxadoline. Based on available data, inhibition of OATP1B1-mediated hepatic uptake appears to reduce both the hepatic first-pass extraction and systemic biliary clearance of eluxadoline.", "source": "DDInter", "management_text": "The recommended dosage of eluxadoline is 75 mg twice daily when used with OATP1B1 inhibitors. Patients should be monitored for adverse effects such as sedation, nausea, vomiting, constipation, abdominal pain, liver enzyme elevations, and pancreatitis.", "mechanism_text": "Metabolism", "recommendation": "The recommended dosage of eluxadoline is 75 mg twice daily when used with OATP1B1 inhibitors.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97826/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Davenport JM, Covington P, Bonifacio L, McIntyre G, Venitz J \"Effect of uptake transporters OAT3 and OATPIBI and efflux transporter MRP2 on the pharmacokinetics of eluxadoline.\" J Clin Pharmacol 55 (2015): 534-42[3] \"Product Information. Viberzi (eluxadoline).\" Actavis Pharma, Inc., Parsippany, NJ.[4] \"Product Information. Viberzi (eluxadoline).\" Actavis Pharma, Inc., Parsippany, NJ.[5] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[6] Cerner Multum, Inc. \"Australian Product Information.\" O 0[7] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[8] \"Product Information. Aptivus (tipranavir).\" Boehringer-Ingelheim, Ridgefield, CT.", "alternatives_a": "Lamivudine, Glecaprevir, Tenofovir alafenamide, Maraviroc, Cabotegravir, Valaciclovir, Zanamivir, Lenacapavir, Velpatasvir, Rilpivirine, Etravirine, More", "alternatives_b": "Opium, Diphenoxylate, Difenoxin", "updated_at": 1767369485}, {"id": 97723, "ingredient1": "Eluxadoline", "ingredient2": "Rosuvastatin", "severity": "Moderate", "effect": "Coadministration with eluxadoline may increase the plasma concentrations of drugs that are substrates of the organic anion transporting polypeptide (OATP) 1B1 and/or breast cancer resistance protein (BCRP) transporters. The mechanism is decreased clearance due to inhibition of OATP1B1-mediated hepatic uptake and BCRP-mediated intestinal and hepatobiliary efflux by eluxadoline.", "source": "DDInter", "management_text": "Caution is advised when eluxadoline is used concomitantly with drugs that are substrates of the OATP1B1 and/or BCRP transporters, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever eluxadoline is added to or withdrawn from therapy.", "mechanism_text": "Others", "recommendation": "Caution is advised when eluxadoline is used concomitantly with drugs that are substrates of the OATP1B1 and/or BCRP transporters, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97827/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Viberzi (eluxadoline).\" Actavis Pharma, Inc., Parsippany, NJ.[3] Richter WO, Jacob BG, Schwandt P \"Interaction between fibre and lovastatin.\" Lancet 338 (1991): 706[4] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors.\" Clin Pharmacol Ther 64 (1998): 477-83[5] Kantola T, Kivisto KT, Neuvonen PJ \"Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid.\" Clin Pharmacol Ther 63 (1998): 397-402[6] \"Product Information. Mevacor (lovastatin).\" Merck & Co, Inc, West Point, PA.[7] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions.\" Br J Clin Pharmacol 46 (1998): 101-10[8] Neuvonen PJ, Backman JT, Niemi M \"Pharmacokinetic comparison of the potential over-the-counter statins simvastatin, lovastatin, fluvastatin and pravastatin.\" Clin Pharmacokinet 47 (2008): 463-74[9] Thompson PD, Clarkson P, Karas RH \"Statin-associated myopathy.\" JAMA 289 (2003): 1681-90[10] \"Product Information. Zocor (simvastatin).\" Merck & Co, Inc, West Point, PA.[11] \"Product Information. Viberzi (eluxadoline).\" Actavis Pharma, Inc., Parsippany, NJ.", "alternatives_a": "Amlodipine, Ramipril, Lisinopril, Perindopril, Acetylsalicylic acid, Niacin, Bempedoic acid, Indapamide, Fenofibrate, Fenofibric acid, Mipomersen, More", "alternatives_b": "Opium, Diphenoxylate, Difenoxin", "updated_at": 1767369485}, {"id": 97724, "ingredient1": "Eluxadoline", "ingredient2": "Saquinavir", "severity": "Major", "effect": "Coadministration with inhibitors of organic anion transporting polypeptide (OATP) 1B1 may significantly increase the plasma concentrations of eluxadoline. Based on available data, inhibition of OATP1B1-mediated hepatic uptake appears to reduce both the hepatic first-pass extraction and systemic biliary clearance of eluxadoline.", "source": "DDInter", "management_text": "The recommended dosage of eluxadoline is 75 mg twice daily when used with OATP1B1 inhibitors. Patients should be monitored for adverse effects such as sedation, nausea, vomiting, constipation, abdominal pain, liver enzyme elevations, and pancreatitis.", "mechanism_text": "Metabolism", "recommendation": "The recommended dosage of eluxadoline is 75 mg twice daily when used with OATP1B1 inhibitors.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97828/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Davenport JM, Covington P, Bonifacio L, McIntyre G, Venitz J \"Effect of uptake transporters OAT3 and OATPIBI and efflux transporter MRP2 on the pharmacokinetics of eluxadoline.\" J Clin Pharmacol 55 (2015): 534-42[3] \"Product Information. Viberzi (eluxadoline).\" Actavis Pharma, Inc., Parsippany, NJ.[4] \"Product Information. Viberzi (eluxadoline).\" Actavis Pharma, Inc., Parsippany, NJ.[5] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[6] Cerner Multum, Inc. \"Australian Product Information.\" O 0[7] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[8] \"Product Information. Aptivus (tipranavir).\" Boehringer-Ingelheim, Ridgefield, CT.", "alternatives_a": "Lamivudine, Glecaprevir, Tenofovir alafenamide, Maraviroc, Cabotegravir, Valaciclovir, Zanamivir, Lenacapavir, Velpatasvir, Rilpivirine, Etravirine, More", "alternatives_b": "Opium, Diphenoxylate, Difenoxin", "updated_at": 1767369485}, {"id": 97725, "ingredient1": "Eluxadoline", "ingredient2": "Scopolamine", "severity": "Moderate", "effect": "The risk of constipation and serious constipation-related adverse reactions may be increased when eluxadoline is used with other drugs that are also associated with this adverse effect.", "source": "DDInter", "management_text": "Concomitant use of eluxadoline with other drugs that can cause constipation such as alosetron, anticholinergics, and opioids should generally be avoided. Loperamide may be used occasionally for acute management of severe diarrhea, but chronic use is not recommended, and it should be discontinued immediately if constipation occurs. Eluxadoline should also be discontinued if constipation occurs for more than 4 days.", "mechanism_text": "Synergism", "recommendation": "Concomitant use of eluxadoline with other drugs that can cause constipation such as alosetron, anticholinergics, and opioids should generally be avoided.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97829/", "reference_text": "[1] \"Product Information. Viberzi (eluxadoline).\" Actavis Pharma, Inc., Parsippany, NJ.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Viberzi (eluxadoline).\" Actavis Pharma, Inc., Parsippany, NJ.", "alternatives_a": "Suvorexant, Flurazepam, Methohexital, Methylphenobarbital, Zolpidem, Pentobarbital, Zaleplon, Dichloralphenazone, Valerian, Temazepam, Butabarbital, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 97726, "ingredient1": "Eluxadoline", "ingredient2": "Sildenafil", "severity": "Moderate", "effect": "It is not known whether, and to what extent, eluxadoline may inhibit CYP450 3A4 and may interact with substrates of the isoenzyme. In vitro studies have shown that eluxadoline is not an inhibitor of CYP450 3A4 at clinically relevant systemic concentrations, but they were not adequate to rule out inhibition of CYP450 3A4 in the gut by eluxadoline. Therefore, the potential for eluxadoline to increase plasma concentrations of oral drugs that are metabolized by CYP450 3A4 should be considered.", "source": "DDInter", "management_text": "Caution is advised when eluxadoline is used with sensitive CYP450 3A4 substrates or substrates with narrow therapeutic ranges. These drugs include, but are not limited to: cisapride, colchicine, cyclosporine, fentanyl, ivacaftor, lovastatin, simvastatin, oral midazolam, triazolam, pimozide, quinidine, sildenafil, ergot derivatives, and macrolide immunosuppressants.", "mechanism_text": "Others", "recommendation": "Caution is advised when eluxadoline is used with sensitive CYP450 3A4 substrates or substrates with narrow therapeutic ranges.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97830/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Viberzi (eluxadoline).\" Actavis Pharma, Inc., Parsippany, NJ.[3] \"Product Information. Viberzi (eluxadoline).\" Actavis Pharma, Inc., Parsippany, NJ.[4] Kupferschmidt HHT, Ha HR, Ziegler WH, Meier PJ, Krahenbuhl S \"Interaction between grapefruit juice and midazolam in humans.\" Clin Pharmacol Ther 58 (1995): 20-8[5] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ \"Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice.\" Clin Pharmacol Ther 58 (1995): 127-31[6] \"Product Information. Valium (diazepam).\" Roche Laboratories, Nutley, NJ.[7] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[8] \"Product Information. Halcion (triazolam).\" Pharmacia and Upjohn, Kalamazoo, MI.[9] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[10] \"Product Information. Xanax (alprazolam).\" Pharmacia and Upjohn, Kalamazoo, MI.", "alternatives_a": "Tamsulosin, Tinidazole, Ascorbic acid, Hydroflumethiazide, Chlorothiazide, Metronidazole, Sulfadiazine, Lactic acid, Mitapivat, Methazolamide, Amphotericin B, More", "alternatives_b": "Diphenoxylate, Difenoxin", "updated_at": 1767369485}, {"id": 97727, "ingredient1": "Eluxadoline", "ingredient2": "Simeprevir", "severity": "Major", "effect": "Coadministration with inhibitors of organic anion transporting polypeptide (OATP) 1B1 may significantly increase the plasma concentrations of eluxadoline. Based on available data, inhibition of OATP1B1-mediated hepatic uptake appears to reduce both the hepatic first-pass extraction and systemic biliary clearance of eluxadoline.", "source": "DDInter", "management_text": "The recommended dosage of eluxadoline is 75 mg twice daily when used with OATP1B1 inhibitors. Patients should be monitored for adverse effects such as sedation, nausea, vomiting, constipation, abdominal pain, liver enzyme elevations, and pancreatitis.", "mechanism_text": "Metabolism", "recommendation": "The recommended dosage of eluxadoline is 75 mg twice daily when used with OATP1B1 inhibitors.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97831/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Davenport JM, Covington P, Bonifacio L, McIntyre G, Venitz J \"Effect of uptake transporters OAT3 and OATPIBI and efflux transporter MRP2 on the pharmacokinetics of eluxadoline.\" J Clin Pharmacol 55 (2015): 534-42[3] \"Product Information. Viberzi (eluxadoline).\" Actavis Pharma, Inc., Parsippany, NJ.[4] \"Product Information. Viberzi (eluxadoline).\" Actavis Pharma, Inc., Parsippany, NJ.[5] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[6] Cerner Multum, Inc. \"Australian Product Information.\" O 0[7] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[8] \"Product Information. Aptivus (tipranavir).\" Boehringer-Ingelheim, Ridgefield, CT.", "alternatives_a": "Tamsulosin, Tinidazole, Ascorbic acid, Hydroflumethiazide, Chlorothiazide, Metronidazole, Sulfadiazine, Lactic acid, Mitapivat, Methazolamide, Amphotericin B, More", "alternatives_b": "Opium, Loperamide, Diphenoxylate, Difenoxin", "updated_at": 1767369485}, {"id": 97728, "ingredient1": "Eluxadoline", "ingredient2": "Simvastatin", "severity": "Moderate", "effect": "Coadministration with eluxadoline may increase the plasma concentrations of drugs that are substrates of the organic anion transporting polypeptide (OATP) 1B1 and/or breast cancer resistance protein (BCRP) transporters. The mechanism is decreased clearance due to inhibition of OATP1B1-mediated hepatic uptake and BCRP-mediated intestinal and hepatobiliary efflux by eluxadoline.", "source": "DDInter", "management_text": "Caution is advised when eluxadoline is used concomitantly with drugs that are substrates of the OATP1B1 and/or BCRP transporters, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever eluxadoline is added to or withdrawn from therapy.", "mechanism_text": "Others", "recommendation": "Caution is advised when eluxadoline is used concomitantly with drugs that are substrates of the OATP1B1 and/or BCRP transporters, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97832/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Viberzi (eluxadoline).\" Actavis Pharma, Inc., Parsippany, NJ.[3] Richter WO, Jacob BG, Schwandt P \"Interaction between fibre and lovastatin.\" Lancet 338 (1991): 706[4] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors.\" Clin Pharmacol Ther 64 (1998): 477-83[5] Kantola T, Kivisto KT, Neuvonen PJ \"Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid.\" Clin Pharmacol Ther 63 (1998): 397-402[6] \"Product Information. Mevacor (lovastatin).\" Merck & Co, Inc, West Point, PA.[7] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions.\" Br J Clin Pharmacol 46 (1998): 101-10[8] Neuvonen PJ, Backman JT, Niemi M \"Pharmacokinetic comparison of the potential over-the-counter statins simvastatin, lovastatin, fluvastatin and pravastatin.\" Clin Pharmacokinet 47 (2008): 463-74[9] Thompson PD, Clarkson P, Karas RH \"Statin-associated myopathy.\" JAMA 289 (2003): 1681-90[10] \"Product Information. Zocor (simvastatin).\" Merck & Co, Inc, West Point, PA.[11] \"Product Information. Viberzi (eluxadoline).\" Actavis Pharma, Inc., Parsippany, NJ.", "alternatives_a": "Glipizide, Acetohexamide, Guar gum, Pramlintide, Alogliptin, Tolazamide, Dulaglutide, Exenatide, Tolbutamide, Miglitol, Glimepiride, More", "alternatives_b": "Opium, Diphenoxylate, Difenoxin", "updated_at": 1767369485}, {"id": 97729, "ingredient1": "Eluxadoline", "ingredient2": "Sirolimus", "severity": "Moderate", "effect": "It is not known whether, and to what extent, eluxadoline may inhibit CYP450 3A4 and may interact with substrates of the isoenzyme. In vitro studies have shown that eluxadoline is not an inhibitor of CYP450 3A4 at clinically relevant systemic concentrations, but they were not adequate to rule out inhibition of CYP450 3A4 in the gut by eluxadoline. Therefore, the potential for eluxadoline to increase plasma concentrations of oral drugs that are metabolized by CYP450 3A4 should be considered.", "source": "DDInter", "management_text": "Caution is advised when eluxadoline is used with sensitive CYP450 3A4 substrates or substrates with narrow therapeutic ranges. These drugs include, but are not limited to: cisapride, colchicine, cyclosporine, fentanyl, ivacaftor, lovastatin, simvastatin, oral midazolam, triazolam, pimozide, quinidine, sildenafil, ergot derivatives, and macrolide immunosuppressants.", "mechanism_text": "Others", "recommendation": "Caution is advised when eluxadoline is used with sensitive CYP450 3A4 substrates or substrates with narrow therapeutic ranges.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97833/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Viberzi (eluxadoline).\" Actavis Pharma, Inc., Parsippany, NJ.[3] \"Product Information. Viberzi (eluxadoline).\" Actavis Pharma, Inc., Parsippany, NJ.[4] Kupferschmidt HHT, Ha HR, Ziegler WH, Meier PJ, Krahenbuhl S \"Interaction between grapefruit juice and midazolam in humans.\" Clin Pharmacol Ther 58 (1995): 20-8[5] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ \"Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice.\" Clin Pharmacol Ther 58 (1995): 127-31[6] \"Product Information. Valium (diazepam).\" Roche Laboratories, Nutley, NJ.[7] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[8] \"Product Information. Halcion (triazolam).\" Pharmacia and Upjohn, Kalamazoo, MI.[9] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[10] \"Product Information. Xanax (alprazolam).\" Pharmacia and Upjohn, Kalamazoo, MI.", "alternatives_a": "Alteplase, Ascorbic acid, Vitamin A, Potassium Iodide, Acetylcysteine, Nandrolone, Heparin, Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, More", "alternatives_b": "Opium, Diphenoxylate, Difenoxin", "updated_at": 1767369485}, {"id": 97730, "ingredient1": "Eluxadoline", "ingredient2": "Solifenacin", "severity": "Moderate", "effect": "The risk of constipation and serious constipation-related adverse reactions may be increased when eluxadoline is used with other drugs that are also associated with this adverse effect.", "source": "DDInter", "management_text": "Concomitant use of eluxadoline with other drugs that can cause constipation such as alosetron, anticholinergics, and opioids should generally be avoided. Loperamide may be used occasionally for acute management of severe diarrhea, but chronic use is not recommended, and it should be discontinued immediately if constipation occurs. Eluxadoline should also be discontinued if constipation occurs for more than 4 days.", "mechanism_text": "Synergism", "recommendation": "Concomitant use of eluxadoline with other drugs that can cause constipation such as alosetron, anticholinergics, and opioids should generally be avoided.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97834/", "reference_text": "[1] \"Product Information. Viberzi (eluxadoline).\" Actavis Pharma, Inc., Parsippany, NJ.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Viberzi (eluxadoline).\" Actavis Pharma, Inc., Parsippany, NJ.", "alternatives_a": "Apomorphine, Pentosan polysulfate, Calcium chloride, Phenazopyridine, Alprostadil, Mirabegron, Acetohydroxamic acid, Yohimbine, Avanafil, Papaverine, Vardenafil, More", "alternatives_b": "Diphenoxylate, Difenoxin", "updated_at": 1767369485}, {"id": 97731, "ingredient1": "Eluxadoline", "ingredient2": "Stiripentol", "severity": "Moderate", "effect": "It is not known whether, and to what extent, eluxadoline may be metabolized by CYP450 isoenzymes and may interact with inhibitors of CYP450 isoenzymes.", "source": "DDInter", "management_text": "As a precautionary measure due to incomplete information on the metabolism of eluxadoline, the manufacturer recommends caution during coadministration with potent inhibitors of various CYP450 isoenzymes. Patients should be monitored for adverse effects such as sedation, nausea, vomiting, constipation, abdominal pain, liver enzyme elevations, and pancreatitis,", "mechanism_text": "Metabolism", "recommendation": "As a precautionary measure due to incomplete information on the metabolism of eluxadoline, the manufacturer recommends caution during coadministration with potent inhibitors of various CYP450 isoenzymes.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97835/", "reference_text": "[1] \"Product Information. Viberzi (eluxadoline).\" Actavis Pharma, Inc., Parsippany, NJ.[2] \"Product Information. Viberzi (eluxadoline).\" Actavis Pharma, Inc., Parsippany, NJ.[3] \"Product Information. Zokinvy (lonafarnib).\" Eiger BioPharmaceuticals, Palo Alto, CA.", "alternatives_a": "Brivaracetam, Topiramate, Ezogabine, Cenobamate, Lamotrigine, Methylphenobarbital, Phenytoin, Ethosuximide, Lacosamide, Levetiracetam, Tiagabine, More", "alternatives_b": "Loperamide", "updated_at": 1767369485}, {"id": 97732, "ingredient1": "Eluxadoline", "ingredient2": "Sufentanil", "severity": "Moderate", "effect": "The risk of constipation and serious constipation-related adverse reactions may be increased when eluxadoline is used with other drugs that are also associated with this adverse effect.", "source": "DDInter", "management_text": "Concomitant use of eluxadoline with other drugs that can cause constipation such as alosetron, anticholinergics, and opioids should generally be avoided. Loperamide may be used occasionally for acute management of severe diarrhea, but chronic use is not recommended, and it should be discontinued immediately if constipation occurs. Eluxadoline should also be discontinued if constipation occurs for more than 4 days.", "mechanism_text": "Synergism", "recommendation": "Concomitant use of eluxadoline with other drugs that can cause constipation such as alosetron, anticholinergics, and opioids should generally be avoided.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97836/", "reference_text": "[1] \"Product Information. Viberzi (eluxadoline).\" Actavis Pharma, Inc., Parsippany, NJ.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Viberzi (eluxadoline).\" Actavis Pharma, Inc., Parsippany, NJ.", "alternatives_a": "Halothane, Thiopental, Sodium oxybate, Isoflurane, Methohexital, Nitrous oxide, Desflurane, Propofol, Enflurane, Esketamine, Sevoflurane, More", "alternatives_b": "Loperamide", "updated_at": 1767369485}, {"id": 97733, "ingredient1": "Eluxadoline", "ingredient2": "Tacrolimus", "severity": "Moderate", "effect": "It is not known whether, and to what extent, eluxadoline may inhibit CYP450 3A4 and may interact with substrates of the isoenzyme. In vitro studies have shown that eluxadoline is not an inhibitor of CYP450 3A4 at clinically relevant systemic concentrations, but they were not adequate to rule out inhibition of CYP450 3A4 in the gut by eluxadoline. Therefore, the potential for eluxadoline to increase plasma concentrations of oral drugs that are metabolized by CYP450 3A4 should be considered.", "source": "DDInter", "management_text": "Caution is advised when eluxadoline is used with sensitive CYP450 3A4 substrates or substrates with narrow therapeutic ranges. These drugs include, but are not limited to: cisapride, colchicine, cyclosporine, fentanyl, ivacaftor, lovastatin, simvastatin, oral midazolam, triazolam, pimozide, quinidine, sildenafil, ergot derivatives, and macrolide immunosuppressants.", "mechanism_text": "Others", "recommendation": "Caution is advised when eluxadoline is used with sensitive CYP450 3A4 substrates or substrates with narrow therapeutic ranges.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97837/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Viberzi (eluxadoline).\" Actavis Pharma, Inc., Parsippany, NJ.[3] \"Product Information. Viberzi (eluxadoline).\" Actavis Pharma, Inc., Parsippany, NJ.[4] Kupferschmidt HHT, Ha HR, Ziegler WH, Meier PJ, Krahenbuhl S \"Interaction between grapefruit juice and midazolam in humans.\" Clin Pharmacol Ther 58 (1995): 20-8[5] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ \"Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice.\" Clin Pharmacol Ther 58 (1995): 127-31[6] \"Product Information. Valium (diazepam).\" Roche Laboratories, Nutley, NJ.[7] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[8] \"Product Information. Halcion (triazolam).\" Pharmacia and Upjohn, Kalamazoo, MI.[9] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[10] \"Product Information. Xanax (alprazolam).\" Pharmacia and Upjohn, Kalamazoo, MI.", "alternatives_a": "Minoxidil, Deoxycholic acid, Calcium gluconate, Pimecrolimus, Magnesium sulfate, Aminobenzoic acid, Finasteride, Ivermectin, Caffeine, Diclofenac, Cromoglicic acid, More", "alternatives_b": "Opium, Diphenoxylate, Difenoxin", "updated_at": 1767369485}, {"id": 97734, "ingredient1": "Eluxadoline", "ingredient2": "Talazoparib", "severity": "Moderate", "effect": "Coadministration with inhibitors of P-glycoprotein (P-gp) and/or breast cancer resistance protein (BCRP) may increase the plasma concentrations of talazoparib, which has been shown in vitro to be a substrate of both efflux membrane transporters.", "source": "DDInter", "management_text": "No initial dosage adjustment is recommended by the manufacturer when talazoparib is coadministered with inhibitors of BCRP and/or P-gp other than amiodarone, carvedilol, clarithromycin, itraconazole, or verapamil. However, patients should be closely monitored for adverse effects such as myelosuppression and myelodysplastic syndrome/acute myeloid leukemia, and dosage adjustments made or treatment withheld as needed in accordance with the product labeling.", "mechanism_text": "Distribution", "recommendation": "No initial dosage adjustment is recommended by the manufacturer when talazoparib is coadministered with inhibitors of BCRP and/or P-gp other than amiodarone, carvedilol, clarithromycin, itraconazole, or verapamil.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97838/", "reference_text": "[1] \"Product Information. Talzenna (talazoparib).\" Pfizer U.S. Pharmaceuticals Group, New York, NY.", "alternatives_a": "Morphine, Diphenoxylate, Opium, Difenoxin, Loperamide", "alternatives_b": "Pertuzumab, Oxaliplatin, Rucaparib, Bortezomib, Tisagenlecleucel, Aminolevulinic acid, Omacetaxine mepesuccinate, Tazemetostat, Altretamine, Tagraxofusp, Pegaspargase, More", "updated_at": 1767369485}, {"id": 97735, "ingredient1": "Eluxadoline", "ingredient2": "Tapentadol", "severity": "Moderate", "effect": "The risk of constipation and serious constipation-related adverse reactions may be increased when eluxadoline is used with other drugs that are also associated with this adverse effect.", "source": "DDInter", "management_text": "Concomitant use of eluxadoline with other drugs that can cause constipation such as alosetron, anticholinergics, and opioids should generally be avoided. Loperamide may be used occasionally for acute management of severe diarrhea, but chronic use is not recommended, and it should be discontinued immediately if constipation occurs. Eluxadoline should also be discontinued if constipation occurs for more than 4 days.", "mechanism_text": "Synergism", "recommendation": "Concomitant use of eluxadoline with other drugs that can cause constipation such as alosetron, anticholinergics, and opioids should generally be avoided.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97839/", "reference_text": "[1] \"Product Information. Viberzi (eluxadoline).\" Actavis Pharma, Inc., Parsippany, NJ.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Viberzi (eluxadoline).\" Actavis Pharma, Inc., Parsippany, NJ.", "alternatives_a": "Naltrexone, Acetaminophen, Ibuprofen, Celecoxib, Acetylsalicylic acid, Naloxone", "alternatives_b": "Loperamide", "updated_at": 1767369485}, {"id": 97736, "ingredient1": "Eluxadoline", "ingredient2": "Telaprevir", "severity": "Moderate", "effect": "It is not known whether, and to what extent, eluxadoline may be metabolized by CYP450 isoenzymes and may interact with inhibitors of CYP450 isoenzymes.", "source": "DDInter", "management_text": "As a precautionary measure due to incomplete information on the metabolism of eluxadoline, the manufacturer recommends caution during coadministration with potent inhibitors of various CYP450 isoenzymes. Patients should be monitored for adverse effects such as sedation, nausea, vomiting, constipation, abdominal pain, liver enzyme elevations, and pancreatitis,", "mechanism_text": "Metabolism", "recommendation": "As a precautionary measure due to incomplete information on the metabolism of eluxadoline, the manufacturer recommends caution during coadministration with potent inhibitors of various CYP450 isoenzymes.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97840/", "reference_text": "[1] \"Product Information. Viberzi (eluxadoline).\" Actavis Pharma, Inc., Parsippany, NJ.[2] \"Product Information. Viberzi (eluxadoline).\" Actavis Pharma, Inc., Parsippany, NJ.[3] \"Product Information. Zokinvy (lonafarnib).\" Eiger BioPharmaceuticals, Palo Alto, CA.", "alternatives_a": "Lamivudine, Glecaprevir, Tenofovir alafenamide, Maraviroc, Cabotegravir, Valaciclovir, Zanamivir, Lenacapavir, Velpatasvir, Rilpivirine, Etravirine, More", "alternatives_b": "Opium, Diphenoxylate, Difenoxin", "updated_at": 1767369485}, {"id": 97737, "ingredient1": "Eluxadoline", "ingredient2": "Telithromycin", "severity": "Moderate", "effect": "It is not known whether, and to what extent, eluxadoline may be metabolized by CYP450 isoenzymes and may interact with inhibitors of CYP450 isoenzymes.", "source": "DDInter", "management_text": "As a precautionary measure due to incomplete information on the metabolism of eluxadoline, the manufacturer recommends caution during coadministration with potent inhibitors of various CYP450 isoenzymes. Patients should be monitored for adverse effects such as sedation, nausea, vomiting, constipation, abdominal pain, liver enzyme elevations, and pancreatitis,", "mechanism_text": "Metabolism", "recommendation": "As a precautionary measure due to incomplete information on the metabolism of eluxadoline, the manufacturer recommends caution during coadministration with potent inhibitors of various CYP450 isoenzymes.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97841/", "reference_text": "[1] \"Product Information. Viberzi (eluxadoline).\" Actavis Pharma, Inc., Parsippany, NJ.[2] \"Product Information. Viberzi (eluxadoline).\" Actavis Pharma, Inc., Parsippany, NJ.[3] \"Product Information. Zokinvy (lonafarnib).\" Eiger BioPharmaceuticals, Palo Alto, CA.", "alternatives_a": "Dirithromycin, Lincomycin, Azithromycin, Clindamycin", "alternatives_b": "Opium, Diphenoxylate, Difenoxin", "updated_at": 1767369485}, {"id": 97738, "ingredient1": "Eluxadoline", "ingredient2": "Temsirolimus", "severity": "Moderate", "effect": "It is not known whether, and to what extent, eluxadoline may inhibit CYP450 3A4 and may interact with substrates of the isoenzyme. In vitro studies have shown that eluxadoline is not an inhibitor of CYP450 3A4 at clinically relevant systemic concentrations, but they were not adequate to rule out inhibition of CYP450 3A4 in the gut by eluxadoline. Therefore, the potential for eluxadoline to increase plasma concentrations of oral drugs that are metabolized by CYP450 3A4 should be considered.", "source": "DDInter", "management_text": "Caution is advised when eluxadoline is used with sensitive CYP450 3A4 substrates or substrates with narrow therapeutic ranges. These drugs include, but are not limited to: cisapride, colchicine, cyclosporine, fentanyl, ivacaftor, lovastatin, simvastatin, oral midazolam, triazolam, pimozide, quinidine, sildenafil, ergot derivatives, and macrolide immunosuppressants.", "mechanism_text": "Others", "recommendation": "Caution is advised when eluxadoline is used with sensitive CYP450 3A4 substrates or substrates with narrow therapeutic ranges.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97842/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Viberzi (eluxadoline).\" Actavis Pharma, Inc., Parsippany, NJ.[3] \"Product Information. Viberzi (eluxadoline).\" Actavis Pharma, Inc., Parsippany, NJ.[4] Kupferschmidt HHT, Ha HR, Ziegler WH, Meier PJ, Krahenbuhl S \"Interaction between grapefruit juice and midazolam in humans.\" Clin Pharmacol Ther 58 (1995): 20-8[5] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ \"Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice.\" Clin Pharmacol Ther 58 (1995): 127-31[6] \"Product Information. Valium (diazepam).\" Roche Laboratories, Nutley, NJ.[7] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[8] \"Product Information. Halcion (triazolam).\" Pharmacia and Upjohn, Kalamazoo, MI.[9] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[10] \"Product Information. Xanax (alprazolam).\" Pharmacia and Upjohn, Kalamazoo, MI.", "alternatives_a": "Entrectinib, Imatinib, Pralsetinib, Dabrafenib, Asciminib, Acalabrutinib, Dacomitinib, Pexidartinib, Pacritinib, Tepotinib, Fedratinib, More", "alternatives_b": "Morphine, Diphenoxylate, Opium, Difenoxin, Loperamide", "updated_at": 1767369485}, {"id": 97739, "ingredient1": "Eluxadoline", "ingredient2": "Terfenadine", "severity": "Moderate", "effect": "It is not known whether, and to what extent, eluxadoline may inhibit CYP450 3A4 and may interact with substrates of the isoenzyme. In vitro studies have shown that eluxadoline is not an inhibitor of CYP450 3A4 at clinically relevant systemic concentrations, but they were not adequate to rule out inhibition of CYP450 3A4 in the gut by eluxadoline. Therefore, the potential for eluxadoline to increase plasma concentrations of oral drugs that are metabolized by CYP450 3A4 should be considered.", "source": "DDInter", "management_text": "Caution is advised when eluxadoline is used with sensitive CYP450 3A4 substrates or substrates with narrow therapeutic ranges. These drugs include, but are not limited to: cisapride, colchicine, cyclosporine, fentanyl, ivacaftor, lovastatin, simvastatin, oral midazolam, triazolam, pimozide, quinidine, sildenafil, ergot derivatives, and macrolide immunosuppressants.", "mechanism_text": "Others", "recommendation": "Caution is advised when eluxadoline is used with sensitive CYP450 3A4 substrates or substrates with narrow therapeutic ranges.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97843/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Viberzi (eluxadoline).\" Actavis Pharma, Inc., Parsippany, NJ.[3] \"Product Information. Viberzi (eluxadoline).\" Actavis Pharma, Inc., Parsippany, NJ.[4] Kupferschmidt HHT, Ha HR, Ziegler WH, Meier PJ, Krahenbuhl S \"Interaction between grapefruit juice and midazolam in humans.\" Clin Pharmacol Ther 58 (1995): 20-8[5] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ \"Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice.\" Clin Pharmacol Ther 58 (1995): 127-31[6] \"Product Information. Valium (diazepam).\" Roche Laboratories, Nutley, NJ.[7] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[8] \"Product Information. Halcion (triazolam).\" Pharmacia and Upjohn, Kalamazoo, MI.[9] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[10] \"Product Information. Xanax (alprazolam).\" Pharmacia and Upjohn, Kalamazoo, MI.", "alternatives_a": "Ketotifen, Levocetirizine, Cetirizine, Loratadine, Trimethobenzamide, Desloratadine, Azelastine", "alternatives_b": "Opium, Diphenoxylate, Morphine, Difenoxin", "updated_at": 1767369485}, {"id": 97740, "ingredient1": "Eluxadoline", "ingredient2": "Thiethylperazine", "severity": "Moderate", "effect": "The risk of constipation and serious constipation-related adverse reactions may be increased when eluxadoline is used with other drugs that are also associated with this adverse effect.", "source": "DDInter", "management_text": "Concomitant use of eluxadoline with other drugs that can cause constipation such as alosetron, anticholinergics, and opioids should generally be avoided. Loperamide may be used occasionally for acute management of severe diarrhea, but chronic use is not recommended, and it should be discontinued immediately if constipation occurs. Eluxadoline should also be discontinued if constipation occurs for more than 4 days.", "mechanism_text": "Synergism", "recommendation": "Concomitant use of eluxadoline with other drugs that can cause constipation such as alosetron, anticholinergics, and opioids should generally be avoided.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97844/", "reference_text": "[1] \"Product Information. Viberzi (eluxadoline).\" Actavis Pharma, Inc., Parsippany, NJ.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Viberzi (eluxadoline).\" Actavis Pharma, Inc., Parsippany, NJ.", "alternatives_a": "Ketotifen, Levocetirizine, Cetirizine, Loratadine, Trimethobenzamide, Desloratadine, Azelastine", "alternatives_b": "Diphenoxylate, Difenoxin", "updated_at": 1767369485}, {"id": 97741, "ingredient1": "Eluxadoline", "ingredient2": "Thioridazine", "severity": "Moderate", "effect": "The risk of constipation and serious constipation-related adverse reactions may be increased when eluxadoline is used with other drugs that are also associated with this adverse effect.", "source": "DDInter", "management_text": "Concomitant use of eluxadoline with other drugs that can cause constipation such as alosetron, anticholinergics, and opioids should generally be avoided. Loperamide may be used occasionally for acute management of severe diarrhea, but chronic use is not recommended, and it should be discontinued immediately if constipation occurs. Eluxadoline should also be discontinued if constipation occurs for more than 4 days.", "mechanism_text": "Synergism", "recommendation": "Concomitant use of eluxadoline with other drugs that can cause constipation such as alosetron, anticholinergics, and opioids should generally be avoided.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97845/", "reference_text": "[1] \"Product Information. Viberzi (eluxadoline).\" Actavis Pharma, Inc., Parsippany, NJ.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Viberzi (eluxadoline).\" Actavis Pharma, Inc., Parsippany, NJ.", "alternatives_a": "Asenapine, Pimavanserin, Ziprasidone, Lumateperone, Iloperidone, Amisulpride, Droperidol, Cariprazine, Brexpiprazole, Paliperidone, Lurasidone", "alternatives_b": "Diphenoxylate, Difenoxin", "updated_at": 1767369485}, {"id": 97742, "ingredient1": "Eluxadoline", "ingredient2": "Thiothixene", "severity": "Moderate", "effect": "The risk of constipation and serious constipation-related adverse reactions may be increased when eluxadoline is used with other drugs that are also associated with this adverse effect.", "source": "DDInter", "management_text": "Concomitant use of eluxadoline with other drugs that can cause constipation such as alosetron, anticholinergics, and opioids should generally be avoided. Loperamide may be used occasionally for acute management of severe diarrhea, but chronic use is not recommended, and it should be discontinued immediately if constipation occurs. Eluxadoline should also be discontinued if constipation occurs for more than 4 days.", "mechanism_text": "Synergism", "recommendation": "Concomitant use of eluxadoline with other drugs that can cause constipation such as alosetron, anticholinergics, and opioids should generally be avoided.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97846/", "reference_text": "[1] \"Product Information. Viberzi (eluxadoline).\" Actavis Pharma, Inc., Parsippany, NJ.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Viberzi (eluxadoline).\" Actavis Pharma, Inc., Parsippany, NJ.", "alternatives_a": "Asenapine, Pimavanserin, Ziprasidone, Lumateperone, Iloperidone, Amisulpride, Droperidol, Cariprazine, Brexpiprazole, Paliperidone, Lurasidone", "alternatives_b": "Diphenoxylate, Difenoxin", "updated_at": 1767369485}, {"id": 97743, "ingredient1": "Eluxadoline", "ingredient2": "Ticlopidine", "severity": "Moderate", "effect": "It is not known whether, and to what extent, eluxadoline may be metabolized by CYP450 isoenzymes and may interact with inhibitors of CYP450 isoenzymes.", "source": "DDInter", "management_text": "As a precautionary measure due to incomplete information on the metabolism of eluxadoline, the manufacturer recommends caution during coadministration with potent inhibitors of various CYP450 isoenzymes. Patients should be monitored for adverse effects such as sedation, nausea, vomiting, constipation, abdominal pain, liver enzyme elevations, and pancreatitis,", "mechanism_text": "Metabolism", "recommendation": "As a precautionary measure due to incomplete information on the metabolism of eluxadoline, the manufacturer recommends caution during coadministration with potent inhibitors of various CYP450 isoenzymes.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97847/", "reference_text": "[1] \"Product Information. Viberzi (eluxadoline).\" Actavis Pharma, Inc., Parsippany, NJ.[2] \"Product Information. Viberzi (eluxadoline).\" Actavis Pharma, Inc., Parsippany, NJ.[3] \"Product Information. Zokinvy (lonafarnib).\" Eiger BioPharmaceuticals, Palo Alto, CA.", "alternatives_a": "Ticagrelor, Betrixaban, Apixaban, Cilostazol, Rivaroxaban, Iloprost, Lepirudin, Acenocoumarol, Urokinase, Cangrelor, Dipyridamole, More", "alternatives_b": "Opium, Loperamide, Diphenoxylate, Difenoxin", "updated_at": 1767369485}, {"id": 97744, "ingredient1": "Eluxadoline", "ingredient2": "Tiotropium", "severity": "Moderate", "effect": "The risk of constipation and serious constipation-related adverse reactions may be increased when eluxadoline is used with other drugs that are also associated with this adverse effect.", "source": "DDInter", "management_text": "Concomitant use of eluxadoline with other drugs that can cause constipation such as alosetron, anticholinergics, and opioids should generally be avoided. Loperamide may be used occasionally for acute management of severe diarrhea, but chronic use is not recommended, and it should be discontinued immediately if constipation occurs. Eluxadoline should also be discontinued if constipation occurs for more than 4 days.", "mechanism_text": "Synergism", "recommendation": "Concomitant use of eluxadoline with other drugs that can cause constipation such as alosetron, anticholinergics, and opioids should generally be avoided.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97848/", "reference_text": "[1] \"Product Information. Viberzi (eluxadoline).\" Actavis Pharma, Inc., Parsippany, NJ.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Viberzi (eluxadoline).\" Actavis Pharma, Inc., Parsippany, NJ.", "alternatives_a": "Mometasone furoate, Terbutaline, Budesonide, Mometasone, Epinephrine, Olodaterol, Fluticasone, Cromoglicic acid, Salbutamol, Orciprenaline, Pirbuterol, More", "alternatives_b": "Opium, Diphenoxylate, Difenoxin", "updated_at": 1767369485}, {"id": 97745, "ingredient1": "Eluxadoline", "ingredient2": "Tipranavir", "severity": "Major", "effect": "Coadministration with inhibitors of organic anion transporting polypeptide (OATP) 1B1 may significantly increase the plasma concentrations of eluxadoline. Based on available data, inhibition of OATP1B1-mediated hepatic uptake appears to reduce both the hepatic first-pass extraction and systemic biliary clearance of eluxadoline.", "source": "DDInter", "management_text": "The recommended dosage of eluxadoline is 75 mg twice daily when used with OATP1B1 inhibitors. Patients should be monitored for adverse effects such as sedation, nausea, vomiting, constipation, abdominal pain, liver enzyme elevations, and pancreatitis.", "mechanism_text": "Metabolism", "recommendation": "The recommended dosage of eluxadoline is 75 mg twice daily when used with OATP1B1 inhibitors.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97849/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Davenport JM, Covington P, Bonifacio L, McIntyre G, Venitz J \"Effect of uptake transporters OAT3 and OATPIBI and efflux transporter MRP2 on the pharmacokinetics of eluxadoline.\" J Clin Pharmacol 55 (2015): 534-42[3] \"Product Information. Viberzi (eluxadoline).\" Actavis Pharma, Inc., Parsippany, NJ.[4] \"Product Information. Viberzi (eluxadoline).\" Actavis Pharma, Inc., Parsippany, NJ.[5] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[6] Cerner Multum, Inc. \"Australian Product Information.\" O 0[7] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[8] \"Product Information. Aptivus (tipranavir).\" Boehringer-Ingelheim, Ridgefield, CT.", "alternatives_a": "Lamivudine, Glecaprevir, Tenofovir alafenamide, Maraviroc, Cabotegravir, Valaciclovir, Zanamivir, Lenacapavir, Velpatasvir, Rilpivirine, Etravirine, More", "alternatives_b": "Opium, Diphenoxylate, Morphine, Difenoxin", "updated_at": 1767369485}, {"id": 97746, "ingredient1": "Eluxadoline", "ingredient2": "Tolterodine", "severity": "Moderate", "effect": "The risk of constipation and serious constipation-related adverse reactions may be increased when eluxadoline is used with other drugs that are also associated with this adverse effect.", "source": "DDInter", "management_text": "Concomitant use of eluxadoline with other drugs that can cause constipation such as alosetron, anticholinergics, and opioids should generally be avoided. Loperamide may be used occasionally for acute management of severe diarrhea, but chronic use is not recommended, and it should be discontinued immediately if constipation occurs. Eluxadoline should also be discontinued if constipation occurs for more than 4 days.", "mechanism_text": "Synergism", "recommendation": "Concomitant use of eluxadoline with other drugs that can cause constipation such as alosetron, anticholinergics, and opioids should generally be avoided.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97850/", "reference_text": "[1] \"Product Information. Viberzi (eluxadoline).\" Actavis Pharma, Inc., Parsippany, NJ.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Viberzi (eluxadoline).\" Actavis Pharma, Inc., Parsippany, NJ.", "alternatives_a": "Apomorphine, Pentosan polysulfate, Calcium chloride, Phenazopyridine, Alprostadil, Mirabegron, Acetohydroxamic acid, Yohimbine, Avanafil, Papaverine, Vardenafil, More", "alternatives_b": "Diphenoxylate, Difenoxin", "updated_at": 1767369485}, {"id": 97747, "ingredient1": "Eluxadoline", "ingredient2": "Triazolam", "severity": "Moderate", "effect": "It is not known whether, and to what extent, eluxadoline may inhibit CYP450 3A4 and may interact with substrates of the isoenzyme. In vitro studies have shown that eluxadoline is not an inhibitor of CYP450 3A4 at clinically relevant systemic concentrations, but they were not adequate to rule out inhibition of CYP450 3A4 in the gut by eluxadoline. Therefore, the potential for eluxadoline to increase plasma concentrations of oral drugs that are metabolized by CYP450 3A4 should be considered.", "source": "DDInter", "management_text": "Caution is advised when eluxadoline is used with sensitive CYP450 3A4 substrates or substrates with narrow therapeutic ranges. These drugs include, but are not limited to: cisapride, colchicine, cyclosporine, fentanyl, ivacaftor, lovastatin, simvastatin, oral midazolam, triazolam, pimozide, quinidine, sildenafil, ergot derivatives, and macrolide immunosuppressants.", "mechanism_text": "Others", "recommendation": "Caution is advised when eluxadoline is used with sensitive CYP450 3A4 substrates or substrates with narrow therapeutic ranges.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97851/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Viberzi (eluxadoline).\" Actavis Pharma, Inc., Parsippany, NJ.[3] \"Product Information. Viberzi (eluxadoline).\" Actavis Pharma, Inc., Parsippany, NJ.[4] Kupferschmidt HHT, Ha HR, Ziegler WH, Meier PJ, Krahenbuhl S \"Interaction between grapefruit juice and midazolam in humans.\" Clin Pharmacol Ther 58 (1995): 20-8[5] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ \"Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice.\" Clin Pharmacol Ther 58 (1995): 127-31[6] \"Product Information. Valium (diazepam).\" Roche Laboratories, Nutley, NJ.[7] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[8] \"Product Information. Halcion (triazolam).\" Pharmacia and Upjohn, Kalamazoo, MI.[9] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[10] \"Product Information. Xanax (alprazolam).\" Pharmacia and Upjohn, Kalamazoo, MI.", "alternatives_a": "Suvorexant, Flurazepam, Methohexital, Methylphenobarbital, Zolpidem, Pentobarbital, Zaleplon, Dichloralphenazone, Valerian, Temazepam, Butabarbital, More", "alternatives_b": "Diphenoxylate, Difenoxin", "updated_at": 1767369485}, {"id": 97748, "ingredient1": "Eluxadoline", "ingredient2": "Trifluoperazine", "severity": "Moderate", "effect": "The risk of constipation and serious constipation-related adverse reactions may be increased when eluxadoline is used with other drugs that are also associated with this adverse effect.", "source": "DDInter", "management_text": "Concomitant use of eluxadoline with other drugs that can cause constipation such as alosetron, anticholinergics, and opioids should generally be avoided. Loperamide may be used occasionally for acute management of severe diarrhea, but chronic use is not recommended, and it should be discontinued immediately if constipation occurs. Eluxadoline should also be discontinued if constipation occurs for more than 4 days.", "mechanism_text": "Synergism", "recommendation": "Concomitant use of eluxadoline with other drugs that can cause constipation such as alosetron, anticholinergics, and opioids should generally be avoided.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97852/", "reference_text": "[1] \"Product Information. Viberzi (eluxadoline).\" Actavis Pharma, Inc., Parsippany, NJ.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Viberzi (eluxadoline).\" Actavis Pharma, Inc., Parsippany, NJ.", "alternatives_a": "Asenapine, Pimavanserin, Ziprasidone, Lumateperone, Iloperidone, Amisulpride, Droperidol, Cariprazine, Brexpiprazole, Paliperidone, Lurasidone", "alternatives_b": "Diphenoxylate, Difenoxin", "updated_at": 1767369485}, {"id": 97749, "ingredient1": "Eluxadoline", "ingredient2": "Triflupromazine", "severity": "Moderate", "effect": "The risk of constipation and serious constipation-related adverse reactions may be increased when eluxadoline is used with other drugs that are also associated with this adverse effect.", "source": "DDInter", "management_text": "Concomitant use of eluxadoline with other drugs that can cause constipation such as alosetron, anticholinergics, and opioids should generally be avoided. Loperamide may be used occasionally for acute management of severe diarrhea, but chronic use is not recommended, and it should be discontinued immediately if constipation occurs. Eluxadoline should also be discontinued if constipation occurs for more than 4 days.", "mechanism_text": "Synergism", "recommendation": "Concomitant use of eluxadoline with other drugs that can cause constipation such as alosetron, anticholinergics, and opioids should generally be avoided.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97853/", "reference_text": "[1] \"Product Information. Viberzi (eluxadoline).\" Actavis Pharma, Inc., Parsippany, NJ.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Viberzi (eluxadoline).\" Actavis Pharma, Inc., Parsippany, NJ.", "alternatives_a": "Asenapine, Pimavanserin, Ziprasidone, Lumateperone, Iloperidone, Amisulpride, Droperidol, Cariprazine, Brexpiprazole, Paliperidone, Lurasidone", "alternatives_b": "Diphenoxylate, Difenoxin", "updated_at": 1767369485}, {"id": 97750, "ingredient1": "Eluxadoline", "ingredient2": "Trihexyphenidyl", "severity": "Moderate", "effect": "The risk of constipation and serious constipation-related adverse reactions may be increased when eluxadoline is used with other drugs that are also associated with this adverse effect.", "source": "DDInter", "management_text": "Concomitant use of eluxadoline with other drugs that can cause constipation such as alosetron, anticholinergics, and opioids should generally be avoided. Loperamide may be used occasionally for acute management of severe diarrhea, but chronic use is not recommended, and it should be discontinued immediately if constipation occurs. Eluxadoline should also be discontinued if constipation occurs for more than 4 days.", "mechanism_text": "Synergism", "recommendation": "Concomitant use of eluxadoline with other drugs that can cause constipation such as alosetron, anticholinergics, and opioids should generally be avoided.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97854/", "reference_text": "[1] \"Product Information. Viberzi (eluxadoline).\" Actavis Pharma, Inc., Parsippany, NJ.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Viberzi (eluxadoline).\" Actavis Pharma, Inc., Parsippany, NJ.", "alternatives_a": "", "alternatives_b": "", "updated_at": 1767369485}, {"id": 97751, "ingredient1": "Eluxadoline", "ingredient2": "Alimemazine", "severity": "Moderate", "effect": "The risk of constipation and serious constipation-related adverse reactions may be increased when eluxadoline is used with other drugs that are also associated with this adverse effect.", "source": "DDInter", "management_text": "Concomitant use of eluxadoline with other drugs that can cause constipation such as alosetron, anticholinergics, and opioids should generally be avoided. Loperamide may be used occasionally for acute management of severe diarrhea, but chronic use is not recommended, and it should be discontinued immediately if constipation occurs. Eluxadoline should also be discontinued if constipation occurs for more than 4 days.", "mechanism_text": "Synergism", "recommendation": "Concomitant use of eluxadoline with other drugs that can cause constipation such as alosetron, anticholinergics, and opioids should generally be avoided.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97855/", "reference_text": "[1] \"Product Information. Viberzi (eluxadoline).\" Actavis Pharma, Inc., Parsippany, NJ.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Viberzi (eluxadoline).\" Actavis Pharma, Inc., Parsippany, NJ.", "alternatives_a": "Ketotifen, Levocetirizine, Cetirizine, Loratadine, Trimethobenzamide, Desloratadine, Azelastine", "alternatives_b": "Diphenoxylate, Difenoxin", "updated_at": 1767369485}, {"id": 97752, "ingredient1": "Eluxadoline", "ingredient2": "Trimipramine", "severity": "Moderate", "effect": "The risk of constipation and serious constipation-related adverse reactions may be increased when eluxadoline is used with other drugs that are also associated with this adverse effect.", "source": "DDInter", "management_text": "Concomitant use of eluxadoline with other drugs that can cause constipation such as alosetron, anticholinergics, and opioids should generally be avoided. Loperamide may be used occasionally for acute management of severe diarrhea, but chronic use is not recommended, and it should be discontinued immediately if constipation occurs. Eluxadoline should also be discontinued if constipation occurs for more than 4 days.", "mechanism_text": "Synergism", "recommendation": "Concomitant use of eluxadoline with other drugs that can cause constipation such as alosetron, anticholinergics, and opioids should generally be avoided.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97856/", "reference_text": "[1] \"Product Information. Viberzi (eluxadoline).\" Actavis Pharma, Inc., Parsippany, NJ.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Viberzi (eluxadoline).\" Actavis Pharma, Inc., Parsippany, NJ.", "alternatives_a": "Citalopram, Sertraline, St. John's Wort, Milnacipran, Vortioxetine, Levomilnacipran, Duloxetine, Isocarboxazid, Viloxazine, Esketamine, Phenelzine, More", "alternatives_b": "Diphenoxylate, Difenoxin", "updated_at": 1767369485}, {"id": 97753, "ingredient1": "Eluxadoline", "ingredient2": "Tripelennamine", "severity": "Moderate", "effect": "The risk of constipation and serious constipation-related adverse reactions may be increased when eluxadoline is used with other drugs that are also associated with this adverse effect.", "source": "DDInter", "management_text": "Concomitant use of eluxadoline with other drugs that can cause constipation such as alosetron, anticholinergics, and opioids should generally be avoided. Loperamide may be used occasionally for acute management of severe diarrhea, but chronic use is not recommended, and it should be discontinued immediately if constipation occurs. Eluxadoline should also be discontinued if constipation occurs for more than 4 days.", "mechanism_text": "Synergism", "recommendation": "Concomitant use of eluxadoline with other drugs that can cause constipation such as alosetron, anticholinergics, and opioids should generally be avoided.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97857/", "reference_text": "[1] \"Product Information. Viberzi (eluxadoline).\" Actavis Pharma, Inc., Parsippany, NJ.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Viberzi (eluxadoline).\" Actavis Pharma, Inc., Parsippany, NJ.", "alternatives_a": "Ketotifen, Levocetirizine, Cetirizine, Loratadine, Trimethobenzamide, Desloratadine, Azelastine, Lidocaine, Tetracaine", "alternatives_b": "Diphenoxylate, Difenoxin", "updated_at": 1767369485}, {"id": 97754, "ingredient1": "Eluxadoline", "ingredient2": "Triprolidine", "severity": "Moderate", "effect": "The risk of constipation and serious constipation-related adverse reactions may be increased when eluxadoline is used with other drugs that are also associated with this adverse effect.", "source": "DDInter", "management_text": "Concomitant use of eluxadoline with other drugs that can cause constipation such as alosetron, anticholinergics, and opioids should generally be avoided. Loperamide may be used occasionally for acute management of severe diarrhea, but chronic use is not recommended, and it should be discontinued immediately if constipation occurs. Eluxadoline should also be discontinued if constipation occurs for more than 4 days.", "mechanism_text": "Synergism", "recommendation": "Concomitant use of eluxadoline with other drugs that can cause constipation such as alosetron, anticholinergics, and opioids should generally be avoided.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97858/", "reference_text": "[1] \"Product Information. Viberzi (eluxadoline).\" Actavis Pharma, Inc., Parsippany, NJ.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Viberzi (eluxadoline).\" Actavis Pharma, Inc., Parsippany, NJ.", "alternatives_a": "Ketotifen, Levocetirizine, Cetirizine, Loratadine, Trimethobenzamide, Desloratadine, Azelastine", "alternatives_b": "Diphenoxylate, Difenoxin", "updated_at": 1767369485}, {"id": 97755, "ingredient1": "Eluxadoline", "ingredient2": "Troleandomycin", "severity": "Moderate", "effect": "It is not known whether, and to what extent, eluxadoline may be metabolized by CYP450 isoenzymes and may interact with inhibitors of CYP450 isoenzymes.", "source": "DDInter", "management_text": "As a precautionary measure due to incomplete information on the metabolism of eluxadoline, the manufacturer recommends caution during coadministration with potent inhibitors of various CYP450 isoenzymes. Patients should be monitored for adverse effects such as sedation, nausea, vomiting, constipation, abdominal pain, liver enzyme elevations, and pancreatitis,", "mechanism_text": "Metabolism", "recommendation": "As a precautionary measure due to incomplete information on the metabolism of eluxadoline, the manufacturer recommends caution during coadministration with potent inhibitors of various CYP450 isoenzymes.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97859/", "reference_text": "[1] \"Product Information. Viberzi (eluxadoline).\" Actavis Pharma, Inc., Parsippany, NJ.[2] \"Product Information. Viberzi (eluxadoline).\" Actavis Pharma, Inc., Parsippany, NJ.[3] \"Product Information. Zokinvy (lonafarnib).\" Eiger BioPharmaceuticals, Palo Alto, CA.", "alternatives_a": "Opium, Diphenoxylate, Morphine, Difenoxin", "alternatives_b": "Dirithromycin, Lincomycin, Azithromycin, Clindamycin", "updated_at": 1767369485}, {"id": 97756, "ingredient1": "Eluxadoline", "ingredient2": "Trospium", "severity": "Moderate", "effect": "The risk of constipation and serious constipation-related adverse reactions may be increased when eluxadoline is used with other drugs that are also associated with this adverse effect.", "source": "DDInter", "management_text": "Concomitant use of eluxadoline with other drugs that can cause constipation such as alosetron, anticholinergics, and opioids should generally be avoided. Loperamide may be used occasionally for acute management of severe diarrhea, but chronic use is not recommended, and it should be discontinued immediately if constipation occurs. Eluxadoline should also be discontinued if constipation occurs for more than 4 days.", "mechanism_text": "Synergism", "recommendation": "Concomitant use of eluxadoline with other drugs that can cause constipation such as alosetron, anticholinergics, and opioids should generally be avoided.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97860/", "reference_text": "[1] \"Product Information. Viberzi (eluxadoline).\" Actavis Pharma, Inc., Parsippany, NJ.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Viberzi (eluxadoline).\" Actavis Pharma, Inc., Parsippany, NJ.", "alternatives_a": "Apomorphine, Pentosan polysulfate, Calcium chloride, Phenazopyridine, Alprostadil, Mirabegron, Acetohydroxamic acid, Yohimbine, Avanafil, Papaverine, Vardenafil, More", "alternatives_b": "Diphenoxylate, Difenoxin", "updated_at": 1767369485}, {"id": 97757, "ingredient1": "Eluxadoline", "ingredient2": "Ubrogepant", "severity": "Moderate", "effect": "Coadministration with breast cancer resistance protein (BCRP) and/or P-glycoprotein (P-gp) only inhibitors may increase the exposure of ubrogepant, which is a substrate of these transporters.", "source": "DDInter", "management_text": "The manufacturer recommends an initial ubrogepant dose of 50 mg when coadministered with BCRP and/or P-gp only inhibitors. If needed, a second 50 mg dose of ubrogepant may be administered at least 2 hours after the initial dose.", "mechanism_text": "Distribution", "recommendation": "The manufacturer recommends an initial ubrogepant dose of 50 mg when coadministered with BCRP and/or P-gp only inhibitors.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97861/", "reference_text": "[1] \"Product Information. Ubrelvy (ubrogepant).\" Allergan Inc, Irvine, CA.[2] \"Product Information. Mavyret (glecaprevir-pibrentasvir).\" Abbott Pharmaceutical, Abbott Park, IL.[3] \"Product Information. Ubrelvy (ubrogepant).\" Allergan Inc, Irvine, CA.", "alternatives_a": "Morphine, Diphenoxylate, Opium, Difenoxin, Loperamide", "alternatives_b": "Frovatriptan, Rimegepant, Eptinezumab, Lasmiditan, Eletriptan, Rizatriptan, Naratriptan, Galcanezumab, Zolmitriptan, Sumatriptan, Erenumab, More", "updated_at": 1767369485}, {"id": 97758, "ingredient1": "Eluxadoline", "ingredient2": "Umeclidinium", "severity": "Moderate", "effect": "The risk of constipation and serious constipation-related adverse reactions may be increased when eluxadoline is used with other drugs that are also associated with this adverse effect.", "source": "DDInter", "management_text": "Concomitant use of eluxadoline with other drugs that can cause constipation such as alosetron, anticholinergics, and opioids should generally be avoided. Loperamide may be used occasionally for acute management of severe diarrhea, but chronic use is not recommended, and it should be discontinued immediately if constipation occurs. Eluxadoline should also be discontinued if constipation occurs for more than 4 days.", "mechanism_text": "Synergism", "recommendation": "Concomitant use of eluxadoline with other drugs that can cause constipation such as alosetron, anticholinergics, and opioids should generally be avoided.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97862/", "reference_text": "[1] \"Product Information. Viberzi (eluxadoline).\" Actavis Pharma, Inc., Parsippany, NJ.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Viberzi (eluxadoline).\" Actavis Pharma, Inc., Parsippany, NJ.", "alternatives_a": "Mometasone furoate, Terbutaline, Budesonide, Mometasone, Epinephrine, Olodaterol, Fluticasone, Cromoglicic acid, Salbutamol, Orciprenaline, Pirbuterol, More", "alternatives_b": "Morphine, Diphenoxylate, Opium, Difenoxin, Loperamide", "updated_at": 1767369485}, {"id": 97759, "ingredient1": "Eluxadoline", "ingredient2": "Voriconazole", "severity": "Moderate", "effect": "It is not known whether, and to what extent, eluxadoline may be metabolized by CYP450 isoenzymes and may interact with inhibitors of CYP450 isoenzymes.", "source": "DDInter", "management_text": "As a precautionary measure due to incomplete information on the metabolism of eluxadoline, the manufacturer recommends caution during coadministration with potent inhibitors of various CYP450 isoenzymes. Patients should be monitored for adverse effects such as sedation, nausea, vomiting, constipation, abdominal pain, liver enzyme elevations, and pancreatitis,", "mechanism_text": "Metabolism", "recommendation": "As a precautionary measure due to incomplete information on the metabolism of eluxadoline, the manufacturer recommends caution during coadministration with potent inhibitors of various CYP450 isoenzymes.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97863/", "reference_text": "[1] \"Product Information. Viberzi (eluxadoline).\" Actavis Pharma, Inc., Parsippany, NJ.[2] \"Product Information. Viberzi (eluxadoline).\" Actavis Pharma, Inc., Parsippany, NJ.[3] \"Product Information. Zokinvy (lonafarnib).\" Eiger BioPharmaceuticals, Palo Alto, CA.", "alternatives_a": "Caspofungin, Micafungin, Amphotericin B, Miconazole, Oteseconazole, Flucytosine, Anidulafungin", "alternatives_b": "Opium, Diphenoxylate, Difenoxin", "updated_at": 1767369485}, {"id": 97760, "ingredient1": "Elvitegravir", "ingredient2": "Aluminum hydroxide", "severity": "Moderate", "effect": "INTERVAL: The concomitant use of antacids may significantly decrease the plasma concentrations of elvitegravir. The mechanism of interaction has not been described. In contrast, when the antacid was given 4 hours before or 4 hours after elvitegravir, no significant differences were observed in elvitegravir pharmacokinetics compared to administration of elvitegravir alone.", "source": "DDInter", "management_text": "Antacid-containing preparations should be administered at least 2 hours before or 2 hours after the elvitegravir dose. Alternatively, H2-receptor antagonists or proton pump inhibitors may be considered, with no dosage adjustment needed.", "mechanism_text": "Others", "recommendation": "Antacid-containing preparations should be administered at least 2 hours before or 2 hours after the elvitegravir dose.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97864/", "reference_text": "[1] Cerner Multum, Inc. \"Australian Product Information.\" O 0[2] \"Product Information. Stribild (cobicistat/elvitegravir/emtricitabine/tenofov).\" Gilead Sciences, Foster City, CA.[3] \"Product Information. Vitekta (elvitegravir).\" Gilead Sciences, Foster City, CA.[4] \"Product Information. Stribild (cobicistat/elvitegravir/emtricitabine/tenofov).\" Gilead Sciences, Foster City, CA.", "alternatives_a": "Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Simeprevir, Valaciclovir, Zanamivir, Lenacapavir, Telaprevir, Etravirine, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 97761, "ingredient1": "Elvitegravir", "ingredient2": "Calcium carbonate", "severity": "Moderate", "effect": "INTERVAL: The concomitant use of antacids may significantly decrease the plasma concentrations of elvitegravir. The mechanism of interaction has not been described. In contrast, when the antacid was given 4 hours before or 4 hours after elvitegravir, no significant differences were observed in elvitegravir pharmacokinetics compared to administration of elvitegravir alone.", "source": "DDInter", "management_text": "Antacid-containing preparations should be administered at least 2 hours before or 2 hours after the elvitegravir dose. Alternatively, H2-receptor antagonists or proton pump inhibitors may be considered, with no dosage adjustment needed.", "mechanism_text": "Others", "recommendation": "Antacid-containing preparations should be administered at least 2 hours before or 2 hours after the elvitegravir dose.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97865/", "reference_text": "[1] Cerner Multum, Inc. \"Australian Product Information.\" O 0[2] \"Product Information. Stribild (cobicistat/elvitegravir/emtricitabine/tenofov).\" Gilead Sciences, Foster City, CA.[3] \"Product Information. Vitekta (elvitegravir).\" Gilead Sciences, Foster City, CA.[4] \"Product Information. Stribild (cobicistat/elvitegravir/emtricitabine/tenofov).\" Gilead Sciences, Foster City, CA.", "alternatives_a": "Calcium glucoheptonate, Calcium chloride, Ascorbic acid, Calcium chloride", "alternatives_b": "Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Simeprevir, Valaciclovir, Zanamivir, Lenacapavir, Telaprevir, Etravirine, More", "updated_at": 1767369485}, {"id": 97762, "ingredient1": "Enzalutamide", "ingredient2": "Elvitegravir", "severity": "Major", "effect": "Coadministration with potent inducers of CYP450 3A4 may significantly decrease the plasma concentrations of elvitegravir, which is primarily metabolized by the isoenzyme.", "source": "DDInter", "management_text": "Given the risk of reduced viral susceptibility and resistance development associated with subtherapeutic drug levels, concomitant use of elvitegravir with potent CYP450 3A4 inducers is generally not recommended. In addition, other antiretroviral agents that are typically combined with elvitegravir may be contraindicated for use with potent CYP450 3A4 inducers.", "mechanism_text": "Metabolism", "recommendation": "Given the risk of reduced viral susceptibility and resistance development associated with subtherapeutic drug levels, concomitant use of elvitegravir with potent CYP450 3A4 inducers is generally not recommended.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97866/", "reference_text": "[1] \"Product Information. Vitekta (elvitegravir).\" Gilead Sciences, Foster City, CA.[2] \"Product Information. Tybost (cobicistat).\" Gilead Sciences, Foster City, CA.[3] \"Product Information. Genvoya (cobicistat/elvitegravir/emtricitabine/tenofov).\" Gilead Sciences, Foster City, CA.[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] \"Product Information. Stribild (cobicistat/elvitegravir/emtricitabine/tenofov).\" Gilead Sciences, Foster City, CA.[6] Cerner Multum, Inc. \"Australian Product Information.\" O 0[7] \"Product Information. Trikafta (elexacaftor/ivacaftor/tezacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[8] \"Product Information. Kalydeco (ivacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[9] \"Product Information. Orkambi (ivacaftor-lumacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[10] \"Product Information. Symdeko 4-Week (ivacaftor-tezacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[11] \"Product Information. Vitekta (elvitegravir).\" Gilead Sciences, Foster City, CA.[12] \"Product Information. Stribild (cobicistat/elvitegravir/emtricitabine/tenofov).\" Gilead Sciences, Foster City, CA.", "alternatives_a": "Darolutamide, Tamoxifen, Anastrozole, Letrozole, Toremifene, Fulvestrant, Abarelix, Flutamide, Relugolix, Bicalutamide, Degarelix, More", "alternatives_b": "Lamivudine, Cabotegravir, Zanamivir, Valaciclovir, Oseltamivir, Acyclovir, Brincidofovir, Stavudine, Elbasvir, Famciclovir, Voxilaprevir, More", "updated_at": 1767369485}, {"id": 97763, "ingredient1": "Erdafitinib", "ingredient2": "Elvitegravir", "severity": "Major", "effect": "Coadministration with moderate inducers of CYP450 2C9 or 3A4 may decrease the plasma concentrations and therapeutic effects of erdafitinib. The mechanism is induction of CYP450 2C9- or 3A4-mediated metabolism of erdafitinib, which has been shown to be metabolized by these isoenzymes.", "source": "DDInter", "management_text": "According to the manufacturer, if a moderate CYP450 2C9 or 3A4 inducer is coadministered at the start of erdafitinib therapy, the recommended dose of erdafitinib should be administered. If a moderate CYP450 2C9 or 3A4 inducer is coadministered after the initial dose increase period, the dose of erdafitinib may be increased up to 9 mg once daily based on serum phosphate levels and tolerability. When a moderate CYP450 2C9 or 3A4 inducer is discontinued, the current dose of erdafitinib may be continued in the absence of erdafitinib toxicity.", "mechanism_text": "Metabolism", "recommendation": "According to the manufacturer, if a moderate CYP450 2C9 or 3A4 inducer is coadministered at the start of erdafitinib therapy, the recommended dose of erdafitinib should be administered.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97867/", "reference_text": "[1] \"Product Information. Balversa (erdafitinib).\" Janssen Products, LP, Horsham, PA.[2] Cronk GA, Wheatley WB, Fellers GF, Albright H \"The relationship of food intake to the absorption of potassium alpha-phenoxyethyl penicillin and potassium phenoxymethyl penicillin from the gastrointestinal tract.\" Am J Med Sci 240 (1960): 219-25[3] Neuvonen PJ, Elonen E, Pentikainen PJ \"Comparative effect of food on absorption of ampicillin and pivampicillin.\" J Int Med Res 5 (1977): 71-6[4] Klein JO, Sabath LD, Finland M \"Laboratory studies on oxacillin. I: in vitro activity against staphylococci and some other bacterial pathogens. II: absorption and urinary excretion in normal young.\" Am J Med Sci 245 (1963): 399-411[5] Welling PG, Huang H, Koch PA, Madsen PO \"Bioavailability of ampicillin and amoxicillin in fasted and nonfasted subjects.\" J Pharm Sci 66 (1977): 549-52[6] McCarthy CG, Finland M \"Absorption and excretion of four penicillins.\" N Engl J Med 263 (1960): 315-26[7] Neu HC \"Antimicrobial activity and human pharmacology of amoxicillin.\" J Infect Dis 129 (1974): s123-31", "alternatives_a": "Lamivudine, Glecaprevir, Simeprevir, Cabotegravir, Zanamivir, Valaciclovir, Lenacapavir, Velpatasvir, Rilpivirine, Dolutegravir, Oseltamivir, More", "alternatives_b": "Entrectinib, Imatinib, Pralsetinib, Asciminib, Acalabrutinib, Dacomitinib, Pacritinib, Tepotinib, Fedratinib, Avapritinib, Larotrectinib, More", "updated_at": 1767369485}, {"id": 97764, "ingredient1": "Eslicarbazepine", "ingredient2": "Elvitegravir", "severity": "Moderate", "effect": "Coadministration with inducers of CYP450 3A4 isoenzymes may reduce the plasma concentrations of elvitegravir, which is primarily metabolized by the isoenzyme.", "source": "DDInter", "management_text": "Given the risk of reduced viral susceptibility and resistance development associated with subtherapeutic antiretroviral drug levels, the manufacturers of elvitegravir single-ingredient and combination products recommend avoiding concomitant use. Alternative treatment combinations that do not include metabolic inducers should be considered whenever possible.", "mechanism_text": "Metabolism", "recommendation": "Given the risk of reduced viral susceptibility and resistance development associated with subtherapeutic antiretroviral drug levels, the manufacturers of elvitegravir single-ingredient and combination products recommend avoiding concomitant use.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97868/", "reference_text": "[1] Cerner Multum, Inc. \"Australian Product Information.\" O 0[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Vitekta (elvitegravir).\" Gilead Sciences, Foster City, CA.[4] \"Product Information. Vitekta (elvitegravir).\" Gilead Sciences, Foster City, CA.[5] \"Product Information. Stribild (cobicistat/elvitegravir/emtricitabine/tenofov).\" Gilead Sciences, Foster City, CA.", "alternatives_a": "Lamivudine, Paritaprevir, Tenofovir alafenamide, Cabotegravir, Zanamivir, Valaciclovir, Velpatasvir, Dolutegravir, Oseltamivir, Acyclovir, Brincidofovir, More", "alternatives_b": "Brivaracetam, Topiramate, Ezogabine, Lamotrigine, Methylphenobarbital, Ethosuximide, Lacosamide, Levetiracetam, Tiagabine, Ethotoin, Clonazepam, More", "updated_at": 1767369485}, {"id": 97765, "ingredient1": "Etonogestrel", "ingredient2": "Elvitegravir", "severity": "Moderate", "effect": "RECOMMENDED: Coadministration with cobicistat and elvitegravir may alter the plasma concentrations of contraceptive hormones. The exact mechanism of interaction has not been described. Clinical effects of increased progestogen levels are not fully known, but may include increased risk of insulin resistance, dyslipidemia, acne, and venous thrombosis.", "source": "DDInter", "management_text": "The potential risks and benefits of using norgestimate-containing contraceptives in combination with cobicistat and elvitegravir should be considered, particularly in women who have risk factors for insulin resistance, dyslipidemia, acne, and venous thrombosis. Coadministration of cobicistat and elvitegravir with other hormonal contraceptives (e.g., contraceptive patch, contraceptive vaginal ring, or injectable contraceptives), oral contraceptives containing progestogens other than norgestimate, or less than 25 mcg of ethinyl estradiol has not been studied and is not recommended. Some authorities recommend that hormonal contraceptives containing at least 30 mcg of ethinyl estradiol with norgestimate should be used in combination with the multi-ingredient antiretroviral formulations containing elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate or elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide. However, the long term effects of increased progesterone exposure are not known. Alternative, nonhormonal methods of contraception may be considered.", "mechanism_text": "Others", "recommendation": "The potential risks and benefits of using norgestimate-containing contraceptives in combination with cobicistat and elvitegravir should be considered, particularly in women who have risk factors for insulin resistance, dyslipidemia, acne, and venous thrombosis.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97869/", "reference_text": "[1] Cerner Multum, Inc. \"Australian Product Information.\" O 0[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Stribild (cobicistat/elvitegravir/emtricitabine/tenofov).\" Gilead Sciences, Foster City, CA.[4] Gunston GD, Mehta U \"Potentially serious drug interactions with grapefruit juice.\" S Afr Med J 90 (2000): 41[5] Bailey DG, Arnold JMO, Spence JD \"Grapefruit juice and drugs - how significant is the interaction.\" Clin Pharmacokinet 26 (1994): 91-8[6] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[7] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions.\" Br J Clin Pharmacol 46 (1998): 101-10[8] Libersa CC, Brique SA, Motte KB, et al. \"Dramatic inhibition of amiodarone metabolism induced by grapefruit juice.\" Br J Clin Pharmacol 49 (2000): 373-8[9] Bailey DG, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit juice felodipine interaction: Effect of naringin and 6',7'-dihydroxybergamottin in humans.\" Clin Pharmacol Ther 64 (1998): 248-56[10] Jonkman JH, Sollie FA, Sauter R, Steinijans VW \"The influence of caffeine on the steady-state pharmacokinetics of theophylline.\" Clin Pharmacol Ther 49 (1991): 248-55[11] Ozdemir M, Aktan Y, Boydag BS, Cingi MI, Musmul A \"Interaction between grapefruit juice and diazepam in humans.\" Eur J Drug Metab Pharmacokinet 23 (1998): 55-9[12] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin.\" Clin Pharmacol Ther 66 (1999): 118-27[13] Bailey DG, Arnold JM, Munoz C, Spence JD \"Grapefruit juice--felodipine interaction: mechanism, predictability, and effect of naringin.\" Clin Pharmacol Ther 53 (1993): 637-42[14] Sigusch H, Hippius M, Henschel L, Kaufmann K, Hoffmann A \"Influence of grapefruit juice on the pharmacokinetics of a slow release nifedipine formulation.\" Pharmazie 49 (1994): 522-4[15] Eagling VA, Profit L, Back DJ \"Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-I protease inhibitor saquinavir by grapefruit juice components.\" Br J Clin Pharmacol 48 (1999): 543-52[16] Damkier P, Hansen LL, Brosen K \"Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine.\" Br J Clin Pharmacol 48 (1999): 829-38[17] Min DI, Ku YM, Geraets DR, Lee HC \"Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers.\" J Clin Pharmacol 36 (1996): 469-76[18] Zaidenstein R, Soback S, Gips M, Avni B, Dishi V, Weissgarten Y, Golik A, Scapa E \"Effect of grapefruit juice on the pharmacokinetics of losartan and its active metabolite E3174 in healthy volunteers.\" Ther Drug Monit 23 (2001): 369-73[19] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84[20] Lee AJ, Chan WK, Harralson AF, Buffum J, Bui BCC \"The effects of grapefruit juice on sertraline metabolism: An in vitro and in vivo study.\" Clin Ther 21 (1999): 1890-9[21] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors.\" Clin Pharmacol Ther 64 (1998): 477-83[22] Garg SK, Kumar N, Bhargava VK, Prabhakar SK \"Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy.\" Clin Pharmacol Ther 64 (1998): 286-8[23] Fuhr U, Maier-Bruggemann A, Blume H, et al. \"Grapefruit juice increases oral nimodipine bioavailability.\" Int J Clin Pharmacol Ther 36 (1998): 126-32[24] Sato J, Nakata H, Owada E, Kikuta T, Umetsu M, Ito K \"Influence of usual intake of dietary caffeine on single-dose kinetics of theophylline in healthy human subjects.\" Eur J Clin Pharmacol 44 (1993): 295-8[25] Edgar B, Bailey D, Bergstrand R, et al \"Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics on felodipine and its potential clinical relevance.\" Eur J Clin Pharmacol 42 (1992): 313-7[26] Kantola T, Kivisto KT, Neuvonen PJ \"Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid.\" Clin Pharmacol Ther 63 (1998): 397-402[27] Dresser GK, Spence JD, Bailey DG \"Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition.\" Clin Pharmacokinet 38 (2000): 41-57[28] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[29] Takanaga H, Ohnishi A, Maatsuo H, et al. \"Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model.\" Br J Clin Pharmacol 49 (2000): 49-58[30] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS \"Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice.\" Br J Clin Pharmacol 42 (1996): p662[31] Bailey DG, Arnold JM, Strong HA, Munoz C, Spence JD \"Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics.\" Clin Pharmacol Ther 54 (1993): 589-94[32] Josefsson M, Zackrisson AL, Ahlner J \"Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers.\" Eur J Clin Pharmacol 51 (1996): 189-93[33] Majeed A, Kareem A \"Effect of grapefruit juice on cyclosporine pharmacokinetics.\" Pediatr Nephrol 10 (1996): 395[34] Flanagan D \"Understanding the grapefruit-drug interaction.\" Gen Dent 53 (2005): 282-5; quiz 286[35] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ \"Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice.\" Clin Pharmacol Ther 58 (1995): 127-31[36] \"Product Information. Vitekta (elvitegravir).\" Gilead Sciences, Foster City, CA.[37] \"Product Information. Stribild (cobicistat/elvitegravir/emtricitabine/tenofov).\" Gilead Sciences, Foster City, CA.[38] Schubert W, Eriksson U, Edgar B, Cullberg G, Hedner T \"Flavonoids in grapefruit juice inhibit the in vitro hepatic metabolism of 17B-estradiol.\" Eur J Drug Metab Pharmacokinet 20 (1995): 219-24[39] Weber A, Jager R, Borner A, et al. \"Can grapefruit juice influence ethinyl estradiol bioavailability?\" Contraception 53 (1996): 41-7", "alternatives_a": "Megestrol acetate, Ulipristal, Estetrol", "alternatives_b": "Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Simeprevir, Cabotegravir, Valaciclovir, Zanamivir, Velpatasvir, Rilpivirine, More", "updated_at": 1767369485}, {"id": 97766, "ingredient1": "Etravirine", "ingredient2": "Elvitegravir", "severity": "Moderate", "effect": "Coadministration with inducers of CYP450 3A4 isoenzymes may reduce the plasma concentrations of elvitegravir, which is primarily metabolized by the isoenzyme.", "source": "DDInter", "management_text": "Given the risk of reduced viral susceptibility and resistance development associated with subtherapeutic antiretroviral drug levels, the manufacturers of elvitegravir single-ingredient and combination products recommend avoiding concomitant use. Alternative treatment combinations that do not include metabolic inducers should be considered whenever possible.", "mechanism_text": "Metabolism", "recommendation": "Given the risk of reduced viral susceptibility and resistance development associated with subtherapeutic antiretroviral drug levels, the manufacturers of elvitegravir single-ingredient and combination products recommend avoiding concomitant use.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97870/", "reference_text": "[1] Cerner Multum, Inc. \"Australian Product Information.\" O 0[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Vitekta (elvitegravir).\" Gilead Sciences, Foster City, CA.[4] \"Product Information. Vitekta (elvitegravir).\" Gilead Sciences, Foster City, CA.[5] \"Product Information. Stribild (cobicistat/elvitegravir/emtricitabine/tenofov).\" Gilead Sciences, Foster City, CA.", "alternatives_a": "Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Amprenavir, Simeprevir, Valaciclovir, Zanamivir, Cabotegravir, Lenacapavir, More", "alternatives_b": "Lamivudine, Cabotegravir, Zanamivir, Valaciclovir, Etravirine, Oseltamivir, Acyclovir, Brincidofovir, Remdesivir, Elbasvir, Famciclovir, More", "updated_at": 1767369485}, {"id": 97767, "ingredient1": "Elvitegravir", "ingredient2": "Ivosidenib", "severity": "Moderate", "effect": "Coadministration with inducers of CYP450 3A4 isoenzymes may reduce the plasma concentrations of elvitegravir, which is primarily metabolized by the isoenzyme.", "source": "DDInter", "management_text": "Given the risk of reduced viral susceptibility and resistance development associated with subtherapeutic antiretroviral drug levels, the manufacturers of elvitegravir single-ingredient and combination products recommend avoiding concomitant use. Alternative treatment combinations that do not include metabolic inducers should be considered whenever possible.", "mechanism_text": "Metabolism", "recommendation": "Given the risk of reduced viral susceptibility and resistance development associated with subtherapeutic antiretroviral drug levels, the manufacturers of elvitegravir single-ingredient and combination products recommend avoiding concomitant use.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97871/", "reference_text": "[1] Cerner Multum, Inc. \"Australian Product Information.\" O 0[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Vitekta (elvitegravir).\" Gilead Sciences, Foster City, CA.[4] \"Product Information. Vitekta (elvitegravir).\" Gilead Sciences, Foster City, CA.[5] \"Product Information. Stribild (cobicistat/elvitegravir/emtricitabine/tenofov).\" Gilead Sciences, Foster City, CA.", "alternatives_a": "Lamivudine, Paritaprevir, Tenofovir alafenamide, Simeprevir, Cabotegravir, Valaciclovir, Zanamivir, Velpatasvir, Oseltamivir, Acyclovir, Brincidofovir, More", "alternatives_b": "Pertuzumab, Olaparib, Oxaliplatin, Rucaparib, Bortezomib, Tisagenlecleucel, Aminolevulinic acid, Omacetaxine mepesuccinate, Tazemetostat, Altretamine, Tagraxofusp, More", "updated_at": 1767369485}, {"id": 97768, "ingredient1": "Elvitegravir", "ingredient2": "Lemborexant", "severity": "Moderate", "effect": "Coadministration with inducers of CYP450 3A4 isoenzymes may reduce the plasma concentrations of elvitegravir, which is primarily metabolized by the isoenzyme.", "source": "DDInter", "management_text": "Given the risk of reduced viral susceptibility and resistance development associated with subtherapeutic antiretroviral drug levels, the manufacturers of elvitegravir single-ingredient and combination products recommend avoiding concomitant use. Alternative treatment combinations that do not include metabolic inducers should be considered whenever possible.", "mechanism_text": "Metabolism", "recommendation": "Given the risk of reduced viral susceptibility and resistance development associated with subtherapeutic antiretroviral drug levels, the manufacturers of elvitegravir single-ingredient and combination products recommend avoiding concomitant use.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97872/", "reference_text": "[1] Cerner Multum, Inc. \"Australian Product Information.\" O 0[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Vitekta (elvitegravir).\" Gilead Sciences, Foster City, CA.[4] \"Product Information. Vitekta (elvitegravir).\" Gilead Sciences, Foster City, CA.[5] \"Product Information. Stribild (cobicistat/elvitegravir/emtricitabine/tenofov).\" Gilead Sciences, Foster City, CA.", "alternatives_a": "Lamivudine, Paritaprevir, Tenofovir alafenamide, Simeprevir, Cabotegravir, Valaciclovir, Zanamivir, Dolutegravir, Oseltamivir, Acyclovir, Brincidofovir, More", "alternatives_b": "Suvorexant, Triazolam, Flurazepam, Methohexital, Methylphenobarbital, Zolpidem, Pentobarbital, Zaleplon, Dichloralphenazone, Valerian, Temazepam, More", "updated_at": 1767369485}, {"id": 97769, "ingredient1": "Elvitegravir", "ingredient2": "Lorlatinib", "severity": "Moderate", "effect": "Coadministration with inducers of CYP450 3A4 isoenzymes may reduce the plasma concentrations of elvitegravir, which is primarily metabolized by the isoenzyme.", "source": "DDInter", "management_text": "Given the risk of reduced viral susceptibility and resistance development associated with subtherapeutic antiretroviral drug levels, the manufacturers of elvitegravir single-ingredient and combination products recommend avoiding concomitant use. Alternative treatment combinations that do not include metabolic inducers should be considered whenever possible.", "mechanism_text": "Metabolism", "recommendation": "Given the risk of reduced viral susceptibility and resistance development associated with subtherapeutic antiretroviral drug levels, the manufacturers of elvitegravir single-ingredient and combination products recommend avoiding concomitant use.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97873/", "reference_text": "[1] Cerner Multum, Inc. \"Australian Product Information.\" O 0[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Vitekta (elvitegravir).\" Gilead Sciences, Foster City, CA.[4] \"Product Information. Vitekta (elvitegravir).\" Gilead Sciences, Foster City, CA.[5] \"Product Information. Stribild (cobicistat/elvitegravir/emtricitabine/tenofov).\" Gilead Sciences, Foster City, CA.", "alternatives_a": "Lamivudine, Cabotegravir, Simeprevir, Zanamivir, Valaciclovir, Oseltamivir, Acyclovir, Brincidofovir, Stavudine, Remdesivir, Elbasvir, More", "alternatives_b": "Entrectinib, Imatinib, Pralsetinib, Asciminib, Acalabrutinib, Dacomitinib, Pacritinib, Tepotinib, Fedratinib, Avapritinib, Larotrectinib, More", "updated_at": 1767369485}, {"id": 97770, "ingredient1": "Elvitegravir", "ingredient2": "Magaldrate", "severity": "Moderate", "effect": "INTERVAL: The concomitant use of antacids may significantly decrease the plasma concentrations of elvitegravir. The mechanism of interaction has not been described. In contrast, when the antacid was given 4 hours before or 4 hours after elvitegravir, no significant differences were observed in elvitegravir pharmacokinetics compared to administration of elvitegravir alone.", "source": "DDInter", "management_text": "Antacid-containing preparations should be administered at least 2 hours before or 2 hours after the elvitegravir dose. Alternatively, H2-receptor antagonists or proton pump inhibitors may be considered, with no dosage adjustment needed.", "mechanism_text": "Others", "recommendation": "Antacid-containing preparations should be administered at least 2 hours before or 2 hours after the elvitegravir dose.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97874/", "reference_text": "[1] Cerner Multum, Inc. \"Australian Product Information.\" O 0[2] \"Product Information. Stribild (cobicistat/elvitegravir/emtricitabine/tenofov).\" Gilead Sciences, Foster City, CA.[3] \"Product Information. Vitekta (elvitegravir).\" Gilead Sciences, Foster City, CA.[4] \"Product Information. Stribild (cobicistat/elvitegravir/emtricitabine/tenofov).\" Gilead Sciences, Foster City, CA.", "alternatives_a": "Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Simeprevir, Valaciclovir, Zanamivir, Lenacapavir, Telaprevir, Etravirine, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 97771, "ingredient1": "Elvitegravir", "ingredient2": "Magnesium carbonate", "severity": "Moderate", "effect": "INTERVAL: The concomitant use of antacids may significantly decrease the plasma concentrations of elvitegravir. The mechanism of interaction has not been described. In contrast, when the antacid was given 4 hours before or 4 hours after elvitegravir, no significant differences were observed in elvitegravir pharmacokinetics compared to administration of elvitegravir alone.", "source": "DDInter", "management_text": "Antacid-containing preparations should be administered at least 2 hours before or 2 hours after the elvitegravir dose. Alternatively, H2-receptor antagonists or proton pump inhibitors may be considered, with no dosage adjustment needed.", "mechanism_text": "Others", "recommendation": "Antacid-containing preparations should be administered at least 2 hours before or 2 hours after the elvitegravir dose.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97875/", "reference_text": "[1] Cerner Multum, Inc. \"Australian Product Information.\" O 0[2] \"Product Information. Stribild (cobicistat/elvitegravir/emtricitabine/tenofov).\" Gilead Sciences, Foster City, CA.[3] \"Product Information. Vitekta (elvitegravir).\" Gilead Sciences, Foster City, CA.[4] \"Product Information. Stribild (cobicistat/elvitegravir/emtricitabine/tenofov).\" Gilead Sciences, Foster City, CA.", "alternatives_a": "Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Simeprevir, Valaciclovir, Zanamivir, Lenacapavir, Telaprevir, Etravirine, More", "alternatives_b": "Hydroxocobalamin, Fomepizole, Ipecac, Nitrous acid, Dexrazoxane, Oxygen, Lanthanum carbonate, Difelikefalin, Cobicistat, Deferoxamine, Levoleucovorin, More", "updated_at": 1767369485}, {"id": 97772, "ingredient1": "Elvitegravir", "ingredient2": "Magnesium hydroxide", "severity": "Moderate", "effect": "INTERVAL: The concomitant use of antacids may significantly decrease the plasma concentrations of elvitegravir. The mechanism of interaction has not been described. In contrast, when the antacid was given 4 hours before or 4 hours after elvitegravir, no significant differences were observed in elvitegravir pharmacokinetics compared to administration of elvitegravir alone.", "source": "DDInter", "management_text": "Antacid-containing preparations should be administered at least 2 hours before or 2 hours after the elvitegravir dose. Alternatively, H2-receptor antagonists or proton pump inhibitors may be considered, with no dosage adjustment needed.", "mechanism_text": "Others", "recommendation": "Antacid-containing preparations should be administered at least 2 hours before or 2 hours after the elvitegravir dose.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97876/", "reference_text": "[1] Cerner Multum, Inc. \"Australian Product Information.\" O 0[2] \"Product Information. Stribild (cobicistat/elvitegravir/emtricitabine/tenofov).\" Gilead Sciences, Foster City, CA.[3] \"Product Information. Vitekta (elvitegravir).\" Gilead Sciences, Foster City, CA.[4] \"Product Information. Stribild (cobicistat/elvitegravir/emtricitabine/tenofov).\" Gilead Sciences, Foster City, CA.", "alternatives_a": "Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Simeprevir, Valaciclovir, Zanamivir, Lenacapavir, Telaprevir, Etravirine, More", "alternatives_b": "Darifenacin, Vardenafil, Tadalafil, Ammonium chloride, Apomorphine, Yohimbine, Papaverine, Oxybutynin, Dimethyl sulfoxide, Pentosan polysulfate, Calcium chloride, More", "updated_at": 1767369485}, {"id": 97773, "ingredient1": "Elvitegravir", "ingredient2": "Medroxyprogesterone acetate", "severity": "Moderate", "effect": "RECOMMENDED: Coadministration with cobicistat and elvitegravir may alter the plasma concentrations of contraceptive hormones. The exact mechanism of interaction has not been described. Clinical effects of increased progestogen levels are not fully known, but may include increased risk of insulin resistance, dyslipidemia, acne, and venous thrombosis.", "source": "DDInter", "management_text": "The potential risks and benefits of using norgestimate-containing contraceptives in combination with cobicistat and elvitegravir should be considered, particularly in women who have risk factors for insulin resistance, dyslipidemia, acne, and venous thrombosis. Coadministration of cobicistat and elvitegravir with other hormonal contraceptives (e.g., contraceptive patch, contraceptive vaginal ring, or injectable contraceptives), oral contraceptives containing progestogens other than norgestimate, or less than 25 mcg of ethinyl estradiol has not been studied and is not recommended. Some authorities recommend that hormonal contraceptives containing at least 30 mcg of ethinyl estradiol with norgestimate should be used in combination with the multi-ingredient antiretroviral formulations containing elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate or elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide. However, the long term effects of increased progesterone exposure are not known. Alternative, nonhormonal methods of contraception may be considered.", "mechanism_text": "Others", "recommendation": "The potential risks and benefits of using norgestimate-containing contraceptives in combination with cobicistat and elvitegravir should be considered, particularly in women who have risk factors for insulin resistance, dyslipidemia, acne, and venous thrombosis.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97877/", "reference_text": "[1] Cerner Multum, Inc. \"Australian Product Information.\" O 0[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Stribild (cobicistat/elvitegravir/emtricitabine/tenofov).\" Gilead Sciences, Foster City, CA.[4] Gunston GD, Mehta U \"Potentially serious drug interactions with grapefruit juice.\" S Afr Med J 90 (2000): 41[5] Bailey DG, Arnold JMO, Spence JD \"Grapefruit juice and drugs - how significant is the interaction.\" Clin Pharmacokinet 26 (1994): 91-8[6] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[7] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions.\" Br J Clin Pharmacol 46 (1998): 101-10[8] Libersa CC, Brique SA, Motte KB, et al. \"Dramatic inhibition of amiodarone metabolism induced by grapefruit juice.\" Br J Clin Pharmacol 49 (2000): 373-8[9] Bailey DG, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit juice felodipine interaction: Effect of naringin and 6',7'-dihydroxybergamottin in humans.\" Clin Pharmacol Ther 64 (1998): 248-56[10] Jonkman JH, Sollie FA, Sauter R, Steinijans VW \"The influence of caffeine on the steady-state pharmacokinetics of theophylline.\" Clin Pharmacol Ther 49 (1991): 248-55[11] Ozdemir M, Aktan Y, Boydag BS, Cingi MI, Musmul A \"Interaction between grapefruit juice and diazepam in humans.\" Eur J Drug Metab Pharmacokinet 23 (1998): 55-9[12] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin.\" Clin Pharmacol Ther 66 (1999): 118-27[13] Bailey DG, Arnold JM, Munoz C, Spence JD \"Grapefruit juice--felodipine interaction: mechanism, predictability, and effect of naringin.\" Clin Pharmacol Ther 53 (1993): 637-42[14] Sigusch H, Hippius M, Henschel L, Kaufmann K, Hoffmann A \"Influence of grapefruit juice on the pharmacokinetics of a slow release nifedipine formulation.\" Pharmazie 49 (1994): 522-4[15] Eagling VA, Profit L, Back DJ \"Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-I protease inhibitor saquinavir by grapefruit juice components.\" Br J Clin Pharmacol 48 (1999): 543-52[16] Damkier P, Hansen LL, Brosen K \"Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine.\" Br J Clin Pharmacol 48 (1999): 829-38[17] Min DI, Ku YM, Geraets DR, Lee HC \"Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers.\" J Clin Pharmacol 36 (1996): 469-76[18] Zaidenstein R, Soback S, Gips M, Avni B, Dishi V, Weissgarten Y, Golik A, Scapa E \"Effect of grapefruit juice on the pharmacokinetics of losartan and its active metabolite E3174 in healthy volunteers.\" Ther Drug Monit 23 (2001): 369-73[19] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84[20] Lee AJ, Chan WK, Harralson AF, Buffum J, Bui BCC \"The effects of grapefruit juice on sertraline metabolism: An in vitro and in vivo study.\" Clin Ther 21 (1999): 1890-9[21] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors.\" Clin Pharmacol Ther 64 (1998): 477-83[22] Garg SK, Kumar N, Bhargava VK, Prabhakar SK \"Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy.\" Clin Pharmacol Ther 64 (1998): 286-8[23] Fuhr U, Maier-Bruggemann A, Blume H, et al. \"Grapefruit juice increases oral nimodipine bioavailability.\" Int J Clin Pharmacol Ther 36 (1998): 126-32[24] Sato J, Nakata H, Owada E, Kikuta T, Umetsu M, Ito K \"Influence of usual intake of dietary caffeine on single-dose kinetics of theophylline in healthy human subjects.\" Eur J Clin Pharmacol 44 (1993): 295-8[25] Edgar B, Bailey D, Bergstrand R, et al \"Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics on felodipine and its potential clinical relevance.\" Eur J Clin Pharmacol 42 (1992): 313-7[26] Kantola T, Kivisto KT, Neuvonen PJ \"Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid.\" Clin Pharmacol Ther 63 (1998): 397-402[27] Dresser GK, Spence JD, Bailey DG \"Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition.\" Clin Pharmacokinet 38 (2000): 41-57[28] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[29] Takanaga H, Ohnishi A, Maatsuo H, et al. \"Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model.\" Br J Clin Pharmacol 49 (2000): 49-58[30] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS \"Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice.\" Br J Clin Pharmacol 42 (1996): p662[31] Bailey DG, Arnold JM, Strong HA, Munoz C, Spence JD \"Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics.\" Clin Pharmacol Ther 54 (1993): 589-94[32] Josefsson M, Zackrisson AL, Ahlner J \"Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers.\" Eur J Clin Pharmacol 51 (1996): 189-93[33] Majeed A, Kareem A \"Effect of grapefruit juice on cyclosporine pharmacokinetics.\" Pediatr Nephrol 10 (1996): 395[34] Flanagan D \"Understanding the grapefruit-drug interaction.\" Gen Dent 53 (2005): 282-5; quiz 286[35] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ \"Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice.\" Clin Pharmacol Ther 58 (1995): 127-31[36] \"Product Information. Vitekta (elvitegravir).\" Gilead Sciences, Foster City, CA.[37] \"Product Information. Stribild (cobicistat/elvitegravir/emtricitabine/tenofov).\" Gilead Sciences, Foster City, CA.[38] Schubert W, Eriksson U, Edgar B, Cullberg G, Hedner T \"Flavonoids in grapefruit juice inhibit the in vitro hepatic metabolism of 17B-estradiol.\" Eur J Drug Metab Pharmacokinet 20 (1995): 219-24[39] Weber A, Jager R, Borner A, et al. \"Can grapefruit juice influence ethinyl estradiol bioavailability?\" Contraception 53 (1996): 41-7", "alternatives_a": "Megestrol acetate, Ulipristal, Estetrol, Megestrol acetate, Progesterone, Megestrol acetate, Progesterone, Diethylstilbestrol, Histrelin, Megestrol acetate, Leuprolide, More", "alternatives_b": "Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Simeprevir, Cabotegravir, Valaciclovir, Zanamivir, Velpatasvir, Rilpivirine, More", "updated_at": 1767369485}, {"id": 97774, "ingredient1": "Elvitegravir", "ingredient2": "Mitotane", "severity": "Major", "effect": "Coadministration with potent inducers of CYP450 3A4 may significantly decrease the plasma concentrations of elvitegravir, which is primarily metabolized by the isoenzyme.", "source": "DDInter", "management_text": "Given the risk of reduced viral susceptibility and resistance development associated with subtherapeutic drug levels, concomitant use of elvitegravir with potent CYP450 3A4 inducers is generally not recommended. In addition, other antiretroviral agents that are typically combined with elvitegravir may be contraindicated for use with potent CYP450 3A4 inducers.", "mechanism_text": "Metabolism", "recommendation": "Given the risk of reduced viral susceptibility and resistance development associated with subtherapeutic drug levels, concomitant use of elvitegravir with potent CYP450 3A4 inducers is generally not recommended.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97878/", "reference_text": "[1] \"Product Information. Vitekta (elvitegravir).\" Gilead Sciences, Foster City, CA.[2] \"Product Information. Tybost (cobicistat).\" Gilead Sciences, Foster City, CA.[3] \"Product Information. Genvoya (cobicistat/elvitegravir/emtricitabine/tenofov).\" Gilead Sciences, Foster City, CA.[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] \"Product Information. Stribild (cobicistat/elvitegravir/emtricitabine/tenofov).\" Gilead Sciences, Foster City, CA.[6] Cerner Multum, Inc. \"Australian Product Information.\" O 0[7] \"Product Information. Trikafta (elexacaftor/ivacaftor/tezacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[8] \"Product Information. Kalydeco (ivacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[9] \"Product Information. Orkambi (ivacaftor-lumacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[10] \"Product Information. Symdeko 4-Week (ivacaftor-tezacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[11] \"Product Information. Vitekta (elvitegravir).\" Gilead Sciences, Foster City, CA.[12] \"Product Information. Stribild (cobicistat/elvitegravir/emtricitabine/tenofov).\" Gilead Sciences, Foster City, CA.", "alternatives_a": "Pertuzumab, Olaparib, Oxaliplatin, Rucaparib, Bortezomib, Tisagenlecleucel, Aminolevulinic acid, Omacetaxine mepesuccinate, Tazemetostat, Altretamine, Tagraxofusp, More", "alternatives_b": "Lamivudine, Paritaprevir, Tenofovir alafenamide, Cabotegravir, Zanamivir, Valaciclovir, Telaprevir, Dolutegravir, Oseltamivir, Acyclovir, Brincidofovir, More", "updated_at": 1767369485}, {"id": 97775, "ingredient1": "Elvitegravir", "ingredient2": "Modafinil", "severity": "Moderate", "effect": "Coadministration with inducers of CYP450 3A4 isoenzymes may reduce the plasma concentrations of elvitegravir, which is primarily metabolized by the isoenzyme.", "source": "DDInter", "management_text": "Given the risk of reduced viral susceptibility and resistance development associated with subtherapeutic antiretroviral drug levels, the manufacturers of elvitegravir single-ingredient and combination products recommend avoiding concomitant use. Alternative treatment combinations that do not include metabolic inducers should be considered whenever possible.", "mechanism_text": "Metabolism", "recommendation": "Given the risk of reduced viral susceptibility and resistance development associated with subtherapeutic antiretroviral drug levels, the manufacturers of elvitegravir single-ingredient and combination products recommend avoiding concomitant use.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97879/", "reference_text": "[1] Cerner Multum, Inc. \"Australian Product Information.\" O 0[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Vitekta (elvitegravir).\" Gilead Sciences, Foster City, CA.[4] \"Product Information. Vitekta (elvitegravir).\" Gilead Sciences, Foster City, CA.[5] \"Product Information. Stribild (cobicistat/elvitegravir/emtricitabine/tenofov).\" Gilead Sciences, Foster City, CA.", "alternatives_a": "Amphetamine, Pemoline, Atomoxetine, Metamfetamine, Lisdexamfetamine, Solriamfetol, Caffeine, Methylphenidate, Dexmethylphenidate, Dextroamphetamine, Armodafinil, Citicoline", "alternatives_b": "Lamivudine, Paritaprevir, Cabotegravir, Simeprevir, Zanamivir, Velpatasvir, Oseltamivir, Brincidofovir, Stavudine, Remdesivir, Elbasvir, More", "updated_at": 1767369485}, {"id": 97776, "ingredient1": "Elvitegravir", "ingredient2": "Nafcillin", "severity": "Moderate", "effect": "Coadministration with inducers of CYP450 3A4 isoenzymes may reduce the plasma concentrations of elvitegravir, which is primarily metabolized by the isoenzyme.", "source": "DDInter", "management_text": "Given the risk of reduced viral susceptibility and resistance development associated with subtherapeutic antiretroviral drug levels, the manufacturers of elvitegravir single-ingredient and combination products recommend avoiding concomitant use. Alternative treatment combinations that do not include metabolic inducers should be considered whenever possible.", "mechanism_text": "Metabolism", "recommendation": "Given the risk of reduced viral susceptibility and resistance development associated with subtherapeutic antiretroviral drug levels, the manufacturers of elvitegravir single-ingredient and combination products recommend avoiding concomitant use.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97880/", "reference_text": "[1] Cerner Multum, Inc. \"Australian Product Information.\" O 0[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Vitekta (elvitegravir).\" Gilead Sciences, Foster City, CA.[4] \"Product Information. Vitekta (elvitegravir).\" Gilead Sciences, Foster City, CA.[5] \"Product Information. Stribild (cobicistat/elvitegravir/emtricitabine/tenofov).\" Gilead Sciences, Foster City, CA.", "alternatives_a": "Sulbactam, Oxacillin, Dicloxacillin, Piperacillin, Meticillin, Carbenicillin, Bacampicillin, Ticarcillin, Mezlocillin, Tazobactam, Cloxacillin, More", "alternatives_b": "Lamivudine, Paritaprevir, Tenofovir alafenamide, Simeprevir, Cabotegravir, Valaciclovir, Zanamivir, Telaprevir, Oseltamivir, Acyclovir, Brincidofovir, More", "updated_at": 1767369485}, {"id": 97777, "ingredient1": "Elvitegravir", "ingredient2": "Nevirapine", "severity": "Moderate", "effect": "Coadministration with inducers of CYP450 3A4 isoenzymes may reduce the plasma concentrations of elvitegravir, which is primarily metabolized by the isoenzyme.", "source": "DDInter", "management_text": "Given the risk of reduced viral susceptibility and resistance development associated with subtherapeutic antiretroviral drug levels, the manufacturers of elvitegravir single-ingredient and combination products recommend avoiding concomitant use. Alternative treatment combinations that do not include metabolic inducers should be considered whenever possible.", "mechanism_text": "Metabolism", "recommendation": "Given the risk of reduced viral susceptibility and resistance development associated with subtherapeutic antiretroviral drug levels, the manufacturers of elvitegravir single-ingredient and combination products recommend avoiding concomitant use.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97881/", "reference_text": "[1] Cerner Multum, Inc. \"Australian Product Information.\" O 0[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Vitekta (elvitegravir).\" Gilead Sciences, Foster City, CA.[4] \"Product Information. Vitekta (elvitegravir).\" Gilead Sciences, Foster City, CA.[5] \"Product Information. Stribild (cobicistat/elvitegravir/emtricitabine/tenofov).\" Gilead Sciences, Foster City, CA.", "alternatives_a": "Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Amprenavir, Simeprevir, Valaciclovir, Zanamivir, Cabotegravir, Lenacapavir, More", "alternatives_b": "Tenofovir alafenamide, Cabotegravir, Zanamivir, Oseltamivir, Brincidofovir, Famciclovir, Voxilaprevir, Tecovirimat, Pibrentasvir, Rimantadine, Telbivudine, More", "updated_at": 1767369485}, {"id": 97778, "ingredient1": "Elvitegravir", "ingredient2": "Norgestrel", "severity": "Moderate", "effect": "RECOMMENDED: Coadministration with cobicistat and elvitegravir may alter the plasma concentrations of contraceptive hormones. The exact mechanism of interaction has not been described. Clinical effects of increased progestogen levels are not fully known, but may include increased risk of insulin resistance, dyslipidemia, acne, and venous thrombosis.", "source": "DDInter", "management_text": "The potential risks and benefits of using norgestimate-containing contraceptives in combination with cobicistat and elvitegravir should be considered, particularly in women who have risk factors for insulin resistance, dyslipidemia, acne, and venous thrombosis. Coadministration of cobicistat and elvitegravir with other hormonal contraceptives (e.g., contraceptive patch, contraceptive vaginal ring, or injectable contraceptives), oral contraceptives containing progestogens other than norgestimate, or less than 25 mcg of ethinyl estradiol has not been studied and is not recommended. Some authorities recommend that hormonal contraceptives containing at least 30 mcg of ethinyl estradiol with norgestimate should be used in combination with the multi-ingredient antiretroviral formulations containing elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate or elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide. However, the long term effects of increased progesterone exposure are not known. Alternative, nonhormonal methods of contraception may be considered.", "mechanism_text": "Others", "recommendation": "The potential risks and benefits of using norgestimate-containing contraceptives in combination with cobicistat and elvitegravir should be considered, particularly in women who have risk factors for insulin resistance, dyslipidemia, acne, and venous thrombosis.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97882/", "reference_text": "[1] Cerner Multum, Inc. \"Australian Product Information.\" O 0[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Stribild (cobicistat/elvitegravir/emtricitabine/tenofov).\" Gilead Sciences, Foster City, CA.[4] Gunston GD, Mehta U \"Potentially serious drug interactions with grapefruit juice.\" S Afr Med J 90 (2000): 41[5] Bailey DG, Arnold JMO, Spence JD \"Grapefruit juice and drugs - how significant is the interaction.\" Clin Pharmacokinet 26 (1994): 91-8[6] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[7] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions.\" Br J Clin Pharmacol 46 (1998): 101-10[8] Libersa CC, Brique SA, Motte KB, et al. \"Dramatic inhibition of amiodarone metabolism induced by grapefruit juice.\" Br J Clin Pharmacol 49 (2000): 373-8[9] Bailey DG, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit juice felodipine interaction: Effect of naringin and 6',7'-dihydroxybergamottin in humans.\" Clin Pharmacol Ther 64 (1998): 248-56[10] Jonkman JH, Sollie FA, Sauter R, Steinijans VW \"The influence of caffeine on the steady-state pharmacokinetics of theophylline.\" Clin Pharmacol Ther 49 (1991): 248-55[11] Ozdemir M, Aktan Y, Boydag BS, Cingi MI, Musmul A \"Interaction between grapefruit juice and diazepam in humans.\" Eur J Drug Metab Pharmacokinet 23 (1998): 55-9[12] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin.\" Clin Pharmacol Ther 66 (1999): 118-27[13] Bailey DG, Arnold JM, Munoz C, Spence JD \"Grapefruit juice--felodipine interaction: mechanism, predictability, and effect of naringin.\" Clin Pharmacol Ther 53 (1993): 637-42[14] Sigusch H, Hippius M, Henschel L, Kaufmann K, Hoffmann A \"Influence of grapefruit juice on the pharmacokinetics of a slow release nifedipine formulation.\" Pharmazie 49 (1994): 522-4[15] Eagling VA, Profit L, Back DJ \"Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-I protease inhibitor saquinavir by grapefruit juice components.\" Br J Clin Pharmacol 48 (1999): 543-52[16] Damkier P, Hansen LL, Brosen K \"Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine.\" Br J Clin Pharmacol 48 (1999): 829-38[17] Min DI, Ku YM, Geraets DR, Lee HC \"Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers.\" J Clin Pharmacol 36 (1996): 469-76[18] Zaidenstein R, Soback S, Gips M, Avni B, Dishi V, Weissgarten Y, Golik A, Scapa E \"Effect of grapefruit juice on the pharmacokinetics of losartan and its active metabolite E3174 in healthy volunteers.\" Ther Drug Monit 23 (2001): 369-73[19] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84[20] Lee AJ, Chan WK, Harralson AF, Buffum J, Bui BCC \"The effects of grapefruit juice on sertraline metabolism: An in vitro and in vivo study.\" Clin Ther 21 (1999): 1890-9[21] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors.\" Clin Pharmacol Ther 64 (1998): 477-83[22] Garg SK, Kumar N, Bhargava VK, Prabhakar SK \"Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy.\" Clin Pharmacol Ther 64 (1998): 286-8[23] Fuhr U, Maier-Bruggemann A, Blume H, et al. \"Grapefruit juice increases oral nimodipine bioavailability.\" Int J Clin Pharmacol Ther 36 (1998): 126-32[24] Sato J, Nakata H, Owada E, Kikuta T, Umetsu M, Ito K \"Influence of usual intake of dietary caffeine on single-dose kinetics of theophylline in healthy human subjects.\" Eur J Clin Pharmacol 44 (1993): 295-8[25] Edgar B, Bailey D, Bergstrand R, et al \"Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics on felodipine and its potential clinical relevance.\" Eur J Clin Pharmacol 42 (1992): 313-7[26] Kantola T, Kivisto KT, Neuvonen PJ \"Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid.\" Clin Pharmacol Ther 63 (1998): 397-402[27] Dresser GK, Spence JD, Bailey DG \"Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition.\" Clin Pharmacokinet 38 (2000): 41-57[28] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[29] Takanaga H, Ohnishi A, Maatsuo H, et al. \"Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model.\" Br J Clin Pharmacol 49 (2000): 49-58[30] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS \"Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice.\" Br J Clin Pharmacol 42 (1996): p662[31] Bailey DG, Arnold JM, Strong HA, Munoz C, Spence JD \"Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics.\" Clin Pharmacol Ther 54 (1993): 589-94[32] Josefsson M, Zackrisson AL, Ahlner J \"Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers.\" Eur J Clin Pharmacol 51 (1996): 189-93[33] Majeed A, Kareem A \"Effect of grapefruit juice on cyclosporine pharmacokinetics.\" Pediatr Nephrol 10 (1996): 395[34] Flanagan D \"Understanding the grapefruit-drug interaction.\" Gen Dent 53 (2005): 282-5; quiz 286[35] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ \"Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice.\" Clin Pharmacol Ther 58 (1995): 127-31[36] \"Product Information. Vitekta (elvitegravir).\" Gilead Sciences, Foster City, CA.[37] \"Product Information. Stribild (cobicistat/elvitegravir/emtricitabine/tenofov).\" Gilead Sciences, Foster City, CA.[38] Schubert W, Eriksson U, Edgar B, Cullberg G, Hedner T \"Flavonoids in grapefruit juice inhibit the in vitro hepatic metabolism of 17B-estradiol.\" Eur J Drug Metab Pharmacokinet 20 (1995): 219-24[39] Weber A, Jager R, Borner A, et al. \"Can grapefruit juice influence ethinyl estradiol bioavailability?\" Contraception 53 (1996): 41-7", "alternatives_a": "Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Simeprevir, Cabotegravir, Valaciclovir, Zanamivir, Velpatasvir, Rilpivirine, More", "alternatives_b": "Megestrol acetate, Progesterone, Megestrol acetate, Ulipristal, Estetrol", "updated_at": 1767369485}, {"id": 97779, "ingredient1": "Elvitegravir", "ingredient2": "Oritavancin", "severity": "Moderate", "effect": "Coadministration with inducers of CYP450 3A4 isoenzymes may reduce the plasma concentrations of elvitegravir, which is primarily metabolized by the isoenzyme.", "source": "DDInter", "management_text": "Given the risk of reduced viral susceptibility and resistance development associated with subtherapeutic antiretroviral drug levels, the manufacturers of elvitegravir single-ingredient and combination products recommend avoiding concomitant use. Alternative treatment combinations that do not include metabolic inducers should be considered whenever possible.", "mechanism_text": "Metabolism", "recommendation": "Given the risk of reduced viral susceptibility and resistance development associated with subtherapeutic antiretroviral drug levels, the manufacturers of elvitegravir single-ingredient and combination products recommend avoiding concomitant use.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97883/", "reference_text": "[1] Cerner Multum, Inc. \"Australian Product Information.\" O 0[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Vitekta (elvitegravir).\" Gilead Sciences, Foster City, CA.[4] \"Product Information. Vitekta (elvitegravir).\" Gilead Sciences, Foster City, CA.[5] \"Product Information. Stribild (cobicistat/elvitegravir/emtricitabine/tenofov).\" Gilead Sciences, Foster City, CA.", "alternatives_a": "Tinidazole, Linezolid, Bacitracin, Polymyxin B, Daptomycin, Vancomycin, Metronidazole, Telavancin, Methenamine, Spectinomycin, Lefamulin, More", "alternatives_b": "Lamivudine, Paritaprevir, Tenofovir alafenamide, Maraviroc, Amprenavir, Simeprevir, Valaciclovir, Zanamivir, Cabotegravir, Telaprevir, Velpatasvir, More", "updated_at": 1767369485}, {"id": 97780, "ingredient1": "Elvitegravir", "ingredient2": "Orlistat", "severity": "Moderate", "effect": "Orlistat may theoretically reduce the gastrointestinal absorption and therapeutic efficacy of antiretroviral agents. The mechanism may involve retention of lipophilic medicines in the gastrointestinal tract or reduced gastrointestinal tract transit time.", "source": "DDInter", "management_text": "The potential reduction in antiretroviral efficacy should be considered before initiating treatment with orlistat. Patients who take antiretroviral medications should be advised to consult their physician before using the non-prescription brand of orlistat.", "mechanism_text": "Absorption", "recommendation": "The potential reduction in antiretroviral efficacy should be considered before initiating treatment with orlistat.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97884/", "reference_text": "[1] MHRA. Medicines and Healthcare Products Regulatory Agency \"Orlistat: theoretical interaction with antiretroviral HIV medicines. Available from: URL: http://www.mhra.gov.uk/Safetyinformation/DrugSafetyUpdate/CON392868\" ([2014 Mar]):[2] \"Product Information. Hivid (zalcitabine).\" Roche Laboratories, Nutley, NJ.", "alternatives_a": "Dexfenfluramine, Naltrexone, Ephedrine, Fenfluramine, Bupropion, Phentermine, Lorcaserin, Sibutramine, Diethylpropion, Mazindol", "alternatives_b": "Paritaprevir, Glecaprevir, Maraviroc, Simeprevir, Cabotegravir, Zanamivir, Lenacapavir, Velpatasvir, Oseltamivir, Cobicistat, Brincidofovir, More", "updated_at": 1767369485}, {"id": 97781, "ingredient1": "Elvitegravir", "ingredient2": "Oxcarbazepine", "severity": "Moderate", "effect": "Coadministration with inducers of CYP450 3A4 isoenzymes may reduce the plasma concentrations of elvitegravir, which is primarily metabolized by the isoenzyme.", "source": "DDInter", "management_text": "Given the risk of reduced viral susceptibility and resistance development associated with subtherapeutic antiretroviral drug levels, the manufacturers of elvitegravir single-ingredient and combination products recommend avoiding concomitant use. Alternative treatment combinations that do not include metabolic inducers should be considered whenever possible.", "mechanism_text": "Metabolism", "recommendation": "Given the risk of reduced viral susceptibility and resistance development associated with subtherapeutic antiretroviral drug levels, the manufacturers of elvitegravir single-ingredient and combination products recommend avoiding concomitant use.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97885/", "reference_text": "[1] Cerner Multum, Inc. \"Australian Product Information.\" O 0[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Vitekta (elvitegravir).\" Gilead Sciences, Foster City, CA.[4] \"Product Information. Vitekta (elvitegravir).\" Gilead Sciences, Foster City, CA.[5] \"Product Information. Stribild (cobicistat/elvitegravir/emtricitabine/tenofov).\" Gilead Sciences, Foster City, CA.", "alternatives_a": "Brivaracetam, Topiramate, Ezogabine, Lamotrigine, Methylphenobarbital, Ethosuximide, Lacosamide, Levetiracetam, Tiagabine, Ethotoin, Clonazepam, More", "alternatives_b": "Lamivudine, Paritaprevir, Zanamivir, Velpatasvir, Oseltamivir, Brincidofovir, Stavudine, Remdesivir, Voxilaprevir, Tecovirimat, Pibrentasvir, More", "updated_at": 1767369485}, {"id": 97782, "ingredient1": "Elvitegravir", "ingredient2": "Pexidartinib", "severity": "Moderate", "effect": "Coadministration with inducers of CYP450 3A4 isoenzymes may reduce the plasma concentrations of elvitegravir, which is primarily metabolized by the isoenzyme.", "source": "DDInter", "management_text": "Given the risk of reduced viral susceptibility and resistance development associated with subtherapeutic antiretroviral drug levels, the manufacturers of elvitegravir single-ingredient and combination products recommend avoiding concomitant use. Alternative treatment combinations that do not include metabolic inducers should be considered whenever possible.", "mechanism_text": "Metabolism", "recommendation": "Given the risk of reduced viral susceptibility and resistance development associated with subtherapeutic antiretroviral drug levels, the manufacturers of elvitegravir single-ingredient and combination products recommend avoiding concomitant use.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97886/", "reference_text": "[1] Cerner Multum, Inc. \"Australian Product Information.\" O 0[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Vitekta (elvitegravir).\" Gilead Sciences, Foster City, CA.[4] \"Product Information. Vitekta (elvitegravir).\" Gilead Sciences, Foster City, CA.[5] \"Product Information. Stribild (cobicistat/elvitegravir/emtricitabine/tenofov).\" Gilead Sciences, Foster City, CA.", "alternatives_a": "Cabotegravir, Zanamivir, Valaciclovir, Oseltamivir, Acyclovir, Elbasvir, Famciclovir, Ribavirin, Tecovirimat, Pibrentasvir, Rimantadine, More", "alternatives_b": "Entrectinib, Imatinib, Pralsetinib, Asciminib, Acalabrutinib, Dacomitinib, Pacritinib, Tepotinib, Fedratinib, Avapritinib, Larotrectinib, More", "updated_at": 1767369485}, {"id": 97783, "ingredient1": "Elvitegravir", "ingredient2": "Phenytoin", "severity": "Major", "effect": "Coadministration with potent inducers of CYP450 3A4 may significantly decrease the plasma concentrations of elvitegravir, which is primarily metabolized by the isoenzyme.", "source": "DDInter", "management_text": "Given the risk of reduced viral susceptibility and resistance development associated with subtherapeutic drug levels, concomitant use of elvitegravir with potent CYP450 3A4 inducers is generally not recommended. In addition, other antiretroviral agents that are typically combined with elvitegravir may be contraindicated for use with potent CYP450 3A4 inducers.", "mechanism_text": "Metabolism", "recommendation": "Given the risk of reduced viral susceptibility and resistance development associated with subtherapeutic drug levels, concomitant use of elvitegravir with potent CYP450 3A4 inducers is generally not recommended.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97887/", "reference_text": "[1] \"Product Information. Vitekta (elvitegravir).\" Gilead Sciences, Foster City, CA.[2] \"Product Information. Tybost (cobicistat).\" Gilead Sciences, Foster City, CA.[3] \"Product Information. Genvoya (cobicistat/elvitegravir/emtricitabine/tenofov).\" Gilead Sciences, Foster City, CA.[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] \"Product Information. Stribild (cobicistat/elvitegravir/emtricitabine/tenofov).\" Gilead Sciences, Foster City, CA.[6] Cerner Multum, Inc. \"Australian Product Information.\" O 0[7] \"Product Information. Trikafta (elexacaftor/ivacaftor/tezacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[8] \"Product Information. Kalydeco (ivacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[9] \"Product Information. Orkambi (ivacaftor-lumacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[10] \"Product Information. Symdeko 4-Week (ivacaftor-tezacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[11] \"Product Information. Vitekta (elvitegravir).\" Gilead Sciences, Foster City, CA.[12] \"Product Information. Stribild (cobicistat/elvitegravir/emtricitabine/tenofov).\" Gilead Sciences, Foster City, CA.", "alternatives_a": "Brivaracetam, Topiramate, Ezogabine, Lamotrigine, Methylphenobarbital, Ethosuximide, Lacosamide, Levetiracetam, Tiagabine, Ethotoin, Clonazepam, More", "alternatives_b": "Paritaprevir, Zanamivir, Velpatasvir, Brincidofovir, Elbasvir, Famciclovir, Voxilaprevir, Tecovirimat, Pibrentasvir, Rimantadine, Valganciclovir, More", "updated_at": 1767369485}, {"id": 97784, "ingredient1": "Elvitegravir", "ingredient2": "Primidone", "severity": "Major", "effect": "Coadministration with potent inducers of CYP450 3A4 may significantly decrease the plasma concentrations of elvitegravir, which is primarily metabolized by the isoenzyme.", "source": "DDInter", "management_text": "Given the risk of reduced viral susceptibility and resistance development associated with subtherapeutic drug levels, concomitant use of elvitegravir with potent CYP450 3A4 inducers is generally not recommended. In addition, other antiretroviral agents that are typically combined with elvitegravir may be contraindicated for use with potent CYP450 3A4 inducers.", "mechanism_text": "Metabolism", "recommendation": "Given the risk of reduced viral susceptibility and resistance development associated with subtherapeutic drug levels, concomitant use of elvitegravir with potent CYP450 3A4 inducers is generally not recommended.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97888/", "reference_text": "[1] \"Product Information. Vitekta (elvitegravir).\" Gilead Sciences, Foster City, CA.[2] \"Product Information. Tybost (cobicistat).\" Gilead Sciences, Foster City, CA.[3] \"Product Information. Genvoya (cobicistat/elvitegravir/emtricitabine/tenofov).\" Gilead Sciences, Foster City, CA.[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] \"Product Information. Stribild (cobicistat/elvitegravir/emtricitabine/tenofov).\" Gilead Sciences, Foster City, CA.[6] Cerner Multum, Inc. \"Australian Product Information.\" O 0[7] \"Product Information. Trikafta (elexacaftor/ivacaftor/tezacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[8] \"Product Information. Kalydeco (ivacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[9] \"Product Information. Orkambi (ivacaftor-lumacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[10] \"Product Information. Symdeko 4-Week (ivacaftor-tezacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[11] \"Product Information. Vitekta (elvitegravir).\" Gilead Sciences, Foster City, CA.[12] \"Product Information. Stribild (cobicistat/elvitegravir/emtricitabine/tenofov).\" Gilead Sciences, Foster City, CA.", "alternatives_a": "Suvorexant, Triazolam, Flurazepam, Methohexital, Methylphenobarbital, Zolpidem, Pentobarbital, Zaleplon, Dichloralphenazone, Valerian, Temazepam, More", "alternatives_b": "Lamivudine, Paritaprevir, Cabotegravir, Zanamivir, Valaciclovir, Velpatasvir, Oseltamivir, Brincidofovir, Stavudine, Elbasvir, Famciclovir, More", "updated_at": 1767369485}, {"id": 97785, "ingredient1": "Elvitegravir", "ingredient2": "Rifabutin", "severity": "Major", "effect": "Coadministration with rifabutin may significantly decrease the plasma concentrations of elvitegravir. The mechanism involves rifabutin induction of CYP450 3A4, the isoenzyme primarily responsible for the metabolic clearance of elvitegravir.", "source": "DDInter", "management_text": "Given the risk of reduced viral susceptibility and resistance development associated with subtherapeutic drug levels, concomitant use of elvitegravir with rifabutin should generally be avoided.", "mechanism_text": "Metabolism", "recommendation": "Given the risk of reduced viral susceptibility and resistance development associated with subtherapeutic drug levels, concomitant use of elvitegravir with rifabutin should generally be avoided.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97889/", "reference_text": "[1] Cerner Multum, Inc. \"Australian Product Information.\" O 0[2] \"Product Information. Stribild (cobicistat/elvitegravir/emtricitabine/tenofov).\" Gilead Sciences, Foster City, CA.[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] \"Product Information. Vitekta (elvitegravir).\" Gilead Sciences, Foster City, CA.[5] \"Product Information. Stribild (cobicistat/elvitegravir/emtricitabine/tenofov).\" Gilead Sciences, Foster City, CA.", "alternatives_a": "Capreomycin, Pyrazinamide, Rifamycin, Bedaquiline, Sulfamethoxazole, Streptomycin, Trimethoprim, Cycloserine, Isoniazid, Ethambutol, Pyridoxine, More", "alternatives_b": "Lamivudine, Paritaprevir, Zanamivir, Valaciclovir, Velpatasvir, Oseltamivir, Acyclovir, Brincidofovir, Stavudine, Remdesivir, Elbasvir, More", "updated_at": 1767369485}, {"id": 97786, "ingredient1": "Elvitegravir", "ingredient2": "Rifampicin", "severity": "Major", "effect": "Coadministration with potent inducers of CYP450 3A4 may significantly decrease the plasma concentrations of elvitegravir, which is primarily metabolized by the isoenzyme.", "source": "DDInter", "management_text": "Given the risk of reduced viral susceptibility and resistance development associated with subtherapeutic drug levels, concomitant use of elvitegravir with potent CYP450 3A4 inducers is generally not recommended. In addition, other antiretroviral agents that are typically combined with elvitegravir may be contraindicated for use with potent CYP450 3A4 inducers.", "mechanism_text": "Metabolism", "recommendation": "Given the risk of reduced viral susceptibility and resistance development associated with subtherapeutic drug levels, concomitant use of elvitegravir with potent CYP450 3A4 inducers is generally not recommended.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97890/", "reference_text": "[1] \"Product Information. Vitekta (elvitegravir).\" Gilead Sciences, Foster City, CA.[2] \"Product Information. Tybost (cobicistat).\" Gilead Sciences, Foster City, CA.[3] \"Product Information. Genvoya (cobicistat/elvitegravir/emtricitabine/tenofov).\" Gilead Sciences, Foster City, CA.[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] \"Product Information. Stribild (cobicistat/elvitegravir/emtricitabine/tenofov).\" Gilead Sciences, Foster City, CA.[6] Cerner Multum, Inc. \"Australian Product Information.\" O 0[7] \"Product Information. Trikafta (elexacaftor/ivacaftor/tezacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[8] \"Product Information. Kalydeco (ivacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[9] \"Product Information. Orkambi (ivacaftor-lumacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[10] \"Product Information. Symdeko 4-Week (ivacaftor-tezacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[11] \"Product Information. Vitekta (elvitegravir).\" Gilead Sciences, Foster City, CA.[12] \"Product Information. Stribild (cobicistat/elvitegravir/emtricitabine/tenofov).\" Gilead Sciences, Foster City, CA.", "alternatives_a": "Capreomycin, Pyrazinamide, Rifamycin, Bedaquiline, Sulfamethoxazole, Streptomycin, Trimethoprim, Cycloserine, Isoniazid, Ethambutol, Pyridoxine, More", "alternatives_b": "Paritaprevir, Zanamivir, Velpatasvir, Elbasvir, Famciclovir, Tecovirimat, Pibrentasvir, Rimantadine, Valganciclovir, Telbivudine, Entecavir, More", "updated_at": 1767369485}, {"id": 97787, "ingredient1": "Elvitegravir", "ingredient2": "Rifapentine", "severity": "Major", "effect": "Coadministration with potent inducers of CYP450 3A4 may significantly decrease the plasma concentrations of elvitegravir, which is primarily metabolized by the isoenzyme.", "source": "DDInter", "management_text": "Given the risk of reduced viral susceptibility and resistance development associated with subtherapeutic drug levels, concomitant use of elvitegravir with potent CYP450 3A4 inducers is generally not recommended. In addition, other antiretroviral agents that are typically combined with elvitegravir may be contraindicated for use with potent CYP450 3A4 inducers.", "mechanism_text": "Metabolism", "recommendation": "Given the risk of reduced viral susceptibility and resistance development associated with subtherapeutic drug levels, concomitant use of elvitegravir with potent CYP450 3A4 inducers is generally not recommended.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97891/", "reference_text": "[1] \"Product Information. Vitekta (elvitegravir).\" Gilead Sciences, Foster City, CA.[2] \"Product Information. Tybost (cobicistat).\" Gilead Sciences, Foster City, CA.[3] \"Product Information. Genvoya (cobicistat/elvitegravir/emtricitabine/tenofov).\" Gilead Sciences, Foster City, CA.[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] \"Product Information. Stribild (cobicistat/elvitegravir/emtricitabine/tenofov).\" Gilead Sciences, Foster City, CA.[6] Cerner Multum, Inc. \"Australian Product Information.\" O 0[7] \"Product Information. Trikafta (elexacaftor/ivacaftor/tezacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[8] \"Product Information. Kalydeco (ivacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[9] \"Product Information. Orkambi (ivacaftor-lumacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[10] \"Product Information. Symdeko 4-Week (ivacaftor-tezacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[11] \"Product Information. Vitekta (elvitegravir).\" Gilead Sciences, Foster City, CA.[12] \"Product Information. Stribild (cobicistat/elvitegravir/emtricitabine/tenofov).\" Gilead Sciences, Foster City, CA.", "alternatives_a": "Capreomycin, Pyrazinamide, Rifamycin, Bedaquiline, Sulfamethoxazole, Streptomycin, Trimethoprim, Cycloserine, Isoniazid, Ethambutol, Pyridoxine, More", "alternatives_b": "Lamivudine, Paritaprevir, Zanamivir, Valaciclovir, Velpatasvir, Oseltamivir, Acyclovir, Brincidofovir, Stavudine, Elbasvir, Famciclovir, More", "updated_at": 1767369485}, {"id": 97788, "ingredient1": "Elvitegravir", "ingredient2": "Rufinamide", "severity": "Moderate", "effect": "Coadministration with inducers of CYP450 3A4 isoenzymes may reduce the plasma concentrations of elvitegravir, which is primarily metabolized by the isoenzyme.", "source": "DDInter", "management_text": "Given the risk of reduced viral susceptibility and resistance development associated with subtherapeutic antiretroviral drug levels, the manufacturers of elvitegravir single-ingredient and combination products recommend avoiding concomitant use. Alternative treatment combinations that do not include metabolic inducers should be considered whenever possible.", "mechanism_text": "Metabolism", "recommendation": "Given the risk of reduced viral susceptibility and resistance development associated with subtherapeutic antiretroviral drug levels, the manufacturers of elvitegravir single-ingredient and combination products recommend avoiding concomitant use.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97892/", "reference_text": "[1] Cerner Multum, Inc. \"Australian Product Information.\" O 0[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Vitekta (elvitegravir).\" Gilead Sciences, Foster City, CA.[4] \"Product Information. Vitekta (elvitegravir).\" Gilead Sciences, Foster City, CA.[5] \"Product Information. Stribild (cobicistat/elvitegravir/emtricitabine/tenofov).\" Gilead Sciences, Foster City, CA.", "alternatives_a": "Brivaracetam, Topiramate, Ezogabine, Lamotrigine, Methylphenobarbital, Ethosuximide, Lacosamide, Levetiracetam, Tiagabine, Ethotoin, Clonazepam, More", "alternatives_b": "Lamivudine, Paritaprevir, Tenofovir alafenamide, Maraviroc, Amprenavir, Simeprevir, Valaciclovir, Zanamivir, Cabotegravir, Velpatasvir, Etravirine, More", "updated_at": 1767369485}, {"id": 97789, "ingredient1": "Elvitegravir", "ingredient2": "Sodium bicarbonate", "severity": "Moderate", "effect": "INTERVAL: The concomitant use of antacids may significantly decrease the plasma concentrations of elvitegravir. The mechanism of interaction has not been described. In contrast, when the antacid was given 4 hours before or 4 hours after elvitegravir, no significant differences were observed in elvitegravir pharmacokinetics compared to administration of elvitegravir alone.", "source": "DDInter", "management_text": "Antacid-containing preparations should be administered at least 2 hours before or 2 hours after the elvitegravir dose. Alternatively, H2-receptor antagonists or proton pump inhibitors may be considered, with no dosage adjustment needed.", "mechanism_text": "Others", "recommendation": "Antacid-containing preparations should be administered at least 2 hours before or 2 hours after the elvitegravir dose.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97893/", "reference_text": "[1] Cerner Multum, Inc. \"Australian Product Information.\" O 0[2] \"Product Information. Stribild (cobicistat/elvitegravir/emtricitabine/tenofov).\" Gilead Sciences, Foster City, CA.[3] \"Product Information. Vitekta (elvitegravir).\" Gilead Sciences, Foster City, CA.[4] \"Product Information. Stribild (cobicistat/elvitegravir/emtricitabine/tenofov).\" Gilead Sciences, Foster City, CA.", "alternatives_a": "Sorbitol, Sulfamethizole, Mannitol, Sodium chloride, Chlorhexidine, Neomycin, Calcium chloride, Potassium chloride, Sodium acetate, Arginine, Sodium glycerophosphate, More", "alternatives_b": "Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Simeprevir, Zanamivir, Lenacapavir, Telaprevir, Etravirine, Cobicistat, Brincidofovir, More", "updated_at": 1767369485}, {"id": 97790, "ingredient1": "Elvitegravir", "ingredient2": "Somapacitan", "severity": "Moderate", "effect": "Coadministration with inducers of CYP450 3A4 isoenzymes may reduce the plasma concentrations of elvitegravir, which is primarily metabolized by the isoenzyme.", "source": "DDInter", "management_text": "Given the risk of reduced viral susceptibility and resistance development associated with subtherapeutic antiretroviral drug levels, the manufacturers of elvitegravir single-ingredient and combination products recommend avoiding concomitant use. Alternative treatment combinations that do not include metabolic inducers should be considered whenever possible.", "mechanism_text": "Metabolism", "recommendation": "Given the risk of reduced viral susceptibility and resistance development associated with subtherapeutic antiretroviral drug levels, the manufacturers of elvitegravir single-ingredient and combination products recommend avoiding concomitant use.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97894/", "reference_text": "[1] Cerner Multum, Inc. \"Australian Product Information.\" O 0[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Vitekta (elvitegravir).\" Gilead Sciences, Foster City, CA.[4] \"Product Information. Vitekta (elvitegravir).\" Gilead Sciences, Foster City, CA.[5] \"Product Information. Stribild (cobicistat/elvitegravir/emtricitabine/tenofov).\" Gilead Sciences, Foster City, CA.", "alternatives_a": "Lamivudine, Tenofovir alafenamide, Simeprevir, Cabotegravir, Zanamivir, Valaciclovir, Oseltamivir, Acyclovir, Brincidofovir, Stavudine, Remdesivir, More", "alternatives_b": "Corticotropin, Mecasermin, Sermorelin, Tesamorelin, Thyrotropin alfa, Somatrem, Tetracosactide, Mecasermin rinfabate, Pegvisomant", "updated_at": 1767369485}, {"id": 97791, "ingredient1": "Elvitegravir", "ingredient2": "Somatotropin", "severity": "Moderate", "effect": "Coadministration with inducers of CYP450 3A4 isoenzymes may reduce the plasma concentrations of elvitegravir, which is primarily metabolized by the isoenzyme.", "source": "DDInter", "management_text": "Given the risk of reduced viral susceptibility and resistance development associated with subtherapeutic antiretroviral drug levels, the manufacturers of elvitegravir single-ingredient and combination products recommend avoiding concomitant use. Alternative treatment combinations that do not include metabolic inducers should be considered whenever possible.", "mechanism_text": "Metabolism", "recommendation": "Given the risk of reduced viral susceptibility and resistance development associated with subtherapeutic antiretroviral drug levels, the manufacturers of elvitegravir single-ingredient and combination products recommend avoiding concomitant use.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97895/", "reference_text": "[1] Cerner Multum, Inc. \"Australian Product Information.\" O 0[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Vitekta (elvitegravir).\" Gilead Sciences, Foster City, CA.[4] \"Product Information. Vitekta (elvitegravir).\" Gilead Sciences, Foster City, CA.[5] \"Product Information. Stribild (cobicistat/elvitegravir/emtricitabine/tenofov).\" Gilead Sciences, Foster City, CA.", "alternatives_a": "Corticotropin, Mecasermin, Sermorelin, Tesamorelin, Thyrotropin alfa, Somatrem, Tetracosactide, Mecasermin rinfabate, Pegvisomant", "alternatives_b": "Lamivudine, Tenofovir alafenamide, Simeprevir, Cabotegravir, Zanamivir, Valaciclovir, Oseltamivir, Acyclovir, Brincidofovir, Stavudine, Remdesivir, More", "updated_at": 1767369485}, {"id": 97792, "ingredient1": "Elvitegravir", "ingredient2": "St. John's Wort", "severity": "Major", "effect": "Coadministration with potent inducers of CYP450 3A4 may significantly decrease the plasma concentrations of elvitegravir, which is primarily metabolized by the isoenzyme.", "source": "DDInter", "management_text": "Given the risk of reduced viral susceptibility and resistance development associated with subtherapeutic drug levels, concomitant use of elvitegravir with potent CYP450 3A4 inducers is generally not recommended. In addition, other antiretroviral agents that are typically combined with elvitegravir may be contraindicated for use with potent CYP450 3A4 inducers.", "mechanism_text": "Metabolism", "recommendation": "Given the risk of reduced viral susceptibility and resistance development associated with subtherapeutic drug levels, concomitant use of elvitegravir with potent CYP450 3A4 inducers is generally not recommended.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97896/", "reference_text": "[1] \"Product Information. Vitekta (elvitegravir).\" Gilead Sciences, Foster City, CA.[2] \"Product Information. Tybost (cobicistat).\" Gilead Sciences, Foster City, CA.[3] \"Product Information. Genvoya (cobicistat/elvitegravir/emtricitabine/tenofov).\" Gilead Sciences, Foster City, CA.[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] \"Product Information. Stribild (cobicistat/elvitegravir/emtricitabine/tenofov).\" Gilead Sciences, Foster City, CA.[6] Cerner Multum, Inc. \"Australian Product Information.\" O 0[7] \"Product Information. Trikafta (elexacaftor/ivacaftor/tezacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[8] \"Product Information. Kalydeco (ivacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[9] \"Product Information. Orkambi (ivacaftor-lumacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[10] \"Product Information. Symdeko 4-Week (ivacaftor-tezacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[11] \"Product Information. Vitekta (elvitegravir).\" Gilead Sciences, Foster City, CA.[12] \"Product Information. Stribild (cobicistat/elvitegravir/emtricitabine/tenofov).\" Gilead Sciences, Foster City, CA.", "alternatives_a": "Citalopram, Sertraline, Maprotiline, Fluoxetine, Milnacipran, Vortioxetine, Levomilnacipran, Doxepin, Duloxetine, Isocarboxazid, Viloxazine, More", "alternatives_b": "Lamivudine, Paritaprevir, Cabotegravir, Zanamivir, Valaciclovir, Velpatasvir, Oseltamivir, Acyclovir, Brincidofovir, Stavudine, Elbasvir, More", "updated_at": 1767369485}, {"id": 97793, "ingredient1": "Elvitegravir", "ingredient2": "Sulfinpyrazone", "severity": "Moderate", "effect": "Coadministration with inducers of CYP450 3A4 isoenzymes may reduce the plasma concentrations of elvitegravir, which is primarily metabolized by the isoenzyme.", "source": "DDInter", "management_text": "Given the risk of reduced viral susceptibility and resistance development associated with subtherapeutic antiretroviral drug levels, the manufacturers of elvitegravir single-ingredient and combination products recommend avoiding concomitant use. Alternative treatment combinations that do not include metabolic inducers should be considered whenever possible.", "mechanism_text": "Metabolism", "recommendation": "Given the risk of reduced viral susceptibility and resistance development associated with subtherapeutic antiretroviral drug levels, the manufacturers of elvitegravir single-ingredient and combination products recommend avoiding concomitant use.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97897/", "reference_text": "[1] Cerner Multum, Inc. \"Australian Product Information.\" O 0[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Vitekta (elvitegravir).\" Gilead Sciences, Foster City, CA.[4] \"Product Information. Vitekta (elvitegravir).\" Gilead Sciences, Foster City, CA.[5] \"Product Information. Stribild (cobicistat/elvitegravir/emtricitabine/tenofov).\" Gilead Sciences, Foster City, CA.", "alternatives_a": "Lesinurad, Febuxostat, Pegloticase, Colchicine, Rasburicase, Probenecid, Allopurinol", "alternatives_b": "Lamivudine, Paritaprevir, Tenofovir alafenamide, Simeprevir, Cabotegravir, Valaciclovir, Zanamivir, Velpatasvir, Oseltamivir, Acyclovir, Brincidofovir, More", "updated_at": 1767369485}, {"id": 97794, "ingredient1": "Elvitegravir", "ingredient2": "Vemurafenib", "severity": "Moderate", "effect": "Coadministration with inducers of CYP450 3A4 isoenzymes may reduce the plasma concentrations of elvitegravir, which is primarily metabolized by the isoenzyme.", "source": "DDInter", "management_text": "Given the risk of reduced viral susceptibility and resistance development associated with subtherapeutic antiretroviral drug levels, the manufacturers of elvitegravir single-ingredient and combination products recommend avoiding concomitant use. Alternative treatment combinations that do not include metabolic inducers should be considered whenever possible.", "mechanism_text": "Metabolism", "recommendation": "Given the risk of reduced viral susceptibility and resistance development associated with subtherapeutic antiretroviral drug levels, the manufacturers of elvitegravir single-ingredient and combination products recommend avoiding concomitant use.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97898/", "reference_text": "[1] Cerner Multum, Inc. \"Australian Product Information.\" O 0[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Vitekta (elvitegravir).\" Gilead Sciences, Foster City, CA.[4] \"Product Information. Vitekta (elvitegravir).\" Gilead Sciences, Foster City, CA.[5] \"Product Information. Stribild (cobicistat/elvitegravir/emtricitabine/tenofov).\" Gilead Sciences, Foster City, CA.", "alternatives_a": "Tamsulosin, Tinidazole, Ascorbic acid, Hydroflumethiazide, Chlorothiazide, Metronidazole, Simeprevir, Rosuvastatin, Sulfadiazine, Lactic acid, Mitapivat, More", "alternatives_b": "Lamivudine, Paritaprevir, Tenofovir alafenamide, Simeprevir, Cabotegravir, Valaciclovir, Zanamivir, Oseltamivir, Acyclovir, Brincidofovir, Stavudine, More", "updated_at": 1767369485}, {"id": 97795, "ingredient1": "Elvitegravir", "ingredient2": "Zinc acetate", "severity": "Major", "effect": "INTERVAL: Coadministration with supplements containing polyvalent cations such as zinc may decrease the plasma concentrations of integrase strand transfer inhibitors (INSTIs) such as elvitegravir and raltegravir. The mechanism involves chelation of the INSTI by polyvalent cations, forming a complex that is poorly absorbed from the gastrointestinal tract. The clinical relevance is unknown.", "source": "DDInter", "management_text": "If concomitant use is required, monitor for virologic efficacy and administer the INSTI such as elvitegravir or raltegravir at least 2 hours before or 6 hours after supplements containing polyvalent cations such as zinc.", "mechanism_text": "Absorption", "recommendation": "If concomitant use is required, monitor for virologic efficacy and administer the INSTI such as elvitegravir or raltegravir at least 2 hours before or 6 hours after supplements containing polyvalent cations such as zinc.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97899/", "reference_text": "[1] US National Library of Medicine \"Guidelines for the use of antiretroviral agents in adults and adolescents with HIV. Available from: URL: https://aidsinfo.nih.gov/guidelines/html/1/adult-and-adolescent-arv-guidelines/287/insti-drug-interactions.\" ([2019, Nov 6]):", "alternatives_a": "Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Amprenavir, Simeprevir, Valaciclovir, Zanamivir, Lenacapavir, Telaprevir, More", "alternatives_b": "Lidocaine, Diltiazem, Tetracaine, Fluocinolone acetonide, Hydrocortisone, Fluocinonide, Isosorbide dinitrate, Procaine, Prednisolone, Betamethasone, Fluorometholone, More", "updated_at": 1767369485}, {"id": 97796, "ingredient1": "Elvitegravir", "ingredient2": "Zinc chloride", "severity": "Major", "effect": "INTERVAL: Coadministration with supplements containing polyvalent cations such as zinc may decrease the plasma concentrations of integrase strand transfer inhibitors (INSTIs) such as elvitegravir and raltegravir. The mechanism involves chelation of the INSTI by polyvalent cations, forming a complex that is poorly absorbed from the gastrointestinal tract. The clinical relevance is unknown.", "source": "DDInter", "management_text": "If concomitant use is required, monitor for virologic efficacy and administer the INSTI such as elvitegravir or raltegravir at least 2 hours before or 6 hours after supplements containing polyvalent cations such as zinc.", "mechanism_text": "Absorption", "recommendation": "If concomitant use is required, monitor for virologic efficacy and administer the INSTI such as elvitegravir or raltegravir at least 2 hours before or 6 hours after supplements containing polyvalent cations such as zinc.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97900/", "reference_text": "[1] US National Library of Medicine \"Guidelines for the use of antiretroviral agents in adults and adolescents with HIV. Available from: URL: https://aidsinfo.nih.gov/guidelines/html/1/adult-and-adolescent-arv-guidelines/287/insti-drug-interactions.\" ([2019, Nov 6]):", "alternatives_a": "Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Amprenavir, Simeprevir, Valaciclovir, Zanamivir, Cabotegravir, Lenacapavir, More", "alternatives_b": "Lidocaine, Diltiazem, Tetracaine, Fluocinolone acetonide, Hydrocortisone, Fluocinonide, Isosorbide dinitrate, Procaine, Prednisolone, Betamethasone, Fluorometholone, More", "updated_at": 1767369485}, {"id": 97797, "ingredient1": "Elvitegravir", "ingredient2": "Zinc gluconate", "severity": "Major", "effect": "INTERVAL: Coadministration with supplements containing polyvalent cations such as zinc may decrease the plasma concentrations of integrase strand transfer inhibitors (INSTIs) such as elvitegravir and raltegravir. The mechanism involves chelation of the INSTI by polyvalent cations, forming a complex that is poorly absorbed from the gastrointestinal tract. The clinical relevance is unknown.", "source": "DDInter", "management_text": "If concomitant use is required, monitor for virologic efficacy and administer the INSTI such as elvitegravir or raltegravir at least 2 hours before or 6 hours after supplements containing polyvalent cations such as zinc.", "mechanism_text": "Absorption", "recommendation": "If concomitant use is required, monitor for virologic efficacy and administer the INSTI such as elvitegravir or raltegravir at least 2 hours before or 6 hours after supplements containing polyvalent cations such as zinc.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97901/", "reference_text": "[1] US National Library of Medicine \"Guidelines for the use of antiretroviral agents in adults and adolescents with HIV. Available from: URL: https://aidsinfo.nih.gov/guidelines/html/1/adult-and-adolescent-arv-guidelines/287/insti-drug-interactions.\" ([2019, Nov 6]):", "alternatives_a": "Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Amprenavir, Simeprevir, Valaciclovir, Zanamivir, Lenacapavir, Telaprevir, More", "alternatives_b": "Lidocaine, Diltiazem, Tetracaine, Fluocinolone acetonide, Hydrocortisone, Fluocinonide, Isosorbide dinitrate, Procaine, Prednisolone, Betamethasone, Fluorometholone, More", "updated_at": 1767369485}, {"id": 97798, "ingredient1": "Elvitegravir", "ingredient2": "Zinc sulfate", "severity": "Major", "effect": "INTERVAL: Coadministration with supplements containing polyvalent cations such as zinc may decrease the plasma concentrations of integrase strand transfer inhibitors (INSTIs) such as elvitegravir and raltegravir. The mechanism involves chelation of the INSTI by polyvalent cations, forming a complex that is poorly absorbed from the gastrointestinal tract. The clinical relevance is unknown.", "source": "DDInter", "management_text": "If concomitant use is required, monitor for virologic efficacy and administer the INSTI such as elvitegravir or raltegravir at least 2 hours before or 6 hours after supplements containing polyvalent cations such as zinc.", "mechanism_text": "Absorption", "recommendation": "If concomitant use is required, monitor for virologic efficacy and administer the INSTI such as elvitegravir or raltegravir at least 2 hours before or 6 hours after supplements containing polyvalent cations such as zinc.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97902/", "reference_text": "[1] US National Library of Medicine \"Guidelines for the use of antiretroviral agents in adults and adolescents with HIV. Available from: URL: https://aidsinfo.nih.gov/guidelines/html/1/adult-and-adolescent-arv-guidelines/287/insti-drug-interactions.\" ([2019, Nov 6]):", "alternatives_a": "Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Amprenavir, Simeprevir, Valaciclovir, Zanamivir, Lenacapavir, Telaprevir, More", "alternatives_b": "Lidocaine, Diltiazem, Tetracaine, Fluocinolone acetonide, Hydrocortisone, Fluocinonide, Isosorbide dinitrate, Procaine, Prednisolone, Betamethasone, Fluorometholone, More", "updated_at": 1767369485}, {"id": 97799, "ingredient1": "Human adenovirus e serotype 4 strain cl-68578 antigen", "ingredient2": "Emapalumab", "severity": "Major", "effect": "The administration of live or live attenuated vaccines during emapalumab therapy may be associated with a risk of disseminated infection due to enhanced replication of vaccine virus or bacteria in the presence of diminished immune competence. Emapalumab is a monoclonal antibody that binds to and neutralizes interferon gamma, which may increase susceptibility to certain pathogens and increase the risk of fatal and serious infections.", "source": "DDInter", "management_text": "The use of live or live attenuated vaccines should be avoided during and for at least 4 weeks after the last dose of emapalumab.", "mechanism_text": "Others", "recommendation": "The use of live or live attenuated vaccines should be avoided during and for at least 4 weeks after the last dose of emapalumab.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97903/", "reference_text": "[1] \"Product Information. Gamifant (emapalumab).\" Sobi Inc, Ardmore, PA.", "alternatives_a": "Apremilast, Pirfenidone, Belumosudil, Teprotumumab, Ravulizumab, Pegcetacoplan, Eculizumab, Sutimlimab", "alternatives_b": "", "updated_at": 1767369485}, {"id": 97800, "ingredient1": "Aminophylline", "ingredient2": "Emapalumab", "severity": "Moderate", "effect": "Plasma concentrations of drugs that are CYP450 substrates may decrease following the initiation of interleukin (IL) inhibitors, tumor necrosis factor (TNF) blockers, or interferon (IFN) inhibitors in patients with chronic inflammatory diseases. Because the formation of hepatic CYP450 enzymes is down-regulated during infection and chronic inflammation by increased levels of certain cytokines (e.g., interleukins-1, -6, and -10; tumor necrosis factor alpha; interferons), treatment targeting these cytokines may restore or normalize CYP450 enzyme levels resulting in increased metabolism of these drugs.", "source": "DDInter", "management_text": "Caution is advised when treatments targeting cytokines such as interleukins, tumor necrosis factors, or interferons are prescribed to patients receiving concomitant drugs that are CYP450 substrates, particularly those with narrow therapeutic ranges (e.g., antiarrhythmics, anticonvulsants, immunosuppressants, theophylline) or sensitive substrates where decreases in plasma levels may be significant or undesirable (e.g., oral contraceptives, statins, benzodiazepines, opioids). Clinical and/or laboratory monitoring should be considered following the initiation or withdrawal of such treatments, and the dosage(s) of the CYP450 substrate(s) adjusted accordingly. The effects of IL inhibitors, TNF blockers, and IFN inhibitors on CYP450 activities may persist for several weeks after stopping therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when treatments targeting cytokines such as interleukins, tumor necrosis factors, or interferons are prescribed to patients receiving concomitant drugs that are CYP450 substrates, particularly those with narrow therapeutic ranges (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97904/", "reference_text": "[1] \"Product Information. Skyrizi (risankizumab).\" AbbVie US LLC, North Chicago, IL.[2] \"Product Information. Cosentyx (secukinumab).\" Novartis Pharmaceuticals, East Hanover, NJ.[3] \"Product Information. Ilaris (canakinumab).\" Novartis Pharmaceuticals, East Hanover, NJ.[4] \"Product Information. Gamifant (emapalumab).\" Sobi Inc, Ardmore, PA.[5] \"Product Information. Kevzara (sarilumab).\" sanofi-aventis, Bridgewater, NJ.[6] \"Product Information. Simponi (golimumab).\" Centocor Inc, Malvern, PA.[7] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[8] \"Product Information. Sylvant (siltuximab).\" Janssen Biotech, Inc., Horsham, PA, PA.[9] \"Product Information. Stelara (ustekinumab).\" Centocor Inc, Malvern, PA.[10] \"Product Information. Ilumya (tildrakizumab).\" Merck & Company Inc, Whitehouse Station, NJ.[11] \"Product Information. Actemra (tocilizumab).\" Genentech, South San Francisco, CA.[12] \"Product Information. Amevive (alefacept).\" Biogen, Cambridge, MA.[13] \"Product Information. Remicade (infliximab).\" Centocor Inc, Malvern, PA.[14] \"Product Information. Taltz Autoinjector (ixekizumab).\" Eli Lilly and Company, Indianapolis, IN.[15] \"Product Information. Arcalyst (rilonacept).\" Regeneron Pharmaceuticals Inc, Tarrytown, NY.[16] Ace LN, Jaffe JM, Kunka RL \"Effect of food and an antacid on quinidine bioavailability.\" Biopharm Drug Dispos 4 (1983): 183-90[17] Min DI, Ku YM, Geraets DR, Lee HC \"Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers.\" J Clin Pharmacol 36 (1996): 469-76[18] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[19] Ha HR, Chen J, Leuenberger PM, Freiburghaus AU, Follah F \"In vitro inhibition of midazolam and quinidine metabolism by flavonoids.\" Eur J Clin Pharmacol 48 (1995): 367-71", "alternatives_a": "Omalizumab, Tezepelumab, Mercaptopurine, Benralizumab, Caffeine, Reslizumab, Montelukast, Dyphylline, Mepolizumab, Roflumilast, Pentoxifylline, More", "alternatives_b": "Cyclosporine, Antithymocyte immunoglobulin (rabbit), Anifrolumab, Ravulizumab, Diroximel fumarate, Methotrexate, Tacrolimus, Abatacept, Upadacitinib, Siponimod, Apremilast, More", "updated_at": 1767369485}, {"id": 97801, "ingredient1": "Emapalumab", "ingredient2": "Bacillus calmette-guerin substrain tice live antigen", "severity": "Major", "effect": "The administration of live or live attenuated vaccines during emapalumab therapy may be associated with a risk of disseminated infection due to enhanced replication of vaccine virus or bacteria in the presence of diminished immune competence. Emapalumab is a monoclonal antibody that binds to and neutralizes interferon gamma, which may increase susceptibility to certain pathogens and increase the risk of fatal and serious infections.", "source": "DDInter", "management_text": "The use of live or live attenuated vaccines should be avoided during and for at least 4 weeks after the last dose of emapalumab.", "mechanism_text": "Others", "recommendation": "The use of live or live attenuated vaccines should be avoided during and for at least 4 weeks after the last dose of emapalumab.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97905/", "reference_text": "[1] \"Product Information. Gamifant (emapalumab).\" Sobi Inc, Ardmore, PA.", "alternatives_a": "Apremilast, Pirfenidone, Belumosudil, Teprotumumab, Ravulizumab, Pegcetacoplan, Eculizumab, Sutimlimab", "alternatives_b": "", "updated_at": 1767369485}, {"id": 97802, "ingredient1": "Emapalumab", "ingredient2": "Bifidobacterium longum infantis", "severity": "Moderate", "effect": "Probiotic use during immunosuppressant or intense antineoplastic therapy may theoretically increase the risk of infections from the live microorganisms contained in probiotic products. Patients may be immunosuppressed if they have recently received or are receiving alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, or long-term topical or inhaled corticosteroids.", "source": "DDInter", "management_text": "Caution is advised when probiotics are used during immunosuppressant or intense antineoplastic therapy. It may be advisable to avoid using probiotics, particularly products containing saccharomyces boulardii, in patients who are significantly immunosuppressed.", "mechanism_text": "Others", "recommendation": "Caution is advised when probiotics are used during immunosuppressant or intense antineoplastic therapy.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97906/", "reference_text": "[1] Borriello SP, Hammes WP, Holzapfel W, et.al \"Safety of probiotics that contain lactobacilli or bifidobacteria.\" Clin Infect Dis 36 (2003): 775-80[2] Salminen MK, Tynkkynen S, Rautelin H, et al. \"Lactobacillus bacteremia during a rapid increase in probiotic use of Lactobacillus rhamnosus GG in Finland.\" Clin Infect Dis 35 (2002): 1155-60[3] Schlegel L, Lemerle S, Geslin P \"Lactobacillus species as opportunistic pathogens in immunocompromised patients.\" Eur J Clin Microbiol Infect Dis 17 (1998): 887-8[4] Salminen MK, Rautelin H, Tynkkynen S, et al. \"Lactobacillus bacteremia, clinical significance, and patient outcome, with special focus on probiotic L. rhamnosus GG.\" Clin Infect Dis 38 (2004): 62-9[5] Husni RN, Gordon SM, Washington JA, Longworth DL \"Lactobacillus bacteremia and endocarditis: review of 45 cases.\" Clin Infect Dis 25 (1997): 1048-55[6] Boyle RJ, Robins-Browne RM, Tang ML \"Probiotic use in clinical practice: what are the risks?\" Am J Clin Nutr 83 (2006): 1256-64[7] Lolis N, Veldekis D, Moraitou H, et.al \"Saccharomyces boulardii fungaemia in an intensive care unit patient treated with caspofungin.\" Crit Care 12 (2008): epub[8] Rautio M, Jousimies-Somer H, Kauma H, et al. \"Liver abscess due to a Lactobacillus rhamnosus strain indistinguishable from L. rhamnosus strain GG.\" Clin Infect Dis 28 (1999): 1159-60[9] Saxelin M, Chuang NH, Chassy B, et.al \"Lactobacilli and bacteremia in southern Finland, 1989-1992\" Clin Infect Dis 22 (1996): 564-6[10] Oggioni MR, Pozzi G, Valensin PE, Galieni P, Bigazzi C \"Recurrent septicemia in an immunocompromised patient due to probiotic strains of Bacillus subtilis.\" J Clin Microbiol 36 (1998): 325-6[11] Mackay AD, Taylor MB, Kibbler CC, Hamilton-Miller JM \"Lactobacillus endocarditis caused by a probiotic organism.\" Clin Microbiol Infect 5 (1999): 290-2", "alternatives_a": "Apremilast, Pirfenidone, Belumosudil, Teprotumumab, Ravulizumab, Pegcetacoplan, Eculizumab, Sutimlimab", "alternatives_b": "", "updated_at": 1767369485}, {"id": 97803, "ingredient1": "Emapalumab", "ingredient2": "Dicoumarol", "severity": "Moderate", "effect": "Plasma concentrations of drugs that are CYP450 substrates may decrease following the initiation of interleukin (IL) inhibitors, tumor necrosis factor (TNF) blockers, or interferon (IFN) inhibitors in patients with chronic inflammatory diseases. Because the formation of hepatic CYP450 enzymes is down-regulated during infection and chronic inflammation by increased levels of certain cytokines (e.g., interleukins-1, -6, and -10; tumor necrosis factor alpha; interferons), treatment targeting these cytokines may restore or normalize CYP450 enzyme levels resulting in increased metabolism of these drugs.", "source": "DDInter", "management_text": "Caution is advised when treatments targeting cytokines such as interleukins, tumor necrosis factors, or interferons are prescribed to patients receiving concomitant drugs that are CYP450 substrates, particularly those with narrow therapeutic ranges (e.g., antiarrhythmics, anticonvulsants, immunosuppressants, theophylline) or sensitive substrates where decreases in plasma levels may be significant or undesirable (e.g., oral contraceptives, statins, benzodiazepines, opioids). Clinical and/or laboratory monitoring should be considered following the initiation or withdrawal of such treatments, and the dosage(s) of the CYP450 substrate(s) adjusted accordingly. The effects of IL inhibitors, TNF blockers, and IFN inhibitors on CYP450 activities may persist for several weeks after stopping therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when treatments targeting cytokines such as interleukins, tumor necrosis factors, or interferons are prescribed to patients receiving concomitant drugs that are CYP450 substrates, particularly those with narrow therapeutic ranges (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97907/", "reference_text": "[1] \"Product Information. Skyrizi (risankizumab).\" AbbVie US LLC, North Chicago, IL.[2] \"Product Information. Cosentyx (secukinumab).\" Novartis Pharmaceuticals, East Hanover, NJ.[3] \"Product Information. Ilaris (canakinumab).\" Novartis Pharmaceuticals, East Hanover, NJ.[4] \"Product Information. Gamifant (emapalumab).\" Sobi Inc, Ardmore, PA.[5] \"Product Information. Kevzara (sarilumab).\" sanofi-aventis, Bridgewater, NJ.[6] \"Product Information. Simponi (golimumab).\" Centocor Inc, Malvern, PA.[7] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[8] \"Product Information. Sylvant (siltuximab).\" Janssen Biotech, Inc., Horsham, PA, PA.[9] \"Product Information. Stelara (ustekinumab).\" Centocor Inc, Malvern, PA.[10] \"Product Information. Ilumya (tildrakizumab).\" Merck & Company Inc, Whitehouse Station, NJ.[11] \"Product Information. Actemra (tocilizumab).\" Genentech, South San Francisco, CA.[12] \"Product Information. Amevive (alefacept).\" Biogen, Cambridge, MA.[13] \"Product Information. Remicade (infliximab).\" Centocor Inc, Malvern, PA.[14] \"Product Information. Taltz Autoinjector (ixekizumab).\" Eli Lilly and Company, Indianapolis, IN.[15] \"Product Information. Arcalyst (rilonacept).\" Regeneron Pharmaceuticals Inc, Tarrytown, NY.[16] Ace LN, Jaffe JM, Kunka RL \"Effect of food and an antacid on quinidine bioavailability.\" Biopharm Drug Dispos 4 (1983): 183-90[17] Min DI, Ku YM, Geraets DR, Lee HC \"Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers.\" J Clin Pharmacol 36 (1996): 469-76[18] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[19] Ha HR, Chen J, Leuenberger PM, Freiburghaus AU, Follah F \"In vitro inhibition of midazolam and quinidine metabolism by flavonoids.\" Eur J Clin Pharmacol 48 (1995): 367-71", "alternatives_a": "Ticagrelor, Betrixaban, Clopidogrel, Cilostazol, Iloprost, Lepirudin, Acenocoumarol, Urokinase, Cangrelor, Dipyridamole, Caplacizumab, More", "alternatives_b": "Antithymocyte immunoglobulin (rabbit), Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Methotrexate, Tacrolimus, Abatacept, Upadacitinib, Siponimod, Apremilast, More", "updated_at": 1767369485}, {"id": 97804, "ingredient1": "Ethosuximide", "ingredient2": "Emapalumab", "severity": "Moderate", "effect": "Plasma concentrations of drugs that are CYP450 substrates may decrease following the initiation of interleukin (IL) inhibitors, tumor necrosis factor (TNF) blockers, or interferon (IFN) inhibitors in patients with chronic inflammatory diseases. Because the formation of hepatic CYP450 enzymes is down-regulated during infection and chronic inflammation by increased levels of certain cytokines (e.g., interleukins-1, -6, and -10; tumor necrosis factor alpha; interferons), treatment targeting these cytokines may restore or normalize CYP450 enzyme levels resulting in increased metabolism of these drugs.", "source": "DDInter", "management_text": "Caution is advised when treatments targeting cytokines such as interleukins, tumor necrosis factors, or interferons are prescribed to patients receiving concomitant drugs that are CYP450 substrates, particularly those with narrow therapeutic ranges (e.g., antiarrhythmics, anticonvulsants, immunosuppressants, theophylline) or sensitive substrates where decreases in plasma levels may be significant or undesirable (e.g., oral contraceptives, statins, benzodiazepines, opioids). Clinical and/or laboratory monitoring should be considered following the initiation or withdrawal of such treatments, and the dosage(s) of the CYP450 substrate(s) adjusted accordingly. The effects of IL inhibitors, TNF blockers, and IFN inhibitors on CYP450 activities may persist for several weeks after stopping therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when treatments targeting cytokines such as interleukins, tumor necrosis factors, or interferons are prescribed to patients receiving concomitant drugs that are CYP450 substrates, particularly those with narrow therapeutic ranges (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97908/", "reference_text": "[1] \"Product Information. Skyrizi (risankizumab).\" AbbVie US LLC, North Chicago, IL.[2] \"Product Information. Cosentyx (secukinumab).\" Novartis Pharmaceuticals, East Hanover, NJ.[3] \"Product Information. Ilaris (canakinumab).\" Novartis Pharmaceuticals, East Hanover, NJ.[4] \"Product Information. Gamifant (emapalumab).\" Sobi Inc, Ardmore, PA.[5] \"Product Information. Kevzara (sarilumab).\" sanofi-aventis, Bridgewater, NJ.[6] \"Product Information. Simponi (golimumab).\" Centocor Inc, Malvern, PA.[7] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[8] \"Product Information. Sylvant (siltuximab).\" Janssen Biotech, Inc., Horsham, PA, PA.[9] \"Product Information. Stelara (ustekinumab).\" Centocor Inc, Malvern, PA.[10] \"Product Information. Ilumya (tildrakizumab).\" Merck & Company Inc, Whitehouse Station, NJ.[11] \"Product Information. Actemra (tocilizumab).\" Genentech, South San Francisco, CA.[12] \"Product Information. Amevive (alefacept).\" Biogen, Cambridge, MA.[13] \"Product Information. Remicade (infliximab).\" Centocor Inc, Malvern, PA.[14] \"Product Information. Taltz Autoinjector (ixekizumab).\" Eli Lilly and Company, Indianapolis, IN.[15] \"Product Information. Arcalyst (rilonacept).\" Regeneron Pharmaceuticals Inc, Tarrytown, NY.[16] Ace LN, Jaffe JM, Kunka RL \"Effect of food and an antacid on quinidine bioavailability.\" Biopharm Drug Dispos 4 (1983): 183-90[17] Min DI, Ku YM, Geraets DR, Lee HC \"Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers.\" J Clin Pharmacol 36 (1996): 469-76[18] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[19] Ha HR, Chen J, Leuenberger PM, Freiburghaus AU, Follah F \"In vitro inhibition of midazolam and quinidine metabolism by flavonoids.\" Eur J Clin Pharmacol 48 (1995): 367-71", "alternatives_a": "Brivaracetam, Topiramate, Ezogabine, Cenobamate, Lamotrigine, Lacosamide, Levetiracetam, Tiagabine, Oxcarbazepine, Ethotoin, Rufinamide, More", "alternatives_b": "Cyclosporine, Antithymocyte immunoglobulin (rabbit), Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Methotrexate, Abatacept, Upadacitinib, Siponimod, Apremilast, More", "updated_at": 1767369485}, {"id": 97805, "ingredient1": "Etonogestrel", "ingredient2": "Emapalumab", "severity": "Moderate", "effect": "Plasma concentrations of drugs that are CYP450 substrates may decrease following the initiation of interleukin (IL) inhibitors, tumor necrosis factor (TNF) blockers, or interferon (IFN) inhibitors in patients with chronic inflammatory diseases. Because the formation of hepatic CYP450 enzymes is down-regulated during infection and chronic inflammation by increased levels of certain cytokines (e.g., interleukins-1, -6, and -10; tumor necrosis factor alpha; interferons), treatment targeting these cytokines may restore or normalize CYP450 enzyme levels resulting in increased metabolism of these drugs.", "source": "DDInter", "management_text": "Caution is advised when treatments targeting cytokines such as interleukins, tumor necrosis factors, or interferons are prescribed to patients receiving concomitant drugs that are CYP450 substrates, particularly those with narrow therapeutic ranges (e.g., antiarrhythmics, anticonvulsants, immunosuppressants, theophylline) or sensitive substrates where decreases in plasma levels may be significant or undesirable (e.g., oral contraceptives, statins, benzodiazepines, opioids). Clinical and/or laboratory monitoring should be considered following the initiation or withdrawal of such treatments, and the dosage(s) of the CYP450 substrate(s) adjusted accordingly. The effects of IL inhibitors, TNF blockers, and IFN inhibitors on CYP450 activities may persist for several weeks after stopping therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when treatments targeting cytokines such as interleukins, tumor necrosis factors, or interferons are prescribed to patients receiving concomitant drugs that are CYP450 substrates, particularly those with narrow therapeutic ranges (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97909/", "reference_text": "[1] \"Product Information. Skyrizi (risankizumab).\" AbbVie US LLC, North Chicago, IL.[2] \"Product Information. Cosentyx (secukinumab).\" Novartis Pharmaceuticals, East Hanover, NJ.[3] \"Product Information. Ilaris (canakinumab).\" Novartis Pharmaceuticals, East Hanover, NJ.[4] \"Product Information. Gamifant (emapalumab).\" Sobi Inc, Ardmore, PA.[5] \"Product Information. Kevzara (sarilumab).\" sanofi-aventis, Bridgewater, NJ.[6] \"Product Information. Simponi (golimumab).\" Centocor Inc, Malvern, PA.[7] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[8] \"Product Information. Sylvant (siltuximab).\" Janssen Biotech, Inc., Horsham, PA, PA.[9] \"Product Information. Stelara (ustekinumab).\" Centocor Inc, Malvern, PA.[10] \"Product Information. Ilumya (tildrakizumab).\" Merck & Company Inc, Whitehouse Station, NJ.[11] \"Product Information. Actemra (tocilizumab).\" Genentech, South San Francisco, CA.[12] \"Product Information. Amevive (alefacept).\" Biogen, Cambridge, MA.[13] \"Product Information. Remicade (infliximab).\" Centocor Inc, Malvern, PA.[14] \"Product Information. Taltz Autoinjector (ixekizumab).\" Eli Lilly and Company, Indianapolis, IN.[15] \"Product Information. Arcalyst (rilonacept).\" Regeneron Pharmaceuticals Inc, Tarrytown, NY.[16] Ace LN, Jaffe JM, Kunka RL \"Effect of food and an antacid on quinidine bioavailability.\" Biopharm Drug Dispos 4 (1983): 183-90[17] Min DI, Ku YM, Geraets DR, Lee HC \"Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers.\" J Clin Pharmacol 36 (1996): 469-76[18] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[19] Ha HR, Chen J, Leuenberger PM, Freiburghaus AU, Follah F \"In vitro inhibition of midazolam and quinidine metabolism by flavonoids.\" Eur J Clin Pharmacol 48 (1995): 367-71", "alternatives_a": "Megestrol acetate, Estetrol, Ulipristal, Estradiol", "alternatives_b": "Antithymocyte immunoglobulin (rabbit), Anifrolumab, Ravulizumab, Diroximel fumarate, Methotrexate, Abatacept, Upadacitinib, Siponimod, Apremilast, Inebilizumab, Belumosudil, More", "updated_at": 1767369485}, {"id": 97806, "ingredient1": "Felodipine", "ingredient2": "Emapalumab", "severity": "Moderate", "effect": "Plasma concentrations of drugs that are CYP450 substrates may decrease following the initiation of interleukin (IL) inhibitors, tumor necrosis factor (TNF) blockers, or interferon (IFN) inhibitors in patients with chronic inflammatory diseases. Because the formation of hepatic CYP450 enzymes is down-regulated during infection and chronic inflammation by increased levels of certain cytokines (e.g., interleukins-1, -6, and -10; tumor necrosis factor alpha; interferons), treatment targeting these cytokines may restore or normalize CYP450 enzyme levels resulting in increased metabolism of these drugs.", "source": "DDInter", "management_text": "Caution is advised when treatments targeting cytokines such as interleukins, tumor necrosis factors, or interferons are prescribed to patients receiving concomitant drugs that are CYP450 substrates, particularly those with narrow therapeutic ranges (e.g., antiarrhythmics, anticonvulsants, immunosuppressants, theophylline) or sensitive substrates where decreases in plasma levels may be significant or undesirable (e.g., oral contraceptives, statins, benzodiazepines, opioids). Clinical and/or laboratory monitoring should be considered following the initiation or withdrawal of such treatments, and the dosage(s) of the CYP450 substrate(s) adjusted accordingly. The effects of IL inhibitors, TNF blockers, and IFN inhibitors on CYP450 activities may persist for several weeks after stopping therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when treatments targeting cytokines such as interleukins, tumor necrosis factors, or interferons are prescribed to patients receiving concomitant drugs that are CYP450 substrates, particularly those with narrow therapeutic ranges (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97910/", "reference_text": "[1] \"Product Information. Skyrizi (risankizumab).\" AbbVie US LLC, North Chicago, IL.[2] \"Product Information. Cosentyx (secukinumab).\" Novartis Pharmaceuticals, East Hanover, NJ.[3] \"Product Information. Ilaris (canakinumab).\" Novartis Pharmaceuticals, East Hanover, NJ.[4] \"Product Information. Gamifant (emapalumab).\" Sobi Inc, Ardmore, PA.[5] \"Product Information. Kevzara (sarilumab).\" sanofi-aventis, Bridgewater, NJ.[6] \"Product Information. Simponi (golimumab).\" Centocor Inc, Malvern, PA.[7] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[8] \"Product Information. Sylvant (siltuximab).\" Janssen Biotech, Inc., Horsham, PA, PA.[9] \"Product Information. Stelara (ustekinumab).\" Centocor Inc, Malvern, PA.[10] \"Product Information. Ilumya (tildrakizumab).\" Merck & Company Inc, Whitehouse Station, NJ.[11] \"Product Information. Actemra (tocilizumab).\" Genentech, South San Francisco, CA.[12] \"Product Information. Amevive (alefacept).\" Biogen, Cambridge, MA.[13] \"Product Information. Remicade (infliximab).\" Centocor Inc, Malvern, PA.[14] \"Product Information. Taltz Autoinjector (ixekizumab).\" Eli Lilly and Company, Indianapolis, IN.[15] \"Product Information. Arcalyst (rilonacept).\" Regeneron Pharmaceuticals Inc, Tarrytown, NY.[16] Ace LN, Jaffe JM, Kunka RL \"Effect of food and an antacid on quinidine bioavailability.\" Biopharm Drug Dispos 4 (1983): 183-90[17] Min DI, Ku YM, Geraets DR, Lee HC \"Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers.\" J Clin Pharmacol 36 (1996): 469-76[18] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[19] Ha HR, Chen J, Leuenberger PM, Freiburghaus AU, Follah F \"In vitro inhibition of midazolam and quinidine metabolism by flavonoids.\" Eur J Clin Pharmacol 48 (1995): 367-71", "alternatives_a": "Propranolol, Metoprolol, Carvedilol, Nebivolol, Bisoprolol, Ivabradine, Sotalol, Acetylsalicylic acid, Atenolol, Clevidipine, Mibefradil, More", "alternatives_b": "Antithymocyte immunoglobulin (rabbit), Anifrolumab, Ravulizumab, Diroximel fumarate, Abatacept, Upadacitinib, Apremilast, Inebilizumab, Cladribine, Belumosudil, Belimumab, More", "updated_at": 1767369485}, {"id": 97807, "ingredient1": "Flecainide", "ingredient2": "Emapalumab", "severity": "Moderate", "effect": "Plasma concentrations of drugs that are CYP450 substrates may decrease following the initiation of interleukin (IL) inhibitors, tumor necrosis factor (TNF) blockers, or interferon (IFN) inhibitors in patients with chronic inflammatory diseases. Because the formation of hepatic CYP450 enzymes is down-regulated during infection and chronic inflammation by increased levels of certain cytokines (e.g., interleukins-1, -6, and -10; tumor necrosis factor alpha; interferons), treatment targeting these cytokines may restore or normalize CYP450 enzyme levels resulting in increased metabolism of these drugs.", "source": "DDInter", "management_text": "Caution is advised when treatments targeting cytokines such as interleukins, tumor necrosis factors, or interferons are prescribed to patients receiving concomitant drugs that are CYP450 substrates, particularly those with narrow therapeutic ranges (e.g., antiarrhythmics, anticonvulsants, immunosuppressants, theophylline) or sensitive substrates where decreases in plasma levels may be significant or undesirable (e.g., oral contraceptives, statins, benzodiazepines, opioids). Clinical and/or laboratory monitoring should be considered following the initiation or withdrawal of such treatments, and the dosage(s) of the CYP450 substrate(s) adjusted accordingly. The effects of IL inhibitors, TNF blockers, and IFN inhibitors on CYP450 activities may persist for several weeks after stopping therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when treatments targeting cytokines such as interleukins, tumor necrosis factors, or interferons are prescribed to patients receiving concomitant drugs that are CYP450 substrates, particularly those with narrow therapeutic ranges (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97911/", "reference_text": "[1] \"Product Information. Skyrizi (risankizumab).\" AbbVie US LLC, North Chicago, IL.[2] \"Product Information. Cosentyx (secukinumab).\" Novartis Pharmaceuticals, East Hanover, NJ.[3] \"Product Information. Ilaris (canakinumab).\" Novartis Pharmaceuticals, East Hanover, NJ.[4] \"Product Information. Gamifant (emapalumab).\" Sobi Inc, Ardmore, PA.[5] \"Product Information. Kevzara (sarilumab).\" sanofi-aventis, Bridgewater, NJ.[6] \"Product Information. Simponi (golimumab).\" Centocor Inc, Malvern, PA.[7] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[8] \"Product Information. Sylvant (siltuximab).\" Janssen Biotech, Inc., Horsham, PA, PA.[9] \"Product Information. Stelara (ustekinumab).\" Centocor Inc, Malvern, PA.[10] \"Product Information. Ilumya (tildrakizumab).\" Merck & Company Inc, Whitehouse Station, NJ.[11] \"Product Information. Actemra (tocilizumab).\" Genentech, South San Francisco, CA.[12] \"Product Information. Amevive (alefacept).\" Biogen, Cambridge, MA.[13] \"Product Information. Remicade (infliximab).\" Centocor Inc, Malvern, PA.[14] \"Product Information. Taltz Autoinjector (ixekizumab).\" Eli Lilly and Company, Indianapolis, IN.[15] \"Product Information. Arcalyst (rilonacept).\" Regeneron Pharmaceuticals Inc, Tarrytown, NY.[16] Ace LN, Jaffe JM, Kunka RL \"Effect of food and an antacid on quinidine bioavailability.\" Biopharm Drug Dispos 4 (1983): 183-90[17] Min DI, Ku YM, Geraets DR, Lee HC \"Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers.\" J Clin Pharmacol 36 (1996): 469-76[18] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[19] Ha HR, Chen J, Leuenberger PM, Freiburghaus AU, Follah F \"In vitro inhibition of midazolam and quinidine metabolism by flavonoids.\" Eur J Clin Pharmacol 48 (1995): 367-71", "alternatives_a": "Tocainide, Dronedarone, Dofetilide, Bretylium, Moricizine, Ibutilide", "alternatives_b": "Antithymocyte immunoglobulin (rabbit), Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Abatacept, Upadacitinib, Apremilast, Inebilizumab, Cladribine, Belumosudil, More", "updated_at": 1767369485}, {"id": 97808, "ingredient1": "Emapalumab", "ingredient2": "Lactobacillus acidophilus", "severity": "Moderate", "effect": "Probiotic use during immunosuppressant or intense antineoplastic therapy may theoretically increase the risk of infections from the live microorganisms contained in probiotic products. Patients may be immunosuppressed if they have recently received or are receiving alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, or long-term topical or inhaled corticosteroids.", "source": "DDInter", "management_text": "Caution is advised when probiotics are used during immunosuppressant or intense antineoplastic therapy. It may be advisable to avoid using probiotics, particularly products containing saccharomyces boulardii, in patients who are significantly immunosuppressed.", "mechanism_text": "Others", "recommendation": "Caution is advised when probiotics are used during immunosuppressant or intense antineoplastic therapy.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97912/", "reference_text": "[1] Borriello SP, Hammes WP, Holzapfel W, et.al \"Safety of probiotics that contain lactobacilli or bifidobacteria.\" Clin Infect Dis 36 (2003): 775-80[2] Salminen MK, Tynkkynen S, Rautelin H, et al. \"Lactobacillus bacteremia during a rapid increase in probiotic use of Lactobacillus rhamnosus GG in Finland.\" Clin Infect Dis 35 (2002): 1155-60[3] Schlegel L, Lemerle S, Geslin P \"Lactobacillus species as opportunistic pathogens in immunocompromised patients.\" Eur J Clin Microbiol Infect Dis 17 (1998): 887-8[4] Salminen MK, Rautelin H, Tynkkynen S, et al. \"Lactobacillus bacteremia, clinical significance, and patient outcome, with special focus on probiotic L. rhamnosus GG.\" Clin Infect Dis 38 (2004): 62-9[5] Husni RN, Gordon SM, Washington JA, Longworth DL \"Lactobacillus bacteremia and endocarditis: review of 45 cases.\" Clin Infect Dis 25 (1997): 1048-55[6] Boyle RJ, Robins-Browne RM, Tang ML \"Probiotic use in clinical practice: what are the risks?\" Am J Clin Nutr 83 (2006): 1256-64[7] Lolis N, Veldekis D, Moraitou H, et.al \"Saccharomyces boulardii fungaemia in an intensive care unit patient treated with caspofungin.\" Crit Care 12 (2008): epub[8] Rautio M, Jousimies-Somer H, Kauma H, et al. \"Liver abscess due to a Lactobacillus rhamnosus strain indistinguishable from L. rhamnosus strain GG.\" Clin Infect Dis 28 (1999): 1159-60[9] Saxelin M, Chuang NH, Chassy B, et.al \"Lactobacilli and bacteremia in southern Finland, 1989-1992\" Clin Infect Dis 22 (1996): 564-6[10] Oggioni MR, Pozzi G, Valensin PE, Galieni P, Bigazzi C \"Recurrent septicemia in an immunocompromised patient due to probiotic strains of Bacillus subtilis.\" J Clin Microbiol 36 (1998): 325-6[11] Mackay AD, Taylor MB, Kibbler CC, Hamilton-Miller JM \"Lactobacillus endocarditis caused by a probiotic organism.\" Clin Microbiol Infect 5 (1999): 290-2", "alternatives_a": "Apremilast, Pirfenidone, Belumosudil, Teprotumumab, Ravulizumab, Pegcetacoplan, Eculizumab, Sutimlimab", "alternatives_b": "", "updated_at": 1767369485}, {"id": 97809, "ingredient1": "Emapalumab", "ingredient2": "Levamlodipine", "severity": "Moderate", "effect": "Plasma concentrations of drugs that are CYP450 substrates may decrease following the initiation of interleukin (IL) inhibitors, tumor necrosis factor (TNF) blockers, or interferon (IFN) inhibitors in patients with chronic inflammatory diseases. Because the formation of hepatic CYP450 enzymes is down-regulated during infection and chronic inflammation by increased levels of certain cytokines (e.g., interleukins-1, -6, and -10; tumor necrosis factor alpha; interferons), treatment targeting these cytokines may restore or normalize CYP450 enzyme levels resulting in increased metabolism of these drugs.", "source": "DDInter", "management_text": "Caution is advised when treatments targeting cytokines such as interleukins, tumor necrosis factors, or interferons are prescribed to patients receiving concomitant drugs that are CYP450 substrates, particularly those with narrow therapeutic ranges (e.g., antiarrhythmics, anticonvulsants, immunosuppressants, theophylline) or sensitive substrates where decreases in plasma levels may be significant or undesirable (e.g., oral contraceptives, statins, benzodiazepines, opioids). Clinical and/or laboratory monitoring should be considered following the initiation or withdrawal of such treatments, and the dosage(s) of the CYP450 substrate(s) adjusted accordingly. The effects of IL inhibitors, TNF blockers, and IFN inhibitors on CYP450 activities may persist for several weeks after stopping therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when treatments targeting cytokines such as interleukins, tumor necrosis factors, or interferons are prescribed to patients receiving concomitant drugs that are CYP450 substrates, particularly those with narrow therapeutic ranges (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97913/", "reference_text": "[1] \"Product Information. Skyrizi (risankizumab).\" AbbVie US LLC, North Chicago, IL.[2] \"Product Information. Cosentyx (secukinumab).\" Novartis Pharmaceuticals, East Hanover, NJ.[3] \"Product Information. Ilaris (canakinumab).\" Novartis Pharmaceuticals, East Hanover, NJ.[4] \"Product Information. Gamifant (emapalumab).\" Sobi Inc, Ardmore, PA.[5] \"Product Information. Kevzara (sarilumab).\" sanofi-aventis, Bridgewater, NJ.[6] \"Product Information. Simponi (golimumab).\" Centocor Inc, Malvern, PA.[7] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[8] \"Product Information. Sylvant (siltuximab).\" Janssen Biotech, Inc., Horsham, PA, PA.[9] \"Product Information. Stelara (ustekinumab).\" Centocor Inc, Malvern, PA.[10] \"Product Information. Ilumya (tildrakizumab).\" Merck & Company Inc, Whitehouse Station, NJ.[11] \"Product Information. Actemra (tocilizumab).\" Genentech, South San Francisco, CA.[12] \"Product Information. Amevive (alefacept).\" Biogen, Cambridge, MA.[13] \"Product Information. Remicade (infliximab).\" Centocor Inc, Malvern, PA.[14] \"Product Information. Taltz Autoinjector (ixekizumab).\" Eli Lilly and Company, Indianapolis, IN.[15] \"Product Information. Arcalyst (rilonacept).\" Regeneron Pharmaceuticals Inc, Tarrytown, NY.[16] Ace LN, Jaffe JM, Kunka RL \"Effect of food and an antacid on quinidine bioavailability.\" Biopharm Drug Dispos 4 (1983): 183-90[17] Min DI, Ku YM, Geraets DR, Lee HC \"Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers.\" J Clin Pharmacol 36 (1996): 469-76[18] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[19] Ha HR, Chen J, Leuenberger PM, Freiburghaus AU, Follah F \"In vitro inhibition of midazolam and quinidine metabolism by flavonoids.\" Eur J Clin Pharmacol 48 (1995): 367-71", "alternatives_a": "Clevidipine, Mibefradil, Celecoxib", "alternatives_b": "Antithymocyte immunoglobulin (rabbit), Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Methotrexate, Abatacept, Upadacitinib, Apremilast, Inebilizumab, Cladribine, More", "updated_at": 1767369485}, {"id": 97810, "ingredient1": "Emapalumab", "ingredient2": "Levonorgestrel", "severity": "Moderate", "effect": "Plasma concentrations of drugs that are CYP450 substrates may decrease following the initiation of interleukin (IL) inhibitors, tumor necrosis factor (TNF) blockers, or interferon (IFN) inhibitors in patients with chronic inflammatory diseases. Because the formation of hepatic CYP450 enzymes is down-regulated during infection and chronic inflammation by increased levels of certain cytokines (e.g., interleukins-1, -6, and -10; tumor necrosis factor alpha; interferons), treatment targeting these cytokines may restore or normalize CYP450 enzyme levels resulting in increased metabolism of these drugs.", "source": "DDInter", "management_text": "Caution is advised when treatments targeting cytokines such as interleukins, tumor necrosis factors, or interferons are prescribed to patients receiving concomitant drugs that are CYP450 substrates, particularly those with narrow therapeutic ranges (e.g., antiarrhythmics, anticonvulsants, immunosuppressants, theophylline) or sensitive substrates where decreases in plasma levels may be significant or undesirable (e.g., oral contraceptives, statins, benzodiazepines, opioids). Clinical and/or laboratory monitoring should be considered following the initiation or withdrawal of such treatments, and the dosage(s) of the CYP450 substrate(s) adjusted accordingly. The effects of IL inhibitors, TNF blockers, and IFN inhibitors on CYP450 activities may persist for several weeks after stopping therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when treatments targeting cytokines such as interleukins, tumor necrosis factors, or interferons are prescribed to patients receiving concomitant drugs that are CYP450 substrates, particularly those with narrow therapeutic ranges (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97914/", "reference_text": "[1] \"Product Information. Skyrizi (risankizumab).\" AbbVie US LLC, North Chicago, IL.[2] \"Product Information. Cosentyx (secukinumab).\" Novartis Pharmaceuticals, East Hanover, NJ.[3] \"Product Information. Ilaris (canakinumab).\" Novartis Pharmaceuticals, East Hanover, NJ.[4] \"Product Information. Gamifant (emapalumab).\" Sobi Inc, Ardmore, PA.[5] \"Product Information. Kevzara (sarilumab).\" sanofi-aventis, Bridgewater, NJ.[6] \"Product Information. Simponi (golimumab).\" Centocor Inc, Malvern, PA.[7] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[8] \"Product Information. Sylvant (siltuximab).\" Janssen Biotech, Inc., Horsham, PA, PA.[9] \"Product Information. Stelara (ustekinumab).\" Centocor Inc, Malvern, PA.[10] \"Product Information. Ilumya (tildrakizumab).\" Merck & Company Inc, Whitehouse Station, NJ.[11] \"Product Information. Actemra (tocilizumab).\" Genentech, South San Francisco, CA.[12] \"Product Information. Amevive (alefacept).\" Biogen, Cambridge, MA.[13] \"Product Information. Remicade (infliximab).\" Centocor Inc, Malvern, PA.[14] \"Product Information. Taltz Autoinjector (ixekizumab).\" Eli Lilly and Company, Indianapolis, IN.[15] \"Product Information. Arcalyst (rilonacept).\" Regeneron Pharmaceuticals Inc, Tarrytown, NY.[16] Ace LN, Jaffe JM, Kunka RL \"Effect of food and an antacid on quinidine bioavailability.\" Biopharm Drug Dispos 4 (1983): 183-90[17] Min DI, Ku YM, Geraets DR, Lee HC \"Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers.\" J Clin Pharmacol 36 (1996): 469-76[18] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[19] Ha HR, Chen J, Leuenberger PM, Freiburghaus AU, Follah F \"In vitro inhibition of midazolam and quinidine metabolism by flavonoids.\" Eur J Clin Pharmacol 48 (1995): 367-71", "alternatives_a": "Megestrol acetate, Estetrol, Ulipristal, Estradiol, Megestrol acetate, Progesterone, Estradiol", "alternatives_b": "Antithymocyte immunoglobulin (rabbit), Anifrolumab, Ravulizumab, Diroximel fumarate, Abatacept, Upadacitinib, Siponimod, Apremilast, Inebilizumab, Belumosudil, Ozanimod, More", "updated_at": 1767369485}, {"id": 97811, "ingredient1": "Emapalumab", "ingredient2": "Lovastatin", "severity": "Moderate", "effect": "Plasma concentrations of drugs that are CYP450 substrates may decrease following the initiation of interleukin (IL) inhibitors, tumor necrosis factor (TNF) blockers, or interferon (IFN) inhibitors in patients with chronic inflammatory diseases. Because the formation of hepatic CYP450 enzymes is down-regulated during infection and chronic inflammation by increased levels of certain cytokines (e.g., interleukins-1, -6, and -10; tumor necrosis factor alpha; interferons), treatment targeting these cytokines may restore or normalize CYP450 enzyme levels resulting in increased metabolism of these drugs.", "source": "DDInter", "management_text": "Caution is advised when treatments targeting cytokines such as interleukins, tumor necrosis factors, or interferons are prescribed to patients receiving concomitant drugs that are CYP450 substrates, particularly those with narrow therapeutic ranges (e.g., antiarrhythmics, anticonvulsants, immunosuppressants, theophylline) or sensitive substrates where decreases in plasma levels may be significant or undesirable (e.g., oral contraceptives, statins, benzodiazepines, opioids). Clinical and/or laboratory monitoring should be considered following the initiation or withdrawal of such treatments, and the dosage(s) of the CYP450 substrate(s) adjusted accordingly. The effects of IL inhibitors, TNF blockers, and IFN inhibitors on CYP450 activities may persist for several weeks after stopping therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when treatments targeting cytokines such as interleukins, tumor necrosis factors, or interferons are prescribed to patients receiving concomitant drugs that are CYP450 substrates, particularly those with narrow therapeutic ranges (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97915/", "reference_text": "[1] \"Product Information. Skyrizi (risankizumab).\" AbbVie US LLC, North Chicago, IL.[2] \"Product Information. Cosentyx (secukinumab).\" Novartis Pharmaceuticals, East Hanover, NJ.[3] \"Product Information. Ilaris (canakinumab).\" Novartis Pharmaceuticals, East Hanover, NJ.[4] \"Product Information. Gamifant (emapalumab).\" Sobi Inc, Ardmore, PA.[5] \"Product Information. Kevzara (sarilumab).\" sanofi-aventis, Bridgewater, NJ.[6] \"Product Information. Simponi (golimumab).\" Centocor Inc, Malvern, PA.[7] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[8] \"Product Information. Sylvant (siltuximab).\" Janssen Biotech, Inc., Horsham, PA, PA.[9] \"Product Information. Stelara (ustekinumab).\" Centocor Inc, Malvern, PA.[10] \"Product Information. Ilumya (tildrakizumab).\" Merck & Company Inc, Whitehouse Station, NJ.[11] \"Product Information. Actemra (tocilizumab).\" Genentech, South San Francisco, CA.[12] \"Product Information. Amevive (alefacept).\" Biogen, Cambridge, MA.[13] \"Product Information. Remicade (infliximab).\" Centocor Inc, Malvern, PA.[14] \"Product Information. Taltz Autoinjector (ixekizumab).\" Eli Lilly and Company, Indianapolis, IN.[15] \"Product Information. Arcalyst (rilonacept).\" Regeneron Pharmaceuticals Inc, Tarrytown, NY.[16] Ace LN, Jaffe JM, Kunka RL \"Effect of food and an antacid on quinidine bioavailability.\" Biopharm Drug Dispos 4 (1983): 183-90[17] Min DI, Ku YM, Geraets DR, Lee HC \"Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers.\" J Clin Pharmacol 36 (1996): 469-76[18] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[19] Ha HR, Chen J, Leuenberger PM, Freiburghaus AU, Follah F \"In vitro inhibition of midazolam and quinidine metabolism by flavonoids.\" Eur J Clin Pharmacol 48 (1995): 367-71", "alternatives_a": "Cholestyramine, Rosuvastatin, Fenofibrate, Mipomersen, Evinacumab, Dextrothyroxine, Probucol, Cerivastatin, Lomitapide, Ezetimibe, Niacin, More", "alternatives_b": "Antithymocyte immunoglobulin (rabbit), Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Abatacept, Upadacitinib, Siponimod, Apremilast, Inebilizumab, Cladribine, More", "updated_at": 1767369485}, {"id": 97812, "ingredient1": "Emapalumab", "ingredient2": "Measles virus vaccine live attenuated", "severity": "Major", "effect": "The administration of live or live attenuated vaccines during emapalumab therapy may be associated with a risk of disseminated infection due to enhanced replication of vaccine virus or bacteria in the presence of diminished immune competence. Emapalumab is a monoclonal antibody that binds to and neutralizes interferon gamma, which may increase susceptibility to certain pathogens and increase the risk of fatal and serious infections.", "source": "DDInter", "management_text": "The use of live or live attenuated vaccines should be avoided during and for at least 4 weeks after the last dose of emapalumab.", "mechanism_text": "Others", "recommendation": "The use of live or live attenuated vaccines should be avoided during and for at least 4 weeks after the last dose of emapalumab.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97916/", "reference_text": "[1] \"Product Information. Gamifant (emapalumab).\" Sobi Inc, Ardmore, PA.", "alternatives_a": "Apremilast, Pirfenidone, Belumosudil, Teprotumumab, Ravulizumab, Pegcetacoplan, Eculizumab, Sutimlimab", "alternatives_b": "", "updated_at": 1767369485}, {"id": 97813, "ingredient1": "Emapalumab", "ingredient2": "Medroxyprogesterone acetate", "severity": "Moderate", "effect": "Plasma concentrations of drugs that are CYP450 substrates may decrease following the initiation of interleukin (IL) inhibitors, tumor necrosis factor (TNF) blockers, or interferon (IFN) inhibitors in patients with chronic inflammatory diseases. Because the formation of hepatic CYP450 enzymes is down-regulated during infection and chronic inflammation by increased levels of certain cytokines (e.g., interleukins-1, -6, and -10; tumor necrosis factor alpha; interferons), treatment targeting these cytokines may restore or normalize CYP450 enzyme levels resulting in increased metabolism of these drugs.", "source": "DDInter", "management_text": "Caution is advised when treatments targeting cytokines such as interleukins, tumor necrosis factors, or interferons are prescribed to patients receiving concomitant drugs that are CYP450 substrates, particularly those with narrow therapeutic ranges (e.g., antiarrhythmics, anticonvulsants, immunosuppressants, theophylline) or sensitive substrates where decreases in plasma levels may be significant or undesirable (e.g., oral contraceptives, statins, benzodiazepines, opioids). Clinical and/or laboratory monitoring should be considered following the initiation or withdrawal of such treatments, and the dosage(s) of the CYP450 substrate(s) adjusted accordingly. The effects of IL inhibitors, TNF blockers, and IFN inhibitors on CYP450 activities may persist for several weeks after stopping therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when treatments targeting cytokines such as interleukins, tumor necrosis factors, or interferons are prescribed to patients receiving concomitant drugs that are CYP450 substrates, particularly those with narrow therapeutic ranges (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97917/", "reference_text": "[1] \"Product Information. Skyrizi (risankizumab).\" AbbVie US LLC, North Chicago, IL.[2] \"Product Information. Cosentyx (secukinumab).\" Novartis Pharmaceuticals, East Hanover, NJ.[3] \"Product Information. Ilaris (canakinumab).\" Novartis Pharmaceuticals, East Hanover, NJ.[4] \"Product Information. Gamifant (emapalumab).\" Sobi Inc, Ardmore, PA.[5] \"Product Information. Kevzara (sarilumab).\" sanofi-aventis, Bridgewater, NJ.[6] \"Product Information. Simponi (golimumab).\" Centocor Inc, Malvern, PA.[7] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[8] \"Product Information. Sylvant (siltuximab).\" Janssen Biotech, Inc., Horsham, PA, PA.[9] \"Product Information. Stelara (ustekinumab).\" Centocor Inc, Malvern, PA.[10] \"Product Information. Ilumya (tildrakizumab).\" Merck & Company Inc, Whitehouse Station, NJ.[11] \"Product Information. Actemra (tocilizumab).\" Genentech, South San Francisco, CA.[12] \"Product Information. Amevive (alefacept).\" Biogen, Cambridge, MA.[13] \"Product Information. Remicade (infliximab).\" Centocor Inc, Malvern, PA.[14] \"Product Information. Taltz Autoinjector (ixekizumab).\" Eli Lilly and Company, Indianapolis, IN.[15] \"Product Information. Arcalyst (rilonacept).\" Regeneron Pharmaceuticals Inc, Tarrytown, NY.[16] Ace LN, Jaffe JM, Kunka RL \"Effect of food and an antacid on quinidine bioavailability.\" Biopharm Drug Dispos 4 (1983): 183-90[17] Min DI, Ku YM, Geraets DR, Lee HC \"Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers.\" J Clin Pharmacol 36 (1996): 469-76[18] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[19] Ha HR, Chen J, Leuenberger PM, Freiburghaus AU, Follah F \"In vitro inhibition of midazolam and quinidine metabolism by flavonoids.\" Eur J Clin Pharmacol 48 (1995): 367-71", "alternatives_a": "Megestrol acetate, Estetrol, Ulipristal, Estradiol, Megestrol acetate, Progesterone, Megestrol acetate, Progesterone, Estradiol, Diethylstilbestrol, Histrelin, More", "alternatives_b": "Antithymocyte immunoglobulin (rabbit), Anifrolumab, Ravulizumab, Diroximel fumarate, Methotrexate, Abatacept, Upadacitinib, Siponimod, Apremilast, Inebilizumab, Belumosudil, More", "updated_at": 1767369485}, {"id": 97814, "ingredient1": "Emapalumab", "ingredient2": "Mephenytoin", "severity": "Moderate", "effect": "Plasma concentrations of drugs that are CYP450 substrates may decrease following the initiation of interleukin (IL) inhibitors, tumor necrosis factor (TNF) blockers, or interferon (IFN) inhibitors in patients with chronic inflammatory diseases. Because the formation of hepatic CYP450 enzymes is down-regulated during infection and chronic inflammation by increased levels of certain cytokines (e.g., interleukins-1, -6, and -10; tumor necrosis factor alpha; interferons), treatment targeting these cytokines may restore or normalize CYP450 enzyme levels resulting in increased metabolism of these drugs.", "source": "DDInter", "management_text": "Caution is advised when treatments targeting cytokines such as interleukins, tumor necrosis factors, or interferons are prescribed to patients receiving concomitant drugs that are CYP450 substrates, particularly those with narrow therapeutic ranges (e.g., antiarrhythmics, anticonvulsants, immunosuppressants, theophylline) or sensitive substrates where decreases in plasma levels may be significant or undesirable (e.g., oral contraceptives, statins, benzodiazepines, opioids). Clinical and/or laboratory monitoring should be considered following the initiation or withdrawal of such treatments, and the dosage(s) of the CYP450 substrate(s) adjusted accordingly. The effects of IL inhibitors, TNF blockers, and IFN inhibitors on CYP450 activities may persist for several weeks after stopping therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when treatments targeting cytokines such as interleukins, tumor necrosis factors, or interferons are prescribed to patients receiving concomitant drugs that are CYP450 substrates, particularly those with narrow therapeutic ranges (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97918/", "reference_text": "[1] \"Product Information. Skyrizi (risankizumab).\" AbbVie US LLC, North Chicago, IL.[2] \"Product Information. Cosentyx (secukinumab).\" Novartis Pharmaceuticals, East Hanover, NJ.[3] \"Product Information. Ilaris (canakinumab).\" Novartis Pharmaceuticals, East Hanover, NJ.[4] \"Product Information. Gamifant (emapalumab).\" Sobi Inc, Ardmore, PA.[5] \"Product Information. Kevzara (sarilumab).\" sanofi-aventis, Bridgewater, NJ.[6] \"Product Information. Simponi (golimumab).\" Centocor Inc, Malvern, PA.[7] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[8] \"Product Information. Sylvant (siltuximab).\" Janssen Biotech, Inc., Horsham, PA, PA.[9] \"Product Information. Stelara (ustekinumab).\" Centocor Inc, Malvern, PA.[10] \"Product Information. Ilumya (tildrakizumab).\" Merck & Company Inc, Whitehouse Station, NJ.[11] \"Product Information. Actemra (tocilizumab).\" Genentech, South San Francisco, CA.[12] \"Product Information. Amevive (alefacept).\" Biogen, Cambridge, MA.[13] \"Product Information. Remicade (infliximab).\" Centocor Inc, Malvern, PA.[14] \"Product Information. Taltz Autoinjector (ixekizumab).\" Eli Lilly and Company, Indianapolis, IN.[15] \"Product Information. Arcalyst (rilonacept).\" Regeneron Pharmaceuticals Inc, Tarrytown, NY.[16] Ace LN, Jaffe JM, Kunka RL \"Effect of food and an antacid on quinidine bioavailability.\" Biopharm Drug Dispos 4 (1983): 183-90[17] Min DI, Ku YM, Geraets DR, Lee HC \"Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers.\" J Clin Pharmacol 36 (1996): 469-76[18] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[19] Ha HR, Chen J, Leuenberger PM, Freiburghaus AU, Follah F \"In vitro inhibition of midazolam and quinidine metabolism by flavonoids.\" Eur J Clin Pharmacol 48 (1995): 367-71", "alternatives_a": "Brivaracetam, Topiramate, Ezogabine, Cenobamate, Lamotrigine, Lacosamide, Levetiracetam, Tiagabine, Oxcarbazepine, Ethotoin, Rufinamide, More", "alternatives_b": "Antithymocyte immunoglobulin (rabbit), Anifrolumab, Ravulizumab, Diroximel fumarate, Tacrolimus, Abatacept, Upadacitinib, Siponimod, Apremilast, Inebilizumab, Belumosudil, More", "updated_at": 1767369485}, {"id": 97815, "ingredient1": "Emapalumab", "ingredient2": "Methylphenobarbital", "severity": "Moderate", "effect": "Plasma concentrations of drugs that are CYP450 substrates may decrease following the initiation of interleukin (IL) inhibitors, tumor necrosis factor (TNF) blockers, or interferon (IFN) inhibitors in patients with chronic inflammatory diseases. Because the formation of hepatic CYP450 enzymes is down-regulated during infection and chronic inflammation by increased levels of certain cytokines (e.g., interleukins-1, -6, and -10; tumor necrosis factor alpha; interferons), treatment targeting these cytokines may restore or normalize CYP450 enzyme levels resulting in increased metabolism of these drugs.", "source": "DDInter", "management_text": "Caution is advised when treatments targeting cytokines such as interleukins, tumor necrosis factors, or interferons are prescribed to patients receiving concomitant drugs that are CYP450 substrates, particularly those with narrow therapeutic ranges (e.g., antiarrhythmics, anticonvulsants, immunosuppressants, theophylline) or sensitive substrates where decreases in plasma levels may be significant or undesirable (e.g., oral contraceptives, statins, benzodiazepines, opioids). Clinical and/or laboratory monitoring should be considered following the initiation or withdrawal of such treatments, and the dosage(s) of the CYP450 substrate(s) adjusted accordingly. The effects of IL inhibitors, TNF blockers, and IFN inhibitors on CYP450 activities may persist for several weeks after stopping therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when treatments targeting cytokines such as interleukins, tumor necrosis factors, or interferons are prescribed to patients receiving concomitant drugs that are CYP450 substrates, particularly those with narrow therapeutic ranges (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97919/", "reference_text": "[1] \"Product Information. Skyrizi (risankizumab).\" AbbVie US LLC, North Chicago, IL.[2] \"Product Information. Cosentyx (secukinumab).\" Novartis Pharmaceuticals, East Hanover, NJ.[3] \"Product Information. Ilaris (canakinumab).\" Novartis Pharmaceuticals, East Hanover, NJ.[4] \"Product Information. Gamifant (emapalumab).\" Sobi Inc, Ardmore, PA.[5] \"Product Information. Kevzara (sarilumab).\" sanofi-aventis, Bridgewater, NJ.[6] \"Product Information. Simponi (golimumab).\" Centocor Inc, Malvern, PA.[7] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[8] \"Product Information. Sylvant (siltuximab).\" Janssen Biotech, Inc., Horsham, PA, PA.[9] \"Product Information. Stelara (ustekinumab).\" Centocor Inc, Malvern, PA.[10] \"Product Information. Ilumya (tildrakizumab).\" Merck & Company Inc, Whitehouse Station, NJ.[11] \"Product Information. Actemra (tocilizumab).\" Genentech, South San Francisco, CA.[12] \"Product Information. Amevive (alefacept).\" Biogen, Cambridge, MA.[13] \"Product Information. Remicade (infliximab).\" Centocor Inc, Malvern, PA.[14] \"Product Information. Taltz Autoinjector (ixekizumab).\" Eli Lilly and Company, Indianapolis, IN.[15] \"Product Information. Arcalyst (rilonacept).\" Regeneron Pharmaceuticals Inc, Tarrytown, NY.[16] Ace LN, Jaffe JM, Kunka RL \"Effect of food and an antacid on quinidine bioavailability.\" Biopharm Drug Dispos 4 (1983): 183-90[17] Min DI, Ku YM, Geraets DR, Lee HC \"Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers.\" J Clin Pharmacol 36 (1996): 469-76[18] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[19] Ha HR, Chen J, Leuenberger PM, Freiburghaus AU, Follah F \"In vitro inhibition of midazolam and quinidine metabolism by flavonoids.\" Eur J Clin Pharmacol 48 (1995): 367-71", "alternatives_a": "Brivaracetam, Topiramate, Ezogabine, Cenobamate, Lamotrigine, Lacosamide, Levetiracetam, Tiagabine, Oxcarbazepine, Ethotoin, Rufinamide, More", "alternatives_b": "Antithymocyte immunoglobulin (rabbit), Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Methotrexate, Abatacept, Upadacitinib, Siponimod, Inebilizumab, Cladribine, More", "updated_at": 1767369485}, {"id": 97816, "ingredient1": "Emapalumab", "ingredient2": "Mexiletine", "severity": "Moderate", "effect": "Plasma concentrations of drugs that are CYP450 substrates may decrease following the initiation of interleukin (IL) inhibitors, tumor necrosis factor (TNF) blockers, or interferon (IFN) inhibitors in patients with chronic inflammatory diseases. Because the formation of hepatic CYP450 enzymes is down-regulated during infection and chronic inflammation by increased levels of certain cytokines (e.g., interleukins-1, -6, and -10; tumor necrosis factor alpha; interferons), treatment targeting these cytokines may restore or normalize CYP450 enzyme levels resulting in increased metabolism of these drugs.", "source": "DDInter", "management_text": "Caution is advised when treatments targeting cytokines such as interleukins, tumor necrosis factors, or interferons are prescribed to patients receiving concomitant drugs that are CYP450 substrates, particularly those with narrow therapeutic ranges (e.g., antiarrhythmics, anticonvulsants, immunosuppressants, theophylline) or sensitive substrates where decreases in plasma levels may be significant or undesirable (e.g., oral contraceptives, statins, benzodiazepines, opioids). Clinical and/or laboratory monitoring should be considered following the initiation or withdrawal of such treatments, and the dosage(s) of the CYP450 substrate(s) adjusted accordingly. The effects of IL inhibitors, TNF blockers, and IFN inhibitors on CYP450 activities may persist for several weeks after stopping therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when treatments targeting cytokines such as interleukins, tumor necrosis factors, or interferons are prescribed to patients receiving concomitant drugs that are CYP450 substrates, particularly those with narrow therapeutic ranges (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97920/", "reference_text": "[1] \"Product Information. Skyrizi (risankizumab).\" AbbVie US LLC, North Chicago, IL.[2] \"Product Information. Cosentyx (secukinumab).\" Novartis Pharmaceuticals, East Hanover, NJ.[3] \"Product Information. Ilaris (canakinumab).\" Novartis Pharmaceuticals, East Hanover, NJ.[4] \"Product Information. Gamifant (emapalumab).\" Sobi Inc, Ardmore, PA.[5] \"Product Information. Kevzara (sarilumab).\" sanofi-aventis, Bridgewater, NJ.[6] \"Product Information. Simponi (golimumab).\" Centocor Inc, Malvern, PA.[7] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[8] \"Product Information. Sylvant (siltuximab).\" Janssen Biotech, Inc., Horsham, PA, PA.[9] \"Product Information. Stelara (ustekinumab).\" Centocor Inc, Malvern, PA.[10] \"Product Information. Ilumya (tildrakizumab).\" Merck & Company Inc, Whitehouse Station, NJ.[11] \"Product Information. Actemra (tocilizumab).\" Genentech, South San Francisco, CA.[12] \"Product Information. Amevive (alefacept).\" Biogen, Cambridge, MA.[13] \"Product Information. Remicade (infliximab).\" Centocor Inc, Malvern, PA.[14] \"Product Information. Taltz Autoinjector (ixekizumab).\" Eli Lilly and Company, Indianapolis, IN.[15] \"Product Information. Arcalyst (rilonacept).\" Regeneron Pharmaceuticals Inc, Tarrytown, NY.[16] Ace LN, Jaffe JM, Kunka RL \"Effect of food and an antacid on quinidine bioavailability.\" Biopharm Drug Dispos 4 (1983): 183-90[17] Min DI, Ku YM, Geraets DR, Lee HC \"Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers.\" J Clin Pharmacol 36 (1996): 469-76[18] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[19] Ha HR, Chen J, Leuenberger PM, Freiburghaus AU, Follah F \"In vitro inhibition of midazolam and quinidine metabolism by flavonoids.\" Eur J Clin Pharmacol 48 (1995): 367-71", "alternatives_a": "Tocainide, Dronedarone, Dofetilide, Bretylium, Moricizine, Ibutilide", "alternatives_b": "Cyclosporine, Antithymocyte immunoglobulin (rabbit), Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Methotrexate, Abatacept, Upadacitinib, Siponimod, Apremilast, More", "updated_at": 1767369485}, {"id": 97817, "ingredient1": "Emapalumab", "ingredient2": "Midazolam", "severity": "Moderate", "effect": "Plasma concentrations of drugs that are CYP450 substrates may decrease following the initiation of interleukin (IL) inhibitors, tumor necrosis factor (TNF) blockers, or interferon (IFN) inhibitors in patients with chronic inflammatory diseases. Because the formation of hepatic CYP450 enzymes is down-regulated during infection and chronic inflammation by increased levels of certain cytokines (e.g., interleukins-1, -6, and -10; tumor necrosis factor alpha; interferons), treatment targeting these cytokines may restore or normalize CYP450 enzyme levels resulting in increased metabolism of these drugs.", "source": "DDInter", "management_text": "Caution is advised when treatments targeting cytokines such as interleukins, tumor necrosis factors, or interferons are prescribed to patients receiving concomitant drugs that are CYP450 substrates, particularly those with narrow therapeutic ranges (e.g., antiarrhythmics, anticonvulsants, immunosuppressants, theophylline) or sensitive substrates where decreases in plasma levels may be significant or undesirable (e.g., oral contraceptives, statins, benzodiazepines, opioids). Clinical and/or laboratory monitoring should be considered following the initiation or withdrawal of such treatments, and the dosage(s) of the CYP450 substrate(s) adjusted accordingly. The effects of IL inhibitors, TNF blockers, and IFN inhibitors on CYP450 activities may persist for several weeks after stopping therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when treatments targeting cytokines such as interleukins, tumor necrosis factors, or interferons are prescribed to patients receiving concomitant drugs that are CYP450 substrates, particularly those with narrow therapeutic ranges (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97921/", "reference_text": "[1] \"Product Information. Skyrizi (risankizumab).\" AbbVie US LLC, North Chicago, IL.[2] \"Product Information. Cosentyx (secukinumab).\" Novartis Pharmaceuticals, East Hanover, NJ.[3] \"Product Information. Ilaris (canakinumab).\" Novartis Pharmaceuticals, East Hanover, NJ.[4] \"Product Information. Gamifant (emapalumab).\" Sobi Inc, Ardmore, PA.[5] \"Product Information. Kevzara (sarilumab).\" sanofi-aventis, Bridgewater, NJ.[6] \"Product Information. Simponi (golimumab).\" Centocor Inc, Malvern, PA.[7] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[8] \"Product Information. Sylvant (siltuximab).\" Janssen Biotech, Inc., Horsham, PA, PA.[9] \"Product Information. Stelara (ustekinumab).\" Centocor Inc, Malvern, PA.[10] \"Product Information. Ilumya (tildrakizumab).\" Merck & Company Inc, Whitehouse Station, NJ.[11] \"Product Information. Actemra (tocilizumab).\" Genentech, South San Francisco, CA.[12] \"Product Information. Amevive (alefacept).\" Biogen, Cambridge, MA.[13] \"Product Information. Remicade (infliximab).\" Centocor Inc, Malvern, PA.[14] \"Product Information. Taltz Autoinjector (ixekizumab).\" Eli Lilly and Company, Indianapolis, IN.[15] \"Product Information. Arcalyst (rilonacept).\" Regeneron Pharmaceuticals Inc, Tarrytown, NY.[16] Ace LN, Jaffe JM, Kunka RL \"Effect of food and an antacid on quinidine bioavailability.\" Biopharm Drug Dispos 4 (1983): 183-90[17] Min DI, Ku YM, Geraets DR, Lee HC \"Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers.\" J Clin Pharmacol 36 (1996): 469-76[18] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[19] Ha HR, Chen J, Leuenberger PM, Freiburghaus AU, Follah F \"In vitro inhibition of midazolam and quinidine metabolism by flavonoids.\" Eur J Clin Pharmacol 48 (1995): 367-71", "alternatives_a": "Suvorexant, Flurazepam, Methohexital, Zolpidem, Pentobarbital, Zaleplon, Dichloralphenazone, Valerian, Temazepam, Butabarbital, Secobarbital, More", "alternatives_b": "Antithymocyte immunoglobulin (rabbit), Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Methotrexate, Abatacept, Upadacitinib, Siponimod, Apremilast, Inebilizumab, More", "updated_at": 1767369485}, {"id": 97818, "ingredient1": "Emapalumab", "ingredient2": "Monomethyl fumarate", "severity": "Moderate", "effect": "The use of monomethyl fumarate (MMF) or its prodrugs, dimethyl fumarate and diroximel fumarate, with other immunosuppressive or myelosuppressive agents may increase the risk of infections.", "source": "DDInter", "management_text": "The safety and efficacy of monomethyl fumarate, dimethyl fumarate, or diroximel fumarate in combination with other immunosuppressive or myelosuppressive agents have not been evaluated. Until further information is available, concomitant use should be avoided if possible.", "mechanism_text": "Synergism", "recommendation": "The safety and efficacy of monomethyl fumarate, dimethyl fumarate, or diroximel fumarate in combination with other immunosuppressive or myelosuppressive agents have not been evaluated.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97922/", "reference_text": "[1] \"Product Information. Vumerity (diroximel fumarate).\" Alkermes, Inc, Cambridge, MA.", "alternatives_a": "Apremilast, Pirfenidone, Belumosudil, Teprotumumab, Ravulizumab, Pegcetacoplan, Eculizumab, Sutimlimab", "alternatives_b": "", "updated_at": 1767369485}, {"id": 97819, "ingredient1": "Emapalumab", "ingredient2": "Mumps virus strain B level jeryl lynn live antigen", "severity": "Major", "effect": "The administration of live or live attenuated vaccines during emapalumab therapy may be associated with a risk of disseminated infection due to enhanced replication of vaccine virus or bacteria in the presence of diminished immune competence. Emapalumab is a monoclonal antibody that binds to and neutralizes interferon gamma, which may increase susceptibility to certain pathogens and increase the risk of fatal and serious infections.", "source": "DDInter", "management_text": "The use of live or live attenuated vaccines should be avoided during and for at least 4 weeks after the last dose of emapalumab.", "mechanism_text": "Others", "recommendation": "The use of live or live attenuated vaccines should be avoided during and for at least 4 weeks after the last dose of emapalumab.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97923/", "reference_text": "[1] \"Product Information. Gamifant (emapalumab).\" Sobi Inc, Ardmore, PA.", "alternatives_a": "Apremilast, Pirfenidone, Belumosudil, Teprotumumab, Ravulizumab, Pegcetacoplan, Eculizumab, Sutimlimab", "alternatives_b": "", "updated_at": 1767369485}, {"id": 97820, "ingredient1": "Emapalumab", "ingredient2": "Nicardipine", "severity": "Moderate", "effect": "Plasma concentrations of drugs that are CYP450 substrates may decrease following the initiation of interleukin (IL) inhibitors, tumor necrosis factor (TNF) blockers, or interferon (IFN) inhibitors in patients with chronic inflammatory diseases. Because the formation of hepatic CYP450 enzymes is down-regulated during infection and chronic inflammation by increased levels of certain cytokines (e.g., interleukins-1, -6, and -10; tumor necrosis factor alpha; interferons), treatment targeting these cytokines may restore or normalize CYP450 enzyme levels resulting in increased metabolism of these drugs.", "source": "DDInter", "management_text": "Caution is advised when treatments targeting cytokines such as interleukins, tumor necrosis factors, or interferons are prescribed to patients receiving concomitant drugs that are CYP450 substrates, particularly those with narrow therapeutic ranges (e.g., antiarrhythmics, anticonvulsants, immunosuppressants, theophylline) or sensitive substrates where decreases in plasma levels may be significant or undesirable (e.g., oral contraceptives, statins, benzodiazepines, opioids). Clinical and/or laboratory monitoring should be considered following the initiation or withdrawal of such treatments, and the dosage(s) of the CYP450 substrate(s) adjusted accordingly. The effects of IL inhibitors, TNF blockers, and IFN inhibitors on CYP450 activities may persist for several weeks after stopping therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when treatments targeting cytokines such as interleukins, tumor necrosis factors, or interferons are prescribed to patients receiving concomitant drugs that are CYP450 substrates, particularly those with narrow therapeutic ranges (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97924/", "reference_text": "[1] \"Product Information. Skyrizi (risankizumab).\" AbbVie US LLC, North Chicago, IL.[2] \"Product Information. Cosentyx (secukinumab).\" Novartis Pharmaceuticals, East Hanover, NJ.[3] \"Product Information. Ilaris (canakinumab).\" Novartis Pharmaceuticals, East Hanover, NJ.[4] \"Product Information. Gamifant (emapalumab).\" Sobi Inc, Ardmore, PA.[5] \"Product Information. Kevzara (sarilumab).\" sanofi-aventis, Bridgewater, NJ.[6] \"Product Information. Simponi (golimumab).\" Centocor Inc, Malvern, PA.[7] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[8] \"Product Information. Sylvant (siltuximab).\" Janssen Biotech, Inc., Horsham, PA, PA.[9] \"Product Information. Stelara (ustekinumab).\" Centocor Inc, Malvern, PA.[10] \"Product Information. Ilumya (tildrakizumab).\" Merck & Company Inc, Whitehouse Station, NJ.[11] \"Product Information. Actemra (tocilizumab).\" Genentech, South San Francisco, CA.[12] \"Product Information. Amevive (alefacept).\" Biogen, Cambridge, MA.[13] \"Product Information. Remicade (infliximab).\" Centocor Inc, Malvern, PA.[14] \"Product Information. Taltz Autoinjector (ixekizumab).\" Eli Lilly and Company, Indianapolis, IN.[15] \"Product Information. Arcalyst (rilonacept).\" Regeneron Pharmaceuticals Inc, Tarrytown, NY.[16] Ace LN, Jaffe JM, Kunka RL \"Effect of food and an antacid on quinidine bioavailability.\" Biopharm Drug Dispos 4 (1983): 183-90[17] Min DI, Ku YM, Geraets DR, Lee HC \"Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers.\" J Clin Pharmacol 36 (1996): 469-76[18] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[19] Ha HR, Chen J, Leuenberger PM, Freiburghaus AU, Follah F \"In vitro inhibition of midazolam and quinidine metabolism by flavonoids.\" Eur J Clin Pharmacol 48 (1995): 367-71", "alternatives_a": "Clevidipine, Mibefradil, Celecoxib", "alternatives_b": "Antithymocyte immunoglobulin (rabbit), Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Abatacept, Upadacitinib, Apremilast, Inebilizumab, Cladribine, Belumosudil, More", "updated_at": 1767369485}, {"id": 97821, "ingredient1": "Emapalumab", "ingredient2": "Nimodipine", "severity": "Moderate", "effect": "Plasma concentrations of drugs that are CYP450 substrates may decrease following the initiation of interleukin (IL) inhibitors, tumor necrosis factor (TNF) blockers, or interferon (IFN) inhibitors in patients with chronic inflammatory diseases. Because the formation of hepatic CYP450 enzymes is down-regulated during infection and chronic inflammation by increased levels of certain cytokines (e.g., interleukins-1, -6, and -10; tumor necrosis factor alpha; interferons), treatment targeting these cytokines may restore or normalize CYP450 enzyme levels resulting in increased metabolism of these drugs.", "source": "DDInter", "management_text": "Caution is advised when treatments targeting cytokines such as interleukins, tumor necrosis factors, or interferons are prescribed to patients receiving concomitant drugs that are CYP450 substrates, particularly those with narrow therapeutic ranges (e.g., antiarrhythmics, anticonvulsants, immunosuppressants, theophylline) or sensitive substrates where decreases in plasma levels may be significant or undesirable (e.g., oral contraceptives, statins, benzodiazepines, opioids). Clinical and/or laboratory monitoring should be considered following the initiation or withdrawal of such treatments, and the dosage(s) of the CYP450 substrate(s) adjusted accordingly. The effects of IL inhibitors, TNF blockers, and IFN inhibitors on CYP450 activities may persist for several weeks after stopping therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when treatments targeting cytokines such as interleukins, tumor necrosis factors, or interferons are prescribed to patients receiving concomitant drugs that are CYP450 substrates, particularly those with narrow therapeutic ranges (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97925/", "reference_text": "[1] \"Product Information. Skyrizi (risankizumab).\" AbbVie US LLC, North Chicago, IL.[2] \"Product Information. Cosentyx (secukinumab).\" Novartis Pharmaceuticals, East Hanover, NJ.[3] \"Product Information. Ilaris (canakinumab).\" Novartis Pharmaceuticals, East Hanover, NJ.[4] \"Product Information. Gamifant (emapalumab).\" Sobi Inc, Ardmore, PA.[5] \"Product Information. Kevzara (sarilumab).\" sanofi-aventis, Bridgewater, NJ.[6] \"Product Information. Simponi (golimumab).\" Centocor Inc, Malvern, PA.[7] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[8] \"Product Information. Sylvant (siltuximab).\" Janssen Biotech, Inc., Horsham, PA, PA.[9] \"Product Information. Stelara (ustekinumab).\" Centocor Inc, Malvern, PA.[10] \"Product Information. Ilumya (tildrakizumab).\" Merck & Company Inc, Whitehouse Station, NJ.[11] \"Product Information. Actemra (tocilizumab).\" Genentech, South San Francisco, CA.[12] \"Product Information. Amevive (alefacept).\" Biogen, Cambridge, MA.[13] \"Product Information. Remicade (infliximab).\" Centocor Inc, Malvern, PA.[14] \"Product Information. Taltz Autoinjector (ixekizumab).\" Eli Lilly and Company, Indianapolis, IN.[15] \"Product Information. Arcalyst (rilonacept).\" Regeneron Pharmaceuticals Inc, Tarrytown, NY.[16] Ace LN, Jaffe JM, Kunka RL \"Effect of food and an antacid on quinidine bioavailability.\" Biopharm Drug Dispos 4 (1983): 183-90[17] Min DI, Ku YM, Geraets DR, Lee HC \"Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers.\" J Clin Pharmacol 36 (1996): 469-76[18] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[19] Ha HR, Chen J, Leuenberger PM, Freiburghaus AU, Follah F \"In vitro inhibition of midazolam and quinidine metabolism by flavonoids.\" Eur J Clin Pharmacol 48 (1995): 367-71", "alternatives_a": "Clevidipine, Mibefradil, Celecoxib", "alternatives_b": "Cyclosporine, Antithymocyte immunoglobulin (rabbit), Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Abatacept, Upadacitinib, Apremilast, Inebilizumab, Belumosudil, More", "updated_at": 1767369485}, {"id": 97822, "ingredient1": "Emapalumab", "ingredient2": "Nisoldipine", "severity": "Moderate", "effect": "Plasma concentrations of drugs that are CYP450 substrates may decrease following the initiation of interleukin (IL) inhibitors, tumor necrosis factor (TNF) blockers, or interferon (IFN) inhibitors in patients with chronic inflammatory diseases. Because the formation of hepatic CYP450 enzymes is down-regulated during infection and chronic inflammation by increased levels of certain cytokines (e.g., interleukins-1, -6, and -10; tumor necrosis factor alpha; interferons), treatment targeting these cytokines may restore or normalize CYP450 enzyme levels resulting in increased metabolism of these drugs.", "source": "DDInter", "management_text": "Caution is advised when treatments targeting cytokines such as interleukins, tumor necrosis factors, or interferons are prescribed to patients receiving concomitant drugs that are CYP450 substrates, particularly those with narrow therapeutic ranges (e.g., antiarrhythmics, anticonvulsants, immunosuppressants, theophylline) or sensitive substrates where decreases in plasma levels may be significant or undesirable (e.g., oral contraceptives, statins, benzodiazepines, opioids). Clinical and/or laboratory monitoring should be considered following the initiation or withdrawal of such treatments, and the dosage(s) of the CYP450 substrate(s) adjusted accordingly. The effects of IL inhibitors, TNF blockers, and IFN inhibitors on CYP450 activities may persist for several weeks after stopping therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when treatments targeting cytokines such as interleukins, tumor necrosis factors, or interferons are prescribed to patients receiving concomitant drugs that are CYP450 substrates, particularly those with narrow therapeutic ranges (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97926/", "reference_text": "[1] \"Product Information. Skyrizi (risankizumab).\" AbbVie US LLC, North Chicago, IL.[2] \"Product Information. Cosentyx (secukinumab).\" Novartis Pharmaceuticals, East Hanover, NJ.[3] \"Product Information. Ilaris (canakinumab).\" Novartis Pharmaceuticals, East Hanover, NJ.[4] \"Product Information. Gamifant (emapalumab).\" Sobi Inc, Ardmore, PA.[5] \"Product Information. Kevzara (sarilumab).\" sanofi-aventis, Bridgewater, NJ.[6] \"Product Information. Simponi (golimumab).\" Centocor Inc, Malvern, PA.[7] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[8] \"Product Information. Sylvant (siltuximab).\" Janssen Biotech, Inc., Horsham, PA, PA.[9] \"Product Information. Stelara (ustekinumab).\" Centocor Inc, Malvern, PA.[10] \"Product Information. Ilumya (tildrakizumab).\" Merck & Company Inc, Whitehouse Station, NJ.[11] \"Product Information. Actemra (tocilizumab).\" Genentech, South San Francisco, CA.[12] \"Product Information. Amevive (alefacept).\" Biogen, Cambridge, MA.[13] \"Product Information. Remicade (infliximab).\" Centocor Inc, Malvern, PA.[14] \"Product Information. Taltz Autoinjector (ixekizumab).\" Eli Lilly and Company, Indianapolis, IN.[15] \"Product Information. Arcalyst (rilonacept).\" Regeneron Pharmaceuticals Inc, Tarrytown, NY.[16] Ace LN, Jaffe JM, Kunka RL \"Effect of food and an antacid on quinidine bioavailability.\" Biopharm Drug Dispos 4 (1983): 183-90[17] Min DI, Ku YM, Geraets DR, Lee HC \"Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers.\" J Clin Pharmacol 36 (1996): 469-76[18] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[19] Ha HR, Chen J, Leuenberger PM, Freiburghaus AU, Follah F \"In vitro inhibition of midazolam and quinidine metabolism by flavonoids.\" Eur J Clin Pharmacol 48 (1995): 367-71", "alternatives_a": "Clevidipine, Mibefradil, Celecoxib", "alternatives_b": "Antithymocyte immunoglobulin (rabbit), Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Abatacept, Upadacitinib, Apremilast, Inebilizumab, Cladribine, Belumosudil, More", "updated_at": 1767369485}, {"id": 97823, "ingredient1": "Emapalumab", "ingredient2": "Oliceridine", "severity": "Moderate", "effect": "Plasma concentrations of drugs that are CYP450 substrates may decrease following the initiation of interleukin (IL) inhibitors, tumor necrosis factor (TNF) blockers, or interferon (IFN) inhibitors in patients with chronic inflammatory diseases. Because the formation of hepatic CYP450 enzymes is down-regulated during infection and chronic inflammation by increased levels of certain cytokines (e.g., interleukins-1, -6, and -10; tumor necrosis factor alpha; interferons), treatment targeting these cytokines may restore or normalize CYP450 enzyme levels resulting in increased metabolism of these drugs.", "source": "DDInter", "management_text": "Caution is advised when treatments targeting cytokines such as interleukins, tumor necrosis factors, or interferons are prescribed to patients receiving concomitant drugs that are CYP450 substrates, particularly those with narrow therapeutic ranges (e.g., antiarrhythmics, anticonvulsants, immunosuppressants, theophylline) or sensitive substrates where decreases in plasma levels may be significant or undesirable (e.g., oral contraceptives, statins, benzodiazepines, opioids). Clinical and/or laboratory monitoring should be considered following the initiation or withdrawal of such treatments, and the dosage(s) of the CYP450 substrate(s) adjusted accordingly. The effects of IL inhibitors, TNF blockers, and IFN inhibitors on CYP450 activities may persist for several weeks after stopping therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when treatments targeting cytokines such as interleukins, tumor necrosis factors, or interferons are prescribed to patients receiving concomitant drugs that are CYP450 substrates, particularly those with narrow therapeutic ranges (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97927/", "reference_text": "[1] \"Product Information. Skyrizi (risankizumab).\" AbbVie US LLC, North Chicago, IL.[2] \"Product Information. Cosentyx (secukinumab).\" Novartis Pharmaceuticals, East Hanover, NJ.[3] \"Product Information. Ilaris (canakinumab).\" Novartis Pharmaceuticals, East Hanover, NJ.[4] \"Product Information. Gamifant (emapalumab).\" Sobi Inc, Ardmore, PA.[5] \"Product Information. Kevzara (sarilumab).\" sanofi-aventis, Bridgewater, NJ.[6] \"Product Information. Simponi (golimumab).\" Centocor Inc, Malvern, PA.[7] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[8] \"Product Information. Sylvant (siltuximab).\" Janssen Biotech, Inc., Horsham, PA, PA.[9] \"Product Information. Stelara (ustekinumab).\" Centocor Inc, Malvern, PA.[10] \"Product Information. Ilumya (tildrakizumab).\" Merck & Company Inc, Whitehouse Station, NJ.[11] \"Product Information. Actemra (tocilizumab).\" Genentech, South San Francisco, CA.[12] \"Product Information. Amevive (alefacept).\" Biogen, Cambridge, MA.[13] \"Product Information. Remicade (infliximab).\" Centocor Inc, Malvern, PA.[14] \"Product Information. Taltz Autoinjector (ixekizumab).\" Eli Lilly and Company, Indianapolis, IN.[15] \"Product Information. Arcalyst (rilonacept).\" Regeneron Pharmaceuticals Inc, Tarrytown, NY.[16] Ace LN, Jaffe JM, Kunka RL \"Effect of food and an antacid on quinidine bioavailability.\" Biopharm Drug Dispos 4 (1983): 183-90[17] Min DI, Ku YM, Geraets DR, Lee HC \"Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers.\" J Clin Pharmacol 36 (1996): 469-76[18] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[19] Ha HR, Chen J, Leuenberger PM, Freiburghaus AU, Follah F \"In vitro inhibition of midazolam and quinidine metabolism by flavonoids.\" Eur J Clin Pharmacol 48 (1995): 367-71", "alternatives_a": "Cyclosporine, Antithymocyte immunoglobulin (rabbit), Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Methotrexate, Abatacept, Upadacitinib, Apremilast, Inebilizumab, More", "alternatives_b": "Naltrexone, Oxymorphone, Pentazocine, Morphine, Butorphanol, Ibuprofen, Codeine, Nalbuphine, Acetaminophen, Tramadol, Dihydrocodeine, More", "updated_at": 1767369485}, {"id": 97824, "ingredient1": "Emapalumab", "ingredient2": "Oxtriphylline", "severity": "Moderate", "effect": "Plasma concentrations of drugs that are CYP450 substrates may decrease following the initiation of interleukin (IL) inhibitors, tumor necrosis factor (TNF) blockers, or interferon (IFN) inhibitors in patients with chronic inflammatory diseases. Because the formation of hepatic CYP450 enzymes is down-regulated during infection and chronic inflammation by increased levels of certain cytokines (e.g., interleukins-1, -6, and -10; tumor necrosis factor alpha; interferons), treatment targeting these cytokines may restore or normalize CYP450 enzyme levels resulting in increased metabolism of these drugs.", "source": "DDInter", "management_text": "Caution is advised when treatments targeting cytokines such as interleukins, tumor necrosis factors, or interferons are prescribed to patients receiving concomitant drugs that are CYP450 substrates, particularly those with narrow therapeutic ranges (e.g., antiarrhythmics, anticonvulsants, immunosuppressants, theophylline) or sensitive substrates where decreases in plasma levels may be significant or undesirable (e.g., oral contraceptives, statins, benzodiazepines, opioids). Clinical and/or laboratory monitoring should be considered following the initiation or withdrawal of such treatments, and the dosage(s) of the CYP450 substrate(s) adjusted accordingly. The effects of IL inhibitors, TNF blockers, and IFN inhibitors on CYP450 activities may persist for several weeks after stopping therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when treatments targeting cytokines such as interleukins, tumor necrosis factors, or interferons are prescribed to patients receiving concomitant drugs that are CYP450 substrates, particularly those with narrow therapeutic ranges (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97928/", "reference_text": "[1] \"Product Information. Skyrizi (risankizumab).\" AbbVie US LLC, North Chicago, IL.[2] \"Product Information. Cosentyx (secukinumab).\" Novartis Pharmaceuticals, East Hanover, NJ.[3] \"Product Information. Ilaris (canakinumab).\" Novartis Pharmaceuticals, East Hanover, NJ.[4] \"Product Information. Gamifant (emapalumab).\" Sobi Inc, Ardmore, PA.[5] \"Product Information. Kevzara (sarilumab).\" sanofi-aventis, Bridgewater, NJ.[6] \"Product Information. Simponi (golimumab).\" Centocor Inc, Malvern, PA.[7] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[8] \"Product Information. Sylvant (siltuximab).\" Janssen Biotech, Inc., Horsham, PA, PA.[9] \"Product Information. Stelara (ustekinumab).\" Centocor Inc, Malvern, PA.[10] \"Product Information. Ilumya (tildrakizumab).\" Merck & Company Inc, Whitehouse Station, NJ.[11] \"Product Information. Actemra (tocilizumab).\" Genentech, South San Francisco, CA.[12] \"Product Information. Amevive (alefacept).\" Biogen, Cambridge, MA.[13] \"Product Information. Remicade (infliximab).\" Centocor Inc, Malvern, PA.[14] \"Product Information. Taltz Autoinjector (ixekizumab).\" Eli Lilly and Company, Indianapolis, IN.[15] \"Product Information. Arcalyst (rilonacept).\" Regeneron Pharmaceuticals Inc, Tarrytown, NY.[16] Ace LN, Jaffe JM, Kunka RL \"Effect of food and an antacid on quinidine bioavailability.\" Biopharm Drug Dispos 4 (1983): 183-90[17] Min DI, Ku YM, Geraets DR, Lee HC \"Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers.\" J Clin Pharmacol 36 (1996): 469-76[18] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[19] Ha HR, Chen J, Leuenberger PM, Freiburghaus AU, Follah F \"In vitro inhibition of midazolam and quinidine metabolism by flavonoids.\" Eur J Clin Pharmacol 48 (1995): 367-71", "alternatives_a": "Omalizumab, Tezepelumab, Mercaptopurine, Benralizumab, Caffeine, Reslizumab, Montelukast, Dyphylline, Mepolizumab, Roflumilast, Pentoxifylline, More", "alternatives_b": "Cyclosporine, Antithymocyte immunoglobulin (rabbit), Anifrolumab, Ravulizumab, Diroximel fumarate, Methotrexate, Tacrolimus, Abatacept, Upadacitinib, Siponimod, Apremilast, More", "updated_at": 1767369485}, {"id": 97825, "ingredient1": "Emapalumab", "ingredient2": "Oxycodone", "severity": "Moderate", "effect": "Plasma concentrations of drugs that are CYP450 substrates may decrease following the initiation of interleukin (IL) inhibitors, tumor necrosis factor (TNF) blockers, or interferon (IFN) inhibitors in patients with chronic inflammatory diseases. Because the formation of hepatic CYP450 enzymes is down-regulated during infection and chronic inflammation by increased levels of certain cytokines (e.g., interleukins-1, -6, and -10; tumor necrosis factor alpha; interferons), treatment targeting these cytokines may restore or normalize CYP450 enzyme levels resulting in increased metabolism of these drugs.", "source": "DDInter", "management_text": "Caution is advised when treatments targeting cytokines such as interleukins, tumor necrosis factors, or interferons are prescribed to patients receiving concomitant drugs that are CYP450 substrates, particularly those with narrow therapeutic ranges (e.g., antiarrhythmics, anticonvulsants, immunosuppressants, theophylline) or sensitive substrates where decreases in plasma levels may be significant or undesirable (e.g., oral contraceptives, statins, benzodiazepines, opioids). Clinical and/or laboratory monitoring should be considered following the initiation or withdrawal of such treatments, and the dosage(s) of the CYP450 substrate(s) adjusted accordingly. The effects of IL inhibitors, TNF blockers, and IFN inhibitors on CYP450 activities may persist for several weeks after stopping therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when treatments targeting cytokines such as interleukins, tumor necrosis factors, or interferons are prescribed to patients receiving concomitant drugs that are CYP450 substrates, particularly those with narrow therapeutic ranges (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97929/", "reference_text": "[1] \"Product Information. Skyrizi (risankizumab).\" AbbVie US LLC, North Chicago, IL.[2] \"Product Information. Cosentyx (secukinumab).\" Novartis Pharmaceuticals, East Hanover, NJ.[3] \"Product Information. Ilaris (canakinumab).\" Novartis Pharmaceuticals, East Hanover, NJ.[4] \"Product Information. Gamifant (emapalumab).\" Sobi Inc, Ardmore, PA.[5] \"Product Information. Kevzara (sarilumab).\" sanofi-aventis, Bridgewater, NJ.[6] \"Product Information. Simponi (golimumab).\" Centocor Inc, Malvern, PA.[7] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[8] \"Product Information. Sylvant (siltuximab).\" Janssen Biotech, Inc., Horsham, PA, PA.[9] \"Product Information. Stelara (ustekinumab).\" Centocor Inc, Malvern, PA.[10] \"Product Information. Ilumya (tildrakizumab).\" Merck & Company Inc, Whitehouse Station, NJ.[11] \"Product Information. Actemra (tocilizumab).\" Genentech, South San Francisco, CA.[12] \"Product Information. Amevive (alefacept).\" Biogen, Cambridge, MA.[13] \"Product Information. Remicade (infliximab).\" Centocor Inc, Malvern, PA.[14] \"Product Information. Taltz Autoinjector (ixekizumab).\" Eli Lilly and Company, Indianapolis, IN.[15] \"Product Information. Arcalyst (rilonacept).\" Regeneron Pharmaceuticals Inc, Tarrytown, NY.[16] Ace LN, Jaffe JM, Kunka RL \"Effect of food and an antacid on quinidine bioavailability.\" Biopharm Drug Dispos 4 (1983): 183-90[17] Min DI, Ku YM, Geraets DR, Lee HC \"Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers.\" J Clin Pharmacol 36 (1996): 469-76[18] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[19] Ha HR, Chen J, Leuenberger PM, Freiburghaus AU, Follah F \"In vitro inhibition of midazolam and quinidine metabolism by flavonoids.\" Eur J Clin Pharmacol 48 (1995): 367-71", "alternatives_a": "Naltrexone, Oxymorphone, Pentazocine, Morphine, Butorphanol, Ibuprofen, Codeine, Nalbuphine, Acetaminophen, Tramadol, Dihydrocodeine, More", "alternatives_b": "Antithymocyte immunoglobulin (rabbit), Anifrolumab, Ravulizumab, Diroximel fumarate, Abatacept, Siponimod, Apremilast, Inebilizumab, Cladribine, Belumosudil, Belimumab, More", "updated_at": 1767369485}, {"id": 97826, "ingredient1": "Emapalumab", "ingredient2": "Phenobarbital", "severity": "Moderate", "effect": "Plasma concentrations of drugs that are CYP450 substrates may decrease following the initiation of interleukin (IL) inhibitors, tumor necrosis factor (TNF) blockers, or interferon (IFN) inhibitors in patients with chronic inflammatory diseases. Because the formation of hepatic CYP450 enzymes is down-regulated during infection and chronic inflammation by increased levels of certain cytokines (e.g., interleukins-1, -6, and -10; tumor necrosis factor alpha; interferons), treatment targeting these cytokines may restore or normalize CYP450 enzyme levels resulting in increased metabolism of these drugs.", "source": "DDInter", "management_text": "Caution is advised when treatments targeting cytokines such as interleukins, tumor necrosis factors, or interferons are prescribed to patients receiving concomitant drugs that are CYP450 substrates, particularly those with narrow therapeutic ranges (e.g., antiarrhythmics, anticonvulsants, immunosuppressants, theophylline) or sensitive substrates where decreases in plasma levels may be significant or undesirable (e.g., oral contraceptives, statins, benzodiazepines, opioids). Clinical and/or laboratory monitoring should be considered following the initiation or withdrawal of such treatments, and the dosage(s) of the CYP450 substrate(s) adjusted accordingly. The effects of IL inhibitors, TNF blockers, and IFN inhibitors on CYP450 activities may persist for several weeks after stopping therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when treatments targeting cytokines such as interleukins, tumor necrosis factors, or interferons are prescribed to patients receiving concomitant drugs that are CYP450 substrates, particularly those with narrow therapeutic ranges (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97930/", "reference_text": "[1] \"Product Information. Skyrizi (risankizumab).\" AbbVie US LLC, North Chicago, IL.[2] \"Product Information. Cosentyx (secukinumab).\" Novartis Pharmaceuticals, East Hanover, NJ.[3] \"Product Information. Ilaris (canakinumab).\" Novartis Pharmaceuticals, East Hanover, NJ.[4] \"Product Information. Gamifant (emapalumab).\" Sobi Inc, Ardmore, PA.[5] \"Product Information. Kevzara (sarilumab).\" sanofi-aventis, Bridgewater, NJ.[6] \"Product Information. Simponi (golimumab).\" Centocor Inc, Malvern, PA.[7] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[8] \"Product Information. Sylvant (siltuximab).\" Janssen Biotech, Inc., Horsham, PA, PA.[9] \"Product Information. Stelara (ustekinumab).\" Centocor Inc, Malvern, PA.[10] \"Product Information. Ilumya (tildrakizumab).\" Merck & Company Inc, Whitehouse Station, NJ.[11] \"Product Information. Actemra (tocilizumab).\" Genentech, South San Francisco, CA.[12] \"Product Information. Amevive (alefacept).\" Biogen, Cambridge, MA.[13] \"Product Information. Remicade (infliximab).\" Centocor Inc, Malvern, PA.[14] \"Product Information. Taltz Autoinjector (ixekizumab).\" Eli Lilly and Company, Indianapolis, IN.[15] \"Product Information. Arcalyst (rilonacept).\" Regeneron Pharmaceuticals Inc, Tarrytown, NY.[16] Ace LN, Jaffe JM, Kunka RL \"Effect of food and an antacid on quinidine bioavailability.\" Biopharm Drug Dispos 4 (1983): 183-90[17] Min DI, Ku YM, Geraets DR, Lee HC \"Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers.\" J Clin Pharmacol 36 (1996): 469-76[18] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[19] Ha HR, Chen J, Leuenberger PM, Freiburghaus AU, Follah F \"In vitro inhibition of midazolam and quinidine metabolism by flavonoids.\" Eur J Clin Pharmacol 48 (1995): 367-71", "alternatives_a": "Suvorexant, Flurazepam, Methohexital, Zolpidem, Pentobarbital, Zaleplon, Dichloralphenazone, Valerian, Temazepam, Butabarbital, Secobarbital, More", "alternatives_b": "Antithymocyte immunoglobulin (rabbit), Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Methotrexate, Abatacept, Inebilizumab, Cladribine, Belimumab, Risankizumab, More", "updated_at": 1767369485}, {"id": 97827, "ingredient1": "Emapalumab", "ingredient2": "Phenytoin", "severity": "Moderate", "effect": "Plasma concentrations of drugs that are CYP450 substrates may decrease following the initiation of interleukin (IL) inhibitors, tumor necrosis factor (TNF) blockers, or interferon (IFN) inhibitors in patients with chronic inflammatory diseases. Because the formation of hepatic CYP450 enzymes is down-regulated during infection and chronic inflammation by increased levels of certain cytokines (e.g., interleukins-1, -6, and -10; tumor necrosis factor alpha; interferons), treatment targeting these cytokines may restore or normalize CYP450 enzyme levels resulting in increased metabolism of these drugs.", "source": "DDInter", "management_text": "Caution is advised when treatments targeting cytokines such as interleukins, tumor necrosis factors, or interferons are prescribed to patients receiving concomitant drugs that are CYP450 substrates, particularly those with narrow therapeutic ranges (e.g., antiarrhythmics, anticonvulsants, immunosuppressants, theophylline) or sensitive substrates where decreases in plasma levels may be significant or undesirable (e.g., oral contraceptives, statins, benzodiazepines, opioids). Clinical and/or laboratory monitoring should be considered following the initiation or withdrawal of such treatments, and the dosage(s) of the CYP450 substrate(s) adjusted accordingly. The effects of IL inhibitors, TNF blockers, and IFN inhibitors on CYP450 activities may persist for several weeks after stopping therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when treatments targeting cytokines such as interleukins, tumor necrosis factors, or interferons are prescribed to patients receiving concomitant drugs that are CYP450 substrates, particularly those with narrow therapeutic ranges (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97931/", "reference_text": "[1] \"Product Information. Skyrizi (risankizumab).\" AbbVie US LLC, North Chicago, IL.[2] \"Product Information. Cosentyx (secukinumab).\" Novartis Pharmaceuticals, East Hanover, NJ.[3] \"Product Information. Ilaris (canakinumab).\" Novartis Pharmaceuticals, East Hanover, NJ.[4] \"Product Information. Gamifant (emapalumab).\" Sobi Inc, Ardmore, PA.[5] \"Product Information. Kevzara (sarilumab).\" sanofi-aventis, Bridgewater, NJ.[6] \"Product Information. Simponi (golimumab).\" Centocor Inc, Malvern, PA.[7] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[8] \"Product Information. Sylvant (siltuximab).\" Janssen Biotech, Inc., Horsham, PA, PA.[9] \"Product Information. Stelara (ustekinumab).\" Centocor Inc, Malvern, PA.[10] \"Product Information. Ilumya (tildrakizumab).\" Merck & Company Inc, Whitehouse Station, NJ.[11] \"Product Information. Actemra (tocilizumab).\" Genentech, South San Francisco, CA.[12] \"Product Information. Amevive (alefacept).\" Biogen, Cambridge, MA.[13] \"Product Information. Remicade (infliximab).\" Centocor Inc, Malvern, PA.[14] \"Product Information. Taltz Autoinjector (ixekizumab).\" Eli Lilly and Company, Indianapolis, IN.[15] \"Product Information. Arcalyst (rilonacept).\" Regeneron Pharmaceuticals Inc, Tarrytown, NY.[16] Ace LN, Jaffe JM, Kunka RL \"Effect of food and an antacid on quinidine bioavailability.\" Biopharm Drug Dispos 4 (1983): 183-90[17] Min DI, Ku YM, Geraets DR, Lee HC \"Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers.\" J Clin Pharmacol 36 (1996): 469-76[18] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[19] Ha HR, Chen J, Leuenberger PM, Freiburghaus AU, Follah F \"In vitro inhibition of midazolam and quinidine metabolism by flavonoids.\" Eur J Clin Pharmacol 48 (1995): 367-71", "alternatives_a": "Brivaracetam, Topiramate, Ezogabine, Cenobamate, Lamotrigine, Lacosamide, Levetiracetam, Tiagabine, Oxcarbazepine, Ethotoin, Rufinamide, More", "alternatives_b": "Antithymocyte immunoglobulin (rabbit), Anifrolumab, Ravulizumab, Diroximel fumarate, Abatacept, Inebilizumab, Ozanimod, Belimumab, Sutimlimab, Risankizumab, Antilymphocyte immunoglobulin (horse), More", "updated_at": 1767369485}, {"id": 97828, "ingredient1": "Emapalumab", "ingredient2": "Primidone", "severity": "Moderate", "effect": "Plasma concentrations of drugs that are CYP450 substrates may decrease following the initiation of interleukin (IL) inhibitors, tumor necrosis factor (TNF) blockers, or interferon (IFN) inhibitors in patients with chronic inflammatory diseases. Because the formation of hepatic CYP450 enzymes is down-regulated during infection and chronic inflammation by increased levels of certain cytokines (e.g., interleukins-1, -6, and -10; tumor necrosis factor alpha; interferons), treatment targeting these cytokines may restore or normalize CYP450 enzyme levels resulting in increased metabolism of these drugs.", "source": "DDInter", "management_text": "Caution is advised when treatments targeting cytokines such as interleukins, tumor necrosis factors, or interferons are prescribed to patients receiving concomitant drugs that are CYP450 substrates, particularly those with narrow therapeutic ranges (e.g., antiarrhythmics, anticonvulsants, immunosuppressants, theophylline) or sensitive substrates where decreases in plasma levels may be significant or undesirable (e.g., oral contraceptives, statins, benzodiazepines, opioids). Clinical and/or laboratory monitoring should be considered following the initiation or withdrawal of such treatments, and the dosage(s) of the CYP450 substrate(s) adjusted accordingly. The effects of IL inhibitors, TNF blockers, and IFN inhibitors on CYP450 activities may persist for several weeks after stopping therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when treatments targeting cytokines such as interleukins, tumor necrosis factors, or interferons are prescribed to patients receiving concomitant drugs that are CYP450 substrates, particularly those with narrow therapeutic ranges (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97932/", "reference_text": "[1] \"Product Information. Skyrizi (risankizumab).\" AbbVie US LLC, North Chicago, IL.[2] \"Product Information. Cosentyx (secukinumab).\" Novartis Pharmaceuticals, East Hanover, NJ.[3] \"Product Information. Ilaris (canakinumab).\" Novartis Pharmaceuticals, East Hanover, NJ.[4] \"Product Information. Gamifant (emapalumab).\" Sobi Inc, Ardmore, PA.[5] \"Product Information. Kevzara (sarilumab).\" sanofi-aventis, Bridgewater, NJ.[6] \"Product Information. Simponi (golimumab).\" Centocor Inc, Malvern, PA.[7] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[8] \"Product Information. Sylvant (siltuximab).\" Janssen Biotech, Inc., Horsham, PA, PA.[9] \"Product Information. Stelara (ustekinumab).\" Centocor Inc, Malvern, PA.[10] \"Product Information. Ilumya (tildrakizumab).\" Merck & Company Inc, Whitehouse Station, NJ.[11] \"Product Information. Actemra (tocilizumab).\" Genentech, South San Francisco, CA.[12] \"Product Information. Amevive (alefacept).\" Biogen, Cambridge, MA.[13] \"Product Information. Remicade (infliximab).\" Centocor Inc, Malvern, PA.[14] \"Product Information. Taltz Autoinjector (ixekizumab).\" Eli Lilly and Company, Indianapolis, IN.[15] \"Product Information. Arcalyst (rilonacept).\" Regeneron Pharmaceuticals Inc, Tarrytown, NY.[16] Ace LN, Jaffe JM, Kunka RL \"Effect of food and an antacid on quinidine bioavailability.\" Biopharm Drug Dispos 4 (1983): 183-90[17] Min DI, Ku YM, Geraets DR, Lee HC \"Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers.\" J Clin Pharmacol 36 (1996): 469-76[18] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[19] Ha HR, Chen J, Leuenberger PM, Freiburghaus AU, Follah F \"In vitro inhibition of midazolam and quinidine metabolism by flavonoids.\" Eur J Clin Pharmacol 48 (1995): 367-71", "alternatives_a": "Suvorexant, Flurazepam, Methohexital, Zolpidem, Pentobarbital, Zaleplon, Dichloralphenazone, Valerian, Temazepam, Butabarbital, Secobarbital, More", "alternatives_b": "Antithymocyte immunoglobulin (rabbit), Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Abatacept, Inebilizumab, Cladribine, Belimumab, Sutimlimab, Risankizumab, More", "updated_at": 1767369485}, {"id": 97829, "ingredient1": "Emapalumab", "ingredient2": "Procainamide", "severity": "Moderate", "effect": "Plasma concentrations of drugs that are CYP450 substrates may decrease following the initiation of interleukin (IL) inhibitors, tumor necrosis factor (TNF) blockers, or interferon (IFN) inhibitors in patients with chronic inflammatory diseases. Because the formation of hepatic CYP450 enzymes is down-regulated during infection and chronic inflammation by increased levels of certain cytokines (e.g., interleukins-1, -6, and -10; tumor necrosis factor alpha; interferons), treatment targeting these cytokines may restore or normalize CYP450 enzyme levels resulting in increased metabolism of these drugs.", "source": "DDInter", "management_text": "Caution is advised when treatments targeting cytokines such as interleukins, tumor necrosis factors, or interferons are prescribed to patients receiving concomitant drugs that are CYP450 substrates, particularly those with narrow therapeutic ranges (e.g., antiarrhythmics, anticonvulsants, immunosuppressants, theophylline) or sensitive substrates where decreases in plasma levels may be significant or undesirable (e.g., oral contraceptives, statins, benzodiazepines, opioids). Clinical and/or laboratory monitoring should be considered following the initiation or withdrawal of such treatments, and the dosage(s) of the CYP450 substrate(s) adjusted accordingly. The effects of IL inhibitors, TNF blockers, and IFN inhibitors on CYP450 activities may persist for several weeks after stopping therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when treatments targeting cytokines such as interleukins, tumor necrosis factors, or interferons are prescribed to patients receiving concomitant drugs that are CYP450 substrates, particularly those with narrow therapeutic ranges (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97933/", "reference_text": "[1] \"Product Information. Skyrizi (risankizumab).\" AbbVie US LLC, North Chicago, IL.[2] \"Product Information. Cosentyx (secukinumab).\" Novartis Pharmaceuticals, East Hanover, NJ.[3] \"Product Information. Ilaris (canakinumab).\" Novartis Pharmaceuticals, East Hanover, NJ.[4] \"Product Information. Gamifant (emapalumab).\" Sobi Inc, Ardmore, PA.[5] \"Product Information. Kevzara (sarilumab).\" sanofi-aventis, Bridgewater, NJ.[6] \"Product Information. Simponi (golimumab).\" Centocor Inc, Malvern, PA.[7] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[8] \"Product Information. Sylvant (siltuximab).\" Janssen Biotech, Inc., Horsham, PA, PA.[9] \"Product Information. Stelara (ustekinumab).\" Centocor Inc, Malvern, PA.[10] \"Product Information. Ilumya (tildrakizumab).\" Merck & Company Inc, Whitehouse Station, NJ.[11] \"Product Information. Actemra (tocilizumab).\" Genentech, South San Francisco, CA.[12] \"Product Information. Amevive (alefacept).\" Biogen, Cambridge, MA.[13] \"Product Information. Remicade (infliximab).\" Centocor Inc, Malvern, PA.[14] \"Product Information. Taltz Autoinjector (ixekizumab).\" Eli Lilly and Company, Indianapolis, IN.[15] \"Product Information. Arcalyst (rilonacept).\" Regeneron Pharmaceuticals Inc, Tarrytown, NY.[16] Ace LN, Jaffe JM, Kunka RL \"Effect of food and an antacid on quinidine bioavailability.\" Biopharm Drug Dispos 4 (1983): 183-90[17] Min DI, Ku YM, Geraets DR, Lee HC \"Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers.\" J Clin Pharmacol 36 (1996): 469-76[18] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[19] Ha HR, Chen J, Leuenberger PM, Freiburghaus AU, Follah F \"In vitro inhibition of midazolam and quinidine metabolism by flavonoids.\" Eur J Clin Pharmacol 48 (1995): 367-71", "alternatives_a": "Tocainide, Dronedarone, Dofetilide, Bretylium, Moricizine, Ibutilide", "alternatives_b": "Cyclosporine, Antithymocyte immunoglobulin (rabbit), Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Methotrexate, Abatacept, Apremilast, Inebilizumab, Belumosudil, More", "updated_at": 1767369485}, {"id": 97830, "ingredient1": "Emapalumab", "ingredient2": "Propafenone", "severity": "Moderate", "effect": "Plasma concentrations of drugs that are CYP450 substrates may decrease following the initiation of interleukin (IL) inhibitors, tumor necrosis factor (TNF) blockers, or interferon (IFN) inhibitors in patients with chronic inflammatory diseases. Because the formation of hepatic CYP450 enzymes is down-regulated during infection and chronic inflammation by increased levels of certain cytokines (e.g., interleukins-1, -6, and -10; tumor necrosis factor alpha; interferons), treatment targeting these cytokines may restore or normalize CYP450 enzyme levels resulting in increased metabolism of these drugs.", "source": "DDInter", "management_text": "Caution is advised when treatments targeting cytokines such as interleukins, tumor necrosis factors, or interferons are prescribed to patients receiving concomitant drugs that are CYP450 substrates, particularly those with narrow therapeutic ranges (e.g., antiarrhythmics, anticonvulsants, immunosuppressants, theophylline) or sensitive substrates where decreases in plasma levels may be significant or undesirable (e.g., oral contraceptives, statins, benzodiazepines, opioids). Clinical and/or laboratory monitoring should be considered following the initiation or withdrawal of such treatments, and the dosage(s) of the CYP450 substrate(s) adjusted accordingly. The effects of IL inhibitors, TNF blockers, and IFN inhibitors on CYP450 activities may persist for several weeks after stopping therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when treatments targeting cytokines such as interleukins, tumor necrosis factors, or interferons are prescribed to patients receiving concomitant drugs that are CYP450 substrates, particularly those with narrow therapeutic ranges (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97934/", "reference_text": "[1] \"Product Information. Skyrizi (risankizumab).\" AbbVie US LLC, North Chicago, IL.[2] \"Product Information. Cosentyx (secukinumab).\" Novartis Pharmaceuticals, East Hanover, NJ.[3] \"Product Information. Ilaris (canakinumab).\" Novartis Pharmaceuticals, East Hanover, NJ.[4] \"Product Information. Gamifant (emapalumab).\" Sobi Inc, Ardmore, PA.[5] \"Product Information. Kevzara (sarilumab).\" sanofi-aventis, Bridgewater, NJ.[6] \"Product Information. Simponi (golimumab).\" Centocor Inc, Malvern, PA.[7] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[8] \"Product Information. Sylvant (siltuximab).\" Janssen Biotech, Inc., Horsham, PA, PA.[9] \"Product Information. Stelara (ustekinumab).\" Centocor Inc, Malvern, PA.[10] \"Product Information. Ilumya (tildrakizumab).\" Merck & Company Inc, Whitehouse Station, NJ.[11] \"Product Information. Actemra (tocilizumab).\" Genentech, South San Francisco, CA.[12] \"Product Information. Amevive (alefacept).\" Biogen, Cambridge, MA.[13] \"Product Information. Remicade (infliximab).\" Centocor Inc, Malvern, PA.[14] \"Product Information. Taltz Autoinjector (ixekizumab).\" Eli Lilly and Company, Indianapolis, IN.[15] \"Product Information. Arcalyst (rilonacept).\" Regeneron Pharmaceuticals Inc, Tarrytown, NY.[16] Ace LN, Jaffe JM, Kunka RL \"Effect of food and an antacid on quinidine bioavailability.\" Biopharm Drug Dispos 4 (1983): 183-90[17] Min DI, Ku YM, Geraets DR, Lee HC \"Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers.\" J Clin Pharmacol 36 (1996): 469-76[18] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[19] Ha HR, Chen J, Leuenberger PM, Freiburghaus AU, Follah F \"In vitro inhibition of midazolam and quinidine metabolism by flavonoids.\" Eur J Clin Pharmacol 48 (1995): 367-71", "alternatives_a": "Tocainide, Dronedarone, Dofetilide, Bretylium, Moricizine, Ibutilide", "alternatives_b": "Antithymocyte immunoglobulin (rabbit), Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Abatacept, Upadacitinib, Apremilast, Inebilizumab, Cladribine, Belumosudil, More", "updated_at": 1767369485}, {"id": 97831, "ingredient1": "Emapalumab", "ingredient2": "Quinidine", "severity": "Moderate", "effect": "Plasma concentrations of drugs that are CYP450 substrates may decrease following the initiation of interleukin (IL) inhibitors, tumor necrosis factor (TNF) blockers, or interferon (IFN) inhibitors in patients with chronic inflammatory diseases. Because the formation of hepatic CYP450 enzymes is down-regulated during infection and chronic inflammation by increased levels of certain cytokines (e.g., interleukins-1, -6, and -10; tumor necrosis factor alpha; interferons), treatment targeting these cytokines may restore or normalize CYP450 enzyme levels resulting in increased metabolism of these drugs.", "source": "DDInter", "management_text": "Caution is advised when treatments targeting cytokines such as interleukins, tumor necrosis factors, or interferons are prescribed to patients receiving concomitant drugs that are CYP450 substrates, particularly those with narrow therapeutic ranges (e.g., antiarrhythmics, anticonvulsants, immunosuppressants, theophylline) or sensitive substrates where decreases in plasma levels may be significant or undesirable (e.g., oral contraceptives, statins, benzodiazepines, opioids). Clinical and/or laboratory monitoring should be considered following the initiation or withdrawal of such treatments, and the dosage(s) of the CYP450 substrate(s) adjusted accordingly. The effects of IL inhibitors, TNF blockers, and IFN inhibitors on CYP450 activities may persist for several weeks after stopping therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when treatments targeting cytokines such as interleukins, tumor necrosis factors, or interferons are prescribed to patients receiving concomitant drugs that are CYP450 substrates, particularly those with narrow therapeutic ranges (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97935/", "reference_text": "[1] \"Product Information. Skyrizi (risankizumab).\" AbbVie US LLC, North Chicago, IL.[2] \"Product Information. Cosentyx (secukinumab).\" Novartis Pharmaceuticals, East Hanover, NJ.[3] \"Product Information. Ilaris (canakinumab).\" Novartis Pharmaceuticals, East Hanover, NJ.[4] \"Product Information. Gamifant (emapalumab).\" Sobi Inc, Ardmore, PA.[5] \"Product Information. Kevzara (sarilumab).\" sanofi-aventis, Bridgewater, NJ.[6] \"Product Information. Simponi (golimumab).\" Centocor Inc, Malvern, PA.[7] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[8] \"Product Information. Sylvant (siltuximab).\" Janssen Biotech, Inc., Horsham, PA, PA.[9] \"Product Information. Stelara (ustekinumab).\" Centocor Inc, Malvern, PA.[10] \"Product Information. Ilumya (tildrakizumab).\" Merck & Company Inc, Whitehouse Station, NJ.[11] \"Product Information. Actemra (tocilizumab).\" Genentech, South San Francisco, CA.[12] \"Product Information. Amevive (alefacept).\" Biogen, Cambridge, MA.[13] \"Product Information. Remicade (infliximab).\" Centocor Inc, Malvern, PA.[14] \"Product Information. Taltz Autoinjector (ixekizumab).\" Eli Lilly and Company, Indianapolis, IN.[15] \"Product Information. Arcalyst (rilonacept).\" Regeneron Pharmaceuticals Inc, Tarrytown, NY.[16] Ace LN, Jaffe JM, Kunka RL \"Effect of food and an antacid on quinidine bioavailability.\" Biopharm Drug Dispos 4 (1983): 183-90[17] Min DI, Ku YM, Geraets DR, Lee HC \"Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers.\" J Clin Pharmacol 36 (1996): 469-76[18] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[19] Ha HR, Chen J, Leuenberger PM, Freiburghaus AU, Follah F \"In vitro inhibition of midazolam and quinidine metabolism by flavonoids.\" Eur J Clin Pharmacol 48 (1995): 367-71", "alternatives_a": "Tocainide, Dronedarone, Dofetilide, Bretylium, Moricizine, Ibutilide", "alternatives_b": "Antithymocyte immunoglobulin (rabbit), Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Abatacept, Upadacitinib, Apremilast, Inebilizumab, Cladribine, Belumosudil, More", "updated_at": 1767369485}, {"id": 97832, "ingredient1": "Emapalumab", "ingredient2": "Rivaroxaban", "severity": "Moderate", "effect": "Plasma concentrations of drugs that are CYP450 substrates may decrease following the initiation of interleukin (IL) inhibitors, tumor necrosis factor (TNF) blockers, or interferon (IFN) inhibitors in patients with chronic inflammatory diseases. Because the formation of hepatic CYP450 enzymes is down-regulated during infection and chronic inflammation by increased levels of certain cytokines (e.g., interleukins-1, -6, and -10; tumor necrosis factor alpha; interferons), treatment targeting these cytokines may restore or normalize CYP450 enzyme levels resulting in increased metabolism of these drugs.", "source": "DDInter", "management_text": "Caution is advised when treatments targeting cytokines such as interleukins, tumor necrosis factors, or interferons are prescribed to patients receiving concomitant drugs that are CYP450 substrates, particularly those with narrow therapeutic ranges (e.g., antiarrhythmics, anticonvulsants, immunosuppressants, theophylline) or sensitive substrates where decreases in plasma levels may be significant or undesirable (e.g., oral contraceptives, statins, benzodiazepines, opioids). Clinical and/or laboratory monitoring should be considered following the initiation or withdrawal of such treatments, and the dosage(s) of the CYP450 substrate(s) adjusted accordingly. The effects of IL inhibitors, TNF blockers, and IFN inhibitors on CYP450 activities may persist for several weeks after stopping therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when treatments targeting cytokines such as interleukins, tumor necrosis factors, or interferons are prescribed to patients receiving concomitant drugs that are CYP450 substrates, particularly those with narrow therapeutic ranges (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97936/", "reference_text": "[1] \"Product Information. Skyrizi (risankizumab).\" AbbVie US LLC, North Chicago, IL.[2] \"Product Information. Cosentyx (secukinumab).\" Novartis Pharmaceuticals, East Hanover, NJ.[3] \"Product Information. Ilaris (canakinumab).\" Novartis Pharmaceuticals, East Hanover, NJ.[4] \"Product Information. Gamifant (emapalumab).\" Sobi Inc, Ardmore, PA.[5] \"Product Information. Kevzara (sarilumab).\" sanofi-aventis, Bridgewater, NJ.[6] \"Product Information. Simponi (golimumab).\" Centocor Inc, Malvern, PA.[7] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[8] \"Product Information. Sylvant (siltuximab).\" Janssen Biotech, Inc., Horsham, PA, PA.[9] \"Product Information. Stelara (ustekinumab).\" Centocor Inc, Malvern, PA.[10] \"Product Information. Ilumya (tildrakizumab).\" Merck & Company Inc, Whitehouse Station, NJ.[11] \"Product Information. Actemra (tocilizumab).\" Genentech, South San Francisco, CA.[12] \"Product Information. Amevive (alefacept).\" Biogen, Cambridge, MA.[13] \"Product Information. Remicade (infliximab).\" Centocor Inc, Malvern, PA.[14] \"Product Information. Taltz Autoinjector (ixekizumab).\" Eli Lilly and Company, Indianapolis, IN.[15] \"Product Information. Arcalyst (rilonacept).\" Regeneron Pharmaceuticals Inc, Tarrytown, NY.[16] Ace LN, Jaffe JM, Kunka RL \"Effect of food and an antacid on quinidine bioavailability.\" Biopharm Drug Dispos 4 (1983): 183-90[17] Min DI, Ku YM, Geraets DR, Lee HC \"Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers.\" J Clin Pharmacol 36 (1996): 469-76[18] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[19] Ha HR, Chen J, Leuenberger PM, Freiburghaus AU, Follah F \"In vitro inhibition of midazolam and quinidine metabolism by flavonoids.\" Eur J Clin Pharmacol 48 (1995): 367-71", "alternatives_a": "Ticagrelor, Betrixaban, Clopidogrel, Cilostazol, Iloprost, Lepirudin, Acenocoumarol, Urokinase, Cangrelor, Dipyridamole, Caplacizumab, More", "alternatives_b": "Antithymocyte immunoglobulin (rabbit), Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Methotrexate, Abatacept, Upadacitinib, Siponimod, Apremilast, Inebilizumab, More", "updated_at": 1767369485}, {"id": 97833, "ingredient1": "Emapalumab", "ingredient2": "Rotavirus vaccine", "severity": "Major", "effect": "The administration of live or live attenuated vaccines during emapalumab therapy may be associated with a risk of disseminated infection due to enhanced replication of vaccine virus or bacteria in the presence of diminished immune competence. Emapalumab is a monoclonal antibody that binds to and neutralizes interferon gamma, which may increase susceptibility to certain pathogens and increase the risk of fatal and serious infections.", "source": "DDInter", "management_text": "The use of live or live attenuated vaccines should be avoided during and for at least 4 weeks after the last dose of emapalumab.", "mechanism_text": "Others", "recommendation": "The use of live or live attenuated vaccines should be avoided during and for at least 4 weeks after the last dose of emapalumab.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97937/", "reference_text": "[1] \"Product Information. Gamifant (emapalumab).\" Sobi Inc, Ardmore, PA.", "alternatives_a": "Apremilast, Pirfenidone, Belumosudil, Teprotumumab, Ravulizumab, Pegcetacoplan, Eculizumab, Sutimlimab", "alternatives_b": "", "updated_at": 1767369485}, {"id": 97834, "ingredient1": "Emapalumab", "ingredient2": "Rubella virus vaccine", "severity": "Major", "effect": "The administration of live or live attenuated vaccines during emapalumab therapy may be associated with a risk of disseminated infection due to enhanced replication of vaccine virus or bacteria in the presence of diminished immune competence. Emapalumab is a monoclonal antibody that binds to and neutralizes interferon gamma, which may increase susceptibility to certain pathogens and increase the risk of fatal and serious infections.", "source": "DDInter", "management_text": "The use of live or live attenuated vaccines should be avoided during and for at least 4 weeks after the last dose of emapalumab.", "mechanism_text": "Others", "recommendation": "The use of live or live attenuated vaccines should be avoided during and for at least 4 weeks after the last dose of emapalumab.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97938/", "reference_text": "[1] \"Product Information. Gamifant (emapalumab).\" Sobi Inc, Ardmore, PA.", "alternatives_a": "Apremilast, Pirfenidone, Belumosudil, Teprotumumab, Ravulizumab, Pegcetacoplan, Eculizumab, Sutimlimab", "alternatives_b": "", "updated_at": 1767369485}, {"id": 97835, "ingredient1": "Emapalumab", "ingredient2": "Simvastatin", "severity": "Moderate", "effect": "Plasma concentrations of drugs that are CYP450 substrates may decrease following the initiation of interleukin (IL) inhibitors, tumor necrosis factor (TNF) blockers, or interferon (IFN) inhibitors in patients with chronic inflammatory diseases. Because the formation of hepatic CYP450 enzymes is down-regulated during infection and chronic inflammation by increased levels of certain cytokines (e.g., interleukins-1, -6, and -10; tumor necrosis factor alpha; interferons), treatment targeting these cytokines may restore or normalize CYP450 enzyme levels resulting in increased metabolism of these drugs.", "source": "DDInter", "management_text": "Caution is advised when treatments targeting cytokines such as interleukins, tumor necrosis factors, or interferons are prescribed to patients receiving concomitant drugs that are CYP450 substrates, particularly those with narrow therapeutic ranges (e.g., antiarrhythmics, anticonvulsants, immunosuppressants, theophylline) or sensitive substrates where decreases in plasma levels may be significant or undesirable (e.g., oral contraceptives, statins, benzodiazepines, opioids). Clinical and/or laboratory monitoring should be considered following the initiation or withdrawal of such treatments, and the dosage(s) of the CYP450 substrate(s) adjusted accordingly. The effects of IL inhibitors, TNF blockers, and IFN inhibitors on CYP450 activities may persist for several weeks after stopping therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when treatments targeting cytokines such as interleukins, tumor necrosis factors, or interferons are prescribed to patients receiving concomitant drugs that are CYP450 substrates, particularly those with narrow therapeutic ranges (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97939/", "reference_text": "[1] \"Product Information. Skyrizi (risankizumab).\" AbbVie US LLC, North Chicago, IL.[2] \"Product Information. Cosentyx (secukinumab).\" Novartis Pharmaceuticals, East Hanover, NJ.[3] \"Product Information. Ilaris (canakinumab).\" Novartis Pharmaceuticals, East Hanover, NJ.[4] \"Product Information. Gamifant (emapalumab).\" Sobi Inc, Ardmore, PA.[5] \"Product Information. Kevzara (sarilumab).\" sanofi-aventis, Bridgewater, NJ.[6] \"Product Information. Simponi (golimumab).\" Centocor Inc, Malvern, PA.[7] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[8] \"Product Information. Sylvant (siltuximab).\" Janssen Biotech, Inc., Horsham, PA, PA.[9] \"Product Information. Stelara (ustekinumab).\" Centocor Inc, Malvern, PA.[10] \"Product Information. Ilumya (tildrakizumab).\" Merck & Company Inc, Whitehouse Station, NJ.[11] \"Product Information. Actemra (tocilizumab).\" Genentech, South San Francisco, CA.[12] \"Product Information. Amevive (alefacept).\" Biogen, Cambridge, MA.[13] \"Product Information. Remicade (infliximab).\" Centocor Inc, Malvern, PA.[14] \"Product Information. Taltz Autoinjector (ixekizumab).\" Eli Lilly and Company, Indianapolis, IN.[15] \"Product Information. Arcalyst (rilonacept).\" Regeneron Pharmaceuticals Inc, Tarrytown, NY.[16] Ace LN, Jaffe JM, Kunka RL \"Effect of food and an antacid on quinidine bioavailability.\" Biopharm Drug Dispos 4 (1983): 183-90[17] Min DI, Ku YM, Geraets DR, Lee HC \"Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers.\" J Clin Pharmacol 36 (1996): 469-76[18] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[19] Ha HR, Chen J, Leuenberger PM, Freiburghaus AU, Follah F \"In vitro inhibition of midazolam and quinidine metabolism by flavonoids.\" Eur J Clin Pharmacol 48 (1995): 367-71", "alternatives_a": "Glipizide, Acetohexamide, Guar gum, Pramlintide, Alogliptin, Rosuvastatin, Tolazamide, Empagliflozin, Dulaglutide, Exenatide, Tolbutamide, More", "alternatives_b": "Antithymocyte immunoglobulin (rabbit), Anifrolumab, Ravulizumab, Diroximel fumarate, Abatacept, Upadacitinib, Siponimod, Apremilast, Inebilizumab, Cladribine, Belumosudil, More", "updated_at": 1767369485}, {"id": 97836, "ingredient1": "Emapalumab", "ingredient2": "Smallpox (Vaccinia) Vaccine, Live", "severity": "Major", "effect": "The administration of live or live attenuated vaccines during emapalumab therapy may be associated with a risk of disseminated infection due to enhanced replication of vaccine virus or bacteria in the presence of diminished immune competence. Emapalumab is a monoclonal antibody that binds to and neutralizes interferon gamma, which may increase susceptibility to certain pathogens and increase the risk of fatal and serious infections.", "source": "DDInter", "management_text": "The use of live or live attenuated vaccines should be avoided during and for at least 4 weeks after the last dose of emapalumab.", "mechanism_text": "Others", "recommendation": "The use of live or live attenuated vaccines should be avoided during and for at least 4 weeks after the last dose of emapalumab.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97940/", "reference_text": "[1] \"Product Information. Gamifant (emapalumab).\" Sobi Inc, Ardmore, PA.", "alternatives_a": "Apremilast, Pirfenidone, Belumosudil, Teprotumumab, Ravulizumab, Pegcetacoplan, Eculizumab, Sutimlimab", "alternatives_b": "", "updated_at": 1767369485}, {"id": 97837, "ingredient1": "Emapalumab", "ingredient2": "Sufentanil", "severity": "Moderate", "effect": "Plasma concentrations of drugs that are CYP450 substrates may decrease following the initiation of interleukin (IL) inhibitors, tumor necrosis factor (TNF) blockers, or interferon (IFN) inhibitors in patients with chronic inflammatory diseases. Because the formation of hepatic CYP450 enzymes is down-regulated during infection and chronic inflammation by increased levels of certain cytokines (e.g., interleukins-1, -6, and -10; tumor necrosis factor alpha; interferons), treatment targeting these cytokines may restore or normalize CYP450 enzyme levels resulting in increased metabolism of these drugs.", "source": "DDInter", "management_text": "Caution is advised when treatments targeting cytokines such as interleukins, tumor necrosis factors, or interferons are prescribed to patients receiving concomitant drugs that are CYP450 substrates, particularly those with narrow therapeutic ranges (e.g., antiarrhythmics, anticonvulsants, immunosuppressants, theophylline) or sensitive substrates where decreases in plasma levels may be significant or undesirable (e.g., oral contraceptives, statins, benzodiazepines, opioids). Clinical and/or laboratory monitoring should be considered following the initiation or withdrawal of such treatments, and the dosage(s) of the CYP450 substrate(s) adjusted accordingly. The effects of IL inhibitors, TNF blockers, and IFN inhibitors on CYP450 activities may persist for several weeks after stopping therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when treatments targeting cytokines such as interleukins, tumor necrosis factors, or interferons are prescribed to patients receiving concomitant drugs that are CYP450 substrates, particularly those with narrow therapeutic ranges (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97941/", "reference_text": "[1] \"Product Information. Skyrizi (risankizumab).\" AbbVie US LLC, North Chicago, IL.[2] \"Product Information. Cosentyx (secukinumab).\" Novartis Pharmaceuticals, East Hanover, NJ.[3] \"Product Information. Ilaris (canakinumab).\" Novartis Pharmaceuticals, East Hanover, NJ.[4] \"Product Information. Gamifant (emapalumab).\" Sobi Inc, Ardmore, PA.[5] \"Product Information. Kevzara (sarilumab).\" sanofi-aventis, Bridgewater, NJ.[6] \"Product Information. Simponi (golimumab).\" Centocor Inc, Malvern, PA.[7] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[8] \"Product Information. Sylvant (siltuximab).\" Janssen Biotech, Inc., Horsham, PA, PA.[9] \"Product Information. Stelara (ustekinumab).\" Centocor Inc, Malvern, PA.[10] \"Product Information. Ilumya (tildrakizumab).\" Merck & Company Inc, Whitehouse Station, NJ.[11] \"Product Information. Actemra (tocilizumab).\" Genentech, South San Francisco, CA.[12] \"Product Information. Amevive (alefacept).\" Biogen, Cambridge, MA.[13] \"Product Information. Remicade (infliximab).\" Centocor Inc, Malvern, PA.[14] \"Product Information. Taltz Autoinjector (ixekizumab).\" Eli Lilly and Company, Indianapolis, IN.[15] \"Product Information. Arcalyst (rilonacept).\" Regeneron Pharmaceuticals Inc, Tarrytown, NY.[16] Ace LN, Jaffe JM, Kunka RL \"Effect of food and an antacid on quinidine bioavailability.\" Biopharm Drug Dispos 4 (1983): 183-90[17] Min DI, Ku YM, Geraets DR, Lee HC \"Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers.\" J Clin Pharmacol 36 (1996): 469-76[18] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[19] Ha HR, Chen J, Leuenberger PM, Freiburghaus AU, Follah F \"In vitro inhibition of midazolam and quinidine metabolism by flavonoids.\" Eur J Clin Pharmacol 48 (1995): 367-71", "alternatives_a": "Halothane, Thiopental, Alfentanil, Remifentanil, Isoflurane, Sodium oxybate, Methohexital, Nitrous oxide, Desflurane, Propofol, Enflurane, More", "alternatives_b": "Cyclosporine, Antithymocyte immunoglobulin (rabbit), Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Methotrexate, Abatacept, Upadacitinib, Siponimod, Apremilast, More", "updated_at": 1767369485}, {"id": 97838, "ingredient1": "Emapalumab", "ingredient2": "Talimogene laherparepvec", "severity": "Major", "effect": "Talimogene laherparepvec is a live, attenuated herpes simplex virus. Administration during immunosuppressant or intense antineoplastic therapy may be associated with a risk of potentially life-threatening disseminated herpetic infection due to enhanced virus replication in the presence of diminished immune competence. Patients may be immunosuppressed if they have recently received or are receiving alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, or long-term topical or inhaled corticosteroids.", "source": "DDInter", "management_text": "Talimogene laherparepvec should not be used in patients receiving immunosuppressive therapy or cancer chemotherapy. Treatment with talimogene laherparepvec may need to be deferred until after such therapy is discontinued and the patient's immune system has sufficiently recovered.", "mechanism_text": "Synergism", "recommendation": "Talimogene laherparepvec should not be used in patients receiving immunosuppressive therapy or cancer chemotherapy.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97942/", "reference_text": "[1] \"Product Information. Imlygic (talimogene laherparepvec).\" Amgen USA, Thousand Oaks, CA.", "alternatives_a": "Pertuzumab, Olaparib, Oxaliplatin, Rucaparib, Bortezomib, Tisagenlecleucel, Aminolevulinic acid, Omacetaxine mepesuccinate, Tazemetostat, Altretamine, Tagraxofusp, More", "alternatives_b": "Apremilast, Pirfenidone, Belumosudil, Teprotumumab, Ravulizumab, Pegcetacoplan, Eculizumab, Sutimlimab", "updated_at": 1767369485}, {"id": 97839, "ingredient1": "Emapalumab", "ingredient2": "Triazolam", "severity": "Moderate", "effect": "Plasma concentrations of drugs that are CYP450 substrates may decrease following the initiation of interleukin (IL) inhibitors, tumor necrosis factor (TNF) blockers, or interferon (IFN) inhibitors in patients with chronic inflammatory diseases. Because the formation of hepatic CYP450 enzymes is down-regulated during infection and chronic inflammation by increased levels of certain cytokines (e.g., interleukins-1, -6, and -10; tumor necrosis factor alpha; interferons), treatment targeting these cytokines may restore or normalize CYP450 enzyme levels resulting in increased metabolism of these drugs.", "source": "DDInter", "management_text": "Caution is advised when treatments targeting cytokines such as interleukins, tumor necrosis factors, or interferons are prescribed to patients receiving concomitant drugs that are CYP450 substrates, particularly those with narrow therapeutic ranges (e.g., antiarrhythmics, anticonvulsants, immunosuppressants, theophylline) or sensitive substrates where decreases in plasma levels may be significant or undesirable (e.g., oral contraceptives, statins, benzodiazepines, opioids). Clinical and/or laboratory monitoring should be considered following the initiation or withdrawal of such treatments, and the dosage(s) of the CYP450 substrate(s) adjusted accordingly. The effects of IL inhibitors, TNF blockers, and IFN inhibitors on CYP450 activities may persist for several weeks after stopping therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when treatments targeting cytokines such as interleukins, tumor necrosis factors, or interferons are prescribed to patients receiving concomitant drugs that are CYP450 substrates, particularly those with narrow therapeutic ranges (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97943/", "reference_text": "[1] \"Product Information. Skyrizi (risankizumab).\" AbbVie US LLC, North Chicago, IL.[2] \"Product Information. Cosentyx (secukinumab).\" Novartis Pharmaceuticals, East Hanover, NJ.[3] \"Product Information. Ilaris (canakinumab).\" Novartis Pharmaceuticals, East Hanover, NJ.[4] \"Product Information. Gamifant (emapalumab).\" Sobi Inc, Ardmore, PA.[5] \"Product Information. Kevzara (sarilumab).\" sanofi-aventis, Bridgewater, NJ.[6] \"Product Information. Simponi (golimumab).\" Centocor Inc, Malvern, PA.[7] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[8] \"Product Information. Sylvant (siltuximab).\" Janssen Biotech, Inc., Horsham, PA, PA.[9] \"Product Information. Stelara (ustekinumab).\" Centocor Inc, Malvern, PA.[10] \"Product Information. Ilumya (tildrakizumab).\" Merck & Company Inc, Whitehouse Station, NJ.[11] \"Product Information. Actemra (tocilizumab).\" Genentech, South San Francisco, CA.[12] \"Product Information. Amevive (alefacept).\" Biogen, Cambridge, MA.[13] \"Product Information. Remicade (infliximab).\" Centocor Inc, Malvern, PA.[14] \"Product Information. Taltz Autoinjector (ixekizumab).\" Eli Lilly and Company, Indianapolis, IN.[15] \"Product Information. Arcalyst (rilonacept).\" Regeneron Pharmaceuticals Inc, Tarrytown, NY.[16] Ace LN, Jaffe JM, Kunka RL \"Effect of food and an antacid on quinidine bioavailability.\" Biopharm Drug Dispos 4 (1983): 183-90[17] Min DI, Ku YM, Geraets DR, Lee HC \"Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers.\" J Clin Pharmacol 36 (1996): 469-76[18] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[19] Ha HR, Chen J, Leuenberger PM, Freiburghaus AU, Follah F \"In vitro inhibition of midazolam and quinidine metabolism by flavonoids.\" Eur J Clin Pharmacol 48 (1995): 367-71", "alternatives_a": "Suvorexant, Flurazepam, Methohexital, Zolpidem, Pentobarbital, Zaleplon, Dichloralphenazone, Valerian, Temazepam, Butabarbital, Secobarbital, More", "alternatives_b": "Antithymocyte immunoglobulin (rabbit), Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Abatacept, Upadacitinib, Siponimod, Apremilast, Inebilizumab, Cladribine, More", "updated_at": 1767369485}, {"id": 97840, "ingredient1": "Emapalumab", "ingredient2": "Typhoid vaccine (live)", "severity": "Major", "effect": "The administration of live or live attenuated vaccines during emapalumab therapy may be associated with a risk of disseminated infection due to enhanced replication of vaccine virus or bacteria in the presence of diminished immune competence. Emapalumab is a monoclonal antibody that binds to and neutralizes interferon gamma, which may increase susceptibility to certain pathogens and increase the risk of fatal and serious infections.", "source": "DDInter", "management_text": "The use of live or live attenuated vaccines should be avoided during and for at least 4 weeks after the last dose of emapalumab.", "mechanism_text": "Others", "recommendation": "The use of live or live attenuated vaccines should be avoided during and for at least 4 weeks after the last dose of emapalumab.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97944/", "reference_text": "[1] \"Product Information. Gamifant (emapalumab).\" Sobi Inc, Ardmore, PA.", "alternatives_a": "Spesolimab, Apremilast, Pirfenidone, Belumosudil, Teprotumumab, Daclizumab, Anifrolumab, Deucravacitinib, Ponesimod, Ravulizumab, Voclosporin, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 97841, "ingredient1": "Emapalumab", "ingredient2": "Varicella Zoster Vaccine (Recombinant)", "severity": "Major", "effect": "The administration of live or live attenuated vaccines during emapalumab therapy may be associated with a risk of disseminated infection due to enhanced replication of vaccine virus or bacteria in the presence of diminished immune competence. Emapalumab is a monoclonal antibody that binds to and neutralizes interferon gamma, which may increase susceptibility to certain pathogens and increase the risk of fatal and serious infections.", "source": "DDInter", "management_text": "The use of live or live attenuated vaccines should be avoided during and for at least 4 weeks after the last dose of emapalumab.", "mechanism_text": "Others", "recommendation": "The use of live or live attenuated vaccines should be avoided during and for at least 4 weeks after the last dose of emapalumab.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97945/", "reference_text": "[1] \"Product Information. Gamifant (emapalumab).\" Sobi Inc, Ardmore, PA.", "alternatives_a": "Apremilast, Pirfenidone, Belumosudil, Teprotumumab, Ravulizumab, Pegcetacoplan, Eculizumab, Sutimlimab", "alternatives_b": "", "updated_at": 1767369485}, {"id": 97842, "ingredient1": "Emapalumab", "ingredient2": "Venetoclax", "severity": "Moderate", "effect": "Plasma concentrations of drugs that are CYP450 substrates may decrease following the initiation of interleukin (IL) inhibitors, tumor necrosis factor (TNF) blockers, or interferon (IFN) inhibitors in patients with chronic inflammatory diseases. Because the formation of hepatic CYP450 enzymes is down-regulated during infection and chronic inflammation by increased levels of certain cytokines (e.g., interleukins-1, -6, and -10; tumor necrosis factor alpha; interferons), treatment targeting these cytokines may restore or normalize CYP450 enzyme levels resulting in increased metabolism of these drugs.", "source": "DDInter", "management_text": "Caution is advised when treatments targeting cytokines such as interleukins, tumor necrosis factors, or interferons are prescribed to patients receiving concomitant drugs that are CYP450 substrates, particularly those with narrow therapeutic ranges (e.g., antiarrhythmics, anticonvulsants, immunosuppressants, theophylline) or sensitive substrates where decreases in plasma levels may be significant or undesirable (e.g., oral contraceptives, statins, benzodiazepines, opioids). Clinical and/or laboratory monitoring should be considered following the initiation or withdrawal of such treatments, and the dosage(s) of the CYP450 substrate(s) adjusted accordingly. The effects of IL inhibitors, TNF blockers, and IFN inhibitors on CYP450 activities may persist for several weeks after stopping therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when treatments targeting cytokines such as interleukins, tumor necrosis factors, or interferons are prescribed to patients receiving concomitant drugs that are CYP450 substrates, particularly those with narrow therapeutic ranges (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97946/", "reference_text": "[1] \"Product Information. Skyrizi (risankizumab).\" AbbVie US LLC, North Chicago, IL.[2] \"Product Information. Cosentyx (secukinumab).\" Novartis Pharmaceuticals, East Hanover, NJ.[3] \"Product Information. Ilaris (canakinumab).\" Novartis Pharmaceuticals, East Hanover, NJ.[4] \"Product Information. Gamifant (emapalumab).\" Sobi Inc, Ardmore, PA.[5] \"Product Information. Kevzara (sarilumab).\" sanofi-aventis, Bridgewater, NJ.[6] \"Product Information. Simponi (golimumab).\" Centocor Inc, Malvern, PA.[7] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[8] \"Product Information. Sylvant (siltuximab).\" Janssen Biotech, Inc., Horsham, PA, PA.[9] \"Product Information. Stelara (ustekinumab).\" Centocor Inc, Malvern, PA.[10] \"Product Information. Ilumya (tildrakizumab).\" Merck & Company Inc, Whitehouse Station, NJ.[11] \"Product Information. Actemra (tocilizumab).\" Genentech, South San Francisco, CA.[12] \"Product Information. Amevive (alefacept).\" Biogen, Cambridge, MA.[13] \"Product Information. Remicade (infliximab).\" Centocor Inc, Malvern, PA.[14] \"Product Information. Taltz Autoinjector (ixekizumab).\" Eli Lilly and Company, Indianapolis, IN.[15] \"Product Information. Arcalyst (rilonacept).\" Regeneron Pharmaceuticals Inc, Tarrytown, NY.[16] Ace LN, Jaffe JM, Kunka RL \"Effect of food and an antacid on quinidine bioavailability.\" Biopharm Drug Dispos 4 (1983): 183-90[17] Min DI, Ku YM, Geraets DR, Lee HC \"Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers.\" J Clin Pharmacol 36 (1996): 469-76[18] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[19] Ha HR, Chen J, Leuenberger PM, Freiburghaus AU, Follah F \"In vitro inhibition of midazolam and quinidine metabolism by flavonoids.\" Eur J Clin Pharmacol 48 (1995): 367-71", "alternatives_a": "Pertuzumab, Olaparib, Oxaliplatin, Rucaparib, Bortezomib, Tisagenlecleucel, Aminolevulinic acid, Omacetaxine mepesuccinate, Tazemetostat, Altretamine, Tagraxofusp, More", "alternatives_b": "Antithymocyte immunoglobulin (rabbit), Anifrolumab, Ravulizumab, Mycophenolic acid, Methotrexate, Abatacept, Apremilast, Inebilizumab, Belumosudil, Thalidomide, Belimumab, More", "updated_at": 1767369485}, {"id": 97843, "ingredient1": "Emapalumab", "ingredient2": "Warfarin", "severity": "Moderate", "effect": "Plasma concentrations of drugs that are CYP450 substrates may decrease following the initiation of interleukin (IL) inhibitors, tumor necrosis factor (TNF) blockers, or interferon (IFN) inhibitors in patients with chronic inflammatory diseases. Because the formation of hepatic CYP450 enzymes is down-regulated during infection and chronic inflammation by increased levels of certain cytokines (e.g., interleukins-1, -6, and -10; tumor necrosis factor alpha; interferons), treatment targeting these cytokines may restore or normalize CYP450 enzyme levels resulting in increased metabolism of these drugs.", "source": "DDInter", "management_text": "Caution is advised when treatments targeting cytokines such as interleukins, tumor necrosis factors, or interferons are prescribed to patients receiving concomitant drugs that are CYP450 substrates, particularly those with narrow therapeutic ranges (e.g., antiarrhythmics, anticonvulsants, immunosuppressants, theophylline) or sensitive substrates where decreases in plasma levels may be significant or undesirable (e.g., oral contraceptives, statins, benzodiazepines, opioids). Clinical and/or laboratory monitoring should be considered following the initiation or withdrawal of such treatments, and the dosage(s) of the CYP450 substrate(s) adjusted accordingly. The effects of IL inhibitors, TNF blockers, and IFN inhibitors on CYP450 activities may persist for several weeks after stopping therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when treatments targeting cytokines such as interleukins, tumor necrosis factors, or interferons are prescribed to patients receiving concomitant drugs that are CYP450 substrates, particularly those with narrow therapeutic ranges (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97947/", "reference_text": "[1] \"Product Information. Skyrizi (risankizumab).\" AbbVie US LLC, North Chicago, IL.[2] \"Product Information. Cosentyx (secukinumab).\" Novartis Pharmaceuticals, East Hanover, NJ.[3] \"Product Information. Ilaris (canakinumab).\" Novartis Pharmaceuticals, East Hanover, NJ.[4] \"Product Information. Gamifant (emapalumab).\" Sobi Inc, Ardmore, PA.[5] \"Product Information. Kevzara (sarilumab).\" sanofi-aventis, Bridgewater, NJ.[6] \"Product Information. Simponi (golimumab).\" Centocor Inc, Malvern, PA.[7] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[8] \"Product Information. Sylvant (siltuximab).\" Janssen Biotech, Inc., Horsham, PA, PA.[9] \"Product Information. Stelara (ustekinumab).\" Centocor Inc, Malvern, PA.[10] \"Product Information. Ilumya (tildrakizumab).\" Merck & Company Inc, Whitehouse Station, NJ.[11] \"Product Information. Actemra (tocilizumab).\" Genentech, South San Francisco, CA.[12] \"Product Information. Amevive (alefacept).\" Biogen, Cambridge, MA.[13] \"Product Information. Remicade (infliximab).\" Centocor Inc, Malvern, PA.[14] \"Product Information. Taltz Autoinjector (ixekizumab).\" Eli Lilly and Company, Indianapolis, IN.[15] \"Product Information. Arcalyst (rilonacept).\" Regeneron Pharmaceuticals Inc, Tarrytown, NY.[16] Ace LN, Jaffe JM, Kunka RL \"Effect of food and an antacid on quinidine bioavailability.\" Biopharm Drug Dispos 4 (1983): 183-90[17] Min DI, Ku YM, Geraets DR, Lee HC \"Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers.\" J Clin Pharmacol 36 (1996): 469-76[18] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[19] Ha HR, Chen J, Leuenberger PM, Freiburghaus AU, Follah F \"In vitro inhibition of midazolam and quinidine metabolism by flavonoids.\" Eur J Clin Pharmacol 48 (1995): 367-71", "alternatives_a": "Ticagrelor, Betrixaban, Clopidogrel, Cilostazol, Iloprost, Lepirudin, Acenocoumarol, Urokinase, Cangrelor, Dipyridamole, Caplacizumab, More", "alternatives_b": "Antithymocyte immunoglobulin (rabbit), Anifrolumab, Ravulizumab, Diroximel fumarate, Abatacept, Upadacitinib, Siponimod, Apremilast, Inebilizumab, Cladribine, Belumosudil, More", "updated_at": 1767369485}, {"id": 97844, "ingredient1": "Emapalumab", "ingredient2": "Yellow Fever Vaccine", "severity": "Major", "effect": "The administration of live or live attenuated vaccines during emapalumab therapy may be associated with a risk of disseminated infection due to enhanced replication of vaccine virus or bacteria in the presence of diminished immune competence. Emapalumab is a monoclonal antibody that binds to and neutralizes interferon gamma, which may increase susceptibility to certain pathogens and increase the risk of fatal and serious infections.", "source": "DDInter", "management_text": "The use of live or live attenuated vaccines should be avoided during and for at least 4 weeks after the last dose of emapalumab.", "mechanism_text": "Others", "recommendation": "The use of live or live attenuated vaccines should be avoided during and for at least 4 weeks after the last dose of emapalumab.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97948/", "reference_text": "[1] \"Product Information. Gamifant (emapalumab).\" Sobi Inc, Ardmore, PA.", "alternatives_a": "Apremilast, Pirfenidone, Belumosudil, Teprotumumab, Ravulizumab, Pegcetacoplan, Eculizumab, Sutimlimab", "alternatives_b": "", "updated_at": 1767369485}, {"id": 97845, "ingredient1": "Emicizumab", "ingredient2": "Coagulation factor VIIa Recombinant Human", "severity": "Moderate", "effect": "Preclinical experiments suggest a possibility for hypercoagulability when emicizumab is used with factor VIIa or factor VIII.", "source": "DDInter", "management_text": "Patients should be monitored for development of thrombosis if emicizumab is coadministered with factors VIIa or VIII.", "mechanism_text": "Synergism", "recommendation": "Patients should be monitored for development of thrombosis if emicizumab is coadministered with factors VIIa or VIII.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97949/", "reference_text": "[1] \"Product Information. Hemlibra (emicizumab).\" Genentech, South San Francisco, CA.", "alternatives_a": "Eltrombopag, Romiplostim, Fostamatinib, Avatrombopag, Emicizumab, Coagulation factor X human, Phylloquinone, Lusutrombopag, Fibrinogen human, Epinephrine, Coagulation Factor IX Human", "alternatives_b": "Eltrombopag, Romiplostim, Fostamatinib, Avatrombopag, Coagulation factor VIIa Recombinant Human, Coagulation factor X human, Phylloquinone, Lusutrombopag, Fibrinogen human, Antihemophilic factor, human recombinant, Epinephrine, Coagulation Factor IX Human", "updated_at": 1767369485}, {"id": 97846, "ingredient1": "Empagliflozin", "ingredient2": "Acetohexamide", "severity": "Moderate", "effect": "Coadministration of a sodium-glucose co-transporter 2 (SGLT-2) inhibitor with an insulin secretagogue (e.g., sulfonylurea, meglitinide) or insulin may potentiate the risk of hypoglycemia.", "source": "DDInter", "management_text": "A lower dosage of the insulin secretagogue or insulin may be required when used in combination with an SGLT-2 inhibitor.", "mechanism_text": "Synergism", "recommendation": "A lower dosage of the insulin secretagogue or insulin may be required when used in combination with an SGLT-2 inhibitor.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97950/", "reference_text": "[1] \"Product Information. Jardiance (empagliflozin).\" Boehringer Ingelheim, Ridgefield, CT.[2] \"Product Information. Steglatro (ertugliflozin).\" Merck & Company Inc, Whitehouse Station, NJ.[3] \"Product Information. Invokana (canagliflozin).\" Janssen Pharmaceuticals, Titusville, NJ.[4] Cerner Multum, Inc. \"Australian Product Information.\" O 0[5] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[6] \"Product Information. Farxiga (dapagliflozin).\" Bristol-Myers Squibb, Princeton, NJ.[7] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[8] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[9] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[10] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[11] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[12] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6[13] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[14] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[15] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[16] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42[17] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[18] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[19] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[20] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[21] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[22] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6[23] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[24] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[25] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[26] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42", "alternatives_a": "Guar gum, Pramlintide, Alogliptin, Rosuvastatin, Empagliflozin, Dulaglutide, Exenatide, Miglitol, Albiglutide, Rosiglitazone, Ertugliflozin, More", "alternatives_b": "Glipizide, Glimepiride, Acetohexamide, Guar gum, Acarbose, Simvastatin, Rosiglitazone, Troglitazone, Chlorpropamide, Rosuvastatin, Tolazamide, More", "updated_at": 1767369485}, {"id": 97847, "ingredient1": "Empagliflozin", "ingredient2": "Aloe Vera Leaf", "severity": "Moderate", "effect": "Concomitant use of oral products containing aloe vera gel may potentiate the hypoglycemic effect of insulin and other antidiabetic agents.", "source": "DDInter", "management_text": "Until more data are available, caution is advised when aloe vera is administered orally to patients receiving insulin or other antidiabetic agents due to the potential for increased risk of hypoglycemia. Patients should be monitored for changes in diabetic medication requirements.", "mechanism_text": "Synergism", "recommendation": "Until more data are available, caution is advised when aloe vera is administered orally to patients receiving insulin or other antidiabetic agents due to the potential for increased risk of hypoglycemia.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97951/", "reference_text": "[1] Yeh GY, Eisenberg DM, Kaptchuk TJ, Phillips RS \"Systemic review of herbs and dietary supplements for glycemic control in diabetes.\" Diabetes Care 26 (2003): 1277-94[2] Tanaka M, Misawa E, Yousuke I, et al \"Identification of five phytosterols from Aloe vera gel as anti-diabetic compounds.\" Biol Pharm Bull 29 (2006): 1418-22[3] Vogller BK \"Aloe vera: a systematic review of its clinical effectiveness.\" Br J Gen Pract 49 (1999): 823-8[4] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[5] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[6] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[7] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42[8] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[9] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[10] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[11] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[12] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[13] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6", "alternatives_a": "Acetohexamide, Guar gum, Simvastatin, Troglitazone, Rosuvastatin", "alternatives_b": "", "updated_at": 1767369485}, {"id": 97848, "ingredient1": "Empagliflozin", "ingredient2": "Amcinonide", "severity": "Minor", "effect": "The efficacy of insulin and other antidiabetic agents may be diminished by topical corticosteroids, particularly during prolonged or indiscriminate use. Corticosteroids can raise blood glucose level by antagonizing the action and suppressing the secretion of insulin, which results in inhibition of peripheral glucose uptake and increased gluconeogenesis. The duration of administration Close clinical monitoring of glycemic control is recommended if topical corticosteroids are administered chronically and/or to large areas in diabetic patients.", "source": "DDInter", "management_text": "-", "mechanism_text": "Antagonism", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97952/", "reference_text": "[1] Pace WE \"Topical corticosteroids.\" Can Med Assoc J 108 (1973): 11 passim[2] Seale JP, Compton MR \"Side-effects of corticosteroid agents.\" Med J Aust 144 (1986): 139-42[3] \"Product Information. Psorcon (diflorasone topical).\" Rhone-Poulenc Rorer, Collegeville, PA.[4] \"Product Information. Temovate (clobetasol).\" Glaxo Wellcome, Research Triangle Park, NC.[5] \"Product Information. Ultravate (halobetasol).\" Bristol-Myers Squibb, Princeton, NJ.[6] Carruthers JA, Staughton RC, August PJ \"Penetration of topical steroid preparations.\" Arch Dermatol 113 (1977): 522[7] Ludvik B, Clodi M, Kautzky-Willer A, Capek M, Hartter E, Pacini G, Prager R \"Effect of dexamethasone on insulin sensitivity, islet amyloid polypeptide and insulin secretion in humans.\" Diabetologia 36 (1993): 84-7[8] \"Product Information. Diprolene (betamethasone topical).\" Schering Laboratories, Kenilworth, NJ.[9] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[10] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[11] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[12] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42[13] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[14] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[15] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[16] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[17] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[18] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6", "alternatives_a": "Budesonide, Hydrocortisone butyrate, Fluticasone, Fluocinonide, Fluorometholone, Clobetasol, Beclomethasone dipropionate", "alternatives_b": "Simvastatin, Guar gum, Rosuvastatin", "updated_at": 1767369485}, {"id": 97849, "ingredient1": "Amprenavir", "ingredient2": "Empagliflozin", "severity": "Moderate", "effect": "The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.", "source": "DDInter", "management_text": "Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.", "mechanism_text": "Antagonism", "recommendation": "Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97953/", "reference_text": "[1] Jori A, Carrara MC \"On the mechanism of the hyperglycaemic effect of chlorpromazine.\" J Pharm Pharmacol 18 (1966): 623-4[2] \"Product Information. Dymelor (acetohexamide)\" Lilly, Eli and Company, Indianapolis, IN.[3] \"Product Information. Thorazine (chlorpromazine).\" SmithKline Beecham, Philadelphia, PA.[4] Blayac JP, Ribes G, Buys D, Puech R, Loubatieres-Mariani MM \"Effects of a new benzothiadiazine derivative, LN 5330, on insulin secretion.\" Arch Int Pharmacodyn Ther 253 (1981): 154-63[5] \"Product Information. Elzonris (tagraxofusp).\" Stemline Therapeutics, New York, NY.[6] \"Product Information. Amaryl (glimepiride).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[7] \"Product Information. Elspar (asparaginase).\" Merck & Co, Inc, West Point, PA.[8] Jones IG, Pickens PT \"Diabetes mellitus following oral diuretics.\" Practitioner 199 (1967): 209-10[9] \"Product Information. Viracept (nelfinavir).\" Agouron Pharma Inc, La Jolla, CA.[10] \"Product Information. Tolinase (tolazamide)\" Pharmacia and Upjohn, Kalamazoo, MI.[11] Mauss S, Wolf E, Jaeger H \"Impaired glucose tolerance in HIV-positive patients receiving and those not receiving protease inhibitors.\" Ann Intern Med 130 (1999): 162-3[12] Virutamasen P, Wongsrichanalai C, Tangkeo P, Nitichai Y, Rienprayoon D \"Metabolic effects of depot-medroxyprogesterone acetate in long-term users: a cross-sectional study.\" Int J Gynaecol Obstet 24 (1986): 291-6[13] Wehring H, Alexander B, Perry PJ \"Diabetes mellitus associated with clozapine therapy.\" Pharmacotherapy 20 (2000): 844-7[14] Spellacy WN, Ellingson AB, Tsibris JC \"The effects of two triphasic oral contraceptives on carbohydrate metabolism in women during 1 year of use.\" Fertil Steril 51 (1989): 71-4[15] Andersen OO, Persson I \"Carbohydrate metabolism during treatment with chlorthalidone and ethacrynic acid.\" Br Med J 2 (1968): 798-801[16] Berlin I \"Prazosin, diuretics, and glucose intolerance.\" Ann Intern Med 119 (1993): 860[17] Malherbe C, Burrill KC, Levin SR, Karam JH, Forsham PH \"Effect of diphenylhydantoin on insulin secretion in man.\" N Engl J Med 286 (1972): 339-42[18] Carter BL, Small RE, Mandel MD, Starkman MT \"Phenytoin-induced hyperglycemia.\" Am J Hosp Pharm 38 (1981): 1508-12[19] Al-Rubeaan K, Ryan EA \"Phenytoin-induced insulin insensitivity.\" Diabet Med 8 (1991): 968-70[20] \"Product Information. Zolinza (vorinostat).\" Merck & Company Inc, West Point, PA.[21] Goldman JA, Neri A, Ovadia J, Eckerling B, Vries A, de \"Effect of chlorothiazide on intravenous glucose tolerance in pregnancy.\" Am J Obstet Gynecol 105 (1969): 556-60[22] Harper R, Ennis CN, Heaney AP, Sheridan B, Gormley M, Atkinson AB, Johnston GD, Bell PM \"A comparison of the effects of low- and conventional-dose thiazide diuretic on insulin action in hypertensive patients with NIDDM.\" Diabetologia 38 (1995): 853-9[23] Seltzer HS, Allen EW \"Hyperglycemia and inhibition of insulin secretion during administration of diazoxide and trichlormethiazide in man.\" Diabetes 18 (1969): 19-28[24] Dube MP, Johnson DL, Currier JS, Leedom JM \"Protease inhibitor-associated hyperglycaemia.\" Lancet 350 (1997): 713-4[25] Leary WP, Reyes AJ \"Drug interactions with diuretics.\" S Afr Med J 65 (1984): 455-61[26] \"Product Information. Reyataz (atazanavir).\" Bristol-Myers Squibb, Princeton, NJ.[27] Pollare T, Lithell H, Berne C \"A comparison of the effects of hydrochlorothiazide and captopril on glucose and lipid metabolism in patients with hypertension.\" N Engl J Med 321 (1989): 868-73[28] Gunnarsson R, Lundgren G, Magnusson G, Ost L, Groth CG \"Steroid diabetes--a sign of overtreatment with steroids in the renal graft recipient?\" Scand J Urol Nephrol Suppl 54 (1980): 135-8[29] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[30] \"Product Information. Synthroid (levothyroxine).\" Abbott Pharmaceutical, Abbott Park, IL.[31] Murphy MB, Kohner E, Lewis PJ, Schumer B, Dollery CT \"Glucose intolerance in hypertensive patients treated with diuretics: a fourteen-year follow-up.\" Lancet 2 (1982): 1293-5[32] \"Product Information. Fortovase (saquinavir)\" Roche Laboratories, Nutley, NJ.[33] Coni NK, Gordon PW, Mukherjee AP, Read PR \"The effect of frusemide and ethacrynic acid on carbohydrate metabolism.\" Age Ageing 3 (1974): 85-90[34] \"Product Information. Norvir (ritonavir).\" Abbott Pharmaceutical, Abbott Park, IL.[35] Domenet JG \"Diabetogenic effect of oral diuretics.\" Br Med J 3 (1968): 188[36] Rowe P, Mather H \"Hyperosmolar non-ketotic diabetes mellitus associated with metolazone.\" Br Med J 291 (1985): 25-6[37] Winchester JF, Kellett RJ, Boddy K, Boyle P, Dargie HJ, Mahaffey ME, Ward DM, Kennedy AC \"Metolazone and bendroflumethiazide in hypertension: physiologic and metabolic observations.\" Clin Pharmacol Ther 28 (1980): 611-8[38] \"Product Information. Carafate (sucralfate).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[39] Tsiodras S, Mantzoros C, Hammer S, Samore M \"Effects of protease inhibitors on hyperglycemia, hyperlipidemia, and lipodystrophy - A 5-year cohort study.\" Arch Intern Med 160 (2000): 2050-6[40] \"Product Information. Apidra (insulin glulisine).\" Aventis Pharmaceuticals, Bridgewater, NJ.[41] \"Product Information. Prezista (darunavir).\" Ortho Biotech Inc, Bridgewater, NJ.[42] Haiba NA, el-Habashy MA, Said SA, Darwish EA, Abdel-Sayed WS, Nayel SE \"Clinical evaluation of two monthly injectable contraceptives and their effects on some metabolic parameters.\" Contraception 39 (1989): 619-32[43] Erle G, Basso M, Federspil G, Sicolo N, Scandellari C \"Effect of chlorpromazine on blood glucose and plasma insulin in man.\" Eur J Clin Pharmacol 11 (1977): 15-8[44] Pickkers P, Schachter M, Hughes AD, Feher MD, Sever PS \"Thiazide-induced hyperglycaemia: a role for calcium-activated potassium channels?\" Diabetologia 39 (1996): 861-4[45] \"Product Information. Lexiva (fosamprenavir).\" GlaxoSmithKline, Research Triangle Park, NC.[46] Curtis J, Horrigan F, Ahearn D, Varney R, Sandler SG \"Chlorthalidone-induced hyperosmolar hyperglycemic nonketotic coma.\" JAMA 220 (1972): 1592-3[47] \"Product Information. Hyperstat I.V. (diazoxide).\" Schering Corp, Kenilworth, NJ.[48] \"Product Information. Piqray (alpelisib).\" Novartis Pharmaceuticals, East Hanover, NJ.[49] Bell DS \"Insulin resistance. An often unrecognized problem accompanying chronic medical disorders.\" Postgrad Med 93 (1993): 99-103,[50] Stambaugh JE, Tucker DC \"Effect of diphenylhydantoin on glucose tolerance in patients with hypoglycemia.\" Diabetes 23 (1974): 679-83[51] \"Product Information. Crixivan (indinavir).\" Merck & Co, Inc, West Point, PA.[52] Miller NR, Moses H \"Transient oculomotor nerve palsy. Association with thiazide-induced glucose intolerance.\" JAMA 240 (1978): 1887-8[53] Javier Z, Gershberg H, Hulse M \"Ovulatory suppressants, estrogens, and carbohydrate metabolism.\" Metabolism 17 (1968): 443-56[54] Goldman JA, Ovadia JL \"The effect of estrogen on intravenous glucose tolerance in woman.\" Am J Obstet Gynecol 103 (1969): 172-8[55] Charan VD, Desai N, Singh AP, Choudhry VP \"Diabetes mellitus and pancreatitis as a complication of L- asparaginase therapy.\" Indian Pediatr 30 (1993): 809-10[56] Seifer DB, Freedman LN, Cavender JR, Baker RA \"Insulin-dependent diabetes mellitus associated with danazol.\" Am J Obstet Gynecol 162 (1990): 474-5[57] \"Product Information. Orinase (tolbutamide)\" Pharmacia and Upjohn, Kalamazoo, MI.[58] Walli R, Demant T \"Impaired glucose tolerance and protease inhibitors.\" Ann Intern Med 129 (1998): 837-8[59] Hannaford PC, Kay CR \"Oral contraceptives and diabetes mellitus.\" BMJ 299 (1989): 1315-6[60] Hardy H, Esch LD, Morse GD \"Glucose disorders associated with HIV and its drug therapy.\" Ann Pharmacother 35 (2001): 343-51[61] Chowdhury FR, Bleicher SJ \"Chlorthalidone--induced hypokalemia and abnormal carbohydrate metabolism.\" Horm Metab Res 2 (1970): 13-6[62] Kaufman MB, Simionatto C \"A review of protease inhibitor-induced hyperglycemia.\" Pharmacotherapy 19 (1999): 114-7[63] Greenstone MA, Shaw AB \"Alternate day corticosteroid causes alternate day hyperglycaemia.\" Postgrad Med J 63 (1987): 761-4[64] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[65] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[66] Elmfeldt D, Berglund G, Wedel H, Wilhelmsen L \"Incidence and importance of metabolic side-effects during antihypertensive therapy.\" Acta Med Scand Suppl 672 (1983): 79-83[67] \"Product Information. Agenerase (amprenavir).\" Glaxo Wellcome, Research Triangle Pk, NC.[68] Diamond MT \"Hyperglycemic hyperosmolar coma associated with hydrochlorothiazide and pancreatitis.\" N Y State J Med 72 (1972): 1741-2[69] \"Product Information. Prandin (repaglinide).\" Novo Nordisk Pharmaceuticals Inc, Princeton, NJ.[70] \"Product Information. Precose (acarbose).\" Bayer, West Haven, CT.[71] \"Product Information. Starlix (nateglinide)\" Novartis Pharmaceuticals, East Hanover, NJ.[72] \"Product Information. Oncaspar (pegaspargase).\" Rhone-Poulenc Rorer, Collegeville, PA.[73] Sotaniemi E, Kontturi M, Larmi T \"Effect of diethylstilbestrol on blood glucose of prostatic cancer patients.\" Invest Urol 10 (1973): 438-41[74] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[75] Petri M, Cumber P, Grimes L, Treby D, Bryant R, Rawlins D, Ising H \"The metabolic effects of thiazide therapy in the elderly: a population study.\" Age Ageing 15 (1986): 151-5[76] Ludvik B, Clodi M, Kautzky-Willer A, Capek M, Hartter E, Pacini G, Prager R \"Effect of dexamethasone on insulin sensitivity, islet amyloid polypeptide and insulin secretion in humans.\" Diabetologia 36 (1993): 84-7[77] \"Product Information. Glucophage (metformin).\" Bristol-Myers Squibb, Princeton, NJ.[78] Chaudhuri ML, Catania J \"A comparison of the effects of bumetanide (Burinex) and frusemide on carbohydrate metabolism in the elderly.\" Br J Clin Pract 42 (1988): 427-9[79] Black DM, Filak AT \"Hyperglycemia with non-insulin-dependent diabetes following intraarticular steroid injection.\" J Fam Pract 28 (1989): 462-3[80] \"Product Information. Megace (megestrol).\" Bristol-Myers Squibb, Princeton, NJ.[81] \"Product Information. Torisel (temsirolimus).\" Wyeth-Ayerst Laboratories, Philadelphia, PA.[82] Schmitz O, Hermansen K, Nielsen OH, Christensen CK, Arnfred J, Hansen HE, Mogensen CE, Orskov H, Beck-Nielsen H \"Insulin action in insulin-dependent diabetics after short-term thiazide therapy.\" Diabetes Care 9 (1986): 631-6[83] Kansal PC, Buse J, Buse MG \"Thiazide diuretics and control of diabetes mellitus.\" South Med J 62 (1969): 1372-9[84] Dimitriadis G, Tegos C, Golfinopoulou L, Roboti C, Raptis S \"Furosemide-induced hyperglycaemia - the implication of glycolytic kinases.\" Horm Metab Res 25 (1993): 557-9[85] \"Product Information. NovoLog Mix 70/30 (insulin aspart-insulin aspart protamine).\" Novo Nordisk Pharmaceuticals Inc, Princeton, NJ.[86] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[87] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[88] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[89] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42[90] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[91] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[92] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[93] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[94] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[95] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6", "alternatives_a": "Lamivudine, Tenofovir alafenamide, Maraviroc, Cabotegravir, Zanamivir, Valaciclovir, Lenacapavir, Telaprevir, Rilpivirine, Etravirine, Dolutegravir, More", "alternatives_b": "Guar gum", "updated_at": 1767369485}, {"id": 97850, "ingredient1": "Amyl Nitrite", "ingredient2": "Empagliflozin", "severity": "Moderate", "effect": "Sodium-glucose co-transporter 2 (SGLT-2) inhibitors may potentiate the hypotensive effects of diuretics and other antihypertensive agents or vasodilators. Inhibition of glucose and sodium co-transport produces mild diuresis and transient natriuresis, resulting in intravascular volume contraction. Volume depletion-related adverse reactions including hypotension, postural dizziness, orthostatic hypotension, syncope, and dehydration can occur after initiating treatment with SGLT-2 inhibitors, and the risk may be increased with concomitant use of other agents that can lower blood pressure.", "source": "DDInter", "management_text": "Caution is advised if SGLT-2 inhibitors are coadministered with diuretics and other hypotensive agents, particularly in the elderly and patients with impaired renal function. Prior to initiating SGLT-2 inhibitors, volume status should be assessed and corrected, if necessary. Clinical and laboratory monitoring are recommended during therapy, including electrolytes, fluid status, renal function, and blood pressure. If volume depletion occurs, treatment with SGLT-2 inhibitors should be interrupted until the condition is corrected.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if SGLT-2 inhibitors are coadministered with diuretics and other hypotensive agents, particularly in the elderly and patients with impaired renal function.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97954/", "reference_text": "[1] \"Product Information. Jardiance (empagliflozin).\" Boehringer Ingelheim, Ridgefield, CT.[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] \"Product Information. Farxiga (dapagliflozin).\" Bristol-Myers Squibb, Princeton, NJ.[5] \"Product Information. Invokana (canagliflozin).\" Janssen Pharmaceuticals, Titusville, NJ.[6] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[7] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[8] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[9] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[10] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[11] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6[12] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[13] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[14] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[15] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42", "alternatives_a": "Hydroxocobalamin, Fomepizole, Ipecac, Dexrazoxane, Oxygen, Lanthanum carbonate, Difelikefalin, Cobicistat, Deferoxamine, Levoleucovorin, Arginine, More", "alternatives_b": "Glipizide, Acetohexamide, Guar gum, Pramlintide, Alogliptin, Rosuvastatin, Tolazamide, Dulaglutide, Exenatide, Tolbutamide, Miglitol, More", "updated_at": 1767369485}, {"id": 97851, "ingredient1": "Empagliflozin", "ingredient2": "Bendroflumethiazide", "severity": "Moderate", "effect": "Sodium-glucose co-transporter 2 (SGLT-2) inhibitors may potentiate the diuretic and hypotensive effects of thiazides. Inhibition of glucose and sodium co-transport produces mild diuresis and transient natriuresis, resulting in intravascular volume contraction.", "source": "DDInter", "management_text": "Caution is advised during concomitant use of SGLT-2 inhibitors and thiazides, particularly in the elderly and patients with impaired renal function. Prior to initiating SGLT-2 inhibitors, volume status should be assessed and corrected, if necessary. Clinical and laboratory monitoring are recommended during therapy, including electrolytes, fluid status, renal function, and blood pressure. Blood glucose should also be monitored more closely. If volume depletion occurs, treatment with SGLT-2 inhibitors should be interrupted until the condition is corrected.", "mechanism_text": "Synergism", "recommendation": "Caution is advised during concomitant use of SGLT-2 inhibitors and thiazides, particularly in the elderly and patients with impaired renal function.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97955/", "reference_text": "[1] \"Product Information. Steglatro (ertugliflozin).\" Merck & Company Inc, Whitehouse Station, NJ.[2] \"Product Information. Invokana (canagliflozin).\" Janssen Pharmaceuticals, Titusville, NJ.[3] \"Product Information. Farxiga (dapagliflozin).\" Bristol-Myers Squibb, Princeton, NJ.[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Jardiance (empagliflozin).\" Boehringer Ingelheim, Ridgefield, CT.[7] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[8] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[9] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[10] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[11] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[12] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6[13] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[14] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[15] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[16] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42", "alternatives_a": "Tinidazole, Ascorbic acid, Metronidazole, Rosuvastatin, Sulfadiazine, Lactic acid, Amphotericin B, Clindamycin, Ciclopirox, Vemurafenib, Ketoconazole, More", "alternatives_b": "Simvastatin, Guar gum, Rosuvastatin", "updated_at": 1767369485}, {"id": 97852, "ingredient1": "Empagliflozin", "ingredient2": "Benzthiazide", "severity": "Moderate", "effect": "Sodium-glucose co-transporter 2 (SGLT-2) inhibitors may potentiate the diuretic and hypotensive effects of thiazides. Inhibition of glucose and sodium co-transport produces mild diuresis and transient natriuresis, resulting in intravascular volume contraction.", "source": "DDInter", "management_text": "Caution is advised during concomitant use of SGLT-2 inhibitors and thiazides, particularly in the elderly and patients with impaired renal function. Prior to initiating SGLT-2 inhibitors, volume status should be assessed and corrected, if necessary. Clinical and laboratory monitoring are recommended during therapy, including electrolytes, fluid status, renal function, and blood pressure. Blood glucose should also be monitored more closely. If volume depletion occurs, treatment with SGLT-2 inhibitors should be interrupted until the condition is corrected.", "mechanism_text": "Synergism", "recommendation": "Caution is advised during concomitant use of SGLT-2 inhibitors and thiazides, particularly in the elderly and patients with impaired renal function.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97956/", "reference_text": "[1] \"Product Information. Steglatro (ertugliflozin).\" Merck & Company Inc, Whitehouse Station, NJ.[2] \"Product Information. Invokana (canagliflozin).\" Janssen Pharmaceuticals, Titusville, NJ.[3] \"Product Information. Farxiga (dapagliflozin).\" Bristol-Myers Squibb, Princeton, NJ.[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Jardiance (empagliflozin).\" Boehringer Ingelheim, Ridgefield, CT.[7] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[8] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[9] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[10] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[11] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[12] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6[13] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[14] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[15] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[16] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42", "alternatives_a": "Tinidazole, Ascorbic acid, Metronidazole, Rosuvastatin, Sulfadiazine, Lactic acid, Amphotericin B, Clindamycin, Ciclopirox, Vemurafenib, Ketoconazole, More", "alternatives_b": "Acetohexamide, Guar gum, Simvastatin, Troglitazone, Rosuvastatin", "updated_at": 1767369485}, {"id": 97853, "ingredient1": "Empagliflozin", "ingredient2": "Bepridil", "severity": "Moderate", "effect": "Sodium-glucose co-transporter 2 (SGLT-2) inhibitors may potentiate the hypotensive effects of diuretics and other antihypertensive agents or vasodilators. Inhibition of glucose and sodium co-transport produces mild diuresis and transient natriuresis, resulting in intravascular volume contraction. Volume depletion-related adverse reactions including hypotension, postural dizziness, orthostatic hypotension, syncope, and dehydration can occur after initiating treatment with SGLT-2 inhibitors, and the risk may be increased with concomitant use of other agents that can lower blood pressure.", "source": "DDInter", "management_text": "Caution is advised if SGLT-2 inhibitors are coadministered with diuretics and other hypotensive agents, particularly in the elderly and patients with impaired renal function. Prior to initiating SGLT-2 inhibitors, volume status should be assessed and corrected, if necessary. Clinical and laboratory monitoring are recommended during therapy, including electrolytes, fluid status, renal function, and blood pressure. If volume depletion occurs, treatment with SGLT-2 inhibitors should be interrupted until the condition is corrected.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if SGLT-2 inhibitors are coadministered with diuretics and other hypotensive agents, particularly in the elderly and patients with impaired renal function.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97957/", "reference_text": "[1] \"Product Information. Jardiance (empagliflozin).\" Boehringer Ingelheim, Ridgefield, CT.[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] \"Product Information. Farxiga (dapagliflozin).\" Bristol-Myers Squibb, Princeton, NJ.[5] \"Product Information. Invokana (canagliflozin).\" Janssen Pharmaceuticals, Titusville, NJ.[6] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[7] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[8] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[9] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[10] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[11] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6[12] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[13] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[14] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[15] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42", "alternatives_a": "Glipizide, Acetohexamide, Guar gum, Pramlintide, Alogliptin, Rosuvastatin, Tolazamide, Dulaglutide, Exenatide, Tolbutamide, Miglitol, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 97854, "ingredient1": "Empagliflozin", "ingredient2": "Carteolol", "severity": "Moderate", "effect": "Sodium-glucose co-transporter 2 (SGLT-2) inhibitors may potentiate the hypotensive effects of diuretics and other antihypertensive agents or vasodilators. Inhibition of glucose and sodium co-transport produces mild diuresis and transient natriuresis, resulting in intravascular volume contraction. Volume depletion-related adverse reactions including hypotension, postural dizziness, orthostatic hypotension, syncope, and dehydration can occur after initiating treatment with SGLT-2 inhibitors, and the risk may be increased with concomitant use of other agents that can lower blood pressure.", "source": "DDInter", "management_text": "Caution is advised if SGLT-2 inhibitors are coadministered with diuretics and other hypotensive agents, particularly in the elderly and patients with impaired renal function. Prior to initiating SGLT-2 inhibitors, volume status should be assessed and corrected, if necessary. Clinical and laboratory monitoring are recommended during therapy, including electrolytes, fluid status, renal function, and blood pressure. If volume depletion occurs, treatment with SGLT-2 inhibitors should be interrupted until the condition is corrected.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if SGLT-2 inhibitors are coadministered with diuretics and other hypotensive agents, particularly in the elderly and patients with impaired renal function.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97958/", "reference_text": "[1] \"Product Information. Jardiance (empagliflozin).\" Boehringer Ingelheim, Ridgefield, CT.[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] \"Product Information. Farxiga (dapagliflozin).\" Bristol-Myers Squibb, Princeton, NJ.[5] \"Product Information. Invokana (canagliflozin).\" Janssen Pharmaceuticals, Titusville, NJ.[6] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[7] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[8] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[9] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[10] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[11] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6[12] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[13] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[14] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[15] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42", "alternatives_a": "Latanoprost, Apraclonidine, Neostigmine, Pilocarpine, Physostigmine, Acetylcholine, Bimatoprost, Travoprost, Brinzolamide, Brimonidine, Levobunolol", "alternatives_b": "Acetohexamide, Guar gum, Pramlintide, Alogliptin, Rosuvastatin, Dulaglutide, Exenatide, Miglitol, Albiglutide, Rosiglitazone, Semaglutide, More", "updated_at": 1767369485}, {"id": 97855, "ingredient1": "Empagliflozin", "ingredient2": "Chlorpromazine", "severity": "Moderate", "effect": "The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.", "source": "DDInter", "management_text": "Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.", "mechanism_text": "Antagonism", "recommendation": "Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97959/", "reference_text": "[1] Jori A, Carrara MC \"On the mechanism of the hyperglycaemic effect of chlorpromazine.\" J Pharm Pharmacol 18 (1966): 623-4[2] \"Product Information. Dymelor (acetohexamide)\" Lilly, Eli and Company, Indianapolis, IN.[3] \"Product Information. Thorazine (chlorpromazine).\" SmithKline Beecham, Philadelphia, PA.[4] Blayac JP, Ribes G, Buys D, Puech R, Loubatieres-Mariani MM \"Effects of a new benzothiadiazine derivative, LN 5330, on insulin secretion.\" Arch Int Pharmacodyn Ther 253 (1981): 154-63[5] \"Product Information. Elzonris (tagraxofusp).\" Stemline Therapeutics, New York, NY.[6] \"Product Information. Amaryl (glimepiride).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[7] \"Product Information. Elspar (asparaginase).\" Merck & Co, Inc, West Point, PA.[8] Jones IG, Pickens PT \"Diabetes mellitus following oral diuretics.\" Practitioner 199 (1967): 209-10[9] \"Product Information. Viracept (nelfinavir).\" Agouron Pharma Inc, La Jolla, CA.[10] \"Product Information. Tolinase (tolazamide)\" Pharmacia and Upjohn, Kalamazoo, MI.[11] Mauss S, Wolf E, Jaeger H \"Impaired glucose tolerance in HIV-positive patients receiving and those not receiving protease inhibitors.\" Ann Intern Med 130 (1999): 162-3[12] Virutamasen P, Wongsrichanalai C, Tangkeo P, Nitichai Y, Rienprayoon D \"Metabolic effects of depot-medroxyprogesterone acetate in long-term users: a cross-sectional study.\" Int J Gynaecol Obstet 24 (1986): 291-6[13] Wehring H, Alexander B, Perry PJ \"Diabetes mellitus associated with clozapine therapy.\" Pharmacotherapy 20 (2000): 844-7[14] Spellacy WN, Ellingson AB, Tsibris JC \"The effects of two triphasic oral contraceptives on carbohydrate metabolism in women during 1 year of use.\" Fertil Steril 51 (1989): 71-4[15] Andersen OO, Persson I \"Carbohydrate metabolism during treatment with chlorthalidone and ethacrynic acid.\" Br Med J 2 (1968): 798-801[16] Berlin I \"Prazosin, diuretics, and glucose intolerance.\" Ann Intern Med 119 (1993): 860[17] Malherbe C, Burrill KC, Levin SR, Karam JH, Forsham PH \"Effect of diphenylhydantoin on insulin secretion in man.\" N Engl J Med 286 (1972): 339-42[18] Carter BL, Small RE, Mandel MD, Starkman MT \"Phenytoin-induced hyperglycemia.\" Am J Hosp Pharm 38 (1981): 1508-12[19] Al-Rubeaan K, Ryan EA \"Phenytoin-induced insulin insensitivity.\" Diabet Med 8 (1991): 968-70[20] \"Product Information. Zolinza (vorinostat).\" Merck & Company Inc, West Point, PA.[21] Goldman JA, Neri A, Ovadia J, Eckerling B, Vries A, de \"Effect of chlorothiazide on intravenous glucose tolerance in pregnancy.\" Am J Obstet Gynecol 105 (1969): 556-60[22] Harper R, Ennis CN, Heaney AP, Sheridan B, Gormley M, Atkinson AB, Johnston GD, Bell PM \"A comparison of the effects of low- and conventional-dose thiazide diuretic on insulin action in hypertensive patients with NIDDM.\" Diabetologia 38 (1995): 853-9[23] Seltzer HS, Allen EW \"Hyperglycemia and inhibition of insulin secretion during administration of diazoxide and trichlormethiazide in man.\" Diabetes 18 (1969): 19-28[24] Dube MP, Johnson DL, Currier JS, Leedom JM \"Protease inhibitor-associated hyperglycaemia.\" Lancet 350 (1997): 713-4[25] Leary WP, Reyes AJ \"Drug interactions with diuretics.\" S Afr Med J 65 (1984): 455-61[26] \"Product Information. Reyataz (atazanavir).\" Bristol-Myers Squibb, Princeton, NJ.[27] Pollare T, Lithell H, Berne C \"A comparison of the effects of hydrochlorothiazide and captopril on glucose and lipid metabolism in patients with hypertension.\" N Engl J Med 321 (1989): 868-73[28] Gunnarsson R, Lundgren G, Magnusson G, Ost L, Groth CG \"Steroid diabetes--a sign of overtreatment with steroids in the renal graft recipient?\" Scand J Urol Nephrol Suppl 54 (1980): 135-8[29] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[30] \"Product Information. Synthroid (levothyroxine).\" Abbott Pharmaceutical, Abbott Park, IL.[31] Murphy MB, Kohner E, Lewis PJ, Schumer B, Dollery CT \"Glucose intolerance in hypertensive patients treated with diuretics: a fourteen-year follow-up.\" Lancet 2 (1982): 1293-5[32] \"Product Information. Fortovase (saquinavir)\" Roche Laboratories, Nutley, NJ.[33] Coni NK, Gordon PW, Mukherjee AP, Read PR \"The effect of frusemide and ethacrynic acid on carbohydrate metabolism.\" Age Ageing 3 (1974): 85-90[34] \"Product Information. Norvir (ritonavir).\" Abbott Pharmaceutical, Abbott Park, IL.[35] Domenet JG \"Diabetogenic effect of oral diuretics.\" Br Med J 3 (1968): 188[36] Rowe P, Mather H \"Hyperosmolar non-ketotic diabetes mellitus associated with metolazone.\" Br Med J 291 (1985): 25-6[37] Winchester JF, Kellett RJ, Boddy K, Boyle P, Dargie HJ, Mahaffey ME, Ward DM, Kennedy AC \"Metolazone and bendroflumethiazide in hypertension: physiologic and metabolic observations.\" Clin Pharmacol Ther 28 (1980): 611-8[38] \"Product Information. Carafate (sucralfate).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[39] Tsiodras S, Mantzoros C, Hammer S, Samore M \"Effects of protease inhibitors on hyperglycemia, hyperlipidemia, and lipodystrophy - A 5-year cohort study.\" Arch Intern Med 160 (2000): 2050-6[40] \"Product Information. Apidra (insulin glulisine).\" Aventis Pharmaceuticals, Bridgewater, NJ.[41] \"Product Information. Prezista (darunavir).\" Ortho Biotech Inc, Bridgewater, NJ.[42] Haiba NA, el-Habashy MA, Said SA, Darwish EA, Abdel-Sayed WS, Nayel SE \"Clinical evaluation of two monthly injectable contraceptives and their effects on some metabolic parameters.\" Contraception 39 (1989): 619-32[43] Erle G, Basso M, Federspil G, Sicolo N, Scandellari C \"Effect of chlorpromazine on blood glucose and plasma insulin in man.\" Eur J Clin Pharmacol 11 (1977): 15-8[44] Pickkers P, Schachter M, Hughes AD, Feher MD, Sever PS \"Thiazide-induced hyperglycaemia: a role for calcium-activated potassium channels?\" Diabetologia 39 (1996): 861-4[45] \"Product Information. Lexiva (fosamprenavir).\" GlaxoSmithKline, Research Triangle Park, NC.[46] Curtis J, Horrigan F, Ahearn D, Varney R, Sandler SG \"Chlorthalidone-induced hyperosmolar hyperglycemic nonketotic coma.\" JAMA 220 (1972): 1592-3[47] \"Product Information. Hyperstat I.V. (diazoxide).\" Schering Corp, Kenilworth, NJ.[48] \"Product Information. Piqray (alpelisib).\" Novartis Pharmaceuticals, East Hanover, NJ.[49] Bell DS \"Insulin resistance. An often unrecognized problem accompanying chronic medical disorders.\" Postgrad Med 93 (1993): 99-103,[50] Stambaugh JE, Tucker DC \"Effect of diphenylhydantoin on glucose tolerance in patients with hypoglycemia.\" Diabetes 23 (1974): 679-83[51] \"Product Information. Crixivan (indinavir).\" Merck & Co, Inc, West Point, PA.[52] Miller NR, Moses H \"Transient oculomotor nerve palsy. Association with thiazide-induced glucose intolerance.\" JAMA 240 (1978): 1887-8[53] Javier Z, Gershberg H, Hulse M \"Ovulatory suppressants, estrogens, and carbohydrate metabolism.\" Metabolism 17 (1968): 443-56[54] Goldman JA, Ovadia JL \"The effect of estrogen on intravenous glucose tolerance in woman.\" Am J Obstet Gynecol 103 (1969): 172-8[55] Charan VD, Desai N, Singh AP, Choudhry VP \"Diabetes mellitus and pancreatitis as a complication of L- asparaginase therapy.\" Indian Pediatr 30 (1993): 809-10[56] Seifer DB, Freedman LN, Cavender JR, Baker RA \"Insulin-dependent diabetes mellitus associated with danazol.\" Am J Obstet Gynecol 162 (1990): 474-5[57] \"Product Information. Orinase (tolbutamide)\" Pharmacia and Upjohn, Kalamazoo, MI.[58] Walli R, Demant T \"Impaired glucose tolerance and protease inhibitors.\" Ann Intern Med 129 (1998): 837-8[59] Hannaford PC, Kay CR \"Oral contraceptives and diabetes mellitus.\" BMJ 299 (1989): 1315-6[60] Hardy H, Esch LD, Morse GD \"Glucose disorders associated with HIV and its drug therapy.\" Ann Pharmacother 35 (2001): 343-51[61] Chowdhury FR, Bleicher SJ \"Chlorthalidone--induced hypokalemia and abnormal carbohydrate metabolism.\" Horm Metab Res 2 (1970): 13-6[62] Kaufman MB, Simionatto C \"A review of protease inhibitor-induced hyperglycemia.\" Pharmacotherapy 19 (1999): 114-7[63] Greenstone MA, Shaw AB \"Alternate day corticosteroid causes alternate day hyperglycaemia.\" Postgrad Med J 63 (1987): 761-4[64] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[65] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[66] Elmfeldt D, Berglund G, Wedel H, Wilhelmsen L \"Incidence and importance of metabolic side-effects during antihypertensive therapy.\" Acta Med Scand Suppl 672 (1983): 79-83[67] \"Product Information. Agenerase (amprenavir).\" Glaxo Wellcome, Research Triangle Pk, NC.[68] Diamond MT \"Hyperglycemic hyperosmolar coma associated with hydrochlorothiazide and pancreatitis.\" N Y State J Med 72 (1972): 1741-2[69] \"Product Information. Prandin (repaglinide).\" Novo Nordisk Pharmaceuticals Inc, Princeton, NJ.[70] \"Product Information. Precose (acarbose).\" Bayer, West Haven, CT.[71] \"Product Information. Starlix (nateglinide)\" Novartis Pharmaceuticals, East Hanover, NJ.[72] \"Product Information. Oncaspar (pegaspargase).\" Rhone-Poulenc Rorer, Collegeville, PA.[73] Sotaniemi E, Kontturi M, Larmi T \"Effect of diethylstilbestrol on blood glucose of prostatic cancer patients.\" Invest Urol 10 (1973): 438-41[74] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[75] Petri M, Cumber P, Grimes L, Treby D, Bryant R, Rawlins D, Ising H \"The metabolic effects of thiazide therapy in the elderly: a population study.\" Age Ageing 15 (1986): 151-5[76] Ludvik B, Clodi M, Kautzky-Willer A, Capek M, Hartter E, Pacini G, Prager R \"Effect of dexamethasone on insulin sensitivity, islet amyloid polypeptide and insulin secretion in humans.\" Diabetologia 36 (1993): 84-7[77] \"Product Information. Glucophage (metformin).\" Bristol-Myers Squibb, Princeton, NJ.[78] Chaudhuri ML, Catania J \"A comparison of the effects of bumetanide (Burinex) and frusemide on carbohydrate metabolism in the elderly.\" Br J Clin Pract 42 (1988): 427-9[79] Black DM, Filak AT \"Hyperglycemia with non-insulin-dependent diabetes following intraarticular steroid injection.\" J Fam Pract 28 (1989): 462-3[80] \"Product Information. Megace (megestrol).\" Bristol-Myers Squibb, Princeton, NJ.[81] \"Product Information. Torisel (temsirolimus).\" Wyeth-Ayerst Laboratories, Philadelphia, PA.[82] Schmitz O, Hermansen K, Nielsen OH, Christensen CK, Arnfred J, Hansen HE, Mogensen CE, Orskov H, Beck-Nielsen H \"Insulin action in insulin-dependent diabetics after short-term thiazide therapy.\" Diabetes Care 9 (1986): 631-6[83] Kansal PC, Buse J, Buse MG \"Thiazide diuretics and control of diabetes mellitus.\" South Med J 62 (1969): 1372-9[84] Dimitriadis G, Tegos C, Golfinopoulou L, Roboti C, Raptis S \"Furosemide-induced hyperglycaemia - the implication of glycolytic kinases.\" Horm Metab Res 25 (1993): 557-9[85] \"Product Information. NovoLog Mix 70/30 (insulin aspart-insulin aspart protamine).\" Novo Nordisk Pharmaceuticals Inc, Princeton, NJ.[86] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[87] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[88] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[89] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42[90] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[91] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[92] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[93] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[94] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[95] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6", "alternatives_a": "Haloperidol, Pimavanserin, Thiothixene, Pimozide, Amisulpride, Loxapine, Molindone, Droperidol", "alternatives_b": "Guar gum, Rosuvastatin", "updated_at": 1767369485}, {"id": 97856, "ingredient1": "Empagliflozin", "ingredient2": "Chromic chloride", "severity": "Moderate", "effect": "Pharmacologic dosages of chromium (200 mcg/day or more for adults) may help improve diabetic control and reduce the requirements for insulin and other antidiabetic agents. Chromium appears to play a role in normal insulin function and glucose utilization.", "source": "DDInter", "management_text": "Until further data are available, therapy with pharmacologic dosages of chromium should be administered cautiously in patients receiving insulin or other antidiabetic agents. Patients should be monitored for changes in diabetic medication requirements.", "mechanism_text": "Synergism", "recommendation": "Until further data are available, therapy with pharmacologic dosages of chromium should be administered cautiously in patients receiving insulin or other antidiabetic agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97960/", "reference_text": "[1] Martin J, Wang ZQ, Zhang XH, et al. \"Chromium picolinate supplementation attenuates body weight gain and increases insulin sensitivity in subjects with type 2 diabetes.\" Diabetes Care 29 (2006): 1826-32[2] Fox GN, Sabovic Z \"Chromium picolinate supplementation for diabetes mellitus.\" J Fam Pract 46 (1998): 83-6[3] Anderson RA, cheng N, Bryden NA, et al \"Elevated intakes of supplemental chromium improve glucose and insulin variables in individuals with type 2 diabetes.\" Diabetes 46 (1997): 1786-91[4] Bratman S, Kroll D. \"The Natural Health Bible: From the Most Trusted Alternative Health Site in the World--Your A-Z Guide to over 300 Conditions, Herbs, Vitamins, and Supplements.\" Roseville, CA: Prima Health (2000):[5] Anderson RA \"Chromium, glucose intolerance and diabetes.\" J Am Coll Nutr 17 (1998): 548-55[6] Abraham AS, Brooks BA, Eylath U \"The effects of chromiium supplementation on serum glucose and lipids in patients with and without non-insulin-dependent diabetes.\" Metabolism 41 (1992): 768-71[7] Mertz W \"Interaction of chromium with insulin: a progress report.\" Nutr Rev 56 (1998): 174-7[8] Althuis MD, Jordan NE, Ludington EA, Wittes JT \"Glucose and insulin responses to dietary chromium supplements: a meta-analysis.\" Am J Clin Nutr 76 (2002): 148-55[9] Gunton JE, Cheung NW, Hitchman R, et al. \"Chromium supplementation does not improve glucose tolerance, insulin sensitivity, or lipid profile: a randomized, placebo-controlled, double-blind trial of supplementation in subjects with impaired glucose tolerance.\" Diabetes Care 28 (2005): 712-3[10] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[11] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[12] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[13] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42[14] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[15] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[16] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[17] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[18] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[19] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6", "alternatives_a": "Simvastatin, Guar gum, Rosuvastatin", "alternatives_b": "", "updated_at": 1767369485}, {"id": 97857, "ingredient1": "Empagliflozin", "ingredient2": "Chromium picolinate", "severity": "Moderate", "effect": "Pharmacologic dosages of chromium (200 mcg/day or more for adults) may help improve diabetic control and reduce the requirements for insulin and other antidiabetic agents. Chromium appears to play a role in normal insulin function and glucose utilization.", "source": "DDInter", "management_text": "Until further data are available, therapy with pharmacologic dosages of chromium should be administered cautiously in patients receiving insulin or other antidiabetic agents. Patients should be monitored for changes in diabetic medication requirements.", "mechanism_text": "Synergism", "recommendation": "Until further data are available, therapy with pharmacologic dosages of chromium should be administered cautiously in patients receiving insulin or other antidiabetic agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97961/", "reference_text": "[1] Martin J, Wang ZQ, Zhang XH, et al. \"Chromium picolinate supplementation attenuates body weight gain and increases insulin sensitivity in subjects with type 2 diabetes.\" Diabetes Care 29 (2006): 1826-32[2] Fox GN, Sabovic Z \"Chromium picolinate supplementation for diabetes mellitus.\" J Fam Pract 46 (1998): 83-6[3] Anderson RA, cheng N, Bryden NA, et al \"Elevated intakes of supplemental chromium improve glucose and insulin variables in individuals with type 2 diabetes.\" Diabetes 46 (1997): 1786-91[4] Bratman S, Kroll D. \"The Natural Health Bible: From the Most Trusted Alternative Health Site in the World--Your A-Z Guide to over 300 Conditions, Herbs, Vitamins, and Supplements.\" Roseville, CA: Prima Health (2000):[5] Anderson RA \"Chromium, glucose intolerance and diabetes.\" J Am Coll Nutr 17 (1998): 548-55[6] Abraham AS, Brooks BA, Eylath U \"The effects of chromiium supplementation on serum glucose and lipids in patients with and without non-insulin-dependent diabetes.\" Metabolism 41 (1992): 768-71[7] Mertz W \"Interaction of chromium with insulin: a progress report.\" Nutr Rev 56 (1998): 174-7[8] Althuis MD, Jordan NE, Ludington EA, Wittes JT \"Glucose and insulin responses to dietary chromium supplements: a meta-analysis.\" Am J Clin Nutr 76 (2002): 148-55[9] Gunton JE, Cheung NW, Hitchman R, et al. \"Chromium supplementation does not improve glucose tolerance, insulin sensitivity, or lipid profile: a randomized, placebo-controlled, double-blind trial of supplementation in subjects with impaired glucose tolerance.\" Diabetes Care 28 (2005): 712-3[10] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[11] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[12] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[13] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42[14] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[15] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[16] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[17] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[18] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[19] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6", "alternatives_a": "Simvastatin, Guar gum, Rosuvastatin", "alternatives_b": "", "updated_at": 1767369485}, {"id": 97858, "ingredient1": "Empagliflozin", "ingredient2": "Cinoxacin", "severity": "Moderate", "effect": "Quinolone antibiotics may interfere with the therapeutic effects of insulin and other antidiabetic agents. The use of quinolones has been associated with disturbances in blood glucose homeostasis possibly stemming from effects on pancreatic beta cell ATP-sensitive potassium channels that regulate insulin secretion. Both hyperglycaemia and hypoglycemia have been reported, usually in diabetic patients receiving concomitant treatment with an oral hypoglycemic agent (e.g., sulfonylurea) or insulin. Although hyperglycaemia is significantly more common and infection itself may be an underlying risk factor, hypoglycemia may cause greater morbidity and mortality.", "source": "DDInter", "management_text": "Blood glucose should be closely monitored whenever quinolones are prescribed to diabetic patients, especially if they are elderly, have renal impairment, or are severely ill. Patients should be apprised of the increased risk of dysglycemia and be particularly alert to potential signs and symptoms of hypoglycemia such as headache, dizziness, drowsiness, nervousness, confusion, tremor, hunger, weakness, perspiration, palpitation, and tachycardia. If hypoglycemia occurs, patients should initiate appropriate remedial therapy immediately, discontinue the quinolone, and contact their physician. Alternative antibiotics may need to be considered.", "mechanism_text": "Antagonism", "recommendation": "Blood glucose should be closely monitored whenever quinolones are prescribed to diabetic patients, especially if they are elderly, have renal impairment, or are severely ill.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97962/", "reference_text": "[1] Gavin JR 3rd, Kubin R, Choudhri S, et al \"Moxifloxacin and glucose homeostasis: a pooled-analysis of the evidence from clinical and postmarketing studies.\" Drug Saf 27 (2004): 671-86[2] Yip C, Lee AJ \"Gatifloxacin-induced hyperglycemia: a case report and summary of the current literature.\" Clin Ther 28 (2006): 1857-66[3] Kelesidis T, Canseco E \"Quinolone-induced hypoglycemia: a life-threatening but potentially reversible side effect.\" Am J Med 123 (2010): e5-6[4] Baker SE, Hangii MC \"Possible gatifloxacin-induced hypoglycemia.\" Ann Pharmacother 36 (2002): 1722-6[5] \"Product Information. Levaquin (levofloxacin).\" Ortho Pharmaceutical Corporation, Raritan, NJ.[6] Frothingham R \"Glucose homeostasis abnormalities associated with use of gatifloxacin.\" Clin Infect Dis 41 (2005): 1269-76[7] Letourneau G, Morrison H, McMorran M \"Gatifloxacin (Tequin): hypoglycemia and hyperglycemia. Available from: URL: http://www.hc-sc.gc.ca/dhp-mps/medeff/bulletin/carn-bcei_v13n3_e.html#1\" ([2003 Jul]):[8] Lin G, Hays DP, Spillane L \"Refractory hypoglycemia from ciprofloxacin and glyburide interaction.\" J Toxicol Clin Toxicol 42 (2004): 295-7[9] \"Product Information. Tequin (gatifloxacin)\" Bristol-Myers Squibb, Princeton, NJ.[10] \"Product Information. Floxin (ofloxacin).\" Ortho Pharmaceutical Corporation, Raritan, NJ.[11] Bhasin R, Arce FC, Pasmantier R \"Hypoglycemia associated with the use of gatifloxacin.\" Am J Med Sci 330 (2005): 250-3[12] Zvonar R \"Gatifloxacin-induced dysglycemia.\" Am J Health Syst Pharm 63 (2006): 2087-2092[13] Rubinstein E \"History of quinolones and their side effects.\" Chemotherapy 47 Suppl 3 (2001): 3-8[14] Park-Wyllie LY, Juurlink DN, Kopp A, et al. \"Outpatient gatifloxacin therapy and dysglycemia in older adults.\" N Engl J Med 354 (2006): 1352-61[15] LeBlanc M, Belanger C, Cossette P \"Severe and resistant hypoglycemia associated with concomitant gatifloxacin and glyburide therapy.\" Pharmacotherapy 24 (2004): 926-31[16] \"Product Information. Cipro (ciprofloxacin).\" Bayer, West Haven, CT.[17] Happe MR, Mulhall BP, Maydonovitch CL, Holtzmuller KC \"Gatifloxacin-induced hyperglycemia.\" Ann Intern Med 141 (2004): 968-9[18] Biggs WS \"Hypoglycemia and hyperglycemia associated with gatifloxacin use in elderly patients.\" J Am Board Fam Pract 16 (2004): 455-7[19] \"Product Information. Raxar (grepafloxacin).\" Glaxo Wellcome, Research Triangle Park, NC.[20] Brogan SE, Cahalan MK \"Gatifloxacin as a possible cause of serious postoperative hypoglycemia.\" Anesth Analg 101 (2005): 635-6[21] Friedrich LV, Dougherty R \"Fatal hypoglycemia associated with levofloxacin.\" Pharmacotherapy 24 (2004): 1807-12[22] Saraya A, Yokokura M, Gonoi T, Seino S \"Effects of fluoroquinolones on insulin secretion and beta-cell ATP-sensitive K(+) channels.\" Eur J Pharmacol 497 (2004): 111-7[23] \"Hypoglycemia and hyperglycemia with fluoroquinolones.\" Med Lett Drugs Ther 45 (2003): 64[24] Gajjar DA, LaCreta FP, Kollia GD, et al. \"Effect of multiple-dose gatifloxacin or ciprofloxacin on glucose homeostasis and insulin production in patients with noninsulin-dependent diabetes mellitus maintained with diet and exercise.\" Pharmacotherapy 20 (6 Pt 2) (2000): s76-86[25] Khovidhunkit W, Sunthornyothin S \"Hypoglycemia, hyperglycemia, and gatifloxacin.\" Ann Intern Med 141 (2004): 969[26] Kanbay M, Aydogan T, Bozalan R, et al. \"A rare but serious side effect of levofloxacin: hypoglycemia in a geriatric patient.\" Diabetes Care 29 (2006): 1716-7[27] Menzies DJ, Dorsainvil PA, Cunha BA, Johnson DH \"Severe and persistent hypoglycemia due to gatifloxacin interaction with oral hypoglycemic agents.\" Am J Med 113 (2002): 232-4[28] Edwards DJ, Bowles SK, Svensson CK, Rybak MJ \"Inhibition of drug metabolism by quinolone antibiotics.\" Clin Pharmacokinet 15 (1988): 194-204[29] Graumlich JF, Habis S, Avelino RR, et al. \"Hypoglycemia in inpatients after gatifloxacin or levofloxacin therapy: nested case-control study.\" Pharmacotherapy 25 (2005): 1296-302[30] \"Product Information. Factive (gemifloxacin).\" GeneSoft Inc, San Francisco, CA.[31] Wang S, Rizvi AA \"Levofloxacin-induced hypoglycemia in a nondiabetic patient.\" Am J Med Sci 331 (2006): 334-5[32] \"Product Information. Noroxin (norfloxacin).\" Merck & Co, Inc, West Point, PA.[33] Zhanel GG, Fontaine S, Adam H, et al. \"A Review of New Fluoroquinolones : Focus on their Use in Respiratory Tract Infections.\" Treat Respir Med 5 (2006): 437-465[34] \"Product Information. Baxdela (delafloxacin).\" Melinta Therapeutics, Lincolnshire, IL.[35] Greenberg AL, Decerbo M, Fan J \"Gatifloxacin therapy associated with hypoglycemia.\" Clin Infect Dis 40 (2005): 1210-1[36] Blommel AL, Lutes RA \"Severe hyperglycemia during renally adjusted gatifloxacin therapy.\" Ann Pharmacother 39 (2005): 1349-52[37] Tomita T, Onishi M, Sato E, Kimura Y, Kihira K \"Gatifloxacin induces augmented insulin release and intracellular insulin.\" Biol Pharm Bull 30 (2007): 644-7[38] Donaldson AR, Vandiver JR, Finch CK \"Possible gatifloxacin-induced hyperglycemia.\" Ann Pharmacother 38 (2004): 602-5[39] \"Product Information. Trovan (trovafloxacin).\" Pfizer US Pharmaceuticals, New York, NY.[40] Roberge RJ, Kaplan R, Frank R, Fore C \"Glyburide-ciprofloxacin interaction with resistant hypoglycemia.\" Ann Emerg Med 36 (2000): 160-3[41] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[42] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[43] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[44] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42[45] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[46] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[47] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[48] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[49] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[50] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6", "alternatives_a": "Simvastatin, Guar gum, Rosuvastatin", "alternatives_b": "", "updated_at": 1767369485}, {"id": 97859, "ingredient1": "Empagliflozin", "ingredient2": "Conjugated estrogens (topical)", "severity": "Moderate", "effect": "The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.", "source": "DDInter", "management_text": "Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.", "mechanism_text": "Antagonism", "recommendation": "Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97963/", "reference_text": "[1] Jori A, Carrara MC \"On the mechanism of the hyperglycaemic effect of chlorpromazine.\" J Pharm Pharmacol 18 (1966): 623-4[2] \"Product Information. Dymelor (acetohexamide)\" Lilly, Eli and Company, Indianapolis, IN.[3] \"Product Information. Thorazine (chlorpromazine).\" SmithKline Beecham, Philadelphia, PA.[4] Blayac JP, Ribes G, Buys D, Puech R, Loubatieres-Mariani MM \"Effects of a new benzothiadiazine derivative, LN 5330, on insulin secretion.\" Arch Int Pharmacodyn Ther 253 (1981): 154-63[5] \"Product Information. Elzonris (tagraxofusp).\" Stemline Therapeutics, New York, NY.[6] \"Product Information. Amaryl (glimepiride).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[7] \"Product Information. Elspar (asparaginase).\" Merck & Co, Inc, West Point, PA.[8] Jones IG, Pickens PT \"Diabetes mellitus following oral diuretics.\" Practitioner 199 (1967): 209-10[9] \"Product Information. Viracept (nelfinavir).\" Agouron Pharma Inc, La Jolla, CA.[10] \"Product Information. Tolinase (tolazamide)\" Pharmacia and Upjohn, Kalamazoo, MI.[11] Mauss S, Wolf E, Jaeger H \"Impaired glucose tolerance in HIV-positive patients receiving and those not receiving protease inhibitors.\" Ann Intern Med 130 (1999): 162-3[12] Virutamasen P, Wongsrichanalai C, Tangkeo P, Nitichai Y, Rienprayoon D \"Metabolic effects of depot-medroxyprogesterone acetate in long-term users: a cross-sectional study.\" Int J Gynaecol Obstet 24 (1986): 291-6[13] Wehring H, Alexander B, Perry PJ \"Diabetes mellitus associated with clozapine therapy.\" Pharmacotherapy 20 (2000): 844-7[14] Spellacy WN, Ellingson AB, Tsibris JC \"The effects of two triphasic oral contraceptives on carbohydrate metabolism in women during 1 year of use.\" Fertil Steril 51 (1989): 71-4[15] Andersen OO, Persson I \"Carbohydrate metabolism during treatment with chlorthalidone and ethacrynic acid.\" Br Med J 2 (1968): 798-801[16] Berlin I \"Prazosin, diuretics, and glucose intolerance.\" Ann Intern Med 119 (1993): 860[17] Malherbe C, Burrill KC, Levin SR, Karam JH, Forsham PH \"Effect of diphenylhydantoin on insulin secretion in man.\" N Engl J Med 286 (1972): 339-42[18] Carter BL, Small RE, Mandel MD, Starkman MT \"Phenytoin-induced hyperglycemia.\" Am J Hosp Pharm 38 (1981): 1508-12[19] Al-Rubeaan K, Ryan EA \"Phenytoin-induced insulin insensitivity.\" Diabet Med 8 (1991): 968-70[20] \"Product Information. Zolinza (vorinostat).\" Merck & Company Inc, West Point, PA.[21] Goldman JA, Neri A, Ovadia J, Eckerling B, Vries A, de \"Effect of chlorothiazide on intravenous glucose tolerance in pregnancy.\" Am J Obstet Gynecol 105 (1969): 556-60[22] Harper R, Ennis CN, Heaney AP, Sheridan B, Gormley M, Atkinson AB, Johnston GD, Bell PM \"A comparison of the effects of low- and conventional-dose thiazide diuretic on insulin action in hypertensive patients with NIDDM.\" Diabetologia 38 (1995): 853-9[23] Seltzer HS, Allen EW \"Hyperglycemia and inhibition of insulin secretion during administration of diazoxide and trichlormethiazide in man.\" Diabetes 18 (1969): 19-28[24] Dube MP, Johnson DL, Currier JS, Leedom JM \"Protease inhibitor-associated hyperglycaemia.\" Lancet 350 (1997): 713-4[25] Leary WP, Reyes AJ \"Drug interactions with diuretics.\" S Afr Med J 65 (1984): 455-61[26] \"Product Information. Reyataz (atazanavir).\" Bristol-Myers Squibb, Princeton, NJ.[27] Pollare T, Lithell H, Berne C \"A comparison of the effects of hydrochlorothiazide and captopril on glucose and lipid metabolism in patients with hypertension.\" N Engl J Med 321 (1989): 868-73[28] Gunnarsson R, Lundgren G, Magnusson G, Ost L, Groth CG \"Steroid diabetes--a sign of overtreatment with steroids in the renal graft recipient?\" Scand J Urol Nephrol Suppl 54 (1980): 135-8[29] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[30] \"Product Information. Synthroid (levothyroxine).\" Abbott Pharmaceutical, Abbott Park, IL.[31] Murphy MB, Kohner E, Lewis PJ, Schumer B, Dollery CT \"Glucose intolerance in hypertensive patients treated with diuretics: a fourteen-year follow-up.\" Lancet 2 (1982): 1293-5[32] \"Product Information. Fortovase (saquinavir)\" Roche Laboratories, Nutley, NJ.[33] Coni NK, Gordon PW, Mukherjee AP, Read PR \"The effect of frusemide and ethacrynic acid on carbohydrate metabolism.\" Age Ageing 3 (1974): 85-90[34] \"Product Information. Norvir (ritonavir).\" Abbott Pharmaceutical, Abbott Park, IL.[35] Domenet JG \"Diabetogenic effect of oral diuretics.\" Br Med J 3 (1968): 188[36] Rowe P, Mather H \"Hyperosmolar non-ketotic diabetes mellitus associated with metolazone.\" Br Med J 291 (1985): 25-6[37] Winchester JF, Kellett RJ, Boddy K, Boyle P, Dargie HJ, Mahaffey ME, Ward DM, Kennedy AC \"Metolazone and bendroflumethiazide in hypertension: physiologic and metabolic observations.\" Clin Pharmacol Ther 28 (1980): 611-8[38] \"Product Information. Carafate (sucralfate).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[39] Tsiodras S, Mantzoros C, Hammer S, Samore M \"Effects of protease inhibitors on hyperglycemia, hyperlipidemia, and lipodystrophy - A 5-year cohort study.\" Arch Intern Med 160 (2000): 2050-6[40] \"Product Information. Apidra (insulin glulisine).\" Aventis Pharmaceuticals, Bridgewater, NJ.[41] \"Product Information. Prezista (darunavir).\" Ortho Biotech Inc, Bridgewater, NJ.[42] Haiba NA, el-Habashy MA, Said SA, Darwish EA, Abdel-Sayed WS, Nayel SE \"Clinical evaluation of two monthly injectable contraceptives and their effects on some metabolic parameters.\" Contraception 39 (1989): 619-32[43] Erle G, Basso M, Federspil G, Sicolo N, Scandellari C \"Effect of chlorpromazine on blood glucose and plasma insulin in man.\" Eur J Clin Pharmacol 11 (1977): 15-8[44] Pickkers P, Schachter M, Hughes AD, Feher MD, Sever PS \"Thiazide-induced hyperglycaemia: a role for calcium-activated potassium channels?\" Diabetologia 39 (1996): 861-4[45] \"Product Information. Lexiva (fosamprenavir).\" GlaxoSmithKline, Research Triangle Park, NC.[46] Curtis J, Horrigan F, Ahearn D, Varney R, Sandler SG \"Chlorthalidone-induced hyperosmolar hyperglycemic nonketotic coma.\" JAMA 220 (1972): 1592-3[47] \"Product Information. Hyperstat I.V. (diazoxide).\" Schering Corp, Kenilworth, NJ.[48] \"Product Information. Piqray (alpelisib).\" Novartis Pharmaceuticals, East Hanover, NJ.[49] Bell DS \"Insulin resistance. An often unrecognized problem accompanying chronic medical disorders.\" Postgrad Med 93 (1993): 99-103,[50] Stambaugh JE, Tucker DC \"Effect of diphenylhydantoin on glucose tolerance in patients with hypoglycemia.\" Diabetes 23 (1974): 679-83[51] \"Product Information. Crixivan (indinavir).\" Merck & Co, Inc, West Point, PA.[52] Miller NR, Moses H \"Transient oculomotor nerve palsy. Association with thiazide-induced glucose intolerance.\" JAMA 240 (1978): 1887-8[53] Javier Z, Gershberg H, Hulse M \"Ovulatory suppressants, estrogens, and carbohydrate metabolism.\" Metabolism 17 (1968): 443-56[54] Goldman JA, Ovadia JL \"The effect of estrogen on intravenous glucose tolerance in woman.\" Am J Obstet Gynecol 103 (1969): 172-8[55] Charan VD, Desai N, Singh AP, Choudhry VP \"Diabetes mellitus and pancreatitis as a complication of L- asparaginase therapy.\" Indian Pediatr 30 (1993): 809-10[56] Seifer DB, Freedman LN, Cavender JR, Baker RA \"Insulin-dependent diabetes mellitus associated with danazol.\" Am J Obstet Gynecol 162 (1990): 474-5[57] \"Product Information. Orinase (tolbutamide)\" Pharmacia and Upjohn, Kalamazoo, MI.[58] Walli R, Demant T \"Impaired glucose tolerance and protease inhibitors.\" Ann Intern Med 129 (1998): 837-8[59] Hannaford PC, Kay CR \"Oral contraceptives and diabetes mellitus.\" BMJ 299 (1989): 1315-6[60] Hardy H, Esch LD, Morse GD \"Glucose disorders associated with HIV and its drug therapy.\" Ann Pharmacother 35 (2001): 343-51[61] Chowdhury FR, Bleicher SJ \"Chlorthalidone--induced hypokalemia and abnormal carbohydrate metabolism.\" Horm Metab Res 2 (1970): 13-6[62] Kaufman MB, Simionatto C \"A review of protease inhibitor-induced hyperglycemia.\" Pharmacotherapy 19 (1999): 114-7[63] Greenstone MA, Shaw AB \"Alternate day corticosteroid causes alternate day hyperglycaemia.\" Postgrad Med J 63 (1987): 761-4[64] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[65] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[66] Elmfeldt D, Berglund G, Wedel H, Wilhelmsen L \"Incidence and importance of metabolic side-effects during antihypertensive therapy.\" Acta Med Scand Suppl 672 (1983): 79-83[67] \"Product Information. Agenerase (amprenavir).\" Glaxo Wellcome, Research Triangle Pk, NC.[68] Diamond MT \"Hyperglycemic hyperosmolar coma associated with hydrochlorothiazide and pancreatitis.\" N Y State J Med 72 (1972): 1741-2[69] \"Product Information. Prandin (repaglinide).\" Novo Nordisk Pharmaceuticals Inc, Princeton, NJ.[70] \"Product Information. Precose (acarbose).\" Bayer, West Haven, CT.[71] \"Product Information. Starlix (nateglinide)\" Novartis Pharmaceuticals, East Hanover, NJ.[72] \"Product Information. Oncaspar (pegaspargase).\" Rhone-Poulenc Rorer, Collegeville, PA.[73] Sotaniemi E, Kontturi M, Larmi T \"Effect of diethylstilbestrol on blood glucose of prostatic cancer patients.\" Invest Urol 10 (1973): 438-41[74] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[75] Petri M, Cumber P, Grimes L, Treby D, Bryant R, Rawlins D, Ising H \"The metabolic effects of thiazide therapy in the elderly: a population study.\" Age Ageing 15 (1986): 151-5[76] Ludvik B, Clodi M, Kautzky-Willer A, Capek M, Hartter E, Pacini G, Prager R \"Effect of dexamethasone on insulin sensitivity, islet amyloid polypeptide and insulin secretion in humans.\" Diabetologia 36 (1993): 84-7[77] \"Product Information. Glucophage (metformin).\" Bristol-Myers Squibb, Princeton, NJ.[78] Chaudhuri ML, Catania J \"A comparison of the effects of bumetanide (Burinex) and frusemide on carbohydrate metabolism in the elderly.\" Br J Clin Pract 42 (1988): 427-9[79] Black DM, Filak AT \"Hyperglycemia with non-insulin-dependent diabetes following intraarticular steroid injection.\" J Fam Pract 28 (1989): 462-3[80] \"Product Information. Megace (megestrol).\" Bristol-Myers Squibb, Princeton, NJ.[81] \"Product Information. Torisel (temsirolimus).\" Wyeth-Ayerst Laboratories, Philadelphia, PA.[82] Schmitz O, Hermansen K, Nielsen OH, Christensen CK, Arnfred J, Hansen HE, Mogensen CE, Orskov H, Beck-Nielsen H \"Insulin action in insulin-dependent diabetics after short-term thiazide therapy.\" Diabetes Care 9 (1986): 631-6[83] Kansal PC, Buse J, Buse MG \"Thiazide diuretics and control of diabetes mellitus.\" South Med J 62 (1969): 1372-9[84] Dimitriadis G, Tegos C, Golfinopoulou L, Roboti C, Raptis S \"Furosemide-induced hyperglycaemia - the implication of glycolytic kinases.\" Horm Metab Res 25 (1993): 557-9[85] \"Product Information. NovoLog Mix 70/30 (insulin aspart-insulin aspart protamine).\" Novo Nordisk Pharmaceuticals Inc, Princeton, NJ.[86] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[87] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[88] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[89] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42[90] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[91] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[92] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[93] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[94] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[95] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6", "alternatives_a": "Bazedoxifene", "alternatives_b": "Simvastatin, Guar gum, Rosuvastatin", "updated_at": 1767369485}, {"id": 97860, "ingredient1": "Empagliflozin", "ingredient2": "Copanlisib", "severity": "Moderate", "effect": "The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.", "source": "DDInter", "management_text": "Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.", "mechanism_text": "Antagonism", "recommendation": "Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97964/", "reference_text": "[1] Jori A, Carrara MC \"On the mechanism of the hyperglycaemic effect of chlorpromazine.\" J Pharm Pharmacol 18 (1966): 623-4[2] \"Product Information. Dymelor (acetohexamide)\" Lilly, Eli and Company, Indianapolis, IN.[3] \"Product Information. Thorazine (chlorpromazine).\" SmithKline Beecham, Philadelphia, PA.[4] Blayac JP, Ribes G, Buys D, Puech R, Loubatieres-Mariani MM \"Effects of a new benzothiadiazine derivative, LN 5330, on insulin secretion.\" Arch Int Pharmacodyn Ther 253 (1981): 154-63[5] \"Product Information. Elzonris (tagraxofusp).\" Stemline Therapeutics, New York, NY.[6] \"Product Information. Amaryl (glimepiride).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[7] \"Product Information. Elspar (asparaginase).\" Merck & Co, Inc, West Point, PA.[8] Jones IG, Pickens PT \"Diabetes mellitus following oral diuretics.\" Practitioner 199 (1967): 209-10[9] \"Product Information. Viracept (nelfinavir).\" Agouron Pharma Inc, La Jolla, CA.[10] \"Product Information. Tolinase (tolazamide)\" Pharmacia and Upjohn, Kalamazoo, MI.[11] Mauss S, Wolf E, Jaeger H \"Impaired glucose tolerance in HIV-positive patients receiving and those not receiving protease inhibitors.\" Ann Intern Med 130 (1999): 162-3[12] Virutamasen P, Wongsrichanalai C, Tangkeo P, Nitichai Y, Rienprayoon D \"Metabolic effects of depot-medroxyprogesterone acetate in long-term users: a cross-sectional study.\" Int J Gynaecol Obstet 24 (1986): 291-6[13] Wehring H, Alexander B, Perry PJ \"Diabetes mellitus associated with clozapine therapy.\" Pharmacotherapy 20 (2000): 844-7[14] Spellacy WN, Ellingson AB, Tsibris JC \"The effects of two triphasic oral contraceptives on carbohydrate metabolism in women during 1 year of use.\" Fertil Steril 51 (1989): 71-4[15] Andersen OO, Persson I \"Carbohydrate metabolism during treatment with chlorthalidone and ethacrynic acid.\" Br Med J 2 (1968): 798-801[16] Berlin I \"Prazosin, diuretics, and glucose intolerance.\" Ann Intern Med 119 (1993): 860[17] Malherbe C, Burrill KC, Levin SR, Karam JH, Forsham PH \"Effect of diphenylhydantoin on insulin secretion in man.\" N Engl J Med 286 (1972): 339-42[18] Carter BL, Small RE, Mandel MD, Starkman MT \"Phenytoin-induced hyperglycemia.\" Am J Hosp Pharm 38 (1981): 1508-12[19] Al-Rubeaan K, Ryan EA \"Phenytoin-induced insulin insensitivity.\" Diabet Med 8 (1991): 968-70[20] \"Product Information. Zolinza (vorinostat).\" Merck & Company Inc, West Point, PA.[21] Goldman JA, Neri A, Ovadia J, Eckerling B, Vries A, de \"Effect of chlorothiazide on intravenous glucose tolerance in pregnancy.\" Am J Obstet Gynecol 105 (1969): 556-60[22] Harper R, Ennis CN, Heaney AP, Sheridan B, Gormley M, Atkinson AB, Johnston GD, Bell PM \"A comparison of the effects of low- and conventional-dose thiazide diuretic on insulin action in hypertensive patients with NIDDM.\" Diabetologia 38 (1995): 853-9[23] Seltzer HS, Allen EW \"Hyperglycemia and inhibition of insulin secretion during administration of diazoxide and trichlormethiazide in man.\" Diabetes 18 (1969): 19-28[24] Dube MP, Johnson DL, Currier JS, Leedom JM \"Protease inhibitor-associated hyperglycaemia.\" Lancet 350 (1997): 713-4[25] Leary WP, Reyes AJ \"Drug interactions with diuretics.\" S Afr Med J 65 (1984): 455-61[26] \"Product Information. Reyataz (atazanavir).\" Bristol-Myers Squibb, Princeton, NJ.[27] Pollare T, Lithell H, Berne C \"A comparison of the effects of hydrochlorothiazide and captopril on glucose and lipid metabolism in patients with hypertension.\" N Engl J Med 321 (1989): 868-73[28] Gunnarsson R, Lundgren G, Magnusson G, Ost L, Groth CG \"Steroid diabetes--a sign of overtreatment with steroids in the renal graft recipient?\" Scand J Urol Nephrol Suppl 54 (1980): 135-8[29] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[30] \"Product Information. Synthroid (levothyroxine).\" Abbott Pharmaceutical, Abbott Park, IL.[31] Murphy MB, Kohner E, Lewis PJ, Schumer B, Dollery CT \"Glucose intolerance in hypertensive patients treated with diuretics: a fourteen-year follow-up.\" Lancet 2 (1982): 1293-5[32] \"Product Information. Fortovase (saquinavir)\" Roche Laboratories, Nutley, NJ.[33] Coni NK, Gordon PW, Mukherjee AP, Read PR \"The effect of frusemide and ethacrynic acid on carbohydrate metabolism.\" Age Ageing 3 (1974): 85-90[34] \"Product Information. Norvir (ritonavir).\" Abbott Pharmaceutical, Abbott Park, IL.[35] Domenet JG \"Diabetogenic effect of oral diuretics.\" Br Med J 3 (1968): 188[36] Rowe P, Mather H \"Hyperosmolar non-ketotic diabetes mellitus associated with metolazone.\" Br Med J 291 (1985): 25-6[37] Winchester JF, Kellett RJ, Boddy K, Boyle P, Dargie HJ, Mahaffey ME, Ward DM, Kennedy AC \"Metolazone and bendroflumethiazide in hypertension: physiologic and metabolic observations.\" Clin Pharmacol Ther 28 (1980): 611-8[38] \"Product Information. Carafate (sucralfate).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[39] Tsiodras S, Mantzoros C, Hammer S, Samore M \"Effects of protease inhibitors on hyperglycemia, hyperlipidemia, and lipodystrophy - A 5-year cohort study.\" Arch Intern Med 160 (2000): 2050-6[40] \"Product Information. Apidra (insulin glulisine).\" Aventis Pharmaceuticals, Bridgewater, NJ.[41] \"Product Information. Prezista (darunavir).\" Ortho Biotech Inc, Bridgewater, NJ.[42] Haiba NA, el-Habashy MA, Said SA, Darwish EA, Abdel-Sayed WS, Nayel SE \"Clinical evaluation of two monthly injectable contraceptives and their effects on some metabolic parameters.\" Contraception 39 (1989): 619-32[43] Erle G, Basso M, Federspil G, Sicolo N, Scandellari C \"Effect of chlorpromazine on blood glucose and plasma insulin in man.\" Eur J Clin Pharmacol 11 (1977): 15-8[44] Pickkers P, Schachter M, Hughes AD, Feher MD, Sever PS \"Thiazide-induced hyperglycaemia: a role for calcium-activated potassium channels?\" Diabetologia 39 (1996): 861-4[45] \"Product Information. Lexiva (fosamprenavir).\" GlaxoSmithKline, Research Triangle Park, NC.[46] Curtis J, Horrigan F, Ahearn D, Varney R, Sandler SG \"Chlorthalidone-induced hyperosmolar hyperglycemic nonketotic coma.\" JAMA 220 (1972): 1592-3[47] \"Product Information. Hyperstat I.V. (diazoxide).\" Schering Corp, Kenilworth, NJ.[48] \"Product Information. Piqray (alpelisib).\" Novartis Pharmaceuticals, East Hanover, NJ.[49] Bell DS \"Insulin resistance. An often unrecognized problem accompanying chronic medical disorders.\" Postgrad Med 93 (1993): 99-103,[50] Stambaugh JE, Tucker DC \"Effect of diphenylhydantoin on glucose tolerance in patients with hypoglycemia.\" Diabetes 23 (1974): 679-83[51] \"Product Information. Crixivan (indinavir).\" Merck & Co, Inc, West Point, PA.[52] Miller NR, Moses H \"Transient oculomotor nerve palsy. Association with thiazide-induced glucose intolerance.\" JAMA 240 (1978): 1887-8[53] Javier Z, Gershberg H, Hulse M \"Ovulatory suppressants, estrogens, and carbohydrate metabolism.\" Metabolism 17 (1968): 443-56[54] Goldman JA, Ovadia JL \"The effect of estrogen on intravenous glucose tolerance in woman.\" Am J Obstet Gynecol 103 (1969): 172-8[55] Charan VD, Desai N, Singh AP, Choudhry VP \"Diabetes mellitus and pancreatitis as a complication of L- asparaginase therapy.\" Indian Pediatr 30 (1993): 809-10[56] Seifer DB, Freedman LN, Cavender JR, Baker RA \"Insulin-dependent diabetes mellitus associated with danazol.\" Am J Obstet Gynecol 162 (1990): 474-5[57] \"Product Information. Orinase (tolbutamide)\" Pharmacia and Upjohn, Kalamazoo, MI.[58] Walli R, Demant T \"Impaired glucose tolerance and protease inhibitors.\" Ann Intern Med 129 (1998): 837-8[59] Hannaford PC, Kay CR \"Oral contraceptives and diabetes mellitus.\" BMJ 299 (1989): 1315-6[60] Hardy H, Esch LD, Morse GD \"Glucose disorders associated with HIV and its drug therapy.\" Ann Pharmacother 35 (2001): 343-51[61] Chowdhury FR, Bleicher SJ \"Chlorthalidone--induced hypokalemia and abnormal carbohydrate metabolism.\" Horm Metab Res 2 (1970): 13-6[62] Kaufman MB, Simionatto C \"A review of protease inhibitor-induced hyperglycemia.\" Pharmacotherapy 19 (1999): 114-7[63] Greenstone MA, Shaw AB \"Alternate day corticosteroid causes alternate day hyperglycaemia.\" Postgrad Med J 63 (1987): 761-4[64] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[65] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[66] Elmfeldt D, Berglund G, Wedel H, Wilhelmsen L \"Incidence and importance of metabolic side-effects during antihypertensive therapy.\" Acta Med Scand Suppl 672 (1983): 79-83[67] \"Product Information. Agenerase (amprenavir).\" Glaxo Wellcome, Research Triangle Pk, NC.[68] Diamond MT \"Hyperglycemic hyperosmolar coma associated with hydrochlorothiazide and pancreatitis.\" N Y State J Med 72 (1972): 1741-2[69] \"Product Information. Prandin (repaglinide).\" Novo Nordisk Pharmaceuticals Inc, Princeton, NJ.[70] \"Product Information. Precose (acarbose).\" Bayer, West Haven, CT.[71] \"Product Information. Starlix (nateglinide)\" Novartis Pharmaceuticals, East Hanover, NJ.[72] \"Product Information. Oncaspar (pegaspargase).\" Rhone-Poulenc Rorer, Collegeville, PA.[73] Sotaniemi E, Kontturi M, Larmi T \"Effect of diethylstilbestrol on blood glucose of prostatic cancer patients.\" Invest Urol 10 (1973): 438-41[74] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[75] Petri M, Cumber P, Grimes L, Treby D, Bryant R, Rawlins D, Ising H \"The metabolic effects of thiazide therapy in the elderly: a population study.\" Age Ageing 15 (1986): 151-5[76] Ludvik B, Clodi M, Kautzky-Willer A, Capek M, Hartter E, Pacini G, Prager R \"Effect of dexamethasone on insulin sensitivity, islet amyloid polypeptide and insulin secretion in humans.\" Diabetologia 36 (1993): 84-7[77] \"Product Information. Glucophage (metformin).\" Bristol-Myers Squibb, Princeton, NJ.[78] Chaudhuri ML, Catania J \"A comparison of the effects of bumetanide (Burinex) and frusemide on carbohydrate metabolism in the elderly.\" Br J Clin Pract 42 (1988): 427-9[79] Black DM, Filak AT \"Hyperglycemia with non-insulin-dependent diabetes following intraarticular steroid injection.\" J Fam Pract 28 (1989): 462-3[80] \"Product Information. Megace (megestrol).\" Bristol-Myers Squibb, Princeton, NJ.[81] \"Product Information. Torisel (temsirolimus).\" Wyeth-Ayerst Laboratories, Philadelphia, PA.[82] Schmitz O, Hermansen K, Nielsen OH, Christensen CK, Arnfred J, Hansen HE, Mogensen CE, Orskov H, Beck-Nielsen H \"Insulin action in insulin-dependent diabetics after short-term thiazide therapy.\" Diabetes Care 9 (1986): 631-6[83] Kansal PC, Buse J, Buse MG \"Thiazide diuretics and control of diabetes mellitus.\" South Med J 62 (1969): 1372-9[84] Dimitriadis G, Tegos C, Golfinopoulou L, Roboti C, Raptis S \"Furosemide-induced hyperglycaemia - the implication of glycolytic kinases.\" Horm Metab Res 25 (1993): 557-9[85] \"Product Information. NovoLog Mix 70/30 (insulin aspart-insulin aspart protamine).\" Novo Nordisk Pharmaceuticals Inc, Princeton, NJ.[86] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[87] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[88] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[89] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42[90] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[91] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[92] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[93] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[94] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[95] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6", "alternatives_a": "Simvastatin, Guar gum, Rosuvastatin", "alternatives_b": "Imatinib, Dabrafenib, Asciminib, Acalabrutinib, Dacomitinib, Pexidartinib, Fedratinib, Avapritinib, Larotrectinib, Bosutinib, Vemurafenib, More", "updated_at": 1767369485}, {"id": 97861, "ingredient1": "Empagliflozin", "ingredient2": "Cyclandelate", "severity": "Moderate", "effect": "Sodium-glucose co-transporter 2 (SGLT-2) inhibitors may potentiate the hypotensive effects of diuretics and other antihypertensive agents or vasodilators. Inhibition of glucose and sodium co-transport produces mild diuresis and transient natriuresis, resulting in intravascular volume contraction. Volume depletion-related adverse reactions including hypotension, postural dizziness, orthostatic hypotension, syncope, and dehydration can occur after initiating treatment with SGLT-2 inhibitors, and the risk may be increased with concomitant use of other agents that can lower blood pressure.", "source": "DDInter", "management_text": "Caution is advised if SGLT-2 inhibitors are coadministered with diuretics and other hypotensive agents, particularly in the elderly and patients with impaired renal function. Prior to initiating SGLT-2 inhibitors, volume status should be assessed and corrected, if necessary. Clinical and laboratory monitoring are recommended during therapy, including electrolytes, fluid status, renal function, and blood pressure. If volume depletion occurs, treatment with SGLT-2 inhibitors should be interrupted until the condition is corrected.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if SGLT-2 inhibitors are coadministered with diuretics and other hypotensive agents, particularly in the elderly and patients with impaired renal function.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97965/", "reference_text": "[1] \"Product Information. Jardiance (empagliflozin).\" Boehringer Ingelheim, Ridgefield, CT.[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] \"Product Information. Farxiga (dapagliflozin).\" Bristol-Myers Squibb, Princeton, NJ.[5] \"Product Information. Invokana (canagliflozin).\" Janssen Pharmaceuticals, Titusville, NJ.[6] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[7] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[8] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[9] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[10] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[11] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6[12] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[13] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[14] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[15] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42", "alternatives_a": "Pentoxifylline", "alternatives_b": "Glipizide, Acetohexamide, Guar gum, Pramlintide, Alogliptin, Rosuvastatin, Tolazamide, Dulaglutide, Exenatide, Tolbutamide, Miglitol, More", "updated_at": 1767369485}, {"id": 97862, "ingredient1": "Empagliflozin", "ingredient2": "Deserpidine", "severity": "Moderate", "effect": "Sodium-glucose co-transporter 2 (SGLT-2) inhibitors may potentiate the hypotensive effects of diuretics and other antihypertensive agents or vasodilators. Inhibition of glucose and sodium co-transport produces mild diuresis and transient natriuresis, resulting in intravascular volume contraction. Volume depletion-related adverse reactions including hypotension, postural dizziness, orthostatic hypotension, syncope, and dehydration can occur after initiating treatment with SGLT-2 inhibitors, and the risk may be increased with concomitant use of other agents that can lower blood pressure.", "source": "DDInter", "management_text": "Caution is advised if SGLT-2 inhibitors are coadministered with diuretics and other hypotensive agents, particularly in the elderly and patients with impaired renal function. Prior to initiating SGLT-2 inhibitors, volume status should be assessed and corrected, if necessary. Clinical and laboratory monitoring are recommended during therapy, including electrolytes, fluid status, renal function, and blood pressure. If volume depletion occurs, treatment with SGLT-2 inhibitors should be interrupted until the condition is corrected.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if SGLT-2 inhibitors are coadministered with diuretics and other hypotensive agents, particularly in the elderly and patients with impaired renal function.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97966/", "reference_text": "[1] \"Product Information. Jardiance (empagliflozin).\" Boehringer Ingelheim, Ridgefield, CT.[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] \"Product Information. Farxiga (dapagliflozin).\" Bristol-Myers Squibb, Princeton, NJ.[5] \"Product Information. Invokana (canagliflozin).\" Janssen Pharmaceuticals, Titusville, NJ.[6] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[7] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[8] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[9] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[10] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[11] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6[12] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[13] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[14] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[15] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42", "alternatives_a": "Acetohexamide, Guar gum, Pramlintide, Alogliptin, Rosuvastatin, Dulaglutide, Exenatide, Miglitol, Albiglutide, Rosiglitazone, Semaglutide, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 97863, "ingredient1": "Empagliflozin", "ingredient2": "Dexamethasone (topical)", "severity": "Minor", "effect": "The efficacy of insulin and other antidiabetic agents may be diminished by topical corticosteroids, particularly during prolonged or indiscriminate use. Corticosteroids can raise blood glucose level by antagonizing the action and suppressing the secretion of insulin, which results in inhibition of peripheral glucose uptake and increased gluconeogenesis. The duration of administration Close clinical monitoring of glycemic control is recommended if topical corticosteroids are administered chronically and/or to large areas in diabetic patients.", "source": "DDInter", "management_text": "-", "mechanism_text": "Antagonism", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97967/", "reference_text": "[1] Pace WE \"Topical corticosteroids.\" Can Med Assoc J 108 (1973): 11 passim[2] Seale JP, Compton MR \"Side-effects of corticosteroid agents.\" Med J Aust 144 (1986): 139-42[3] \"Product Information. Psorcon (diflorasone topical).\" Rhone-Poulenc Rorer, Collegeville, PA.[4] \"Product Information. Temovate (clobetasol).\" Glaxo Wellcome, Research Triangle Park, NC.[5] \"Product Information. Ultravate (halobetasol).\" Bristol-Myers Squibb, Princeton, NJ.[6] Carruthers JA, Staughton RC, August PJ \"Penetration of topical steroid preparations.\" Arch Dermatol 113 (1977): 522[7] Ludvik B, Clodi M, Kautzky-Willer A, Capek M, Hartter E, Pacini G, Prager R \"Effect of dexamethasone on insulin sensitivity, islet amyloid polypeptide and insulin secretion in humans.\" Diabetologia 36 (1993): 84-7[8] \"Product Information. Diprolene (betamethasone topical).\" Schering Laboratories, Kenilworth, NJ.[9] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[10] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[11] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[12] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42[13] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[14] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[15] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[16] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[17] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[18] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6", "alternatives_a": "Ciclesonide, Mupirocin, Budesonide, Mometasone, Flunisolide, Olopatadine, Vitamin A, Fluticasone, Ipratropium, Cromoglicic acid, Hyaluronic acid, More", "alternatives_b": "Acetohexamide, Guar gum, Simvastatin, Troglitazone, Rosuvastatin", "updated_at": 1767369485}, {"id": 97864, "ingredient1": "Empagliflozin", "ingredient2": "Dexfenfluramine", "severity": "Moderate", "effect": "Since weight loss may affect glycemic control and increase the risk of hypoglycemia in type 2 diabetes mellitus, patients receiving anorectic drugs may require periodic adjustments of their antidiabetic medications.", "source": "DDInter", "management_text": "Blood glucose should be closely monitored during weight loss treatment, and appropriate changes made to the antidiabetic drug regimen as needed. Patients should be apprised of the risk of hypoglycemia and be alert to potential signs and symptoms such as headache, dizziness, drowsiness, nervousness, confusion, tremor, hunger, weakness, perspiration, palpitation, and tachycardia.", "mechanism_text": "Synergism", "recommendation": "Blood glucose should be closely monitored during weight loss treatment, and appropriate changes made to the antidiabetic drug regimen as needed.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97968/", "reference_text": "[1] \"Product Information. Xenical (orlistat).\" Roche Laboratories, Nutley, NJ.[2] \"Product Information. Didrex (benzphetamine)\" Pharmacia and Upjohn, Kalamazoo, MI.[3] \"Product Information. Suprenza (phentermine).\" Akrimax Pharmaceuticals, Cranford, NJ.[4] \"Product Information. Belviq (lorcaserin).\" Eisai Inc, Teaneck, NJ.[5] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[6] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[7] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[8] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42[9] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[10] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[11] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[12] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[13] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[14] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6[15] Mendelson J, Jones RT, Upton R, Jacob P 3rd \"Methamphetamine and ethanol interactions in humans.\" Clin Pharmacol Ther 57 (1995): 559-68[16] \"Product Information. Didrex (benzphetamine)\" Pharmacia and Upjohn, Kalamazoo, MI.[17] \"Product Information. Suprenza (phentermine).\" Akrimax Pharmaceuticals, Cranford, NJ.", "alternatives_a": "Bupropion, Naltrexone", "alternatives_b": "Acetohexamide, Guar gum, Simvastatin, Troglitazone, Rosuvastatin", "updated_at": 1767369485}, {"id": 97865, "ingredient1": "Empagliflozin", "ingredient2": "Dienestrol (topical)", "severity": "Moderate", "effect": "The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.", "source": "DDInter", "management_text": "Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.", "mechanism_text": "Antagonism", "recommendation": "Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97969/", "reference_text": "[1] Jori A, Carrara MC \"On the mechanism of the hyperglycaemic effect of chlorpromazine.\" J Pharm Pharmacol 18 (1966): 623-4[2] \"Product Information. Dymelor (acetohexamide)\" Lilly, Eli and Company, Indianapolis, IN.[3] \"Product Information. Thorazine (chlorpromazine).\" SmithKline Beecham, Philadelphia, PA.[4] Blayac JP, Ribes G, Buys D, Puech R, Loubatieres-Mariani MM \"Effects of a new benzothiadiazine derivative, LN 5330, on insulin secretion.\" Arch Int Pharmacodyn Ther 253 (1981): 154-63[5] \"Product Information. Elzonris (tagraxofusp).\" Stemline Therapeutics, New York, NY.[6] \"Product Information. Amaryl (glimepiride).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[7] \"Product Information. Elspar (asparaginase).\" Merck & Co, Inc, West Point, PA.[8] Jones IG, Pickens PT \"Diabetes mellitus following oral diuretics.\" Practitioner 199 (1967): 209-10[9] \"Product Information. Viracept (nelfinavir).\" Agouron Pharma Inc, La Jolla, CA.[10] \"Product Information. Tolinase (tolazamide)\" Pharmacia and Upjohn, Kalamazoo, MI.[11] Mauss S, Wolf E, Jaeger H \"Impaired glucose tolerance in HIV-positive patients receiving and those not receiving protease inhibitors.\" Ann Intern Med 130 (1999): 162-3[12] Virutamasen P, Wongsrichanalai C, Tangkeo P, Nitichai Y, Rienprayoon D \"Metabolic effects of depot-medroxyprogesterone acetate in long-term users: a cross-sectional study.\" Int J Gynaecol Obstet 24 (1986): 291-6[13] Wehring H, Alexander B, Perry PJ \"Diabetes mellitus associated with clozapine therapy.\" Pharmacotherapy 20 (2000): 844-7[14] Spellacy WN, Ellingson AB, Tsibris JC \"The effects of two triphasic oral contraceptives on carbohydrate metabolism in women during 1 year of use.\" Fertil Steril 51 (1989): 71-4[15] Andersen OO, Persson I \"Carbohydrate metabolism during treatment with chlorthalidone and ethacrynic acid.\" Br Med J 2 (1968): 798-801[16] Berlin I \"Prazosin, diuretics, and glucose intolerance.\" Ann Intern Med 119 (1993): 860[17] Malherbe C, Burrill KC, Levin SR, Karam JH, Forsham PH \"Effect of diphenylhydantoin on insulin secretion in man.\" N Engl J Med 286 (1972): 339-42[18] Carter BL, Small RE, Mandel MD, Starkman MT \"Phenytoin-induced hyperglycemia.\" Am J Hosp Pharm 38 (1981): 1508-12[19] Al-Rubeaan K, Ryan EA \"Phenytoin-induced insulin insensitivity.\" Diabet Med 8 (1991): 968-70[20] \"Product Information. Zolinza (vorinostat).\" Merck & Company Inc, West Point, PA.[21] Goldman JA, Neri A, Ovadia J, Eckerling B, Vries A, de \"Effect of chlorothiazide on intravenous glucose tolerance in pregnancy.\" Am J Obstet Gynecol 105 (1969): 556-60[22] Harper R, Ennis CN, Heaney AP, Sheridan B, Gormley M, Atkinson AB, Johnston GD, Bell PM \"A comparison of the effects of low- and conventional-dose thiazide diuretic on insulin action in hypertensive patients with NIDDM.\" Diabetologia 38 (1995): 853-9[23] Seltzer HS, Allen EW \"Hyperglycemia and inhibition of insulin secretion during administration of diazoxide and trichlormethiazide in man.\" Diabetes 18 (1969): 19-28[24] Dube MP, Johnson DL, Currier JS, Leedom JM \"Protease inhibitor-associated hyperglycaemia.\" Lancet 350 (1997): 713-4[25] Leary WP, Reyes AJ \"Drug interactions with diuretics.\" S Afr Med J 65 (1984): 455-61[26] \"Product Information. Reyataz (atazanavir).\" Bristol-Myers Squibb, Princeton, NJ.[27] Pollare T, Lithell H, Berne C \"A comparison of the effects of hydrochlorothiazide and captopril on glucose and lipid metabolism in patients with hypertension.\" N Engl J Med 321 (1989): 868-73[28] Gunnarsson R, Lundgren G, Magnusson G, Ost L, Groth CG \"Steroid diabetes--a sign of overtreatment with steroids in the renal graft recipient?\" Scand J Urol Nephrol Suppl 54 (1980): 135-8[29] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[30] \"Product Information. Synthroid (levothyroxine).\" Abbott Pharmaceutical, Abbott Park, IL.[31] Murphy MB, Kohner E, Lewis PJ, Schumer B, Dollery CT \"Glucose intolerance in hypertensive patients treated with diuretics: a fourteen-year follow-up.\" Lancet 2 (1982): 1293-5[32] \"Product Information. Fortovase (saquinavir)\" Roche Laboratories, Nutley, NJ.[33] Coni NK, Gordon PW, Mukherjee AP, Read PR \"The effect of frusemide and ethacrynic acid on carbohydrate metabolism.\" Age Ageing 3 (1974): 85-90[34] \"Product Information. Norvir (ritonavir).\" Abbott Pharmaceutical, Abbott Park, IL.[35] Domenet JG \"Diabetogenic effect of oral diuretics.\" Br Med J 3 (1968): 188[36] Rowe P, Mather H \"Hyperosmolar non-ketotic diabetes mellitus associated with metolazone.\" Br Med J 291 (1985): 25-6[37] Winchester JF, Kellett RJ, Boddy K, Boyle P, Dargie HJ, Mahaffey ME, Ward DM, Kennedy AC \"Metolazone and bendroflumethiazide in hypertension: physiologic and metabolic observations.\" Clin Pharmacol Ther 28 (1980): 611-8[38] \"Product Information. Carafate (sucralfate).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[39] Tsiodras S, Mantzoros C, Hammer S, Samore M \"Effects of protease inhibitors on hyperglycemia, hyperlipidemia, and lipodystrophy - A 5-year cohort study.\" Arch Intern Med 160 (2000): 2050-6[40] \"Product Information. Apidra (insulin glulisine).\" Aventis Pharmaceuticals, Bridgewater, NJ.[41] \"Product Information. Prezista (darunavir).\" Ortho Biotech Inc, Bridgewater, NJ.[42] Haiba NA, el-Habashy MA, Said SA, Darwish EA, Abdel-Sayed WS, Nayel SE \"Clinical evaluation of two monthly injectable contraceptives and their effects on some metabolic parameters.\" Contraception 39 (1989): 619-32[43] Erle G, Basso M, Federspil G, Sicolo N, Scandellari C \"Effect of chlorpromazine on blood glucose and plasma insulin in man.\" Eur J Clin Pharmacol 11 (1977): 15-8[44] Pickkers P, Schachter M, Hughes AD, Feher MD, Sever PS \"Thiazide-induced hyperglycaemia: a role for calcium-activated potassium channels?\" Diabetologia 39 (1996): 861-4[45] \"Product Information. Lexiva (fosamprenavir).\" GlaxoSmithKline, Research Triangle Park, NC.[46] Curtis J, Horrigan F, Ahearn D, Varney R, Sandler SG \"Chlorthalidone-induced hyperosmolar hyperglycemic nonketotic coma.\" JAMA 220 (1972): 1592-3[47] \"Product Information. Hyperstat I.V. (diazoxide).\" Schering Corp, Kenilworth, NJ.[48] \"Product Information. Piqray (alpelisib).\" Novartis Pharmaceuticals, East Hanover, NJ.[49] Bell DS \"Insulin resistance. An often unrecognized problem accompanying chronic medical disorders.\" Postgrad Med 93 (1993): 99-103,[50] Stambaugh JE, Tucker DC \"Effect of diphenylhydantoin on glucose tolerance in patients with hypoglycemia.\" Diabetes 23 (1974): 679-83[51] \"Product Information. Crixivan (indinavir).\" Merck & Co, Inc, West Point, PA.[52] Miller NR, Moses H \"Transient oculomotor nerve palsy. Association with thiazide-induced glucose intolerance.\" JAMA 240 (1978): 1887-8[53] Javier Z, Gershberg H, Hulse M \"Ovulatory suppressants, estrogens, and carbohydrate metabolism.\" Metabolism 17 (1968): 443-56[54] Goldman JA, Ovadia JL \"The effect of estrogen on intravenous glucose tolerance in woman.\" Am J Obstet Gynecol 103 (1969): 172-8[55] Charan VD, Desai N, Singh AP, Choudhry VP \"Diabetes mellitus and pancreatitis as a complication of L- asparaginase therapy.\" Indian Pediatr 30 (1993): 809-10[56] Seifer DB, Freedman LN, Cavender JR, Baker RA \"Insulin-dependent diabetes mellitus associated with danazol.\" Am J Obstet Gynecol 162 (1990): 474-5[57] \"Product Information. Orinase (tolbutamide)\" Pharmacia and Upjohn, Kalamazoo, MI.[58] Walli R, Demant T \"Impaired glucose tolerance and protease inhibitors.\" Ann Intern Med 129 (1998): 837-8[59] Hannaford PC, Kay CR \"Oral contraceptives and diabetes mellitus.\" BMJ 299 (1989): 1315-6[60] Hardy H, Esch LD, Morse GD \"Glucose disorders associated with HIV and its drug therapy.\" Ann Pharmacother 35 (2001): 343-51[61] Chowdhury FR, Bleicher SJ \"Chlorthalidone--induced hypokalemia and abnormal carbohydrate metabolism.\" Horm Metab Res 2 (1970): 13-6[62] Kaufman MB, Simionatto C \"A review of protease inhibitor-induced hyperglycemia.\" Pharmacotherapy 19 (1999): 114-7[63] Greenstone MA, Shaw AB \"Alternate day corticosteroid causes alternate day hyperglycaemia.\" Postgrad Med J 63 (1987): 761-4[64] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[65] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[66] Elmfeldt D, Berglund G, Wedel H, Wilhelmsen L \"Incidence and importance of metabolic side-effects during antihypertensive therapy.\" Acta Med Scand Suppl 672 (1983): 79-83[67] \"Product Information. Agenerase (amprenavir).\" Glaxo Wellcome, Research Triangle Pk, NC.[68] Diamond MT \"Hyperglycemic hyperosmolar coma associated with hydrochlorothiazide and pancreatitis.\" N Y State J Med 72 (1972): 1741-2[69] \"Product Information. Prandin (repaglinide).\" Novo Nordisk Pharmaceuticals Inc, Princeton, NJ.[70] \"Product Information. Precose (acarbose).\" Bayer, West Haven, CT.[71] \"Product Information. Starlix (nateglinide)\" Novartis Pharmaceuticals, East Hanover, NJ.[72] \"Product Information. Oncaspar (pegaspargase).\" Rhone-Poulenc Rorer, Collegeville, PA.[73] Sotaniemi E, Kontturi M, Larmi T \"Effect of diethylstilbestrol on blood glucose of prostatic cancer patients.\" Invest Urol 10 (1973): 438-41[74] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[75] Petri M, Cumber P, Grimes L, Treby D, Bryant R, Rawlins D, Ising H \"The metabolic effects of thiazide therapy in the elderly: a population study.\" Age Ageing 15 (1986): 151-5[76] Ludvik B, Clodi M, Kautzky-Willer A, Capek M, Hartter E, Pacini G, Prager R \"Effect of dexamethasone on insulin sensitivity, islet amyloid polypeptide and insulin secretion in humans.\" Diabetologia 36 (1993): 84-7[77] \"Product Information. Glucophage (metformin).\" Bristol-Myers Squibb, Princeton, NJ.[78] Chaudhuri ML, Catania J \"A comparison of the effects of bumetanide (Burinex) and frusemide on carbohydrate metabolism in the elderly.\" Br J Clin Pract 42 (1988): 427-9[79] Black DM, Filak AT \"Hyperglycemia with non-insulin-dependent diabetes following intraarticular steroid injection.\" J Fam Pract 28 (1989): 462-3[80] \"Product Information. Megace (megestrol).\" Bristol-Myers Squibb, Princeton, NJ.[81] \"Product Information. Torisel (temsirolimus).\" Wyeth-Ayerst Laboratories, Philadelphia, PA.[82] Schmitz O, Hermansen K, Nielsen OH, Christensen CK, Arnfred J, Hansen HE, Mogensen CE, Orskov H, Beck-Nielsen H \"Insulin action in insulin-dependent diabetics after short-term thiazide therapy.\" Diabetes Care 9 (1986): 631-6[83] Kansal PC, Buse J, Buse MG \"Thiazide diuretics and control of diabetes mellitus.\" South Med J 62 (1969): 1372-9[84] Dimitriadis G, Tegos C, Golfinopoulou L, Roboti C, Raptis S \"Furosemide-induced hyperglycaemia - the implication of glycolytic kinases.\" Horm Metab Res 25 (1993): 557-9[85] \"Product Information. NovoLog Mix 70/30 (insulin aspart-insulin aspart protamine).\" Novo Nordisk Pharmaceuticals Inc, Princeton, NJ.[86] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[87] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[88] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[89] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42[90] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[91] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[92] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[93] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[94] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[95] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6", "alternatives_a": "Acetohexamide, Guar gum, Simvastatin, Troglitazone, Rosuvastatin", "alternatives_b": "", "updated_at": 1767369485}, {"id": 97866, "ingredient1": "Empagliflozin", "ingredient2": "Diethylstilbestrol", "severity": "Moderate", "effect": "The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.", "source": "DDInter", "management_text": "Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.", "mechanism_text": "Antagonism", "recommendation": "Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97970/", "reference_text": "[1] Jori A, Carrara MC \"On the mechanism of the hyperglycaemic effect of chlorpromazine.\" J Pharm Pharmacol 18 (1966): 623-4[2] \"Product Information. Dymelor (acetohexamide)\" Lilly, Eli and Company, Indianapolis, IN.[3] \"Product Information. Thorazine (chlorpromazine).\" SmithKline Beecham, Philadelphia, PA.[4] Blayac JP, Ribes G, Buys D, Puech R, Loubatieres-Mariani MM \"Effects of a new benzothiadiazine derivative, LN 5330, on insulin secretion.\" Arch Int Pharmacodyn Ther 253 (1981): 154-63[5] \"Product Information. Elzonris (tagraxofusp).\" Stemline Therapeutics, New York, NY.[6] \"Product Information. Amaryl (glimepiride).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[7] \"Product Information. Elspar (asparaginase).\" Merck & Co, Inc, West Point, PA.[8] Jones IG, Pickens PT \"Diabetes mellitus following oral diuretics.\" Practitioner 199 (1967): 209-10[9] \"Product Information. Viracept (nelfinavir).\" Agouron Pharma Inc, La Jolla, CA.[10] \"Product Information. Tolinase (tolazamide)\" Pharmacia and Upjohn, Kalamazoo, MI.[11] Mauss S, Wolf E, Jaeger H \"Impaired glucose tolerance in HIV-positive patients receiving and those not receiving protease inhibitors.\" Ann Intern Med 130 (1999): 162-3[12] Virutamasen P, Wongsrichanalai C, Tangkeo P, Nitichai Y, Rienprayoon D \"Metabolic effects of depot-medroxyprogesterone acetate in long-term users: a cross-sectional study.\" Int J Gynaecol Obstet 24 (1986): 291-6[13] Wehring H, Alexander B, Perry PJ \"Diabetes mellitus associated with clozapine therapy.\" Pharmacotherapy 20 (2000): 844-7[14] Spellacy WN, Ellingson AB, Tsibris JC \"The effects of two triphasic oral contraceptives on carbohydrate metabolism in women during 1 year of use.\" Fertil Steril 51 (1989): 71-4[15] Andersen OO, Persson I \"Carbohydrate metabolism during treatment with chlorthalidone and ethacrynic acid.\" Br Med J 2 (1968): 798-801[16] Berlin I \"Prazosin, diuretics, and glucose intolerance.\" Ann Intern Med 119 (1993): 860[17] Malherbe C, Burrill KC, Levin SR, Karam JH, Forsham PH \"Effect of diphenylhydantoin on insulin secretion in man.\" N Engl J Med 286 (1972): 339-42[18] Carter BL, Small RE, Mandel MD, Starkman MT \"Phenytoin-induced hyperglycemia.\" Am J Hosp Pharm 38 (1981): 1508-12[19] Al-Rubeaan K, Ryan EA \"Phenytoin-induced insulin insensitivity.\" Diabet Med 8 (1991): 968-70[20] \"Product Information. Zolinza (vorinostat).\" Merck & Company Inc, West Point, PA.[21] Goldman JA, Neri A, Ovadia J, Eckerling B, Vries A, de \"Effect of chlorothiazide on intravenous glucose tolerance in pregnancy.\" Am J Obstet Gynecol 105 (1969): 556-60[22] Harper R, Ennis CN, Heaney AP, Sheridan B, Gormley M, Atkinson AB, Johnston GD, Bell PM \"A comparison of the effects of low- and conventional-dose thiazide diuretic on insulin action in hypertensive patients with NIDDM.\" Diabetologia 38 (1995): 853-9[23] Seltzer HS, Allen EW \"Hyperglycemia and inhibition of insulin secretion during administration of diazoxide and trichlormethiazide in man.\" Diabetes 18 (1969): 19-28[24] Dube MP, Johnson DL, Currier JS, Leedom JM \"Protease inhibitor-associated hyperglycaemia.\" Lancet 350 (1997): 713-4[25] Leary WP, Reyes AJ \"Drug interactions with diuretics.\" S Afr Med J 65 (1984): 455-61[26] \"Product Information. Reyataz (atazanavir).\" Bristol-Myers Squibb, Princeton, NJ.[27] Pollare T, Lithell H, Berne C \"A comparison of the effects of hydrochlorothiazide and captopril on glucose and lipid metabolism in patients with hypertension.\" N Engl J Med 321 (1989): 868-73[28] Gunnarsson R, Lundgren G, Magnusson G, Ost L, Groth CG \"Steroid diabetes--a sign of overtreatment with steroids in the renal graft recipient?\" Scand J Urol Nephrol Suppl 54 (1980): 135-8[29] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[30] \"Product Information. Synthroid (levothyroxine).\" Abbott Pharmaceutical, Abbott Park, IL.[31] Murphy MB, Kohner E, Lewis PJ, Schumer B, Dollery CT \"Glucose intolerance in hypertensive patients treated with diuretics: a fourteen-year follow-up.\" Lancet 2 (1982): 1293-5[32] \"Product Information. Fortovase (saquinavir)\" Roche Laboratories, Nutley, NJ.[33] Coni NK, Gordon PW, Mukherjee AP, Read PR \"The effect of frusemide and ethacrynic acid on carbohydrate metabolism.\" Age Ageing 3 (1974): 85-90[34] \"Product Information. Norvir (ritonavir).\" Abbott Pharmaceutical, Abbott Park, IL.[35] Domenet JG \"Diabetogenic effect of oral diuretics.\" Br Med J 3 (1968): 188[36] Rowe P, Mather H \"Hyperosmolar non-ketotic diabetes mellitus associated with metolazone.\" Br Med J 291 (1985): 25-6[37] Winchester JF, Kellett RJ, Boddy K, Boyle P, Dargie HJ, Mahaffey ME, Ward DM, Kennedy AC \"Metolazone and bendroflumethiazide in hypertension: physiologic and metabolic observations.\" Clin Pharmacol Ther 28 (1980): 611-8[38] \"Product Information. Carafate (sucralfate).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[39] Tsiodras S, Mantzoros C, Hammer S, Samore M \"Effects of protease inhibitors on hyperglycemia, hyperlipidemia, and lipodystrophy - A 5-year cohort study.\" Arch Intern Med 160 (2000): 2050-6[40] \"Product Information. Apidra (insulin glulisine).\" Aventis Pharmaceuticals, Bridgewater, NJ.[41] \"Product Information. Prezista (darunavir).\" Ortho Biotech Inc, Bridgewater, NJ.[42] Haiba NA, el-Habashy MA, Said SA, Darwish EA, Abdel-Sayed WS, Nayel SE \"Clinical evaluation of two monthly injectable contraceptives and their effects on some metabolic parameters.\" Contraception 39 (1989): 619-32[43] Erle G, Basso M, Federspil G, Sicolo N, Scandellari C \"Effect of chlorpromazine on blood glucose and plasma insulin in man.\" Eur J Clin Pharmacol 11 (1977): 15-8[44] Pickkers P, Schachter M, Hughes AD, Feher MD, Sever PS \"Thiazide-induced hyperglycaemia: a role for calcium-activated potassium channels?\" Diabetologia 39 (1996): 861-4[45] \"Product Information. Lexiva (fosamprenavir).\" GlaxoSmithKline, Research Triangle Park, NC.[46] Curtis J, Horrigan F, Ahearn D, Varney R, Sandler SG \"Chlorthalidone-induced hyperosmolar hyperglycemic nonketotic coma.\" JAMA 220 (1972): 1592-3[47] \"Product Information. Hyperstat I.V. (diazoxide).\" Schering Corp, Kenilworth, NJ.[48] \"Product Information. Piqray (alpelisib).\" Novartis Pharmaceuticals, East Hanover, NJ.[49] Bell DS \"Insulin resistance. An often unrecognized problem accompanying chronic medical disorders.\" Postgrad Med 93 (1993): 99-103,[50] Stambaugh JE, Tucker DC \"Effect of diphenylhydantoin on glucose tolerance in patients with hypoglycemia.\" Diabetes 23 (1974): 679-83[51] \"Product Information. Crixivan (indinavir).\" Merck & Co, Inc, West Point, PA.[52] Miller NR, Moses H \"Transient oculomotor nerve palsy. Association with thiazide-induced glucose intolerance.\" JAMA 240 (1978): 1887-8[53] Javier Z, Gershberg H, Hulse M \"Ovulatory suppressants, estrogens, and carbohydrate metabolism.\" Metabolism 17 (1968): 443-56[54] Goldman JA, Ovadia JL \"The effect of estrogen on intravenous glucose tolerance in woman.\" Am J Obstet Gynecol 103 (1969): 172-8[55] Charan VD, Desai N, Singh AP, Choudhry VP \"Diabetes mellitus and pancreatitis as a complication of L- asparaginase therapy.\" Indian Pediatr 30 (1993): 809-10[56] Seifer DB, Freedman LN, Cavender JR, Baker RA \"Insulin-dependent diabetes mellitus associated with danazol.\" Am J Obstet Gynecol 162 (1990): 474-5[57] \"Product Information. Orinase (tolbutamide)\" Pharmacia and Upjohn, Kalamazoo, MI.[58] Walli R, Demant T \"Impaired glucose tolerance and protease inhibitors.\" Ann Intern Med 129 (1998): 837-8[59] Hannaford PC, Kay CR \"Oral contraceptives and diabetes mellitus.\" BMJ 299 (1989): 1315-6[60] Hardy H, Esch LD, Morse GD \"Glucose disorders associated with HIV and its drug therapy.\" Ann Pharmacother 35 (2001): 343-51[61] Chowdhury FR, Bleicher SJ \"Chlorthalidone--induced hypokalemia and abnormal carbohydrate metabolism.\" Horm Metab Res 2 (1970): 13-6[62] Kaufman MB, Simionatto C \"A review of protease inhibitor-induced hyperglycemia.\" Pharmacotherapy 19 (1999): 114-7[63] Greenstone MA, Shaw AB \"Alternate day corticosteroid causes alternate day hyperglycaemia.\" Postgrad Med J 63 (1987): 761-4[64] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[65] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[66] Elmfeldt D, Berglund G, Wedel H, Wilhelmsen L \"Incidence and importance of metabolic side-effects during antihypertensive therapy.\" Acta Med Scand Suppl 672 (1983): 79-83[67] \"Product Information. Agenerase (amprenavir).\" Glaxo Wellcome, Research Triangle Pk, NC.[68] Diamond MT \"Hyperglycemic hyperosmolar coma associated with hydrochlorothiazide and pancreatitis.\" N Y State J Med 72 (1972): 1741-2[69] \"Product Information. Prandin (repaglinide).\" Novo Nordisk Pharmaceuticals Inc, Princeton, NJ.[70] \"Product Information. Precose (acarbose).\" Bayer, West Haven, CT.[71] \"Product Information. Starlix (nateglinide)\" Novartis Pharmaceuticals, East Hanover, NJ.[72] \"Product Information. Oncaspar (pegaspargase).\" Rhone-Poulenc Rorer, Collegeville, PA.[73] Sotaniemi E, Kontturi M, Larmi T \"Effect of diethylstilbestrol on blood glucose of prostatic cancer patients.\" Invest Urol 10 (1973): 438-41[74] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[75] Petri M, Cumber P, Grimes L, Treby D, Bryant R, Rawlins D, Ising H \"The metabolic effects of thiazide therapy in the elderly: a population study.\" Age Ageing 15 (1986): 151-5[76] Ludvik B, Clodi M, Kautzky-Willer A, Capek M, Hartter E, Pacini G, Prager R \"Effect of dexamethasone on insulin sensitivity, islet amyloid polypeptide and insulin secretion in humans.\" Diabetologia 36 (1993): 84-7[77] \"Product Information. Glucophage (metformin).\" Bristol-Myers Squibb, Princeton, NJ.[78] Chaudhuri ML, Catania J \"A comparison of the effects of bumetanide (Burinex) and frusemide on carbohydrate metabolism in the elderly.\" Br J Clin Pract 42 (1988): 427-9[79] Black DM, Filak AT \"Hyperglycemia with non-insulin-dependent diabetes following intraarticular steroid injection.\" J Fam Pract 28 (1989): 462-3[80] \"Product Information. Megace (megestrol).\" Bristol-Myers Squibb, Princeton, NJ.[81] \"Product Information. Torisel (temsirolimus).\" Wyeth-Ayerst Laboratories, Philadelphia, PA.[82] Schmitz O, Hermansen K, Nielsen OH, Christensen CK, Arnfred J, Hansen HE, Mogensen CE, Orskov H, Beck-Nielsen H \"Insulin action in insulin-dependent diabetics after short-term thiazide therapy.\" Diabetes Care 9 (1986): 631-6[83] Kansal PC, Buse J, Buse MG \"Thiazide diuretics and control of diabetes mellitus.\" South Med J 62 (1969): 1372-9[84] Dimitriadis G, Tegos C, Golfinopoulou L, Roboti C, Raptis S \"Furosemide-induced hyperglycaemia - the implication of glycolytic kinases.\" Horm Metab Res 25 (1993): 557-9[85] \"Product Information. NovoLog Mix 70/30 (insulin aspart-insulin aspart protamine).\" Novo Nordisk Pharmaceuticals Inc, Princeton, NJ.[86] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[87] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[88] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[89] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42[90] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[91] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[92] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[93] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[94] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[95] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6", "alternatives_a": "Bicalutamide, Bazedoxifene", "alternatives_b": "Acetohexamide, Guar gum, Simvastatin, Troglitazone, Rosuvastatin", "updated_at": 1767369485}, {"id": 97867, "ingredient1": "Empagliflozin", "ingredient2": "Dobutamine", "severity": "Moderate", "effect": "The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.", "source": "DDInter", "management_text": "Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.", "mechanism_text": "Antagonism", "recommendation": "Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97971/", "reference_text": "[1] Jori A, Carrara MC \"On the mechanism of the hyperglycaemic effect of chlorpromazine.\" J Pharm Pharmacol 18 (1966): 623-4[2] \"Product Information. Dymelor (acetohexamide)\" Lilly, Eli and Company, Indianapolis, IN.[3] \"Product Information. Thorazine (chlorpromazine).\" SmithKline Beecham, Philadelphia, PA.[4] Blayac JP, Ribes G, Buys D, Puech R, Loubatieres-Mariani MM \"Effects of a new benzothiadiazine derivative, LN 5330, on insulin secretion.\" Arch Int Pharmacodyn Ther 253 (1981): 154-63[5] \"Product Information. Elzonris (tagraxofusp).\" Stemline Therapeutics, New York, NY.[6] \"Product Information. Amaryl (glimepiride).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[7] \"Product Information. Elspar (asparaginase).\" Merck & Co, Inc, West Point, PA.[8] Jones IG, Pickens PT \"Diabetes mellitus following oral diuretics.\" Practitioner 199 (1967): 209-10[9] \"Product Information. Viracept (nelfinavir).\" Agouron Pharma Inc, La Jolla, CA.[10] \"Product Information. Tolinase (tolazamide)\" Pharmacia and Upjohn, Kalamazoo, MI.[11] Mauss S, Wolf E, Jaeger H \"Impaired glucose tolerance in HIV-positive patients receiving and those not receiving protease inhibitors.\" Ann Intern Med 130 (1999): 162-3[12] Virutamasen P, Wongsrichanalai C, Tangkeo P, Nitichai Y, Rienprayoon D \"Metabolic effects of depot-medroxyprogesterone acetate in long-term users: a cross-sectional study.\" Int J Gynaecol Obstet 24 (1986): 291-6[13] Wehring H, Alexander B, Perry PJ \"Diabetes mellitus associated with clozapine therapy.\" Pharmacotherapy 20 (2000): 844-7[14] Spellacy WN, Ellingson AB, Tsibris JC \"The effects of two triphasic oral contraceptives on carbohydrate metabolism in women during 1 year of use.\" Fertil Steril 51 (1989): 71-4[15] Andersen OO, Persson I \"Carbohydrate metabolism during treatment with chlorthalidone and ethacrynic acid.\" Br Med J 2 (1968): 798-801[16] Berlin I \"Prazosin, diuretics, and glucose intolerance.\" Ann Intern Med 119 (1993): 860[17] Malherbe C, Burrill KC, Levin SR, Karam JH, Forsham PH \"Effect of diphenylhydantoin on insulin secretion in man.\" N Engl J Med 286 (1972): 339-42[18] Carter BL, Small RE, Mandel MD, Starkman MT \"Phenytoin-induced hyperglycemia.\" Am J Hosp Pharm 38 (1981): 1508-12[19] Al-Rubeaan K, Ryan EA \"Phenytoin-induced insulin insensitivity.\" Diabet Med 8 (1991): 968-70[20] \"Product Information. Zolinza (vorinostat).\" Merck & Company Inc, West Point, PA.[21] Goldman JA, Neri A, Ovadia J, Eckerling B, Vries A, de \"Effect of chlorothiazide on intravenous glucose tolerance in pregnancy.\" Am J Obstet Gynecol 105 (1969): 556-60[22] Harper R, Ennis CN, Heaney AP, Sheridan B, Gormley M, Atkinson AB, Johnston GD, Bell PM \"A comparison of the effects of low- and conventional-dose thiazide diuretic on insulin action in hypertensive patients with NIDDM.\" Diabetologia 38 (1995): 853-9[23] Seltzer HS, Allen EW \"Hyperglycemia and inhibition of insulin secretion during administration of diazoxide and trichlormethiazide in man.\" Diabetes 18 (1969): 19-28[24] Dube MP, Johnson DL, Currier JS, Leedom JM \"Protease inhibitor-associated hyperglycaemia.\" Lancet 350 (1997): 713-4[25] Leary WP, Reyes AJ \"Drug interactions with diuretics.\" S Afr Med J 65 (1984): 455-61[26] \"Product Information. Reyataz (atazanavir).\" Bristol-Myers Squibb, Princeton, NJ.[27] Pollare T, Lithell H, Berne C \"A comparison of the effects of hydrochlorothiazide and captopril on glucose and lipid metabolism in patients with hypertension.\" N Engl J Med 321 (1989): 868-73[28] Gunnarsson R, Lundgren G, Magnusson G, Ost L, Groth CG \"Steroid diabetes--a sign of overtreatment with steroids in the renal graft recipient?\" Scand J Urol Nephrol Suppl 54 (1980): 135-8[29] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[30] \"Product Information. Synthroid (levothyroxine).\" Abbott Pharmaceutical, Abbott Park, IL.[31] Murphy MB, Kohner E, Lewis PJ, Schumer B, Dollery CT \"Glucose intolerance in hypertensive patients treated with diuretics: a fourteen-year follow-up.\" Lancet 2 (1982): 1293-5[32] \"Product Information. Fortovase (saquinavir)\" Roche Laboratories, Nutley, NJ.[33] Coni NK, Gordon PW, Mukherjee AP, Read PR \"The effect of frusemide and ethacrynic acid on carbohydrate metabolism.\" Age Ageing 3 (1974): 85-90[34] \"Product Information. Norvir (ritonavir).\" Abbott Pharmaceutical, Abbott Park, IL.[35] Domenet JG \"Diabetogenic effect of oral diuretics.\" Br Med J 3 (1968): 188[36] Rowe P, Mather H \"Hyperosmolar non-ketotic diabetes mellitus associated with metolazone.\" Br Med J 291 (1985): 25-6[37] Winchester JF, Kellett RJ, Boddy K, Boyle P, Dargie HJ, Mahaffey ME, Ward DM, Kennedy AC \"Metolazone and bendroflumethiazide in hypertension: physiologic and metabolic observations.\" Clin Pharmacol Ther 28 (1980): 611-8[38] \"Product Information. Carafate (sucralfate).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[39] Tsiodras S, Mantzoros C, Hammer S, Samore M \"Effects of protease inhibitors on hyperglycemia, hyperlipidemia, and lipodystrophy - A 5-year cohort study.\" Arch Intern Med 160 (2000): 2050-6[40] \"Product Information. Apidra (insulin glulisine).\" Aventis Pharmaceuticals, Bridgewater, NJ.[41] \"Product Information. Prezista (darunavir).\" Ortho Biotech Inc, Bridgewater, NJ.[42] Haiba NA, el-Habashy MA, Said SA, Darwish EA, Abdel-Sayed WS, Nayel SE \"Clinical evaluation of two monthly injectable contraceptives and their effects on some metabolic parameters.\" Contraception 39 (1989): 619-32[43] Erle G, Basso M, Federspil G, Sicolo N, Scandellari C \"Effect of chlorpromazine on blood glucose and plasma insulin in man.\" Eur J Clin Pharmacol 11 (1977): 15-8[44] Pickkers P, Schachter M, Hughes AD, Feher MD, Sever PS \"Thiazide-induced hyperglycaemia: a role for calcium-activated potassium channels?\" Diabetologia 39 (1996): 861-4[45] \"Product Information. Lexiva (fosamprenavir).\" GlaxoSmithKline, Research Triangle Park, NC.[46] Curtis J, Horrigan F, Ahearn D, Varney R, Sandler SG \"Chlorthalidone-induced hyperosmolar hyperglycemic nonketotic coma.\" JAMA 220 (1972): 1592-3[47] \"Product Information. Hyperstat I.V. (diazoxide).\" Schering Corp, Kenilworth, NJ.[48] \"Product Information. Piqray (alpelisib).\" Novartis Pharmaceuticals, East Hanover, NJ.[49] Bell DS \"Insulin resistance. An often unrecognized problem accompanying chronic medical disorders.\" Postgrad Med 93 (1993): 99-103,[50] Stambaugh JE, Tucker DC \"Effect of diphenylhydantoin on glucose tolerance in patients with hypoglycemia.\" Diabetes 23 (1974): 679-83[51] \"Product Information. Crixivan (indinavir).\" Merck & Co, Inc, West Point, PA.[52] Miller NR, Moses H \"Transient oculomotor nerve palsy. Association with thiazide-induced glucose intolerance.\" JAMA 240 (1978): 1887-8[53] Javier Z, Gershberg H, Hulse M \"Ovulatory suppressants, estrogens, and carbohydrate metabolism.\" Metabolism 17 (1968): 443-56[54] Goldman JA, Ovadia JL \"The effect of estrogen on intravenous glucose tolerance in woman.\" Am J Obstet Gynecol 103 (1969): 172-8[55] Charan VD, Desai N, Singh AP, Choudhry VP \"Diabetes mellitus and pancreatitis as a complication of L- asparaginase therapy.\" Indian Pediatr 30 (1993): 809-10[56] Seifer DB, Freedman LN, Cavender JR, Baker RA \"Insulin-dependent diabetes mellitus associated with danazol.\" Am J Obstet Gynecol 162 (1990): 474-5[57] \"Product Information. Orinase (tolbutamide)\" Pharmacia and Upjohn, Kalamazoo, MI.[58] Walli R, Demant T \"Impaired glucose tolerance and protease inhibitors.\" Ann Intern Med 129 (1998): 837-8[59] Hannaford PC, Kay CR \"Oral contraceptives and diabetes mellitus.\" BMJ 299 (1989): 1315-6[60] Hardy H, Esch LD, Morse GD \"Glucose disorders associated with HIV and its drug therapy.\" Ann Pharmacother 35 (2001): 343-51[61] Chowdhury FR, Bleicher SJ \"Chlorthalidone--induced hypokalemia and abnormal carbohydrate metabolism.\" Horm Metab Res 2 (1970): 13-6[62] Kaufman MB, Simionatto C \"A review of protease inhibitor-induced hyperglycemia.\" Pharmacotherapy 19 (1999): 114-7[63] Greenstone MA, Shaw AB \"Alternate day corticosteroid causes alternate day hyperglycaemia.\" Postgrad Med J 63 (1987): 761-4[64] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[65] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[66] Elmfeldt D, Berglund G, Wedel H, Wilhelmsen L \"Incidence and importance of metabolic side-effects during antihypertensive therapy.\" Acta Med Scand Suppl 672 (1983): 79-83[67] \"Product Information. Agenerase (amprenavir).\" Glaxo Wellcome, Research Triangle Pk, NC.[68] Diamond MT \"Hyperglycemic hyperosmolar coma associated with hydrochlorothiazide and pancreatitis.\" N Y State J Med 72 (1972): 1741-2[69] \"Product Information. Prandin (repaglinide).\" Novo Nordisk Pharmaceuticals Inc, Princeton, NJ.[70] \"Product Information. Precose (acarbose).\" Bayer, West Haven, CT.[71] \"Product Information. Starlix (nateglinide)\" Novartis Pharmaceuticals, East Hanover, NJ.[72] \"Product Information. Oncaspar (pegaspargase).\" Rhone-Poulenc Rorer, Collegeville, PA.[73] Sotaniemi E, Kontturi M, Larmi T \"Effect of diethylstilbestrol on blood glucose of prostatic cancer patients.\" Invest Urol 10 (1973): 438-41[74] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[75] Petri M, Cumber P, Grimes L, Treby D, Bryant R, Rawlins D, Ising H \"The metabolic effects of thiazide therapy in the elderly: a population study.\" Age Ageing 15 (1986): 151-5[76] Ludvik B, Clodi M, Kautzky-Willer A, Capek M, Hartter E, Pacini G, Prager R \"Effect of dexamethasone on insulin sensitivity, islet amyloid polypeptide and insulin secretion in humans.\" Diabetologia 36 (1993): 84-7[77] \"Product Information. Glucophage (metformin).\" Bristol-Myers Squibb, Princeton, NJ.[78] Chaudhuri ML, Catania J \"A comparison of the effects of bumetanide (Burinex) and frusemide on carbohydrate metabolism in the elderly.\" Br J Clin Pract 42 (1988): 427-9[79] Black DM, Filak AT \"Hyperglycemia with non-insulin-dependent diabetes following intraarticular steroid injection.\" J Fam Pract 28 (1989): 462-3[80] \"Product Information. Megace (megestrol).\" Bristol-Myers Squibb, Princeton, NJ.[81] \"Product Information. Torisel (temsirolimus).\" Wyeth-Ayerst Laboratories, Philadelphia, PA.[82] Schmitz O, Hermansen K, Nielsen OH, Christensen CK, Arnfred J, Hansen HE, Mogensen CE, Orskov H, Beck-Nielsen H \"Insulin action in insulin-dependent diabetics after short-term thiazide therapy.\" Diabetes Care 9 (1986): 631-6[83] Kansal PC, Buse J, Buse MG \"Thiazide diuretics and control of diabetes mellitus.\" South Med J 62 (1969): 1372-9[84] Dimitriadis G, Tegos C, Golfinopoulou L, Roboti C, Raptis S \"Furosemide-induced hyperglycaemia - the implication of glycolytic kinases.\" Horm Metab Res 25 (1993): 557-9[85] \"Product Information. NovoLog Mix 70/30 (insulin aspart-insulin aspart protamine).\" Novo Nordisk Pharmaceuticals Inc, Princeton, NJ.[86] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[87] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[88] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[89] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42[90] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[91] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[92] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[93] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[94] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[95] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6", "alternatives_a": "Droxidopa, Midodrine, Amrinone, Angiotensin II, Milrinone, Arbutamine", "alternatives_b": "Guar gum, Rosuvastatin", "updated_at": 1767369485}, {"id": 97868, "ingredient1": "Enalapril", "ingredient2": "Empagliflozin", "severity": "Moderate", "effect": "Sodium-glucose co-transporter 2 (SGLT-2) inhibitors may potentiate the hypotensive effects of diuretics and other antihypertensive agents or vasodilators. Inhibition of glucose and sodium co-transport produces mild diuresis and transient natriuresis, resulting in intravascular volume contraction. Volume depletion-related adverse reactions including hypotension, postural dizziness, orthostatic hypotension, syncope, and dehydration can occur after initiating treatment with SGLT-2 inhibitors, and the risk may be increased with concomitant use of other agents that can lower blood pressure.", "source": "DDInter", "management_text": "Caution is advised if SGLT-2 inhibitors are coadministered with diuretics and other hypotensive agents, particularly in the elderly and patients with impaired renal function. Prior to initiating SGLT-2 inhibitors, volume status should be assessed and corrected, if necessary. Clinical and laboratory monitoring are recommended during therapy, including electrolytes, fluid status, renal function, and blood pressure. If volume depletion occurs, treatment with SGLT-2 inhibitors should be interrupted until the condition is corrected.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if SGLT-2 inhibitors are coadministered with diuretics and other hypotensive agents, particularly in the elderly and patients with impaired renal function.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97972/", "reference_text": "[1] \"Product Information. Jardiance (empagliflozin).\" Boehringer Ingelheim, Ridgefield, CT.[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] \"Product Information. Farxiga (dapagliflozin).\" Bristol-Myers Squibb, Princeton, NJ.[5] \"Product Information. Invokana (canagliflozin).\" Janssen Pharmaceuticals, Titusville, NJ.[6] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[7] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[8] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[9] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[10] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[11] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6[12] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[13] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[14] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[15] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42", "alternatives_a": "Lixisenatide, Albiglutide, Guar gum, Pramlintide, Liraglutide, Troglitazone, Semaglutide, Dulaglutide, Miglitol", "alternatives_b": "", "updated_at": 1767369485}, {"id": 97869, "ingredient1": "Enasidenib", "ingredient2": "Empagliflozin", "severity": "Moderate", "effect": "Based on in vitro data, coadministration with enasidenib may increase the plasma concentrations of drugs that are substrates of the transporters, organic anion transporting polypeptides (OATP) 1B1/1B3 and breast cancer resistance protein (BCRP). The proposed mechanism is decreased clearance due to enasidenib -mediated inhibition of OATP1B1/1B3 and BCRP transporters.", "source": "DDInter", "management_text": "Caution is advised when enasidenib is used concurrently with medications that are substrates of OATP 1B1/1B3 and/or BCRP, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever enasidenib is added to or withdrawn from therapy.", "mechanism_text": "Distribution", "recommendation": "Caution is advised when enasidenib is used concurrently with medications that are substrates of OATP 1B1/1B3 and/or BCRP, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97973/", "reference_text": "[1] \"Product Information. Idhifa (enasidenib).\" Celgene Corporation, Summit, NJ.[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] \"Product Information. Mavyret (glecaprevir-pibrentasvir).\" Abbott Pharmaceutical, Abbott Park, IL.", "alternatives_a": "Glipizide, Acetohexamide, Guar gum, Pramlintide, Alogliptin, Tolazamide, Dulaglutide, Exenatide, Tolbutamide, Miglitol, Glimepiride, More", "alternatives_b": "Pertuzumab, Olaparib, Oxaliplatin, Rucaparib, Tisagenlecleucel, Aminolevulinic acid, Tazemetostat, Altretamine, Ixazomib, Sotorasib, Belzutifan, More", "updated_at": 1767369485}, {"id": 97870, "ingredient1": "Encorafenib", "ingredient2": "Empagliflozin", "severity": "Moderate", "effect": "Coadministration with encorafenib may theoretically increase the plasma concentrations of drugs that are substrates of P-glycoprotein (P-gp), breast cancer resistance protein (BCRP), organic cation transporter (OCT2), organic anion transporter (OAT1, OAT3), or organic anion transporting polypeptide (OATP1B1, OATP1B3). The proposed mechanism is decreased clearance due to inhibition of the corresponding transporter by encorafenib.", "source": "DDInter", "management_text": "Caution is advised if encorafenib must be used concomitantly with drugs that are substrates of the affected transporters, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever encorafenib is added to or withdrawn from therapy.", "mechanism_text": "Excretion", "recommendation": "Caution is advised if encorafenib must be used concomitantly with drugs that are substrates of the affected transporters, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97974/", "reference_text": "[1] \"Product Information. Braftovi (encorafenib).\" Array BioPharma Inc., Boulder, CO.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Braftovi (encorafenib).\" Array BioPharma Inc., Boulder, CO.[4] \"Product Information. Lonsurf (tipiracil-trifluridine).\" Taiho Oncology, Inc., Princeton, NJ.", "alternatives_a": "Glipizide, Acetohexamide, Guar gum, Pramlintide, Alogliptin, Tolazamide, Dulaglutide, Exenatide, Tolbutamide, Miglitol, Glimepiride, More", "alternatives_b": "Imatinib, Dabrafenib, Asciminib, Acalabrutinib, Dacomitinib, Pexidartinib, Fedratinib, Avapritinib, Larotrectinib, Bosutinib, Vemurafenib, More", "updated_at": 1767369485}, {"id": 97871, "ingredient1": "Enfortumab vedotin", "ingredient2": "Empagliflozin", "severity": "Moderate", "effect": "The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.", "source": "DDInter", "management_text": "Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.", "mechanism_text": "Antagonism", "recommendation": "Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97975/", "reference_text": "[1] Jori A, Carrara MC \"On the mechanism of the hyperglycaemic effect of chlorpromazine.\" J Pharm Pharmacol 18 (1966): 623-4[2] \"Product Information. Dymelor (acetohexamide)\" Lilly, Eli and Company, Indianapolis, IN.[3] \"Product Information. Thorazine (chlorpromazine).\" SmithKline Beecham, Philadelphia, PA.[4] Blayac JP, Ribes G, Buys D, Puech R, Loubatieres-Mariani MM \"Effects of a new benzothiadiazine derivative, LN 5330, on insulin secretion.\" Arch Int Pharmacodyn Ther 253 (1981): 154-63[5] \"Product Information. Elzonris (tagraxofusp).\" Stemline Therapeutics, New York, NY.[6] \"Product Information. Amaryl (glimepiride).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[7] \"Product Information. Elspar (asparaginase).\" Merck & Co, Inc, West Point, PA.[8] Jones IG, Pickens PT \"Diabetes mellitus following oral diuretics.\" Practitioner 199 (1967): 209-10[9] \"Product Information. Viracept (nelfinavir).\" Agouron Pharma Inc, La Jolla, CA.[10] \"Product Information. Tolinase (tolazamide)\" Pharmacia and Upjohn, Kalamazoo, MI.[11] Mauss S, Wolf E, Jaeger H \"Impaired glucose tolerance in HIV-positive patients receiving and those not receiving protease inhibitors.\" Ann Intern Med 130 (1999): 162-3[12] Virutamasen P, Wongsrichanalai C, Tangkeo P, Nitichai Y, Rienprayoon D \"Metabolic effects of depot-medroxyprogesterone acetate in long-term users: a cross-sectional study.\" Int J Gynaecol Obstet 24 (1986): 291-6[13] Wehring H, Alexander B, Perry PJ \"Diabetes mellitus associated with clozapine therapy.\" Pharmacotherapy 20 (2000): 844-7[14] Spellacy WN, Ellingson AB, Tsibris JC \"The effects of two triphasic oral contraceptives on carbohydrate metabolism in women during 1 year of use.\" Fertil Steril 51 (1989): 71-4[15] Andersen OO, Persson I \"Carbohydrate metabolism during treatment with chlorthalidone and ethacrynic acid.\" Br Med J 2 (1968): 798-801[16] Berlin I \"Prazosin, diuretics, and glucose intolerance.\" Ann Intern Med 119 (1993): 860[17] Malherbe C, Burrill KC, Levin SR, Karam JH, Forsham PH \"Effect of diphenylhydantoin on insulin secretion in man.\" N Engl J Med 286 (1972): 339-42[18] Carter BL, Small RE, Mandel MD, Starkman MT \"Phenytoin-induced hyperglycemia.\" Am J Hosp Pharm 38 (1981): 1508-12[19] Al-Rubeaan K, Ryan EA \"Phenytoin-induced insulin insensitivity.\" Diabet Med 8 (1991): 968-70[20] \"Product Information. Zolinza (vorinostat).\" Merck & Company Inc, West Point, PA.[21] Goldman JA, Neri A, Ovadia J, Eckerling B, Vries A, de \"Effect of chlorothiazide on intravenous glucose tolerance in pregnancy.\" Am J Obstet Gynecol 105 (1969): 556-60[22] Harper R, Ennis CN, Heaney AP, Sheridan B, Gormley M, Atkinson AB, Johnston GD, Bell PM \"A comparison of the effects of low- and conventional-dose thiazide diuretic on insulin action in hypertensive patients with NIDDM.\" Diabetologia 38 (1995): 853-9[23] Seltzer HS, Allen EW \"Hyperglycemia and inhibition of insulin secretion during administration of diazoxide and trichlormethiazide in man.\" Diabetes 18 (1969): 19-28[24] Dube MP, Johnson DL, Currier JS, Leedom JM \"Protease inhibitor-associated hyperglycaemia.\" Lancet 350 (1997): 713-4[25] Leary WP, Reyes AJ \"Drug interactions with diuretics.\" S Afr Med J 65 (1984): 455-61[26] \"Product Information. Reyataz (atazanavir).\" Bristol-Myers Squibb, Princeton, NJ.[27] Pollare T, Lithell H, Berne C \"A comparison of the effects of hydrochlorothiazide and captopril on glucose and lipid metabolism in patients with hypertension.\" N Engl J Med 321 (1989): 868-73[28] Gunnarsson R, Lundgren G, Magnusson G, Ost L, Groth CG \"Steroid diabetes--a sign of overtreatment with steroids in the renal graft recipient?\" Scand J Urol Nephrol Suppl 54 (1980): 135-8[29] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[30] \"Product Information. Synthroid (levothyroxine).\" Abbott Pharmaceutical, Abbott Park, IL.[31] Murphy MB, Kohner E, Lewis PJ, Schumer B, Dollery CT \"Glucose intolerance in hypertensive patients treated with diuretics: a fourteen-year follow-up.\" Lancet 2 (1982): 1293-5[32] \"Product Information. Fortovase (saquinavir)\" Roche Laboratories, Nutley, NJ.[33] Coni NK, Gordon PW, Mukherjee AP, Read PR \"The effect of frusemide and ethacrynic acid on carbohydrate metabolism.\" Age Ageing 3 (1974): 85-90[34] \"Product Information. Norvir (ritonavir).\" Abbott Pharmaceutical, Abbott Park, IL.[35] Domenet JG \"Diabetogenic effect of oral diuretics.\" Br Med J 3 (1968): 188[36] Rowe P, Mather H \"Hyperosmolar non-ketotic diabetes mellitus associated with metolazone.\" Br Med J 291 (1985): 25-6[37] Winchester JF, Kellett RJ, Boddy K, Boyle P, Dargie HJ, Mahaffey ME, Ward DM, Kennedy AC \"Metolazone and bendroflumethiazide in hypertension: physiologic and metabolic observations.\" Clin Pharmacol Ther 28 (1980): 611-8[38] \"Product Information. Carafate (sucralfate).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[39] Tsiodras S, Mantzoros C, Hammer S, Samore M \"Effects of protease inhibitors on hyperglycemia, hyperlipidemia, and lipodystrophy - A 5-year cohort study.\" Arch Intern Med 160 (2000): 2050-6[40] \"Product Information. Apidra (insulin glulisine).\" Aventis Pharmaceuticals, Bridgewater, NJ.[41] \"Product Information. Prezista (darunavir).\" Ortho Biotech Inc, Bridgewater, NJ.[42] Haiba NA, el-Habashy MA, Said SA, Darwish EA, Abdel-Sayed WS, Nayel SE \"Clinical evaluation of two monthly injectable contraceptives and their effects on some metabolic parameters.\" Contraception 39 (1989): 619-32[43] Erle G, Basso M, Federspil G, Sicolo N, Scandellari C \"Effect of chlorpromazine on blood glucose and plasma insulin in man.\" Eur J Clin Pharmacol 11 (1977): 15-8[44] Pickkers P, Schachter M, Hughes AD, Feher MD, Sever PS \"Thiazide-induced hyperglycaemia: a role for calcium-activated potassium channels?\" Diabetologia 39 (1996): 861-4[45] \"Product Information. Lexiva (fosamprenavir).\" GlaxoSmithKline, Research Triangle Park, NC.[46] Curtis J, Horrigan F, Ahearn D, Varney R, Sandler SG \"Chlorthalidone-induced hyperosmolar hyperglycemic nonketotic coma.\" JAMA 220 (1972): 1592-3[47] \"Product Information. Hyperstat I.V. (diazoxide).\" Schering Corp, Kenilworth, NJ.[48] \"Product Information. Piqray (alpelisib).\" Novartis Pharmaceuticals, East Hanover, NJ.[49] Bell DS \"Insulin resistance. An often unrecognized problem accompanying chronic medical disorders.\" Postgrad Med 93 (1993): 99-103,[50] Stambaugh JE, Tucker DC \"Effect of diphenylhydantoin on glucose tolerance in patients with hypoglycemia.\" Diabetes 23 (1974): 679-83[51] \"Product Information. Crixivan (indinavir).\" Merck & Co, Inc, West Point, PA.[52] Miller NR, Moses H \"Transient oculomotor nerve palsy. Association with thiazide-induced glucose intolerance.\" JAMA 240 (1978): 1887-8[53] Javier Z, Gershberg H, Hulse M \"Ovulatory suppressants, estrogens, and carbohydrate metabolism.\" Metabolism 17 (1968): 443-56[54] Goldman JA, Ovadia JL \"The effect of estrogen on intravenous glucose tolerance in woman.\" Am J Obstet Gynecol 103 (1969): 172-8[55] Charan VD, Desai N, Singh AP, Choudhry VP \"Diabetes mellitus and pancreatitis as a complication of L- asparaginase therapy.\" Indian Pediatr 30 (1993): 809-10[56] Seifer DB, Freedman LN, Cavender JR, Baker RA \"Insulin-dependent diabetes mellitus associated with danazol.\" Am J Obstet Gynecol 162 (1990): 474-5[57] \"Product Information. Orinase (tolbutamide)\" Pharmacia and Upjohn, Kalamazoo, MI.[58] Walli R, Demant T \"Impaired glucose tolerance and protease inhibitors.\" Ann Intern Med 129 (1998): 837-8[59] Hannaford PC, Kay CR \"Oral contraceptives and diabetes mellitus.\" BMJ 299 (1989): 1315-6[60] Hardy H, Esch LD, Morse GD \"Glucose disorders associated with HIV and its drug therapy.\" Ann Pharmacother 35 (2001): 343-51[61] Chowdhury FR, Bleicher SJ \"Chlorthalidone--induced hypokalemia and abnormal carbohydrate metabolism.\" Horm Metab Res 2 (1970): 13-6[62] Kaufman MB, Simionatto C \"A review of protease inhibitor-induced hyperglycemia.\" Pharmacotherapy 19 (1999): 114-7[63] Greenstone MA, Shaw AB \"Alternate day corticosteroid causes alternate day hyperglycaemia.\" Postgrad Med J 63 (1987): 761-4[64] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[65] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[66] Elmfeldt D, Berglund G, Wedel H, Wilhelmsen L \"Incidence and importance of metabolic side-effects during antihypertensive therapy.\" Acta Med Scand Suppl 672 (1983): 79-83[67] \"Product Information. Agenerase (amprenavir).\" Glaxo Wellcome, Research Triangle Pk, NC.[68] Diamond MT \"Hyperglycemic hyperosmolar coma associated with hydrochlorothiazide and pancreatitis.\" N Y State J Med 72 (1972): 1741-2[69] \"Product Information. Prandin (repaglinide).\" Novo Nordisk Pharmaceuticals Inc, Princeton, NJ.[70] \"Product Information. Precose (acarbose).\" Bayer, West Haven, CT.[71] \"Product Information. Starlix (nateglinide)\" Novartis Pharmaceuticals, East Hanover, NJ.[72] \"Product Information. Oncaspar (pegaspargase).\" Rhone-Poulenc Rorer, Collegeville, PA.[73] Sotaniemi E, Kontturi M, Larmi T \"Effect of diethylstilbestrol on blood glucose of prostatic cancer patients.\" Invest Urol 10 (1973): 438-41[74] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[75] Petri M, Cumber P, Grimes L, Treby D, Bryant R, Rawlins D, Ising H \"The metabolic effects of thiazide therapy in the elderly: a population study.\" Age Ageing 15 (1986): 151-5[76] Ludvik B, Clodi M, Kautzky-Willer A, Capek M, Hartter E, Pacini G, Prager R \"Effect of dexamethasone on insulin sensitivity, islet amyloid polypeptide and insulin secretion in humans.\" Diabetologia 36 (1993): 84-7[77] \"Product Information. Glucophage (metformin).\" Bristol-Myers Squibb, Princeton, NJ.[78] Chaudhuri ML, Catania J \"A comparison of the effects of bumetanide (Burinex) and frusemide on carbohydrate metabolism in the elderly.\" Br J Clin Pract 42 (1988): 427-9[79] Black DM, Filak AT \"Hyperglycemia with non-insulin-dependent diabetes following intraarticular steroid injection.\" J Fam Pract 28 (1989): 462-3[80] \"Product Information. Megace (megestrol).\" Bristol-Myers Squibb, Princeton, NJ.[81] \"Product Information. Torisel (temsirolimus).\" Wyeth-Ayerst Laboratories, Philadelphia, PA.[82] Schmitz O, Hermansen K, Nielsen OH, Christensen CK, Arnfred J, Hansen HE, Mogensen CE, Orskov H, Beck-Nielsen H \"Insulin action in insulin-dependent diabetics after short-term thiazide therapy.\" Diabetes Care 9 (1986): 631-6[83] Kansal PC, Buse J, Buse MG \"Thiazide diuretics and control of diabetes mellitus.\" South Med J 62 (1969): 1372-9[84] Dimitriadis G, Tegos C, Golfinopoulou L, Roboti C, Raptis S \"Furosemide-induced hyperglycaemia - the implication of glycolytic kinases.\" Horm Metab Res 25 (1993): 557-9[85] \"Product Information. NovoLog Mix 70/30 (insulin aspart-insulin aspart protamine).\" Novo Nordisk Pharmaceuticals Inc, Princeton, NJ.[86] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[87] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[88] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[89] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42[90] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[91] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[92] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[93] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[94] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[95] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6", "alternatives_a": "Guar gum", "alternatives_b": "Pertuzumab, Cetuximab, Avelumab, Panitumumab, Obinutuzumab, Bevacizumab, Necitumumab, Dostarlimab, Ramucirumab, Atezolizumab, Amivantamab, More", "updated_at": 1767369485}, {"id": 97872, "ingredient1": "Enoxacin", "ingredient2": "Empagliflozin", "severity": "Moderate", "effect": "Quinolone antibiotics may interfere with the therapeutic effects of insulin and other antidiabetic agents. The use of quinolones has been associated with disturbances in blood glucose homeostasis possibly stemming from effects on pancreatic beta cell ATP-sensitive potassium channels that regulate insulin secretion. Both hyperglycaemia and hypoglycemia have been reported, usually in diabetic patients receiving concomitant treatment with an oral hypoglycemic agent (e.g., sulfonylurea) or insulin. Although hyperglycaemia is significantly more common and infection itself may be an underlying risk factor, hypoglycemia may cause greater morbidity and mortality.", "source": "DDInter", "management_text": "Blood glucose should be closely monitored whenever quinolones are prescribed to diabetic patients, especially if they are elderly, have renal impairment, or are severely ill. Patients should be apprised of the increased risk of dysglycemia and be particularly alert to potential signs and symptoms of hypoglycemia such as headache, dizziness, drowsiness, nervousness, confusion, tremor, hunger, weakness, perspiration, palpitation, and tachycardia. If hypoglycemia occurs, patients should initiate appropriate remedial therapy immediately, discontinue the quinolone, and contact their physician. Alternative antibiotics may need to be considered.", "mechanism_text": "Antagonism", "recommendation": "Blood glucose should be closely monitored whenever quinolones are prescribed to diabetic patients, especially if they are elderly, have renal impairment, or are severely ill.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97976/", "reference_text": "[1] Gavin JR 3rd, Kubin R, Choudhri S, et al \"Moxifloxacin and glucose homeostasis: a pooled-analysis of the evidence from clinical and postmarketing studies.\" Drug Saf 27 (2004): 671-86[2] Yip C, Lee AJ \"Gatifloxacin-induced hyperglycemia: a case report and summary of the current literature.\" Clin Ther 28 (2006): 1857-66[3] Kelesidis T, Canseco E \"Quinolone-induced hypoglycemia: a life-threatening but potentially reversible side effect.\" Am J Med 123 (2010): e5-6[4] Baker SE, Hangii MC \"Possible gatifloxacin-induced hypoglycemia.\" Ann Pharmacother 36 (2002): 1722-6[5] \"Product Information. Levaquin (levofloxacin).\" Ortho Pharmaceutical Corporation, Raritan, NJ.[6] Frothingham R \"Glucose homeostasis abnormalities associated with use of gatifloxacin.\" Clin Infect Dis 41 (2005): 1269-76[7] Letourneau G, Morrison H, McMorran M \"Gatifloxacin (Tequin): hypoglycemia and hyperglycemia. Available from: URL: http://www.hc-sc.gc.ca/dhp-mps/medeff/bulletin/carn-bcei_v13n3_e.html#1\" ([2003 Jul]):[8] Lin G, Hays DP, Spillane L \"Refractory hypoglycemia from ciprofloxacin and glyburide interaction.\" J Toxicol Clin Toxicol 42 (2004): 295-7[9] \"Product Information. Tequin (gatifloxacin)\" Bristol-Myers Squibb, Princeton, NJ.[10] \"Product Information. Floxin (ofloxacin).\" Ortho Pharmaceutical Corporation, Raritan, NJ.[11] Bhasin R, Arce FC, Pasmantier R \"Hypoglycemia associated with the use of gatifloxacin.\" Am J Med Sci 330 (2005): 250-3[12] Zvonar R \"Gatifloxacin-induced dysglycemia.\" Am J Health Syst Pharm 63 (2006): 2087-2092[13] Rubinstein E \"History of quinolones and their side effects.\" Chemotherapy 47 Suppl 3 (2001): 3-8[14] Park-Wyllie LY, Juurlink DN, Kopp A, et al. \"Outpatient gatifloxacin therapy and dysglycemia in older adults.\" N Engl J Med 354 (2006): 1352-61[15] LeBlanc M, Belanger C, Cossette P \"Severe and resistant hypoglycemia associated with concomitant gatifloxacin and glyburide therapy.\" Pharmacotherapy 24 (2004): 926-31[16] \"Product Information. Cipro (ciprofloxacin).\" Bayer, West Haven, CT.[17] Happe MR, Mulhall BP, Maydonovitch CL, Holtzmuller KC \"Gatifloxacin-induced hyperglycemia.\" Ann Intern Med 141 (2004): 968-9[18] Biggs WS \"Hypoglycemia and hyperglycemia associated with gatifloxacin use in elderly patients.\" J Am Board Fam Pract 16 (2004): 455-7[19] \"Product Information. Raxar (grepafloxacin).\" Glaxo Wellcome, Research Triangle Park, NC.[20] Brogan SE, Cahalan MK \"Gatifloxacin as a possible cause of serious postoperative hypoglycemia.\" Anesth Analg 101 (2005): 635-6[21] Friedrich LV, Dougherty R \"Fatal hypoglycemia associated with levofloxacin.\" Pharmacotherapy 24 (2004): 1807-12[22] Saraya A, Yokokura M, Gonoi T, Seino S \"Effects of fluoroquinolones on insulin secretion and beta-cell ATP-sensitive K(+) channels.\" Eur J Pharmacol 497 (2004): 111-7[23] \"Hypoglycemia and hyperglycemia with fluoroquinolones.\" Med Lett Drugs Ther 45 (2003): 64[24] Gajjar DA, LaCreta FP, Kollia GD, et al. \"Effect of multiple-dose gatifloxacin or ciprofloxacin on glucose homeostasis and insulin production in patients with noninsulin-dependent diabetes mellitus maintained with diet and exercise.\" Pharmacotherapy 20 (6 Pt 2) (2000): s76-86[25] Khovidhunkit W, Sunthornyothin S \"Hypoglycemia, hyperglycemia, and gatifloxacin.\" Ann Intern Med 141 (2004): 969[26] Kanbay M, Aydogan T, Bozalan R, et al. \"A rare but serious side effect of levofloxacin: hypoglycemia in a geriatric patient.\" Diabetes Care 29 (2006): 1716-7[27] Menzies DJ, Dorsainvil PA, Cunha BA, Johnson DH \"Severe and persistent hypoglycemia due to gatifloxacin interaction with oral hypoglycemic agents.\" Am J Med 113 (2002): 232-4[28] Edwards DJ, Bowles SK, Svensson CK, Rybak MJ \"Inhibition of drug metabolism by quinolone antibiotics.\" Clin Pharmacokinet 15 (1988): 194-204[29] Graumlich JF, Habis S, Avelino RR, et al. \"Hypoglycemia in inpatients after gatifloxacin or levofloxacin therapy: nested case-control study.\" Pharmacotherapy 25 (2005): 1296-302[30] \"Product Information. Factive (gemifloxacin).\" GeneSoft Inc, San Francisco, CA.[31] Wang S, Rizvi AA \"Levofloxacin-induced hypoglycemia in a nondiabetic patient.\" Am J Med Sci 331 (2006): 334-5[32] \"Product Information. Noroxin (norfloxacin).\" Merck & Co, Inc, West Point, PA.[33] Zhanel GG, Fontaine S, Adam H, et al. \"A Review of New Fluoroquinolones : Focus on their Use in Respiratory Tract Infections.\" Treat Respir Med 5 (2006): 437-465[34] \"Product Information. Baxdela (delafloxacin).\" Melinta Therapeutics, Lincolnshire, IL.[35] Greenberg AL, Decerbo M, Fan J \"Gatifloxacin therapy associated with hypoglycemia.\" Clin Infect Dis 40 (2005): 1210-1[36] Blommel AL, Lutes RA \"Severe hyperglycemia during renally adjusted gatifloxacin therapy.\" Ann Pharmacother 39 (2005): 1349-52[37] Tomita T, Onishi M, Sato E, Kimura Y, Kihira K \"Gatifloxacin induces augmented insulin release and intracellular insulin.\" Biol Pharm Bull 30 (2007): 644-7[38] Donaldson AR, Vandiver JR, Finch CK \"Possible gatifloxacin-induced hyperglycemia.\" Ann Pharmacother 38 (2004): 602-5[39] \"Product Information. Trovan (trovafloxacin).\" Pfizer US Pharmaceuticals, New York, NY.[40] Roberge RJ, Kaplan R, Frank R, Fore C \"Glyburide-ciprofloxacin interaction with resistant hypoglycemia.\" Ann Emerg Med 36 (2000): 160-3[41] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[42] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[43] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[44] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42[45] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[46] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[47] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[48] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[49] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[50] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6", "alternatives_a": "Acetohexamide, Guar gum, Simvastatin, Troglitazone, Rosuvastatin", "alternatives_b": "", "updated_at": 1767369485}, {"id": 97873, "ingredient1": "Entrectinib", "ingredient2": "Empagliflozin", "severity": "Moderate", "effect": "Coadministration with entrectinib may increase the plasma concentrations of drugs that are substrates of the breast cancer resistance protein (BCRP) transporter. The proposed mechanisms, based on in vitro data, is decreased clearance due to entrectinib-mediated inhibition of BCRP transport protein.", "source": "DDInter", "management_text": "Caution is advised when entrectinib is prescribed with drugs that are BCRP substrates, particularly those with a narrow therapeutic range such as methotrexate, mitoxantrone, topotecan, and lapatinib. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever entrectinib is added to or withdrawn from therapy.", "mechanism_text": "Others", "recommendation": "Caution is advised when entrectinib is prescribed with drugs that are BCRP substrates, particularly those with a narrow therapeutic range such as methotrexate, mitoxantrone, topotecan, and lapatinib.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97977/", "reference_text": "[1] \"Product Information. Rozlytrek (entrectinib).\" Genentech, South San Francisco, CA.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] Cerner Multum, Inc. \"Australian Product Information.\" O 0[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] \"Product Information. Rozlytrek (entrectinib).\" Genentech, South San Francisco, CA.", "alternatives_a": "Glipizide, Acetohexamide, Guar gum, Pramlintide, Alogliptin, Tolazamide, Dulaglutide, Exenatide, Tolbutamide, Miglitol, Glimepiride, More", "alternatives_b": "Imatinib, Dabrafenib, Asciminib, Acalabrutinib, Dacomitinib, Pexidartinib, Fedratinib, Avapritinib, Larotrectinib, Bosutinib, Vemurafenib, More", "updated_at": 1767369485}, {"id": 97874, "ingredient1": "Enzalutamide", "ingredient2": "Empagliflozin", "severity": "Moderate", "effect": "Coadministration with enzalutamide may decrease the plasma concentrations of drugs that are substrates of CYP450 3A4, 2C9, 2C19, and/or P-glycoprotein (P-gp) efflux transporter. The proposed mechanism involves accelerated clearance via these routes due to enzalutamide-mediated induction. The resulting plasma concentrations will depend on the sensitivity of the affected drugs to these isoenzymes.", "source": "DDInter", "management_text": "Caution is advised when enzalutamide is used concomitantly with drugs that are substrates of CYP450 3A4, 2C9, 2C19, and/or P-gp, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever enzalutamide is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when enzalutamide is used concomitantly with drugs that are substrates of CYP450 3A4, 2C9, 2C19, and/or P-gp, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97978/", "reference_text": "[1] Cerner Multum, Inc. \"Australian Product Information.\" O 0[2] \"Product Information. Xtandi (enzalutamide).\" Astellas Pharma US, Inc, Deerfield, IL.[3] Benoist G, van Oort I, et al \"Drug-drug interaction potential in men treated with enzalutamide: Mind the gap.\" Br J Clin Pharmacol 0 (2017): epub[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0", "alternatives_a": "Tamoxifen, Anastrozole, Letrozole, Toremifene, Fulvestrant, Abarelix, Flutamide, Relugolix, Bicalutamide, Degarelix, Nilutamide, More", "alternatives_b": "Acetohexamide, Guar gum, Pramlintide, Alogliptin, Tolazamide, Dulaglutide, Exenatide, Miglitol, Albiglutide, Rosiglitazone, Ertugliflozin, More", "updated_at": 1767369485}, {"id": 97875, "ingredient1": "Ephedrine", "ingredient2": "Empagliflozin", "severity": "Moderate", "effect": "The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.", "source": "DDInter", "management_text": "Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.", "mechanism_text": "Antagonism", "recommendation": "Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97979/", "reference_text": "[1] Jori A, Carrara MC \"On the mechanism of the hyperglycaemic effect of chlorpromazine.\" J Pharm Pharmacol 18 (1966): 623-4[2] \"Product Information. Dymelor (acetohexamide)\" Lilly, Eli and Company, Indianapolis, IN.[3] \"Product Information. Thorazine (chlorpromazine).\" SmithKline Beecham, Philadelphia, PA.[4] Blayac JP, Ribes G, Buys D, Puech R, Loubatieres-Mariani MM \"Effects of a new benzothiadiazine derivative, LN 5330, on insulin secretion.\" Arch Int Pharmacodyn Ther 253 (1981): 154-63[5] \"Product Information. Elzonris (tagraxofusp).\" Stemline Therapeutics, New York, NY.[6] \"Product Information. Amaryl (glimepiride).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[7] \"Product Information. Elspar (asparaginase).\" Merck & Co, Inc, West Point, PA.[8] Jones IG, Pickens PT \"Diabetes mellitus following oral diuretics.\" Practitioner 199 (1967): 209-10[9] \"Product Information. Viracept (nelfinavir).\" Agouron Pharma Inc, La Jolla, CA.[10] \"Product Information. Tolinase (tolazamide)\" Pharmacia and Upjohn, Kalamazoo, MI.[11] Mauss S, Wolf E, Jaeger H \"Impaired glucose tolerance in HIV-positive patients receiving and those not receiving protease inhibitors.\" Ann Intern Med 130 (1999): 162-3[12] Virutamasen P, Wongsrichanalai C, Tangkeo P, Nitichai Y, Rienprayoon D \"Metabolic effects of depot-medroxyprogesterone acetate in long-term users: a cross-sectional study.\" Int J Gynaecol Obstet 24 (1986): 291-6[13] Wehring H, Alexander B, Perry PJ \"Diabetes mellitus associated with clozapine therapy.\" Pharmacotherapy 20 (2000): 844-7[14] Spellacy WN, Ellingson AB, Tsibris JC \"The effects of two triphasic oral contraceptives on carbohydrate metabolism in women during 1 year of use.\" Fertil Steril 51 (1989): 71-4[15] Andersen OO, Persson I \"Carbohydrate metabolism during treatment with chlorthalidone and ethacrynic acid.\" Br Med J 2 (1968): 798-801[16] Berlin I \"Prazosin, diuretics, and glucose intolerance.\" Ann Intern Med 119 (1993): 860[17] Malherbe C, Burrill KC, Levin SR, Karam JH, Forsham PH \"Effect of diphenylhydantoin on insulin secretion in man.\" N Engl J Med 286 (1972): 339-42[18] Carter BL, Small RE, Mandel MD, Starkman MT \"Phenytoin-induced hyperglycemia.\" Am J Hosp Pharm 38 (1981): 1508-12[19] Al-Rubeaan K, Ryan EA \"Phenytoin-induced insulin insensitivity.\" Diabet Med 8 (1991): 968-70[20] \"Product Information. Zolinza (vorinostat).\" Merck & Company Inc, West Point, PA.[21] Goldman JA, Neri A, Ovadia J, Eckerling B, Vries A, de \"Effect of chlorothiazide on intravenous glucose tolerance in pregnancy.\" Am J Obstet Gynecol 105 (1969): 556-60[22] Harper R, Ennis CN, Heaney AP, Sheridan B, Gormley M, Atkinson AB, Johnston GD, Bell PM \"A comparison of the effects of low- and conventional-dose thiazide diuretic on insulin action in hypertensive patients with NIDDM.\" Diabetologia 38 (1995): 853-9[23] Seltzer HS, Allen EW \"Hyperglycemia and inhibition of insulin secretion during administration of diazoxide and trichlormethiazide in man.\" Diabetes 18 (1969): 19-28[24] Dube MP, Johnson DL, Currier JS, Leedom JM \"Protease inhibitor-associated hyperglycaemia.\" Lancet 350 (1997): 713-4[25] Leary WP, Reyes AJ \"Drug interactions with diuretics.\" S Afr Med J 65 (1984): 455-61[26] \"Product Information. Reyataz (atazanavir).\" Bristol-Myers Squibb, Princeton, NJ.[27] Pollare T, Lithell H, Berne C \"A comparison of the effects of hydrochlorothiazide and captopril on glucose and lipid metabolism in patients with hypertension.\" N Engl J Med 321 (1989): 868-73[28] Gunnarsson R, Lundgren G, Magnusson G, Ost L, Groth CG \"Steroid diabetes--a sign of overtreatment with steroids in the renal graft recipient?\" Scand J Urol Nephrol Suppl 54 (1980): 135-8[29] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[30] \"Product Information. Synthroid (levothyroxine).\" Abbott Pharmaceutical, Abbott Park, IL.[31] Murphy MB, Kohner E, Lewis PJ, Schumer B, Dollery CT \"Glucose intolerance in hypertensive patients treated with diuretics: a fourteen-year follow-up.\" Lancet 2 (1982): 1293-5[32] \"Product Information. Fortovase (saquinavir)\" Roche Laboratories, Nutley, NJ.[33] Coni NK, Gordon PW, Mukherjee AP, Read PR \"The effect of frusemide and ethacrynic acid on carbohydrate metabolism.\" Age Ageing 3 (1974): 85-90[34] \"Product Information. Norvir (ritonavir).\" Abbott Pharmaceutical, Abbott Park, IL.[35] Domenet JG \"Diabetogenic effect of oral diuretics.\" Br Med J 3 (1968): 188[36] Rowe P, Mather H \"Hyperosmolar non-ketotic diabetes mellitus associated with metolazone.\" Br Med J 291 (1985): 25-6[37] Winchester JF, Kellett RJ, Boddy K, Boyle P, Dargie HJ, Mahaffey ME, Ward DM, Kennedy AC \"Metolazone and bendroflumethiazide in hypertension: physiologic and metabolic observations.\" Clin Pharmacol Ther 28 (1980): 611-8[38] \"Product Information. Carafate (sucralfate).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[39] Tsiodras S, Mantzoros C, Hammer S, Samore M \"Effects of protease inhibitors on hyperglycemia, hyperlipidemia, and lipodystrophy - A 5-year cohort study.\" Arch Intern Med 160 (2000): 2050-6[40] \"Product Information. Apidra (insulin glulisine).\" Aventis Pharmaceuticals, Bridgewater, NJ.[41] \"Product Information. Prezista (darunavir).\" Ortho Biotech Inc, Bridgewater, NJ.[42] Haiba NA, el-Habashy MA, Said SA, Darwish EA, Abdel-Sayed WS, Nayel SE \"Clinical evaluation of two monthly injectable contraceptives and their effects on some metabolic parameters.\" Contraception 39 (1989): 619-32[43] Erle G, Basso M, Federspil G, Sicolo N, Scandellari C \"Effect of chlorpromazine on blood glucose and plasma insulin in man.\" Eur J Clin Pharmacol 11 (1977): 15-8[44] Pickkers P, Schachter M, Hughes AD, Feher MD, Sever PS \"Thiazide-induced hyperglycaemia: a role for calcium-activated potassium channels?\" Diabetologia 39 (1996): 861-4[45] \"Product Information. Lexiva (fosamprenavir).\" GlaxoSmithKline, Research Triangle Park, NC.[46] Curtis J, Horrigan F, Ahearn D, Varney R, Sandler SG \"Chlorthalidone-induced hyperosmolar hyperglycemic nonketotic coma.\" JAMA 220 (1972): 1592-3[47] \"Product Information. Hyperstat I.V. (diazoxide).\" Schering Corp, Kenilworth, NJ.[48] \"Product Information. Piqray (alpelisib).\" Novartis Pharmaceuticals, East Hanover, NJ.[49] Bell DS \"Insulin resistance. An often unrecognized problem accompanying chronic medical disorders.\" Postgrad Med 93 (1993): 99-103,[50] Stambaugh JE, Tucker DC \"Effect of diphenylhydantoin on glucose tolerance in patients with hypoglycemia.\" Diabetes 23 (1974): 679-83[51] \"Product Information. Crixivan (indinavir).\" Merck & Co, Inc, West Point, PA.[52] Miller NR, Moses H \"Transient oculomotor nerve palsy. Association with thiazide-induced glucose intolerance.\" JAMA 240 (1978): 1887-8[53] Javier Z, Gershberg H, Hulse M \"Ovulatory suppressants, estrogens, and carbohydrate metabolism.\" Metabolism 17 (1968): 443-56[54] Goldman JA, Ovadia JL \"The effect of estrogen on intravenous glucose tolerance in woman.\" Am J Obstet Gynecol 103 (1969): 172-8[55] Charan VD, Desai N, Singh AP, Choudhry VP \"Diabetes mellitus and pancreatitis as a complication of L- asparaginase therapy.\" Indian Pediatr 30 (1993): 809-10[56] Seifer DB, Freedman LN, Cavender JR, Baker RA \"Insulin-dependent diabetes mellitus associated with danazol.\" Am J Obstet Gynecol 162 (1990): 474-5[57] \"Product Information. Orinase (tolbutamide)\" Pharmacia and Upjohn, Kalamazoo, MI.[58] Walli R, Demant T \"Impaired glucose tolerance and protease inhibitors.\" Ann Intern Med 129 (1998): 837-8[59] Hannaford PC, Kay CR \"Oral contraceptives and diabetes mellitus.\" BMJ 299 (1989): 1315-6[60] Hardy H, Esch LD, Morse GD \"Glucose disorders associated with HIV and its drug therapy.\" Ann Pharmacother 35 (2001): 343-51[61] Chowdhury FR, Bleicher SJ \"Chlorthalidone--induced hypokalemia and abnormal carbohydrate metabolism.\" Horm Metab Res 2 (1970): 13-6[62] Kaufman MB, Simionatto C \"A review of protease inhibitor-induced hyperglycemia.\" Pharmacotherapy 19 (1999): 114-7[63] Greenstone MA, Shaw AB \"Alternate day corticosteroid causes alternate day hyperglycaemia.\" Postgrad Med J 63 (1987): 761-4[64] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[65] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[66] Elmfeldt D, Berglund G, Wedel H, Wilhelmsen L \"Incidence and importance of metabolic side-effects during antihypertensive therapy.\" Acta Med Scand Suppl 672 (1983): 79-83[67] \"Product Information. Agenerase (amprenavir).\" Glaxo Wellcome, Research Triangle Pk, NC.[68] Diamond MT \"Hyperglycemic hyperosmolar coma associated with hydrochlorothiazide and pancreatitis.\" N Y State J Med 72 (1972): 1741-2[69] \"Product Information. Prandin (repaglinide).\" Novo Nordisk Pharmaceuticals Inc, Princeton, NJ.[70] \"Product Information. Precose (acarbose).\" Bayer, West Haven, CT.[71] \"Product Information. Starlix (nateglinide)\" Novartis Pharmaceuticals, East Hanover, NJ.[72] \"Product Information. Oncaspar (pegaspargase).\" Rhone-Poulenc Rorer, Collegeville, PA.[73] Sotaniemi E, Kontturi M, Larmi T \"Effect of diethylstilbestrol on blood glucose of prostatic cancer patients.\" Invest Urol 10 (1973): 438-41[74] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[75] Petri M, Cumber P, Grimes L, Treby D, Bryant R, Rawlins D, Ising H \"The metabolic effects of thiazide therapy in the elderly: a population study.\" Age Ageing 15 (1986): 151-5[76] Ludvik B, Clodi M, Kautzky-Willer A, Capek M, Hartter E, Pacini G, Prager R \"Effect of dexamethasone on insulin sensitivity, islet amyloid polypeptide and insulin secretion in humans.\" Diabetologia 36 (1993): 84-7[77] \"Product Information. Glucophage (metformin).\" Bristol-Myers Squibb, Princeton, NJ.[78] Chaudhuri ML, Catania J \"A comparison of the effects of bumetanide (Burinex) and frusemide on carbohydrate metabolism in the elderly.\" Br J Clin Pract 42 (1988): 427-9[79] Black DM, Filak AT \"Hyperglycemia with non-insulin-dependent diabetes following intraarticular steroid injection.\" J Fam Pract 28 (1989): 462-3[80] \"Product Information. Megace (megestrol).\" Bristol-Myers Squibb, Princeton, NJ.[81] \"Product Information. Torisel (temsirolimus).\" Wyeth-Ayerst Laboratories, Philadelphia, PA.[82] Schmitz O, Hermansen K, Nielsen OH, Christensen CK, Arnfred J, Hansen HE, Mogensen CE, Orskov H, Beck-Nielsen H \"Insulin action in insulin-dependent diabetics after short-term thiazide therapy.\" Diabetes Care 9 (1986): 631-6[83] Kansal PC, Buse J, Buse MG \"Thiazide diuretics and control of diabetes mellitus.\" South Med J 62 (1969): 1372-9[84] Dimitriadis G, Tegos C, Golfinopoulou L, Roboti C, Raptis S \"Furosemide-induced hyperglycaemia - the implication of glycolytic kinases.\" Horm Metab Res 25 (1993): 557-9[85] \"Product Information. NovoLog Mix 70/30 (insulin aspart-insulin aspart protamine).\" Novo Nordisk Pharmaceuticals Inc, Princeton, NJ.[86] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[87] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[88] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[89] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42[90] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[91] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[92] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[93] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[94] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[95] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6", "alternatives_a": "Ketorolac, Homatropine, Atropine, Scopolamine, Methscopolamine, Tropicamide, Ciclesonide, Mupirocin, Budesonide, Mometasone, Flunisolide, More", "alternatives_b": "Simvastatin, Guar gum, Rosuvastatin", "updated_at": 1767369485}, {"id": 97876, "ingredient1": "Eplerenone", "ingredient2": "Empagliflozin", "severity": "Moderate", "effect": "Sodium-glucose co-transporter 2 (SGLT-2) inhibitors may potentiate the hypotensive effects of diuretics and other antihypertensive agents or vasodilators. Inhibition of glucose and sodium co-transport produces mild diuresis and transient natriuresis, resulting in intravascular volume contraction. Volume depletion-related adverse reactions including hypotension, postural dizziness, orthostatic hypotension, syncope, and dehydration can occur after initiating treatment with SGLT-2 inhibitors, and the risk may be increased with concomitant use of other agents that can lower blood pressure.", "source": "DDInter", "management_text": "Caution is advised if SGLT-2 inhibitors are coadministered with diuretics and other hypotensive agents, particularly in the elderly and patients with impaired renal function. Prior to initiating SGLT-2 inhibitors, volume status should be assessed and corrected, if necessary. Clinical and laboratory monitoring are recommended during therapy, including electrolytes, fluid status, renal function, and blood pressure. If volume depletion occurs, treatment with SGLT-2 inhibitors should be interrupted until the condition is corrected.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if SGLT-2 inhibitors are coadministered with diuretics and other hypotensive agents, particularly in the elderly and patients with impaired renal function.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97980/", "reference_text": "[1] \"Product Information. Jardiance (empagliflozin).\" Boehringer Ingelheim, Ridgefield, CT.[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] \"Product Information. Farxiga (dapagliflozin).\" Bristol-Myers Squibb, Princeton, NJ.[5] \"Product Information. Invokana (canagliflozin).\" Janssen Pharmaceuticals, Titusville, NJ.[6] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[7] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[8] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[9] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[10] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[11] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6[12] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[13] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[14] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[15] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42", "alternatives_a": "Finerenone", "alternatives_b": "Glipizide, Acetohexamide, Guar gum, Pramlintide, Alogliptin, Tolazamide, Dulaglutide, Exenatide, Tolbutamide, Miglitol, Glimepiride, More", "updated_at": 1767369485}, {"id": 97877, "ingredient1": "Epoprostenol", "ingredient2": "Empagliflozin", "severity": "Moderate", "effect": "Sodium-glucose co-transporter 2 (SGLT-2) inhibitors may potentiate the hypotensive effects of diuretics and other antihypertensive agents or vasodilators. Inhibition of glucose and sodium co-transport produces mild diuresis and transient natriuresis, resulting in intravascular volume contraction. Volume depletion-related adverse reactions including hypotension, postural dizziness, orthostatic hypotension, syncope, and dehydration can occur after initiating treatment with SGLT-2 inhibitors, and the risk may be increased with concomitant use of other agents that can lower blood pressure.", "source": "DDInter", "management_text": "Caution is advised if SGLT-2 inhibitors are coadministered with diuretics and other hypotensive agents, particularly in the elderly and patients with impaired renal function. Prior to initiating SGLT-2 inhibitors, volume status should be assessed and corrected, if necessary. Clinical and laboratory monitoring are recommended during therapy, including electrolytes, fluid status, renal function, and blood pressure. If volume depletion occurs, treatment with SGLT-2 inhibitors should be interrupted until the condition is corrected.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if SGLT-2 inhibitors are coadministered with diuretics and other hypotensive agents, particularly in the elderly and patients with impaired renal function.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97981/", "reference_text": "[1] \"Product Information. Jardiance (empagliflozin).\" Boehringer Ingelheim, Ridgefield, CT.[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] \"Product Information. Farxiga (dapagliflozin).\" Bristol-Myers Squibb, Princeton, NJ.[5] \"Product Information. Invokana (canagliflozin).\" Janssen Pharmaceuticals, Titusville, NJ.[6] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[7] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[8] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[9] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[10] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[11] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6[12] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[13] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[14] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[15] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42", "alternatives_a": "Ticagrelor, Betrixaban, Apixaban, Cilostazol, Rivaroxaban, Clopidogrel, Lepirudin, Acenocoumarol, Urokinase, Cangrelor, Dipyridamole, More", "alternatives_b": "Glipizide, Acetohexamide, Guar gum, Pramlintide, Alogliptin, Rosuvastatin, Tolazamide, Dulaglutide, Exenatide, Tolbutamide, Miglitol, More", "updated_at": 1767369485}, {"id": 97878, "ingredient1": "Eprosartan", "ingredient2": "Empagliflozin", "severity": "Moderate", "effect": "Sodium-glucose co-transporter 2 (SGLT-2) inhibitors may potentiate the hypotensive effects of diuretics and other antihypertensive agents or vasodilators. Inhibition of glucose and sodium co-transport produces mild diuresis and transient natriuresis, resulting in intravascular volume contraction. Volume depletion-related adverse reactions including hypotension, postural dizziness, orthostatic hypotension, syncope, and dehydration can occur after initiating treatment with SGLT-2 inhibitors, and the risk may be increased with concomitant use of other agents that can lower blood pressure.", "source": "DDInter", "management_text": "Caution is advised if SGLT-2 inhibitors are coadministered with diuretics and other hypotensive agents, particularly in the elderly and patients with impaired renal function. Prior to initiating SGLT-2 inhibitors, volume status should be assessed and corrected, if necessary. Clinical and laboratory monitoring are recommended during therapy, including electrolytes, fluid status, renal function, and blood pressure. If volume depletion occurs, treatment with SGLT-2 inhibitors should be interrupted until the condition is corrected.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if SGLT-2 inhibitors are coadministered with diuretics and other hypotensive agents, particularly in the elderly and patients with impaired renal function.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97982/", "reference_text": "[1] \"Product Information. Jardiance (empagliflozin).\" Boehringer Ingelheim, Ridgefield, CT.[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] \"Product Information. Farxiga (dapagliflozin).\" Bristol-Myers Squibb, Princeton, NJ.[5] \"Product Information. Invokana (canagliflozin).\" Janssen Pharmaceuticals, Titusville, NJ.[6] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[7] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[8] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[9] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[10] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[11] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6[12] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[13] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[14] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[15] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42", "alternatives_a": "Sacubitril", "alternatives_b": "Glipizide, Acetohexamide, Guar gum, Pramlintide, Alogliptin, Rosuvastatin, Tolazamide, Dulaglutide, Tolbutamide, Miglitol, Glimepiride, More", "updated_at": 1767369485}, {"id": 97879, "ingredient1": "Erdafitinib", "ingredient2": "Empagliflozin", "severity": "Moderate", "effect": "Coadministration with erdafitinib may increase the plasma concentrations of drugs that are substrates of the P-glycoprotein (P-gp) efflux transporter, resulting in increased toxicity of these drugs. In vitro, erdafitinib has been shown to be an inhibitor of P-gp.", "source": "DDInter", "management_text": "Concomitant use of erdafitinib and P-gp substrates should generally be avoided. If concomitant use is required, administer erdafitinib at least 6 hours before or after administration of P-gp substrates with narrow therapeutic ranges.", "mechanism_text": "Distribution", "recommendation": "Concomitant use of erdafitinib and P-gp substrates should generally be avoided.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97983/", "reference_text": "[1] \"Product Information. Balversa (erdafitinib).\" Janssen Products, LP, Horsham, PA.", "alternatives_a": "Glipizide, Acetohexamide, Guar gum, Pramlintide, Alogliptin, Rosuvastatin, Tolazamide, Dulaglutide, Exenatide, Tolbutamide, Miglitol, More", "alternatives_b": "Imatinib, Dabrafenib, Asciminib, Acalabrutinib, Dacomitinib, Pexidartinib, Fedratinib, Avapritinib, Larotrectinib, Bosutinib, Vemurafenib, More", "updated_at": 1767369485}, {"id": 97880, "ingredient1": "Esmolol", "ingredient2": "Empagliflozin", "severity": "Moderate", "effect": "Sodium-glucose co-transporter 2 (SGLT-2) inhibitors may potentiate the hypotensive effects of diuretics and other antihypertensive agents or vasodilators. Inhibition of glucose and sodium co-transport produces mild diuresis and transient natriuresis, resulting in intravascular volume contraction. Volume depletion-related adverse reactions including hypotension, postural dizziness, orthostatic hypotension, syncope, and dehydration can occur after initiating treatment with SGLT-2 inhibitors, and the risk may be increased with concomitant use of other agents that can lower blood pressure.", "source": "DDInter", "management_text": "Caution is advised if SGLT-2 inhibitors are coadministered with diuretics and other hypotensive agents, particularly in the elderly and patients with impaired renal function. Prior to initiating SGLT-2 inhibitors, volume status should be assessed and corrected, if necessary. Clinical and laboratory monitoring are recommended during therapy, including electrolytes, fluid status, renal function, and blood pressure. If volume depletion occurs, treatment with SGLT-2 inhibitors should be interrupted until the condition is corrected.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if SGLT-2 inhibitors are coadministered with diuretics and other hypotensive agents, particularly in the elderly and patients with impaired renal function.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97984/", "reference_text": "[1] \"Product Information. Jardiance (empagliflozin).\" Boehringer Ingelheim, Ridgefield, CT.[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] \"Product Information. Farxiga (dapagliflozin).\" Bristol-Myers Squibb, Princeton, NJ.[5] \"Product Information. Invokana (canagliflozin).\" Janssen Pharmaceuticals, Titusville, NJ.[6] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[7] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[8] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[9] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[10] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[11] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6[12] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[13] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[14] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[15] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42", "alternatives_a": "Guar gum, Pramlintide, Alogliptin, Rosuvastatin, Dulaglutide, Exenatide, Miglitol, Albiglutide, Rosiglitazone, Semaglutide, Pioglitazone, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 97881, "ingredient1": "Esterified estrogens", "ingredient2": "Empagliflozin", "severity": "Moderate", "effect": "The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.", "source": "DDInter", "management_text": "Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.", "mechanism_text": "Antagonism", "recommendation": "Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97985/", "reference_text": "[1] Jori A, Carrara MC \"On the mechanism of the hyperglycaemic effect of chlorpromazine.\" J Pharm Pharmacol 18 (1966): 623-4[2] \"Product Information. Dymelor (acetohexamide)\" Lilly, Eli and Company, Indianapolis, IN.[3] \"Product Information. Thorazine (chlorpromazine).\" SmithKline Beecham, Philadelphia, PA.[4] Blayac JP, Ribes G, Buys D, Puech R, Loubatieres-Mariani MM \"Effects of a new benzothiadiazine derivative, LN 5330, on insulin secretion.\" Arch Int Pharmacodyn Ther 253 (1981): 154-63[5] \"Product Information. Elzonris (tagraxofusp).\" Stemline Therapeutics, New York, NY.[6] \"Product Information. Amaryl (glimepiride).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[7] \"Product Information. Elspar (asparaginase).\" Merck & Co, Inc, West Point, PA.[8] Jones IG, Pickens PT \"Diabetes mellitus following oral diuretics.\" Practitioner 199 (1967): 209-10[9] \"Product Information. Viracept (nelfinavir).\" Agouron Pharma Inc, La Jolla, CA.[10] \"Product Information. Tolinase (tolazamide)\" Pharmacia and Upjohn, Kalamazoo, MI.[11] Mauss S, Wolf E, Jaeger H \"Impaired glucose tolerance in HIV-positive patients receiving and those not receiving protease inhibitors.\" Ann Intern Med 130 (1999): 162-3[12] Virutamasen P, Wongsrichanalai C, Tangkeo P, Nitichai Y, Rienprayoon D \"Metabolic effects of depot-medroxyprogesterone acetate in long-term users: a cross-sectional study.\" Int J Gynaecol Obstet 24 (1986): 291-6[13] Wehring H, Alexander B, Perry PJ \"Diabetes mellitus associated with clozapine therapy.\" Pharmacotherapy 20 (2000): 844-7[14] Spellacy WN, Ellingson AB, Tsibris JC \"The effects of two triphasic oral contraceptives on carbohydrate metabolism in women during 1 year of use.\" Fertil Steril 51 (1989): 71-4[15] Andersen OO, Persson I \"Carbohydrate metabolism during treatment with chlorthalidone and ethacrynic acid.\" Br Med J 2 (1968): 798-801[16] Berlin I \"Prazosin, diuretics, and glucose intolerance.\" Ann Intern Med 119 (1993): 860[17] Malherbe C, Burrill KC, Levin SR, Karam JH, Forsham PH \"Effect of diphenylhydantoin on insulin secretion in man.\" N Engl J Med 286 (1972): 339-42[18] Carter BL, Small RE, Mandel MD, Starkman MT \"Phenytoin-induced hyperglycemia.\" Am J Hosp Pharm 38 (1981): 1508-12[19] Al-Rubeaan K, Ryan EA \"Phenytoin-induced insulin insensitivity.\" Diabet Med 8 (1991): 968-70[20] \"Product Information. Zolinza (vorinostat).\" Merck & Company Inc, West Point, PA.[21] Goldman JA, Neri A, Ovadia J, Eckerling B, Vries A, de \"Effect of chlorothiazide on intravenous glucose tolerance in pregnancy.\" Am J Obstet Gynecol 105 (1969): 556-60[22] Harper R, Ennis CN, Heaney AP, Sheridan B, Gormley M, Atkinson AB, Johnston GD, Bell PM \"A comparison of the effects of low- and conventional-dose thiazide diuretic on insulin action in hypertensive patients with NIDDM.\" Diabetologia 38 (1995): 853-9[23] Seltzer HS, Allen EW \"Hyperglycemia and inhibition of insulin secretion during administration of diazoxide and trichlormethiazide in man.\" Diabetes 18 (1969): 19-28[24] Dube MP, Johnson DL, Currier JS, Leedom JM \"Protease inhibitor-associated hyperglycaemia.\" Lancet 350 (1997): 713-4[25] Leary WP, Reyes AJ \"Drug interactions with diuretics.\" S Afr Med J 65 (1984): 455-61[26] \"Product Information. Reyataz (atazanavir).\" Bristol-Myers Squibb, Princeton, NJ.[27] Pollare T, Lithell H, Berne C \"A comparison of the effects of hydrochlorothiazide and captopril on glucose and lipid metabolism in patients with hypertension.\" N Engl J Med 321 (1989): 868-73[28] Gunnarsson R, Lundgren G, Magnusson G, Ost L, Groth CG \"Steroid diabetes--a sign of overtreatment with steroids in the renal graft recipient?\" Scand J Urol Nephrol Suppl 54 (1980): 135-8[29] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[30] \"Product Information. Synthroid (levothyroxine).\" Abbott Pharmaceutical, Abbott Park, IL.[31] Murphy MB, Kohner E, Lewis PJ, Schumer B, Dollery CT \"Glucose intolerance in hypertensive patients treated with diuretics: a fourteen-year follow-up.\" Lancet 2 (1982): 1293-5[32] \"Product Information. Fortovase (saquinavir)\" Roche Laboratories, Nutley, NJ.[33] Coni NK, Gordon PW, Mukherjee AP, Read PR \"The effect of frusemide and ethacrynic acid on carbohydrate metabolism.\" Age Ageing 3 (1974): 85-90[34] \"Product Information. Norvir (ritonavir).\" Abbott Pharmaceutical, Abbott Park, IL.[35] Domenet JG \"Diabetogenic effect of oral diuretics.\" Br Med J 3 (1968): 188[36] Rowe P, Mather H \"Hyperosmolar non-ketotic diabetes mellitus associated with metolazone.\" Br Med J 291 (1985): 25-6[37] Winchester JF, Kellett RJ, Boddy K, Boyle P, Dargie HJ, Mahaffey ME, Ward DM, Kennedy AC \"Metolazone and bendroflumethiazide in hypertension: physiologic and metabolic observations.\" Clin Pharmacol Ther 28 (1980): 611-8[38] \"Product Information. Carafate (sucralfate).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[39] Tsiodras S, Mantzoros C, Hammer S, Samore M \"Effects of protease inhibitors on hyperglycemia, hyperlipidemia, and lipodystrophy - A 5-year cohort study.\" Arch Intern Med 160 (2000): 2050-6[40] \"Product Information. Apidra (insulin glulisine).\" Aventis Pharmaceuticals, Bridgewater, NJ.[41] \"Product Information. Prezista (darunavir).\" Ortho Biotech Inc, Bridgewater, NJ.[42] Haiba NA, el-Habashy MA, Said SA, Darwish EA, Abdel-Sayed WS, Nayel SE \"Clinical evaluation of two monthly injectable contraceptives and their effects on some metabolic parameters.\" Contraception 39 (1989): 619-32[43] Erle G, Basso M, Federspil G, Sicolo N, Scandellari C \"Effect of chlorpromazine on blood glucose and plasma insulin in man.\" Eur J Clin Pharmacol 11 (1977): 15-8[44] Pickkers P, Schachter M, Hughes AD, Feher MD, Sever PS \"Thiazide-induced hyperglycaemia: a role for calcium-activated potassium channels?\" Diabetologia 39 (1996): 861-4[45] \"Product Information. Lexiva (fosamprenavir).\" GlaxoSmithKline, Research Triangle Park, NC.[46] Curtis J, Horrigan F, Ahearn D, Varney R, Sandler SG \"Chlorthalidone-induced hyperosmolar hyperglycemic nonketotic coma.\" JAMA 220 (1972): 1592-3[47] \"Product Information. Hyperstat I.V. (diazoxide).\" Schering Corp, Kenilworth, NJ.[48] \"Product Information. Piqray (alpelisib).\" Novartis Pharmaceuticals, East Hanover, NJ.[49] Bell DS \"Insulin resistance. An often unrecognized problem accompanying chronic medical disorders.\" Postgrad Med 93 (1993): 99-103,[50] Stambaugh JE, Tucker DC \"Effect of diphenylhydantoin on glucose tolerance in patients with hypoglycemia.\" Diabetes 23 (1974): 679-83[51] \"Product Information. Crixivan (indinavir).\" Merck & Co, Inc, West Point, PA.[52] Miller NR, Moses H \"Transient oculomotor nerve palsy. Association with thiazide-induced glucose intolerance.\" JAMA 240 (1978): 1887-8[53] Javier Z, Gershberg H, Hulse M \"Ovulatory suppressants, estrogens, and carbohydrate metabolism.\" Metabolism 17 (1968): 443-56[54] Goldman JA, Ovadia JL \"The effect of estrogen on intravenous glucose tolerance in woman.\" Am J Obstet Gynecol 103 (1969): 172-8[55] Charan VD, Desai N, Singh AP, Choudhry VP \"Diabetes mellitus and pancreatitis as a complication of L- asparaginase therapy.\" Indian Pediatr 30 (1993): 809-10[56] Seifer DB, Freedman LN, Cavender JR, Baker RA \"Insulin-dependent diabetes mellitus associated with danazol.\" Am J Obstet Gynecol 162 (1990): 474-5[57] \"Product Information. Orinase (tolbutamide)\" Pharmacia and Upjohn, Kalamazoo, MI.[58] Walli R, Demant T \"Impaired glucose tolerance and protease inhibitors.\" Ann Intern Med 129 (1998): 837-8[59] Hannaford PC, Kay CR \"Oral contraceptives and diabetes mellitus.\" BMJ 299 (1989): 1315-6[60] Hardy H, Esch LD, Morse GD \"Glucose disorders associated with HIV and its drug therapy.\" Ann Pharmacother 35 (2001): 343-51[61] Chowdhury FR, Bleicher SJ \"Chlorthalidone--induced hypokalemia and abnormal carbohydrate metabolism.\" Horm Metab Res 2 (1970): 13-6[62] Kaufman MB, Simionatto C \"A review of protease inhibitor-induced hyperglycemia.\" Pharmacotherapy 19 (1999): 114-7[63] Greenstone MA, Shaw AB \"Alternate day corticosteroid causes alternate day hyperglycaemia.\" Postgrad Med J 63 (1987): 761-4[64] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[65] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[66] Elmfeldt D, Berglund G, Wedel H, Wilhelmsen L \"Incidence and importance of metabolic side-effects during antihypertensive therapy.\" Acta Med Scand Suppl 672 (1983): 79-83[67] \"Product Information. Agenerase (amprenavir).\" Glaxo Wellcome, Research Triangle Pk, NC.[68] Diamond MT \"Hyperglycemic hyperosmolar coma associated with hydrochlorothiazide and pancreatitis.\" N Y State J Med 72 (1972): 1741-2[69] \"Product Information. Prandin (repaglinide).\" Novo Nordisk Pharmaceuticals Inc, Princeton, NJ.[70] \"Product Information. Precose (acarbose).\" Bayer, West Haven, CT.[71] \"Product Information. Starlix (nateglinide)\" Novartis Pharmaceuticals, East Hanover, NJ.[72] \"Product Information. Oncaspar (pegaspargase).\" Rhone-Poulenc Rorer, Collegeville, PA.[73] Sotaniemi E, Kontturi M, Larmi T \"Effect of diethylstilbestrol on blood glucose of prostatic cancer patients.\" Invest Urol 10 (1973): 438-41[74] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[75] Petri M, Cumber P, Grimes L, Treby D, Bryant R, Rawlins D, Ising H \"The metabolic effects of thiazide therapy in the elderly: a population study.\" Age Ageing 15 (1986): 151-5[76] Ludvik B, Clodi M, Kautzky-Willer A, Capek M, Hartter E, Pacini G, Prager R \"Effect of dexamethasone on insulin sensitivity, islet amyloid polypeptide and insulin secretion in humans.\" Diabetologia 36 (1993): 84-7[77] \"Product Information. Glucophage (metformin).\" Bristol-Myers Squibb, Princeton, NJ.[78] Chaudhuri ML, Catania J \"A comparison of the effects of bumetanide (Burinex) and frusemide on carbohydrate metabolism in the elderly.\" Br J Clin Pract 42 (1988): 427-9[79] Black DM, Filak AT \"Hyperglycemia with non-insulin-dependent diabetes following intraarticular steroid injection.\" J Fam Pract 28 (1989): 462-3[80] \"Product Information. Megace (megestrol).\" Bristol-Myers Squibb, Princeton, NJ.[81] \"Product Information. Torisel (temsirolimus).\" Wyeth-Ayerst Laboratories, Philadelphia, PA.[82] Schmitz O, Hermansen K, Nielsen OH, Christensen CK, Arnfred J, Hansen HE, Mogensen CE, Orskov H, Beck-Nielsen H \"Insulin action in insulin-dependent diabetics after short-term thiazide therapy.\" Diabetes Care 9 (1986): 631-6[83] Kansal PC, Buse J, Buse MG \"Thiazide diuretics and control of diabetes mellitus.\" South Med J 62 (1969): 1372-9[84] Dimitriadis G, Tegos C, Golfinopoulou L, Roboti C, Raptis S \"Furosemide-induced hyperglycaemia - the implication of glycolytic kinases.\" Horm Metab Res 25 (1993): 557-9[85] \"Product Information. NovoLog Mix 70/30 (insulin aspart-insulin aspart protamine).\" Novo Nordisk Pharmaceuticals Inc, Princeton, NJ.[86] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[87] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[88] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[89] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42[90] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[91] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[92] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[93] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[94] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[95] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6", "alternatives_a": "Simvastatin, Guar gum, Rosuvastatin", "alternatives_b": "", "updated_at": 1767369485}, {"id": 97882, "ingredient1": "Estradiol (topical)", "ingredient2": "Empagliflozin", "severity": "Moderate", "effect": "The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.", "source": "DDInter", "management_text": "Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.", "mechanism_text": "Antagonism", "recommendation": "Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97986/", "reference_text": "[1] Jori A, Carrara MC \"On the mechanism of the hyperglycaemic effect of chlorpromazine.\" J Pharm Pharmacol 18 (1966): 623-4[2] \"Product Information. Dymelor (acetohexamide)\" Lilly, Eli and Company, Indianapolis, IN.[3] \"Product Information. Thorazine (chlorpromazine).\" SmithKline Beecham, Philadelphia, PA.[4] Blayac JP, Ribes G, Buys D, Puech R, Loubatieres-Mariani MM \"Effects of a new benzothiadiazine derivative, LN 5330, on insulin secretion.\" Arch Int Pharmacodyn Ther 253 (1981): 154-63[5] \"Product Information. Elzonris (tagraxofusp).\" Stemline Therapeutics, New York, NY.[6] \"Product Information. Amaryl (glimepiride).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[7] \"Product Information. Elspar (asparaginase).\" Merck & Co, Inc, West Point, PA.[8] Jones IG, Pickens PT \"Diabetes mellitus following oral diuretics.\" Practitioner 199 (1967): 209-10[9] \"Product Information. Viracept (nelfinavir).\" Agouron Pharma Inc, La Jolla, CA.[10] \"Product Information. Tolinase (tolazamide)\" Pharmacia and Upjohn, Kalamazoo, MI.[11] Mauss S, Wolf E, Jaeger H \"Impaired glucose tolerance in HIV-positive patients receiving and those not receiving protease inhibitors.\" Ann Intern Med 130 (1999): 162-3[12] Virutamasen P, Wongsrichanalai C, Tangkeo P, Nitichai Y, Rienprayoon D \"Metabolic effects of depot-medroxyprogesterone acetate in long-term users: a cross-sectional study.\" Int J Gynaecol Obstet 24 (1986): 291-6[13] Wehring H, Alexander B, Perry PJ \"Diabetes mellitus associated with clozapine therapy.\" Pharmacotherapy 20 (2000): 844-7[14] Spellacy WN, Ellingson AB, Tsibris JC \"The effects of two triphasic oral contraceptives on carbohydrate metabolism in women during 1 year of use.\" Fertil Steril 51 (1989): 71-4[15] Andersen OO, Persson I \"Carbohydrate metabolism during treatment with chlorthalidone and ethacrynic acid.\" Br Med J 2 (1968): 798-801[16] Berlin I \"Prazosin, diuretics, and glucose intolerance.\" Ann Intern Med 119 (1993): 860[17] Malherbe C, Burrill KC, Levin SR, Karam JH, Forsham PH \"Effect of diphenylhydantoin on insulin secretion in man.\" N Engl J Med 286 (1972): 339-42[18] Carter BL, Small RE, Mandel MD, Starkman MT \"Phenytoin-induced hyperglycemia.\" Am J Hosp Pharm 38 (1981): 1508-12[19] Al-Rubeaan K, Ryan EA \"Phenytoin-induced insulin insensitivity.\" Diabet Med 8 (1991): 968-70[20] \"Product Information. Zolinza (vorinostat).\" Merck & Company Inc, West Point, PA.[21] Goldman JA, Neri A, Ovadia J, Eckerling B, Vries A, de \"Effect of chlorothiazide on intravenous glucose tolerance in pregnancy.\" Am J Obstet Gynecol 105 (1969): 556-60[22] Harper R, Ennis CN, Heaney AP, Sheridan B, Gormley M, Atkinson AB, Johnston GD, Bell PM \"A comparison of the effects of low- and conventional-dose thiazide diuretic on insulin action in hypertensive patients with NIDDM.\" Diabetologia 38 (1995): 853-9[23] Seltzer HS, Allen EW \"Hyperglycemia and inhibition of insulin secretion during administration of diazoxide and trichlormethiazide in man.\" Diabetes 18 (1969): 19-28[24] Dube MP, Johnson DL, Currier JS, Leedom JM \"Protease inhibitor-associated hyperglycaemia.\" Lancet 350 (1997): 713-4[25] Leary WP, Reyes AJ \"Drug interactions with diuretics.\" S Afr Med J 65 (1984): 455-61[26] \"Product Information. Reyataz (atazanavir).\" Bristol-Myers Squibb, Princeton, NJ.[27] Pollare T, Lithell H, Berne C \"A comparison of the effects of hydrochlorothiazide and captopril on glucose and lipid metabolism in patients with hypertension.\" N Engl J Med 321 (1989): 868-73[28] Gunnarsson R, Lundgren G, Magnusson G, Ost L, Groth CG \"Steroid diabetes--a sign of overtreatment with steroids in the renal graft recipient?\" Scand J Urol Nephrol Suppl 54 (1980): 135-8[29] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[30] \"Product Information. Synthroid (levothyroxine).\" Abbott Pharmaceutical, Abbott Park, IL.[31] Murphy MB, Kohner E, Lewis PJ, Schumer B, Dollery CT \"Glucose intolerance in hypertensive patients treated with diuretics: a fourteen-year follow-up.\" Lancet 2 (1982): 1293-5[32] \"Product Information. Fortovase (saquinavir)\" Roche Laboratories, Nutley, NJ.[33] Coni NK, Gordon PW, Mukherjee AP, Read PR \"The effect of frusemide and ethacrynic acid on carbohydrate metabolism.\" Age Ageing 3 (1974): 85-90[34] \"Product Information. Norvir (ritonavir).\" Abbott Pharmaceutical, Abbott Park, IL.[35] Domenet JG \"Diabetogenic effect of oral diuretics.\" Br Med J 3 (1968): 188[36] Rowe P, Mather H \"Hyperosmolar non-ketotic diabetes mellitus associated with metolazone.\" Br Med J 291 (1985): 25-6[37] Winchester JF, Kellett RJ, Boddy K, Boyle P, Dargie HJ, Mahaffey ME, Ward DM, Kennedy AC \"Metolazone and bendroflumethiazide in hypertension: physiologic and metabolic observations.\" Clin Pharmacol Ther 28 (1980): 611-8[38] \"Product Information. Carafate (sucralfate).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[39] Tsiodras S, Mantzoros C, Hammer S, Samore M \"Effects of protease inhibitors on hyperglycemia, hyperlipidemia, and lipodystrophy - A 5-year cohort study.\" Arch Intern Med 160 (2000): 2050-6[40] \"Product Information. Apidra (insulin glulisine).\" Aventis Pharmaceuticals, Bridgewater, NJ.[41] \"Product Information. Prezista (darunavir).\" Ortho Biotech Inc, Bridgewater, NJ.[42] Haiba NA, el-Habashy MA, Said SA, Darwish EA, Abdel-Sayed WS, Nayel SE \"Clinical evaluation of two monthly injectable contraceptives and their effects on some metabolic parameters.\" Contraception 39 (1989): 619-32[43] Erle G, Basso M, Federspil G, Sicolo N, Scandellari C \"Effect of chlorpromazine on blood glucose and plasma insulin in man.\" Eur J Clin Pharmacol 11 (1977): 15-8[44] Pickkers P, Schachter M, Hughes AD, Feher MD, Sever PS \"Thiazide-induced hyperglycaemia: a role for calcium-activated potassium channels?\" Diabetologia 39 (1996): 861-4[45] \"Product Information. Lexiva (fosamprenavir).\" GlaxoSmithKline, Research Triangle Park, NC.[46] Curtis J, Horrigan F, Ahearn D, Varney R, Sandler SG \"Chlorthalidone-induced hyperosmolar hyperglycemic nonketotic coma.\" JAMA 220 (1972): 1592-3[47] \"Product Information. Hyperstat I.V. (diazoxide).\" Schering Corp, Kenilworth, NJ.[48] \"Product Information. Piqray (alpelisib).\" Novartis Pharmaceuticals, East Hanover, NJ.[49] Bell DS \"Insulin resistance. An often unrecognized problem accompanying chronic medical disorders.\" Postgrad Med 93 (1993): 99-103,[50] Stambaugh JE, Tucker DC \"Effect of diphenylhydantoin on glucose tolerance in patients with hypoglycemia.\" Diabetes 23 (1974): 679-83[51] \"Product Information. Crixivan (indinavir).\" Merck & Co, Inc, West Point, PA.[52] Miller NR, Moses H \"Transient oculomotor nerve palsy. Association with thiazide-induced glucose intolerance.\" JAMA 240 (1978): 1887-8[53] Javier Z, Gershberg H, Hulse M \"Ovulatory suppressants, estrogens, and carbohydrate metabolism.\" Metabolism 17 (1968): 443-56[54] Goldman JA, Ovadia JL \"The effect of estrogen on intravenous glucose tolerance in woman.\" Am J Obstet Gynecol 103 (1969): 172-8[55] Charan VD, Desai N, Singh AP, Choudhry VP \"Diabetes mellitus and pancreatitis as a complication of L- asparaginase therapy.\" Indian Pediatr 30 (1993): 809-10[56] Seifer DB, Freedman LN, Cavender JR, Baker RA \"Insulin-dependent diabetes mellitus associated with danazol.\" Am J Obstet Gynecol 162 (1990): 474-5[57] \"Product Information. Orinase (tolbutamide)\" Pharmacia and Upjohn, Kalamazoo, MI.[58] Walli R, Demant T \"Impaired glucose tolerance and protease inhibitors.\" Ann Intern Med 129 (1998): 837-8[59] Hannaford PC, Kay CR \"Oral contraceptives and diabetes mellitus.\" BMJ 299 (1989): 1315-6[60] Hardy H, Esch LD, Morse GD \"Glucose disorders associated with HIV and its drug therapy.\" Ann Pharmacother 35 (2001): 343-51[61] Chowdhury FR, Bleicher SJ \"Chlorthalidone--induced hypokalemia and abnormal carbohydrate metabolism.\" Horm Metab Res 2 (1970): 13-6[62] Kaufman MB, Simionatto C \"A review of protease inhibitor-induced hyperglycemia.\" Pharmacotherapy 19 (1999): 114-7[63] Greenstone MA, Shaw AB \"Alternate day corticosteroid causes alternate day hyperglycaemia.\" Postgrad Med J 63 (1987): 761-4[64] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[65] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[66] Elmfeldt D, Berglund G, Wedel H, Wilhelmsen L \"Incidence and importance of metabolic side-effects during antihypertensive therapy.\" Acta Med Scand Suppl 672 (1983): 79-83[67] \"Product Information. Agenerase (amprenavir).\" Glaxo Wellcome, Research Triangle Pk, NC.[68] Diamond MT \"Hyperglycemic hyperosmolar coma associated with hydrochlorothiazide and pancreatitis.\" N Y State J Med 72 (1972): 1741-2[69] \"Product Information. Prandin (repaglinide).\" Novo Nordisk Pharmaceuticals Inc, Princeton, NJ.[70] \"Product Information. Precose (acarbose).\" Bayer, West Haven, CT.[71] \"Product Information. Starlix (nateglinide)\" Novartis Pharmaceuticals, East Hanover, NJ.[72] \"Product Information. Oncaspar (pegaspargase).\" Rhone-Poulenc Rorer, Collegeville, PA.[73] Sotaniemi E, Kontturi M, Larmi T \"Effect of diethylstilbestrol on blood glucose of prostatic cancer patients.\" Invest Urol 10 (1973): 438-41[74] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[75] Petri M, Cumber P, Grimes L, Treby D, Bryant R, Rawlins D, Ising H \"The metabolic effects of thiazide therapy in the elderly: a population study.\" Age Ageing 15 (1986): 151-5[76] Ludvik B, Clodi M, Kautzky-Willer A, Capek M, Hartter E, Pacini G, Prager R \"Effect of dexamethasone on insulin sensitivity, islet amyloid polypeptide and insulin secretion in humans.\" Diabetologia 36 (1993): 84-7[77] \"Product Information. Glucophage (metformin).\" Bristol-Myers Squibb, Princeton, NJ.[78] Chaudhuri ML, Catania J \"A comparison of the effects of bumetanide (Burinex) and frusemide on carbohydrate metabolism in the elderly.\" Br J Clin Pract 42 (1988): 427-9[79] Black DM, Filak AT \"Hyperglycemia with non-insulin-dependent diabetes following intraarticular steroid injection.\" J Fam Pract 28 (1989): 462-3[80] \"Product Information. Megace (megestrol).\" Bristol-Myers Squibb, Princeton, NJ.[81] \"Product Information. Torisel (temsirolimus).\" Wyeth-Ayerst Laboratories, Philadelphia, PA.[82] Schmitz O, Hermansen K, Nielsen OH, Christensen CK, Arnfred J, Hansen HE, Mogensen CE, Orskov H, Beck-Nielsen H \"Insulin action in insulin-dependent diabetics after short-term thiazide therapy.\" Diabetes Care 9 (1986): 631-6[83] Kansal PC, Buse J, Buse MG \"Thiazide diuretics and control of diabetes mellitus.\" South Med J 62 (1969): 1372-9[84] Dimitriadis G, Tegos C, Golfinopoulou L, Roboti C, Raptis S \"Furosemide-induced hyperglycaemia - the implication of glycolytic kinases.\" Horm Metab Res 25 (1993): 557-9[85] \"Product Information. NovoLog Mix 70/30 (insulin aspart-insulin aspart protamine).\" Novo Nordisk Pharmaceuticals Inc, Princeton, NJ.[86] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[87] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[88] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[89] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42[90] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[91] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[92] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[93] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[94] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[95] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6", "alternatives_a": "Bazedoxifene, Testosterone, Prasterone, Methyltestosterone, Ulipristal, Norelgestromin, Nafarelin, Cetrorelix, Ganirelix, Relugolix, Gonadorelin", "alternatives_b": "Simvastatin, Guar gum, Rosuvastatin", "updated_at": 1767369485}, {"id": 97883, "ingredient1": "Estramustine", "ingredient2": "Empagliflozin", "severity": "Moderate", "effect": "The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.", "source": "DDInter", "management_text": "Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.", "mechanism_text": "Antagonism", "recommendation": "Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97987/", "reference_text": "[1] Jori A, Carrara MC \"On the mechanism of the hyperglycaemic effect of chlorpromazine.\" J Pharm Pharmacol 18 (1966): 623-4[2] \"Product Information. Dymelor (acetohexamide)\" Lilly, Eli and Company, Indianapolis, IN.[3] \"Product Information. Thorazine (chlorpromazine).\" SmithKline Beecham, Philadelphia, PA.[4] Blayac JP, Ribes G, Buys D, Puech R, Loubatieres-Mariani MM \"Effects of a new benzothiadiazine derivative, LN 5330, on insulin secretion.\" Arch Int Pharmacodyn Ther 253 (1981): 154-63[5] \"Product Information. Elzonris (tagraxofusp).\" Stemline Therapeutics, New York, NY.[6] \"Product Information. Amaryl (glimepiride).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[7] \"Product Information. Elspar (asparaginase).\" Merck & Co, Inc, West Point, PA.[8] Jones IG, Pickens PT \"Diabetes mellitus following oral diuretics.\" Practitioner 199 (1967): 209-10[9] \"Product Information. Viracept (nelfinavir).\" Agouron Pharma Inc, La Jolla, CA.[10] \"Product Information. Tolinase (tolazamide)\" Pharmacia and Upjohn, Kalamazoo, MI.[11] Mauss S, Wolf E, Jaeger H \"Impaired glucose tolerance in HIV-positive patients receiving and those not receiving protease inhibitors.\" Ann Intern Med 130 (1999): 162-3[12] Virutamasen P, Wongsrichanalai C, Tangkeo P, Nitichai Y, Rienprayoon D \"Metabolic effects of depot-medroxyprogesterone acetate in long-term users: a cross-sectional study.\" Int J Gynaecol Obstet 24 (1986): 291-6[13] Wehring H, Alexander B, Perry PJ \"Diabetes mellitus associated with clozapine therapy.\" Pharmacotherapy 20 (2000): 844-7[14] Spellacy WN, Ellingson AB, Tsibris JC \"The effects of two triphasic oral contraceptives on carbohydrate metabolism in women during 1 year of use.\" Fertil Steril 51 (1989): 71-4[15] Andersen OO, Persson I \"Carbohydrate metabolism during treatment with chlorthalidone and ethacrynic acid.\" Br Med J 2 (1968): 798-801[16] Berlin I \"Prazosin, diuretics, and glucose intolerance.\" Ann Intern Med 119 (1993): 860[17] Malherbe C, Burrill KC, Levin SR, Karam JH, Forsham PH \"Effect of diphenylhydantoin on insulin secretion in man.\" N Engl J Med 286 (1972): 339-42[18] Carter BL, Small RE, Mandel MD, Starkman MT \"Phenytoin-induced hyperglycemia.\" Am J Hosp Pharm 38 (1981): 1508-12[19] Al-Rubeaan K, Ryan EA \"Phenytoin-induced insulin insensitivity.\" Diabet Med 8 (1991): 968-70[20] \"Product Information. Zolinza (vorinostat).\" Merck & Company Inc, West Point, PA.[21] Goldman JA, Neri A, Ovadia J, Eckerling B, Vries A, de \"Effect of chlorothiazide on intravenous glucose tolerance in pregnancy.\" Am J Obstet Gynecol 105 (1969): 556-60[22] Harper R, Ennis CN, Heaney AP, Sheridan B, Gormley M, Atkinson AB, Johnston GD, Bell PM \"A comparison of the effects of low- and conventional-dose thiazide diuretic on insulin action in hypertensive patients with NIDDM.\" Diabetologia 38 (1995): 853-9[23] Seltzer HS, Allen EW \"Hyperglycemia and inhibition of insulin secretion during administration of diazoxide and trichlormethiazide in man.\" Diabetes 18 (1969): 19-28[24] Dube MP, Johnson DL, Currier JS, Leedom JM \"Protease inhibitor-associated hyperglycaemia.\" Lancet 350 (1997): 713-4[25] Leary WP, Reyes AJ \"Drug interactions with diuretics.\" S Afr Med J 65 (1984): 455-61[26] \"Product Information. Reyataz (atazanavir).\" Bristol-Myers Squibb, Princeton, NJ.[27] Pollare T, Lithell H, Berne C \"A comparison of the effects of hydrochlorothiazide and captopril on glucose and lipid metabolism in patients with hypertension.\" N Engl J Med 321 (1989): 868-73[28] Gunnarsson R, Lundgren G, Magnusson G, Ost L, Groth CG \"Steroid diabetes--a sign of overtreatment with steroids in the renal graft recipient?\" Scand J Urol Nephrol Suppl 54 (1980): 135-8[29] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[30] \"Product Information. Synthroid (levothyroxine).\" Abbott Pharmaceutical, Abbott Park, IL.[31] Murphy MB, Kohner E, Lewis PJ, Schumer B, Dollery CT \"Glucose intolerance in hypertensive patients treated with diuretics: a fourteen-year follow-up.\" Lancet 2 (1982): 1293-5[32] \"Product Information. Fortovase (saquinavir)\" Roche Laboratories, Nutley, NJ.[33] Coni NK, Gordon PW, Mukherjee AP, Read PR \"The effect of frusemide and ethacrynic acid on carbohydrate metabolism.\" Age Ageing 3 (1974): 85-90[34] \"Product Information. Norvir (ritonavir).\" Abbott Pharmaceutical, Abbott Park, IL.[35] Domenet JG \"Diabetogenic effect of oral diuretics.\" Br Med J 3 (1968): 188[36] Rowe P, Mather H \"Hyperosmolar non-ketotic diabetes mellitus associated with metolazone.\" Br Med J 291 (1985): 25-6[37] Winchester JF, Kellett RJ, Boddy K, Boyle P, Dargie HJ, Mahaffey ME, Ward DM, Kennedy AC \"Metolazone and bendroflumethiazide in hypertension: physiologic and metabolic observations.\" Clin Pharmacol Ther 28 (1980): 611-8[38] \"Product Information. Carafate (sucralfate).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[39] Tsiodras S, Mantzoros C, Hammer S, Samore M \"Effects of protease inhibitors on hyperglycemia, hyperlipidemia, and lipodystrophy - A 5-year cohort study.\" Arch Intern Med 160 (2000): 2050-6[40] \"Product Information. Apidra (insulin glulisine).\" Aventis Pharmaceuticals, Bridgewater, NJ.[41] \"Product Information. Prezista (darunavir).\" Ortho Biotech Inc, Bridgewater, NJ.[42] Haiba NA, el-Habashy MA, Said SA, Darwish EA, Abdel-Sayed WS, Nayel SE \"Clinical evaluation of two monthly injectable contraceptives and their effects on some metabolic parameters.\" Contraception 39 (1989): 619-32[43] Erle G, Basso M, Federspil G, Sicolo N, Scandellari C \"Effect of chlorpromazine on blood glucose and plasma insulin in man.\" Eur J Clin Pharmacol 11 (1977): 15-8[44] Pickkers P, Schachter M, Hughes AD, Feher MD, Sever PS \"Thiazide-induced hyperglycaemia: a role for calcium-activated potassium channels?\" Diabetologia 39 (1996): 861-4[45] \"Product Information. Lexiva (fosamprenavir).\" GlaxoSmithKline, Research Triangle Park, NC.[46] Curtis J, Horrigan F, Ahearn D, Varney R, Sandler SG \"Chlorthalidone-induced hyperosmolar hyperglycemic nonketotic coma.\" JAMA 220 (1972): 1592-3[47] \"Product Information. Hyperstat I.V. (diazoxide).\" Schering Corp, Kenilworth, NJ.[48] \"Product Information. Piqray (alpelisib).\" Novartis Pharmaceuticals, East Hanover, NJ.[49] Bell DS \"Insulin resistance. An often unrecognized problem accompanying chronic medical disorders.\" Postgrad Med 93 (1993): 99-103,[50] Stambaugh JE, Tucker DC \"Effect of diphenylhydantoin on glucose tolerance in patients with hypoglycemia.\" Diabetes 23 (1974): 679-83[51] \"Product Information. Crixivan (indinavir).\" Merck & Co, Inc, West Point, PA.[52] Miller NR, Moses H \"Transient oculomotor nerve palsy. Association with thiazide-induced glucose intolerance.\" JAMA 240 (1978): 1887-8[53] Javier Z, Gershberg H, Hulse M \"Ovulatory suppressants, estrogens, and carbohydrate metabolism.\" Metabolism 17 (1968): 443-56[54] Goldman JA, Ovadia JL \"The effect of estrogen on intravenous glucose tolerance in woman.\" Am J Obstet Gynecol 103 (1969): 172-8[55] Charan VD, Desai N, Singh AP, Choudhry VP \"Diabetes mellitus and pancreatitis as a complication of L- asparaginase therapy.\" Indian Pediatr 30 (1993): 809-10[56] Seifer DB, Freedman LN, Cavender JR, Baker RA \"Insulin-dependent diabetes mellitus associated with danazol.\" Am J Obstet Gynecol 162 (1990): 474-5[57] \"Product Information. Orinase (tolbutamide)\" Pharmacia and Upjohn, Kalamazoo, MI.[58] Walli R, Demant T \"Impaired glucose tolerance and protease inhibitors.\" Ann Intern Med 129 (1998): 837-8[59] Hannaford PC, Kay CR \"Oral contraceptives and diabetes mellitus.\" BMJ 299 (1989): 1315-6[60] Hardy H, Esch LD, Morse GD \"Glucose disorders associated with HIV and its drug therapy.\" Ann Pharmacother 35 (2001): 343-51[61] Chowdhury FR, Bleicher SJ \"Chlorthalidone--induced hypokalemia and abnormal carbohydrate metabolism.\" Horm Metab Res 2 (1970): 13-6[62] Kaufman MB, Simionatto C \"A review of protease inhibitor-induced hyperglycemia.\" Pharmacotherapy 19 (1999): 114-7[63] Greenstone MA, Shaw AB \"Alternate day corticosteroid causes alternate day hyperglycaemia.\" Postgrad Med J 63 (1987): 761-4[64] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[65] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[66] Elmfeldt D, Berglund G, Wedel H, Wilhelmsen L \"Incidence and importance of metabolic side-effects during antihypertensive therapy.\" Acta Med Scand Suppl 672 (1983): 79-83[67] \"Product Information. Agenerase (amprenavir).\" Glaxo Wellcome, Research Triangle Pk, NC.[68] Diamond MT \"Hyperglycemic hyperosmolar coma associated with hydrochlorothiazide and pancreatitis.\" N Y State J Med 72 (1972): 1741-2[69] \"Product Information. Prandin (repaglinide).\" Novo Nordisk Pharmaceuticals Inc, Princeton, NJ.[70] \"Product Information. Precose (acarbose).\" Bayer, West Haven, CT.[71] \"Product Information. Starlix (nateglinide)\" Novartis Pharmaceuticals, East Hanover, NJ.[72] \"Product Information. Oncaspar (pegaspargase).\" Rhone-Poulenc Rorer, Collegeville, PA.[73] Sotaniemi E, Kontturi M, Larmi T \"Effect of diethylstilbestrol on blood glucose of prostatic cancer patients.\" Invest Urol 10 (1973): 438-41[74] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[75] Petri M, Cumber P, Grimes L, Treby D, Bryant R, Rawlins D, Ising H \"The metabolic effects of thiazide therapy in the elderly: a population study.\" Age Ageing 15 (1986): 151-5[76] Ludvik B, Clodi M, Kautzky-Willer A, Capek M, Hartter E, Pacini G, Prager R \"Effect of dexamethasone on insulin sensitivity, islet amyloid polypeptide and insulin secretion in humans.\" Diabetologia 36 (1993): 84-7[77] \"Product Information. Glucophage (metformin).\" Bristol-Myers Squibb, Princeton, NJ.[78] Chaudhuri ML, Catania J \"A comparison of the effects of bumetanide (Burinex) and frusemide on carbohydrate metabolism in the elderly.\" Br J Clin Pract 42 (1988): 427-9[79] Black DM, Filak AT \"Hyperglycemia with non-insulin-dependent diabetes following intraarticular steroid injection.\" J Fam Pract 28 (1989): 462-3[80] \"Product Information. Megace (megestrol).\" Bristol-Myers Squibb, Princeton, NJ.[81] \"Product Information. Torisel (temsirolimus).\" Wyeth-Ayerst Laboratories, Philadelphia, PA.[82] Schmitz O, Hermansen K, Nielsen OH, Christensen CK, Arnfred J, Hansen HE, Mogensen CE, Orskov H, Beck-Nielsen H \"Insulin action in insulin-dependent diabetics after short-term thiazide therapy.\" Diabetes Care 9 (1986): 631-6[83] Kansal PC, Buse J, Buse MG \"Thiazide diuretics and control of diabetes mellitus.\" South Med J 62 (1969): 1372-9[84] Dimitriadis G, Tegos C, Golfinopoulou L, Roboti C, Raptis S \"Furosemide-induced hyperglycaemia - the implication of glycolytic kinases.\" Horm Metab Res 25 (1993): 557-9[85] \"Product Information. NovoLog Mix 70/30 (insulin aspart-insulin aspart protamine).\" Novo Nordisk Pharmaceuticals Inc, Princeton, NJ.[86] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[87] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[88] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[89] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42[90] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[91] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[92] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[93] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[94] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[95] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6", "alternatives_a": "Pertuzumab, Olaparib, Oxaliplatin, Rucaparib, Tisagenlecleucel, Aminolevulinic acid, Tazemetostat, Altretamine, Ixazomib, Sotorasib, Belzutifan, More", "alternatives_b": "Simvastatin, Guar gum, Rosuvastatin", "updated_at": 1767369485}, {"id": 97884, "ingredient1": "Estrone", "ingredient2": "Empagliflozin", "severity": "Moderate", "effect": "The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.", "source": "DDInter", "management_text": "Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.", "mechanism_text": "Antagonism", "recommendation": "Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97988/", "reference_text": "[1] Jori A, Carrara MC \"On the mechanism of the hyperglycaemic effect of chlorpromazine.\" J Pharm Pharmacol 18 (1966): 623-4[2] \"Product Information. Dymelor (acetohexamide)\" Lilly, Eli and Company, Indianapolis, IN.[3] \"Product Information. Thorazine (chlorpromazine).\" SmithKline Beecham, Philadelphia, PA.[4] Blayac JP, Ribes G, Buys D, Puech R, Loubatieres-Mariani MM \"Effects of a new benzothiadiazine derivative, LN 5330, on insulin secretion.\" Arch Int Pharmacodyn Ther 253 (1981): 154-63[5] \"Product Information. Elzonris (tagraxofusp).\" Stemline Therapeutics, New York, NY.[6] \"Product Information. Amaryl (glimepiride).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[7] \"Product Information. Elspar (asparaginase).\" Merck & Co, Inc, West Point, PA.[8] Jones IG, Pickens PT \"Diabetes mellitus following oral diuretics.\" Practitioner 199 (1967): 209-10[9] \"Product Information. Viracept (nelfinavir).\" Agouron Pharma Inc, La Jolla, CA.[10] \"Product Information. Tolinase (tolazamide)\" Pharmacia and Upjohn, Kalamazoo, MI.[11] Mauss S, Wolf E, Jaeger H \"Impaired glucose tolerance in HIV-positive patients receiving and those not receiving protease inhibitors.\" Ann Intern Med 130 (1999): 162-3[12] Virutamasen P, Wongsrichanalai C, Tangkeo P, Nitichai Y, Rienprayoon D \"Metabolic effects of depot-medroxyprogesterone acetate in long-term users: a cross-sectional study.\" Int J Gynaecol Obstet 24 (1986): 291-6[13] Wehring H, Alexander B, Perry PJ \"Diabetes mellitus associated with clozapine therapy.\" Pharmacotherapy 20 (2000): 844-7[14] Spellacy WN, Ellingson AB, Tsibris JC \"The effects of two triphasic oral contraceptives on carbohydrate metabolism in women during 1 year of use.\" Fertil Steril 51 (1989): 71-4[15] Andersen OO, Persson I \"Carbohydrate metabolism during treatment with chlorthalidone and ethacrynic acid.\" Br Med J 2 (1968): 798-801[16] Berlin I \"Prazosin, diuretics, and glucose intolerance.\" Ann Intern Med 119 (1993): 860[17] Malherbe C, Burrill KC, Levin SR, Karam JH, Forsham PH \"Effect of diphenylhydantoin on insulin secretion in man.\" N Engl J Med 286 (1972): 339-42[18] Carter BL, Small RE, Mandel MD, Starkman MT \"Phenytoin-induced hyperglycemia.\" Am J Hosp Pharm 38 (1981): 1508-12[19] Al-Rubeaan K, Ryan EA \"Phenytoin-induced insulin insensitivity.\" Diabet Med 8 (1991): 968-70[20] \"Product Information. Zolinza (vorinostat).\" Merck & Company Inc, West Point, PA.[21] Goldman JA, Neri A, Ovadia J, Eckerling B, Vries A, de \"Effect of chlorothiazide on intravenous glucose tolerance in pregnancy.\" Am J Obstet Gynecol 105 (1969): 556-60[22] Harper R, Ennis CN, Heaney AP, Sheridan B, Gormley M, Atkinson AB, Johnston GD, Bell PM \"A comparison of the effects of low- and conventional-dose thiazide diuretic on insulin action in hypertensive patients with NIDDM.\" Diabetologia 38 (1995): 853-9[23] Seltzer HS, Allen EW \"Hyperglycemia and inhibition of insulin secretion during administration of diazoxide and trichlormethiazide in man.\" Diabetes 18 (1969): 19-28[24] Dube MP, Johnson DL, Currier JS, Leedom JM \"Protease inhibitor-associated hyperglycaemia.\" Lancet 350 (1997): 713-4[25] Leary WP, Reyes AJ \"Drug interactions with diuretics.\" S Afr Med J 65 (1984): 455-61[26] \"Product Information. Reyataz (atazanavir).\" Bristol-Myers Squibb, Princeton, NJ.[27] Pollare T, Lithell H, Berne C \"A comparison of the effects of hydrochlorothiazide and captopril on glucose and lipid metabolism in patients with hypertension.\" N Engl J Med 321 (1989): 868-73[28] Gunnarsson R, Lundgren G, Magnusson G, Ost L, Groth CG \"Steroid diabetes--a sign of overtreatment with steroids in the renal graft recipient?\" Scand J Urol Nephrol Suppl 54 (1980): 135-8[29] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[30] \"Product Information. Synthroid (levothyroxine).\" Abbott Pharmaceutical, Abbott Park, IL.[31] Murphy MB, Kohner E, Lewis PJ, Schumer B, Dollery CT \"Glucose intolerance in hypertensive patients treated with diuretics: a fourteen-year follow-up.\" Lancet 2 (1982): 1293-5[32] \"Product Information. Fortovase (saquinavir)\" Roche Laboratories, Nutley, NJ.[33] Coni NK, Gordon PW, Mukherjee AP, Read PR \"The effect of frusemide and ethacrynic acid on carbohydrate metabolism.\" Age Ageing 3 (1974): 85-90[34] \"Product Information. Norvir (ritonavir).\" Abbott Pharmaceutical, Abbott Park, IL.[35] Domenet JG \"Diabetogenic effect of oral diuretics.\" Br Med J 3 (1968): 188[36] Rowe P, Mather H \"Hyperosmolar non-ketotic diabetes mellitus associated with metolazone.\" Br Med J 291 (1985): 25-6[37] Winchester JF, Kellett RJ, Boddy K, Boyle P, Dargie HJ, Mahaffey ME, Ward DM, Kennedy AC \"Metolazone and bendroflumethiazide in hypertension: physiologic and metabolic observations.\" Clin Pharmacol Ther 28 (1980): 611-8[38] \"Product Information. Carafate (sucralfate).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[39] Tsiodras S, Mantzoros C, Hammer S, Samore M \"Effects of protease inhibitors on hyperglycemia, hyperlipidemia, and lipodystrophy - A 5-year cohort study.\" Arch Intern Med 160 (2000): 2050-6[40] \"Product Information. Apidra (insulin glulisine).\" Aventis Pharmaceuticals, Bridgewater, NJ.[41] \"Product Information. Prezista (darunavir).\" Ortho Biotech Inc, Bridgewater, NJ.[42] Haiba NA, el-Habashy MA, Said SA, Darwish EA, Abdel-Sayed WS, Nayel SE \"Clinical evaluation of two monthly injectable contraceptives and their effects on some metabolic parameters.\" Contraception 39 (1989): 619-32[43] Erle G, Basso M, Federspil G, Sicolo N, Scandellari C \"Effect of chlorpromazine on blood glucose and plasma insulin in man.\" Eur J Clin Pharmacol 11 (1977): 15-8[44] Pickkers P, Schachter M, Hughes AD, Feher MD, Sever PS \"Thiazide-induced hyperglycaemia: a role for calcium-activated potassium channels?\" Diabetologia 39 (1996): 861-4[45] \"Product Information. Lexiva (fosamprenavir).\" GlaxoSmithKline, Research Triangle Park, NC.[46] Curtis J, Horrigan F, Ahearn D, Varney R, Sandler SG \"Chlorthalidone-induced hyperosmolar hyperglycemic nonketotic coma.\" JAMA 220 (1972): 1592-3[47] \"Product Information. Hyperstat I.V. (diazoxide).\" Schering Corp, Kenilworth, NJ.[48] \"Product Information. Piqray (alpelisib).\" Novartis Pharmaceuticals, East Hanover, NJ.[49] Bell DS \"Insulin resistance. An often unrecognized problem accompanying chronic medical disorders.\" Postgrad Med 93 (1993): 99-103,[50] Stambaugh JE, Tucker DC \"Effect of diphenylhydantoin on glucose tolerance in patients with hypoglycemia.\" Diabetes 23 (1974): 679-83[51] \"Product Information. Crixivan (indinavir).\" Merck & Co, Inc, West Point, PA.[52] Miller NR, Moses H \"Transient oculomotor nerve palsy. Association with thiazide-induced glucose intolerance.\" JAMA 240 (1978): 1887-8[53] Javier Z, Gershberg H, Hulse M \"Ovulatory suppressants, estrogens, and carbohydrate metabolism.\" Metabolism 17 (1968): 443-56[54] Goldman JA, Ovadia JL \"The effect of estrogen on intravenous glucose tolerance in woman.\" Am J Obstet Gynecol 103 (1969): 172-8[55] Charan VD, Desai N, Singh AP, Choudhry VP \"Diabetes mellitus and pancreatitis as a complication of L- asparaginase therapy.\" Indian Pediatr 30 (1993): 809-10[56] Seifer DB, Freedman LN, Cavender JR, Baker RA \"Insulin-dependent diabetes mellitus associated with danazol.\" Am J Obstet Gynecol 162 (1990): 474-5[57] \"Product Information. Orinase (tolbutamide)\" Pharmacia and Upjohn, Kalamazoo, MI.[58] Walli R, Demant T \"Impaired glucose tolerance and protease inhibitors.\" Ann Intern Med 129 (1998): 837-8[59] Hannaford PC, Kay CR \"Oral contraceptives and diabetes mellitus.\" BMJ 299 (1989): 1315-6[60] Hardy H, Esch LD, Morse GD \"Glucose disorders associated with HIV and its drug therapy.\" Ann Pharmacother 35 (2001): 343-51[61] Chowdhury FR, Bleicher SJ \"Chlorthalidone--induced hypokalemia and abnormal carbohydrate metabolism.\" Horm Metab Res 2 (1970): 13-6[62] Kaufman MB, Simionatto C \"A review of protease inhibitor-induced hyperglycemia.\" Pharmacotherapy 19 (1999): 114-7[63] Greenstone MA, Shaw AB \"Alternate day corticosteroid causes alternate day hyperglycaemia.\" Postgrad Med J 63 (1987): 761-4[64] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[65] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[66] Elmfeldt D, Berglund G, Wedel H, Wilhelmsen L \"Incidence and importance of metabolic side-effects during antihypertensive therapy.\" Acta Med Scand Suppl 672 (1983): 79-83[67] \"Product Information. Agenerase (amprenavir).\" Glaxo Wellcome, Research Triangle Pk, NC.[68] Diamond MT \"Hyperglycemic hyperosmolar coma associated with hydrochlorothiazide and pancreatitis.\" N Y State J Med 72 (1972): 1741-2[69] \"Product Information. Prandin (repaglinide).\" Novo Nordisk Pharmaceuticals Inc, Princeton, NJ.[70] \"Product Information. Precose (acarbose).\" Bayer, West Haven, CT.[71] \"Product Information. Starlix (nateglinide)\" Novartis Pharmaceuticals, East Hanover, NJ.[72] \"Product Information. Oncaspar (pegaspargase).\" Rhone-Poulenc Rorer, Collegeville, PA.[73] Sotaniemi E, Kontturi M, Larmi T \"Effect of diethylstilbestrol on blood glucose of prostatic cancer patients.\" Invest Urol 10 (1973): 438-41[74] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[75] Petri M, Cumber P, Grimes L, Treby D, Bryant R, Rawlins D, Ising H \"The metabolic effects of thiazide therapy in the elderly: a population study.\" Age Ageing 15 (1986): 151-5[76] Ludvik B, Clodi M, Kautzky-Willer A, Capek M, Hartter E, Pacini G, Prager R \"Effect of dexamethasone on insulin sensitivity, islet amyloid polypeptide and insulin secretion in humans.\" Diabetologia 36 (1993): 84-7[77] \"Product Information. Glucophage (metformin).\" Bristol-Myers Squibb, Princeton, NJ.[78] Chaudhuri ML, Catania J \"A comparison of the effects of bumetanide (Burinex) and frusemide on carbohydrate metabolism in the elderly.\" Br J Clin Pract 42 (1988): 427-9[79] Black DM, Filak AT \"Hyperglycemia with non-insulin-dependent diabetes following intraarticular steroid injection.\" J Fam Pract 28 (1989): 462-3[80] \"Product Information. Megace (megestrol).\" Bristol-Myers Squibb, Princeton, NJ.[81] \"Product Information. Torisel (temsirolimus).\" Wyeth-Ayerst Laboratories, Philadelphia, PA.[82] Schmitz O, Hermansen K, Nielsen OH, Christensen CK, Arnfred J, Hansen HE, Mogensen CE, Orskov H, Beck-Nielsen H \"Insulin action in insulin-dependent diabetics after short-term thiazide therapy.\" Diabetes Care 9 (1986): 631-6[83] Kansal PC, Buse J, Buse MG \"Thiazide diuretics and control of diabetes mellitus.\" South Med J 62 (1969): 1372-9[84] Dimitriadis G, Tegos C, Golfinopoulou L, Roboti C, Raptis S \"Furosemide-induced hyperglycaemia - the implication of glycolytic kinases.\" Horm Metab Res 25 (1993): 557-9[85] \"Product Information. NovoLog Mix 70/30 (insulin aspart-insulin aspart protamine).\" Novo Nordisk Pharmaceuticals Inc, Princeton, NJ.[86] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[87] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[88] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[89] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42[90] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[91] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[92] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[93] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[94] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[95] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6", "alternatives_a": "Bazedoxifene", "alternatives_b": "Acetohexamide, Guar gum, Simvastatin, Troglitazone, Rosuvastatin", "updated_at": 1767369485}, {"id": 97885, "ingredient1": "Estrone sulfate", "ingredient2": "Empagliflozin", "severity": "Moderate", "effect": "The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.", "source": "DDInter", "management_text": "Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.", "mechanism_text": "Antagonism", "recommendation": "Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97989/", "reference_text": "[1] Jori A, Carrara MC \"On the mechanism of the hyperglycaemic effect of chlorpromazine.\" J Pharm Pharmacol 18 (1966): 623-4[2] \"Product Information. Dymelor (acetohexamide)\" Lilly, Eli and Company, Indianapolis, IN.[3] \"Product Information. Thorazine (chlorpromazine).\" SmithKline Beecham, Philadelphia, PA.[4] Blayac JP, Ribes G, Buys D, Puech R, Loubatieres-Mariani MM \"Effects of a new benzothiadiazine derivative, LN 5330, on insulin secretion.\" Arch Int Pharmacodyn Ther 253 (1981): 154-63[5] \"Product Information. Elzonris (tagraxofusp).\" Stemline Therapeutics, New York, NY.[6] \"Product Information. Amaryl (glimepiride).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[7] \"Product Information. Elspar (asparaginase).\" Merck & Co, Inc, West Point, PA.[8] Jones IG, Pickens PT \"Diabetes mellitus following oral diuretics.\" Practitioner 199 (1967): 209-10[9] \"Product Information. Viracept (nelfinavir).\" Agouron Pharma Inc, La Jolla, CA.[10] \"Product Information. Tolinase (tolazamide)\" Pharmacia and Upjohn, Kalamazoo, MI.[11] Mauss S, Wolf E, Jaeger H \"Impaired glucose tolerance in HIV-positive patients receiving and those not receiving protease inhibitors.\" Ann Intern Med 130 (1999): 162-3[12] Virutamasen P, Wongsrichanalai C, Tangkeo P, Nitichai Y, Rienprayoon D \"Metabolic effects of depot-medroxyprogesterone acetate in long-term users: a cross-sectional study.\" Int J Gynaecol Obstet 24 (1986): 291-6[13] Wehring H, Alexander B, Perry PJ \"Diabetes mellitus associated with clozapine therapy.\" Pharmacotherapy 20 (2000): 844-7[14] Spellacy WN, Ellingson AB, Tsibris JC \"The effects of two triphasic oral contraceptives on carbohydrate metabolism in women during 1 year of use.\" Fertil Steril 51 (1989): 71-4[15] Andersen OO, Persson I \"Carbohydrate metabolism during treatment with chlorthalidone and ethacrynic acid.\" Br Med J 2 (1968): 798-801[16] Berlin I \"Prazosin, diuretics, and glucose intolerance.\" Ann Intern Med 119 (1993): 860[17] Malherbe C, Burrill KC, Levin SR, Karam JH, Forsham PH \"Effect of diphenylhydantoin on insulin secretion in man.\" N Engl J Med 286 (1972): 339-42[18] Carter BL, Small RE, Mandel MD, Starkman MT \"Phenytoin-induced hyperglycemia.\" Am J Hosp Pharm 38 (1981): 1508-12[19] Al-Rubeaan K, Ryan EA \"Phenytoin-induced insulin insensitivity.\" Diabet Med 8 (1991): 968-70[20] \"Product Information. Zolinza (vorinostat).\" Merck & Company Inc, West Point, PA.[21] Goldman JA, Neri A, Ovadia J, Eckerling B, Vries A, de \"Effect of chlorothiazide on intravenous glucose tolerance in pregnancy.\" Am J Obstet Gynecol 105 (1969): 556-60[22] Harper R, Ennis CN, Heaney AP, Sheridan B, Gormley M, Atkinson AB, Johnston GD, Bell PM \"A comparison of the effects of low- and conventional-dose thiazide diuretic on insulin action in hypertensive patients with NIDDM.\" Diabetologia 38 (1995): 853-9[23] Seltzer HS, Allen EW \"Hyperglycemia and inhibition of insulin secretion during administration of diazoxide and trichlormethiazide in man.\" Diabetes 18 (1969): 19-28[24] Dube MP, Johnson DL, Currier JS, Leedom JM \"Protease inhibitor-associated hyperglycaemia.\" Lancet 350 (1997): 713-4[25] Leary WP, Reyes AJ \"Drug interactions with diuretics.\" S Afr Med J 65 (1984): 455-61[26] \"Product Information. Reyataz (atazanavir).\" Bristol-Myers Squibb, Princeton, NJ.[27] Pollare T, Lithell H, Berne C \"A comparison of the effects of hydrochlorothiazide and captopril on glucose and lipid metabolism in patients with hypertension.\" N Engl J Med 321 (1989): 868-73[28] Gunnarsson R, Lundgren G, Magnusson G, Ost L, Groth CG \"Steroid diabetes--a sign of overtreatment with steroids in the renal graft recipient?\" Scand J Urol Nephrol Suppl 54 (1980): 135-8[29] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[30] \"Product Information. Synthroid (levothyroxine).\" Abbott Pharmaceutical, Abbott Park, IL.[31] Murphy MB, Kohner E, Lewis PJ, Schumer B, Dollery CT \"Glucose intolerance in hypertensive patients treated with diuretics: a fourteen-year follow-up.\" Lancet 2 (1982): 1293-5[32] \"Product Information. Fortovase (saquinavir)\" Roche Laboratories, Nutley, NJ.[33] Coni NK, Gordon PW, Mukherjee AP, Read PR \"The effect of frusemide and ethacrynic acid on carbohydrate metabolism.\" Age Ageing 3 (1974): 85-90[34] \"Product Information. Norvir (ritonavir).\" Abbott Pharmaceutical, Abbott Park, IL.[35] Domenet JG \"Diabetogenic effect of oral diuretics.\" Br Med J 3 (1968): 188[36] Rowe P, Mather H \"Hyperosmolar non-ketotic diabetes mellitus associated with metolazone.\" Br Med J 291 (1985): 25-6[37] Winchester JF, Kellett RJ, Boddy K, Boyle P, Dargie HJ, Mahaffey ME, Ward DM, Kennedy AC \"Metolazone and bendroflumethiazide in hypertension: physiologic and metabolic observations.\" Clin Pharmacol Ther 28 (1980): 611-8[38] \"Product Information. Carafate (sucralfate).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[39] Tsiodras S, Mantzoros C, Hammer S, Samore M \"Effects of protease inhibitors on hyperglycemia, hyperlipidemia, and lipodystrophy - A 5-year cohort study.\" Arch Intern Med 160 (2000): 2050-6[40] \"Product Information. Apidra (insulin glulisine).\" Aventis Pharmaceuticals, Bridgewater, NJ.[41] \"Product Information. Prezista (darunavir).\" Ortho Biotech Inc, Bridgewater, NJ.[42] Haiba NA, el-Habashy MA, Said SA, Darwish EA, Abdel-Sayed WS, Nayel SE \"Clinical evaluation of two monthly injectable contraceptives and their effects on some metabolic parameters.\" Contraception 39 (1989): 619-32[43] Erle G, Basso M, Federspil G, Sicolo N, Scandellari C \"Effect of chlorpromazine on blood glucose and plasma insulin in man.\" Eur J Clin Pharmacol 11 (1977): 15-8[44] Pickkers P, Schachter M, Hughes AD, Feher MD, Sever PS \"Thiazide-induced hyperglycaemia: a role for calcium-activated potassium channels?\" Diabetologia 39 (1996): 861-4[45] \"Product Information. Lexiva (fosamprenavir).\" GlaxoSmithKline, Research Triangle Park, NC.[46] Curtis J, Horrigan F, Ahearn D, Varney R, Sandler SG \"Chlorthalidone-induced hyperosmolar hyperglycemic nonketotic coma.\" JAMA 220 (1972): 1592-3[47] \"Product Information. Hyperstat I.V. (diazoxide).\" Schering Corp, Kenilworth, NJ.[48] \"Product Information. Piqray (alpelisib).\" Novartis Pharmaceuticals, East Hanover, NJ.[49] Bell DS \"Insulin resistance. An often unrecognized problem accompanying chronic medical disorders.\" Postgrad Med 93 (1993): 99-103,[50] Stambaugh JE, Tucker DC \"Effect of diphenylhydantoin on glucose tolerance in patients with hypoglycemia.\" Diabetes 23 (1974): 679-83[51] \"Product Information. Crixivan (indinavir).\" Merck & Co, Inc, West Point, PA.[52] Miller NR, Moses H \"Transient oculomotor nerve palsy. Association with thiazide-induced glucose intolerance.\" JAMA 240 (1978): 1887-8[53] Javier Z, Gershberg H, Hulse M \"Ovulatory suppressants, estrogens, and carbohydrate metabolism.\" Metabolism 17 (1968): 443-56[54] Goldman JA, Ovadia JL \"The effect of estrogen on intravenous glucose tolerance in woman.\" Am J Obstet Gynecol 103 (1969): 172-8[55] Charan VD, Desai N, Singh AP, Choudhry VP \"Diabetes mellitus and pancreatitis as a complication of L- asparaginase therapy.\" Indian Pediatr 30 (1993): 809-10[56] Seifer DB, Freedman LN, Cavender JR, Baker RA \"Insulin-dependent diabetes mellitus associated with danazol.\" Am J Obstet Gynecol 162 (1990): 474-5[57] \"Product Information. Orinase (tolbutamide)\" Pharmacia and Upjohn, Kalamazoo, MI.[58] Walli R, Demant T \"Impaired glucose tolerance and protease inhibitors.\" Ann Intern Med 129 (1998): 837-8[59] Hannaford PC, Kay CR \"Oral contraceptives and diabetes mellitus.\" BMJ 299 (1989): 1315-6[60] Hardy H, Esch LD, Morse GD \"Glucose disorders associated with HIV and its drug therapy.\" Ann Pharmacother 35 (2001): 343-51[61] Chowdhury FR, Bleicher SJ \"Chlorthalidone--induced hypokalemia and abnormal carbohydrate metabolism.\" Horm Metab Res 2 (1970): 13-6[62] Kaufman MB, Simionatto C \"A review of protease inhibitor-induced hyperglycemia.\" Pharmacotherapy 19 (1999): 114-7[63] Greenstone MA, Shaw AB \"Alternate day corticosteroid causes alternate day hyperglycaemia.\" Postgrad Med J 63 (1987): 761-4[64] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[65] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[66] Elmfeldt D, Berglund G, Wedel H, Wilhelmsen L \"Incidence and importance of metabolic side-effects during antihypertensive therapy.\" Acta Med Scand Suppl 672 (1983): 79-83[67] \"Product Information. Agenerase (amprenavir).\" Glaxo Wellcome, Research Triangle Pk, NC.[68] Diamond MT \"Hyperglycemic hyperosmolar coma associated with hydrochlorothiazide and pancreatitis.\" N Y State J Med 72 (1972): 1741-2[69] \"Product Information. Prandin (repaglinide).\" Novo Nordisk Pharmaceuticals Inc, Princeton, NJ.[70] \"Product Information. Precose (acarbose).\" Bayer, West Haven, CT.[71] \"Product Information. Starlix (nateglinide)\" Novartis Pharmaceuticals, East Hanover, NJ.[72] \"Product Information. Oncaspar (pegaspargase).\" Rhone-Poulenc Rorer, Collegeville, PA.[73] Sotaniemi E, Kontturi M, Larmi T \"Effect of diethylstilbestrol on blood glucose of prostatic cancer patients.\" Invest Urol 10 (1973): 438-41[74] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[75] Petri M, Cumber P, Grimes L, Treby D, Bryant R, Rawlins D, Ising H \"The metabolic effects of thiazide therapy in the elderly: a population study.\" Age Ageing 15 (1986): 151-5[76] Ludvik B, Clodi M, Kautzky-Willer A, Capek M, Hartter E, Pacini G, Prager R \"Effect of dexamethasone on insulin sensitivity, islet amyloid polypeptide and insulin secretion in humans.\" Diabetologia 36 (1993): 84-7[77] \"Product Information. Glucophage (metformin).\" Bristol-Myers Squibb, Princeton, NJ.[78] Chaudhuri ML, Catania J \"A comparison of the effects of bumetanide (Burinex) and frusemide on carbohydrate metabolism in the elderly.\" Br J Clin Pract 42 (1988): 427-9[79] Black DM, Filak AT \"Hyperglycemia with non-insulin-dependent diabetes following intraarticular steroid injection.\" J Fam Pract 28 (1989): 462-3[80] \"Product Information. Megace (megestrol).\" Bristol-Myers Squibb, Princeton, NJ.[81] \"Product Information. Torisel (temsirolimus).\" Wyeth-Ayerst Laboratories, Philadelphia, PA.[82] Schmitz O, Hermansen K, Nielsen OH, Christensen CK, Arnfred J, Hansen HE, Mogensen CE, Orskov H, Beck-Nielsen H \"Insulin action in insulin-dependent diabetics after short-term thiazide therapy.\" Diabetes Care 9 (1986): 631-6[83] Kansal PC, Buse J, Buse MG \"Thiazide diuretics and control of diabetes mellitus.\" South Med J 62 (1969): 1372-9[84] Dimitriadis G, Tegos C, Golfinopoulou L, Roboti C, Raptis S \"Furosemide-induced hyperglycaemia - the implication of glycolytic kinases.\" Horm Metab Res 25 (1993): 557-9[85] \"Product Information. NovoLog Mix 70/30 (insulin aspart-insulin aspart protamine).\" Novo Nordisk Pharmaceuticals Inc, Princeton, NJ.[86] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[87] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[88] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[89] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42[90] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[91] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[92] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[93] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[94] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[95] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6", "alternatives_a": "Simvastatin, Guar gum, Rosuvastatin", "alternatives_b": "", "updated_at": 1767369485}, {"id": 97886, "ingredient1": "Estrone sulfate (topical)", "ingredient2": "Empagliflozin", "severity": "Moderate", "effect": "The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.", "source": "DDInter", "management_text": "Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.", "mechanism_text": "Antagonism", "recommendation": "Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97990/", "reference_text": "[1] Jori A, Carrara MC \"On the mechanism of the hyperglycaemic effect of chlorpromazine.\" J Pharm Pharmacol 18 (1966): 623-4[2] \"Product Information. Dymelor (acetohexamide)\" Lilly, Eli and Company, Indianapolis, IN.[3] \"Product Information. Thorazine (chlorpromazine).\" SmithKline Beecham, Philadelphia, PA.[4] Blayac JP, Ribes G, Buys D, Puech R, Loubatieres-Mariani MM \"Effects of a new benzothiadiazine derivative, LN 5330, on insulin secretion.\" Arch Int Pharmacodyn Ther 253 (1981): 154-63[5] \"Product Information. Elzonris (tagraxofusp).\" Stemline Therapeutics, New York, NY.[6] \"Product Information. Amaryl (glimepiride).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[7] \"Product Information. Elspar (asparaginase).\" Merck & Co, Inc, West Point, PA.[8] Jones IG, Pickens PT \"Diabetes mellitus following oral diuretics.\" Practitioner 199 (1967): 209-10[9] \"Product Information. Viracept (nelfinavir).\" Agouron Pharma Inc, La Jolla, CA.[10] \"Product Information. Tolinase (tolazamide)\" Pharmacia and Upjohn, Kalamazoo, MI.[11] Mauss S, Wolf E, Jaeger H \"Impaired glucose tolerance in HIV-positive patients receiving and those not receiving protease inhibitors.\" Ann Intern Med 130 (1999): 162-3[12] Virutamasen P, Wongsrichanalai C, Tangkeo P, Nitichai Y, Rienprayoon D \"Metabolic effects of depot-medroxyprogesterone acetate in long-term users: a cross-sectional study.\" Int J Gynaecol Obstet 24 (1986): 291-6[13] Wehring H, Alexander B, Perry PJ \"Diabetes mellitus associated with clozapine therapy.\" Pharmacotherapy 20 (2000): 844-7[14] Spellacy WN, Ellingson AB, Tsibris JC \"The effects of two triphasic oral contraceptives on carbohydrate metabolism in women during 1 year of use.\" Fertil Steril 51 (1989): 71-4[15] Andersen OO, Persson I \"Carbohydrate metabolism during treatment with chlorthalidone and ethacrynic acid.\" Br Med J 2 (1968): 798-801[16] Berlin I \"Prazosin, diuretics, and glucose intolerance.\" Ann Intern Med 119 (1993): 860[17] Malherbe C, Burrill KC, Levin SR, Karam JH, Forsham PH \"Effect of diphenylhydantoin on insulin secretion in man.\" N Engl J Med 286 (1972): 339-42[18] Carter BL, Small RE, Mandel MD, Starkman MT \"Phenytoin-induced hyperglycemia.\" Am J Hosp Pharm 38 (1981): 1508-12[19] Al-Rubeaan K, Ryan EA \"Phenytoin-induced insulin insensitivity.\" Diabet Med 8 (1991): 968-70[20] \"Product Information. Zolinza (vorinostat).\" Merck & Company Inc, West Point, PA.[21] Goldman JA, Neri A, Ovadia J, Eckerling B, Vries A, de \"Effect of chlorothiazide on intravenous glucose tolerance in pregnancy.\" Am J Obstet Gynecol 105 (1969): 556-60[22] Harper R, Ennis CN, Heaney AP, Sheridan B, Gormley M, Atkinson AB, Johnston GD, Bell PM \"A comparison of the effects of low- and conventional-dose thiazide diuretic on insulin action in hypertensive patients with NIDDM.\" Diabetologia 38 (1995): 853-9[23] Seltzer HS, Allen EW \"Hyperglycemia and inhibition of insulin secretion during administration of diazoxide and trichlormethiazide in man.\" Diabetes 18 (1969): 19-28[24] Dube MP, Johnson DL, Currier JS, Leedom JM \"Protease inhibitor-associated hyperglycaemia.\" Lancet 350 (1997): 713-4[25] Leary WP, Reyes AJ \"Drug interactions with diuretics.\" S Afr Med J 65 (1984): 455-61[26] \"Product Information. Reyataz (atazanavir).\" Bristol-Myers Squibb, Princeton, NJ.[27] Pollare T, Lithell H, Berne C \"A comparison of the effects of hydrochlorothiazide and captopril on glucose and lipid metabolism in patients with hypertension.\" N Engl J Med 321 (1989): 868-73[28] Gunnarsson R, Lundgren G, Magnusson G, Ost L, Groth CG \"Steroid diabetes--a sign of overtreatment with steroids in the renal graft recipient?\" Scand J Urol Nephrol Suppl 54 (1980): 135-8[29] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[30] \"Product Information. Synthroid (levothyroxine).\" Abbott Pharmaceutical, Abbott Park, IL.[31] Murphy MB, Kohner E, Lewis PJ, Schumer B, Dollery CT \"Glucose intolerance in hypertensive patients treated with diuretics: a fourteen-year follow-up.\" Lancet 2 (1982): 1293-5[32] \"Product Information. Fortovase (saquinavir)\" Roche Laboratories, Nutley, NJ.[33] Coni NK, Gordon PW, Mukherjee AP, Read PR \"The effect of frusemide and ethacrynic acid on carbohydrate metabolism.\" Age Ageing 3 (1974): 85-90[34] \"Product Information. Norvir (ritonavir).\" Abbott Pharmaceutical, Abbott Park, IL.[35] Domenet JG \"Diabetogenic effect of oral diuretics.\" Br Med J 3 (1968): 188[36] Rowe P, Mather H \"Hyperosmolar non-ketotic diabetes mellitus associated with metolazone.\" Br Med J 291 (1985): 25-6[37] Winchester JF, Kellett RJ, Boddy K, Boyle P, Dargie HJ, Mahaffey ME, Ward DM, Kennedy AC \"Metolazone and bendroflumethiazide in hypertension: physiologic and metabolic observations.\" Clin Pharmacol Ther 28 (1980): 611-8[38] \"Product Information. Carafate (sucralfate).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[39] Tsiodras S, Mantzoros C, Hammer S, Samore M \"Effects of protease inhibitors on hyperglycemia, hyperlipidemia, and lipodystrophy - A 5-year cohort study.\" Arch Intern Med 160 (2000): 2050-6[40] \"Product Information. Apidra (insulin glulisine).\" Aventis Pharmaceuticals, Bridgewater, NJ.[41] \"Product Information. Prezista (darunavir).\" Ortho Biotech Inc, Bridgewater, NJ.[42] Haiba NA, el-Habashy MA, Said SA, Darwish EA, Abdel-Sayed WS, Nayel SE \"Clinical evaluation of two monthly injectable contraceptives and their effects on some metabolic parameters.\" Contraception 39 (1989): 619-32[43] Erle G, Basso M, Federspil G, Sicolo N, Scandellari C \"Effect of chlorpromazine on blood glucose and plasma insulin in man.\" Eur J Clin Pharmacol 11 (1977): 15-8[44] Pickkers P, Schachter M, Hughes AD, Feher MD, Sever PS \"Thiazide-induced hyperglycaemia: a role for calcium-activated potassium channels?\" Diabetologia 39 (1996): 861-4[45] \"Product Information. Lexiva (fosamprenavir).\" GlaxoSmithKline, Research Triangle Park, NC.[46] Curtis J, Horrigan F, Ahearn D, Varney R, Sandler SG \"Chlorthalidone-induced hyperosmolar hyperglycemic nonketotic coma.\" JAMA 220 (1972): 1592-3[47] \"Product Information. Hyperstat I.V. (diazoxide).\" Schering Corp, Kenilworth, NJ.[48] \"Product Information. Piqray (alpelisib).\" Novartis Pharmaceuticals, East Hanover, NJ.[49] Bell DS \"Insulin resistance. An often unrecognized problem accompanying chronic medical disorders.\" Postgrad Med 93 (1993): 99-103,[50] Stambaugh JE, Tucker DC \"Effect of diphenylhydantoin on glucose tolerance in patients with hypoglycemia.\" Diabetes 23 (1974): 679-83[51] \"Product Information. Crixivan (indinavir).\" Merck & Co, Inc, West Point, PA.[52] Miller NR, Moses H \"Transient oculomotor nerve palsy. Association with thiazide-induced glucose intolerance.\" JAMA 240 (1978): 1887-8[53] Javier Z, Gershberg H, Hulse M \"Ovulatory suppressants, estrogens, and carbohydrate metabolism.\" Metabolism 17 (1968): 443-56[54] Goldman JA, Ovadia JL \"The effect of estrogen on intravenous glucose tolerance in woman.\" Am J Obstet Gynecol 103 (1969): 172-8[55] Charan VD, Desai N, Singh AP, Choudhry VP \"Diabetes mellitus and pancreatitis as a complication of L- asparaginase therapy.\" Indian Pediatr 30 (1993): 809-10[56] Seifer DB, Freedman LN, Cavender JR, Baker RA \"Insulin-dependent diabetes mellitus associated with danazol.\" Am J Obstet Gynecol 162 (1990): 474-5[57] \"Product Information. Orinase (tolbutamide)\" Pharmacia and Upjohn, Kalamazoo, MI.[58] Walli R, Demant T \"Impaired glucose tolerance and protease inhibitors.\" Ann Intern Med 129 (1998): 837-8[59] Hannaford PC, Kay CR \"Oral contraceptives and diabetes mellitus.\" BMJ 299 (1989): 1315-6[60] Hardy H, Esch LD, Morse GD \"Glucose disorders associated with HIV and its drug therapy.\" Ann Pharmacother 35 (2001): 343-51[61] Chowdhury FR, Bleicher SJ \"Chlorthalidone--induced hypokalemia and abnormal carbohydrate metabolism.\" Horm Metab Res 2 (1970): 13-6[62] Kaufman MB, Simionatto C \"A review of protease inhibitor-induced hyperglycemia.\" Pharmacotherapy 19 (1999): 114-7[63] Greenstone MA, Shaw AB \"Alternate day corticosteroid causes alternate day hyperglycaemia.\" Postgrad Med J 63 (1987): 761-4[64] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[65] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[66] Elmfeldt D, Berglund G, Wedel H, Wilhelmsen L \"Incidence and importance of metabolic side-effects during antihypertensive therapy.\" Acta Med Scand Suppl 672 (1983): 79-83[67] \"Product Information. Agenerase (amprenavir).\" Glaxo Wellcome, Research Triangle Pk, NC.[68] Diamond MT \"Hyperglycemic hyperosmolar coma associated with hydrochlorothiazide and pancreatitis.\" N Y State J Med 72 (1972): 1741-2[69] \"Product Information. Prandin (repaglinide).\" Novo Nordisk Pharmaceuticals Inc, Princeton, NJ.[70] \"Product Information. Precose (acarbose).\" Bayer, West Haven, CT.[71] \"Product Information. Starlix (nateglinide)\" Novartis Pharmaceuticals, East Hanover, NJ.[72] \"Product Information. Oncaspar (pegaspargase).\" Rhone-Poulenc Rorer, Collegeville, PA.[73] Sotaniemi E, Kontturi M, Larmi T \"Effect of diethylstilbestrol on blood glucose of prostatic cancer patients.\" Invest Urol 10 (1973): 438-41[74] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[75] Petri M, Cumber P, Grimes L, Treby D, Bryant R, Rawlins D, Ising H \"The metabolic effects of thiazide therapy in the elderly: a population study.\" Age Ageing 15 (1986): 151-5[76] Ludvik B, Clodi M, Kautzky-Willer A, Capek M, Hartter E, Pacini G, Prager R \"Effect of dexamethasone on insulin sensitivity, islet amyloid polypeptide and insulin secretion in humans.\" Diabetologia 36 (1993): 84-7[77] \"Product Information. Glucophage (metformin).\" Bristol-Myers Squibb, Princeton, NJ.[78] Chaudhuri ML, Catania J \"A comparison of the effects of bumetanide (Burinex) and frusemide on carbohydrate metabolism in the elderly.\" Br J Clin Pract 42 (1988): 427-9[79] Black DM, Filak AT \"Hyperglycemia with non-insulin-dependent diabetes following intraarticular steroid injection.\" J Fam Pract 28 (1989): 462-3[80] \"Product Information. Megace (megestrol).\" Bristol-Myers Squibb, Princeton, NJ.[81] \"Product Information. Torisel (temsirolimus).\" Wyeth-Ayerst Laboratories, Philadelphia, PA.[82] Schmitz O, Hermansen K, Nielsen OH, Christensen CK, Arnfred J, Hansen HE, Mogensen CE, Orskov H, Beck-Nielsen H \"Insulin action in insulin-dependent diabetics after short-term thiazide therapy.\" Diabetes Care 9 (1986): 631-6[83] Kansal PC, Buse J, Buse MG \"Thiazide diuretics and control of diabetes mellitus.\" South Med J 62 (1969): 1372-9[84] Dimitriadis G, Tegos C, Golfinopoulou L, Roboti C, Raptis S \"Furosemide-induced hyperglycaemia - the implication of glycolytic kinases.\" Horm Metab Res 25 (1993): 557-9[85] \"Product Information. NovoLog Mix 70/30 (insulin aspart-insulin aspart protamine).\" Novo Nordisk Pharmaceuticals Inc, Princeton, NJ.[86] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[87] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[88] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[89] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42[90] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[91] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[92] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[93] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[94] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[95] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6", "alternatives_a": "Simvastatin, Guar gum, Rosuvastatin", "alternatives_b": "", "updated_at": 1767369485}, {"id": 97887, "ingredient1": "Etacrynic acid", "ingredient2": "Empagliflozin", "severity": "Moderate", "effect": "Sodium-glucose co-transporter 2 (SGLT-2) inhibitors may potentiate the diuretic and hypotensive effects of loop diuretics. Inhibition of glucose and sodium co-transport produces mild diuresis and transient natriuresis, resulting in intravascular volume contraction. Volume depletion-related adverse reactions including hypotension, postural dizziness, orthostatic hypotension, syncope, dehydration, acute kidney injury, and renal function impairment can occur after initiating treatment with SGLT-2 inhibitors, and the risk is increased with concomitant use of diuretics.", "source": "DDInter", "management_text": "Caution is advised during concomitant use of SGLT-2 inhibitors and loop diuretics, particularly in the elderly and patients with impaired renal function. Prior to initiating SGLT-2 inhibitors, volume status should be assessed and corrected, if necessary. Clinical and laboratory monitoring are recommended during therapy, including electrolytes, fluid status, renal function, and blood pressure. Blood glucose should also be monitored more closely. If volume depletion occurs, treatment with SGLT-2 inhibitors should be interrupted until the condition is corrected.", "mechanism_text": "Synergism", "recommendation": "Caution is advised during concomitant use of SGLT-2 inhibitors and loop diuretics, particularly in the elderly and patients with impaired renal function.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97991/", "reference_text": "[1] \"Product Information. Jardiance (empagliflozin).\" Boehringer Ingelheim, Ridgefield, CT.[2] \"Product Information. Invokana (canagliflozin).\" Janssen Pharmaceuticals, Titusville, NJ.[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] \"Product Information. Farxiga (dapagliflozin).\" Bristol-Myers Squibb, Princeton, NJ.[5] \"Product Information. Steglatro (ertugliflozin).\" Merck & Company Inc, Whitehouse Station, NJ.[6] Cerner Multum, Inc. \"Australian Product Information.\" O 0[7] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[8] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[9] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[10] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[11] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[12] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6[13] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[14] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[15] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[16] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42", "alternatives_a": "Simvastatin, Guar gum, Rosuvastatin", "alternatives_b": "", "updated_at": 1767369485}, {"id": 97888, "ingredient1": "Etonogestrel", "ingredient2": "Empagliflozin", "severity": "Moderate", "effect": "The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.", "source": "DDInter", "management_text": "Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.", "mechanism_text": "Antagonism", "recommendation": "Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97992/", "reference_text": "[1] Jori A, Carrara MC \"On the mechanism of the hyperglycaemic effect of chlorpromazine.\" J Pharm Pharmacol 18 (1966): 623-4[2] \"Product Information. Dymelor (acetohexamide)\" Lilly, Eli and Company, Indianapolis, IN.[3] \"Product Information. Thorazine (chlorpromazine).\" SmithKline Beecham, Philadelphia, PA.[4] Blayac JP, Ribes G, Buys D, Puech R, Loubatieres-Mariani MM \"Effects of a new benzothiadiazine derivative, LN 5330, on insulin secretion.\" Arch Int Pharmacodyn Ther 253 (1981): 154-63[5] \"Product Information. Elzonris (tagraxofusp).\" Stemline Therapeutics, New York, NY.[6] \"Product Information. Amaryl (glimepiride).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[7] \"Product Information. Elspar (asparaginase).\" Merck & Co, Inc, West Point, PA.[8] Jones IG, Pickens PT \"Diabetes mellitus following oral diuretics.\" Practitioner 199 (1967): 209-10[9] \"Product Information. Viracept (nelfinavir).\" Agouron Pharma Inc, La Jolla, CA.[10] \"Product Information. Tolinase (tolazamide)\" Pharmacia and Upjohn, Kalamazoo, MI.[11] Mauss S, Wolf E, Jaeger H \"Impaired glucose tolerance in HIV-positive patients receiving and those not receiving protease inhibitors.\" Ann Intern Med 130 (1999): 162-3[12] Virutamasen P, Wongsrichanalai C, Tangkeo P, Nitichai Y, Rienprayoon D \"Metabolic effects of depot-medroxyprogesterone acetate in long-term users: a cross-sectional study.\" Int J Gynaecol Obstet 24 (1986): 291-6[13] Wehring H, Alexander B, Perry PJ \"Diabetes mellitus associated with clozapine therapy.\" Pharmacotherapy 20 (2000): 844-7[14] Spellacy WN, Ellingson AB, Tsibris JC \"The effects of two triphasic oral contraceptives on carbohydrate metabolism in women during 1 year of use.\" Fertil Steril 51 (1989): 71-4[15] Andersen OO, Persson I \"Carbohydrate metabolism during treatment with chlorthalidone and ethacrynic acid.\" Br Med J 2 (1968): 798-801[16] Berlin I \"Prazosin, diuretics, and glucose intolerance.\" Ann Intern Med 119 (1993): 860[17] Malherbe C, Burrill KC, Levin SR, Karam JH, Forsham PH \"Effect of diphenylhydantoin on insulin secretion in man.\" N Engl J Med 286 (1972): 339-42[18] Carter BL, Small RE, Mandel MD, Starkman MT \"Phenytoin-induced hyperglycemia.\" Am J Hosp Pharm 38 (1981): 1508-12[19] Al-Rubeaan K, Ryan EA \"Phenytoin-induced insulin insensitivity.\" Diabet Med 8 (1991): 968-70[20] \"Product Information. Zolinza (vorinostat).\" Merck & Company Inc, West Point, PA.[21] Goldman JA, Neri A, Ovadia J, Eckerling B, Vries A, de \"Effect of chlorothiazide on intravenous glucose tolerance in pregnancy.\" Am J Obstet Gynecol 105 (1969): 556-60[22] Harper R, Ennis CN, Heaney AP, Sheridan B, Gormley M, Atkinson AB, Johnston GD, Bell PM \"A comparison of the effects of low- and conventional-dose thiazide diuretic on insulin action in hypertensive patients with NIDDM.\" Diabetologia 38 (1995): 853-9[23] Seltzer HS, Allen EW \"Hyperglycemia and inhibition of insulin secretion during administration of diazoxide and trichlormethiazide in man.\" Diabetes 18 (1969): 19-28[24] Dube MP, Johnson DL, Currier JS, Leedom JM \"Protease inhibitor-associated hyperglycaemia.\" Lancet 350 (1997): 713-4[25] Leary WP, Reyes AJ \"Drug interactions with diuretics.\" S Afr Med J 65 (1984): 455-61[26] \"Product Information. Reyataz (atazanavir).\" Bristol-Myers Squibb, Princeton, NJ.[27] Pollare T, Lithell H, Berne C \"A comparison of the effects of hydrochlorothiazide and captopril on glucose and lipid metabolism in patients with hypertension.\" N Engl J Med 321 (1989): 868-73[28] Gunnarsson R, Lundgren G, Magnusson G, Ost L, Groth CG \"Steroid diabetes--a sign of overtreatment with steroids in the renal graft recipient?\" Scand J Urol Nephrol Suppl 54 (1980): 135-8[29] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[30] \"Product Information. Synthroid (levothyroxine).\" Abbott Pharmaceutical, Abbott Park, IL.[31] Murphy MB, Kohner E, Lewis PJ, Schumer B, Dollery CT \"Glucose intolerance in hypertensive patients treated with diuretics: a fourteen-year follow-up.\" Lancet 2 (1982): 1293-5[32] \"Product Information. Fortovase (saquinavir)\" Roche Laboratories, Nutley, NJ.[33] Coni NK, Gordon PW, Mukherjee AP, Read PR \"The effect of frusemide and ethacrynic acid on carbohydrate metabolism.\" Age Ageing 3 (1974): 85-90[34] \"Product Information. Norvir (ritonavir).\" Abbott Pharmaceutical, Abbott Park, IL.[35] Domenet JG \"Diabetogenic effect of oral diuretics.\" Br Med J 3 (1968): 188[36] Rowe P, Mather H \"Hyperosmolar non-ketotic diabetes mellitus associated with metolazone.\" Br Med J 291 (1985): 25-6[37] Winchester JF, Kellett RJ, Boddy K, Boyle P, Dargie HJ, Mahaffey ME, Ward DM, Kennedy AC \"Metolazone and bendroflumethiazide in hypertension: physiologic and metabolic observations.\" Clin Pharmacol Ther 28 (1980): 611-8[38] \"Product Information. Carafate (sucralfate).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[39] Tsiodras S, Mantzoros C, Hammer S, Samore M \"Effects of protease inhibitors on hyperglycemia, hyperlipidemia, and lipodystrophy - A 5-year cohort study.\" Arch Intern Med 160 (2000): 2050-6[40] \"Product Information. Apidra (insulin glulisine).\" Aventis Pharmaceuticals, Bridgewater, NJ.[41] \"Product Information. Prezista (darunavir).\" Ortho Biotech Inc, Bridgewater, NJ.[42] Haiba NA, el-Habashy MA, Said SA, Darwish EA, Abdel-Sayed WS, Nayel SE \"Clinical evaluation of two monthly injectable contraceptives and their effects on some metabolic parameters.\" Contraception 39 (1989): 619-32[43] Erle G, Basso M, Federspil G, Sicolo N, Scandellari C \"Effect of chlorpromazine on blood glucose and plasma insulin in man.\" Eur J Clin Pharmacol 11 (1977): 15-8[44] Pickkers P, Schachter M, Hughes AD, Feher MD, Sever PS \"Thiazide-induced hyperglycaemia: a role for calcium-activated potassium channels?\" Diabetologia 39 (1996): 861-4[45] \"Product Information. Lexiva (fosamprenavir).\" GlaxoSmithKline, Research Triangle Park, NC.[46] Curtis J, Horrigan F, Ahearn D, Varney R, Sandler SG \"Chlorthalidone-induced hyperosmolar hyperglycemic nonketotic coma.\" JAMA 220 (1972): 1592-3[47] \"Product Information. Hyperstat I.V. (diazoxide).\" Schering Corp, Kenilworth, NJ.[48] \"Product Information. Piqray (alpelisib).\" Novartis Pharmaceuticals, East Hanover, NJ.[49] Bell DS \"Insulin resistance. An often unrecognized problem accompanying chronic medical disorders.\" Postgrad Med 93 (1993): 99-103,[50] Stambaugh JE, Tucker DC \"Effect of diphenylhydantoin on glucose tolerance in patients with hypoglycemia.\" Diabetes 23 (1974): 679-83[51] \"Product Information. Crixivan (indinavir).\" Merck & Co, Inc, West Point, PA.[52] Miller NR, Moses H \"Transient oculomotor nerve palsy. Association with thiazide-induced glucose intolerance.\" JAMA 240 (1978): 1887-8[53] Javier Z, Gershberg H, Hulse M \"Ovulatory suppressants, estrogens, and carbohydrate metabolism.\" Metabolism 17 (1968): 443-56[54] Goldman JA, Ovadia JL \"The effect of estrogen on intravenous glucose tolerance in woman.\" Am J Obstet Gynecol 103 (1969): 172-8[55] Charan VD, Desai N, Singh AP, Choudhry VP \"Diabetes mellitus and pancreatitis as a complication of L- asparaginase therapy.\" Indian Pediatr 30 (1993): 809-10[56] Seifer DB, Freedman LN, Cavender JR, Baker RA \"Insulin-dependent diabetes mellitus associated with danazol.\" Am J Obstet Gynecol 162 (1990): 474-5[57] \"Product Information. Orinase (tolbutamide)\" Pharmacia and Upjohn, Kalamazoo, MI.[58] Walli R, Demant T \"Impaired glucose tolerance and protease inhibitors.\" Ann Intern Med 129 (1998): 837-8[59] Hannaford PC, Kay CR \"Oral contraceptives and diabetes mellitus.\" BMJ 299 (1989): 1315-6[60] Hardy H, Esch LD, Morse GD \"Glucose disorders associated with HIV and its drug therapy.\" Ann Pharmacother 35 (2001): 343-51[61] Chowdhury FR, Bleicher SJ \"Chlorthalidone--induced hypokalemia and abnormal carbohydrate metabolism.\" Horm Metab Res 2 (1970): 13-6[62] Kaufman MB, Simionatto C \"A review of protease inhibitor-induced hyperglycemia.\" Pharmacotherapy 19 (1999): 114-7[63] Greenstone MA, Shaw AB \"Alternate day corticosteroid causes alternate day hyperglycaemia.\" Postgrad Med J 63 (1987): 761-4[64] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[65] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[66] Elmfeldt D, Berglund G, Wedel H, Wilhelmsen L \"Incidence and importance of metabolic side-effects during antihypertensive therapy.\" Acta Med Scand Suppl 672 (1983): 79-83[67] \"Product Information. Agenerase (amprenavir).\" Glaxo Wellcome, Research Triangle Pk, NC.[68] Diamond MT \"Hyperglycemic hyperosmolar coma associated with hydrochlorothiazide and pancreatitis.\" N Y State J Med 72 (1972): 1741-2[69] \"Product Information. Prandin (repaglinide).\" Novo Nordisk Pharmaceuticals Inc, Princeton, NJ.[70] \"Product Information. Precose (acarbose).\" Bayer, West Haven, CT.[71] \"Product Information. Starlix (nateglinide)\" Novartis Pharmaceuticals, East Hanover, NJ.[72] \"Product Information. Oncaspar (pegaspargase).\" Rhone-Poulenc Rorer, Collegeville, PA.[73] Sotaniemi E, Kontturi M, Larmi T \"Effect of diethylstilbestrol on blood glucose of prostatic cancer patients.\" Invest Urol 10 (1973): 438-41[74] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[75] Petri M, Cumber P, Grimes L, Treby D, Bryant R, Rawlins D, Ising H \"The metabolic effects of thiazide therapy in the elderly: a population study.\" Age Ageing 15 (1986): 151-5[76] Ludvik B, Clodi M, Kautzky-Willer A, Capek M, Hartter E, Pacini G, Prager R \"Effect of dexamethasone on insulin sensitivity, islet amyloid polypeptide and insulin secretion in humans.\" Diabetologia 36 (1993): 84-7[77] \"Product Information. Glucophage (metformin).\" Bristol-Myers Squibb, Princeton, NJ.[78] Chaudhuri ML, Catania J \"A comparison of the effects of bumetanide (Burinex) and frusemide on carbohydrate metabolism in the elderly.\" Br J Clin Pract 42 (1988): 427-9[79] Black DM, Filak AT \"Hyperglycemia with non-insulin-dependent diabetes following intraarticular steroid injection.\" J Fam Pract 28 (1989): 462-3[80] \"Product Information. Megace (megestrol).\" Bristol-Myers Squibb, Princeton, NJ.[81] \"Product Information. Torisel (temsirolimus).\" Wyeth-Ayerst Laboratories, Philadelphia, PA.[82] Schmitz O, Hermansen K, Nielsen OH, Christensen CK, Arnfred J, Hansen HE, Mogensen CE, Orskov H, Beck-Nielsen H \"Insulin action in insulin-dependent diabetics after short-term thiazide therapy.\" Diabetes Care 9 (1986): 631-6[83] Kansal PC, Buse J, Buse MG \"Thiazide diuretics and control of diabetes mellitus.\" South Med J 62 (1969): 1372-9[84] Dimitriadis G, Tegos C, Golfinopoulou L, Roboti C, Raptis S \"Furosemide-induced hyperglycaemia - the implication of glycolytic kinases.\" Horm Metab Res 25 (1993): 557-9[85] \"Product Information. NovoLog Mix 70/30 (insulin aspart-insulin aspart protamine).\" Novo Nordisk Pharmaceuticals Inc, Princeton, NJ.[86] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[87] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[88] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[89] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42[90] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[91] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[92] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[93] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[94] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[95] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6", "alternatives_a": "Ulipristal, Norelgestromin", "alternatives_b": "Simvastatin, Guar gum", "updated_at": 1767369485}, {"id": 97889, "ingredient1": "Everolimus", "ingredient2": "Empagliflozin", "severity": "Moderate", "effect": "The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.", "source": "DDInter", "management_text": "Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.", "mechanism_text": "Antagonism", "recommendation": "Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97993/", "reference_text": "[1] Jori A, Carrara MC \"On the mechanism of the hyperglycaemic effect of chlorpromazine.\" J Pharm Pharmacol 18 (1966): 623-4[2] \"Product Information. Dymelor (acetohexamide)\" Lilly, Eli and Company, Indianapolis, IN.[3] \"Product Information. Thorazine (chlorpromazine).\" SmithKline Beecham, Philadelphia, PA.[4] Blayac JP, Ribes G, Buys D, Puech R, Loubatieres-Mariani MM \"Effects of a new benzothiadiazine derivative, LN 5330, on insulin secretion.\" Arch Int Pharmacodyn Ther 253 (1981): 154-63[5] \"Product Information. Elzonris (tagraxofusp).\" Stemline Therapeutics, New York, NY.[6] \"Product Information. Amaryl (glimepiride).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[7] \"Product Information. Elspar (asparaginase).\" Merck & Co, Inc, West Point, PA.[8] Jones IG, Pickens PT \"Diabetes mellitus following oral diuretics.\" Practitioner 199 (1967): 209-10[9] \"Product Information. Viracept (nelfinavir).\" Agouron Pharma Inc, La Jolla, CA.[10] \"Product Information. Tolinase (tolazamide)\" Pharmacia and Upjohn, Kalamazoo, MI.[11] Mauss S, Wolf E, Jaeger H \"Impaired glucose tolerance in HIV-positive patients receiving and those not receiving protease inhibitors.\" Ann Intern Med 130 (1999): 162-3[12] Virutamasen P, Wongsrichanalai C, Tangkeo P, Nitichai Y, Rienprayoon D \"Metabolic effects of depot-medroxyprogesterone acetate in long-term users: a cross-sectional study.\" Int J Gynaecol Obstet 24 (1986): 291-6[13] Wehring H, Alexander B, Perry PJ \"Diabetes mellitus associated with clozapine therapy.\" Pharmacotherapy 20 (2000): 844-7[14] Spellacy WN, Ellingson AB, Tsibris JC \"The effects of two triphasic oral contraceptives on carbohydrate metabolism in women during 1 year of use.\" Fertil Steril 51 (1989): 71-4[15] Andersen OO, Persson I \"Carbohydrate metabolism during treatment with chlorthalidone and ethacrynic acid.\" Br Med J 2 (1968): 798-801[16] Berlin I \"Prazosin, diuretics, and glucose intolerance.\" Ann Intern Med 119 (1993): 860[17] Malherbe C, Burrill KC, Levin SR, Karam JH, Forsham PH \"Effect of diphenylhydantoin on insulin secretion in man.\" N Engl J Med 286 (1972): 339-42[18] Carter BL, Small RE, Mandel MD, Starkman MT \"Phenytoin-induced hyperglycemia.\" Am J Hosp Pharm 38 (1981): 1508-12[19] Al-Rubeaan K, Ryan EA \"Phenytoin-induced insulin insensitivity.\" Diabet Med 8 (1991): 968-70[20] \"Product Information. Zolinza (vorinostat).\" Merck & Company Inc, West Point, PA.[21] Goldman JA, Neri A, Ovadia J, Eckerling B, Vries A, de \"Effect of chlorothiazide on intravenous glucose tolerance in pregnancy.\" Am J Obstet Gynecol 105 (1969): 556-60[22] Harper R, Ennis CN, Heaney AP, Sheridan B, Gormley M, Atkinson AB, Johnston GD, Bell PM \"A comparison of the effects of low- and conventional-dose thiazide diuretic on insulin action in hypertensive patients with NIDDM.\" Diabetologia 38 (1995): 853-9[23] Seltzer HS, Allen EW \"Hyperglycemia and inhibition of insulin secretion during administration of diazoxide and trichlormethiazide in man.\" Diabetes 18 (1969): 19-28[24] Dube MP, Johnson DL, Currier JS, Leedom JM \"Protease inhibitor-associated hyperglycaemia.\" Lancet 350 (1997): 713-4[25] Leary WP, Reyes AJ \"Drug interactions with diuretics.\" S Afr Med J 65 (1984): 455-61[26] \"Product Information. Reyataz (atazanavir).\" Bristol-Myers Squibb, Princeton, NJ.[27] Pollare T, Lithell H, Berne C \"A comparison of the effects of hydrochlorothiazide and captopril on glucose and lipid metabolism in patients with hypertension.\" N Engl J Med 321 (1989): 868-73[28] Gunnarsson R, Lundgren G, Magnusson G, Ost L, Groth CG \"Steroid diabetes--a sign of overtreatment with steroids in the renal graft recipient?\" Scand J Urol Nephrol Suppl 54 (1980): 135-8[29] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[30] \"Product Information. Synthroid (levothyroxine).\" Abbott Pharmaceutical, Abbott Park, IL.[31] Murphy MB, Kohner E, Lewis PJ, Schumer B, Dollery CT \"Glucose intolerance in hypertensive patients treated with diuretics: a fourteen-year follow-up.\" Lancet 2 (1982): 1293-5[32] \"Product Information. Fortovase (saquinavir)\" Roche Laboratories, Nutley, NJ.[33] Coni NK, Gordon PW, Mukherjee AP, Read PR \"The effect of frusemide and ethacrynic acid on carbohydrate metabolism.\" Age Ageing 3 (1974): 85-90[34] \"Product Information. Norvir (ritonavir).\" Abbott Pharmaceutical, Abbott Park, IL.[35] Domenet JG \"Diabetogenic effect of oral diuretics.\" Br Med J 3 (1968): 188[36] Rowe P, Mather H \"Hyperosmolar non-ketotic diabetes mellitus associated with metolazone.\" Br Med J 291 (1985): 25-6[37] Winchester JF, Kellett RJ, Boddy K, Boyle P, Dargie HJ, Mahaffey ME, Ward DM, Kennedy AC \"Metolazone and bendroflumethiazide in hypertension: physiologic and metabolic observations.\" Clin Pharmacol Ther 28 (1980): 611-8[38] \"Product Information. Carafate (sucralfate).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[39] Tsiodras S, Mantzoros C, Hammer S, Samore M \"Effects of protease inhibitors on hyperglycemia, hyperlipidemia, and lipodystrophy - A 5-year cohort study.\" Arch Intern Med 160 (2000): 2050-6[40] \"Product Information. Apidra (insulin glulisine).\" Aventis Pharmaceuticals, Bridgewater, NJ.[41] \"Product Information. Prezista (darunavir).\" Ortho Biotech Inc, Bridgewater, NJ.[42] Haiba NA, el-Habashy MA, Said SA, Darwish EA, Abdel-Sayed WS, Nayel SE \"Clinical evaluation of two monthly injectable contraceptives and their effects on some metabolic parameters.\" Contraception 39 (1989): 619-32[43] Erle G, Basso M, Federspil G, Sicolo N, Scandellari C \"Effect of chlorpromazine on blood glucose and plasma insulin in man.\" Eur J Clin Pharmacol 11 (1977): 15-8[44] Pickkers P, Schachter M, Hughes AD, Feher MD, Sever PS \"Thiazide-induced hyperglycaemia: a role for calcium-activated potassium channels?\" Diabetologia 39 (1996): 861-4[45] \"Product Information. Lexiva (fosamprenavir).\" GlaxoSmithKline, Research Triangle Park, NC.[46] Curtis J, Horrigan F, Ahearn D, Varney R, Sandler SG \"Chlorthalidone-induced hyperosmolar hyperglycemic nonketotic coma.\" JAMA 220 (1972): 1592-3[47] \"Product Information. Hyperstat I.V. (diazoxide).\" Schering Corp, Kenilworth, NJ.[48] \"Product Information. Piqray (alpelisib).\" Novartis Pharmaceuticals, East Hanover, NJ.[49] Bell DS \"Insulin resistance. An often unrecognized problem accompanying chronic medical disorders.\" Postgrad Med 93 (1993): 99-103,[50] Stambaugh JE, Tucker DC \"Effect of diphenylhydantoin on glucose tolerance in patients with hypoglycemia.\" Diabetes 23 (1974): 679-83[51] \"Product Information. Crixivan (indinavir).\" Merck & Co, Inc, West Point, PA.[52] Miller NR, Moses H \"Transient oculomotor nerve palsy. Association with thiazide-induced glucose intolerance.\" JAMA 240 (1978): 1887-8[53] Javier Z, Gershberg H, Hulse M \"Ovulatory suppressants, estrogens, and carbohydrate metabolism.\" Metabolism 17 (1968): 443-56[54] Goldman JA, Ovadia JL \"The effect of estrogen on intravenous glucose tolerance in woman.\" Am J Obstet Gynecol 103 (1969): 172-8[55] Charan VD, Desai N, Singh AP, Choudhry VP \"Diabetes mellitus and pancreatitis as a complication of L- asparaginase therapy.\" Indian Pediatr 30 (1993): 809-10[56] Seifer DB, Freedman LN, Cavender JR, Baker RA \"Insulin-dependent diabetes mellitus associated with danazol.\" Am J Obstet Gynecol 162 (1990): 474-5[57] \"Product Information. Orinase (tolbutamide)\" Pharmacia and Upjohn, Kalamazoo, MI.[58] Walli R, Demant T \"Impaired glucose tolerance and protease inhibitors.\" Ann Intern Med 129 (1998): 837-8[59] Hannaford PC, Kay CR \"Oral contraceptives and diabetes mellitus.\" BMJ 299 (1989): 1315-6[60] Hardy H, Esch LD, Morse GD \"Glucose disorders associated with HIV and its drug therapy.\" Ann Pharmacother 35 (2001): 343-51[61] Chowdhury FR, Bleicher SJ \"Chlorthalidone--induced hypokalemia and abnormal carbohydrate metabolism.\" Horm Metab Res 2 (1970): 13-6[62] Kaufman MB, Simionatto C \"A review of protease inhibitor-induced hyperglycemia.\" Pharmacotherapy 19 (1999): 114-7[63] Greenstone MA, Shaw AB \"Alternate day corticosteroid causes alternate day hyperglycaemia.\" Postgrad Med J 63 (1987): 761-4[64] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[65] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[66] Elmfeldt D, Berglund G, Wedel H, Wilhelmsen L \"Incidence and importance of metabolic side-effects during antihypertensive therapy.\" Acta Med Scand Suppl 672 (1983): 79-83[67] \"Product Information. Agenerase (amprenavir).\" Glaxo Wellcome, Research Triangle Pk, NC.[68] Diamond MT \"Hyperglycemic hyperosmolar coma associated with hydrochlorothiazide and pancreatitis.\" N Y State J Med 72 (1972): 1741-2[69] \"Product Information. Prandin (repaglinide).\" Novo Nordisk Pharmaceuticals Inc, Princeton, NJ.[70] \"Product Information. Precose (acarbose).\" Bayer, West Haven, CT.[71] \"Product Information. Starlix (nateglinide)\" Novartis Pharmaceuticals, East Hanover, NJ.[72] \"Product Information. Oncaspar (pegaspargase).\" Rhone-Poulenc Rorer, Collegeville, PA.[73] Sotaniemi E, Kontturi M, Larmi T \"Effect of diethylstilbestrol on blood glucose of prostatic cancer patients.\" Invest Urol 10 (1973): 438-41[74] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[75] Petri M, Cumber P, Grimes L, Treby D, Bryant R, Rawlins D, Ising H \"The metabolic effects of thiazide therapy in the elderly: a population study.\" Age Ageing 15 (1986): 151-5[76] Ludvik B, Clodi M, Kautzky-Willer A, Capek M, Hartter E, Pacini G, Prager R \"Effect of dexamethasone on insulin sensitivity, islet amyloid polypeptide and insulin secretion in humans.\" Diabetologia 36 (1993): 84-7[77] \"Product Information. Glucophage (metformin).\" Bristol-Myers Squibb, Princeton, NJ.[78] Chaudhuri ML, Catania J \"A comparison of the effects of bumetanide (Burinex) and frusemide on carbohydrate metabolism in the elderly.\" Br J Clin Pract 42 (1988): 427-9[79] Black DM, Filak AT \"Hyperglycemia with non-insulin-dependent diabetes following intraarticular steroid injection.\" J Fam Pract 28 (1989): 462-3[80] \"Product Information. Megace (megestrol).\" Bristol-Myers Squibb, Princeton, NJ.[81] \"Product Information. Torisel (temsirolimus).\" Wyeth-Ayerst Laboratories, Philadelphia, PA.[82] Schmitz O, Hermansen K, Nielsen OH, Christensen CK, Arnfred J, Hansen HE, Mogensen CE, Orskov H, Beck-Nielsen H \"Insulin action in insulin-dependent diabetics after short-term thiazide therapy.\" Diabetes Care 9 (1986): 631-6[83] Kansal PC, Buse J, Buse MG \"Thiazide diuretics and control of diabetes mellitus.\" South Med J 62 (1969): 1372-9[84] Dimitriadis G, Tegos C, Golfinopoulou L, Roboti C, Raptis S \"Furosemide-induced hyperglycaemia - the implication of glycolytic kinases.\" Horm Metab Res 25 (1993): 557-9[85] \"Product Information. NovoLog Mix 70/30 (insulin aspart-insulin aspart protamine).\" Novo Nordisk Pharmaceuticals Inc, Princeton, NJ.[86] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[87] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[88] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[89] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42[90] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[91] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[92] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[93] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[94] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[95] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6", "alternatives_a": "Imatinib, Dabrafenib, Asciminib, Acalabrutinib, Dacomitinib, Pexidartinib, Fedratinib, Avapritinib, Larotrectinib, Bosutinib, Vemurafenib, More", "alternatives_b": "Guar gum, Simvastatin, Rosuvastatin, Repaglinide, Pioglitazone", "updated_at": 1767369485}, {"id": 97890, "ingredient1": "Felodipine", "ingredient2": "Empagliflozin", "severity": "Moderate", "effect": "Sodium-glucose co-transporter 2 (SGLT-2) inhibitors may potentiate the hypotensive effects of diuretics and other antihypertensive agents or vasodilators. Inhibition of glucose and sodium co-transport produces mild diuresis and transient natriuresis, resulting in intravascular volume contraction. Volume depletion-related adverse reactions including hypotension, postural dizziness, orthostatic hypotension, syncope, and dehydration can occur after initiating treatment with SGLT-2 inhibitors, and the risk may be increased with concomitant use of other agents that can lower blood pressure.", "source": "DDInter", "management_text": "Caution is advised if SGLT-2 inhibitors are coadministered with diuretics and other hypotensive agents, particularly in the elderly and patients with impaired renal function. Prior to initiating SGLT-2 inhibitors, volume status should be assessed and corrected, if necessary. Clinical and laboratory monitoring are recommended during therapy, including electrolytes, fluid status, renal function, and blood pressure. If volume depletion occurs, treatment with SGLT-2 inhibitors should be interrupted until the condition is corrected.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if SGLT-2 inhibitors are coadministered with diuretics and other hypotensive agents, particularly in the elderly and patients with impaired renal function.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97994/", "reference_text": "[1] \"Product Information. Jardiance (empagliflozin).\" Boehringer Ingelheim, Ridgefield, CT.[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] \"Product Information. Farxiga (dapagliflozin).\" Bristol-Myers Squibb, Princeton, NJ.[5] \"Product Information. Invokana (canagliflozin).\" Janssen Pharmaceuticals, Titusville, NJ.[6] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[7] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[8] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[9] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[10] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[11] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6[12] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[13] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[14] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[15] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42", "alternatives_a": "Acetylsalicylic acid, Ivabradine, Celecoxib", "alternatives_b": "Exenatide, Lixisenatide, Albiglutide, Acetohexamide, Guar gum, Pramlintide, Sitagliptin, Alogliptin, Liraglutide, Chlorpropamide, Semaglutide, More", "updated_at": 1767369485}, {"id": 97891, "ingredient1": "Fenfluramine", "ingredient2": "Empagliflozin", "severity": "Moderate", "effect": "Since weight loss may affect glycemic control and increase the risk of hypoglycemia in type 2 diabetes mellitus, patients receiving anorectic drugs may require periodic adjustments of their antidiabetic medications.", "source": "DDInter", "management_text": "Blood glucose should be closely monitored during weight loss treatment, and appropriate changes made to the antidiabetic drug regimen as needed. Patients should be apprised of the risk of hypoglycemia and be alert to potential signs and symptoms such as headache, dizziness, drowsiness, nervousness, confusion, tremor, hunger, weakness, perspiration, palpitation, and tachycardia.", "mechanism_text": "Synergism", "recommendation": "Blood glucose should be closely monitored during weight loss treatment, and appropriate changes made to the antidiabetic drug regimen as needed.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97995/", "reference_text": "[1] \"Product Information. Xenical (orlistat).\" Roche Laboratories, Nutley, NJ.[2] \"Product Information. Didrex (benzphetamine)\" Pharmacia and Upjohn, Kalamazoo, MI.[3] \"Product Information. Suprenza (phentermine).\" Akrimax Pharmaceuticals, Cranford, NJ.[4] \"Product Information. Belviq (lorcaserin).\" Eisai Inc, Teaneck, NJ.[5] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[6] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[7] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[8] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42[9] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[10] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[11] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[12] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[13] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[14] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6[15] Mendelson J, Jones RT, Upton R, Jacob P 3rd \"Methamphetamine and ethanol interactions in humans.\" Clin Pharmacol Ther 57 (1995): 559-68[16] \"Product Information. Didrex (benzphetamine)\" Pharmacia and Upjohn, Kalamazoo, MI.[17] \"Product Information. Suprenza (phentermine).\" Akrimax Pharmaceuticals, Cranford, NJ.", "alternatives_a": "Bupropion, Naltrexone, Brivaracetam, Topiramate, Ezogabine, Cenobamate, Lamotrigine, Methylphenobarbital, Ethosuximide, Lacosamide, Levetiracetam, More", "alternatives_b": "Simvastatin, Guar gum, Rosuvastatin", "updated_at": 1767369485}, {"id": 97892, "ingredient1": "Fenoldopam", "ingredient2": "Empagliflozin", "severity": "Moderate", "effect": "Sodium-glucose co-transporter 2 (SGLT-2) inhibitors may potentiate the hypotensive effects of diuretics and other antihypertensive agents or vasodilators. Inhibition of glucose and sodium co-transport produces mild diuresis and transient natriuresis, resulting in intravascular volume contraction. Volume depletion-related adverse reactions including hypotension, postural dizziness, orthostatic hypotension, syncope, and dehydration can occur after initiating treatment with SGLT-2 inhibitors, and the risk may be increased with concomitant use of other agents that can lower blood pressure.", "source": "DDInter", "management_text": "Caution is advised if SGLT-2 inhibitors are coadministered with diuretics and other hypotensive agents, particularly in the elderly and patients with impaired renal function. Prior to initiating SGLT-2 inhibitors, volume status should be assessed and corrected, if necessary. Clinical and laboratory monitoring are recommended during therapy, including electrolytes, fluid status, renal function, and blood pressure. If volume depletion occurs, treatment with SGLT-2 inhibitors should be interrupted until the condition is corrected.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if SGLT-2 inhibitors are coadministered with diuretics and other hypotensive agents, particularly in the elderly and patients with impaired renal function.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97996/", "reference_text": "[1] \"Product Information. Jardiance (empagliflozin).\" Boehringer Ingelheim, Ridgefield, CT.[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] \"Product Information. Farxiga (dapagliflozin).\" Bristol-Myers Squibb, Princeton, NJ.[5] \"Product Information. Invokana (canagliflozin).\" Janssen Pharmaceuticals, Titusville, NJ.[6] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[7] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[8] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[9] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[10] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[11] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6[12] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[13] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[14] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[15] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42", "alternatives_a": "Droxidopa, Midodrine, Amrinone, Angiotensin II, Milrinone, Arbutamine", "alternatives_b": "Glipizide, Acetohexamide, Guar gum, Pramlintide, Alogliptin, Rosuvastatin, Tolazamide, Dulaglutide, Exenatide, Tolbutamide, Miglitol, More", "updated_at": 1767369485}, {"id": 97893, "ingredient1": "Fludrocortisone", "ingredient2": "Empagliflozin", "severity": "Moderate", "effect": "The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.", "source": "DDInter", "management_text": "Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.", "mechanism_text": "Antagonism", "recommendation": "Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97997/", "reference_text": "[1] Jori A, Carrara MC \"On the mechanism of the hyperglycaemic effect of chlorpromazine.\" J Pharm Pharmacol 18 (1966): 623-4[2] \"Product Information. Dymelor (acetohexamide)\" Lilly, Eli and Company, Indianapolis, IN.[3] \"Product Information. Thorazine (chlorpromazine).\" SmithKline Beecham, Philadelphia, PA.[4] Blayac JP, Ribes G, Buys D, Puech R, Loubatieres-Mariani MM \"Effects of a new benzothiadiazine derivative, LN 5330, on insulin secretion.\" Arch Int Pharmacodyn Ther 253 (1981): 154-63[5] \"Product Information. Elzonris (tagraxofusp).\" Stemline Therapeutics, New York, NY.[6] \"Product Information. Amaryl (glimepiride).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[7] \"Product Information. Elspar (asparaginase).\" Merck & Co, Inc, West Point, PA.[8] Jones IG, Pickens PT \"Diabetes mellitus following oral diuretics.\" Practitioner 199 (1967): 209-10[9] \"Product Information. Viracept (nelfinavir).\" Agouron Pharma Inc, La Jolla, CA.[10] \"Product Information. Tolinase (tolazamide)\" Pharmacia and Upjohn, Kalamazoo, MI.[11] Mauss S, Wolf E, Jaeger H \"Impaired glucose tolerance in HIV-positive patients receiving and those not receiving protease inhibitors.\" Ann Intern Med 130 (1999): 162-3[12] Virutamasen P, Wongsrichanalai C, Tangkeo P, Nitichai Y, Rienprayoon D \"Metabolic effects of depot-medroxyprogesterone acetate in long-term users: a cross-sectional study.\" Int J Gynaecol Obstet 24 (1986): 291-6[13] Wehring H, Alexander B, Perry PJ \"Diabetes mellitus associated with clozapine therapy.\" Pharmacotherapy 20 (2000): 844-7[14] Spellacy WN, Ellingson AB, Tsibris JC \"The effects of two triphasic oral contraceptives on carbohydrate metabolism in women during 1 year of use.\" Fertil Steril 51 (1989): 71-4[15] Andersen OO, Persson I \"Carbohydrate metabolism during treatment with chlorthalidone and ethacrynic acid.\" Br Med J 2 (1968): 798-801[16] Berlin I \"Prazosin, diuretics, and glucose intolerance.\" Ann Intern Med 119 (1993): 860[17] Malherbe C, Burrill KC, Levin SR, Karam JH, Forsham PH \"Effect of diphenylhydantoin on insulin secretion in man.\" N Engl J Med 286 (1972): 339-42[18] Carter BL, Small RE, Mandel MD, Starkman MT \"Phenytoin-induced hyperglycemia.\" Am J Hosp Pharm 38 (1981): 1508-12[19] Al-Rubeaan K, Ryan EA \"Phenytoin-induced insulin insensitivity.\" Diabet Med 8 (1991): 968-70[20] \"Product Information. Zolinza (vorinostat).\" Merck & Company Inc, West Point, PA.[21] Goldman JA, Neri A, Ovadia J, Eckerling B, Vries A, de \"Effect of chlorothiazide on intravenous glucose tolerance in pregnancy.\" Am J Obstet Gynecol 105 (1969): 556-60[22] Harper R, Ennis CN, Heaney AP, Sheridan B, Gormley M, Atkinson AB, Johnston GD, Bell PM \"A comparison of the effects of low- and conventional-dose thiazide diuretic on insulin action in hypertensive patients with NIDDM.\" Diabetologia 38 (1995): 853-9[23] Seltzer HS, Allen EW \"Hyperglycemia and inhibition of insulin secretion during administration of diazoxide and trichlormethiazide in man.\" Diabetes 18 (1969): 19-28[24] Dube MP, Johnson DL, Currier JS, Leedom JM \"Protease inhibitor-associated hyperglycaemia.\" Lancet 350 (1997): 713-4[25] Leary WP, Reyes AJ \"Drug interactions with diuretics.\" S Afr Med J 65 (1984): 455-61[26] \"Product Information. Reyataz (atazanavir).\" Bristol-Myers Squibb, Princeton, NJ.[27] Pollare T, Lithell H, Berne C \"A comparison of the effects of hydrochlorothiazide and captopril on glucose and lipid metabolism in patients with hypertension.\" N Engl J Med 321 (1989): 868-73[28] Gunnarsson R, Lundgren G, Magnusson G, Ost L, Groth CG \"Steroid diabetes--a sign of overtreatment with steroids in the renal graft recipient?\" Scand J Urol Nephrol Suppl 54 (1980): 135-8[29] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[30] \"Product Information. Synthroid (levothyroxine).\" Abbott Pharmaceutical, Abbott Park, IL.[31] Murphy MB, Kohner E, Lewis PJ, Schumer B, Dollery CT \"Glucose intolerance in hypertensive patients treated with diuretics: a fourteen-year follow-up.\" Lancet 2 (1982): 1293-5[32] \"Product Information. Fortovase (saquinavir)\" Roche Laboratories, Nutley, NJ.[33] Coni NK, Gordon PW, Mukherjee AP, Read PR \"The effect of frusemide and ethacrynic acid on carbohydrate metabolism.\" Age Ageing 3 (1974): 85-90[34] \"Product Information. Norvir (ritonavir).\" Abbott Pharmaceutical, Abbott Park, IL.[35] Domenet JG \"Diabetogenic effect of oral diuretics.\" Br Med J 3 (1968): 188[36] Rowe P, Mather H \"Hyperosmolar non-ketotic diabetes mellitus associated with metolazone.\" Br Med J 291 (1985): 25-6[37] Winchester JF, Kellett RJ, Boddy K, Boyle P, Dargie HJ, Mahaffey ME, Ward DM, Kennedy AC \"Metolazone and bendroflumethiazide in hypertension: physiologic and metabolic observations.\" Clin Pharmacol Ther 28 (1980): 611-8[38] \"Product Information. Carafate (sucralfate).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[39] Tsiodras S, Mantzoros C, Hammer S, Samore M \"Effects of protease inhibitors on hyperglycemia, hyperlipidemia, and lipodystrophy - A 5-year cohort study.\" Arch Intern Med 160 (2000): 2050-6[40] \"Product Information. Apidra (insulin glulisine).\" Aventis Pharmaceuticals, Bridgewater, NJ.[41] \"Product Information. Prezista (darunavir).\" Ortho Biotech Inc, Bridgewater, NJ.[42] Haiba NA, el-Habashy MA, Said SA, Darwish EA, Abdel-Sayed WS, Nayel SE \"Clinical evaluation of two monthly injectable contraceptives and their effects on some metabolic parameters.\" Contraception 39 (1989): 619-32[43] Erle G, Basso M, Federspil G, Sicolo N, Scandellari C \"Effect of chlorpromazine on blood glucose and plasma insulin in man.\" Eur J Clin Pharmacol 11 (1977): 15-8[44] Pickkers P, Schachter M, Hughes AD, Feher MD, Sever PS \"Thiazide-induced hyperglycaemia: a role for calcium-activated potassium channels?\" Diabetologia 39 (1996): 861-4[45] \"Product Information. Lexiva (fosamprenavir).\" GlaxoSmithKline, Research Triangle Park, NC.[46] Curtis J, Horrigan F, Ahearn D, Varney R, Sandler SG \"Chlorthalidone-induced hyperosmolar hyperglycemic nonketotic coma.\" JAMA 220 (1972): 1592-3[47] \"Product Information. Hyperstat I.V. (diazoxide).\" Schering Corp, Kenilworth, NJ.[48] \"Product Information. Piqray (alpelisib).\" Novartis Pharmaceuticals, East Hanover, NJ.[49] Bell DS \"Insulin resistance. An often unrecognized problem accompanying chronic medical disorders.\" Postgrad Med 93 (1993): 99-103,[50] Stambaugh JE, Tucker DC \"Effect of diphenylhydantoin on glucose tolerance in patients with hypoglycemia.\" Diabetes 23 (1974): 679-83[51] \"Product Information. Crixivan (indinavir).\" Merck & Co, Inc, West Point, PA.[52] Miller NR, Moses H \"Transient oculomotor nerve palsy. Association with thiazide-induced glucose intolerance.\" JAMA 240 (1978): 1887-8[53] Javier Z, Gershberg H, Hulse M \"Ovulatory suppressants, estrogens, and carbohydrate metabolism.\" Metabolism 17 (1968): 443-56[54] Goldman JA, Ovadia JL \"The effect of estrogen on intravenous glucose tolerance in woman.\" Am J Obstet Gynecol 103 (1969): 172-8[55] Charan VD, Desai N, Singh AP, Choudhry VP \"Diabetes mellitus and pancreatitis as a complication of L- asparaginase therapy.\" Indian Pediatr 30 (1993): 809-10[56] Seifer DB, Freedman LN, Cavender JR, Baker RA \"Insulin-dependent diabetes mellitus associated with danazol.\" Am J Obstet Gynecol 162 (1990): 474-5[57] \"Product Information. Orinase (tolbutamide)\" Pharmacia and Upjohn, Kalamazoo, MI.[58] Walli R, Demant T \"Impaired glucose tolerance and protease inhibitors.\" Ann Intern Med 129 (1998): 837-8[59] Hannaford PC, Kay CR \"Oral contraceptives and diabetes mellitus.\" BMJ 299 (1989): 1315-6[60] Hardy H, Esch LD, Morse GD \"Glucose disorders associated with HIV and its drug therapy.\" Ann Pharmacother 35 (2001): 343-51[61] Chowdhury FR, Bleicher SJ \"Chlorthalidone--induced hypokalemia and abnormal carbohydrate metabolism.\" Horm Metab Res 2 (1970): 13-6[62] Kaufman MB, Simionatto C \"A review of protease inhibitor-induced hyperglycemia.\" Pharmacotherapy 19 (1999): 114-7[63] Greenstone MA, Shaw AB \"Alternate day corticosteroid causes alternate day hyperglycaemia.\" Postgrad Med J 63 (1987): 761-4[64] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[65] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[66] Elmfeldt D, Berglund G, Wedel H, Wilhelmsen L \"Incidence and importance of metabolic side-effects during antihypertensive therapy.\" Acta Med Scand Suppl 672 (1983): 79-83[67] \"Product Information. Agenerase (amprenavir).\" Glaxo Wellcome, Research Triangle Pk, NC.[68] Diamond MT \"Hyperglycemic hyperosmolar coma associated with hydrochlorothiazide and pancreatitis.\" N Y State J Med 72 (1972): 1741-2[69] \"Product Information. Prandin (repaglinide).\" Novo Nordisk Pharmaceuticals Inc, Princeton, NJ.[70] \"Product Information. Precose (acarbose).\" Bayer, West Haven, CT.[71] \"Product Information. Starlix (nateglinide)\" Novartis Pharmaceuticals, East Hanover, NJ.[72] \"Product Information. Oncaspar (pegaspargase).\" Rhone-Poulenc Rorer, Collegeville, PA.[73] Sotaniemi E, Kontturi M, Larmi T \"Effect of diethylstilbestrol on blood glucose of prostatic cancer patients.\" Invest Urol 10 (1973): 438-41[74] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[75] Petri M, Cumber P, Grimes L, Treby D, Bryant R, Rawlins D, Ising H \"The metabolic effects of thiazide therapy in the elderly: a population study.\" Age Ageing 15 (1986): 151-5[76] Ludvik B, Clodi M, Kautzky-Willer A, Capek M, Hartter E, Pacini G, Prager R \"Effect of dexamethasone on insulin sensitivity, islet amyloid polypeptide and insulin secretion in humans.\" Diabetologia 36 (1993): 84-7[77] \"Product Information. Glucophage (metformin).\" Bristol-Myers Squibb, Princeton, NJ.[78] Chaudhuri ML, Catania J \"A comparison of the effects of bumetanide (Burinex) and frusemide on carbohydrate metabolism in the elderly.\" Br J Clin Pract 42 (1988): 427-9[79] Black DM, Filak AT \"Hyperglycemia with non-insulin-dependent diabetes following intraarticular steroid injection.\" J Fam Pract 28 (1989): 462-3[80] \"Product Information. Megace (megestrol).\" Bristol-Myers Squibb, Princeton, NJ.[81] \"Product Information. Torisel (temsirolimus).\" Wyeth-Ayerst Laboratories, Philadelphia, PA.[82] Schmitz O, Hermansen K, Nielsen OH, Christensen CK, Arnfred J, Hansen HE, Mogensen CE, Orskov H, Beck-Nielsen H \"Insulin action in insulin-dependent diabetics after short-term thiazide therapy.\" Diabetes Care 9 (1986): 631-6[83] Kansal PC, Buse J, Buse MG \"Thiazide diuretics and control of diabetes mellitus.\" South Med J 62 (1969): 1372-9[84] Dimitriadis G, Tegos C, Golfinopoulou L, Roboti C, Raptis S \"Furosemide-induced hyperglycaemia - the implication of glycolytic kinases.\" Horm Metab Res 25 (1993): 557-9[85] \"Product Information. NovoLog Mix 70/30 (insulin aspart-insulin aspart protamine).\" Novo Nordisk Pharmaceuticals Inc, Princeton, NJ.[86] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[87] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[88] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[89] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42[90] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[91] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[92] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[93] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[94] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[95] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6", "alternatives_a": "Fluorometholone, Indomethacin, Diclofenac", "alternatives_b": "Simvastatin, Guar gum, Rosuvastatin", "updated_at": 1767369485}, {"id": 97894, "ingredient1": "Fluocinonide (topical)", "ingredient2": "Empagliflozin", "severity": "Minor", "effect": "The efficacy of insulin and other antidiabetic agents may be diminished by topical corticosteroids, particularly during prolonged or indiscriminate use. Corticosteroids can raise blood glucose level by antagonizing the action and suppressing the secretion of insulin, which results in inhibition of peripheral glucose uptake and increased gluconeogenesis. The duration of administration Close clinical monitoring of glycemic control is recommended if topical corticosteroids are administered chronically and/or to large areas in diabetic patients.", "source": "DDInter", "management_text": "-", "mechanism_text": "Antagonism", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97998/", "reference_text": "[1] Pace WE \"Topical corticosteroids.\" Can Med Assoc J 108 (1973): 11 passim[2] Seale JP, Compton MR \"Side-effects of corticosteroid agents.\" Med J Aust 144 (1986): 139-42[3] \"Product Information. Psorcon (diflorasone topical).\" Rhone-Poulenc Rorer, Collegeville, PA.[4] \"Product Information. Temovate (clobetasol).\" Glaxo Wellcome, Research Triangle Park, NC.[5] \"Product Information. Ultravate (halobetasol).\" Bristol-Myers Squibb, Princeton, NJ.[6] Carruthers JA, Staughton RC, August PJ \"Penetration of topical steroid preparations.\" Arch Dermatol 113 (1977): 522[7] Ludvik B, Clodi M, Kautzky-Willer A, Capek M, Hartter E, Pacini G, Prager R \"Effect of dexamethasone on insulin sensitivity, islet amyloid polypeptide and insulin secretion in humans.\" Diabetologia 36 (1993): 84-7[8] \"Product Information. Diprolene (betamethasone topical).\" Schering Laboratories, Kenilworth, NJ.[9] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[10] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[11] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[12] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42[13] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[14] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[15] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[16] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[17] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[18] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6", "alternatives_a": "Lidocaine, Zinc sulfate, Tetracaine, Zinc acetate, Fluocinonide, Zinc chloride, Procaine, Fluorometholone, Zinc gluconate, Budesonide, Hydrocortisone butyrate, More", "alternatives_b": "Simvastatin, Guar gum, Rosuvastatin", "updated_at": 1767369485}, {"id": 97895, "ingredient1": "Fluphenazine", "ingredient2": "Empagliflozin", "severity": "Moderate", "effect": "The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.", "source": "DDInter", "management_text": "Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.", "mechanism_text": "Antagonism", "recommendation": "Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/97999/", "reference_text": "[1] Jori A, Carrara MC \"On the mechanism of the hyperglycaemic effect of chlorpromazine.\" J Pharm Pharmacol 18 (1966): 623-4[2] \"Product Information. Dymelor (acetohexamide)\" Lilly, Eli and Company, Indianapolis, IN.[3] \"Product Information. Thorazine (chlorpromazine).\" SmithKline Beecham, Philadelphia, PA.[4] Blayac JP, Ribes G, Buys D, Puech R, Loubatieres-Mariani MM \"Effects of a new benzothiadiazine derivative, LN 5330, on insulin secretion.\" Arch Int Pharmacodyn Ther 253 (1981): 154-63[5] \"Product Information. Elzonris (tagraxofusp).\" Stemline Therapeutics, New York, NY.[6] \"Product Information. Amaryl (glimepiride).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[7] \"Product Information. Elspar (asparaginase).\" Merck & Co, Inc, West Point, PA.[8] Jones IG, Pickens PT \"Diabetes mellitus following oral diuretics.\" Practitioner 199 (1967): 209-10[9] \"Product Information. Viracept (nelfinavir).\" Agouron Pharma Inc, La Jolla, CA.[10] \"Product Information. Tolinase (tolazamide)\" Pharmacia and Upjohn, Kalamazoo, MI.[11] Mauss S, Wolf E, Jaeger H \"Impaired glucose tolerance in HIV-positive patients receiving and those not receiving protease inhibitors.\" Ann Intern Med 130 (1999): 162-3[12] Virutamasen P, Wongsrichanalai C, Tangkeo P, Nitichai Y, Rienprayoon D \"Metabolic effects of depot-medroxyprogesterone acetate in long-term users: a cross-sectional study.\" Int J Gynaecol Obstet 24 (1986): 291-6[13] Wehring H, Alexander B, Perry PJ \"Diabetes mellitus associated with clozapine therapy.\" Pharmacotherapy 20 (2000): 844-7[14] Spellacy WN, Ellingson AB, Tsibris JC \"The effects of two triphasic oral contraceptives on carbohydrate metabolism in women during 1 year of use.\" Fertil Steril 51 (1989): 71-4[15] Andersen OO, Persson I \"Carbohydrate metabolism during treatment with chlorthalidone and ethacrynic acid.\" Br Med J 2 (1968): 798-801[16] Berlin I \"Prazosin, diuretics, and glucose intolerance.\" Ann Intern Med 119 (1993): 860[17] Malherbe C, Burrill KC, Levin SR, Karam JH, Forsham PH \"Effect of diphenylhydantoin on insulin secretion in man.\" N Engl J Med 286 (1972): 339-42[18] Carter BL, Small RE, Mandel MD, Starkman MT \"Phenytoin-induced hyperglycemia.\" Am J Hosp Pharm 38 (1981): 1508-12[19] Al-Rubeaan K, Ryan EA \"Phenytoin-induced insulin insensitivity.\" Diabet Med 8 (1991): 968-70[20] \"Product Information. Zolinza (vorinostat).\" Merck & Company Inc, West Point, PA.[21] Goldman JA, Neri A, Ovadia J, Eckerling B, Vries A, de \"Effect of chlorothiazide on intravenous glucose tolerance in pregnancy.\" Am J Obstet Gynecol 105 (1969): 556-60[22] Harper R, Ennis CN, Heaney AP, Sheridan B, Gormley M, Atkinson AB, Johnston GD, Bell PM \"A comparison of the effects of low- and conventional-dose thiazide diuretic on insulin action in hypertensive patients with NIDDM.\" Diabetologia 38 (1995): 853-9[23] Seltzer HS, Allen EW \"Hyperglycemia and inhibition of insulin secretion during administration of diazoxide and trichlormethiazide in man.\" Diabetes 18 (1969): 19-28[24] Dube MP, Johnson DL, Currier JS, Leedom JM \"Protease inhibitor-associated hyperglycaemia.\" Lancet 350 (1997): 713-4[25] Leary WP, Reyes AJ \"Drug interactions with diuretics.\" S Afr Med J 65 (1984): 455-61[26] \"Product Information. Reyataz (atazanavir).\" Bristol-Myers Squibb, Princeton, NJ.[27] Pollare T, Lithell H, Berne C \"A comparison of the effects of hydrochlorothiazide and captopril on glucose and lipid metabolism in patients with hypertension.\" N Engl J Med 321 (1989): 868-73[28] Gunnarsson R, Lundgren G, Magnusson G, Ost L, Groth CG \"Steroid diabetes--a sign of overtreatment with steroids in the renal graft recipient?\" Scand J Urol Nephrol Suppl 54 (1980): 135-8[29] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[30] \"Product Information. Synthroid (levothyroxine).\" Abbott Pharmaceutical, Abbott Park, IL.[31] Murphy MB, Kohner E, Lewis PJ, Schumer B, Dollery CT \"Glucose intolerance in hypertensive patients treated with diuretics: a fourteen-year follow-up.\" Lancet 2 (1982): 1293-5[32] \"Product Information. Fortovase (saquinavir)\" Roche Laboratories, Nutley, NJ.[33] Coni NK, Gordon PW, Mukherjee AP, Read PR \"The effect of frusemide and ethacrynic acid on carbohydrate metabolism.\" Age Ageing 3 (1974): 85-90[34] \"Product Information. Norvir (ritonavir).\" Abbott Pharmaceutical, Abbott Park, IL.[35] Domenet JG \"Diabetogenic effect of oral diuretics.\" Br Med J 3 (1968): 188[36] Rowe P, Mather H \"Hyperosmolar non-ketotic diabetes mellitus associated with metolazone.\" Br Med J 291 (1985): 25-6[37] Winchester JF, Kellett RJ, Boddy K, Boyle P, Dargie HJ, Mahaffey ME, Ward DM, Kennedy AC \"Metolazone and bendroflumethiazide in hypertension: physiologic and metabolic observations.\" Clin Pharmacol Ther 28 (1980): 611-8[38] \"Product Information. Carafate (sucralfate).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[39] Tsiodras S, Mantzoros C, Hammer S, Samore M \"Effects of protease inhibitors on hyperglycemia, hyperlipidemia, and lipodystrophy - A 5-year cohort study.\" Arch Intern Med 160 (2000): 2050-6[40] \"Product Information. Apidra (insulin glulisine).\" Aventis Pharmaceuticals, Bridgewater, NJ.[41] \"Product Information. Prezista (darunavir).\" Ortho Biotech Inc, Bridgewater, NJ.[42] Haiba NA, el-Habashy MA, Said SA, Darwish EA, Abdel-Sayed WS, Nayel SE \"Clinical evaluation of two monthly injectable contraceptives and their effects on some metabolic parameters.\" Contraception 39 (1989): 619-32[43] Erle G, Basso M, Federspil G, Sicolo N, Scandellari C \"Effect of chlorpromazine on blood glucose and plasma insulin in man.\" Eur J Clin Pharmacol 11 (1977): 15-8[44] Pickkers P, Schachter M, Hughes AD, Feher MD, Sever PS \"Thiazide-induced hyperglycaemia: a role for calcium-activated potassium channels?\" Diabetologia 39 (1996): 861-4[45] \"Product Information. Lexiva (fosamprenavir).\" GlaxoSmithKline, Research Triangle Park, NC.[46] Curtis J, Horrigan F, Ahearn D, Varney R, Sandler SG \"Chlorthalidone-induced hyperosmolar hyperglycemic nonketotic coma.\" JAMA 220 (1972): 1592-3[47] \"Product Information. Hyperstat I.V. (diazoxide).\" Schering Corp, Kenilworth, NJ.[48] \"Product Information. Piqray (alpelisib).\" Novartis Pharmaceuticals, East Hanover, NJ.[49] Bell DS \"Insulin resistance. An often unrecognized problem accompanying chronic medical disorders.\" Postgrad Med 93 (1993): 99-103,[50] Stambaugh JE, Tucker DC \"Effect of diphenylhydantoin on glucose tolerance in patients with hypoglycemia.\" Diabetes 23 (1974): 679-83[51] \"Product Information. Crixivan (indinavir).\" Merck & Co, Inc, West Point, PA.[52] Miller NR, Moses H \"Transient oculomotor nerve palsy. Association with thiazide-induced glucose intolerance.\" JAMA 240 (1978): 1887-8[53] Javier Z, Gershberg H, Hulse M \"Ovulatory suppressants, estrogens, and carbohydrate metabolism.\" Metabolism 17 (1968): 443-56[54] Goldman JA, Ovadia JL \"The effect of estrogen on intravenous glucose tolerance in woman.\" Am J Obstet Gynecol 103 (1969): 172-8[55] Charan VD, Desai N, Singh AP, Choudhry VP \"Diabetes mellitus and pancreatitis as a complication of L- asparaginase therapy.\" Indian Pediatr 30 (1993): 809-10[56] Seifer DB, Freedman LN, Cavender JR, Baker RA \"Insulin-dependent diabetes mellitus associated with danazol.\" Am J Obstet Gynecol 162 (1990): 474-5[57] \"Product Information. Orinase (tolbutamide)\" Pharmacia and Upjohn, Kalamazoo, MI.[58] Walli R, Demant T \"Impaired glucose tolerance and protease inhibitors.\" Ann Intern Med 129 (1998): 837-8[59] Hannaford PC, Kay CR \"Oral contraceptives and diabetes mellitus.\" BMJ 299 (1989): 1315-6[60] Hardy H, Esch LD, Morse GD \"Glucose disorders associated with HIV and its drug therapy.\" Ann Pharmacother 35 (2001): 343-51[61] Chowdhury FR, Bleicher SJ \"Chlorthalidone--induced hypokalemia and abnormal carbohydrate metabolism.\" Horm Metab Res 2 (1970): 13-6[62] Kaufman MB, Simionatto C \"A review of protease inhibitor-induced hyperglycemia.\" Pharmacotherapy 19 (1999): 114-7[63] Greenstone MA, Shaw AB \"Alternate day corticosteroid causes alternate day hyperglycaemia.\" Postgrad Med J 63 (1987): 761-4[64] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[65] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[66] Elmfeldt D, Berglund G, Wedel H, Wilhelmsen L \"Incidence and importance of metabolic side-effects during antihypertensive therapy.\" Acta Med Scand Suppl 672 (1983): 79-83[67] \"Product Information. Agenerase (amprenavir).\" Glaxo Wellcome, Research Triangle Pk, NC.[68] Diamond MT \"Hyperglycemic hyperosmolar coma associated with hydrochlorothiazide and pancreatitis.\" N Y State J Med 72 (1972): 1741-2[69] \"Product Information. Prandin (repaglinide).\" Novo Nordisk Pharmaceuticals Inc, Princeton, NJ.[70] \"Product Information. Precose (acarbose).\" Bayer, West Haven, CT.[71] \"Product Information. Starlix (nateglinide)\" Novartis Pharmaceuticals, East Hanover, NJ.[72] \"Product Information. Oncaspar (pegaspargase).\" Rhone-Poulenc Rorer, Collegeville, PA.[73] Sotaniemi E, Kontturi M, Larmi T \"Effect of diethylstilbestrol on blood glucose of prostatic cancer patients.\" Invest Urol 10 (1973): 438-41[74] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[75] Petri M, Cumber P, Grimes L, Treby D, Bryant R, Rawlins D, Ising H \"The metabolic effects of thiazide therapy in the elderly: a population study.\" Age Ageing 15 (1986): 151-5[76] Ludvik B, Clodi M, Kautzky-Willer A, Capek M, Hartter E, Pacini G, Prager R \"Effect of dexamethasone on insulin sensitivity, islet amyloid polypeptide and insulin secretion in humans.\" Diabetologia 36 (1993): 84-7[77] \"Product Information. Glucophage (metformin).\" Bristol-Myers Squibb, Princeton, NJ.[78] Chaudhuri ML, Catania J \"A comparison of the effects of bumetanide (Burinex) and frusemide on carbohydrate metabolism in the elderly.\" Br J Clin Pract 42 (1988): 427-9[79] Black DM, Filak AT \"Hyperglycemia with non-insulin-dependent diabetes following intraarticular steroid injection.\" J Fam Pract 28 (1989): 462-3[80] \"Product Information. Megace (megestrol).\" Bristol-Myers Squibb, Princeton, NJ.[81] \"Product Information. Torisel (temsirolimus).\" Wyeth-Ayerst Laboratories, Philadelphia, PA.[82] Schmitz O, Hermansen K, Nielsen OH, Christensen CK, Arnfred J, Hansen HE, Mogensen CE, Orskov H, Beck-Nielsen H \"Insulin action in insulin-dependent diabetics after short-term thiazide therapy.\" Diabetes Care 9 (1986): 631-6[83] Kansal PC, Buse J, Buse MG \"Thiazide diuretics and control of diabetes mellitus.\" South Med J 62 (1969): 1372-9[84] Dimitriadis G, Tegos C, Golfinopoulou L, Roboti C, Raptis S \"Furosemide-induced hyperglycaemia - the implication of glycolytic kinases.\" Horm Metab Res 25 (1993): 557-9[85] \"Product Information. NovoLog Mix 70/30 (insulin aspart-insulin aspart protamine).\" Novo Nordisk Pharmaceuticals Inc, Princeton, NJ.[86] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[87] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[88] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[89] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42[90] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[91] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[92] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[93] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[94] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[95] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6", "alternatives_a": "Haloperidol, Pimavanserin, Thiothixene, Pimozide, Amisulpride, Loxapine, Molindone, Droperidol", "alternatives_b": "Guar gum, Rosuvastatin", "updated_at": 1767369485}, {"id": 97896, "ingredient1": "Flurandrenolide (topical)", "ingredient2": "Empagliflozin", "severity": "Minor", "effect": "The efficacy of insulin and other antidiabetic agents may be diminished by topical corticosteroids, particularly during prolonged or indiscriminate use. Corticosteroids can raise blood glucose level by antagonizing the action and suppressing the secretion of insulin, which results in inhibition of peripheral glucose uptake and increased gluconeogenesis. The duration of administration Close clinical monitoring of glycemic control is recommended if topical corticosteroids are administered chronically and/or to large areas in diabetic patients.", "source": "DDInter", "management_text": "-", "mechanism_text": "Antagonism", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/98000/", "reference_text": "[1] Pace WE \"Topical corticosteroids.\" Can Med Assoc J 108 (1973): 11 passim[2] Seale JP, Compton MR \"Side-effects of corticosteroid agents.\" Med J Aust 144 (1986): 139-42[3] \"Product Information. Psorcon (diflorasone topical).\" Rhone-Poulenc Rorer, Collegeville, PA.[4] \"Product Information. Temovate (clobetasol).\" Glaxo Wellcome, Research Triangle Park, NC.[5] \"Product Information. Ultravate (halobetasol).\" Bristol-Myers Squibb, Princeton, NJ.[6] Carruthers JA, Staughton RC, August PJ \"Penetration of topical steroid preparations.\" Arch Dermatol 113 (1977): 522[7] Ludvik B, Clodi M, Kautzky-Willer A, Capek M, Hartter E, Pacini G, Prager R \"Effect of dexamethasone on insulin sensitivity, islet amyloid polypeptide and insulin secretion in humans.\" Diabetologia 36 (1993): 84-7[8] \"Product Information. Diprolene (betamethasone topical).\" Schering Laboratories, Kenilworth, NJ.[9] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[10] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[11] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[12] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42[13] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[14] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[15] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[16] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[17] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[18] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6", "alternatives_a": "Simvastatin, Guar gum, Rosuvastatin", "alternatives_b": "", "updated_at": 1767369485}, {"id": 97897, "ingredient1": "Gatifloxacin", "ingredient2": "Empagliflozin", "severity": "Major", "effect": "Gatifloxacin may interfere with the therapeutic effects of insulin and other antidiabetic agents. The use of various quinolones has been associated with disturbances in blood glucose homeostasis possibly stemming from effects on pancreatic beta cell ATP-sensitive potassium channels that regulate insulin secretion.", "source": "DDInter", "management_text": "The use of gatifloxacin is contraindicated in patients with diabetes mellitus. Other quinolones may be safer alternatives in such patients, although all quinolones should be used with caution. Blood glucose should be closely monitored whenever quinolones are prescribed to patients receiving insulin or other antidiabetic agents, especially if they are elderly or have renal impairment. Patients should learn to recognize the symptoms of hypoglycemia such as headache, dizziness, drowsiness, nervousness, confusion, tremor, hunger, weakness, perspiration, palpitation, and tachycardia. If hypo- or hyperglycemia occur during quinolone therapy, patients should initiate appropriate remedial therapy immediately, discontinue the antibiotic, and contact their physician.", "mechanism_text": "Antagonism", "recommendation": "The use of gatifloxacin is contraindicated in patients with diabetes mellitus.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/98001/", "reference_text": "[1] Happe MR, Mulhall BP, Maydonovitch CL, Holtzmuller KC \"Gatifloxacin-induced hyperglycemia.\" Ann Intern Med 141 (2004): 968-9[2] Greenberg AL, Decerbo M, Fan J \"Gatifloxacin therapy associated with hypoglycemia.\" Clin Infect Dis 40 (2005): 1210-1[3] Park-Wyllie LY, Juurlink DN, Kopp A, et al. \"Outpatient gatifloxacin therapy and dysglycemia in older adults.\" N Engl J Med 354 (2006): 1352-61[4] \"Hypoglycemia and hyperglycemia with fluoroquinolones.\" Med Lett Drugs Ther 45 (2003): 64[5] Blommel AL, Lutes RA \"Severe hyperglycemia during renally adjusted gatifloxacin therapy.\" Ann Pharmacother 39 (2005): 1349-52[6] Gavin JR 3rd, Kubin R, Choudhri S, et al \"Moxifloxacin and glucose homeostasis: a pooled-analysis of the evidence from clinical and postmarketing studies.\" Drug Saf 27 (2004): 671-86[7] Zhanel GG, Fontaine S, Adam H, et al. \"A Review of New Fluoroquinolones : Focus on their Use in Respiratory Tract Infections.\" Treat Respir Med 5 (2006): 437-465[8] Rubinstein E \"History of quinolones and their side effects.\" Chemotherapy 47 Suppl 3 (2001): 3-8[9] Frothingham R \"Glucose homeostasis abnormalities associated with use of gatifloxacin.\" Clin Infect Dis 41 (2005): 1269-76[10] Tomita T, Onishi M, Sato E, Kimura Y, Kihira K \"Gatifloxacin induces augmented insulin release and intracellular insulin.\" Biol Pharm Bull 30 (2007): 644-7[11] Donaldson AR, Vandiver JR, Finch CK \"Possible gatifloxacin-induced hyperglycemia.\" Ann Pharmacother 38 (2004): 602-5[12] Bhasin R, Arce FC, Pasmantier R \"Hypoglycemia associated with the use of gatifloxacin.\" Am J Med Sci 330 (2005): 250-3[13] Gajjar DA, LaCreta FP, Kollia GD, et al. \"Effect of multiple-dose gatifloxacin or ciprofloxacin on glucose homeostasis and insulin production in patients with noninsulin-dependent diabetes mellitus maintained with diet and exercise.\" Pharmacotherapy 20 (6 Pt 2) (2000): s76-86[14] Menzies DJ, Dorsainvil PA, Cunha BA, Johnson DH \"Severe and persistent hypoglycemia due to gatifloxacin interaction with oral hypoglycemic agents.\" Am J Med 113 (2002): 232-4[15] Baker SE, Hangii MC \"Possible gatifloxacin-induced hypoglycemia.\" Ann Pharmacother 36 (2002): 1722-6[16] Graumlich JF, Habis S, Avelino RR, et al. \"Hypoglycemia in inpatients after gatifloxacin or levofloxacin therapy: nested case-control study.\" Pharmacotherapy 25 (2005): 1296-302[17] Letourneau G, Morrison H, McMorran M \"Gatifloxacin (Tequin): hypoglycemia and hyperglycemia. Available from: URL: http://www.hc-sc.gc.ca/dhp-mps/medeff/bulletin/carn-bcei_v13n3_e.html#1\" ([2003 Jul]):[18] Lin G, Hays DP, Spillane L \"Refractory hypoglycemia from ciprofloxacin and glyburide interaction.\" J Toxicol Clin Toxicol 42 (2004): 295-7[19] Saraya A, Yokokura M, Gonoi T, Seino S \"Effects of fluoroquinolones on insulin secretion and beta-cell ATP-sensitive K(+) channels.\" Eur J Pharmacol 497 (2004): 111-7[20] Roberge RJ, Kaplan R, Frank R, Fore C \"Glyburide-ciprofloxacin interaction with resistant hypoglycemia.\" Ann Emerg Med 36 (2000): 160-3[21] Brogan SE, Cahalan MK \"Gatifloxacin as a possible cause of serious postoperative hypoglycemia.\" Anesth Analg 101 (2005): 635-6[22] Khovidhunkit W, Sunthornyothin S \"Hypoglycemia, hyperglycemia, and gatifloxacin.\" Ann Intern Med 141 (2004): 969[23] LeBlanc M, Belanger C, Cossette P \"Severe and resistant hypoglycemia associated with concomitant gatifloxacin and glyburide therapy.\" Pharmacotherapy 24 (2004): 926-31[24] Biggs WS \"Hypoglycemia and hyperglycemia associated with gatifloxacin use in elderly patients.\" J Am Board Fam Pract 16 (2004): 455-7[25] Yip C, Lee AJ \"Gatifloxacin-induced hyperglycemia: a case report and summary of the current literature.\" Clin Ther 28 (2006): 1857-66[26] Zvonar R \"Gatifloxacin-induced dysglycemia.\" Am J Health Syst Pharm 63 (2006): 2087-2092[27] \"Product Information. Tequin (gatifloxacin)\" Bristol-Myers Squibb, Princeton, NJ.[28] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[29] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[30] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[31] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42[32] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[33] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[34] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[35] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[36] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[37] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6[38] \"Product Information. Tequin (gatifloxacin)\" Bristol-Myers Squibb, Princeton, NJ.[39] Wallace AW, Victory JM, Amsden GW \"Lack of bioequivalence of gatifloxacin when coadministered with calcium-fortified orange juice in healthy volunteers.\" J Clin Pharmacol 43 (2003): 92-6", "alternatives_a": "Rifamycin, Kanamycin, Ampicillin, Azithromycin, Acyclovir, Netilmicin, Polymyxin B, Famciclovir, Cefuroxime, Trifluridine, Tobramycin, More", "alternatives_b": "Guar gum", "updated_at": 1767369485}, {"id": 97898, "ingredient1": "Ginseng", "ingredient2": "Empagliflozin", "severity": "Moderate", "effect": "Coadministration of ginseng with antidiabetic drugs may potentiate the risk of hypoglycemia. Clinical data are conflicting. Some small studies have reported that ginseng reduced the blood levels of glucose and/or glycosylated hemoglobin (HbA1C) in diabetic patients, whereas others have not. Furthermore, the lack of standardized preparations of ginseng may limit the generalization of study results.", "source": "DDInter", "management_text": "Until more information is available, blood glucose should be monitored if antidiabetic agents are used concomitantly with ginseng. Patients should be advised on the potential signs and symptoms of hypoglycemia (e.g., headache, dizziness, drowsiness, nervousness, confusion, tremor, hunger, weakness, perspiration, palpitation, and tachycardia), how to treat it, and to contact their doctor if it occurs. Patients should also be advised to take precautions to avoid hypoglycemia while driving or operating hazardous machinery.", "mechanism_text": "Synergism", "recommendation": "Until more information is available, blood glucose should be monitored if antidiabetic agents are used concomitantly with ginseng.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/98002/", "reference_text": "[1] Win HH, Anderson R \"Hypoglycemia due to \"conception-enhancing\" oral supplement.\" Endocr Pract 24 (2019): 88-9[2] Vuksan V, Sievenpiper JL, Koo VY, et.al \"Efficacy and safety of Panax ginseng berry extract on glycemic control: A 12-wk randomized, double-blind, and placebo controlled trial.\" Arch Intern Med 160 (2000): 1009-13[3] Vuksan V, Sievenpiper JL, Koo VY, et al \"American ginseng (Panax quinquefolius L) reduces postprandial glycemia in nondiabetic subjects and subjects with type 2 diabetes mellitus.\" Arch Intern Med 160 (2000): 1009-13[4] Carabin IG, Burdock GA, Chatzidakis C \"Safety assessment of panax ginseng.\" Int J Toxicol 19 (2000): 293-301[5] Vuksan V, Sung MK, Sievenpiper JL, et.al \"Korean red ginseng (Panax ginseng) improves glucose and insulin regulation in well-controlled, type 2 diabetes: results of a randomized, double-blind, placebo-controlled study of efficacy and safety.\" Nutr Metab Cardiovasc Dis 18 (2008): 46-56[6] Sotaniemi EA, Haapakoski E, Rautio A \"Ginseng therapy in non-insulin-dependent diabetic patients.\" Diabetes Care 18 (1995): 1373-5[7] Vuskan V, Xu ZZ, Jovanovski E, et.al \"Efficacy and safety of American ginseng (Panax quinquefolius L) extract on glycemic control and cardiovascular risk factors in individuals with type 2 diabetes: a double-blind, randomized, cross-over clinical trial.\" Eur J Nutr 58 (2019): 1237-45[8] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[9] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[10] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[11] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42[12] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[13] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[14] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[15] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[16] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[17] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6", "alternatives_a": "Simvastatin, Guar gum, Rosuvastatin", "alternatives_b": "", "updated_at": 1767369485}, {"id": 97899, "ingredient1": "Glasdegib", "ingredient2": "Empagliflozin", "severity": "Moderate", "effect": "Coadministration with glasdegib may increase the plasma concentrations of drugs that are substrates of the P-glycoprotein (P-gp) and/or breast cancer resistance protein (BCRP) efflux transporters.", "source": "DDInter", "management_text": "Caution is advised if glasdegib is coadministered with drugs that are substrates of P-gp and/or BCRP, particularly those with a narrow therapeutic range. Clinical and laboratory monitoring should be considered whenever glasdegib is added to or withdrawn from therapy with these drugs, and dosages adjusted as necessary. Patients should be monitored for the development of adverse effects.", "mechanism_text": "Absorption", "recommendation": "Caution is advised if glasdegib is coadministered with drugs that are substrates of P-gp and/or BCRP, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/98003/", "reference_text": "[1] \"Product Information. Daurismo (glasdegib).\" Pfizer U.S. Pharmaceuticals Group, New York, NY.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Daurismo (glasdegib).\" Pfizer U.S. Pharmaceuticals Group, New York, NY.", "alternatives_a": "Glipizide, Acetohexamide, Guar gum, Pramlintide, Alogliptin, Tolazamide, Dulaglutide, Exenatide, Tolbutamide, Miglitol, Glimepiride, More", "alternatives_b": "Pertuzumab, Olaparib, Oxaliplatin, Rucaparib, Tisagenlecleucel, Aminolevulinic acid, Tazemetostat, Altretamine, Ixazomib, Sotorasib, Belzutifan, More", "updated_at": 1767369485}, {"id": 97900, "ingredient1": "Glimepiride", "ingredient2": "Empagliflozin", "severity": "Moderate", "effect": "Coadministration of a sodium-glucose co-transporter 2 (SGLT-2) inhibitor with an insulin secretagogue (e.g., sulfonylurea, meglitinide) or insulin may potentiate the risk of hypoglycemia.", "source": "DDInter", "management_text": "A lower dosage of the insulin secretagogue or insulin may be required when used in combination with an SGLT-2 inhibitor.", "mechanism_text": "Synergism", "recommendation": "A lower dosage of the insulin secretagogue or insulin may be required when used in combination with an SGLT-2 inhibitor.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/98004/", "reference_text": "[1] \"Product Information. Jardiance (empagliflozin).\" Boehringer Ingelheim, Ridgefield, CT.[2] \"Product Information. Steglatro (ertugliflozin).\" Merck & Company Inc, Whitehouse Station, NJ.[3] \"Product Information. Invokana (canagliflozin).\" Janssen Pharmaceuticals, Titusville, NJ.[4] Cerner Multum, Inc. \"Australian Product Information.\" O 0[5] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[6] \"Product Information. Farxiga (dapagliflozin).\" Bristol-Myers Squibb, Princeton, NJ.[7] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[8] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[9] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[10] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[11] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[12] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6[13] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[14] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[15] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[16] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42[17] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[18] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[19] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[20] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[21] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[22] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6[23] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[24] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[25] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[26] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42", "alternatives_a": "Guar gum, Pramlintide, Alogliptin, Rosuvastatin, Empagliflozin, Dulaglutide, Exenatide, Miglitol, Albiglutide, Rosiglitazone, Ertugliflozin, More", "alternatives_b": "Glimepiride, Acetohexamide, Troglitazone, Chlorpropamide, Tolazamide, Tolbutamide", "updated_at": 1767369485}, {"id": 97901, "ingredient1": "Glipizide", "ingredient2": "Empagliflozin", "severity": "Moderate", "effect": "Coadministration of a sodium-glucose co-transporter 2 (SGLT-2) inhibitor with an insulin secretagogue (e.g., sulfonylurea, meglitinide) or insulin may potentiate the risk of hypoglycemia.", "source": "DDInter", "management_text": "A lower dosage of the insulin secretagogue or insulin may be required when used in combination with an SGLT-2 inhibitor.", "mechanism_text": "Synergism", "recommendation": "A lower dosage of the insulin secretagogue or insulin may be required when used in combination with an SGLT-2 inhibitor.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/98005/", "reference_text": "[1] \"Product Information. Jardiance (empagliflozin).\" Boehringer Ingelheim, Ridgefield, CT.[2] \"Product Information. Steglatro (ertugliflozin).\" Merck & Company Inc, Whitehouse Station, NJ.[3] \"Product Information. Invokana (canagliflozin).\" Janssen Pharmaceuticals, Titusville, NJ.[4] Cerner Multum, Inc. \"Australian Product Information.\" O 0[5] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[6] \"Product Information. Farxiga (dapagliflozin).\" Bristol-Myers Squibb, Princeton, NJ.[7] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[8] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[9] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[10] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[11] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[12] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6[13] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[14] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[15] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[16] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42[17] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[18] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[19] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[20] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[21] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[22] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6[23] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[24] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[25] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[26] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42", "alternatives_a": "Guar gum, Pramlintide, Alogliptin, Rosuvastatin, Empagliflozin, Dulaglutide, Exenatide, Miglitol, Albiglutide, Rosiglitazone, Ertugliflozin, More", "alternatives_b": "Glipizide, Acetohexamide, Troglitazone, Tolazamide, Tolbutamide", "updated_at": 1767369485}, {"id": 97902, "ingredient1": "Glyburide", "ingredient2": "Empagliflozin", "severity": "Moderate", "effect": "Coadministration of a sodium-glucose co-transporter 2 (SGLT-2) inhibitor with an insulin secretagogue (e.g., sulfonylurea, meglitinide) or insulin may potentiate the risk of hypoglycemia.", "source": "DDInter", "management_text": "A lower dosage of the insulin secretagogue or insulin may be required when used in combination with an SGLT-2 inhibitor.", "mechanism_text": "Synergism", "recommendation": "A lower dosage of the insulin secretagogue or insulin may be required when used in combination with an SGLT-2 inhibitor.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/98006/", "reference_text": "[1] \"Product Information. Jardiance (empagliflozin).\" Boehringer Ingelheim, Ridgefield, CT.[2] \"Product Information. Steglatro (ertugliflozin).\" Merck & Company Inc, Whitehouse Station, NJ.[3] \"Product Information. Invokana (canagliflozin).\" Janssen Pharmaceuticals, Titusville, NJ.[4] Cerner Multum, Inc. \"Australian Product Information.\" O 0[5] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[6] \"Product Information. Farxiga (dapagliflozin).\" Bristol-Myers Squibb, Princeton, NJ.[7] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[8] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[9] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[10] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[11] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[12] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6[13] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[14] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[15] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[16] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42[17] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[18] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[19] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[20] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[21] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[22] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6[23] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[24] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[25] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[26] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42", "alternatives_a": "Guar gum, Pramlintide, Alogliptin, Rosuvastatin, Empagliflozin, Dulaglutide, Exenatide, Miglitol, Albiglutide, Rosiglitazone, Ertugliflozin, More", "alternatives_b": "Acetohexamide, Troglitazone, Tolazamide, Glyburide, Tolbutamide", "updated_at": 1767369485}, {"id": 97903, "ingredient1": "Goserelin", "ingredient2": "Empagliflozin", "severity": "Moderate", "effect": "The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.", "source": "DDInter", "management_text": "Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.", "mechanism_text": "Antagonism", "recommendation": "Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/98007/", "reference_text": "[1] Jori A, Carrara MC \"On the mechanism of the hyperglycaemic effect of chlorpromazine.\" J Pharm Pharmacol 18 (1966): 623-4[2] \"Product Information. Dymelor (acetohexamide)\" Lilly, Eli and Company, Indianapolis, IN.[3] \"Product Information. Thorazine (chlorpromazine).\" SmithKline Beecham, Philadelphia, PA.[4] Blayac JP, Ribes G, Buys D, Puech R, Loubatieres-Mariani MM \"Effects of a new benzothiadiazine derivative, LN 5330, on insulin secretion.\" Arch Int Pharmacodyn Ther 253 (1981): 154-63[5] \"Product Information. Elzonris (tagraxofusp).\" Stemline Therapeutics, New York, NY.[6] \"Product Information. Amaryl (glimepiride).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[7] \"Product Information. Elspar (asparaginase).\" Merck & Co, Inc, West Point, PA.[8] Jones IG, Pickens PT \"Diabetes mellitus following oral diuretics.\" Practitioner 199 (1967): 209-10[9] \"Product Information. Viracept (nelfinavir).\" Agouron Pharma Inc, La Jolla, CA.[10] \"Product Information. Tolinase (tolazamide)\" Pharmacia and Upjohn, Kalamazoo, MI.[11] Mauss S, Wolf E, Jaeger H \"Impaired glucose tolerance in HIV-positive patients receiving and those not receiving protease inhibitors.\" Ann Intern Med 130 (1999): 162-3[12] Virutamasen P, Wongsrichanalai C, Tangkeo P, Nitichai Y, Rienprayoon D \"Metabolic effects of depot-medroxyprogesterone acetate in long-term users: a cross-sectional study.\" Int J Gynaecol Obstet 24 (1986): 291-6[13] Wehring H, Alexander B, Perry PJ \"Diabetes mellitus associated with clozapine therapy.\" Pharmacotherapy 20 (2000): 844-7[14] Spellacy WN, Ellingson AB, Tsibris JC \"The effects of two triphasic oral contraceptives on carbohydrate metabolism in women during 1 year of use.\" Fertil Steril 51 (1989): 71-4[15] Andersen OO, Persson I \"Carbohydrate metabolism during treatment with chlorthalidone and ethacrynic acid.\" Br Med J 2 (1968): 798-801[16] Berlin I \"Prazosin, diuretics, and glucose intolerance.\" Ann Intern Med 119 (1993): 860[17] Malherbe C, Burrill KC, Levin SR, Karam JH, Forsham PH \"Effect of diphenylhydantoin on insulin secretion in man.\" N Engl J Med 286 (1972): 339-42[18] Carter BL, Small RE, Mandel MD, Starkman MT \"Phenytoin-induced hyperglycemia.\" Am J Hosp Pharm 38 (1981): 1508-12[19] Al-Rubeaan K, Ryan EA \"Phenytoin-induced insulin insensitivity.\" Diabet Med 8 (1991): 968-70[20] \"Product Information. Zolinza (vorinostat).\" Merck & Company Inc, West Point, PA.[21] Goldman JA, Neri A, Ovadia J, Eckerling B, Vries A, de \"Effect of chlorothiazide on intravenous glucose tolerance in pregnancy.\" Am J Obstet Gynecol 105 (1969): 556-60[22] Harper R, Ennis CN, Heaney AP, Sheridan B, Gormley M, Atkinson AB, Johnston GD, Bell PM \"A comparison of the effects of low- and conventional-dose thiazide diuretic on insulin action in hypertensive patients with NIDDM.\" Diabetologia 38 (1995): 853-9[23] Seltzer HS, Allen EW \"Hyperglycemia and inhibition of insulin secretion during administration of diazoxide and trichlormethiazide in man.\" Diabetes 18 (1969): 19-28[24] Dube MP, Johnson DL, Currier JS, Leedom JM \"Protease inhibitor-associated hyperglycaemia.\" Lancet 350 (1997): 713-4[25] Leary WP, Reyes AJ \"Drug interactions with diuretics.\" S Afr Med J 65 (1984): 455-61[26] \"Product Information. Reyataz (atazanavir).\" Bristol-Myers Squibb, Princeton, NJ.[27] Pollare T, Lithell H, Berne C \"A comparison of the effects of hydrochlorothiazide and captopril on glucose and lipid metabolism in patients with hypertension.\" N Engl J Med 321 (1989): 868-73[28] Gunnarsson R, Lundgren G, Magnusson G, Ost L, Groth CG \"Steroid diabetes--a sign of overtreatment with steroids in the renal graft recipient?\" Scand J Urol Nephrol Suppl 54 (1980): 135-8[29] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[30] \"Product Information. Synthroid (levothyroxine).\" Abbott Pharmaceutical, Abbott Park, IL.[31] Murphy MB, Kohner E, Lewis PJ, Schumer B, Dollery CT \"Glucose intolerance in hypertensive patients treated with diuretics: a fourteen-year follow-up.\" Lancet 2 (1982): 1293-5[32] \"Product Information. Fortovase (saquinavir)\" Roche Laboratories, Nutley, NJ.[33] Coni NK, Gordon PW, Mukherjee AP, Read PR \"The effect of frusemide and ethacrynic acid on carbohydrate metabolism.\" Age Ageing 3 (1974): 85-90[34] \"Product Information. Norvir (ritonavir).\" Abbott Pharmaceutical, Abbott Park, IL.[35] Domenet JG \"Diabetogenic effect of oral diuretics.\" Br Med J 3 (1968): 188[36] Rowe P, Mather H \"Hyperosmolar non-ketotic diabetes mellitus associated with metolazone.\" Br Med J 291 (1985): 25-6[37] Winchester JF, Kellett RJ, Boddy K, Boyle P, Dargie HJ, Mahaffey ME, Ward DM, Kennedy AC \"Metolazone and bendroflumethiazide in hypertension: physiologic and metabolic observations.\" Clin Pharmacol Ther 28 (1980): 611-8[38] \"Product Information. Carafate (sucralfate).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[39] Tsiodras S, Mantzoros C, Hammer S, Samore M \"Effects of protease inhibitors on hyperglycemia, hyperlipidemia, and lipodystrophy - A 5-year cohort study.\" Arch Intern Med 160 (2000): 2050-6[40] \"Product Information. Apidra (insulin glulisine).\" Aventis Pharmaceuticals, Bridgewater, NJ.[41] \"Product Information. Prezista (darunavir).\" Ortho Biotech Inc, Bridgewater, NJ.[42] Haiba NA, el-Habashy MA, Said SA, Darwish EA, Abdel-Sayed WS, Nayel SE \"Clinical evaluation of two monthly injectable contraceptives and their effects on some metabolic parameters.\" Contraception 39 (1989): 619-32[43] Erle G, Basso M, Federspil G, Sicolo N, Scandellari C \"Effect of chlorpromazine on blood glucose and plasma insulin in man.\" Eur J Clin Pharmacol 11 (1977): 15-8[44] Pickkers P, Schachter M, Hughes AD, Feher MD, Sever PS \"Thiazide-induced hyperglycaemia: a role for calcium-activated potassium channels?\" Diabetologia 39 (1996): 861-4[45] \"Product Information. Lexiva (fosamprenavir).\" GlaxoSmithKline, Research Triangle Park, NC.[46] Curtis J, Horrigan F, Ahearn D, Varney R, Sandler SG \"Chlorthalidone-induced hyperosmolar hyperglycemic nonketotic coma.\" JAMA 220 (1972): 1592-3[47] \"Product Information. Hyperstat I.V. (diazoxide).\" Schering Corp, Kenilworth, NJ.[48] \"Product Information. Piqray (alpelisib).\" Novartis Pharmaceuticals, East Hanover, NJ.[49] Bell DS \"Insulin resistance. An often unrecognized problem accompanying chronic medical disorders.\" Postgrad Med 93 (1993): 99-103,[50] Stambaugh JE, Tucker DC \"Effect of diphenylhydantoin on glucose tolerance in patients with hypoglycemia.\" Diabetes 23 (1974): 679-83[51] \"Product Information. Crixivan (indinavir).\" Merck & Co, Inc, West Point, PA.[52] Miller NR, Moses H \"Transient oculomotor nerve palsy. Association with thiazide-induced glucose intolerance.\" JAMA 240 (1978): 1887-8[53] Javier Z, Gershberg H, Hulse M \"Ovulatory suppressants, estrogens, and carbohydrate metabolism.\" Metabolism 17 (1968): 443-56[54] Goldman JA, Ovadia JL \"The effect of estrogen on intravenous glucose tolerance in woman.\" Am J Obstet Gynecol 103 (1969): 172-8[55] Charan VD, Desai N, Singh AP, Choudhry VP \"Diabetes mellitus and pancreatitis as a complication of L- asparaginase therapy.\" Indian Pediatr 30 (1993): 809-10[56] Seifer DB, Freedman LN, Cavender JR, Baker RA \"Insulin-dependent diabetes mellitus associated with danazol.\" Am J Obstet Gynecol 162 (1990): 474-5[57] \"Product Information. Orinase (tolbutamide)\" Pharmacia and Upjohn, Kalamazoo, MI.[58] Walli R, Demant T \"Impaired glucose tolerance and protease inhibitors.\" Ann Intern Med 129 (1998): 837-8[59] Hannaford PC, Kay CR \"Oral contraceptives and diabetes mellitus.\" BMJ 299 (1989): 1315-6[60] Hardy H, Esch LD, Morse GD \"Glucose disorders associated with HIV and its drug therapy.\" Ann Pharmacother 35 (2001): 343-51[61] Chowdhury FR, Bleicher SJ \"Chlorthalidone--induced hypokalemia and abnormal carbohydrate metabolism.\" Horm Metab Res 2 (1970): 13-6[62] Kaufman MB, Simionatto C \"A review of protease inhibitor-induced hyperglycemia.\" Pharmacotherapy 19 (1999): 114-7[63] Greenstone MA, Shaw AB \"Alternate day corticosteroid causes alternate day hyperglycaemia.\" Postgrad Med J 63 (1987): 761-4[64] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[65] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[66] Elmfeldt D, Berglund G, Wedel H, Wilhelmsen L \"Incidence and importance of metabolic side-effects during antihypertensive therapy.\" Acta Med Scand Suppl 672 (1983): 79-83[67] \"Product Information. Agenerase (amprenavir).\" Glaxo Wellcome, Research Triangle Pk, NC.[68] Diamond MT \"Hyperglycemic hyperosmolar coma associated with hydrochlorothiazide and pancreatitis.\" N Y State J Med 72 (1972): 1741-2[69] \"Product Information. Prandin (repaglinide).\" Novo Nordisk Pharmaceuticals Inc, Princeton, NJ.[70] \"Product Information. Precose (acarbose).\" Bayer, West Haven, CT.[71] \"Product Information. Starlix (nateglinide)\" Novartis Pharmaceuticals, East Hanover, NJ.[72] \"Product Information. Oncaspar (pegaspargase).\" Rhone-Poulenc Rorer, Collegeville, PA.[73] Sotaniemi E, Kontturi M, Larmi T \"Effect of diethylstilbestrol on blood glucose of prostatic cancer patients.\" Invest Urol 10 (1973): 438-41[74] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[75] Petri M, Cumber P, Grimes L, Treby D, Bryant R, Rawlins D, Ising H \"The metabolic effects of thiazide therapy in the elderly: a population study.\" Age Ageing 15 (1986): 151-5[76] Ludvik B, Clodi M, Kautzky-Willer A, Capek M, Hartter E, Pacini G, Prager R \"Effect of dexamethasone on insulin sensitivity, islet amyloid polypeptide and insulin secretion in humans.\" Diabetologia 36 (1993): 84-7[77] \"Product Information. Glucophage (metformin).\" Bristol-Myers Squibb, Princeton, NJ.[78] Chaudhuri ML, Catania J \"A comparison of the effects of bumetanide (Burinex) and frusemide on carbohydrate metabolism in the elderly.\" Br J Clin Pract 42 (1988): 427-9[79] Black DM, Filak AT \"Hyperglycemia with non-insulin-dependent diabetes following intraarticular steroid injection.\" J Fam Pract 28 (1989): 462-3[80] \"Product Information. Megace (megestrol).\" Bristol-Myers Squibb, Princeton, NJ.[81] \"Product Information. Torisel (temsirolimus).\" Wyeth-Ayerst Laboratories, Philadelphia, PA.[82] Schmitz O, Hermansen K, Nielsen OH, Christensen CK, Arnfred J, Hansen HE, Mogensen CE, Orskov H, Beck-Nielsen H \"Insulin action in insulin-dependent diabetics after short-term thiazide therapy.\" Diabetes Care 9 (1986): 631-6[83] Kansal PC, Buse J, Buse MG \"Thiazide diuretics and control of diabetes mellitus.\" South Med J 62 (1969): 1372-9[84] Dimitriadis G, Tegos C, Golfinopoulou L, Roboti C, Raptis S \"Furosemide-induced hyperglycaemia - the implication of glycolytic kinases.\" Horm Metab Res 25 (1993): 557-9[85] \"Product Information. NovoLog Mix 70/30 (insulin aspart-insulin aspart protamine).\" Novo Nordisk Pharmaceuticals Inc, Princeton, NJ.[86] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[87] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[88] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[89] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42[90] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[91] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[92] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[93] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[94] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[95] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6", "alternatives_a": "Bicalutamide", "alternatives_b": "Guar gum", "updated_at": 1767369485}, {"id": 97904, "ingredient1": "Grepafloxacin", "ingredient2": "Empagliflozin", "severity": "Moderate", "effect": "Quinolone antibiotics may interfere with the therapeutic effects of insulin and other antidiabetic agents. The use of quinolones has been associated with disturbances in blood glucose homeostasis possibly stemming from effects on pancreatic beta cell ATP-sensitive potassium channels that regulate insulin secretion. Both hyperglycaemia and hypoglycemia have been reported, usually in diabetic patients receiving concomitant treatment with an oral hypoglycemic agent (e.g., sulfonylurea) or insulin. Although hyperglycaemia is significantly more common and infection itself may be an underlying risk factor, hypoglycemia may cause greater morbidity and mortality.", "source": "DDInter", "management_text": "Blood glucose should be closely monitored whenever quinolones are prescribed to diabetic patients, especially if they are elderly, have renal impairment, or are severely ill. Patients should be apprised of the increased risk of dysglycemia and be particularly alert to potential signs and symptoms of hypoglycemia such as headache, dizziness, drowsiness, nervousness, confusion, tremor, hunger, weakness, perspiration, palpitation, and tachycardia. If hypoglycemia occurs, patients should initiate appropriate remedial therapy immediately, discontinue the quinolone, and contact their physician. Alternative antibiotics may need to be considered.", "mechanism_text": "Antagonism", "recommendation": "Blood glucose should be closely monitored whenever quinolones are prescribed to diabetic patients, especially if they are elderly, have renal impairment, or are severely ill.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/98008/", "reference_text": "[1] Gavin JR 3rd, Kubin R, Choudhri S, et al \"Moxifloxacin and glucose homeostasis: a pooled-analysis of the evidence from clinical and postmarketing studies.\" Drug Saf 27 (2004): 671-86[2] Yip C, Lee AJ \"Gatifloxacin-induced hyperglycemia: a case report and summary of the current literature.\" Clin Ther 28 (2006): 1857-66[3] Kelesidis T, Canseco E \"Quinolone-induced hypoglycemia: a life-threatening but potentially reversible side effect.\" Am J Med 123 (2010): e5-6[4] Baker SE, Hangii MC \"Possible gatifloxacin-induced hypoglycemia.\" Ann Pharmacother 36 (2002): 1722-6[5] \"Product Information. Levaquin (levofloxacin).\" Ortho Pharmaceutical Corporation, Raritan, NJ.[6] Frothingham R \"Glucose homeostasis abnormalities associated with use of gatifloxacin.\" Clin Infect Dis 41 (2005): 1269-76[7] Letourneau G, Morrison H, McMorran M \"Gatifloxacin (Tequin): hypoglycemia and hyperglycemia. Available from: URL: http://www.hc-sc.gc.ca/dhp-mps/medeff/bulletin/carn-bcei_v13n3_e.html#1\" ([2003 Jul]):[8] Lin G, Hays DP, Spillane L \"Refractory hypoglycemia from ciprofloxacin and glyburide interaction.\" J Toxicol Clin Toxicol 42 (2004): 295-7[9] \"Product Information. Tequin (gatifloxacin)\" Bristol-Myers Squibb, Princeton, NJ.[10] \"Product Information. Floxin (ofloxacin).\" Ortho Pharmaceutical Corporation, Raritan, NJ.[11] Bhasin R, Arce FC, Pasmantier R \"Hypoglycemia associated with the use of gatifloxacin.\" Am J Med Sci 330 (2005): 250-3[12] Zvonar R \"Gatifloxacin-induced dysglycemia.\" Am J Health Syst Pharm 63 (2006): 2087-2092[13] Rubinstein E \"History of quinolones and their side effects.\" Chemotherapy 47 Suppl 3 (2001): 3-8[14] Park-Wyllie LY, Juurlink DN, Kopp A, et al. \"Outpatient gatifloxacin therapy and dysglycemia in older adults.\" N Engl J Med 354 (2006): 1352-61[15] LeBlanc M, Belanger C, Cossette P \"Severe and resistant hypoglycemia associated with concomitant gatifloxacin and glyburide therapy.\" Pharmacotherapy 24 (2004): 926-31[16] \"Product Information. Cipro (ciprofloxacin).\" Bayer, West Haven, CT.[17] Happe MR, Mulhall BP, Maydonovitch CL, Holtzmuller KC \"Gatifloxacin-induced hyperglycemia.\" Ann Intern Med 141 (2004): 968-9[18] Biggs WS \"Hypoglycemia and hyperglycemia associated with gatifloxacin use in elderly patients.\" J Am Board Fam Pract 16 (2004): 455-7[19] \"Product Information. Raxar (grepafloxacin).\" Glaxo Wellcome, Research Triangle Park, NC.[20] Brogan SE, Cahalan MK \"Gatifloxacin as a possible cause of serious postoperative hypoglycemia.\" Anesth Analg 101 (2005): 635-6[21] Friedrich LV, Dougherty R \"Fatal hypoglycemia associated with levofloxacin.\" Pharmacotherapy 24 (2004): 1807-12[22] Saraya A, Yokokura M, Gonoi T, Seino S \"Effects of fluoroquinolones on insulin secretion and beta-cell ATP-sensitive K(+) channels.\" Eur J Pharmacol 497 (2004): 111-7[23] \"Hypoglycemia and hyperglycemia with fluoroquinolones.\" Med Lett Drugs Ther 45 (2003): 64[24] Gajjar DA, LaCreta FP, Kollia GD, et al. \"Effect of multiple-dose gatifloxacin or ciprofloxacin on glucose homeostasis and insulin production in patients with noninsulin-dependent diabetes mellitus maintained with diet and exercise.\" Pharmacotherapy 20 (6 Pt 2) (2000): s76-86[25] Khovidhunkit W, Sunthornyothin S \"Hypoglycemia, hyperglycemia, and gatifloxacin.\" Ann Intern Med 141 (2004): 969[26] Kanbay M, Aydogan T, Bozalan R, et al. \"A rare but serious side effect of levofloxacin: hypoglycemia in a geriatric patient.\" Diabetes Care 29 (2006): 1716-7[27] Menzies DJ, Dorsainvil PA, Cunha BA, Johnson DH \"Severe and persistent hypoglycemia due to gatifloxacin interaction with oral hypoglycemic agents.\" Am J Med 113 (2002): 232-4[28] Edwards DJ, Bowles SK, Svensson CK, Rybak MJ \"Inhibition of drug metabolism by quinolone antibiotics.\" Clin Pharmacokinet 15 (1988): 194-204[29] Graumlich JF, Habis S, Avelino RR, et al. \"Hypoglycemia in inpatients after gatifloxacin or levofloxacin therapy: nested case-control study.\" Pharmacotherapy 25 (2005): 1296-302[30] \"Product Information. Factive (gemifloxacin).\" GeneSoft Inc, San Francisco, CA.[31] Wang S, Rizvi AA \"Levofloxacin-induced hypoglycemia in a nondiabetic patient.\" Am J Med Sci 331 (2006): 334-5[32] \"Product Information. Noroxin (norfloxacin).\" Merck & Co, Inc, West Point, PA.[33] Zhanel GG, Fontaine S, Adam H, et al. \"A Review of New Fluoroquinolones : Focus on their Use in Respiratory Tract Infections.\" Treat Respir Med 5 (2006): 437-465[34] \"Product Information. Baxdela (delafloxacin).\" Melinta Therapeutics, Lincolnshire, IL.[35] Greenberg AL, Decerbo M, Fan J \"Gatifloxacin therapy associated with hypoglycemia.\" Clin Infect Dis 40 (2005): 1210-1[36] Blommel AL, Lutes RA \"Severe hyperglycemia during renally adjusted gatifloxacin therapy.\" Ann Pharmacother 39 (2005): 1349-52[37] Tomita T, Onishi M, Sato E, Kimura Y, Kihira K \"Gatifloxacin induces augmented insulin release and intracellular insulin.\" Biol Pharm Bull 30 (2007): 644-7[38] Donaldson AR, Vandiver JR, Finch CK \"Possible gatifloxacin-induced hyperglycemia.\" Ann Pharmacother 38 (2004): 602-5[39] \"Product Information. Trovan (trovafloxacin).\" Pfizer US Pharmaceuticals, New York, NY.[40] Roberge RJ, Kaplan R, Frank R, Fore C \"Glyburide-ciprofloxacin interaction with resistant hypoglycemia.\" Ann Emerg Med 36 (2000): 160-3[41] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[42] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[43] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[44] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42[45] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[46] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[47] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[48] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[49] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[50] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6", "alternatives_a": "Troglitazone, Rosuvastatin, Acetohexamide, Guar gum", "alternatives_b": "", "updated_at": 1767369485}, {"id": 97905, "ingredient1": "Guanabenz", "ingredient2": "Empagliflozin", "severity": "Moderate", "effect": "Sodium-glucose co-transporter 2 (SGLT-2) inhibitors may potentiate the hypotensive effects of diuretics and other antihypertensive agents or vasodilators. Inhibition of glucose and sodium co-transport produces mild diuresis and transient natriuresis, resulting in intravascular volume contraction. Volume depletion-related adverse reactions including hypotension, postural dizziness, orthostatic hypotension, syncope, and dehydration can occur after initiating treatment with SGLT-2 inhibitors, and the risk may be increased with concomitant use of other agents that can lower blood pressure.", "source": "DDInter", "management_text": "Caution is advised if SGLT-2 inhibitors are coadministered with diuretics and other hypotensive agents, particularly in the elderly and patients with impaired renal function. Prior to initiating SGLT-2 inhibitors, volume status should be assessed and corrected, if necessary. Clinical and laboratory monitoring are recommended during therapy, including electrolytes, fluid status, renal function, and blood pressure. If volume depletion occurs, treatment with SGLT-2 inhibitors should be interrupted until the condition is corrected.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if SGLT-2 inhibitors are coadministered with diuretics and other hypotensive agents, particularly in the elderly and patients with impaired renal function.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/98009/", "reference_text": "[1] \"Product Information. Jardiance (empagliflozin).\" Boehringer Ingelheim, Ridgefield, CT.[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] \"Product Information. Farxiga (dapagliflozin).\" Bristol-Myers Squibb, Princeton, NJ.[5] \"Product Information. Invokana (canagliflozin).\" Janssen Pharmaceuticals, Titusville, NJ.[6] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[7] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[8] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[9] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[10] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[11] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6[12] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[13] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[14] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[15] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42", "alternatives_a": "Glipizide, Acetohexamide, Guar gum, Pramlintide, Alogliptin, Rosuvastatin, Tolazamide, Dulaglutide, Exenatide, Tolbutamide, Miglitol, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 97906, "ingredient1": "Guanadrel", "ingredient2": "Empagliflozin", "severity": "Moderate", "effect": "Sodium-glucose co-transporter 2 (SGLT-2) inhibitors may potentiate the hypotensive effects of diuretics and other antihypertensive agents or vasodilators. Inhibition of glucose and sodium co-transport produces mild diuresis and transient natriuresis, resulting in intravascular volume contraction. Volume depletion-related adverse reactions including hypotension, postural dizziness, orthostatic hypotension, syncope, and dehydration can occur after initiating treatment with SGLT-2 inhibitors, and the risk may be increased with concomitant use of other agents that can lower blood pressure.", "source": "DDInter", "management_text": "Caution is advised if SGLT-2 inhibitors are coadministered with diuretics and other hypotensive agents, particularly in the elderly and patients with impaired renal function. Prior to initiating SGLT-2 inhibitors, volume status should be assessed and corrected, if necessary. Clinical and laboratory monitoring are recommended during therapy, including electrolytes, fluid status, renal function, and blood pressure. If volume depletion occurs, treatment with SGLT-2 inhibitors should be interrupted until the condition is corrected.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if SGLT-2 inhibitors are coadministered with diuretics and other hypotensive agents, particularly in the elderly and patients with impaired renal function.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/98010/", "reference_text": "[1] \"Product Information. Jardiance (empagliflozin).\" Boehringer Ingelheim, Ridgefield, CT.[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] \"Product Information. Farxiga (dapagliflozin).\" Bristol-Myers Squibb, Princeton, NJ.[5] \"Product Information. Invokana (canagliflozin).\" Janssen Pharmaceuticals, Titusville, NJ.[6] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[7] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[8] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[9] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[10] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[11] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6[12] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[13] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[14] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[15] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42", "alternatives_a": "Guar gum, Pramlintide, Alogliptin, Rosuvastatin, Dulaglutide, Exenatide, Miglitol, Albiglutide, Rosiglitazone, Semaglutide, Pioglitazone, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 97907, "ingredient1": "Guanethidine", "ingredient2": "Empagliflozin", "severity": "Moderate", "effect": "Sodium-glucose co-transporter 2 (SGLT-2) inhibitors may potentiate the hypotensive effects of diuretics and other antihypertensive agents or vasodilators. Inhibition of glucose and sodium co-transport produces mild diuresis and transient natriuresis, resulting in intravascular volume contraction. Volume depletion-related adverse reactions including hypotension, postural dizziness, orthostatic hypotension, syncope, and dehydration can occur after initiating treatment with SGLT-2 inhibitors, and the risk may be increased with concomitant use of other agents that can lower blood pressure.", "source": "DDInter", "management_text": "Caution is advised if SGLT-2 inhibitors are coadministered with diuretics and other hypotensive agents, particularly in the elderly and patients with impaired renal function. Prior to initiating SGLT-2 inhibitors, volume status should be assessed and corrected, if necessary. Clinical and laboratory monitoring are recommended during therapy, including electrolytes, fluid status, renal function, and blood pressure. If volume depletion occurs, treatment with SGLT-2 inhibitors should be interrupted until the condition is corrected.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if SGLT-2 inhibitors are coadministered with diuretics and other hypotensive agents, particularly in the elderly and patients with impaired renal function.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/98011/", "reference_text": "[1] \"Product Information. Jardiance (empagliflozin).\" Boehringer Ingelheim, Ridgefield, CT.[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] \"Product Information. Farxiga (dapagliflozin).\" Bristol-Myers Squibb, Princeton, NJ.[5] \"Product Information. Invokana (canagliflozin).\" Janssen Pharmaceuticals, Titusville, NJ.[6] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[7] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[8] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[9] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[10] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[11] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6[12] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[13] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[14] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[15] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42", "alternatives_a": "Latanoprost, Apraclonidine, Neostigmine, Pilocarpine, Physostigmine, Acetylcholine, Bimatoprost, Travoprost, Brinzolamide, Brimonidine, Levobunolol", "alternatives_b": "Guar gum, Pramlintide, Alogliptin, Rosuvastatin, Dulaglutide, Exenatide, Miglitol, Albiglutide, Rosiglitazone, Semaglutide, Pioglitazone, More", "updated_at": 1767369485}, {"id": 97908, "ingredient1": "Guanfacine", "ingredient2": "Empagliflozin", "severity": "Moderate", "effect": "Sodium-glucose co-transporter 2 (SGLT-2) inhibitors may potentiate the hypotensive effects of diuretics and other antihypertensive agents or vasodilators. Inhibition of glucose and sodium co-transport produces mild diuresis and transient natriuresis, resulting in intravascular volume contraction. Volume depletion-related adverse reactions including hypotension, postural dizziness, orthostatic hypotension, syncope, and dehydration can occur after initiating treatment with SGLT-2 inhibitors, and the risk may be increased with concomitant use of other agents that can lower blood pressure.", "source": "DDInter", "management_text": "Caution is advised if SGLT-2 inhibitors are coadministered with diuretics and other hypotensive agents, particularly in the elderly and patients with impaired renal function. Prior to initiating SGLT-2 inhibitors, volume status should be assessed and corrected, if necessary. Clinical and laboratory monitoring are recommended during therapy, including electrolytes, fluid status, renal function, and blood pressure. If volume depletion occurs, treatment with SGLT-2 inhibitors should be interrupted until the condition is corrected.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if SGLT-2 inhibitors are coadministered with diuretics and other hypotensive agents, particularly in the elderly and patients with impaired renal function.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/98012/", "reference_text": "[1] \"Product Information. Jardiance (empagliflozin).\" Boehringer Ingelheim, Ridgefield, CT.[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] \"Product Information. Farxiga (dapagliflozin).\" Bristol-Myers Squibb, Princeton, NJ.[5] \"Product Information. Invokana (canagliflozin).\" Janssen Pharmaceuticals, Titusville, NJ.[6] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[7] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[8] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[9] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[10] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[11] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6[12] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[13] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[14] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[15] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42", "alternatives_a": "Glipizide, Acetohexamide, Guar gum, Pramlintide, Alogliptin, Rosuvastatin, Tolazamide, Dulaglutide, Exenatide, Tolbutamide, Miglitol, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 97909, "ingredient1": "Halcinonide (topical)", "ingredient2": "Empagliflozin", "severity": "Minor", "effect": "The efficacy of insulin and other antidiabetic agents may be diminished by topical corticosteroids, particularly during prolonged or indiscriminate use. Corticosteroids can raise blood glucose level by antagonizing the action and suppressing the secretion of insulin, which results in inhibition of peripheral glucose uptake and increased gluconeogenesis. The duration of administration Close clinical monitoring of glycemic control is recommended if topical corticosteroids are administered chronically and/or to large areas in diabetic patients.", "source": "DDInter", "management_text": "-", "mechanism_text": "Antagonism", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/98013/", "reference_text": "[1] Pace WE \"Topical corticosteroids.\" Can Med Assoc J 108 (1973): 11 passim[2] Seale JP, Compton MR \"Side-effects of corticosteroid agents.\" Med J Aust 144 (1986): 139-42[3] \"Product Information. Psorcon (diflorasone topical).\" Rhone-Poulenc Rorer, Collegeville, PA.[4] \"Product Information. Temovate (clobetasol).\" Glaxo Wellcome, Research Triangle Park, NC.[5] \"Product Information. Ultravate (halobetasol).\" Bristol-Myers Squibb, Princeton, NJ.[6] Carruthers JA, Staughton RC, August PJ \"Penetration of topical steroid preparations.\" Arch Dermatol 113 (1977): 522[7] Ludvik B, Clodi M, Kautzky-Willer A, Capek M, Hartter E, Pacini G, Prager R \"Effect of dexamethasone on insulin sensitivity, islet amyloid polypeptide and insulin secretion in humans.\" Diabetologia 36 (1993): 84-7[8] \"Product Information. Diprolene (betamethasone topical).\" Schering Laboratories, Kenilworth, NJ.[9] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[10] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[11] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[12] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42[13] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[14] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[15] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[16] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[17] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[18] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6", "alternatives_a": "Simvastatin, Guar gum, Rosuvastatin", "alternatives_b": "", "updated_at": 1767369485}, {"id": 97910, "ingredient1": "Empagliflozin", "ingredient2": "Ulobetasol (topical)", "severity": "Minor", "effect": "The efficacy of insulin and other antidiabetic agents may be diminished by topical corticosteroids, particularly during prolonged or indiscriminate use. Corticosteroids can raise blood glucose level by antagonizing the action and suppressing the secretion of insulin, which results in inhibition of peripheral glucose uptake and increased gluconeogenesis. The duration of administration Close clinical monitoring of glycemic control is recommended if topical corticosteroids are administered chronically and/or to large areas in diabetic patients.", "source": "DDInter", "management_text": "-", "mechanism_text": "Antagonism", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/98014/", "reference_text": "[1] Pace WE \"Topical corticosteroids.\" Can Med Assoc J 108 (1973): 11 passim[2] Seale JP, Compton MR \"Side-effects of corticosteroid agents.\" Med J Aust 144 (1986): 139-42[3] \"Product Information. Psorcon (diflorasone topical).\" Rhone-Poulenc Rorer, Collegeville, PA.[4] \"Product Information. Temovate (clobetasol).\" Glaxo Wellcome, Research Triangle Park, NC.[5] \"Product Information. Ultravate (halobetasol).\" Bristol-Myers Squibb, Princeton, NJ.[6] Carruthers JA, Staughton RC, August PJ \"Penetration of topical steroid preparations.\" Arch Dermatol 113 (1977): 522[7] Ludvik B, Clodi M, Kautzky-Willer A, Capek M, Hartter E, Pacini G, Prager R \"Effect of dexamethasone on insulin sensitivity, islet amyloid polypeptide and insulin secretion in humans.\" Diabetologia 36 (1993): 84-7[8] \"Product Information. Diprolene (betamethasone topical).\" Schering Laboratories, Kenilworth, NJ.[9] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[10] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[11] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[12] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42[13] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[14] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[15] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[16] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[17] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[18] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6", "alternatives_a": "Ulipristal, Norelgestromin, Ulipristal, Mifepristone, Raloxifene, Bazedoxifene, Prasterone", "alternatives_b": "Simvastatin, Guar gum, Rosuvastatin", "updated_at": 1767369485}, {"id": 97911, "ingredient1": "Histrelin", "ingredient2": "Empagliflozin", "severity": "Moderate", "effect": "The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.", "source": "DDInter", "management_text": "Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.", "mechanism_text": "Antagonism", "recommendation": "Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/98015/", "reference_text": "[1] Jori A, Carrara MC \"On the mechanism of the hyperglycaemic effect of chlorpromazine.\" J Pharm Pharmacol 18 (1966): 623-4[2] \"Product Information. Dymelor (acetohexamide)\" Lilly, Eli and Company, Indianapolis, IN.[3] \"Product Information. Thorazine (chlorpromazine).\" SmithKline Beecham, Philadelphia, PA.[4] Blayac JP, Ribes G, Buys D, Puech R, Loubatieres-Mariani MM \"Effects of a new benzothiadiazine derivative, LN 5330, on insulin secretion.\" Arch Int Pharmacodyn Ther 253 (1981): 154-63[5] \"Product Information. Elzonris (tagraxofusp).\" Stemline Therapeutics, New York, NY.[6] \"Product Information. Amaryl (glimepiride).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[7] \"Product Information. Elspar (asparaginase).\" Merck & Co, Inc, West Point, PA.[8] Jones IG, Pickens PT \"Diabetes mellitus following oral diuretics.\" Practitioner 199 (1967): 209-10[9] \"Product Information. Viracept (nelfinavir).\" Agouron Pharma Inc, La Jolla, CA.[10] \"Product Information. Tolinase (tolazamide)\" Pharmacia and Upjohn, Kalamazoo, MI.[11] Mauss S, Wolf E, Jaeger H \"Impaired glucose tolerance in HIV-positive patients receiving and those not receiving protease inhibitors.\" Ann Intern Med 130 (1999): 162-3[12] Virutamasen P, Wongsrichanalai C, Tangkeo P, Nitichai Y, Rienprayoon D \"Metabolic effects of depot-medroxyprogesterone acetate in long-term users: a cross-sectional study.\" Int J Gynaecol Obstet 24 (1986): 291-6[13] Wehring H, Alexander B, Perry PJ \"Diabetes mellitus associated with clozapine therapy.\" Pharmacotherapy 20 (2000): 844-7[14] Spellacy WN, Ellingson AB, Tsibris JC \"The effects of two triphasic oral contraceptives on carbohydrate metabolism in women during 1 year of use.\" Fertil Steril 51 (1989): 71-4[15] Andersen OO, Persson I \"Carbohydrate metabolism during treatment with chlorthalidone and ethacrynic acid.\" Br Med J 2 (1968): 798-801[16] Berlin I \"Prazosin, diuretics, and glucose intolerance.\" Ann Intern Med 119 (1993): 860[17] Malherbe C, Burrill KC, Levin SR, Karam JH, Forsham PH \"Effect of diphenylhydantoin on insulin secretion in man.\" N Engl J Med 286 (1972): 339-42[18] Carter BL, Small RE, Mandel MD, Starkman MT \"Phenytoin-induced hyperglycemia.\" Am J Hosp Pharm 38 (1981): 1508-12[19] Al-Rubeaan K, Ryan EA \"Phenytoin-induced insulin insensitivity.\" Diabet Med 8 (1991): 968-70[20] \"Product Information. Zolinza (vorinostat).\" Merck & Company Inc, West Point, PA.[21] Goldman JA, Neri A, Ovadia J, Eckerling B, Vries A, de \"Effect of chlorothiazide on intravenous glucose tolerance in pregnancy.\" Am J Obstet Gynecol 105 (1969): 556-60[22] Harper R, Ennis CN, Heaney AP, Sheridan B, Gormley M, Atkinson AB, Johnston GD, Bell PM \"A comparison of the effects of low- and conventional-dose thiazide diuretic on insulin action in hypertensive patients with NIDDM.\" Diabetologia 38 (1995): 853-9[23] Seltzer HS, Allen EW \"Hyperglycemia and inhibition of insulin secretion during administration of diazoxide and trichlormethiazide in man.\" Diabetes 18 (1969): 19-28[24] Dube MP, Johnson DL, Currier JS, Leedom JM \"Protease inhibitor-associated hyperglycaemia.\" Lancet 350 (1997): 713-4[25] Leary WP, Reyes AJ \"Drug interactions with diuretics.\" S Afr Med J 65 (1984): 455-61[26] \"Product Information. Reyataz (atazanavir).\" Bristol-Myers Squibb, Princeton, NJ.[27] Pollare T, Lithell H, Berne C \"A comparison of the effects of hydrochlorothiazide and captopril on glucose and lipid metabolism in patients with hypertension.\" N Engl J Med 321 (1989): 868-73[28] Gunnarsson R, Lundgren G, Magnusson G, Ost L, Groth CG \"Steroid diabetes--a sign of overtreatment with steroids in the renal graft recipient?\" Scand J Urol Nephrol Suppl 54 (1980): 135-8[29] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[30] \"Product Information. Synthroid (levothyroxine).\" Abbott Pharmaceutical, Abbott Park, IL.[31] Murphy MB, Kohner E, Lewis PJ, Schumer B, Dollery CT \"Glucose intolerance in hypertensive patients treated with diuretics: a fourteen-year follow-up.\" Lancet 2 (1982): 1293-5[32] \"Product Information. Fortovase (saquinavir)\" Roche Laboratories, Nutley, NJ.[33] Coni NK, Gordon PW, Mukherjee AP, Read PR \"The effect of frusemide and ethacrynic acid on carbohydrate metabolism.\" Age Ageing 3 (1974): 85-90[34] \"Product Information. Norvir (ritonavir).\" Abbott Pharmaceutical, Abbott Park, IL.[35] Domenet JG \"Diabetogenic effect of oral diuretics.\" Br Med J 3 (1968): 188[36] Rowe P, Mather H \"Hyperosmolar non-ketotic diabetes mellitus associated with metolazone.\" Br Med J 291 (1985): 25-6[37] Winchester JF, Kellett RJ, Boddy K, Boyle P, Dargie HJ, Mahaffey ME, Ward DM, Kennedy AC \"Metolazone and bendroflumethiazide in hypertension: physiologic and metabolic observations.\" Clin Pharmacol Ther 28 (1980): 611-8[38] \"Product Information. Carafate (sucralfate).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[39] Tsiodras S, Mantzoros C, Hammer S, Samore M \"Effects of protease inhibitors on hyperglycemia, hyperlipidemia, and lipodystrophy - A 5-year cohort study.\" Arch Intern Med 160 (2000): 2050-6[40] \"Product Information. Apidra (insulin glulisine).\" Aventis Pharmaceuticals, Bridgewater, NJ.[41] \"Product Information. Prezista (darunavir).\" Ortho Biotech Inc, Bridgewater, NJ.[42] Haiba NA, el-Habashy MA, Said SA, Darwish EA, Abdel-Sayed WS, Nayel SE \"Clinical evaluation of two monthly injectable contraceptives and their effects on some metabolic parameters.\" Contraception 39 (1989): 619-32[43] Erle G, Basso M, Federspil G, Sicolo N, Scandellari C \"Effect of chlorpromazine on blood glucose and plasma insulin in man.\" Eur J Clin Pharmacol 11 (1977): 15-8[44] Pickkers P, Schachter M, Hughes AD, Feher MD, Sever PS \"Thiazide-induced hyperglycaemia: a role for calcium-activated potassium channels?\" Diabetologia 39 (1996): 861-4[45] \"Product Information. Lexiva (fosamprenavir).\" GlaxoSmithKline, Research Triangle Park, NC.[46] Curtis J, Horrigan F, Ahearn D, Varney R, Sandler SG \"Chlorthalidone-induced hyperosmolar hyperglycemic nonketotic coma.\" JAMA 220 (1972): 1592-3[47] \"Product Information. Hyperstat I.V. (diazoxide).\" Schering Corp, Kenilworth, NJ.[48] \"Product Information. Piqray (alpelisib).\" Novartis Pharmaceuticals, East Hanover, NJ.[49] Bell DS \"Insulin resistance. An often unrecognized problem accompanying chronic medical disorders.\" Postgrad Med 93 (1993): 99-103,[50] Stambaugh JE, Tucker DC \"Effect of diphenylhydantoin on glucose tolerance in patients with hypoglycemia.\" Diabetes 23 (1974): 679-83[51] \"Product Information. Crixivan (indinavir).\" Merck & Co, Inc, West Point, PA.[52] Miller NR, Moses H \"Transient oculomotor nerve palsy. Association with thiazide-induced glucose intolerance.\" JAMA 240 (1978): 1887-8[53] Javier Z, Gershberg H, Hulse M \"Ovulatory suppressants, estrogens, and carbohydrate metabolism.\" Metabolism 17 (1968): 443-56[54] Goldman JA, Ovadia JL \"The effect of estrogen on intravenous glucose tolerance in woman.\" Am J Obstet Gynecol 103 (1969): 172-8[55] Charan VD, Desai N, Singh AP, Choudhry VP \"Diabetes mellitus and pancreatitis as a complication of L- asparaginase therapy.\" Indian Pediatr 30 (1993): 809-10[56] Seifer DB, Freedman LN, Cavender JR, Baker RA \"Insulin-dependent diabetes mellitus associated with danazol.\" Am J Obstet Gynecol 162 (1990): 474-5[57] \"Product Information. Orinase (tolbutamide)\" Pharmacia and Upjohn, Kalamazoo, MI.[58] Walli R, Demant T \"Impaired glucose tolerance and protease inhibitors.\" Ann Intern Med 129 (1998): 837-8[59] Hannaford PC, Kay CR \"Oral contraceptives and diabetes mellitus.\" BMJ 299 (1989): 1315-6[60] Hardy H, Esch LD, Morse GD \"Glucose disorders associated with HIV and its drug therapy.\" Ann Pharmacother 35 (2001): 343-51[61] Chowdhury FR, Bleicher SJ \"Chlorthalidone--induced hypokalemia and abnormal carbohydrate metabolism.\" Horm Metab Res 2 (1970): 13-6[62] Kaufman MB, Simionatto C \"A review of protease inhibitor-induced hyperglycemia.\" Pharmacotherapy 19 (1999): 114-7[63] Greenstone MA, Shaw AB \"Alternate day corticosteroid causes alternate day hyperglycaemia.\" Postgrad Med J 63 (1987): 761-4[64] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[65] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[66] Elmfeldt D, Berglund G, Wedel H, Wilhelmsen L \"Incidence and importance of metabolic side-effects during antihypertensive therapy.\" Acta Med Scand Suppl 672 (1983): 79-83[67] \"Product Information. Agenerase (amprenavir).\" Glaxo Wellcome, Research Triangle Pk, NC.[68] Diamond MT \"Hyperglycemic hyperosmolar coma associated with hydrochlorothiazide and pancreatitis.\" N Y State J Med 72 (1972): 1741-2[69] \"Product Information. Prandin (repaglinide).\" Novo Nordisk Pharmaceuticals Inc, Princeton, NJ.[70] \"Product Information. Precose (acarbose).\" Bayer, West Haven, CT.[71] \"Product Information. Starlix (nateglinide)\" Novartis Pharmaceuticals, East Hanover, NJ.[72] \"Product Information. Oncaspar (pegaspargase).\" Rhone-Poulenc Rorer, Collegeville, PA.[73] Sotaniemi E, Kontturi M, Larmi T \"Effect of diethylstilbestrol on blood glucose of prostatic cancer patients.\" Invest Urol 10 (1973): 438-41[74] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[75] Petri M, Cumber P, Grimes L, Treby D, Bryant R, Rawlins D, Ising H \"The metabolic effects of thiazide therapy in the elderly: a population study.\" Age Ageing 15 (1986): 151-5[76] Ludvik B, Clodi M, Kautzky-Willer A, Capek M, Hartter E, Pacini G, Prager R \"Effect of dexamethasone on insulin sensitivity, islet amyloid polypeptide and insulin secretion in humans.\" Diabetologia 36 (1993): 84-7[77] \"Product Information. Glucophage (metformin).\" Bristol-Myers Squibb, Princeton, NJ.[78] Chaudhuri ML, Catania J \"A comparison of the effects of bumetanide (Burinex) and frusemide on carbohydrate metabolism in the elderly.\" Br J Clin Pract 42 (1988): 427-9[79] Black DM, Filak AT \"Hyperglycemia with non-insulin-dependent diabetes following intraarticular steroid injection.\" J Fam Pract 28 (1989): 462-3[80] \"Product Information. Megace (megestrol).\" Bristol-Myers Squibb, Princeton, NJ.[81] \"Product Information. Torisel (temsirolimus).\" Wyeth-Ayerst Laboratories, Philadelphia, PA.[82] Schmitz O, Hermansen K, Nielsen OH, Christensen CK, Arnfred J, Hansen HE, Mogensen CE, Orskov H, Beck-Nielsen H \"Insulin action in insulin-dependent diabetics after short-term thiazide therapy.\" Diabetes Care 9 (1986): 631-6[83] Kansal PC, Buse J, Buse MG \"Thiazide diuretics and control of diabetes mellitus.\" South Med J 62 (1969): 1372-9[84] Dimitriadis G, Tegos C, Golfinopoulou L, Roboti C, Raptis S \"Furosemide-induced hyperglycaemia - the implication of glycolytic kinases.\" Horm Metab Res 25 (1993): 557-9[85] \"Product Information. NovoLog Mix 70/30 (insulin aspart-insulin aspart protamine).\" Novo Nordisk Pharmaceuticals Inc, Princeton, NJ.[86] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[87] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[88] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[89] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42[90] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[91] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[92] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[93] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[94] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[95] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6", "alternatives_a": "Bicalutamide", "alternatives_b": "Simvastatin, Guar gum, Rosuvastatin", "updated_at": 1767369485}, {"id": 97912, "ingredient1": "Hydralazine", "ingredient2": "Empagliflozin", "severity": "Moderate", "effect": "Sodium-glucose co-transporter 2 (SGLT-2) inhibitors may potentiate the hypotensive effects of diuretics and other antihypertensive agents or vasodilators. Inhibition of glucose and sodium co-transport produces mild diuresis and transient natriuresis, resulting in intravascular volume contraction. Volume depletion-related adverse reactions including hypotension, postural dizziness, orthostatic hypotension, syncope, and dehydration can occur after initiating treatment with SGLT-2 inhibitors, and the risk may be increased with concomitant use of other agents that can lower blood pressure.", "source": "DDInter", "management_text": "Caution is advised if SGLT-2 inhibitors are coadministered with diuretics and other hypotensive agents, particularly in the elderly and patients with impaired renal function. Prior to initiating SGLT-2 inhibitors, volume status should be assessed and corrected, if necessary. Clinical and laboratory monitoring are recommended during therapy, including electrolytes, fluid status, renal function, and blood pressure. If volume depletion occurs, treatment with SGLT-2 inhibitors should be interrupted until the condition is corrected.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if SGLT-2 inhibitors are coadministered with diuretics and other hypotensive agents, particularly in the elderly and patients with impaired renal function.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/98016/", "reference_text": "[1] \"Product Information. Jardiance (empagliflozin).\" Boehringer Ingelheim, Ridgefield, CT.[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] \"Product Information. Farxiga (dapagliflozin).\" Bristol-Myers Squibb, Princeton, NJ.[5] \"Product Information. Invokana (canagliflozin).\" Janssen Pharmaceuticals, Titusville, NJ.[6] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[7] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[8] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[9] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[10] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[11] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6[12] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[13] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[14] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[15] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42", "alternatives_a": "Glipizide, Acetohexamide, Guar gum, Pramlintide, Alogliptin, Tolazamide, Dulaglutide, Exenatide, Tolbutamide, Miglitol, Glimepiride, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 97913, "ingredient1": "Hydroflumethiazide", "ingredient2": "Empagliflozin", "severity": "Moderate", "effect": "Sodium-glucose co-transporter 2 (SGLT-2) inhibitors may potentiate the diuretic and hypotensive effects of thiazides. Inhibition of glucose and sodium co-transport produces mild diuresis and transient natriuresis, resulting in intravascular volume contraction.", "source": "DDInter", "management_text": "Caution is advised during concomitant use of SGLT-2 inhibitors and thiazides, particularly in the elderly and patients with impaired renal function. Prior to initiating SGLT-2 inhibitors, volume status should be assessed and corrected, if necessary. Clinical and laboratory monitoring are recommended during therapy, including electrolytes, fluid status, renal function, and blood pressure. Blood glucose should also be monitored more closely. If volume depletion occurs, treatment with SGLT-2 inhibitors should be interrupted until the condition is corrected.", "mechanism_text": "Synergism", "recommendation": "Caution is advised during concomitant use of SGLT-2 inhibitors and thiazides, particularly in the elderly and patients with impaired renal function.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/98017/", "reference_text": "[1] \"Product Information. Steglatro (ertugliflozin).\" Merck & Company Inc, Whitehouse Station, NJ.[2] \"Product Information. Invokana (canagliflozin).\" Janssen Pharmaceuticals, Titusville, NJ.[3] \"Product Information. Farxiga (dapagliflozin).\" Bristol-Myers Squibb, Princeton, NJ.[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Jardiance (empagliflozin).\" Boehringer Ingelheim, Ridgefield, CT.[7] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[8] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[9] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[10] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[11] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[12] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6[13] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[14] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[15] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[16] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42", "alternatives_a": "Tinidazole, Ascorbic acid, Metronidazole, Rosuvastatin, Sulfadiazine, Lactic acid, Amphotericin B, Clindamycin, Ciclopirox, Vemurafenib, Ketoconazole, More", "alternatives_b": "Simvastatin, Guar gum, Rosuvastatin", "updated_at": 1767369485}, {"id": 97914, "ingredient1": "Iloperidone", "ingredient2": "Empagliflozin", "severity": "Moderate", "effect": "The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.", "source": "DDInter", "management_text": "Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.", "mechanism_text": "Antagonism", "recommendation": "Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/98018/", "reference_text": "[1] Jori A, Carrara MC \"On the mechanism of the hyperglycaemic effect of chlorpromazine.\" J Pharm Pharmacol 18 (1966): 623-4[2] \"Product Information. Dymelor (acetohexamide)\" Lilly, Eli and Company, Indianapolis, IN.[3] \"Product Information. Thorazine (chlorpromazine).\" SmithKline Beecham, Philadelphia, PA.[4] Blayac JP, Ribes G, Buys D, Puech R, Loubatieres-Mariani MM \"Effects of a new benzothiadiazine derivative, LN 5330, on insulin secretion.\" Arch Int Pharmacodyn Ther 253 (1981): 154-63[5] \"Product Information. Elzonris (tagraxofusp).\" Stemline Therapeutics, New York, NY.[6] \"Product Information. Amaryl (glimepiride).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[7] \"Product Information. Elspar (asparaginase).\" Merck & Co, Inc, West Point, PA.[8] Jones IG, Pickens PT \"Diabetes mellitus following oral diuretics.\" Practitioner 199 (1967): 209-10[9] \"Product Information. Viracept (nelfinavir).\" Agouron Pharma Inc, La Jolla, CA.[10] \"Product Information. Tolinase (tolazamide)\" Pharmacia and Upjohn, Kalamazoo, MI.[11] Mauss S, Wolf E, Jaeger H \"Impaired glucose tolerance in HIV-positive patients receiving and those not receiving protease inhibitors.\" Ann Intern Med 130 (1999): 162-3[12] Virutamasen P, Wongsrichanalai C, Tangkeo P, Nitichai Y, Rienprayoon D \"Metabolic effects of depot-medroxyprogesterone acetate in long-term users: a cross-sectional study.\" Int J Gynaecol Obstet 24 (1986): 291-6[13] Wehring H, Alexander B, Perry PJ \"Diabetes mellitus associated with clozapine therapy.\" Pharmacotherapy 20 (2000): 844-7[14] Spellacy WN, Ellingson AB, Tsibris JC \"The effects of two triphasic oral contraceptives on carbohydrate metabolism in women during 1 year of use.\" Fertil Steril 51 (1989): 71-4[15] Andersen OO, Persson I \"Carbohydrate metabolism during treatment with chlorthalidone and ethacrynic acid.\" Br Med J 2 (1968): 798-801[16] Berlin I \"Prazosin, diuretics, and glucose intolerance.\" Ann Intern Med 119 (1993): 860[17] Malherbe C, Burrill KC, Levin SR, Karam JH, Forsham PH \"Effect of diphenylhydantoin on insulin secretion in man.\" N Engl J Med 286 (1972): 339-42[18] Carter BL, Small RE, Mandel MD, Starkman MT \"Phenytoin-induced hyperglycemia.\" Am J Hosp Pharm 38 (1981): 1508-12[19] Al-Rubeaan K, Ryan EA \"Phenytoin-induced insulin insensitivity.\" Diabet Med 8 (1991): 968-70[20] \"Product Information. Zolinza (vorinostat).\" Merck & Company Inc, West Point, PA.[21] Goldman JA, Neri A, Ovadia J, Eckerling B, Vries A, de \"Effect of chlorothiazide on intravenous glucose tolerance in pregnancy.\" Am J Obstet Gynecol 105 (1969): 556-60[22] Harper R, Ennis CN, Heaney AP, Sheridan B, Gormley M, Atkinson AB, Johnston GD, Bell PM \"A comparison of the effects of low- and conventional-dose thiazide diuretic on insulin action in hypertensive patients with NIDDM.\" Diabetologia 38 (1995): 853-9[23] Seltzer HS, Allen EW \"Hyperglycemia and inhibition of insulin secretion during administration of diazoxide and trichlormethiazide in man.\" Diabetes 18 (1969): 19-28[24] Dube MP, Johnson DL, Currier JS, Leedom JM \"Protease inhibitor-associated hyperglycaemia.\" Lancet 350 (1997): 713-4[25] Leary WP, Reyes AJ \"Drug interactions with diuretics.\" S Afr Med J 65 (1984): 455-61[26] \"Product Information. Reyataz (atazanavir).\" Bristol-Myers Squibb, Princeton, NJ.[27] Pollare T, Lithell H, Berne C \"A comparison of the effects of hydrochlorothiazide and captopril on glucose and lipid metabolism in patients with hypertension.\" N Engl J Med 321 (1989): 868-73[28] Gunnarsson R, Lundgren G, Magnusson G, Ost L, Groth CG \"Steroid diabetes--a sign of overtreatment with steroids in the renal graft recipient?\" Scand J Urol Nephrol Suppl 54 (1980): 135-8[29] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[30] \"Product Information. Synthroid (levothyroxine).\" Abbott Pharmaceutical, Abbott Park, IL.[31] Murphy MB, Kohner E, Lewis PJ, Schumer B, Dollery CT \"Glucose intolerance in hypertensive patients treated with diuretics: a fourteen-year follow-up.\" Lancet 2 (1982): 1293-5[32] \"Product Information. Fortovase (saquinavir)\" Roche Laboratories, Nutley, NJ.[33] Coni NK, Gordon PW, Mukherjee AP, Read PR \"The effect of frusemide and ethacrynic acid on carbohydrate metabolism.\" Age Ageing 3 (1974): 85-90[34] \"Product Information. Norvir (ritonavir).\" Abbott Pharmaceutical, Abbott Park, IL.[35] Domenet JG \"Diabetogenic effect of oral diuretics.\" Br Med J 3 (1968): 188[36] Rowe P, Mather H \"Hyperosmolar non-ketotic diabetes mellitus associated with metolazone.\" Br Med J 291 (1985): 25-6[37] Winchester JF, Kellett RJ, Boddy K, Boyle P, Dargie HJ, Mahaffey ME, Ward DM, Kennedy AC \"Metolazone and bendroflumethiazide in hypertension: physiologic and metabolic observations.\" Clin Pharmacol Ther 28 (1980): 611-8[38] \"Product Information. Carafate (sucralfate).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[39] Tsiodras S, Mantzoros C, Hammer S, Samore M \"Effects of protease inhibitors on hyperglycemia, hyperlipidemia, and lipodystrophy - A 5-year cohort study.\" Arch Intern Med 160 (2000): 2050-6[40] \"Product Information. Apidra (insulin glulisine).\" Aventis Pharmaceuticals, Bridgewater, NJ.[41] \"Product Information. Prezista (darunavir).\" Ortho Biotech Inc, Bridgewater, NJ.[42] Haiba NA, el-Habashy MA, Said SA, Darwish EA, Abdel-Sayed WS, Nayel SE \"Clinical evaluation of two monthly injectable contraceptives and their effects on some metabolic parameters.\" Contraception 39 (1989): 619-32[43] Erle G, Basso M, Federspil G, Sicolo N, Scandellari C \"Effect of chlorpromazine on blood glucose and plasma insulin in man.\" Eur J Clin Pharmacol 11 (1977): 15-8[44] Pickkers P, Schachter M, Hughes AD, Feher MD, Sever PS \"Thiazide-induced hyperglycaemia: a role for calcium-activated potassium channels?\" Diabetologia 39 (1996): 861-4[45] \"Product Information. Lexiva (fosamprenavir).\" GlaxoSmithKline, Research Triangle Park, NC.[46] Curtis J, Horrigan F, Ahearn D, Varney R, Sandler SG \"Chlorthalidone-induced hyperosmolar hyperglycemic nonketotic coma.\" JAMA 220 (1972): 1592-3[47] \"Product Information. Hyperstat I.V. (diazoxide).\" Schering Corp, Kenilworth, NJ.[48] \"Product Information. Piqray (alpelisib).\" Novartis Pharmaceuticals, East Hanover, NJ.[49] Bell DS \"Insulin resistance. An often unrecognized problem accompanying chronic medical disorders.\" Postgrad Med 93 (1993): 99-103,[50] Stambaugh JE, Tucker DC \"Effect of diphenylhydantoin on glucose tolerance in patients with hypoglycemia.\" Diabetes 23 (1974): 679-83[51] \"Product Information. Crixivan (indinavir).\" Merck & Co, Inc, West Point, PA.[52] Miller NR, Moses H \"Transient oculomotor nerve palsy. Association with thiazide-induced glucose intolerance.\" JAMA 240 (1978): 1887-8[53] Javier Z, Gershberg H, Hulse M \"Ovulatory suppressants, estrogens, and carbohydrate metabolism.\" Metabolism 17 (1968): 443-56[54] Goldman JA, Ovadia JL \"The effect of estrogen on intravenous glucose tolerance in woman.\" Am J Obstet Gynecol 103 (1969): 172-8[55] Charan VD, Desai N, Singh AP, Choudhry VP \"Diabetes mellitus and pancreatitis as a complication of L- asparaginase therapy.\" Indian Pediatr 30 (1993): 809-10[56] Seifer DB, Freedman LN, Cavender JR, Baker RA \"Insulin-dependent diabetes mellitus associated with danazol.\" Am J Obstet Gynecol 162 (1990): 474-5[57] \"Product Information. Orinase (tolbutamide)\" Pharmacia and Upjohn, Kalamazoo, MI.[58] Walli R, Demant T \"Impaired glucose tolerance and protease inhibitors.\" Ann Intern Med 129 (1998): 837-8[59] Hannaford PC, Kay CR \"Oral contraceptives and diabetes mellitus.\" BMJ 299 (1989): 1315-6[60] Hardy H, Esch LD, Morse GD \"Glucose disorders associated with HIV and its drug therapy.\" Ann Pharmacother 35 (2001): 343-51[61] Chowdhury FR, Bleicher SJ \"Chlorthalidone--induced hypokalemia and abnormal carbohydrate metabolism.\" Horm Metab Res 2 (1970): 13-6[62] Kaufman MB, Simionatto C \"A review of protease inhibitor-induced hyperglycemia.\" Pharmacotherapy 19 (1999): 114-7[63] Greenstone MA, Shaw AB \"Alternate day corticosteroid causes alternate day hyperglycaemia.\" Postgrad Med J 63 (1987): 761-4[64] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[65] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[66] Elmfeldt D, Berglund G, Wedel H, Wilhelmsen L \"Incidence and importance of metabolic side-effects during antihypertensive therapy.\" Acta Med Scand Suppl 672 (1983): 79-83[67] \"Product Information. Agenerase (amprenavir).\" Glaxo Wellcome, Research Triangle Pk, NC.[68] Diamond MT \"Hyperglycemic hyperosmolar coma associated with hydrochlorothiazide and pancreatitis.\" N Y State J Med 72 (1972): 1741-2[69] \"Product Information. Prandin (repaglinide).\" Novo Nordisk Pharmaceuticals Inc, Princeton, NJ.[70] \"Product Information. Precose (acarbose).\" Bayer, West Haven, CT.[71] \"Product Information. Starlix (nateglinide)\" Novartis Pharmaceuticals, East Hanover, NJ.[72] \"Product Information. Oncaspar (pegaspargase).\" Rhone-Poulenc Rorer, Collegeville, PA.[73] Sotaniemi E, Kontturi M, Larmi T \"Effect of diethylstilbestrol on blood glucose of prostatic cancer patients.\" Invest Urol 10 (1973): 438-41[74] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[75] Petri M, Cumber P, Grimes L, Treby D, Bryant R, Rawlins D, Ising H \"The metabolic effects of thiazide therapy in the elderly: a population study.\" Age Ageing 15 (1986): 151-5[76] Ludvik B, Clodi M, Kautzky-Willer A, Capek M, Hartter E, Pacini G, Prager R \"Effect of dexamethasone on insulin sensitivity, islet amyloid polypeptide and insulin secretion in humans.\" Diabetologia 36 (1993): 84-7[77] \"Product Information. Glucophage (metformin).\" Bristol-Myers Squibb, Princeton, NJ.[78] Chaudhuri ML, Catania J \"A comparison of the effects of bumetanide (Burinex) and frusemide on carbohydrate metabolism in the elderly.\" Br J Clin Pract 42 (1988): 427-9[79] Black DM, Filak AT \"Hyperglycemia with non-insulin-dependent diabetes following intraarticular steroid injection.\" J Fam Pract 28 (1989): 462-3[80] \"Product Information. Megace (megestrol).\" Bristol-Myers Squibb, Princeton, NJ.[81] \"Product Information. Torisel (temsirolimus).\" Wyeth-Ayerst Laboratories, Philadelphia, PA.[82] Schmitz O, Hermansen K, Nielsen OH, Christensen CK, Arnfred J, Hansen HE, Mogensen CE, Orskov H, Beck-Nielsen H \"Insulin action in insulin-dependent diabetics after short-term thiazide therapy.\" Diabetes Care 9 (1986): 631-6[83] Kansal PC, Buse J, Buse MG \"Thiazide diuretics and control of diabetes mellitus.\" South Med J 62 (1969): 1372-9[84] Dimitriadis G, Tegos C, Golfinopoulou L, Roboti C, Raptis S \"Furosemide-induced hyperglycaemia - the implication of glycolytic kinases.\" Horm Metab Res 25 (1993): 557-9[85] \"Product Information. NovoLog Mix 70/30 (insulin aspart-insulin aspart protamine).\" Novo Nordisk Pharmaceuticals Inc, Princeton, NJ.[86] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[87] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[88] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[89] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42[90] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[91] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[92] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[93] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[94] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[95] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6", "alternatives_a": "Haloperidol, Pimavanserin, Thiothixene, Pimozide, Amisulpride, Loxapine, Molindone, Droperidol", "alternatives_b": "Simvastatin, Guar gum, Rosuvastatin", "updated_at": 1767369485}, {"id": 97915, "ingredient1": "Iloprost", "ingredient2": "Empagliflozin", "severity": "Moderate", "effect": "Sodium-glucose co-transporter 2 (SGLT-2) inhibitors may potentiate the hypotensive effects of diuretics and other antihypertensive agents or vasodilators. Inhibition of glucose and sodium co-transport produces mild diuresis and transient natriuresis, resulting in intravascular volume contraction. Volume depletion-related adverse reactions including hypotension, postural dizziness, orthostatic hypotension, syncope, and dehydration can occur after initiating treatment with SGLT-2 inhibitors, and the risk may be increased with concomitant use of other agents that can lower blood pressure.", "source": "DDInter", "management_text": "Caution is advised if SGLT-2 inhibitors are coadministered with diuretics and other hypotensive agents, particularly in the elderly and patients with impaired renal function. Prior to initiating SGLT-2 inhibitors, volume status should be assessed and corrected, if necessary. Clinical and laboratory monitoring are recommended during therapy, including electrolytes, fluid status, renal function, and blood pressure. If volume depletion occurs, treatment with SGLT-2 inhibitors should be interrupted until the condition is corrected.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if SGLT-2 inhibitors are coadministered with diuretics and other hypotensive agents, particularly in the elderly and patients with impaired renal function.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/98019/", "reference_text": "[1] \"Product Information. Jardiance (empagliflozin).\" Boehringer Ingelheim, Ridgefield, CT.[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] \"Product Information. Farxiga (dapagliflozin).\" Bristol-Myers Squibb, Princeton, NJ.[5] \"Product Information. Invokana (canagliflozin).\" Janssen Pharmaceuticals, Titusville, NJ.[6] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[7] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[8] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[9] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[10] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[11] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6[12] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[13] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[14] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[15] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42", "alternatives_a": "Ticagrelor, Betrixaban, Apixaban, Cilostazol, Rivaroxaban, Clopidogrel, Lepirudin, Acenocoumarol, Urokinase, Cangrelor, Dipyridamole, More", "alternatives_b": "Glipizide, Acetohexamide, Guar gum, Pramlintide, Alogliptin, Tolazamide, Dulaglutide, Exenatide, Tolbutamide, Miglitol, Glimepiride, More", "updated_at": 1767369485}, {"id": 97916, "ingredient1": "Indacaterol", "ingredient2": "Empagliflozin", "severity": "Moderate", "effect": "The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.", "source": "DDInter", "management_text": "Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.", "mechanism_text": "Antagonism", "recommendation": "Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/98020/", "reference_text": "[1] Jori A, Carrara MC \"On the mechanism of the hyperglycaemic effect of chlorpromazine.\" J Pharm Pharmacol 18 (1966): 623-4[2] \"Product Information. Dymelor (acetohexamide)\" Lilly, Eli and Company, Indianapolis, IN.[3] \"Product Information. Thorazine (chlorpromazine).\" SmithKline Beecham, Philadelphia, PA.[4] Blayac JP, Ribes G, Buys D, Puech R, Loubatieres-Mariani MM \"Effects of a new benzothiadiazine derivative, LN 5330, on insulin secretion.\" Arch Int Pharmacodyn Ther 253 (1981): 154-63[5] \"Product Information. Elzonris (tagraxofusp).\" Stemline Therapeutics, New York, NY.[6] \"Product Information. Amaryl (glimepiride).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[7] \"Product Information. Elspar (asparaginase).\" Merck & Co, Inc, West Point, PA.[8] Jones IG, Pickens PT \"Diabetes mellitus following oral diuretics.\" Practitioner 199 (1967): 209-10[9] \"Product Information. Viracept (nelfinavir).\" Agouron Pharma Inc, La Jolla, CA.[10] \"Product Information. Tolinase (tolazamide)\" Pharmacia and Upjohn, Kalamazoo, MI.[11] Mauss S, Wolf E, Jaeger H \"Impaired glucose tolerance in HIV-positive patients receiving and those not receiving protease inhibitors.\" Ann Intern Med 130 (1999): 162-3[12] Virutamasen P, Wongsrichanalai C, Tangkeo P, Nitichai Y, Rienprayoon D \"Metabolic effects of depot-medroxyprogesterone acetate in long-term users: a cross-sectional study.\" Int J Gynaecol Obstet 24 (1986): 291-6[13] Wehring H, Alexander B, Perry PJ \"Diabetes mellitus associated with clozapine therapy.\" Pharmacotherapy 20 (2000): 844-7[14] Spellacy WN, Ellingson AB, Tsibris JC \"The effects of two triphasic oral contraceptives on carbohydrate metabolism in women during 1 year of use.\" Fertil Steril 51 (1989): 71-4[15] Andersen OO, Persson I \"Carbohydrate metabolism during treatment with chlorthalidone and ethacrynic acid.\" Br Med J 2 (1968): 798-801[16] Berlin I \"Prazosin, diuretics, and glucose intolerance.\" Ann Intern Med 119 (1993): 860[17] Malherbe C, Burrill KC, Levin SR, Karam JH, Forsham PH \"Effect of diphenylhydantoin on insulin secretion in man.\" N Engl J Med 286 (1972): 339-42[18] Carter BL, Small RE, Mandel MD, Starkman MT \"Phenytoin-induced hyperglycemia.\" Am J Hosp Pharm 38 (1981): 1508-12[19] Al-Rubeaan K, Ryan EA \"Phenytoin-induced insulin insensitivity.\" Diabet Med 8 (1991): 968-70[20] \"Product Information. Zolinza (vorinostat).\" Merck & Company Inc, West Point, PA.[21] Goldman JA, Neri A, Ovadia J, Eckerling B, Vries A, de \"Effect of chlorothiazide on intravenous glucose tolerance in pregnancy.\" Am J Obstet Gynecol 105 (1969): 556-60[22] Harper R, Ennis CN, Heaney AP, Sheridan B, Gormley M, Atkinson AB, Johnston GD, Bell PM \"A comparison of the effects of low- and conventional-dose thiazide diuretic on insulin action in hypertensive patients with NIDDM.\" Diabetologia 38 (1995): 853-9[23] Seltzer HS, Allen EW \"Hyperglycemia and inhibition of insulin secretion during administration of diazoxide and trichlormethiazide in man.\" Diabetes 18 (1969): 19-28[24] Dube MP, Johnson DL, Currier JS, Leedom JM \"Protease inhibitor-associated hyperglycaemia.\" Lancet 350 (1997): 713-4[25] Leary WP, Reyes AJ \"Drug interactions with diuretics.\" S Afr Med J 65 (1984): 455-61[26] \"Product Information. Reyataz (atazanavir).\" Bristol-Myers Squibb, Princeton, NJ.[27] Pollare T, Lithell H, Berne C \"A comparison of the effects of hydrochlorothiazide and captopril on glucose and lipid metabolism in patients with hypertension.\" N Engl J Med 321 (1989): 868-73[28] Gunnarsson R, Lundgren G, Magnusson G, Ost L, Groth CG \"Steroid diabetes--a sign of overtreatment with steroids in the renal graft recipient?\" Scand J Urol Nephrol Suppl 54 (1980): 135-8[29] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[30] \"Product Information. Synthroid (levothyroxine).\" Abbott Pharmaceutical, Abbott Park, IL.[31] Murphy MB, Kohner E, Lewis PJ, Schumer B, Dollery CT \"Glucose intolerance in hypertensive patients treated with diuretics: a fourteen-year follow-up.\" Lancet 2 (1982): 1293-5[32] \"Product Information. Fortovase (saquinavir)\" Roche Laboratories, Nutley, NJ.[33] Coni NK, Gordon PW, Mukherjee AP, Read PR \"The effect of frusemide and ethacrynic acid on carbohydrate metabolism.\" Age Ageing 3 (1974): 85-90[34] \"Product Information. Norvir (ritonavir).\" Abbott Pharmaceutical, Abbott Park, IL.[35] Domenet JG \"Diabetogenic effect of oral diuretics.\" Br Med J 3 (1968): 188[36] Rowe P, Mather H \"Hyperosmolar non-ketotic diabetes mellitus associated with metolazone.\" Br Med J 291 (1985): 25-6[37] Winchester JF, Kellett RJ, Boddy K, Boyle P, Dargie HJ, Mahaffey ME, Ward DM, Kennedy AC \"Metolazone and bendroflumethiazide in hypertension: physiologic and metabolic observations.\" Clin Pharmacol Ther 28 (1980): 611-8[38] \"Product Information. Carafate (sucralfate).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[39] Tsiodras S, Mantzoros C, Hammer S, Samore M \"Effects of protease inhibitors on hyperglycemia, hyperlipidemia, and lipodystrophy - A 5-year cohort study.\" Arch Intern Med 160 (2000): 2050-6[40] \"Product Information. Apidra (insulin glulisine).\" Aventis Pharmaceuticals, Bridgewater, NJ.[41] \"Product Information. Prezista (darunavir).\" Ortho Biotech Inc, Bridgewater, NJ.[42] Haiba NA, el-Habashy MA, Said SA, Darwish EA, Abdel-Sayed WS, Nayel SE \"Clinical evaluation of two monthly injectable contraceptives and their effects on some metabolic parameters.\" Contraception 39 (1989): 619-32[43] Erle G, Basso M, Federspil G, Sicolo N, Scandellari C \"Effect of chlorpromazine on blood glucose and plasma insulin in man.\" Eur J Clin Pharmacol 11 (1977): 15-8[44] Pickkers P, Schachter M, Hughes AD, Feher MD, Sever PS \"Thiazide-induced hyperglycaemia: a role for calcium-activated potassium channels?\" Diabetologia 39 (1996): 861-4[45] \"Product Information. Lexiva (fosamprenavir).\" GlaxoSmithKline, Research Triangle Park, NC.[46] Curtis J, Horrigan F, Ahearn D, Varney R, Sandler SG \"Chlorthalidone-induced hyperosmolar hyperglycemic nonketotic coma.\" JAMA 220 (1972): 1592-3[47] \"Product Information. Hyperstat I.V. (diazoxide).\" Schering Corp, Kenilworth, NJ.[48] \"Product Information. Piqray (alpelisib).\" Novartis Pharmaceuticals, East Hanover, NJ.[49] Bell DS \"Insulin resistance. An often unrecognized problem accompanying chronic medical disorders.\" Postgrad Med 93 (1993): 99-103,[50] Stambaugh JE, Tucker DC \"Effect of diphenylhydantoin on glucose tolerance in patients with hypoglycemia.\" Diabetes 23 (1974): 679-83[51] \"Product Information. Crixivan (indinavir).\" Merck & Co, Inc, West Point, PA.[52] Miller NR, Moses H \"Transient oculomotor nerve palsy. Association with thiazide-induced glucose intolerance.\" JAMA 240 (1978): 1887-8[53] Javier Z, Gershberg H, Hulse M \"Ovulatory suppressants, estrogens, and carbohydrate metabolism.\" Metabolism 17 (1968): 443-56[54] Goldman JA, Ovadia JL \"The effect of estrogen on intravenous glucose tolerance in woman.\" Am J Obstet Gynecol 103 (1969): 172-8[55] Charan VD, Desai N, Singh AP, Choudhry VP \"Diabetes mellitus and pancreatitis as a complication of L- asparaginase therapy.\" Indian Pediatr 30 (1993): 809-10[56] Seifer DB, Freedman LN, Cavender JR, Baker RA \"Insulin-dependent diabetes mellitus associated with danazol.\" Am J Obstet Gynecol 162 (1990): 474-5[57] \"Product Information. Orinase (tolbutamide)\" Pharmacia and Upjohn, Kalamazoo, MI.[58] Walli R, Demant T \"Impaired glucose tolerance and protease inhibitors.\" Ann Intern Med 129 (1998): 837-8[59] Hannaford PC, Kay CR \"Oral contraceptives and diabetes mellitus.\" BMJ 299 (1989): 1315-6[60] Hardy H, Esch LD, Morse GD \"Glucose disorders associated with HIV and its drug therapy.\" Ann Pharmacother 35 (2001): 343-51[61] Chowdhury FR, Bleicher SJ \"Chlorthalidone--induced hypokalemia and abnormal carbohydrate metabolism.\" Horm Metab Res 2 (1970): 13-6[62] Kaufman MB, Simionatto C \"A review of protease inhibitor-induced hyperglycemia.\" Pharmacotherapy 19 (1999): 114-7[63] Greenstone MA, Shaw AB \"Alternate day corticosteroid causes alternate day hyperglycaemia.\" Postgrad Med J 63 (1987): 761-4[64] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[65] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[66] Elmfeldt D, Berglund G, Wedel H, Wilhelmsen L \"Incidence and importance of metabolic side-effects during antihypertensive therapy.\" Acta Med Scand Suppl 672 (1983): 79-83[67] \"Product Information. Agenerase (amprenavir).\" Glaxo Wellcome, Research Triangle Pk, NC.[68] Diamond MT \"Hyperglycemic hyperosmolar coma associated with hydrochlorothiazide and pancreatitis.\" N Y State J Med 72 (1972): 1741-2[69] \"Product Information. Prandin (repaglinide).\" Novo Nordisk Pharmaceuticals Inc, Princeton, NJ.[70] \"Product Information. Precose (acarbose).\" Bayer, West Haven, CT.[71] \"Product Information. Starlix (nateglinide)\" Novartis Pharmaceuticals, East Hanover, NJ.[72] \"Product Information. Oncaspar (pegaspargase).\" Rhone-Poulenc Rorer, Collegeville, PA.[73] Sotaniemi E, Kontturi M, Larmi T \"Effect of diethylstilbestrol on blood glucose of prostatic cancer patients.\" Invest Urol 10 (1973): 438-41[74] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[75] Petri M, Cumber P, Grimes L, Treby D, Bryant R, Rawlins D, Ising H \"The metabolic effects of thiazide therapy in the elderly: a population study.\" Age Ageing 15 (1986): 151-5[76] Ludvik B, Clodi M, Kautzky-Willer A, Capek M, Hartter E, Pacini G, Prager R \"Effect of dexamethasone on insulin sensitivity, islet amyloid polypeptide and insulin secretion in humans.\" Diabetologia 36 (1993): 84-7[77] \"Product Information. Glucophage (metformin).\" Bristol-Myers Squibb, Princeton, NJ.[78] Chaudhuri ML, Catania J \"A comparison of the effects of bumetanide (Burinex) and frusemide on carbohydrate metabolism in the elderly.\" Br J Clin Pract 42 (1988): 427-9[79] Black DM, Filak AT \"Hyperglycemia with non-insulin-dependent diabetes following intraarticular steroid injection.\" J Fam Pract 28 (1989): 462-3[80] \"Product Information. Megace (megestrol).\" Bristol-Myers Squibb, Princeton, NJ.[81] \"Product Information. Torisel (temsirolimus).\" Wyeth-Ayerst Laboratories, Philadelphia, PA.[82] Schmitz O, Hermansen K, Nielsen OH, Christensen CK, Arnfred J, Hansen HE, Mogensen CE, Orskov H, Beck-Nielsen H \"Insulin action in insulin-dependent diabetics after short-term thiazide therapy.\" Diabetes Care 9 (1986): 631-6[83] Kansal PC, Buse J, Buse MG \"Thiazide diuretics and control of diabetes mellitus.\" South Med J 62 (1969): 1372-9[84] Dimitriadis G, Tegos C, Golfinopoulou L, Roboti C, Raptis S \"Furosemide-induced hyperglycaemia - the implication of glycolytic kinases.\" Horm Metab Res 25 (1993): 557-9[85] \"Product Information. NovoLog Mix 70/30 (insulin aspart-insulin aspart protamine).\" Novo Nordisk Pharmaceuticals Inc, Princeton, NJ.[86] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[87] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[88] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[89] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42[90] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[91] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[92] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[93] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[94] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[95] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6", "alternatives_a": "Umeclidinium, Budesonide, Glycopyrronium, Aclidinium, Mometasone, Fluticasone, Cromoglicic acid, Ipratropium, Pirbuterol, Bitolterol, Olodaterol, More", "alternatives_b": "Acetohexamide, Guar gum, Pramlintide, Simvastatin, Rosuvastatin, Tolazamide", "updated_at": 1767369485}, {"id": 97917, "ingredient1": "Indapamide", "ingredient2": "Empagliflozin", "severity": "Moderate", "effect": "Sodium-glucose co-transporter 2 (SGLT-2) inhibitors may potentiate the diuretic and hypotensive effects of thiazides. Inhibition of glucose and sodium co-transport produces mild diuresis and transient natriuresis, resulting in intravascular volume contraction.", "source": "DDInter", "management_text": "Caution is advised during concomitant use of SGLT-2 inhibitors and thiazides, particularly in the elderly and patients with impaired renal function. Prior to initiating SGLT-2 inhibitors, volume status should be assessed and corrected, if necessary. Clinical and laboratory monitoring are recommended during therapy, including electrolytes, fluid status, renal function, and blood pressure. Blood glucose should also be monitored more closely. If volume depletion occurs, treatment with SGLT-2 inhibitors should be interrupted until the condition is corrected.", "mechanism_text": "Synergism", "recommendation": "Caution is advised during concomitant use of SGLT-2 inhibitors and thiazides, particularly in the elderly and patients with impaired renal function.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/98021/", "reference_text": "[1] \"Product Information. Steglatro (ertugliflozin).\" Merck & Company Inc, Whitehouse Station, NJ.[2] \"Product Information. Invokana (canagliflozin).\" Janssen Pharmaceuticals, Titusville, NJ.[3] \"Product Information. Farxiga (dapagliflozin).\" Bristol-Myers Squibb, Princeton, NJ.[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Jardiance (empagliflozin).\" Boehringer Ingelheim, Ridgefield, CT.[7] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[8] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[9] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[10] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[11] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[12] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6[13] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[14] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[15] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[16] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42", "alternatives_a": "Tinidazole, Ascorbic acid, Metronidazole, Rosuvastatin, Sulfadiazine, Lactic acid, Amphotericin B, Clindamycin, Ciclopirox, Vemurafenib, Ketoconazole, More", "alternatives_b": "Guar gum", "updated_at": 1767369485}, {"id": 97918, "ingredient1": "Indinavir", "ingredient2": "Empagliflozin", "severity": "Moderate", "effect": "The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.", "source": "DDInter", "management_text": "Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.", "mechanism_text": "Antagonism", "recommendation": "Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/98022/", "reference_text": "[1] Jori A, Carrara MC \"On the mechanism of the hyperglycaemic effect of chlorpromazine.\" J Pharm Pharmacol 18 (1966): 623-4[2] \"Product Information. Dymelor (acetohexamide)\" Lilly, Eli and Company, Indianapolis, IN.[3] \"Product Information. Thorazine (chlorpromazine).\" SmithKline Beecham, Philadelphia, PA.[4] Blayac JP, Ribes G, Buys D, Puech R, Loubatieres-Mariani MM \"Effects of a new benzothiadiazine derivative, LN 5330, on insulin secretion.\" Arch Int Pharmacodyn Ther 253 (1981): 154-63[5] \"Product Information. Elzonris (tagraxofusp).\" Stemline Therapeutics, New York, NY.[6] \"Product Information. Amaryl (glimepiride).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[7] \"Product Information. Elspar (asparaginase).\" Merck & Co, Inc, West Point, PA.[8] Jones IG, Pickens PT \"Diabetes mellitus following oral diuretics.\" Practitioner 199 (1967): 209-10[9] \"Product Information. Viracept (nelfinavir).\" Agouron Pharma Inc, La Jolla, CA.[10] \"Product Information. Tolinase (tolazamide)\" Pharmacia and Upjohn, Kalamazoo, MI.[11] Mauss S, Wolf E, Jaeger H \"Impaired glucose tolerance in HIV-positive patients receiving and those not receiving protease inhibitors.\" Ann Intern Med 130 (1999): 162-3[12] Virutamasen P, Wongsrichanalai C, Tangkeo P, Nitichai Y, Rienprayoon D \"Metabolic effects of depot-medroxyprogesterone acetate in long-term users: a cross-sectional study.\" Int J Gynaecol Obstet 24 (1986): 291-6[13] Wehring H, Alexander B, Perry PJ \"Diabetes mellitus associated with clozapine therapy.\" Pharmacotherapy 20 (2000): 844-7[14] Spellacy WN, Ellingson AB, Tsibris JC \"The effects of two triphasic oral contraceptives on carbohydrate metabolism in women during 1 year of use.\" Fertil Steril 51 (1989): 71-4[15] Andersen OO, Persson I \"Carbohydrate metabolism during treatment with chlorthalidone and ethacrynic acid.\" Br Med J 2 (1968): 798-801[16] Berlin I \"Prazosin, diuretics, and glucose intolerance.\" Ann Intern Med 119 (1993): 860[17] Malherbe C, Burrill KC, Levin SR, Karam JH, Forsham PH \"Effect of diphenylhydantoin on insulin secretion in man.\" N Engl J Med 286 (1972): 339-42[18] Carter BL, Small RE, Mandel MD, Starkman MT \"Phenytoin-induced hyperglycemia.\" Am J Hosp Pharm 38 (1981): 1508-12[19] Al-Rubeaan K, Ryan EA \"Phenytoin-induced insulin insensitivity.\" Diabet Med 8 (1991): 968-70[20] \"Product Information. Zolinza (vorinostat).\" Merck & Company Inc, West Point, PA.[21] Goldman JA, Neri A, Ovadia J, Eckerling B, Vries A, de \"Effect of chlorothiazide on intravenous glucose tolerance in pregnancy.\" Am J Obstet Gynecol 105 (1969): 556-60[22] Harper R, Ennis CN, Heaney AP, Sheridan B, Gormley M, Atkinson AB, Johnston GD, Bell PM \"A comparison of the effects of low- and conventional-dose thiazide diuretic on insulin action in hypertensive patients with NIDDM.\" Diabetologia 38 (1995): 853-9[23] Seltzer HS, Allen EW \"Hyperglycemia and inhibition of insulin secretion during administration of diazoxide and trichlormethiazide in man.\" Diabetes 18 (1969): 19-28[24] Dube MP, Johnson DL, Currier JS, Leedom JM \"Protease inhibitor-associated hyperglycaemia.\" Lancet 350 (1997): 713-4[25] Leary WP, Reyes AJ \"Drug interactions with diuretics.\" S Afr Med J 65 (1984): 455-61[26] \"Product Information. Reyataz (atazanavir).\" Bristol-Myers Squibb, Princeton, NJ.[27] Pollare T, Lithell H, Berne C \"A comparison of the effects of hydrochlorothiazide and captopril on glucose and lipid metabolism in patients with hypertension.\" N Engl J Med 321 (1989): 868-73[28] Gunnarsson R, Lundgren G, Magnusson G, Ost L, Groth CG \"Steroid diabetes--a sign of overtreatment with steroids in the renal graft recipient?\" Scand J Urol Nephrol Suppl 54 (1980): 135-8[29] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[30] \"Product Information. Synthroid (levothyroxine).\" Abbott Pharmaceutical, Abbott Park, IL.[31] Murphy MB, Kohner E, Lewis PJ, Schumer B, Dollery CT \"Glucose intolerance in hypertensive patients treated with diuretics: a fourteen-year follow-up.\" Lancet 2 (1982): 1293-5[32] \"Product Information. Fortovase (saquinavir)\" Roche Laboratories, Nutley, NJ.[33] Coni NK, Gordon PW, Mukherjee AP, Read PR \"The effect of frusemide and ethacrynic acid on carbohydrate metabolism.\" Age Ageing 3 (1974): 85-90[34] \"Product Information. Norvir (ritonavir).\" Abbott Pharmaceutical, Abbott Park, IL.[35] Domenet JG \"Diabetogenic effect of oral diuretics.\" Br Med J 3 (1968): 188[36] Rowe P, Mather H \"Hyperosmolar non-ketotic diabetes mellitus associated with metolazone.\" Br Med J 291 (1985): 25-6[37] Winchester JF, Kellett RJ, Boddy K, Boyle P, Dargie HJ, Mahaffey ME, Ward DM, Kennedy AC \"Metolazone and bendroflumethiazide in hypertension: physiologic and metabolic observations.\" Clin Pharmacol Ther 28 (1980): 611-8[38] \"Product Information. Carafate (sucralfate).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[39] Tsiodras S, Mantzoros C, Hammer S, Samore M \"Effects of protease inhibitors on hyperglycemia, hyperlipidemia, and lipodystrophy - A 5-year cohort study.\" Arch Intern Med 160 (2000): 2050-6[40] \"Product Information. Apidra (insulin glulisine).\" Aventis Pharmaceuticals, Bridgewater, NJ.[41] \"Product Information. Prezista (darunavir).\" Ortho Biotech Inc, Bridgewater, NJ.[42] Haiba NA, el-Habashy MA, Said SA, Darwish EA, Abdel-Sayed WS, Nayel SE \"Clinical evaluation of two monthly injectable contraceptives and their effects on some metabolic parameters.\" Contraception 39 (1989): 619-32[43] Erle G, Basso M, Federspil G, Sicolo N, Scandellari C \"Effect of chlorpromazine on blood glucose and plasma insulin in man.\" Eur J Clin Pharmacol 11 (1977): 15-8[44] Pickkers P, Schachter M, Hughes AD, Feher MD, Sever PS \"Thiazide-induced hyperglycaemia: a role for calcium-activated potassium channels?\" Diabetologia 39 (1996): 861-4[45] \"Product Information. Lexiva (fosamprenavir).\" GlaxoSmithKline, Research Triangle Park, NC.[46] Curtis J, Horrigan F, Ahearn D, Varney R, Sandler SG \"Chlorthalidone-induced hyperosmolar hyperglycemic nonketotic coma.\" JAMA 220 (1972): 1592-3[47] \"Product Information. Hyperstat I.V. (diazoxide).\" Schering Corp, Kenilworth, NJ.[48] \"Product Information. Piqray (alpelisib).\" Novartis Pharmaceuticals, East Hanover, NJ.[49] Bell DS \"Insulin resistance. An often unrecognized problem accompanying chronic medical disorders.\" Postgrad Med 93 (1993): 99-103,[50] Stambaugh JE, Tucker DC \"Effect of diphenylhydantoin on glucose tolerance in patients with hypoglycemia.\" Diabetes 23 (1974): 679-83[51] \"Product Information. Crixivan (indinavir).\" Merck & Co, Inc, West Point, PA.[52] Miller NR, Moses H \"Transient oculomotor nerve palsy. Association with thiazide-induced glucose intolerance.\" JAMA 240 (1978): 1887-8[53] Javier Z, Gershberg H, Hulse M \"Ovulatory suppressants, estrogens, and carbohydrate metabolism.\" Metabolism 17 (1968): 443-56[54] Goldman JA, Ovadia JL \"The effect of estrogen on intravenous glucose tolerance in woman.\" Am J Obstet Gynecol 103 (1969): 172-8[55] Charan VD, Desai N, Singh AP, Choudhry VP \"Diabetes mellitus and pancreatitis as a complication of L- asparaginase therapy.\" Indian Pediatr 30 (1993): 809-10[56] Seifer DB, Freedman LN, Cavender JR, Baker RA \"Insulin-dependent diabetes mellitus associated with danazol.\" Am J Obstet Gynecol 162 (1990): 474-5[57] \"Product Information. Orinase (tolbutamide)\" Pharmacia and Upjohn, Kalamazoo, MI.[58] Walli R, Demant T \"Impaired glucose tolerance and protease inhibitors.\" Ann Intern Med 129 (1998): 837-8[59] Hannaford PC, Kay CR \"Oral contraceptives and diabetes mellitus.\" BMJ 299 (1989): 1315-6[60] Hardy H, Esch LD, Morse GD \"Glucose disorders associated with HIV and its drug therapy.\" Ann Pharmacother 35 (2001): 343-51[61] Chowdhury FR, Bleicher SJ \"Chlorthalidone--induced hypokalemia and abnormal carbohydrate metabolism.\" Horm Metab Res 2 (1970): 13-6[62] Kaufman MB, Simionatto C \"A review of protease inhibitor-induced hyperglycemia.\" Pharmacotherapy 19 (1999): 114-7[63] Greenstone MA, Shaw AB \"Alternate day corticosteroid causes alternate day hyperglycaemia.\" Postgrad Med J 63 (1987): 761-4[64] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[65] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[66] Elmfeldt D, Berglund G, Wedel H, Wilhelmsen L \"Incidence and importance of metabolic side-effects during antihypertensive therapy.\" Acta Med Scand Suppl 672 (1983): 79-83[67] \"Product Information. Agenerase (amprenavir).\" Glaxo Wellcome, Research Triangle Pk, NC.[68] Diamond MT \"Hyperglycemic hyperosmolar coma associated with hydrochlorothiazide and pancreatitis.\" N Y State J Med 72 (1972): 1741-2[69] \"Product Information. Prandin (repaglinide).\" Novo Nordisk Pharmaceuticals Inc, Princeton, NJ.[70] \"Product Information. Precose (acarbose).\" Bayer, West Haven, CT.[71] \"Product Information. Starlix (nateglinide)\" Novartis Pharmaceuticals, East Hanover, NJ.[72] \"Product Information. Oncaspar (pegaspargase).\" Rhone-Poulenc Rorer, Collegeville, PA.[73] Sotaniemi E, Kontturi M, Larmi T \"Effect of diethylstilbestrol on blood glucose of prostatic cancer patients.\" Invest Urol 10 (1973): 438-41[74] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[75] Petri M, Cumber P, Grimes L, Treby D, Bryant R, Rawlins D, Ising H \"The metabolic effects of thiazide therapy in the elderly: a population study.\" Age Ageing 15 (1986): 151-5[76] Ludvik B, Clodi M, Kautzky-Willer A, Capek M, Hartter E, Pacini G, Prager R \"Effect of dexamethasone on insulin sensitivity, islet amyloid polypeptide and insulin secretion in humans.\" Diabetologia 36 (1993): 84-7[77] \"Product Information. Glucophage (metformin).\" Bristol-Myers Squibb, Princeton, NJ.[78] Chaudhuri ML, Catania J \"A comparison of the effects of bumetanide (Burinex) and frusemide on carbohydrate metabolism in the elderly.\" Br J Clin Pract 42 (1988): 427-9[79] Black DM, Filak AT \"Hyperglycemia with non-insulin-dependent diabetes following intraarticular steroid injection.\" J Fam Pract 28 (1989): 462-3[80] \"Product Information. Megace (megestrol).\" Bristol-Myers Squibb, Princeton, NJ.[81] \"Product Information. Torisel (temsirolimus).\" Wyeth-Ayerst Laboratories, Philadelphia, PA.[82] Schmitz O, Hermansen K, Nielsen OH, Christensen CK, Arnfred J, Hansen HE, Mogensen CE, Orskov H, Beck-Nielsen H \"Insulin action in insulin-dependent diabetics after short-term thiazide therapy.\" Diabetes Care 9 (1986): 631-6[83] Kansal PC, Buse J, Buse MG \"Thiazide diuretics and control of diabetes mellitus.\" South Med J 62 (1969): 1372-9[84] Dimitriadis G, Tegos C, Golfinopoulou L, Roboti C, Raptis S \"Furosemide-induced hyperglycaemia - the implication of glycolytic kinases.\" Horm Metab Res 25 (1993): 557-9[85] \"Product Information. NovoLog Mix 70/30 (insulin aspart-insulin aspart protamine).\" Novo Nordisk Pharmaceuticals Inc, Princeton, NJ.[86] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[87] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[88] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[89] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42[90] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[91] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[92] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[93] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[94] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[95] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6", "alternatives_a": "Lamivudine, Tenofovir alafenamide, Maraviroc, Cabotegravir, Zanamivir, Valaciclovir, Lenacapavir, Telaprevir, Rilpivirine, Etravirine, Dolutegravir, More", "alternatives_b": "Guar gum", "updated_at": 1767369485}, {"id": 97919, "ingredient1": "Insulin human", "ingredient2": "Empagliflozin", "severity": "Moderate", "effect": "Coadministration of a sodium-glucose co-transporter 2 (SGLT-2) inhibitor with an insulin secretagogue (e.g., sulfonylurea, meglitinide) or insulin may potentiate the risk of hypoglycemia.", "source": "DDInter", "management_text": "A lower dosage of the insulin secretagogue or insulin may be required when used in combination with an SGLT-2 inhibitor.", "mechanism_text": "Synergism", "recommendation": "A lower dosage of the insulin secretagogue or insulin may be required when used in combination with an SGLT-2 inhibitor.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/98023/", "reference_text": "[1] \"Product Information. Jardiance (empagliflozin).\" Boehringer Ingelheim, Ridgefield, CT.[2] \"Product Information. Steglatro (ertugliflozin).\" Merck & Company Inc, Whitehouse Station, NJ.[3] \"Product Information. Invokana (canagliflozin).\" Janssen Pharmaceuticals, Titusville, NJ.[4] Cerner Multum, Inc. \"Australian Product Information.\" O 0[5] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[6] \"Product Information. Farxiga (dapagliflozin).\" Bristol-Myers Squibb, Princeton, NJ.[7] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[8] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[9] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[10] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[11] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[12] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6[13] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[14] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[15] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[16] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42[17] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[18] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[19] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[20] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[21] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[22] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6[23] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[24] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[25] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[26] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42", "alternatives_a": "Liraglutide, Lixisenatide", "alternatives_b": "Acarbose, Simvastatin, Nateglinide, Rosuvastatin, Repaglinide", "updated_at": 1767369485}, {"id": 97920, "ingredient1": "Insulin aspart (aspart)", "ingredient2": "Empagliflozin", "severity": "Moderate", "effect": "Coadministration of a sodium-glucose co-transporter 2 (SGLT-2) inhibitor with an insulin secretagogue (e.g., sulfonylurea, meglitinide) or insulin may potentiate the risk of hypoglycemia.", "source": "DDInter", "management_text": "A lower dosage of the insulin secretagogue or insulin may be required when used in combination with an SGLT-2 inhibitor.", "mechanism_text": "Synergism", "recommendation": "A lower dosage of the insulin secretagogue or insulin may be required when used in combination with an SGLT-2 inhibitor.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/98024/", "reference_text": "[1] \"Product Information. Jardiance (empagliflozin).\" Boehringer Ingelheim, Ridgefield, CT.[2] \"Product Information. Steglatro (ertugliflozin).\" Merck & Company Inc, Whitehouse Station, NJ.[3] \"Product Information. Invokana (canagliflozin).\" Janssen Pharmaceuticals, Titusville, NJ.[4] Cerner Multum, Inc. \"Australian Product Information.\" O 0[5] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[6] \"Product Information. Farxiga (dapagliflozin).\" Bristol-Myers Squibb, Princeton, NJ.[7] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[8] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[9] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[10] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[11] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[12] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6[13] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[14] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[15] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[16] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42[17] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[18] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[19] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[20] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[21] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[22] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6[23] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[24] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[25] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[26] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42", "alternatives_a": "Acarbose, Simvastatin, Nateglinide, Rosuvastatin, Repaglinide", "alternatives_b": "", "updated_at": 1767369485}, {"id": 97921, "ingredient1": "Insulin aspart (aspart protamine)", "ingredient2": "Empagliflozin", "severity": "Moderate", "effect": "Coadministration of a sodium-glucose co-transporter 2 (SGLT-2) inhibitor with an insulin secretagogue (e.g., sulfonylurea, meglitinide) or insulin may potentiate the risk of hypoglycemia.", "source": "DDInter", "management_text": "A lower dosage of the insulin secretagogue or insulin may be required when used in combination with an SGLT-2 inhibitor.", "mechanism_text": "Synergism", "recommendation": "A lower dosage of the insulin secretagogue or insulin may be required when used in combination with an SGLT-2 inhibitor.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/98025/", "reference_text": "[1] \"Product Information. Jardiance (empagliflozin).\" Boehringer Ingelheim, Ridgefield, CT.[2] \"Product Information. Steglatro (ertugliflozin).\" Merck & Company Inc, Whitehouse Station, NJ.[3] \"Product Information. Invokana (canagliflozin).\" Janssen Pharmaceuticals, Titusville, NJ.[4] Cerner Multum, Inc. \"Australian Product Information.\" O 0[5] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[6] \"Product Information. Farxiga (dapagliflozin).\" Bristol-Myers Squibb, Princeton, NJ.[7] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[8] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[9] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[10] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[11] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[12] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6[13] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[14] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[15] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[16] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42[17] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[18] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[19] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[20] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[21] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[22] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6[23] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[24] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[25] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[26] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42", "alternatives_a": "Acarbose, Simvastatin, Nateglinide, Rosuvastatin, Repaglinide", "alternatives_b": "", "updated_at": 1767369485}, {"id": 97922, "ingredient1": "Insulin degludec", "ingredient2": "Empagliflozin", "severity": "Moderate", "effect": "Coadministration of a sodium-glucose co-transporter 2 (SGLT-2) inhibitor with an insulin secretagogue (e.g., sulfonylurea, meglitinide) or insulin may potentiate the risk of hypoglycemia.", "source": "DDInter", "management_text": "A lower dosage of the insulin secretagogue or insulin may be required when used in combination with an SGLT-2 inhibitor.", "mechanism_text": "Synergism", "recommendation": "A lower dosage of the insulin secretagogue or insulin may be required when used in combination with an SGLT-2 inhibitor.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/98026/", "reference_text": "[1] \"Product Information. Jardiance (empagliflozin).\" Boehringer Ingelheim, Ridgefield, CT.[2] \"Product Information. Steglatro (ertugliflozin).\" Merck & Company Inc, Whitehouse Station, NJ.[3] \"Product Information. Invokana (canagliflozin).\" Janssen Pharmaceuticals, Titusville, NJ.[4] Cerner Multum, Inc. \"Australian Product Information.\" O 0[5] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[6] \"Product Information. Farxiga (dapagliflozin).\" Bristol-Myers Squibb, Princeton, NJ.[7] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[8] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[9] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[10] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[11] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[12] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6[13] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[14] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[15] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[16] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42[17] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[18] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[19] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[20] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[21] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[22] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6[23] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[24] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[25] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[26] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42", "alternatives_a": "Acarbose, Simvastatin, Chlorpropamide, Nateglinide, Rosuvastatin, Repaglinide", "alternatives_b": "Liraglutide, Lixisenatide", "updated_at": 1767369485}, {"id": 97923, "ingredient1": "Insulin detemir", "ingredient2": "Empagliflozin", "severity": "Moderate", "effect": "Coadministration of a sodium-glucose co-transporter 2 (SGLT-2) inhibitor with an insulin secretagogue (e.g., sulfonylurea, meglitinide) or insulin may potentiate the risk of hypoglycemia.", "source": "DDInter", "management_text": "A lower dosage of the insulin secretagogue or insulin may be required when used in combination with an SGLT-2 inhibitor.", "mechanism_text": "Synergism", "recommendation": "A lower dosage of the insulin secretagogue or insulin may be required when used in combination with an SGLT-2 inhibitor.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/98027/", "reference_text": "[1] \"Product Information. Jardiance (empagliflozin).\" Boehringer Ingelheim, Ridgefield, CT.[2] \"Product Information. Steglatro (ertugliflozin).\" Merck & Company Inc, Whitehouse Station, NJ.[3] \"Product Information. Invokana (canagliflozin).\" Janssen Pharmaceuticals, Titusville, NJ.[4] Cerner Multum, Inc. \"Australian Product Information.\" O 0[5] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[6] \"Product Information. Farxiga (dapagliflozin).\" Bristol-Myers Squibb, Princeton, NJ.[7] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[8] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[9] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[10] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[11] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[12] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6[13] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[14] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[15] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[16] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42[17] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[18] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[19] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[20] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[21] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[22] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6[23] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[24] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[25] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[26] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42", "alternatives_a": "Liraglutide, Lixisenatide", "alternatives_b": "Acarbose, Simvastatin, Nateglinide, Rosuvastatin, Repaglinide", "updated_at": 1767369485}, {"id": 97924, "ingredient1": "Insulin glargine", "ingredient2": "Empagliflozin", "severity": "Moderate", "effect": "Coadministration of a sodium-glucose co-transporter 2 (SGLT-2) inhibitor with an insulin secretagogue (e.g., sulfonylurea, meglitinide) or insulin may potentiate the risk of hypoglycemia.", "source": "DDInter", "management_text": "A lower dosage of the insulin secretagogue or insulin may be required when used in combination with an SGLT-2 inhibitor.", "mechanism_text": "Synergism", "recommendation": "A lower dosage of the insulin secretagogue or insulin may be required when used in combination with an SGLT-2 inhibitor.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/98028/", "reference_text": "[1] \"Product Information. Jardiance (empagliflozin).\" Boehringer Ingelheim, Ridgefield, CT.[2] \"Product Information. Steglatro (ertugliflozin).\" Merck & Company Inc, Whitehouse Station, NJ.[3] \"Product Information. Invokana (canagliflozin).\" Janssen Pharmaceuticals, Titusville, NJ.[4] Cerner Multum, Inc. \"Australian Product Information.\" O 0[5] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[6] \"Product Information. Farxiga (dapagliflozin).\" Bristol-Myers Squibb, Princeton, NJ.[7] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[8] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[9] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[10] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[11] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[12] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6[13] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[14] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[15] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[16] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42[17] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[18] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[19] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[20] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[21] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[22] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6[23] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[24] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[25] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[26] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42", "alternatives_a": "Liraglutide, Lixisenatide", "alternatives_b": "Acarbose, Simvastatin, Nateglinide, Rosuvastatin, Repaglinide", "updated_at": 1767369485}, {"id": 97925, "ingredient1": "Insulin glulisine", "ingredient2": "Empagliflozin", "severity": "Moderate", "effect": "Coadministration of a sodium-glucose co-transporter 2 (SGLT-2) inhibitor with an insulin secretagogue (e.g., sulfonylurea, meglitinide) or insulin may potentiate the risk of hypoglycemia.", "source": "DDInter", "management_text": "A lower dosage of the insulin secretagogue or insulin may be required when used in combination with an SGLT-2 inhibitor.", "mechanism_text": "Synergism", "recommendation": "A lower dosage of the insulin secretagogue or insulin may be required when used in combination with an SGLT-2 inhibitor.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/98029/", "reference_text": "[1] \"Product Information. Jardiance (empagliflozin).\" Boehringer Ingelheim, Ridgefield, CT.[2] \"Product Information. Steglatro (ertugliflozin).\" Merck & Company Inc, Whitehouse Station, NJ.[3] \"Product Information. Invokana (canagliflozin).\" Janssen Pharmaceuticals, Titusville, NJ.[4] Cerner Multum, Inc. \"Australian Product Information.\" O 0[5] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[6] \"Product Information. Farxiga (dapagliflozin).\" Bristol-Myers Squibb, Princeton, NJ.[7] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[8] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[9] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[10] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[11] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[12] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6[13] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[14] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[15] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[16] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42[17] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[18] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[19] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[20] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[21] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[22] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6[23] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[24] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[25] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[26] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42", "alternatives_a": "Liraglutide, Lixisenatide", "alternatives_b": "Acarbose, Simvastatin, Nateglinide, Rosuvastatin, Repaglinide", "updated_at": 1767369485}, {"id": 97926, "ingredient1": "Insulin human (inhalation, rapid acting)", "ingredient2": "Empagliflozin", "severity": "Moderate", "effect": "Coadministration of a sodium-glucose co-transporter 2 (SGLT-2) inhibitor with an insulin secretagogue (e.g., sulfonylurea, meglitinide) or insulin may potentiate the risk of hypoglycemia.", "source": "DDInter", "management_text": "A lower dosage of the insulin secretagogue or insulin may be required when used in combination with an SGLT-2 inhibitor.", "mechanism_text": "Synergism", "recommendation": "A lower dosage of the insulin secretagogue or insulin may be required when used in combination with an SGLT-2 inhibitor.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/98030/", "reference_text": "[1] \"Product Information. Jardiance (empagliflozin).\" Boehringer Ingelheim, Ridgefield, CT.[2] \"Product Information. Steglatro (ertugliflozin).\" Merck & Company Inc, Whitehouse Station, NJ.[3] \"Product Information. Invokana (canagliflozin).\" Janssen Pharmaceuticals, Titusville, NJ.[4] Cerner Multum, Inc. \"Australian Product Information.\" O 0[5] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[6] \"Product Information. Farxiga (dapagliflozin).\" Bristol-Myers Squibb, Princeton, NJ.[7] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[8] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[9] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[10] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[11] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[12] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6[13] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[14] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[15] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[16] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42[17] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[18] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[19] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[20] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[21] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[22] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6[23] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[24] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[25] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[26] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42", "alternatives_a": "Liraglutide, Lixisenatide", "alternatives_b": "Acarbose, Simvastatin, Nateglinide, Rosuvastatin, Repaglinide", "updated_at": 1767369485}, {"id": 97927, "ingredient1": "Insulin human (isophane)", "ingredient2": "Empagliflozin", "severity": "Moderate", "effect": "Coadministration of a sodium-glucose co-transporter 2 (SGLT-2) inhibitor with an insulin secretagogue (e.g., sulfonylurea, meglitinide) or insulin may potentiate the risk of hypoglycemia.", "source": "DDInter", "management_text": "A lower dosage of the insulin secretagogue or insulin may be required when used in combination with an SGLT-2 inhibitor.", "mechanism_text": "Synergism", "recommendation": "A lower dosage of the insulin secretagogue or insulin may be required when used in combination with an SGLT-2 inhibitor.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/98031/", "reference_text": "[1] \"Product Information. Jardiance (empagliflozin).\" Boehringer Ingelheim, Ridgefield, CT.[2] \"Product Information. Steglatro (ertugliflozin).\" Merck & Company Inc, Whitehouse Station, NJ.[3] \"Product Information. Invokana (canagliflozin).\" Janssen Pharmaceuticals, Titusville, NJ.[4] Cerner Multum, Inc. \"Australian Product Information.\" O 0[5] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[6] \"Product Information. Farxiga (dapagliflozin).\" Bristol-Myers Squibb, Princeton, NJ.[7] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[8] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[9] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[10] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[11] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[12] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6[13] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[14] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[15] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[16] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42[17] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[18] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[19] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[20] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[21] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[22] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6[23] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[24] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[25] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[26] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42", "alternatives_a": "Liraglutide, Lixisenatide", "alternatives_b": "Simvastatin, Nateglinide, Acarbose, Rosuvastatin", "updated_at": 1767369485}, {"id": 97928, "ingredient1": "Insulin lispro", "ingredient2": "Empagliflozin", "severity": "Moderate", "effect": "Coadministration of a sodium-glucose co-transporter 2 (SGLT-2) inhibitor with an insulin secretagogue (e.g., sulfonylurea, meglitinide) or insulin may potentiate the risk of hypoglycemia.", "source": "DDInter", "management_text": "A lower dosage of the insulin secretagogue or insulin may be required when used in combination with an SGLT-2 inhibitor.", "mechanism_text": "Synergism", "recommendation": "A lower dosage of the insulin secretagogue or insulin may be required when used in combination with an SGLT-2 inhibitor.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/98032/", "reference_text": "[1] \"Product Information. Jardiance (empagliflozin).\" Boehringer Ingelheim, Ridgefield, CT.[2] \"Product Information. Steglatro (ertugliflozin).\" Merck & Company Inc, Whitehouse Station, NJ.[3] \"Product Information. Invokana (canagliflozin).\" Janssen Pharmaceuticals, Titusville, NJ.[4] Cerner Multum, Inc. \"Australian Product Information.\" O 0[5] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[6] \"Product Information. Farxiga (dapagliflozin).\" Bristol-Myers Squibb, Princeton, NJ.[7] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[8] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[9] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[10] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[11] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[12] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6[13] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[14] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[15] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[16] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42[17] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[18] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[19] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[20] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[21] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[22] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6[23] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[24] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[25] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[26] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42", "alternatives_a": "Liraglutide, Lixisenatide", "alternatives_b": "Acarbose, Simvastatin, Nateglinide, Rosuvastatin, Repaglinide", "updated_at": 1767369485}, {"id": 97929, "ingredient1": "Insulin lispro (protamine)", "ingredient2": "Empagliflozin", "severity": "Moderate", "effect": "Coadministration of a sodium-glucose co-transporter 2 (SGLT-2) inhibitor with an insulin secretagogue (e.g., sulfonylurea, meglitinide) or insulin may potentiate the risk of hypoglycemia.", "source": "DDInter", "management_text": "A lower dosage of the insulin secretagogue or insulin may be required when used in combination with an SGLT-2 inhibitor.", "mechanism_text": "Synergism", "recommendation": "A lower dosage of the insulin secretagogue or insulin may be required when used in combination with an SGLT-2 inhibitor.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/98033/", "reference_text": "[1] \"Product Information. Jardiance (empagliflozin).\" Boehringer Ingelheim, Ridgefield, CT.[2] \"Product Information. Steglatro (ertugliflozin).\" Merck & Company Inc, Whitehouse Station, NJ.[3] \"Product Information. Invokana (canagliflozin).\" Janssen Pharmaceuticals, Titusville, NJ.[4] Cerner Multum, Inc. \"Australian Product Information.\" O 0[5] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[6] \"Product Information. Farxiga (dapagliflozin).\" Bristol-Myers Squibb, Princeton, NJ.[7] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[8] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[9] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[10] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[11] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[12] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6[13] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[14] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[15] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[16] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42[17] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[18] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[19] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[20] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[21] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[22] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6[23] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[24] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[25] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[26] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42", "alternatives_a": "Acarbose, Simvastatin, Nateglinide, Rosuvastatin, Repaglinide", "alternatives_b": "", "updated_at": 1767369485}, {"id": 97930, "ingredient1": "Insulin human (regular)", "ingredient2": "Empagliflozin", "severity": "Moderate", "effect": "Coadministration of a sodium-glucose co-transporter 2 (SGLT-2) inhibitor with an insulin secretagogue (e.g., sulfonylurea, meglitinide) or insulin may potentiate the risk of hypoglycemia.", "source": "DDInter", "management_text": "A lower dosage of the insulin secretagogue or insulin may be required when used in combination with an SGLT-2 inhibitor.", "mechanism_text": "Synergism", "recommendation": "A lower dosage of the insulin secretagogue or insulin may be required when used in combination with an SGLT-2 inhibitor.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/98034/", "reference_text": "[1] \"Product Information. Jardiance (empagliflozin).\" Boehringer Ingelheim, Ridgefield, CT.[2] \"Product Information. Steglatro (ertugliflozin).\" Merck & Company Inc, Whitehouse Station, NJ.[3] \"Product Information. Invokana (canagliflozin).\" Janssen Pharmaceuticals, Titusville, NJ.[4] Cerner Multum, Inc. \"Australian Product Information.\" O 0[5] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[6] \"Product Information. Farxiga (dapagliflozin).\" Bristol-Myers Squibb, Princeton, NJ.[7] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[8] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[9] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[10] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[11] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[12] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6[13] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[14] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[15] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[16] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42[17] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[18] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[19] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[20] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[21] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[22] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6[23] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[24] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[25] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[26] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42", "alternatives_a": "Liraglutide, Lixisenatide", "alternatives_b": "Acarbose, Guar gum, Simvastatin, Nateglinide, Rosuvastatin, Repaglinide", "updated_at": 1767369485}, {"id": 97931, "ingredient1": "Insulin human (zinc)", "ingredient2": "Empagliflozin", "severity": "Moderate", "effect": "Coadministration of a sodium-glucose co-transporter 2 (SGLT-2) inhibitor with an insulin secretagogue (e.g., sulfonylurea, meglitinide) or insulin may potentiate the risk of hypoglycemia.", "source": "DDInter", "management_text": "A lower dosage of the insulin secretagogue or insulin may be required when used in combination with an SGLT-2 inhibitor.", "mechanism_text": "Synergism", "recommendation": "A lower dosage of the insulin secretagogue or insulin may be required when used in combination with an SGLT-2 inhibitor.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/98035/", "reference_text": "[1] \"Product Information. Jardiance (empagliflozin).\" Boehringer Ingelheim, Ridgefield, CT.[2] \"Product Information. Steglatro (ertugliflozin).\" Merck & Company Inc, Whitehouse Station, NJ.[3] \"Product Information. Invokana (canagliflozin).\" Janssen Pharmaceuticals, Titusville, NJ.[4] Cerner Multum, Inc. \"Australian Product Information.\" O 0[5] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[6] \"Product Information. Farxiga (dapagliflozin).\" Bristol-Myers Squibb, Princeton, NJ.[7] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[8] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[9] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[10] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[11] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[12] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6[13] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[14] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[15] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[16] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42[17] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[18] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[19] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[20] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[21] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[22] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6[23] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[24] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[25] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[26] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42", "alternatives_a": "Liraglutide, Lixisenatide", "alternatives_b": "Acarbose, Simvastatin, Nateglinide, Rosuvastatin, Repaglinide", "updated_at": 1767369485}, {"id": 97932, "ingredient1": "Insulin human (zinc extended)", "ingredient2": "Empagliflozin", "severity": "Moderate", "effect": "Coadministration of a sodium-glucose co-transporter 2 (SGLT-2) inhibitor with an insulin secretagogue (e.g., sulfonylurea, meglitinide) or insulin may potentiate the risk of hypoglycemia.", "source": "DDInter", "management_text": "A lower dosage of the insulin secretagogue or insulin may be required when used in combination with an SGLT-2 inhibitor.", "mechanism_text": "Synergism", "recommendation": "A lower dosage of the insulin secretagogue or insulin may be required when used in combination with an SGLT-2 inhibitor.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/98036/", "reference_text": "[1] \"Product Information. Jardiance (empagliflozin).\" Boehringer Ingelheim, Ridgefield, CT.[2] \"Product Information. Steglatro (ertugliflozin).\" Merck & Company Inc, Whitehouse Station, NJ.[3] \"Product Information. Invokana (canagliflozin).\" Janssen Pharmaceuticals, Titusville, NJ.[4] Cerner Multum, Inc. \"Australian Product Information.\" O 0[5] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[6] \"Product Information. Farxiga (dapagliflozin).\" Bristol-Myers Squibb, Princeton, NJ.[7] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[8] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[9] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[10] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[11] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[12] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6[13] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[14] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[15] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[16] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42[17] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[18] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[19] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[20] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[21] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[22] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6[23] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[24] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[25] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[26] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42", "alternatives_a": "Liraglutide, Lixisenatide", "alternatives_b": "Acarbose, Guar gum, Simvastatin, Nateglinide, Rosuvastatin, Repaglinide", "updated_at": 1767369485}, {"id": 97933, "ingredient1": "Irbesartan", "ingredient2": "Empagliflozin", "severity": "Moderate", "effect": "Sodium-glucose co-transporter 2 (SGLT-2) inhibitors may potentiate the hypotensive effects of diuretics and other antihypertensive agents or vasodilators. Inhibition of glucose and sodium co-transport produces mild diuresis and transient natriuresis, resulting in intravascular volume contraction. Volume depletion-related adverse reactions including hypotension, postural dizziness, orthostatic hypotension, syncope, and dehydration can occur after initiating treatment with SGLT-2 inhibitors, and the risk may be increased with concomitant use of other agents that can lower blood pressure.", "source": "DDInter", "management_text": "Caution is advised if SGLT-2 inhibitors are coadministered with diuretics and other hypotensive agents, particularly in the elderly and patients with impaired renal function. Prior to initiating SGLT-2 inhibitors, volume status should be assessed and corrected, if necessary. Clinical and laboratory monitoring are recommended during therapy, including electrolytes, fluid status, renal function, and blood pressure. If volume depletion occurs, treatment with SGLT-2 inhibitors should be interrupted until the condition is corrected.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if SGLT-2 inhibitors are coadministered with diuretics and other hypotensive agents, particularly in the elderly and patients with impaired renal function.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/98037/", "reference_text": "[1] \"Product Information. Jardiance (empagliflozin).\" Boehringer Ingelheim, Ridgefield, CT.[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] \"Product Information. Farxiga (dapagliflozin).\" Bristol-Myers Squibb, Princeton, NJ.[5] \"Product Information. Invokana (canagliflozin).\" Janssen Pharmaceuticals, Titusville, NJ.[6] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[7] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[8] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[9] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[10] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[11] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6[12] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[13] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[14] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[15] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42", "alternatives_a": "Sacubitril", "alternatives_b": "Lixisenatide, Albiglutide, Acetohexamide, Guar gum, Pramlintide, Sitagliptin, Alogliptin, Liraglutide, Troglitazone, Semaglutide, Linagliptin, More", "updated_at": 1767369485}, {"id": 97934, "ingredient1": "Isavuconazonium", "ingredient2": "Empagliflozin", "severity": "Moderate", "effect": "Coadministration with isavuconazonium sulfate (prodrug of isavuconazole) may increase the plasma concentrations of drugs that are substrates of P-glycoprotein (P-gp), such as dabigatran. The proposed mechanism is isavuconazole inhibition of P-gp-mediated efflux of these drugs.", "source": "DDInter", "management_text": "Caution is advised if isavuconazonium sulfate is used concomitantly with drugs that are substrates of P-gp, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring should be considered whenever isavuconazonium sulfate is added to or withdrawn from therapy with these drugs. Patients receiving concomitant dabigatran should be monitored closely for the development of bleeding complications and the dosage of dabigatran adjusted as necessary.", "mechanism_text": "Absorption", "recommendation": "Caution is advised if isavuconazonium sulfate is used concomitantly with drugs that are substrates of P-gp, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/98038/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Mekinist (trametinib).\" GlaxoSmithKline, Research Triangle Park, NC.", "alternatives_a": "Glipizide, Acetohexamide, Guar gum, Pramlintide, Alogliptin, Rosuvastatin, Tolazamide, Dulaglutide, Exenatide, Tolbutamide, Miglitol, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 97935, "ingredient1": "Isoniazid", "ingredient2": "Empagliflozin", "severity": "Moderate", "effect": "The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.", "source": "DDInter", "management_text": "Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.", "mechanism_text": "Antagonism", "recommendation": "Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/98039/", "reference_text": "[1] Jori A, Carrara MC \"On the mechanism of the hyperglycaemic effect of chlorpromazine.\" J Pharm Pharmacol 18 (1966): 623-4[2] \"Product Information. Dymelor (acetohexamide)\" Lilly, Eli and Company, Indianapolis, IN.[3] \"Product Information. Thorazine (chlorpromazine).\" SmithKline Beecham, Philadelphia, PA.[4] Blayac JP, Ribes G, Buys D, Puech R, Loubatieres-Mariani MM \"Effects of a new benzothiadiazine derivative, LN 5330, on insulin secretion.\" Arch Int Pharmacodyn Ther 253 (1981): 154-63[5] \"Product Information. Elzonris (tagraxofusp).\" Stemline Therapeutics, New York, NY.[6] \"Product Information. Amaryl (glimepiride).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[7] \"Product Information. Elspar (asparaginase).\" Merck & Co, Inc, West Point, PA.[8] Jones IG, Pickens PT \"Diabetes mellitus following oral diuretics.\" Practitioner 199 (1967): 209-10[9] \"Product Information. Viracept (nelfinavir).\" Agouron Pharma Inc, La Jolla, CA.[10] \"Product Information. Tolinase (tolazamide)\" Pharmacia and Upjohn, Kalamazoo, MI.[11] Mauss S, Wolf E, Jaeger H \"Impaired glucose tolerance in HIV-positive patients receiving and those not receiving protease inhibitors.\" Ann Intern Med 130 (1999): 162-3[12] Virutamasen P, Wongsrichanalai C, Tangkeo P, Nitichai Y, Rienprayoon D \"Metabolic effects of depot-medroxyprogesterone acetate in long-term users: a cross-sectional study.\" Int J Gynaecol Obstet 24 (1986): 291-6[13] Wehring H, Alexander B, Perry PJ \"Diabetes mellitus associated with clozapine therapy.\" Pharmacotherapy 20 (2000): 844-7[14] Spellacy WN, Ellingson AB, Tsibris JC \"The effects of two triphasic oral contraceptives on carbohydrate metabolism in women during 1 year of use.\" Fertil Steril 51 (1989): 71-4[15] Andersen OO, Persson I \"Carbohydrate metabolism during treatment with chlorthalidone and ethacrynic acid.\" Br Med J 2 (1968): 798-801[16] Berlin I \"Prazosin, diuretics, and glucose intolerance.\" Ann Intern Med 119 (1993): 860[17] Malherbe C, Burrill KC, Levin SR, Karam JH, Forsham PH \"Effect of diphenylhydantoin on insulin secretion in man.\" N Engl J Med 286 (1972): 339-42[18] Carter BL, Small RE, Mandel MD, Starkman MT \"Phenytoin-induced hyperglycemia.\" Am J Hosp Pharm 38 (1981): 1508-12[19] Al-Rubeaan K, Ryan EA \"Phenytoin-induced insulin insensitivity.\" Diabet Med 8 (1991): 968-70[20] \"Product Information. Zolinza (vorinostat).\" Merck & Company Inc, West Point, PA.[21] Goldman JA, Neri A, Ovadia J, Eckerling B, Vries A, de \"Effect of chlorothiazide on intravenous glucose tolerance in pregnancy.\" Am J Obstet Gynecol 105 (1969): 556-60[22] Harper R, Ennis CN, Heaney AP, Sheridan B, Gormley M, Atkinson AB, Johnston GD, Bell PM \"A comparison of the effects of low- and conventional-dose thiazide diuretic on insulin action in hypertensive patients with NIDDM.\" Diabetologia 38 (1995): 853-9[23] Seltzer HS, Allen EW \"Hyperglycemia and inhibition of insulin secretion during administration of diazoxide and trichlormethiazide in man.\" Diabetes 18 (1969): 19-28[24] Dube MP, Johnson DL, Currier JS, Leedom JM \"Protease inhibitor-associated hyperglycaemia.\" Lancet 350 (1997): 713-4[25] Leary WP, Reyes AJ \"Drug interactions with diuretics.\" S Afr Med J 65 (1984): 455-61[26] \"Product Information. Reyataz (atazanavir).\" Bristol-Myers Squibb, Princeton, NJ.[27] Pollare T, Lithell H, Berne C \"A comparison of the effects of hydrochlorothiazide and captopril on glucose and lipid metabolism in patients with hypertension.\" N Engl J Med 321 (1989): 868-73[28] Gunnarsson R, Lundgren G, Magnusson G, Ost L, Groth CG \"Steroid diabetes--a sign of overtreatment with steroids in the renal graft recipient?\" Scand J Urol Nephrol Suppl 54 (1980): 135-8[29] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[30] \"Product Information. Synthroid (levothyroxine).\" Abbott Pharmaceutical, Abbott Park, IL.[31] Murphy MB, Kohner E, Lewis PJ, Schumer B, Dollery CT \"Glucose intolerance in hypertensive patients treated with diuretics: a fourteen-year follow-up.\" Lancet 2 (1982): 1293-5[32] \"Product Information. Fortovase (saquinavir)\" Roche Laboratories, Nutley, NJ.[33] Coni NK, Gordon PW, Mukherjee AP, Read PR \"The effect of frusemide and ethacrynic acid on carbohydrate metabolism.\" Age Ageing 3 (1974): 85-90[34] \"Product Information. Norvir (ritonavir).\" Abbott Pharmaceutical, Abbott Park, IL.[35] Domenet JG \"Diabetogenic effect of oral diuretics.\" Br Med J 3 (1968): 188[36] Rowe P, Mather H \"Hyperosmolar non-ketotic diabetes mellitus associated with metolazone.\" Br Med J 291 (1985): 25-6[37] Winchester JF, Kellett RJ, Boddy K, Boyle P, Dargie HJ, Mahaffey ME, Ward DM, Kennedy AC \"Metolazone and bendroflumethiazide in hypertension: physiologic and metabolic observations.\" Clin Pharmacol Ther 28 (1980): 611-8[38] \"Product Information. Carafate (sucralfate).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[39] Tsiodras S, Mantzoros C, Hammer S, Samore M \"Effects of protease inhibitors on hyperglycemia, hyperlipidemia, and lipodystrophy - A 5-year cohort study.\" Arch Intern Med 160 (2000): 2050-6[40] \"Product Information. Apidra (insulin glulisine).\" Aventis Pharmaceuticals, Bridgewater, NJ.[41] \"Product Information. Prezista (darunavir).\" Ortho Biotech Inc, Bridgewater, NJ.[42] Haiba NA, el-Habashy MA, Said SA, Darwish EA, Abdel-Sayed WS, Nayel SE \"Clinical evaluation of two monthly injectable contraceptives and their effects on some metabolic parameters.\" Contraception 39 (1989): 619-32[43] Erle G, Basso M, Federspil G, Sicolo N, Scandellari C \"Effect of chlorpromazine on blood glucose and plasma insulin in man.\" Eur J Clin Pharmacol 11 (1977): 15-8[44] Pickkers P, Schachter M, Hughes AD, Feher MD, Sever PS \"Thiazide-induced hyperglycaemia: a role for calcium-activated potassium channels?\" Diabetologia 39 (1996): 861-4[45] \"Product Information. Lexiva (fosamprenavir).\" GlaxoSmithKline, Research Triangle Park, NC.[46] Curtis J, Horrigan F, Ahearn D, Varney R, Sandler SG \"Chlorthalidone-induced hyperosmolar hyperglycemic nonketotic coma.\" JAMA 220 (1972): 1592-3[47] \"Product Information. Hyperstat I.V. (diazoxide).\" Schering Corp, Kenilworth, NJ.[48] \"Product Information. Piqray (alpelisib).\" Novartis Pharmaceuticals, East Hanover, NJ.[49] Bell DS \"Insulin resistance. An often unrecognized problem accompanying chronic medical disorders.\" Postgrad Med 93 (1993): 99-103,[50] Stambaugh JE, Tucker DC \"Effect of diphenylhydantoin on glucose tolerance in patients with hypoglycemia.\" Diabetes 23 (1974): 679-83[51] \"Product Information. Crixivan (indinavir).\" Merck & Co, Inc, West Point, PA.[52] Miller NR, Moses H \"Transient oculomotor nerve palsy. Association with thiazide-induced glucose intolerance.\" JAMA 240 (1978): 1887-8[53] Javier Z, Gershberg H, Hulse M \"Ovulatory suppressants, estrogens, and carbohydrate metabolism.\" Metabolism 17 (1968): 443-56[54] Goldman JA, Ovadia JL \"The effect of estrogen on intravenous glucose tolerance in woman.\" Am J Obstet Gynecol 103 (1969): 172-8[55] Charan VD, Desai N, Singh AP, Choudhry VP \"Diabetes mellitus and pancreatitis as a complication of L- asparaginase therapy.\" Indian Pediatr 30 (1993): 809-10[56] Seifer DB, Freedman LN, Cavender JR, Baker RA \"Insulin-dependent diabetes mellitus associated with danazol.\" Am J Obstet Gynecol 162 (1990): 474-5[57] \"Product Information. Orinase (tolbutamide)\" Pharmacia and Upjohn, Kalamazoo, MI.[58] Walli R, Demant T \"Impaired glucose tolerance and protease inhibitors.\" Ann Intern Med 129 (1998): 837-8[59] Hannaford PC, Kay CR \"Oral contraceptives and diabetes mellitus.\" BMJ 299 (1989): 1315-6[60] Hardy H, Esch LD, Morse GD \"Glucose disorders associated with HIV and its drug therapy.\" Ann Pharmacother 35 (2001): 343-51[61] Chowdhury FR, Bleicher SJ \"Chlorthalidone--induced hypokalemia and abnormal carbohydrate metabolism.\" Horm Metab Res 2 (1970): 13-6[62] Kaufman MB, Simionatto C \"A review of protease inhibitor-induced hyperglycemia.\" Pharmacotherapy 19 (1999): 114-7[63] Greenstone MA, Shaw AB \"Alternate day corticosteroid causes alternate day hyperglycaemia.\" Postgrad Med J 63 (1987): 761-4[64] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[65] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[66] Elmfeldt D, Berglund G, Wedel H, Wilhelmsen L \"Incidence and importance of metabolic side-effects during antihypertensive therapy.\" Acta Med Scand Suppl 672 (1983): 79-83[67] \"Product Information. Agenerase (amprenavir).\" Glaxo Wellcome, Research Triangle Pk, NC.[68] Diamond MT \"Hyperglycemic hyperosmolar coma associated with hydrochlorothiazide and pancreatitis.\" N Y State J Med 72 (1972): 1741-2[69] \"Product Information. Prandin (repaglinide).\" Novo Nordisk Pharmaceuticals Inc, Princeton, NJ.[70] \"Product Information. Precose (acarbose).\" Bayer, West Haven, CT.[71] \"Product Information. Starlix (nateglinide)\" Novartis Pharmaceuticals, East Hanover, NJ.[72] \"Product Information. Oncaspar (pegaspargase).\" Rhone-Poulenc Rorer, Collegeville, PA.[73] Sotaniemi E, Kontturi M, Larmi T \"Effect of diethylstilbestrol on blood glucose of prostatic cancer patients.\" Invest Urol 10 (1973): 438-41[74] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[75] Petri M, Cumber P, Grimes L, Treby D, Bryant R, Rawlins D, Ising H \"The metabolic effects of thiazide therapy in the elderly: a population study.\" Age Ageing 15 (1986): 151-5[76] Ludvik B, Clodi M, Kautzky-Willer A, Capek M, Hartter E, Pacini G, Prager R \"Effect of dexamethasone on insulin sensitivity, islet amyloid polypeptide and insulin secretion in humans.\" Diabetologia 36 (1993): 84-7[77] \"Product Information. Glucophage (metformin).\" Bristol-Myers Squibb, Princeton, NJ.[78] Chaudhuri ML, Catania J \"A comparison of the effects of bumetanide (Burinex) and frusemide on carbohydrate metabolism in the elderly.\" Br J Clin Pract 42 (1988): 427-9[79] Black DM, Filak AT \"Hyperglycemia with non-insulin-dependent diabetes following intraarticular steroid injection.\" J Fam Pract 28 (1989): 462-3[80] \"Product Information. Megace (megestrol).\" Bristol-Myers Squibb, Princeton, NJ.[81] \"Product Information. Torisel (temsirolimus).\" Wyeth-Ayerst Laboratories, Philadelphia, PA.[82] Schmitz O, Hermansen K, Nielsen OH, Christensen CK, Arnfred J, Hansen HE, Mogensen CE, Orskov H, Beck-Nielsen H \"Insulin action in insulin-dependent diabetics after short-term thiazide therapy.\" Diabetes Care 9 (1986): 631-6[83] Kansal PC, Buse J, Buse MG \"Thiazide diuretics and control of diabetes mellitus.\" South Med J 62 (1969): 1372-9[84] Dimitriadis G, Tegos C, Golfinopoulou L, Roboti C, Raptis S \"Furosemide-induced hyperglycaemia - the implication of glycolytic kinases.\" Horm Metab Res 25 (1993): 557-9[85] \"Product Information. NovoLog Mix 70/30 (insulin aspart-insulin aspart protamine).\" Novo Nordisk Pharmaceuticals Inc, Princeton, NJ.[86] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[87] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[88] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[89] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42[90] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[91] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[92] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[93] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[94] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[95] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6", "alternatives_a": "Capreomycin, Pyrazinamide, Rifamycin, Bedaquiline, Sulfamethoxazole, Rifapentine, Streptomycin, Trimethoprim, Cycloserine, Rifabutin, Ethambutol, More", "alternatives_b": "Guar gum", "updated_at": 1767369485}, {"id": 97936, "ingredient1": "Isoprenaline", "ingredient2": "Empagliflozin", "severity": "Moderate", "effect": "The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.", "source": "DDInter", "management_text": "Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.", "mechanism_text": "Antagonism", "recommendation": "Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/98040/", "reference_text": "[1] Jori A, Carrara MC \"On the mechanism of the hyperglycaemic effect of chlorpromazine.\" J Pharm Pharmacol 18 (1966): 623-4[2] \"Product Information. Dymelor (acetohexamide)\" Lilly, Eli and Company, Indianapolis, IN.[3] \"Product Information. Thorazine (chlorpromazine).\" SmithKline Beecham, Philadelphia, PA.[4] Blayac JP, Ribes G, Buys D, Puech R, Loubatieres-Mariani MM \"Effects of a new benzothiadiazine derivative, LN 5330, on insulin secretion.\" Arch Int Pharmacodyn Ther 253 (1981): 154-63[5] \"Product Information. Elzonris (tagraxofusp).\" Stemline Therapeutics, New York, NY.[6] \"Product Information. Amaryl (glimepiride).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[7] \"Product Information. Elspar (asparaginase).\" Merck & Co, Inc, West Point, PA.[8] Jones IG, Pickens PT \"Diabetes mellitus following oral diuretics.\" Practitioner 199 (1967): 209-10[9] \"Product Information. Viracept (nelfinavir).\" Agouron Pharma Inc, La Jolla, CA.[10] \"Product Information. Tolinase (tolazamide)\" Pharmacia and Upjohn, Kalamazoo, MI.[11] Mauss S, Wolf E, Jaeger H \"Impaired glucose tolerance in HIV-positive patients receiving and those not receiving protease inhibitors.\" Ann Intern Med 130 (1999): 162-3[12] Virutamasen P, Wongsrichanalai C, Tangkeo P, Nitichai Y, Rienprayoon D \"Metabolic effects of depot-medroxyprogesterone acetate in long-term users: a cross-sectional study.\" Int J Gynaecol Obstet 24 (1986): 291-6[13] Wehring H, Alexander B, Perry PJ \"Diabetes mellitus associated with clozapine therapy.\" Pharmacotherapy 20 (2000): 844-7[14] Spellacy WN, Ellingson AB, Tsibris JC \"The effects of two triphasic oral contraceptives on carbohydrate metabolism in women during 1 year of use.\" Fertil Steril 51 (1989): 71-4[15] Andersen OO, Persson I \"Carbohydrate metabolism during treatment with chlorthalidone and ethacrynic acid.\" Br Med J 2 (1968): 798-801[16] Berlin I \"Prazosin, diuretics, and glucose intolerance.\" Ann Intern Med 119 (1993): 860[17] Malherbe C, Burrill KC, Levin SR, Karam JH, Forsham PH \"Effect of diphenylhydantoin on insulin secretion in man.\" N Engl J Med 286 (1972): 339-42[18] Carter BL, Small RE, Mandel MD, Starkman MT \"Phenytoin-induced hyperglycemia.\" Am J Hosp Pharm 38 (1981): 1508-12[19] Al-Rubeaan K, Ryan EA \"Phenytoin-induced insulin insensitivity.\" Diabet Med 8 (1991): 968-70[20] \"Product Information. Zolinza (vorinostat).\" Merck & Company Inc, West Point, PA.[21] Goldman JA, Neri A, Ovadia J, Eckerling B, Vries A, de \"Effect of chlorothiazide on intravenous glucose tolerance in pregnancy.\" Am J Obstet Gynecol 105 (1969): 556-60[22] Harper R, Ennis CN, Heaney AP, Sheridan B, Gormley M, Atkinson AB, Johnston GD, Bell PM \"A comparison of the effects of low- and conventional-dose thiazide diuretic on insulin action in hypertensive patients with NIDDM.\" Diabetologia 38 (1995): 853-9[23] Seltzer HS, Allen EW \"Hyperglycemia and inhibition of insulin secretion during administration of diazoxide and trichlormethiazide in man.\" Diabetes 18 (1969): 19-28[24] Dube MP, Johnson DL, Currier JS, Leedom JM \"Protease inhibitor-associated hyperglycaemia.\" Lancet 350 (1997): 713-4[25] Leary WP, Reyes AJ \"Drug interactions with diuretics.\" S Afr Med J 65 (1984): 455-61[26] \"Product Information. Reyataz (atazanavir).\" Bristol-Myers Squibb, Princeton, NJ.[27] Pollare T, Lithell H, Berne C \"A comparison of the effects of hydrochlorothiazide and captopril on glucose and lipid metabolism in patients with hypertension.\" N Engl J Med 321 (1989): 868-73[28] Gunnarsson R, Lundgren G, Magnusson G, Ost L, Groth CG \"Steroid diabetes--a sign of overtreatment with steroids in the renal graft recipient?\" Scand J Urol Nephrol Suppl 54 (1980): 135-8[29] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[30] \"Product Information. Synthroid (levothyroxine).\" Abbott Pharmaceutical, Abbott Park, IL.[31] Murphy MB, Kohner E, Lewis PJ, Schumer B, Dollery CT \"Glucose intolerance in hypertensive patients treated with diuretics: a fourteen-year follow-up.\" Lancet 2 (1982): 1293-5[32] \"Product Information. Fortovase (saquinavir)\" Roche Laboratories, Nutley, NJ.[33] Coni NK, Gordon PW, Mukherjee AP, Read PR \"The effect of frusemide and ethacrynic acid on carbohydrate metabolism.\" Age Ageing 3 (1974): 85-90[34] \"Product Information. Norvir (ritonavir).\" Abbott Pharmaceutical, Abbott Park, IL.[35] Domenet JG \"Diabetogenic effect of oral diuretics.\" Br Med J 3 (1968): 188[36] Rowe P, Mather H \"Hyperosmolar non-ketotic diabetes mellitus associated with metolazone.\" Br Med J 291 (1985): 25-6[37] Winchester JF, Kellett RJ, Boddy K, Boyle P, Dargie HJ, Mahaffey ME, Ward DM, Kennedy AC \"Metolazone and bendroflumethiazide in hypertension: physiologic and metabolic observations.\" Clin Pharmacol Ther 28 (1980): 611-8[38] \"Product Information. Carafate (sucralfate).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[39] Tsiodras S, Mantzoros C, Hammer S, Samore M \"Effects of protease inhibitors on hyperglycemia, hyperlipidemia, and lipodystrophy - A 5-year cohort study.\" Arch Intern Med 160 (2000): 2050-6[40] \"Product Information. Apidra (insulin glulisine).\" Aventis Pharmaceuticals, Bridgewater, NJ.[41] \"Product Information. Prezista (darunavir).\" Ortho Biotech Inc, Bridgewater, NJ.[42] Haiba NA, el-Habashy MA, Said SA, Darwish EA, Abdel-Sayed WS, Nayel SE \"Clinical evaluation of two monthly injectable contraceptives and their effects on some metabolic parameters.\" Contraception 39 (1989): 619-32[43] Erle G, Basso M, Federspil G, Sicolo N, Scandellari C \"Effect of chlorpromazine on blood glucose and plasma insulin in man.\" Eur J Clin Pharmacol 11 (1977): 15-8[44] Pickkers P, Schachter M, Hughes AD, Feher MD, Sever PS \"Thiazide-induced hyperglycaemia: a role for calcium-activated potassium channels?\" Diabetologia 39 (1996): 861-4[45] \"Product Information. Lexiva (fosamprenavir).\" GlaxoSmithKline, Research Triangle Park, NC.[46] Curtis J, Horrigan F, Ahearn D, Varney R, Sandler SG \"Chlorthalidone-induced hyperosmolar hyperglycemic nonketotic coma.\" JAMA 220 (1972): 1592-3[47] \"Product Information. Hyperstat I.V. (diazoxide).\" Schering Corp, Kenilworth, NJ.[48] \"Product Information. Piqray (alpelisib).\" Novartis Pharmaceuticals, East Hanover, NJ.[49] Bell DS \"Insulin resistance. An often unrecognized problem accompanying chronic medical disorders.\" Postgrad Med 93 (1993): 99-103,[50] Stambaugh JE, Tucker DC \"Effect of diphenylhydantoin on glucose tolerance in patients with hypoglycemia.\" Diabetes 23 (1974): 679-83[51] \"Product Information. Crixivan (indinavir).\" Merck & Co, Inc, West Point, PA.[52] Miller NR, Moses H \"Transient oculomotor nerve palsy. Association with thiazide-induced glucose intolerance.\" JAMA 240 (1978): 1887-8[53] Javier Z, Gershberg H, Hulse M \"Ovulatory suppressants, estrogens, and carbohydrate metabolism.\" Metabolism 17 (1968): 443-56[54] Goldman JA, Ovadia JL \"The effect of estrogen on intravenous glucose tolerance in woman.\" Am J Obstet Gynecol 103 (1969): 172-8[55] Charan VD, Desai N, Singh AP, Choudhry VP \"Diabetes mellitus and pancreatitis as a complication of L- asparaginase therapy.\" Indian Pediatr 30 (1993): 809-10[56] Seifer DB, Freedman LN, Cavender JR, Baker RA \"Insulin-dependent diabetes mellitus associated with danazol.\" Am J Obstet Gynecol 162 (1990): 474-5[57] \"Product Information. Orinase (tolbutamide)\" Pharmacia and Upjohn, Kalamazoo, MI.[58] Walli R, Demant T \"Impaired glucose tolerance and protease inhibitors.\" Ann Intern Med 129 (1998): 837-8[59] Hannaford PC, Kay CR \"Oral contraceptives and diabetes mellitus.\" BMJ 299 (1989): 1315-6[60] Hardy H, Esch LD, Morse GD \"Glucose disorders associated with HIV and its drug therapy.\" Ann Pharmacother 35 (2001): 343-51[61] Chowdhury FR, Bleicher SJ \"Chlorthalidone--induced hypokalemia and abnormal carbohydrate metabolism.\" Horm Metab Res 2 (1970): 13-6[62] Kaufman MB, Simionatto C \"A review of protease inhibitor-induced hyperglycemia.\" Pharmacotherapy 19 (1999): 114-7[63] Greenstone MA, Shaw AB \"Alternate day corticosteroid causes alternate day hyperglycaemia.\" Postgrad Med J 63 (1987): 761-4[64] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[65] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[66] Elmfeldt D, Berglund G, Wedel H, Wilhelmsen L \"Incidence and importance of metabolic side-effects during antihypertensive therapy.\" Acta Med Scand Suppl 672 (1983): 79-83[67] \"Product Information. Agenerase (amprenavir).\" Glaxo Wellcome, Research Triangle Pk, NC.[68] Diamond MT \"Hyperglycemic hyperosmolar coma associated with hydrochlorothiazide and pancreatitis.\" N Y State J Med 72 (1972): 1741-2[69] \"Product Information. Prandin (repaglinide).\" Novo Nordisk Pharmaceuticals Inc, Princeton, NJ.[70] \"Product Information. Precose (acarbose).\" Bayer, West Haven, CT.[71] \"Product Information. Starlix (nateglinide)\" Novartis Pharmaceuticals, East Hanover, NJ.[72] \"Product Information. Oncaspar (pegaspargase).\" Rhone-Poulenc Rorer, Collegeville, PA.[73] Sotaniemi E, Kontturi M, Larmi T \"Effect of diethylstilbestrol on blood glucose of prostatic cancer patients.\" Invest Urol 10 (1973): 438-41[74] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[75] Petri M, Cumber P, Grimes L, Treby D, Bryant R, Rawlins D, Ising H \"The metabolic effects of thiazide therapy in the elderly: a population study.\" Age Ageing 15 (1986): 151-5[76] Ludvik B, Clodi M, Kautzky-Willer A, Capek M, Hartter E, Pacini G, Prager R \"Effect of dexamethasone on insulin sensitivity, islet amyloid polypeptide and insulin secretion in humans.\" Diabetologia 36 (1993): 84-7[77] \"Product Information. Glucophage (metformin).\" Bristol-Myers Squibb, Princeton, NJ.[78] Chaudhuri ML, Catania J \"A comparison of the effects of bumetanide (Burinex) and frusemide on carbohydrate metabolism in the elderly.\" Br J Clin Pract 42 (1988): 427-9[79] Black DM, Filak AT \"Hyperglycemia with non-insulin-dependent diabetes following intraarticular steroid injection.\" J Fam Pract 28 (1989): 462-3[80] \"Product Information. Megace (megestrol).\" Bristol-Myers Squibb, Princeton, NJ.[81] \"Product Information. Torisel (temsirolimus).\" Wyeth-Ayerst Laboratories, Philadelphia, PA.[82] Schmitz O, Hermansen K, Nielsen OH, Christensen CK, Arnfred J, Hansen HE, Mogensen CE, Orskov H, Beck-Nielsen H \"Insulin action in insulin-dependent diabetics after short-term thiazide therapy.\" Diabetes Care 9 (1986): 631-6[83] Kansal PC, Buse J, Buse MG \"Thiazide diuretics and control of diabetes mellitus.\" South Med J 62 (1969): 1372-9[84] Dimitriadis G, Tegos C, Golfinopoulou L, Roboti C, Raptis S \"Furosemide-induced hyperglycaemia - the implication of glycolytic kinases.\" Horm Metab Res 25 (1993): 557-9[85] \"Product Information. NovoLog Mix 70/30 (insulin aspart-insulin aspart protamine).\" Novo Nordisk Pharmaceuticals Inc, Princeton, NJ.[86] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[87] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[88] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[89] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42[90] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[91] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[92] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[93] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[94] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[95] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6", "alternatives_a": "Droxidopa, Midodrine, Amrinone, Angiotensin II, Milrinone, Arbutamine, Umeclidinium, Budesonide, Glycopyrronium, Aclidinium, Mometasone, More", "alternatives_b": "Simvastatin, Guar gum, Rosuvastatin", "updated_at": 1767369485}, {"id": 97937, "ingredient1": "Isosorbide dinitrate", "ingredient2": "Empagliflozin", "severity": "Moderate", "effect": "Sodium-glucose co-transporter 2 (SGLT-2) inhibitors may potentiate the hypotensive effects of diuretics and other antihypertensive agents or vasodilators. Inhibition of glucose and sodium co-transport produces mild diuresis and transient natriuresis, resulting in intravascular volume contraction. Volume depletion-related adverse reactions including hypotension, postural dizziness, orthostatic hypotension, syncope, and dehydration can occur after initiating treatment with SGLT-2 inhibitors, and the risk may be increased with concomitant use of other agents that can lower blood pressure.", "source": "DDInter", "management_text": "Caution is advised if SGLT-2 inhibitors are coadministered with diuretics and other hypotensive agents, particularly in the elderly and patients with impaired renal function. Prior to initiating SGLT-2 inhibitors, volume status should be assessed and corrected, if necessary. Clinical and laboratory monitoring are recommended during therapy, including electrolytes, fluid status, renal function, and blood pressure. If volume depletion occurs, treatment with SGLT-2 inhibitors should be interrupted until the condition is corrected.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if SGLT-2 inhibitors are coadministered with diuretics and other hypotensive agents, particularly in the elderly and patients with impaired renal function.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/98041/", "reference_text": "[1] \"Product Information. Jardiance (empagliflozin).\" Boehringer Ingelheim, Ridgefield, CT.[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] \"Product Information. Farxiga (dapagliflozin).\" Bristol-Myers Squibb, Princeton, NJ.[5] \"Product Information. Invokana (canagliflozin).\" Janssen Pharmaceuticals, Titusville, NJ.[6] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[7] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[8] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[9] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[10] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[11] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6[12] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[13] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[14] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[15] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42", "alternatives_a": "Vericiguat, Lidocaine, Zinc sulfate, Tetracaine, Zinc acetate, Fluocinonide, Zinc chloride, Procaine, Fluorometholone, Zinc gluconate", "alternatives_b": "Exenatide, Lixisenatide, Albiglutide, Acetohexamide, Guar gum, Pramlintide, Sitagliptin, Alogliptin, Liraglutide, Troglitazone, Semaglutide, More", "updated_at": 1767369485}, {"id": 97938, "ingredient1": "Isosorbide mononitrate", "ingredient2": "Empagliflozin", "severity": "Moderate", "effect": "Sodium-glucose co-transporter 2 (SGLT-2) inhibitors may potentiate the hypotensive effects of diuretics and other antihypertensive agents or vasodilators. Inhibition of glucose and sodium co-transport produces mild diuresis and transient natriuresis, resulting in intravascular volume contraction. Volume depletion-related adverse reactions including hypotension, postural dizziness, orthostatic hypotension, syncope, and dehydration can occur after initiating treatment with SGLT-2 inhibitors, and the risk may be increased with concomitant use of other agents that can lower blood pressure.", "source": "DDInter", "management_text": "Caution is advised if SGLT-2 inhibitors are coadministered with diuretics and other hypotensive agents, particularly in the elderly and patients with impaired renal function. Prior to initiating SGLT-2 inhibitors, volume status should be assessed and corrected, if necessary. Clinical and laboratory monitoring are recommended during therapy, including electrolytes, fluid status, renal function, and blood pressure. If volume depletion occurs, treatment with SGLT-2 inhibitors should be interrupted until the condition is corrected.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if SGLT-2 inhibitors are coadministered with diuretics and other hypotensive agents, particularly in the elderly and patients with impaired renal function.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/98042/", "reference_text": "[1] \"Product Information. Jardiance (empagliflozin).\" Boehringer Ingelheim, Ridgefield, CT.[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] \"Product Information. Farxiga (dapagliflozin).\" Bristol-Myers Squibb, Princeton, NJ.[5] \"Product Information. Invokana (canagliflozin).\" Janssen Pharmaceuticals, Titusville, NJ.[6] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[7] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[8] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[9] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[10] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[11] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6[12] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[13] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[14] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[15] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42", "alternatives_a": "Vericiguat", "alternatives_b": "Exenatide, Lixisenatide, Albiglutide, Acetohexamide, Guar gum, Pramlintide, Sitagliptin, Alogliptin, Liraglutide, Troglitazone, Semaglutide, More", "updated_at": 1767369485}, {"id": 97939, "ingredient1": "Isoxsuprine", "ingredient2": "Empagliflozin", "severity": "Moderate", "effect": "Sodium-glucose co-transporter 2 (SGLT-2) inhibitors may potentiate the hypotensive effects of diuretics and other antihypertensive agents or vasodilators. Inhibition of glucose and sodium co-transport produces mild diuresis and transient natriuresis, resulting in intravascular volume contraction. Volume depletion-related adverse reactions including hypotension, postural dizziness, orthostatic hypotension, syncope, and dehydration can occur after initiating treatment with SGLT-2 inhibitors, and the risk may be increased with concomitant use of other agents that can lower blood pressure.", "source": "DDInter", "management_text": "Caution is advised if SGLT-2 inhibitors are coadministered with diuretics and other hypotensive agents, particularly in the elderly and patients with impaired renal function. Prior to initiating SGLT-2 inhibitors, volume status should be assessed and corrected, if necessary. Clinical and laboratory monitoring are recommended during therapy, including electrolytes, fluid status, renal function, and blood pressure. If volume depletion occurs, treatment with SGLT-2 inhibitors should be interrupted until the condition is corrected.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if SGLT-2 inhibitors are coadministered with diuretics and other hypotensive agents, particularly in the elderly and patients with impaired renal function.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/98043/", "reference_text": "[1] \"Product Information. Jardiance (empagliflozin).\" Boehringer Ingelheim, Ridgefield, CT.[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] \"Product Information. Farxiga (dapagliflozin).\" Bristol-Myers Squibb, Princeton, NJ.[5] \"Product Information. Invokana (canagliflozin).\" Janssen Pharmaceuticals, Titusville, NJ.[6] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[7] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[8] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[9] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[10] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[11] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6[12] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[13] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[14] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[15] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42", "alternatives_a": "Pentoxifylline", "alternatives_b": "Glipizide, Acetohexamide, Guar gum, Pramlintide, Alogliptin, Rosuvastatin, Tolazamide, Dulaglutide, Exenatide, Tolbutamide, Miglitol, More", "updated_at": 1767369485}, {"id": 97940, "ingredient1": "Empagliflozin", "ingredient2": "Labetalol", "severity": "Moderate", "effect": "Sodium-glucose co-transporter 2 (SGLT-2) inhibitors may potentiate the hypotensive effects of diuretics and other antihypertensive agents or vasodilators. Inhibition of glucose and sodium co-transport produces mild diuresis and transient natriuresis, resulting in intravascular volume contraction. Volume depletion-related adverse reactions including hypotension, postural dizziness, orthostatic hypotension, syncope, and dehydration can occur after initiating treatment with SGLT-2 inhibitors, and the risk may be increased with concomitant use of other agents that can lower blood pressure.", "source": "DDInter", "management_text": "Caution is advised if SGLT-2 inhibitors are coadministered with diuretics and other hypotensive agents, particularly in the elderly and patients with impaired renal function. Prior to initiating SGLT-2 inhibitors, volume status should be assessed and corrected, if necessary. Clinical and laboratory monitoring are recommended during therapy, including electrolytes, fluid status, renal function, and blood pressure. If volume depletion occurs, treatment with SGLT-2 inhibitors should be interrupted until the condition is corrected.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if SGLT-2 inhibitors are coadministered with diuretics and other hypotensive agents, particularly in the elderly and patients with impaired renal function.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/98044/", "reference_text": "[1] \"Product Information. Jardiance (empagliflozin).\" Boehringer Ingelheim, Ridgefield, CT.[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] \"Product Information. Farxiga (dapagliflozin).\" Bristol-Myers Squibb, Princeton, NJ.[5] \"Product Information. Invokana (canagliflozin).\" Janssen Pharmaceuticals, Titusville, NJ.[6] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[7] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[8] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[9] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[10] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[11] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6[12] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[13] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[14] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[15] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42", "alternatives_a": "Lixisenatide, Albiglutide, Guar gum, Acarbose, Pramlintide, Sitagliptin, Alogliptin, Liraglutide, Troglitazone, Semaglutide, Linagliptin, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 97941, "ingredient1": "Empagliflozin", "ingredient2": "Lanreotide", "severity": "Moderate", "effect": "Somatostatin analogs may alter the therapeutic response to insulin and other antidiabetic agents. Somatostatin analogs can induce hyperglycemia and, less frequently, hypoglycemia, by inhibiting the secretion of various counter-regulatory hormones involved in glucose homeostasis (i.e., glucagon, insulin, growth hormone, incretin hormones).", "source": "DDInter", "management_text": "Close monitoring of diabetic control is recommended if somatostatin analogs are prescribed to patients with preexisting diabetes. Glycemic status including fasting plasma glucose and/or hemoglobin A1c should be assessed prior to initiation of therapy and periodically during therapy in accordance with manufacturer's product labeling, and the antidiabetic treatment adjusted as necessary.", "mechanism_text": "Antagonism", "recommendation": "Close monitoring of diabetic control is recommended if somatostatin analogs are prescribed to patients with preexisting diabetes.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/98045/", "reference_text": "[1] Williams G, Fuessl HS, Burrin JM, Chilvers E, Bloom SR \"Postprandial glycaemic effects of a long-acting somatostatin analogue (octreotide) in non-insulin diabetes mellitus.\" Horm Metab Res 20 (1988): 168-70[2] \"Product Information. Somatuline Depot (lanreotide).\" Ipsen Inc, Milford, MA.[3] \"Product Information. Sandostatin (octreotide).\" Sandoz Pharmaceuticals Corporation, East Hanover, NJ.[4] Hadjidakis DJ, Halvatsiotis PG, Ioannou YJ, Mavrokefalos PJ, Raptis SA \"The effects of the somatostatin analogue SMS 201-995 on carbohydrate homeostasis of insulin-dependent diabetics as assessed by the artificial endocrine pancreas.\" Diabetes Res Clin Pract 5 (1988): 91-8[5] Rios MS, Navascues I, Saban J, Ordonez A, Sevilla F, Del Pozo E \"Somatostatin analog SMS 201-995 and insulin needs in insulin-dependent diabetic patients studied by means of an artificial pancreas.\" J Clin Endocrinol Metab 63 (1986): 1071-4[6] \"Product Information. Signifor (pasireotide).\" Novartis Pharmaceuticals, East Hanover, NJ.[7] Giustina A, Girelli A, Buffoli MG, et al \"Low-dose octreotide is able to cause a maximal inhibition of the glycemic responses to a mixed meal in obese type 2 diabetic patients treated with insulin.\" Diabetes Res Clin Pract 14 (1991): 47-54[8] Davies RR, Miller M, Turner SJ, et al \"Effects of somatostatin analogue SMS 201-995 in non-insulin-dependent diabetes.\" Clin Endocrinol (Oxf) 25 (1986): 739-47[9] Di Mauro M, Le Moli R, Nicoletti F, Lunetta F \"Effects of octreotide on the glycemic levels in insulin-dependent diabetic patients. Comparative study between administration through multiple subcutaneous injections and continuous subcutaneous infusion.\" Diabetologia 36(Suppl 1) (1993): A138[10] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[11] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[12] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[13] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[14] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[15] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6[16] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[17] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[18] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[19] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42", "alternatives_a": "Nafarelin, Cetrorelix, Ganirelix, Relugolix, Gonadorelin", "alternatives_b": "Simvastatin, Guar gum, Rosuvastatin", "updated_at": 1767369485}, {"id": 97942, "ingredient1": "Empagliflozin", "ingredient2": "Lasmiditan", "severity": "Moderate", "effect": "Coadministration with lasmiditan may increase the plasma concentrations of drugs that are substrates of the P-glycoprotein (P-gp) and/or breast cancer resistance protein (BCRP) transporters. The proposed mechanism, based on in vitro data, involves decreased clearance due to inhibition of P-gp and BCRP by lasmiditan.", "source": "DDInter", "management_text": "Concomitant use of lasmiditan with drugs that are P-gp and/or BCRP substrates should be avoided when possible. If coadministration is required, patients should be carefully monitored for increased adverse reactions of these drugs and dosing adjusted as necessary.", "mechanism_text": "Distribution", "recommendation": "Concomitant use of lasmiditan with drugs that are P-gp and/or BCRP substrates should be avoided when possible.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/98046/", "reference_text": "[1] \"Product Information. Reyvow (lasmiditan).\" Lilly, Eli and Company, Indianapolis, IN.", "alternatives_a": "Glipizide, Acetohexamide, Guar gum, Pramlintide, Alogliptin, Tolazamide, Dulaglutide, Exenatide, Tolbutamide, Miglitol, Glimepiride, More", "alternatives_b": "Frovatriptan, Dihydroergotamine, Rimegepant, Eptinezumab, Atogepant, Eletriptan, Rizatriptan, Ubrogepant, Ergotamine, Naratriptan, Galcanezumab, More", "updated_at": 1767369485}, {"id": 97943, "ingredient1": "Empagliflozin", "ingredient2": "Leuprolide", "severity": "Moderate", "effect": "The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.", "source": "DDInter", "management_text": "Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.", "mechanism_text": "Antagonism", "recommendation": "Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/98047/", "reference_text": "[1] Jori A, Carrara MC \"On the mechanism of the hyperglycaemic effect of chlorpromazine.\" J Pharm Pharmacol 18 (1966): 623-4[2] \"Product Information. Dymelor (acetohexamide)\" Lilly, Eli and Company, Indianapolis, IN.[3] \"Product Information. Thorazine (chlorpromazine).\" SmithKline Beecham, Philadelphia, PA.[4] Blayac JP, Ribes G, Buys D, Puech R, Loubatieres-Mariani MM \"Effects of a new benzothiadiazine derivative, LN 5330, on insulin secretion.\" Arch Int Pharmacodyn Ther 253 (1981): 154-63[5] \"Product Information. Elzonris (tagraxofusp).\" Stemline Therapeutics, New York, NY.[6] \"Product Information. Amaryl (glimepiride).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[7] \"Product Information. Elspar (asparaginase).\" Merck & Co, Inc, West Point, PA.[8] Jones IG, Pickens PT \"Diabetes mellitus following oral diuretics.\" Practitioner 199 (1967): 209-10[9] \"Product Information. Viracept (nelfinavir).\" Agouron Pharma Inc, La Jolla, CA.[10] \"Product Information. Tolinase (tolazamide)\" Pharmacia and Upjohn, Kalamazoo, MI.[11] Mauss S, Wolf E, Jaeger H \"Impaired glucose tolerance in HIV-positive patients receiving and those not receiving protease inhibitors.\" Ann Intern Med 130 (1999): 162-3[12] Virutamasen P, Wongsrichanalai C, Tangkeo P, Nitichai Y, Rienprayoon D \"Metabolic effects of depot-medroxyprogesterone acetate in long-term users: a cross-sectional study.\" Int J Gynaecol Obstet 24 (1986): 291-6[13] Wehring H, Alexander B, Perry PJ \"Diabetes mellitus associated with clozapine therapy.\" Pharmacotherapy 20 (2000): 844-7[14] Spellacy WN, Ellingson AB, Tsibris JC \"The effects of two triphasic oral contraceptives on carbohydrate metabolism in women during 1 year of use.\" Fertil Steril 51 (1989): 71-4[15] Andersen OO, Persson I \"Carbohydrate metabolism during treatment with chlorthalidone and ethacrynic acid.\" Br Med J 2 (1968): 798-801[16] Berlin I \"Prazosin, diuretics, and glucose intolerance.\" Ann Intern Med 119 (1993): 860[17] Malherbe C, Burrill KC, Levin SR, Karam JH, Forsham PH \"Effect of diphenylhydantoin on insulin secretion in man.\" N Engl J Med 286 (1972): 339-42[18] Carter BL, Small RE, Mandel MD, Starkman MT \"Phenytoin-induced hyperglycemia.\" Am J Hosp Pharm 38 (1981): 1508-12[19] Al-Rubeaan K, Ryan EA \"Phenytoin-induced insulin insensitivity.\" Diabet Med 8 (1991): 968-70[20] \"Product Information. Zolinza (vorinostat).\" Merck & Company Inc, West Point, PA.[21] Goldman JA, Neri A, Ovadia J, Eckerling B, Vries A, de \"Effect of chlorothiazide on intravenous glucose tolerance in pregnancy.\" Am J Obstet Gynecol 105 (1969): 556-60[22] Harper R, Ennis CN, Heaney AP, Sheridan B, Gormley M, Atkinson AB, Johnston GD, Bell PM \"A comparison of the effects of low- and conventional-dose thiazide diuretic on insulin action in hypertensive patients with NIDDM.\" Diabetologia 38 (1995): 853-9[23] Seltzer HS, Allen EW \"Hyperglycemia and inhibition of insulin secretion during administration of diazoxide and trichlormethiazide in man.\" Diabetes 18 (1969): 19-28[24] Dube MP, Johnson DL, Currier JS, Leedom JM \"Protease inhibitor-associated hyperglycaemia.\" Lancet 350 (1997): 713-4[25] Leary WP, Reyes AJ \"Drug interactions with diuretics.\" S Afr Med J 65 (1984): 455-61[26] \"Product Information. Reyataz (atazanavir).\" Bristol-Myers Squibb, Princeton, NJ.[27] Pollare T, Lithell H, Berne C \"A comparison of the effects of hydrochlorothiazide and captopril on glucose and lipid metabolism in patients with hypertension.\" N Engl J Med 321 (1989): 868-73[28] Gunnarsson R, Lundgren G, Magnusson G, Ost L, Groth CG \"Steroid diabetes--a sign of overtreatment with steroids in the renal graft recipient?\" Scand J Urol Nephrol Suppl 54 (1980): 135-8[29] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[30] \"Product Information. Synthroid (levothyroxine).\" Abbott Pharmaceutical, Abbott Park, IL.[31] Murphy MB, Kohner E, Lewis PJ, Schumer B, Dollery CT \"Glucose intolerance in hypertensive patients treated with diuretics: a fourteen-year follow-up.\" Lancet 2 (1982): 1293-5[32] \"Product Information. Fortovase (saquinavir)\" Roche Laboratories, Nutley, NJ.[33] Coni NK, Gordon PW, Mukherjee AP, Read PR \"The effect of frusemide and ethacrynic acid on carbohydrate metabolism.\" Age Ageing 3 (1974): 85-90[34] \"Product Information. Norvir (ritonavir).\" Abbott Pharmaceutical, Abbott Park, IL.[35] Domenet JG \"Diabetogenic effect of oral diuretics.\" Br Med J 3 (1968): 188[36] Rowe P, Mather H \"Hyperosmolar non-ketotic diabetes mellitus associated with metolazone.\" Br Med J 291 (1985): 25-6[37] Winchester JF, Kellett RJ, Boddy K, Boyle P, Dargie HJ, Mahaffey ME, Ward DM, Kennedy AC \"Metolazone and bendroflumethiazide in hypertension: physiologic and metabolic observations.\" Clin Pharmacol Ther 28 (1980): 611-8[38] \"Product Information. Carafate (sucralfate).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[39] Tsiodras S, Mantzoros C, Hammer S, Samore M \"Effects of protease inhibitors on hyperglycemia, hyperlipidemia, and lipodystrophy - A 5-year cohort study.\" Arch Intern Med 160 (2000): 2050-6[40] \"Product Information. Apidra (insulin glulisine).\" Aventis Pharmaceuticals, Bridgewater, NJ.[41] \"Product Information. Prezista (darunavir).\" Ortho Biotech Inc, Bridgewater, NJ.[42] Haiba NA, el-Habashy MA, Said SA, Darwish EA, Abdel-Sayed WS, Nayel SE \"Clinical evaluation of two monthly injectable contraceptives and their effects on some metabolic parameters.\" Contraception 39 (1989): 619-32[43] Erle G, Basso M, Federspil G, Sicolo N, Scandellari C \"Effect of chlorpromazine on blood glucose and plasma insulin in man.\" Eur J Clin Pharmacol 11 (1977): 15-8[44] Pickkers P, Schachter M, Hughes AD, Feher MD, Sever PS \"Thiazide-induced hyperglycaemia: a role for calcium-activated potassium channels?\" Diabetologia 39 (1996): 861-4[45] \"Product Information. Lexiva (fosamprenavir).\" GlaxoSmithKline, Research Triangle Park, NC.[46] Curtis J, Horrigan F, Ahearn D, Varney R, Sandler SG \"Chlorthalidone-induced hyperosmolar hyperglycemic nonketotic coma.\" JAMA 220 (1972): 1592-3[47] \"Product Information. Hyperstat I.V. (diazoxide).\" Schering Corp, Kenilworth, NJ.[48] \"Product Information. Piqray (alpelisib).\" Novartis Pharmaceuticals, East Hanover, NJ.[49] Bell DS \"Insulin resistance. An often unrecognized problem accompanying chronic medical disorders.\" Postgrad Med 93 (1993): 99-103,[50] Stambaugh JE, Tucker DC \"Effect of diphenylhydantoin on glucose tolerance in patients with hypoglycemia.\" Diabetes 23 (1974): 679-83[51] \"Product Information. Crixivan (indinavir).\" Merck & Co, Inc, West Point, PA.[52] Miller NR, Moses H \"Transient oculomotor nerve palsy. Association with thiazide-induced glucose intolerance.\" JAMA 240 (1978): 1887-8[53] Javier Z, Gershberg H, Hulse M \"Ovulatory suppressants, estrogens, and carbohydrate metabolism.\" Metabolism 17 (1968): 443-56[54] Goldman JA, Ovadia JL \"The effect of estrogen on intravenous glucose tolerance in woman.\" Am J Obstet Gynecol 103 (1969): 172-8[55] Charan VD, Desai N, Singh AP, Choudhry VP \"Diabetes mellitus and pancreatitis as a complication of L- asparaginase therapy.\" Indian Pediatr 30 (1993): 809-10[56] Seifer DB, Freedman LN, Cavender JR, Baker RA \"Insulin-dependent diabetes mellitus associated with danazol.\" Am J Obstet Gynecol 162 (1990): 474-5[57] \"Product Information. Orinase (tolbutamide)\" Pharmacia and Upjohn, Kalamazoo, MI.[58] Walli R, Demant T \"Impaired glucose tolerance and protease inhibitors.\" Ann Intern Med 129 (1998): 837-8[59] Hannaford PC, Kay CR \"Oral contraceptives and diabetes mellitus.\" BMJ 299 (1989): 1315-6[60] Hardy H, Esch LD, Morse GD \"Glucose disorders associated with HIV and its drug therapy.\" Ann Pharmacother 35 (2001): 343-51[61] Chowdhury FR, Bleicher SJ \"Chlorthalidone--induced hypokalemia and abnormal carbohydrate metabolism.\" Horm Metab Res 2 (1970): 13-6[62] Kaufman MB, Simionatto C \"A review of protease inhibitor-induced hyperglycemia.\" Pharmacotherapy 19 (1999): 114-7[63] Greenstone MA, Shaw AB \"Alternate day corticosteroid causes alternate day hyperglycaemia.\" Postgrad Med J 63 (1987): 761-4[64] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[65] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[66] Elmfeldt D, Berglund G, Wedel H, Wilhelmsen L \"Incidence and importance of metabolic side-effects during antihypertensive therapy.\" Acta Med Scand Suppl 672 (1983): 79-83[67] \"Product Information. Agenerase (amprenavir).\" Glaxo Wellcome, Research Triangle Pk, NC.[68] Diamond MT \"Hyperglycemic hyperosmolar coma associated with hydrochlorothiazide and pancreatitis.\" N Y State J Med 72 (1972): 1741-2[69] \"Product Information. Prandin (repaglinide).\" Novo Nordisk Pharmaceuticals Inc, Princeton, NJ.[70] \"Product Information. Precose (acarbose).\" Bayer, West Haven, CT.[71] \"Product Information. Starlix (nateglinide)\" Novartis Pharmaceuticals, East Hanover, NJ.[72] \"Product Information. Oncaspar (pegaspargase).\" Rhone-Poulenc Rorer, Collegeville, PA.[73] Sotaniemi E, Kontturi M, Larmi T \"Effect of diethylstilbestrol on blood glucose of prostatic cancer patients.\" Invest Urol 10 (1973): 438-41[74] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[75] Petri M, Cumber P, Grimes L, Treby D, Bryant R, Rawlins D, Ising H \"The metabolic effects of thiazide therapy in the elderly: a population study.\" Age Ageing 15 (1986): 151-5[76] Ludvik B, Clodi M, Kautzky-Willer A, Capek M, Hartter E, Pacini G, Prager R \"Effect of dexamethasone on insulin sensitivity, islet amyloid polypeptide and insulin secretion in humans.\" Diabetologia 36 (1993): 84-7[77] \"Product Information. Glucophage (metformin).\" Bristol-Myers Squibb, Princeton, NJ.[78] Chaudhuri ML, Catania J \"A comparison of the effects of bumetanide (Burinex) and frusemide on carbohydrate metabolism in the elderly.\" Br J Clin Pract 42 (1988): 427-9[79] Black DM, Filak AT \"Hyperglycemia with non-insulin-dependent diabetes following intraarticular steroid injection.\" J Fam Pract 28 (1989): 462-3[80] \"Product Information. Megace (megestrol).\" Bristol-Myers Squibb, Princeton, NJ.[81] \"Product Information. Torisel (temsirolimus).\" Wyeth-Ayerst Laboratories, Philadelphia, PA.[82] Schmitz O, Hermansen K, Nielsen OH, Christensen CK, Arnfred J, Hansen HE, Mogensen CE, Orskov H, Beck-Nielsen H \"Insulin action in insulin-dependent diabetics after short-term thiazide therapy.\" Diabetes Care 9 (1986): 631-6[83] Kansal PC, Buse J, Buse MG \"Thiazide diuretics and control of diabetes mellitus.\" South Med J 62 (1969): 1372-9[84] Dimitriadis G, Tegos C, Golfinopoulou L, Roboti C, Raptis S \"Furosemide-induced hyperglycaemia - the implication of glycolytic kinases.\" Horm Metab Res 25 (1993): 557-9[85] \"Product Information. NovoLog Mix 70/30 (insulin aspart-insulin aspart protamine).\" Novo Nordisk Pharmaceuticals Inc, Princeton, NJ.[86] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[87] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[88] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[89] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42[90] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[91] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[92] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[93] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[94] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[95] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6", "alternatives_a": "Bicalutamide", "alternatives_b": "Simvastatin, Guar gum, Rosuvastatin", "updated_at": 1767369485}, {"id": 97944, "ingredient1": "Empagliflozin", "ingredient2": "Levamlodipine", "severity": "Moderate", "effect": "Sodium-glucose co-transporter 2 (SGLT-2) inhibitors may potentiate the hypotensive effects of diuretics and other antihypertensive agents or vasodilators. Inhibition of glucose and sodium co-transport produces mild diuresis and transient natriuresis, resulting in intravascular volume contraction. Volume depletion-related adverse reactions including hypotension, postural dizziness, orthostatic hypotension, syncope, and dehydration can occur after initiating treatment with SGLT-2 inhibitors, and the risk may be increased with concomitant use of other agents that can lower blood pressure.", "source": "DDInter", "management_text": "Caution is advised if SGLT-2 inhibitors are coadministered with diuretics and other hypotensive agents, particularly in the elderly and patients with impaired renal function. Prior to initiating SGLT-2 inhibitors, volume status should be assessed and corrected, if necessary. Clinical and laboratory monitoring are recommended during therapy, including electrolytes, fluid status, renal function, and blood pressure. If volume depletion occurs, treatment with SGLT-2 inhibitors should be interrupted until the condition is corrected.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if SGLT-2 inhibitors are coadministered with diuretics and other hypotensive agents, particularly in the elderly and patients with impaired renal function.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/98048/", "reference_text": "[1] \"Product Information. Jardiance (empagliflozin).\" Boehringer Ingelheim, Ridgefield, CT.[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] \"Product Information. Farxiga (dapagliflozin).\" Bristol-Myers Squibb, Princeton, NJ.[5] \"Product Information. Invokana (canagliflozin).\" Janssen Pharmaceuticals, Titusville, NJ.[6] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[7] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[8] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[9] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[10] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[11] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6[12] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[13] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[14] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[15] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42", "alternatives_a": "Glipizide, Acetohexamide, Guar gum, Pramlintide, Alogliptin, Rosuvastatin, Tolazamide, Dulaglutide, Exenatide, Tolbutamide, Miglitol, More", "alternatives_b": "Celecoxib", "updated_at": 1767369485}, {"id": 97945, "ingredient1": "Empagliflozin", "ingredient2": "Levofloxacin", "severity": "Moderate", "effect": "Quinolone antibiotics may interfere with the therapeutic effects of insulin and other antidiabetic agents. The use of quinolones has been associated with disturbances in blood glucose homeostasis possibly stemming from effects on pancreatic beta cell ATP-sensitive potassium channels that regulate insulin secretion. Both hyperglycaemia and hypoglycemia have been reported, usually in diabetic patients receiving concomitant treatment with an oral hypoglycemic agent (e.g., sulfonylurea) or insulin. Although hyperglycaemia is significantly more common and infection itself may be an underlying risk factor, hypoglycemia may cause greater morbidity and mortality.", "source": "DDInter", "management_text": "Blood glucose should be closely monitored whenever quinolones are prescribed to diabetic patients, especially if they are elderly, have renal impairment, or are severely ill. Patients should be apprised of the increased risk of dysglycemia and be particularly alert to potential signs and symptoms of hypoglycemia such as headache, dizziness, drowsiness, nervousness, confusion, tremor, hunger, weakness, perspiration, palpitation, and tachycardia. If hypoglycemia occurs, patients should initiate appropriate remedial therapy immediately, discontinue the quinolone, and contact their physician. Alternative antibiotics may need to be considered.", "mechanism_text": "Antagonism", "recommendation": "Blood glucose should be closely monitored whenever quinolones are prescribed to diabetic patients, especially if they are elderly, have renal impairment, or are severely ill.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/98049/", "reference_text": "[1] Gavin JR 3rd, Kubin R, Choudhri S, et al \"Moxifloxacin and glucose homeostasis: a pooled-analysis of the evidence from clinical and postmarketing studies.\" Drug Saf 27 (2004): 671-86[2] Yip C, Lee AJ \"Gatifloxacin-induced hyperglycemia: a case report and summary of the current literature.\" Clin Ther 28 (2006): 1857-66[3] Kelesidis T, Canseco E \"Quinolone-induced hypoglycemia: a life-threatening but potentially reversible side effect.\" Am J Med 123 (2010): e5-6[4] Baker SE, Hangii MC \"Possible gatifloxacin-induced hypoglycemia.\" Ann Pharmacother 36 (2002): 1722-6[5] \"Product Information. Levaquin (levofloxacin).\" Ortho Pharmaceutical Corporation, Raritan, NJ.[6] Frothingham R \"Glucose homeostasis abnormalities associated with use of gatifloxacin.\" Clin Infect Dis 41 (2005): 1269-76[7] Letourneau G, Morrison H, McMorran M \"Gatifloxacin (Tequin): hypoglycemia and hyperglycemia. Available from: URL: http://www.hc-sc.gc.ca/dhp-mps/medeff/bulletin/carn-bcei_v13n3_e.html#1\" ([2003 Jul]):[8] Lin G, Hays DP, Spillane L \"Refractory hypoglycemia from ciprofloxacin and glyburide interaction.\" J Toxicol Clin Toxicol 42 (2004): 295-7[9] \"Product Information. Tequin (gatifloxacin)\" Bristol-Myers Squibb, Princeton, NJ.[10] \"Product Information. Floxin (ofloxacin).\" Ortho Pharmaceutical Corporation, Raritan, NJ.[11] Bhasin R, Arce FC, Pasmantier R \"Hypoglycemia associated with the use of gatifloxacin.\" Am J Med Sci 330 (2005): 250-3[12] Zvonar R \"Gatifloxacin-induced dysglycemia.\" Am J Health Syst Pharm 63 (2006): 2087-2092[13] Rubinstein E \"History of quinolones and their side effects.\" Chemotherapy 47 Suppl 3 (2001): 3-8[14] Park-Wyllie LY, Juurlink DN, Kopp A, et al. \"Outpatient gatifloxacin therapy and dysglycemia in older adults.\" N Engl J Med 354 (2006): 1352-61[15] LeBlanc M, Belanger C, Cossette P \"Severe and resistant hypoglycemia associated with concomitant gatifloxacin and glyburide therapy.\" Pharmacotherapy 24 (2004): 926-31[16] \"Product Information. Cipro (ciprofloxacin).\" Bayer, West Haven, CT.[17] Happe MR, Mulhall BP, Maydonovitch CL, Holtzmuller KC \"Gatifloxacin-induced hyperglycemia.\" Ann Intern Med 141 (2004): 968-9[18] Biggs WS \"Hypoglycemia and hyperglycemia associated with gatifloxacin use in elderly patients.\" J Am Board Fam Pract 16 (2004): 455-7[19] \"Product Information. Raxar (grepafloxacin).\" Glaxo Wellcome, Research Triangle Park, NC.[20] Brogan SE, Cahalan MK \"Gatifloxacin as a possible cause of serious postoperative hypoglycemia.\" Anesth Analg 101 (2005): 635-6[21] Friedrich LV, Dougherty R \"Fatal hypoglycemia associated with levofloxacin.\" Pharmacotherapy 24 (2004): 1807-12[22] Saraya A, Yokokura M, Gonoi T, Seino S \"Effects of fluoroquinolones on insulin secretion and beta-cell ATP-sensitive K(+) channels.\" Eur J Pharmacol 497 (2004): 111-7[23] \"Hypoglycemia and hyperglycemia with fluoroquinolones.\" Med Lett Drugs Ther 45 (2003): 64[24] Gajjar DA, LaCreta FP, Kollia GD, et al. \"Effect of multiple-dose gatifloxacin or ciprofloxacin on glucose homeostasis and insulin production in patients with noninsulin-dependent diabetes mellitus maintained with diet and exercise.\" Pharmacotherapy 20 (6 Pt 2) (2000): s76-86[25] Khovidhunkit W, Sunthornyothin S \"Hypoglycemia, hyperglycemia, and gatifloxacin.\" Ann Intern Med 141 (2004): 969[26] Kanbay M, Aydogan T, Bozalan R, et al. \"A rare but serious side effect of levofloxacin: hypoglycemia in a geriatric patient.\" Diabetes Care 29 (2006): 1716-7[27] Menzies DJ, Dorsainvil PA, Cunha BA, Johnson DH \"Severe and persistent hypoglycemia due to gatifloxacin interaction with oral hypoglycemic agents.\" Am J Med 113 (2002): 232-4[28] Edwards DJ, Bowles SK, Svensson CK, Rybak MJ \"Inhibition of drug metabolism by quinolone antibiotics.\" Clin Pharmacokinet 15 (1988): 194-204[29] Graumlich JF, Habis S, Avelino RR, et al. \"Hypoglycemia in inpatients after gatifloxacin or levofloxacin therapy: nested case-control study.\" Pharmacotherapy 25 (2005): 1296-302[30] \"Product Information. Factive (gemifloxacin).\" GeneSoft Inc, San Francisco, CA.[31] Wang S, Rizvi AA \"Levofloxacin-induced hypoglycemia in a nondiabetic patient.\" Am J Med Sci 331 (2006): 334-5[32] \"Product Information. Noroxin (norfloxacin).\" Merck & Co, Inc, West Point, PA.[33] Zhanel GG, Fontaine S, Adam H, et al. \"A Review of New Fluoroquinolones : Focus on their Use in Respiratory Tract Infections.\" Treat Respir Med 5 (2006): 437-465[34] \"Product Information. Baxdela (delafloxacin).\" Melinta Therapeutics, Lincolnshire, IL.[35] Greenberg AL, Decerbo M, Fan J \"Gatifloxacin therapy associated with hypoglycemia.\" Clin Infect Dis 40 (2005): 1210-1[36] Blommel AL, Lutes RA \"Severe hyperglycemia during renally adjusted gatifloxacin therapy.\" Ann Pharmacother 39 (2005): 1349-52[37] Tomita T, Onishi M, Sato E, Kimura Y, Kihira K \"Gatifloxacin induces augmented insulin release and intracellular insulin.\" Biol Pharm Bull 30 (2007): 644-7[38] Donaldson AR, Vandiver JR, Finch CK \"Possible gatifloxacin-induced hyperglycemia.\" Ann Pharmacother 38 (2004): 602-5[39] \"Product Information. Trovan (trovafloxacin).\" Pfizer US Pharmaceuticals, New York, NY.[40] Roberge RJ, Kaplan R, Frank R, Fore C \"Glyburide-ciprofloxacin interaction with resistant hypoglycemia.\" Ann Emerg Med 36 (2000): 160-3[41] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[42] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[43] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[44] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42[45] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[46] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[47] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[48] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[49] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[50] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6", "alternatives_a": "Tinidazole, Pantoprazole, Tetracycline, Dexlansoprazole, Rabeprazole, Misoprostol, Bismuth subcitrate potassium, Metronidazole, Famotidine, Rifabutin, Cimetidine, More", "alternatives_b": "Simvastatin, Guar gum, Rosuvastatin", "updated_at": 1767369485}, {"id": 97946, "ingredient1": "Empagliflozin", "ingredient2": "Levonorgestrel", "severity": "Moderate", "effect": "The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.", "source": "DDInter", "management_text": "Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.", "mechanism_text": "Antagonism", "recommendation": "Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/98050/", "reference_text": "[1] Jori A, Carrara MC \"On the mechanism of the hyperglycaemic effect of chlorpromazine.\" J Pharm Pharmacol 18 (1966): 623-4[2] \"Product Information. Dymelor (acetohexamide)\" Lilly, Eli and Company, Indianapolis, IN.[3] \"Product Information. Thorazine (chlorpromazine).\" SmithKline Beecham, Philadelphia, PA.[4] Blayac JP, Ribes G, Buys D, Puech R, Loubatieres-Mariani MM \"Effects of a new benzothiadiazine derivative, LN 5330, on insulin secretion.\" Arch Int Pharmacodyn Ther 253 (1981): 154-63[5] \"Product Information. Elzonris (tagraxofusp).\" Stemline Therapeutics, New York, NY.[6] \"Product Information. Amaryl (glimepiride).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[7] \"Product Information. Elspar (asparaginase).\" Merck & Co, Inc, West Point, PA.[8] Jones IG, Pickens PT \"Diabetes mellitus following oral diuretics.\" Practitioner 199 (1967): 209-10[9] \"Product Information. Viracept (nelfinavir).\" Agouron Pharma Inc, La Jolla, CA.[10] \"Product Information. Tolinase (tolazamide)\" Pharmacia and Upjohn, Kalamazoo, MI.[11] Mauss S, Wolf E, Jaeger H \"Impaired glucose tolerance in HIV-positive patients receiving and those not receiving protease inhibitors.\" Ann Intern Med 130 (1999): 162-3[12] Virutamasen P, Wongsrichanalai C, Tangkeo P, Nitichai Y, Rienprayoon D \"Metabolic effects of depot-medroxyprogesterone acetate in long-term users: a cross-sectional study.\" Int J Gynaecol Obstet 24 (1986): 291-6[13] Wehring H, Alexander B, Perry PJ \"Diabetes mellitus associated with clozapine therapy.\" Pharmacotherapy 20 (2000): 844-7[14] Spellacy WN, Ellingson AB, Tsibris JC \"The effects of two triphasic oral contraceptives on carbohydrate metabolism in women during 1 year of use.\" Fertil Steril 51 (1989): 71-4[15] Andersen OO, Persson I \"Carbohydrate metabolism during treatment with chlorthalidone and ethacrynic acid.\" Br Med J 2 (1968): 798-801[16] Berlin I \"Prazosin, diuretics, and glucose intolerance.\" Ann Intern Med 119 (1993): 860[17] Malherbe C, Burrill KC, Levin SR, Karam JH, Forsham PH \"Effect of diphenylhydantoin on insulin secretion in man.\" N Engl J Med 286 (1972): 339-42[18] Carter BL, Small RE, Mandel MD, Starkman MT \"Phenytoin-induced hyperglycemia.\" Am J Hosp Pharm 38 (1981): 1508-12[19] Al-Rubeaan K, Ryan EA \"Phenytoin-induced insulin insensitivity.\" Diabet Med 8 (1991): 968-70[20] \"Product Information. Zolinza (vorinostat).\" Merck & Company Inc, West Point, PA.[21] Goldman JA, Neri A, Ovadia J, Eckerling B, Vries A, de \"Effect of chlorothiazide on intravenous glucose tolerance in pregnancy.\" Am J Obstet Gynecol 105 (1969): 556-60[22] Harper R, Ennis CN, Heaney AP, Sheridan B, Gormley M, Atkinson AB, Johnston GD, Bell PM \"A comparison of the effects of low- and conventional-dose thiazide diuretic on insulin action in hypertensive patients with NIDDM.\" Diabetologia 38 (1995): 853-9[23] Seltzer HS, Allen EW \"Hyperglycemia and inhibition of insulin secretion during administration of diazoxide and trichlormethiazide in man.\" Diabetes 18 (1969): 19-28[24] Dube MP, Johnson DL, Currier JS, Leedom JM \"Protease inhibitor-associated hyperglycaemia.\" Lancet 350 (1997): 713-4[25] Leary WP, Reyes AJ \"Drug interactions with diuretics.\" S Afr Med J 65 (1984): 455-61[26] \"Product Information. Reyataz (atazanavir).\" Bristol-Myers Squibb, Princeton, NJ.[27] Pollare T, Lithell H, Berne C \"A comparison of the effects of hydrochlorothiazide and captopril on glucose and lipid metabolism in patients with hypertension.\" N Engl J Med 321 (1989): 868-73[28] Gunnarsson R, Lundgren G, Magnusson G, Ost L, Groth CG \"Steroid diabetes--a sign of overtreatment with steroids in the renal graft recipient?\" Scand J Urol Nephrol Suppl 54 (1980): 135-8[29] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[30] \"Product Information. Synthroid (levothyroxine).\" Abbott Pharmaceutical, Abbott Park, IL.[31] Murphy MB, Kohner E, Lewis PJ, Schumer B, Dollery CT \"Glucose intolerance in hypertensive patients treated with diuretics: a fourteen-year follow-up.\" Lancet 2 (1982): 1293-5[32] \"Product Information. Fortovase (saquinavir)\" Roche Laboratories, Nutley, NJ.[33] Coni NK, Gordon PW, Mukherjee AP, Read PR \"The effect of frusemide and ethacrynic acid on carbohydrate metabolism.\" Age Ageing 3 (1974): 85-90[34] \"Product Information. Norvir (ritonavir).\" Abbott Pharmaceutical, Abbott Park, IL.[35] Domenet JG \"Diabetogenic effect of oral diuretics.\" Br Med J 3 (1968): 188[36] Rowe P, Mather H \"Hyperosmolar non-ketotic diabetes mellitus associated with metolazone.\" Br Med J 291 (1985): 25-6[37] Winchester JF, Kellett RJ, Boddy K, Boyle P, Dargie HJ, Mahaffey ME, Ward DM, Kennedy AC \"Metolazone and bendroflumethiazide in hypertension: physiologic and metabolic observations.\" Clin Pharmacol Ther 28 (1980): 611-8[38] \"Product Information. Carafate (sucralfate).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[39] Tsiodras S, Mantzoros C, Hammer S, Samore M \"Effects of protease inhibitors on hyperglycemia, hyperlipidemia, and lipodystrophy - A 5-year cohort study.\" Arch Intern Med 160 (2000): 2050-6[40] \"Product Information. Apidra (insulin glulisine).\" Aventis Pharmaceuticals, Bridgewater, NJ.[41] \"Product Information. Prezista (darunavir).\" Ortho Biotech Inc, Bridgewater, NJ.[42] Haiba NA, el-Habashy MA, Said SA, Darwish EA, Abdel-Sayed WS, Nayel SE \"Clinical evaluation of two monthly injectable contraceptives and their effects on some metabolic parameters.\" Contraception 39 (1989): 619-32[43] Erle G, Basso M, Federspil G, Sicolo N, Scandellari C \"Effect of chlorpromazine on blood glucose and plasma insulin in man.\" Eur J Clin Pharmacol 11 (1977): 15-8[44] Pickkers P, Schachter M, Hughes AD, Feher MD, Sever PS \"Thiazide-induced hyperglycaemia: a role for calcium-activated potassium channels?\" Diabetologia 39 (1996): 861-4[45] \"Product Information. Lexiva (fosamprenavir).\" GlaxoSmithKline, Research Triangle Park, NC.[46] Curtis J, Horrigan F, Ahearn D, Varney R, Sandler SG \"Chlorthalidone-induced hyperosmolar hyperglycemic nonketotic coma.\" JAMA 220 (1972): 1592-3[47] \"Product Information. Hyperstat I.V. (diazoxide).\" Schering Corp, Kenilworth, NJ.[48] \"Product Information. Piqray (alpelisib).\" Novartis Pharmaceuticals, East Hanover, NJ.[49] Bell DS \"Insulin resistance. An often unrecognized problem accompanying chronic medical disorders.\" Postgrad Med 93 (1993): 99-103,[50] Stambaugh JE, Tucker DC \"Effect of diphenylhydantoin on glucose tolerance in patients with hypoglycemia.\" Diabetes 23 (1974): 679-83[51] \"Product Information. Crixivan (indinavir).\" Merck & Co, Inc, West Point, PA.[52] Miller NR, Moses H \"Transient oculomotor nerve palsy. Association with thiazide-induced glucose intolerance.\" JAMA 240 (1978): 1887-8[53] Javier Z, Gershberg H, Hulse M \"Ovulatory suppressants, estrogens, and carbohydrate metabolism.\" Metabolism 17 (1968): 443-56[54] Goldman JA, Ovadia JL \"The effect of estrogen on intravenous glucose tolerance in woman.\" Am J Obstet Gynecol 103 (1969): 172-8[55] Charan VD, Desai N, Singh AP, Choudhry VP \"Diabetes mellitus and pancreatitis as a complication of L- asparaginase therapy.\" Indian Pediatr 30 (1993): 809-10[56] Seifer DB, Freedman LN, Cavender JR, Baker RA \"Insulin-dependent diabetes mellitus associated with danazol.\" Am J Obstet Gynecol 162 (1990): 474-5[57] \"Product Information. Orinase (tolbutamide)\" Pharmacia and Upjohn, Kalamazoo, MI.[58] Walli R, Demant T \"Impaired glucose tolerance and protease inhibitors.\" Ann Intern Med 129 (1998): 837-8[59] Hannaford PC, Kay CR \"Oral contraceptives and diabetes mellitus.\" BMJ 299 (1989): 1315-6[60] Hardy H, Esch LD, Morse GD \"Glucose disorders associated with HIV and its drug therapy.\" Ann Pharmacother 35 (2001): 343-51[61] Chowdhury FR, Bleicher SJ \"Chlorthalidone--induced hypokalemia and abnormal carbohydrate metabolism.\" Horm Metab Res 2 (1970): 13-6[62] Kaufman MB, Simionatto C \"A review of protease inhibitor-induced hyperglycemia.\" Pharmacotherapy 19 (1999): 114-7[63] Greenstone MA, Shaw AB \"Alternate day corticosteroid causes alternate day hyperglycaemia.\" Postgrad Med J 63 (1987): 761-4[64] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[65] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[66] Elmfeldt D, Berglund G, Wedel H, Wilhelmsen L \"Incidence and importance of metabolic side-effects during antihypertensive therapy.\" Acta Med Scand Suppl 672 (1983): 79-83[67] \"Product Information. Agenerase (amprenavir).\" Glaxo Wellcome, Research Triangle Pk, NC.[68] Diamond MT \"Hyperglycemic hyperosmolar coma associated with hydrochlorothiazide and pancreatitis.\" N Y State J Med 72 (1972): 1741-2[69] \"Product Information. Prandin (repaglinide).\" Novo Nordisk Pharmaceuticals Inc, Princeton, NJ.[70] \"Product Information. Precose (acarbose).\" Bayer, West Haven, CT.[71] \"Product Information. Starlix (nateglinide)\" Novartis Pharmaceuticals, East Hanover, NJ.[72] \"Product Information. Oncaspar (pegaspargase).\" Rhone-Poulenc Rorer, Collegeville, PA.[73] Sotaniemi E, Kontturi M, Larmi T \"Effect of diethylstilbestrol on blood glucose of prostatic cancer patients.\" Invest Urol 10 (1973): 438-41[74] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[75] Petri M, Cumber P, Grimes L, Treby D, Bryant R, Rawlins D, Ising H \"The metabolic effects of thiazide therapy in the elderly: a population study.\" Age Ageing 15 (1986): 151-5[76] Ludvik B, Clodi M, Kautzky-Willer A, Capek M, Hartter E, Pacini G, Prager R \"Effect of dexamethasone on insulin sensitivity, islet amyloid polypeptide and insulin secretion in humans.\" Diabetologia 36 (1993): 84-7[77] \"Product Information. Glucophage (metformin).\" Bristol-Myers Squibb, Princeton, NJ.[78] Chaudhuri ML, Catania J \"A comparison of the effects of bumetanide (Burinex) and frusemide on carbohydrate metabolism in the elderly.\" Br J Clin Pract 42 (1988): 427-9[79] Black DM, Filak AT \"Hyperglycemia with non-insulin-dependent diabetes following intraarticular steroid injection.\" J Fam Pract 28 (1989): 462-3[80] \"Product Information. Megace (megestrol).\" Bristol-Myers Squibb, Princeton, NJ.[81] \"Product Information. Torisel (temsirolimus).\" Wyeth-Ayerst Laboratories, Philadelphia, PA.[82] Schmitz O, Hermansen K, Nielsen OH, Christensen CK, Arnfred J, Hansen HE, Mogensen CE, Orskov H, Beck-Nielsen H \"Insulin action in insulin-dependent diabetics after short-term thiazide therapy.\" Diabetes Care 9 (1986): 631-6[83] Kansal PC, Buse J, Buse MG \"Thiazide diuretics and control of diabetes mellitus.\" South Med J 62 (1969): 1372-9[84] Dimitriadis G, Tegos C, Golfinopoulou L, Roboti C, Raptis S \"Furosemide-induced hyperglycaemia - the implication of glycolytic kinases.\" Horm Metab Res 25 (1993): 557-9[85] \"Product Information. NovoLog Mix 70/30 (insulin aspart-insulin aspart protamine).\" Novo Nordisk Pharmaceuticals Inc, Princeton, NJ.[86] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[87] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[88] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[89] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42[90] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[91] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[92] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[93] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[94] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[95] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6", "alternatives_a": "Ulipristal, Norelgestromin", "alternatives_b": "Guar gum", "updated_at": 1767369485}, {"id": 97947, "ingredient1": "Empagliflozin", "ingredient2": "Levothyroxine", "severity": "Moderate", "effect": "The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.", "source": "DDInter", "management_text": "Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.", "mechanism_text": "Antagonism", "recommendation": "Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/98051/", "reference_text": "[1] Jori A, Carrara MC \"On the mechanism of the hyperglycaemic effect of chlorpromazine.\" J Pharm Pharmacol 18 (1966): 623-4[2] \"Product Information. Dymelor (acetohexamide)\" Lilly, Eli and Company, Indianapolis, IN.[3] \"Product Information. Thorazine (chlorpromazine).\" SmithKline Beecham, Philadelphia, PA.[4] Blayac JP, Ribes G, Buys D, Puech R, Loubatieres-Mariani MM \"Effects of a new benzothiadiazine derivative, LN 5330, on insulin secretion.\" Arch Int Pharmacodyn Ther 253 (1981): 154-63[5] \"Product Information. Elzonris (tagraxofusp).\" Stemline Therapeutics, New York, NY.[6] \"Product Information. Amaryl (glimepiride).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[7] \"Product Information. Elspar (asparaginase).\" Merck & Co, Inc, West Point, PA.[8] Jones IG, Pickens PT \"Diabetes mellitus following oral diuretics.\" Practitioner 199 (1967): 209-10[9] \"Product Information. Viracept (nelfinavir).\" Agouron Pharma Inc, La Jolla, CA.[10] \"Product Information. Tolinase (tolazamide)\" Pharmacia and Upjohn, Kalamazoo, MI.[11] Mauss S, Wolf E, Jaeger H \"Impaired glucose tolerance in HIV-positive patients receiving and those not receiving protease inhibitors.\" Ann Intern Med 130 (1999): 162-3[12] Virutamasen P, Wongsrichanalai C, Tangkeo P, Nitichai Y, Rienprayoon D \"Metabolic effects of depot-medroxyprogesterone acetate in long-term users: a cross-sectional study.\" Int J Gynaecol Obstet 24 (1986): 291-6[13] Wehring H, Alexander B, Perry PJ \"Diabetes mellitus associated with clozapine therapy.\" Pharmacotherapy 20 (2000): 844-7[14] Spellacy WN, Ellingson AB, Tsibris JC \"The effects of two triphasic oral contraceptives on carbohydrate metabolism in women during 1 year of use.\" Fertil Steril 51 (1989): 71-4[15] Andersen OO, Persson I \"Carbohydrate metabolism during treatment with chlorthalidone and ethacrynic acid.\" Br Med J 2 (1968): 798-801[16] Berlin I \"Prazosin, diuretics, and glucose intolerance.\" Ann Intern Med 119 (1993): 860[17] Malherbe C, Burrill KC, Levin SR, Karam JH, Forsham PH \"Effect of diphenylhydantoin on insulin secretion in man.\" N Engl J Med 286 (1972): 339-42[18] Carter BL, Small RE, Mandel MD, Starkman MT \"Phenytoin-induced hyperglycemia.\" Am J Hosp Pharm 38 (1981): 1508-12[19] Al-Rubeaan K, Ryan EA \"Phenytoin-induced insulin insensitivity.\" Diabet Med 8 (1991): 968-70[20] \"Product Information. Zolinza (vorinostat).\" Merck & Company Inc, West Point, PA.[21] Goldman JA, Neri A, Ovadia J, Eckerling B, Vries A, de \"Effect of chlorothiazide on intravenous glucose tolerance in pregnancy.\" Am J Obstet Gynecol 105 (1969): 556-60[22] Harper R, Ennis CN, Heaney AP, Sheridan B, Gormley M, Atkinson AB, Johnston GD, Bell PM \"A comparison of the effects of low- and conventional-dose thiazide diuretic on insulin action in hypertensive patients with NIDDM.\" Diabetologia 38 (1995): 853-9[23] Seltzer HS, Allen EW \"Hyperglycemia and inhibition of insulin secretion during administration of diazoxide and trichlormethiazide in man.\" Diabetes 18 (1969): 19-28[24] Dube MP, Johnson DL, Currier JS, Leedom JM \"Protease inhibitor-associated hyperglycaemia.\" Lancet 350 (1997): 713-4[25] Leary WP, Reyes AJ \"Drug interactions with diuretics.\" S Afr Med J 65 (1984): 455-61[26] \"Product Information. Reyataz (atazanavir).\" Bristol-Myers Squibb, Princeton, NJ.[27] Pollare T, Lithell H, Berne C \"A comparison of the effects of hydrochlorothiazide and captopril on glucose and lipid metabolism in patients with hypertension.\" N Engl J Med 321 (1989): 868-73[28] Gunnarsson R, Lundgren G, Magnusson G, Ost L, Groth CG \"Steroid diabetes--a sign of overtreatment with steroids in the renal graft recipient?\" Scand J Urol Nephrol Suppl 54 (1980): 135-8[29] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[30] \"Product Information. Synthroid (levothyroxine).\" Abbott Pharmaceutical, Abbott Park, IL.[31] Murphy MB, Kohner E, Lewis PJ, Schumer B, Dollery CT \"Glucose intolerance in hypertensive patients treated with diuretics: a fourteen-year follow-up.\" Lancet 2 (1982): 1293-5[32] \"Product Information. Fortovase (saquinavir)\" Roche Laboratories, Nutley, NJ.[33] Coni NK, Gordon PW, Mukherjee AP, Read PR \"The effect of frusemide and ethacrynic acid on carbohydrate metabolism.\" Age Ageing 3 (1974): 85-90[34] \"Product Information. Norvir (ritonavir).\" Abbott Pharmaceutical, Abbott Park, IL.[35] Domenet JG \"Diabetogenic effect of oral diuretics.\" Br Med J 3 (1968): 188[36] Rowe P, Mather H \"Hyperosmolar non-ketotic diabetes mellitus associated with metolazone.\" Br Med J 291 (1985): 25-6[37] Winchester JF, Kellett RJ, Boddy K, Boyle P, Dargie HJ, Mahaffey ME, Ward DM, Kennedy AC \"Metolazone and bendroflumethiazide in hypertension: physiologic and metabolic observations.\" Clin Pharmacol Ther 28 (1980): 611-8[38] \"Product Information. Carafate (sucralfate).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[39] Tsiodras S, Mantzoros C, Hammer S, Samore M \"Effects of protease inhibitors on hyperglycemia, hyperlipidemia, and lipodystrophy - A 5-year cohort study.\" Arch Intern Med 160 (2000): 2050-6[40] \"Product Information. Apidra (insulin glulisine).\" Aventis Pharmaceuticals, Bridgewater, NJ.[41] \"Product Information. Prezista (darunavir).\" Ortho Biotech Inc, Bridgewater, NJ.[42] Haiba NA, el-Habashy MA, Said SA, Darwish EA, Abdel-Sayed WS, Nayel SE \"Clinical evaluation of two monthly injectable contraceptives and their effects on some metabolic parameters.\" Contraception 39 (1989): 619-32[43] Erle G, Basso M, Federspil G, Sicolo N, Scandellari C \"Effect of chlorpromazine on blood glucose and plasma insulin in man.\" Eur J Clin Pharmacol 11 (1977): 15-8[44] Pickkers P, Schachter M, Hughes AD, Feher MD, Sever PS \"Thiazide-induced hyperglycaemia: a role for calcium-activated potassium channels?\" Diabetologia 39 (1996): 861-4[45] \"Product Information. Lexiva (fosamprenavir).\" GlaxoSmithKline, Research Triangle Park, NC.[46] Curtis J, Horrigan F, Ahearn D, Varney R, Sandler SG \"Chlorthalidone-induced hyperosmolar hyperglycemic nonketotic coma.\" JAMA 220 (1972): 1592-3[47] \"Product Information. Hyperstat I.V. (diazoxide).\" Schering Corp, Kenilworth, NJ.[48] \"Product Information. Piqray (alpelisib).\" Novartis Pharmaceuticals, East Hanover, NJ.[49] Bell DS \"Insulin resistance. An often unrecognized problem accompanying chronic medical disorders.\" Postgrad Med 93 (1993): 99-103,[50] Stambaugh JE, Tucker DC \"Effect of diphenylhydantoin on glucose tolerance in patients with hypoglycemia.\" Diabetes 23 (1974): 679-83[51] \"Product Information. Crixivan (indinavir).\" Merck & Co, Inc, West Point, PA.[52] Miller NR, Moses H \"Transient oculomotor nerve palsy. Association with thiazide-induced glucose intolerance.\" JAMA 240 (1978): 1887-8[53] Javier Z, Gershberg H, Hulse M \"Ovulatory suppressants, estrogens, and carbohydrate metabolism.\" Metabolism 17 (1968): 443-56[54] Goldman JA, Ovadia JL \"The effect of estrogen on intravenous glucose tolerance in woman.\" Am J Obstet Gynecol 103 (1969): 172-8[55] Charan VD, Desai N, Singh AP, Choudhry VP \"Diabetes mellitus and pancreatitis as a complication of L- asparaginase therapy.\" Indian Pediatr 30 (1993): 809-10[56] Seifer DB, Freedman LN, Cavender JR, Baker RA \"Insulin-dependent diabetes mellitus associated with danazol.\" Am J Obstet Gynecol 162 (1990): 474-5[57] \"Product Information. Orinase (tolbutamide)\" Pharmacia and Upjohn, Kalamazoo, MI.[58] Walli R, Demant T \"Impaired glucose tolerance and protease inhibitors.\" Ann Intern Med 129 (1998): 837-8[59] Hannaford PC, Kay CR \"Oral contraceptives and diabetes mellitus.\" BMJ 299 (1989): 1315-6[60] Hardy H, Esch LD, Morse GD \"Glucose disorders associated with HIV and its drug therapy.\" Ann Pharmacother 35 (2001): 343-51[61] Chowdhury FR, Bleicher SJ \"Chlorthalidone--induced hypokalemia and abnormal carbohydrate metabolism.\" Horm Metab Res 2 (1970): 13-6[62] Kaufman MB, Simionatto C \"A review of protease inhibitor-induced hyperglycemia.\" Pharmacotherapy 19 (1999): 114-7[63] Greenstone MA, Shaw AB \"Alternate day corticosteroid causes alternate day hyperglycaemia.\" Postgrad Med J 63 (1987): 761-4[64] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[65] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[66] Elmfeldt D, Berglund G, Wedel H, Wilhelmsen L \"Incidence and importance of metabolic side-effects during antihypertensive therapy.\" Acta Med Scand Suppl 672 (1983): 79-83[67] \"Product Information. Agenerase (amprenavir).\" Glaxo Wellcome, Research Triangle Pk, NC.[68] Diamond MT \"Hyperglycemic hyperosmolar coma associated with hydrochlorothiazide and pancreatitis.\" N Y State J Med 72 (1972): 1741-2[69] \"Product Information. Prandin (repaglinide).\" Novo Nordisk Pharmaceuticals Inc, Princeton, NJ.[70] \"Product Information. Precose (acarbose).\" Bayer, West Haven, CT.[71] \"Product Information. Starlix (nateglinide)\" Novartis Pharmaceuticals, East Hanover, NJ.[72] \"Product Information. Oncaspar (pegaspargase).\" Rhone-Poulenc Rorer, Collegeville, PA.[73] Sotaniemi E, Kontturi M, Larmi T \"Effect of diethylstilbestrol on blood glucose of prostatic cancer patients.\" Invest Urol 10 (1973): 438-41[74] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[75] Petri M, Cumber P, Grimes L, Treby D, Bryant R, Rawlins D, Ising H \"The metabolic effects of thiazide therapy in the elderly: a population study.\" Age Ageing 15 (1986): 151-5[76] Ludvik B, Clodi M, Kautzky-Willer A, Capek M, Hartter E, Pacini G, Prager R \"Effect of dexamethasone on insulin sensitivity, islet amyloid polypeptide and insulin secretion in humans.\" Diabetologia 36 (1993): 84-7[77] \"Product Information. Glucophage (metformin).\" Bristol-Myers Squibb, Princeton, NJ.[78] Chaudhuri ML, Catania J \"A comparison of the effects of bumetanide (Burinex) and frusemide on carbohydrate metabolism in the elderly.\" Br J Clin Pract 42 (1988): 427-9[79] Black DM, Filak AT \"Hyperglycemia with non-insulin-dependent diabetes following intraarticular steroid injection.\" J Fam Pract 28 (1989): 462-3[80] \"Product Information. Megace (megestrol).\" Bristol-Myers Squibb, Princeton, NJ.[81] \"Product Information. Torisel (temsirolimus).\" Wyeth-Ayerst Laboratories, Philadelphia, PA.[82] Schmitz O, Hermansen K, Nielsen OH, Christensen CK, Arnfred J, Hansen HE, Mogensen CE, Orskov H, Beck-Nielsen H \"Insulin action in insulin-dependent diabetics after short-term thiazide therapy.\" Diabetes Care 9 (1986): 631-6[83] Kansal PC, Buse J, Buse MG \"Thiazide diuretics and control of diabetes mellitus.\" South Med J 62 (1969): 1372-9[84] Dimitriadis G, Tegos C, Golfinopoulou L, Roboti C, Raptis S \"Furosemide-induced hyperglycaemia - the implication of glycolytic kinases.\" Horm Metab Res 25 (1993): 557-9[85] \"Product Information. NovoLog Mix 70/30 (insulin aspart-insulin aspart protamine).\" Novo Nordisk Pharmaceuticals Inc, Princeton, NJ.[86] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[87] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[88] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[89] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42[90] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[91] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[92] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[93] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[94] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[95] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6", "alternatives_a": "Guar gum", "alternatives_b": "", "updated_at": 1767369485}, {"id": 97948, "ingredient1": "Empagliflozin", "ingredient2": "Liothyronine", "severity": "Moderate", "effect": "The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.", "source": "DDInter", "management_text": "Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.", "mechanism_text": "Antagonism", "recommendation": "Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/98052/", "reference_text": "[1] Jori A, Carrara MC \"On the mechanism of the hyperglycaemic effect of chlorpromazine.\" J Pharm Pharmacol 18 (1966): 623-4[2] \"Product Information. Dymelor (acetohexamide)\" Lilly, Eli and Company, Indianapolis, IN.[3] \"Product Information. Thorazine (chlorpromazine).\" SmithKline Beecham, Philadelphia, PA.[4] Blayac JP, Ribes G, Buys D, Puech R, Loubatieres-Mariani MM \"Effects of a new benzothiadiazine derivative, LN 5330, on insulin secretion.\" Arch Int Pharmacodyn Ther 253 (1981): 154-63[5] \"Product Information. Elzonris (tagraxofusp).\" Stemline Therapeutics, New York, NY.[6] \"Product Information. Amaryl (glimepiride).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[7] \"Product Information. Elspar (asparaginase).\" Merck & Co, Inc, West Point, PA.[8] Jones IG, Pickens PT \"Diabetes mellitus following oral diuretics.\" Practitioner 199 (1967): 209-10[9] \"Product Information. Viracept (nelfinavir).\" Agouron Pharma Inc, La Jolla, CA.[10] \"Product Information. Tolinase (tolazamide)\" Pharmacia and Upjohn, Kalamazoo, MI.[11] Mauss S, Wolf E, Jaeger H \"Impaired glucose tolerance in HIV-positive patients receiving and those not receiving protease inhibitors.\" Ann Intern Med 130 (1999): 162-3[12] Virutamasen P, Wongsrichanalai C, Tangkeo P, Nitichai Y, Rienprayoon D \"Metabolic effects of depot-medroxyprogesterone acetate in long-term users: a cross-sectional study.\" Int J Gynaecol Obstet 24 (1986): 291-6[13] Wehring H, Alexander B, Perry PJ \"Diabetes mellitus associated with clozapine therapy.\" Pharmacotherapy 20 (2000): 844-7[14] Spellacy WN, Ellingson AB, Tsibris JC \"The effects of two triphasic oral contraceptives on carbohydrate metabolism in women during 1 year of use.\" Fertil Steril 51 (1989): 71-4[15] Andersen OO, Persson I \"Carbohydrate metabolism during treatment with chlorthalidone and ethacrynic acid.\" Br Med J 2 (1968): 798-801[16] Berlin I \"Prazosin, diuretics, and glucose intolerance.\" Ann Intern Med 119 (1993): 860[17] Malherbe C, Burrill KC, Levin SR, Karam JH, Forsham PH \"Effect of diphenylhydantoin on insulin secretion in man.\" N Engl J Med 286 (1972): 339-42[18] Carter BL, Small RE, Mandel MD, Starkman MT \"Phenytoin-induced hyperglycemia.\" Am J Hosp Pharm 38 (1981): 1508-12[19] Al-Rubeaan K, Ryan EA \"Phenytoin-induced insulin insensitivity.\" Diabet Med 8 (1991): 968-70[20] \"Product Information. Zolinza (vorinostat).\" Merck & Company Inc, West Point, PA.[21] Goldman JA, Neri A, Ovadia J, Eckerling B, Vries A, de \"Effect of chlorothiazide on intravenous glucose tolerance in pregnancy.\" Am J Obstet Gynecol 105 (1969): 556-60[22] Harper R, Ennis CN, Heaney AP, Sheridan B, Gormley M, Atkinson AB, Johnston GD, Bell PM \"A comparison of the effects of low- and conventional-dose thiazide diuretic on insulin action in hypertensive patients with NIDDM.\" Diabetologia 38 (1995): 853-9[23] Seltzer HS, Allen EW \"Hyperglycemia and inhibition of insulin secretion during administration of diazoxide and trichlormethiazide in man.\" Diabetes 18 (1969): 19-28[24] Dube MP, Johnson DL, Currier JS, Leedom JM \"Protease inhibitor-associated hyperglycaemia.\" Lancet 350 (1997): 713-4[25] Leary WP, Reyes AJ \"Drug interactions with diuretics.\" S Afr Med J 65 (1984): 455-61[26] \"Product Information. Reyataz (atazanavir).\" Bristol-Myers Squibb, Princeton, NJ.[27] Pollare T, Lithell H, Berne C \"A comparison of the effects of hydrochlorothiazide and captopril on glucose and lipid metabolism in patients with hypertension.\" N Engl J Med 321 (1989): 868-73[28] Gunnarsson R, Lundgren G, Magnusson G, Ost L, Groth CG \"Steroid diabetes--a sign of overtreatment with steroids in the renal graft recipient?\" Scand J Urol Nephrol Suppl 54 (1980): 135-8[29] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[30] \"Product Information. Synthroid (levothyroxine).\" Abbott Pharmaceutical, Abbott Park, IL.[31] Murphy MB, Kohner E, Lewis PJ, Schumer B, Dollery CT \"Glucose intolerance in hypertensive patients treated with diuretics: a fourteen-year follow-up.\" Lancet 2 (1982): 1293-5[32] \"Product Information. Fortovase (saquinavir)\" Roche Laboratories, Nutley, NJ.[33] Coni NK, Gordon PW, Mukherjee AP, Read PR \"The effect of frusemide and ethacrynic acid on carbohydrate metabolism.\" Age Ageing 3 (1974): 85-90[34] \"Product Information. Norvir (ritonavir).\" Abbott Pharmaceutical, Abbott Park, IL.[35] Domenet JG \"Diabetogenic effect of oral diuretics.\" Br Med J 3 (1968): 188[36] Rowe P, Mather H \"Hyperosmolar non-ketotic diabetes mellitus associated with metolazone.\" Br Med J 291 (1985): 25-6[37] Winchester JF, Kellett RJ, Boddy K, Boyle P, Dargie HJ, Mahaffey ME, Ward DM, Kennedy AC \"Metolazone and bendroflumethiazide in hypertension: physiologic and metabolic observations.\" Clin Pharmacol Ther 28 (1980): 611-8[38] \"Product Information. Carafate (sucralfate).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[39] Tsiodras S, Mantzoros C, Hammer S, Samore M \"Effects of protease inhibitors on hyperglycemia, hyperlipidemia, and lipodystrophy - A 5-year cohort study.\" Arch Intern Med 160 (2000): 2050-6[40] \"Product Information. Apidra (insulin glulisine).\" Aventis Pharmaceuticals, Bridgewater, NJ.[41] \"Product Information. Prezista (darunavir).\" Ortho Biotech Inc, Bridgewater, NJ.[42] Haiba NA, el-Habashy MA, Said SA, Darwish EA, Abdel-Sayed WS, Nayel SE \"Clinical evaluation of two monthly injectable contraceptives and their effects on some metabolic parameters.\" Contraception 39 (1989): 619-32[43] Erle G, Basso M, Federspil G, Sicolo N, Scandellari C \"Effect of chlorpromazine on blood glucose and plasma insulin in man.\" Eur J Clin Pharmacol 11 (1977): 15-8[44] Pickkers P, Schachter M, Hughes AD, Feher MD, Sever PS \"Thiazide-induced hyperglycaemia: a role for calcium-activated potassium channels?\" Diabetologia 39 (1996): 861-4[45] \"Product Information. Lexiva (fosamprenavir).\" GlaxoSmithKline, Research Triangle Park, NC.[46] Curtis J, Horrigan F, Ahearn D, Varney R, Sandler SG \"Chlorthalidone-induced hyperosmolar hyperglycemic nonketotic coma.\" JAMA 220 (1972): 1592-3[47] \"Product Information. Hyperstat I.V. (diazoxide).\" Schering Corp, Kenilworth, NJ.[48] \"Product Information. Piqray (alpelisib).\" Novartis Pharmaceuticals, East Hanover, NJ.[49] Bell DS \"Insulin resistance. An often unrecognized problem accompanying chronic medical disorders.\" Postgrad Med 93 (1993): 99-103,[50] Stambaugh JE, Tucker DC \"Effect of diphenylhydantoin on glucose tolerance in patients with hypoglycemia.\" Diabetes 23 (1974): 679-83[51] \"Product Information. Crixivan (indinavir).\" Merck & Co, Inc, West Point, PA.[52] Miller NR, Moses H \"Transient oculomotor nerve palsy. Association with thiazide-induced glucose intolerance.\" JAMA 240 (1978): 1887-8[53] Javier Z, Gershberg H, Hulse M \"Ovulatory suppressants, estrogens, and carbohydrate metabolism.\" Metabolism 17 (1968): 443-56[54] Goldman JA, Ovadia JL \"The effect of estrogen on intravenous glucose tolerance in woman.\" Am J Obstet Gynecol 103 (1969): 172-8[55] Charan VD, Desai N, Singh AP, Choudhry VP \"Diabetes mellitus and pancreatitis as a complication of L- asparaginase therapy.\" Indian Pediatr 30 (1993): 809-10[56] Seifer DB, Freedman LN, Cavender JR, Baker RA \"Insulin-dependent diabetes mellitus associated with danazol.\" Am J Obstet Gynecol 162 (1990): 474-5[57] \"Product Information. Orinase (tolbutamide)\" Pharmacia and Upjohn, Kalamazoo, MI.[58] Walli R, Demant T \"Impaired glucose tolerance and protease inhibitors.\" Ann Intern Med 129 (1998): 837-8[59] Hannaford PC, Kay CR \"Oral contraceptives and diabetes mellitus.\" BMJ 299 (1989): 1315-6[60] Hardy H, Esch LD, Morse GD \"Glucose disorders associated with HIV and its drug therapy.\" Ann Pharmacother 35 (2001): 343-51[61] Chowdhury FR, Bleicher SJ \"Chlorthalidone--induced hypokalemia and abnormal carbohydrate metabolism.\" Horm Metab Res 2 (1970): 13-6[62] Kaufman MB, Simionatto C \"A review of protease inhibitor-induced hyperglycemia.\" Pharmacotherapy 19 (1999): 114-7[63] Greenstone MA, Shaw AB \"Alternate day corticosteroid causes alternate day hyperglycaemia.\" Postgrad Med J 63 (1987): 761-4[64] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[65] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[66] Elmfeldt D, Berglund G, Wedel H, Wilhelmsen L \"Incidence and importance of metabolic side-effects during antihypertensive therapy.\" Acta Med Scand Suppl 672 (1983): 79-83[67] \"Product Information. Agenerase (amprenavir).\" Glaxo Wellcome, Research Triangle Pk, NC.[68] Diamond MT \"Hyperglycemic hyperosmolar coma associated with hydrochlorothiazide and pancreatitis.\" N Y State J Med 72 (1972): 1741-2[69] \"Product Information. Prandin (repaglinide).\" Novo Nordisk Pharmaceuticals Inc, Princeton, NJ.[70] \"Product Information. Precose (acarbose).\" Bayer, West Haven, CT.[71] \"Product Information. Starlix (nateglinide)\" Novartis Pharmaceuticals, East Hanover, NJ.[72] \"Product Information. Oncaspar (pegaspargase).\" Rhone-Poulenc Rorer, Collegeville, PA.[73] Sotaniemi E, Kontturi M, Larmi T \"Effect of diethylstilbestrol on blood glucose of prostatic cancer patients.\" Invest Urol 10 (1973): 438-41[74] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[75] Petri M, Cumber P, Grimes L, Treby D, Bryant R, Rawlins D, Ising H \"The metabolic effects of thiazide therapy in the elderly: a population study.\" Age Ageing 15 (1986): 151-5[76] Ludvik B, Clodi M, Kautzky-Willer A, Capek M, Hartter E, Pacini G, Prager R \"Effect of dexamethasone on insulin sensitivity, islet amyloid polypeptide and insulin secretion in humans.\" Diabetologia 36 (1993): 84-7[77] \"Product Information. Glucophage (metformin).\" Bristol-Myers Squibb, Princeton, NJ.[78] Chaudhuri ML, Catania J \"A comparison of the effects of bumetanide (Burinex) and frusemide on carbohydrate metabolism in the elderly.\" Br J Clin Pract 42 (1988): 427-9[79] Black DM, Filak AT \"Hyperglycemia with non-insulin-dependent diabetes following intraarticular steroid injection.\" J Fam Pract 28 (1989): 462-3[80] \"Product Information. Megace (megestrol).\" Bristol-Myers Squibb, Princeton, NJ.[81] \"Product Information. Torisel (temsirolimus).\" Wyeth-Ayerst Laboratories, Philadelphia, PA.[82] Schmitz O, Hermansen K, Nielsen OH, Christensen CK, Arnfred J, Hansen HE, Mogensen CE, Orskov H, Beck-Nielsen H \"Insulin action in insulin-dependent diabetics after short-term thiazide therapy.\" Diabetes Care 9 (1986): 631-6[83] Kansal PC, Buse J, Buse MG \"Thiazide diuretics and control of diabetes mellitus.\" South Med J 62 (1969): 1372-9[84] Dimitriadis G, Tegos C, Golfinopoulou L, Roboti C, Raptis S \"Furosemide-induced hyperglycaemia - the implication of glycolytic kinases.\" Horm Metab Res 25 (1993): 557-9[85] \"Product Information. NovoLog Mix 70/30 (insulin aspart-insulin aspart protamine).\" Novo Nordisk Pharmaceuticals Inc, Princeton, NJ.[86] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[87] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[88] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[89] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42[90] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[91] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[92] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[93] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[94] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[95] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6", "alternatives_a": "Guar gum", "alternatives_b": "", "updated_at": 1767369485}, {"id": 97949, "ingredient1": "Empagliflozin", "ingredient2": "Liotrix", "severity": "Moderate", "effect": "The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.", "source": "DDInter", "management_text": "Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.", "mechanism_text": "Antagonism", "recommendation": "Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/98053/", "reference_text": "[1] Jori A, Carrara MC \"On the mechanism of the hyperglycaemic effect of chlorpromazine.\" J Pharm Pharmacol 18 (1966): 623-4[2] \"Product Information. Dymelor (acetohexamide)\" Lilly, Eli and Company, Indianapolis, IN.[3] \"Product Information. Thorazine (chlorpromazine).\" SmithKline Beecham, Philadelphia, PA.[4] Blayac JP, Ribes G, Buys D, Puech R, Loubatieres-Mariani MM \"Effects of a new benzothiadiazine derivative, LN 5330, on insulin secretion.\" Arch Int Pharmacodyn Ther 253 (1981): 154-63[5] \"Product Information. Elzonris (tagraxofusp).\" Stemline Therapeutics, New York, NY.[6] \"Product Information. Amaryl (glimepiride).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[7] \"Product Information. Elspar (asparaginase).\" Merck & Co, Inc, West Point, PA.[8] Jones IG, Pickens PT \"Diabetes mellitus following oral diuretics.\" Practitioner 199 (1967): 209-10[9] \"Product Information. Viracept (nelfinavir).\" Agouron Pharma Inc, La Jolla, CA.[10] \"Product Information. Tolinase (tolazamide)\" Pharmacia and Upjohn, Kalamazoo, MI.[11] Mauss S, Wolf E, Jaeger H \"Impaired glucose tolerance in HIV-positive patients receiving and those not receiving protease inhibitors.\" Ann Intern Med 130 (1999): 162-3[12] Virutamasen P, Wongsrichanalai C, Tangkeo P, Nitichai Y, Rienprayoon D \"Metabolic effects of depot-medroxyprogesterone acetate in long-term users: a cross-sectional study.\" Int J Gynaecol Obstet 24 (1986): 291-6[13] Wehring H, Alexander B, Perry PJ \"Diabetes mellitus associated with clozapine therapy.\" Pharmacotherapy 20 (2000): 844-7[14] Spellacy WN, Ellingson AB, Tsibris JC \"The effects of two triphasic oral contraceptives on carbohydrate metabolism in women during 1 year of use.\" Fertil Steril 51 (1989): 71-4[15] Andersen OO, Persson I \"Carbohydrate metabolism during treatment with chlorthalidone and ethacrynic acid.\" Br Med J 2 (1968): 798-801[16] Berlin I \"Prazosin, diuretics, and glucose intolerance.\" Ann Intern Med 119 (1993): 860[17] Malherbe C, Burrill KC, Levin SR, Karam JH, Forsham PH \"Effect of diphenylhydantoin on insulin secretion in man.\" N Engl J Med 286 (1972): 339-42[18] Carter BL, Small RE, Mandel MD, Starkman MT \"Phenytoin-induced hyperglycemia.\" Am J Hosp Pharm 38 (1981): 1508-12[19] Al-Rubeaan K, Ryan EA \"Phenytoin-induced insulin insensitivity.\" Diabet Med 8 (1991): 968-70[20] \"Product Information. Zolinza (vorinostat).\" Merck & Company Inc, West Point, PA.[21] Goldman JA, Neri A, Ovadia J, Eckerling B, Vries A, de \"Effect of chlorothiazide on intravenous glucose tolerance in pregnancy.\" Am J Obstet Gynecol 105 (1969): 556-60[22] Harper R, Ennis CN, Heaney AP, Sheridan B, Gormley M, Atkinson AB, Johnston GD, Bell PM \"A comparison of the effects of low- and conventional-dose thiazide diuretic on insulin action in hypertensive patients with NIDDM.\" Diabetologia 38 (1995): 853-9[23] Seltzer HS, Allen EW \"Hyperglycemia and inhibition of insulin secretion during administration of diazoxide and trichlormethiazide in man.\" Diabetes 18 (1969): 19-28[24] Dube MP, Johnson DL, Currier JS, Leedom JM \"Protease inhibitor-associated hyperglycaemia.\" Lancet 350 (1997): 713-4[25] Leary WP, Reyes AJ \"Drug interactions with diuretics.\" S Afr Med J 65 (1984): 455-61[26] \"Product Information. Reyataz (atazanavir).\" Bristol-Myers Squibb, Princeton, NJ.[27] Pollare T, Lithell H, Berne C \"A comparison of the effects of hydrochlorothiazide and captopril on glucose and lipid metabolism in patients with hypertension.\" N Engl J Med 321 (1989): 868-73[28] Gunnarsson R, Lundgren G, Magnusson G, Ost L, Groth CG \"Steroid diabetes--a sign of overtreatment with steroids in the renal graft recipient?\" Scand J Urol Nephrol Suppl 54 (1980): 135-8[29] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[30] \"Product Information. Synthroid (levothyroxine).\" Abbott Pharmaceutical, Abbott Park, IL.[31] Murphy MB, Kohner E, Lewis PJ, Schumer B, Dollery CT \"Glucose intolerance in hypertensive patients treated with diuretics: a fourteen-year follow-up.\" Lancet 2 (1982): 1293-5[32] \"Product Information. Fortovase (saquinavir)\" Roche Laboratories, Nutley, NJ.[33] Coni NK, Gordon PW, Mukherjee AP, Read PR \"The effect of frusemide and ethacrynic acid on carbohydrate metabolism.\" Age Ageing 3 (1974): 85-90[34] \"Product Information. Norvir (ritonavir).\" Abbott Pharmaceutical, Abbott Park, IL.[35] Domenet JG \"Diabetogenic effect of oral diuretics.\" Br Med J 3 (1968): 188[36] Rowe P, Mather H \"Hyperosmolar non-ketotic diabetes mellitus associated with metolazone.\" Br Med J 291 (1985): 25-6[37] Winchester JF, Kellett RJ, Boddy K, Boyle P, Dargie HJ, Mahaffey ME, Ward DM, Kennedy AC \"Metolazone and bendroflumethiazide in hypertension: physiologic and metabolic observations.\" Clin Pharmacol Ther 28 (1980): 611-8[38] \"Product Information. Carafate (sucralfate).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[39] Tsiodras S, Mantzoros C, Hammer S, Samore M \"Effects of protease inhibitors on hyperglycemia, hyperlipidemia, and lipodystrophy - A 5-year cohort study.\" Arch Intern Med 160 (2000): 2050-6[40] \"Product Information. Apidra (insulin glulisine).\" Aventis Pharmaceuticals, Bridgewater, NJ.[41] \"Product Information. Prezista (darunavir).\" Ortho Biotech Inc, Bridgewater, NJ.[42] Haiba NA, el-Habashy MA, Said SA, Darwish EA, Abdel-Sayed WS, Nayel SE \"Clinical evaluation of two monthly injectable contraceptives and their effects on some metabolic parameters.\" Contraception 39 (1989): 619-32[43] Erle G, Basso M, Federspil G, Sicolo N, Scandellari C \"Effect of chlorpromazine on blood glucose and plasma insulin in man.\" Eur J Clin Pharmacol 11 (1977): 15-8[44] Pickkers P, Schachter M, Hughes AD, Feher MD, Sever PS \"Thiazide-induced hyperglycaemia: a role for calcium-activated potassium channels?\" Diabetologia 39 (1996): 861-4[45] \"Product Information. Lexiva (fosamprenavir).\" GlaxoSmithKline, Research Triangle Park, NC.[46] Curtis J, Horrigan F, Ahearn D, Varney R, Sandler SG \"Chlorthalidone-induced hyperosmolar hyperglycemic nonketotic coma.\" JAMA 220 (1972): 1592-3[47] \"Product Information. Hyperstat I.V. (diazoxide).\" Schering Corp, Kenilworth, NJ.[48] \"Product Information. Piqray (alpelisib).\" Novartis Pharmaceuticals, East Hanover, NJ.[49] Bell DS \"Insulin resistance. An often unrecognized problem accompanying chronic medical disorders.\" Postgrad Med 93 (1993): 99-103,[50] Stambaugh JE, Tucker DC \"Effect of diphenylhydantoin on glucose tolerance in patients with hypoglycemia.\" Diabetes 23 (1974): 679-83[51] \"Product Information. Crixivan (indinavir).\" Merck & Co, Inc, West Point, PA.[52] Miller NR, Moses H \"Transient oculomotor nerve palsy. Association with thiazide-induced glucose intolerance.\" JAMA 240 (1978): 1887-8[53] Javier Z, Gershberg H, Hulse M \"Ovulatory suppressants, estrogens, and carbohydrate metabolism.\" Metabolism 17 (1968): 443-56[54] Goldman JA, Ovadia JL \"The effect of estrogen on intravenous glucose tolerance in woman.\" Am J Obstet Gynecol 103 (1969): 172-8[55] Charan VD, Desai N, Singh AP, Choudhry VP \"Diabetes mellitus and pancreatitis as a complication of L- asparaginase therapy.\" Indian Pediatr 30 (1993): 809-10[56] Seifer DB, Freedman LN, Cavender JR, Baker RA \"Insulin-dependent diabetes mellitus associated with danazol.\" Am J Obstet Gynecol 162 (1990): 474-5[57] \"Product Information. Orinase (tolbutamide)\" Pharmacia and Upjohn, Kalamazoo, MI.[58] Walli R, Demant T \"Impaired glucose tolerance and protease inhibitors.\" Ann Intern Med 129 (1998): 837-8[59] Hannaford PC, Kay CR \"Oral contraceptives and diabetes mellitus.\" BMJ 299 (1989): 1315-6[60] Hardy H, Esch LD, Morse GD \"Glucose disorders associated with HIV and its drug therapy.\" Ann Pharmacother 35 (2001): 343-51[61] Chowdhury FR, Bleicher SJ \"Chlorthalidone--induced hypokalemia and abnormal carbohydrate metabolism.\" Horm Metab Res 2 (1970): 13-6[62] Kaufman MB, Simionatto C \"A review of protease inhibitor-induced hyperglycemia.\" Pharmacotherapy 19 (1999): 114-7[63] Greenstone MA, Shaw AB \"Alternate day corticosteroid causes alternate day hyperglycaemia.\" Postgrad Med J 63 (1987): 761-4[64] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[65] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[66] Elmfeldt D, Berglund G, Wedel H, Wilhelmsen L \"Incidence and importance of metabolic side-effects during antihypertensive therapy.\" Acta Med Scand Suppl 672 (1983): 79-83[67] \"Product Information. Agenerase (amprenavir).\" Glaxo Wellcome, Research Triangle Pk, NC.[68] Diamond MT \"Hyperglycemic hyperosmolar coma associated with hydrochlorothiazide and pancreatitis.\" N Y State J Med 72 (1972): 1741-2[69] \"Product Information. Prandin (repaglinide).\" Novo Nordisk Pharmaceuticals Inc, Princeton, NJ.[70] \"Product Information. Precose (acarbose).\" Bayer, West Haven, CT.[71] \"Product Information. Starlix (nateglinide)\" Novartis Pharmaceuticals, East Hanover, NJ.[72] \"Product Information. Oncaspar (pegaspargase).\" Rhone-Poulenc Rorer, Collegeville, PA.[73] Sotaniemi E, Kontturi M, Larmi T \"Effect of diethylstilbestrol on blood glucose of prostatic cancer patients.\" Invest Urol 10 (1973): 438-41[74] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[75] Petri M, Cumber P, Grimes L, Treby D, Bryant R, Rawlins D, Ising H \"The metabolic effects of thiazide therapy in the elderly: a population study.\" Age Ageing 15 (1986): 151-5[76] Ludvik B, Clodi M, Kautzky-Willer A, Capek M, Hartter E, Pacini G, Prager R \"Effect of dexamethasone on insulin sensitivity, islet amyloid polypeptide and insulin secretion in humans.\" Diabetologia 36 (1993): 84-7[77] \"Product Information. Glucophage (metformin).\" Bristol-Myers Squibb, Princeton, NJ.[78] Chaudhuri ML, Catania J \"A comparison of the effects of bumetanide (Burinex) and frusemide on carbohydrate metabolism in the elderly.\" Br J Clin Pract 42 (1988): 427-9[79] Black DM, Filak AT \"Hyperglycemia with non-insulin-dependent diabetes following intraarticular steroid injection.\" J Fam Pract 28 (1989): 462-3[80] \"Product Information. Megace (megestrol).\" Bristol-Myers Squibb, Princeton, NJ.[81] \"Product Information. Torisel (temsirolimus).\" Wyeth-Ayerst Laboratories, Philadelphia, PA.[82] Schmitz O, Hermansen K, Nielsen OH, Christensen CK, Arnfred J, Hansen HE, Mogensen CE, Orskov H, Beck-Nielsen H \"Insulin action in insulin-dependent diabetics after short-term thiazide therapy.\" Diabetes Care 9 (1986): 631-6[83] Kansal PC, Buse J, Buse MG \"Thiazide diuretics and control of diabetes mellitus.\" South Med J 62 (1969): 1372-9[84] Dimitriadis G, Tegos C, Golfinopoulou L, Roboti C, Raptis S \"Furosemide-induced hyperglycaemia - the implication of glycolytic kinases.\" Horm Metab Res 25 (1993): 557-9[85] \"Product Information. NovoLog Mix 70/30 (insulin aspart-insulin aspart protamine).\" Novo Nordisk Pharmaceuticals Inc, Princeton, NJ.[86] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[87] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[88] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[89] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42[90] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[91] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[92] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[93] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[94] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[95] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6", "alternatives_a": "Guar gum, Rosuvastatin", "alternatives_b": "", "updated_at": 1767369485}, {"id": 97950, "ingredient1": "Empagliflozin", "ingredient2": "Lisinopril", "severity": "Moderate", "effect": "Sodium-glucose co-transporter 2 (SGLT-2) inhibitors may potentiate the hypotensive effects of diuretics and other antihypertensive agents or vasodilators. Inhibition of glucose and sodium co-transport produces mild diuresis and transient natriuresis, resulting in intravascular volume contraction. Volume depletion-related adverse reactions including hypotension, postural dizziness, orthostatic hypotension, syncope, and dehydration can occur after initiating treatment with SGLT-2 inhibitors, and the risk may be increased with concomitant use of other agents that can lower blood pressure.", "source": "DDInter", "management_text": "Caution is advised if SGLT-2 inhibitors are coadministered with diuretics and other hypotensive agents, particularly in the elderly and patients with impaired renal function. Prior to initiating SGLT-2 inhibitors, volume status should be assessed and corrected, if necessary. Clinical and laboratory monitoring are recommended during therapy, including electrolytes, fluid status, renal function, and blood pressure. If volume depletion occurs, treatment with SGLT-2 inhibitors should be interrupted until the condition is corrected.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if SGLT-2 inhibitors are coadministered with diuretics and other hypotensive agents, particularly in the elderly and patients with impaired renal function.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/98054/", "reference_text": "[1] \"Product Information. Jardiance (empagliflozin).\" Boehringer Ingelheim, Ridgefield, CT.[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] \"Product Information. Farxiga (dapagliflozin).\" Bristol-Myers Squibb, Princeton, NJ.[5] \"Product Information. Invokana (canagliflozin).\" Janssen Pharmaceuticals, Titusville, NJ.[6] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[7] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[8] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[9] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[10] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[11] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6[12] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[13] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[14] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[15] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42", "alternatives_a": "Atorvastatin, Simvastatin, Lovastatin, Rosuvastatin, Pravastatin, Acetylsalicylic acid, Ezetimibe, Fenofibrate", "alternatives_b": "Lixisenatide, Albiglutide, Guar gum, Pramlintide, Troglitazone, Semaglutide, Dulaglutide, Miglitol", "updated_at": 1767369485}, {"id": 97951, "ingredient1": "Empagliflozin", "ingredient2": "Lithium carbonate", "severity": "Moderate", "effect": "Lithium may interfere with the therapeutic effects of insulin and other antidiabetic agents.", "source": "DDInter", "management_text": "Blood glucose should be monitored more closely following initiation or discontinuation of lithium in patients receiving insulin or other antidiabetic agents. If hypo- or hyperglycemia occur during lithium therapy, patients should initiate appropriate remedial therapy immediately and contact their physician. Dosage adjustments may be required if an interaction is suspected.", "mechanism_text": "Others", "recommendation": "Blood glucose should be monitored more closely following initiation or discontinuation of lithium in patients receiving insulin or other antidiabetic agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/98055/", "reference_text": "[1] \"Product Information. Lantus (insulin glargine)\" Aventis Pharmaceuticals, Swiftwater, PA.[2] \"Product Information. NovoLog Mix 70/30 FlexPen (insulin aspart-insulin aspart protamine).\" Novo Nordisk Pharmaceuticals Inc, Princeton, NJ.[3] \"Product Information. Apidra (insulin glulisine).\" Aventis Pharmaceuticals, Bridgewater, NJ.[4] Shopsin B, Stern S, Gershon S \"Altered carbohydrate metabolism during treatment with lithium carbonate.\" Arch Gen Psychiatry 26 (1972): 566-71[5] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[6] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[7] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[8] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[9] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[10] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[11] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[12] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[13] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[14] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6[15] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[16] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[17] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[18] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42", "alternatives_a": "Simvastatin, Guar gum, Rosuvastatin", "alternatives_b": "", "updated_at": 1767369485}, {"id": 97952, "ingredient1": "Empagliflozin", "ingredient2": "Lofexidine", "severity": "Moderate", "effect": "Sodium-glucose co-transporter 2 (SGLT-2) inhibitors may potentiate the hypotensive effects of diuretics and other antihypertensive agents or vasodilators. Inhibition of glucose and sodium co-transport produces mild diuresis and transient natriuresis, resulting in intravascular volume contraction. Volume depletion-related adverse reactions including hypotension, postural dizziness, orthostatic hypotension, syncope, and dehydration can occur after initiating treatment with SGLT-2 inhibitors, and the risk may be increased with concomitant use of other agents that can lower blood pressure.", "source": "DDInter", "management_text": "Caution is advised if SGLT-2 inhibitors are coadministered with diuretics and other hypotensive agents, particularly in the elderly and patients with impaired renal function. Prior to initiating SGLT-2 inhibitors, volume status should be assessed and corrected, if necessary. Clinical and laboratory monitoring are recommended during therapy, including electrolytes, fluid status, renal function, and blood pressure. If volume depletion occurs, treatment with SGLT-2 inhibitors should be interrupted until the condition is corrected.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if SGLT-2 inhibitors are coadministered with diuretics and other hypotensive agents, particularly in the elderly and patients with impaired renal function.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/98056/", "reference_text": "[1] \"Product Information. Jardiance (empagliflozin).\" Boehringer Ingelheim, Ridgefield, CT.[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] \"Product Information. Farxiga (dapagliflozin).\" Bristol-Myers Squibb, Princeton, NJ.[5] \"Product Information. Invokana (canagliflozin).\" Janssen Pharmaceuticals, Titusville, NJ.[6] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[7] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[8] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[9] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[10] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[11] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6[12] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[13] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[14] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[15] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42", "alternatives_a": "Diamorphine, Acamprosate, Naltrexone, Varenicline, Disulfiram, Methadone, Levacetylmethadol, Nalmefene, Nicotine, Buprenorphine", "alternatives_b": "Glipizide, Acetohexamide, Guar gum, Pramlintide, Alogliptin, Rosuvastatin, Tolazamide, Dulaglutide, Exenatide, Tolbutamide, Miglitol, More", "updated_at": 1767369485}, {"id": 97953, "ingredient1": "Empagliflozin", "ingredient2": "Lomefloxacin", "severity": "Moderate", "effect": "Quinolone antibiotics may interfere with the therapeutic effects of insulin and other antidiabetic agents. The use of quinolones has been associated with disturbances in blood glucose homeostasis possibly stemming from effects on pancreatic beta cell ATP-sensitive potassium channels that regulate insulin secretion. Both hyperglycaemia and hypoglycemia have been reported, usually in diabetic patients receiving concomitant treatment with an oral hypoglycemic agent (e.g., sulfonylurea) or insulin. Although hyperglycaemia is significantly more common and infection itself may be an underlying risk factor, hypoglycemia may cause greater morbidity and mortality.", "source": "DDInter", "management_text": "Blood glucose should be closely monitored whenever quinolones are prescribed to diabetic patients, especially if they are elderly, have renal impairment, or are severely ill. Patients should be apprised of the increased risk of dysglycemia and be particularly alert to potential signs and symptoms of hypoglycemia such as headache, dizziness, drowsiness, nervousness, confusion, tremor, hunger, weakness, perspiration, palpitation, and tachycardia. If hypoglycemia occurs, patients should initiate appropriate remedial therapy immediately, discontinue the quinolone, and contact their physician. Alternative antibiotics may need to be considered.", "mechanism_text": "Antagonism", "recommendation": "Blood glucose should be closely monitored whenever quinolones are prescribed to diabetic patients, especially if they are elderly, have renal impairment, or are severely ill.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/98057/", "reference_text": "[1] Gavin JR 3rd, Kubin R, Choudhri S, et al \"Moxifloxacin and glucose homeostasis: a pooled-analysis of the evidence from clinical and postmarketing studies.\" Drug Saf 27 (2004): 671-86[2] Yip C, Lee AJ \"Gatifloxacin-induced hyperglycemia: a case report and summary of the current literature.\" Clin Ther 28 (2006): 1857-66[3] Kelesidis T, Canseco E \"Quinolone-induced hypoglycemia: a life-threatening but potentially reversible side effect.\" Am J Med 123 (2010): e5-6[4] Baker SE, Hangii MC \"Possible gatifloxacin-induced hypoglycemia.\" Ann Pharmacother 36 (2002): 1722-6[5] \"Product Information. Levaquin (levofloxacin).\" Ortho Pharmaceutical Corporation, Raritan, NJ.[6] Frothingham R \"Glucose homeostasis abnormalities associated with use of gatifloxacin.\" Clin Infect Dis 41 (2005): 1269-76[7] Letourneau G, Morrison H, McMorran M \"Gatifloxacin (Tequin): hypoglycemia and hyperglycemia. Available from: URL: http://www.hc-sc.gc.ca/dhp-mps/medeff/bulletin/carn-bcei_v13n3_e.html#1\" ([2003 Jul]):[8] Lin G, Hays DP, Spillane L \"Refractory hypoglycemia from ciprofloxacin and glyburide interaction.\" J Toxicol Clin Toxicol 42 (2004): 295-7[9] \"Product Information. Tequin (gatifloxacin)\" Bristol-Myers Squibb, Princeton, NJ.[10] \"Product Information. Floxin (ofloxacin).\" Ortho Pharmaceutical Corporation, Raritan, NJ.[11] Bhasin R, Arce FC, Pasmantier R \"Hypoglycemia associated with the use of gatifloxacin.\" Am J Med Sci 330 (2005): 250-3[12] Zvonar R \"Gatifloxacin-induced dysglycemia.\" Am J Health Syst Pharm 63 (2006): 2087-2092[13] Rubinstein E \"History of quinolones and their side effects.\" Chemotherapy 47 Suppl 3 (2001): 3-8[14] Park-Wyllie LY, Juurlink DN, Kopp A, et al. \"Outpatient gatifloxacin therapy and dysglycemia in older adults.\" N Engl J Med 354 (2006): 1352-61[15] LeBlanc M, Belanger C, Cossette P \"Severe and resistant hypoglycemia associated with concomitant gatifloxacin and glyburide therapy.\" Pharmacotherapy 24 (2004): 926-31[16] \"Product Information. Cipro (ciprofloxacin).\" Bayer, West Haven, CT.[17] Happe MR, Mulhall BP, Maydonovitch CL, Holtzmuller KC \"Gatifloxacin-induced hyperglycemia.\" Ann Intern Med 141 (2004): 968-9[18] Biggs WS \"Hypoglycemia and hyperglycemia associated with gatifloxacin use in elderly patients.\" J Am Board Fam Pract 16 (2004): 455-7[19] \"Product Information. Raxar (grepafloxacin).\" Glaxo Wellcome, Research Triangle Park, NC.[20] Brogan SE, Cahalan MK \"Gatifloxacin as a possible cause of serious postoperative hypoglycemia.\" Anesth Analg 101 (2005): 635-6[21] Friedrich LV, Dougherty R \"Fatal hypoglycemia associated with levofloxacin.\" Pharmacotherapy 24 (2004): 1807-12[22] Saraya A, Yokokura M, Gonoi T, Seino S \"Effects of fluoroquinolones on insulin secretion and beta-cell ATP-sensitive K(+) channels.\" Eur J Pharmacol 497 (2004): 111-7[23] \"Hypoglycemia and hyperglycemia with fluoroquinolones.\" Med Lett Drugs Ther 45 (2003): 64[24] Gajjar DA, LaCreta FP, Kollia GD, et al. \"Effect of multiple-dose gatifloxacin or ciprofloxacin on glucose homeostasis and insulin production in patients with noninsulin-dependent diabetes mellitus maintained with diet and exercise.\" Pharmacotherapy 20 (6 Pt 2) (2000): s76-86[25] Khovidhunkit W, Sunthornyothin S \"Hypoglycemia, hyperglycemia, and gatifloxacin.\" Ann Intern Med 141 (2004): 969[26] Kanbay M, Aydogan T, Bozalan R, et al. \"A rare but serious side effect of levofloxacin: hypoglycemia in a geriatric patient.\" Diabetes Care 29 (2006): 1716-7[27] Menzies DJ, Dorsainvil PA, Cunha BA, Johnson DH \"Severe and persistent hypoglycemia due to gatifloxacin interaction with oral hypoglycemic agents.\" Am J Med 113 (2002): 232-4[28] Edwards DJ, Bowles SK, Svensson CK, Rybak MJ \"Inhibition of drug metabolism by quinolone antibiotics.\" Clin Pharmacokinet 15 (1988): 194-204[29] Graumlich JF, Habis S, Avelino RR, et al. \"Hypoglycemia in inpatients after gatifloxacin or levofloxacin therapy: nested case-control study.\" Pharmacotherapy 25 (2005): 1296-302[30] \"Product Information. Factive (gemifloxacin).\" GeneSoft Inc, San Francisco, CA.[31] Wang S, Rizvi AA \"Levofloxacin-induced hypoglycemia in a nondiabetic patient.\" Am J Med Sci 331 (2006): 334-5[32] \"Product Information. Noroxin (norfloxacin).\" Merck & Co, Inc, West Point, PA.[33] Zhanel GG, Fontaine S, Adam H, et al. \"A Review of New Fluoroquinolones : Focus on their Use in Respiratory Tract Infections.\" Treat Respir Med 5 (2006): 437-465[34] \"Product Information. Baxdela (delafloxacin).\" Melinta Therapeutics, Lincolnshire, IL.[35] Greenberg AL, Decerbo M, Fan J \"Gatifloxacin therapy associated with hypoglycemia.\" Clin Infect Dis 40 (2005): 1210-1[36] Blommel AL, Lutes RA \"Severe hyperglycemia during renally adjusted gatifloxacin therapy.\" Ann Pharmacother 39 (2005): 1349-52[37] Tomita T, Onishi M, Sato E, Kimura Y, Kihira K \"Gatifloxacin induces augmented insulin release and intracellular insulin.\" Biol Pharm Bull 30 (2007): 644-7[38] Donaldson AR, Vandiver JR, Finch CK \"Possible gatifloxacin-induced hyperglycemia.\" Ann Pharmacother 38 (2004): 602-5[39] \"Product Information. Trovan (trovafloxacin).\" Pfizer US Pharmaceuticals, New York, NY.[40] Roberge RJ, Kaplan R, Frank R, Fore C \"Glyburide-ciprofloxacin interaction with resistant hypoglycemia.\" Ann Emerg Med 36 (2000): 160-3[41] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[42] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[43] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[44] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42[45] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[46] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[47] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[48] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[49] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[50] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6", "alternatives_a": "Rifamycin, Kanamycin, Ampicillin, Azithromycin, Acyclovir, Netilmicin, Polymyxin B, Famciclovir, Cefuroxime, Trifluridine, Tobramycin, More", "alternatives_b": "Acetohexamide, Guar gum, Simvastatin, Troglitazone, Rosuvastatin", "updated_at": 1767369485}, {"id": 97954, "ingredient1": "Empagliflozin", "ingredient2": "Lonafarnib", "severity": "Moderate", "effect": "Coadministration with lonafarnib may increase the plasma concentrations of drugs that are substrates of the P-glycoprotein (P-gp) efflux transporter.", "source": "DDInter", "management_text": "Caution is advised when lonafarnib is used concomitantly with drugs that are sensitive P-gp substrates, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever lonafarnib is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when lonafarnib is used concomitantly with drugs that are sensitive P-gp substrates, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/98058/", "reference_text": "[1] \"Product Information. Zokinvy (lonafarnib).\" Eiger BioPharmaceuticals, Palo Alto, CA.[2] \"Product Information. Zokinvy (lonafarnib).\" Eiger BioPharmaceuticals, Palo Alto, CA.", "alternatives_a": "Teduglutide, Fosdenopterin, Miglustat, Imiglucerase, Asfotase alfa, Glycerol phenylbutyrate, Pegvaliase, Triethylenetetramine, Sapropterin, Zinc acetate, Phenylbutyric acid, More", "alternatives_b": "Glipizide, Acetohexamide, Guar gum, Pramlintide, Alogliptin, Rosuvastatin, Tolazamide, Dulaglutide, Exenatide, Miglitol, Glimepiride, More", "updated_at": 1767369485}, {"id": 97955, "ingredient1": "Empagliflozin", "ingredient2": "Lorlatinib", "severity": "Moderate", "effect": "Coadministration with lorlatinib may decrease the plasma concentrations of drugs that are substrates of the uridine diphosphate glucuronosyl transferase (UGT) enzymes. The proposed mechanism involves decreased metabolic clearance due to induction of UGT by lorlatinib.", "source": "DDInter", "management_text": "Caution is advised when lorlatinib is used concurrently with drugs that are known UGT substrates, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever lorlatinib is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when lorlatinib is used concurrently with drugs that are known UGT substrates, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/98059/", "reference_text": "[1] Cerner Multum, Inc. \"Australian Product Information.\" O 0[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Lorbrena (lorlatinib).\" Pfizer U.S. Pharmaceuticals Group, New York, NY.[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] \"Product Information. Lorbrena (lorlatinib).\" Pfizer U.S. Pharmaceuticals Group, New York, NY.", "alternatives_a": "Lixisenatide, Albiglutide, Guar gum, Acarbose, Pramlintide, Sitagliptin, Canagliflozin, Alogliptin, Liraglutide, Ertugliflozin, Semaglutide, More", "alternatives_b": "Imatinib, Dabrafenib, Asciminib, Acalabrutinib, Dacomitinib, Pexidartinib, Fedratinib, Avapritinib, Larotrectinib, Bosutinib, Vemurafenib, More", "updated_at": 1767369485}, {"id": 97956, "ingredient1": "Empagliflozin", "ingredient2": "Losartan", "severity": "Moderate", "effect": "Sodium-glucose co-transporter 2 (SGLT-2) inhibitors may potentiate the hypotensive effects of diuretics and other antihypertensive agents or vasodilators. Inhibition of glucose and sodium co-transport produces mild diuresis and transient natriuresis, resulting in intravascular volume contraction. Volume depletion-related adverse reactions including hypotension, postural dizziness, orthostatic hypotension, syncope, and dehydration can occur after initiating treatment with SGLT-2 inhibitors, and the risk may be increased with concomitant use of other agents that can lower blood pressure.", "source": "DDInter", "management_text": "Caution is advised if SGLT-2 inhibitors are coadministered with diuretics and other hypotensive agents, particularly in the elderly and patients with impaired renal function. Prior to initiating SGLT-2 inhibitors, volume status should be assessed and corrected, if necessary. Clinical and laboratory monitoring are recommended during therapy, including electrolytes, fluid status, renal function, and blood pressure. If volume depletion occurs, treatment with SGLT-2 inhibitors should be interrupted until the condition is corrected.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if SGLT-2 inhibitors are coadministered with diuretics and other hypotensive agents, particularly in the elderly and patients with impaired renal function.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/98060/", "reference_text": "[1] \"Product Information. Jardiance (empagliflozin).\" Boehringer Ingelheim, Ridgefield, CT.[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] \"Product Information. Farxiga (dapagliflozin).\" Bristol-Myers Squibb, Princeton, NJ.[5] \"Product Information. Invokana (canagliflozin).\" Janssen Pharmaceuticals, Titusville, NJ.[6] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[7] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[8] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[9] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[10] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[11] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6[12] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[13] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[14] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[15] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42", "alternatives_a": "Sacubitril", "alternatives_b": "Lixisenatide, Albiglutide, Acetohexamide, Guar gum, Pramlintide, Sitagliptin, Alogliptin, Liraglutide, Chlorpropamide, Semaglutide, Linagliptin, More", "updated_at": 1767369485}, {"id": 97957, "ingredient1": "Empagliflozin", "ingredient2": "Lumateperone", "severity": "Moderate", "effect": "The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.", "source": "DDInter", "management_text": "Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.", "mechanism_text": "Antagonism", "recommendation": "Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/98061/", "reference_text": "[1] Jori A, Carrara MC \"On the mechanism of the hyperglycaemic effect of chlorpromazine.\" J Pharm Pharmacol 18 (1966): 623-4[2] \"Product Information. Dymelor (acetohexamide)\" Lilly, Eli and Company, Indianapolis, IN.[3] \"Product Information. Thorazine (chlorpromazine).\" SmithKline Beecham, Philadelphia, PA.[4] Blayac JP, Ribes G, Buys D, Puech R, Loubatieres-Mariani MM \"Effects of a new benzothiadiazine derivative, LN 5330, on insulin secretion.\" Arch Int Pharmacodyn Ther 253 (1981): 154-63[5] \"Product Information. Elzonris (tagraxofusp).\" Stemline Therapeutics, New York, NY.[6] \"Product Information. Amaryl (glimepiride).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[7] \"Product Information. Elspar (asparaginase).\" Merck & Co, Inc, West Point, PA.[8] Jones IG, Pickens PT \"Diabetes mellitus following oral diuretics.\" Practitioner 199 (1967): 209-10[9] \"Product Information. Viracept (nelfinavir).\" Agouron Pharma Inc, La Jolla, CA.[10] \"Product Information. Tolinase (tolazamide)\" Pharmacia and Upjohn, Kalamazoo, MI.[11] Mauss S, Wolf E, Jaeger H \"Impaired glucose tolerance in HIV-positive patients receiving and those not receiving protease inhibitors.\" Ann Intern Med 130 (1999): 162-3[12] Virutamasen P, Wongsrichanalai C, Tangkeo P, Nitichai Y, Rienprayoon D \"Metabolic effects of depot-medroxyprogesterone acetate in long-term users: a cross-sectional study.\" Int J Gynaecol Obstet 24 (1986): 291-6[13] Wehring H, Alexander B, Perry PJ \"Diabetes mellitus associated with clozapine therapy.\" Pharmacotherapy 20 (2000): 844-7[14] Spellacy WN, Ellingson AB, Tsibris JC \"The effects of two triphasic oral contraceptives on carbohydrate metabolism in women during 1 year of use.\" Fertil Steril 51 (1989): 71-4[15] Andersen OO, Persson I \"Carbohydrate metabolism during treatment with chlorthalidone and ethacrynic acid.\" Br Med J 2 (1968): 798-801[16] Berlin I \"Prazosin, diuretics, and glucose intolerance.\" Ann Intern Med 119 (1993): 860[17] Malherbe C, Burrill KC, Levin SR, Karam JH, Forsham PH \"Effect of diphenylhydantoin on insulin secretion in man.\" N Engl J Med 286 (1972): 339-42[18] Carter BL, Small RE, Mandel MD, Starkman MT \"Phenytoin-induced hyperglycemia.\" Am J Hosp Pharm 38 (1981): 1508-12[19] Al-Rubeaan K, Ryan EA \"Phenytoin-induced insulin insensitivity.\" Diabet Med 8 (1991): 968-70[20] \"Product Information. Zolinza (vorinostat).\" Merck & Company Inc, West Point, PA.[21] Goldman JA, Neri A, Ovadia J, Eckerling B, Vries A, de \"Effect of chlorothiazide on intravenous glucose tolerance in pregnancy.\" Am J Obstet Gynecol 105 (1969): 556-60[22] Harper R, Ennis CN, Heaney AP, Sheridan B, Gormley M, Atkinson AB, Johnston GD, Bell PM \"A comparison of the effects of low- and conventional-dose thiazide diuretic on insulin action in hypertensive patients with NIDDM.\" Diabetologia 38 (1995): 853-9[23] Seltzer HS, Allen EW \"Hyperglycemia and inhibition of insulin secretion during administration of diazoxide and trichlormethiazide in man.\" Diabetes 18 (1969): 19-28[24] Dube MP, Johnson DL, Currier JS, Leedom JM \"Protease inhibitor-associated hyperglycaemia.\" Lancet 350 (1997): 713-4[25] Leary WP, Reyes AJ \"Drug interactions with diuretics.\" S Afr Med J 65 (1984): 455-61[26] \"Product Information. Reyataz (atazanavir).\" Bristol-Myers Squibb, Princeton, NJ.[27] Pollare T, Lithell H, Berne C \"A comparison of the effects of hydrochlorothiazide and captopril on glucose and lipid metabolism in patients with hypertension.\" N Engl J Med 321 (1989): 868-73[28] Gunnarsson R, Lundgren G, Magnusson G, Ost L, Groth CG \"Steroid diabetes--a sign of overtreatment with steroids in the renal graft recipient?\" Scand J Urol Nephrol Suppl 54 (1980): 135-8[29] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[30] \"Product Information. Synthroid (levothyroxine).\" Abbott Pharmaceutical, Abbott Park, IL.[31] Murphy MB, Kohner E, Lewis PJ, Schumer B, Dollery CT \"Glucose intolerance in hypertensive patients treated with diuretics: a fourteen-year follow-up.\" Lancet 2 (1982): 1293-5[32] \"Product Information. Fortovase (saquinavir)\" Roche Laboratories, Nutley, NJ.[33] Coni NK, Gordon PW, Mukherjee AP, Read PR \"The effect of frusemide and ethacrynic acid on carbohydrate metabolism.\" Age Ageing 3 (1974): 85-90[34] \"Product Information. Norvir (ritonavir).\" Abbott Pharmaceutical, Abbott Park, IL.[35] Domenet JG \"Diabetogenic effect of oral diuretics.\" Br Med J 3 (1968): 188[36] Rowe P, Mather H \"Hyperosmolar non-ketotic diabetes mellitus associated with metolazone.\" Br Med J 291 (1985): 25-6[37] Winchester JF, Kellett RJ, Boddy K, Boyle P, Dargie HJ, Mahaffey ME, Ward DM, Kennedy AC \"Metolazone and bendroflumethiazide in hypertension: physiologic and metabolic observations.\" Clin Pharmacol Ther 28 (1980): 611-8[38] \"Product Information. Carafate (sucralfate).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[39] Tsiodras S, Mantzoros C, Hammer S, Samore M \"Effects of protease inhibitors on hyperglycemia, hyperlipidemia, and lipodystrophy - A 5-year cohort study.\" Arch Intern Med 160 (2000): 2050-6[40] \"Product Information. Apidra (insulin glulisine).\" Aventis Pharmaceuticals, Bridgewater, NJ.[41] \"Product Information. Prezista (darunavir).\" Ortho Biotech Inc, Bridgewater, NJ.[42] Haiba NA, el-Habashy MA, Said SA, Darwish EA, Abdel-Sayed WS, Nayel SE \"Clinical evaluation of two monthly injectable contraceptives and their effects on some metabolic parameters.\" Contraception 39 (1989): 619-32[43] Erle G, Basso M, Federspil G, Sicolo N, Scandellari C \"Effect of chlorpromazine on blood glucose and plasma insulin in man.\" Eur J Clin Pharmacol 11 (1977): 15-8[44] Pickkers P, Schachter M, Hughes AD, Feher MD, Sever PS \"Thiazide-induced hyperglycaemia: a role for calcium-activated potassium channels?\" Diabetologia 39 (1996): 861-4[45] \"Product Information. Lexiva (fosamprenavir).\" GlaxoSmithKline, Research Triangle Park, NC.[46] Curtis J, Horrigan F, Ahearn D, Varney R, Sandler SG \"Chlorthalidone-induced hyperosmolar hyperglycemic nonketotic coma.\" JAMA 220 (1972): 1592-3[47] \"Product Information. Hyperstat I.V. (diazoxide).\" Schering Corp, Kenilworth, NJ.[48] \"Product Information. Piqray (alpelisib).\" Novartis Pharmaceuticals, East Hanover, NJ.[49] Bell DS \"Insulin resistance. An often unrecognized problem accompanying chronic medical disorders.\" Postgrad Med 93 (1993): 99-103,[50] Stambaugh JE, Tucker DC \"Effect of diphenylhydantoin on glucose tolerance in patients with hypoglycemia.\" Diabetes 23 (1974): 679-83[51] \"Product Information. Crixivan (indinavir).\" Merck & Co, Inc, West Point, PA.[52] Miller NR, Moses H \"Transient oculomotor nerve palsy. Association with thiazide-induced glucose intolerance.\" JAMA 240 (1978): 1887-8[53] Javier Z, Gershberg H, Hulse M \"Ovulatory suppressants, estrogens, and carbohydrate metabolism.\" Metabolism 17 (1968): 443-56[54] Goldman JA, Ovadia JL \"The effect of estrogen on intravenous glucose tolerance in woman.\" Am J Obstet Gynecol 103 (1969): 172-8[55] Charan VD, Desai N, Singh AP, Choudhry VP \"Diabetes mellitus and pancreatitis as a complication of L- asparaginase therapy.\" Indian Pediatr 30 (1993): 809-10[56] Seifer DB, Freedman LN, Cavender JR, Baker RA \"Insulin-dependent diabetes mellitus associated with danazol.\" Am J Obstet Gynecol 162 (1990): 474-5[57] \"Product Information. Orinase (tolbutamide)\" Pharmacia and Upjohn, Kalamazoo, MI.[58] Walli R, Demant T \"Impaired glucose tolerance and protease inhibitors.\" Ann Intern Med 129 (1998): 837-8[59] Hannaford PC, Kay CR \"Oral contraceptives and diabetes mellitus.\" BMJ 299 (1989): 1315-6[60] Hardy H, Esch LD, Morse GD \"Glucose disorders associated with HIV and its drug therapy.\" Ann Pharmacother 35 (2001): 343-51[61] Chowdhury FR, Bleicher SJ \"Chlorthalidone--induced hypokalemia and abnormal carbohydrate metabolism.\" Horm Metab Res 2 (1970): 13-6[62] Kaufman MB, Simionatto C \"A review of protease inhibitor-induced hyperglycemia.\" Pharmacotherapy 19 (1999): 114-7[63] Greenstone MA, Shaw AB \"Alternate day corticosteroid causes alternate day hyperglycaemia.\" Postgrad Med J 63 (1987): 761-4[64] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[65] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[66] Elmfeldt D, Berglund G, Wedel H, Wilhelmsen L \"Incidence and importance of metabolic side-effects during antihypertensive therapy.\" Acta Med Scand Suppl 672 (1983): 79-83[67] \"Product Information. Agenerase (amprenavir).\" Glaxo Wellcome, Research Triangle Pk, NC.[68] Diamond MT \"Hyperglycemic hyperosmolar coma associated with hydrochlorothiazide and pancreatitis.\" N Y State J Med 72 (1972): 1741-2[69] \"Product Information. Prandin (repaglinide).\" Novo Nordisk Pharmaceuticals Inc, Princeton, NJ.[70] \"Product Information. Precose (acarbose).\" Bayer, West Haven, CT.[71] \"Product Information. Starlix (nateglinide)\" Novartis Pharmaceuticals, East Hanover, NJ.[72] \"Product Information. Oncaspar (pegaspargase).\" Rhone-Poulenc Rorer, Collegeville, PA.[73] Sotaniemi E, Kontturi M, Larmi T \"Effect of diethylstilbestrol on blood glucose of prostatic cancer patients.\" Invest Urol 10 (1973): 438-41[74] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[75] Petri M, Cumber P, Grimes L, Treby D, Bryant R, Rawlins D, Ising H \"The metabolic effects of thiazide therapy in the elderly: a population study.\" Age Ageing 15 (1986): 151-5[76] Ludvik B, Clodi M, Kautzky-Willer A, Capek M, Hartter E, Pacini G, Prager R \"Effect of dexamethasone on insulin sensitivity, islet amyloid polypeptide and insulin secretion in humans.\" Diabetologia 36 (1993): 84-7[77] \"Product Information. Glucophage (metformin).\" Bristol-Myers Squibb, Princeton, NJ.[78] Chaudhuri ML, Catania J \"A comparison of the effects of bumetanide (Burinex) and frusemide on carbohydrate metabolism in the elderly.\" Br J Clin Pract 42 (1988): 427-9[79] Black DM, Filak AT \"Hyperglycemia with non-insulin-dependent diabetes following intraarticular steroid injection.\" J Fam Pract 28 (1989): 462-3[80] \"Product Information. Megace (megestrol).\" Bristol-Myers Squibb, Princeton, NJ.[81] \"Product Information. Torisel (temsirolimus).\" Wyeth-Ayerst Laboratories, Philadelphia, PA.[82] Schmitz O, Hermansen K, Nielsen OH, Christensen CK, Arnfred J, Hansen HE, Mogensen CE, Orskov H, Beck-Nielsen H \"Insulin action in insulin-dependent diabetics after short-term thiazide therapy.\" Diabetes Care 9 (1986): 631-6[83] Kansal PC, Buse J, Buse MG \"Thiazide diuretics and control of diabetes mellitus.\" South Med J 62 (1969): 1372-9[84] Dimitriadis G, Tegos C, Golfinopoulou L, Roboti C, Raptis S \"Furosemide-induced hyperglycaemia - the implication of glycolytic kinases.\" Horm Metab Res 25 (1993): 557-9[85] \"Product Information. NovoLog Mix 70/30 (insulin aspart-insulin aspart protamine).\" Novo Nordisk Pharmaceuticals Inc, Princeton, NJ.[86] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[87] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[88] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[89] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42[90] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[91] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[92] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[93] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[94] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[95] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6", "alternatives_a": "Haloperidol, Pimavanserin, Thiothixene, Pimozide, Amisulpride, Loxapine, Molindone, Droperidol", "alternatives_b": "Simvastatin, Guar gum, Rosuvastatin", "updated_at": 1767369485}, {"id": 97958, "ingredient1": "Empagliflozin", "ingredient2": "Lurasidone", "severity": "Moderate", "effect": "The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.", "source": "DDInter", "management_text": "Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.", "mechanism_text": "Antagonism", "recommendation": "Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/98062/", "reference_text": "[1] Jori A, Carrara MC \"On the mechanism of the hyperglycaemic effect of chlorpromazine.\" J Pharm Pharmacol 18 (1966): 623-4[2] \"Product Information. Dymelor (acetohexamide)\" Lilly, Eli and Company, Indianapolis, IN.[3] \"Product Information. Thorazine (chlorpromazine).\" SmithKline Beecham, Philadelphia, PA.[4] Blayac JP, Ribes G, Buys D, Puech R, Loubatieres-Mariani MM \"Effects of a new benzothiadiazine derivative, LN 5330, on insulin secretion.\" Arch Int Pharmacodyn Ther 253 (1981): 154-63[5] \"Product Information. Elzonris (tagraxofusp).\" Stemline Therapeutics, New York, NY.[6] \"Product Information. Amaryl (glimepiride).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[7] \"Product Information. Elspar (asparaginase).\" Merck & Co, Inc, West Point, PA.[8] Jones IG, Pickens PT \"Diabetes mellitus following oral diuretics.\" Practitioner 199 (1967): 209-10[9] \"Product Information. Viracept (nelfinavir).\" Agouron Pharma Inc, La Jolla, CA.[10] \"Product Information. Tolinase (tolazamide)\" Pharmacia and Upjohn, Kalamazoo, MI.[11] Mauss S, Wolf E, Jaeger H \"Impaired glucose tolerance in HIV-positive patients receiving and those not receiving protease inhibitors.\" Ann Intern Med 130 (1999): 162-3[12] Virutamasen P, Wongsrichanalai C, Tangkeo P, Nitichai Y, Rienprayoon D \"Metabolic effects of depot-medroxyprogesterone acetate in long-term users: a cross-sectional study.\" Int J Gynaecol Obstet 24 (1986): 291-6[13] Wehring H, Alexander B, Perry PJ \"Diabetes mellitus associated with clozapine therapy.\" Pharmacotherapy 20 (2000): 844-7[14] Spellacy WN, Ellingson AB, Tsibris JC \"The effects of two triphasic oral contraceptives on carbohydrate metabolism in women during 1 year of use.\" Fertil Steril 51 (1989): 71-4[15] Andersen OO, Persson I \"Carbohydrate metabolism during treatment with chlorthalidone and ethacrynic acid.\" Br Med J 2 (1968): 798-801[16] Berlin I \"Prazosin, diuretics, and glucose intolerance.\" Ann Intern Med 119 (1993): 860[17] Malherbe C, Burrill KC, Levin SR, Karam JH, Forsham PH \"Effect of diphenylhydantoin on insulin secretion in man.\" N Engl J Med 286 (1972): 339-42[18] Carter BL, Small RE, Mandel MD, Starkman MT \"Phenytoin-induced hyperglycemia.\" Am J Hosp Pharm 38 (1981): 1508-12[19] Al-Rubeaan K, Ryan EA \"Phenytoin-induced insulin insensitivity.\" Diabet Med 8 (1991): 968-70[20] \"Product Information. Zolinza (vorinostat).\" Merck & Company Inc, West Point, PA.[21] Goldman JA, Neri A, Ovadia J, Eckerling B, Vries A, de \"Effect of chlorothiazide on intravenous glucose tolerance in pregnancy.\" Am J Obstet Gynecol 105 (1969): 556-60[22] Harper R, Ennis CN, Heaney AP, Sheridan B, Gormley M, Atkinson AB, Johnston GD, Bell PM \"A comparison of the effects of low- and conventional-dose thiazide diuretic on insulin action in hypertensive patients with NIDDM.\" Diabetologia 38 (1995): 853-9[23] Seltzer HS, Allen EW \"Hyperglycemia and inhibition of insulin secretion during administration of diazoxide and trichlormethiazide in man.\" Diabetes 18 (1969): 19-28[24] Dube MP, Johnson DL, Currier JS, Leedom JM \"Protease inhibitor-associated hyperglycaemia.\" Lancet 350 (1997): 713-4[25] Leary WP, Reyes AJ \"Drug interactions with diuretics.\" S Afr Med J 65 (1984): 455-61[26] \"Product Information. Reyataz (atazanavir).\" Bristol-Myers Squibb, Princeton, NJ.[27] Pollare T, Lithell H, Berne C \"A comparison of the effects of hydrochlorothiazide and captopril on glucose and lipid metabolism in patients with hypertension.\" N Engl J Med 321 (1989): 868-73[28] Gunnarsson R, Lundgren G, Magnusson G, Ost L, Groth CG \"Steroid diabetes--a sign of overtreatment with steroids in the renal graft recipient?\" Scand J Urol Nephrol Suppl 54 (1980): 135-8[29] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[30] \"Product Information. Synthroid (levothyroxine).\" Abbott Pharmaceutical, Abbott Park, IL.[31] Murphy MB, Kohner E, Lewis PJ, Schumer B, Dollery CT \"Glucose intolerance in hypertensive patients treated with diuretics: a fourteen-year follow-up.\" Lancet 2 (1982): 1293-5[32] \"Product Information. Fortovase (saquinavir)\" Roche Laboratories, Nutley, NJ.[33] Coni NK, Gordon PW, Mukherjee AP, Read PR \"The effect of frusemide and ethacrynic acid on carbohydrate metabolism.\" Age Ageing 3 (1974): 85-90[34] \"Product Information. Norvir (ritonavir).\" Abbott Pharmaceutical, Abbott Park, IL.[35] Domenet JG \"Diabetogenic effect of oral diuretics.\" Br Med J 3 (1968): 188[36] Rowe P, Mather H \"Hyperosmolar non-ketotic diabetes mellitus associated with metolazone.\" Br Med J 291 (1985): 25-6[37] Winchester JF, Kellett RJ, Boddy K, Boyle P, Dargie HJ, Mahaffey ME, Ward DM, Kennedy AC \"Metolazone and bendroflumethiazide in hypertension: physiologic and metabolic observations.\" Clin Pharmacol Ther 28 (1980): 611-8[38] \"Product Information. Carafate (sucralfate).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[39] Tsiodras S, Mantzoros C, Hammer S, Samore M \"Effects of protease inhibitors on hyperglycemia, hyperlipidemia, and lipodystrophy - A 5-year cohort study.\" Arch Intern Med 160 (2000): 2050-6[40] \"Product Information. Apidra (insulin glulisine).\" Aventis Pharmaceuticals, Bridgewater, NJ.[41] \"Product Information. Prezista (darunavir).\" Ortho Biotech Inc, Bridgewater, NJ.[42] Haiba NA, el-Habashy MA, Said SA, Darwish EA, Abdel-Sayed WS, Nayel SE \"Clinical evaluation of two monthly injectable contraceptives and their effects on some metabolic parameters.\" Contraception 39 (1989): 619-32[43] Erle G, Basso M, Federspil G, Sicolo N, Scandellari C \"Effect of chlorpromazine on blood glucose and plasma insulin in man.\" Eur J Clin Pharmacol 11 (1977): 15-8[44] Pickkers P, Schachter M, Hughes AD, Feher MD, Sever PS \"Thiazide-induced hyperglycaemia: a role for calcium-activated potassium channels?\" Diabetologia 39 (1996): 861-4[45] \"Product Information. Lexiva (fosamprenavir).\" GlaxoSmithKline, Research Triangle Park, NC.[46] Curtis J, Horrigan F, Ahearn D, Varney R, Sandler SG \"Chlorthalidone-induced hyperosmolar hyperglycemic nonketotic coma.\" JAMA 220 (1972): 1592-3[47] \"Product Information. Hyperstat I.V. (diazoxide).\" Schering Corp, Kenilworth, NJ.[48] \"Product Information. Piqray (alpelisib).\" Novartis Pharmaceuticals, East Hanover, NJ.[49] Bell DS \"Insulin resistance. An often unrecognized problem accompanying chronic medical disorders.\" Postgrad Med 93 (1993): 99-103,[50] Stambaugh JE, Tucker DC \"Effect of diphenylhydantoin on glucose tolerance in patients with hypoglycemia.\" Diabetes 23 (1974): 679-83[51] \"Product Information. Crixivan (indinavir).\" Merck & Co, Inc, West Point, PA.[52] Miller NR, Moses H \"Transient oculomotor nerve palsy. Association with thiazide-induced glucose intolerance.\" JAMA 240 (1978): 1887-8[53] Javier Z, Gershberg H, Hulse M \"Ovulatory suppressants, estrogens, and carbohydrate metabolism.\" Metabolism 17 (1968): 443-56[54] Goldman JA, Ovadia JL \"The effect of estrogen on intravenous glucose tolerance in woman.\" Am J Obstet Gynecol 103 (1969): 172-8[55] Charan VD, Desai N, Singh AP, Choudhry VP \"Diabetes mellitus and pancreatitis as a complication of L- asparaginase therapy.\" Indian Pediatr 30 (1993): 809-10[56] Seifer DB, Freedman LN, Cavender JR, Baker RA \"Insulin-dependent diabetes mellitus associated with danazol.\" Am J Obstet Gynecol 162 (1990): 474-5[57] \"Product Information. Orinase (tolbutamide)\" Pharmacia and Upjohn, Kalamazoo, MI.[58] Walli R, Demant T \"Impaired glucose tolerance and protease inhibitors.\" Ann Intern Med 129 (1998): 837-8[59] Hannaford PC, Kay CR \"Oral contraceptives and diabetes mellitus.\" BMJ 299 (1989): 1315-6[60] Hardy H, Esch LD, Morse GD \"Glucose disorders associated with HIV and its drug therapy.\" Ann Pharmacother 35 (2001): 343-51[61] Chowdhury FR, Bleicher SJ \"Chlorthalidone--induced hypokalemia and abnormal carbohydrate metabolism.\" Horm Metab Res 2 (1970): 13-6[62] Kaufman MB, Simionatto C \"A review of protease inhibitor-induced hyperglycemia.\" Pharmacotherapy 19 (1999): 114-7[63] Greenstone MA, Shaw AB \"Alternate day corticosteroid causes alternate day hyperglycaemia.\" Postgrad Med J 63 (1987): 761-4[64] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[65] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[66] Elmfeldt D, Berglund G, Wedel H, Wilhelmsen L \"Incidence and importance of metabolic side-effects during antihypertensive therapy.\" Acta Med Scand Suppl 672 (1983): 79-83[67] \"Product Information. Agenerase (amprenavir).\" Glaxo Wellcome, Research Triangle Pk, NC.[68] Diamond MT \"Hyperglycemic hyperosmolar coma associated with hydrochlorothiazide and pancreatitis.\" N Y State J Med 72 (1972): 1741-2[69] \"Product Information. Prandin (repaglinide).\" Novo Nordisk Pharmaceuticals Inc, Princeton, NJ.[70] \"Product Information. Precose (acarbose).\" Bayer, West Haven, CT.[71] \"Product Information. Starlix (nateglinide)\" Novartis Pharmaceuticals, East Hanover, NJ.[72] \"Product Information. Oncaspar (pegaspargase).\" Rhone-Poulenc Rorer, Collegeville, PA.[73] Sotaniemi E, Kontturi M, Larmi T \"Effect of diethylstilbestrol on blood glucose of prostatic cancer patients.\" Invest Urol 10 (1973): 438-41[74] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[75] Petri M, Cumber P, Grimes L, Treby D, Bryant R, Rawlins D, Ising H \"The metabolic effects of thiazide therapy in the elderly: a population study.\" Age Ageing 15 (1986): 151-5[76] Ludvik B, Clodi M, Kautzky-Willer A, Capek M, Hartter E, Pacini G, Prager R \"Effect of dexamethasone on insulin sensitivity, islet amyloid polypeptide and insulin secretion in humans.\" Diabetologia 36 (1993): 84-7[77] \"Product Information. Glucophage (metformin).\" Bristol-Myers Squibb, Princeton, NJ.[78] Chaudhuri ML, Catania J \"A comparison of the effects of bumetanide (Burinex) and frusemide on carbohydrate metabolism in the elderly.\" Br J Clin Pract 42 (1988): 427-9[79] Black DM, Filak AT \"Hyperglycemia with non-insulin-dependent diabetes following intraarticular steroid injection.\" J Fam Pract 28 (1989): 462-3[80] \"Product Information. Megace (megestrol).\" Bristol-Myers Squibb, Princeton, NJ.[81] \"Product Information. Torisel (temsirolimus).\" Wyeth-Ayerst Laboratories, Philadelphia, PA.[82] Schmitz O, Hermansen K, Nielsen OH, Christensen CK, Arnfred J, Hansen HE, Mogensen CE, Orskov H, Beck-Nielsen H \"Insulin action in insulin-dependent diabetics after short-term thiazide therapy.\" Diabetes Care 9 (1986): 631-6[83] Kansal PC, Buse J, Buse MG \"Thiazide diuretics and control of diabetes mellitus.\" South Med J 62 (1969): 1372-9[84] Dimitriadis G, Tegos C, Golfinopoulou L, Roboti C, Raptis S \"Furosemide-induced hyperglycaemia - the implication of glycolytic kinases.\" Horm Metab Res 25 (1993): 557-9[85] \"Product Information. NovoLog Mix 70/30 (insulin aspart-insulin aspart protamine).\" Novo Nordisk Pharmaceuticals Inc, Princeton, NJ.[86] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[87] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[88] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[89] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42[90] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[91] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[92] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[93] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[94] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[95] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6", "alternatives_a": "Haloperidol, Pimavanserin, Thiothixene, Pimozide, Amisulpride, Loxapine, Molindone, Droperidol", "alternatives_b": "Simvastatin, Guar gum, Rosuvastatin", "updated_at": 1767369485}, {"id": 97959, "ingredient1": "Empagliflozin", "ingredient2": "Mannitol", "severity": "Moderate", "effect": "Sodium-glucose co-transporter 2 (SGLT-2) inhibitors may potentiate the hypotensive effects of diuretics and other antihypertensive agents or vasodilators. Inhibition of glucose and sodium co-transport produces mild diuresis and transient natriuresis, resulting in intravascular volume contraction. Volume depletion-related adverse reactions including hypotension, postural dizziness, orthostatic hypotension, syncope, and dehydration can occur after initiating treatment with SGLT-2 inhibitors, and the risk may be increased with concomitant use of other agents that can lower blood pressure.", "source": "DDInter", "management_text": "Caution is advised if SGLT-2 inhibitors are coadministered with diuretics and other hypotensive agents, particularly in the elderly and patients with impaired renal function. Prior to initiating SGLT-2 inhibitors, volume status should be assessed and corrected, if necessary. Clinical and laboratory monitoring are recommended during therapy, including electrolytes, fluid status, renal function, and blood pressure. If volume depletion occurs, treatment with SGLT-2 inhibitors should be interrupted until the condition is corrected.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if SGLT-2 inhibitors are coadministered with diuretics and other hypotensive agents, particularly in the elderly and patients with impaired renal function.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/98063/", "reference_text": "[1] \"Product Information. Jardiance (empagliflozin).\" Boehringer Ingelheim, Ridgefield, CT.[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] \"Product Information. Farxiga (dapagliflozin).\" Bristol-Myers Squibb, Princeton, NJ.[5] \"Product Information. Invokana (canagliflozin).\" Janssen Pharmaceuticals, Titusville, NJ.[6] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[7] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[8] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[9] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[10] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[11] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6[12] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[13] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[14] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[15] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42", "alternatives_a": "Sorbitol, Sulfamethizole, Sodium citrate, Magnesium citrate, Sodium bicarbonate, Sodium chloride, Chlorhexidine, Neomycin, Alvimopan, Sorbitol, Tegaserod, More", "alternatives_b": "Acetohexamide, Guar gum, Pramlintide, Alogliptin, Rosuvastatin, Tolazamide, Dulaglutide, Tolbutamide, Miglitol, Albiglutide, Rosiglitazone, More", "updated_at": 1767369485}, {"id": 97960, "ingredient1": "Empagliflozin", "ingredient2": "Mazindol", "severity": "Moderate", "effect": "Since weight loss may affect glycemic control and increase the risk of hypoglycemia in type 2 diabetes mellitus, patients receiving anorectic drugs may require periodic adjustments of their antidiabetic medications.", "source": "DDInter", "management_text": "Blood glucose should be closely monitored during weight loss treatment, and appropriate changes made to the antidiabetic drug regimen as needed. Patients should be apprised of the risk of hypoglycemia and be alert to potential signs and symptoms such as headache, dizziness, drowsiness, nervousness, confusion, tremor, hunger, weakness, perspiration, palpitation, and tachycardia.", "mechanism_text": "Synergism", "recommendation": "Blood glucose should be closely monitored during weight loss treatment, and appropriate changes made to the antidiabetic drug regimen as needed.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/98064/", "reference_text": "[1] \"Product Information. Xenical (orlistat).\" Roche Laboratories, Nutley, NJ.[2] \"Product Information. Didrex (benzphetamine)\" Pharmacia and Upjohn, Kalamazoo, MI.[3] \"Product Information. Suprenza (phentermine).\" Akrimax Pharmaceuticals, Cranford, NJ.[4] \"Product Information. Belviq (lorcaserin).\" Eisai Inc, Teaneck, NJ.[5] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[6] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[7] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[8] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42[9] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[10] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[11] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[12] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[13] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[14] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6[15] Mendelson J, Jones RT, Upton R, Jacob P 3rd \"Methamphetamine and ethanol interactions in humans.\" Clin Pharmacol Ther 57 (1995): 559-68[16] \"Product Information. Didrex (benzphetamine)\" Pharmacia and Upjohn, Kalamazoo, MI.[17] \"Product Information. Suprenza (phentermine).\" Akrimax Pharmaceuticals, Cranford, NJ.", "alternatives_a": "Bupropion, Naltrexone", "alternatives_b": "Acetohexamide, Guar gum, Simvastatin, Troglitazone, Rosuvastatin", "updated_at": 1767369485}, {"id": 97961, "ingredient1": "Empagliflozin", "ingredient2": "Mecamylamine", "severity": "Moderate", "effect": "Sodium-glucose co-transporter 2 (SGLT-2) inhibitors may potentiate the hypotensive effects of diuretics and other antihypertensive agents or vasodilators. Inhibition of glucose and sodium co-transport produces mild diuresis and transient natriuresis, resulting in intravascular volume contraction. Volume depletion-related adverse reactions including hypotension, postural dizziness, orthostatic hypotension, syncope, and dehydration can occur after initiating treatment with SGLT-2 inhibitors, and the risk may be increased with concomitant use of other agents that can lower blood pressure.", "source": "DDInter", "management_text": "Caution is advised if SGLT-2 inhibitors are coadministered with diuretics and other hypotensive agents, particularly in the elderly and patients with impaired renal function. Prior to initiating SGLT-2 inhibitors, volume status should be assessed and corrected, if necessary. Clinical and laboratory monitoring are recommended during therapy, including electrolytes, fluid status, renal function, and blood pressure. If volume depletion occurs, treatment with SGLT-2 inhibitors should be interrupted until the condition is corrected.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if SGLT-2 inhibitors are coadministered with diuretics and other hypotensive agents, particularly in the elderly and patients with impaired renal function.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/98065/", "reference_text": "[1] \"Product Information. Jardiance (empagliflozin).\" Boehringer Ingelheim, Ridgefield, CT.[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] \"Product Information. Farxiga (dapagliflozin).\" Bristol-Myers Squibb, Princeton, NJ.[5] \"Product Information. Invokana (canagliflozin).\" Janssen Pharmaceuticals, Titusville, NJ.[6] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[7] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[8] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[9] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[10] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[11] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6[12] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[13] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[14] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[15] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42", "alternatives_a": "Glipizide, Acetohexamide, Guar gum, Pramlintide, Alogliptin, Rosuvastatin, Tolazamide, Dulaglutide, Exenatide, Tolbutamide, Miglitol, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 97962, "ingredient1": "Empagliflozin", "ingredient2": "Medroxyprogesterone acetate", "severity": "Moderate", "effect": "The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.", "source": "DDInter", "management_text": "Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.", "mechanism_text": "Antagonism", "recommendation": "Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/98066/", "reference_text": "[1] Jori A, Carrara MC \"On the mechanism of the hyperglycaemic effect of chlorpromazine.\" J Pharm Pharmacol 18 (1966): 623-4[2] \"Product Information. Dymelor (acetohexamide)\" Lilly, Eli and Company, Indianapolis, IN.[3] \"Product Information. Thorazine (chlorpromazine).\" SmithKline Beecham, Philadelphia, PA.[4] Blayac JP, Ribes G, Buys D, Puech R, Loubatieres-Mariani MM \"Effects of a new benzothiadiazine derivative, LN 5330, on insulin secretion.\" Arch Int Pharmacodyn Ther 253 (1981): 154-63[5] \"Product Information. Elzonris (tagraxofusp).\" Stemline Therapeutics, New York, NY.[6] \"Product Information. Amaryl (glimepiride).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[7] \"Product Information. Elspar (asparaginase).\" Merck & Co, Inc, West Point, PA.[8] Jones IG, Pickens PT \"Diabetes mellitus following oral diuretics.\" Practitioner 199 (1967): 209-10[9] \"Product Information. Viracept (nelfinavir).\" Agouron Pharma Inc, La Jolla, CA.[10] \"Product Information. Tolinase (tolazamide)\" Pharmacia and Upjohn, Kalamazoo, MI.[11] Mauss S, Wolf E, Jaeger H \"Impaired glucose tolerance in HIV-positive patients receiving and those not receiving protease inhibitors.\" Ann Intern Med 130 (1999): 162-3[12] Virutamasen P, Wongsrichanalai C, Tangkeo P, Nitichai Y, Rienprayoon D \"Metabolic effects of depot-medroxyprogesterone acetate in long-term users: a cross-sectional study.\" Int J Gynaecol Obstet 24 (1986): 291-6[13] Wehring H, Alexander B, Perry PJ \"Diabetes mellitus associated with clozapine therapy.\" Pharmacotherapy 20 (2000): 844-7[14] Spellacy WN, Ellingson AB, Tsibris JC \"The effects of two triphasic oral contraceptives on carbohydrate metabolism in women during 1 year of use.\" Fertil Steril 51 (1989): 71-4[15] Andersen OO, Persson I \"Carbohydrate metabolism during treatment with chlorthalidone and ethacrynic acid.\" Br Med J 2 (1968): 798-801[16] Berlin I \"Prazosin, diuretics, and glucose intolerance.\" Ann Intern Med 119 (1993): 860[17] Malherbe C, Burrill KC, Levin SR, Karam JH, Forsham PH \"Effect of diphenylhydantoin on insulin secretion in man.\" N Engl J Med 286 (1972): 339-42[18] Carter BL, Small RE, Mandel MD, Starkman MT \"Phenytoin-induced hyperglycemia.\" Am J Hosp Pharm 38 (1981): 1508-12[19] Al-Rubeaan K, Ryan EA \"Phenytoin-induced insulin insensitivity.\" Diabet Med 8 (1991): 968-70[20] \"Product Information. Zolinza (vorinostat).\" Merck & Company Inc, West Point, PA.[21] Goldman JA, Neri A, Ovadia J, Eckerling B, Vries A, de \"Effect of chlorothiazide on intravenous glucose tolerance in pregnancy.\" Am J Obstet Gynecol 105 (1969): 556-60[22] Harper R, Ennis CN, Heaney AP, Sheridan B, Gormley M, Atkinson AB, Johnston GD, Bell PM \"A comparison of the effects of low- and conventional-dose thiazide diuretic on insulin action in hypertensive patients with NIDDM.\" Diabetologia 38 (1995): 853-9[23] Seltzer HS, Allen EW \"Hyperglycemia and inhibition of insulin secretion during administration of diazoxide and trichlormethiazide in man.\" Diabetes 18 (1969): 19-28[24] Dube MP, Johnson DL, Currier JS, Leedom JM \"Protease inhibitor-associated hyperglycaemia.\" Lancet 350 (1997): 713-4[25] Leary WP, Reyes AJ \"Drug interactions with diuretics.\" S Afr Med J 65 (1984): 455-61[26] \"Product Information. Reyataz (atazanavir).\" Bristol-Myers Squibb, Princeton, NJ.[27] Pollare T, Lithell H, Berne C \"A comparison of the effects of hydrochlorothiazide and captopril on glucose and lipid metabolism in patients with hypertension.\" N Engl J Med 321 (1989): 868-73[28] Gunnarsson R, Lundgren G, Magnusson G, Ost L, Groth CG \"Steroid diabetes--a sign of overtreatment with steroids in the renal graft recipient?\" Scand J Urol Nephrol Suppl 54 (1980): 135-8[29] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[30] \"Product Information. Synthroid (levothyroxine).\" Abbott Pharmaceutical, Abbott Park, IL.[31] Murphy MB, Kohner E, Lewis PJ, Schumer B, Dollery CT \"Glucose intolerance in hypertensive patients treated with diuretics: a fourteen-year follow-up.\" Lancet 2 (1982): 1293-5[32] \"Product Information. Fortovase (saquinavir)\" Roche Laboratories, Nutley, NJ.[33] Coni NK, Gordon PW, Mukherjee AP, Read PR \"The effect of frusemide and ethacrynic acid on carbohydrate metabolism.\" Age Ageing 3 (1974): 85-90[34] \"Product Information. Norvir (ritonavir).\" Abbott Pharmaceutical, Abbott Park, IL.[35] Domenet JG \"Diabetogenic effect of oral diuretics.\" Br Med J 3 (1968): 188[36] Rowe P, Mather H \"Hyperosmolar non-ketotic diabetes mellitus associated with metolazone.\" Br Med J 291 (1985): 25-6[37] Winchester JF, Kellett RJ, Boddy K, Boyle P, Dargie HJ, Mahaffey ME, Ward DM, Kennedy AC \"Metolazone and bendroflumethiazide in hypertension: physiologic and metabolic observations.\" Clin Pharmacol Ther 28 (1980): 611-8[38] \"Product Information. Carafate (sucralfate).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[39] Tsiodras S, Mantzoros C, Hammer S, Samore M \"Effects of protease inhibitors on hyperglycemia, hyperlipidemia, and lipodystrophy - A 5-year cohort study.\" Arch Intern Med 160 (2000): 2050-6[40] \"Product Information. Apidra (insulin glulisine).\" Aventis Pharmaceuticals, Bridgewater, NJ.[41] \"Product Information. Prezista (darunavir).\" Ortho Biotech Inc, Bridgewater, NJ.[42] Haiba NA, el-Habashy MA, Said SA, Darwish EA, Abdel-Sayed WS, Nayel SE \"Clinical evaluation of two monthly injectable contraceptives and their effects on some metabolic parameters.\" Contraception 39 (1989): 619-32[43] Erle G, Basso M, Federspil G, Sicolo N, Scandellari C \"Effect of chlorpromazine on blood glucose and plasma insulin in man.\" Eur J Clin Pharmacol 11 (1977): 15-8[44] Pickkers P, Schachter M, Hughes AD, Feher MD, Sever PS \"Thiazide-induced hyperglycaemia: a role for calcium-activated potassium channels?\" Diabetologia 39 (1996): 861-4[45] \"Product Information. Lexiva (fosamprenavir).\" GlaxoSmithKline, Research Triangle Park, NC.[46] Curtis J, Horrigan F, Ahearn D, Varney R, Sandler SG \"Chlorthalidone-induced hyperosmolar hyperglycemic nonketotic coma.\" JAMA 220 (1972): 1592-3[47] \"Product Information. Hyperstat I.V. (diazoxide).\" Schering Corp, Kenilworth, NJ.[48] \"Product Information. Piqray (alpelisib).\" Novartis Pharmaceuticals, East Hanover, NJ.[49] Bell DS \"Insulin resistance. An often unrecognized problem accompanying chronic medical disorders.\" Postgrad Med 93 (1993): 99-103,[50] Stambaugh JE, Tucker DC \"Effect of diphenylhydantoin on glucose tolerance in patients with hypoglycemia.\" Diabetes 23 (1974): 679-83[51] \"Product Information. Crixivan (indinavir).\" Merck & Co, Inc, West Point, PA.[52] Miller NR, Moses H \"Transient oculomotor nerve palsy. Association with thiazide-induced glucose intolerance.\" JAMA 240 (1978): 1887-8[53] Javier Z, Gershberg H, Hulse M \"Ovulatory suppressants, estrogens, and carbohydrate metabolism.\" Metabolism 17 (1968): 443-56[54] Goldman JA, Ovadia JL \"The effect of estrogen on intravenous glucose tolerance in woman.\" Am J Obstet Gynecol 103 (1969): 172-8[55] Charan VD, Desai N, Singh AP, Choudhry VP \"Diabetes mellitus and pancreatitis as a complication of L- asparaginase therapy.\" Indian Pediatr 30 (1993): 809-10[56] Seifer DB, Freedman LN, Cavender JR, Baker RA \"Insulin-dependent diabetes mellitus associated with danazol.\" Am J Obstet Gynecol 162 (1990): 474-5[57] \"Product Information. Orinase (tolbutamide)\" Pharmacia and Upjohn, Kalamazoo, MI.[58] Walli R, Demant T \"Impaired glucose tolerance and protease inhibitors.\" Ann Intern Med 129 (1998): 837-8[59] Hannaford PC, Kay CR \"Oral contraceptives and diabetes mellitus.\" BMJ 299 (1989): 1315-6[60] Hardy H, Esch LD, Morse GD \"Glucose disorders associated with HIV and its drug therapy.\" Ann Pharmacother 35 (2001): 343-51[61] Chowdhury FR, Bleicher SJ \"Chlorthalidone--induced hypokalemia and abnormal carbohydrate metabolism.\" Horm Metab Res 2 (1970): 13-6[62] Kaufman MB, Simionatto C \"A review of protease inhibitor-induced hyperglycemia.\" Pharmacotherapy 19 (1999): 114-7[63] Greenstone MA, Shaw AB \"Alternate day corticosteroid causes alternate day hyperglycaemia.\" Postgrad Med J 63 (1987): 761-4[64] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[65] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[66] Elmfeldt D, Berglund G, Wedel H, Wilhelmsen L \"Incidence and importance of metabolic side-effects during antihypertensive therapy.\" Acta Med Scand Suppl 672 (1983): 79-83[67] \"Product Information. Agenerase (amprenavir).\" Glaxo Wellcome, Research Triangle Pk, NC.[68] Diamond MT \"Hyperglycemic hyperosmolar coma associated with hydrochlorothiazide and pancreatitis.\" N Y State J Med 72 (1972): 1741-2[69] \"Product Information. Prandin (repaglinide).\" Novo Nordisk Pharmaceuticals Inc, Princeton, NJ.[70] \"Product Information. Precose (acarbose).\" Bayer, West Haven, CT.[71] \"Product Information. Starlix (nateglinide)\" Novartis Pharmaceuticals, East Hanover, NJ.[72] \"Product Information. Oncaspar (pegaspargase).\" Rhone-Poulenc Rorer, Collegeville, PA.[73] Sotaniemi E, Kontturi M, Larmi T \"Effect of diethylstilbestrol on blood glucose of prostatic cancer patients.\" Invest Urol 10 (1973): 438-41[74] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[75] Petri M, Cumber P, Grimes L, Treby D, Bryant R, Rawlins D, Ising H \"The metabolic effects of thiazide therapy in the elderly: a population study.\" Age Ageing 15 (1986): 151-5[76] Ludvik B, Clodi M, Kautzky-Willer A, Capek M, Hartter E, Pacini G, Prager R \"Effect of dexamethasone on insulin sensitivity, islet amyloid polypeptide and insulin secretion in humans.\" Diabetologia 36 (1993): 84-7[77] \"Product Information. Glucophage (metformin).\" Bristol-Myers Squibb, Princeton, NJ.[78] Chaudhuri ML, Catania J \"A comparison of the effects of bumetanide (Burinex) and frusemide on carbohydrate metabolism in the elderly.\" Br J Clin Pract 42 (1988): 427-9[79] Black DM, Filak AT \"Hyperglycemia with non-insulin-dependent diabetes following intraarticular steroid injection.\" J Fam Pract 28 (1989): 462-3[80] \"Product Information. Megace (megestrol).\" Bristol-Myers Squibb, Princeton, NJ.[81] \"Product Information. Torisel (temsirolimus).\" Wyeth-Ayerst Laboratories, Philadelphia, PA.[82] Schmitz O, Hermansen K, Nielsen OH, Christensen CK, Arnfred J, Hansen HE, Mogensen CE, Orskov H, Beck-Nielsen H \"Insulin action in insulin-dependent diabetics after short-term thiazide therapy.\" Diabetes Care 9 (1986): 631-6[83] Kansal PC, Buse J, Buse MG \"Thiazide diuretics and control of diabetes mellitus.\" South Med J 62 (1969): 1372-9[84] Dimitriadis G, Tegos C, Golfinopoulou L, Roboti C, Raptis S \"Furosemide-induced hyperglycaemia - the implication of glycolytic kinases.\" Horm Metab Res 25 (1993): 557-9[85] \"Product Information. NovoLog Mix 70/30 (insulin aspart-insulin aspart protamine).\" Novo Nordisk Pharmaceuticals Inc, Princeton, NJ.[86] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[87] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[88] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[89] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42[90] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[91] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[92] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[93] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[94] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[95] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6", "alternatives_a": "Ulipristal, Norelgestromin, Bicalutamide", "alternatives_b": "Simvastatin, Guar gum", "updated_at": 1767369485}, {"id": 97963, "ingredient1": "Empagliflozin", "ingredient2": "Megestrol acetate", "severity": "Moderate", "effect": "The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.", "source": "DDInter", "management_text": "Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.", "mechanism_text": "Antagonism", "recommendation": "Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/98067/", "reference_text": "[1] Jori A, Carrara MC \"On the mechanism of the hyperglycaemic effect of chlorpromazine.\" J Pharm Pharmacol 18 (1966): 623-4[2] \"Product Information. Dymelor (acetohexamide)\" Lilly, Eli and Company, Indianapolis, IN.[3] \"Product Information. Thorazine (chlorpromazine).\" SmithKline Beecham, Philadelphia, PA.[4] Blayac JP, Ribes G, Buys D, Puech R, Loubatieres-Mariani MM \"Effects of a new benzothiadiazine derivative, LN 5330, on insulin secretion.\" Arch Int Pharmacodyn Ther 253 (1981): 154-63[5] \"Product Information. Elzonris (tagraxofusp).\" Stemline Therapeutics, New York, NY.[6] \"Product Information. Amaryl (glimepiride).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[7] \"Product Information. Elspar (asparaginase).\" Merck & Co, Inc, West Point, PA.[8] Jones IG, Pickens PT \"Diabetes mellitus following oral diuretics.\" Practitioner 199 (1967): 209-10[9] \"Product Information. Viracept (nelfinavir).\" Agouron Pharma Inc, La Jolla, CA.[10] \"Product Information. Tolinase (tolazamide)\" Pharmacia and Upjohn, Kalamazoo, MI.[11] Mauss S, Wolf E, Jaeger H \"Impaired glucose tolerance in HIV-positive patients receiving and those not receiving protease inhibitors.\" Ann Intern Med 130 (1999): 162-3[12] Virutamasen P, Wongsrichanalai C, Tangkeo P, Nitichai Y, Rienprayoon D \"Metabolic effects of depot-medroxyprogesterone acetate in long-term users: a cross-sectional study.\" Int J Gynaecol Obstet 24 (1986): 291-6[13] Wehring H, Alexander B, Perry PJ \"Diabetes mellitus associated with clozapine therapy.\" Pharmacotherapy 20 (2000): 844-7[14] Spellacy WN, Ellingson AB, Tsibris JC \"The effects of two triphasic oral contraceptives on carbohydrate metabolism in women during 1 year of use.\" Fertil Steril 51 (1989): 71-4[15] Andersen OO, Persson I \"Carbohydrate metabolism during treatment with chlorthalidone and ethacrynic acid.\" Br Med J 2 (1968): 798-801[16] Berlin I \"Prazosin, diuretics, and glucose intolerance.\" Ann Intern Med 119 (1993): 860[17] Malherbe C, Burrill KC, Levin SR, Karam JH, Forsham PH \"Effect of diphenylhydantoin on insulin secretion in man.\" N Engl J Med 286 (1972): 339-42[18] Carter BL, Small RE, Mandel MD, Starkman MT \"Phenytoin-induced hyperglycemia.\" Am J Hosp Pharm 38 (1981): 1508-12[19] Al-Rubeaan K, Ryan EA \"Phenytoin-induced insulin insensitivity.\" Diabet Med 8 (1991): 968-70[20] \"Product Information. Zolinza (vorinostat).\" Merck & Company Inc, West Point, PA.[21] Goldman JA, Neri A, Ovadia J, Eckerling B, Vries A, de \"Effect of chlorothiazide on intravenous glucose tolerance in pregnancy.\" Am J Obstet Gynecol 105 (1969): 556-60[22] Harper R, Ennis CN, Heaney AP, Sheridan B, Gormley M, Atkinson AB, Johnston GD, Bell PM \"A comparison of the effects of low- and conventional-dose thiazide diuretic on insulin action in hypertensive patients with NIDDM.\" Diabetologia 38 (1995): 853-9[23] Seltzer HS, Allen EW \"Hyperglycemia and inhibition of insulin secretion during administration of diazoxide and trichlormethiazide in man.\" Diabetes 18 (1969): 19-28[24] Dube MP, Johnson DL, Currier JS, Leedom JM \"Protease inhibitor-associated hyperglycaemia.\" Lancet 350 (1997): 713-4[25] Leary WP, Reyes AJ \"Drug interactions with diuretics.\" S Afr Med J 65 (1984): 455-61[26] \"Product Information. Reyataz (atazanavir).\" Bristol-Myers Squibb, Princeton, NJ.[27] Pollare T, Lithell H, Berne C \"A comparison of the effects of hydrochlorothiazide and captopril on glucose and lipid metabolism in patients with hypertension.\" N Engl J Med 321 (1989): 868-73[28] Gunnarsson R, Lundgren G, Magnusson G, Ost L, Groth CG \"Steroid diabetes--a sign of overtreatment with steroids in the renal graft recipient?\" Scand J Urol Nephrol Suppl 54 (1980): 135-8[29] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[30] \"Product Information. Synthroid (levothyroxine).\" Abbott Pharmaceutical, Abbott Park, IL.[31] Murphy MB, Kohner E, Lewis PJ, Schumer B, Dollery CT \"Glucose intolerance in hypertensive patients treated with diuretics: a fourteen-year follow-up.\" Lancet 2 (1982): 1293-5[32] \"Product Information. Fortovase (saquinavir)\" Roche Laboratories, Nutley, NJ.[33] Coni NK, Gordon PW, Mukherjee AP, Read PR \"The effect of frusemide and ethacrynic acid on carbohydrate metabolism.\" Age Ageing 3 (1974): 85-90[34] \"Product Information. Norvir (ritonavir).\" Abbott Pharmaceutical, Abbott Park, IL.[35] Domenet JG \"Diabetogenic effect of oral diuretics.\" Br Med J 3 (1968): 188[36] Rowe P, Mather H \"Hyperosmolar non-ketotic diabetes mellitus associated with metolazone.\" Br Med J 291 (1985): 25-6[37] Winchester JF, Kellett RJ, Boddy K, Boyle P, Dargie HJ, Mahaffey ME, Ward DM, Kennedy AC \"Metolazone and bendroflumethiazide in hypertension: physiologic and metabolic observations.\" Clin Pharmacol Ther 28 (1980): 611-8[38] \"Product Information. Carafate (sucralfate).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[39] Tsiodras S, Mantzoros C, Hammer S, Samore M \"Effects of protease inhibitors on hyperglycemia, hyperlipidemia, and lipodystrophy - A 5-year cohort study.\" Arch Intern Med 160 (2000): 2050-6[40] \"Product Information. Apidra (insulin glulisine).\" Aventis Pharmaceuticals, Bridgewater, NJ.[41] \"Product Information. Prezista (darunavir).\" Ortho Biotech Inc, Bridgewater, NJ.[42] Haiba NA, el-Habashy MA, Said SA, Darwish EA, Abdel-Sayed WS, Nayel SE \"Clinical evaluation of two monthly injectable contraceptives and their effects on some metabolic parameters.\" Contraception 39 (1989): 619-32[43] Erle G, Basso M, Federspil G, Sicolo N, Scandellari C \"Effect of chlorpromazine on blood glucose and plasma insulin in man.\" Eur J Clin Pharmacol 11 (1977): 15-8[44] Pickkers P, Schachter M, Hughes AD, Feher MD, Sever PS \"Thiazide-induced hyperglycaemia: a role for calcium-activated potassium channels?\" Diabetologia 39 (1996): 861-4[45] \"Product Information. Lexiva (fosamprenavir).\" GlaxoSmithKline, Research Triangle Park, NC.[46] Curtis J, Horrigan F, Ahearn D, Varney R, Sandler SG \"Chlorthalidone-induced hyperosmolar hyperglycemic nonketotic coma.\" JAMA 220 (1972): 1592-3[47] \"Product Information. Hyperstat I.V. (diazoxide).\" Schering Corp, Kenilworth, NJ.[48] \"Product Information. Piqray (alpelisib).\" Novartis Pharmaceuticals, East Hanover, NJ.[49] Bell DS \"Insulin resistance. An often unrecognized problem accompanying chronic medical disorders.\" Postgrad Med 93 (1993): 99-103,[50] Stambaugh JE, Tucker DC \"Effect of diphenylhydantoin on glucose tolerance in patients with hypoglycemia.\" Diabetes 23 (1974): 679-83[51] \"Product Information. Crixivan (indinavir).\" Merck & Co, Inc, West Point, PA.[52] Miller NR, Moses H \"Transient oculomotor nerve palsy. Association with thiazide-induced glucose intolerance.\" JAMA 240 (1978): 1887-8[53] Javier Z, Gershberg H, Hulse M \"Ovulatory suppressants, estrogens, and carbohydrate metabolism.\" Metabolism 17 (1968): 443-56[54] Goldman JA, Ovadia JL \"The effect of estrogen on intravenous glucose tolerance in woman.\" Am J Obstet Gynecol 103 (1969): 172-8[55] Charan VD, Desai N, Singh AP, Choudhry VP \"Diabetes mellitus and pancreatitis as a complication of L- asparaginase therapy.\" Indian Pediatr 30 (1993): 809-10[56] Seifer DB, Freedman LN, Cavender JR, Baker RA \"Insulin-dependent diabetes mellitus associated with danazol.\" Am J Obstet Gynecol 162 (1990): 474-5[57] \"Product Information. Orinase (tolbutamide)\" Pharmacia and Upjohn, Kalamazoo, MI.[58] Walli R, Demant T \"Impaired glucose tolerance and protease inhibitors.\" Ann Intern Med 129 (1998): 837-8[59] Hannaford PC, Kay CR \"Oral contraceptives and diabetes mellitus.\" BMJ 299 (1989): 1315-6[60] Hardy H, Esch LD, Morse GD \"Glucose disorders associated with HIV and its drug therapy.\" Ann Pharmacother 35 (2001): 343-51[61] Chowdhury FR, Bleicher SJ \"Chlorthalidone--induced hypokalemia and abnormal carbohydrate metabolism.\" Horm Metab Res 2 (1970): 13-6[62] Kaufman MB, Simionatto C \"A review of protease inhibitor-induced hyperglycemia.\" Pharmacotherapy 19 (1999): 114-7[63] Greenstone MA, Shaw AB \"Alternate day corticosteroid causes alternate day hyperglycaemia.\" Postgrad Med J 63 (1987): 761-4[64] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[65] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[66] Elmfeldt D, Berglund G, Wedel H, Wilhelmsen L \"Incidence and importance of metabolic side-effects during antihypertensive therapy.\" Acta Med Scand Suppl 672 (1983): 79-83[67] \"Product Information. Agenerase (amprenavir).\" Glaxo Wellcome, Research Triangle Pk, NC.[68] Diamond MT \"Hyperglycemic hyperosmolar coma associated with hydrochlorothiazide and pancreatitis.\" N Y State J Med 72 (1972): 1741-2[69] \"Product Information. Prandin (repaglinide).\" Novo Nordisk Pharmaceuticals Inc, Princeton, NJ.[70] \"Product Information. Precose (acarbose).\" Bayer, West Haven, CT.[71] \"Product Information. Starlix (nateglinide)\" Novartis Pharmaceuticals, East Hanover, NJ.[72] \"Product Information. Oncaspar (pegaspargase).\" Rhone-Poulenc Rorer, Collegeville, PA.[73] Sotaniemi E, Kontturi M, Larmi T \"Effect of diethylstilbestrol on blood glucose of prostatic cancer patients.\" Invest Urol 10 (1973): 438-41[74] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[75] Petri M, Cumber P, Grimes L, Treby D, Bryant R, Rawlins D, Ising H \"The metabolic effects of thiazide therapy in the elderly: a population study.\" Age Ageing 15 (1986): 151-5[76] Ludvik B, Clodi M, Kautzky-Willer A, Capek M, Hartter E, Pacini G, Prager R \"Effect of dexamethasone on insulin sensitivity, islet amyloid polypeptide and insulin secretion in humans.\" Diabetologia 36 (1993): 84-7[77] \"Product Information. Glucophage (metformin).\" Bristol-Myers Squibb, Princeton, NJ.[78] Chaudhuri ML, Catania J \"A comparison of the effects of bumetanide (Burinex) and frusemide on carbohydrate metabolism in the elderly.\" Br J Clin Pract 42 (1988): 427-9[79] Black DM, Filak AT \"Hyperglycemia with non-insulin-dependent diabetes following intraarticular steroid injection.\" J Fam Pract 28 (1989): 462-3[80] \"Product Information. Megace (megestrol).\" Bristol-Myers Squibb, Princeton, NJ.[81] \"Product Information. Torisel (temsirolimus).\" Wyeth-Ayerst Laboratories, Philadelphia, PA.[82] Schmitz O, Hermansen K, Nielsen OH, Christensen CK, Arnfred J, Hansen HE, Mogensen CE, Orskov H, Beck-Nielsen H \"Insulin action in insulin-dependent diabetics after short-term thiazide therapy.\" Diabetes Care 9 (1986): 631-6[83] Kansal PC, Buse J, Buse MG \"Thiazide diuretics and control of diabetes mellitus.\" South Med J 62 (1969): 1372-9[84] Dimitriadis G, Tegos C, Golfinopoulou L, Roboti C, Raptis S \"Furosemide-induced hyperglycaemia - the implication of glycolytic kinases.\" Horm Metab Res 25 (1993): 557-9[85] \"Product Information. NovoLog Mix 70/30 (insulin aspart-insulin aspart protamine).\" Novo Nordisk Pharmaceuticals Inc, Princeton, NJ.[86] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[87] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[88] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[89] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42[90] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[91] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[92] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[93] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[94] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[95] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6", "alternatives_a": "Ulipristal, Norelgestromin, Bicalutamide", "alternatives_b": "Simvastatin, Guar gum, Rosuvastatin", "updated_at": 1767369485}, {"id": 97964, "ingredient1": "Empagliflozin", "ingredient2": "Mephentermine", "severity": "Moderate", "effect": "The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.", "source": "DDInter", "management_text": "Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.", "mechanism_text": "Antagonism", "recommendation": "Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/98068/", "reference_text": "[1] Jori A, Carrara MC \"On the mechanism of the hyperglycaemic effect of chlorpromazine.\" J Pharm Pharmacol 18 (1966): 623-4[2] \"Product Information. Dymelor (acetohexamide)\" Lilly, Eli and Company, Indianapolis, IN.[3] \"Product Information. Thorazine (chlorpromazine).\" SmithKline Beecham, Philadelphia, PA.[4] Blayac JP, Ribes G, Buys D, Puech R, Loubatieres-Mariani MM \"Effects of a new benzothiadiazine derivative, LN 5330, on insulin secretion.\" Arch Int Pharmacodyn Ther 253 (1981): 154-63[5] \"Product Information. Elzonris (tagraxofusp).\" Stemline Therapeutics, New York, NY.[6] \"Product Information. Amaryl (glimepiride).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[7] \"Product Information. Elspar (asparaginase).\" Merck & Co, Inc, West Point, PA.[8] Jones IG, Pickens PT \"Diabetes mellitus following oral diuretics.\" Practitioner 199 (1967): 209-10[9] \"Product Information. Viracept (nelfinavir).\" Agouron Pharma Inc, La Jolla, CA.[10] \"Product Information. Tolinase (tolazamide)\" Pharmacia and Upjohn, Kalamazoo, MI.[11] Mauss S, Wolf E, Jaeger H \"Impaired glucose tolerance in HIV-positive patients receiving and those not receiving protease inhibitors.\" Ann Intern Med 130 (1999): 162-3[12] Virutamasen P, Wongsrichanalai C, Tangkeo P, Nitichai Y, Rienprayoon D \"Metabolic effects of depot-medroxyprogesterone acetate in long-term users: a cross-sectional study.\" Int J Gynaecol Obstet 24 (1986): 291-6[13] Wehring H, Alexander B, Perry PJ \"Diabetes mellitus associated with clozapine therapy.\" Pharmacotherapy 20 (2000): 844-7[14] Spellacy WN, Ellingson AB, Tsibris JC \"The effects of two triphasic oral contraceptives on carbohydrate metabolism in women during 1 year of use.\" Fertil Steril 51 (1989): 71-4[15] Andersen OO, Persson I \"Carbohydrate metabolism during treatment with chlorthalidone and ethacrynic acid.\" Br Med J 2 (1968): 798-801[16] Berlin I \"Prazosin, diuretics, and glucose intolerance.\" Ann Intern Med 119 (1993): 860[17] Malherbe C, Burrill KC, Levin SR, Karam JH, Forsham PH \"Effect of diphenylhydantoin on insulin secretion in man.\" N Engl J Med 286 (1972): 339-42[18] Carter BL, Small RE, Mandel MD, Starkman MT \"Phenytoin-induced hyperglycemia.\" Am J Hosp Pharm 38 (1981): 1508-12[19] Al-Rubeaan K, Ryan EA \"Phenytoin-induced insulin insensitivity.\" Diabet Med 8 (1991): 968-70[20] \"Product Information. Zolinza (vorinostat).\" Merck & Company Inc, West Point, PA.[21] Goldman JA, Neri A, Ovadia J, Eckerling B, Vries A, de \"Effect of chlorothiazide on intravenous glucose tolerance in pregnancy.\" Am J Obstet Gynecol 105 (1969): 556-60[22] Harper R, Ennis CN, Heaney AP, Sheridan B, Gormley M, Atkinson AB, Johnston GD, Bell PM \"A comparison of the effects of low- and conventional-dose thiazide diuretic on insulin action in hypertensive patients with NIDDM.\" Diabetologia 38 (1995): 853-9[23] Seltzer HS, Allen EW \"Hyperglycemia and inhibition of insulin secretion during administration of diazoxide and trichlormethiazide in man.\" Diabetes 18 (1969): 19-28[24] Dube MP, Johnson DL, Currier JS, Leedom JM \"Protease inhibitor-associated hyperglycaemia.\" Lancet 350 (1997): 713-4[25] Leary WP, Reyes AJ \"Drug interactions with diuretics.\" S Afr Med J 65 (1984): 455-61[26] \"Product Information. Reyataz (atazanavir).\" Bristol-Myers Squibb, Princeton, NJ.[27] Pollare T, Lithell H, Berne C \"A comparison of the effects of hydrochlorothiazide and captopril on glucose and lipid metabolism in patients with hypertension.\" N Engl J Med 321 (1989): 868-73[28] Gunnarsson R, Lundgren G, Magnusson G, Ost L, Groth CG \"Steroid diabetes--a sign of overtreatment with steroids in the renal graft recipient?\" Scand J Urol Nephrol Suppl 54 (1980): 135-8[29] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[30] \"Product Information. Synthroid (levothyroxine).\" Abbott Pharmaceutical, Abbott Park, IL.[31] Murphy MB, Kohner E, Lewis PJ, Schumer B, Dollery CT \"Glucose intolerance in hypertensive patients treated with diuretics: a fourteen-year follow-up.\" Lancet 2 (1982): 1293-5[32] \"Product Information. Fortovase (saquinavir)\" Roche Laboratories, Nutley, NJ.[33] Coni NK, Gordon PW, Mukherjee AP, Read PR \"The effect of frusemide and ethacrynic acid on carbohydrate metabolism.\" Age Ageing 3 (1974): 85-90[34] \"Product Information. Norvir (ritonavir).\" Abbott Pharmaceutical, Abbott Park, IL.[35] Domenet JG \"Diabetogenic effect of oral diuretics.\" Br Med J 3 (1968): 188[36] Rowe P, Mather H \"Hyperosmolar non-ketotic diabetes mellitus associated with metolazone.\" Br Med J 291 (1985): 25-6[37] Winchester JF, Kellett RJ, Boddy K, Boyle P, Dargie HJ, Mahaffey ME, Ward DM, Kennedy AC \"Metolazone and bendroflumethiazide in hypertension: physiologic and metabolic observations.\" Clin Pharmacol Ther 28 (1980): 611-8[38] \"Product Information. Carafate (sucralfate).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[39] Tsiodras S, Mantzoros C, Hammer S, Samore M \"Effects of protease inhibitors on hyperglycemia, hyperlipidemia, and lipodystrophy - A 5-year cohort study.\" Arch Intern Med 160 (2000): 2050-6[40] \"Product Information. Apidra (insulin glulisine).\" Aventis Pharmaceuticals, Bridgewater, NJ.[41] \"Product Information. Prezista (darunavir).\" Ortho Biotech Inc, Bridgewater, NJ.[42] Haiba NA, el-Habashy MA, Said SA, Darwish EA, Abdel-Sayed WS, Nayel SE \"Clinical evaluation of two monthly injectable contraceptives and their effects on some metabolic parameters.\" Contraception 39 (1989): 619-32[43] Erle G, Basso M, Federspil G, Sicolo N, Scandellari C \"Effect of chlorpromazine on blood glucose and plasma insulin in man.\" Eur J Clin Pharmacol 11 (1977): 15-8[44] Pickkers P, Schachter M, Hughes AD, Feher MD, Sever PS \"Thiazide-induced hyperglycaemia: a role for calcium-activated potassium channels?\" Diabetologia 39 (1996): 861-4[45] \"Product Information. Lexiva (fosamprenavir).\" GlaxoSmithKline, Research Triangle Park, NC.[46] Curtis J, Horrigan F, Ahearn D, Varney R, Sandler SG \"Chlorthalidone-induced hyperosmolar hyperglycemic nonketotic coma.\" JAMA 220 (1972): 1592-3[47] \"Product Information. Hyperstat I.V. (diazoxide).\" Schering Corp, Kenilworth, NJ.[48] \"Product Information. Piqray (alpelisib).\" Novartis Pharmaceuticals, East Hanover, NJ.[49] Bell DS \"Insulin resistance. An often unrecognized problem accompanying chronic medical disorders.\" Postgrad Med 93 (1993): 99-103,[50] Stambaugh JE, Tucker DC \"Effect of diphenylhydantoin on glucose tolerance in patients with hypoglycemia.\" Diabetes 23 (1974): 679-83[51] \"Product Information. Crixivan (indinavir).\" Merck & Co, Inc, West Point, PA.[52] Miller NR, Moses H \"Transient oculomotor nerve palsy. Association with thiazide-induced glucose intolerance.\" JAMA 240 (1978): 1887-8[53] Javier Z, Gershberg H, Hulse M \"Ovulatory suppressants, estrogens, and carbohydrate metabolism.\" Metabolism 17 (1968): 443-56[54] Goldman JA, Ovadia JL \"The effect of estrogen on intravenous glucose tolerance in woman.\" Am J Obstet Gynecol 103 (1969): 172-8[55] Charan VD, Desai N, Singh AP, Choudhry VP \"Diabetes mellitus and pancreatitis as a complication of L- asparaginase therapy.\" Indian Pediatr 30 (1993): 809-10[56] Seifer DB, Freedman LN, Cavender JR, Baker RA \"Insulin-dependent diabetes mellitus associated with danazol.\" Am J Obstet Gynecol 162 (1990): 474-5[57] \"Product Information. Orinase (tolbutamide)\" Pharmacia and Upjohn, Kalamazoo, MI.[58] Walli R, Demant T \"Impaired glucose tolerance and protease inhibitors.\" Ann Intern Med 129 (1998): 837-8[59] Hannaford PC, Kay CR \"Oral contraceptives and diabetes mellitus.\" BMJ 299 (1989): 1315-6[60] Hardy H, Esch LD, Morse GD \"Glucose disorders associated with HIV and its drug therapy.\" Ann Pharmacother 35 (2001): 343-51[61] Chowdhury FR, Bleicher SJ \"Chlorthalidone--induced hypokalemia and abnormal carbohydrate metabolism.\" Horm Metab Res 2 (1970): 13-6[62] Kaufman MB, Simionatto C \"A review of protease inhibitor-induced hyperglycemia.\" Pharmacotherapy 19 (1999): 114-7[63] Greenstone MA, Shaw AB \"Alternate day corticosteroid causes alternate day hyperglycaemia.\" Postgrad Med J 63 (1987): 761-4[64] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[65] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[66] Elmfeldt D, Berglund G, Wedel H, Wilhelmsen L \"Incidence and importance of metabolic side-effects during antihypertensive therapy.\" Acta Med Scand Suppl 672 (1983): 79-83[67] \"Product Information. Agenerase (amprenavir).\" Glaxo Wellcome, Research Triangle Pk, NC.[68] Diamond MT \"Hyperglycemic hyperosmolar coma associated with hydrochlorothiazide and pancreatitis.\" N Y State J Med 72 (1972): 1741-2[69] \"Product Information. Prandin (repaglinide).\" Novo Nordisk Pharmaceuticals Inc, Princeton, NJ.[70] \"Product Information. Precose (acarbose).\" Bayer, West Haven, CT.[71] \"Product Information. Starlix (nateglinide)\" Novartis Pharmaceuticals, East Hanover, NJ.[72] \"Product Information. Oncaspar (pegaspargase).\" Rhone-Poulenc Rorer, Collegeville, PA.[73] Sotaniemi E, Kontturi M, Larmi T \"Effect of diethylstilbestrol on blood glucose of prostatic cancer patients.\" Invest Urol 10 (1973): 438-41[74] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[75] Petri M, Cumber P, Grimes L, Treby D, Bryant R, Rawlins D, Ising H \"The metabolic effects of thiazide therapy in the elderly: a population study.\" Age Ageing 15 (1986): 151-5[76] Ludvik B, Clodi M, Kautzky-Willer A, Capek M, Hartter E, Pacini G, Prager R \"Effect of dexamethasone on insulin sensitivity, islet amyloid polypeptide and insulin secretion in humans.\" Diabetologia 36 (1993): 84-7[77] \"Product Information. Glucophage (metformin).\" Bristol-Myers Squibb, Princeton, NJ.[78] Chaudhuri ML, Catania J \"A comparison of the effects of bumetanide (Burinex) and frusemide on carbohydrate metabolism in the elderly.\" Br J Clin Pract 42 (1988): 427-9[79] Black DM, Filak AT \"Hyperglycemia with non-insulin-dependent diabetes following intraarticular steroid injection.\" J Fam Pract 28 (1989): 462-3[80] \"Product Information. Megace (megestrol).\" Bristol-Myers Squibb, Princeton, NJ.[81] \"Product Information. Torisel (temsirolimus).\" Wyeth-Ayerst Laboratories, Philadelphia, PA.[82] Schmitz O, Hermansen K, Nielsen OH, Christensen CK, Arnfred J, Hansen HE, Mogensen CE, Orskov H, Beck-Nielsen H \"Insulin action in insulin-dependent diabetics after short-term thiazide therapy.\" Diabetes Care 9 (1986): 631-6[83] Kansal PC, Buse J, Buse MG \"Thiazide diuretics and control of diabetes mellitus.\" South Med J 62 (1969): 1372-9[84] Dimitriadis G, Tegos C, Golfinopoulou L, Roboti C, Raptis S \"Furosemide-induced hyperglycaemia - the implication of glycolytic kinases.\" Horm Metab Res 25 (1993): 557-9[85] \"Product Information. NovoLog Mix 70/30 (insulin aspart-insulin aspart protamine).\" Novo Nordisk Pharmaceuticals Inc, Princeton, NJ.[86] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[87] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[88] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[89] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42[90] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[91] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[92] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[93] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[94] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[95] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6", "alternatives_a": "Droxidopa, Midodrine, Amrinone, Angiotensin II, Milrinone, Arbutamine", "alternatives_b": "Acetohexamide, Guar gum, Simvastatin, Troglitazone, Rosuvastatin", "updated_at": 1767369485}, {"id": 97965, "ingredient1": "Empagliflozin", "ingredient2": "Mesoridazine", "severity": "Moderate", "effect": "The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.", "source": "DDInter", "management_text": "Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.", "mechanism_text": "Antagonism", "recommendation": "Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/98069/", "reference_text": "[1] Jori A, Carrara MC \"On the mechanism of the hyperglycaemic effect of chlorpromazine.\" J Pharm Pharmacol 18 (1966): 623-4[2] \"Product Information. Dymelor (acetohexamide)\" Lilly, Eli and Company, Indianapolis, IN.[3] \"Product Information. Thorazine (chlorpromazine).\" SmithKline Beecham, Philadelphia, PA.[4] Blayac JP, Ribes G, Buys D, Puech R, Loubatieres-Mariani MM \"Effects of a new benzothiadiazine derivative, LN 5330, on insulin secretion.\" Arch Int Pharmacodyn Ther 253 (1981): 154-63[5] \"Product Information. Elzonris (tagraxofusp).\" Stemline Therapeutics, New York, NY.[6] \"Product Information. Amaryl (glimepiride).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[7] \"Product Information. Elspar (asparaginase).\" Merck & Co, Inc, West Point, PA.[8] Jones IG, Pickens PT \"Diabetes mellitus following oral diuretics.\" Practitioner 199 (1967): 209-10[9] \"Product Information. Viracept (nelfinavir).\" Agouron Pharma Inc, La Jolla, CA.[10] \"Product Information. Tolinase (tolazamide)\" Pharmacia and Upjohn, Kalamazoo, MI.[11] Mauss S, Wolf E, Jaeger H \"Impaired glucose tolerance in HIV-positive patients receiving and those not receiving protease inhibitors.\" Ann Intern Med 130 (1999): 162-3[12] Virutamasen P, Wongsrichanalai C, Tangkeo P, Nitichai Y, Rienprayoon D \"Metabolic effects of depot-medroxyprogesterone acetate in long-term users: a cross-sectional study.\" Int J Gynaecol Obstet 24 (1986): 291-6[13] Wehring H, Alexander B, Perry PJ \"Diabetes mellitus associated with clozapine therapy.\" Pharmacotherapy 20 (2000): 844-7[14] Spellacy WN, Ellingson AB, Tsibris JC \"The effects of two triphasic oral contraceptives on carbohydrate metabolism in women during 1 year of use.\" Fertil Steril 51 (1989): 71-4[15] Andersen OO, Persson I \"Carbohydrate metabolism during treatment with chlorthalidone and ethacrynic acid.\" Br Med J 2 (1968): 798-801[16] Berlin I \"Prazosin, diuretics, and glucose intolerance.\" Ann Intern Med 119 (1993): 860[17] Malherbe C, Burrill KC, Levin SR, Karam JH, Forsham PH \"Effect of diphenylhydantoin on insulin secretion in man.\" N Engl J Med 286 (1972): 339-42[18] Carter BL, Small RE, Mandel MD, Starkman MT \"Phenytoin-induced hyperglycemia.\" Am J Hosp Pharm 38 (1981): 1508-12[19] Al-Rubeaan K, Ryan EA \"Phenytoin-induced insulin insensitivity.\" Diabet Med 8 (1991): 968-70[20] \"Product Information. Zolinza (vorinostat).\" Merck & Company Inc, West Point, PA.[21] Goldman JA, Neri A, Ovadia J, Eckerling B, Vries A, de \"Effect of chlorothiazide on intravenous glucose tolerance in pregnancy.\" Am J Obstet Gynecol 105 (1969): 556-60[22] Harper R, Ennis CN, Heaney AP, Sheridan B, Gormley M, Atkinson AB, Johnston GD, Bell PM \"A comparison of the effects of low- and conventional-dose thiazide diuretic on insulin action in hypertensive patients with NIDDM.\" Diabetologia 38 (1995): 853-9[23] Seltzer HS, Allen EW \"Hyperglycemia and inhibition of insulin secretion during administration of diazoxide and trichlormethiazide in man.\" Diabetes 18 (1969): 19-28[24] Dube MP, Johnson DL, Currier JS, Leedom JM \"Protease inhibitor-associated hyperglycaemia.\" Lancet 350 (1997): 713-4[25] Leary WP, Reyes AJ \"Drug interactions with diuretics.\" S Afr Med J 65 (1984): 455-61[26] \"Product Information. Reyataz (atazanavir).\" Bristol-Myers Squibb, Princeton, NJ.[27] Pollare T, Lithell H, Berne C \"A comparison of the effects of hydrochlorothiazide and captopril on glucose and lipid metabolism in patients with hypertension.\" N Engl J Med 321 (1989): 868-73[28] Gunnarsson R, Lundgren G, Magnusson G, Ost L, Groth CG \"Steroid diabetes--a sign of overtreatment with steroids in the renal graft recipient?\" Scand J Urol Nephrol Suppl 54 (1980): 135-8[29] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[30] \"Product Information. Synthroid (levothyroxine).\" Abbott Pharmaceutical, Abbott Park, IL.[31] Murphy MB, Kohner E, Lewis PJ, Schumer B, Dollery CT \"Glucose intolerance in hypertensive patients treated with diuretics: a fourteen-year follow-up.\" Lancet 2 (1982): 1293-5[32] \"Product Information. Fortovase (saquinavir)\" Roche Laboratories, Nutley, NJ.[33] Coni NK, Gordon PW, Mukherjee AP, Read PR \"The effect of frusemide and ethacrynic acid on carbohydrate metabolism.\" Age Ageing 3 (1974): 85-90[34] \"Product Information. Norvir (ritonavir).\" Abbott Pharmaceutical, Abbott Park, IL.[35] Domenet JG \"Diabetogenic effect of oral diuretics.\" Br Med J 3 (1968): 188[36] Rowe P, Mather H \"Hyperosmolar non-ketotic diabetes mellitus associated with metolazone.\" Br Med J 291 (1985): 25-6[37] Winchester JF, Kellett RJ, Boddy K, Boyle P, Dargie HJ, Mahaffey ME, Ward DM, Kennedy AC \"Metolazone and bendroflumethiazide in hypertension: physiologic and metabolic observations.\" Clin Pharmacol Ther 28 (1980): 611-8[38] \"Product Information. Carafate (sucralfate).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[39] Tsiodras S, Mantzoros C, Hammer S, Samore M \"Effects of protease inhibitors on hyperglycemia, hyperlipidemia, and lipodystrophy - A 5-year cohort study.\" Arch Intern Med 160 (2000): 2050-6[40] \"Product Information. Apidra (insulin glulisine).\" Aventis Pharmaceuticals, Bridgewater, NJ.[41] \"Product Information. Prezista (darunavir).\" Ortho Biotech Inc, Bridgewater, NJ.[42] Haiba NA, el-Habashy MA, Said SA, Darwish EA, Abdel-Sayed WS, Nayel SE \"Clinical evaluation of two monthly injectable contraceptives and their effects on some metabolic parameters.\" Contraception 39 (1989): 619-32[43] Erle G, Basso M, Federspil G, Sicolo N, Scandellari C \"Effect of chlorpromazine on blood glucose and plasma insulin in man.\" Eur J Clin Pharmacol 11 (1977): 15-8[44] Pickkers P, Schachter M, Hughes AD, Feher MD, Sever PS \"Thiazide-induced hyperglycaemia: a role for calcium-activated potassium channels?\" Diabetologia 39 (1996): 861-4[45] \"Product Information. Lexiva (fosamprenavir).\" GlaxoSmithKline, Research Triangle Park, NC.[46] Curtis J, Horrigan F, Ahearn D, Varney R, Sandler SG \"Chlorthalidone-induced hyperosmolar hyperglycemic nonketotic coma.\" JAMA 220 (1972): 1592-3[47] \"Product Information. Hyperstat I.V. (diazoxide).\" Schering Corp, Kenilworth, NJ.[48] \"Product Information. Piqray (alpelisib).\" Novartis Pharmaceuticals, East Hanover, NJ.[49] Bell DS \"Insulin resistance. An often unrecognized problem accompanying chronic medical disorders.\" Postgrad Med 93 (1993): 99-103,[50] Stambaugh JE, Tucker DC \"Effect of diphenylhydantoin on glucose tolerance in patients with hypoglycemia.\" Diabetes 23 (1974): 679-83[51] \"Product Information. Crixivan (indinavir).\" Merck & Co, Inc, West Point, PA.[52] Miller NR, Moses H \"Transient oculomotor nerve palsy. Association with thiazide-induced glucose intolerance.\" JAMA 240 (1978): 1887-8[53] Javier Z, Gershberg H, Hulse M \"Ovulatory suppressants, estrogens, and carbohydrate metabolism.\" Metabolism 17 (1968): 443-56[54] Goldman JA, Ovadia JL \"The effect of estrogen on intravenous glucose tolerance in woman.\" Am J Obstet Gynecol 103 (1969): 172-8[55] Charan VD, Desai N, Singh AP, Choudhry VP \"Diabetes mellitus and pancreatitis as a complication of L- asparaginase therapy.\" Indian Pediatr 30 (1993): 809-10[56] Seifer DB, Freedman LN, Cavender JR, Baker RA \"Insulin-dependent diabetes mellitus associated with danazol.\" Am J Obstet Gynecol 162 (1990): 474-5[57] \"Product Information. Orinase (tolbutamide)\" Pharmacia and Upjohn, Kalamazoo, MI.[58] Walli R, Demant T \"Impaired glucose tolerance and protease inhibitors.\" Ann Intern Med 129 (1998): 837-8[59] Hannaford PC, Kay CR \"Oral contraceptives and diabetes mellitus.\" BMJ 299 (1989): 1315-6[60] Hardy H, Esch LD, Morse GD \"Glucose disorders associated with HIV and its drug therapy.\" Ann Pharmacother 35 (2001): 343-51[61] Chowdhury FR, Bleicher SJ \"Chlorthalidone--induced hypokalemia and abnormal carbohydrate metabolism.\" Horm Metab Res 2 (1970): 13-6[62] Kaufman MB, Simionatto C \"A review of protease inhibitor-induced hyperglycemia.\" Pharmacotherapy 19 (1999): 114-7[63] Greenstone MA, Shaw AB \"Alternate day corticosteroid causes alternate day hyperglycaemia.\" Postgrad Med J 63 (1987): 761-4[64] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[65] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[66] Elmfeldt D, Berglund G, Wedel H, Wilhelmsen L \"Incidence and importance of metabolic side-effects during antihypertensive therapy.\" Acta Med Scand Suppl 672 (1983): 79-83[67] \"Product Information. Agenerase (amprenavir).\" Glaxo Wellcome, Research Triangle Pk, NC.[68] Diamond MT \"Hyperglycemic hyperosmolar coma associated with hydrochlorothiazide and pancreatitis.\" N Y State J Med 72 (1972): 1741-2[69] \"Product Information. Prandin (repaglinide).\" Novo Nordisk Pharmaceuticals Inc, Princeton, NJ.[70] \"Product Information. Precose (acarbose).\" Bayer, West Haven, CT.[71] \"Product Information. Starlix (nateglinide)\" Novartis Pharmaceuticals, East Hanover, NJ.[72] \"Product Information. Oncaspar (pegaspargase).\" Rhone-Poulenc Rorer, Collegeville, PA.[73] Sotaniemi E, Kontturi M, Larmi T \"Effect of diethylstilbestrol on blood glucose of prostatic cancer patients.\" Invest Urol 10 (1973): 438-41[74] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[75] Petri M, Cumber P, Grimes L, Treby D, Bryant R, Rawlins D, Ising H \"The metabolic effects of thiazide therapy in the elderly: a population study.\" Age Ageing 15 (1986): 151-5[76] Ludvik B, Clodi M, Kautzky-Willer A, Capek M, Hartter E, Pacini G, Prager R \"Effect of dexamethasone on insulin sensitivity, islet amyloid polypeptide and insulin secretion in humans.\" Diabetologia 36 (1993): 84-7[77] \"Product Information. Glucophage (metformin).\" Bristol-Myers Squibb, Princeton, NJ.[78] Chaudhuri ML, Catania J \"A comparison of the effects of bumetanide (Burinex) and frusemide on carbohydrate metabolism in the elderly.\" Br J Clin Pract 42 (1988): 427-9[79] Black DM, Filak AT \"Hyperglycemia with non-insulin-dependent diabetes following intraarticular steroid injection.\" J Fam Pract 28 (1989): 462-3[80] \"Product Information. Megace (megestrol).\" Bristol-Myers Squibb, Princeton, NJ.[81] \"Product Information. Torisel (temsirolimus).\" Wyeth-Ayerst Laboratories, Philadelphia, PA.[82] Schmitz O, Hermansen K, Nielsen OH, Christensen CK, Arnfred J, Hansen HE, Mogensen CE, Orskov H, Beck-Nielsen H \"Insulin action in insulin-dependent diabetics after short-term thiazide therapy.\" Diabetes Care 9 (1986): 631-6[83] Kansal PC, Buse J, Buse MG \"Thiazide diuretics and control of diabetes mellitus.\" South Med J 62 (1969): 1372-9[84] Dimitriadis G, Tegos C, Golfinopoulou L, Roboti C, Raptis S \"Furosemide-induced hyperglycaemia - the implication of glycolytic kinases.\" Horm Metab Res 25 (1993): 557-9[85] \"Product Information. NovoLog Mix 70/30 (insulin aspart-insulin aspart protamine).\" Novo Nordisk Pharmaceuticals Inc, Princeton, NJ.[86] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[87] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[88] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[89] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42[90] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[91] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[92] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[93] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[94] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[95] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6", "alternatives_a": "Haloperidol, Pimavanserin, Thiothixene, Pimozide, Amisulpride, Loxapine, Molindone, Droperidol", "alternatives_b": "Simvastatin, Guar gum, Rosuvastatin", "updated_at": 1767369485}, {"id": 97966, "ingredient1": "Empagliflozin", "ingredient2": "Orciprenaline", "severity": "Moderate", "effect": "The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.", "source": "DDInter", "management_text": "Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.", "mechanism_text": "Antagonism", "recommendation": "Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/98070/", "reference_text": "[1] Jori A, Carrara MC \"On the mechanism of the hyperglycaemic effect of chlorpromazine.\" J Pharm Pharmacol 18 (1966): 623-4[2] \"Product Information. Dymelor (acetohexamide)\" Lilly, Eli and Company, Indianapolis, IN.[3] \"Product Information. Thorazine (chlorpromazine).\" SmithKline Beecham, Philadelphia, PA.[4] Blayac JP, Ribes G, Buys D, Puech R, Loubatieres-Mariani MM \"Effects of a new benzothiadiazine derivative, LN 5330, on insulin secretion.\" Arch Int Pharmacodyn Ther 253 (1981): 154-63[5] \"Product Information. Elzonris (tagraxofusp).\" Stemline Therapeutics, New York, NY.[6] \"Product Information. Amaryl (glimepiride).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[7] \"Product Information. Elspar (asparaginase).\" Merck & Co, Inc, West Point, PA.[8] Jones IG, Pickens PT \"Diabetes mellitus following oral diuretics.\" Practitioner 199 (1967): 209-10[9] \"Product Information. Viracept (nelfinavir).\" Agouron Pharma Inc, La Jolla, CA.[10] \"Product Information. Tolinase (tolazamide)\" Pharmacia and Upjohn, Kalamazoo, MI.[11] Mauss S, Wolf E, Jaeger H \"Impaired glucose tolerance in HIV-positive patients receiving and those not receiving protease inhibitors.\" Ann Intern Med 130 (1999): 162-3[12] Virutamasen P, Wongsrichanalai C, Tangkeo P, Nitichai Y, Rienprayoon D \"Metabolic effects of depot-medroxyprogesterone acetate in long-term users: a cross-sectional study.\" Int J Gynaecol Obstet 24 (1986): 291-6[13] Wehring H, Alexander B, Perry PJ \"Diabetes mellitus associated with clozapine therapy.\" Pharmacotherapy 20 (2000): 844-7[14] Spellacy WN, Ellingson AB, Tsibris JC \"The effects of two triphasic oral contraceptives on carbohydrate metabolism in women during 1 year of use.\" Fertil Steril 51 (1989): 71-4[15] Andersen OO, Persson I \"Carbohydrate metabolism during treatment with chlorthalidone and ethacrynic acid.\" Br Med J 2 (1968): 798-801[16] Berlin I \"Prazosin, diuretics, and glucose intolerance.\" Ann Intern Med 119 (1993): 860[17] Malherbe C, Burrill KC, Levin SR, Karam JH, Forsham PH \"Effect of diphenylhydantoin on insulin secretion in man.\" N Engl J Med 286 (1972): 339-42[18] Carter BL, Small RE, Mandel MD, Starkman MT \"Phenytoin-induced hyperglycemia.\" Am J Hosp Pharm 38 (1981): 1508-12[19] Al-Rubeaan K, Ryan EA \"Phenytoin-induced insulin insensitivity.\" Diabet Med 8 (1991): 968-70[20] \"Product Information. Zolinza (vorinostat).\" Merck & Company Inc, West Point, PA.[21] Goldman JA, Neri A, Ovadia J, Eckerling B, Vries A, de \"Effect of chlorothiazide on intravenous glucose tolerance in pregnancy.\" Am J Obstet Gynecol 105 (1969): 556-60[22] Harper R, Ennis CN, Heaney AP, Sheridan B, Gormley M, Atkinson AB, Johnston GD, Bell PM \"A comparison of the effects of low- and conventional-dose thiazide diuretic on insulin action in hypertensive patients with NIDDM.\" Diabetologia 38 (1995): 853-9[23] Seltzer HS, Allen EW \"Hyperglycemia and inhibition of insulin secretion during administration of diazoxide and trichlormethiazide in man.\" Diabetes 18 (1969): 19-28[24] Dube MP, Johnson DL, Currier JS, Leedom JM \"Protease inhibitor-associated hyperglycaemia.\" Lancet 350 (1997): 713-4[25] Leary WP, Reyes AJ \"Drug interactions with diuretics.\" S Afr Med J 65 (1984): 455-61[26] \"Product Information. Reyataz (atazanavir).\" Bristol-Myers Squibb, Princeton, NJ.[27] Pollare T, Lithell H, Berne C \"A comparison of the effects of hydrochlorothiazide and captopril on glucose and lipid metabolism in patients with hypertension.\" N Engl J Med 321 (1989): 868-73[28] Gunnarsson R, Lundgren G, Magnusson G, Ost L, Groth CG \"Steroid diabetes--a sign of overtreatment with steroids in the renal graft recipient?\" Scand J Urol Nephrol Suppl 54 (1980): 135-8[29] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[30] \"Product Information. Synthroid (levothyroxine).\" Abbott Pharmaceutical, Abbott Park, IL.[31] Murphy MB, Kohner E, Lewis PJ, Schumer B, Dollery CT \"Glucose intolerance in hypertensive patients treated with diuretics: a fourteen-year follow-up.\" Lancet 2 (1982): 1293-5[32] \"Product Information. Fortovase (saquinavir)\" Roche Laboratories, Nutley, NJ.[33] Coni NK, Gordon PW, Mukherjee AP, Read PR \"The effect of frusemide and ethacrynic acid on carbohydrate metabolism.\" Age Ageing 3 (1974): 85-90[34] \"Product Information. Norvir (ritonavir).\" Abbott Pharmaceutical, Abbott Park, IL.[35] Domenet JG \"Diabetogenic effect of oral diuretics.\" Br Med J 3 (1968): 188[36] Rowe P, Mather H \"Hyperosmolar non-ketotic diabetes mellitus associated with metolazone.\" Br Med J 291 (1985): 25-6[37] Winchester JF, Kellett RJ, Boddy K, Boyle P, Dargie HJ, Mahaffey ME, Ward DM, Kennedy AC \"Metolazone and bendroflumethiazide in hypertension: physiologic and metabolic observations.\" Clin Pharmacol Ther 28 (1980): 611-8[38] \"Product Information. Carafate (sucralfate).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[39] Tsiodras S, Mantzoros C, Hammer S, Samore M \"Effects of protease inhibitors on hyperglycemia, hyperlipidemia, and lipodystrophy - A 5-year cohort study.\" Arch Intern Med 160 (2000): 2050-6[40] \"Product Information. Apidra (insulin glulisine).\" Aventis Pharmaceuticals, Bridgewater, NJ.[41] \"Product Information. Prezista (darunavir).\" Ortho Biotech Inc, Bridgewater, NJ.[42] Haiba NA, el-Habashy MA, Said SA, Darwish EA, Abdel-Sayed WS, Nayel SE \"Clinical evaluation of two monthly injectable contraceptives and their effects on some metabolic parameters.\" Contraception 39 (1989): 619-32[43] Erle G, Basso M, Federspil G, Sicolo N, Scandellari C \"Effect of chlorpromazine on blood glucose and plasma insulin in man.\" Eur J Clin Pharmacol 11 (1977): 15-8[44] Pickkers P, Schachter M, Hughes AD, Feher MD, Sever PS \"Thiazide-induced hyperglycaemia: a role for calcium-activated potassium channels?\" Diabetologia 39 (1996): 861-4[45] \"Product Information. Lexiva (fosamprenavir).\" GlaxoSmithKline, Research Triangle Park, NC.[46] Curtis J, Horrigan F, Ahearn D, Varney R, Sandler SG \"Chlorthalidone-induced hyperosmolar hyperglycemic nonketotic coma.\" JAMA 220 (1972): 1592-3[47] \"Product Information. Hyperstat I.V. (diazoxide).\" Schering Corp, Kenilworth, NJ.[48] \"Product Information. Piqray (alpelisib).\" Novartis Pharmaceuticals, East Hanover, NJ.[49] Bell DS \"Insulin resistance. An often unrecognized problem accompanying chronic medical disorders.\" Postgrad Med 93 (1993): 99-103,[50] Stambaugh JE, Tucker DC \"Effect of diphenylhydantoin on glucose tolerance in patients with hypoglycemia.\" Diabetes 23 (1974): 679-83[51] \"Product Information. Crixivan (indinavir).\" Merck & Co, Inc, West Point, PA.[52] Miller NR, Moses H \"Transient oculomotor nerve palsy. Association with thiazide-induced glucose intolerance.\" JAMA 240 (1978): 1887-8[53] Javier Z, Gershberg H, Hulse M \"Ovulatory suppressants, estrogens, and carbohydrate metabolism.\" Metabolism 17 (1968): 443-56[54] Goldman JA, Ovadia JL \"The effect of estrogen on intravenous glucose tolerance in woman.\" Am J Obstet Gynecol 103 (1969): 172-8[55] Charan VD, Desai N, Singh AP, Choudhry VP \"Diabetes mellitus and pancreatitis as a complication of L- asparaginase therapy.\" Indian Pediatr 30 (1993): 809-10[56] Seifer DB, Freedman LN, Cavender JR, Baker RA \"Insulin-dependent diabetes mellitus associated with danazol.\" Am J Obstet Gynecol 162 (1990): 474-5[57] \"Product Information. Orinase (tolbutamide)\" Pharmacia and Upjohn, Kalamazoo, MI.[58] Walli R, Demant T \"Impaired glucose tolerance and protease inhibitors.\" Ann Intern Med 129 (1998): 837-8[59] Hannaford PC, Kay CR \"Oral contraceptives and diabetes mellitus.\" BMJ 299 (1989): 1315-6[60] Hardy H, Esch LD, Morse GD \"Glucose disorders associated with HIV and its drug therapy.\" Ann Pharmacother 35 (2001): 343-51[61] Chowdhury FR, Bleicher SJ \"Chlorthalidone--induced hypokalemia and abnormal carbohydrate metabolism.\" Horm Metab Res 2 (1970): 13-6[62] Kaufman MB, Simionatto C \"A review of protease inhibitor-induced hyperglycemia.\" Pharmacotherapy 19 (1999): 114-7[63] Greenstone MA, Shaw AB \"Alternate day corticosteroid causes alternate day hyperglycaemia.\" Postgrad Med J 63 (1987): 761-4[64] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[65] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[66] Elmfeldt D, Berglund G, Wedel H, Wilhelmsen L \"Incidence and importance of metabolic side-effects during antihypertensive therapy.\" Acta Med Scand Suppl 672 (1983): 79-83[67] \"Product Information. Agenerase (amprenavir).\" Glaxo Wellcome, Research Triangle Pk, NC.[68] Diamond MT \"Hyperglycemic hyperosmolar coma associated with hydrochlorothiazide and pancreatitis.\" N Y State J Med 72 (1972): 1741-2[69] \"Product Information. Prandin (repaglinide).\" Novo Nordisk Pharmaceuticals Inc, Princeton, NJ.[70] \"Product Information. Precose (acarbose).\" Bayer, West Haven, CT.[71] \"Product Information. Starlix (nateglinide)\" Novartis Pharmaceuticals, East Hanover, NJ.[72] \"Product Information. Oncaspar (pegaspargase).\" Rhone-Poulenc Rorer, Collegeville, PA.[73] Sotaniemi E, Kontturi M, Larmi T \"Effect of diethylstilbestrol on blood glucose of prostatic cancer patients.\" Invest Urol 10 (1973): 438-41[74] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[75] Petri M, Cumber P, Grimes L, Treby D, Bryant R, Rawlins D, Ising H \"The metabolic effects of thiazide therapy in the elderly: a population study.\" Age Ageing 15 (1986): 151-5[76] Ludvik B, Clodi M, Kautzky-Willer A, Capek M, Hartter E, Pacini G, Prager R \"Effect of dexamethasone on insulin sensitivity, islet amyloid polypeptide and insulin secretion in humans.\" Diabetologia 36 (1993): 84-7[77] \"Product Information. Glucophage (metformin).\" Bristol-Myers Squibb, Princeton, NJ.[78] Chaudhuri ML, Catania J \"A comparison of the effects of bumetanide (Burinex) and frusemide on carbohydrate metabolism in the elderly.\" Br J Clin Pract 42 (1988): 427-9[79] Black DM, Filak AT \"Hyperglycemia with non-insulin-dependent diabetes following intraarticular steroid injection.\" J Fam Pract 28 (1989): 462-3[80] \"Product Information. Megace (megestrol).\" Bristol-Myers Squibb, Princeton, NJ.[81] \"Product Information. Torisel (temsirolimus).\" Wyeth-Ayerst Laboratories, Philadelphia, PA.[82] Schmitz O, Hermansen K, Nielsen OH, Christensen CK, Arnfred J, Hansen HE, Mogensen CE, Orskov H, Beck-Nielsen H \"Insulin action in insulin-dependent diabetics after short-term thiazide therapy.\" Diabetes Care 9 (1986): 631-6[83] Kansal PC, Buse J, Buse MG \"Thiazide diuretics and control of diabetes mellitus.\" South Med J 62 (1969): 1372-9[84] Dimitriadis G, Tegos C, Golfinopoulou L, Roboti C, Raptis S \"Furosemide-induced hyperglycaemia - the implication of glycolytic kinases.\" Horm Metab Res 25 (1993): 557-9[85] \"Product Information. NovoLog Mix 70/30 (insulin aspart-insulin aspart protamine).\" Novo Nordisk Pharmaceuticals Inc, Princeton, NJ.[86] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[87] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[88] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[89] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42[90] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[91] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[92] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[93] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[94] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[95] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6", "alternatives_a": "Umeclidinium, Budesonide, Glycopyrronium, Aclidinium, Mometasone, Fluticasone, Cromoglicic acid, Ipratropium, Pirbuterol, Bitolterol, Olodaterol, More", "alternatives_b": "Simvastatin, Guar gum, Rosuvastatin", "updated_at": 1767369485}, {"id": 97967, "ingredient1": "Empagliflozin", "ingredient2": "Metaraminol", "severity": "Moderate", "effect": "The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.", "source": "DDInter", "management_text": "Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.", "mechanism_text": "Antagonism", "recommendation": "Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/98071/", "reference_text": "[1] Jori A, Carrara MC \"On the mechanism of the hyperglycaemic effect of chlorpromazine.\" J Pharm Pharmacol 18 (1966): 623-4[2] \"Product Information. Dymelor (acetohexamide)\" Lilly, Eli and Company, Indianapolis, IN.[3] \"Product Information. Thorazine (chlorpromazine).\" SmithKline Beecham, Philadelphia, PA.[4] Blayac JP, Ribes G, Buys D, Puech R, Loubatieres-Mariani MM \"Effects of a new benzothiadiazine derivative, LN 5330, on insulin secretion.\" Arch Int Pharmacodyn Ther 253 (1981): 154-63[5] \"Product Information. Elzonris (tagraxofusp).\" Stemline Therapeutics, New York, NY.[6] \"Product Information. Amaryl (glimepiride).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[7] \"Product Information. Elspar (asparaginase).\" Merck & Co, Inc, West Point, PA.[8] Jones IG, Pickens PT \"Diabetes mellitus following oral diuretics.\" Practitioner 199 (1967): 209-10[9] \"Product Information. Viracept (nelfinavir).\" Agouron Pharma Inc, La Jolla, CA.[10] \"Product Information. Tolinase (tolazamide)\" Pharmacia and Upjohn, Kalamazoo, MI.[11] Mauss S, Wolf E, Jaeger H \"Impaired glucose tolerance in HIV-positive patients receiving and those not receiving protease inhibitors.\" Ann Intern Med 130 (1999): 162-3[12] Virutamasen P, Wongsrichanalai C, Tangkeo P, Nitichai Y, Rienprayoon D \"Metabolic effects of depot-medroxyprogesterone acetate in long-term users: a cross-sectional study.\" Int J Gynaecol Obstet 24 (1986): 291-6[13] Wehring H, Alexander B, Perry PJ \"Diabetes mellitus associated with clozapine therapy.\" Pharmacotherapy 20 (2000): 844-7[14] Spellacy WN, Ellingson AB, Tsibris JC \"The effects of two triphasic oral contraceptives on carbohydrate metabolism in women during 1 year of use.\" Fertil Steril 51 (1989): 71-4[15] Andersen OO, Persson I \"Carbohydrate metabolism during treatment with chlorthalidone and ethacrynic acid.\" Br Med J 2 (1968): 798-801[16] Berlin I \"Prazosin, diuretics, and glucose intolerance.\" Ann Intern Med 119 (1993): 860[17] Malherbe C, Burrill KC, Levin SR, Karam JH, Forsham PH \"Effect of diphenylhydantoin on insulin secretion in man.\" N Engl J Med 286 (1972): 339-42[18] Carter BL, Small RE, Mandel MD, Starkman MT \"Phenytoin-induced hyperglycemia.\" Am J Hosp Pharm 38 (1981): 1508-12[19] Al-Rubeaan K, Ryan EA \"Phenytoin-induced insulin insensitivity.\" Diabet Med 8 (1991): 968-70[20] \"Product Information. Zolinza (vorinostat).\" Merck & Company Inc, West Point, PA.[21] Goldman JA, Neri A, Ovadia J, Eckerling B, Vries A, de \"Effect of chlorothiazide on intravenous glucose tolerance in pregnancy.\" Am J Obstet Gynecol 105 (1969): 556-60[22] Harper R, Ennis CN, Heaney AP, Sheridan B, Gormley M, Atkinson AB, Johnston GD, Bell PM \"A comparison of the effects of low- and conventional-dose thiazide diuretic on insulin action in hypertensive patients with NIDDM.\" Diabetologia 38 (1995): 853-9[23] Seltzer HS, Allen EW \"Hyperglycemia and inhibition of insulin secretion during administration of diazoxide and trichlormethiazide in man.\" Diabetes 18 (1969): 19-28[24] Dube MP, Johnson DL, Currier JS, Leedom JM \"Protease inhibitor-associated hyperglycaemia.\" Lancet 350 (1997): 713-4[25] Leary WP, Reyes AJ \"Drug interactions with diuretics.\" S Afr Med J 65 (1984): 455-61[26] \"Product Information. Reyataz (atazanavir).\" Bristol-Myers Squibb, Princeton, NJ.[27] Pollare T, Lithell H, Berne C \"A comparison of the effects of hydrochlorothiazide and captopril on glucose and lipid metabolism in patients with hypertension.\" N Engl J Med 321 (1989): 868-73[28] Gunnarsson R, Lundgren G, Magnusson G, Ost L, Groth CG \"Steroid diabetes--a sign of overtreatment with steroids in the renal graft recipient?\" Scand J Urol Nephrol Suppl 54 (1980): 135-8[29] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[30] \"Product Information. Synthroid (levothyroxine).\" Abbott Pharmaceutical, Abbott Park, IL.[31] Murphy MB, Kohner E, Lewis PJ, Schumer B, Dollery CT \"Glucose intolerance in hypertensive patients treated with diuretics: a fourteen-year follow-up.\" Lancet 2 (1982): 1293-5[32] \"Product Information. Fortovase (saquinavir)\" Roche Laboratories, Nutley, NJ.[33] Coni NK, Gordon PW, Mukherjee AP, Read PR \"The effect of frusemide and ethacrynic acid on carbohydrate metabolism.\" Age Ageing 3 (1974): 85-90[34] \"Product Information. Norvir (ritonavir).\" Abbott Pharmaceutical, Abbott Park, IL.[35] Domenet JG \"Diabetogenic effect of oral diuretics.\" Br Med J 3 (1968): 188[36] Rowe P, Mather H \"Hyperosmolar non-ketotic diabetes mellitus associated with metolazone.\" Br Med J 291 (1985): 25-6[37] Winchester JF, Kellett RJ, Boddy K, Boyle P, Dargie HJ, Mahaffey ME, Ward DM, Kennedy AC \"Metolazone and bendroflumethiazide in hypertension: physiologic and metabolic observations.\" Clin Pharmacol Ther 28 (1980): 611-8[38] \"Product Information. Carafate (sucralfate).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[39] Tsiodras S, Mantzoros C, Hammer S, Samore M \"Effects of protease inhibitors on hyperglycemia, hyperlipidemia, and lipodystrophy - A 5-year cohort study.\" Arch Intern Med 160 (2000): 2050-6[40] \"Product Information. Apidra (insulin glulisine).\" Aventis Pharmaceuticals, Bridgewater, NJ.[41] \"Product Information. Prezista (darunavir).\" Ortho Biotech Inc, Bridgewater, NJ.[42] Haiba NA, el-Habashy MA, Said SA, Darwish EA, Abdel-Sayed WS, Nayel SE \"Clinical evaluation of two monthly injectable contraceptives and their effects on some metabolic parameters.\" Contraception 39 (1989): 619-32[43] Erle G, Basso M, Federspil G, Sicolo N, Scandellari C \"Effect of chlorpromazine on blood glucose and plasma insulin in man.\" Eur J Clin Pharmacol 11 (1977): 15-8[44] Pickkers P, Schachter M, Hughes AD, Feher MD, Sever PS \"Thiazide-induced hyperglycaemia: a role for calcium-activated potassium channels?\" Diabetologia 39 (1996): 861-4[45] \"Product Information. Lexiva (fosamprenavir).\" GlaxoSmithKline, Research Triangle Park, NC.[46] Curtis J, Horrigan F, Ahearn D, Varney R, Sandler SG \"Chlorthalidone-induced hyperosmolar hyperglycemic nonketotic coma.\" JAMA 220 (1972): 1592-3[47] \"Product Information. Hyperstat I.V. (diazoxide).\" Schering Corp, Kenilworth, NJ.[48] \"Product Information. Piqray (alpelisib).\" Novartis Pharmaceuticals, East Hanover, NJ.[49] Bell DS \"Insulin resistance. An often unrecognized problem accompanying chronic medical disorders.\" Postgrad Med 93 (1993): 99-103,[50] Stambaugh JE, Tucker DC \"Effect of diphenylhydantoin on glucose tolerance in patients with hypoglycemia.\" Diabetes 23 (1974): 679-83[51] \"Product Information. Crixivan (indinavir).\" Merck & Co, Inc, West Point, PA.[52] Miller NR, Moses H \"Transient oculomotor nerve palsy. Association with thiazide-induced glucose intolerance.\" JAMA 240 (1978): 1887-8[53] Javier Z, Gershberg H, Hulse M \"Ovulatory suppressants, estrogens, and carbohydrate metabolism.\" Metabolism 17 (1968): 443-56[54] Goldman JA, Ovadia JL \"The effect of estrogen on intravenous glucose tolerance in woman.\" Am J Obstet Gynecol 103 (1969): 172-8[55] Charan VD, Desai N, Singh AP, Choudhry VP \"Diabetes mellitus and pancreatitis as a complication of L- asparaginase therapy.\" Indian Pediatr 30 (1993): 809-10[56] Seifer DB, Freedman LN, Cavender JR, Baker RA \"Insulin-dependent diabetes mellitus associated with danazol.\" Am J Obstet Gynecol 162 (1990): 474-5[57] \"Product Information. Orinase (tolbutamide)\" Pharmacia and Upjohn, Kalamazoo, MI.[58] Walli R, Demant T \"Impaired glucose tolerance and protease inhibitors.\" Ann Intern Med 129 (1998): 837-8[59] Hannaford PC, Kay CR \"Oral contraceptives and diabetes mellitus.\" BMJ 299 (1989): 1315-6[60] Hardy H, Esch LD, Morse GD \"Glucose disorders associated with HIV and its drug therapy.\" Ann Pharmacother 35 (2001): 343-51[61] Chowdhury FR, Bleicher SJ \"Chlorthalidone--induced hypokalemia and abnormal carbohydrate metabolism.\" Horm Metab Res 2 (1970): 13-6[62] Kaufman MB, Simionatto C \"A review of protease inhibitor-induced hyperglycemia.\" Pharmacotherapy 19 (1999): 114-7[63] Greenstone MA, Shaw AB \"Alternate day corticosteroid causes alternate day hyperglycaemia.\" Postgrad Med J 63 (1987): 761-4[64] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[65] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[66] Elmfeldt D, Berglund G, Wedel H, Wilhelmsen L \"Incidence and importance of metabolic side-effects during antihypertensive therapy.\" Acta Med Scand Suppl 672 (1983): 79-83[67] \"Product Information. Agenerase (amprenavir).\" Glaxo Wellcome, Research Triangle Pk, NC.[68] Diamond MT \"Hyperglycemic hyperosmolar coma associated with hydrochlorothiazide and pancreatitis.\" N Y State J Med 72 (1972): 1741-2[69] \"Product Information. Prandin (repaglinide).\" Novo Nordisk Pharmaceuticals Inc, Princeton, NJ.[70] \"Product Information. Precose (acarbose).\" Bayer, West Haven, CT.[71] \"Product Information. Starlix (nateglinide)\" Novartis Pharmaceuticals, East Hanover, NJ.[72] \"Product Information. Oncaspar (pegaspargase).\" Rhone-Poulenc Rorer, Collegeville, PA.[73] Sotaniemi E, Kontturi M, Larmi T \"Effect of diethylstilbestrol on blood glucose of prostatic cancer patients.\" Invest Urol 10 (1973): 438-41[74] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[75] Petri M, Cumber P, Grimes L, Treby D, Bryant R, Rawlins D, Ising H \"The metabolic effects of thiazide therapy in the elderly: a population study.\" Age Ageing 15 (1986): 151-5[76] Ludvik B, Clodi M, Kautzky-Willer A, Capek M, Hartter E, Pacini G, Prager R \"Effect of dexamethasone on insulin sensitivity, islet amyloid polypeptide and insulin secretion in humans.\" Diabetologia 36 (1993): 84-7[77] \"Product Information. Glucophage (metformin).\" Bristol-Myers Squibb, Princeton, NJ.[78] Chaudhuri ML, Catania J \"A comparison of the effects of bumetanide (Burinex) and frusemide on carbohydrate metabolism in the elderly.\" Br J Clin Pract 42 (1988): 427-9[79] Black DM, Filak AT \"Hyperglycemia with non-insulin-dependent diabetes following intraarticular steroid injection.\" J Fam Pract 28 (1989): 462-3[80] \"Product Information. Megace (megestrol).\" Bristol-Myers Squibb, Princeton, NJ.[81] \"Product Information. Torisel (temsirolimus).\" Wyeth-Ayerst Laboratories, Philadelphia, PA.[82] Schmitz O, Hermansen K, Nielsen OH, Christensen CK, Arnfred J, Hansen HE, Mogensen CE, Orskov H, Beck-Nielsen H \"Insulin action in insulin-dependent diabetics after short-term thiazide therapy.\" Diabetes Care 9 (1986): 631-6[83] Kansal PC, Buse J, Buse MG \"Thiazide diuretics and control of diabetes mellitus.\" South Med J 62 (1969): 1372-9[84] Dimitriadis G, Tegos C, Golfinopoulou L, Roboti C, Raptis S \"Furosemide-induced hyperglycaemia - the implication of glycolytic kinases.\" Horm Metab Res 25 (1993): 557-9[85] \"Product Information. NovoLog Mix 70/30 (insulin aspart-insulin aspart protamine).\" Novo Nordisk Pharmaceuticals Inc, Princeton, NJ.[86] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[87] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[88] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[89] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42[90] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[91] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[92] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[93] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[94] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[95] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6", "alternatives_a": "Droxidopa, Midodrine, Amrinone, Angiotensin II, Milrinone, Arbutamine", "alternatives_b": "Acetohexamide, Guar gum, Simvastatin, Troglitazone, Rosuvastatin", "updated_at": 1767369485}, {"id": 97968, "ingredient1": "Empagliflozin", "ingredient2": "Metamfetamine", "severity": "Moderate", "effect": "Since weight loss may affect glycemic control and increase the risk of hypoglycemia in type 2 diabetes mellitus, patients receiving anorectic drugs may require periodic adjustments of their antidiabetic medications.", "source": "DDInter", "management_text": "Blood glucose should be closely monitored during weight loss treatment, and appropriate changes made to the antidiabetic drug regimen as needed. Patients should be apprised of the risk of hypoglycemia and be alert to potential signs and symptoms such as headache, dizziness, drowsiness, nervousness, confusion, tremor, hunger, weakness, perspiration, palpitation, and tachycardia.", "mechanism_text": "Synergism", "recommendation": "Blood glucose should be closely monitored during weight loss treatment, and appropriate changes made to the antidiabetic drug regimen as needed.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/98072/", "reference_text": "[1] \"Product Information. Xenical (orlistat).\" Roche Laboratories, Nutley, NJ.[2] \"Product Information. Didrex (benzphetamine)\" Pharmacia and Upjohn, Kalamazoo, MI.[3] \"Product Information. Suprenza (phentermine).\" Akrimax Pharmaceuticals, Cranford, NJ.[4] \"Product Information. Belviq (lorcaserin).\" Eisai Inc, Teaneck, NJ.[5] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[6] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[7] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[8] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42[9] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[10] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[11] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[12] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[13] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[14] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6[15] Mendelson J, Jones RT, Upton R, Jacob P 3rd \"Methamphetamine and ethanol interactions in humans.\" Clin Pharmacol Ther 57 (1995): 559-68[16] \"Product Information. Didrex (benzphetamine)\" Pharmacia and Upjohn, Kalamazoo, MI.[17] \"Product Information. Suprenza (phentermine).\" Akrimax Pharmaceuticals, Cranford, NJ.", "alternatives_a": "Amphetamine, Pemoline, Atomoxetine, Lisdexamfetamine, Solriamfetol, Caffeine, Methylphenidate, Dexmethylphenidate, Dextroamphetamine, Armodafinil, Citicoline, Modafinil", "alternatives_b": "Simvastatin, Guar gum, Rosuvastatin", "updated_at": 1767369485}, {"id": 97969, "ingredient1": "Empagliflozin", "ingredient2": "Methazolamide", "severity": "Moderate", "effect": "The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.", "source": "DDInter", "management_text": "Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.", "mechanism_text": "Antagonism", "recommendation": "Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/98073/", "reference_text": "[1] Jori A, Carrara MC \"On the mechanism of the hyperglycaemic effect of chlorpromazine.\" J Pharm Pharmacol 18 (1966): 623-4[2] \"Product Information. Dymelor (acetohexamide)\" Lilly, Eli and Company, Indianapolis, IN.[3] \"Product Information. Thorazine (chlorpromazine).\" SmithKline Beecham, Philadelphia, PA.[4] Blayac JP, Ribes G, Buys D, Puech R, Loubatieres-Mariani MM \"Effects of a new benzothiadiazine derivative, LN 5330, on insulin secretion.\" Arch Int Pharmacodyn Ther 253 (1981): 154-63[5] \"Product Information. Elzonris (tagraxofusp).\" Stemline Therapeutics, New York, NY.[6] \"Product Information. Amaryl (glimepiride).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[7] \"Product Information. Elspar (asparaginase).\" Merck & Co, Inc, West Point, PA.[8] Jones IG, Pickens PT \"Diabetes mellitus following oral diuretics.\" Practitioner 199 (1967): 209-10[9] \"Product Information. Viracept (nelfinavir).\" Agouron Pharma Inc, La Jolla, CA.[10] \"Product Information. Tolinase (tolazamide)\" Pharmacia and Upjohn, Kalamazoo, MI.[11] Mauss S, Wolf E, Jaeger H \"Impaired glucose tolerance in HIV-positive patients receiving and those not receiving protease inhibitors.\" Ann Intern Med 130 (1999): 162-3[12] Virutamasen P, Wongsrichanalai C, Tangkeo P, Nitichai Y, Rienprayoon D \"Metabolic effects of depot-medroxyprogesterone acetate in long-term users: a cross-sectional study.\" Int J Gynaecol Obstet 24 (1986): 291-6[13] Wehring H, Alexander B, Perry PJ \"Diabetes mellitus associated with clozapine therapy.\" Pharmacotherapy 20 (2000): 844-7[14] Spellacy WN, Ellingson AB, Tsibris JC \"The effects of two triphasic oral contraceptives on carbohydrate metabolism in women during 1 year of use.\" Fertil Steril 51 (1989): 71-4[15] Andersen OO, Persson I \"Carbohydrate metabolism during treatment with chlorthalidone and ethacrynic acid.\" Br Med J 2 (1968): 798-801[16] Berlin I \"Prazosin, diuretics, and glucose intolerance.\" Ann Intern Med 119 (1993): 860[17] Malherbe C, Burrill KC, Levin SR, Karam JH, Forsham PH \"Effect of diphenylhydantoin on insulin secretion in man.\" N Engl J Med 286 (1972): 339-42[18] Carter BL, Small RE, Mandel MD, Starkman MT \"Phenytoin-induced hyperglycemia.\" Am J Hosp Pharm 38 (1981): 1508-12[19] Al-Rubeaan K, Ryan EA \"Phenytoin-induced insulin insensitivity.\" Diabet Med 8 (1991): 968-70[20] \"Product Information. Zolinza (vorinostat).\" Merck & Company Inc, West Point, PA.[21] Goldman JA, Neri A, Ovadia J, Eckerling B, Vries A, de \"Effect of chlorothiazide on intravenous glucose tolerance in pregnancy.\" Am J Obstet Gynecol 105 (1969): 556-60[22] Harper R, Ennis CN, Heaney AP, Sheridan B, Gormley M, Atkinson AB, Johnston GD, Bell PM \"A comparison of the effects of low- and conventional-dose thiazide diuretic on insulin action in hypertensive patients with NIDDM.\" Diabetologia 38 (1995): 853-9[23] Seltzer HS, Allen EW \"Hyperglycemia and inhibition of insulin secretion during administration of diazoxide and trichlormethiazide in man.\" Diabetes 18 (1969): 19-28[24] Dube MP, Johnson DL, Currier JS, Leedom JM \"Protease inhibitor-associated hyperglycaemia.\" Lancet 350 (1997): 713-4[25] Leary WP, Reyes AJ \"Drug interactions with diuretics.\" S Afr Med J 65 (1984): 455-61[26] \"Product Information. Reyataz (atazanavir).\" Bristol-Myers Squibb, Princeton, NJ.[27] Pollare T, Lithell H, Berne C \"A comparison of the effects of hydrochlorothiazide and captopril on glucose and lipid metabolism in patients with hypertension.\" N Engl J Med 321 (1989): 868-73[28] Gunnarsson R, Lundgren G, Magnusson G, Ost L, Groth CG \"Steroid diabetes--a sign of overtreatment with steroids in the renal graft recipient?\" Scand J Urol Nephrol Suppl 54 (1980): 135-8[29] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[30] \"Product Information. Synthroid (levothyroxine).\" Abbott Pharmaceutical, Abbott Park, IL.[31] Murphy MB, Kohner E, Lewis PJ, Schumer B, Dollery CT \"Glucose intolerance in hypertensive patients treated with diuretics: a fourteen-year follow-up.\" Lancet 2 (1982): 1293-5[32] \"Product Information. Fortovase (saquinavir)\" Roche Laboratories, Nutley, NJ.[33] Coni NK, Gordon PW, Mukherjee AP, Read PR \"The effect of frusemide and ethacrynic acid on carbohydrate metabolism.\" Age Ageing 3 (1974): 85-90[34] \"Product Information. Norvir (ritonavir).\" Abbott Pharmaceutical, Abbott Park, IL.[35] Domenet JG \"Diabetogenic effect of oral diuretics.\" Br Med J 3 (1968): 188[36] Rowe P, Mather H \"Hyperosmolar non-ketotic diabetes mellitus associated with metolazone.\" Br Med J 291 (1985): 25-6[37] Winchester JF, Kellett RJ, Boddy K, Boyle P, Dargie HJ, Mahaffey ME, Ward DM, Kennedy AC \"Metolazone and bendroflumethiazide in hypertension: physiologic and metabolic observations.\" Clin Pharmacol Ther 28 (1980): 611-8[38] \"Product Information. Carafate (sucralfate).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[39] Tsiodras S, Mantzoros C, Hammer S, Samore M \"Effects of protease inhibitors on hyperglycemia, hyperlipidemia, and lipodystrophy - A 5-year cohort study.\" Arch Intern Med 160 (2000): 2050-6[40] \"Product Information. Apidra (insulin glulisine).\" Aventis Pharmaceuticals, Bridgewater, NJ.[41] \"Product Information. Prezista (darunavir).\" Ortho Biotech Inc, Bridgewater, NJ.[42] Haiba NA, el-Habashy MA, Said SA, Darwish EA, Abdel-Sayed WS, Nayel SE \"Clinical evaluation of two monthly injectable contraceptives and their effects on some metabolic parameters.\" Contraception 39 (1989): 619-32[43] Erle G, Basso M, Federspil G, Sicolo N, Scandellari C \"Effect of chlorpromazine on blood glucose and plasma insulin in man.\" Eur J Clin Pharmacol 11 (1977): 15-8[44] Pickkers P, Schachter M, Hughes AD, Feher MD, Sever PS \"Thiazide-induced hyperglycaemia: a role for calcium-activated potassium channels?\" Diabetologia 39 (1996): 861-4[45] \"Product Information. Lexiva (fosamprenavir).\" GlaxoSmithKline, Research Triangle Park, NC.[46] Curtis J, Horrigan F, Ahearn D, Varney R, Sandler SG \"Chlorthalidone-induced hyperosmolar hyperglycemic nonketotic coma.\" JAMA 220 (1972): 1592-3[47] \"Product Information. Hyperstat I.V. (diazoxide).\" Schering Corp, Kenilworth, NJ.[48] \"Product Information. Piqray (alpelisib).\" Novartis Pharmaceuticals, East Hanover, NJ.[49] Bell DS \"Insulin resistance. An often unrecognized problem accompanying chronic medical disorders.\" Postgrad Med 93 (1993): 99-103,[50] Stambaugh JE, Tucker DC \"Effect of diphenylhydantoin on glucose tolerance in patients with hypoglycemia.\" Diabetes 23 (1974): 679-83[51] \"Product Information. Crixivan (indinavir).\" Merck & Co, Inc, West Point, PA.[52] Miller NR, Moses H \"Transient oculomotor nerve palsy. Association with thiazide-induced glucose intolerance.\" JAMA 240 (1978): 1887-8[53] Javier Z, Gershberg H, Hulse M \"Ovulatory suppressants, estrogens, and carbohydrate metabolism.\" Metabolism 17 (1968): 443-56[54] Goldman JA, Ovadia JL \"The effect of estrogen on intravenous glucose tolerance in woman.\" Am J Obstet Gynecol 103 (1969): 172-8[55] Charan VD, Desai N, Singh AP, Choudhry VP \"Diabetes mellitus and pancreatitis as a complication of L- asparaginase therapy.\" Indian Pediatr 30 (1993): 809-10[56] Seifer DB, Freedman LN, Cavender JR, Baker RA \"Insulin-dependent diabetes mellitus associated with danazol.\" Am J Obstet Gynecol 162 (1990): 474-5[57] \"Product Information. Orinase (tolbutamide)\" Pharmacia and Upjohn, Kalamazoo, MI.[58] Walli R, Demant T \"Impaired glucose tolerance and protease inhibitors.\" Ann Intern Med 129 (1998): 837-8[59] Hannaford PC, Kay CR \"Oral contraceptives and diabetes mellitus.\" BMJ 299 (1989): 1315-6[60] Hardy H, Esch LD, Morse GD \"Glucose disorders associated with HIV and its drug therapy.\" Ann Pharmacother 35 (2001): 343-51[61] Chowdhury FR, Bleicher SJ \"Chlorthalidone--induced hypokalemia and abnormal carbohydrate metabolism.\" Horm Metab Res 2 (1970): 13-6[62] Kaufman MB, Simionatto C \"A review of protease inhibitor-induced hyperglycemia.\" Pharmacotherapy 19 (1999): 114-7[63] Greenstone MA, Shaw AB \"Alternate day corticosteroid causes alternate day hyperglycaemia.\" Postgrad Med J 63 (1987): 761-4[64] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[65] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[66] Elmfeldt D, Berglund G, Wedel H, Wilhelmsen L \"Incidence and importance of metabolic side-effects during antihypertensive therapy.\" Acta Med Scand Suppl 672 (1983): 79-83[67] \"Product Information. Agenerase (amprenavir).\" Glaxo Wellcome, Research Triangle Pk, NC.[68] Diamond MT \"Hyperglycemic hyperosmolar coma associated with hydrochlorothiazide and pancreatitis.\" N Y State J Med 72 (1972): 1741-2[69] \"Product Information. Prandin (repaglinide).\" Novo Nordisk Pharmaceuticals Inc, Princeton, NJ.[70] \"Product Information. Precose (acarbose).\" Bayer, West Haven, CT.[71] \"Product Information. Starlix (nateglinide)\" Novartis Pharmaceuticals, East Hanover, NJ.[72] \"Product Information. Oncaspar (pegaspargase).\" Rhone-Poulenc Rorer, Collegeville, PA.[73] Sotaniemi E, Kontturi M, Larmi T \"Effect of diethylstilbestrol on blood glucose of prostatic cancer patients.\" Invest Urol 10 (1973): 438-41[74] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[75] Petri M, Cumber P, Grimes L, Treby D, Bryant R, Rawlins D, Ising H \"The metabolic effects of thiazide therapy in the elderly: a population study.\" Age Ageing 15 (1986): 151-5[76] Ludvik B, Clodi M, Kautzky-Willer A, Capek M, Hartter E, Pacini G, Prager R \"Effect of dexamethasone on insulin sensitivity, islet amyloid polypeptide and insulin secretion in humans.\" Diabetologia 36 (1993): 84-7[77] \"Product Information. Glucophage (metformin).\" Bristol-Myers Squibb, Princeton, NJ.[78] Chaudhuri ML, Catania J \"A comparison of the effects of bumetanide (Burinex) and frusemide on carbohydrate metabolism in the elderly.\" Br J Clin Pract 42 (1988): 427-9[79] Black DM, Filak AT \"Hyperglycemia with non-insulin-dependent diabetes following intraarticular steroid injection.\" J Fam Pract 28 (1989): 462-3[80] \"Product Information. Megace (megestrol).\" Bristol-Myers Squibb, Princeton, NJ.[81] \"Product Information. Torisel (temsirolimus).\" Wyeth-Ayerst Laboratories, Philadelphia, PA.[82] Schmitz O, Hermansen K, Nielsen OH, Christensen CK, Arnfred J, Hansen HE, Mogensen CE, Orskov H, Beck-Nielsen H \"Insulin action in insulin-dependent diabetics after short-term thiazide therapy.\" Diabetes Care 9 (1986): 631-6[83] Kansal PC, Buse J, Buse MG \"Thiazide diuretics and control of diabetes mellitus.\" South Med J 62 (1969): 1372-9[84] Dimitriadis G, Tegos C, Golfinopoulou L, Roboti C, Raptis S \"Furosemide-induced hyperglycaemia - the implication of glycolytic kinases.\" Horm Metab Res 25 (1993): 557-9[85] \"Product Information. NovoLog Mix 70/30 (insulin aspart-insulin aspart protamine).\" Novo Nordisk Pharmaceuticals Inc, Princeton, NJ.[86] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[87] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[88] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[89] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42[90] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[91] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[92] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[93] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[94] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[95] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6", "alternatives_a": "Tinidazole, Ascorbic acid, Metronidazole, Rosuvastatin, Sulfadiazine, Lactic acid, Amphotericin B, Clindamycin, Ciclopirox, Vemurafenib, Ketoconazole, More", "alternatives_b": "Simvastatin, Guar gum, Rosuvastatin", "updated_at": 1767369485}, {"id": 97970, "ingredient1": "Empagliflozin", "ingredient2": "Methdilazine", "severity": "Moderate", "effect": "The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.", "source": "DDInter", "management_text": "Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.", "mechanism_text": "Antagonism", "recommendation": "Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/98074/", "reference_text": "[1] Jori A, Carrara MC \"On the mechanism of the hyperglycaemic effect of chlorpromazine.\" J Pharm Pharmacol 18 (1966): 623-4[2] \"Product Information. Dymelor (acetohexamide)\" Lilly, Eli and Company, Indianapolis, IN.[3] \"Product Information. Thorazine (chlorpromazine).\" SmithKline Beecham, Philadelphia, PA.[4] Blayac JP, Ribes G, Buys D, Puech R, Loubatieres-Mariani MM \"Effects of a new benzothiadiazine derivative, LN 5330, on insulin secretion.\" Arch Int Pharmacodyn Ther 253 (1981): 154-63[5] \"Product Information. Elzonris (tagraxofusp).\" Stemline Therapeutics, New York, NY.[6] \"Product Information. Amaryl (glimepiride).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[7] \"Product Information. Elspar (asparaginase).\" Merck & Co, Inc, West Point, PA.[8] Jones IG, Pickens PT \"Diabetes mellitus following oral diuretics.\" Practitioner 199 (1967): 209-10[9] \"Product Information. Viracept (nelfinavir).\" Agouron Pharma Inc, La Jolla, CA.[10] \"Product Information. Tolinase (tolazamide)\" Pharmacia and Upjohn, Kalamazoo, MI.[11] Mauss S, Wolf E, Jaeger H \"Impaired glucose tolerance in HIV-positive patients receiving and those not receiving protease inhibitors.\" Ann Intern Med 130 (1999): 162-3[12] Virutamasen P, Wongsrichanalai C, Tangkeo P, Nitichai Y, Rienprayoon D \"Metabolic effects of depot-medroxyprogesterone acetate in long-term users: a cross-sectional study.\" Int J Gynaecol Obstet 24 (1986): 291-6[13] Wehring H, Alexander B, Perry PJ \"Diabetes mellitus associated with clozapine therapy.\" Pharmacotherapy 20 (2000): 844-7[14] Spellacy WN, Ellingson AB, Tsibris JC \"The effects of two triphasic oral contraceptives on carbohydrate metabolism in women during 1 year of use.\" Fertil Steril 51 (1989): 71-4[15] Andersen OO, Persson I \"Carbohydrate metabolism during treatment with chlorthalidone and ethacrynic acid.\" Br Med J 2 (1968): 798-801[16] Berlin I \"Prazosin, diuretics, and glucose intolerance.\" Ann Intern Med 119 (1993): 860[17] Malherbe C, Burrill KC, Levin SR, Karam JH, Forsham PH \"Effect of diphenylhydantoin on insulin secretion in man.\" N Engl J Med 286 (1972): 339-42[18] Carter BL, Small RE, Mandel MD, Starkman MT \"Phenytoin-induced hyperglycemia.\" Am J Hosp Pharm 38 (1981): 1508-12[19] Al-Rubeaan K, Ryan EA \"Phenytoin-induced insulin insensitivity.\" Diabet Med 8 (1991): 968-70[20] \"Product Information. Zolinza (vorinostat).\" Merck & Company Inc, West Point, PA.[21] Goldman JA, Neri A, Ovadia J, Eckerling B, Vries A, de \"Effect of chlorothiazide on intravenous glucose tolerance in pregnancy.\" Am J Obstet Gynecol 105 (1969): 556-60[22] Harper R, Ennis CN, Heaney AP, Sheridan B, Gormley M, Atkinson AB, Johnston GD, Bell PM \"A comparison of the effects of low- and conventional-dose thiazide diuretic on insulin action in hypertensive patients with NIDDM.\" Diabetologia 38 (1995): 853-9[23] Seltzer HS, Allen EW \"Hyperglycemia and inhibition of insulin secretion during administration of diazoxide and trichlormethiazide in man.\" Diabetes 18 (1969): 19-28[24] Dube MP, Johnson DL, Currier JS, Leedom JM \"Protease inhibitor-associated hyperglycaemia.\" Lancet 350 (1997): 713-4[25] Leary WP, Reyes AJ \"Drug interactions with diuretics.\" S Afr Med J 65 (1984): 455-61[26] \"Product Information. Reyataz (atazanavir).\" Bristol-Myers Squibb, Princeton, NJ.[27] Pollare T, Lithell H, Berne C \"A comparison of the effects of hydrochlorothiazide and captopril on glucose and lipid metabolism in patients with hypertension.\" N Engl J Med 321 (1989): 868-73[28] Gunnarsson R, Lundgren G, Magnusson G, Ost L, Groth CG \"Steroid diabetes--a sign of overtreatment with steroids in the renal graft recipient?\" Scand J Urol Nephrol Suppl 54 (1980): 135-8[29] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[30] \"Product Information. Synthroid (levothyroxine).\" Abbott Pharmaceutical, Abbott Park, IL.[31] Murphy MB, Kohner E, Lewis PJ, Schumer B, Dollery CT \"Glucose intolerance in hypertensive patients treated with diuretics: a fourteen-year follow-up.\" Lancet 2 (1982): 1293-5[32] \"Product Information. Fortovase (saquinavir)\" Roche Laboratories, Nutley, NJ.[33] Coni NK, Gordon PW, Mukherjee AP, Read PR \"The effect of frusemide and ethacrynic acid on carbohydrate metabolism.\" Age Ageing 3 (1974): 85-90[34] \"Product Information. Norvir (ritonavir).\" Abbott Pharmaceutical, Abbott Park, IL.[35] Domenet JG \"Diabetogenic effect of oral diuretics.\" Br Med J 3 (1968): 188[36] Rowe P, Mather H \"Hyperosmolar non-ketotic diabetes mellitus associated with metolazone.\" Br Med J 291 (1985): 25-6[37] Winchester JF, Kellett RJ, Boddy K, Boyle P, Dargie HJ, Mahaffey ME, Ward DM, Kennedy AC \"Metolazone and bendroflumethiazide in hypertension: physiologic and metabolic observations.\" Clin Pharmacol Ther 28 (1980): 611-8[38] \"Product Information. Carafate (sucralfate).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[39] Tsiodras S, Mantzoros C, Hammer S, Samore M \"Effects of protease inhibitors on hyperglycemia, hyperlipidemia, and lipodystrophy - A 5-year cohort study.\" Arch Intern Med 160 (2000): 2050-6[40] \"Product Information. Apidra (insulin glulisine).\" Aventis Pharmaceuticals, Bridgewater, NJ.[41] \"Product Information. Prezista (darunavir).\" Ortho Biotech Inc, Bridgewater, NJ.[42] Haiba NA, el-Habashy MA, Said SA, Darwish EA, Abdel-Sayed WS, Nayel SE \"Clinical evaluation of two monthly injectable contraceptives and their effects on some metabolic parameters.\" Contraception 39 (1989): 619-32[43] Erle G, Basso M, Federspil G, Sicolo N, Scandellari C \"Effect of chlorpromazine on blood glucose and plasma insulin in man.\" Eur J Clin Pharmacol 11 (1977): 15-8[44] Pickkers P, Schachter M, Hughes AD, Feher MD, Sever PS \"Thiazide-induced hyperglycaemia: a role for calcium-activated potassium channels?\" Diabetologia 39 (1996): 861-4[45] \"Product Information. Lexiva (fosamprenavir).\" GlaxoSmithKline, Research Triangle Park, NC.[46] Curtis J, Horrigan F, Ahearn D, Varney R, Sandler SG \"Chlorthalidone-induced hyperosmolar hyperglycemic nonketotic coma.\" JAMA 220 (1972): 1592-3[47] \"Product Information. Hyperstat I.V. (diazoxide).\" Schering Corp, Kenilworth, NJ.[48] \"Product Information. Piqray (alpelisib).\" Novartis Pharmaceuticals, East Hanover, NJ.[49] Bell DS \"Insulin resistance. An often unrecognized problem accompanying chronic medical disorders.\" Postgrad Med 93 (1993): 99-103,[50] Stambaugh JE, Tucker DC \"Effect of diphenylhydantoin on glucose tolerance in patients with hypoglycemia.\" Diabetes 23 (1974): 679-83[51] \"Product Information. Crixivan (indinavir).\" Merck & Co, Inc, West Point, PA.[52] Miller NR, Moses H \"Transient oculomotor nerve palsy. Association with thiazide-induced glucose intolerance.\" JAMA 240 (1978): 1887-8[53] Javier Z, Gershberg H, Hulse M \"Ovulatory suppressants, estrogens, and carbohydrate metabolism.\" Metabolism 17 (1968): 443-56[54] Goldman JA, Ovadia JL \"The effect of estrogen on intravenous glucose tolerance in woman.\" Am J Obstet Gynecol 103 (1969): 172-8[55] Charan VD, Desai N, Singh AP, Choudhry VP \"Diabetes mellitus and pancreatitis as a complication of L- asparaginase therapy.\" Indian Pediatr 30 (1993): 809-10[56] Seifer DB, Freedman LN, Cavender JR, Baker RA \"Insulin-dependent diabetes mellitus associated with danazol.\" Am J Obstet Gynecol 162 (1990): 474-5[57] \"Product Information. Orinase (tolbutamide)\" Pharmacia and Upjohn, Kalamazoo, MI.[58] Walli R, Demant T \"Impaired glucose tolerance and protease inhibitors.\" Ann Intern Med 129 (1998): 837-8[59] Hannaford PC, Kay CR \"Oral contraceptives and diabetes mellitus.\" BMJ 299 (1989): 1315-6[60] Hardy H, Esch LD, Morse GD \"Glucose disorders associated with HIV and its drug therapy.\" Ann Pharmacother 35 (2001): 343-51[61] Chowdhury FR, Bleicher SJ \"Chlorthalidone--induced hypokalemia and abnormal carbohydrate metabolism.\" Horm Metab Res 2 (1970): 13-6[62] Kaufman MB, Simionatto C \"A review of protease inhibitor-induced hyperglycemia.\" Pharmacotherapy 19 (1999): 114-7[63] Greenstone MA, Shaw AB \"Alternate day corticosteroid causes alternate day hyperglycaemia.\" Postgrad Med J 63 (1987): 761-4[64] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[65] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[66] Elmfeldt D, Berglund G, Wedel H, Wilhelmsen L \"Incidence and importance of metabolic side-effects during antihypertensive therapy.\" Acta Med Scand Suppl 672 (1983): 79-83[67] \"Product Information. Agenerase (amprenavir).\" Glaxo Wellcome, Research Triangle Pk, NC.[68] Diamond MT \"Hyperglycemic hyperosmolar coma associated with hydrochlorothiazide and pancreatitis.\" N Y State J Med 72 (1972): 1741-2[69] \"Product Information. Prandin (repaglinide).\" Novo Nordisk Pharmaceuticals Inc, Princeton, NJ.[70] \"Product Information. Precose (acarbose).\" Bayer, West Haven, CT.[71] \"Product Information. Starlix (nateglinide)\" Novartis Pharmaceuticals, East Hanover, NJ.[72] \"Product Information. Oncaspar (pegaspargase).\" Rhone-Poulenc Rorer, Collegeville, PA.[73] Sotaniemi E, Kontturi M, Larmi T \"Effect of diethylstilbestrol on blood glucose of prostatic cancer patients.\" Invest Urol 10 (1973): 438-41[74] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[75] Petri M, Cumber P, Grimes L, Treby D, Bryant R, Rawlins D, Ising H \"The metabolic effects of thiazide therapy in the elderly: a population study.\" Age Ageing 15 (1986): 151-5[76] Ludvik B, Clodi M, Kautzky-Willer A, Capek M, Hartter E, Pacini G, Prager R \"Effect of dexamethasone on insulin sensitivity, islet amyloid polypeptide and insulin secretion in humans.\" Diabetologia 36 (1993): 84-7[77] \"Product Information. Glucophage (metformin).\" Bristol-Myers Squibb, Princeton, NJ.[78] Chaudhuri ML, Catania J \"A comparison of the effects of bumetanide (Burinex) and frusemide on carbohydrate metabolism in the elderly.\" Br J Clin Pract 42 (1988): 427-9[79] Black DM, Filak AT \"Hyperglycemia with non-insulin-dependent diabetes following intraarticular steroid injection.\" J Fam Pract 28 (1989): 462-3[80] \"Product Information. Megace (megestrol).\" Bristol-Myers Squibb, Princeton, NJ.[81] \"Product Information. Torisel (temsirolimus).\" Wyeth-Ayerst Laboratories, Philadelphia, PA.[82] Schmitz O, Hermansen K, Nielsen OH, Christensen CK, Arnfred J, Hansen HE, Mogensen CE, Orskov H, Beck-Nielsen H \"Insulin action in insulin-dependent diabetics after short-term thiazide therapy.\" Diabetes Care 9 (1986): 631-6[83] Kansal PC, Buse J, Buse MG \"Thiazide diuretics and control of diabetes mellitus.\" South Med J 62 (1969): 1372-9[84] Dimitriadis G, Tegos C, Golfinopoulou L, Roboti C, Raptis S \"Furosemide-induced hyperglycaemia - the implication of glycolytic kinases.\" Horm Metab Res 25 (1993): 557-9[85] \"Product Information. NovoLog Mix 70/30 (insulin aspart-insulin aspart protamine).\" Novo Nordisk Pharmaceuticals Inc, Princeton, NJ.[86] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[87] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[88] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[89] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42[90] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[91] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[92] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[93] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[94] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[95] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6", "alternatives_a": "Ketotifen, Mepyramine, Levocetirizine, Chlorcyclizine, Cetirizine, Acrivastine, Triprolidine, Tripelennamine, Azelastine, Dexbrompheniramine, Clemastine, More", "alternatives_b": "Acetohexamide, Guar gum, Simvastatin, Troglitazone, Rosuvastatin", "updated_at": 1767369485}, {"id": 97971, "ingredient1": "Empagliflozin", "ingredient2": "Methotrimeprazine", "severity": "Moderate", "effect": "The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.", "source": "DDInter", "management_text": "Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.", "mechanism_text": "Antagonism", "recommendation": "Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/98075/", "reference_text": "[1] Jori A, Carrara MC \"On the mechanism of the hyperglycaemic effect of chlorpromazine.\" J Pharm Pharmacol 18 (1966): 623-4[2] \"Product Information. Dymelor (acetohexamide)\" Lilly, Eli and Company, Indianapolis, IN.[3] \"Product Information. Thorazine (chlorpromazine).\" SmithKline Beecham, Philadelphia, PA.[4] Blayac JP, Ribes G, Buys D, Puech R, Loubatieres-Mariani MM \"Effects of a new benzothiadiazine derivative, LN 5330, on insulin secretion.\" Arch Int Pharmacodyn Ther 253 (1981): 154-63[5] \"Product Information. Elzonris (tagraxofusp).\" Stemline Therapeutics, New York, NY.[6] \"Product Information. Amaryl (glimepiride).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[7] \"Product Information. Elspar (asparaginase).\" Merck & Co, Inc, West Point, PA.[8] Jones IG, Pickens PT \"Diabetes mellitus following oral diuretics.\" Practitioner 199 (1967): 209-10[9] \"Product Information. Viracept (nelfinavir).\" Agouron Pharma Inc, La Jolla, CA.[10] \"Product Information. Tolinase (tolazamide)\" Pharmacia and Upjohn, Kalamazoo, MI.[11] Mauss S, Wolf E, Jaeger H \"Impaired glucose tolerance in HIV-positive patients receiving and those not receiving protease inhibitors.\" Ann Intern Med 130 (1999): 162-3[12] Virutamasen P, Wongsrichanalai C, Tangkeo P, Nitichai Y, Rienprayoon D \"Metabolic effects of depot-medroxyprogesterone acetate in long-term users: a cross-sectional study.\" Int J Gynaecol Obstet 24 (1986): 291-6[13] Wehring H, Alexander B, Perry PJ \"Diabetes mellitus associated with clozapine therapy.\" Pharmacotherapy 20 (2000): 844-7[14] Spellacy WN, Ellingson AB, Tsibris JC \"The effects of two triphasic oral contraceptives on carbohydrate metabolism in women during 1 year of use.\" Fertil Steril 51 (1989): 71-4[15] Andersen OO, Persson I \"Carbohydrate metabolism during treatment with chlorthalidone and ethacrynic acid.\" Br Med J 2 (1968): 798-801[16] Berlin I \"Prazosin, diuretics, and glucose intolerance.\" Ann Intern Med 119 (1993): 860[17] Malherbe C, Burrill KC, Levin SR, Karam JH, Forsham PH \"Effect of diphenylhydantoin on insulin secretion in man.\" N Engl J Med 286 (1972): 339-42[18] Carter BL, Small RE, Mandel MD, Starkman MT \"Phenytoin-induced hyperglycemia.\" Am J Hosp Pharm 38 (1981): 1508-12[19] Al-Rubeaan K, Ryan EA \"Phenytoin-induced insulin insensitivity.\" Diabet Med 8 (1991): 968-70[20] \"Product Information. Zolinza (vorinostat).\" Merck & Company Inc, West Point, PA.[21] Goldman JA, Neri A, Ovadia J, Eckerling B, Vries A, de \"Effect of chlorothiazide on intravenous glucose tolerance in pregnancy.\" Am J Obstet Gynecol 105 (1969): 556-60[22] Harper R, Ennis CN, Heaney AP, Sheridan B, Gormley M, Atkinson AB, Johnston GD, Bell PM \"A comparison of the effects of low- and conventional-dose thiazide diuretic on insulin action in hypertensive patients with NIDDM.\" Diabetologia 38 (1995): 853-9[23] Seltzer HS, Allen EW \"Hyperglycemia and inhibition of insulin secretion during administration of diazoxide and trichlormethiazide in man.\" Diabetes 18 (1969): 19-28[24] Dube MP, Johnson DL, Currier JS, Leedom JM \"Protease inhibitor-associated hyperglycaemia.\" Lancet 350 (1997): 713-4[25] Leary WP, Reyes AJ \"Drug interactions with diuretics.\" S Afr Med J 65 (1984): 455-61[26] \"Product Information. Reyataz (atazanavir).\" Bristol-Myers Squibb, Princeton, NJ.[27] Pollare T, Lithell H, Berne C \"A comparison of the effects of hydrochlorothiazide and captopril on glucose and lipid metabolism in patients with hypertension.\" N Engl J Med 321 (1989): 868-73[28] Gunnarsson R, Lundgren G, Magnusson G, Ost L, Groth CG \"Steroid diabetes--a sign of overtreatment with steroids in the renal graft recipient?\" Scand J Urol Nephrol Suppl 54 (1980): 135-8[29] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[30] \"Product Information. Synthroid (levothyroxine).\" Abbott Pharmaceutical, Abbott Park, IL.[31] Murphy MB, Kohner E, Lewis PJ, Schumer B, Dollery CT \"Glucose intolerance in hypertensive patients treated with diuretics: a fourteen-year follow-up.\" Lancet 2 (1982): 1293-5[32] \"Product Information. Fortovase (saquinavir)\" Roche Laboratories, Nutley, NJ.[33] Coni NK, Gordon PW, Mukherjee AP, Read PR \"The effect of frusemide and ethacrynic acid on carbohydrate metabolism.\" Age Ageing 3 (1974): 85-90[34] \"Product Information. Norvir (ritonavir).\" Abbott Pharmaceutical, Abbott Park, IL.[35] Domenet JG \"Diabetogenic effect of oral diuretics.\" Br Med J 3 (1968): 188[36] Rowe P, Mather H \"Hyperosmolar non-ketotic diabetes mellitus associated with metolazone.\" Br Med J 291 (1985): 25-6[37] Winchester JF, Kellett RJ, Boddy K, Boyle P, Dargie HJ, Mahaffey ME, Ward DM, Kennedy AC \"Metolazone and bendroflumethiazide in hypertension: physiologic and metabolic observations.\" Clin Pharmacol Ther 28 (1980): 611-8[38] \"Product Information. Carafate (sucralfate).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[39] Tsiodras S, Mantzoros C, Hammer S, Samore M \"Effects of protease inhibitors on hyperglycemia, hyperlipidemia, and lipodystrophy - A 5-year cohort study.\" Arch Intern Med 160 (2000): 2050-6[40] \"Product Information. Apidra (insulin glulisine).\" Aventis Pharmaceuticals, Bridgewater, NJ.[41] \"Product Information. Prezista (darunavir).\" Ortho Biotech Inc, Bridgewater, NJ.[42] Haiba NA, el-Habashy MA, Said SA, Darwish EA, Abdel-Sayed WS, Nayel SE \"Clinical evaluation of two monthly injectable contraceptives and their effects on some metabolic parameters.\" Contraception 39 (1989): 619-32[43] Erle G, Basso M, Federspil G, Sicolo N, Scandellari C \"Effect of chlorpromazine on blood glucose and plasma insulin in man.\" Eur J Clin Pharmacol 11 (1977): 15-8[44] Pickkers P, Schachter M, Hughes AD, Feher MD, Sever PS \"Thiazide-induced hyperglycaemia: a role for calcium-activated potassium channels?\" Diabetologia 39 (1996): 861-4[45] \"Product Information. Lexiva (fosamprenavir).\" GlaxoSmithKline, Research Triangle Park, NC.[46] Curtis J, Horrigan F, Ahearn D, Varney R, Sandler SG \"Chlorthalidone-induced hyperosmolar hyperglycemic nonketotic coma.\" JAMA 220 (1972): 1592-3[47] \"Product Information. Hyperstat I.V. (diazoxide).\" Schering Corp, Kenilworth, NJ.[48] \"Product Information. Piqray (alpelisib).\" Novartis Pharmaceuticals, East Hanover, NJ.[49] Bell DS \"Insulin resistance. An often unrecognized problem accompanying chronic medical disorders.\" Postgrad Med 93 (1993): 99-103,[50] Stambaugh JE, Tucker DC \"Effect of diphenylhydantoin on glucose tolerance in patients with hypoglycemia.\" Diabetes 23 (1974): 679-83[51] \"Product Information. Crixivan (indinavir).\" Merck & Co, Inc, West Point, PA.[52] Miller NR, Moses H \"Transient oculomotor nerve palsy. Association with thiazide-induced glucose intolerance.\" JAMA 240 (1978): 1887-8[53] Javier Z, Gershberg H, Hulse M \"Ovulatory suppressants, estrogens, and carbohydrate metabolism.\" Metabolism 17 (1968): 443-56[54] Goldman JA, Ovadia JL \"The effect of estrogen on intravenous glucose tolerance in woman.\" Am J Obstet Gynecol 103 (1969): 172-8[55] Charan VD, Desai N, Singh AP, Choudhry VP \"Diabetes mellitus and pancreatitis as a complication of L- asparaginase therapy.\" Indian Pediatr 30 (1993): 809-10[56] Seifer DB, Freedman LN, Cavender JR, Baker RA \"Insulin-dependent diabetes mellitus associated with danazol.\" Am J Obstet Gynecol 162 (1990): 474-5[57] \"Product Information. Orinase (tolbutamide)\" Pharmacia and Upjohn, Kalamazoo, MI.[58] Walli R, Demant T \"Impaired glucose tolerance and protease inhibitors.\" Ann Intern Med 129 (1998): 837-8[59] Hannaford PC, Kay CR \"Oral contraceptives and diabetes mellitus.\" BMJ 299 (1989): 1315-6[60] Hardy H, Esch LD, Morse GD \"Glucose disorders associated with HIV and its drug therapy.\" Ann Pharmacother 35 (2001): 343-51[61] Chowdhury FR, Bleicher SJ \"Chlorthalidone--induced hypokalemia and abnormal carbohydrate metabolism.\" Horm Metab Res 2 (1970): 13-6[62] Kaufman MB, Simionatto C \"A review of protease inhibitor-induced hyperglycemia.\" Pharmacotherapy 19 (1999): 114-7[63] Greenstone MA, Shaw AB \"Alternate day corticosteroid causes alternate day hyperglycaemia.\" Postgrad Med J 63 (1987): 761-4[64] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[65] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[66] Elmfeldt D, Berglund G, Wedel H, Wilhelmsen L \"Incidence and importance of metabolic side-effects during antihypertensive therapy.\" Acta Med Scand Suppl 672 (1983): 79-83[67] \"Product Information. Agenerase (amprenavir).\" Glaxo Wellcome, Research Triangle Pk, NC.[68] Diamond MT \"Hyperglycemic hyperosmolar coma associated with hydrochlorothiazide and pancreatitis.\" N Y State J Med 72 (1972): 1741-2[69] \"Product Information. Prandin (repaglinide).\" Novo Nordisk Pharmaceuticals Inc, Princeton, NJ.[70] \"Product Information. Precose (acarbose).\" Bayer, West Haven, CT.[71] \"Product Information. Starlix (nateglinide)\" Novartis Pharmaceuticals, East Hanover, NJ.[72] \"Product Information. Oncaspar (pegaspargase).\" Rhone-Poulenc Rorer, Collegeville, PA.[73] Sotaniemi E, Kontturi M, Larmi T \"Effect of diethylstilbestrol on blood glucose of prostatic cancer patients.\" Invest Urol 10 (1973): 438-41[74] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[75] Petri M, Cumber P, Grimes L, Treby D, Bryant R, Rawlins D, Ising H \"The metabolic effects of thiazide therapy in the elderly: a population study.\" Age Ageing 15 (1986): 151-5[76] Ludvik B, Clodi M, Kautzky-Willer A, Capek M, Hartter E, Pacini G, Prager R \"Effect of dexamethasone on insulin sensitivity, islet amyloid polypeptide and insulin secretion in humans.\" Diabetologia 36 (1993): 84-7[77] \"Product Information. Glucophage (metformin).\" Bristol-Myers Squibb, Princeton, NJ.[78] Chaudhuri ML, Catania J \"A comparison of the effects of bumetanide (Burinex) and frusemide on carbohydrate metabolism in the elderly.\" Br J Clin Pract 42 (1988): 427-9[79] Black DM, Filak AT \"Hyperglycemia with non-insulin-dependent diabetes following intraarticular steroid injection.\" J Fam Pract 28 (1989): 462-3[80] \"Product Information. Megace (megestrol).\" Bristol-Myers Squibb, Princeton, NJ.[81] \"Product Information. Torisel (temsirolimus).\" Wyeth-Ayerst Laboratories, Philadelphia, PA.[82] Schmitz O, Hermansen K, Nielsen OH, Christensen CK, Arnfred J, Hansen HE, Mogensen CE, Orskov H, Beck-Nielsen H \"Insulin action in insulin-dependent diabetics after short-term thiazide therapy.\" Diabetes Care 9 (1986): 631-6[83] Kansal PC, Buse J, Buse MG \"Thiazide diuretics and control of diabetes mellitus.\" South Med J 62 (1969): 1372-9[84] Dimitriadis G, Tegos C, Golfinopoulou L, Roboti C, Raptis S \"Furosemide-induced hyperglycaemia - the implication of glycolytic kinases.\" Horm Metab Res 25 (1993): 557-9[85] \"Product Information. NovoLog Mix 70/30 (insulin aspart-insulin aspart protamine).\" Novo Nordisk Pharmaceuticals Inc, Princeton, NJ.[86] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[87] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[88] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[89] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42[90] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[91] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[92] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[93] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[94] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[95] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6", "alternatives_a": "Haloperidol, Pimavanserin, Thiothixene, Pimozide, Amisulpride, Loxapine, Molindone, Droperidol", "alternatives_b": "Acetohexamide, Guar gum, Simvastatin, Troglitazone, Rosuvastatin", "updated_at": 1767369485}, {"id": 97972, "ingredient1": "Empagliflozin", "ingredient2": "Methoxamine", "severity": "Moderate", "effect": "The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.", "source": "DDInter", "management_text": "Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.", "mechanism_text": "Antagonism", "recommendation": "Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/98076/", "reference_text": "[1] Jori A, Carrara MC \"On the mechanism of the hyperglycaemic effect of chlorpromazine.\" J Pharm Pharmacol 18 (1966): 623-4[2] \"Product Information. Dymelor (acetohexamide)\" Lilly, Eli and Company, Indianapolis, IN.[3] \"Product Information. Thorazine (chlorpromazine).\" SmithKline Beecham, Philadelphia, PA.[4] Blayac JP, Ribes G, Buys D, Puech R, Loubatieres-Mariani MM \"Effects of a new benzothiadiazine derivative, LN 5330, on insulin secretion.\" Arch Int Pharmacodyn Ther 253 (1981): 154-63[5] \"Product Information. Elzonris (tagraxofusp).\" Stemline Therapeutics, New York, NY.[6] \"Product Information. Amaryl (glimepiride).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[7] \"Product Information. Elspar (asparaginase).\" Merck & Co, Inc, West Point, PA.[8] Jones IG, Pickens PT \"Diabetes mellitus following oral diuretics.\" Practitioner 199 (1967): 209-10[9] \"Product Information. Viracept (nelfinavir).\" Agouron Pharma Inc, La Jolla, CA.[10] \"Product Information. Tolinase (tolazamide)\" Pharmacia and Upjohn, Kalamazoo, MI.[11] Mauss S, Wolf E, Jaeger H \"Impaired glucose tolerance in HIV-positive patients receiving and those not receiving protease inhibitors.\" Ann Intern Med 130 (1999): 162-3[12] Virutamasen P, Wongsrichanalai C, Tangkeo P, Nitichai Y, Rienprayoon D \"Metabolic effects of depot-medroxyprogesterone acetate in long-term users: a cross-sectional study.\" Int J Gynaecol Obstet 24 (1986): 291-6[13] Wehring H, Alexander B, Perry PJ \"Diabetes mellitus associated with clozapine therapy.\" Pharmacotherapy 20 (2000): 844-7[14] Spellacy WN, Ellingson AB, Tsibris JC \"The effects of two triphasic oral contraceptives on carbohydrate metabolism in women during 1 year of use.\" Fertil Steril 51 (1989): 71-4[15] Andersen OO, Persson I \"Carbohydrate metabolism during treatment with chlorthalidone and ethacrynic acid.\" Br Med J 2 (1968): 798-801[16] Berlin I \"Prazosin, diuretics, and glucose intolerance.\" Ann Intern Med 119 (1993): 860[17] Malherbe C, Burrill KC, Levin SR, Karam JH, Forsham PH \"Effect of diphenylhydantoin on insulin secretion in man.\" N Engl J Med 286 (1972): 339-42[18] Carter BL, Small RE, Mandel MD, Starkman MT \"Phenytoin-induced hyperglycemia.\" Am J Hosp Pharm 38 (1981): 1508-12[19] Al-Rubeaan K, Ryan EA \"Phenytoin-induced insulin insensitivity.\" Diabet Med 8 (1991): 968-70[20] \"Product Information. Zolinza (vorinostat).\" Merck & Company Inc, West Point, PA.[21] Goldman JA, Neri A, Ovadia J, Eckerling B, Vries A, de \"Effect of chlorothiazide on intravenous glucose tolerance in pregnancy.\" Am J Obstet Gynecol 105 (1969): 556-60[22] Harper R, Ennis CN, Heaney AP, Sheridan B, Gormley M, Atkinson AB, Johnston GD, Bell PM \"A comparison of the effects of low- and conventional-dose thiazide diuretic on insulin action in hypertensive patients with NIDDM.\" Diabetologia 38 (1995): 853-9[23] Seltzer HS, Allen EW \"Hyperglycemia and inhibition of insulin secretion during administration of diazoxide and trichlormethiazide in man.\" Diabetes 18 (1969): 19-28[24] Dube MP, Johnson DL, Currier JS, Leedom JM \"Protease inhibitor-associated hyperglycaemia.\" Lancet 350 (1997): 713-4[25] Leary WP, Reyes AJ \"Drug interactions with diuretics.\" S Afr Med J 65 (1984): 455-61[26] \"Product Information. Reyataz (atazanavir).\" Bristol-Myers Squibb, Princeton, NJ.[27] Pollare T, Lithell H, Berne C \"A comparison of the effects of hydrochlorothiazide and captopril on glucose and lipid metabolism in patients with hypertension.\" N Engl J Med 321 (1989): 868-73[28] Gunnarsson R, Lundgren G, Magnusson G, Ost L, Groth CG \"Steroid diabetes--a sign of overtreatment with steroids in the renal graft recipient?\" Scand J Urol Nephrol Suppl 54 (1980): 135-8[29] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[30] \"Product Information. Synthroid (levothyroxine).\" Abbott Pharmaceutical, Abbott Park, IL.[31] Murphy MB, Kohner E, Lewis PJ, Schumer B, Dollery CT \"Glucose intolerance in hypertensive patients treated with diuretics: a fourteen-year follow-up.\" Lancet 2 (1982): 1293-5[32] \"Product Information. Fortovase (saquinavir)\" Roche Laboratories, Nutley, NJ.[33] Coni NK, Gordon PW, Mukherjee AP, Read PR \"The effect of frusemide and ethacrynic acid on carbohydrate metabolism.\" Age Ageing 3 (1974): 85-90[34] \"Product Information. Norvir (ritonavir).\" Abbott Pharmaceutical, Abbott Park, IL.[35] Domenet JG \"Diabetogenic effect of oral diuretics.\" Br Med J 3 (1968): 188[36] Rowe P, Mather H \"Hyperosmolar non-ketotic diabetes mellitus associated with metolazone.\" Br Med J 291 (1985): 25-6[37] Winchester JF, Kellett RJ, Boddy K, Boyle P, Dargie HJ, Mahaffey ME, Ward DM, Kennedy AC \"Metolazone and bendroflumethiazide in hypertension: physiologic and metabolic observations.\" Clin Pharmacol Ther 28 (1980): 611-8[38] \"Product Information. Carafate (sucralfate).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[39] Tsiodras S, Mantzoros C, Hammer S, Samore M \"Effects of protease inhibitors on hyperglycemia, hyperlipidemia, and lipodystrophy - A 5-year cohort study.\" Arch Intern Med 160 (2000): 2050-6[40] \"Product Information. Apidra (insulin glulisine).\" Aventis Pharmaceuticals, Bridgewater, NJ.[41] \"Product Information. Prezista (darunavir).\" Ortho Biotech Inc, Bridgewater, NJ.[42] Haiba NA, el-Habashy MA, Said SA, Darwish EA, Abdel-Sayed WS, Nayel SE \"Clinical evaluation of two monthly injectable contraceptives and their effects on some metabolic parameters.\" Contraception 39 (1989): 619-32[43] Erle G, Basso M, Federspil G, Sicolo N, Scandellari C \"Effect of chlorpromazine on blood glucose and plasma insulin in man.\" Eur J Clin Pharmacol 11 (1977): 15-8[44] Pickkers P, Schachter M, Hughes AD, Feher MD, Sever PS \"Thiazide-induced hyperglycaemia: a role for calcium-activated potassium channels?\" Diabetologia 39 (1996): 861-4[45] \"Product Information. Lexiva (fosamprenavir).\" GlaxoSmithKline, Research Triangle Park, NC.[46] Curtis J, Horrigan F, Ahearn D, Varney R, Sandler SG \"Chlorthalidone-induced hyperosmolar hyperglycemic nonketotic coma.\" JAMA 220 (1972): 1592-3[47] \"Product Information. Hyperstat I.V. (diazoxide).\" Schering Corp, Kenilworth, NJ.[48] \"Product Information. Piqray (alpelisib).\" Novartis Pharmaceuticals, East Hanover, NJ.[49] Bell DS \"Insulin resistance. An often unrecognized problem accompanying chronic medical disorders.\" Postgrad Med 93 (1993): 99-103,[50] Stambaugh JE, Tucker DC \"Effect of diphenylhydantoin on glucose tolerance in patients with hypoglycemia.\" Diabetes 23 (1974): 679-83[51] \"Product Information. Crixivan (indinavir).\" Merck & Co, Inc, West Point, PA.[52] Miller NR, Moses H \"Transient oculomotor nerve palsy. Association with thiazide-induced glucose intolerance.\" JAMA 240 (1978): 1887-8[53] Javier Z, Gershberg H, Hulse M \"Ovulatory suppressants, estrogens, and carbohydrate metabolism.\" Metabolism 17 (1968): 443-56[54] Goldman JA, Ovadia JL \"The effect of estrogen on intravenous glucose tolerance in woman.\" Am J Obstet Gynecol 103 (1969): 172-8[55] Charan VD, Desai N, Singh AP, Choudhry VP \"Diabetes mellitus and pancreatitis as a complication of L- asparaginase therapy.\" Indian Pediatr 30 (1993): 809-10[56] Seifer DB, Freedman LN, Cavender JR, Baker RA \"Insulin-dependent diabetes mellitus associated with danazol.\" Am J Obstet Gynecol 162 (1990): 474-5[57] \"Product Information. Orinase (tolbutamide)\" Pharmacia and Upjohn, Kalamazoo, MI.[58] Walli R, Demant T \"Impaired glucose tolerance and protease inhibitors.\" Ann Intern Med 129 (1998): 837-8[59] Hannaford PC, Kay CR \"Oral contraceptives and diabetes mellitus.\" BMJ 299 (1989): 1315-6[60] Hardy H, Esch LD, Morse GD \"Glucose disorders associated with HIV and its drug therapy.\" Ann Pharmacother 35 (2001): 343-51[61] Chowdhury FR, Bleicher SJ \"Chlorthalidone--induced hypokalemia and abnormal carbohydrate metabolism.\" Horm Metab Res 2 (1970): 13-6[62] Kaufman MB, Simionatto C \"A review of protease inhibitor-induced hyperglycemia.\" Pharmacotherapy 19 (1999): 114-7[63] Greenstone MA, Shaw AB \"Alternate day corticosteroid causes alternate day hyperglycaemia.\" Postgrad Med J 63 (1987): 761-4[64] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[65] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[66] Elmfeldt D, Berglund G, Wedel H, Wilhelmsen L \"Incidence and importance of metabolic side-effects during antihypertensive therapy.\" Acta Med Scand Suppl 672 (1983): 79-83[67] \"Product Information. Agenerase (amprenavir).\" Glaxo Wellcome, Research Triangle Pk, NC.[68] Diamond MT \"Hyperglycemic hyperosmolar coma associated with hydrochlorothiazide and pancreatitis.\" N Y State J Med 72 (1972): 1741-2[69] \"Product Information. Prandin (repaglinide).\" Novo Nordisk Pharmaceuticals Inc, Princeton, NJ.[70] \"Product Information. Precose (acarbose).\" Bayer, West Haven, CT.[71] \"Product Information. Starlix (nateglinide)\" Novartis Pharmaceuticals, East Hanover, NJ.[72] \"Product Information. Oncaspar (pegaspargase).\" Rhone-Poulenc Rorer, Collegeville, PA.[73] Sotaniemi E, Kontturi M, Larmi T \"Effect of diethylstilbestrol on blood glucose of prostatic cancer patients.\" Invest Urol 10 (1973): 438-41[74] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[75] Petri M, Cumber P, Grimes L, Treby D, Bryant R, Rawlins D, Ising H \"The metabolic effects of thiazide therapy in the elderly: a population study.\" Age Ageing 15 (1986): 151-5[76] Ludvik B, Clodi M, Kautzky-Willer A, Capek M, Hartter E, Pacini G, Prager R \"Effect of dexamethasone on insulin sensitivity, islet amyloid polypeptide and insulin secretion in humans.\" Diabetologia 36 (1993): 84-7[77] \"Product Information. Glucophage (metformin).\" Bristol-Myers Squibb, Princeton, NJ.[78] Chaudhuri ML, Catania J \"A comparison of the effects of bumetanide (Burinex) and frusemide on carbohydrate metabolism in the elderly.\" Br J Clin Pract 42 (1988): 427-9[79] Black DM, Filak AT \"Hyperglycemia with non-insulin-dependent diabetes following intraarticular steroid injection.\" J Fam Pract 28 (1989): 462-3[80] \"Product Information. Megace (megestrol).\" Bristol-Myers Squibb, Princeton, NJ.[81] \"Product Information. Torisel (temsirolimus).\" Wyeth-Ayerst Laboratories, Philadelphia, PA.[82] Schmitz O, Hermansen K, Nielsen OH, Christensen CK, Arnfred J, Hansen HE, Mogensen CE, Orskov H, Beck-Nielsen H \"Insulin action in insulin-dependent diabetics after short-term thiazide therapy.\" Diabetes Care 9 (1986): 631-6[83] Kansal PC, Buse J, Buse MG \"Thiazide diuretics and control of diabetes mellitus.\" South Med J 62 (1969): 1372-9[84] Dimitriadis G, Tegos C, Golfinopoulou L, Roboti C, Raptis S \"Furosemide-induced hyperglycaemia - the implication of glycolytic kinases.\" Horm Metab Res 25 (1993): 557-9[85] \"Product Information. NovoLog Mix 70/30 (insulin aspart-insulin aspart protamine).\" Novo Nordisk Pharmaceuticals Inc, Princeton, NJ.[86] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[87] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[88] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[89] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42[90] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[91] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[92] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[93] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[94] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[95] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6", "alternatives_a": "Droxidopa, Midodrine, Amrinone, Angiotensin II, Milrinone, Arbutamine", "alternatives_b": "Acetohexamide, Guar gum, Simvastatin, Troglitazone, Rosuvastatin", "updated_at": 1767369485}, {"id": 97973, "ingredient1": "Empagliflozin", "ingredient2": "Methyldopa", "severity": "Moderate", "effect": "Sodium-glucose co-transporter 2 (SGLT-2) inhibitors may potentiate the hypotensive effects of diuretics and other antihypertensive agents or vasodilators. Inhibition of glucose and sodium co-transport produces mild diuresis and transient natriuresis, resulting in intravascular volume contraction. Volume depletion-related adverse reactions including hypotension, postural dizziness, orthostatic hypotension, syncope, and dehydration can occur after initiating treatment with SGLT-2 inhibitors, and the risk may be increased with concomitant use of other agents that can lower blood pressure.", "source": "DDInter", "management_text": "Caution is advised if SGLT-2 inhibitors are coadministered with diuretics and other hypotensive agents, particularly in the elderly and patients with impaired renal function. Prior to initiating SGLT-2 inhibitors, volume status should be assessed and corrected, if necessary. Clinical and laboratory monitoring are recommended during therapy, including electrolytes, fluid status, renal function, and blood pressure. If volume depletion occurs, treatment with SGLT-2 inhibitors should be interrupted until the condition is corrected.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if SGLT-2 inhibitors are coadministered with diuretics and other hypotensive agents, particularly in the elderly and patients with impaired renal function.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/98077/", "reference_text": "[1] \"Product Information. Jardiance (empagliflozin).\" Boehringer Ingelheim, Ridgefield, CT.[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] \"Product Information. Farxiga (dapagliflozin).\" Bristol-Myers Squibb, Princeton, NJ.[5] \"Product Information. Invokana (canagliflozin).\" Janssen Pharmaceuticals, Titusville, NJ.[6] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[7] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[8] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[9] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[10] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[11] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6[12] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[13] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[14] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[15] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42", "alternatives_a": "Lixisenatide, Albiglutide, Guar gum, Pramlintide, Sitagliptin, Alogliptin, Liraglutide, Troglitazone, Semaglutide, Linagliptin, Nateglinide, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 97974, "ingredient1": "Empagliflozin", "ingredient2": "Methylprednisolone", "severity": "Moderate", "effect": "The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.", "source": "DDInter", "management_text": "Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.", "mechanism_text": "Antagonism", "recommendation": "Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/98078/", "reference_text": "[1] Jori A, Carrara MC \"On the mechanism of the hyperglycaemic effect of chlorpromazine.\" J Pharm Pharmacol 18 (1966): 623-4[2] \"Product Information. Dymelor (acetohexamide)\" Lilly, Eli and Company, Indianapolis, IN.[3] \"Product Information. Thorazine (chlorpromazine).\" SmithKline Beecham, Philadelphia, PA.[4] Blayac JP, Ribes G, Buys D, Puech R, Loubatieres-Mariani MM \"Effects of a new benzothiadiazine derivative, LN 5330, on insulin secretion.\" Arch Int Pharmacodyn Ther 253 (1981): 154-63[5] \"Product Information. Elzonris (tagraxofusp).\" Stemline Therapeutics, New York, NY.[6] \"Product Information. Amaryl (glimepiride).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[7] \"Product Information. Elspar (asparaginase).\" Merck & Co, Inc, West Point, PA.[8] Jones IG, Pickens PT \"Diabetes mellitus following oral diuretics.\" Practitioner 199 (1967): 209-10[9] \"Product Information. Viracept (nelfinavir).\" Agouron Pharma Inc, La Jolla, CA.[10] \"Product Information. Tolinase (tolazamide)\" Pharmacia and Upjohn, Kalamazoo, MI.[11] Mauss S, Wolf E, Jaeger H \"Impaired glucose tolerance in HIV-positive patients receiving and those not receiving protease inhibitors.\" Ann Intern Med 130 (1999): 162-3[12] Virutamasen P, Wongsrichanalai C, Tangkeo P, Nitichai Y, Rienprayoon D \"Metabolic effects of depot-medroxyprogesterone acetate in long-term users: a cross-sectional study.\" Int J Gynaecol Obstet 24 (1986): 291-6[13] Wehring H, Alexander B, Perry PJ \"Diabetes mellitus associated with clozapine therapy.\" Pharmacotherapy 20 (2000): 844-7[14] Spellacy WN, Ellingson AB, Tsibris JC \"The effects of two triphasic oral contraceptives on carbohydrate metabolism in women during 1 year of use.\" Fertil Steril 51 (1989): 71-4[15] Andersen OO, Persson I \"Carbohydrate metabolism during treatment with chlorthalidone and ethacrynic acid.\" Br Med J 2 (1968): 798-801[16] Berlin I \"Prazosin, diuretics, and glucose intolerance.\" Ann Intern Med 119 (1993): 860[17] Malherbe C, Burrill KC, Levin SR, Karam JH, Forsham PH \"Effect of diphenylhydantoin on insulin secretion in man.\" N Engl J Med 286 (1972): 339-42[18] Carter BL, Small RE, Mandel MD, Starkman MT \"Phenytoin-induced hyperglycemia.\" Am J Hosp Pharm 38 (1981): 1508-12[19] Al-Rubeaan K, Ryan EA \"Phenytoin-induced insulin insensitivity.\" Diabet Med 8 (1991): 968-70[20] \"Product Information. Zolinza (vorinostat).\" Merck & Company Inc, West Point, PA.[21] Goldman JA, Neri A, Ovadia J, Eckerling B, Vries A, de \"Effect of chlorothiazide on intravenous glucose tolerance in pregnancy.\" Am J Obstet Gynecol 105 (1969): 556-60[22] Harper R, Ennis CN, Heaney AP, Sheridan B, Gormley M, Atkinson AB, Johnston GD, Bell PM \"A comparison of the effects of low- and conventional-dose thiazide diuretic on insulin action in hypertensive patients with NIDDM.\" Diabetologia 38 (1995): 853-9[23] Seltzer HS, Allen EW \"Hyperglycemia and inhibition of insulin secretion during administration of diazoxide and trichlormethiazide in man.\" Diabetes 18 (1969): 19-28[24] Dube MP, Johnson DL, Currier JS, Leedom JM \"Protease inhibitor-associated hyperglycaemia.\" Lancet 350 (1997): 713-4[25] Leary WP, Reyes AJ \"Drug interactions with diuretics.\" S Afr Med J 65 (1984): 455-61[26] \"Product Information. Reyataz (atazanavir).\" Bristol-Myers Squibb, Princeton, NJ.[27] Pollare T, Lithell H, Berne C \"A comparison of the effects of hydrochlorothiazide and captopril on glucose and lipid metabolism in patients with hypertension.\" N Engl J Med 321 (1989): 868-73[28] Gunnarsson R, Lundgren G, Magnusson G, Ost L, Groth CG \"Steroid diabetes--a sign of overtreatment with steroids in the renal graft recipient?\" Scand J Urol Nephrol Suppl 54 (1980): 135-8[29] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[30] \"Product Information. Synthroid (levothyroxine).\" Abbott Pharmaceutical, Abbott Park, IL.[31] Murphy MB, Kohner E, Lewis PJ, Schumer B, Dollery CT \"Glucose intolerance in hypertensive patients treated with diuretics: a fourteen-year follow-up.\" Lancet 2 (1982): 1293-5[32] \"Product Information. Fortovase (saquinavir)\" Roche Laboratories, Nutley, NJ.[33] Coni NK, Gordon PW, Mukherjee AP, Read PR \"The effect of frusemide and ethacrynic acid on carbohydrate metabolism.\" Age Ageing 3 (1974): 85-90[34] \"Product Information. Norvir (ritonavir).\" Abbott Pharmaceutical, Abbott Park, IL.[35] Domenet JG \"Diabetogenic effect of oral diuretics.\" Br Med J 3 (1968): 188[36] Rowe P, Mather H \"Hyperosmolar non-ketotic diabetes mellitus associated with metolazone.\" Br Med J 291 (1985): 25-6[37] Winchester JF, Kellett RJ, Boddy K, Boyle P, Dargie HJ, Mahaffey ME, Ward DM, Kennedy AC \"Metolazone and bendroflumethiazide in hypertension: physiologic and metabolic observations.\" Clin Pharmacol Ther 28 (1980): 611-8[38] \"Product Information. Carafate (sucralfate).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[39] Tsiodras S, Mantzoros C, Hammer S, Samore M \"Effects of protease inhibitors on hyperglycemia, hyperlipidemia, and lipodystrophy - A 5-year cohort study.\" Arch Intern Med 160 (2000): 2050-6[40] \"Product Information. Apidra (insulin glulisine).\" Aventis Pharmaceuticals, Bridgewater, NJ.[41] \"Product Information. Prezista (darunavir).\" Ortho Biotech Inc, Bridgewater, NJ.[42] Haiba NA, el-Habashy MA, Said SA, Darwish EA, Abdel-Sayed WS, Nayel SE \"Clinical evaluation of two monthly injectable contraceptives and their effects on some metabolic parameters.\" Contraception 39 (1989): 619-32[43] Erle G, Basso M, Federspil G, Sicolo N, Scandellari C \"Effect of chlorpromazine on blood glucose and plasma insulin in man.\" Eur J Clin Pharmacol 11 (1977): 15-8[44] Pickkers P, Schachter M, Hughes AD, Feher MD, Sever PS \"Thiazide-induced hyperglycaemia: a role for calcium-activated potassium channels?\" Diabetologia 39 (1996): 861-4[45] \"Product Information. Lexiva (fosamprenavir).\" GlaxoSmithKline, Research Triangle Park, NC.[46] Curtis J, Horrigan F, Ahearn D, Varney R, Sandler SG \"Chlorthalidone-induced hyperosmolar hyperglycemic nonketotic coma.\" JAMA 220 (1972): 1592-3[47] \"Product Information. Hyperstat I.V. (diazoxide).\" Schering Corp, Kenilworth, NJ.[48] \"Product Information. Piqray (alpelisib).\" Novartis Pharmaceuticals, East Hanover, NJ.[49] Bell DS \"Insulin resistance. An often unrecognized problem accompanying chronic medical disorders.\" Postgrad Med 93 (1993): 99-103,[50] Stambaugh JE, Tucker DC \"Effect of diphenylhydantoin on glucose tolerance in patients with hypoglycemia.\" Diabetes 23 (1974): 679-83[51] \"Product Information. Crixivan (indinavir).\" Merck & Co, Inc, West Point, PA.[52] Miller NR, Moses H \"Transient oculomotor nerve palsy. Association with thiazide-induced glucose intolerance.\" JAMA 240 (1978): 1887-8[53] Javier Z, Gershberg H, Hulse M \"Ovulatory suppressants, estrogens, and carbohydrate metabolism.\" Metabolism 17 (1968): 443-56[54] Goldman JA, Ovadia JL \"The effect of estrogen on intravenous glucose tolerance in woman.\" Am J Obstet Gynecol 103 (1969): 172-8[55] Charan VD, Desai N, Singh AP, Choudhry VP \"Diabetes mellitus and pancreatitis as a complication of L- asparaginase therapy.\" Indian Pediatr 30 (1993): 809-10[56] Seifer DB, Freedman LN, Cavender JR, Baker RA \"Insulin-dependent diabetes mellitus associated with danazol.\" Am J Obstet Gynecol 162 (1990): 474-5[57] \"Product Information. Orinase (tolbutamide)\" Pharmacia and Upjohn, Kalamazoo, MI.[58] Walli R, Demant T \"Impaired glucose tolerance and protease inhibitors.\" Ann Intern Med 129 (1998): 837-8[59] Hannaford PC, Kay CR \"Oral contraceptives and diabetes mellitus.\" BMJ 299 (1989): 1315-6[60] Hardy H, Esch LD, Morse GD \"Glucose disorders associated with HIV and its drug therapy.\" Ann Pharmacother 35 (2001): 343-51[61] Chowdhury FR, Bleicher SJ \"Chlorthalidone--induced hypokalemia and abnormal carbohydrate metabolism.\" Horm Metab Res 2 (1970): 13-6[62] Kaufman MB, Simionatto C \"A review of protease inhibitor-induced hyperglycemia.\" Pharmacotherapy 19 (1999): 114-7[63] Greenstone MA, Shaw AB \"Alternate day corticosteroid causes alternate day hyperglycaemia.\" Postgrad Med J 63 (1987): 761-4[64] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[65] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[66] Elmfeldt D, Berglund G, Wedel H, Wilhelmsen L \"Incidence and importance of metabolic side-effects during antihypertensive therapy.\" Acta Med Scand Suppl 672 (1983): 79-83[67] \"Product Information. Agenerase (amprenavir).\" Glaxo Wellcome, Research Triangle Pk, NC.[68] Diamond MT \"Hyperglycemic hyperosmolar coma associated with hydrochlorothiazide and pancreatitis.\" N Y State J Med 72 (1972): 1741-2[69] \"Product Information. Prandin (repaglinide).\" Novo Nordisk Pharmaceuticals Inc, Princeton, NJ.[70] \"Product Information. Precose (acarbose).\" Bayer, West Haven, CT.[71] \"Product Information. Starlix (nateglinide)\" Novartis Pharmaceuticals, East Hanover, NJ.[72] \"Product Information. Oncaspar (pegaspargase).\" Rhone-Poulenc Rorer, Collegeville, PA.[73] Sotaniemi E, Kontturi M, Larmi T \"Effect of diethylstilbestrol on blood glucose of prostatic cancer patients.\" Invest Urol 10 (1973): 438-41[74] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[75] Petri M, Cumber P, Grimes L, Treby D, Bryant R, Rawlins D, Ising H \"The metabolic effects of thiazide therapy in the elderly: a population study.\" Age Ageing 15 (1986): 151-5[76] Ludvik B, Clodi M, Kautzky-Willer A, Capek M, Hartter E, Pacini G, Prager R \"Effect of dexamethasone on insulin sensitivity, islet amyloid polypeptide and insulin secretion in humans.\" Diabetologia 36 (1993): 84-7[77] \"Product Information. Glucophage (metformin).\" Bristol-Myers Squibb, Princeton, NJ.[78] Chaudhuri ML, Catania J \"A comparison of the effects of bumetanide (Burinex) and frusemide on carbohydrate metabolism in the elderly.\" Br J Clin Pract 42 (1988): 427-9[79] Black DM, Filak AT \"Hyperglycemia with non-insulin-dependent diabetes following intraarticular steroid injection.\" J Fam Pract 28 (1989): 462-3[80] \"Product Information. Megace (megestrol).\" Bristol-Myers Squibb, Princeton, NJ.[81] \"Product Information. Torisel (temsirolimus).\" Wyeth-Ayerst Laboratories, Philadelphia, PA.[82] Schmitz O, Hermansen K, Nielsen OH, Christensen CK, Arnfred J, Hansen HE, Mogensen CE, Orskov H, Beck-Nielsen H \"Insulin action in insulin-dependent diabetics after short-term thiazide therapy.\" Diabetes Care 9 (1986): 631-6[83] Kansal PC, Buse J, Buse MG \"Thiazide diuretics and control of diabetes mellitus.\" South Med J 62 (1969): 1372-9[84] Dimitriadis G, Tegos C, Golfinopoulou L, Roboti C, Raptis S \"Furosemide-induced hyperglycaemia - the implication of glycolytic kinases.\" Horm Metab Res 25 (1993): 557-9[85] \"Product Information. NovoLog Mix 70/30 (insulin aspart-insulin aspart protamine).\" Novo Nordisk Pharmaceuticals Inc, Princeton, NJ.[86] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[87] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[88] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[89] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42[90] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[91] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[92] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[93] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[94] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[95] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6", "alternatives_a": "Minocycline, Clindamycin, Vitamin A, Isotretinoin, Chloramphenicol, Fluorometholone, Tretinoin, Erythromycin, Dapsone, Azelaic acid, Adapalene, More", "alternatives_b": "Guar gum", "updated_at": 1767369485}, {"id": 97975, "ingredient1": "Empagliflozin", "ingredient2": "Methylprednisolone (topical)", "severity": "Minor", "effect": "The efficacy of insulin and other antidiabetic agents may be diminished by topical corticosteroids, particularly during prolonged or indiscriminate use. Corticosteroids can raise blood glucose level by antagonizing the action and suppressing the secretion of insulin, which results in inhibition of peripheral glucose uptake and increased gluconeogenesis. The duration of administration Close clinical monitoring of glycemic control is recommended if topical corticosteroids are administered chronically and/or to large areas in diabetic patients.", "source": "DDInter", "management_text": "-", "mechanism_text": "Antagonism", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/98079/", "reference_text": "[1] Pace WE \"Topical corticosteroids.\" Can Med Assoc J 108 (1973): 11 passim[2] Seale JP, Compton MR \"Side-effects of corticosteroid agents.\" Med J Aust 144 (1986): 139-42[3] \"Product Information. Psorcon (diflorasone topical).\" Rhone-Poulenc Rorer, Collegeville, PA.[4] \"Product Information. Temovate (clobetasol).\" Glaxo Wellcome, Research Triangle Park, NC.[5] \"Product Information. Ultravate (halobetasol).\" Bristol-Myers Squibb, Princeton, NJ.[6] Carruthers JA, Staughton RC, August PJ \"Penetration of topical steroid preparations.\" Arch Dermatol 113 (1977): 522[7] Ludvik B, Clodi M, Kautzky-Willer A, Capek M, Hartter E, Pacini G, Prager R \"Effect of dexamethasone on insulin sensitivity, islet amyloid polypeptide and insulin secretion in humans.\" Diabetologia 36 (1993): 84-7[8] \"Product Information. Diprolene (betamethasone topical).\" Schering Laboratories, Kenilworth, NJ.[9] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[10] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[11] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[12] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42[13] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[14] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[15] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[16] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[17] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[18] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6", "alternatives_a": "Minocycline, Clindamycin, Vitamin A, Isotretinoin, Chloramphenicol, Fluorometholone, Tretinoin, Erythromycin, Dapsone, Azelaic acid, Adapalene, More", "alternatives_b": "Simvastatin, Guar gum, Rosuvastatin", "updated_at": 1767369485}, {"id": 97976, "ingredient1": "Empagliflozin", "ingredient2": "Metolazone", "severity": "Moderate", "effect": "Sodium-glucose co-transporter 2 (SGLT-2) inhibitors may potentiate the diuretic and hypotensive effects of thiazides. Inhibition of glucose and sodium co-transport produces mild diuresis and transient natriuresis, resulting in intravascular volume contraction.", "source": "DDInter", "management_text": "Caution is advised during concomitant use of SGLT-2 inhibitors and thiazides, particularly in the elderly and patients with impaired renal function. Prior to initiating SGLT-2 inhibitors, volume status should be assessed and corrected, if necessary. Clinical and laboratory monitoring are recommended during therapy, including electrolytes, fluid status, renal function, and blood pressure. Blood glucose should also be monitored more closely. If volume depletion occurs, treatment with SGLT-2 inhibitors should be interrupted until the condition is corrected.", "mechanism_text": "Synergism", "recommendation": "Caution is advised during concomitant use of SGLT-2 inhibitors and thiazides, particularly in the elderly and patients with impaired renal function.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/98080/", "reference_text": "[1] \"Product Information. Steglatro (ertugliflozin).\" Merck & Company Inc, Whitehouse Station, NJ.[2] \"Product Information. Invokana (canagliflozin).\" Janssen Pharmaceuticals, Titusville, NJ.[3] \"Product Information. Farxiga (dapagliflozin).\" Bristol-Myers Squibb, Princeton, NJ.[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Jardiance (empagliflozin).\" Boehringer Ingelheim, Ridgefield, CT.[7] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[8] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[9] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[10] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[11] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[12] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6[13] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[14] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[15] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[16] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42", "alternatives_a": "Tinidazole, Ascorbic acid, Metronidazole, Rosuvastatin, Sulfadiazine, Lactic acid, Amphotericin B, Clindamycin, Ciclopirox, Vemurafenib, Ketoconazole, More", "alternatives_b": "Guar gum", "updated_at": 1767369485}, {"id": 97977, "ingredient1": "Empagliflozin", "ingredient2": "Metoprolol", "severity": "Moderate", "effect": "Sodium-glucose co-transporter 2 (SGLT-2) inhibitors may potentiate the hypotensive effects of diuretics and other antihypertensive agents or vasodilators. Inhibition of glucose and sodium co-transport produces mild diuresis and transient natriuresis, resulting in intravascular volume contraction. Volume depletion-related adverse reactions including hypotension, postural dizziness, orthostatic hypotension, syncope, and dehydration can occur after initiating treatment with SGLT-2 inhibitors, and the risk may be increased with concomitant use of other agents that can lower blood pressure.", "source": "DDInter", "management_text": "Caution is advised if SGLT-2 inhibitors are coadministered with diuretics and other hypotensive agents, particularly in the elderly and patients with impaired renal function. Prior to initiating SGLT-2 inhibitors, volume status should be assessed and corrected, if necessary. Clinical and laboratory monitoring are recommended during therapy, including electrolytes, fluid status, renal function, and blood pressure. If volume depletion occurs, treatment with SGLT-2 inhibitors should be interrupted until the condition is corrected.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if SGLT-2 inhibitors are coadministered with diuretics and other hypotensive agents, particularly in the elderly and patients with impaired renal function.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/98081/", "reference_text": "[1] \"Product Information. Jardiance (empagliflozin).\" Boehringer Ingelheim, Ridgefield, CT.[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] \"Product Information. Farxiga (dapagliflozin).\" Bristol-Myers Squibb, Princeton, NJ.[5] \"Product Information. Invokana (canagliflozin).\" Janssen Pharmaceuticals, Titusville, NJ.[6] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[7] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[8] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[9] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[10] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[11] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6[12] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[13] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[14] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[15] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42", "alternatives_a": "Acetylsalicylic acid, Ivabradine", "alternatives_b": "Lixisenatide, Albiglutide, Guar gum, Pramlintide, Sitagliptin, Alogliptin, Liraglutide, Troglitazone, Semaglutide, Linagliptin, Dulaglutide, More", "updated_at": 1767369485}, {"id": 97978, "ingredient1": "Empagliflozin", "ingredient2": "Metyrosine", "severity": "Moderate", "effect": "Sodium-glucose co-transporter 2 (SGLT-2) inhibitors may potentiate the hypotensive effects of diuretics and other antihypertensive agents or vasodilators. Inhibition of glucose and sodium co-transport produces mild diuresis and transient natriuresis, resulting in intravascular volume contraction. Volume depletion-related adverse reactions including hypotension, postural dizziness, orthostatic hypotension, syncope, and dehydration can occur after initiating treatment with SGLT-2 inhibitors, and the risk may be increased with concomitant use of other agents that can lower blood pressure.", "source": "DDInter", "management_text": "Caution is advised if SGLT-2 inhibitors are coadministered with diuretics and other hypotensive agents, particularly in the elderly and patients with impaired renal function. Prior to initiating SGLT-2 inhibitors, volume status should be assessed and corrected, if necessary. Clinical and laboratory monitoring are recommended during therapy, including electrolytes, fluid status, renal function, and blood pressure. If volume depletion occurs, treatment with SGLT-2 inhibitors should be interrupted until the condition is corrected.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if SGLT-2 inhibitors are coadministered with diuretics and other hypotensive agents, particularly in the elderly and patients with impaired renal function.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/98082/", "reference_text": "[1] \"Product Information. Jardiance (empagliflozin).\" Boehringer Ingelheim, Ridgefield, CT.[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] \"Product Information. Farxiga (dapagliflozin).\" Bristol-Myers Squibb, Princeton, NJ.[5] \"Product Information. Invokana (canagliflozin).\" Janssen Pharmaceuticals, Titusville, NJ.[6] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[7] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[8] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[9] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[10] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[11] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6[12] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[13] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[14] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[15] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42", "alternatives_a": "Macitentan", "alternatives_b": "Glipizide, Acetohexamide, Guar gum, Pramlintide, Alogliptin, Rosuvastatin, Tolazamide, Dulaglutide, Exenatide, Tolbutamide, Miglitol, More", "updated_at": 1767369485}, {"id": 97979, "ingredient1": "Empagliflozin", "ingredient2": "Midostaurin", "severity": "Moderate", "effect": "The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.", "source": "DDInter", "management_text": "Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.", "mechanism_text": "Antagonism", "recommendation": "Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/98083/", "reference_text": "[1] Jori A, Carrara MC \"On the mechanism of the hyperglycaemic effect of chlorpromazine.\" J Pharm Pharmacol 18 (1966): 623-4[2] \"Product Information. Dymelor (acetohexamide)\" Lilly, Eli and Company, Indianapolis, IN.[3] \"Product Information. Thorazine (chlorpromazine).\" SmithKline Beecham, Philadelphia, PA.[4] Blayac JP, Ribes G, Buys D, Puech R, Loubatieres-Mariani MM \"Effects of a new benzothiadiazine derivative, LN 5330, on insulin secretion.\" Arch Int Pharmacodyn Ther 253 (1981): 154-63[5] \"Product Information. Elzonris (tagraxofusp).\" Stemline Therapeutics, New York, NY.[6] \"Product Information. Amaryl (glimepiride).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[7] \"Product Information. Elspar (asparaginase).\" Merck & Co, Inc, West Point, PA.[8] Jones IG, Pickens PT \"Diabetes mellitus following oral diuretics.\" Practitioner 199 (1967): 209-10[9] \"Product Information. Viracept (nelfinavir).\" Agouron Pharma Inc, La Jolla, CA.[10] \"Product Information. Tolinase (tolazamide)\" Pharmacia and Upjohn, Kalamazoo, MI.[11] Mauss S, Wolf E, Jaeger H \"Impaired glucose tolerance in HIV-positive patients receiving and those not receiving protease inhibitors.\" Ann Intern Med 130 (1999): 162-3[12] Virutamasen P, Wongsrichanalai C, Tangkeo P, Nitichai Y, Rienprayoon D \"Metabolic effects of depot-medroxyprogesterone acetate in long-term users: a cross-sectional study.\" Int J Gynaecol Obstet 24 (1986): 291-6[13] Wehring H, Alexander B, Perry PJ \"Diabetes mellitus associated with clozapine therapy.\" Pharmacotherapy 20 (2000): 844-7[14] Spellacy WN, Ellingson AB, Tsibris JC \"The effects of two triphasic oral contraceptives on carbohydrate metabolism in women during 1 year of use.\" Fertil Steril 51 (1989): 71-4[15] Andersen OO, Persson I \"Carbohydrate metabolism during treatment with chlorthalidone and ethacrynic acid.\" Br Med J 2 (1968): 798-801[16] Berlin I \"Prazosin, diuretics, and glucose intolerance.\" Ann Intern Med 119 (1993): 860[17] Malherbe C, Burrill KC, Levin SR, Karam JH, Forsham PH \"Effect of diphenylhydantoin on insulin secretion in man.\" N Engl J Med 286 (1972): 339-42[18] Carter BL, Small RE, Mandel MD, Starkman MT \"Phenytoin-induced hyperglycemia.\" Am J Hosp Pharm 38 (1981): 1508-12[19] Al-Rubeaan K, Ryan EA \"Phenytoin-induced insulin insensitivity.\" Diabet Med 8 (1991): 968-70[20] \"Product Information. Zolinza (vorinostat).\" Merck & Company Inc, West Point, PA.[21] Goldman JA, Neri A, Ovadia J, Eckerling B, Vries A, de \"Effect of chlorothiazide on intravenous glucose tolerance in pregnancy.\" Am J Obstet Gynecol 105 (1969): 556-60[22] Harper R, Ennis CN, Heaney AP, Sheridan B, Gormley M, Atkinson AB, Johnston GD, Bell PM \"A comparison of the effects of low- and conventional-dose thiazide diuretic on insulin action in hypertensive patients with NIDDM.\" Diabetologia 38 (1995): 853-9[23] Seltzer HS, Allen EW \"Hyperglycemia and inhibition of insulin secretion during administration of diazoxide and trichlormethiazide in man.\" Diabetes 18 (1969): 19-28[24] Dube MP, Johnson DL, Currier JS, Leedom JM \"Protease inhibitor-associated hyperglycaemia.\" Lancet 350 (1997): 713-4[25] Leary WP, Reyes AJ \"Drug interactions with diuretics.\" S Afr Med J 65 (1984): 455-61[26] \"Product Information. Reyataz (atazanavir).\" Bristol-Myers Squibb, Princeton, NJ.[27] Pollare T, Lithell H, Berne C \"A comparison of the effects of hydrochlorothiazide and captopril on glucose and lipid metabolism in patients with hypertension.\" N Engl J Med 321 (1989): 868-73[28] Gunnarsson R, Lundgren G, Magnusson G, Ost L, Groth CG \"Steroid diabetes--a sign of overtreatment with steroids in the renal graft recipient?\" Scand J Urol Nephrol Suppl 54 (1980): 135-8[29] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[30] \"Product Information. Synthroid (levothyroxine).\" Abbott Pharmaceutical, Abbott Park, IL.[31] Murphy MB, Kohner E, Lewis PJ, Schumer B, Dollery CT \"Glucose intolerance in hypertensive patients treated with diuretics: a fourteen-year follow-up.\" Lancet 2 (1982): 1293-5[32] \"Product Information. Fortovase (saquinavir)\" Roche Laboratories, Nutley, NJ.[33] Coni NK, Gordon PW, Mukherjee AP, Read PR \"The effect of frusemide and ethacrynic acid on carbohydrate metabolism.\" Age Ageing 3 (1974): 85-90[34] \"Product Information. Norvir (ritonavir).\" Abbott Pharmaceutical, Abbott Park, IL.[35] Domenet JG \"Diabetogenic effect of oral diuretics.\" Br Med J 3 (1968): 188[36] Rowe P, Mather H \"Hyperosmolar non-ketotic diabetes mellitus associated with metolazone.\" Br Med J 291 (1985): 25-6[37] Winchester JF, Kellett RJ, Boddy K, Boyle P, Dargie HJ, Mahaffey ME, Ward DM, Kennedy AC \"Metolazone and bendroflumethiazide in hypertension: physiologic and metabolic observations.\" Clin Pharmacol Ther 28 (1980): 611-8[38] \"Product Information. Carafate (sucralfate).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[39] Tsiodras S, Mantzoros C, Hammer S, Samore M \"Effects of protease inhibitors on hyperglycemia, hyperlipidemia, and lipodystrophy - A 5-year cohort study.\" Arch Intern Med 160 (2000): 2050-6[40] \"Product Information. Apidra (insulin glulisine).\" Aventis Pharmaceuticals, Bridgewater, NJ.[41] \"Product Information. Prezista (darunavir).\" Ortho Biotech Inc, Bridgewater, NJ.[42] Haiba NA, el-Habashy MA, Said SA, Darwish EA, Abdel-Sayed WS, Nayel SE \"Clinical evaluation of two monthly injectable contraceptives and their effects on some metabolic parameters.\" Contraception 39 (1989): 619-32[43] Erle G, Basso M, Federspil G, Sicolo N, Scandellari C \"Effect of chlorpromazine on blood glucose and plasma insulin in man.\" Eur J Clin Pharmacol 11 (1977): 15-8[44] Pickkers P, Schachter M, Hughes AD, Feher MD, Sever PS \"Thiazide-induced hyperglycaemia: a role for calcium-activated potassium channels?\" Diabetologia 39 (1996): 861-4[45] \"Product Information. Lexiva (fosamprenavir).\" GlaxoSmithKline, Research Triangle Park, NC.[46] Curtis J, Horrigan F, Ahearn D, Varney R, Sandler SG \"Chlorthalidone-induced hyperosmolar hyperglycemic nonketotic coma.\" JAMA 220 (1972): 1592-3[47] \"Product Information. Hyperstat I.V. (diazoxide).\" Schering Corp, Kenilworth, NJ.[48] \"Product Information. Piqray (alpelisib).\" Novartis Pharmaceuticals, East Hanover, NJ.[49] Bell DS \"Insulin resistance. An often unrecognized problem accompanying chronic medical disorders.\" Postgrad Med 93 (1993): 99-103,[50] Stambaugh JE, Tucker DC \"Effect of diphenylhydantoin on glucose tolerance in patients with hypoglycemia.\" Diabetes 23 (1974): 679-83[51] \"Product Information. Crixivan (indinavir).\" Merck & Co, Inc, West Point, PA.[52] Miller NR, Moses H \"Transient oculomotor nerve palsy. Association with thiazide-induced glucose intolerance.\" JAMA 240 (1978): 1887-8[53] Javier Z, Gershberg H, Hulse M \"Ovulatory suppressants, estrogens, and carbohydrate metabolism.\" Metabolism 17 (1968): 443-56[54] Goldman JA, Ovadia JL \"The effect of estrogen on intravenous glucose tolerance in woman.\" Am J Obstet Gynecol 103 (1969): 172-8[55] Charan VD, Desai N, Singh AP, Choudhry VP \"Diabetes mellitus and pancreatitis as a complication of L- asparaginase therapy.\" Indian Pediatr 30 (1993): 809-10[56] Seifer DB, Freedman LN, Cavender JR, Baker RA \"Insulin-dependent diabetes mellitus associated with danazol.\" Am J Obstet Gynecol 162 (1990): 474-5[57] \"Product Information. Orinase (tolbutamide)\" Pharmacia and Upjohn, Kalamazoo, MI.[58] Walli R, Demant T \"Impaired glucose tolerance and protease inhibitors.\" Ann Intern Med 129 (1998): 837-8[59] Hannaford PC, Kay CR \"Oral contraceptives and diabetes mellitus.\" BMJ 299 (1989): 1315-6[60] Hardy H, Esch LD, Morse GD \"Glucose disorders associated with HIV and its drug therapy.\" Ann Pharmacother 35 (2001): 343-51[61] Chowdhury FR, Bleicher SJ \"Chlorthalidone--induced hypokalemia and abnormal carbohydrate metabolism.\" Horm Metab Res 2 (1970): 13-6[62] Kaufman MB, Simionatto C \"A review of protease inhibitor-induced hyperglycemia.\" Pharmacotherapy 19 (1999): 114-7[63] Greenstone MA, Shaw AB \"Alternate day corticosteroid causes alternate day hyperglycaemia.\" Postgrad Med J 63 (1987): 761-4[64] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[65] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[66] Elmfeldt D, Berglund G, Wedel H, Wilhelmsen L \"Incidence and importance of metabolic side-effects during antihypertensive therapy.\" Acta Med Scand Suppl 672 (1983): 79-83[67] \"Product Information. Agenerase (amprenavir).\" Glaxo Wellcome, Research Triangle Pk, NC.[68] Diamond MT \"Hyperglycemic hyperosmolar coma associated with hydrochlorothiazide and pancreatitis.\" N Y State J Med 72 (1972): 1741-2[69] \"Product Information. Prandin (repaglinide).\" Novo Nordisk Pharmaceuticals Inc, Princeton, NJ.[70] \"Product Information. Precose (acarbose).\" Bayer, West Haven, CT.[71] \"Product Information. Starlix (nateglinide)\" Novartis Pharmaceuticals, East Hanover, NJ.[72] \"Product Information. Oncaspar (pegaspargase).\" Rhone-Poulenc Rorer, Collegeville, PA.[73] Sotaniemi E, Kontturi M, Larmi T \"Effect of diethylstilbestrol on blood glucose of prostatic cancer patients.\" Invest Urol 10 (1973): 438-41[74] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[75] Petri M, Cumber P, Grimes L, Treby D, Bryant R, Rawlins D, Ising H \"The metabolic effects of thiazide therapy in the elderly: a population study.\" Age Ageing 15 (1986): 151-5[76] Ludvik B, Clodi M, Kautzky-Willer A, Capek M, Hartter E, Pacini G, Prager R \"Effect of dexamethasone on insulin sensitivity, islet amyloid polypeptide and insulin secretion in humans.\" Diabetologia 36 (1993): 84-7[77] \"Product Information. Glucophage (metformin).\" Bristol-Myers Squibb, Princeton, NJ.[78] Chaudhuri ML, Catania J \"A comparison of the effects of bumetanide (Burinex) and frusemide on carbohydrate metabolism in the elderly.\" Br J Clin Pract 42 (1988): 427-9[79] Black DM, Filak AT \"Hyperglycemia with non-insulin-dependent diabetes following intraarticular steroid injection.\" J Fam Pract 28 (1989): 462-3[80] \"Product Information. Megace (megestrol).\" Bristol-Myers Squibb, Princeton, NJ.[81] \"Product Information. Torisel (temsirolimus).\" Wyeth-Ayerst Laboratories, Philadelphia, PA.[82] Schmitz O, Hermansen K, Nielsen OH, Christensen CK, Arnfred J, Hansen HE, Mogensen CE, Orskov H, Beck-Nielsen H \"Insulin action in insulin-dependent diabetics after short-term thiazide therapy.\" Diabetes Care 9 (1986): 631-6[83] Kansal PC, Buse J, Buse MG \"Thiazide diuretics and control of diabetes mellitus.\" South Med J 62 (1969): 1372-9[84] Dimitriadis G, Tegos C, Golfinopoulou L, Roboti C, Raptis S \"Furosemide-induced hyperglycaemia - the implication of glycolytic kinases.\" Horm Metab Res 25 (1993): 557-9[85] \"Product Information. NovoLog Mix 70/30 (insulin aspart-insulin aspart protamine).\" Novo Nordisk Pharmaceuticals Inc, Princeton, NJ.[86] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[87] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[88] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[89] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42[90] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[91] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[92] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[93] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[94] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[95] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6", "alternatives_a": "Imatinib, Dabrafenib, Asciminib, Acalabrutinib, Dacomitinib, Pexidartinib, Fedratinib, Avapritinib, Larotrectinib, Bosutinib, Vemurafenib, More", "alternatives_b": "Guar gum", "updated_at": 1767369485}, {"id": 97980, "ingredient1": "Empagliflozin", "ingredient2": "Minoxidil", "severity": "Moderate", "effect": "Sodium-glucose co-transporter 2 (SGLT-2) inhibitors may potentiate the hypotensive effects of diuretics and other antihypertensive agents or vasodilators. Inhibition of glucose and sodium co-transport produces mild diuresis and transient natriuresis, resulting in intravascular volume contraction. Volume depletion-related adverse reactions including hypotension, postural dizziness, orthostatic hypotension, syncope, and dehydration can occur after initiating treatment with SGLT-2 inhibitors, and the risk may be increased with concomitant use of other agents that can lower blood pressure.", "source": "DDInter", "management_text": "Caution is advised if SGLT-2 inhibitors are coadministered with diuretics and other hypotensive agents, particularly in the elderly and patients with impaired renal function. Prior to initiating SGLT-2 inhibitors, volume status should be assessed and corrected, if necessary. Clinical and laboratory monitoring are recommended during therapy, including electrolytes, fluid status, renal function, and blood pressure. If volume depletion occurs, treatment with SGLT-2 inhibitors should be interrupted until the condition is corrected.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if SGLT-2 inhibitors are coadministered with diuretics and other hypotensive agents, particularly in the elderly and patients with impaired renal function.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/98084/", "reference_text": "[1] \"Product Information. Jardiance (empagliflozin).\" Boehringer Ingelheim, Ridgefield, CT.[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] \"Product Information. Farxiga (dapagliflozin).\" Bristol-Myers Squibb, Princeton, NJ.[5] \"Product Information. Invokana (canagliflozin).\" Janssen Pharmaceuticals, Titusville, NJ.[6] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[7] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[8] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[9] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[10] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[11] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6[12] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[13] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[14] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[15] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42", "alternatives_a": "Deoxycholic acid, Calcium gluconate, Pimecrolimus, Magnesium sulfate, Glycopyrronium, Aminobenzoic acid, Finasteride, Ivermectin, Caffeine, Diclofenac, Cromoglicic acid, More", "alternatives_b": "Acetohexamide, Guar gum, Pramlintide, Alogliptin, Tolazamide, Dulaglutide, Exenatide, Tolbutamide, Miglitol, Glimepiride, Albiglutide, More", "updated_at": 1767369485}, {"id": 97981, "ingredient1": "Empagliflozin", "ingredient2": "Moexipril", "severity": "Moderate", "effect": "Sodium-glucose co-transporter 2 (SGLT-2) inhibitors may potentiate the hypotensive effects of diuretics and other antihypertensive agents or vasodilators. Inhibition of glucose and sodium co-transport produces mild diuresis and transient natriuresis, resulting in intravascular volume contraction. Volume depletion-related adverse reactions including hypotension, postural dizziness, orthostatic hypotension, syncope, and dehydration can occur after initiating treatment with SGLT-2 inhibitors, and the risk may be increased with concomitant use of other agents that can lower blood pressure.", "source": "DDInter", "management_text": "Caution is advised if SGLT-2 inhibitors are coadministered with diuretics and other hypotensive agents, particularly in the elderly and patients with impaired renal function. Prior to initiating SGLT-2 inhibitors, volume status should be assessed and corrected, if necessary. Clinical and laboratory monitoring are recommended during therapy, including electrolytes, fluid status, renal function, and blood pressure. If volume depletion occurs, treatment with SGLT-2 inhibitors should be interrupted until the condition is corrected.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if SGLT-2 inhibitors are coadministered with diuretics and other hypotensive agents, particularly in the elderly and patients with impaired renal function.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/98085/", "reference_text": "[1] \"Product Information. Jardiance (empagliflozin).\" Boehringer Ingelheim, Ridgefield, CT.[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] \"Product Information. Farxiga (dapagliflozin).\" Bristol-Myers Squibb, Princeton, NJ.[5] \"Product Information. Invokana (canagliflozin).\" Janssen Pharmaceuticals, Titusville, NJ.[6] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[7] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[8] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[9] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[10] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[11] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6[12] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[13] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[14] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[15] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42", "alternatives_a": "Lixisenatide, Albiglutide, Guar gum, Acarbose, Pramlintide, Liraglutide, Troglitazone, Semaglutide, Dulaglutide, Miglitol", "alternatives_b": "", "updated_at": 1767369485}, {"id": 97982, "ingredient1": "Empagliflozin", "ingredient2": "Moxifloxacin", "severity": "Moderate", "effect": "Quinolone antibiotics may interfere with the therapeutic effects of insulin and other antidiabetic agents. The use of quinolones has been associated with disturbances in blood glucose homeostasis possibly stemming from effects on pancreatic beta cell ATP-sensitive potassium channels that regulate insulin secretion. Both hyperglycaemia and hypoglycemia have been reported, usually in diabetic patients receiving concomitant treatment with an oral hypoglycemic agent (e.g., sulfonylurea) or insulin. Although hyperglycaemia is significantly more common and infection itself may be an underlying risk factor, hypoglycemia may cause greater morbidity and mortality.", "source": "DDInter", "management_text": "Blood glucose should be closely monitored whenever quinolones are prescribed to diabetic patients, especially if they are elderly, have renal impairment, or are severely ill. Patients should be apprised of the increased risk of dysglycemia and be particularly alert to potential signs and symptoms of hypoglycemia such as headache, dizziness, drowsiness, nervousness, confusion, tremor, hunger, weakness, perspiration, palpitation, and tachycardia. If hypoglycemia occurs, patients should initiate appropriate remedial therapy immediately, discontinue the quinolone, and contact their physician. Alternative antibiotics may need to be considered.", "mechanism_text": "Antagonism", "recommendation": "Blood glucose should be closely monitored whenever quinolones are prescribed to diabetic patients, especially if they are elderly, have renal impairment, or are severely ill.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/98086/", "reference_text": "[1] Gavin JR 3rd, Kubin R, Choudhri S, et al \"Moxifloxacin and glucose homeostasis: a pooled-analysis of the evidence from clinical and postmarketing studies.\" Drug Saf 27 (2004): 671-86[2] Yip C, Lee AJ \"Gatifloxacin-induced hyperglycemia: a case report and summary of the current literature.\" Clin Ther 28 (2006): 1857-66[3] Kelesidis T, Canseco E \"Quinolone-induced hypoglycemia: a life-threatening but potentially reversible side effect.\" Am J Med 123 (2010): e5-6[4] Baker SE, Hangii MC \"Possible gatifloxacin-induced hypoglycemia.\" Ann Pharmacother 36 (2002): 1722-6[5] \"Product Information. Levaquin (levofloxacin).\" Ortho Pharmaceutical Corporation, Raritan, NJ.[6] Frothingham R \"Glucose homeostasis abnormalities associated with use of gatifloxacin.\" Clin Infect Dis 41 (2005): 1269-76[7] Letourneau G, Morrison H, McMorran M \"Gatifloxacin (Tequin): hypoglycemia and hyperglycemia. Available from: URL: http://www.hc-sc.gc.ca/dhp-mps/medeff/bulletin/carn-bcei_v13n3_e.html#1\" ([2003 Jul]):[8] Lin G, Hays DP, Spillane L \"Refractory hypoglycemia from ciprofloxacin and glyburide interaction.\" J Toxicol Clin Toxicol 42 (2004): 295-7[9] \"Product Information. Tequin (gatifloxacin)\" Bristol-Myers Squibb, Princeton, NJ.[10] \"Product Information. Floxin (ofloxacin).\" Ortho Pharmaceutical Corporation, Raritan, NJ.[11] Bhasin R, Arce FC, Pasmantier R \"Hypoglycemia associated with the use of gatifloxacin.\" Am J Med Sci 330 (2005): 250-3[12] Zvonar R \"Gatifloxacin-induced dysglycemia.\" Am J Health Syst Pharm 63 (2006): 2087-2092[13] Rubinstein E \"History of quinolones and their side effects.\" Chemotherapy 47 Suppl 3 (2001): 3-8[14] Park-Wyllie LY, Juurlink DN, Kopp A, et al. \"Outpatient gatifloxacin therapy and dysglycemia in older adults.\" N Engl J Med 354 (2006): 1352-61[15] LeBlanc M, Belanger C, Cossette P \"Severe and resistant hypoglycemia associated with concomitant gatifloxacin and glyburide therapy.\" Pharmacotherapy 24 (2004): 926-31[16] \"Product Information. Cipro (ciprofloxacin).\" Bayer, West Haven, CT.[17] Happe MR, Mulhall BP, Maydonovitch CL, Holtzmuller KC \"Gatifloxacin-induced hyperglycemia.\" Ann Intern Med 141 (2004): 968-9[18] Biggs WS \"Hypoglycemia and hyperglycemia associated with gatifloxacin use in elderly patients.\" J Am Board Fam Pract 16 (2004): 455-7[19] \"Product Information. Raxar (grepafloxacin).\" Glaxo Wellcome, Research Triangle Park, NC.[20] Brogan SE, Cahalan MK \"Gatifloxacin as a possible cause of serious postoperative hypoglycemia.\" Anesth Analg 101 (2005): 635-6[21] Friedrich LV, Dougherty R \"Fatal hypoglycemia associated with levofloxacin.\" Pharmacotherapy 24 (2004): 1807-12[22] Saraya A, Yokokura M, Gonoi T, Seino S \"Effects of fluoroquinolones on insulin secretion and beta-cell ATP-sensitive K(+) channels.\" Eur J Pharmacol 497 (2004): 111-7[23] \"Hypoglycemia and hyperglycemia with fluoroquinolones.\" Med Lett Drugs Ther 45 (2003): 64[24] Gajjar DA, LaCreta FP, Kollia GD, et al. \"Effect of multiple-dose gatifloxacin or ciprofloxacin on glucose homeostasis and insulin production in patients with noninsulin-dependent diabetes mellitus maintained with diet and exercise.\" Pharmacotherapy 20 (6 Pt 2) (2000): s76-86[25] Khovidhunkit W, Sunthornyothin S \"Hypoglycemia, hyperglycemia, and gatifloxacin.\" Ann Intern Med 141 (2004): 969[26] Kanbay M, Aydogan T, Bozalan R, et al. \"A rare but serious side effect of levofloxacin: hypoglycemia in a geriatric patient.\" Diabetes Care 29 (2006): 1716-7[27] Menzies DJ, Dorsainvil PA, Cunha BA, Johnson DH \"Severe and persistent hypoglycemia due to gatifloxacin interaction with oral hypoglycemic agents.\" Am J Med 113 (2002): 232-4[28] Edwards DJ, Bowles SK, Svensson CK, Rybak MJ \"Inhibition of drug metabolism by quinolone antibiotics.\" Clin Pharmacokinet 15 (1988): 194-204[29] Graumlich JF, Habis S, Avelino RR, et al. \"Hypoglycemia in inpatients after gatifloxacin or levofloxacin therapy: nested case-control study.\" Pharmacotherapy 25 (2005): 1296-302[30] \"Product Information. Factive (gemifloxacin).\" GeneSoft Inc, San Francisco, CA.[31] Wang S, Rizvi AA \"Levofloxacin-induced hypoglycemia in a nondiabetic patient.\" Am J Med Sci 331 (2006): 334-5[32] \"Product Information. Noroxin (norfloxacin).\" Merck & Co, Inc, West Point, PA.[33] Zhanel GG, Fontaine S, Adam H, et al. \"A Review of New Fluoroquinolones : Focus on their Use in Respiratory Tract Infections.\" Treat Respir Med 5 (2006): 437-465[34] \"Product Information. Baxdela (delafloxacin).\" Melinta Therapeutics, Lincolnshire, IL.[35] Greenberg AL, Decerbo M, Fan J \"Gatifloxacin therapy associated with hypoglycemia.\" Clin Infect Dis 40 (2005): 1210-1[36] Blommel AL, Lutes RA \"Severe hyperglycemia during renally adjusted gatifloxacin therapy.\" Ann Pharmacother 39 (2005): 1349-52[37] Tomita T, Onishi M, Sato E, Kimura Y, Kihira K \"Gatifloxacin induces augmented insulin release and intracellular insulin.\" Biol Pharm Bull 30 (2007): 644-7[38] Donaldson AR, Vandiver JR, Finch CK \"Possible gatifloxacin-induced hyperglycemia.\" Ann Pharmacother 38 (2004): 602-5[39] \"Product Information. Trovan (trovafloxacin).\" Pfizer US Pharmaceuticals, New York, NY.[40] Roberge RJ, Kaplan R, Frank R, Fore C \"Glyburide-ciprofloxacin interaction with resistant hypoglycemia.\" Ann Emerg Med 36 (2000): 160-3[41] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[42] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[43] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[44] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42[45] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[46] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[47] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[48] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[49] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[50] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6", "alternatives_a": "Rifamycin, Kanamycin, Ampicillin, Azithromycin, Acyclovir, Netilmicin, Polymyxin B, Famciclovir, Cefuroxime, Trifluridine, Tobramycin, More", "alternatives_b": "Guar gum", "updated_at": 1767369485}, {"id": 97983, "ingredient1": "Empagliflozin", "ingredient2": "Nadolol", "severity": "Moderate", "effect": "Sodium-glucose co-transporter 2 (SGLT-2) inhibitors may potentiate the hypotensive effects of diuretics and other antihypertensive agents or vasodilators. Inhibition of glucose and sodium co-transport produces mild diuresis and transient natriuresis, resulting in intravascular volume contraction. Volume depletion-related adverse reactions including hypotension, postural dizziness, orthostatic hypotension, syncope, and dehydration can occur after initiating treatment with SGLT-2 inhibitors, and the risk may be increased with concomitant use of other agents that can lower blood pressure.", "source": "DDInter", "management_text": "Caution is advised if SGLT-2 inhibitors are coadministered with diuretics and other hypotensive agents, particularly in the elderly and patients with impaired renal function. Prior to initiating SGLT-2 inhibitors, volume status should be assessed and corrected, if necessary. Clinical and laboratory monitoring are recommended during therapy, including electrolytes, fluid status, renal function, and blood pressure. If volume depletion occurs, treatment with SGLT-2 inhibitors should be interrupted until the condition is corrected.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if SGLT-2 inhibitors are coadministered with diuretics and other hypotensive agents, particularly in the elderly and patients with impaired renal function.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/98087/", "reference_text": "[1] \"Product Information. Jardiance (empagliflozin).\" Boehringer Ingelheim, Ridgefield, CT.[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] \"Product Information. Farxiga (dapagliflozin).\" Bristol-Myers Squibb, Princeton, NJ.[5] \"Product Information. Invokana (canagliflozin).\" Janssen Pharmaceuticals, Titusville, NJ.[6] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[7] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[8] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[9] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[10] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[11] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6[12] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[13] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[14] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[15] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42", "alternatives_a": "Lixisenatide, Albiglutide, Guar gum, Pramlintide, Sitagliptin, Alogliptin, Liraglutide, Troglitazone, Semaglutide, Linagliptin, Dulaglutide, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 97984, "ingredient1": "Empagliflozin", "ingredient2": "Nalidixic acid", "severity": "Moderate", "effect": "Quinolone antibiotics may interfere with the therapeutic effects of insulin and other antidiabetic agents. The use of quinolones has been associated with disturbances in blood glucose homeostasis possibly stemming from effects on pancreatic beta cell ATP-sensitive potassium channels that regulate insulin secretion. Both hyperglycaemia and hypoglycemia have been reported, usually in diabetic patients receiving concomitant treatment with an oral hypoglycemic agent (e.g., sulfonylurea) or insulin. Although hyperglycaemia is significantly more common and infection itself may be an underlying risk factor, hypoglycemia may cause greater morbidity and mortality.", "source": "DDInter", "management_text": "Blood glucose should be closely monitored whenever quinolones are prescribed to diabetic patients, especially if they are elderly, have renal impairment, or are severely ill. Patients should be apprised of the increased risk of dysglycemia and be particularly alert to potential signs and symptoms of hypoglycemia such as headache, dizziness, drowsiness, nervousness, confusion, tremor, hunger, weakness, perspiration, palpitation, and tachycardia. If hypoglycemia occurs, patients should initiate appropriate remedial therapy immediately, discontinue the quinolone, and contact their physician. Alternative antibiotics may need to be considered.", "mechanism_text": "Antagonism", "recommendation": "Blood glucose should be closely monitored whenever quinolones are prescribed to diabetic patients, especially if they are elderly, have renal impairment, or are severely ill.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/98088/", "reference_text": "[1] Gavin JR 3rd, Kubin R, Choudhri S, et al \"Moxifloxacin and glucose homeostasis: a pooled-analysis of the evidence from clinical and postmarketing studies.\" Drug Saf 27 (2004): 671-86[2] Yip C, Lee AJ \"Gatifloxacin-induced hyperglycemia: a case report and summary of the current literature.\" Clin Ther 28 (2006): 1857-66[3] Kelesidis T, Canseco E \"Quinolone-induced hypoglycemia: a life-threatening but potentially reversible side effect.\" Am J Med 123 (2010): e5-6[4] Baker SE, Hangii MC \"Possible gatifloxacin-induced hypoglycemia.\" Ann Pharmacother 36 (2002): 1722-6[5] \"Product Information. Levaquin (levofloxacin).\" Ortho Pharmaceutical Corporation, Raritan, NJ.[6] Frothingham R \"Glucose homeostasis abnormalities associated with use of gatifloxacin.\" Clin Infect Dis 41 (2005): 1269-76[7] Letourneau G, Morrison H, McMorran M \"Gatifloxacin (Tequin): hypoglycemia and hyperglycemia. Available from: URL: http://www.hc-sc.gc.ca/dhp-mps/medeff/bulletin/carn-bcei_v13n3_e.html#1\" ([2003 Jul]):[8] Lin G, Hays DP, Spillane L \"Refractory hypoglycemia from ciprofloxacin and glyburide interaction.\" J Toxicol Clin Toxicol 42 (2004): 295-7[9] \"Product Information. Tequin (gatifloxacin)\" Bristol-Myers Squibb, Princeton, NJ.[10] \"Product Information. Floxin (ofloxacin).\" Ortho Pharmaceutical Corporation, Raritan, NJ.[11] Bhasin R, Arce FC, Pasmantier R \"Hypoglycemia associated with the use of gatifloxacin.\" Am J Med Sci 330 (2005): 250-3[12] Zvonar R \"Gatifloxacin-induced dysglycemia.\" Am J Health Syst Pharm 63 (2006): 2087-2092[13] Rubinstein E \"History of quinolones and their side effects.\" Chemotherapy 47 Suppl 3 (2001): 3-8[14] Park-Wyllie LY, Juurlink DN, Kopp A, et al. \"Outpatient gatifloxacin therapy and dysglycemia in older adults.\" N Engl J Med 354 (2006): 1352-61[15] LeBlanc M, Belanger C, Cossette P \"Severe and resistant hypoglycemia associated with concomitant gatifloxacin and glyburide therapy.\" Pharmacotherapy 24 (2004): 926-31[16] \"Product Information. Cipro (ciprofloxacin).\" Bayer, West Haven, CT.[17] Happe MR, Mulhall BP, Maydonovitch CL, Holtzmuller KC \"Gatifloxacin-induced hyperglycemia.\" Ann Intern Med 141 (2004): 968-9[18] Biggs WS \"Hypoglycemia and hyperglycemia associated with gatifloxacin use in elderly patients.\" J Am Board Fam Pract 16 (2004): 455-7[19] \"Product Information. Raxar (grepafloxacin).\" Glaxo Wellcome, Research Triangle Park, NC.[20] Brogan SE, Cahalan MK \"Gatifloxacin as a possible cause of serious postoperative hypoglycemia.\" Anesth Analg 101 (2005): 635-6[21] Friedrich LV, Dougherty R \"Fatal hypoglycemia associated with levofloxacin.\" Pharmacotherapy 24 (2004): 1807-12[22] Saraya A, Yokokura M, Gonoi T, Seino S \"Effects of fluoroquinolones on insulin secretion and beta-cell ATP-sensitive K(+) channels.\" Eur J Pharmacol 497 (2004): 111-7[23] \"Hypoglycemia and hyperglycemia with fluoroquinolones.\" Med Lett Drugs Ther 45 (2003): 64[24] Gajjar DA, LaCreta FP, Kollia GD, et al. \"Effect of multiple-dose gatifloxacin or ciprofloxacin on glucose homeostasis and insulin production in patients with noninsulin-dependent diabetes mellitus maintained with diet and exercise.\" Pharmacotherapy 20 (6 Pt 2) (2000): s76-86[25] Khovidhunkit W, Sunthornyothin S \"Hypoglycemia, hyperglycemia, and gatifloxacin.\" Ann Intern Med 141 (2004): 969[26] Kanbay M, Aydogan T, Bozalan R, et al. \"A rare but serious side effect of levofloxacin: hypoglycemia in a geriatric patient.\" Diabetes Care 29 (2006): 1716-7[27] Menzies DJ, Dorsainvil PA, Cunha BA, Johnson DH \"Severe and persistent hypoglycemia due to gatifloxacin interaction with oral hypoglycemic agents.\" Am J Med 113 (2002): 232-4[28] Edwards DJ, Bowles SK, Svensson CK, Rybak MJ \"Inhibition of drug metabolism by quinolone antibiotics.\" Clin Pharmacokinet 15 (1988): 194-204[29] Graumlich JF, Habis S, Avelino RR, et al. \"Hypoglycemia in inpatients after gatifloxacin or levofloxacin therapy: nested case-control study.\" Pharmacotherapy 25 (2005): 1296-302[30] \"Product Information. Factive (gemifloxacin).\" GeneSoft Inc, San Francisco, CA.[31] Wang S, Rizvi AA \"Levofloxacin-induced hypoglycemia in a nondiabetic patient.\" Am J Med Sci 331 (2006): 334-5[32] \"Product Information. Noroxin (norfloxacin).\" Merck & Co, Inc, West Point, PA.[33] Zhanel GG, Fontaine S, Adam H, et al. \"A Review of New Fluoroquinolones : Focus on their Use in Respiratory Tract Infections.\" Treat Respir Med 5 (2006): 437-465[34] \"Product Information. Baxdela (delafloxacin).\" Melinta Therapeutics, Lincolnshire, IL.[35] Greenberg AL, Decerbo M, Fan J \"Gatifloxacin therapy associated with hypoglycemia.\" Clin Infect Dis 40 (2005): 1210-1[36] Blommel AL, Lutes RA \"Severe hyperglycemia during renally adjusted gatifloxacin therapy.\" Ann Pharmacother 39 (2005): 1349-52[37] Tomita T, Onishi M, Sato E, Kimura Y, Kihira K \"Gatifloxacin induces augmented insulin release and intracellular insulin.\" Biol Pharm Bull 30 (2007): 644-7[38] Donaldson AR, Vandiver JR, Finch CK \"Possible gatifloxacin-induced hyperglycemia.\" Ann Pharmacother 38 (2004): 602-5[39] \"Product Information. Trovan (trovafloxacin).\" Pfizer US Pharmaceuticals, New York, NY.[40] Roberge RJ, Kaplan R, Frank R, Fore C \"Glyburide-ciprofloxacin interaction with resistant hypoglycemia.\" Ann Emerg Med 36 (2000): 160-3[41] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[42] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[43] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[44] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42[45] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[46] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[47] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[48] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[49] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[50] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6", "alternatives_a": "Simvastatin, Guar gum, Rosuvastatin", "alternatives_b": "", "updated_at": 1767369485}, {"id": 97985, "ingredient1": "Empagliflozin", "ingredient2": "Nateglinide", "severity": "Moderate", "effect": "Coadministration of a sodium-glucose co-transporter 2 (SGLT-2) inhibitor with an insulin secretagogue (e.g., sulfonylurea, meglitinide) or insulin may potentiate the risk of hypoglycemia.", "source": "DDInter", "management_text": "A lower dosage of the insulin secretagogue or insulin may be required when used in combination with an SGLT-2 inhibitor.", "mechanism_text": "Synergism", "recommendation": "A lower dosage of the insulin secretagogue or insulin may be required when used in combination with an SGLT-2 inhibitor.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/98089/", "reference_text": "[1] \"Product Information. Jardiance (empagliflozin).\" Boehringer Ingelheim, Ridgefield, CT.[2] \"Product Information. Steglatro (ertugliflozin).\" Merck & Company Inc, Whitehouse Station, NJ.[3] \"Product Information. Invokana (canagliflozin).\" Janssen Pharmaceuticals, Titusville, NJ.[4] Cerner Multum, Inc. \"Australian Product Information.\" O 0[5] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[6] \"Product Information. Farxiga (dapagliflozin).\" Bristol-Myers Squibb, Princeton, NJ.[7] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[8] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[9] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[10] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[11] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[12] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6[13] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[14] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[15] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[16] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42[17] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[18] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[19] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[20] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[21] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[22] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6[23] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[24] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[25] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[26] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42", "alternatives_a": "Guar gum, Pramlintide, Alogliptin, Rosuvastatin, Empagliflozin, Dulaglutide, Exenatide, Miglitol, Albiglutide, Rosiglitazone, Ertugliflozin, More", "alternatives_b": "Troglitazone, Miglitol, Nateglinide", "updated_at": 1767369485}, {"id": 97986, "ingredient1": "Empagliflozin", "ingredient2": "Nebivolol", "severity": "Moderate", "effect": "Sodium-glucose co-transporter 2 (SGLT-2) inhibitors may potentiate the hypotensive effects of diuretics and other antihypertensive agents or vasodilators. Inhibition of glucose and sodium co-transport produces mild diuresis and transient natriuresis, resulting in intravascular volume contraction. Volume depletion-related adverse reactions including hypotension, postural dizziness, orthostatic hypotension, syncope, and dehydration can occur after initiating treatment with SGLT-2 inhibitors, and the risk may be increased with concomitant use of other agents that can lower blood pressure.", "source": "DDInter", "management_text": "Caution is advised if SGLT-2 inhibitors are coadministered with diuretics and other hypotensive agents, particularly in the elderly and patients with impaired renal function. Prior to initiating SGLT-2 inhibitors, volume status should be assessed and corrected, if necessary. Clinical and laboratory monitoring are recommended during therapy, including electrolytes, fluid status, renal function, and blood pressure. If volume depletion occurs, treatment with SGLT-2 inhibitors should be interrupted until the condition is corrected.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if SGLT-2 inhibitors are coadministered with diuretics and other hypotensive agents, particularly in the elderly and patients with impaired renal function.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/98090/", "reference_text": "[1] \"Product Information. Jardiance (empagliflozin).\" Boehringer Ingelheim, Ridgefield, CT.[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] \"Product Information. Farxiga (dapagliflozin).\" Bristol-Myers Squibb, Princeton, NJ.[5] \"Product Information. Invokana (canagliflozin).\" Janssen Pharmaceuticals, Titusville, NJ.[6] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[7] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[8] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[9] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[10] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[11] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6[12] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[13] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[14] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[15] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42", "alternatives_a": "Acetylsalicylic acid, Ivabradine, Sacubitril", "alternatives_b": "Guar gum, Pramlintide, Alogliptin, Rosuvastatin, Dulaglutide, Exenatide, Miglitol, Albiglutide, Rosiglitazone, Semaglutide, Pioglitazone, More", "updated_at": 1767369485}, {"id": 97987, "ingredient1": "Empagliflozin", "ingredient2": "Nelfinavir", "severity": "Moderate", "effect": "The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.", "source": "DDInter", "management_text": "Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.", "mechanism_text": "Antagonism", "recommendation": "Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/98091/", "reference_text": "[1] Jori A, Carrara MC \"On the mechanism of the hyperglycaemic effect of chlorpromazine.\" J Pharm Pharmacol 18 (1966): 623-4[2] \"Product Information. Dymelor (acetohexamide)\" Lilly, Eli and Company, Indianapolis, IN.[3] \"Product Information. Thorazine (chlorpromazine).\" SmithKline Beecham, Philadelphia, PA.[4] Blayac JP, Ribes G, Buys D, Puech R, Loubatieres-Mariani MM \"Effects of a new benzothiadiazine derivative, LN 5330, on insulin secretion.\" Arch Int Pharmacodyn Ther 253 (1981): 154-63[5] \"Product Information. Elzonris (tagraxofusp).\" Stemline Therapeutics, New York, NY.[6] \"Product Information. Amaryl (glimepiride).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[7] \"Product Information. Elspar (asparaginase).\" Merck & Co, Inc, West Point, PA.[8] Jones IG, Pickens PT \"Diabetes mellitus following oral diuretics.\" Practitioner 199 (1967): 209-10[9] \"Product Information. Viracept (nelfinavir).\" Agouron Pharma Inc, La Jolla, CA.[10] \"Product Information. Tolinase (tolazamide)\" Pharmacia and Upjohn, Kalamazoo, MI.[11] Mauss S, Wolf E, Jaeger H \"Impaired glucose tolerance in HIV-positive patients receiving and those not receiving protease inhibitors.\" Ann Intern Med 130 (1999): 162-3[12] Virutamasen P, Wongsrichanalai C, Tangkeo P, Nitichai Y, Rienprayoon D \"Metabolic effects of depot-medroxyprogesterone acetate in long-term users: a cross-sectional study.\" Int J Gynaecol Obstet 24 (1986): 291-6[13] Wehring H, Alexander B, Perry PJ \"Diabetes mellitus associated with clozapine therapy.\" Pharmacotherapy 20 (2000): 844-7[14] Spellacy WN, Ellingson AB, Tsibris JC \"The effects of two triphasic oral contraceptives on carbohydrate metabolism in women during 1 year of use.\" Fertil Steril 51 (1989): 71-4[15] Andersen OO, Persson I \"Carbohydrate metabolism during treatment with chlorthalidone and ethacrynic acid.\" Br Med J 2 (1968): 798-801[16] Berlin I \"Prazosin, diuretics, and glucose intolerance.\" Ann Intern Med 119 (1993): 860[17] Malherbe C, Burrill KC, Levin SR, Karam JH, Forsham PH \"Effect of diphenylhydantoin on insulin secretion in man.\" N Engl J Med 286 (1972): 339-42[18] Carter BL, Small RE, Mandel MD, Starkman MT \"Phenytoin-induced hyperglycemia.\" Am J Hosp Pharm 38 (1981): 1508-12[19] Al-Rubeaan K, Ryan EA \"Phenytoin-induced insulin insensitivity.\" Diabet Med 8 (1991): 968-70[20] \"Product Information. Zolinza (vorinostat).\" Merck & Company Inc, West Point, PA.[21] Goldman JA, Neri A, Ovadia J, Eckerling B, Vries A, de \"Effect of chlorothiazide on intravenous glucose tolerance in pregnancy.\" Am J Obstet Gynecol 105 (1969): 556-60[22] Harper R, Ennis CN, Heaney AP, Sheridan B, Gormley M, Atkinson AB, Johnston GD, Bell PM \"A comparison of the effects of low- and conventional-dose thiazide diuretic on insulin action in hypertensive patients with NIDDM.\" Diabetologia 38 (1995): 853-9[23] Seltzer HS, Allen EW \"Hyperglycemia and inhibition of insulin secretion during administration of diazoxide and trichlormethiazide in man.\" Diabetes 18 (1969): 19-28[24] Dube MP, Johnson DL, Currier JS, Leedom JM \"Protease inhibitor-associated hyperglycaemia.\" Lancet 350 (1997): 713-4[25] Leary WP, Reyes AJ \"Drug interactions with diuretics.\" S Afr Med J 65 (1984): 455-61[26] \"Product Information. Reyataz (atazanavir).\" Bristol-Myers Squibb, Princeton, NJ.[27] Pollare T, Lithell H, Berne C \"A comparison of the effects of hydrochlorothiazide and captopril on glucose and lipid metabolism in patients with hypertension.\" N Engl J Med 321 (1989): 868-73[28] Gunnarsson R, Lundgren G, Magnusson G, Ost L, Groth CG \"Steroid diabetes--a sign of overtreatment with steroids in the renal graft recipient?\" Scand J Urol Nephrol Suppl 54 (1980): 135-8[29] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[30] \"Product Information. Synthroid (levothyroxine).\" Abbott Pharmaceutical, Abbott Park, IL.[31] Murphy MB, Kohner E, Lewis PJ, Schumer B, Dollery CT \"Glucose intolerance in hypertensive patients treated with diuretics: a fourteen-year follow-up.\" Lancet 2 (1982): 1293-5[32] \"Product Information. Fortovase (saquinavir)\" Roche Laboratories, Nutley, NJ.[33] Coni NK, Gordon PW, Mukherjee AP, Read PR \"The effect of frusemide and ethacrynic acid on carbohydrate metabolism.\" Age Ageing 3 (1974): 85-90[34] \"Product Information. Norvir (ritonavir).\" Abbott Pharmaceutical, Abbott Park, IL.[35] Domenet JG \"Diabetogenic effect of oral diuretics.\" Br Med J 3 (1968): 188[36] Rowe P, Mather H \"Hyperosmolar non-ketotic diabetes mellitus associated with metolazone.\" Br Med J 291 (1985): 25-6[37] Winchester JF, Kellett RJ, Boddy K, Boyle P, Dargie HJ, Mahaffey ME, Ward DM, Kennedy AC \"Metolazone and bendroflumethiazide in hypertension: physiologic and metabolic observations.\" Clin Pharmacol Ther 28 (1980): 611-8[38] \"Product Information. Carafate (sucralfate).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[39] Tsiodras S, Mantzoros C, Hammer S, Samore M \"Effects of protease inhibitors on hyperglycemia, hyperlipidemia, and lipodystrophy - A 5-year cohort study.\" Arch Intern Med 160 (2000): 2050-6[40] \"Product Information. Apidra (insulin glulisine).\" Aventis Pharmaceuticals, Bridgewater, NJ.[41] \"Product Information. Prezista (darunavir).\" Ortho Biotech Inc, Bridgewater, NJ.[42] Haiba NA, el-Habashy MA, Said SA, Darwish EA, Abdel-Sayed WS, Nayel SE \"Clinical evaluation of two monthly injectable contraceptives and their effects on some metabolic parameters.\" Contraception 39 (1989): 619-32[43] Erle G, Basso M, Federspil G, Sicolo N, Scandellari C \"Effect of chlorpromazine on blood glucose and plasma insulin in man.\" Eur J Clin Pharmacol 11 (1977): 15-8[44] Pickkers P, Schachter M, Hughes AD, Feher MD, Sever PS \"Thiazide-induced hyperglycaemia: a role for calcium-activated potassium channels?\" Diabetologia 39 (1996): 861-4[45] \"Product Information. Lexiva (fosamprenavir).\" GlaxoSmithKline, Research Triangle Park, NC.[46] Curtis J, Horrigan F, Ahearn D, Varney R, Sandler SG \"Chlorthalidone-induced hyperosmolar hyperglycemic nonketotic coma.\" JAMA 220 (1972): 1592-3[47] \"Product Information. Hyperstat I.V. (diazoxide).\" Schering Corp, Kenilworth, NJ.[48] \"Product Information. Piqray (alpelisib).\" Novartis Pharmaceuticals, East Hanover, NJ.[49] Bell DS \"Insulin resistance. An often unrecognized problem accompanying chronic medical disorders.\" Postgrad Med 93 (1993): 99-103,[50] Stambaugh JE, Tucker DC \"Effect of diphenylhydantoin on glucose tolerance in patients with hypoglycemia.\" Diabetes 23 (1974): 679-83[51] \"Product Information. Crixivan (indinavir).\" Merck & Co, Inc, West Point, PA.[52] Miller NR, Moses H \"Transient oculomotor nerve palsy. Association with thiazide-induced glucose intolerance.\" JAMA 240 (1978): 1887-8[53] Javier Z, Gershberg H, Hulse M \"Ovulatory suppressants, estrogens, and carbohydrate metabolism.\" Metabolism 17 (1968): 443-56[54] Goldman JA, Ovadia JL \"The effect of estrogen on intravenous glucose tolerance in woman.\" Am J Obstet Gynecol 103 (1969): 172-8[55] Charan VD, Desai N, Singh AP, Choudhry VP \"Diabetes mellitus and pancreatitis as a complication of L- asparaginase therapy.\" Indian Pediatr 30 (1993): 809-10[56] Seifer DB, Freedman LN, Cavender JR, Baker RA \"Insulin-dependent diabetes mellitus associated with danazol.\" Am J Obstet Gynecol 162 (1990): 474-5[57] \"Product Information. Orinase (tolbutamide)\" Pharmacia and Upjohn, Kalamazoo, MI.[58] Walli R, Demant T \"Impaired glucose tolerance and protease inhibitors.\" Ann Intern Med 129 (1998): 837-8[59] Hannaford PC, Kay CR \"Oral contraceptives and diabetes mellitus.\" BMJ 299 (1989): 1315-6[60] Hardy H, Esch LD, Morse GD \"Glucose disorders associated with HIV and its drug therapy.\" Ann Pharmacother 35 (2001): 343-51[61] Chowdhury FR, Bleicher SJ \"Chlorthalidone--induced hypokalemia and abnormal carbohydrate metabolism.\" Horm Metab Res 2 (1970): 13-6[62] Kaufman MB, Simionatto C \"A review of protease inhibitor-induced hyperglycemia.\" Pharmacotherapy 19 (1999): 114-7[63] Greenstone MA, Shaw AB \"Alternate day corticosteroid causes alternate day hyperglycaemia.\" Postgrad Med J 63 (1987): 761-4[64] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[65] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[66] Elmfeldt D, Berglund G, Wedel H, Wilhelmsen L \"Incidence and importance of metabolic side-effects during antihypertensive therapy.\" Acta Med Scand Suppl 672 (1983): 79-83[67] \"Product Information. Agenerase (amprenavir).\" Glaxo Wellcome, Research Triangle Pk, NC.[68] Diamond MT \"Hyperglycemic hyperosmolar coma associated with hydrochlorothiazide and pancreatitis.\" N Y State J Med 72 (1972): 1741-2[69] \"Product Information. Prandin (repaglinide).\" Novo Nordisk Pharmaceuticals Inc, Princeton, NJ.[70] \"Product Information. Precose (acarbose).\" Bayer, West Haven, CT.[71] \"Product Information. Starlix (nateglinide)\" Novartis Pharmaceuticals, East Hanover, NJ.[72] \"Product Information. Oncaspar (pegaspargase).\" Rhone-Poulenc Rorer, Collegeville, PA.[73] Sotaniemi E, Kontturi M, Larmi T \"Effect of diethylstilbestrol on blood glucose of prostatic cancer patients.\" Invest Urol 10 (1973): 438-41[74] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[75] Petri M, Cumber P, Grimes L, Treby D, Bryant R, Rawlins D, Ising H \"The metabolic effects of thiazide therapy in the elderly: a population study.\" Age Ageing 15 (1986): 151-5[76] Ludvik B, Clodi M, Kautzky-Willer A, Capek M, Hartter E, Pacini G, Prager R \"Effect of dexamethasone on insulin sensitivity, islet amyloid polypeptide and insulin secretion in humans.\" Diabetologia 36 (1993): 84-7[77] \"Product Information. Glucophage (metformin).\" Bristol-Myers Squibb, Princeton, NJ.[78] Chaudhuri ML, Catania J \"A comparison of the effects of bumetanide (Burinex) and frusemide on carbohydrate metabolism in the elderly.\" Br J Clin Pract 42 (1988): 427-9[79] Black DM, Filak AT \"Hyperglycemia with non-insulin-dependent diabetes following intraarticular steroid injection.\" J Fam Pract 28 (1989): 462-3[80] \"Product Information. Megace (megestrol).\" Bristol-Myers Squibb, Princeton, NJ.[81] \"Product Information. Torisel (temsirolimus).\" Wyeth-Ayerst Laboratories, Philadelphia, PA.[82] Schmitz O, Hermansen K, Nielsen OH, Christensen CK, Arnfred J, Hansen HE, Mogensen CE, Orskov H, Beck-Nielsen H \"Insulin action in insulin-dependent diabetics after short-term thiazide therapy.\" Diabetes Care 9 (1986): 631-6[83] Kansal PC, Buse J, Buse MG \"Thiazide diuretics and control of diabetes mellitus.\" South Med J 62 (1969): 1372-9[84] Dimitriadis G, Tegos C, Golfinopoulou L, Roboti C, Raptis S \"Furosemide-induced hyperglycaemia - the implication of glycolytic kinases.\" Horm Metab Res 25 (1993): 557-9[85] \"Product Information. NovoLog Mix 70/30 (insulin aspart-insulin aspart protamine).\" Novo Nordisk Pharmaceuticals Inc, Princeton, NJ.[86] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[87] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[88] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[89] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42[90] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[91] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[92] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[93] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[94] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[95] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6", "alternatives_a": "Lamivudine, Tenofovir alafenamide, Maraviroc, Cabotegravir, Zanamivir, Valaciclovir, Lenacapavir, Telaprevir, Rilpivirine, Etravirine, Dolutegravir, More", "alternatives_b": "Guar gum", "updated_at": 1767369485}, {"id": 97988, "ingredient1": "Empagliflozin", "ingredient2": "Neratinib", "severity": "Moderate", "effect": "Coadministration with neratinib may increase the plasma concentrations and the risk of adverse effects of drugs that are substrates of the breast cancer resistance protein (BCRP) transporter, such as dabigatran, rosuvastatin, sulfasazine, and topotecan. The proposed mechanisms, based on in vitro data, is decreased clearance due to neratinib-mediated inhibition of BCRP transport protein. There are no clinical data regarding the use of neratinib with BCRP substrates.", "source": "DDInter", "management_text": "Caution is advised if neratinib is used concomitantly with drugs that are substrates of BCRP transport protein, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring should be considered whenever neratinib is added to or withdrawn from therapy with these drugs. Patients should be monitored for the development of adverse effects.", "mechanism_text": "Others", "recommendation": "Caution is advised if neratinib is used concomitantly with drugs that are substrates of BCRP transport protein, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/98092/", "reference_text": "[1] Cerner Multum, Inc. \"Australian Product Information.\" O 0[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] Abbas R, Hug BA, Leister C, Burns J, Sonnichsen D \"Pharmacokinetics of oral neratinib during co-administration of ketoconazole in healthy subjects.\" Br J Clin Pharmacol 71 (2011): 522-7[4] \"Product Information. Nerlynx (neratinib).\" Puma Biotechnology, Inc., Los Angeles, CA.", "alternatives_a": "Glipizide, Acetohexamide, Guar gum, Pramlintide, Alogliptin, Tolazamide, Dulaglutide, Exenatide, Tolbutamide, Miglitol, Glimepiride, More", "alternatives_b": "Imatinib, Dabrafenib, Asciminib, Acalabrutinib, Dacomitinib, Pexidartinib, Fedratinib, Avapritinib, Larotrectinib, Bosutinib, Vemurafenib, More", "updated_at": 1767369485}, {"id": 97989, "ingredient1": "Empagliflozin", "ingredient2": "Nesiritide", "severity": "Moderate", "effect": "Sodium-glucose co-transporter 2 (SGLT-2) inhibitors may potentiate the hypotensive effects of diuretics and other antihypertensive agents or vasodilators. Inhibition of glucose and sodium co-transport produces mild diuresis and transient natriuresis, resulting in intravascular volume contraction. Volume depletion-related adverse reactions including hypotension, postural dizziness, orthostatic hypotension, syncope, and dehydration can occur after initiating treatment with SGLT-2 inhibitors, and the risk may be increased with concomitant use of other agents that can lower blood pressure.", "source": "DDInter", "management_text": "Caution is advised if SGLT-2 inhibitors are coadministered with diuretics and other hypotensive agents, particularly in the elderly and patients with impaired renal function. Prior to initiating SGLT-2 inhibitors, volume status should be assessed and corrected, if necessary. Clinical and laboratory monitoring are recommended during therapy, including electrolytes, fluid status, renal function, and blood pressure. If volume depletion occurs, treatment with SGLT-2 inhibitors should be interrupted until the condition is corrected.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if SGLT-2 inhibitors are coadministered with diuretics and other hypotensive agents, particularly in the elderly and patients with impaired renal function.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/98093/", "reference_text": "[1] \"Product Information. Jardiance (empagliflozin).\" Boehringer Ingelheim, Ridgefield, CT.[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] \"Product Information. Farxiga (dapagliflozin).\" Bristol-Myers Squibb, Princeton, NJ.[5] \"Product Information. Invokana (canagliflozin).\" Janssen Pharmaceuticals, Titusville, NJ.[6] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[7] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[8] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[9] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[10] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[11] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6[12] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[13] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[14] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[15] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42", "alternatives_a": "Vericiguat", "alternatives_b": "Glipizide, Acetohexamide, Guar gum, Pramlintide, Alogliptin, Rosuvastatin, Tolazamide, Dulaglutide, Exenatide, Tolbutamide, Miglitol, More", "updated_at": 1767369485}, {"id": 97990, "ingredient1": "Empagliflozin", "ingredient2": "Niacin", "severity": "Moderate", "effect": "The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.", "source": "DDInter", "management_text": "Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.", "mechanism_text": "Antagonism", "recommendation": "Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/98094/", "reference_text": "[1] Jori A, Carrara MC \"On the mechanism of the hyperglycaemic effect of chlorpromazine.\" J Pharm Pharmacol 18 (1966): 623-4[2] \"Product Information. Dymelor (acetohexamide)\" Lilly, Eli and Company, Indianapolis, IN.[3] \"Product Information. Thorazine (chlorpromazine).\" SmithKline Beecham, Philadelphia, PA.[4] Blayac JP, Ribes G, Buys D, Puech R, Loubatieres-Mariani MM \"Effects of a new benzothiadiazine derivative, LN 5330, on insulin secretion.\" Arch Int Pharmacodyn Ther 253 (1981): 154-63[5] \"Product Information. Elzonris (tagraxofusp).\" Stemline Therapeutics, New York, NY.[6] \"Product Information. Amaryl (glimepiride).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[7] \"Product Information. Elspar (asparaginase).\" Merck & Co, Inc, West Point, PA.[8] Jones IG, Pickens PT \"Diabetes mellitus following oral diuretics.\" Practitioner 199 (1967): 209-10[9] \"Product Information. Viracept (nelfinavir).\" Agouron Pharma Inc, La Jolla, CA.[10] \"Product Information. Tolinase (tolazamide)\" Pharmacia and Upjohn, Kalamazoo, MI.[11] Mauss S, Wolf E, Jaeger H \"Impaired glucose tolerance in HIV-positive patients receiving and those not receiving protease inhibitors.\" Ann Intern Med 130 (1999): 162-3[12] Virutamasen P, Wongsrichanalai C, Tangkeo P, Nitichai Y, Rienprayoon D \"Metabolic effects of depot-medroxyprogesterone acetate in long-term users: a cross-sectional study.\" Int J Gynaecol Obstet 24 (1986): 291-6[13] Wehring H, Alexander B, Perry PJ \"Diabetes mellitus associated with clozapine therapy.\" Pharmacotherapy 20 (2000): 844-7[14] Spellacy WN, Ellingson AB, Tsibris JC \"The effects of two triphasic oral contraceptives on carbohydrate metabolism in women during 1 year of use.\" Fertil Steril 51 (1989): 71-4[15] Andersen OO, Persson I \"Carbohydrate metabolism during treatment with chlorthalidone and ethacrynic acid.\" Br Med J 2 (1968): 798-801[16] Berlin I \"Prazosin, diuretics, and glucose intolerance.\" Ann Intern Med 119 (1993): 860[17] Malherbe C, Burrill KC, Levin SR, Karam JH, Forsham PH \"Effect of diphenylhydantoin on insulin secretion in man.\" N Engl J Med 286 (1972): 339-42[18] Carter BL, Small RE, Mandel MD, Starkman MT \"Phenytoin-induced hyperglycemia.\" Am J Hosp Pharm 38 (1981): 1508-12[19] Al-Rubeaan K, Ryan EA \"Phenytoin-induced insulin insensitivity.\" Diabet Med 8 (1991): 968-70[20] \"Product Information. Zolinza (vorinostat).\" Merck & Company Inc, West Point, PA.[21] Goldman JA, Neri A, Ovadia J, Eckerling B, Vries A, de \"Effect of chlorothiazide on intravenous glucose tolerance in pregnancy.\" Am J Obstet Gynecol 105 (1969): 556-60[22] Harper R, Ennis CN, Heaney AP, Sheridan B, Gormley M, Atkinson AB, Johnston GD, Bell PM \"A comparison of the effects of low- and conventional-dose thiazide diuretic on insulin action in hypertensive patients with NIDDM.\" Diabetologia 38 (1995): 853-9[23] Seltzer HS, Allen EW \"Hyperglycemia and inhibition of insulin secretion during administration of diazoxide and trichlormethiazide in man.\" Diabetes 18 (1969): 19-28[24] Dube MP, Johnson DL, Currier JS, Leedom JM \"Protease inhibitor-associated hyperglycaemia.\" Lancet 350 (1997): 713-4[25] Leary WP, Reyes AJ \"Drug interactions with diuretics.\" S Afr Med J 65 (1984): 455-61[26] \"Product Information. Reyataz (atazanavir).\" Bristol-Myers Squibb, Princeton, NJ.[27] Pollare T, Lithell H, Berne C \"A comparison of the effects of hydrochlorothiazide and captopril on glucose and lipid metabolism in patients with hypertension.\" N Engl J Med 321 (1989): 868-73[28] Gunnarsson R, Lundgren G, Magnusson G, Ost L, Groth CG \"Steroid diabetes--a sign of overtreatment with steroids in the renal graft recipient?\" Scand J Urol Nephrol Suppl 54 (1980): 135-8[29] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[30] \"Product Information. Synthroid (levothyroxine).\" Abbott Pharmaceutical, Abbott Park, IL.[31] Murphy MB, Kohner E, Lewis PJ, Schumer B, Dollery CT \"Glucose intolerance in hypertensive patients treated with diuretics: a fourteen-year follow-up.\" Lancet 2 (1982): 1293-5[32] \"Product Information. Fortovase (saquinavir)\" Roche Laboratories, Nutley, NJ.[33] Coni NK, Gordon PW, Mukherjee AP, Read PR \"The effect of frusemide and ethacrynic acid on carbohydrate metabolism.\" Age Ageing 3 (1974): 85-90[34] \"Product Information. Norvir (ritonavir).\" Abbott Pharmaceutical, Abbott Park, IL.[35] Domenet JG \"Diabetogenic effect of oral diuretics.\" Br Med J 3 (1968): 188[36] Rowe P, Mather H \"Hyperosmolar non-ketotic diabetes mellitus associated with metolazone.\" Br Med J 291 (1985): 25-6[37] Winchester JF, Kellett RJ, Boddy K, Boyle P, Dargie HJ, Mahaffey ME, Ward DM, Kennedy AC \"Metolazone and bendroflumethiazide in hypertension: physiologic and metabolic observations.\" Clin Pharmacol Ther 28 (1980): 611-8[38] \"Product Information. Carafate (sucralfate).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[39] Tsiodras S, Mantzoros C, Hammer S, Samore M \"Effects of protease inhibitors on hyperglycemia, hyperlipidemia, and lipodystrophy - A 5-year cohort study.\" Arch Intern Med 160 (2000): 2050-6[40] \"Product Information. Apidra (insulin glulisine).\" Aventis Pharmaceuticals, Bridgewater, NJ.[41] \"Product Information. Prezista (darunavir).\" Ortho Biotech Inc, Bridgewater, NJ.[42] Haiba NA, el-Habashy MA, Said SA, Darwish EA, Abdel-Sayed WS, Nayel SE \"Clinical evaluation of two monthly injectable contraceptives and their effects on some metabolic parameters.\" Contraception 39 (1989): 619-32[43] Erle G, Basso M, Federspil G, Sicolo N, Scandellari C \"Effect of chlorpromazine on blood glucose and plasma insulin in man.\" Eur J Clin Pharmacol 11 (1977): 15-8[44] Pickkers P, Schachter M, Hughes AD, Feher MD, Sever PS \"Thiazide-induced hyperglycaemia: a role for calcium-activated potassium channels?\" Diabetologia 39 (1996): 861-4[45] \"Product Information. Lexiva (fosamprenavir).\" GlaxoSmithKline, Research Triangle Park, NC.[46] Curtis J, Horrigan F, Ahearn D, Varney R, Sandler SG \"Chlorthalidone-induced hyperosmolar hyperglycemic nonketotic coma.\" JAMA 220 (1972): 1592-3[47] \"Product Information. Hyperstat I.V. (diazoxide).\" Schering Corp, Kenilworth, NJ.[48] \"Product Information. Piqray (alpelisib).\" Novartis Pharmaceuticals, East Hanover, NJ.[49] Bell DS \"Insulin resistance. An often unrecognized problem accompanying chronic medical disorders.\" Postgrad Med 93 (1993): 99-103,[50] Stambaugh JE, Tucker DC \"Effect of diphenylhydantoin on glucose tolerance in patients with hypoglycemia.\" Diabetes 23 (1974): 679-83[51] \"Product Information. Crixivan (indinavir).\" Merck & Co, Inc, West Point, PA.[52] Miller NR, Moses H \"Transient oculomotor nerve palsy. Association with thiazide-induced glucose intolerance.\" JAMA 240 (1978): 1887-8[53] Javier Z, Gershberg H, Hulse M \"Ovulatory suppressants, estrogens, and carbohydrate metabolism.\" Metabolism 17 (1968): 443-56[54] Goldman JA, Ovadia JL \"The effect of estrogen on intravenous glucose tolerance in woman.\" Am J Obstet Gynecol 103 (1969): 172-8[55] Charan VD, Desai N, Singh AP, Choudhry VP \"Diabetes mellitus and pancreatitis as a complication of L- asparaginase therapy.\" Indian Pediatr 30 (1993): 809-10[56] Seifer DB, Freedman LN, Cavender JR, Baker RA \"Insulin-dependent diabetes mellitus associated with danazol.\" Am J Obstet Gynecol 162 (1990): 474-5[57] \"Product Information. Orinase (tolbutamide)\" Pharmacia and Upjohn, Kalamazoo, MI.[58] Walli R, Demant T \"Impaired glucose tolerance and protease inhibitors.\" Ann Intern Med 129 (1998): 837-8[59] Hannaford PC, Kay CR \"Oral contraceptives and diabetes mellitus.\" BMJ 299 (1989): 1315-6[60] Hardy H, Esch LD, Morse GD \"Glucose disorders associated with HIV and its drug therapy.\" Ann Pharmacother 35 (2001): 343-51[61] Chowdhury FR, Bleicher SJ \"Chlorthalidone--induced hypokalemia and abnormal carbohydrate metabolism.\" Horm Metab Res 2 (1970): 13-6[62] Kaufman MB, Simionatto C \"A review of protease inhibitor-induced hyperglycemia.\" Pharmacotherapy 19 (1999): 114-7[63] Greenstone MA, Shaw AB \"Alternate day corticosteroid causes alternate day hyperglycaemia.\" Postgrad Med J 63 (1987): 761-4[64] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[65] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[66] Elmfeldt D, Berglund G, Wedel H, Wilhelmsen L \"Incidence and importance of metabolic side-effects during antihypertensive therapy.\" Acta Med Scand Suppl 672 (1983): 79-83[67] \"Product Information. Agenerase (amprenavir).\" Glaxo Wellcome, Research Triangle Pk, NC.[68] Diamond MT \"Hyperglycemic hyperosmolar coma associated with hydrochlorothiazide and pancreatitis.\" N Y State J Med 72 (1972): 1741-2[69] \"Product Information. Prandin (repaglinide).\" Novo Nordisk Pharmaceuticals Inc, Princeton, NJ.[70] \"Product Information. Precose (acarbose).\" Bayer, West Haven, CT.[71] \"Product Information. Starlix (nateglinide)\" Novartis Pharmaceuticals, East Hanover, NJ.[72] \"Product Information. Oncaspar (pegaspargase).\" Rhone-Poulenc Rorer, Collegeville, PA.[73] Sotaniemi E, Kontturi M, Larmi T \"Effect of diethylstilbestrol on blood glucose of prostatic cancer patients.\" Invest Urol 10 (1973): 438-41[74] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[75] Petri M, Cumber P, Grimes L, Treby D, Bryant R, Rawlins D, Ising H \"The metabolic effects of thiazide therapy in the elderly: a population study.\" Age Ageing 15 (1986): 151-5[76] Ludvik B, Clodi M, Kautzky-Willer A, Capek M, Hartter E, Pacini G, Prager R \"Effect of dexamethasone on insulin sensitivity, islet amyloid polypeptide and insulin secretion in humans.\" Diabetologia 36 (1993): 84-7[77] \"Product Information. Glucophage (metformin).\" Bristol-Myers Squibb, Princeton, NJ.[78] Chaudhuri ML, Catania J \"A comparison of the effects of bumetanide (Burinex) and frusemide on carbohydrate metabolism in the elderly.\" Br J Clin Pract 42 (1988): 427-9[79] Black DM, Filak AT \"Hyperglycemia with non-insulin-dependent diabetes following intraarticular steroid injection.\" J Fam Pract 28 (1989): 462-3[80] \"Product Information. Megace (megestrol).\" Bristol-Myers Squibb, Princeton, NJ.[81] \"Product Information. Torisel (temsirolimus).\" Wyeth-Ayerst Laboratories, Philadelphia, PA.[82] Schmitz O, Hermansen K, Nielsen OH, Christensen CK, Arnfred J, Hansen HE, Mogensen CE, Orskov H, Beck-Nielsen H \"Insulin action in insulin-dependent diabetics after short-term thiazide therapy.\" Diabetes Care 9 (1986): 631-6[83] Kansal PC, Buse J, Buse MG \"Thiazide diuretics and control of diabetes mellitus.\" South Med J 62 (1969): 1372-9[84] Dimitriadis G, Tegos C, Golfinopoulou L, Roboti C, Raptis S \"Furosemide-induced hyperglycaemia - the implication of glycolytic kinases.\" Horm Metab Res 25 (1993): 557-9[85] \"Product Information. NovoLog Mix 70/30 (insulin aspart-insulin aspart protamine).\" Novo Nordisk Pharmaceuticals Inc, Princeton, NJ.[86] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[87] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[88] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[89] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42[90] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[91] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[92] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[93] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[94] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[95] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6", "alternatives_a": "Cholestyramine, Rosuvastatin, Fenofibrate, Mipomersen, Evinacumab, Dextrothyroxine, Simvastatin, Probucol, Cerivastatin, Lomitapide, Ezetimibe, More", "alternatives_b": "Guar gum", "updated_at": 1767369485}, {"id": 97991, "ingredient1": "Empagliflozin", "ingredient2": "Nicotinamide", "severity": "Moderate", "effect": "The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.", "source": "DDInter", "management_text": "Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.", "mechanism_text": "Antagonism", "recommendation": "Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/98095/", "reference_text": "[1] Jori A, Carrara MC \"On the mechanism of the hyperglycaemic effect of chlorpromazine.\" J Pharm Pharmacol 18 (1966): 623-4[2] \"Product Information. Dymelor (acetohexamide)\" Lilly, Eli and Company, Indianapolis, IN.[3] \"Product Information. Thorazine (chlorpromazine).\" SmithKline Beecham, Philadelphia, PA.[4] Blayac JP, Ribes G, Buys D, Puech R, Loubatieres-Mariani MM \"Effects of a new benzothiadiazine derivative, LN 5330, on insulin secretion.\" Arch Int Pharmacodyn Ther 253 (1981): 154-63[5] \"Product Information. Elzonris (tagraxofusp).\" Stemline Therapeutics, New York, NY.[6] \"Product Information. Amaryl (glimepiride).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[7] \"Product Information. Elspar (asparaginase).\" Merck & Co, Inc, West Point, PA.[8] Jones IG, Pickens PT \"Diabetes mellitus following oral diuretics.\" Practitioner 199 (1967): 209-10[9] \"Product Information. Viracept (nelfinavir).\" Agouron Pharma Inc, La Jolla, CA.[10] \"Product Information. Tolinase (tolazamide)\" Pharmacia and Upjohn, Kalamazoo, MI.[11] Mauss S, Wolf E, Jaeger H \"Impaired glucose tolerance in HIV-positive patients receiving and those not receiving protease inhibitors.\" Ann Intern Med 130 (1999): 162-3[12] Virutamasen P, Wongsrichanalai C, Tangkeo P, Nitichai Y, Rienprayoon D \"Metabolic effects of depot-medroxyprogesterone acetate in long-term users: a cross-sectional study.\" Int J Gynaecol Obstet 24 (1986): 291-6[13] Wehring H, Alexander B, Perry PJ \"Diabetes mellitus associated with clozapine therapy.\" Pharmacotherapy 20 (2000): 844-7[14] Spellacy WN, Ellingson AB, Tsibris JC \"The effects of two triphasic oral contraceptives on carbohydrate metabolism in women during 1 year of use.\" Fertil Steril 51 (1989): 71-4[15] Andersen OO, Persson I \"Carbohydrate metabolism during treatment with chlorthalidone and ethacrynic acid.\" Br Med J 2 (1968): 798-801[16] Berlin I \"Prazosin, diuretics, and glucose intolerance.\" Ann Intern Med 119 (1993): 860[17] Malherbe C, Burrill KC, Levin SR, Karam JH, Forsham PH \"Effect of diphenylhydantoin on insulin secretion in man.\" N Engl J Med 286 (1972): 339-42[18] Carter BL, Small RE, Mandel MD, Starkman MT \"Phenytoin-induced hyperglycemia.\" Am J Hosp Pharm 38 (1981): 1508-12[19] Al-Rubeaan K, Ryan EA \"Phenytoin-induced insulin insensitivity.\" Diabet Med 8 (1991): 968-70[20] \"Product Information. Zolinza (vorinostat).\" Merck & Company Inc, West Point, PA.[21] Goldman JA, Neri A, Ovadia J, Eckerling B, Vries A, de \"Effect of chlorothiazide on intravenous glucose tolerance in pregnancy.\" Am J Obstet Gynecol 105 (1969): 556-60[22] Harper R, Ennis CN, Heaney AP, Sheridan B, Gormley M, Atkinson AB, Johnston GD, Bell PM \"A comparison of the effects of low- and conventional-dose thiazide diuretic on insulin action in hypertensive patients with NIDDM.\" Diabetologia 38 (1995): 853-9[23] Seltzer HS, Allen EW \"Hyperglycemia and inhibition of insulin secretion during administration of diazoxide and trichlormethiazide in man.\" Diabetes 18 (1969): 19-28[24] Dube MP, Johnson DL, Currier JS, Leedom JM \"Protease inhibitor-associated hyperglycaemia.\" Lancet 350 (1997): 713-4[25] Leary WP, Reyes AJ \"Drug interactions with diuretics.\" S Afr Med J 65 (1984): 455-61[26] \"Product Information. Reyataz (atazanavir).\" Bristol-Myers Squibb, Princeton, NJ.[27] Pollare T, Lithell H, Berne C \"A comparison of the effects of hydrochlorothiazide and captopril on glucose and lipid metabolism in patients with hypertension.\" N Engl J Med 321 (1989): 868-73[28] Gunnarsson R, Lundgren G, Magnusson G, Ost L, Groth CG \"Steroid diabetes--a sign of overtreatment with steroids in the renal graft recipient?\" Scand J Urol Nephrol Suppl 54 (1980): 135-8[29] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[30] \"Product Information. Synthroid (levothyroxine).\" Abbott Pharmaceutical, Abbott Park, IL.[31] Murphy MB, Kohner E, Lewis PJ, Schumer B, Dollery CT \"Glucose intolerance in hypertensive patients treated with diuretics: a fourteen-year follow-up.\" Lancet 2 (1982): 1293-5[32] \"Product Information. Fortovase (saquinavir)\" Roche Laboratories, Nutley, NJ.[33] Coni NK, Gordon PW, Mukherjee AP, Read PR \"The effect of frusemide and ethacrynic acid on carbohydrate metabolism.\" Age Ageing 3 (1974): 85-90[34] \"Product Information. Norvir (ritonavir).\" Abbott Pharmaceutical, Abbott Park, IL.[35] Domenet JG \"Diabetogenic effect of oral diuretics.\" Br Med J 3 (1968): 188[36] Rowe P, Mather H \"Hyperosmolar non-ketotic diabetes mellitus associated with metolazone.\" Br Med J 291 (1985): 25-6[37] Winchester JF, Kellett RJ, Boddy K, Boyle P, Dargie HJ, Mahaffey ME, Ward DM, Kennedy AC \"Metolazone and bendroflumethiazide in hypertension: physiologic and metabolic observations.\" Clin Pharmacol Ther 28 (1980): 611-8[38] \"Product Information. Carafate (sucralfate).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[39] Tsiodras S, Mantzoros C, Hammer S, Samore M \"Effects of protease inhibitors on hyperglycemia, hyperlipidemia, and lipodystrophy - A 5-year cohort study.\" Arch Intern Med 160 (2000): 2050-6[40] \"Product Information. Apidra (insulin glulisine).\" Aventis Pharmaceuticals, Bridgewater, NJ.[41] \"Product Information. Prezista (darunavir).\" Ortho Biotech Inc, Bridgewater, NJ.[42] Haiba NA, el-Habashy MA, Said SA, Darwish EA, Abdel-Sayed WS, Nayel SE \"Clinical evaluation of two monthly injectable contraceptives and their effects on some metabolic parameters.\" Contraception 39 (1989): 619-32[43] Erle G, Basso M, Federspil G, Sicolo N, Scandellari C \"Effect of chlorpromazine on blood glucose and plasma insulin in man.\" Eur J Clin Pharmacol 11 (1977): 15-8[44] Pickkers P, Schachter M, Hughes AD, Feher MD, Sever PS \"Thiazide-induced hyperglycaemia: a role for calcium-activated potassium channels?\" Diabetologia 39 (1996): 861-4[45] \"Product Information. Lexiva (fosamprenavir).\" GlaxoSmithKline, Research Triangle Park, NC.[46] Curtis J, Horrigan F, Ahearn D, Varney R, Sandler SG \"Chlorthalidone-induced hyperosmolar hyperglycemic nonketotic coma.\" JAMA 220 (1972): 1592-3[47] \"Product Information. Hyperstat I.V. (diazoxide).\" Schering Corp, Kenilworth, NJ.[48] \"Product Information. Piqray (alpelisib).\" Novartis Pharmaceuticals, East Hanover, NJ.[49] Bell DS \"Insulin resistance. An often unrecognized problem accompanying chronic medical disorders.\" Postgrad Med 93 (1993): 99-103,[50] Stambaugh JE, Tucker DC \"Effect of diphenylhydantoin on glucose tolerance in patients with hypoglycemia.\" Diabetes 23 (1974): 679-83[51] \"Product Information. Crixivan (indinavir).\" Merck & Co, Inc, West Point, PA.[52] Miller NR, Moses H \"Transient oculomotor nerve palsy. Association with thiazide-induced glucose intolerance.\" JAMA 240 (1978): 1887-8[53] Javier Z, Gershberg H, Hulse M \"Ovulatory suppressants, estrogens, and carbohydrate metabolism.\" Metabolism 17 (1968): 443-56[54] Goldman JA, Ovadia JL \"The effect of estrogen on intravenous glucose tolerance in woman.\" Am J Obstet Gynecol 103 (1969): 172-8[55] Charan VD, Desai N, Singh AP, Choudhry VP \"Diabetes mellitus and pancreatitis as a complication of L- asparaginase therapy.\" Indian Pediatr 30 (1993): 809-10[56] Seifer DB, Freedman LN, Cavender JR, Baker RA \"Insulin-dependent diabetes mellitus associated with danazol.\" Am J Obstet Gynecol 162 (1990): 474-5[57] \"Product Information. Orinase (tolbutamide)\" Pharmacia and Upjohn, Kalamazoo, MI.[58] Walli R, Demant T \"Impaired glucose tolerance and protease inhibitors.\" Ann Intern Med 129 (1998): 837-8[59] Hannaford PC, Kay CR \"Oral contraceptives and diabetes mellitus.\" BMJ 299 (1989): 1315-6[60] Hardy H, Esch LD, Morse GD \"Glucose disorders associated with HIV and its drug therapy.\" Ann Pharmacother 35 (2001): 343-51[61] Chowdhury FR, Bleicher SJ \"Chlorthalidone--induced hypokalemia and abnormal carbohydrate metabolism.\" Horm Metab Res 2 (1970): 13-6[62] Kaufman MB, Simionatto C \"A review of protease inhibitor-induced hyperglycemia.\" Pharmacotherapy 19 (1999): 114-7[63] Greenstone MA, Shaw AB \"Alternate day corticosteroid causes alternate day hyperglycaemia.\" Postgrad Med J 63 (1987): 761-4[64] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[65] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[66] Elmfeldt D, Berglund G, Wedel H, Wilhelmsen L \"Incidence and importance of metabolic side-effects during antihypertensive therapy.\" Acta Med Scand Suppl 672 (1983): 79-83[67] \"Product Information. Agenerase (amprenavir).\" Glaxo Wellcome, Research Triangle Pk, NC.[68] Diamond MT \"Hyperglycemic hyperosmolar coma associated with hydrochlorothiazide and pancreatitis.\" N Y State J Med 72 (1972): 1741-2[69] \"Product Information. Prandin (repaglinide).\" Novo Nordisk Pharmaceuticals Inc, Princeton, NJ.[70] \"Product Information. Precose (acarbose).\" Bayer, West Haven, CT.[71] \"Product Information. Starlix (nateglinide)\" Novartis Pharmaceuticals, East Hanover, NJ.[72] \"Product Information. Oncaspar (pegaspargase).\" Rhone-Poulenc Rorer, Collegeville, PA.[73] Sotaniemi E, Kontturi M, Larmi T \"Effect of diethylstilbestrol on blood glucose of prostatic cancer patients.\" Invest Urol 10 (1973): 438-41[74] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[75] Petri M, Cumber P, Grimes L, Treby D, Bryant R, Rawlins D, Ising H \"The metabolic effects of thiazide therapy in the elderly: a population study.\" Age Ageing 15 (1986): 151-5[76] Ludvik B, Clodi M, Kautzky-Willer A, Capek M, Hartter E, Pacini G, Prager R \"Effect of dexamethasone on insulin sensitivity, islet amyloid polypeptide and insulin secretion in humans.\" Diabetologia 36 (1993): 84-7[77] \"Product Information. Glucophage (metformin).\" Bristol-Myers Squibb, Princeton, NJ.[78] Chaudhuri ML, Catania J \"A comparison of the effects of bumetanide (Burinex) and frusemide on carbohydrate metabolism in the elderly.\" Br J Clin Pract 42 (1988): 427-9[79] Black DM, Filak AT \"Hyperglycemia with non-insulin-dependent diabetes following intraarticular steroid injection.\" J Fam Pract 28 (1989): 462-3[80] \"Product Information. Megace (megestrol).\" Bristol-Myers Squibb, Princeton, NJ.[81] \"Product Information. Torisel (temsirolimus).\" Wyeth-Ayerst Laboratories, Philadelphia, PA.[82] Schmitz O, Hermansen K, Nielsen OH, Christensen CK, Arnfred J, Hansen HE, Mogensen CE, Orskov H, Beck-Nielsen H \"Insulin action in insulin-dependent diabetics after short-term thiazide therapy.\" Diabetes Care 9 (1986): 631-6[83] Kansal PC, Buse J, Buse MG \"Thiazide diuretics and control of diabetes mellitus.\" South Med J 62 (1969): 1372-9[84] Dimitriadis G, Tegos C, Golfinopoulou L, Roboti C, Raptis S \"Furosemide-induced hyperglycaemia - the implication of glycolytic kinases.\" Horm Metab Res 25 (1993): 557-9[85] \"Product Information. NovoLog Mix 70/30 (insulin aspart-insulin aspart protamine).\" Novo Nordisk Pharmaceuticals Inc, Princeton, NJ.[86] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[87] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[88] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[89] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42[90] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[91] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[92] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[93] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[94] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[95] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6", "alternatives_a": "Pyridoxine", "alternatives_b": "Acetohexamide, Guar gum, Simvastatin, Troglitazone, Rosuvastatin", "updated_at": 1767369485}, {"id": 97992, "ingredient1": "Empagliflozin", "ingredient2": "Nicardipine", "severity": "Moderate", "effect": "Sodium-glucose co-transporter 2 (SGLT-2) inhibitors may potentiate the hypotensive effects of diuretics and other antihypertensive agents or vasodilators. Inhibition of glucose and sodium co-transport produces mild diuresis and transient natriuresis, resulting in intravascular volume contraction. Volume depletion-related adverse reactions including hypotension, postural dizziness, orthostatic hypotension, syncope, and dehydration can occur after initiating treatment with SGLT-2 inhibitors, and the risk may be increased with concomitant use of other agents that can lower blood pressure.", "source": "DDInter", "management_text": "Caution is advised if SGLT-2 inhibitors are coadministered with diuretics and other hypotensive agents, particularly in the elderly and patients with impaired renal function. Prior to initiating SGLT-2 inhibitors, volume status should be assessed and corrected, if necessary. Clinical and laboratory monitoring are recommended during therapy, including electrolytes, fluid status, renal function, and blood pressure. If volume depletion occurs, treatment with SGLT-2 inhibitors should be interrupted until the condition is corrected.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if SGLT-2 inhibitors are coadministered with diuretics and other hypotensive agents, particularly in the elderly and patients with impaired renal function.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/98096/", "reference_text": "[1] \"Product Information. Jardiance (empagliflozin).\" Boehringer Ingelheim, Ridgefield, CT.[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] \"Product Information. Farxiga (dapagliflozin).\" Bristol-Myers Squibb, Princeton, NJ.[5] \"Product Information. Invokana (canagliflozin).\" Janssen Pharmaceuticals, Titusville, NJ.[6] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[7] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[8] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[9] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[10] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[11] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6[12] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[13] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[14] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[15] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42", "alternatives_a": "Celecoxib", "alternatives_b": "Glipizide, Acetohexamide, Guar gum, Pramlintide, Alogliptin, Rosuvastatin, Tolazamide, Dulaglutide, Exenatide, Tolbutamide, Miglitol, More", "updated_at": 1767369485}, {"id": 97993, "ingredient1": "Empagliflozin", "ingredient2": "Nimodipine", "severity": "Moderate", "effect": "Sodium-glucose co-transporter 2 (SGLT-2) inhibitors may potentiate the hypotensive effects of diuretics and other antihypertensive agents or vasodilators. Inhibition of glucose and sodium co-transport produces mild diuresis and transient natriuresis, resulting in intravascular volume contraction. Volume depletion-related adverse reactions including hypotension, postural dizziness, orthostatic hypotension, syncope, and dehydration can occur after initiating treatment with SGLT-2 inhibitors, and the risk may be increased with concomitant use of other agents that can lower blood pressure.", "source": "DDInter", "management_text": "Caution is advised if SGLT-2 inhibitors are coadministered with diuretics and other hypotensive agents, particularly in the elderly and patients with impaired renal function. Prior to initiating SGLT-2 inhibitors, volume status should be assessed and corrected, if necessary. Clinical and laboratory monitoring are recommended during therapy, including electrolytes, fluid status, renal function, and blood pressure. If volume depletion occurs, treatment with SGLT-2 inhibitors should be interrupted until the condition is corrected.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if SGLT-2 inhibitors are coadministered with diuretics and other hypotensive agents, particularly in the elderly and patients with impaired renal function.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/98097/", "reference_text": "[1] \"Product Information. Jardiance (empagliflozin).\" Boehringer Ingelheim, Ridgefield, CT.[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] \"Product Information. Farxiga (dapagliflozin).\" Bristol-Myers Squibb, Princeton, NJ.[5] \"Product Information. Invokana (canagliflozin).\" Janssen Pharmaceuticals, Titusville, NJ.[6] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[7] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[8] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[9] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[10] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[11] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6[12] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[13] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[14] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[15] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42", "alternatives_a": "Celecoxib", "alternatives_b": "Glipizide, Acetohexamide, Guar gum, Pramlintide, Alogliptin, Rosuvastatin, Tolazamide, Dulaglutide, Exenatide, Tolbutamide, Miglitol, More", "updated_at": 1767369485}, {"id": 97994, "ingredient1": "Empagliflozin", "ingredient2": "Nisoldipine", "severity": "Moderate", "effect": "Sodium-glucose co-transporter 2 (SGLT-2) inhibitors may potentiate the hypotensive effects of diuretics and other antihypertensive agents or vasodilators. Inhibition of glucose and sodium co-transport produces mild diuresis and transient natriuresis, resulting in intravascular volume contraction. Volume depletion-related adverse reactions including hypotension, postural dizziness, orthostatic hypotension, syncope, and dehydration can occur after initiating treatment with SGLT-2 inhibitors, and the risk may be increased with concomitant use of other agents that can lower blood pressure.", "source": "DDInter", "management_text": "Caution is advised if SGLT-2 inhibitors are coadministered with diuretics and other hypotensive agents, particularly in the elderly and patients with impaired renal function. Prior to initiating SGLT-2 inhibitors, volume status should be assessed and corrected, if necessary. Clinical and laboratory monitoring are recommended during therapy, including electrolytes, fluid status, renal function, and blood pressure. If volume depletion occurs, treatment with SGLT-2 inhibitors should be interrupted until the condition is corrected.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if SGLT-2 inhibitors are coadministered with diuretics and other hypotensive agents, particularly in the elderly and patients with impaired renal function.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/98098/", "reference_text": "[1] \"Product Information. Jardiance (empagliflozin).\" Boehringer Ingelheim, Ridgefield, CT.[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] \"Product Information. Farxiga (dapagliflozin).\" Bristol-Myers Squibb, Princeton, NJ.[5] \"Product Information. Invokana (canagliflozin).\" Janssen Pharmaceuticals, Titusville, NJ.[6] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[7] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[8] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[9] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[10] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[11] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6[12] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[13] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[14] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[15] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42", "alternatives_a": "Celecoxib", "alternatives_b": "Acetohexamide, Guar gum, Pramlintide, Alogliptin, Tolazamide, Dulaglutide, Exenatide, Tolbutamide, Miglitol, Glimepiride, Albiglutide, More", "updated_at": 1767369485}, {"id": 97995, "ingredient1": "Empagliflozin", "ingredient2": "Nitisinone", "severity": "Moderate", "effect": "Coadministration with nitisinone may increase the plasma concentrations and the risk of adverse effects of drugs that are substrates of organic anion transporter 1 and/or 3 (OAT1/OAT3) .", "source": "DDInter", "management_text": "Caution is advised if nitisinone is used in combination with OAT1/OAT3 substrates. Patients should be monitored for potential adverse reactions related to increased plasma concentrations of the OAT1/OAT3 substrate.", "mechanism_text": "Distribution", "recommendation": "Caution is advised if nitisinone is used in combination with OAT1/OAT3 substrates.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/98099/", "reference_text": "[1] \"Product Information. Orfadin (nitisinone).\" Orphan Pharmaceuticals USA, Inc, Nashville, TN.[2] \"Product Information. Cytovene (ganciclovir).\" Genentech, South San Francisco, CA.[3] Jung D, Griffy K, Dorr A \"Effect of food on high-dose oral ganciclovir disposition in HIV-positive subjects.\" J Clin Pharmacol 39 (1999): 161-5[4] Lavelle J, Follansbee S, Trapnell CB, Buhles WC, Griffy KG, Jung D, Dorr A, Conner J \"Effect of food on the relative bioavailability of oral ganciclovir.\" J Clin Pharmacol 36 (1996): 238-41[5] Gunston GD, Mehta U \"Potentially serious drug interactions with grapefruit juice.\" S Afr Med J 90 (2000): 41[6] Bailey DG, Arnold JMO, Spence JD \"Grapefruit juice and drugs - how significant is the interaction.\" Clin Pharmacokinet 26 (1994): 91-8[7] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[8] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions.\" Br J Clin Pharmacol 46 (1998): 101-10[9] Libersa CC, Brique SA, Motte KB, et al. \"Dramatic inhibition of amiodarone metabolism induced by grapefruit juice.\" Br J Clin Pharmacol 49 (2000): 373-8[10] Bailey DG, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit juice felodipine interaction: Effect of naringin and 6',7'-dihydroxybergamottin in humans.\" Clin Pharmacol Ther 64 (1998): 248-56[11] Jonkman JH, Sollie FA, Sauter R, Steinijans VW \"The influence of caffeine on the steady-state pharmacokinetics of theophylline.\" Clin Pharmacol Ther 49 (1991): 248-55[12] Ozdemir M, Aktan Y, Boydag BS, Cingi MI, Musmul A \"Interaction between grapefruit juice and diazepam in humans.\" Eur J Drug Metab Pharmacokinet 23 (1998): 55-9[13] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin.\" Clin Pharmacol Ther 66 (1999): 118-27[14] Bailey DG, Arnold JM, Munoz C, Spence JD \"Grapefruit juice--felodipine interaction: mechanism, predictability, and effect of naringin.\" Clin Pharmacol Ther 53 (1993): 637-42[15] Sigusch H, Hippius M, Henschel L, Kaufmann K, Hoffmann A \"Influence of grapefruit juice on the pharmacokinetics of a slow release nifedipine formulation.\" Pharmazie 49 (1994): 522-4[16] Eagling VA, Profit L, Back DJ \"Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-I protease inhibitor saquinavir by grapefruit juice components.\" Br J Clin Pharmacol 48 (1999): 543-52[17] Damkier P, Hansen LL, Brosen K \"Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine.\" Br J Clin Pharmacol 48 (1999): 829-38[18] Min DI, Ku YM, Geraets DR, Lee HC \"Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers.\" J Clin Pharmacol 36 (1996): 469-76[19] Zaidenstein R, Soback S, Gips M, Avni B, Dishi V, Weissgarten Y, Golik A, Scapa E \"Effect of grapefruit juice on the pharmacokinetics of losartan and its active metabolite E3174 in healthy volunteers.\" Ther Drug Monit 23 (2001): 369-73[20] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84[21] Lee AJ, Chan WK, Harralson AF, Buffum J, Bui BCC \"The effects of grapefruit juice on sertraline metabolism: An in vitro and in vivo study.\" Clin Ther 21 (1999): 1890-9[22] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors.\" Clin Pharmacol Ther 64 (1998): 477-83[23] Garg SK, Kumar N, Bhargava VK, Prabhakar SK \"Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy.\" Clin Pharmacol Ther 64 (1998): 286-8[24] Fuhr U, Maier-Bruggemann A, Blume H, et al. \"Grapefruit juice increases oral nimodipine bioavailability.\" Int J Clin Pharmacol Ther 36 (1998): 126-32[25] Sato J, Nakata H, Owada E, Kikuta T, Umetsu M, Ito K \"Influence of usual intake of dietary caffeine on single-dose kinetics of theophylline in healthy human subjects.\" Eur J Clin Pharmacol 44 (1993): 295-8[26] Edgar B, Bailey D, Bergstrand R, et al \"Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics on felodipine and its potential clinical relevance.\" Eur J Clin Pharmacol 42 (1992): 313-7[27] Kantola T, Kivisto KT, Neuvonen PJ \"Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid.\" Clin Pharmacol Ther 63 (1998): 397-402[28] Dresser GK, Spence JD, Bailey DG \"Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition.\" Clin Pharmacokinet 38 (2000): 41-57[29] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[30] Takanaga H, Ohnishi A, Maatsuo H, et al. \"Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model.\" Br J Clin Pharmacol 49 (2000): 49-58[31] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS \"Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice.\" Br J Clin Pharmacol 42 (1996): p662[32] Bailey DG, Arnold JM, Strong HA, Munoz C, Spence JD \"Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics.\" Clin Pharmacol Ther 54 (1993): 589-94[33] Josefsson M, Zackrisson AL, Ahlner J \"Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers.\" Eur J Clin Pharmacol 51 (1996): 189-93[34] Majeed A, Kareem A \"Effect of grapefruit juice on cyclosporine pharmacokinetics.\" Pediatr Nephrol 10 (1996): 395[35] Flanagan D \"Understanding the grapefruit-drug interaction.\" Gen Dent 53 (2005): 282-5; quiz 286[36] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ \"Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice.\" Clin Pharmacol Ther 58 (1995): 127-31", "alternatives_a": "Teduglutide, Fosdenopterin, Miglustat, Imiglucerase, Asfotase alfa, Glycerol phenylbutyrate, Pegvaliase, Triethylenetetramine, Sapropterin, Zinc acetate, Phenylbutyric acid, More", "alternatives_b": "Glipizide, Guar gum, Pramlintide, Alogliptin, Rosuvastatin, Dulaglutide, Exenatide, Miglitol, Albiglutide, Rosiglitazone, Ertugliflozin, More", "updated_at": 1767369485}, {"id": 97996, "ingredient1": "Empagliflozin", "ingredient2": "Nitroglycerin", "severity": "Moderate", "effect": "Sodium-glucose co-transporter 2 (SGLT-2) inhibitors may potentiate the hypotensive effects of diuretics and other antihypertensive agents or vasodilators. Inhibition of glucose and sodium co-transport produces mild diuresis and transient natriuresis, resulting in intravascular volume contraction. Volume depletion-related adverse reactions including hypotension, postural dizziness, orthostatic hypotension, syncope, and dehydration can occur after initiating treatment with SGLT-2 inhibitors, and the risk may be increased with concomitant use of other agents that can lower blood pressure.", "source": "DDInter", "management_text": "Caution is advised if SGLT-2 inhibitors are coadministered with diuretics and other hypotensive agents, particularly in the elderly and patients with impaired renal function. Prior to initiating SGLT-2 inhibitors, volume status should be assessed and corrected, if necessary. Clinical and laboratory monitoring are recommended during therapy, including electrolytes, fluid status, renal function, and blood pressure. If volume depletion occurs, treatment with SGLT-2 inhibitors should be interrupted until the condition is corrected.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if SGLT-2 inhibitors are coadministered with diuretics and other hypotensive agents, particularly in the elderly and patients with impaired renal function.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/98100/", "reference_text": "[1] \"Product Information. Jardiance (empagliflozin).\" Boehringer Ingelheim, Ridgefield, CT.[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] \"Product Information. Farxiga (dapagliflozin).\" Bristol-Myers Squibb, Princeton, NJ.[5] \"Product Information. Invokana (canagliflozin).\" Janssen Pharmaceuticals, Titusville, NJ.[6] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[7] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[8] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[9] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[10] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[11] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6[12] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[13] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[14] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[15] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42", "alternatives_a": "Vericiguat, Lidocaine, Zinc sulfate, Tetracaine, Zinc acetate, Fluocinonide, Zinc chloride, Procaine, Fluorometholone, Zinc gluconate", "alternatives_b": "Exenatide, Lixisenatide, Albiglutide, Acetohexamide, Guar gum, Pramlintide, Sitagliptin, Alogliptin, Liraglutide, Troglitazone, Semaglutide, More", "updated_at": 1767369485}, {"id": 97997, "ingredient1": "Empagliflozin", "ingredient2": "Nitroprusside", "severity": "Moderate", "effect": "Sodium-glucose co-transporter 2 (SGLT-2) inhibitors may potentiate the hypotensive effects of diuretics and other antihypertensive agents or vasodilators. Inhibition of glucose and sodium co-transport produces mild diuresis and transient natriuresis, resulting in intravascular volume contraction. Volume depletion-related adverse reactions including hypotension, postural dizziness, orthostatic hypotension, syncope, and dehydration can occur after initiating treatment with SGLT-2 inhibitors, and the risk may be increased with concomitant use of other agents that can lower blood pressure.", "source": "DDInter", "management_text": "Caution is advised if SGLT-2 inhibitors are coadministered with diuretics and other hypotensive agents, particularly in the elderly and patients with impaired renal function. Prior to initiating SGLT-2 inhibitors, volume status should be assessed and corrected, if necessary. Clinical and laboratory monitoring are recommended during therapy, including electrolytes, fluid status, renal function, and blood pressure. If volume depletion occurs, treatment with SGLT-2 inhibitors should be interrupted until the condition is corrected.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if SGLT-2 inhibitors are coadministered with diuretics and other hypotensive agents, particularly in the elderly and patients with impaired renal function.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/98101/", "reference_text": "[1] \"Product Information. Jardiance (empagliflozin).\" Boehringer Ingelheim, Ridgefield, CT.[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] \"Product Information. Farxiga (dapagliflozin).\" Bristol-Myers Squibb, Princeton, NJ.[5] \"Product Information. Invokana (canagliflozin).\" Janssen Pharmaceuticals, Titusville, NJ.[6] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[7] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[8] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[9] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[10] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[11] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6[12] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[13] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[14] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[15] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42", "alternatives_a": "Glipizide, Acetohexamide, Guar gum, Pramlintide, Alogliptin, Rosuvastatin, Tolazamide, Dulaglutide, Exenatide, Tolbutamide, Miglitol, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 97998, "ingredient1": "Empagliflozin", "ingredient2": "Norepinephrine", "severity": "Moderate", "effect": "The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.", "source": "DDInter", "management_text": "Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.", "mechanism_text": "Antagonism", "recommendation": "Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/98102/", "reference_text": "[1] Jori A, Carrara MC \"On the mechanism of the hyperglycaemic effect of chlorpromazine.\" J Pharm Pharmacol 18 (1966): 623-4[2] \"Product Information. Dymelor (acetohexamide)\" Lilly, Eli and Company, Indianapolis, IN.[3] \"Product Information. Thorazine (chlorpromazine).\" SmithKline Beecham, Philadelphia, PA.[4] Blayac JP, Ribes G, Buys D, Puech R, Loubatieres-Mariani MM \"Effects of a new benzothiadiazine derivative, LN 5330, on insulin secretion.\" Arch Int Pharmacodyn Ther 253 (1981): 154-63[5] \"Product Information. Elzonris (tagraxofusp).\" Stemline Therapeutics, New York, NY.[6] \"Product Information. Amaryl (glimepiride).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[7] \"Product Information. Elspar (asparaginase).\" Merck & Co, Inc, West Point, PA.[8] Jones IG, Pickens PT \"Diabetes mellitus following oral diuretics.\" Practitioner 199 (1967): 209-10[9] \"Product Information. Viracept (nelfinavir).\" Agouron Pharma Inc, La Jolla, CA.[10] \"Product Information. Tolinase (tolazamide)\" Pharmacia and Upjohn, Kalamazoo, MI.[11] Mauss S, Wolf E, Jaeger H \"Impaired glucose tolerance in HIV-positive patients receiving and those not receiving protease inhibitors.\" Ann Intern Med 130 (1999): 162-3[12] Virutamasen P, Wongsrichanalai C, Tangkeo P, Nitichai Y, Rienprayoon D \"Metabolic effects of depot-medroxyprogesterone acetate in long-term users: a cross-sectional study.\" Int J Gynaecol Obstet 24 (1986): 291-6[13] Wehring H, Alexander B, Perry PJ \"Diabetes mellitus associated with clozapine therapy.\" Pharmacotherapy 20 (2000): 844-7[14] Spellacy WN, Ellingson AB, Tsibris JC \"The effects of two triphasic oral contraceptives on carbohydrate metabolism in women during 1 year of use.\" Fertil Steril 51 (1989): 71-4[15] Andersen OO, Persson I \"Carbohydrate metabolism during treatment with chlorthalidone and ethacrynic acid.\" Br Med J 2 (1968): 798-801[16] Berlin I \"Prazosin, diuretics, and glucose intolerance.\" Ann Intern Med 119 (1993): 860[17] Malherbe C, Burrill KC, Levin SR, Karam JH, Forsham PH \"Effect of diphenylhydantoin on insulin secretion in man.\" N Engl J Med 286 (1972): 339-42[18] Carter BL, Small RE, Mandel MD, Starkman MT \"Phenytoin-induced hyperglycemia.\" Am J Hosp Pharm 38 (1981): 1508-12[19] Al-Rubeaan K, Ryan EA \"Phenytoin-induced insulin insensitivity.\" Diabet Med 8 (1991): 968-70[20] \"Product Information. Zolinza (vorinostat).\" Merck & Company Inc, West Point, PA.[21] Goldman JA, Neri A, Ovadia J, Eckerling B, Vries A, de \"Effect of chlorothiazide on intravenous glucose tolerance in pregnancy.\" Am J Obstet Gynecol 105 (1969): 556-60[22] Harper R, Ennis CN, Heaney AP, Sheridan B, Gormley M, Atkinson AB, Johnston GD, Bell PM \"A comparison of the effects of low- and conventional-dose thiazide diuretic on insulin action in hypertensive patients with NIDDM.\" Diabetologia 38 (1995): 853-9[23] Seltzer HS, Allen EW \"Hyperglycemia and inhibition of insulin secretion during administration of diazoxide and trichlormethiazide in man.\" Diabetes 18 (1969): 19-28[24] Dube MP, Johnson DL, Currier JS, Leedom JM \"Protease inhibitor-associated hyperglycaemia.\" Lancet 350 (1997): 713-4[25] Leary WP, Reyes AJ \"Drug interactions with diuretics.\" S Afr Med J 65 (1984): 455-61[26] \"Product Information. Reyataz (atazanavir).\" Bristol-Myers Squibb, Princeton, NJ.[27] Pollare T, Lithell H, Berne C \"A comparison of the effects of hydrochlorothiazide and captopril on glucose and lipid metabolism in patients with hypertension.\" N Engl J Med 321 (1989): 868-73[28] Gunnarsson R, Lundgren G, Magnusson G, Ost L, Groth CG \"Steroid diabetes--a sign of overtreatment with steroids in the renal graft recipient?\" Scand J Urol Nephrol Suppl 54 (1980): 135-8[29] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[30] \"Product Information. Synthroid (levothyroxine).\" Abbott Pharmaceutical, Abbott Park, IL.[31] Murphy MB, Kohner E, Lewis PJ, Schumer B, Dollery CT \"Glucose intolerance in hypertensive patients treated with diuretics: a fourteen-year follow-up.\" Lancet 2 (1982): 1293-5[32] \"Product Information. Fortovase (saquinavir)\" Roche Laboratories, Nutley, NJ.[33] Coni NK, Gordon PW, Mukherjee AP, Read PR \"The effect of frusemide and ethacrynic acid on carbohydrate metabolism.\" Age Ageing 3 (1974): 85-90[34] \"Product Information. Norvir (ritonavir).\" Abbott Pharmaceutical, Abbott Park, IL.[35] Domenet JG \"Diabetogenic effect of oral diuretics.\" Br Med J 3 (1968): 188[36] Rowe P, Mather H \"Hyperosmolar non-ketotic diabetes mellitus associated with metolazone.\" Br Med J 291 (1985): 25-6[37] Winchester JF, Kellett RJ, Boddy K, Boyle P, Dargie HJ, Mahaffey ME, Ward DM, Kennedy AC \"Metolazone and bendroflumethiazide in hypertension: physiologic and metabolic observations.\" Clin Pharmacol Ther 28 (1980): 611-8[38] \"Product Information. Carafate (sucralfate).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[39] Tsiodras S, Mantzoros C, Hammer S, Samore M \"Effects of protease inhibitors on hyperglycemia, hyperlipidemia, and lipodystrophy - A 5-year cohort study.\" Arch Intern Med 160 (2000): 2050-6[40] \"Product Information. Apidra (insulin glulisine).\" Aventis Pharmaceuticals, Bridgewater, NJ.[41] \"Product Information. Prezista (darunavir).\" Ortho Biotech Inc, Bridgewater, NJ.[42] Haiba NA, el-Habashy MA, Said SA, Darwish EA, Abdel-Sayed WS, Nayel SE \"Clinical evaluation of two monthly injectable contraceptives and their effects on some metabolic parameters.\" Contraception 39 (1989): 619-32[43] Erle G, Basso M, Federspil G, Sicolo N, Scandellari C \"Effect of chlorpromazine on blood glucose and plasma insulin in man.\" Eur J Clin Pharmacol 11 (1977): 15-8[44] Pickkers P, Schachter M, Hughes AD, Feher MD, Sever PS \"Thiazide-induced hyperglycaemia: a role for calcium-activated potassium channels?\" Diabetologia 39 (1996): 861-4[45] \"Product Information. Lexiva (fosamprenavir).\" GlaxoSmithKline, Research Triangle Park, NC.[46] Curtis J, Horrigan F, Ahearn D, Varney R, Sandler SG \"Chlorthalidone-induced hyperosmolar hyperglycemic nonketotic coma.\" JAMA 220 (1972): 1592-3[47] \"Product Information. Hyperstat I.V. (diazoxide).\" Schering Corp, Kenilworth, NJ.[48] \"Product Information. Piqray (alpelisib).\" Novartis Pharmaceuticals, East Hanover, NJ.[49] Bell DS \"Insulin resistance. An often unrecognized problem accompanying chronic medical disorders.\" Postgrad Med 93 (1993): 99-103,[50] Stambaugh JE, Tucker DC \"Effect of diphenylhydantoin on glucose tolerance in patients with hypoglycemia.\" Diabetes 23 (1974): 679-83[51] \"Product Information. Crixivan (indinavir).\" Merck & Co, Inc, West Point, PA.[52] Miller NR, Moses H \"Transient oculomotor nerve palsy. Association with thiazide-induced glucose intolerance.\" JAMA 240 (1978): 1887-8[53] Javier Z, Gershberg H, Hulse M \"Ovulatory suppressants, estrogens, and carbohydrate metabolism.\" Metabolism 17 (1968): 443-56[54] Goldman JA, Ovadia JL \"The effect of estrogen on intravenous glucose tolerance in woman.\" Am J Obstet Gynecol 103 (1969): 172-8[55] Charan VD, Desai N, Singh AP, Choudhry VP \"Diabetes mellitus and pancreatitis as a complication of L- asparaginase therapy.\" Indian Pediatr 30 (1993): 809-10[56] Seifer DB, Freedman LN, Cavender JR, Baker RA \"Insulin-dependent diabetes mellitus associated with danazol.\" Am J Obstet Gynecol 162 (1990): 474-5[57] \"Product Information. Orinase (tolbutamide)\" Pharmacia and Upjohn, Kalamazoo, MI.[58] Walli R, Demant T \"Impaired glucose tolerance and protease inhibitors.\" Ann Intern Med 129 (1998): 837-8[59] Hannaford PC, Kay CR \"Oral contraceptives and diabetes mellitus.\" BMJ 299 (1989): 1315-6[60] Hardy H, Esch LD, Morse GD \"Glucose disorders associated with HIV and its drug therapy.\" Ann Pharmacother 35 (2001): 343-51[61] Chowdhury FR, Bleicher SJ \"Chlorthalidone--induced hypokalemia and abnormal carbohydrate metabolism.\" Horm Metab Res 2 (1970): 13-6[62] Kaufman MB, Simionatto C \"A review of protease inhibitor-induced hyperglycemia.\" Pharmacotherapy 19 (1999): 114-7[63] Greenstone MA, Shaw AB \"Alternate day corticosteroid causes alternate day hyperglycaemia.\" Postgrad Med J 63 (1987): 761-4[64] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[65] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[66] Elmfeldt D, Berglund G, Wedel H, Wilhelmsen L \"Incidence and importance of metabolic side-effects during antihypertensive therapy.\" Acta Med Scand Suppl 672 (1983): 79-83[67] \"Product Information. Agenerase (amprenavir).\" Glaxo Wellcome, Research Triangle Pk, NC.[68] Diamond MT \"Hyperglycemic hyperosmolar coma associated with hydrochlorothiazide and pancreatitis.\" N Y State J Med 72 (1972): 1741-2[69] \"Product Information. Prandin (repaglinide).\" Novo Nordisk Pharmaceuticals Inc, Princeton, NJ.[70] \"Product Information. Precose (acarbose).\" Bayer, West Haven, CT.[71] \"Product Information. Starlix (nateglinide)\" Novartis Pharmaceuticals, East Hanover, NJ.[72] \"Product Information. Oncaspar (pegaspargase).\" Rhone-Poulenc Rorer, Collegeville, PA.[73] Sotaniemi E, Kontturi M, Larmi T \"Effect of diethylstilbestrol on blood glucose of prostatic cancer patients.\" Invest Urol 10 (1973): 438-41[74] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[75] Petri M, Cumber P, Grimes L, Treby D, Bryant R, Rawlins D, Ising H \"The metabolic effects of thiazide therapy in the elderly: a population study.\" Age Ageing 15 (1986): 151-5[76] Ludvik B, Clodi M, Kautzky-Willer A, Capek M, Hartter E, Pacini G, Prager R \"Effect of dexamethasone on insulin sensitivity, islet amyloid polypeptide and insulin secretion in humans.\" Diabetologia 36 (1993): 84-7[77] \"Product Information. Glucophage (metformin).\" Bristol-Myers Squibb, Princeton, NJ.[78] Chaudhuri ML, Catania J \"A comparison of the effects of bumetanide (Burinex) and frusemide on carbohydrate metabolism in the elderly.\" Br J Clin Pract 42 (1988): 427-9[79] Black DM, Filak AT \"Hyperglycemia with non-insulin-dependent diabetes following intraarticular steroid injection.\" J Fam Pract 28 (1989): 462-3[80] \"Product Information. Megace (megestrol).\" Bristol-Myers Squibb, Princeton, NJ.[81] \"Product Information. Torisel (temsirolimus).\" Wyeth-Ayerst Laboratories, Philadelphia, PA.[82] Schmitz O, Hermansen K, Nielsen OH, Christensen CK, Arnfred J, Hansen HE, Mogensen CE, Orskov H, Beck-Nielsen H \"Insulin action in insulin-dependent diabetics after short-term thiazide therapy.\" Diabetes Care 9 (1986): 631-6[83] Kansal PC, Buse J, Buse MG \"Thiazide diuretics and control of diabetes mellitus.\" South Med J 62 (1969): 1372-9[84] Dimitriadis G, Tegos C, Golfinopoulou L, Roboti C, Raptis S \"Furosemide-induced hyperglycaemia - the implication of glycolytic kinases.\" Horm Metab Res 25 (1993): 557-9[85] \"Product Information. NovoLog Mix 70/30 (insulin aspart-insulin aspart protamine).\" Novo Nordisk Pharmaceuticals Inc, Princeton, NJ.[86] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[87] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[88] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[89] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42[90] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[91] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[92] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[93] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[94] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[95] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6", "alternatives_a": "Droxidopa, Midodrine, Amrinone, Angiotensin II, Milrinone, Arbutamine", "alternatives_b": "Simvastatin, Guar gum, Rosuvastatin", "updated_at": 1767369485}, {"id": 97999, "ingredient1": "Empagliflozin", "ingredient2": "Norfloxacin", "severity": "Moderate", "effect": "Quinolone antibiotics may interfere with the therapeutic effects of insulin and other antidiabetic agents. The use of quinolones has been associated with disturbances in blood glucose homeostasis possibly stemming from effects on pancreatic beta cell ATP-sensitive potassium channels that regulate insulin secretion. Both hyperglycaemia and hypoglycemia have been reported, usually in diabetic patients receiving concomitant treatment with an oral hypoglycemic agent (e.g., sulfonylurea) or insulin. Although hyperglycaemia is significantly more common and infection itself may be an underlying risk factor, hypoglycemia may cause greater morbidity and mortality.", "source": "DDInter", "management_text": "Blood glucose should be closely monitored whenever quinolones are prescribed to diabetic patients, especially if they are elderly, have renal impairment, or are severely ill. Patients should be apprised of the increased risk of dysglycemia and be particularly alert to potential signs and symptoms of hypoglycemia such as headache, dizziness, drowsiness, nervousness, confusion, tremor, hunger, weakness, perspiration, palpitation, and tachycardia. If hypoglycemia occurs, patients should initiate appropriate remedial therapy immediately, discontinue the quinolone, and contact their physician. Alternative antibiotics may need to be considered.", "mechanism_text": "Antagonism", "recommendation": "Blood glucose should be closely monitored whenever quinolones are prescribed to diabetic patients, especially if they are elderly, have renal impairment, or are severely ill.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/98103/", "reference_text": "[1] Gavin JR 3rd, Kubin R, Choudhri S, et al \"Moxifloxacin and glucose homeostasis: a pooled-analysis of the evidence from clinical and postmarketing studies.\" Drug Saf 27 (2004): 671-86[2] Yip C, Lee AJ \"Gatifloxacin-induced hyperglycemia: a case report and summary of the current literature.\" Clin Ther 28 (2006): 1857-66[3] Kelesidis T, Canseco E \"Quinolone-induced hypoglycemia: a life-threatening but potentially reversible side effect.\" Am J Med 123 (2010): e5-6[4] Baker SE, Hangii MC \"Possible gatifloxacin-induced hypoglycemia.\" Ann Pharmacother 36 (2002): 1722-6[5] \"Product Information. Levaquin (levofloxacin).\" Ortho Pharmaceutical Corporation, Raritan, NJ.[6] Frothingham R \"Glucose homeostasis abnormalities associated with use of gatifloxacin.\" Clin Infect Dis 41 (2005): 1269-76[7] Letourneau G, Morrison H, McMorran M \"Gatifloxacin (Tequin): hypoglycemia and hyperglycemia. Available from: URL: http://www.hc-sc.gc.ca/dhp-mps/medeff/bulletin/carn-bcei_v13n3_e.html#1\" ([2003 Jul]):[8] Lin G, Hays DP, Spillane L \"Refractory hypoglycemia from ciprofloxacin and glyburide interaction.\" J Toxicol Clin Toxicol 42 (2004): 295-7[9] \"Product Information. Tequin (gatifloxacin)\" Bristol-Myers Squibb, Princeton, NJ.[10] \"Product Information. Floxin (ofloxacin).\" Ortho Pharmaceutical Corporation, Raritan, NJ.[11] Bhasin R, Arce FC, Pasmantier R \"Hypoglycemia associated with the use of gatifloxacin.\" Am J Med Sci 330 (2005): 250-3[12] Zvonar R \"Gatifloxacin-induced dysglycemia.\" Am J Health Syst Pharm 63 (2006): 2087-2092[13] Rubinstein E \"History of quinolones and their side effects.\" Chemotherapy 47 Suppl 3 (2001): 3-8[14] Park-Wyllie LY, Juurlink DN, Kopp A, et al. \"Outpatient gatifloxacin therapy and dysglycemia in older adults.\" N Engl J Med 354 (2006): 1352-61[15] LeBlanc M, Belanger C, Cossette P \"Severe and resistant hypoglycemia associated with concomitant gatifloxacin and glyburide therapy.\" Pharmacotherapy 24 (2004): 926-31[16] \"Product Information. Cipro (ciprofloxacin).\" Bayer, West Haven, CT.[17] Happe MR, Mulhall BP, Maydonovitch CL, Holtzmuller KC \"Gatifloxacin-induced hyperglycemia.\" Ann Intern Med 141 (2004): 968-9[18] Biggs WS \"Hypoglycemia and hyperglycemia associated with gatifloxacin use in elderly patients.\" J Am Board Fam Pract 16 (2004): 455-7[19] \"Product Information. Raxar (grepafloxacin).\" Glaxo Wellcome, Research Triangle Park, NC.[20] Brogan SE, Cahalan MK \"Gatifloxacin as a possible cause of serious postoperative hypoglycemia.\" Anesth Analg 101 (2005): 635-6[21] Friedrich LV, Dougherty R \"Fatal hypoglycemia associated with levofloxacin.\" Pharmacotherapy 24 (2004): 1807-12[22] Saraya A, Yokokura M, Gonoi T, Seino S \"Effects of fluoroquinolones on insulin secretion and beta-cell ATP-sensitive K(+) channels.\" Eur J Pharmacol 497 (2004): 111-7[23] \"Hypoglycemia and hyperglycemia with fluoroquinolones.\" Med Lett Drugs Ther 45 (2003): 64[24] Gajjar DA, LaCreta FP, Kollia GD, et al. \"Effect of multiple-dose gatifloxacin or ciprofloxacin on glucose homeostasis and insulin production in patients with noninsulin-dependent diabetes mellitus maintained with diet and exercise.\" Pharmacotherapy 20 (6 Pt 2) (2000): s76-86[25] Khovidhunkit W, Sunthornyothin S \"Hypoglycemia, hyperglycemia, and gatifloxacin.\" Ann Intern Med 141 (2004): 969[26] Kanbay M, Aydogan T, Bozalan R, et al. \"A rare but serious side effect of levofloxacin: hypoglycemia in a geriatric patient.\" Diabetes Care 29 (2006): 1716-7[27] Menzies DJ, Dorsainvil PA, Cunha BA, Johnson DH \"Severe and persistent hypoglycemia due to gatifloxacin interaction with oral hypoglycemic agents.\" Am J Med 113 (2002): 232-4[28] Edwards DJ, Bowles SK, Svensson CK, Rybak MJ \"Inhibition of drug metabolism by quinolone antibiotics.\" Clin Pharmacokinet 15 (1988): 194-204[29] Graumlich JF, Habis S, Avelino RR, et al. \"Hypoglycemia in inpatients after gatifloxacin or levofloxacin therapy: nested case-control study.\" Pharmacotherapy 25 (2005): 1296-302[30] \"Product Information. Factive (gemifloxacin).\" GeneSoft Inc, San Francisco, CA.[31] Wang S, Rizvi AA \"Levofloxacin-induced hypoglycemia in a nondiabetic patient.\" Am J Med Sci 331 (2006): 334-5[32] \"Product Information. Noroxin (norfloxacin).\" Merck & Co, Inc, West Point, PA.[33] Zhanel GG, Fontaine S, Adam H, et al. \"A Review of New Fluoroquinolones : Focus on their Use in Respiratory Tract Infections.\" Treat Respir Med 5 (2006): 437-465[34] \"Product Information. Baxdela (delafloxacin).\" Melinta Therapeutics, Lincolnshire, IL.[35] Greenberg AL, Decerbo M, Fan J \"Gatifloxacin therapy associated with hypoglycemia.\" Clin Infect Dis 40 (2005): 1210-1[36] Blommel AL, Lutes RA \"Severe hyperglycemia during renally adjusted gatifloxacin therapy.\" Ann Pharmacother 39 (2005): 1349-52[37] Tomita T, Onishi M, Sato E, Kimura Y, Kihira K \"Gatifloxacin induces augmented insulin release and intracellular insulin.\" Biol Pharm Bull 30 (2007): 644-7[38] Donaldson AR, Vandiver JR, Finch CK \"Possible gatifloxacin-induced hyperglycemia.\" Ann Pharmacother 38 (2004): 602-5[39] \"Product Information. Trovan (trovafloxacin).\" Pfizer US Pharmaceuticals, New York, NY.[40] Roberge RJ, Kaplan R, Frank R, Fore C \"Glyburide-ciprofloxacin interaction with resistant hypoglycemia.\" Ann Emerg Med 36 (2000): 160-3[41] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[42] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[43] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[44] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42[45] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[46] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[47] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[48] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[49] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[50] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6", "alternatives_a": "Tinidazole, Tetracycline, Cefepime, Fluconazole, Metronidazole, Cefuroxime, Secnidazole, Cefixime, Azithromycin, Amikacin, Rifamycin, More", "alternatives_b": "Guar gum", "updated_at": 1767369485}, {"id": 98000, "ingredient1": "Empagliflozin", "ingredient2": "Octreotide", "severity": "Moderate", "effect": "Somatostatin analogs may alter the therapeutic response to insulin and other antidiabetic agents. Somatostatin analogs can induce hyperglycemia and, less frequently, hypoglycemia, by inhibiting the secretion of various counter-regulatory hormones involved in glucose homeostasis (i.e., glucagon, insulin, growth hormone, incretin hormones).", "source": "DDInter", "management_text": "Close monitoring of diabetic control is recommended if somatostatin analogs are prescribed to patients with preexisting diabetes. Glycemic status including fasting plasma glucose and/or hemoglobin A1c should be assessed prior to initiation of therapy and periodically during therapy in accordance with manufacturer's product labeling, and the antidiabetic treatment adjusted as necessary.", "mechanism_text": "Antagonism", "recommendation": "Close monitoring of diabetic control is recommended if somatostatin analogs are prescribed to patients with preexisting diabetes.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/98104/", "reference_text": "[1] Williams G, Fuessl HS, Burrin JM, Chilvers E, Bloom SR \"Postprandial glycaemic effects of a long-acting somatostatin analogue (octreotide) in non-insulin diabetes mellitus.\" Horm Metab Res 20 (1988): 168-70[2] \"Product Information. Somatuline Depot (lanreotide).\" Ipsen Inc, Milford, MA.[3] \"Product Information. Sandostatin (octreotide).\" Sandoz Pharmaceuticals Corporation, East Hanover, NJ.[4] Hadjidakis DJ, Halvatsiotis PG, Ioannou YJ, Mavrokefalos PJ, Raptis SA \"The effects of the somatostatin analogue SMS 201-995 on carbohydrate homeostasis of insulin-dependent diabetics as assessed by the artificial endocrine pancreas.\" Diabetes Res Clin Pract 5 (1988): 91-8[5] Rios MS, Navascues I, Saban J, Ordonez A, Sevilla F, Del Pozo E \"Somatostatin analog SMS 201-995 and insulin needs in insulin-dependent diabetic patients studied by means of an artificial pancreas.\" J Clin Endocrinol Metab 63 (1986): 1071-4[6] \"Product Information. Signifor (pasireotide).\" Novartis Pharmaceuticals, East Hanover, NJ.[7] Giustina A, Girelli A, Buffoli MG, et al \"Low-dose octreotide is able to cause a maximal inhibition of the glycemic responses to a mixed meal in obese type 2 diabetic patients treated with insulin.\" Diabetes Res Clin Pract 14 (1991): 47-54[8] Davies RR, Miller M, Turner SJ, et al \"Effects of somatostatin analogue SMS 201-995 in non-insulin-dependent diabetes.\" Clin Endocrinol (Oxf) 25 (1986): 739-47[9] Di Mauro M, Le Moli R, Nicoletti F, Lunetta F \"Effects of octreotide on the glycemic levels in insulin-dependent diabetic patients. Comparative study between administration through multiple subcutaneous injections and continuous subcutaneous infusion.\" Diabetologia 36(Suppl 1) (1993): A138[10] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[11] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[12] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[13] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[14] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[15] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6[16] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[17] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[18] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[19] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42", "alternatives_a": "Nafarelin, Cetrorelix, Ganirelix, Relugolix, Gonadorelin", "alternatives_b": "Guar gum", "updated_at": 1767369485}]